<SEC-DOCUMENT>0001193125-14-065170.txt : 20140224
<SEC-HEADER>0001193125-14-065170.hdr.sgml : 20140224
<ACCEPTANCE-DATETIME>20140224170103
ACCESSION NUMBER:		0001193125-14-065170
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140224
DATE AS OF CHANGE:		20140224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		14637709

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d657040d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington,&nbsp;D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form&nbsp;10-K
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2013 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 0-30171 </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>68-0359556</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>501 Canal Boulevard,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Richmond, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94804</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(510)&nbsp;970-6000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name, former
address and former fiscal year, if changed since last report) </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act:
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:64.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:156.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on Which Registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.01&nbsp;par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>NASDAQ Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to
submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and will not
be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">The aggregate market value of the voting stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on
June&nbsp;30, 2013 (the last business day of the registrant&#146;s most recently completed second fiscal quarter), as reported on the NASDAQ Global Select Market was $405,023,312. For purposes of this calculation, directors and executive officers of
the registrant have been deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of the latest practicable date. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:111.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Outstanding at February&nbsp;1, 2014</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center">Common Stock, $0.01&nbsp;par value per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">62,736,879 shares</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:106.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parts Into Which Incorporated</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center">Proxy Statement for the 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Part&nbsp;III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center">Annual Meeting of Stockholders</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx657040_1">PART&nbsp;I</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_2">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_3">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1B.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_4">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_5">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_6">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_7">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx657040_8">PART&nbsp;II</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_9">Market for the Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_10">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;7A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_12">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_13">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;9A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_15">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;9B.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx657040_17">PART&nbsp;III</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_18">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_19">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_21">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_22">Principal Accounting Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx657040_23">PART&nbsp;IV</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx657040_24">Exhibits and Financial Statement Schedules</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization
activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product development and commercialization of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering, acquisition and other strategic transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues from existing and new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficiency of our cash resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as: &#147;anticipates,&#148; &#147;believes,&#148;
&#147;continues,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;should&#148; and &#147;will.&#148; These statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in
greater detail under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Results of Operations&#148; in this Form 10-K. Sangamo undertakes no obligation to publicly release any revisions to
forward-looking statements to reflect events or circumstances arising after the date of this report. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report on
Form&nbsp;10-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Sangamo
BioSciences, Inc. This report also contains trademarks and trade names that are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="tx657040_1"></A><B>PART&nbsp;I</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_2"></A><B>ITEM&nbsp;1 &#150; BUSINESS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Our current mission is to develop ZFP Therapeutics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or human therapeutics based on our proprietary ZFP technology, through early stage clinical testing, strategically partner with biopharmaceutical companies at points of value inflection and have
the partner execute late-stage clinical trials and commercial development. In the long-term, our goal is to integrate marketing and development operations and to capture the value of late-stage and commercial ZFP Therapeutic products for ourselves.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and our licensed partners, are the leaders in the research, development and commercialization of zinc finger DNA-binding proteins
(ZFPs), a naturally occurring class of proteins. We have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to modify DNA sequences in a
variety of ways and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. As ZFPs act at the DNA level, they have broad potential applications in several areas including human therapeutics, plant agriculture and
research reagents, as well as production of transgenic animals and cell-line engineering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main focus for our company is the
development of novel human therapeutics and we are building a pipeline of ZFP Therapeutics. Our lead ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of our ZFN
technology and is being evaluated in ongoing clinical trials, a Phase 2 study (SB-728-902, Cohort 5) and a Phase 1/2 study (SB-728-1101) in HIV-infected subjects. We expect to present data from this program at appropriate scientific and medical
meetings in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2014, we established a collaborative partnership with Biogen Idec Inc. (Biogen) to research, develop
and commercialize our preclinical ZFP Therapeutic development program, in hemoglobinopathies, and targeting sickle cell disease (SCD) and beta-thalassemia. We also have a collaborative partnership with Shire International GmbH, formerly Shire AG,
(Shire) to research, develop and commercialize certain of our preclinical ZFP Therapeutic development programs, including programs in hemophilia, Huntington&#146;s disease (HD) and other monogenic diseases. We have proprietary preclinical programs
in several lysosomal storage disorders (LSDs). In addition, we have research stage programs in other monogenic diseases, including certain immunodeficiencies, as well as central nervous system (CNS) disorders and cancer immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the potential commercial applications of ZFPs are broad-based and we have entered into strategic partnerships in fields outside
human therapeutics to facilitate the sale or licensing of our ZFP platform as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon our ZFP technology
as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, we have provided DAS with access to our ZFP technology and the exclusive rights
to use it to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. DAS markets our ZFN technology under the trademark EXZACT<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Precision Technology. We
have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic or prophylactic purposes. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, we acquired Ceregene, Inc. (Ceregene), a privately held biotechnology
company focused on the development of adeno-associated virus (AAV) gene therapies. The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110, an AAV expressing nerve growth factor (NGF) for the treatment of
Alzheimer&#146;s disease (AD) that is currently in a Phase 2 clinical trial, certain intellectual property rights relating to the manufacturing of AAV, certain toxicology data and safety and efficacy data from Ceregene&#146;s human clinical trials.
We believe that these additional assets provide valuable reference materials for us in the preparation and filing of Investigative New Drug (IND) applications for our <I>in vivo</I> ZFP Therapeutics, particularly those that target the brain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a substantial intellectual property position in the design, selection, composition and use of engineered ZFPs to support our
commercial activities. As of February&nbsp;7, 2014, we either owned outright or have exclusively licensed the commercial rights to approximately 462 patents issued in the United States and foreign national jurisdictions, and we have 536 patent
applications owned and licensed pending worldwide, including patents acquired from Ceregene. We continue to license and file new patent applications that strengthen our core and accessory patent portfolio. We believe that our intellectual property
position is a critical element in our ability to research, develop and commercialize products and services based on ZFP technology across our chosen applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DNA, Genes, and Proteins </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DNA is present
in all cells except mature red blood cells, and encodes the inherited characteristics of all living organisms. A cell&#146;s DNA is organized in chromosomes as thousands of individual units called genes. Genes encode proteins, which are assembled
through the process of transcription&#151;whereby DNA is transcribed into ribonucleic acid (RNA)&#151;and, subsequently, translation&#151;whereby RNA is translated into protein (Figure 1). Proteins are involved in virtually all cell functions. DNA,
RNA and proteins comprise many of the targets for pharmaceutical drug discovery and therapeutic intervention. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g657040g97x50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schematic of the relationship between the human genome, DNA, RNA and protein </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The human body is composed of specialized cells that perform different functions and are thus
organized into tissues and organs. All somatic cells in an individual&#146;s body contain the same set of genes. However, only a fraction of these genes are turned on, or expressed, in an individual human cell at any given time. Genes are regulated
(i.e. turned on or turned off) in response to a wide variety of stimuli and developmental signals. Distinct sets of genes are expressed in different cell types. It is this pattern of gene expression that determines the structure, biological function
and health of all cells, tissues and organisms. The aberrant expression of certain genes can lead to disease. Similarly, a mistake in the DNA sequence of a gene can result in corresponding error in the protein encoded by the gene, which may have
serious consequences for the cell and its function. A number of disorders have been identified that are caused by the inheritance of a single defective gene. These so-called monogenic diseases include hemophilia, HD, SCD and LSDs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zinc finger DNA-binding proteins</B> (<B>ZFPs) are Transcription Factors</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transcription factors are proteins that bind to DNA and regulate gene expression. A transcription factor recognizes and binds to a specific DNA
sequence within or near a particular gene and causes expression of that gene to be &#147;turned on&#148; (activated) or &#147;turned off&#148; (repressed). ZFPs are the largest class of naturally occurring transcription factors in organisms from
yeast to humans. In higher organisms, naturally occurring transcription factors typically comprise two principal domains: the first is a DNA-binding domain, (designated in Figure 2 as the &#147;Recognition Domain&#148;) which recognizes a target DNA
sequence and thereby directs the transcription factor to the proper chromosomal location; the second is a functional domain that causes the target gene to be activated or repressed. Sangamo has added to these naturally occurring functional domains
to include domains enabling genome modification at the site determined by the DNA-binding domain. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g657040g62s27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schematic of the two-domain structure of a ZFP Therapeutic </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Engineered ZFP Nucleases (ZFNs) can be designed for Gene Modification and Engineered Zinc Finger Protein
Transcription Factors (ZFP TFs) for Gene Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with the two-domain structure of natural ZFP transcription factors, we
take a modular approach to the design of the proteins that we engineer. The ZFP portion, the DNA-recognition domain, is typically composed of three or more zinc fingers. Each individual finger recognizes and binds to a three-four base pair sequence
of DNA and multiple fingers can be linked together to recognize longer stretches of DNA, thereby improving specificity. By modifying the amino acids of a ZFP, we can engineer novel ZFPs capable of recognizing pre-selected DNA sequences within, or
near, virtually any gene. We use the engineered ZFP DNA-binding domain linked to a functional domain. The ZFP DNA-binding domain brings the functional domain into the proximity of the gene of interest. Our ability to use our highly specific ZFP
technology to precisely target a DNA sequence in a gene of interest provides us with a range of gene editing and gene regulation functions that can be applied in many different cell types. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our engineered ZFPs can be attached to a cleavage domain of a restriction endonuclease, an enzyme that cuts DNA, creating a zinc finger
nuclease or ZFN. The ZFN is able to recognize its intended gene target through its engineered ZFP DNA-binding domain. When a pair of such ZFNs is bound to the DNA in the correct orientation and spacing, the DNA sequence is cut between the ZFP
binding sites. DNA binding by both ZFNs is necessary for cleavage, and both domains of the restriction endonuclease must be present in the correct orientation to interact with each other, in order to mediate DNA cleavage. This break in the DNA
triggers a natural process of DNA repair in the cell. The repair process can be harnessed to achieve one of several outcomes that may be therapeutically useful (Figure&nbsp;3). If cells are simply treated with ZFNs alone the repair process joins the
two ends of the broken DNA together and frequently results in the loss of a small amount of genetic material at the site of the break. This disrupts the original DNA sequence and can result in the generation of a shortened or non-functional protein,
effectively &#147;knocking out&#148; the protein. We believe that ZFN-mediated gene modification may be used to disrupt a gene that is involved in disease pathology such as disruption, or knock out, of the CCR5 gene to treat HIV infection. We are
also using ZFN-mediated gene disruption of the <I>BCL11A</I> gene in HSCs as a potentially curative treatment for SCD and beta-thalassemia in our collaboration with Biogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast, if cells are treated with ZFNs in the presence of an additional DNA sequence that encodes the correct gene sequence (referred to
as a &#147;donor&#148; DNA), the cell can use the donor as a template to correct the cell&#146;s gene as it repairs the break resulting in ZFN-mediated gene correction. ZFN-mediated gene correction enables a corrected gene to be expressed in its
natural chromosomal context and may provide a novel approach for the precise repair of DNA sequence mutations responsible for monogenic diseases such as X-linked severe combined immunodeficiency (X-linked SCID). In addition, by making the donor
sequence a gene-sized segment of DNA, a new copy of a gene can also be precisely added into the genome at a specific location. The ability to place a gene-sized segment of DNA specifically into a pre-determined location in the genome broadens the
range of mutations of a gene that can be corrected in a single step and eliminates the insertional mutagenesis concerns associated with traditional gene replacement approaches, in which the insertion of a new corrective copy of the gene typically
occurs at random locations in the genome. Our In Vivo Protein Replacement Platform (IVPRP), in which our ZFN technology is used to insert a gene encoding a therapeutic protein into a safe harbor site such as the <I>Albumin</I> gene, is an approach
that we are investigating for the potential long-term treatment of hemophilia and LSDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can also create ZFP TFs which are capable of
controlling or regulating the expression of a target gene in the desired manner (Figure&nbsp;3). For instance, attaching an activation domain to a ZFP will cause a target gene to be &#147;turned on.&#148; Alternatively, a repression domain causes
the gene to be &#147;turned off.&#148; We have a preclinical ZFP Therapeutic program for HD in which we are evaluating a ZFP TF designed to differentially down regulate the mutated disease-causing <I>Huntingtin</I> (HTT) gene, while leaving
expression of the normal gene unchanged. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P>&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g657040g51t67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZFP Therapeutics can be designed to accomplish a range of functions in gene editing and gene regulation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have designed, engineered and assembled several thousand ZFPs and have tested many of these proteins for their affinity, or
tightness of binding, to their DNA target, as well as their specificity, or preference for their intended DNA target. We have developed methods for the design, selection and assembly of ZFPs capable of binding to a wide spectrum of DNA sequences and
genes. We have linked ZFPs to numerous functional domains to create gene-specific ZFP TFs and have demonstrated the ability of these ZFP TFs to regulate hundreds of genes in dozens of different cell types and in whole organisms, including mice,
rats, rabbits, pigs, fruit flies, worms, zebrafish and yeast, and in plant species including canola and maize. We and our collaborators have published data in peer-reviewed scientific journals on the transcriptional function of ZFP TFs, successful
and highly-specific gene modification using ZFNs and the resulting changes in the behavior of the target cell, tissue or organism. ZFNs are currently being used to generate transgenic animals and cell lines that have specific genetic modifications
that make them useful models of human disease. These high value biologic tools are being used by academics, and biotechnology and pharmaceutical companies for medical research and drug development. We have ongoing clinical trials to evaluate the
safety and efficacy of ZFNs in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have several strategies for the application of our ZFP Therapeutics depending on the disease or
indication. We can deliver these therapeutic proteins <I>ex vivo</I> (outside the body) to isolated cells of the blood, such as T-cells, in the case of our clinical HIV program, and HSCs for our preclinical programs in HIV and monogenic blood
diseases such as SCD and beta-thalassemia. We are also developing ZFP Therapeutics in which we deliver our therapeutic proteins <I>in vivo</I>, either systemically (directly into the blood stream) as in our hemophilia and LSD programs, or directly
into a specific tissue such as the brain as in our HD program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZFP Therapeutics Provide the Opportunity to Develop a New Class of Human Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With our ability to generate gene-specific ZFNs for the disruption or addition/correction of target genes and DNA sequences and ZFP TFs for the
activation or repression of genes and with multiple strategies for administration, we are focused on developing a new class of highly differentiated human therapeutics. We believe that as more genes are linked to specific diseases, the clinical
breadth and scope of our ZFP Therapeutic applications may be substantial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our ZFP technology provides a unique and
proprietary basis for a broad new class of drugs that have differential competitive advantages over small-molecule drugs, protein pharmaceuticals and RNA-based and conventional gene therapy approaches, enabling us to pursue the development of
therapies for a broad range of unmet medical needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, ZFP Therapeutics can: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Provide novel activities such as gene modification and regulation of gene expression to address drug targets.</B> Engineered ZFNs enable the disruption, correction or targeted addition of a gene sequence and ZFP TFs
enable not only repression of the expression of a therapeutically relevant gene but also its activation in a cell. This gives our technology a degree of flexibility not seen in other drug platforms. Our ZFN gene editing technology, which requires
only brief cellular expression of ZFNs, allows the permanent correction of a mutation in a defective gene in a highly specific fashion. This provides a novel therapeutic and potentially life-long clinical benefit in the treatment of monogenic
diseases, such as hemophilia and SCD. In contrast, direct modification of genes cannot be achieved using antisense RNA, or siRNA, which act by interfering with the expression of cellular RNA, or conventional small molecules, antibodies, or other
protein pharmaceuticals that primarily act to &#147;block&#148; or antagonize the action of a protein. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Provide therapeutic solutions for targets that cannot be effectively addressed by existing drug modalities.</B> ZFNs and ZFP TFs act through a mechanism that is unique among biological drugs: direct modification or
regulation of the disease-related or therapeutic gene as opposed to the RNA or protein target encoded by that gene. Following the genomics revolution of the 1990s, the sequencing and publication of the human genome, pharmaceutical and biotechnology
companies have validated and characterized many new drug targets. Many of these targets have a direct role in disease processes but cannot be bound or modulated for therapeutic purposes by small molecules. Alternative therapeutic approaches may be
required to modulate the biological activity of these so-called &#147;non-druggable&#148; targets. This may create a significant clinical and commercial opportunity for the therapeutic modification or regulation of disease-associated genes using
engineered ZFNs or ZFP TFs. Thus, a target which may be intractable to treatment using a small molecule or monoclonal antibody can be modified, turned on or turned off at the DNA level using ZFP technology. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Provide high specificity and selectivity for targets.</B> ZFP Therapeutics can be designed to act with high specificity and we have published such data (<I>Proc. Natl. Acad. Sci (2003)&nbsp;vol:100, 11997-12002; J
Neurosci. (2010)&nbsp;30(49):16469-74; Nat Biotechnol. (2008)&nbsp;26(7):808-16 and Nature (2011)478(7369):391-4</I>). In addition, as there are only two copies of each gene, there are generally only two targets per cell for a ZFP Therapeutic, which
means that ZFNs and ZFP TFs need to be available in the cell in very low concentrations. In contrast, drugs that act on protein and RNA targets that are naturally present in higher cellular concentrations need to be administered in higher
concentrations. Many small molecule and RNA-based approaches either affect multiple targets demonstrating so-called &#147;off-target effects&#148; or are toxic in the concentrations required to be therapeutically effective. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THERAPEUTIC PRODUCT DEVELOPMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZFP Therapeutic Product Development Programs </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g657040g38k71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sangamo&#146;s Therapeutic Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Stage Programs </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.55pt; font-size:8pt; font-family:Times New Roman"><B>Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Targeted Indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage of<BR>Development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Protocol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestones</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SB-728-T</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">HIV/AIDS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SB-728-902,&nbsp;Cohort&nbsp;5</FONT></FONT> (CCR5 delta-32 heterozygotes)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Trial initiated in January 2012. Enrollment completed, in long-term follow-up. Data presented in 2013.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase&nbsp;1/2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SB-728-1101</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Trial initiated in January 2012. Data presented in 2013. Six additional subjects to be enrolled at higher Cytoxan doses, further 12 subjects will be enrolled at optimum Cytoxan dose. Data expected in 2014.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SB-728-902, <FONT STYLE="white-space:nowrap">Cohorts&nbsp;1-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Enrollment completed, in long-term follow-up.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SB-728-T*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Enrollment completed, in long-term follow-up.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CERE-110</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(AAV-NGF)&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Alzheimer&#146;s&nbsp;disease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Direct delivery to the brain of AAV expressing NGF. All subjects treated, in two year follow-up. Data expected in 2015.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Table 1: Summary of our ongoing clinical trials. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(*Investigator sponsored trial) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIV infection results in the death of immune system cells, particularly CD4+ T-cells, and thus leads to AIDS, a condition in which the
body&#146;s immune system is depleted to such a degree that the patient is unable to fight off common infections. Ultimately, these patients succumb to opportunistic infections or cancers. According to UNAIDS/WHO, over 2.5&nbsp;million people were
newly infected with HIV in 2011. An estimated 1.7&nbsp;million people died of AIDS in the same year. There are now over 34&nbsp;million people living with HIV and AIDS worldwide. The United States Centers for Disease Control and Prevention (CDC)
estimates that, in 2009 in the United States alone, there were 1.2&nbsp;million people living with HIV/AIDS. Approximately 50,000 new infections occurred each year between 2006 and 2009, and more than 21,000 people with AIDS died in 2009. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatments and Unmet Medical Need </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there are over 30 antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA) to treat people infected with HIV.
These drugs fall into four major classes: reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and entry and fusion inhibitors. This latter class also includes a small molecule antagonist of the CCR5 receptor, Selzentry<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (maraviroc). This drug is being used in combination with other antiretroviral agents for treatment-experienced adult patients infected with CCR5-tropic HIV-1 strains that are resistant to
multiple antiretroviral agents. The drug carries a black box warning of liver toxicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As HIV reproduces, variants of the virus emerge,
including some that are resistant to antiretroviral drugs. Therefore, doctors recommend that people infected with HIV take a combination of antiretroviral drugs known as highly active antiretroviral therapy, or ART. This strategy typically combines
drugs from at least three different classes of antiretroviral drugs. Currently available drugs do not cure HIV infection or AIDS. They can suppress the virus, even to undetectable levels, but they cannot eliminate HIV from the body. Hence, people
with HIV need to take antiretroviral drugs continuously. The drugs are expensive and can have significant side effects over time. There is no therapeutic approach available which protects CD4+ T-cells, reduces viral load and does not require daily
dosing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sangamo&#146;s Therapeutic Approach </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our therapeutic approach aims to use our ZFN-mediated gene editing technology to replicate a naturally occurring human mutation which renders
individuals largely resistant to infection with the most common strain of HIV. CCR5 is a co-receptor for HIV entry into T-cells and if CCR5 is not expressed on their surface HIV infects them with lower efficiency. A population of individuals that is
immune to HIV infection, despite multiple exposures to the virus, has been identified and extensively studied. The majority of these individuals have a natural mutation, CCR5 delta-32, resulting in the expression of a shortened, or truncated, and
non-functional CCR5 protein. This mutation appears to have no observable deleterious effect. Individuals who carry the CCR5 delta-32 mutation on only one of their two CCR5 gene copies (heterozygotes), tend to take longer to develop AIDS and are
classified as so-called &#147;long-term non-progressors.&#148; In addition, a study published in <I>Blood</I> in December 2010 reported an effective cure when an AIDS patient with leukemia received a bone marrow transplant from a &#147;matched&#148;
donor with this CCR5 delta-32 mutation. This approach transferred the HSCs residing in the bone marrow from the delta-32 donor, and provided a self-renewable and potentially lifelong source of HIV-resistant immune cells. After transplantation, the
AIDS patient was able to discontinue all <FONT STYLE="white-space:nowrap">anti-HIV</FONT> drug treatments, CD4 counts increased and viral load dropped to an undetectable level, demonstrating effective transplantation of protection from HIV
infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our ZFN-mediated gene disruption technology to disrupt the CCR5 gene in cells of a patient&#146;s immune system
to make these cells permanently resistant to HIV infection. The aim is to provide a population of HIV-resistant cells that can fight HIV and opportunistic infections mimicking the situation in individuals that carry the natural mutation. In December
2008, in collaboration with scientists at the University of Pennsylvania, an IND was filed for a Phase 1 trial of our CCR5 ZFP Therapeutic, SB-728-T. This single-dose, investigator-sponsored trial began enrolling subjects in February 2009, at the
University of Pennsylvania. In September 2009, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we filed an IND application and initiated a dose-escalation Phase 1 clinical trial (SB-728-902) of SB-728-T. Both Phase 1 studies were in HIV-infected individuals who were on ART. The studies
were designed primarily to evaluate the safety and tolerability of this ZFP&nbsp;Therapeutic approach; however, subjects&#146; CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden were also monitored. Preliminary data from both trials
were presented in the first quarter of 2011 and demonstrated that the approach was well-tolerated in these subjects. In addition, we observed durable engraftment and persistence of SB-728-T, the ability of these cells to traffic to the gut mucosa
and improvements in the overall CD4 T-cell count and the CD4:CD8 ratio in multiple subjects. Data from the study carried out at the University of Pennsylvania demonstrated that the treatment was well tolerated and that ZFN-modified cells show
long-term engraftment and have a survival advantage over non-modified cells during an ART treatment interruption (TI). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012,
we announced the initiation of two new studies (SB-728-1101 and SB-728-902, Cohort 5), based on data from our Phase 1 trials that demonstrated a correlation between the estimated numbers of circulating engrafted cells in which both copies of the
CCR5 gene were modified (biallelic modification) and the reduction in viral load in treated subjects that underwent a TI. Using different approaches, both studies aim to increase the engraftment of cells that have undergone biallelic modification in
SB-728-T-treated subjects and to evaluate the effect of increasing the numbers of these cells on the immune system and on viral load during a TI. Ten CCR5 delta-32 heterozygote subjects have been accrued and treated on the SB-728-902, Cohort 5 study
and twelve subjects have been accrued and treated on the SB-728-1101 study, a trial which evaluated the effect of increasing doses of Cytoxan conditioning prior to SB-728-T administration on engraftment of cells that have undergone biallelic ZFN
modification. Data presented at scientific meetings in 2013 further supported a correlation between the estimated numbers of engrafted biallelically modified cells and the reduction in viral load with one subject in the SB-728-902 study
demonstrating a prolonged control of viral load at or below the limits of detection during TI. An additional six subjects are being enrolled into SB-728-1101 for evaluation of the effect of higher doses of Cytoxan and a further twelve subjects will
be treated at the optimum Cytoxan dose. We expect to present data from the SB-728-1101 study in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have a preclinical stage
program to investigate this approach to treating HIV in HSCs. Together with our collaborators at City of Hope Medical Center and the University of Southern California, we have funding for this program from a four-year $14.5 million Disease Team
Research Award granted by the California Institute for Regenerative Medicine (CIRM), a State of California entity, in October 2009. We have received $5.2 million in funding through December&nbsp;31, 2013, which is our total prescribed amount under
the agreement. In 2014, we expect to file an IND application based on this work. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Programs Acquired from Ceregene </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CERE-110 (AAV-NGF), a gene therapy approach designed to deliver NGF directly to the brain using an AAV vector for the treatment of AD, was
developed by Ceregene. The program and ongoing Phase 2 clinical trial were assets that we acquired from Ceregene in October 2013. In November 2013, we released preliminary data from a Phase 1 dose escalation study of CERE-110 demonstrating that
surgical delivery of CERE-110 to the brain results in the long-term expression of bioactive NGF, the therapeutic protein. Clinicians also observed apparent stabilization of brain cell metabolic activity in treated subjects, as determined by
PET-scans measuring glucose use, which may reflect a slowing of cell deterioration. The treatment was well-tolerated at all dose levels. The Phase 2 clinical trial is fully accrued and is being carried out in collaboration with the Alzheimer&#146;s
Disease Cooperative Study (ADCS) based at the University of California San Diego (UCSD) and funded by a grant from the National Institute on Aging (NIA). Forty-nine (49)&nbsp;patients with mild to moderate AD have been treated with a single
administration of CERE-110 at ten clinical sites throughout the U.S. Approximately half of the patients received CERE-110 while the other half received an appropriate sham surgery control treatment. Patients are being followed for a minimum of two
years with respect to safety, brain imaging as well as standard tests used in Alzheimer&#146;s clinical trials to measure cognitive function and quality of life. Enrollment was completed in March 2013 and we expect to present data in 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZFP Therapeutic Pre-Clinical Stage Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Programs Partnered with Shire </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemophilia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemophilia, a rare bleeding disorder in which the blood does not clot normally, is an example of a monogenic disease (a disease
that is caused by a genetic defect in a single gene). There are several types of hemophilia caused by mutations in genes that encode factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia
experience bleeding episodes after injuries and spontaneous bleeding episodes that often leads to joint disease such as arthritis. The most prevalent form of the disease, hemophilia A, is caused by a defect in clotting Factor VIII, while defects in
clotting Factor IX lead to hemophilia B. The most severe forms of hemophilia affect males. According to the National Hemophilia Foundation, hemophilia A occurs in about one in every 5,000 male births in the US with approximately 25,000 males
currently affected in the US, and hemophilia B in about 1 in every 25,000 male births with approximately 5,000 males currently affected. The standard treatment for individuals with hemophilia is replacement of the defective clotting factor with
regular infusion of recombinant clotting factors or plasma concentrates. These therapies are expensive, carry the risk of transmission of blood-borne diseases such as hepatitis and other viral infections and sometimes stimulate the body to produce
antibodies against the factors that inhibit the benefits of treatment. In these situations, other clotting factors such as Factor VII and X may be used to treat patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In collaboration with Shire, we are working on four gene targets, clotting factors VII, VIII, IX and X to develop ZFP Therapeutics to treat
hemophilia. Using our ZFN technology we are pursuing two approaches in the development of these therapeutics: correction of the disease-causing mutation in the endogenous copy of the Factor VIII or IX gene and addition of a new correct copy of the
Factor VIII or IX gene into a safe-harbor site, the Albumin gene or locus, using our In Vivo Protein Replacement Platform (IVPRP). We have published data demonstrating functional correction of the human factor IX gene in the liver by direct
intravenous delivery of ZFNs in a mouse model of the disease. We have ongoing preclinical studies to develop therapies for hemophilia A and B which will provide a permanent correction that would reduce or eliminate the need for infusions of clotting
factor products. Our goal is to submit IND applications for these ZFP Therapeutics in 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Huntington&#146;s disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Huntington&#146;s disease (HD) is an inherited, progressive neurologic disease for which there is no treatment or cure. The disease is caused
by a particular type of mutation in a single gene, the HTT gene. Most patients inherit one normal and one defective or mutant copy of the HTT gene, which is enough to cause HD. The mutation is characterized by expansion of a repeated stretch of DNA
sequence within the gene called a &#147;CAG repeat.&#148; A normal copy of the HTT gene usually has 10 to 29 of these CAG repeats but a defective copy has many more&#151;generally greater than 39 repeats. While the protein produced by the normal
copy of the gene appears to be essential for development (mice lacking the gene do not survive to birth), the product of the mutated gene is damaging to nerve cells. Symptoms, which include deterioration of muscle control, cognition and memory,
usually develop between 35 and 44 years of age. It is known that the greater the number of CAG repeats, the earlier the onset. HD is usually fatal within 10 to 20 years after the onset of symptoms. The disease has a high prevalence for an inherited
disorder, affecting approximately 30,000 people (one in 10,000) in the US. An additional 150,000 people in the U.S. carry a 50% risk of developing the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research in animal models of the disease has shown that lowering the levels of the defective HTT protein can prevent, or even reverse, disease
progression. However, to date most &#147;HTT-lowering&#148; methods decrease levels of both the normal and mutant forms of HTT, raising potential safety concerns given the importance of normal HTT protein. In collaboration with Shire, we are
developing ZFP TFs that can selectively repress the expression of the mutant disease-causing form of HTT while leaving expression levels of the normal gene unchanged. Preclinical studies in animal models of the disease are ongoing and our goal is to
file an IND application for a ZFP Therapeutic for HD in 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Programs Partnered with Biogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemoglobinopathies: Sickle cell disease and Beta-thalassemia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations in the genes encoding globin, the oxygen carrying protein of red blood cells, lead to hemoglobinopathies such as sickle cell disease
(SCD) and beta-thalassemia. The mutation that gives rise to SCD causes the red blood cells to form an abnormal sickle or crescent shape. The cells are fragile and deliver less oxygen to the body&#146;s tissues. They can also get stuck more easily in
small blood vessels and break into pieces that can interrupt healthy blood flow which further decrease the amount of oxygen flowing to body tissues. Almost all patients with SCD have painful episodes (called crises), which can last from hours to
days. Current standard of care is to manage and control symptoms, and to limit the number of crises. Treatments include blood transfusions, iron-chelation therapy and administration of hydroxyurea, pain medications and antibiotics. As of 2011, the
CDC estimates that there are 90,000 to 100,000 Americans living with SCD which occurs in approximately 1 out of every 500 African-American births and 1 out of every 36,000 Hispanic-American births. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several forms of beta-thalassemia. Broadly, the disorder results in excessive destruction of red blood cells leading to
life-threatening anemia, enlarged spleen, liver and heart, and bone abnormalities. Beta-thalassemia major is a severe form of thalassemia that requires regular, often monthly, blood transfusions and subsequent iron-chelation therapy to treat iron
overload. The CDC estimates that 1,000 people have <FONT STYLE="white-space:nowrap">beta-thalassemia</FONT> major in the United States, and an unknown number carry the genetic trait and can pass it on to their children. Thalassemia is most common
among people of Mediterranean descent and is also found among people from the Arabian Peninsula, Iran, Africa, Southeast Asia and Southern China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing ZFP Therapeutics for both SCD and beta-thalassemia based on the use of our ZFN gene editing technology in a patient&#146;s
own (autologous) bone marrow stem cells. Our ZFN genome editing technology enables multiple approaches to the correction of SCD and beta-thalassemia. Both diseases manifest in the months after birth, when patients switch from producing functional
fetal gamma-globin to a mutant form of adult beta-globin, which results in their condition. Naturally occurring increased levels of therapeutic fetal hemoglobin have been shown to reduce the severity of both SCD and beta-thalassemia disorders. In
HSCs, our genome editing technology can be used to precisely disrupt key transcriptional regulators, such as <I>BCL11A</I>, to reverse the switch from expression of the mutant adult beta-globin back to the production of functional fetal
gamma-globin. Alternatively, the technology can be used to precisely insert a new corrected beta-globin gene to replace the defective copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A bone marrow transplant (BMT), of HSCs from a &#147;matched&#148; related donor (allogeneic BMT) is curative for both diseases. However, this
therapy is limited due to the scarcity of matched donors and the significant risk of Graft versus Host Disease (GvHD) after transplantation of the foreign cells. By performing genome editing in HSCs that are isolated from and subsequently returned
to the same patient (i.e. an autologous HSC transplant), our approach eliminates both the need for a matched donor and the risk of acute and chronic GvHD. The ultimate goal of this approach is to develop a one-time curative treatment for SCD and
beta-thalassemia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2013, CIRM granted us a $6.4 million Strategic Partnership Award to develop this potentially curative ZFP
Therapeutic for beta-thalassemia. The four-year grant provides matching funds for preclinical studies that will support an IND application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients, which will be carried out at
Children&#146;s Hospital&nbsp;&amp; Research Center Oakland, and City of Hope. We are in currently in preclinical development in collaboration with Biogen and our goal is to file an IND application for beta-thalassemia in 2014 and for SCD in 2015.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proprietary Research Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lysosomal
Storage Disorders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lysosomal storage disorders (LSDs) are a heterogeneous group of inherited disorders including Fabry disease,
Gaucher disease, Pompe disease and Hurler syndrome. They are caused by defects in genes that encode </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proteins known as enzymes, which break down and eliminate unwanted substances in the cells of the body. These enzymes are found in structures called lysosomes which act as recycling sites in
cells, breaking down unwanted material into simple products for the cell to use to build new materials. A defect in a lysosomal enzyme leads to the accumulation of toxic levels of the substance that the enzyme would normally eliminate and resulting
cell damage which can lead to serious health problems. There are nearly 50 of these disorders altogether and they may affect different parts of the body, including the skeleton, brain, skin, heart and CNS. While their individual incidence tends to
be rare, this group as a whole has a prevalence of more than 1:5,000 live births according to the National Institute of Neurological Disorders and Stroke. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no cure for LSDs, and treatments have not yet been developed for many of these diseases. For certain disorders, including Gaucher and
Fabry, enzyme replacement therapies (ERTs) are available. However, these require frequent administration, are costly and there is a risk that over time patients develop an immunogenic response to the administered protein lessening its efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a genetic approach to enzyme replacement for several LSDs based on systemic delivery of our ZFN gene editing technology to
the liver to enable production of the corrective enzyme by the body. We are in preclinical development with several product candidates and our goal is to file two IND applications for such product candidates in 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZFP Therapeutic Research Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have research stage programs in other monogenic diseases, in CNS disorders and in cancer immunotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATE RELATIONSHIPS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
established collaborative and strategic partnerships for our ZFP Therapeutic programs and in non-therapeutic areas. We will continue to pursue further partnerships when appropriate with selected pharmaceutical, biotechnology and chemical companies
to fund internal research and development activities and to assist in product development and commercialization. We are applying our ZFP technology platform to several commercial applications in which our products provide us and our strategic
partners and collaborators with potential technical, competitive and economic advantages. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Therapeutic Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and License Agreement with Shire International GmbH (formerly Shire AG) in Human Therapeutics and Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2012, we entered into a collaboration and license agreement with Shire, pursuant to which we are collaborating to research,
develop and commercialize human therapeutics and diagnostics based on our ZFP technology. Under the agreement, the two companies may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets are
blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets would be used for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for
treating HD. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the agreement, we have granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to
use our ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial research term of the agreement is six years and is subject to extensions upon mutual agreement and under other specified
circumstances. We are responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimburses us for our internal and external research
program-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we received an upfront license fee of $13.0 million. In addition, for each gene target, we
are eligible to receive $33.5 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as $180 million in payments upon the achievement of specified commercialization and sales milestones.
The total amount of potential milestone payments for each of the seven gene targets, assuming the achievement of all specified milestones in the Agreement, is $213.5 million. The milestone payments for each gene target through the acceptance of an
IND or CTA submission total $8.5 million. We will also receive royalty payments that are a tiered double-digit percentage of net sales of products developed under the collaboration. To date, we have not received any payments from Shire related to
milestone or royalty payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement may be terminated by (i)&nbsp;us or Shire, in whole or in part, for the uncured material
breach of the other party, (ii)&nbsp;us or Shire for the bankruptcy or other insolvency proceeding of the other party and (iii)&nbsp;Shire, in its entirety, beginning 24 months after the effective date of the agreement upon 90 days&#146; advance
written notice. In addition, Shire may terminate the agreement with respect to an individual gene target at any time, and under certain circumstances may designate a replacement gene target for a terminated gene target. As a result, actual future
milestone payments could be lower than the amounts stated above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and License Agreement with Biogen Idec Inc. in Human Therapeutics
and Diagnostics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2014, we entered into an exclusive worldwide collaboration and license agreement with Biogen focused on
the development of therapeutics for hemoglobinopathies, and targeting beta-thalassemia and SCD. Under the agreement, the two companies will jointly conduct two research programs: the beta-thalassemia program and the SCD program. In the
beta-thalassemia program, we are responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the
submission of an IND application for ZFP therapeutics intended to treat SCD. Biogen will reimburse us for our internal and external program-related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under both programs, Biogen is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed
products developed under the agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any of our remaining activities. Furthermore, we have an
option to co-promote in the United States any licensed product to treat beta-thalassemia and SCD developed under the agreement, and Biogen will compensate us for such co-promotion activities. Subject to the terms of the agreement, we have granted
Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products
developed under the agreement. We have also granted Biogen a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, of our interest in certain other intellectual property developed pursuant to the agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we will receive an upfront license fee of $20.0 million and are eligible to receive development milestone payments
upon the achievement of specified regulatory, clinical development and commercialization milestones. The total amount of potential regulatory, clinical development, commercialization and sales milestone payments, assuming the achievement of all
specified milestones in the agreement, is $293.8 million, including Phase 1 milestone payments of $7.5 million for each of the beta-thalassemia and SCD programs. In addition, we will also receive royalty payments for each licensed product that are a
tiered double-digit percentage of annual net sales of each product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement may be terminated by (i)&nbsp;us or Biogen for the uncured material breach of the
other party, (ii)&nbsp;us or Biogen for the bankruptcy or other insolvency proceeding of the other party; (iii)&nbsp;Biogen, upon 180 days&#146; advance written notice to us and (iv)&nbsp;Biogen, for certain safety reasons upon written notice to,
and after consultation with, us. As a result actual future milestone payments could be lower than the amounts stated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement
will become effective upon the satisfaction of certain customary conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Partnerships in Non Therapeutic Applications of the Technology
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line
Engineering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2007, we entered into a license agreement with Sigma. Under the license agreement, we agreed to provide Sigma
with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagents products and services in the research field, excluding certain agricultural research uses that we previously
licensed to DAS. Under the agreement, we and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using our ZFP technology during which time we assisted Sigma in connection with its efforts to market and sell
services employing our technology in the research field. We transferred the ZFP manufacturing technology to Sigma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, we
expanded the license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain
ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0&nbsp;million, consisting of a $4.9 million purchase of 636,133 shares of our common stock, valued at
$4.9&nbsp;million, and a $15.1 million upfront license fee. Under the terms of the agreement, we are eligible to receive commercial license fees of $5.0 million based on a percentage of net sales and sublicensing revenue and thereafter a reduced
royalty rate of 10.5% of net sales and sublicensing revenue. During the term of the license agreement, Sigma is obligated to pay us minimum annual payments, a share of certain revenues received by Sigma from sublicensees and royalty payments on the
sale of licensed products and services. Sigma also has the right to sublicense the ZFP technology for research applications and we will receive 50% of any sublicensing revenues in the first two years and 25% of any sublicensing revenues thereafter.
We retain the sole right to use and license our ZFP technology for GMP production purposes, for the production of materials used in or administered to humans, and for any other industrial commercial use. In addition, upon the achievement of certain
cumulative commercial milestones Sigma will make milestone payments to us up to an aggregate of $25.0 million. The agreements may be terminated by Sigma at any time with a 90-day notice or by either party upon an uncured material breach of the other
party. As a result, actual future milestone payments could be lower than the amounts stated above. In the event of any termination, all rights to use our ZFP technology will revert to us, and Sigma will no longer be permitted to practice our ZFP
technology or to develop or, except in limited circumstances, commercialize any products derived from our ZFP technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Programs and
Partners in Transgenic Animal and Commercial Protein Production Cell-line Engineering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our agreement with Sigma, we
marketed our ZFP TF and ZFN technology and intellectual property in products and areas outside ZFP Therapeutics directly to the pharmaceutical and biotechnology industry. We established agreements in cell line engineering for pharmaceutical protein
production with Genentech and in the development of transgenic animals with Open Monoclonal Technology, Inc. (OMT) and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche). </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has continuing obligations to pay us an annual technology access fee and, for each
product developed by Genentech containing a protein expressed by the modified cell line created using our ZFN technology, aggregate milestone payments of up to $5.4 million upon achievement of specified milestones relating to the development and
commercialization of such products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any given OMT product, OMT has the right to buy out its future royalty payment obligations under
the license agreement by paying a lump sum fee to us. Roche will pay milestone payments upon the achievement of certain clinical development milestones relating to products produced under such commercial license, and low-single-digit royalties on
sales of such products. The aggregate milestone payments for therapeutic products will not exceed $5.75 million, but the diagnostics milestone payments are not similarly capped. Under the research and license agreement, on a product-by-product
basis, Roche has the right to buy out its future royalty payment obligations by paying specified fixed amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Dow AgroSciences in
Plant Agriculture </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators have shown that ZFNs and ZFP TFs can be used to regulate and modify genes in plants.
The ability to regulate gene expression with engineered ZFP TFs may lead to the creation of new plants that increase crop yields, lower production costs and are more resistant to herbicides, pesticides, and plant pathogens, which could permit the
development of branded agricultural products with unique nutritional and processing characteristics. In addition, ZFNs may be used to facilitate the efficient and reproducible generation of transgenic plants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2005, we entered into an exclusive commercial license with DAS. Under this agreement, we provided DAS with access to our
proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. We have retained rights to use plants or plant-derived
products to deliver ZFNs and ZFP TFs into humans or animals for diagnostic, therapeutic, or prophylactic purposes. Our agreement with DAS provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to
obtain a commercial license to sell products incorporating or derived from plant cells generated using our ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to supply DAS and its sublicensees with ZFNs and ZFP TFs for both research and commercial use over the initial three year period of
the agreement and have amended and extended this provision. The agreement also provides for minimum sublicense fees each year due to us every October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million
and total $25.3 million over 11&nbsp;years. Furthermore, DAS has the right to sublicense our ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and we will be entitled to 25% of any cash consideration received by
DAS under such sublicenses. We do not have any performance obligations with respect to the sublicensing activities to be conducted by DAS. DAS has the right to terminate the agreement at any time; accordingly, our actual sublicense fees over the
term of the agreement could be lower than $25.3 million. In addition, each party may terminate the agreement upon an uncured material breach of the agreement by the other party. In the event of any termination of the agreement, all rights to use our
ZFP technology will revert to us, and DAS will no longer be permitted to practice our ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from our ZFP technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Funding from Research Foundations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>California
Institute for Regenerative Medicine </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, CIRM granted a $14.5 million Disease Team Research Award to develop an HIV
therapy based on the application of ZFN gene editing technology in HSCs. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern
California, City of Hope National Medical Center and Sangamo BioSciences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Through December&nbsp;31, 2013, we have received total funding of $5.2 million, which is the total amount awarded to us as prescribed in the agreement. The award is intended to substantially fund
our research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and conditions of the agreement, payments from us or our collaborators, resulting from sales of a commercial
product resulting from research and development efforts supported by the grant, not to exceed two times the amount we receive in funding under the agreement with CIRM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2013, CIRM granted us a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia
based on the application of our ZFN gene editing technology in HSCs. The four year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia
patients which will be carried out at Children&#146;s Hospital&nbsp;&amp; Research Center Oakland, and City of Hope in collaboration with our partner in this program, Biogen. The State of California has the right to receive, subject to the terms and
conditions of the agreement between us and CIRM, payment from us, or our collaborators, from sales of a commercial product resulting from research and development efforts supported by grants, in accordance with Title 17, California Code of
Regulations, Section 100600. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ACQUISITION OF CEREGENE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, we acquired Ceregene, a privately held biotechnology company focused on the development of AAV gene therapies,
pursuant to an Agreement and Plan of Merger (the Merger Agreement). The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110, an AAV-NGF for the treatment of AD that is currently in a Phase 2 clinical trial. In
addition to the clinical assets acquired, we acquired certain intellectual property rights relating to the manufacturing of AAV, and certain toxicology data and safety and efficacy data from Ceregene&#146;s human clinical trials, which will be used
in the preparation and filing of IND applications for our <I>in vivo</I> ZFP Therapeutics, particularly those that target the brain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, the aggregate consideration paid by us at closing consisted of 100,000 shares of our common stock, with an
approximate fair value of $1.2 million. In addition, we may be required to make contingent earn-out payments to the stockholders of Ceregene as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we grant a third-party license to develop and commercialize Ceregene&#146;s CERE-110 for the treatment of AD or CERE-120 for the treatment of Parkinson&#146;s diseases or HD (the Earn-Out Products), we are required
to pay a double-digit percentage of any upfront and milestone payments we receive for such license, subject to certain reductions based on expenses incurred by us in the development of the Earn-Out Products; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we commercialize any Earn-Out Product ourselves, we are required to pay, for each Earn-Out Product, royalty-like payments as a percentage of net sales that range in the low double-digits depending upon the amount of
net sales, subject to certain reductions by us. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTELLECTUAL PROPERTY AND TECHNOLOGY LICENSES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents and licenses are important to our business. Our strategy is to file or license patent applications to protect technology, inventions
and improvements to inventions that we consider important for the development of our technology. We seek patent protection and licenses that relate to our technology and candidates in our pipeline and/or may be important to our future. We have filed
numerous patents and patent applications with the United States Patent and Trademark Office (USPTO) and foreign jurisdictions. This proprietary intellectual property includes methods relating to the design of zinc finger and TALE (Transcription
activator-like effector) proteins, therapeutic applications of genome editing technology, enabling technologies related to our platform and the use of genome editing across a variety of applications. We rely on a combination of patent, copyright,
trademark, proprietary know&#150;how, continuing technological innovations, trade secret laws, as well as confidentiality agreements, materials transfer agreements, research agreements and licensing agreements, to establish and protect our
proprietary rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Technology Licenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have licensed intellectual property directed to the design, selection, and use of ZFPs, ZFNs and ZFP TFs for gene modification and
regulation from the Massachusetts Institute of Technology, Johnson&nbsp;&amp; Johnson, The Scripps Research Institute, The Johns Hopkins University, Harvard University, the Medical Research Council, the California Institute of Technology, City of
Hope and the University of Utah. These licenses grant us rights to make, use and sell ZFPs, ZFNs and ZFP TFs under 13 families of patent filings. As of February&nbsp;7, 2014, these patent filings have resulted in 19 issued U.S. patents and 46
granted foreign patents, with 6 currently pending U.S. patent applications and 26 pending applications in foreign patent offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
believe that these in-licensed patents and patent applications include several of the early and important patent filings directed at the design, selection, composition and use of ZFPs, ZFNs and ZFP TFs, particularly the agreements with Johns Hopkins
University, the Massachusetts Institute of Technology, Johnson&nbsp;&amp; Johnson and The Scripps Research Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have licensed
intellectual property directed to the composition of two AAV vectors (AAV5 and AAV6) from the National Institute of Health and the University of Washington, respectively.&nbsp;The AAV5 license from the National Institute of Health is a nonexclusive
license that will expire in 2021.&nbsp;The AAV6 license from the University of Washington is also a non-exclusive license and will expire in 2017.&nbsp;Additionally, Sangamo has licensed intellectual property from the National Institutes of Health
(NIH) relating to methods of production of production of AAV.&nbsp;This license will expire in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Johns Hopkins University </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a license agreement with the Johns Hopkins University, or JHU, on June&nbsp;29, 1995, as subsequently amended, whereby JHU
granted us a worldwide exclusive license to technology and patents relating to nuclease and gene targeting technology for all fields of use, including the right to sublicense. Under the license agreement, we are obligated to pay low single-digit
royalties on licensed product sales, a low single-digit percentage of license fees received from sublicensees and a high single-digit or low teens percentage of sublicense royalties received from sublicensees for sales of products. We are subject to
an annual minimum royalty, which we currently pay. The license agreement expires upon the expiration of the last patent covered by the license agreement. Although many of the JHU in-licensed patents have now expired, based on currently issued
patents, the license agreement will terminate on or about August&nbsp;14, 2014. JHU may terminate the license agreement upon a material default by us that remains uncured following written notice. We may terminate the license agreement at any time
upon six months&#146; written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Massachusetts Institute of Technology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a patent license agreement with the Massachusetts Institute of Technology, or MIT, on May&nbsp;9, 1996, as subsequently
amended, whereby MIT granted us a worldwide exclusive license to technology and patents relating to the design, selection and use of ZFPs for all fields of use, including the right to sublicense. Under the patent license agreement, we are obligated
to pay an annual license fee, low single-digit royalties of product sales, an up-front sublicense and annual sublicense fees, a percentage of its sublicense revenues, and milestone payments upon achievement of certain commercial development
milestones. The aggregate milestone payments under the patent license agreement are $450,000, of which $150,000 has been paid. The patent license agreement expires upon the expiration of the last patent covered by the patent license agreement. Based
on currently issued patents and currently filed patent applications, the patent license agreement will terminate on or about September&nbsp;23, 2025. MIT may terminate the license agreement upon a material default by us that remains uncured
following written notice. We may terminate the license agreement at any time upon six months&#146; written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Johnson&nbsp;&amp; Johnson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a sublicense agreement with Johnson&nbsp;&amp; Johnson on May&nbsp;9, 1996, whereby Johnson&nbsp;&amp; Johnson granted us a
worldwide exclusive sublicense to technology and patents for the research, development and commercialization of human and animal therapeutic and diagnostic products using engineered ZFPs, including the right to sublicense. These patents were
originally exclusively licensed by Johnson&nbsp;&amp; Johnson from The Scripps Research Institute. Under the sublicense agreement, we will pay low single-digit royalty payments based upon sales of license products by us or our sublicensees and a
milestone payment upon the achievement of a commercial development milestone. The sublicense agreement expires upon the expiration of the last patent covered by the sublicense agreement. Based on currently issued patents and currently filed patent
applications, the sublicense agreement will terminate on or about June&nbsp;5, 2018. Johnson&nbsp;&amp; Johnson has the right to terminate the sublicense agreement upon a breach or default by us that remains uncured following written notice of such
default. We may terminate the sublicense agreement at any time upon sixty days&#146; written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Scripps Research Institute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a license agreement with The Scripps Research Institute on March&nbsp;14, 2000, as subsequently amended, whereby The Scripps
Research Institute granted us a worldwide exclusive license to technology and patents for the research, development and commercialization of products and services using engineered ZFPs, excluding the use of these engineered ZFPs in plant
agriculture, therapeutics and diagnostics. Under the license agreement, we are required to pay a low-single digit royalty on sales of licensed products by us and our sublicensees, subject to an annual minimum. The license agreement expires upon the
expiration of the last patent covered by the license agreement. Based on currently issued patents and currently filed patent applications, the license agreement will terminate on or about June&nbsp;5, 2018. Each party may terminate the license
agreement upon a material default by the other party that remains uncured following written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sangamo Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our in-licensed patent portfolio, as of February&nbsp;7, 2014, we had 133 families of Sangamo-owned or co-owned patent filings,
including 107 issued U.S. patents, 290 granted foreign patents, 122 pending U.S. patent applications and 382 pending foreign patent applications. These patent filings are directed to the design, composition and use of ZFPs, ZFNs, ZFP TFs and TALE
proteins. Sangamo&#146;s acquisition of Ceregene&#146;s patent estate has also brought patent filings relating to AAV, needle technology and specific methods of treating diseases of the CNS and ocular diseases. In this acquisition, Sangamo acquired
7 patent families, comprising 8 issued U.S. patents, 23 issued foreign patents, 3 pending U.S. Patent applications and 13 pending foreign patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The earliest patents in our portfolio are set to begin expiring in 2015, with the majority of our currently issued patents expiring between
2019 and 2021. However, these patents in our estate may be subject to Patent Term Adjustment (due to delays in patent prosecution by the USPTO), Patent Term Extension (due to review of a patented product by a regulatory agency) or terminal
disclaimer. Additionally, patents that may be issued from our pending applications will extend the patent exclusivity of our patent estate. Accordingly, all dates given above for patent expirations are estimates and the actual dates of expirations
may differ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our licensed patents and patent applications, as well as the issued Sangamo patents and pending Sangamo
patent applications, in the aggregate, will provide us with a substantial intellectual property position in our commercial development of ZFP technology. In this regard, patents issued to us, applied for by us, or exclusively and non-exclusively
licensed to us, cover the following types of inventions, processes and products: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>ZFP and ZFN design, engineering and compositions:</I> includes DNA target site selection and zinc finger binding domain design (see newly issued US8617807, US8383766 and 8524874) and nuclease domain design, target
site arrays, ZFP libraries databases and methods of construction, as well as methods to increase zinc finger binding specificity, linker designs and methods of making modified plant zinc finger proteins; <I> </I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>ZFP targeted regulation of endogenous genes:</I> methods relating to activation and inhibition of endogenous cellular genes, identification of accessible regions within chromatin, and regulation of endogenous plant
genes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>ZFP Therapeutics:</I> Treatment of Huntington&#146;s Disease (see US Patent Publication US 20130253040), cancer therapeutics, treatment of head and neck cancer, glioblastoma, pain (see newly issued 8466267),
modulation of cardiac contractility and methods to regulate the glucocorticoid receptor, treatments for HIV (see US8268618 and US patent publication US20120294838); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>ZFN Therapeutics:</I> Treatments for HIV (see newly issued US8524221 and US8569253), SCD and beta-thalassemia , In Vivo Protein Replacement Platform for treatment of hemophilia and lysosomal storage diseases (see
patent publication US 20130177983 and 20140017212), genome editing (see newly issued US8524500, US8349810 and US8409861), models for Parkinson&#146;s Disease (see US patent publication US20120192301), regulation of the expression of PD1 to block
PD1-dependent immune suppression in both chronic infectious diseases and malignancies (see newly issued US8563314); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Non-Therapeutic Applications of ZFPs:</I> Methods for linking genes and phenotypes, identification of genes, analysis of gene regulation, structure and biological function, methods of agricultural biotechnology (see
newly issued US8399218 and US8592645), methods of altering cellular differentiation state, and methods of introducing exogenous nucleic acids of interest into a safe harbor locus; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Non-Therapeutic Applications of ZFNs:</I> Methods for identification of regulatory DNA sequences, prediction of patient response to drug therapeutics, and development of cell lines for improved protein production ,
(see newly issued US8597912); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>TALE protein methods of design and use</I> (see newly issued US8586526 and US8623618); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Methods of use with stem cells</I> (see published US patent application US20120252122). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We have been advised that certain aspects of our technology can give us and our collaborators independence from third party patent
claims to gene sequences. In general, under United States patent law, a patent may be obtained for any new and useful process, machine, manufacture, or composition of matter. An underlying theme of United States patent law, as related to
biotechnology, is that the sequence of a gene, as it exists in the chromosome, is not new, even when newly discovered, unless it is isolated or modified from its normal chromosomal context. As a result, patent courts have held that a DNA sequence
must be purified, isolated or modified to be patentable. Accordingly, U.S. patent claims to DNA sequences can cover only isolated, purified or modified nucleic acid sequences (e.g., a purified DNA fragment or a DNA sequence inserted into a vector).
We have been advised that U.S. patent claims to DNA sequences do not, and cannot, cover gene sequences as they exist in their natural chromosomal environment, and international patent law is even more stringent than U.S. patent law in this regard.
Most current methods for over-expression of a gene or protein involve the introduction into a cell of a vector containing a DNA encoding the protein to be over-expressed. Since such a vector contains isolated sequences which encode the protein, it
would be covered by any patent claims to those sequences. In contrast, our methods for over-expression utilize ZFP TFs that target endogenous genes as they exist in the<I> </I>chromosome. As a result, our gene regulation methods do not require the
use of isolated DNA sequences encoding the protein to be over-expressed and, our counsel has advised us, do not infringe patent claims to such sequences. Notwithstanding this advice, we realize that others could take a contrary position that could
result in litigation. While we believe that we would prevail in any such litigation, the uncertainties involved in litigation generally make it impossible to provide assurance as to the ultimate outcome of such matters. See <I>&#147;Risk
Factors&#151;Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar to ours, we cannot ensure the proprietary protection of our technologies and products.&#148;
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical and biotechnology firms, including our patent position,
are uncertain and involve complex legal and factual questions for which important legal tenets are largely unresolved. Patent applications may not result in the issuance of patents and the coverage claimed in a patent application may be
significantly reduced before a patent is issued. Although we have filed for patents on some aspects of our technology, we cannot provide assurances that patents will be issued as a result of these pending applications or that any patent that has
been or may be issued will be upheld. The laws of some foreign countries may not protect our proprietary rights to the same extent as do the laws of the United States. Our issued US patent US8153399 is currently the subject of a re-examination
procedure. We do not know what the outcome of this procedure will be. The claims of this patent may be amended such that claim scope is reduced or the patent may be revoked as a result of this procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, third parties may assert patent, copyright trademark, and other intellectual property rights to technologies that are important
to our business. Any claims asserting that our products infringe or may infringe proprietary rights of third parties, if determined adversely to us, could significantly harm our business. See <I>&#147;Risk Factors&#151;Because it is difficult and
costly to protect our proprietary rights, and third parties have filed patent applications that are similar to ours, we cannot ensure the proprietary protection of our technologies and products.&#148;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estimated Licensing and Other Contingent Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are successful in the development and commercialization of our products, we will be obligated by our license agreements to make
sublicensing, milestone and royalty payments to some or all of the licensors mentioned above, including payments due pursuant to the acquisition of Ceregene. We plan to continue to license and generate intellectual property internally covering the
design, selection, composition and use of ZFPs; the genes encoding these proteins; the application of ZFPs, ZFNs, and ZFP TFs in ZFP Therapeutics; and non-therapeutic applications of the technology including applications in research and plant
agriculture, and intellectual property relating to TALE design and use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPETITION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and our licensed partners, are the leaders in the research, development, and commercialization of DNA binding proteins for gene
modification and regulation of gene expression. We are aware of several companies focused on other methods for and modifying genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of ZFP
gene regulation and gene modification technology. The field of applied gene regulation and gene modification is highly competitive and we expect competition to persist and intensify in the future from a number of different sources, including
pharmaceutical, agricultural, and biotechnology companies; academic and research institutions; and government agencies that will seek to develop ZFPs as well as technologies that will compete with our ZFP technology platform, such as TALE proteins
and the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our competitors may succeed in
obtaining patent protection, receiving FDA approval, or commercializing ZFP Therapeutics or other competitive products before us. If we commence commercial product sales, we may be competing against companies with greater marketing and manufacturing
capabilities, areas in which we have limited or no experience. In addition, any product candidate that we successfully develop may compete with existing products that have long histories of safe and effective use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are in the clinical development phase of operations and have no current therapeutic product sales, we believe the following
companies, products and/or technologies may potentially be competitive with our technology or our products under development: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Small molecules in development from both in-house drug discovery programs of pharmaceutical companies such as Pfizer, Inc., GlaxoSmithKline (GSK),
Novartis, Merck&nbsp;&amp; Co., Inc., as well as from </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
biotechnology companies with expertise and capabilities in small molecule discovery and development such as Gilead and Genzyme. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Monoclonal antibody companies and product candidates from certain biotechnology firms such as Genentech, Inc. and Amgen. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as Pfizer, Baxter, Bayer, Novo Nordisk, Genzyme, Shire, BioMarin, Biogen and numerous other pharmaceutical and biotechnology
firms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gene therapy companies developing gene-based products in clinical trials. uniQure&#146;s product for lipoprotein lipase deficiency (LPLD) was recently approved in Europe but no other products have yet been approved. Our
competitors in this category may include but not be limited to uniQure, bluebird bio, RegenX, Asklepios, Spark and Lentigen Corporation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cell therapy companies developing cell-based products. Our competitors in this category may include Dendreon and Adaptimmune. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nuclease technologies, under development for therapeutic applications of genome modification including companies such as Editas developing the CRISPR/Cas9 system, Cellectis SA developing TALE nucleases and Cellectis SA
and Precision BioSciences, Inc. that are developing meganucleases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Antisense therapeutics and RNA interference technology, including RNAi and microRNA, which are technologies that may compete with ZFP Therapeutics in the development of novel therapeutic products acting through the
regulation of gene expression. These technologies are being developed by several companies including Alnylam Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Genzyme (a Sanofi Company) and Regulus Therapeutics, LLC. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for
establishing relationships with academic and research institutions; and for licenses to proprietary technology. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more
effective or less costly than ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to compete successfully will depend, in part, on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop safe, efficacious and commercially attractive proprietary products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain access to gene transfer technology on commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain required regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain qualified scientific and product development personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into collaborative and strategic partnerships with others, including our competitors, to develop our technology and product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and enforce patents, licenses or other proprietary protection for our products and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">formulate, manufacture, market and sell any product that we develop; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and maintain products that reach the market first and are technologically superior to or are of lower cost than other products in the market. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GOVERNMENT REGULATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research,
testing manufacturing and marketing of human therapeutics are extensively regulated in the United States and the rest of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before marketing in the United States, any therapeutic or pharmaceutical products we develop must undergo rigorous preclinical testing
(generally conducted in animals) and clinical trials in humans and an extensive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory clearance process implemented by the U.S.&nbsp;Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act. The FDA regulates, among other things, the development,
testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale and distribution of biopharmaceutical products. The regulatory review and approval process, which includes preclinical testing and
clinical trials of each product candidate, is lengthy, expensive and uncertain. Securing FDA approval requires the submission of extensive preclinical and clinical data and supporting information including manufacturing information and stability
data to the FDA for each indication to establish a product candidate&#146;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing
requirements for post-marketing studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before commencing clinical investigations in humans in the United States, we must carry out
preclinical testing. In addition, our proposed clinical studies require review from the Recombinant DNA Advisory Committee (RAC), which is the advisory board to the NIH, focusing on clinical trials involving gene transfer. We typically submit a
proposed clinical protocol and other product-related information to the RAC three to six months prior to the expected IND application filing date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical tests include laboratory and animal studies to evaluate product characteristics, potential safety and efficacy. The results of
these studies must be submitted to the FDA as part of an IND Application, which must be reviewed by the FDA before proposed clinical testing in humans can begin. The FDA has 30&nbsp;days to comment on the application and if the agency has no
comments, we or our clinical partner may begin clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are lengthy and are typically conducted in three
sequential phases, but the phases may overlap or be combined. At each stage of testing, the proposed clinical protocol must be reviewed by the FDA and reviewed and approved by an independent ethics committee or institutional review board of each
participating center before it can begin. Phase&nbsp;1 usually involves the initial introduction of the investigational drug into small numbers of healthy volunteers or patients to evaluate certain factors, including its safety and dose tolerance.
Phase&nbsp;2 usually involves trials in a limited patient population to evaluate dosage tolerance and appropriate dosage, identify possible adverse effects and safety risks, and evaluate preliminary efficacy of the drug for specific indications.
Phase&nbsp;3 trials usually further evaluate clinical efficacy and test further for safety by using the drug in its final form in an expanded patient population. Phase 2 and 3 trials must be registered in a government database of clinical trials.
Later clinical trials may fail to support the findings of earlier trials, which can delay, limit or prevent regulatory approvals. We filed a Phase&nbsp;1 clinical protocol for review by the RAC in the fourth quarter of 2004, an IND application in
January 2005, and Phase&nbsp;2 protocols for review by the FDA in 2006, 2007 and 2009 for our first product candidate, SB-509, for the potential treatment of diabetic neuropathy. In addition, in 2008 we filed an IND application for SB-509 for the
treatment of ALS. We have also filed a Phase&nbsp;1 clinical protocol for review by the RAC for our HIV (SB-728-T) program. In&nbsp;October 2010 and January 2012 we initiated Phase 1/2 clinical trials and a Phase 2 trial of this ZFP Therapeutic in
subjects infected with HIV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the acquisition of Ceregene, we acquired and assumed sponsorship of two INDs on file at FDA for
the use of AAV to deliver nerve growth factors. CERE-110 is an investigational agent using AAV delivery of human NGF to the brain for the treatment of Alzheimer&#146;s disease and is currently being evaluated in a fully enrolled Phase 2 clinical
trial. CERE-120 uses AAV delivery of human neurturin to the brain for treatment of Parkinson&#146;s disease. Subjects are undergoing long-term follow-up observation after being treated in completed Phase 1 and 2 studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of the preclinical and clinical testing of a pharmaceutical product are submitted to the FDA in the form of a New Drug Application
(NDA), or a Biologic License Application (BLA), for approval to commence commercial sales. In responding to an NDA or a BLA, the FDA may grant marketing approval, grant conditional approval (such as an accelerated approval), request additional
information or deny the application if the FDA determines that the application does not provide an adequate basis for approval. Most research and development projects fail to produce data sufficiently compelling to enable progression through all of
the stages </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of development and to obtain FDA approval for commercial sale. See also &#147;<I>Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and we may encounter
unanticipated toxicity or adverse events or fail to demonstrate efficacy, causing us to delay, suspend or terminate the development of a ZFP Therapeutic. If these potential products are not approved, we will not be able to commercialize those
products</I>.&#148; under &#147;Risk Factors&#148; below in Part I, Item&nbsp;1A of this Form 10-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, our
ability to market a product is contingent upon receiving marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing, and reimbursement vary widely
from country to country. At present, foreign marketing authorizations are applied for at a national level; although, within the European Union (EU), a centralized registration procedure is available to companies wishing to market an &#147;Advanced
Therapies&#148; product in more than one EU member state. If the regulatory authority is presented with adequate evidence of safety, quality, and efficacy, they will grant a marketing authorization. This foreign regulatory approval process involves
all of the risks associated with FDA clearance discussed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We have hired personnel with expertise in preclinical and clinical
development of therapeutic programs, clinical manufacturing and regulatory affairs to assist us in developing our programs and obtaining appropriate regulatory approvals as required. We also intend to work with collaborators who have experience in
clinical development to assist us in obtaining regulatory approvals for collaborative products. <I>See Risk Factors&#151;&#147;Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and if these potential
products are not approved, we will not be able to commercialize those products and&#151;Regulatory approval, if granted, may be limited to specific uses or geographic areas which could limit our ability to generate revenues.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYEES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2014,
we had 85&nbsp;full-time employees, all of whom are located at our headquarters in Richmond, California. None of our employees are represented by a collective bargaining organization or covered by a collective bargaining agreement, nor have we
experienced work stoppages. We believe that our relations with our employees are good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AVAILABLE INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in June 1995 in the state of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo can be found on the internet at http://www.sangamo.com. We make available free of charge, on or through our internet site, our annual,
quarterly, and current reports and any amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
Information contained in our internet site is not part of, nor incorporated by reference into, this report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_3"></A>ITEM&nbsp;1A &#150; RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Form 10-K contains forward-looking information based on our current expectations. Because our actual results may differ materially from
any forward-looking statements made by or on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and loss per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Development, Commercialization and Regulatory Approval of our Products and Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>ZFP Therapeutics have undergone limited testing in humans and our ZFP Therapeutics may fail safety studies in clinical trials.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting an on-going Phase 2 clinical trial and an on-going Phase 1/2 clinical trial of our ZFP Therapeutics for the
treatment of HIV/AIDS. Preliminary data from these studies demonstrated that, to date, treatment of aviremic HIV-infected subjects with SB-728-T has been well-tolerated. In addition, we have previously completed enrollment and the treatment phase of
a Phase 1 and several Phase 2 clinical trials of our ZFP Therapeutic, SB-509, for diabetic neuropathy and ALS and the drug was well tolerated in these studies. However, if one of our ZFP Therapeutic fails one of its safety studies, it could reduce
our ability to attract new investors and corporate partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of these studies are designed primarily to evaluate the safety and
tolerability of this ZFP Therapeutic approach. Our clinical studies are a highly visible test of our ZFP Therapeutics, and our investors assess the value of our technology primarily based on the continued progress of ZFP Therapeutic products into
and through clinical trials. If clinical trials of our ZFP Therapeutic products were halted due to safety concerns, this would negatively affect our operations and the value of our stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our progress in early Phase 1 and Phase 2 trials may not be indicative of long-term efficacy in late stage clinical trials. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results in early phases of clinical testing are based upon limited numbers of patients and a limited follow-up period. Typically, our
Phase 1 clinical trials for indications of safety enroll less than 25 patients. Our Phase 2 and late-stage clinical trials generally enroll a larger number of patients. Accordingly, any positive data obtained in early Phase 1 and Phase 2 trials may
not be indicative of long-term efficacy in late-stage clinical trials. In September 2011, we announced preliminary data from our Phase 1 clinical program to develop SB-728-T for the treatment of HIV/AIDS. The data demonstrated a statistically
significant relationship between SB-728-T and the reduction of HIV viral load. In January 2012, we initiated a Phase 2 clinical study (SB-728-902, Cohort 5) and a Phase 1/2 clinical study (SB-728-1101) for the treatment of HIV/AIDS. In December
2013, we presented data from all cohorts of these two clinical trials. Three of seven evaluable subjects in Cohort 5 showed a decrease of greater than one log in their viral load during a sixteen week treatment interruption (TI) with one subject
achieving a transiently undetectable viral load during the TI period and one subject achieving a viral load during TI at or below the limit of detection for a prolonged period (20 weeks as of December 2013) In subjects in which viral load decreased,
a measurable anti-HIV immune response was also observed. Additional data were presented from the Company&#146;s Phase 1 study (SB-728-902, Cohorts 1-3) that demonstrated a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV
reservoir using a sensitive test for integrated HIV DNA in nine of nine subjects over a 36 month period (median decrease 0.9 logs). Additional subjects have been enrolled into the SB-728-1101 study to define the optimum dose of Cytoxan required to
safely enhance engraftment and an additional 12 subjects will be enrolled to further test this dose. However, there is no guarantee that these and other future studies of SB-728-T in later stage trials involving larger patient groups may produce
positive or similar results as those obtained in earlier trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the initial results from the Phase 1 clinical trial of our
ZFP Therapeutic product, SB-509, became available in the first half of 2006 and the complete data set was presented in June 2008. The primary end point of the trial was clinical and laboratory safety; however, we collected some preliminary efficacy
data that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
showed trends of clinical improvement in some subjects. Notwithstanding this preliminary efficacy data, the top-line data from our Phase 2b clinical study for SB-509-901 did not meet the key
primary or secondary endpoints for the study and as a result we discontinued development of our SB-509 program in October 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number
of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials even after achieving promising results in earlier stage clinical trials. If a larger population of patients does not
experience positive results, or if these results are not reproducible, our products may not receive approval from the FDA. Failure to confirm favorable results from earlier trials by demonstrating the safety and effectiveness of our ZFP Therapeutic
products in late stage clinical trials with larger patient populations could have a material adverse effect on our business that would cause our stock price to decline significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and we may encounter unanticipated
toxicity or adverse events or fail to demonstrate efficacy, causing us to delay, suspend or terminate the development of a ZFP Therapeutic. If these potential products are not approved, we will not be able to commercialize those products.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA must approve any human therapeutic product before it can be marketed in the United States. The process for receiving
regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before commencing clinical trials in humans, we must submit an IND application to the FDA. The FDA has 30 days to comment on the application
and if the agency has no comments, we or our commercial partner may begin clinical trials. While we have stated our intention to file additional IND applications during the next several years, this is only a statement of intent, and we may not be
able to do so because the associated product candidates may not meet the necessary preclinical requirements. In addition, there can be no assurance that, once filed, an IND application will result in the actual initiation of clinical trials.
Clinical trials are subject to oversight by institutional review boards and the FDA. In addition, our proposed clinical studies require review from the Recombinant DNA Advisory Committee (RAC), which is the advisory board to the National Institutes
of Health (NIH), focusing on clinical trials involving gene transfer. We will typically submit a proposed clinical protocol and other product-related information to the RAC three to six months prior to the expected IND application filing date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must be conducted in conformance with the FDA&#146;s good clinical practices, within the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) and other applicable regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must meet requirements for Institutional Review Board (IRB) oversight; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must follow Institutional Biosafety Committee (IBC) and NIH RAC guidelines where applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must meet requirements for informed consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are subject to continuing FDA oversight; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may require oversight by a Data Safety Monitoring Board (DSMB); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may require large numbers of test subjects; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may be suspended by a commercial partner, the FDA, or us at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in
the IND application or the conduct of these trials. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in conducting clinical trials. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have ongoing Phase&nbsp;1/2 and 2 trials of a ZFP Therapeutic for HIV/AIDS and an ongoing Phase&nbsp;2 trial to evaluate the safety and
efficacy of AAV-NGF for Alzheimers disease. However, the FDA will require additional clinical testing which involves significantly greater resources, commitments and expertise and so it is likely that we would need to enter into a collaborative
relationship with a pharmaceutical company that could assume responsibility for late-stage development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
limited experience in conducting advanced clinical trials and may not possess the necessary resources and expertise to complete such trials. We have entered into collaborative agreements with Shire and Biogen to provide funding and assistance in the
development of our ZFP Therapeutics through the clinical trial process. Under the agreement with Shire, we are responsible for all activities through submission of IND Applications and European CTAs and Shire is responsible for clinical development
and commercialization of products arising from the alliance. Under the Agreement with Biogen, we are responsible for all research and development through the first human clinical trial for the treatment of beta-thalassemia and both parties are
responsible for research and development through the submission of IND for ZFP Therapeutics to treat sickle cell disease (SCD). However, there is no guarantee that we will be able to enter into future collaborative relationships with third parties
that can provide us with the funding and expertise for later stage trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>While we have stated that we intend to file IND
applications for several ZFP Therapeutic programs over the next two years, we may encounter difficulties that may delay, suspend or scale back our efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have previously announced a strategy for our ZFP Therapeutic programs that enables the potential filing of eight IND applications by the
end of 2015. The preparation and submission of IND applications requires us to conduct rigorous and time-consuming preclinical testing, studies, and documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and
clinical protocol of new ZFP Therapeutic products. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our ZFP
Therapeutic products and fail to demonstrate consistency in the formulation of the drug. Our pre-clinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional
preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. Furthermore, the filing of several IND applications involves significant cost and labor, and we may not have
sufficient resources and personnel to complete the filing of all intended IND applications, which may force us to scale back the number of IND applications or forego potential IND applications that we believe are promising. Any delay, suspension or
reduction of our efforts to pursue our pre-clinical and IND strategy could have a material adverse effect on our business and cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to find acceptable patients or may experience delays in enrolling patients for our clinical trials. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience difficulties or delays in recruiting and enrolling a sufficient number of patients to participate in our clinical trials due
to a variety of reasons, including competition from other clinical trial programs for the same indication, failure of patients to meet our enrollment criteria and premature withdraws of patients prior to the completion of clinical trials. The FDA
and institutional review boards may also require large numbers of patients, and the FDA may require that we repeat a clinical trial. Any delay resulting from our failure to enroll a sufficient number of patients on a timely basis may have a material
adverse affect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>As we cannot predict whether or when we will obtain regulatory approval to commercialize our
product candidates, we cannot predict the timing of any future revenue from these product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize any
of our ZFP Therapeutics to generate revenue until the appropriate regulatory authorities have reviewed and approved the applications for the product candidates. We cannot ensure that the regulatory agencies will complete their review processes in a
timely manner or that we will obtain regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval for any product candidate that we or our collaborators develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of
the product and requires the expenditure of substantial resources. Regulatory approval processes outside the United States include all of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based
upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory approval, if granted, will be limited to specific uses or geographic areas, which could limit our ability to generate
revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory approval will be limited to the indicated use for which we can market a product. Further, once regulatory
approval for a product is obtained, the product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer, and manufacturing
facility, including withdrawal of the product from the market. In Japan and Europe, regulatory agencies also set or approve prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even
if regulatory clearance of a product is granted, this clearance is limited to those specific states and conditions for which the product is useful, as demonstrated through clinical trials. We cannot ensure that any ZFP Therapeutic product developed
by us, alone or with others, will prove to be safe and effective in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing clearance in a given country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, our ability to market a product is contingent upon receiving a marketing authorization from appropriate regulatory
authorities; therefore we cannot predict whether or when we would be permitted to commercialize our product. These foreign regulatory approval processes include all of the risks associated with FDA clearance described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Commercialization of our technologies will depend, in part, on strategic partnering with other companies. If we are not able to find
partners in the future or our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or products, which could slow our growth and decrease the value of our stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to rely, to some extent, on our strategic partners to provide funding in support of our research and to perform independent research
and preclinical and clinical testing. Our technology is broad based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from our technologies or the resources or capabilities
to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic partnerships to help us develop and commercialize ZFP Therapeutic products. If we are unable to find partners or if
the partners we find, such as Shire and Biogen, are unable or unwilling to advance our programs, or if they do not diligently pursue product approval, this may slow our progress and defer our revenues. Our partners may sublicense or abandon
development programs or we may have disagreements with our partners, which would cause associated product development to slow or cease. There can be no assurance that we will be able to establish further strategic collaborations for ZFP Therapeutic
product development. We may require significant time to secure collaborations or partners because we need to effectively market the benefits of our technology to these future collaborators and partners, which may direct the attention and resources
of our research and development personnel and management away from our primary business operations. Further, each collaboration or partnering arrangement will involve the negotiation of terms that may be unique to each collaborator or partner. These
business development efforts may not result in a collaboration or partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of partnering agreements would not only delay or
terminate the potential development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test ZFP Therapeutic candidates for specific genes. If any partner fails to conduct the
collaborative activities successfully and in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under typical partnering agreements we would expect to receive revenue for the research and
development of a ZFP Therapeutic product based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner
as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. For more information on risks relating to our third party collaborative agreements, see &#147;Risks
Relating to our Collaborative Relationships.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to license gene transfer technologies that we may need to
commercialize our ZFP technology. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the
cell. We have licensed certain gene transfer technologies for our ZFP in research. We are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for <I>in vitro</I> and <I>in vivo</I> applications,
including ZFP Therapeutics. However, we may not be able to license the gene transfer technologies required to develop and commercialize our ZFP Therapeutics. We have not developed our own gene transfer technologies, and we rely on our ability to
enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. The inability to obtain a license to use gene transfer technologies with entities
which own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our gene regulation and gene modification technology is relatively new, and if we are unable to use this technology in all our intended
applications, it would limit our revenue opportunities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology involves a relatively new approach to gene regulation and
gene modification. Although we have generated ZFPs for thousands of gene sequences, we have not created ZFPs for all gene sequences and may not be able do so, which could limit the usefulness of our technology. In addition, while we have
demonstrated the function of engineered ZFNs and ZFP TFs in mammalian cells, yeast, insects, plants and animals, we have not yet demonstrated clinical benefit of this technology in humans, and the failure to do so could restrict our ability to
develop commercially viable products. If we, and our collaborators or strategic partners, are unable to extend our results to new commercially important genes, experimental animal models, and human clinical studies, we may be unable to use our
technology in all its intended applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected value and utility of our ZFNs and ZFP TFs is in part based on our belief that
the targeted modification of genes or specific regulation of gene expression may enable us to develop a new therapeutic approach as well as to help scientists better understand the role of genes in disease, and to aid their efforts in drug discovery
and development. We also believe that ZFP-mediated targeted gene editing and gene regulation will have utility in agricultural applications. There is only a limited understanding of the role of specific genes in all these fields. Life sciences
companies have developed or commercialized only a few products in any of these fields based on results from genomic research or the ability to regulate gene expression. We, our collaborators or our strategic partners, may not be able to use our
technology to identify and validate drug targets or to develop commercial products in the intended markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective delivery of ZFNs
and ZFP TFs into the appropriate target cells and tissues is critical to the success of the therapeutic applications of our ZFP technology. In order to have a meaningful therapeutic effect, the ZFP Therapeutic must be delivered to sufficient numbers
of cells in the targeted tissue. The ZFN or ZFP TF must be present in that tissue for sufficient time to effect either modification of a therapeutically relevant gene or regulation of its expression. In our current clinical and preclinical programs,
we administer our ZFP Therapeutics as a nucleic acid that encodes the ZFN or ZFP TF. We use different formulations to deliver the ZFP Therapeutic depending on the required duration of expression, the targeted tissue and the indication that we intend
to treat. However, there can be no assurances that we will be able to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are conducting proprietary research to discover ZFP Therapeutic product candidates.
These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary research programs consist of research which is funded solely by us or by grant funding and in which we retain exclusive rights
to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners and in which we may share rights to any resulting products. Conducting proprietary research programs
may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or
strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners which could reduce our revenue and delay or terminate our
product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our
management and staff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our technology proves to be effective, it still may not lead to commercially viable products.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our collaborators or strategic partners are successful in using our ZFP technology in drug discovery, protein production,
therapeutic development, or plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with our technology. To date, no company has received marketing approval or has developed or
commercialized any therapeutic or agricultural products based on our technology. Should our technology fail to provide safe, effective, useful, or commercially viable approaches to the discovery and development of these products, this would
significantly limit our business and future growth and would adversely affect our value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product development efforts
are successful and even if the requisite regulatory approvals are obtained, our ZFP Therapeutics may not gain market acceptance among physicians, patients, healthcare payers and the medical community. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of additional factors may limit the market acceptance of our ZFP Therapeutic products including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rate of adoption by healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rate of a product&#146;s acceptance by the target population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market entry relative to competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price of our product relative to alternative therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of third-party reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extent of marketing efforts by us and third-party distributors or agents retained by us; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">side effects or unfavorable publicity concerning our products or similar products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore,
even after we have obtained the required regulatory approval for our ZFP Therapeutic products, we may not be able to commercialize these products successfully if we cannot achieve an adequate level of market acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently have the infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for us to commercialize our therapeutic products directly, we would need to develop, or obtain through outsourcing
arrangements, the capability to manufacture, market and sell our products on a commercial scale. Currently we do not have the ability nor the financial resources to establish the infrastructure and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organizations needed to execute these functions, including such infrastructure needed for the commercialization of any product from our HIV/AIDS or Alzheimer&#146;s disease program, which can be
complex and costly. If we are unable to establish adequate manufacturing, sales, marketing and distribution capabilities, we will not be able to directly commercialize our therapeutics products, which would limit our future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to fully realize the expected benefits from the acquisition of Ceregene, Inc., and the operation of the new business
of Ceregene, Inc. may subject us to additional risks. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, we acquired Ceregene, including all of its
therapeutic programs and related intellectual property and other assets. Although we expect to realize strategic, operational and financial benefits as a result of the acquisition, we cannot be certain whether, and to what extent, such benefits will
be achieved in the future. In particular, the success of the acquisition will depend on our ability to efficiently and successfully integrate Ceregene&#146;s business, including the prosecution of its CERE-110 Phase 2 clinical trial, and to apply
Ceregene&#146;s technology to advance our ZFP Therapeutics. There is no guarantee that any existing and future clinical trials of Ceregene&#146;s product candidates, including CERE-110 for the treatment of AD, will produce positive results, and
failure to do so may adversely affect our ability to validate the AAV delivery technology and apply such technology to our ZFP products as well as negatively impact our stock price. In April 2013, Ceregene reported that its top line data for the
CERE-120 Phase 2b clinical trial for Parkinson&#146;s disease did not demonstrate statistically significant efficacy in the primary endpoint. In November 2013, we presented early positive data from Phase 1 clinical trial of CERE-110 demonstrating
that the drug was well-tolerated and resulted in appropriate delivery of the therapeutics. However, even if we obtain positive data from such clinical trials, there is no guarantee that the AAV delivery technology can be applied to our ZFP
Therapeutics safely and effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Ceregene also subjects us to additional operational and financial risks,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional costs that we may need to incur in order to conduct and complete Ceregene&#146;s therapeutic programs, including the CERE-110 Phase 2 clinical trial, and to comply with new regulatory requirements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties acquiring and developing the necessary expertise to continue the development of AAV technologies and other acquired assets of Ceregene; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in coordinating research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties in the business relationships with our collaborators and suppliers due to the acquisition; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of previous experiences in conducting Phase 2 trials of a gene therapy based on AAV vector delivery system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the market price of our common stock may decline as a result of the merger if the integration of Ceregene is unsuccessful, takes
longer than expected or fails to achieve the expected benefits to the extent anticipated by financial analysts or investors, or the effect of the acquisition on our financial results is otherwise not consistent with the expectations of financial
analysts or investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate
our commercial opportunity. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products that we or our collaborators or strategic partners develop by using our ZFP technology
platform will enter into highly competitive markets. Even if we are able to generate ZFP Therapeutics that are safe and effective for their intended use, competing technologies may prove to be more effective or less
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and
less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP TFs have broad application in the life sciences industry and compete with a broad array of new technologies and
approaches being applied to genetic research by many companies. Competing proprietary technologies with our product development focus include but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For ZFP Therapeutics: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">small molecule drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monoclonal antibodies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recombinant proteins; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gene therapy/cDNAs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">antisense; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">siRNA and microRNA approaches, exon skipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CRISPR/Cas9 technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TALE proteins; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">meganucleases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For our Non-Therapeutic Applications: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For protein production: gene amplification, meganucleases, TALE technology, insulator technology, mini-chromosomes and CRISPR/Cas9 technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For target validation: antisense, siRNA, TALE technology and CRISPR/Cas9 technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For plant agriculture: recombination approaches, mutagenesis approaches, meganucleases, TALE technology, CRISPR/Cas9 technology, mini-chromosomes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For transgenic animals: somatic nuclear transfer, embryonic stem cell, TALE, CRISPR/Cas9 technology and transposase technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantially greater capital resources than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">larger research and development staffs and facilities than ours; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater experience in product development and in obtaining regulatory approvals and patent protection. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These organizations also compete with us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract parties for acquisitions, joint ventures or other collaborations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. In addition, any products that
we develop may compete with existing products or services that are well established in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adverse public perception in the field of gene therapy may negatively impact regulatory
approval of, or demand for, our potential products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potential therapeutic products are delivered to patients as gene-based
drugs, or gene therapy. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims
that gene therapy is unsafe, and, consequently, our products may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy in general could result in greater government regulation and stricter labeling
requirements of gene therapy products, including any of our products, and could cause a decrease in the demand for any products we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laws or public sentiment may limit the production of genetically modified agricultural products, and these laws could reduce our
partner&#146;s ability to sell such products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetically modified products are currently subject to public debate and heightened
regulatory scrutiny, either of which could prevent or delay production of agricultural products. We have a research license and commercial option agreement with DAS through which we provide DAS with access to our proprietary ZFP technology and the
exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants or plant cell cultures. The field-testing, production and marketing of genetically modified plants and plant
products are subject to federal, state, local and foreign governmental regulation. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of our genetically modified products in a
timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our product development programs or the commercialization of
resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA currently applies the same regulatory standards to foods developed through genetic engineering as those
applied to foods developed through traditional plant breeding. Genetically engineered food products, however, will be subject to pre-market review if these products raise safety questions or are deemed to be food additives. Governmental authorities
could also, for social or other purposes, limit the use of genetically modified products created with our gene regulation technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the regulatory approval for genetically modified products developed under our agreement with DAS was obtained, our success will also
depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public
attitudes. Our genetically modified products may not gain public acceptance. The subject of genetically modified organisms has received negative publicity in the United States and particularly in Europe, and such publicity has aroused public debate.
The adverse publicity in Europe could lead to greater regulation and trade restrictions on imports of genetically altered products. Similar adverse public reaction or sentiment in the United States to genetic research and its resulting products
could result in greater domestic regulation and could decrease the demand for our technology and products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Finances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable
future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated operating losses since we began operations in 1995. Our net losses for the years ended
December&nbsp;31, 2013, 2012 and 2011 were $26.6 million, $22.3 million and $35.8 million, respectively. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have
been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from
strategic partnering agreements, other collaborations in non-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. As of December&nbsp;31, 2013, we had an accumulated deficit of $302.1
million. From 2005 to date, we have generated an aggregate of approximately $231.4 million in net proceeds from the sale of our equity securities. We expect to continue to incur additional operating losses for the next several years as we continue
to expand and extend our research and development activities into human therapeutic product development. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are
unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to raise additional capital, which would harm our ability to develop our technology and products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect
capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and ZFP Therapeutic product development activities. While we believe our financial resources will be adequate to sustain
our current operations at least through 2015, we may need to seek additional sources of capital through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approval of potential
products, a process that could cost in excess of hundreds of millions of dollars per product. Furthermore, we may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity
markets for emerging biotechnology companies and general economic and market conditions. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will
materially adversely affect our business and our ability to develop our technology and ZFP Therapeutic products. Furthermore, any sales of additional equity securities may result in dilutions to our stockholders and any debt financing may include
business and financial covenants that restricts our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are at the development phase of operations and may not succeed
or become profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began operations in 1995 and are in the early phases of ZFP Therapeutic product development, and we have
incurred significant losses since inception. To date, our revenues have been generated from strategic partners, other collaborations in non-therapeutic applications of our technology, and federal government and research foundation grants. Our focus
on higher-value therapeutic product development and related strategic partnerships requires us to incur substantial expenses associated with product development. In addition, the preclinical or clinical failure of any single product may have a
significant effect on the actual or perceived value of our stock. Our business is subject to all of the risks inherent in the development of a new technology, which includes the need to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain qualified scientific and technical staff and management, particularly scientific staff with expertise to develop our early-stage technology into therapeutic products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain sufficient capital to support the expense of developing our technology platform and developing, testing and commercializing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop a market for our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully transition from a company with a research focus to a company capable of supporting commercial activities. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Relationships with Collaborators and Strategic Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit
our ability to implement our strategies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If conflicts arise between our corporate or academic collaborators or strategic partners
and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the
products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the
withdrawal of partner support for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our collaborators or strategic partners could also become our
competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us
prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborators and strategic partners may control aspects of our clinical trials, which could result in delays and other obstacles in
the commercialization of our proposed products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some programs, we depend on third party collaborators and strategic partners
to design and conduct our clinical trials. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these
collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012, we entered into a research and collaborative agreement with Shire, pursuant to which we are engaging in a joint program with
Shire to research, develop and commercialize human therapeutics and diagnostics for hemophilia, Huntington&#146;s disease and other monogenic diseases based on our ZFP technology. Under this agreement, we are responsible for all research activities
through the submission of an IND or CTA, while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Under the agreement,
we may be eligible to receive milestone payments upon the achievement of specified clinical development, commercialization and post-commercialization milestones. The total amount of potential milestone payments for each gene target, assuming the
achievements of all specified milestones in the agreement, is $213.5 million. We may receive royalty payments based on specified percentages of net sales of products, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in January 2014, we entered into a collaborative agreement with Biogen for the clinical development and commercialization of
therapeutics based on our ZFP technology for hemoglobinopathies, including beta-thalassemia and SCD. Under the Agreement, we are responsible for all discovery, research and development activities through the first human clinical trial for the first
ZFP therapeutic developed for the treatment of beta-thalassemia. In the SCD program, both parties are responsible for research and development activities through the submission of an IND. Under both programs, Biogen is responsible for subsequent
clinical development, manufacturing and commercialization of licensed products developed under the Agreement. Under the agreement with Biogen, we may be eligible to receive payments upon the achievement of specified regulatory, clinical development,
commercialization, and sales milestones of up to $293.8 million. We may also receive royalty payments based on specified percentage of annual net sales of products, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these agreements with Biogen and Shire will have control and broad discretion over all or certain aspects of the clinical development
and commercialization of any product developed under the agreements, and we will have little, if any, influence on how these programs will be conducted. Our lack of control over the clinical development in our agreement with Biogen and Shire could
cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective
agreement(s), Biogen and Shire have certain rights to terminate the agreements by providing us with advance notices, therefore the actual milestone payments that we may receive under these agreements may be lower than the full amounts stated above.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborators or strategic partners may decide to adopt alternative technologies or may
be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP technology.
Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so,
this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of
our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If any of these events occur, we may not be able to develop our technologies or
commercialize our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not successfully commercialize ZFP-based research reagents, ZFP-modified cell lines for
commercial protein production, or ZFP-engineered transgenic animals under our license agreement with Sigma-Aldrich Corporation or ZFP-based agricultural products with Dow AgroSciences, or if Sigma-Aldrich Corporation or Dow AgroSciences terminates
our agreements, our ability to generate revenue under these license agreements may be limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2007, we entered into a
license agreement with Sigma to collaborate in the application and development of ZFP-based products for use in the laboratory research reagents markets. The agreement provides Sigma with access to our ZFP technology and the exclusive right to use
our ZFP technology to develop and commercialize products for use as research reagents and to offer services in related research fields. This relationship was expanded in October 2009 when we amended our license agreement with Sigma to provide Sigma
with the exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and, certain ZFP-engineered transgenic animals for commercial applications. In June 2008, following a research period,
DAS exercised its commercial license option under a license agreement with us relating to plant agriculture. This agreement provides DAS with the exclusive right to develop agricultural products using our ZFP technology in plant cells, plants, or
plant cell cultures. Both companies also have the right to sublicense our technology in their respective areas. In addition to upfront payments, we may also receive additional license fees, shared sublicensing revenues, royalty payments and
milestone payments depending on the success of the development and commercialization of the licensed products and services covered under both agreements. The commercial milestones and royalties are typically based upon net sales of licensed
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that we or our collaboration partners will succeed in the development of commercially viable products in
these fields of use, and there is no guarantee that we or our collaboration partners will achieve the milestones set forth in the respective license agreements. To the extent we or our collaboration partners do not succeed in developing and
commercializing products or if we or our collaboration partners fail to achieve such milestones, our revenues and benefits under the license agreements will be limited. In addition, the respective license agreements may be terminated by Sigma and
DAS at any time by providing us with a 90-day notice. In the event Sigma or DAS decides to terminate the license agreements, our ability to generate revenue under such license agreements will cease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborations with outside scientists may be subject to change, which could limit our access to their expertise. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We work with scientific advisors and collaborators at academic research institutions. These scientists are not our employees and may have
other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their
services. Although our scientific advisors and academic collaborators sign agreements not to disclose our confidential information, it is possible that some of our valuable proprietary knowledge may become publicly known through them, which may
cause competitive harm to our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Intellectual Property and Business Operation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar
to ours, we cannot ensure the proprietary protection of our technologies and products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part
on obtaining patent protection of our technology and successfully defending any of our patents that may be challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and
factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in patents we own or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to various license agreements that give us rights under specified patents and patent applications. Our current licenses, as our
future licenses frequently will, contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may
be forced to delay or terminate our product development and research activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our present and any future sublicenses,
since our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master license or fail to inform us of useful improvements in, or additions to, the
underlying intellectual property owned by the original licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to exercise the same degree of control over intellectual
property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent
applications may not be prosecuted as we desire or in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is
uncertain, and we cannot ensure that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors were the first to make the inventions covered by each of our pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors were the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others will not have an adverse effect on our ability to do business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our pending patent applications will result in issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued or licensed to us or our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued or licensed to us will not be challenged and invalidated by third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will develop additional products, processes or technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Others
have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE and
other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents have been issued, although we have no current plans to use the associated inventions. If these or other patents issue, it is possible
that the holder of any patent or patents granted on these applications may bring an infringement action against our collaborators, strategic partners, or us claiming damages and seeking to enjoin commercial activities relating to the affected
products and processes. The costs of litigating the claim could be substantial. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as
valid and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforceable and our products or processes were found to infringe the patent or patents, we could be prevented from making, using or selling the relevant product or process unless we could obtain
a license or were able to design around the patent claims. We can give no assurance that such a license would be available on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent
claims. There may be significant litigation in the genomics industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of our
managerial and financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect technology where we believe patent protection is not appropriate
or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other
proprietary information or enforce these confidentiality agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborators, strategic partners, and scientific advisors have
rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be
able to receive patent protection or protect our proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we use biological and hazardous materials in a manner
that causes injury or violates laws, we may be liable for damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled
use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we
employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal
of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials.
However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the
use, storage, handling, and disposal of these materials and specified waste products. To date, we have not experienced significant costs in complying with regulations regarding the use of these materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to attract, retain, and motivate skilled personnel and cultivate key academic collaborations will delay our product development
programs and our research and development efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our continued ability to attract, retain and motivate
highly qualified management and scientific personnel and our ability to develop and maintain important relationships with leading research and academic institutions and scientists. Competition for personnel and academic and other research
collaborations is intense. We have experienced a rate of employee turnover that we believe is typical of emerging biotechnology companies. If we lose the services of personnel with the necessary skills, it could significantly impede the achievement
of our research and development objectives. If we fail to negotiate additional acceptable collaborations with academic and other research institutions and scientists, or if our existing collaborations are unsuccessful, our ZFP Therapeutic
development programs may be delayed or may not succeed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Common Stock and Corporate Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the twelve months ended December&nbsp;31, 2013, the closing price of our common stock price, as reported by the NASDAQ Global Select
Market, ranged from a low of $6.15 to high of $14.38. During the twelve months ended December&nbsp;31, 2012, the closing price of our common stock price ranged from a low of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$2.95 to a high of $6.49. Volatility in our common stock could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market
price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or collaborators providing updates on the progress or development status of ZFP Therapeutics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data from clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation or termination of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall market and economic conditions including the equity markets for emerging biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deviations in our results of operations from the guidance given by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreases in our cash balances; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes, by one or more of Sangamo&#146;s security analysts, in recommendations, ratings or coverage of our stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price is also influenced by public perception of gene therapy and government regulation of potential products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked
SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy. Stock prices of these companies
declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with X-linked SCID, or whether the specific company&#146;s clinical trials were placed on hold in connection with these events.
Other potential adverse events in the field of gene therapy may occur in the future that could result in greater governmental regulation of our potential products and potential regulatory delays relating to the testing or approval of our potential
products. These external events may have a negative impact on public perception of our business, which could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our certificate of incorporation and Delaware law could make an acquisition of the Company more difficult
and could prevent attempts by our stockholders to remove or replace current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-takeover provisions of Delaware law
and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may
issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the
price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock
would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state that stockholders may not act by written consent but only at a stockholders&#146; meeting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#146; meetings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from calling a special meeting of stockholders. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to
Section&nbsp;203 of the Delaware General Corporation Law, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#147;interested stockholder&#148; and may not engage in &#147;business
combinations&#148; with us for a period of three years from the time the person acquired 15% or more or our voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_4"></A>ITEM&nbsp;1B &#150; UNRESOLVED STAFF COMMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_5"></A>ITEM&nbsp;2
&#150; PROPERTIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently lease approximately 27,000&nbsp;square feet of research and office space located at 501 Canal Boulevard
in Richmond, California. The lease expires in August of 2019. We believe such facilities are sufficient for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_6"></A><B>ITEM&nbsp;3 &#150; LEGAL PROCEEDINGS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not a party to any material pending legal proceeding. From time to time, we may be involved in legal proceeding arising in the ordinary
course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_7"></A><B>ITEM&nbsp;4 &#150; MINE SAFETY DISCLOSURES</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not Applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_8"></A>PART&nbsp;II </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx657040_9"></A>ITEM&nbsp;5&nbsp;&#150;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MARKET FOR THE REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has traded on the NASDAQ Global Select Market under the symbol &#147;SGMO&#148; since our initial public offering on
April&nbsp;6, 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high and low closing prices of our common stock for each quarterly period during the last two fiscal years as
reported by the NASDAQ Global Select Market were as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2014, there were 82 holders of record of Sangamo&#146;s common stock. This number does not include &#147;street
name&#148; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo has not paid dividends on its common stock, and currently does not plan to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Trading Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our
directors, executive officers and other insiders, including Edward O. Lanphier II, President and CEO, have adopted stock trading plans pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and have made sales, from time to
time, pursuant to such plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Performance Graph </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g657040g80k35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The above Stock Performance Graph and related information shall not be deemed &#147;soliciting
material&#148; or to be &#147;filed&#148; with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as
amended, except to the extent that the Company specifically incorporates it by reference into such filing. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx657040_10"></A>ITEM</B></TD>
<TD ALIGN="left" VALIGN="top"><B>6 &#150; SELECTED FINANCIAL DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following Selected Financial Data should be read
in conjunction with &#147;Item&nbsp;7&#151;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Item&nbsp;8&#151;Financial Statements and Supplementary Data&#148; included elsewhere in this
Annual Report on Form&nbsp;10-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Financial Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2010</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2009</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,198</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,821</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,935</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,402</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income/(expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,854</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,587</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.55</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2010</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2009</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, marketable securities, and interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302,133</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275,509</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253,245</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217,495</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192,641</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_11"></A>ITEM&nbsp;7 &#150; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, without limitation, statements containing the words &#147;believes,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;continue,&#148; and other words of similar import or the negative of those terms or
expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited
to, the &#147;Risk Factors&#148; described in Part&nbsp;I, Item&nbsp;1A. You should read the following discussion and analysis along with the &#147;Selected Financial Data&#148; and the financial statements and notes attached to those statements
included elsewhere in this report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins
for the development of novel therapeutic strategies for unmet medical needs. Our scientific and business development endeavors currently focus on the engineering of novel zinc finger DNA-binding proteins (ZFPs) for the regulation and modification of
genes. Our strategy is to develop highly specific ZFP nucleases (ZFNs) and ZFP transcription factors (ZFP TFs) through early stage clinical testing and strategically partner with biopharmaceutical companies at points of value inflection to execute
late-stage clinical trials and commercial development. In the long-term, our goal is to integrate marketing and development operations and to capture the value of late-stage and commercial ZFP Therapeutic products for ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities.
To date, we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborations and research grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues have consisted primarily of revenues from our corporate partners for ZFNs and ZFP TFs, contractual payments from strategic
partners for research programs and research milestones, and research grant funding. We expect revenues will continue to fluctuate from period to period and there can be no assurance that new collaborations or partner funding will continue beyond
their initial terms or that we are able to meet the milestones specified in these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the development of our ZFP technology
platform, we are focusing our resources on higher-value ZFP Therapeutic product development. We are conducting a Phase 2 and a Phase 1/2 clinical trial to evaluate a ZFP Therapeutic for the treatment of HIV/AIDS. Development of novel therapeutic
products is costly and is subject to a lengthy and uncertain regulatory process by the FDA. Our future products will be gene-based therapeutics. Adverse events in both our own clinical program and other programs may have a negative impact on
regulatory approval, the willingness of potential commercial partners to enter into agreements and the perception of the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
January 2012, we established a collaborative partnership with Shire International GmbH, formerly Shire AG, (Shire) to research, develop and commercialize some of our preclinical ZFP Therapeutic development programs, including programs in hemophilia,
Huntington&#146;s disease (HD) and other monogenic diseases. In January 2014, we established a collaborative partnership with Biogen Idec Inc. (Biogen) to discover, develop, seek regulatory approval for and commercialize therapeutics based on
Sangamo&#146;s ZFP technology for hemoglobinopathies, including beta thalassemia and sickle cell disease (SCD). We also have proprietary preclinical programs in lysosomal storage disorders (LSDs). In addition, we have research stage programs in
other monogenic diseases, in central nervous system (CNS) disorders and in cancer immunotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the potential commercial applications of ZFPs are broad-based and we have entered into
strategic partnerships in fields outside human therapeutics to facilitate the sale or licensing of our ZFP platform as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon our ZFP technology
as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, we have provided DAS with access to our ZFP technology and the exclusive rights
to use it to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. DAS markets our ZFN technology under the trademark EXZACT<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> Precision Technology. We
have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic or prophylactic purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, we acquired Ceregene, Inc. (Ceregene), a privately held biotechnology company focused on the development of
adeno-associated virus (AAV) gene therapies. The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110, for the treatment of Alzheimer&#146;s disease (AD) that is currently in a Phase 2 clinical trial, certain
intellectual property rights relating to the manufacturing of AAV, certain toxicology data and safety and efficacy data from Ceregene&#146;s human clinical trials. We believe that these additional assets provide valuable reference materials for us
in the preparation and filing of IND applications for our <I>in vivo</I> ZFP Therapeutics, particularly those that target the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
the year ended December&nbsp;31, 2013, we incurred a consolidated net loss of $26.6 million, or $0.48 per share, compared to a consolidated net loss of $22.3 million, or $0.42 per share, for the same period in 2012. As of December&nbsp;31, 2013, we
had cash, cash equivalents, marketable securities and interest receivable totaling $131.8&nbsp;million compared to $76.3 million as of December&nbsp;31, 2013. As of December&nbsp;31, 2013, we had an accumulated deficit of $302.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial
statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments
that affect the reported amounts in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe
the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the
services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements
typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#146;s product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements prior to the adoption of ASU No.&nbsp;2009-13, Revenue
Recognition &#150; Multiple Deliverable Revenue Arrangements (ASU 2009-13)</I> . For revenue arrangements entered into before January&nbsp;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units
of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated
among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, we recognized
nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if we had continuing performance obligations. We
estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements after the adoption of ASU 2009-13.</I> ASU 2009-13 amended the accounting standards for certain multiple
element revenue arrangements to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy, also called the relative selling price method, where the selling price for an element is based on
vendor-specific objective evidence (VSOE), if available; third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the selling price hierarchy. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after
January&nbsp;1, 2011, the Company will allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each
deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The
collaboration and license agreement entered into with Shire in January 2012 was evaluated under these updated accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company recognizes milestone payments, which are subject to substantive contingencies, upon completion of specified
milestones, which represents the culmination of an earnings process, according to contract terms. Fees from licensees upon sublicensing Sangamo technologies by them to third parties (sublicense fees) are recognized as revenue in the period such fees
are due. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The
Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not
been earned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo&#146;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses
for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
accounted for the acquisition of Ceregene in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations. ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration
transferred to and the assets acquired, liabilities assumed and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill
acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as intangible assets at the time of acquisition; requires acquisition-related expenses and restructuring costs to be
recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business
combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued
liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to our investment securities
consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development expenses as incurred. Research and development expenses consist of direct
and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of our
testing processes and procedures and related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and
development that have no alternative future use are expensed as incurred. Expenses resulting from clinical trials are recorded when incurred based in part on factors such as estimates of work performed, patient enrollment, progress of patient
studies and other events. We make good faith estimates that we believe to be accurate, but the actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our
clinical development plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure and recognize compensation expense for all stock-based payment awards made to our employees and directors, including employee stock
options, employee stock purchases related to the Employee Share Purchase Plan (ESPP) and restricted stock units (RSUs), on estimated fair values. The fair value of stock-based awards is amortized over the vesting period of the award using a
straight-line method over the requisite service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To estimate the value of a stock option award and purchases related to ESPP, we
use the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While
estimates of expected life and volatility are derived primarily from our historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. To estimate the
value of RSUs, we use the closing market value of our common stock on the date the award is issued. Further, we are required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ
from those estimates. If factors change and different assumptions are employed in determining the fair value of stock-based awards, the stock-based compensation expense recorded in future periods may differ significantly from what was recorded in
the current period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Years Ended December&nbsp;31, 2013, 2012 and 2011 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><B>(In thousands, except percentage values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(740</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues
over the next several years will primarily be derived from our collaboration agreements with Shire, Biogen, Sigma and DAS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from
our corporate collaboration agreements were $21.7 million in 2013, $18.2 million in 2012 and $6.1 million in 2011. The increase in revenue from collaborations in 2013 compared to 2012 was primarily due to an increase of $5.4 million in revenues from
Shire, partially offset by a decrease of $1.7 million in revenues from DAS related to research and manufacturing services. The increase in revenue from collaborations in 2012 compared to 2011 was primarily due to $11.0 million in revenues from our
agreement with Shire which we entered into in January 2012. Revenues related to Shire included amortization of a $13.0 million upfront license payment and revenues for research services provided to Shire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research grant revenues were $2.5 million in 2013, $3.5 million in 2012 and $4.2 million in 2011. The decrease of $1.0 million in 2013 from
2012 was mainly due to the termination of our agreements with the CHDI Foundation, Inc. (CHDI) and the Juvenile Diabetes Research Foundation International (JDRF) in 2012. The decrease was partially offset by revenues related to other grant
agreements. The decrease of $0.7 million in 2012 from 2011 was primarily due to a decrease in revenues of $0.5 million from the California Institute for Regenerative Medicine (CIRM) as well as $0.4 million from the Michael J. Fox Foundation for
Parkinson&#146;s Research (MJFF), partially offset by an increase in revenues of $0.2 million from JDRF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013, revenues related to
Shire and DAS represented 68% and 12%, respectively, of total revenues. During 2012, revenues related to Shire, Sigma and DAS represented 51%, 11% and 22%, respectively, of total revenues. During 2011, revenues related to Sigma, DAS, CIRM and CHDI
represented 15%, 43%, 18% and 11% of total revenues, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><B>(In thousands, except percentage values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,898</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,287</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to
increase in the next several years if we are successful in advancing our HIV/AIDS program in the clinic and if we are able to progress our earlier stage ZFP therapeutic product candidates into clinical trials including our programs under
collaboration with Shire and Biogen. Pursuant to the terms of the agreements with Shire and Biogen, future expenses related to research and certain development activities will be reimbursed to Sangamo, including employee and external research costs.
The reimbursement funds received from Shire and Biogen will be recognized as revenue as the costs are incurred and collection is reasonably assured. We also continue to fulfill our obligations under the terms of our non-therapeutic collaborations
with Sigma and DAS. In addition, to the extent we continue to receive royalties from Sigma, we will incur fees related to certain technologies that we have in-licensed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $37.0 million in 2013, $31.7 million in 2012 and $32.1 million in 2011. The increase of $5.3 million in
research and development expenses in 2013 was primarily due to an increase in internal and external research expenses related to our pre-clinical ZFP Therapeutic programs, including our programs under our collaboration with Shire, of $5.0 million.
Additionally, personnel related expenses, including salaries and stock-based compensation expenses, increased by $1.2 million. These increases were partially offset by a decrease in clinical and manufacturing expenses of $1.1 million, primarily
related to our HIV/AIDS program </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease of $0.4 million in 2012 compared to 2011 was primarily due to a decrease in clinical and
manufacturing expenses related to our HIV/AIDS program as well as our terminated SB-509 program of $4.5 million and a decrease in stock-based compensation expenses of $0.8 million, partially offset by an increase in expenses related to our
pre-clinical ZFP Therapeutic programs of $3.5 million, including our programs under collaboration with Shire, as well as an increase in personnel related expenses of $0.8 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Drug development is inherently uncertain and the successful completion of our development programs is subject to numerous technological
challenges and risks and we cannot presently estimate anticipated completion dates for any of our programs. Material cash inflows associated with the sale of products, if any, which result from our research efforts are not expected for at least five
years. See Risk Factors&#151; <I>&#147;Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and if these potential products are not approved, we will not be able to commercialize these products&#148; and
&#147;Our gene regulation and gene modification technology is relatively new, and if we are unable to use this technology in all our intended applications, it would limit our revenue opportunities.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows research and development expenses for our primary clinical development program, SB-728-T, expenses associated with other
clinical stage programs as well as expenses related to our preclinical and research stage programs, including our therapeutic programs under collaboration with Shire and non-therapeutic collaborations. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:33.75pt; font-size:8pt; font-family:Times New Roman"><B>Programs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SB-728-T clinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other clinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pre-clinical and research programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative
personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we pursue commercial development of our therapeutic leads we expect the business
aspects of the Company to become more complex. We may be required in the future to add personnel and incur additional costs related to the maturity of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $13.8 million in 2013, $12.1 million in 2012 and $14.0 million in 2012. The increase in general and
administrative expenses of $1.7 million in 2013 was primarily due to an increase of $0.9 million in personnel related expenses, including salaries and stock-based compensation expenses, and an increase in professional services expenses of $0.9
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease of $1.9 million in 2012 from 2011 was primarily due to a decrease in stock-based compensation expenses of $1.9
million as well as a decrease in professional services expenses of $0.8 million, partially offset by an increase in personnel related expenses of $0.6 million due to increased headcount, salaries and incentive compensation and an increase in other
allocated facility expenses of $0.2 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income was $0.1 million in 2013 and 2011, and other expense was $0.1 million in 2012. The expense in 2012 was primarily related to
disposal of fixed assets, partially offset by interest income of $0.1&nbsp;million. Other income in 2013 and 2011 was comprised of interest income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had cash, cash equivalents, marketable securities and interest receivable totaling $131.8&nbsp;million
compared to $76.3 million as of December&nbsp;31, 2012, with the increase primarily attributable to the completion of an underwritten public offering of the Company&#146;s common stock in September 2013, in which 7,015,000 shares of Sangamo common
stock were sold at a public offering price of $10.58 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were
approximately $69.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most significant use of capital pertains to salaries and benefits for our employees and external
research and development expenses, such as manufacturing, clinical trials and preclinical activity, related to our ZFP Therapeutic programs. Our cash and investment balances are held in a variety of interest bearing instruments, including
obligations of U.S. government agencies, U.S. treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital
preservation and liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012, we entered into a collaboration and license agreement with Shire, pursuant to which we are
collaborating with Shire to research, develop and commercialize certain gene targets in human therapeutics and diagnostics for hemophilia, HD and other monogenic diseases based on our ZFP technology. Under the Agreement, we received an upfront
license fee of $13.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2014, we entered into a collaboration and license agreement with Biogen,
pursuant to which Sangamo and Biogen will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#146;s ZFP technology for hemoglobinopathies, including beta-thalassemia and SCD. Under the
Agreement, we will receive an upfront license fee of $20.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we acquired Ceregene&#146;s therapeutic programs,
including a Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">CERE-110</FONT> for the treatment of AD. The operations of Ceregene&#146;s business, including the conduct of clinical trials, are funded by an award granted by the NIH, and we
do not expect to incur significant cash expenditure to continue such operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cash Flow </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating activities.</I></B> For all periods, net cash used in operating activities primarily reflects our net operating losses adjusted
for non-cash items including stock-based compensation expense. Net cash used in operating activities was $19.5 million in 2013 compared to $8.1 million in 2012. The increase in net cash used in operations in 2013 was primarily due to an increase in
research and development expenses related to our pre-clinical research programs and an increase in deferred revenues in 2012 related to the $13.0 million upfront payment from Shire pursuant to the collaboration and license agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $8.1 million in 2012 compared to $25.9 million in 2011. The decrease in net cash used in operating
activities in 2012 compared to 2011 was primarily the result of a $13.0&nbsp;million upfront payment related to our collaboration and license agreement entered into with Shire in January 2012, as well as lower clinical trial related expenses in 2012
compared to 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing activities.</I></B> Net cash used in investing activities was $68.1 million in 2013. Net cash provided
by investing activities was $11.3 million in 2012. Net cash used in investing activities was $20.0 million in 2011. Cash flows from investing activities for all periods primarily related to purchases, sales and maturities of marketable securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing activities.</I></B> Net cash provided by financing activities was $76.1 million in 2013, $1.7 million in 2012 and $51.9
million in 2011. Net cash provided by financing activities in 2013 was primarily attributable to $69.5 million in net proceeds from a public offering of the Company&#146;s common stock in September 2013, as well as proceeds from the issuance of
common stock upon exercise of stock options. Net cash provided by financing activities in 2012 primarily related to proceeds from the issuance of common stock upon exercise of stock options. Net cash provided by financing activities in 2011 was
primarily attributable to $50.2 million in net proceeds from a public offering of the Company&#146;s common stock in April 2011, as well as proceeds from the issuance of common stock upon exercise of stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating Capital and Capital Expenditure Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in
the future, in particular to support our product development endeavors, we believe that the available cash resources as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our
currently planned operations through 2015. Future capital requirements will be substantial and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations, including
ZFP Therapeutic development activities, through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of
operation.&nbsp;Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our technology
and our ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilutions to our stockholders, and any debt financing may include covenants that restrict our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many forward looking factors, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of our collaboration agreements with Shire and Biogen; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays that may be caused by changing regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and terms of future in-licensing and out-licensing transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of procuring clinical and commercial supplies of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or invest in businesses, products or technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible costs of litigation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no provision for income taxes because we have only
incurred losses since our inception. As of December&nbsp;31, 2013, we had net operating loss carryforwards for federal and state income tax purposes of approximately $208.8&nbsp;million and $199.0 million, respectively. If not utilized, the net
federal and state operating loss carryforwards will begin to expire in 2014. We also have federal and state research tax credit carryforwards of $6.2&nbsp;million and $6.5 million, respectively. The federal research credits will begin to expire in
2018 while the state research credits have no expiration date. Utilization of our net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations
provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commercial Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had contractual obligations and commercial commitments as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:82.75pt; font-size:8pt; font-family:Times New Roman"><B>Contractual Obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than<BR>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;Than<BR>5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contractual obligations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating leases consist of base rents for facilities we occupy in Richmond, California. License obligations
consist of ongoing license maintenance fees associated with cancelable in-licensed patent agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_12"></A>ITEM&nbsp;7A &#150; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market risk relates to our cash, cash equivalents and investments. The goals of our investment policy are preservation
of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To
achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities in our investment portfolio are not leveraged, are classified as available-for-sale and are, due to their short-term nature,
subject to minimal interest rate risk. Our investments currently consist of U.S. Treasury securities, U.S. government-sponsored enterprise securities and corporate notes. Our investment policy, approved by our Board of Directors, limits the amount
we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in
our investment portfolio. We do not believe that a decrease in interest rates would have a material negative impact on the value of our investment portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_13"></A><B>ITEM&nbsp;8 &#150; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_25">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_26">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_27">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_28">Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_29">Consolidated Statements of Stockholders&#146; Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_30">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx657040_31">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_25"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Sangamo BioSciences, Inc. as of December&nbsp;31, 2013 and 2012, and
the related consolidated statements of operations, comprehensive loss, stockholders&#146; equity, and cash flows for each of the three years in the period ended December&nbsp;31, 2013. These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted
our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of
Sangamo BioSciences, Inc. as of December&nbsp;31, 2013 and 2012, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2013, in conformity with U.S. generally accepted accounting
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the
effectiveness of Sangamo BioSciences Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2013, based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (1992 framework) and our report dated February&nbsp;24, 2014 expressed an unqualified opinion thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/&nbsp;ERNST&nbsp;&amp; YOUNG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_26"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share<BR>and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, non-current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, in-process research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and employee benefits</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Escrow liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, non-current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01&nbsp;par value; 80,000,000&nbsp;shares authorized, 62,243,892 and 53,058,525 shares issued and outstanding at
December&nbsp;31, 2013 and 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302,133</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275,509</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_27"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,706</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,198</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,821</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_28"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in unrealized gain on available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,638</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,250</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,732</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:410pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_29"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income/ (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(In thousands, except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,377,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">272,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(217,495</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in connection with underwritten public offering, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock under employee stock purchase plan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,732</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,554,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(253,245</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock under employee stock purchase plan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,250</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,058,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(275,509</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in connection with underwritten public offering, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,015,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,889,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock under employee stock purchase plan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in connection with acquisition of Ceregene, Inc.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,243,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">423,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(302,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_30"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,624</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,264</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,750</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss&nbsp;to net&nbsp;cash&nbsp;used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premium / discount on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Escrow liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,414</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,503</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,482</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,082</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,895</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,894</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,428</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,974</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sales of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquistion of Ceregene, Inc., net of cash received</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(432</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(723</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by / (used in) investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,999</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from public offering of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid related to net share settlement of equity awards</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase / (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosures of noncash investing activities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of shares of common stock issued pursuant to the acquisition of Ceregene Inc.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_31"></A>SANGAMO BIOSCIENCES, INC. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES&nbsp;TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1 &#150; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sangamo </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo
BioSciences, Inc. (the Company or Sangamo) was incorporated in the State of Delaware on June&nbsp;22, 1995 and is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#146;s gene
regulation and gene modification technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). Potential applications of Sangamo&#146;s technology include development of human
therapeutics, plant agriculture and enhancement of pharmaceutical protein production. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require
several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance
of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&nbsp;31, 2013, along with expected revenues from collaborations, strategic partnerships and research grants, will be adequate to
fund its operations at least through 2015. Sangamo will need to raise substantial additional capital to fund subsequent operations and complete the development and commercialization of its products. Additional capital may not be available on terms
acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#146;s business and ability to develop its technology and ZFP Therapeutic products would be harmed.
Furthermore, any sales of additional equity securities may result in dilutions to the Company&#146;s stockholders, and any debt financing may include covenants that restrict the Company&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo acquired Ceregene, Inc. (Ceregene) on October&nbsp;1, 2013. Under the merger agreement, Sangamo obtained Ceregene&#146;s therapeutic
programs, including CERE-110 for the treatment of Alzheimer&#146;s disease (AD) that is currently in a Phase 2 clinical trial. Sangamo also acquired certain intellectual property rights relating to the manufacturing of AAV, and certain toxicology
data and safety and efficacy data from Ceregene&#146;s human clinical trials which will enhance and expand the application of Sangamo&#146;s<I> in vivo</I> ZFP Therapeutics, particularly those that target the brain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual
results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
accounted for the acquisition of Ceregene in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations. ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration
transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business
combination; requires purchased in-process research and development to be capitalized at fair value as intangible assets at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the
business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash
equivalents. Cash and cash equivalents consist of deposits in money market investment accounts, government sponsored entity debt securities, US Treasury debt securities and corporate bank accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the acquisition of Ceregene, Sangamo was required to set aside $0.3 million in an escrow account until October&nbsp;1, 2014. The
cash hold in escrow was recorded as restricted cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market
prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the
fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value
has been less than the Company&#146;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#146;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery
in the market value. Realized gains and losses on available-for-sale securities are included in other (expense)/income, which is determined using the specific identification method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent
consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#146;s investment securities generally can consist of the US Treasury, various major corporations, governmental
agencies and financial institutions with high credit standing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line
method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The
Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from
research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable,
and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties
on future licensee&#146;s product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements prior to the adoption of ASU No.&nbsp;2009-13, Revenue
Recognition&#151;Multiple Deliverable Revenue Arrangements (ASU 2009-13)</I>. For revenue arrangements entered into before January&nbsp;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered
items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to
the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance
obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements after the adoption of ASU 2009-13.</I> ASU 2009-13 amended the accounting standards for certain
multiple element revenue arrangements to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (VSOE), if available;
third-party evidence (TPE), if available and VSOE is not available; or the best estimate of selling price (ESP), if neither VSOE nor TPE is available; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after
January&nbsp;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable
using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and
license agreement entered into with Shire International GmbH, formerly Shire AG, (Shire) in January 2012 was evaluated under these amended accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These
milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the
Company&#146;s performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due.
Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development
costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo&#146;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and
development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013, revenues related to Shire, Sigma-Aldrich Corporation (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%,
respectively, of total revenues. During 2012, revenues related Shire, Sigma and DAS represented 51%, 11% and 22% of total revenues, respectively. During 2011, revenues related to Sigma, DAS, California Institute for Regenerative Medicine (CIRM) and
CHDI Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total revenues, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated
overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&#146;s testing processes
and procedures and as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development
that have no alternative future use are expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including
employee share options, restricted stuck units (RSUs) and employee share purchases related to the Employee Share Purchase Plan (ESPP), based on estimated fair values at grant date. The fair value of stock-based awards is amortized over the vesting
period of the award using a straight-line method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To estimate the value of an award, the Company uses the Black-Scholes option pricing
model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility
are derived primarily from the Company&#146;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company is required to estimate
forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation
expense only for those awards that are expected to vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Assets &#150; In-Process Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets related to in-process research and development costs, or IPR&amp;D, are considered to be indefinite-lived until the
completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed
finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets
will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D
projects below their respective carrying amounts. The Company observed no impairment indicators of the recorded IPR&amp;D in the year ended December&nbsp;31, 2013 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill represents the
excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual
basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the goodwill below its carrying amount. The Company observed no impairment
indicators of the recorded goodwill in the year ended December&nbsp;31, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the merger agreement with Ceregene, the Company may be required to make contingent earn-out payments if the Company grants a third-party
license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of these product candidates itself. These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">earn-out</FONT> payments will become payable in the period they are earned. In accordance with ASC Topic 805, Business Combinations, the Company determined the
fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. Future changes to the fair value of the contingent consideration will be determined each period and charged
to expense in the &#147;Changes in fair value of contingent liability&#148; expense line item in the Consolidated Statements of Operations under operating expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense
has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in
effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss
per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of
common stock and potential dilutive securities outstanding during the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Sangamo is in a net loss position, diluted net loss
per share excludes the effects of common stock equivalents consisting of options, which are all anti-dilutive. All stock options outstanding were excluded from the calculation of diluted net loss per share. Stock option outstanding at the end of
2013, 2012 and 2011 were 8,405,864, 9,184,346 and 8,346,190, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal
reporting. As of December&nbsp;31, 2013 and 2012, all of the Company&#146;s assets were maintained in the U.S. For the years ended December&nbsp;31, 2013, 2012 and 2011, 100% of revenues and operating expenses were generated and incurred in the U.S.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2013, the FASB issued ASU No.&nbsp;2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated
Other Comprehensive Income. This newly issued accounting standard requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. This ASU is effective for reporting periods
beginning after December&nbsp;15, 2012. The Company adopted this standard in the first quarter of 2013 and the adoption of this standard did not have an impact on its financial position or results of operations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2 &#150;FAIR VALUE MEASUREMENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents,
available-for-sale securities and contingent consideration liability.&nbsp;The fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in
measuring fair value as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1: Unadjusted quoted prices in active markets that are accessible at the
measurement date for identical, unrestricted assets or liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2: Quoted prices in markets that are not active,
or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3: Prices or valuation techniques that require inputs that are both
significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When observable market
prices for identical securities that are traded in less active markets are used, the Company classifies its available-for-sale debt instruments as Level 2. When observable market prices for identical securities are not available, available-for-sale
debt instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing as well as model processes. These models are proprietary valuation models of pricing providers or brokers. These valuation
models incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including
market research publications. For certain security types, additional inputs may be used, or some of the Standard Inputs may not be applicable.&nbsp;Evaluators may prioritize inputs differently on any given day for any security based on market
conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
fair value measurements of cash equivalents, available-for-sale securities and contingent consideration liabilities are identified at the following levels within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2013<BR>Fair&nbsp;Value&nbsp;Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012<BR>Fair&nbsp;Value&nbsp;Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company initially recorded a liability on the acquisition date of the estimated fair value of contingent consideration payments to former
Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene,
or if the Company commercializes any of these product candidates itself. The fair values of these Level 3 liabilities are estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and
assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows, and developing appropriate discount rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent changes in the fair value of these contingent consideration liabilities are recorded
to the &#147;Change in fair value of contingent liability&#148; expense line item in the Consolidated Statements of Operations under operating expenses. From the acquisition date of October&nbsp;1, 2013 through December&nbsp;31, 2013, the recognized
amount of the liability for contingent consideration increased by $0.1 million primarily as the result of the passage of time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value on date of acquisition (October 1, 2013)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3 &#150;MARKETABLE SECURITIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the Company&#146;s cash equivalents and available-for-sale securities (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>(Losses)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, all of the Company&#146;s investments had maturity dates within two years and
there were no material unrealized losses during 2013. Approximately 70% of the Company&#146;s available-for-sale securities mature within the next twelve months of the date of the balance sheet date and approximately 30% of the Company&#146;s
available-for-sale securities have maturities between twelve and twenty-four months from the date of the balance sheet date. The Company had no material realized losses or other-than-temporary impairments of available-for-sale securities for the
years ended December&nbsp;31, 2013, 2012 and 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4 &#150; STOCK-BASED COMPENSATION </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows total stock-based compensation expense recognized in the consolidated statements of operations (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, total stock-based compensation expense related to unvested stock options to be
recognized in future periods was $11.2&nbsp;million, which is expected to be expensed over a weighted-average period of 2.87 years. As of December&nbsp;31, 2013, total compensation expense related to unvested RSUs to be recognized in future periods
was $5.4 million, which is expected to be expensed over a weighted-average period of 1.98 years. There was no capitalized stock-based employee compensation expense as of December&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Valuation Assumptions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employee
stock-based compensation expense was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company primarily bases its determination of expected volatility through its assessment of the historical volatility of its common stock.
The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average estimated fair value per share of options granted during 2013, 2012 and 2011 was $8.29, $3.76 and $3.20, respectively,
based upon the assumption in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.50-1.88</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.74-1.34</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.93-2.11</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of option (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.36-5.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.40-5.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.39-5.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield of stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.87-0.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.83-0.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees purchased approximately 181,000, 175,000 and 153,000 shares of common stock through the 2010
Purchase Plan at an average exercise price of $2.75, $2.61 and $3.02 per share during the fiscal years 2013, 2012 and 2011, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average estimated fair value of shares purchased under the Company&#146;s ESPP during 2013, 2012 and 2011 were $1.47, $2.51 and
$1.62, respectively, based upon the assumptions in the Black-Scholes valuation model. The weighted&#150;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.05-0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.05-0.30</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.05-0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of option (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5-2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5-2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5-2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield of stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.51-0.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93-1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58-0.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5 &#150; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and License Agreement with Shire International GmbH, formerly Shire AG, in Human Therapeutics and Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012, the Company entered into a collaboration and license agreement (the Agreement) with Shire pursuant to which the Company and
Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#146;s ZFP technology. Under the Agreement, the Company and Shire may develop potential human therapeutic or
diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia. In June
2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington&#146;s disease (HD), an inherited neurodegenerative disease for which there are currently no therapies available to slow the disease progression. Shire
has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use
Sangamo&#146;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Agreement is six years and is subject to extensions upon mutual
agreement and under other specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, the Company is responsible for all research
activities through the submission of an Investigative New Drug Application (IND) or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program
from and after the acceptance of an IND or CTA for the product. Shire reimburses Sangamo for its internal and external research program-related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, the Company received an upfront license fee of $13.0 million. In addition, the Company will also be eligible to receive
$33.5 million in payments upon the achievement of specified research, regulatory, clinical development milestones, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million, as well as $180
million in payments upon the achievement of specified commercialization and sales milestones. The total amount of potential milestone payments for each of the seven gene targets, assuming the achievement of all specified milestones in the Agreement,
is $213.5 million. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no
products have been approved and therefore no royalty fees have been earned under the Agreement with Shire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All contingent payments under
the Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Agreement with Shire based on the authoritative guidance for research and development milestones and determined that
certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&nbsp;that can
be achieved based in whole or in part on either the Company&#146;s performance or on the occurrence of a specific outcome resulting from the Company&#146;s performance, (ii)&nbsp;for which there was substantive uncertainty at the date the agreement
was entered into that the event would be achieved and (iii)&nbsp;that would result in additional payments being due to the Company. Accordingly, revenue for the achievement of milestones that are determined to be substantive will be recognized in
its entirety in the period when the milestone is achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities.
The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Agreement. As a result, the Company will recognize
revenue from the upfront payment on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
straight-line basis over a six-year initial research term during which the Company will perform research services. As of December&nbsp;31, 2013, the Company has deferred revenue of $8.9 million
related to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues recognized under the agreement with Shire for the years ended December&nbsp;31, 2013 and 2012, were
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues related to Shire Collaboration:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of upfront fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Related costs and expenses incurred under the Shire agreement were $14.2 million and $7.7 million during the
twelve months ended December&nbsp;31, 2013 and 2012, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents,
Transgenic Animal and Commercial Protein Production Cell-line Engineering </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2007, Sangamo entered into a license agreement
with Sigma. Under the license agreement, Sangamo agreed to provide Sigma with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research
field, excluding certain agricultural research uses that Sangamo previously licensed to DAS. Under the agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo&#146;s ZFP
technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company&#146;s ZFP technology in the research field. Sangamo has transferred the ZFP manufacturing technology to
Sigma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement,
Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma
made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo is also eligible to receive commercial license
fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones
Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues recognized under the agreement with Sigma for
the years ended December&nbsp;31, 2013, 2012 and 2011, were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue related to Sigma Collaboration:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License fee and milestone revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Related costs and expenses incurred under the Sigma agreement were $0.2 million, $0.3 million and
$0.5 million during 2013, 2012 and 2011, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Dow AgroSciences in Plant Agriculture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2005, Sangamo entered into an exclusive commercial license with DAS. Under this agreement, Sangamo is providing DAS with access to
its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or
plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The Company&#146;s agreement with DAS provided for an initial three-year
research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company&#146;s ZFP technology, including agricultural crops,
industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0&nbsp;million, payment of the remaining $2.3 million of the previously agreed $4.0&nbsp;million in research
milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#146;s ZFP technology to third parties for use in plant cells, plants, or
plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and
research services through December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement also provides for minimum sublicense fees each year due to Sangamo every
October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any performance obligations with respect to the sublicensing activities to be
conducted by DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company&#146;s actual sublicense fees over the term of the agreement could be lower than $25.3&nbsp;million. In addition, each party may terminate the
agreement upon an uncured material breach of the agreement by the other party. In the event of any termination of the agreement, all rights to use the Company&#146;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to
practice Sangamo&#146;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#146;s ZFP technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues under the agreement were $3.0 million, $4.7 million and $4.5 million during 2013, 2012 and 2011, respectively. Related costs and
expenses incurred under the agreement were $0.4 million, $0.6 million and $0.9 million during 2013, 2012 and 2011, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Funding from Research
Foundations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>California Institute for Regenerative Medicine - HIV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, CIRM, a State of California entity, granted a $14.5 million Disease Team Research Award to develop an HIV/AIDS therapy based
on the application of ZFN gene editing technology in hematopoietic stem cells (HSCs). The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of
Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo received funds totaling $5.2 million from the total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in
the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo&#146;s research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and
conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and development efforts supported by the grant, not to exceed two times the amount Sangamo receives in
funding under the agreement with CIRM. As of December&nbsp;31, 2013, all revenues under the award have been recognized and all funds have been received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development performed under the CIRM grant agreement were
$1.2 million, $1.2 million and $1.7 million during 2013, 2012 and 2011, respectively. Related costs during 2013, 2012 and 2011 were $1.8 million, $1.2 million and $2.0 million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>California Institute for Regenerative Medicine - Beta-Thalassemia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2013, CIRM granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for
beta-thalassemia based on the application of its ZFN gene editing technology in HSCs. The four year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial in transfusion-dependent
beta-thalassemia patients. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo, or its collaborators, from sales of a commercial product resulting
from research and development efforts supported by the grant, in accordance with Title 17, California Code of Regulations, Section 100600. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue attributable to research and development performed under the CIRM grant agreement for beta-thalassemia was $0.1 million in 2013.
Related costs during 2013 were $0.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CHDI Foundation, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2011, Sangamo entered into an agreement with the CHDI to develop a novel therapeutic for HD based on Sangamo&#146;s proprietary ZFP
technology. The ZFP therapeutic approach targets the gene that causes HD, an inherited neurodegenerative disease for which there are currently no therapies available to slow the disease progression. Under the agreement with CHDI, and subject to its
terms and conditions, CHDI paid the Company $1.3 million, the total funds due under the agreement, over a period of one year which is intended to substantially fund the Company&#146;s research efforts related to the agreement. During 2012, the
agreement was amended to extend the project through August 2012 and to increase total potential funding from $1.3 million to $2.1 million, plus reimbursement for certain direct expenses related to the project. The agreement with CHDI terminated on
August&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development performed under the CHDI collaboration agreement were $1.1
million during 2012 and 2011. Related costs during 2012 and 2011 were $1.1 million and $1.2 million, respectively. There were no such revenues or related costs in 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Juvenile Diabetes Research Foundation International </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2006, Sangamo entered into an agreement with the Juvenile Diabetes Research Foundation International (JDRF)&nbsp;to provide
financial support for one of Sangamo&#146;s Phase 2 human clinical studies of the Company&#146;s product candidate SB-509, a ZFP Therapeutic that was in development for the treatment of diabetic neuropathy. In January 2010, JDRF and Sangamo amended
the agreement and, subject to its terms and conditions, JDRF agreed to provide additional funding of up to $3.0 million for a Phase 2b trial in diabetic neuropathy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2011, the Company announced that it would not pursue additional clinical development of the SB-509 program. In March 2012, the
Company received a final payment of $0.8 million for work performed under the agreement. The Company does not expect to receive additional funding under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development activities performed under the JDRF agreements were $0.8 million and $0.5 million during
2012 and 2011. There were no such revenues or related costs in 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Michael J. Fox Foundation for Parkinson&#146;s Research </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2007, the Company entered into a partnership with the Michael J. Fox Foundation for Parkinson&#146;s Research (MJFF)&nbsp;to provide
financial support of the Company&#146;s program to develop ZFP TFs to activate the expression of glial cell line-derived neurotrophic factor (GDNF). Under the agreement with MJFF and subject to its terms and conditions, MJFF paid the Company $1.0
million, the total funds due under the agreement. In June 2010, the Company received a commitment for additional funding of $0.9 million from MJFF to support further studies of ZFP TF activators of GDNF and intended to substantially fund Sangamo
research efforts related to the agreement. The Company has received the entire $1.9 million in funding available under the agreements with MJFF and does not expect to receive any further funding under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue attributable to research and development performed under the MJFF agreement was $0.4 million in 2011. There were no such revenues in
2013 or 2012. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6 &#150; ACQUISITION OF CEREGENE </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2013, Sangamo and its wholly-owned subsidiary CG Acquisition Sub, Inc., a Delaware corporation, entered
into an Agreement and Plan of Merger (the Merger Agreement) with Ceregene, and a stockholders&#146; representative. Pursuant to the Merger Agreement, the Company acquired all outstanding shares of Ceregene, a privately held biotechnology company
focused on the development of AAV gene therapies. The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110 for the treatment of AD is currently in a Phase 2 clinical trial. In addition to the clinical assets
acquired, the Company acquired certain intellectual property rights relating to the manufacturing of AAV, and certain toxicology data and safety and efficacy data from Ceregene&#146;s human clinical trials, which will be used in the preparation and
filing of IND applications for Sangamo&#146;s<I> in vivo</I> ZFP Therapeutics, particularly those that target the brain. The acquisition closed on October&nbsp;1, 2013 (the Closing Date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, the aggregate consideration transferred or transferable by Sangamo to former Ceregene stockholders at closing
consisted of 100,000 shares of Sangamo common stock, with an approximate fair value of $1.2 million. In addition, Sangamo may be required to make contingent earn-out payments (the Earn-Out Payments) to the stockholders of Ceregene as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the Company grants a third-party license to develop and commercialize Ceregene&#146;s CERE-110 for the treatment of (AD) or CERE-120 for the treatment of Parkinson&#146;s diseases or HD (the Earn-Out Products), the
Company is required to pay a double digit percentage of any upfront and milestone payments the Company receives for such license, subject to certain reductions based on expenses incurred by the Company in the development of the Earn-Out Products;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the Company commercializes any Earn-Out Product itself, the Company is required to pay, for each Earn-Out Product, royalty-like earnout payments as a percentage of net sales that range in the low double digits
depending upon the amount of net sales, subject to certain reductions by the Company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on the Closing Date, Sangamo,
Ceregene and certain of Ceregene&#146;s stockholders entered into an indemnity escrow agreement, pursuant to which $0.3 million of Ceregene remaining cash was deposited in an escrow account for the benefit of Sangamo to satisfy indemnity obligations
of the stockholders under the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Merger Agreement, each issued and outstanding share of Ceregene
capital stock was cancelled and converted into the right to receive the merger consideration described in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Ceregene acquisition was accounted for as a business combination in accordance with the guidance ASC Topic 805. The operating results of Ceregene after the Closing Date have been included in the Company&#146;s Consolidated Statements of Operations.
The Company&#146;s Consolidated Balance Sheet as of December&nbsp;31, 2013 reflects the acquisition of Ceregene. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consideration Transferred </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the estimated fair value of the consideration transferred by Sangamo to the Ceregene stockholders on the Closing
Date (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sangamo shares of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent earn-out</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total purchase consideration</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Estimate of Assets Acquired and Liabilities Assumed </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the estimated fair value of the net assets acquired as of the Closing Date (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets acquired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities assumed</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets acquired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets for in-process research and development (IPR&amp;D) consist of Ceregene&#146;s two clinical product candidates, CERE-110 for
the treatment of AD and CERE-120 for the treatment of Parkinson&#146;s disease. The Company determined that the combined Closing Date estimated fair values of CERE-110 and CERE-120 was $1.9 million. The Company used an income approach, which is a
measurement of the present value of the net economic benefit or cost expected to be derived from an asset or liability, to measure the fair value of these two product candidates. Under the income approach, an intangible asset&#146;s fair value is
equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To calculate the fair value of CERE-110 and CERE-120 under the income approach, the Company used probability-weighted cash flows discounted at
a rate considered appropriate given the inherent risks associated with this type of asset. The Company estimated a present value discount rate based on the estimated weighted-average cost of capital for companies with profiles substantially similar
to that of Ceregene. This estimates the rate that market participants would use to value this asset. Cash flows were generally assumed to extend either through or beyond the patent life of the asset, depending on the circumstances particular to the
asset. In addition, the Company compensated for additional risks, including the phase of development, historical clinical results and the lack of approved gene therapy products, by probability-adjusting the Company&#146;s estimation of the expected
future cash flows for these product candidates. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions. The projected cash flows from this project were based on key assumptions such as
estimates of revenues and operating profits related to the project considering its stage of development; the time and resources needed to complete the development and approval of the related product candidate; the life of the potential
commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a drug compound such as obtaining marketing approval from the FDA and other regulatory agencies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of these assets and estimated fair values at the Closing Date is as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Value&nbsp;of&nbsp;Intangible<BR>Assets Acquired</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CERE-110 for the treatment of Alzheimer&#146;s disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CERE-120 for the treatment of Parkinson&#146;s disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total identifiable intangible assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPR&amp;D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the
associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&amp;D is not amortized during this period, but rather tested for impairment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The excess of the
consideration transferred over the fair values assigned to the assets acquired and liabilities assumed was $1.6 million, which represents the goodwill amount resulting from the acquisition. Goodwill represents benefits that Sangamo believes will
result from combining its operations with the operations of Ceregene and any intangible assets that do not qualify for separate recognition, as well as any future, yet unidentified products. Goodwill recorded includes $0.7 million related to a
deferred tax liability. The deferred tax liability is due to the Company&#146;s recognition of the acquired IPR&amp;D assets for financial statement purposes but not for tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the goodwill is expected to be deductible for income tax purposes. The Company will test goodwill for impairment on an annual basis or
sooner, if deemed necessary. As of December&nbsp;31, 2013, there were no changes in the Goodwill recorded from the acquisition of Ceregene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability for Contingent Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the transfer of Sangamo common stock, the Company may be required to make contingent Earn-Out Payments if the Company grants a
third-party license to develop and commercialize the Earn-Out Products or if the Company commercializes any Earn-Out Product itself. These payments are a percentage of any upfront or milestone payments received in the case Sangamo grants a
third-party license to develop and commercialize the Earn-Out Products, or are a percentage of net sales in the case Sangamo develops and commercialized the Earn-Out Products itself. The total maximum payment is not limited, other than due to size
of the upfront and milestone payments received or the net sales of the products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the liability for the contingent
consideration recognized on the Close Date was $1.5 million. The Company determined the fair value of the liability for the contingent consideration based on a probability-weighted discounted cash flow analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the contingent consideration liability associated with those future earnout payments was based upon reasonable assumptions.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Escrow Account Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
the Closing Date, $0.3 million of Ceregene&#146;s remaining cash, payable to the Ceregene stockholders, was placed in an escrow account to be held until October&nbsp;1, 2014, to secure the indemnification rights of Sangamo and other indemnities with
respect to certain matters, including breaches of general representations and warranties included in the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition-Related
Transaction Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized $0.1 million in acquisition-related transaction expenses in the year ended
December&nbsp;31, 2013. These costs are included in the &#147;General and administrative&#148; expense line item in the Consolidated Statement of Operations for the year ended December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues and Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ceregene did not record any revenues for the period from the Close Date to December&nbsp;31, 2013. There were no material operating expenses
included in Sangamo&#146;s Consolidated Statement of Operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proforma Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited supplemental pro forma information presents the Company&#146;s financial results as if the acquisition of Ceregene had occurred on
January&nbsp;1, 2012. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January&nbsp;1, 2012, nor are they indicative
of any future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7 &#150; PROPERTY AND EQUIPMENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,521</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,952</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $0.6 million for 2013, 2012 and 2011. In 2012, the Company disposed
of $0.5 million in fixed assets with associated accumulated depreciation of $0.4 million. The Company recognized a $0.1 million loss on the write-off of these assets. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8 &#150; COMMITMENTS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo occupies office and laboratory space under operating leases in Richmond, California. On August&nbsp;1, 2013, Sangamo
amended its lease agreement wherein the lease was extended through August 2019. Rent expenses were $0.7 million in 2013 and $0.6 million for 2012, and 2011. Future minimum payments under contractual obligations at December&nbsp;31, 2013 consist of
the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:41.50pt; font-size:8pt; font-family:Times New Roman"><B>Fiscal Year:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Lease</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9 &#150; STOCKHOLDERS&#146; EQUITY </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has 5,000,000 preferred shares authorized, which may be issued at the Board of director&#146;s discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;23, 2013, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 7,015,000 shares of its common stock, including 915,000 shares issued to the Underwriters pursuant to a 30-day
overallotment option, at a public offering price of $10.58 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were
approximately $69.5 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;18, 2013, Sangamo&#146;s board of directors adopted, subject to stockholder approval, the Company&#146;s 2013 Stock Incentive
Plan (the 2013 Plan) as the successor to the Company&#146;s 2004 Stock Incentive Plan (the 2004 Plan). At the Annual Meeting of Stockholders held on June&nbsp;12, 2013, the 2013 Plan was approved by the Company&#146;s stockholders and became
effective. In connection with the approval by stockholders of the 2013 Plan, outstanding awards under the 2004 Plan were transferred to the 2013 Plan. The 2004 Plan was terminated and no further awards will be made pursuant to the 2004 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2013 Plan, the option exercise price per share will generally not be less than 100 percent of the fair value per share of common
stock on the option grant date, and the option term will not exceed ten years. If the person to whom the option is granted is a 10 percent stockholder, and the option granted qualifies as an Incentive Stock Option Grant, then the exercise price per
share will not be less than 110 percent of the fair value per share of common stock on the option grant date, and the option term will not exceed five years. Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent
one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination. Certain options previously granted under the 2004 Plan to the Company&#146;s non-employee directors
are structured so that they may be exercised prior to vesting, with the related shares subject to Sangamo&#146;s right to repurchase any shares that have not vested pursuant to the vesting schedule in effect for such award at the exercise price paid
if the option holder&#146;s board service terminates. Approximately 14.1&nbsp;million shares were initially reserved for issuance under the 2013 Plan, including 9.7&nbsp;million shares of common stock subject to outstanding awards previously granted
under the 2004 Plan that were transferred to the 2013 Plan, and an additional 4.4&nbsp;million shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of
shares of common stock reserved for issuance under the 2013 Plan will be reduced: (i)&nbsp;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&nbsp;on a 1-for-1 basis
for each share of common stock issued pursuant to a full value award granted under the plan prior to the plan effective date, and (iii)&nbsp;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a
full-value award granted under the plan on or after the plan effective date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to any outstanding options or other awards
under the 2013 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those options or awards will be available for subsequent issuance under the 2013 Plan. Any unvested shares issued under the 2013 Plan that the
Company subsequently purchases, pursuant to repurchase rights under the 2013 Plan, will be added back to the number of shares reserved for issuance under the 2013 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the
share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the plan. There are no net counting provisions in effect under the 2013 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo&#146;s 2010 Employee Stock Purchase Plan (Purchase Plan), which supersedes the 2000 Employee Stock Purchase Plan, provides a total
reserve of 2,100,000&nbsp;shares of common stock for issuance under the Purchase Plan. Eligible employees may purchase common stock at 85&nbsp;percent of the lesser of the fair market value of Sangamo&#146;s common stock on the first day of the
applicable two-year offering period or the last day of the applicable six-month purchase period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Activity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of Sangamo&#146;s stock option activity is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;per<BR>Share&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining<BR>Contractual&nbsp;Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,184,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,715,123</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,559</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,405,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and expected to vest at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,046,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,800,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Newly created shares are issued upon exercise of options. There were no shares subject to Sangamo&#146;s right
of repurchase as of December&nbsp;31, 2013. The intrinsic value of options exercised was $8.9 million, $0.6 million and $1.0 million during 2013, 2012 and 2011, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, the aggregate intrinsic values of the outstanding and exercisable options were $56.4&nbsp;million and $41.1
million, respectively. The aggregate intrinsic value of options vested and expected to vest during 2013, 2012 and 2011 was $54.9 million, $8.5 million and $0.1 million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes information with respect to stock options outstanding at December&nbsp;31, 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding and Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:81.05pt; font-size:8pt; font-family:Times New Roman"><B>Range of Exercise Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares of<BR>common&nbsp;stock<BR>subject&nbsp;to&nbsp;options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining<BR>Contractual&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>common&nbsp;stock<BR>subject to<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.55&nbsp;&#150;&nbsp;$3.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.45&nbsp;&#150;&nbsp;$3.45</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.80&nbsp;&#150;&nbsp;$5.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.35&nbsp;&#150;&nbsp;$5.35</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.41&nbsp;&#150;&nbsp;$5.41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.42&nbsp;&#150;&nbsp;$5.66</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.70&nbsp;&#150;&nbsp;$5.70</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.86&nbsp;&#150;&nbsp;$6.82</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">749,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.92&nbsp;&#150;&nbsp;$11.99</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$12.12&nbsp;&#150;&nbsp;$14.62</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,092,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,405,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,800,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013 and 2012, the Company issued 392,500 and 486,750 Restricted Stock Units (RSUs), respectively. The RSUs issued in 2013 and 2012 had
a grant date fair value of $12.12 and $5.41, respectively. These awards will vest as follows: one-third of the award will vest in a series of three successive equal annual installments. During 2011, the Company issued 550,000 RSUs at a grant date
fair value of $2.55. These awards will vest as follows: one-third of the award will vest on the second anniversary of the award date and two-thirds of the award will vest on the third anniversary of the award date. The aggregate value of shares
vested during 2013, 2012 and 2011 was $4.1 million, $0.1 million and $0.2 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of Sangamo&#146;s RSU activity
is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining<BR>Contractual&nbsp;Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs outstanding at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs awarded</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs released</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(341,843</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,063,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs vested and expected to vest at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSUs that vested in 2013, 2012 and 2011 were net-share settled such that the Company withheld shares with
value equivalent to the employees&#146; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 167,138 and 8,937
for 2013 and 2011, respectively, and were based on the value of the RSUs on their respective vesting dates as determined by the Company&#146;s closing stock price. There were no such shares withheld in 2012. Total payments for the employees&#146;
tax obligations to taxing authorities were $2.0 million and $0.1 million in 2013 and 2011, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows.&nbsp;These net-share settlements had the effect of
share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, there were 2,929,590 shares were reserved for future awards under the Company&#146;s 2013 Plan and 1,527,763
shares of common stock reserved for future issuance under the Purchase Plan. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10 &#150; INCOME TAXES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded no income tax expense. The principal difference between the statutory tax rate of 34% and the
Company&#146;s effective tax rate is due to the Company permanent differences related to stock compensation and its change in valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying
amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><B><I>Assets:</I></B></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax asset</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,107</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,216</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><U>Liabilities:</U></I></B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liability related to intangible assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of accounting for the acquisition of Ceregene, the Company recorded goodwill and intangible assets.
The intangible assets acquired are for the use in a particular research and development project IPR&amp;D and are considered indefinite-lived assets. They will remain indefinite lived until the completion or abandonment of the associated research
and development efforts. Since the intangible assets acquired have no tax basis, a deferred tax liability was established due to the difference between the book and tax bases for those assets. The indefinite-lived asset is not treated as a future
source of income and, therefore, no valuation allowance is released until the assets are amortized or abandoned, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of deferred
tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $14.9 million, $5.4
million and $19.7 million for the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. As of December&nbsp;31, 2013, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately
$209&nbsp;million and $199 million, respectively. If not utilized, the net federal and state operating loss carryforwards will begin to expire in 2018 and 2014 respectively. The Company also has federal and state research tax credit carryforwards of
$6.2&nbsp;million and $6.5 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#146;s net operating loss carryforwards and research tax
credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net
operating loss carryforwards and research tax credit carryforwards before utilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files Federal and state income tax
returns with varying statutes of limitations. The tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files a UK income tax return, and the tax years from 2007 and
thereafter remain open to examination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s practice is to recognize interest and/or penalties related to income tax
matters in income tax expense. As of December&nbsp;31, 2013, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event
that any unrecognized tax benefits are recognized, the effective tax rate will not be affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity related to the Company&#146;s unrecognized tax
benefits (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for tax positions of prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions for tax positions of prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11 &#150; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 12 &#150; EMPLOYEE BENEFIT PLAN </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined-contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code covering all
full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan is intended to qualify under Section&nbsp;401 of the Internal Revenue Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company matched contributions by employees equal to 50% of the first 6% of employee contributions up to a limit of $1,500 in 2013 and
$1,000 in 2012. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan were $0.1 million in both years ended December&nbsp;31, 2013 and 2012. There were no such contributions in 2011. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 13 &#150; QUARTERLY FINANCIAL DATA (UNAUDITED) </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&nbsp;31,
2013. The unaudited information set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. The operating results for any quarter are not
indicative of results for any future period. All data is in thousands except per common share data. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Q4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,885</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,450</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,145</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,144</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,268</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,728</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,790</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,478</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 14 &#150; SUBSEQUENT EVENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2014, the Company entered into a Global Research, Development and Commercialization Collaboration and
License Agreement (the Agreement) with Biogen Idec Inc. (Biogen), pursuant to which Sangamo and Biogen will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#146;s ZFP technology for
hemoglobinopathies, including beta-thalassemia and sickle cell disease (SCD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Agreement, Sangamo and Biogen will jointly
conduct two research programs: the beta-thalassemia program and the SCD program. In the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP
therapeutic developed under the Agreement for the treatment of beta-thalassemia. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to
treat SCD. Under both programs, Biogen is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the Agreement. At the end of specified research terms for each program or
under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&nbsp;licensed product to treat beta-thalassemia
and SCD&nbsp;developed under the Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Agreement, Sangamo will receive an upfront license fee of $20.0 million. Biogen will reimburse Sangamo for its costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive
development milestone payments upon the achievement of specified regulatory, clinical development and commercialization milestones. The total amount of potential regulatory, clinical development, commercialization and sales milestone payments,
assuming the achievement of all specified milestones in the Agreement, is $293.8 million, including Phase 1 milestone payments of $7.5 million for each of the beta-thalassemia and SCD programs. In addition, Biogen agrees to pay Sangamo incremental
royalties for each licensed product that are tiered double-digit percentage of annual net sales of such product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of
the Agreement, Sangamo grants Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and
commercializing licensed products developed under the Agreement. Sangamo also grants Biogen a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, of Sangamo&#146;s interest in certain other intellectual
property developed pursuant to the Agreement. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_14"></A>ITEM&nbsp;9 &#150; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_15">
</A>ITEM&nbsp;9A &#150; CONTROLS AND PROCEDURES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(I) Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures to ensure that information we are required to disclose in reports that we file or submit under
the Securities Exchange Act of 1934, as amended (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission&#146;s (SEC) rules and forms. Our management evaluated, with the
participation of our chief executive officer (CEO) and our chief financial officer (CFO), the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) under the Exchange Act. Based on that evaluation, our
CEO and CFO concluded that our disclosure controls and procedures were effective, at a reasonable assurance level, as of December&nbsp;31, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(II)
Management&#146;s Report on Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting refers to the process
designed by, or under the supervision of, our CEO and CFO, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of
the Company are being made only in accordance with authorizations of management and directors of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#146;s assets that could have a material effect on the financial statements.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management is responsible for establishing and maintaining an adequate internal control over financial reporting for the
Company. Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human
diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations,
there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is
possible to design into the process safeguards to reduce, though not eliminate, this risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the supervision and with the
participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in
&#147;Internal Control&#151;Integrated Framework&#148; issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework). Based on our evaluation under the framework set forth in &#147;Internal Control&#151;Integrated
Framework,&#148; our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2013. The effectiveness of our internal control over financial reporting as of December&nbsp;31, 2013 has been audited
by Ernst&nbsp;&amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no significant changes in our internal control over financial reporting that have materially affected, or are reasonably
likely to materially affect internal control over financial reporting during the fiscal quarter ended December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(III) Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited Sangamo BioSciences, Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2013, based on
criteria established in <I>Internal Control&#151;Integrated Framework</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) (the COSO criteria). Sangamo BioSciences, Inc.&#146;s management is responsible
for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#146;s Report on Internal Control Over Financial
Reporting. Our responsibility is to express an opinion on the company&#146;s internal control over financial reporting based on our audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered
necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles. A company&#146;s internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company&#146;s assets that could have a material effect on the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, Sangamo BioSciences, Inc.
maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2013 based on the COSO criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated
balance sheets of Sangamo BioSciences, Inc. as of December&nbsp;31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, stockholders&#146; equity, and cash flows for each of the three years in the period ended
December&nbsp;31, 2013 and our report dated February&nbsp;24, 2014 expressed an unqualified opinion thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/&nbsp;ERNST&nbsp;&amp; YOUNG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_16"></A>ITEM&nbsp;9B &#150; OTHER INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_17"></A>PART&nbsp;III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information required by Part&nbsp;III is omitted from this Report on Form&nbsp;10-K since we intend to file our definitive Proxy
Statement for our next Annual Meeting of Stockholders, pursuant to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended (the 2014 Proxy Statement), no later than April&nbsp;30, 2014, and certain information to be included in the
2014 Proxy Statement is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_18"></A><B>ITEM&nbsp;10 &#150; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item concerning our directors, executive officers, Section&nbsp;16 compliance and
corporate governance matters is incorporated by reference to the information set forth in the sections titled &#147;Election of Directors,&#148; &#147;Management,&#148; and &#147;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance&#148; in
our 2014 Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx657040_19"></A><B>ITEM&nbsp;11 &#150; EXECUTIVE COMPENSATION</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the
sections titled &#147;Executive Compensation&#148; in our 2014 Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:10%; text-indent:-10%; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_20"></A>ITEM&nbsp;12 &#150; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item regarding security ownership of certain beneficial owners and management is
incorporated by reference to the information set forth in the section titled &#147;Security Ownership of Certain Beneficial Owners and Management&#148; and &#147;Equity Compensation Plans&#148; in our 2014 Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:10%; text-indent:-10%; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_21"></A>ITEM&nbsp;13 &#150; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item regarding certain relationships and related transactions is incorporated by reference to the
information set forth in the section titled &#147;Certain Relationships and Related Transactions&#148; in our 2014 Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_22">
</A>ITEM&nbsp;14 &#150; PRINCIPAL ACCOUNTING FEES AND SERVICES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item regarding principal accounting
fees and services is incorporated by reference to the information set forth in the section titled &#147;Principal Accounting Fees and Services&#148; in our 2014 Proxy Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx657040_23"></A>PART&nbsp;IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx657040_24"></A>ITEM&nbsp;15 &#150; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The following documents are included as part of this Annual Report on Form 10-K: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. Financial Statements&#151;See Index to Consolidated Financial Statements in Item&nbsp;8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. Financial Statement Schedules&#151;Not Applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3. Exhibits&#151;See Index to Exhibits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized, on February&nbsp;24, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SANGAMO BIOSCIENCES, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>DWARD</SMALL> O.
L<SMALL>ANPHIER</SMALL> II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Edward O. Lanphier&nbsp;II</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B></B><B><I>President, Chief Executive Officer and Director</I></B><B></B></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the
following persons on behalf of the registrant and in the capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>DWARD</SMALL> O. L<SMALL>ANPHIER</SMALL>
II</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Edward O. Lanphier&nbsp;II</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director&nbsp;(Principal&nbsp;Executive&nbsp;Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24,&nbsp;2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;H. W<SMALL>ARD</SMALL> W<SMALL>OLFF</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>H. Ward Wolff</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt">Executive&nbsp;Vice&nbsp;President&nbsp;and<BR>Chief&nbsp;Financial&nbsp;Officer&nbsp;(Principal&nbsp;Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;W<SMALL>ILLIAM</SMALL> R.
R<SMALL>INGO</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William R. Ringo</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director and Chairman of the Board</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>AUL</SMALL>&nbsp;B.
C<SMALL>LEVELAND</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Paul B. Cleveland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;/&nbsp;<SMALL>S</SMALL>&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>TEPHEN</SMALL>&nbsp;G.&nbsp;
D<SMALL>ILLY</SMALL>,&nbsp;M.B.B.S,&nbsp;P<SMALL>H</SMALL>.D&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen G. Dilly, M.B.B.S, Ph.D</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL> W. L<SMALL>ARSON</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>John W. Larson</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>TEVEN</SMALL> J. M<SMALL>ENTO</SMALL>,
P<SMALL>H</SMALL>.D</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Steven J. Mento, Ph.D</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/ <SMALL>S</SMALL> /&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>AIRA</SMALL>
R<SMALL>AMASASTRY</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Saira Ramasastry</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt">February&nbsp;24, 2014</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement dated September 18, 2013 (incorporated by reference to the Company&#146;s Form 8-K filed on September 18, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 to the Company&#146;s Registration Statement on Form&nbsp;S-1/A (Registration No.&nbsp;333-30134) filed April 4, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws (incorporated by reference to Exhibit&nbsp;3.2 to the Company&#146;s Registration Statement on Form&nbsp;S-1/A (Registration No.&nbsp;333-30134) filed April 4, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit&nbsp;4.1 to the Company&#146;s Registration Statement on Form&nbsp;S-1/A (Registration No.&nbsp;333-30134) filed April 4, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2000 Employee Stock Purchase Plan (incorporated by reference to Exhibit&nbsp;10.2 to the Company&#146;s Registration Statement on Form&nbsp;S-1/A (Registration No.&nbsp;333-30134) filed February&nbsp;24, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement entered into between Sangamo and each of its directors and executive officers (incorporated by reference to Exhibit&nbsp;10.4 to the Company&#146;s Registration Statement on Form&nbsp;S-1/A
(Registration No.&nbsp;333-30134) filed February&nbsp;24, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sublicense Agreement, by and between Sangamo and Johnson&nbsp;&amp; Johnson, dated May&nbsp;9, 1996 (incorporated by reference to Exhibit&nbsp;10.3 to the Company&#146;s Annual Report on Form&nbsp;10-K/A filed April 22,
2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated May&nbsp;9, 1996, as amended by the First Amendment, dated December 10, 1997 (incorporated by reference to Exhibit&nbsp;10.4 to the
Company&#146;s Annual Report on Form&nbsp;10-K/A filed April 22, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement between Sangamo and the Johns Hopkins University, dated June 25, 1995, as amended by Amendment No. 1, dated July 16, 1998 (incorporated by reference to Exhibit&nbsp;10.5 to the Company&#146;s Annual Report on
Form&nbsp;10-K/A filed April 22, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Triple Net Laboratory Lease, between Sangamo and Point Richmond R&amp;D Associates II, LLC, dated May&nbsp;23, 1997 (incorporated by reference to Sangamo&#146;s Registration Statement on Form&nbsp;S-1 (Reg. No.&nbsp;333-30314), as
amended).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, between Sangamo and Edward O. Lanphier II, dated June&nbsp;1, 1997 (incorporated by reference to Exhibit&nbsp;10.15 to the Company&#146;s Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1/A</FONT> (Registration No.&nbsp;333-30134) filed March&nbsp;14, 2000).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated December 2, 1998 (incorporated by reference to Exhibit 10.8 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 2 to License Agreement between Sangamo and the Johns Hopkins University, effective as of July 26, 1999 (incorporated by reference to Exhibit 10.9 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated September&nbsp;1, 1999 (incorporated by reference to Exhibit 10.10 to the Company&#146;s Annual Report on Form&nbsp;10-K,
filed March&nbsp;5, 2010).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, effective as of February 10, 2000 (incorporated by reference to Exhibit 10.11 to the Company&#146;s Annual Report on
Form&nbsp;10-K, filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 3 to License Agreement between Sangamo and the Johns Hopkins University, effective as of March 10, 2000 (incorporated by reference to Exhibit 10.12 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Scripps Research Institute and Sangamo, dated March&nbsp;14, 2000 (incorporated by reference to Exhibit 10.13 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;5,
2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, effective as of December 15, 2000 (incorporated by reference to Exhibit 10.14 to the Company&#146;s Annual Report on
Form&nbsp;10-K, filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Triple Net Laboratory Lease, between Sangamo and Point Richmond R&amp;D Associates II, LLC, dated March&nbsp;12, 2004 (incorporated by reference to Sangamo&#146;s Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2004).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.16&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sixth Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated September 1, 2005 (incorporated by reference to Exhibit 10.17 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research and Commercial Option License Agreement, dated October&nbsp;5, 2005, between Sangamo and Dow AgroSciences LLC (incorporated by reference to Exhibit&nbsp;10.23 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;16, 2006).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research, Development and Commercialization Agreement dated October&nbsp;24, 2006 between Sangamo and Juvenile Diabetes Research Foundation International (incorporated by reference to Exhibit 10.19 to the Company&#146;s Annual
Report on Form&nbsp;10-K, filed March&nbsp;1, 2007).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seventh Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated October 27, 2006 (incorporated by reference to Exhibit 10.20 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment of Research and Commercial Option License Agreement between Sangamo and Dow AgroSciences LLC, dated November 7, 2006 (incorporated by reference to Exhibit 10.21 to the Company&#146;s Annual Report on Form&nbsp;10-K,
filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eighth Amendment to Patent License Agreement between Sangamo and Massachusetts Institute of Technology, dated February 1, 2007 (incorporated by reference to Exhibit 10.23 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.22&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research and License Agreement between Sangamo and Genentech, Inc., dated April 27, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q, filed August&nbsp;9, 2007).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.23&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 4 to License Agreement between Sangamo and the Johns Hopkins University, effective as of May 21, 2007 (incorporated by reference to Exhibit 10.25 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed
March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.24&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement between Sangamo and Sigma-Aldrich Corporation, dated July 10, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form 10-Q, filed November&nbsp;1, 2007).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment of the License Agreement between Sigma-Aldrich Corporation and Sangamo, dated November 9, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q filed on November 6,
2009).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.26&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement between Sangamo and Sigma-Aldrich Corporation, dated February&nbsp;25, 2008 (incorporated by reference to Exhibit 10.2 to the Company&#146;s Form&nbsp;10-Q filed on May&nbsp;9, 2008).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.27&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Research and License Agreement between Sangamo and Genentech, Inc., dated February&nbsp;27, 2008 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q filed on May 9, 2008).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.29&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement between Sangamo and Open Monoclonal Technology, Inc., dated April 2, 2008 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form 10-Q filed on August 7, 2008).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.29</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment to License Agreement by and between The Scripps Research Institute and Sangamo, dated April 29, 2008 (incorporated by reference to Exhibit 10.32 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;5,
2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.30&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Research and License Agreement between Sangamo and F. Hoffmann-La Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc., dated July 2, 2008 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form
10-Q filed on November 4, 2008).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.31&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement between Sangamo and Sigma-Aldrich Corporation, dated July&nbsp;2, 2008 (incorporated by reference to Exhibit 10.2 to the Company&#146;s Form 10-Q filed on November&nbsp;4, 2008).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.32&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement between Sangamo and Pfizer Inc., dated December 19, 2008 (incorporated by reference to Exhibit 10.25 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;3, 2009).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.33(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between Sangamo and H. Ward Wolff, dated December 31, 2008 (incorporated by reference to Exhibit 10.26 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;3,
2009).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.34(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to Employment Agreement between Sangamo and Edward O. Lanphier, dated December 31, 2008 (incorporated by reference to Exhibit 10.27 to the Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;3,
2009).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.35&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amendment of Research and Commercial Option License Agreement between Sangamo and Dow AgroSciences LLC, dated February 13, 2009 (incorporated by reference to Exhibit 10.39 to the Company&#146;s Annual Report on
Form&nbsp;10-K, filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.36</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Amendment of Research and Commercial Option License Agreement between Sangamo and Dow AgroSciences LLC, dated February 28, 2009 (incorporated by reference to Exhibit 10.40 to the Company&#146;s Annual Report on Form&nbsp;10-K,
filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.37&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amendment of the License Agreement between Sigma-Aldrich Corporation and Sangamo, dated September 25, 2009 (incorporated by reference to Exhibit 10.2 to the Company&#146;s Form&nbsp;10-Q filed on November 6, 2009).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.38&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Amendment to the License Agreement between Sigma-Aldrich Corporation and Sangamo, dated October 2, 2009 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q filed on November 6, 2009).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.39&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to the Research, Development and Commercialization Agreement between Sangamo and Juvenile Diabetes Research Foundation International, dated January 8, 2010 (incorporated by reference to Exhibit 10.44 to the
Company&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.40</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment of Research and Commercial Option License Agreement between Sangamo and Dow AgroSciences LLC, dated January 8, 2010 (incorporated by reference to Exhibit 10.45 to the Company&#146;s Annual Report on Form&nbsp;10-K,
filed March&nbsp;5, 2010).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.41</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Non-Employee Director Restricted Stock Issuance Agreement (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q filed on August 5, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.42</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment of the Research and Commercial License Option Agreement between Sangamo BioSciences, Inc. and Dow AgroSciences LLC, dated May 14, 2010 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q
filed on November 3, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.43&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sixth Amendment of the Research and Commercial License Option Agreement between Sangamo BioSciences, Inc. and Dow AgroSciences LLC, dated August 27, 2010 (incorporated by reference to Exhibit 10.2 to the Company&#146;s
Form&nbsp;10-Q filed on November 3, 2010).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.44&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seventh Amendment of the Research and Commercial License Option Agreement between Sangamo BioSciences, Inc. and Dow AgroSciences LLC, dated December 3, 2010 (incorporated by reference to Exhibit 10.49 to the Company&#146;s Form 10-K
filed on February 16, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.45&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement Amendment regarding the Research and Commercial License Option Agreement between Sangamo BioSciences, Inc. and Dow AgroSciences LLC, dated December 3, 2010 (incorporated by reference to Exhibit 10.50 to the
Company&#146;s Form 10-K filed on February 16, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.46&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement between Sangamo and Sigma-Aldrich Corporation, dated March 1, 2011 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form 10-Q filed on August 5, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.47&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter dated May&nbsp;19, 2011 from Dow AgroSciences LLC (&#147;DAS&#148;) to Sangamo amending the Research and Commercial License Option Agreement between DAS and Sangamo, dated as of October&nbsp;1, 2005, as amended (incorporated
by reference to Exhibit 10.2 to the Company&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> filed on August&nbsp;5, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.48(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between Sangamo and Edward O. Lanphier II, dated June 21, 2011 (incorporated by reference to Exhibit 10.3 to the Company&#146;s Form 10-Q filed on August 5, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.49(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between Sangamo and Dr. Geoff Nichol, dated June&nbsp;17, 2011 (incorporated by reference to Exhibit 10.4 to the Company&#146;s Form 10-Q filed on August&nbsp;5, 2011).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.50(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between Sangamo and H. Ward Wolff, dated December 15, 2011 (incorporated by reference to Exhibit&nbsp;10.55 to Company&#146;s Form&nbsp;10-K filed on February&nbsp;23, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.51(+)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Stock Unit Agreement under the Company&#146;s 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form 8-K filed on December 3, 2007).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.52&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration and License Agreement between Sangamo and Shire AG, dated January 31, 2012 (incorporated by reference to Exhibit 10.57 to the Company&#146;s Form 10-K filed on February 23, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.53</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment of the License Agreement between Sangamo and Sigma-Aldrich Corporation, dated as of September 14, 2012 (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form&nbsp;10-Q filed on November 2,
2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.54</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sangamo BioSciences, Inc. Incentive Compensation Plan (incorporated by reference to Exhibit&nbsp;10.1 to the Company&#146;s Form 8-K filed on June 27, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.55</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agreement and Plan of Merger by and among Sangamo BoSciences, Inc., Merger Sub and Ceregene and the Stockholders&#146; Representative (incorporated by reference to the Company&#146;s Form 8-K filed on October 7,
2013).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<h5 align="left"><a href="#INDEX">Index to Financial Statements</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sangamo BioSciences, Inc. 2013 Stock Incentive Plan (incorporated by reference to Appendix A to Sangamo&#146;s proxy statement on Schedule 14-A filed with the SEC on April 25, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Company</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rule&nbsp;13a-14(a) Certification of Principal Executive Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rule&nbsp;13a-14(a) Certification of Principal Financial Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section&nbsp;1350.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been granted for certain information contained in this document pursuant to an order of the Securities and Exchange Commission. Such information has been omitted and filed separately with the
Securities and Exchange Commission. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(+)</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan or arrangement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>d657040dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of the Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gendaq
Limited (U.K.) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ceregene Inc. (Delaware) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d657040dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the Registration Statements Form S-8 (No.&nbsp;333-189621) and in the Registration Statement
Form S-3 (No.&nbsp;333-179634) and in the related prospectuses of Sangamo BioSciences, Inc. of our reports dated February&nbsp;24, 2014, with respect to the consolidated financial statements of Sangamo BioSciences, Inc., and the effectiveness of
internal control over financial reporting of Sangamo BioSciences, Inc., included in its Annual Report (Form 10-K) for the year ended December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/&nbsp;Ernst&nbsp;&amp; Young LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d657040dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHIEF EXECUTIVE OFFICER CERTIFICATE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I,
Edward O. Lanphier II, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 10-K of Sangamo BioSciences, Inc. (the &#147;registrant&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a &#150; 15(f) and 15d &#150; 15 (f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;24, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d657040dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRINCIPAL FINANCIAL OFFICER CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, H. Ward Wolff, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 10-K of Sangamo BioSciences, Inc. (the &#147;registrant&#148;) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a &#150; 15(f) and 15d &#150; 15 (f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;24, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d657040dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>Prepared by R.R. Donnelley Financial -- EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the undersigned hereby certifies pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of
2002, in his capacity as an officer of Sangamo BioSciences, Inc. (the &#147;Company&#148;), that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) the Annual Report of the Company on Form 10-K for
the year ended December&nbsp;31, 2013, as filed with the Securities and Exchange Commission (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2014</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Financial and Accounting Officer)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2014</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>sgmo-20131231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:sgmo="http://sangamo.com/20131231" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sgmo-20131231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <sgmo:OneTimeLicenseFeeEarned contextRef="eol_PE72223---1310-K0008_STD_0_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_60CAB446-CFDA-43E6-A535-F657CE4638A2_3001_0">6000000</sgmo:OneTimeLicenseFeeEarned>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-K0008_STD_0_20061031_0_925277x1044992" id="id_3014833_6B09407D-0432-4197-8A23-749F79A85D8C_2001_0">2006-10-31</sgmo:AgreementDate>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-K0008_STD_0_20070131_0_925277x998276" id="id_3014833_996A7ADF-A1A4-44DB-8194-2D9D228BEE17_2001_0">2007-01-31</sgmo:AgreementDate>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-K0008_STD_0_20091031_0_925277x1137514" id="id_3014833_E69900F0-8E70-42FD-A85D-76B82D68F385_2001_3">2009-10-31</sgmo:AgreementDate>
  <sgmo:ExpectedAmountToBeReceivedForResearchAndDevelopment contextRef="eol_PE72223---1310-K0008_STD_0_20091031_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_E69900F0-8E70-42FD-A85D-76B82D68F385_2001_2">5200000</sgmo:ExpectedAmountToBeReceivedForResearchAndDevelopment>
  <sgmo:RoyaltyRevenuesExpectedToBeReceived contextRef="eol_PE72223---1310-K0008_STD_0_20091031_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_F523AE14-87D2-4EC2-A555-079F083BB936_2001_0">5000000</sgmo:RoyaltyRevenuesExpectedToBeReceived>
  <sgmo:AdditionalMilestonePaymentUnderAgreement contextRef="eol_PE72223---1310-K0008_STD_0_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_F523AE14-87D2-4EC2-A555-079F083BB936_1001_2">25000000</sgmo:AdditionalMilestonePaymentUnderAgreement>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20140201_0" unitRef="shares" decimals="INF" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_2_8">62736879</dei:EntityCommonStockSharesOutstanding>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-K0008_STD_0_20110430_0_925277x1019175" id="id_3014833_7193F4BF-AB42-4371-B9F7-D1BB1F3171D9_2001_1">2011-04-30</sgmo:AgreementDate>
  <sgmo:FundsDueUnderAgreement contextRef="eol_PE72223---1310-K0008_STD_0_20110430_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_7193F4BF-AB42-4371-B9F7-D1BB1F3171D9_2001_0">1300000</sgmo:FundsDueUnderAgreement>
  <sgmo:FundingReceivedFromResearchGrant contextRef="eol_PE72223---1310-K0008_STD_0_20100630_0_925277x998276_926233x931915" unitRef="iso4217_USD" decimals="-5" id="id_3014833_996A7ADF-A1A4-44DB-8194-2D9D228BEE17_1002_3">900000</sgmo:FundingReceivedFromResearchGrant>
  <dei:EntityPublicFloat contextRef="eol_PE72223---1310-K0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_3_9">405023312</dei:EntityPublicFloat>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_2001_0">1896000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1006_1">55907000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2001_31">10784000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1005_1">-6000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1004_1">-217495000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1001_2">45377739</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1001_1">454000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_1003_1">272954000</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_3014833_B6D90074-80D8-4FE2-B3C8-38FD2D08B9D6_1003_0">8346190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1003_0">2750000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3006_14">80132000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1003_31">16766000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_772F398A-E5AB-41FB-887E-9313BCAFE498_1003_2">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3005_14">12000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3004_14">-253245000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3001_15">52554795</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3001_14">526000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_3003_14">332839000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_33">53058525</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_32">53058525</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_1001_1">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3014833_B6D90074-80D8-4FE2-B3C8-38FD2D08B9D6_1002_0">9184346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_31">80000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_30">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_2_4">2952000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_34">339848000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_2_0">3046000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_2_2">238000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_9">88216000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_22">8790000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_36">26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1002_0">2734000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_13" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_3014833_C6988B3E-CC07-4959-80E4-003681789B32_2001_0">1510</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_37">64896000</us-gaap:StockholdersEquity>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_2_4">20000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_19">2473000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_6" />
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_18">4013000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_35">-275509000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_21">2304000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_14" />
  <us-gaap:CommonStockValue contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_29">531000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_2_3">94000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_38">82533000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Liabilities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_26">17637000</us-gaap:Liabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_23">8847000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_27" />
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_3">41868000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_9">68365000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_9_1">73262000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_5">7375000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_10">12584000</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_6">296000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_2">73129000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_8">88216000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:Assets contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_15">82533000</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_1_3">73288000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_2">21679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_5">4129000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_10" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_2_3">4495000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_3">6770000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_9_4">73288000</us-gaap:MarketableSecurities>
  <us-gaap:OtherAssets contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_14">41000</us-gaap:OtherAssets>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_8">203000</us-gaap:OtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_772F398A-E5AB-41FB-887E-9313BCAFE498_1002_2">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_7">937000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_4">190000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_2_11">1543000</us-gaap:PropertyPlantAndEquipmentNet>
  <sgmo:AccruedClinicalTrialExpense contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_2_1">615000</sgmo:AccruedClinicalTrialExpense>
  <sgmo:DeferredTaxAssetsCapitalizedResearch contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1002_4">5000</sgmo:DeferredTaxAssetsCapitalizedResearch>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_9_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_9_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <sgmo:PostAmendmentFundsDueUnderAgreement contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_7193F4BF-AB42-4371-B9F7-D1BB1F3171D9_1003_4">2100000</sgmo:PostAmendmentFundsDueUnderAgreement>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_5005_25">26000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_5004_25">-275509000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_5001_26">53058525</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_5001_25">531000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_5003_25">339848000</us-gaap:StockholdersEquity>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_5_1">2997000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_5_4">2997000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_5_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_5_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x925736_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_1002_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x925851_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_1003_2">57449000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x929831_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_1004_2" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_8_1">54426000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_1001_2">57449000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_8_4">54452000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_8_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_8_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_2002_1">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x925851_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_2003_1" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_2004_1" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_6_1">15839000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_2001_1">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_6_4">15839000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_6_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_6_2" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_0D6E8D90-9BF9-4416-9575-550181B14D60_1001_1">1036750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_2_3">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_3_3">57449000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_9AC90A95-9205-4DED-99CE-FFE45AFCE126_4_3" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x923325" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_1002_2">1046000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x928802" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_2002_0">2950000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x932226" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_3002_1">499000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_7_1">18836000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_7_4">18836000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_7_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_7_2" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_33">62243892</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_5EF23B67-B49F-440C-8EB5-017B99E73EF4_3001_7">5800931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1011_3">8405864</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_32">62243892</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_3001_5">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_B6D90074-80D8-4FE2-B3C8-38FD2D08B9D6_1001_0">8405864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_3001_6">7.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1011_6">6.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_3B5D5450-5F39-4748-BE29-E5A6E200C55F_1001_0">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_5EF23B67-B49F-440C-8EB5-017B99E73EF4_3001_6">8046932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_3001_7">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1011_5">5800931</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_31">80000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_30">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_1">668000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_1_4">3521000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_25">748000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_34">423209000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_6">3861000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_1_0">3022000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_1_2">510000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_3">709000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_9">103107000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_22">10131000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_36">12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_5">496000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_D90B170C-33A2-4968-AB1C-7E6475008A24_1_0">700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1001_4">3182000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_13">-748000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3014833_C6988B3E-CC07-4959-80E4-003681789B32_1001_3">1570</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_37">121710000</us-gaap:StockholdersEquity>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_1_4" />
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_19">3194000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_F3E468A8-D88C-4A09-9D25-423A3A0C2FA9_1_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_24">1570000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_4">730000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:DeferredRevenue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_6">-3563000</us-gaap:DeferredRevenue>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_18">4380000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_35">-302133000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_21">2282000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_14">-748000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_29">622000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_1_3">121000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_38">140838000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Liabilities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_26">19128000</us-gaap:Liabilities>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_2">688000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_23">6679000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1_4">1570000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_27" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_FC1ADE5C-17D9-4372-9C06-DCE1CE0305AE_1_0">570000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_3">82627000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_9">97274000</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_13">1585000</us-gaap:Goodwill>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_4_1">128212000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_5">7927000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_10">38663000</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_7">320000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_6">457000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_2">81944000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1001_2">199000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_8">103107000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:Assets contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_15">140838000</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1_2">128224000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_98619707-DF1D-4E9E-9F3B-6BB4E8E49ACA_1001_2">54849000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_2">10186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8B7839B3-0D0F-4706-B696-B9A7822BF7E2_2001_0">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_5">3155000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_12">1870000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_10" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_1_3">4927000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_3">7996000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_772F398A-E5AB-41FB-887E-9313BCAFE498_1001_1">41073000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_4_4">128224000</us-gaap:MarketableSecurities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_772F398A-E5AB-41FB-887E-9313BCAFE498_1001_0">56425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:OtherAssets contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_14">40000</us-gaap:OtherAssets>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_8">191000</us-gaap:OtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_772F398A-E5AB-41FB-887E-9313BCAFE498_1001_2">54900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1001_1">209000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_7">1677000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_4">338000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_11">1406000</us-gaap:PropertyPlantAndEquipmentNet>
  <sgmo:EmployersMatchingContributionPercentageTowardsEmployeesContribution contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="pure" decimals="2" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_1001_1">0.06</sgmo:EmployersMatchingContributionPercentageTowardsEmployeesContribution>
  <sgmo:CommonStockExchangeRatio contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="pure" decimals="0" id="id_3014833_40E52C5C-A3EF-48B9-A51E-90197601C5CD_1_0">1</sgmo:CommonStockExchangeRatio>
  <sgmo:AccruedClinicalTrialExpense contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A8D74962-0C20-43D4-860D-5A7171D03772_1_1">727000</sgmo:AccruedClinicalTrialExpense>
  <sgmo:EscrowLiability contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_F24B3B77-76E1-4D7D-AB5C-F6E75211D2BD_1_20">275000</sgmo:EscrowLiability>
  <sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_1001_0">P2Y</sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities>
  <sgmo:DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1001_5">6500000</sgmo:DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal>
  <sgmo:DeferredTaxAssetsCapitalizedResearch contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_1CA754D3-797A-4B6E-94B9-D33858A27660_1001_4" />
  <sgmo:RestrictedCashAndCashEquivalent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_42C6B44E-AF34-4809-89DA-AC161812BC7C_1_0">300000</sgmo:RestrictedCashAndCashEquivalent>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_4_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_4_2">12000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <sgmo:StockSplitRatioOnCommonStock contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0" id="id_3014833_40E52C5C-A3EF-48B9-A51E-90197601C5CD_1_1">1.33 shares</sgmo:StockSplitRatioOnCommonStock>
  <sgmo:FundingReceivedFromResearchGrant contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_925277x998276" unitRef="iso4217_USD" decimals="-5" id="id_3014833_996A7ADF-A1A4-44DB-8194-2D9D228BEE17_2003_1">1900000</sgmo:FundingReceivedFromResearchGrant>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1002418" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1007_3">945120</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1002418" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1007_6">5.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1002418" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1007_5">676970</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1014875" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1003_3">661565</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1014875" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1003_6">4.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1014875" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1003_5">596146</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1048263" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1006_3">60500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1048263" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1006_6">5.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1048263" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1006_5">60500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1053915" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1005_3">1134524</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1053915" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1005_6">5.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1053915" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1005_5">270040</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1097982" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1009_3">365342</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1097982" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1009_6">8.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1097982" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1009_5">267361</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1124646" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1004_3">909866</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1124646" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1004_6">5.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1124646" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1004_5">909866</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1139642" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1010_3">2092700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1139642" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1010_6">14.05</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1139642" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1010_5">1087000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x949918" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1008_3">899022</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x949918" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1008_6">6.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x949918" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1008_5">749020</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x960261" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1001_3">212844</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x960261" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1001_6">2.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x960261" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1001_5">59647</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x975231" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1002_3">1124381</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x975231" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1002_6">3.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x975231" unitRef="shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_1002_5">1124381</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_7005_40">12000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_7004_40">-302133000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_7001_41">62243892</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_7001_40">622000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_7003_40">423209000</us-gaap:StockholdersEquity>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_5">748000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B42BB679-584B-4910-8345-0BC40CAC4A9D_1001_0">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_7">846000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_6">98000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <us-gaap:Goodwill contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_3">1585000</us-gaap:Goodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_2">1870000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_1">22000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-5" id="id_3014833_384E037A-A5C0-4E0E-A4C4-1FE15C6DE8B5_1_0">100000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_0">79000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_8">2710000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_E1F0B6C7-BD2A-4C0B-B018-0520914D13A0_1001_4">3556000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588_931868x1237600" unitRef="iso4217_USD" decimals="-3" id="id_3014833_C8BA1F1E-5FD3-48A8-8C80-893AC8A8F59E_1001_1">1640000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588_931868x1237605" unitRef="iso4217_USD" decimals="-3" id="id_3014833_C8BA1F1E-5FD3-48A8-8C80-893AC8A8F59E_1002_1">230000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1001_3">1570000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x925736" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1002_3" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1003_3" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_1004_3">1570000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x925736_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2002_1" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x925851_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2003_1">121290000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2004_1" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_3_1">121278000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_3_4">121290000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_3_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_3_2">12000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2001_1">121290000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3002_0">6934000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x925851_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3003_0" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3004_0" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_1_1">6934000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3001_0">6934000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_1_4">6934000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_1_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_1_2" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_0D6E8D90-9BF9-4416-9575-550181B14D60_4001_5">1063657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8B7839B3-0D0F-4706-B696-B9A7822BF7E2_3001_2">5400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A403FE74-14F4-4B6A-AF14-D72FC6328C39_2001_1">14774000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867" unitRef="iso4217_USD" decimals="-3" id="id_3014833_A403FE74-14F4-4B6A-AF14-D72FC6328C39_2001_2">12860000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_0D6E8D90-9BF9-4416-9575-550181B14D60_4001_6">925882</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929039x930113" unitRef="iso4217_USD" decimals="-6" id="id_3014833_9D7A7CD5-C250-4116-A437-20C5AC1BA37A_1001_1">0</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_2_2">6934000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_3_2">121290000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_4_4">1570000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_3134BBDF-3F26-402E-A65E-AD21C7B4535C_4_2" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x923325" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_1001_2">1156000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x928802" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_2001_0">3208000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x932226" unitRef="iso4217_USD" decimals="-3" id="id_3014833_5CC25781-DEA5-47FC-9C76-3B727AF04AB4_3001_1">563000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x1044748" unitRef="shares" decimals="-5" id="id_3014833_2B02C763-9580-4B66-AD86-59C1CBF6A206_1001_0">14100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x1044748" unitRef="shares" decimals="-5" id="id_3014833_2B02C763-9580-4B66-AD86-59C1CBF6A206_1001_1">9700000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x1044748" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_3001_1">P10Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x1044748" unitRef="shares" decimals="INF" id="id_3014833_AB0A95FA-FFFF-43B6-98E1-72DBEA5DA59B_1001_0">2929590</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x929710" unitRef="shares" decimals="INF" id="id_3014833_B86D4AAD-E931-4575-8099-EA275FFF8951_2001_0">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x929710" unitRef="shares" decimals="INF" id="id_3014833_AB0A95FA-FFFF-43B6-98E1-72DBEA5DA59B_2001_1">1527763</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_2_1">6934000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_2_4">6934000</us-gaap:MarketableSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_2_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_B09C835B-4F80-47F6-891E-81F32E83A9A9_2_2" />
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-K0008_STD_0_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_54D8D38A-94EE-4A87-AE26-90F4F9088D37_1001_0">8900000</us-gaap:DeferredRevenueCurrent>
  <sgmo:MilestonePaymentsPayable contextRef="eol_PE72223---1310-K0008_STD_0_20140108_0_926233x1246050_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_3014833_070C032A-18A9-4CF4-8FB1-3F2346373692_1002_1">7500000</sgmo:MilestonePaymentsPayable>
  <sgmo:MilestonePaymentsPayable contextRef="eol_PE72223---1310-K0008_STD_0_20140108_0_926233x1246051_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_3014833_070C032A-18A9-4CF4-8FB1-3F2346373692_1003_1">7500000</sgmo:MilestonePaymentsPayable>
  <sgmo:MilestonePaymentsPayable contextRef="eol_PE72223---1310-K0008_STD_0_20140108_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_3014833_070C032A-18A9-4CF4-8FB1-3F2346373692_1001_0">293800000</sgmo:MilestonePaymentsPayable>
  <us-gaap:LicenseCosts contextRef="eol_PE72223---1310-K0008_STD_3_20140108_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_3014833_C349B5DC-C7C4-4B63-A1BC-40776ECD4030_1001_0">20000000</us-gaap:LicenseCosts>
  <sgmo:NumberOfResearchProgram contextRef="eol_PE72223---1310-K0008_STD_3_20140108_0_932504x931597" unitRef="Program" decimals="INF" id="id_3014833_0609000C-320F-41B6-A468-B8FD01913BB3_1001_0">2</sgmo:NumberOfResearchProgram>
  <sgmo:AgreementToReceive contextRef="eol_PE72223---1310-K0008_STD_30_20110430_0_925277x1019175" id="id_3014833_7193F4BF-AB42-4371-B9F7-D1BB1F3171D9_1001_2">P1Y</sgmo:AgreementToReceive>
  <sgmo:NumberOfGeneTargets contextRef="eol_PE72223---1310-K0008_STD_30_20120630_0_933025x992959" unitRef="Targets" decimals="INF" id="id_3014833_E6D85C3D-4E51-41E3-BCC9-5CB00BCD0DC9_1002_2">5</sgmo:NumberOfGeneTargets>
  <sgmo:NumberOfAdditionalGeneTargets contextRef="eol_PE72223---1310-K0008_STD_30_20120630_0_933025x992959" unitRef="Targets" decimals="INF" id="id_3014833_E6D85C3D-4E51-41E3-BCC9-5CB00BCD0DC9_1002_3">2</sgmo:NumberOfAdditionalGeneTargets>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_926233x928673_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_60CAB446-CFDA-43E6-A535-F657CE4638A2_1001_2">4000000</us-gaap:RoyaltyRevenue>
  <sgmo:AnnualFeesRelatedToAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_926437x923140_933025x1094419" unitRef="iso4217_USD" decimals="1" id="id_3014833_03F441FE-46B0-48AD-A8C6-2B48D1F04C12_2_500000">3.0</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:AnnualFeesRelatedToAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_926437x932953_933025x1094419" unitRef="iso4217_USD" decimals="1" id="id_3014833_03F441FE-46B0-48AD-A8C6-2B48D1F04C12_1_400000">250000.0</sgmo:AnnualFeesRelatedToAgreement>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_60CAB446-CFDA-43E6-A535-F657CE4638A2_2001_1">2300000</us-gaap:RoyaltyRevenue>
  <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419" id="id_3014833_03F441FE-46B0-48AD-A8C6-2B48D1F04C12_3_600001">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419" id="id_3014833_9B5B712D-8D77-4229-B009-2F7E67DF3A5A_1001_0">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:FeeDue contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_03F441FE-46B0-48AD-A8C6-2B48D1F04C12_3_600002">25300000</sgmo:FeeDue>
  <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing contextRef="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419" unitRef="pure" decimals="2" id="id_3014833_60CAB446-CFDA-43E6-A535-F657CE4638A2_2001_3">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
  <sgmo:GrantFundingAmount contextRef="eol_PE72223---1310-K0008_STD_31_20070131_0_925277x998276_926233x931915" unitRef="iso4217_USD" decimals="-5" id="id_3014833_996A7ADF-A1A4-44DB-8194-2D9D228BEE17_1001_2">1000000</sgmo:GrantFundingAmount>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20070731_0_933025x982693" id="id_3014833_EE21AD87-0744-4005-A750-52249FF09317_1001_0">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:GrantFundingAmount contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_E69900F0-8E70-42FD-A85D-76B82D68F385_1001_0">14500000</sgmo:GrantFundingAmount>
  <sgmo:AgreementToReceive contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_925277x1137514" id="id_3014833_E69900F0-8E70-42FD-A85D-76B82D68F385_1001_1">P4Y</sgmo:AgreementToReceive>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_926233x1007904_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5256986F-8EB8-44DD-8E1D-44BA569E5984_1001_3">15100000</sgmo:UpfrontLicenseFee>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_933025x982693" unitRef="shares" decimals="INF" id="id_3014833_5256986F-8EB8-44DD-8E1D-44BA569E5984_2001_2">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5256986F-8EB8-44DD-8E1D-44BA569E5984_2001_1">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5256986F-8EB8-44DD-8E1D-44BA569E5984_2001_0">20000000</sgmo:UpfrontLicenseFee>
  <sgmo:ReducedRoyaltyRate contextRef="eol_PE72223---1310-K0008_STD_31_20091031_0_933025x982693" unitRef="pure" decimals="3" id="id_3014833_F523AE14-87D2-4EC2-A555-079F083BB936_1002_1">0.105</sgmo:ReducedRoyaltyRate>
  <sgmo:GrantFundingAmountMaximumUnderAmendedAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20100131_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_3014833_6B09407D-0432-4197-8A23-749F79A85D8C_1002_1">3000000</sgmo:GrantFundingAmountMaximumUnderAmendedAgreement>
  <sgmo:AggregateNumberOfGeneTargets contextRef="eol_PE72223---1310-K0008_STD_31_20120131_0_933025x992959" unitRef="Targets" decimals="INF" id="id_3014833_E6D85C3D-4E51-41E3-BCC9-5CB00BCD0DC9_1001_0">7</sgmo:AggregateNumberOfGeneTargets>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-K0008_STD_31_20120131_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8E58C979-920E-423A-B1B0-09E6A3BB26E2_1001_0">13000000</sgmo:UpfrontLicenseFee>
  <sgmo:NumberOfInitialGeneTargets contextRef="eol_PE72223---1310-K0008_STD_31_20120131_0_933025x992959" unitRef="Targets" decimals="INF" id="id_3014833_E6D85C3D-4E51-41E3-BCC9-5CB00BCD0DC9_1001_1">4</sgmo:NumberOfInitialGeneTargets>
  <sgmo:GrantFundingAmount contextRef="eol_PE72223---1310-K0008_STD_31_20130531_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_27D873DE-4412-4732-BFA0-3554F38BA5EB_1001_0">6400000</sgmo:GrantFundingAmount>
  <sgmo:AgreementToReceive contextRef="eol_PE72223---1310-K0008_STD_31_20130531_0_925277x1137514" id="id_3014833_27D873DE-4412-4732-BFA0-3554F38BA5EB_1001_1">P4Y</sgmo:AgreementToReceive>
  <sgmo:ProceedsReceivedForWorkPerformedUnderAgreement contextRef="eol_PE72223---1310-K0008_STD_31_20120331_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_3014833_01013383-9B13-4545-B48C-68F31838DFBA_1001_0">800000</sgmo:ProceedsReceivedForWorkPerformedUnderAgreement>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="eol_PE72223---1310-K0008_STD_31_20130923_0_926607x960063_932980x930643" unitRef="shares" decimals="INF" id="id_3014833_9E505008-B8CD-4D78-BF4E-5831980FB097_1001_3">915000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE72223---1310-K0008_STD_31_20130923_0_932980x930643" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_9E505008-B8CD-4D78-BF4E-5831980FB097_2001_1">10.58</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE72223---1310-K0008_STD_31_20130923_0_932980x930643" unitRef="shares" decimals="INF" id="id_3014833_9E505008-B8CD-4D78-BF4E-5831980FB097_2001_0">7015000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <sgmo:NetProceedsFromIssuancePublicOffering contextRef="eol_PE72223---1310-K0008_STD_31_20130923_0_932980x930643" unitRef="iso4217_USD" decimals="-5" id="id_3014833_9E505008-B8CD-4D78-BF4E-5831980FB097_2001_2">69500000</sgmo:NetProceedsFromIssuancePublicOffering>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="shares" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_13">50512000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockDividendsShares contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="shares" decimals="INF" id="id_3014833_41A51777-B557-4068-8627-C5800A37D5FE_3_0">8937</us-gaap:StockDividendsShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7BCC4C84-4B6C-4753-8D50-0EA1194D648D_3_0">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_17">-25895000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_12">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_5">1194000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_3_2">265000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_3">10319000</us-gaap:Revenues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_41A51777-B557-4068-8627-C5800A37D5FE_3_1">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_13">13000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_3_1">589000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_13">-35732000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_19">112974000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_2">4209000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_9">-35821000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_3_0">19700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_11">-6000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_27">48000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_12">553000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_10">71000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_11">-35750000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_7">463000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_9">8081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_3">50219000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_23">576000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4006_11">18000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_3_5">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_3_3">0</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_20">83412000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
  <us-gaap:ProceedsFromSaleOfInvestmentProjects contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_21">10139000</us-gaap:ProceedsFromSaleOfInvestmentProjects>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_15">315000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_6">14042000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_29">51876000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_16">-64000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_14">-139000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_6DD4FFC5-8A13-4AE9-AF85-02F098514F1F_3_1">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_5">8081000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_30">5982000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_28">1772000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_24">-19999000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_5">32098000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_3_4">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_3">646000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_3_2">8081000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_8">46140000</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_4">1576000</us-gaap:AmortizationOfDebtDiscountPremium>
  <sgmo:RentalExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_CBEE8630-30BE-4666-B35B-713000DFEF15_3_0">600000</sgmo:RentalExpenses>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_3_1">6110000</sgmo:CollaborationAgreements>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7585E592-E971-4766-9D0D-CE2E3324E167_3_0">1.62</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <sgmo:ProceedsFromIssuanceInitialPublicOfferingNetOfCosts contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_3_26">50152000</sgmo:ProceedsFromIssuanceInitialPublicOfferingNetOfCosts>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_923497x921516" unitRef="pure" decimals="INF" id="id_3014833_A534DA7E-1824-4B96-B58C-98890B20C09E_1003_0">1.00</us-gaap:ConcentrationRiskPercentage1>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AE3ACBB-5758-4F75-B0BF-3535AFE6B7DD_1002_1">1200000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AE3ACBB-5758-4F75-B0BF-3535AFE6B7DD_1002_0">1100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AF1170E-D1A9-42C5-BEC4-B457528B097E_1002_0">500000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_1003_1">2000000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_2003_0">1700000</sgmo:ResearchGrantRevenue>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x998276_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_46099742-376E-4708-B01E-618D0ABE95A9_1003_0">400000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_C9597BB3-8A9A-4AFA-958F-CEE3BBE101AB_1003_0">500000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1007_0">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1007_2">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1007_1">P5Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1006_0">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1006_2">0.0085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1006_1">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1006_0">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1006_2">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1006_1">P5Y4M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1005_0">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1005_2">0.0058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1005_1">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_1003_1">4312000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_2003_0">3769000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4005_11">18000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4004_12">-35750000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_8">152640</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_6">324416</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_4">6700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_5">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_7">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4001_3">67000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4003_5">1191000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4003_7">461000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4003_9">8081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_4003_3">50152000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1003_0">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_929038x929867" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1003_1">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_929038x929867" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1003_9">200000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_929362x924898" unitRef="pure" decimals="2" id="id_3014833_72596D9D-85AC-40AA-97B1-3597184A3C58_1003_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_930809x929710" unitRef="pure" decimals="2" id="id_3014833_1E2E4706-3A9E-4863-84D1-355BC259CFE1_1003_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_930809x929710" unitRef="shares" decimals="INF" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1003_0">153000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_930809x929710" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1003_1">3.02</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1019175" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_1003_4">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1003_0">4500000</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1003_1">900000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1137514" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_2003_3">0.18</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x971461" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_3003_2">0.43</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x982693" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_4003_1">0.15</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1003_3">1609000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1003_2">671000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1003_1">938000</us-gaap:RoyaltyRevenue>
  <dei:TradingSymbol contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_0">SGMO</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_1">SANGAMO BIOSCIENCES INC</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_5">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DEBB4640-2227-4AEF-A15F-6C1EBC5CAF31_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_7">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DEBB4640-2227-4AEF-A15F-6C1EBC5CAF31_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DEBB4640-2227-4AEF-A15F-6C1EBC5CAF31_1_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DEBB4640-2227-4AEF-A15F-6C1EBC5CAF31_1_2">2013-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_2">0001001233</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_4">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DEBB4640-2227-4AEF-A15F-6C1EBC5CAF31_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8A6114D7-B7B4-43C0-95C3-837DFC8DF206_1_6">No</dei:EntityVoluntaryFilers>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_F861B432-4C78-4A0F-8CC4-5E3C972B16BA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 4 &amp;#x2013; STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table shows total stock-based compensation expense
 recognized in the consolidated statements of operations (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,942&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,338&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of December&amp;#xA0;31, 2013, total stock-based compensation
 expense related to unvested stock options to be recognized in
 future periods was $11.2&amp;#xA0;million, which is expected to be
 expensed over a weighted-average period of 2.87 years. As of
 December&amp;#xA0;31, 2013, total compensation expense related to
 unvested RSUs to be recognized in future periods was $5.4 million,
 which is expected to be expensed over a weighted-average period of
 1.98 years. There was no capitalized stock-based employee
 compensation expense as of December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Valuation Assumptions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The employee stock-based compensation expense was determined using
 the Black-Scholes option valuation model. Option valuation models
 require the input of subjective assumptions and these assumptions
 can vary over time.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company primarily bases its determination of expected
 volatility through its assessment of the historical volatility of
 its common stock. The Company relied on its historical exercise and
 post-vested termination activity for estimating its expected term
 for use in determining the fair value of these options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The weighted-average estimated fair value per share of options
 granted during 2013, 2012 and 2011 was $8.29, $3.76 and $3.20,
 respectively, based upon the assumption in the Black-Scholes
 valuation model. The assumptions used for estimating the fair value
 of the employee stock options are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.50-1.88&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.74-1.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.93-2.11&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected life of option (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.36-5.38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40-5.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.39-5.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield of stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.87-0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.83-0.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Employees purchased approximately 181,000, 175,000 and 153,000
 shares of common stock through the 2010 Purchase Plan at an average
 exercise price of $2.75, $2.61 and $3.02 per share during the
 fiscal years 2013, 2012 and 2011, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The weighted-average estimated fair value of shares purchased under
 the Company&amp;#x2019;s ESPP during 2013, 2012 and 2011 were $1.47,
 $2.51 and $1.62, respectively, based upon the assumptions in the
 Black-Scholes valuation model. The weighted&amp;#x2013;average
 assumptions used for estimating the fair value of the ESPP purchase
 rights are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.61&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.30&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.61&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected life of option (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield of stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.51-0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.93-1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.58-0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_6BC8B99E-9A39-4A92-A3B7-CAA10BC09895_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Accounts payable and accrued liabilities consist of the following
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,022&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrued clinical trial expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total accounts payable and accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_10DBD2F7-3E07-4D81-AEEC-D61BD1749EA8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 8 &amp;#x2013; COMMITMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo occupies office and laboratory space under operating leases
 in Richmond, California. On August&amp;#xA0;1, 2013, Sangamo amended
 its lease agreement wherein the lease was extended through August
 2019. Rent expenses were $0.7 million in 2013 and $0.6 million for
 2012, and 2011. Future minimum payments under contractual
 obligations at December&amp;#xA0;31, 2013 consist of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 41.5pt"&gt;
 &lt;b&gt;Fiscal Year:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Operating&lt;br /&gt;
 Lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;668&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;688&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;496&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total minimum payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="-5" id="id_3014833_2B02C763-9580-4B66-AD86-59C1CBF6A206_2_2">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_3FF3AE09-B644-460F-8CD9-1DAABE09AD6A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of Sangamo&amp;#x2019;s RSU activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&amp;#xA0;Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,036,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs awarded&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs released&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(341,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,063,657&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs vested and expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;925,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_856FFE84-C26B-49AC-ABA9-B61E91E4F507_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The table below summarizes the Company&amp;#x2019;s cash equivalents and
 available-for-sale securities (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 (Losses)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="Segments" decimals="INF" id="id_3014833_A534DA7E-1824-4B96-B58C-98890B20C09E_1_1">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2011_4">P6Y3M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_2465C9C9-C233-42AB-A392-6FC2C5F87767_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company measures and recognizes compensation expense for all
 stock-based payment awards made to Sangamo employees and directors,
 including employee share options, restricted stuck units (RSUs) and
 employee share purchases related to the Employee Share Purchase
 Plan (ESPP), based on estimated fair values at grant date. The fair
 value of stock-based awards is amortized over the vesting period of
 the award using a straight-line method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 To estimate the value of an award, the Company uses the
 Black-Scholes option pricing model. This model requires inputs such
 as expected life, expected volatility and risk-free interest rate.
 These inputs are subjective and generally require significant
 analysis and judgment to develop. While estimates of expected life
 and volatility are derived primarily from the Company&amp;#x2019;s
 historical data, the risk-free rate is based on the U.S. Treasury
 yield curve in effect at the time of grant commensurate with the
 expected life assumption. Further, the Company is required to
 estimate forfeitures at the time of grant and revise those
 estimates in subsequent periods if actual forfeitures differ from
 those estimates. The Company uses historical data to estimate
 pre-vesting option forfeitures and record stock-based compensation
 expense only for those awards that are expected to vest.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_C6988B3E-CC07-4959-80E4-003681789B32_1_1">2013-10-01</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_E452F2EA-CD34-4FEA-9B4B-46B9E5A4BA44_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The carrying amounts for financial instruments consisting of cash
 and cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value due to their short
 maturities. Marketable securities and contingent consideration
 liabilities are stated at their estimated fair values. The
 counterparties to the agreements relating to the Company&amp;#x2019;s
 investment securities generally can consist of the US Treasury,
 various major corporations, governmental agencies and financial
 institutions with high credit standing.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:BusinessCombinationsPolicy contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_00EECDDE-4AC4-41DE-82CB-8A833CD3CC68_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company accounted for the acquisition of Ceregene in accordance
 with Accounting Standards Codification (ASC) Topic 805, Business
 Combinations. ASC Topic 805 establishes principles and requirements
 for recognizing and measuring the total consideration transferred
 to and the assets acquired, liabilities assumed and any
 non-controlling interests in the acquired target in a business
 combination. ASC Topic 805 also provides guidance for recognizing
 and measuring goodwill acquired in a business combination; requires
 purchased in-process research and development to be capitalized at
 fair value as intangible assets at the time of acquisition;
 requires acquisition-related expenses and restructuring costs to be
 recognized separately from the business combination; expands the
 definition of what constitutes a business; and requires the
 acquirer to disclose information that users may need to evaluate
 and understand the financial effect of the business
 combination.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_18ACC75B-337B-4B94-996E-51DF524ECE0C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&amp;#x2019;s product sales.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements prior to the adoption of ASU
 No.&amp;#xA0;2009-13, Revenue Recognition&amp;#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)&lt;/i&gt;. For revenue arrangements
 entered into before January&amp;#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements after the adoption of ASU
 2009-13.&lt;/i&gt; ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (VSOE), if available;
 third-party evidence (TPE), if available and VSOE is not available;
 or the best estimate of selling price (ESP), if neither VSOE nor
 TPE is available; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&amp;#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire International GmbH, formerly Shire AG,
 (Shire) in January 2012 was evaluated under these amended
 accounting standards.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&amp;#x2019;s performance.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo&amp;#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During 2013, revenues related to Shire, Sigma-Aldrich Corporation
 (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%,
 respectively, of total revenues. During 2012, revenues related
 Shire, Sigma and DAS represented 51%, 11% and 22% of total
 revenues, respectively. During 2011, revenues related to Sigma,
 DAS, California Institute for Regenerative Medicine (CIRM) and CHDI
 Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total
 revenues, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_F0561B61-4110-4E8B-9119-5F95CC2889FA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;NOTE 5 &amp;#x2013; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC
 ALLIANCES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Collaboration Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Collaboration and License Agreement with Shire International
 GmbH, formerly Shire AG, in Human Therapeutics and
 Diagnostics&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2012, the Company entered into a collaboration and
 license agreement (the Agreement) with Shire pursuant to which the
 Company and Shire collaborate to research, develop and
 commercialize human therapeutics and diagnostics for monogenic
 diseases based on Sangamo&amp;#x2019;s ZFP technology. Under the
 Agreement, the Company and Shire may develop potential human
 therapeutic or diagnostic products for seven gene targets. The
 initial four gene targets selected were blood clotting Factors VII,
 VIII, IX and X, and products developed for such initial gene
 targets will be used for treating or diagnosing hemophilia. In June
 2012, Shire selected a fifth gene target for the development of a
 ZFP therapeutic for Huntington&amp;#x2019;s disease (HD), an inherited
 neurodegenerative disease for which there are currently no
 therapies available to slow the disease progression. Shire has the
 right, subject to certain limitations, to designate two additional
 gene targets. Pursuant to the Agreement, the Company granted Shire
 an exclusive, world-wide, royalty-bearing license, with the right
 to grant sublicenses, to use Sangamo&amp;#x2019;s ZFP technology for the
 purpose of developing and commercializing human therapeutic and
 diagnostic products for the gene targets. The initial research term
 of the Agreement is six years and is subject to extensions upon
 mutual agreement and under other specified circumstances.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Under the terms of the Agreement, the Company is responsible for
 all research activities through the submission of an Investigative
 New Drug Application (IND) or European Clinical Trial Application
 (CTA), while Shire is responsible for clinical development and
 commercialization of products generated from the research program
 from and after the acceptance of an IND or CTA for the product.
 Shire reimburses Sangamo for its internal and external research
 program-related costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Under the agreement, the Company received an upfront license fee of
 $13.0 million. In addition, the Company will also be eligible to
 receive $33.5 million in payments upon the achievement of specified
 research, regulatory, clinical development milestones, including
 payments for each gene target through the acceptance of an IND or
 CTA submission totaling $8.5 million, as well as $180 million in
 payments upon the achievement of specified commercialization and
 sales milestones. The total amount of potential milestone payments
 for each of the seven gene targets, assuming the achievement of all
 specified milestones in the Agreement, is $213.5 million. The
 Company will also be eligible to receive royalty payments that are
 a tiered double-digit percentage of net sales of licensed product
 sold by Shire or its sublicensees developed under the
 collaboration, if any. To date, no products have been approved and
 therefore no royalty fees have been earned under the Agreement with
 Shire.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 All contingent payments under the Agreement, when earned, will be
 non-refundable and non-creditable. The Company has evaluated the
 contingent payments under the Agreement with Shire based on the
 authoritative guidance for research and development milestones and
 determined that certain of these payments meet the definition of a
 milestone and that all such milestones are evaluated to determine
 if they are considered substantive milestones. Milestones are
 considered substantive if they are related to events (i)&amp;#xA0;that
 can be achieved based in whole or in part on either the
 Company&amp;#x2019;s performance or on the occurrence of a specific
 outcome resulting from the Company&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there was substantive uncertainty at the date
 the agreement was entered into that the event would be achieved and
 (iii)&amp;#xA0;that would result in additional payments being due to
 the Company. Accordingly, revenue for the achievement of milestones
 that are determined to be substantive will be recognized in its
 entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Revenue for the achievement
 of milestones that are not substantive will be recognized over the
 remaining period of the Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has identified the deliverables within the arrangement
 as a license to the technology and on-going research services
 activities. The Company has concluded that the license is not a
 separate unit of accounting as it does not have stand-alone value
 to Shire apart from the research services to be performed pursuant
 to the Agreement. As a result, the Company will recognize revenue
 from the upfront payment on a straight-line basis over a six-year
 initial research term during which the Company will perform
 research services. As of December&amp;#xA0;31, 2013, the Company has
 deferred revenue of $8.9 million related to this Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues recognized under the agreement with Shire for the years
 ended December&amp;#xA0;31, 2013 and 2012, were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December 31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues related to Shire Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Amortization of upfront fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Related costs and expenses incurred under the Shire agreement were
 $14.2 million and $7.7 million during the twelve months ended
 December&amp;#xA0;31, 2013 and 2012, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;&lt;i&gt;Agreement with Sigma-Aldrich Corporation in Laboratory
 Research Reagents, Transgenic Animal and Commercial Protein
 Production Cell-line Engineering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July 2007, Sangamo entered into a license agreement with Sigma.
 Under the license agreement, Sangamo agreed to provide Sigma with
 access to its proprietary ZFP technology and the exclusive right to
 use the technology to develop and commercialize research reagent
 products and services in the research field, excluding certain
 agricultural research uses that Sangamo previously licensed to DAS.
 Under the agreement, Sangamo and Sigma agreed to conduct a
 three-year research program to develop laboratory research reagents
 using Sangamo&amp;#x2019;s ZFP technology during which time Sangamo
 agreed to assist Sigma in connection with its efforts to market and
 sell services employing the Company&amp;#x2019;s ZFP technology in the
 research field. Sangamo has transferred the ZFP manufacturing
 technology to Sigma.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In October 2009, Sangamo expanded its license agreement with Sigma.
 In addition to the original terms of the license agreement, Sigma
 received exclusive rights to develop and distribute ZFP-modified
 cell lines for commercial production of protein pharmaceuticals and
 certain ZFP-engineered transgenic animals for commercial
 applications. Under the terms of the agreement, Sigma made an
 upfront cash payment of $20.0 million consisting of a $4.9 million
 purchase of 636,133 shares of Sangamo common stock, valued at $4.9
 million, and a $15.1 million upfront license fee. Sangamo is also
 eligible to receive commercial license fees of $5.0 million based
 upon a percentage of net sales and sublicensing revenue and
 thereafter a reduced royalty rate of 10.5% of net sales and
 sublicensing revenue. In addition, upon the achievement of certain
 cumulative commercial milestones Sigma will make milestone payments
 to Sangamo up to an aggregate of $25.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues recognized under the agreement with Sigma for the years
 ended December&amp;#xA0;31, 2013, 2012 and 2011, were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December 31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenue related to Sigma Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Royalty revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 License fee and milestone revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Related costs and expenses incurred under the Sigma agreement were
 $0.2 million, $0.3 million and $0.5 million during 2013, 2012 and
 2011, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Agreement with Dow AgroSciences in Plant
 Agriculture&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2005, Sangamo entered into an exclusive commercial
 license with DAS. Under this agreement, Sangamo is providing DAS
 with access to its proprietary ZFP technology and the exclusive
 right to use the technology to modify the genomes or alter the
 nucleic acid or protein expression of plant cells, plants, or plant
 cell cultures. Sangamo has retained rights to use plants or
 plant-derived products to deliver ZFP transcription factors (ZFP
 TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic,
 therapeutic or prophylactic purposes. The Company&amp;#x2019;s agreement
 with DAS provided for an initial three-year research term. In June
 2008, DAS exercised its option under the agreement to obtain a
 commercial license to sell products incorporating or derived from
 plant cells generated using the Company&amp;#x2019;s ZFP technology,
 including agricultural crops, industrial products and plant-derived
 biopharmaceuticals. The exercise of the option triggered a one-time
 commercial license fee of $6.0&amp;#xA0;million, payment of the
 remaining $2.3 million of the previously agreed $4.0&amp;#xA0;million
 in research milestones, development and commercialization milestone
 payments for each product, and royalties on sales of products.
 Furthermore, DAS has the right to sublicense Sangamo&amp;#x2019;s ZFP
 technology to third parties for use in plant cells, plants, or
 plant cell cultures, and Sangamo will be entitled to 25% of any
 cash consideration received by DAS under such sublicenses. In
 December 2010, the Company amended its agreement with DAS to extend
 the period of reagent manufacturing services and research services
 through December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The agreement also provides for minimum sublicense fees each year
 due to Sangamo every October, provided the agreement is not
 terminated by DAS. Annual fees range from $250,000 to $3.0 million
 and total $25.3 million over 11 years. The Company does not have
 any performance obligations with respect to the sublicensing
 activities to be conducted by DAS. DAS has the right to terminate
 the agreement at any time; accordingly, the Company&amp;#x2019;s actual
 sublicense fees over the term of the agreement could be lower than
 $25.3&amp;#xA0;million. In addition, each party may terminate the
 agreement upon an uncured material breach of the agreement by the
 other party. In the event of any termination of the agreement, all
 rights to use the Company&amp;#x2019;s ZFP technology will revert to
 Sangamo, and DAS will no longer be permitted to practice
 Sangamo&amp;#x2019;s ZFP technology or to develop or, except in limited
 circumstances, commercialize any products derived from the
 Company&amp;#x2019;s ZFP technology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues under the agreement were $3.0 million, $4.7 million and
 $4.5 million during 2013, 2012 and 2011, respectively. Related
 costs and expenses incurred under the agreement were $0.4 million,
 $0.6 million and $0.9 million during 2013, 2012 and 2011,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Funding from Research Foundations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;California Institute for Regenerative Medicine -
 HIV&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2009, CIRM, a State of California entity, granted a
 $14.5 million Disease Team Research Award to develop an HIV/AIDS
 therapy based on the application of ZFN gene editing technology in
 hematopoietic stem cells (HSCs). The four year grant supports an
 innovative research project conducted by a multidisciplinary team
 of investigators, including investigators from the University of
 Southern California, City of Hope National Medical Center and
 Sangamo BioSciences. Sangamo received funds totaling $5.2 million
 from the total amount awarded based on expenses incurred for
 research and development efforts by Sangamo as prescribed in the
 agreement, and subject to its terms and conditions. The award is
 intended to substantially fund Sangamo&amp;#x2019;s research and
 development efforts related to the agreement. The State of
 California has the right to receive, subject to the terms and
 conditions of the agreement between Sangamo and CIRM, payments from
 Sangamo resulting from sales of a commercial product resulting from
 research and development efforts supported by the grant, not to
 exceed two times the amount Sangamo receives in funding under the
 agreement with CIRM. As of December&amp;#xA0;31, 2013, all revenues
 under the award have been recognized and all funds have been
 received.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Revenues attributable to research and development performed under
 the CIRM grant agreement were $1.2 million, $1.2 million and $1.7
 million during 2013, 2012 and 2011, respectively. Related costs
 during 2013, 2012 and 2011 were $1.8 million, $1.2 million and $2.0
 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;California Institute for Regenerative Medicine -
 Beta-Thalassemia&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2013, CIRM granted the Company a $6.4 million Strategic
 Partnership Award to develop a potentially curative ZFP Therapeutic
 for beta-thalassemia based on the application of its ZFN gene
 editing technology in HSCs. The four year grant provides matching
 funds for preclinical work that will support an IND application and
 a Phase 1 clinical trial in transfusion-dependent beta-thalassemia
 patients. The State of California has the right to receive, subject
 to the terms and conditions of the agreement between Sangamo and
 CIRM, payments from Sangamo, or its collaborators, from sales of a
 commercial product resulting from research and development efforts
 supported by the grant, in accordance with Title 17, California
 Code of Regulations, Section 100600.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue attributable to research and development performed under
 the CIRM grant agreement for beta-thalassemia was $0.1 million in
 2013. Related costs during 2013 were $0.4 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;CHDI Foundation, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In April 2011, Sangamo entered into an agreement with the CHDI to
 develop a novel therapeutic for HD based on Sangamo&amp;#x2019;s
 proprietary ZFP technology. The ZFP therapeutic approach targets
 the gene that causes HD, an inherited neurodegenerative disease for
 which there are currently no therapies available to slow the
 disease progression. Under the agreement with CHDI, and subject to
 its terms and conditions, CHDI paid the Company $1.3 million, the
 total funds due under the agreement, over a period of one year
 which is intended to substantially fund the Company&amp;#x2019;s
 research efforts related to the agreement. During 2012, the
 agreement was amended to extend the project through August 2012 and
 to increase total potential funding from $1.3 million to $2.1
 million, plus reimbursement for certain direct expenses related to
 the project. The agreement with CHDI terminated on August&amp;#xA0;31,
 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues attributable to research and development performed under
 the CHDI collaboration agreement were $1.1 million during 2012 and
 2011. Related costs during 2012 and 2011 were $1.1 million and $1.2
 million, respectively. There were no such revenues or related costs
 in 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;The Juvenile Diabetes Research Foundation
 International&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October&amp;#xA0;2006, Sangamo entered into an agreement with the
 Juvenile Diabetes Research Foundation International (JDRF)&amp;#xA0;to
 provide financial support for one of Sangamo&amp;#x2019;s Phase 2 human
 clinical studies of the Company&amp;#x2019;s product candidate SB-509, a
 ZFP Therapeutic that was in development for the treatment of
 diabetic neuropathy. In January 2010, JDRF and Sangamo amended the
 agreement and, subject to its terms and conditions, JDRF agreed to
 provide additional funding of up to $3.0 million for a Phase 2b
 trial in diabetic neuropathy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In October 2011, the Company announced that it would not pursue
 additional clinical development of the SB-509 program. In March
 2012, the Company received a final payment of $0.8 million for work
 performed under the agreement. The Company does not expect to
 receive additional funding under the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues attributable to research and development activities
 performed under the JDRF agreements were $0.8 million and $0.5
 million during 2012 and 2011. There were no such revenues or
 related costs in 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;The Michael J. Fox Foundation for Parkinson&amp;#x2019;s
 Research&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2007, the Company entered into a partnership with the
 Michael J. Fox Foundation for Parkinson&amp;#x2019;s Research
 (MJFF)&amp;#xA0;to provide financial support of the Company&amp;#x2019;s
 program to develop ZFP TFs to activate the expression of glial cell
 line-derived neurotrophic factor (GDNF). Under the agreement with
 MJFF and subject to its terms and conditions, MJFF paid the Company
 $1.0 million, the total funds due under the agreement. In June
 2010, the Company received a commitment for additional funding of
 $0.9 million from MJFF to support further studies of ZFP TF
 activators of GDNF and intended to substantially fund Sangamo
 research efforts related to the agreement. The Company has received
 the entire $1.9 million in funding available under the agreements
 with MJFF and does not expect to receive any further funding under
 this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue attributable to research and development performed under
 the MJFF agreement was $0.4 million in 2011. There were no such
 revenues in 2013 or 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_3C00CF84-8E66-4B6C-80E1-C926407D6CBA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of these assets and estimated fair values at the Closing
 Date is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Value&amp;#xA0;of&amp;#xA0;Intangible&lt;br /&gt;
 Assets Acquired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 CERE-110 for the treatment of Alzheimer&amp;#x2019;s disease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 CERE-120 for the treatment of Parkinson&amp;#x2019;s disease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total identifiable intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_3CF2A38E-68B4-4AFE-8E18-4FFA452D313B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 A summary of Sangamo&amp;#x2019;s stock option activity is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;per&lt;br /&gt;
 Share&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,184,346&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,119,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,715,123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(182,559&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,405,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;56,425&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested and expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,046,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,849&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,800,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_5774F7A6-4555-4EC5-A41A-4603BAF2E12A_1_1">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_5001_4">8.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1_7">The RSUs will vest as follows:  One-third on second anniversary and two-thirds will vest on  the third anniversary of the award date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_DC812068-25BC-46EB-B169-789F5747B93B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes information with respect to stock
 options outstanding at December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="45%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Options Outstanding and
 Exercisable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 81.05pt"&gt;
 &lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares of&lt;br /&gt;
 common&amp;#xA0;stock&lt;br /&gt;
 subject&amp;#xA0;to&amp;#xA0;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares&amp;#xA0;of&lt;br /&gt;
 common&amp;#xA0;stock&lt;br /&gt;
 subject to&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $2.55&amp;#xA0;&amp;#x2013;&amp;#xA0;$3.25&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $3.45&amp;#xA0;&amp;#x2013;&amp;#xA0;$3.45&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,124,381&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,124,381&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $3.80&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.26&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;661,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.35&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.35&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;909,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;909,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.41&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.41&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,134,524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.42&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.66&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.70&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.70&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;945,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;676,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.86&amp;#xA0;&amp;#x2013;&amp;#xA0;$6.82&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;899,022&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;749,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $6.92&amp;#xA0;&amp;#x2013;&amp;#xA0;$11.99&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;365,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;267,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $12.12&amp;#xA0;&amp;#x2013;&amp;#xA0;$14.62&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,092,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.83&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,087,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,405,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,800,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_F95EF120-2071-4EF8-BD67-52E2762CDDC0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,950&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,521&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_79CC78EF-D528-4346-8BF0-AC8DB0D930EB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 7 &amp;#x2013; PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,950&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,156&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,521&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,543&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Depreciation and amortization expense was $0.6 million for 2013,
 2012 and 2011. In 2012, the Company disposed of $0.5 million in
 fixed assets with associated accumulated depreciation of $0.4
 million. The Company recognized a $0.1 million loss on the
 write-off of these assets.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_907436F7-2E18-47C1-A4C6-7265043EB89B_3001_2">P6Y3M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_881190D0-43FE-4FDC-9264-48E6556D43A6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the estimated fair value of the net
 assets acquired as of the Closing Date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash and equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounts receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Identifiable intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,585&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounts payable and accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total liabilities assumed&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(846&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_5B856317-ACD4-4416-A288-61DF1041128F_1_0">&lt;div&gt;
 &lt;p&gt;Future minimum payments under contractual obligations at
 December&amp;#xA0;31, 2013 consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 41.5pt"&gt;
 &lt;b&gt;Fiscal Year:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Operating&lt;br /&gt;
 Lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;668&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;688&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;496&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total minimum payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_36FA2038-FBCF-4A31-AF97-ACA53269A7D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The weighted-average estimated fair value of shares purchased under
 the Company&amp;#x2019;s ESPP during 2013, 2012 and 2011 were $1.47,
 $2.51 and $1.62, respectively, based upon the assumptions in the
 Black-Scholes valuation model. The weighted&amp;#x2013;average
 assumptions used for estimating the fair value of the ESPP purchase
 rights are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.61&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.30&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.05-0.61&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of option (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.5-2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield of stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.51-0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.93-1.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.58-0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;!-- xbrl,n --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_B07E3632-5255-4059-BFCF-8C09B1406A19_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value measurements of cash equivalents, available-for-sale
 securities and contingent consideration liabilities are identified
 at the following levels within the fair value hierarchy (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Contingent consideration liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_BBC011ED-3468-4DFB-8214-2F5C33DA1817_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 13 &amp;#x2013; QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth certain unaudited quarterly
 financial data for the eight quarters ended December&amp;#xA0;31, 2013.
 The unaudited information set forth below has been prepared on the
 same basis as the audited information and includes all adjustments
 necessary to present fairly the information set forth herein. The
 operating results for any quarter are not indicative of results for
 any future period. All data is in thousands except per common share
 data.&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,707&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,526&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,885&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,728&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1_8">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_BBF34BD1-7E22-41F3-A6D0-A86271D89201_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;NOTE 1 &amp;#x2013; ORGANIZATION AND SUMMARY OF SIGNIFICANT
 ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Sangamo&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo BioSciences, Inc. (the Company or Sangamo) was incorporated
 in the State of Delaware on June&amp;#xA0;22, 1995 and is focused on
 the research, development and commercialization of novel
 therapeutic strategies for unmet medical needs. Sangamo&amp;#x2019;s
 gene regulation and gene modification technology platform is
 enabled by the engineering of a class of transcription factors
 known as zinc finger DNA-binding proteins (ZFPs). Potential
 applications of Sangamo&amp;#x2019;s technology include development of
 human therapeutics, plant agriculture and enhancement of
 pharmaceutical protein production. Sangamo will require additional
 financial resources to complete the development and
 commercialization of its products including ZFP Therapeutics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Sangamo is currently working on a number of long-term development
 projects that will involve experimental technology. The projects
 may require several years and substantial expenditures to complete
 and ultimately may be unsuccessful. The Company plans to finance
 operations with available cash resources, collaborations and
 strategic partnerships funds, research grants and from the issuance
 of equity or debt securities. Sangamo believes that its available
 cash, cash equivalents and investments as of December&amp;#xA0;31,
 2013, along with expected revenues from collaborations, strategic
 partnerships and research grants, will be adequate to fund its
 operations at least through 2015. Sangamo will need to raise
 substantial additional capital to fund subsequent operations and
 complete the development and commercialization of its products.
 Additional capital may not be available on terms acceptable to the
 Company, or at all. If adequate funds are not available, or if the
 terms of potential funding sources are unfavorable, the
 Company&amp;#x2019;s business and ability to develop its technology and
 ZFP Therapeutic products would be harmed. Furthermore, any sales of
 additional equity securities may result in dilutions to the
 Company&amp;#x2019;s stockholders, and any debt financing may include
 covenants that restrict the Company&amp;#x2019;s business.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Sangamo acquired Ceregene, Inc. (Ceregene) on October&amp;#xA0;1, 2013.
 Under the merger agreement, Sangamo obtained Ceregene&amp;#x2019;s
 therapeutic programs, including CERE-110 for the treatment of
 Alzheimer&amp;#x2019;s disease (AD) that is currently in a Phase 2
 clinical trial. Sangamo also acquired certain intellectual property
 rights relating to the manufacturing of AAV, and certain toxicology
 data and safety and efficacy data from Ceregene&amp;#x2019;s human
 clinical trials which will enhance and expand the application of
 Sangamo&amp;#x2019;s &lt;i&gt;in vivo&lt;/i&gt; ZFP Therapeutics, particularly those
 that target the brain.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. Actual results
 could differ from those estimates. The consolidated financial
 statements include the accounts of Sangamo and its wholly owned
 subsidiaries, Ceregene and Gendaq Limited, after elimination of all
 intercompany balances and transactions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company accounted for the acquisition of Ceregene in accordance
 with Accounting Standards Codification (ASC) Topic 805, Business
 Combinations. ASC Topic 805 establishes principles and requirements
 for recognizing and measuring the total consideration transferred
 to and the assets acquired, liabilities assumed and any
 non-controlling interests in the acquired target in a business
 combination. ASC Topic 805 also provides guidance for recognizing
 and measuring goodwill acquired in a business combination; requires
 purchased in-process research and development to be capitalized at
 fair value as intangible assets at the time of acquisition;
 requires acquisition-related expenses and restructuring costs to be
 recognized separately from the business combination; expands the
 definition of what constitutes a business; and requires the
 acquirer to disclose information that users may need to evaluate
 and understand the financial effect of the business
 combination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo considers all highly liquid investments purchased with
 original maturities of three months or less at the purchase date to
 be cash equivalents. Cash and cash equivalents consist of deposits
 in money market investment accounts, government sponsored entity
 debt securities, US Treasury debt securities and corporate bank
 accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As part of the acquisition of Ceregene, Sangamo was required to set
 aside $0.3 million in an escrow account until October&amp;#xA0;1, 2014.
 The cash hold in escrow was recorded as restricted cash.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at estimated fair value based on quoted
 market prices or observable market inputs of almost identical
 assets, with the unrealized holding gains and losses included in
 accumulated other comprehensive income.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s investments are subject to a periodic
 impairment review. The Company recognizes an impairment charge when
 a decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&amp;#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&amp;#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value. Realized gains and losses on available-for-sale
 securities are included in other (expense)/income, which is
 determined using the specific identification method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The carrying amounts for financial instruments consisting of cash
 and cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value due to their short
 maturities. Marketable securities and contingent consideration
 liabilities are stated at their estimated fair values. The
 counterparties to the agreements relating to the Company&amp;#x2019;s
 investment securities generally can consist of the US Treasury,
 various major corporations, governmental agencies and financial
 institutions with high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation is calculated using the
 straight-line method based on the estimated useful lives of the
 related assets (generally three to five years). For leasehold
 improvements, amortization is calculated using the straight-line
 method based on the shorter of the useful life or the lease term.
 The Company reviews its property and equipment for impairment
 whenever events or changes in circumstances indicate that the
 carrying amount of an asset may not be recoverable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&amp;#x2019;s product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Multiple Element Arrangements prior to the adoption of ASU
 No.&amp;#xA0;2009-13, Revenue Recognition&amp;#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)&lt;/i&gt;. For revenue arrangements
 entered into before January&amp;#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Multiple Element Arrangements after the adoption of ASU
 2009-13.&lt;/i&gt; ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (VSOE), if available;
 third-party evidence (TPE), if available and VSOE is not available;
 or the best estimate of selling price (ESP), if neither VSOE nor
 TPE is available; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&amp;#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire International GmbH, formerly Shire AG,
 (Shire) in January 2012 was evaluated under these amended
 accounting standards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&amp;#x2019;s performance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Sangamo&amp;#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During 2013, revenues related to Shire, Sigma-Aldrich Corporation
 (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%,
 respectively, of total revenues. During 2012, revenues related
 Shire, Sigma and DAS represented 51%, 11% and 22% of total
 revenues, respectively. During 2011, revenues related to Sigma,
 DAS, California Institute for Regenerative Medicine (CIRM) and CHDI
 Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total
 revenues, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development costs are expensed as incurred. Research
 and development expenses consist of direct and research-related
 allocated overhead costs such as facilities costs, salaries and
 related personnel costs, and material and supply costs. In
 addition, research and development expenses include costs related
 to clinical trials, validation of the Company&amp;#x2019;s testing
 processes and procedures and as well as related overhead expenses.
 Research and development costs incurred in connection with
 collaborator-funded activities are expensed as incurred. Costs to
 acquire technologies that are utilized in research and development
 that have no alternative future use are expensed as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company measures and recognizes compensation expense for all
 stock-based payment awards made to Sangamo employees and directors,
 including employee share options, restricted stuck units (RSUs) and
 employee share purchases related to the Employee Share Purchase
 Plan (ESPP), based on estimated fair values at grant date. The fair
 value of stock-based awards is amortized over the vesting period of
 the award using a straight-line method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 To estimate the value of an award, the Company uses the
 Black-Scholes option pricing model. This model requires inputs such
 as expected life, expected volatility and risk-free interest rate.
 These inputs are subjective and generally require significant
 analysis and judgment to develop. While estimates of expected life
 and volatility are derived primarily from the Company&amp;#x2019;s
 historical data, the risk-free rate is based on the U.S. Treasury
 yield curve in effect at the time of grant commensurate with the
 expected life assumption. Further, the Company is required to
 estimate forfeitures at the time of grant and revise those
 estimates in subsequent periods if actual forfeitures differ from
 those estimates. The Company uses historical data to estimate
 pre-vesting option forfeitures and record stock-based compensation
 expense only for those awards that are expected to vest.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Intangible Assets &amp;#x2013; In-Process Research and
 Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Intangible assets related to in-process research and development
 costs, or IPR&amp;amp;D, are considered to be indefinite-lived until
 the completion or abandonment of the associated research and
 development efforts. If and when development is complete, which
 generally occurs if and when regulatory approval to market a
 product is obtained, the associated assets would be deemed
 finite-lived and would then be amortized based on their respective
 estimated useful lives at that point in time. Prior to completion
 of the research and development efforts, the assets are considered
 indefinite-lived. During this period, the assets will not be
 amortized but will be tested for impairment on an annual basis and
 between annual tests if the Company becomes aware of any events
 occurring or changes in circumstances that would indicate a
 reduction in the fair value of the IPR&amp;amp;D projects below their
 respective carrying amounts. The Company observed no impairment
 indicators of the recorded IPR&amp;amp;D in the year ended
 December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Goodwill represents the excess of the consideration transferred
 over the estimated fair values of assets acquired and liabilities
 assumed in a business combination and is considered to be
 indefinite-lived. Goodwill is not amortized but is tested for
 impairment on an annual basis and between annual tests if the
 Company becomes aware of any events occurring or changes in
 circumstances that would indicate a reduction in the fair value of
 the goodwill below its carrying amount. The Company observed no
 impairment indicators of the recorded goodwill in the year ended
 December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Contingent Consideration Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Under the merger agreement with Ceregene, the Company may be
 required to make contingent earn-out payments if the Company grants
 a third-party license to develop and commercialize certain product
 candidates acquired from Ceregene, or if the Company commercializes
 any of these product candidates itself. These &lt;font style="WHITE-SPACE: nowrap"&gt;earn-out&lt;/font&gt; payments will become payable
 in the period they are earned. In accordance with ASC Topic 805,
 Business Combinations, the Company determined the fair value of
 this liability for contingent consideration on the acquisition date
 using a probability-weighted discounted cash flow analysis. Future
 changes to the fair value of the contingent consideration will be
 determined each period and charged to expense in the &amp;#x201C;Changes
 in fair value of contingent liability&amp;#x201D; expense line item in
 the Consolidated Statements of Operations under operating
 expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Income tax expense has been provided using the liability method.
 Deferred tax assets and liabilities are determined based on the
 difference between the financial statement and tax bases of assets
 and liabilities as measured by the enacted tax rates that will be
 in effect when these differences reverse. The Company provides a
 valuation allowance against net deferred tax assets if, based upon
 the available evidence, it is not more likely than not that the
 deferred tax assets will be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are all anti-dilutive. All stock options
 outstanding were excluded from the calculation of diluted net loss
 per share. Stock option outstanding at the end of 2013, 2012 and
 2011 were 8,405,864, 9,184,346 and 8,346,190, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company operates in one segment. Management uses one
 measurement of profitability and does not segregate its business
 for internal reporting. As of December&amp;#xA0;31, 2013 and 2012, all
 of the Company&amp;#x2019;s assets were maintained in the U.S. For the
 years ended December&amp;#xA0;31, 2013, 2012 and 2011, 100% of revenues
 and operating expenses were generated and incurred in the U.S.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2013, the FASB issued ASU No.&amp;#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income. This newly issued
 accounting standard requires an entity to provide information about
 the amounts reclassified out of accumulated other comprehensive
 income by component. This ASU is effective for reporting periods
 beginning after December&amp;#xA0;15, 2012. The Company adopted this
 standard in the first quarter of 2013 and the adoption of this
 standard did not have an impact on its financial position or
 results of operations.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_C73C7485-273D-4B00-9B84-9A1FCC405399_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 11 &amp;#x2013; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Accounts payable and accrued liabilities consist of the following
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,022&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrued clinical trial expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total accounts payable and accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,380&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;!-- xbrl,n --&gt;

 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_13">55974000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_E6CB08BC-A43A-45E8-867A-194FD51AE5EB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;NOTE 9 &amp;#x2013; STOCKHOLDERS&amp;#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has 5,000,000 preferred shares authorized, which may be
 issued at the Board of director&amp;#x2019;s discretion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;23, 2013, Sangamo completed an underwritten
 public offering of its common stock, in which the Company sold an
 aggregate of 7,015,000 shares of its common stock, including
 915,000 shares issued to the Underwriters pursuant to a 30-day
 overallotment option, at a public offering price of $10.58 per
 share. The net proceeds to Sangamo from the sale of shares in this
 offering, after deducting underwriting discounts and commissions
 and other estimated offering expenses, were approximately $69.5
 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On April&amp;#xA0;18, 2013, Sangamo&amp;#x2019;s board of directors adopted,
 subject to stockholder approval, the Company&amp;#x2019;s 2013 Stock
 Incentive Plan (the 2013 Plan) as the successor to the
 Company&amp;#x2019;s 2004 Stock Incentive Plan (the 2004 Plan). At the
 Annual Meeting of Stockholders held on June&amp;#xA0;12, 2013, the 2013
 Plan was approved by the Company&amp;#x2019;s stockholders and became
 effective. In connection with the approval by stockholders of the
 2013 Plan, outstanding awards under the 2004 Plan were transferred
 to the 2013 Plan. The 2004 Plan was terminated and no further
 awards will be made pursuant to the 2004 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Under the 2013 Plan, the option exercise price per share will
 generally not be less than 100 percent of the fair value per share
 of common stock on the option grant date, and the option term will
 not exceed ten years. If the person to whom the option is granted
 is a 10 percent stockholder, and the option granted qualifies as an
 Incentive Stock Option Grant, then the exercise price per share
 will not be less than 110 percent of the fair value per share of
 common stock on the option grant date, and the option term will not
 exceed five years. Options granted under the 2013 Plan generally
 vest over four years at a rate of 25 percent one year from the
 grant date and one thirty-sixth per month thereafter and expire ten
 years after the grant, or earlier upon employment termination.
 Certain options previously granted under the 2004 Plan to the
 Company&amp;#x2019;s non-employee directors are structured so that they
 may be exercised prior to vesting, with the related shares subject
 to Sangamo&amp;#x2019;s right to repurchase any shares that have not
 vested pursuant to the vesting schedule in effect for such award at
 the exercise price paid if the option holder&amp;#x2019;s board service
 terminates. Approximately 14.1&amp;#xA0;million shares were initially
 reserved for issuance under the 2013 Plan, including
 9.7&amp;#xA0;million shares of common stock subject to outstanding
 awards previously granted under the 2004 Plan that were transferred
 to the 2013 Plan, and an additional 4.4&amp;#xA0;million shares of
 common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The number of shares of common stock reserved for issuance under
 the 2013 Plan will be reduced: (i)&amp;#xA0;on a 1-for-1 basis for each
 share of common stock subject to a stock option or stock
 appreciation right granted under the plan, (ii)&amp;#xA0;on a 1-for-1
 basis for each share of common stock issued pursuant to a full
 value award granted under the plan prior to the plan effective
 date, and (iii)&amp;#xA0;by a fixed ratio of 1.33 shares of common
 stock for each share of common stock issued pursuant to a
 full-value award granted under the plan on or after the plan
 effective date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Shares subject to any outstanding options or other awards under the
 2013 Plan that expire or otherwise terminate prior to the issuance
 of the shares subject to those options or awards will be available
 for subsequent issuance under the 2013 Plan. Any unvested shares
 issued under the 2013 Plan that the Company subsequently purchases,
 pursuant to repurchase rights under the 2013 Plan, will be added
 back to the number of shares reserved for issuance under the 2013
 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the
 ratio at which the share reserve was debited for the original
 award) and will accordingly be available for subsequent issuance in
 accordance with the terms of the plan. There are no net counting
 provisions in effect under the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo&amp;#x2019;s 2010 Employee Stock Purchase Plan (Purchase Plan),
 which supersedes the 2000 Employee Stock Purchase Plan, provides a
 total reserve of 2,100,000&amp;#xA0;shares of common stock for issuance
 under the Purchase Plan. Eligible employees may purchase common
 stock at 85&amp;#xA0;percent of the lesser of the fair market value of
 Sangamo&amp;#x2019;s common stock on the first day of the applicable
 two-year offering period or the last day of the applicable
 six-month purchase period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Option Activity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 A summary of Sangamo&amp;#x2019;s stock option activity is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;per&lt;br /&gt;
 Share&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,184,346&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,119,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,715,123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(182,559&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,405,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;56,425&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested and expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,046,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,849&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,800,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Newly created shares are issued upon exercise of options. There
 were no shares subject to Sangamo&amp;#x2019;s right of repurchase as of
 December&amp;#xA0;31, 2013. The intrinsic value of options exercised
 was $8.9 million, $0.6 million and $1.0 million during 2013, 2012
 and 2011, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At December&amp;#xA0;31, 2013, the aggregate intrinsic values of the
 outstanding and exercisable options were $56.4&amp;#xA0;million and
 $41.1 million, respectively. The aggregate intrinsic value of
 options vested and expected to vest during 2013, 2012 and 2011 was
 $54.9 million, $8.5 million and $0.1 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes information with respect to stock
 options outstanding at December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="45%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Options Outstanding and
 Exercisable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 81.05pt"&gt;
 &lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares of&lt;br /&gt;
 common&amp;#xA0;stock&lt;br /&gt;
 subject&amp;#xA0;to&amp;#xA0;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 Shares&amp;#xA0;of&lt;br /&gt;
 common&amp;#xA0;stock&lt;br /&gt;
 subject to&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $2.55&amp;#xA0;&amp;#x2013;&amp;#xA0;$3.25&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;212,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $3.45&amp;#xA0;&amp;#x2013;&amp;#xA0;$3.45&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,124,381&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,124,381&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $3.80&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.26&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;661,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.35&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.35&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;909,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;909,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.41&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.41&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,134,524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;270,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.42&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.66&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.70&amp;#xA0;&amp;#x2013;&amp;#xA0;$5.70&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;945,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;676,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $5.86&amp;#xA0;&amp;#x2013;&amp;#xA0;$6.82&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;899,022&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;749,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.45&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $6.92&amp;#xA0;&amp;#x2013;&amp;#xA0;$11.99&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;365,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;267,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 $12.12&amp;#xA0;&amp;#x2013;&amp;#xA0;$14.62&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,092,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.83&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,087,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,405,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,800,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 During 2013 and 2012, the Company issued 392,500 and 486,750
 Restricted Stock Units (RSUs), respectively. The RSUs issued in
 2013 and 2012 had a grant date fair value of $12.12 and $5.41,
 respectively. These awards will vest as follows: one-third of the
 award will vest in a series of three successive equal annual
 installments. During 2011, the Company issued 550,000 RSUs at a
 grant date fair value of $2.55. These awards will vest as follows:
 one-third of the award will vest on the second anniversary of the
 award date and two-thirds of the award will vest on the third
 anniversary of the award date. The aggregate value of shares vested
 during 2013, 2012 and 2011 was $4.1 million, $0.1 million and $0.2
 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of Sangamo&amp;#x2019;s RSU activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&amp;#xA0;Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,036,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs awarded&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs released&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(341,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,063,657&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 RSUs vested and expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;925,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 RSUs that vested in 2013, 2012 and 2011 were net-share settled such
 that the Company withheld shares with value equivalent to the
 employees&amp;#x2019; minimum statutory obligation for the applicable
 income and other employment taxes, and remitted the cash to the
 appropriate taxing authorities. The total shares withheld were
 approximately 167,138 and 8,937 for 2013 and 2011, respectively,
 and were based on the value of the RSUs on their respective vesting
 dates as determined by the Company&amp;#x2019;s closing stock price.
 There were no such shares withheld in 2012. Total payments for the
 employees&amp;#x2019; tax obligations to taxing authorities were $2.0
 million and $0.1 million in 2013 and 2011, respectively, and are
 reflected as a financing activity within the Consolidated
 Statements of Cash Flows.&amp;#xA0;These net-share settlements had the
 effect of share repurchases by the Company as they reduced and
 retired the number of shares that would have otherwise been issued
 as a result of the vesting and did not represent an expense to the
 Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013, there were 2,929,590 shares were
 reserved for future awards under the Company&amp;#x2019;s 2013 Plan and
 1,527,763 shares of common stock reserved for future issuance under
 the Purchase Plan.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;/p&gt;


 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_5001_2">11.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockDividendsShares contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_41A51777-B557-4068-8627-C5800A37D5FE_1_0">167138</us-gaap:StockDividendsShares>
  <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_C73C0B5D-4C21-4766-B82E-9F7A174F21F6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the activity related to the
 Company&amp;#x2019;s unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,896&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Additions based on tax positions related to the current year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;589&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Additions for tax positions of prior years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reductions for tax positions of prior years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(227&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_1_0">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_563AC546-CAD8-40BB-8117-0FD2B9A6986E_1_0">&lt;div&gt;From the acquisition date of October&amp;#xA0;1, 2013 through
 December&amp;#xA0;31, 2013, the recognized amount of the liability for
 contingent consideration increased by $0.1 million primarily as the
 result of the passage of time.
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="20%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Fair value on date of acquisition (October 1, 2013)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Fair value at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;!-- xbrl,n --&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_F143EDF2-7CB5-447C-8A94-6743159BC137_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth certain unaudited quarterly
 financial data for the eight quarters ended December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Q4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,707&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,526&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,885&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,728&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_1614F4CB-8521-44AD-9020-EE579BA4C5C3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Goodwill represents the excess of the consideration transferred
 over the estimated fair values of assets acquired and liabilities
 assumed in a business combination and is considered to be
 indefinite-lived. Goodwill is not amortized but is tested for
 impairment on an annual basis and between annual tests if the
 Company becomes aware of any events occurring or changes in
 circumstances that would indicate a reduction in the fair value of
 the goodwill below its carrying amount. The Company observed no
 impairment indicators of the recorded goodwill in the year ended
 December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7BCC4C84-4B6C-4753-8D50-0EA1194D648D_1_0">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:MarketableSecuritiesPolicy contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_1D7BAE16-62CC-49F0-9CAC-6C2A2A220DB5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at estimated fair value based on quoted
 market prices or observable market inputs of almost identical
 assets, with the unrealized holding gains and losses included in
 accumulated other comprehensive income.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s investments are subject to a periodic
 impairment review. The Company recognizes an impairment charge when
 a decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&amp;#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&amp;#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value. Realized gains and losses on available-for-sale
 securities are included in other (expense)/income, which is
 determined using the specific identification method.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_F97D6726-B399-4B15-949B-391C7754652A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the estimated fair value of the
 consideration transferred by Sangamo to the Ceregene stockholders
 on the Closing Date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Sangamo shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Contingent earn-out&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total purchase consideration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_9E88CB40-6DE0-48A0-BAC5-41186C952DBA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation is calculated using the
 straight-line method based on the estimated useful lives of the
 related assets (generally three to five years). For leasehold
 improvements, amortization is calculated using the straight-line
 method based on the shorter of the useful life or the lease term.
 The Company reviews its property and equipment for impairment
 whenever events or changes in circumstances indicate that the
 carrying amount of an asset may not be recoverable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_220CA71A-4394-4D47-8B76-2DE10B6FECC0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo considers all highly liquid investments purchased with
 original maturities of three months or less at the purchase date to
 be cash equivalents. Cash and cash equivalents consist of deposits
 in money market investment accounts, government sponsored entity
 debt securities, US Treasury debt securities and corporate bank
 accounts.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As part of the acquisition of Ceregene, Sangamo was required to set
 aside $0.3 million in an escrow account until October&amp;#xA0;1, 2014.
 The cash hold in escrow was recorded as restricted cash.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_A1FAC0F3-2AFB-4482-86D5-DFC9EEE6DED7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 6 &amp;#x2013; ACQUISITION OF CEREGENE&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On August&amp;#xA0;23, 2013, Sangamo and its wholly-owned subsidiary CG
 Acquisition Sub, Inc., a Delaware corporation, entered into an
 Agreement and Plan of Merger (the Merger Agreement) with Ceregene,
 and a stockholders&amp;#x2019; representative. Pursuant to the Merger
 Agreement, the Company acquired all outstanding shares of Ceregene,
 a privately held biotechnology company focused on the development
 of AAV gene therapies. The acquired assets include all of
 Ceregene&amp;#x2019;s therapeutic programs, including CERE-110 for the
 treatment of AD is currently in a Phase 2 clinical trial. In
 addition to the clinical assets acquired, the Company acquired
 certain intellectual property rights relating to the manufacturing
 of AAV, and certain toxicology data and safety and efficacy data
 from Ceregene&amp;#x2019;s human clinical trials, which will be used in
 the preparation and filing of IND applications for Sangamo&amp;#x2019;s
 &lt;i&gt;in vivo&lt;/i&gt; ZFP Therapeutics, particularly those that target the
 brain. The acquisition closed on October&amp;#xA0;1, 2013 (the Closing
 Date).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Under the Merger Agreement, the aggregate consideration transferred
 or transferable by Sangamo to former Ceregene stockholders at
 closing consisted of 100,000 shares of Sangamo common stock, with
 an approximate fair value of $1.2 million. In addition, Sangamo may
 be required to make contingent earn-out payments (the Earn-Out
 Payments) to the stockholders of Ceregene as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;If the Company grants a third-party
 license to develop and commercialize Ceregene&amp;#x2019;s CERE-110 for
 the treatment of (AD) or CERE-120 for the treatment of
 Parkinson&amp;#x2019;s diseases or HD (the Earn-Out Products), the
 Company is required to pay a double digit percentage of any upfront
 and milestone payments the Company receives for such license,
 subject to certain reductions based on expenses incurred by the
 Company in the development of the Earn-Out Products; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;If the Company commercializes any
 Earn-Out Product itself, the Company is required to pay, for each
 Earn-Out Product, royalty-like earnout payments as a percentage of
 net sales that range in the low double digits depending upon the
 amount of net sales, subject to certain reductions by the
 Company.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Also on the Closing Date, Sangamo, Ceregene and certain of
 Ceregene&amp;#x2019;s stockholders entered into an indemnity escrow
 agreement, pursuant to which $0.3 million of Ceregene remaining
 cash was deposited in an escrow account for the benefit of Sangamo
 to satisfy indemnity obligations of the stockholders under the
 Merger Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In accordance with the Merger Agreement, each issued and
 outstanding share of Ceregene capital stock was cancelled and
 converted into the right to receive the merger consideration
 described in the Merger Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Ceregene acquisition was accounted for as a business
 combination in accordance with the guidance ASC Topic 805. The
 operating results of Ceregene after the Closing Date have been
 included in the Company&amp;#x2019;s Consolidated Statements of
 Operations. The Company&amp;#x2019;s Consolidated Balance Sheet as of
 December&amp;#xA0;31, 2013 reflects the acquisition of Ceregene.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Consideration Transferred&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the estimated fair value of the
 consideration transferred by Sangamo to the Ceregene stockholders
 on the Closing Date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Sangamo shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Contingent earn-out&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total purchase consideration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Estimate of Assets Acquired and Liabilities
 Assumed&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the estimated fair value of the net
 assets acquired as of the Closing Date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash and equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounts receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Identifiable intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,585&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounts payable and accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total liabilities assumed&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(846&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Intangible assets for in-process research and development
 (IPR&amp;amp;D) consist of Ceregene&amp;#x2019;s two clinical product
 candidates, CERE-110 for the treatment of AD and CERE-120 for the
 treatment of Parkinson&amp;#x2019;s disease. The Company determined that
 the combined Closing Date estimated fair values of CERE-110 and
 CERE-120 was $1.9 million. The Company used an income approach,
 which is a measurement of the present value of the net economic
 benefit or cost expected to be derived from an asset or liability,
 to measure the fair value of these two product candidates. Under
 the income approach, an intangible asset&amp;#x2019;s fair value is
 equal to the present value of the incremental after-tax cash flows
 (excess earnings) attributable solely to the intangible asset over
 its remaining useful life.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 To calculate the fair value of CERE-110 and CERE-120 under the
 income approach, the Company used probability-weighted cash flows
 discounted at a rate considered appropriate given the inherent
 risks associated with this type of asset. The Company estimated a
 present value discount rate based on the estimated weighted-average
 cost of capital for companies with profiles substantially similar
 to that of Ceregene. This estimates the rate that market
 participants would use to value this asset. Cash flows were
 generally assumed to extend either through or beyond the patent
 life of the asset, depending on the circumstances particular to the
 asset. In addition, the Company compensated for additional risks,
 including the phase of development, historical clinical results and
 the lack of approved gene therapy products, by
 probability-adjusting the Company&amp;#x2019;s estimation of the
 expected future cash flows for these product candidates. The
 Company believes that the level and timing of cash flows
 appropriately reflect market participant assumptions. The projected
 cash flows from this project were based on key assumptions such as
 estimates of revenues and operating profits related to the project
 considering its stage of development; the time and resources needed
 to complete the development and approval of the related product
 candidate; the life of the potential commercialized product and
 associated risks, including the inherent difficulties and
 uncertainties in developing a drug compound such as obtaining
 marketing approval from the FDA and other regulatory agencies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 A summary of these assets and estimated fair values at the Closing
 Date is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Value&amp;#xA0;of&amp;#xA0;Intangible&lt;br /&gt;
 Assets Acquired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 CERE-110 for the treatment of Alzheimer&amp;#x2019;s disease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 CERE-120 for the treatment of Parkinson&amp;#x2019;s disease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total identifiable intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 IPR&amp;amp;D is an intangible asset classified as an indefinite-lived
 until the completion or abandonment of the associated research and
 development effort, and will be amortized over an estimated useful
 life to be determined at the date the project is completed.
 IPR&amp;amp;D is not amortized during this period, but rather tested
 for impairment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The excess of the consideration transferred over the fair values
 assigned to the assets acquired and liabilities assumed was $1.6
 million, which represents the goodwill amount resulting from the
 acquisition. Goodwill represents benefits that Sangamo believes
 will result from combining its operations with the operations of
 Ceregene and any intangible assets that do not qualify for separate
 recognition, as well as any future, yet unidentified products.
 Goodwill recorded includes $0.7 million related to a deferred tax
 liability. The deferred tax liability is due to the Company&amp;#x2019;s
 recognition of the acquired IPR&amp;amp;D assets for financial
 statement purposes but not for tax purposes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 None of the goodwill is expected to be deductible for income tax
 purposes. The Company will test goodwill for impairment on an
 annual basis or sooner, if deemed necessary. As of
 December&amp;#xA0;31, 2013, there were no changes in the Goodwill
 recorded from the acquisition of Ceregene.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Liability for Contingent Consideration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In addition to the transfer of Sangamo common stock, the Company
 may be required to make contingent Earn-Out Payments if the Company
 grants a third-party license to develop and commercialize the
 Earn-Out Products or if the Company commercializes any Earn-Out
 Product itself. These payments are a percentage of any upfront or
 milestone payments received in the case Sangamo grants a
 third-party license to develop and commercialize the Earn-Out
 Products, or are a percentage of net sales in the case Sangamo
 develops and commercialized the Earn-Out Products itself. The total
 maximum payment is not limited, other than due to size of the
 upfront and milestone payments received or the net sales of the
 products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the liability for the contingent consideration
 recognized on the Close Date was $1.5 million. The Company
 determined the fair value of the liability for the contingent
 consideration based on a probability-weighted discounted cash flow
 analysis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the contingent consideration liability associated
 with those future earnout payments was based upon reasonable
 assumptions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Escrow Account Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On the Closing Date, $0.3 million of Ceregene&amp;#x2019;s remaining
 cash, payable to the Ceregene stockholders, was placed in an escrow
 account to be held until October&amp;#xA0;1, 2014, to secure the
 indemnification rights of Sangamo and other indemnities with
 respect to certain matters, including breaches of general
 representations and warranties included in the Merger
 Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Acquisition-Related Transaction Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company recognized $0.1 million in acquisition-related
 transaction expenses in the year ended December&amp;#xA0;31, 2013.
 These costs are included in the &amp;#x201C;General and
 administrative&amp;#x201D; expense line item in the Consolidated
 Statement of Operations for the year ended December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues and Operating Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Ceregene did not record any revenues for the period from the Close
 Date to December&amp;#xA0;31, 2013. There were no material operating
 expenses included in Sangamo&amp;#x2019;s Consolidated Statement of
 Operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Proforma Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following unaudited supplemental pro forma information presents
 the Company&amp;#x2019;s financial results as if the acquisition of
 Ceregene had occurred on January&amp;#xA0;1, 2012. This supplemental
 pro forma information has been prepared for comparative purposes
 and does not purport to be indicative of what would have occurred
 had the acquisition been made on January&amp;#xA0;1, 2012, nor are they
 indicative of any future results.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands&amp;#xA0;except&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_E2A6A7FB-0E70-490F-9DBE-020518A5EE63_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table shows total stock-based compensation expense
 recognized in the consolidated statements of operations (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,942&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,338&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_17">-19482000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_12">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_BA84B5DC-B6D2-41F7-94C7-4DBC5959E7F2_5001_3">4.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_5EF23B67-B49F-440C-8EB5-017B99E73EF4_5001_2">1119200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_53F73C8E-0D59-4DE4-8184-ED371EED6D9B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 14 &amp;#x2013; SUBSEQUENT EVENT&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On January&amp;#xA0;8, 2014, the Company entered into a Global
 Research, Development and Commercialization Collaboration and
 License Agreement (the Agreement) with Biogen Idec Inc. (Biogen),
 pursuant to which Sangamo and Biogen will collaborate to discover,
 develop, seek regulatory approval for and commercialize
 therapeutics based on Sangamo&amp;#x2019;s ZFP technology for
 hemoglobinopathies, including beta-thalassemia and sickle cell
 disease (SCD).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Agreement, Sangamo and Biogen will jointly conduct two
 research programs: the beta-thalassemia program and the SCD
 program. In the beta-thalassemia program, Sangamo is responsible
 for all discovery, research and development activities through the
 first human clinical trial for the first ZFP therapeutic developed
 under the Agreement for the treatment of beta-thalassemia. In the
 SCD program, both parties are responsible for research and
 development activities through the submission of an IND application
 for ZFP therapeutics intended to treat SCD. Under both programs,
 Biogen is responsible for subsequent worldwide clinical
 development, manufacturing and commercialization of licensed
 products developed under the Agreement. At the end of specified
 research terms for each program or under certain specified
 circumstances, Biogen retains the right to step in and take over
 any remaining activities of Sangamo. Furthermore, Sangamo has an
 option to co-promote in the United States any&amp;#xA0;licensed product
 to treat beta-thalassemia and SCD&amp;#xA0;developed under the
 Agreement, and Biogen agrees to compensate Sangamo for such
 co-promotion activities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Agreement, Sangamo will receive an upfront license fee of
 $20.0 million. Biogen will reimburse Sangamo for its costs incurred
 in connection with research and development activities conducted by
 Sangamo. In addition, Sangamo is eligible to receive development
 milestone payments upon the achievement of specified regulatory,
 clinical development and commercialization milestones. The total
 amount of potential regulatory, clinical development,
 commercialization and sales milestone payments, assuming the
 achievement of all specified milestones in the Agreement, is $293.8
 million, including Phase 1 milestone payments of $7.5 million for
 each of the beta-thalassemia and SCD programs. In addition, Biogen
 agrees to pay Sangamo incremental royalties for each licensed
 product that are tiered double-digit percentage of annual net sales
 of such product.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Subject to the terms of the Agreement, Sangamo grants Biogen an
 exclusive, royalty-bearing license, with the right to grant
 sublicenses, to use certain ZFP and other technology controlled by
 Sangamo for the purpose of researching, developing, manufacturing
 and commercializing licensed products developed under the
 Agreement. Sangamo also grants Biogen a non-exclusive, worldwide,
 royalty free, fully paid license, with the right to grant
 sublicenses, of Sangamo&amp;#x2019;s interest in certain other
 intellectual property developed pursuant to the Agreement.&lt;/p&gt;
 &lt;!-- /xbrl,ns --&gt;

 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8B7839B3-0D0F-4706-B696-B9A7822BF7E2_1_1">P2Y10M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_D168B964-A85B-4A85-BE8E-A6FE47940864_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 10 &amp;#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company recorded no income tax expense. The principal
 difference between the statutory tax rate of 34% and the
 Company&amp;#x2019;s effective tax rate is due to the Company permanent
 differences related to stock compensation and its change in
 valuation allowance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Deferred income taxes reflect the net tax effects of temporary
 differences between the carrying amounts of assets and liabilities
 for financial reporting purposes and the amounts used for income
 tax purposes. Significant components of the Company&amp;#x2019;s
 deferred tax assets are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;u&gt;&lt;b&gt;&lt;i&gt;Assets:&lt;/i&gt;&lt;/b&gt;&lt;/u&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capitalized research&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,677&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;937&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(103,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(88,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Liabilities:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax liability related to intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As part of accounting for the acquisition of Ceregene, the Company
 recorded goodwill and intangible assets. The intangible assets
 acquired are for the use in a particular research and development
 project IPR&amp;amp;D and are considered indefinite-lived assets. They
 will remain indefinite lived until the completion or abandonment of
 the associated research and development efforts. Since the
 intangible assets acquired have no tax basis, a deferred tax
 liability was established due to the difference between the book
 and tax bases for those assets. The indefinite-lived asset is not
 treated as a future source of income and, therefore, no valuation
 allowance is released until the assets are amortized or
 abandoned,&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Realization of deferred tax assets is dependent upon future
 earnings, if any, the timing and amount of which are uncertain.
 Accordingly, the net deferred tax assets have been fully offset by
 a valuation allowance. The valuation allowance increased by $14.9
 million, $5.4 million and $19.7 million for the years ended
 December&amp;#xA0;31, 2013, 2012 and 2011, respectively. As of
 December&amp;#xA0;31, 2013, Sangamo had net operating loss
 carryforwards for federal and state income tax purposes of
 approximately $209&amp;#xA0;million and $199 million, respectively. If
 not utilized, the net federal and state operating loss
 carryforwards will begin to expire in 2018 and 2014 respectively.
 The Company also has federal and state research tax credit
 carryforwards of $6.2&amp;#xA0;million and $6.5 million, respectively.
 The federal research credits will begin to expire in 2018 while the
 state research credits have no expiration date. Utilization of the
 Company&amp;#x2019;s net operating loss carryforwards and research tax
 credit carryforwards may be subject to substantial annual
 limitations due to the ownership change limitations provided by the
 Internal Revenue Code and similar state provisions. The annual
 limitation could result in the expiration of the net operating loss
 carryforwards and research tax credit carryforwards before
 utilization.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company files U.S and state income tax returns with varying
 statutes of limitations. The tax years from 1998 forward remain
 open to examination due to the carryover of net operating losses or
 tax credits. The Company also files a UK income tax return, and the
 tax years from 2007 and thereafter remain open to examination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s practice is to recognize interest and/or
 penalties related to income tax matters in income tax expense. As
 of December&amp;#xA0;31, 2013, the Company had no accrued interest
 and/or penalties. The unrecognized tax benefits may change during
 the next year for items that arise in the ordinary course of
 business. In the event that any unrecognized tax benefits are
 recognized, the effective tax rate will not be affected.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the activity related to the
 Company&amp;#x2019;s unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,896&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Additions based on tax positions related to the current year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;589&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Additions for tax positions of prior years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reductions for tax positions of prior years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(227&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_1C46CDB3-514B-4B25-82AA-4194E46DCEC3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Intangible Assets &amp;#x2013; In-Process Research and
 Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Intangible assets related to in-process research and development
 costs, or IPR&amp;amp;D, are considered to be indefinite-lived until
 the completion or abandonment of the associated research and
 development efforts. If and when development is complete, which
 generally occurs if and when regulatory approval to market a
 product is obtained, the associated assets would be deemed
 finite-lived and would then be amortized based on their respective
 estimated useful lives at that point in time. Prior to completion
 of the research and development efforts, the assets are considered
 indefinite-lived. During this period, the assets will not be
 amortized but will be tested for impairment on an annual basis and
 between annual tests if the Company becomes aware of any events
 occurring or changes in circumstances that would indicate a
 reduction in the fair value of the IPR&amp;amp;D projects below their
 respective carrying amounts. The Company observed no impairment
 indicators of the recorded IPR&amp;amp;D in the year ended
 December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_866EC961-9004-4A56-8DD6-D038DC751E43_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development costs are expensed as incurred. Research
 and development expenses consist of direct and research-related
 allocated overhead costs such as facilities costs, salaries and
 related personnel costs, and material and supply costs. In
 addition, research and development expenses include costs related
 to clinical trials, validation of the Company&amp;#x2019;s testing
 processes and procedures and as well as related overhead expenses.
 Research and development costs incurred in connection with
 collaborator-funded activities are expensed as incurred. Costs to
 acquire technologies that are utilized in research and development
 that have no alternative future use are expensed as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_EBB66DE0-263F-4A72-BE5A-B50E861E3D17_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. Actual results
 could differ from those estimates. The consolidated financial
 statements include the accounts of Sangamo and its wholly owned
 subsidiaries, Ceregene and Gendaq Limited, after elimination of all
 intercompany balances and transactions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_907436F7-2E18-47C1-A4C6-7265043EB89B_3001_4">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_907436F7-2E18-47C1-A4C6-7265043EB89B_3001_3">P6Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_30822293-9D19-4FA8-B30D-26396A0F8FFB_1_0">&lt;div&gt;
 &lt;p&gt;This supplemental pro forma information has been prepared for
 comparative purposes and does not purport to be indicative of what
 would have occurred had the acquisition been made on
 January&amp;#xA0;1, 2012, nor are they indicative of any future
 results.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands&amp;#xA0;except&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_37DFC565-D84A-4F10-A4E6-4B9C225C7F35_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 12 &amp;#x2013; EMPLOYEE BENEFIT PLAN&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company sponsors a defined-contribution savings plan under
 Section&amp;#xA0;401(k) of the Internal Revenue Code covering all
 full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan
 is intended to qualify under Section&amp;#xA0;401 of the Internal
 Revenue Code.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;The Company matched
 contributions by employees equal to 50% of the first 6% of employee
 contributions up to a limit of $1,500 in 2013 and $1,000 in 2012.
 Matching funds are fully vested when contributed. Contributions to
 the Sangamo 401(k) Plan were $0.1 million in both years ended
 December&amp;#xA0;31, 2013 and 2012. There were no such contributions
 in 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_5EF23B67-B49F-440C-8EB5-017B99E73EF4_5001_3">1715123</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8F246A8D-2CBC-46E9-A668-EB70B08DAA02_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company operates in one segment. Management uses one
 measurement of profitability and does not segregate its business
 for internal reporting. As of December&amp;#xA0;31, 2013 and 2012, all
 of the Company&amp;#x2019;s assets were maintained in the U.S. For the
 years ended December&amp;#xA0;31, 2013, 2012 and 2011, 100% of revenues
 and operating expenses were generated and incurred in the U.S.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_8DED0432-397B-436D-BD6B-D8A0D9D9B305_1_0">&lt;div&gt;
 &lt;p&gt;Significant components of the Company&amp;#x2019;s deferred tax
 assets are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;u&gt;&lt;b&gt;&lt;i&gt;Assets:&lt;/i&gt;&lt;/b&gt;&lt;/u&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capitalized research&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,677&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;937&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(103,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(88,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Liabilities:&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax liability related to intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3014833_5EF23B67-B49F-440C-8EB5-017B99E73EF4_5001_4">182559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3014833_C6988B3E-CC07-4959-80E4-003681789B32_1_2">60</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_D29F0270-979F-43E3-A5C4-7882155A9F8B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are all anti-dilutive. All stock options
 outstanding were excluded from the calculation of diluted net loss
 per share. Stock option outstanding at the end of 2013, 2012 and
 2011 were 8,405,864, 9,184,346 and 8,346,190, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_3CC5AE19-DBF7-4240-8EDB-A8142C92B9EC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The assumptions used for estimating the fair value of the employee
 stock options are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.50-1.88&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.74-1.34&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.93-2.11&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of option (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.36-5.38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40-5.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.39-5.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield of stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.87-0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.83-0.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_78718261-03FF-4708-9D4E-90F38A09D09E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 3 &amp;#x2013;MARKETABLE SECURITIES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The table below summarizes the Company&amp;#x2019;s cash equivalents and
 available-for-sale securities (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 (Losses)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,212&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013, all of the Company&amp;#x2019;s
 investments had maturity dates within two years and there were no
 material unrealized losses during 2013. Approximately 70% of the
 Company&amp;#x2019;s available-for-sale securities mature within the
 next twelve months of the date of the balance sheet date and
 approximately 30% of the Company&amp;#x2019;s available-for-sale
 securities have maturities between twelve and twenty-four months
 from the date of the balance sheet date. The Company had no
 material realized losses or other-than-temporary impairments of
 available-for-sale securities for the years ended December&amp;#xA0;31,
 2013, 2012 and 2011.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_B9453922-FDA0-4CBC-B930-742B2056978A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Income tax expense has been provided using the liability method.
 Deferred tax assets and liabilities are determined based on the
 difference between the financial statement and tax bases of assets
 and liabilities as measured by the enacted tax rates that will be
 in effect when these differences reverse. The Company provides a
 valuation allowance against net deferred tax assets if, based upon
 the available evidence, it is not more likely than not that the
 deferred tax assets will be realized.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_29">6118000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1_2">153000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_3">24133000</us-gaap:Revenues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_41A51777-B557-4068-8627-C5800A37D5FE_1_1">2000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_13">160000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1_1">294000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_39">-26638000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_19">118894000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_22">-79000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_2">2455000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_9">-26706000</us-gaap:OperatingIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_33">1200000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A54E4C6D-F128-4B06-AC04-82E700E91984_1_3">100000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1_0">14900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_11">148000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_27">2015000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_12">-1008000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_10">82000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_11">-26624000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_31">496000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_35">6146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_9">320000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_27">69492000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_23">432000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9006_37">-14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_1_5">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_1_3">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_20">51129000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_1_3" />
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_15">721000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_6">13800000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_29">76107000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_1_2">1500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_7">60000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_16">-2190000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_14">269000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_6DD4FFC5-8A13-4AE9-AF85-02F098514F1F_1_1">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_5">6146000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_30">-11493000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_28">8630000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3014833_8B7839B3-0D0F-4706-B696-B9A7822BF7E2_1_4">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_24">-68118000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_5">36979000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_1_4">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_3">569000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_4E619FF7-015F-4CA6-BE1D-C500989714D4_1_0">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_2C29A6C5-E043-4747-9AC3-07DE627EBA62_1_0">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_1_2">6146000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_8">50839000</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_4">912000</us-gaap:AmortizationOfDebtDiscountPremium>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="INF" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_1_3">1.10</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder>
  <sgmo:IncomeTaxExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3014833_5774F7A6-4555-4EC5-A41A-4603BAF2E12A_1_0">0</sgmo:IncomeTaxExpense>
  <sgmo:RentalExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_CBEE8630-30BE-4666-B35B-713000DFEF15_1_0">700000</sgmo:RentalExpenses>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_1_1">21678000</sgmo:CollaborationAgreements>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7585E592-E971-4766-9D0D-CE2E3324E167_1_0">1.47</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <sgmo:AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_1_2">0.70</sgmo:AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_1_4">P5Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder>
  <sgmo:FairValueMeasurementsDisclosureTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_4EBD287C-1F5B-4BD1-83C3-4E07A3503B41_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 2 &amp;#x2013;FAIR VALUE MEASUREMENT&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company measures certain assets and liabilities at fair value
 on a recurring basis, including cash equivalents,
 available-for-sale securities and contingent consideration
 liability.&amp;#xA0;The fair value is determined based on a three-tier
 hierarchy under the authoritative guidance for fair value
 measurements and disclosures that prioritizes the inputs used in
 measuring fair value as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Level 2: Quoted prices in markets that are not active, or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 When observable market prices for identical securities that are
 traded in less active markets are used, the Company classifies its
 available-for-sale debt instruments as Level 2. When observable
 market prices for identical securities are not available,
 available-for-sale debt instruments are priced using benchmark
 curves, benchmarking of like securities, sector groupings, and
 matrix pricing as well as model processes. These models are
 proprietary valuation models of pricing providers or brokers. These
 valuation models incorporate a number of inputs, including, listed
 in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the Standard Inputs may
 not be applicable.&amp;#xA0;Evaluators may prioritize inputs
 differently on any given day for any security based on market
 conditions, and not all inputs listed are available for use in the
 evaluation process for each security evaluation on any given
 day.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value measurements of cash equivalents, available-for-sale
 securities and contingent consideration liabilities are identified
 at the following levels within the fair value hierarchy (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Contingent consideration liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Contingent Consideration Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company initially recorded a liability on the acquisition date
 of the estimated fair value of contingent consideration payments to
 former Ceregene stockholders, as outlined under the terms of the
 merger agreement with Ceregene. These contingent payments are owed
 if the Company grants a third-party license to develop and
 commercialize certain product candidates acquired from Ceregene, or
 if the Company commercializes any of these product candidates
 itself. The fair values of these Level 3 liabilities are estimated
 using a probability-weighted discounted cash flow analysis. Such
 valuations require significant estimates and assumptions including
 but not limited to: determining the timing and estimated costs to
 complete the in-process projects, projecting regulatory approvals,
 estimating future cash flows, and developing appropriate discount
 rates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Subsequent changes in the fair value of these contingent
 consideration liabilities are recorded to the &amp;#x201C;Change in fair
 value of contingent liability&amp;#x201D; expense line item in the
 Consolidated Statements of Operations under operating expenses.
 From the acquisition date of October&amp;#xA0;1, 2013 through
 December&amp;#xA0;31, 2013, the recognized amount of the liability for
 contingent consideration increased by $0.1 million primarily as the
 result of the passage of time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="20%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value on date of acquisition (October 1, 2013)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</sgmo:FairValueMeasurementsDisclosureTextBlock>
  <sgmo:AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_1_3">0.30</sgmo:AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1_4">0.33</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary>
  <sgmo:ContingentConsiderationPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_D9697AAF-AA09-464C-9994-C923A3487DE8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Contingent Consideration Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the merger agreement with Ceregene, the Company may be
 required to make contingent earn-out payments if the Company grants
 a third-party license to develop and commercialize certain product
 candidates acquired from Ceregene, or if the Company commercializes
 any of these product candidates itself. These earn-out payments
 will become payable in the period they are earned. In accordance
 with ASC Topic 805, Business Combinations, the Company determined
 the fair value of this liability for contingent consideration on
 the acquisition date using a probability-weighted discounted cash
 flow analysis. Future changes to the fair value of the contingent
 consideration will be determined each period and charged to expense
 in the &amp;#x201C;Changes in fair value of contingent liability&amp;#x201D;
 expense line item in the Consolidated Statements of Operations
 under operating expenses.&lt;/p&gt;
 &lt;/div&gt;</sgmo:ContingentConsiderationPolicyTextBlock>
  <sgmo:SpecifiedStockholderOwnershipPercentage contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_1_2">0.10</sgmo:SpecifiedStockholderOwnershipPercentage>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1_5">0.67</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary>
  <sgmo:OperatingLossCarryforwardsExpirationYear contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1_3">2014</sgmo:OperatingLossCarryforwardsExpirationYear>
  <sgmo:ProceedsFromIssuanceInitialPublicOfferingNetOfCosts contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_26">69492000</sgmo:ProceedsFromIssuanceInitialPublicOfferingNetOfCosts>
  <sgmo:FederalResearchTaxCreditCarryforwardExpirationYear contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_1_6">2018</sgmo:FederalResearchTaxCreditCarryforwardExpirationYear>
  <sgmo:RecentlyAccountingPronouncementsPolicyTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_EBA63EC0-1ADB-4F5D-9B4C-850D6614522D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the FASB issued ASU No.&amp;#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income. This newly issued
 accounting standard requires an entity to provide information about
 the amounts reclassified out of accumulated other comprehensive
 income by component. This ASU is effective for reporting periods
 beginning after December&amp;#xA0;15, 2012. The Company adopted this
 standard in the first quarter of 2013 and the adoption of this
 standard did not have an impact on its financial position or
 results of operations.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;&lt;/div&gt;</sgmo:RecentlyAccountingPronouncementsPolicyTextBlock>
  <sgmo:CashEquivalentMaturityPeriodHighlyLiquidInvestment contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_1903CBC3-71EF-49C6-9336-567D06345A37_1_0">Three months or less</sgmo:CashEquivalentMaturityPeriodHighlyLiquidInvestment>
  <sgmo:PotentialRoyaltyPaymentsToEntity contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" id="id_3014833_40F19540-6AFE-41E3-B261-015DB56D5E93_1_0">Two  times the amount Sangamo receives in funding under the agreement</sgmo:PotentialRoyaltyPaymentsToEntity>
  <sgmo:IncreaseDecreaseInEscrowLiabilities contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_10">275000</sgmo:IncreaseDecreaseInEscrowLiabilities>
  <sgmo:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_1_34">1200000</sgmo:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_923497x921516" unitRef="pure" decimals="INF" id="id_3014833_A534DA7E-1824-4B96-B58C-98890B20C09E_1001_0">1.00</us-gaap:ConcentrationRiskPercentage1>
  <sgmo:ContractualAgreementTerminationDate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1019175" id="id_3014833_7193F4BF-AB42-4371-B9F7-D1BB1F3171D9_1002_3">2012-08-30</sgmo:ContractualAgreementTerminationDate>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_1001_1">1800000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_2001_0">1200000</sgmo:ResearchGrantRevenue>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514_926233x928673_926634x1247035" unitRef="iso4217_USD" decimals="-5" id="id_3014833_D38BA2A2-473A-4656-A22E-E4009164609F_1001_0">100000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514_926233x928673_926634x1247035" unitRef="iso4217_USD" decimals="-5" id="id_3014833_D38BA2A2-473A-4656-A22E-E4009164609F_1001_1">400000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x998276_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_46099742-376E-4708-B01E-618D0ABE95A9_1001_0">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_C9597BB3-8A9A-4AFA-958F-CEE3BBE101AB_1001_0">200000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140" id="id_3014833_B1825436-61C0-420F-AF67-B4BEABA59E62_2_0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1003_0">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1003_1">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1002_0">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1002_2">0.0085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1002_1">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953" id="id_3014833_B1825436-61C0-420F-AF67-B4BEABA59E62_1_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1002_0">0.0150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1002_1">P5Y4M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1001_0">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1001_2">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1001_1">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_1001_1">2942000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_2001_0">3204000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1002418" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2007_4">P6Y11M5D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1002418" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2007_1">5.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1002418" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2007_2">5.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1014875" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2003_4">P3Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1014875" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2003_1">3.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1014875" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2003_2">5.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1048263" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2006_4">P5Y2M27D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1048263" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2006_1">5.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1048263" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2006_2">5.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1053915" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2005_4">P8Y10M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1053915" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2005_1">5.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1053915" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2005_2">5.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1097982" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2009_4">P5Y5M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1097982" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2009_1">6.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1097982" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2009_2">11.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1124646" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2004_4">P5Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1124646" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2004_1">5.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1124646" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2004_2">5.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1139642" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2010_4">P6Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1139642" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2010_1">12.12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1139642" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2010_2">14.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x949918" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2008_4">P5Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x949918" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2008_1">5.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x949918" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2008_2">6.82</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x960261" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2001_4">P7Y9M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x960261" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2001_1">2.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x960261" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2001_2">3.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x975231" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2002_4">P4Y11M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x975231" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2002_1">3.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x975231" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3014833_79FA5554-374F-4F7C-AE54-4A060DD667B1_2002_2">3.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9005_37">-14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9004_38">-26624000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_34">99998</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_32">180551</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_30">1889818</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_28">7015000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_29">19000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_33">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_31">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9001_27">70000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9003_29">6099000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9003_33">1199000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9003_31">495000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9003_35">6146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_9003_27">69422000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_485707D0-B437-48E9-B57A-6804A8C88B49_1001_1">-0.55</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="shares" decimals="INF" id="id_3014833_9BCBD99E-2506-4CF7-9452-84F352FA323E_2_0">100000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-6" id="id_3014833_3221C47B-69FA-4DF8-825D-97B2892EC458_1_0">0</us-gaap:GoodwillPeriodIncreaseDecrease>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_7C76299F-DADC-4387-9EC7-D032940150D3_1_2">2710000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:EscrowDepositDisbursementsRelatedToPropertyAcquisition1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-5" id="id_3014833_15CBBC84-05EB-492F-BC93-BE4E002EB3B4_1_0">300000</us-gaap:EscrowDepositDisbursementsRelatedToPropertyAcquisition1>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_485707D0-B437-48E9-B57A-6804A8C88B49_1001_0">-30997000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_7C76299F-DADC-4387-9EC7-D032940150D3_1_0">1200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-6" id="id_3014833_FC1906BB-2476-410A-8516-EDEF68853C60_1_0">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-5" id="id_3014833_1EA9F847-4F3E-4AB5-9615-547608EAB467_1_0">1900000</us-gaap:ResearchAndDevelopmentInProcess>
  <sgmo:BusinessAcquisitionContingentConsiderationEarnoutPayment contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_7C76299F-DADC-4387-9EC7-D032940150D3_1_1">1510000</sgmo:BusinessAcquisitionContingentConsiderationEarnoutPayment>
  <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x926520" unitRef="shares" decimals="0" id="id_3014833_6DD4FFC5-8A13-4AE9-AF85-02F098514F1F_1001_0">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x926520_930809x1044748" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_1001_5">Options granted under the 2013 Plan generally vest over four years at a  rate of 25 percent one year from the grant date and one thirty-sixth per month  thereafter and expire ten years after the grant, or earlier upon employment  termination.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x926520_930809x1044748" unitRef="pure" decimals="2" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_1001_7">0.25</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_0D6E8D90-9BF9-4416-9575-550181B14D60_5001_4">23750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" id="id_3014833_15F28E8F-98B7-4D59-8948-17985C9DC995_2001_1">P1Y5M16D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_0">392500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_6">These awards will vest as follows:  one-third of the award will vest in a series of three successive equal annual  installments.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_1">12.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" id="id_3014833_8B7839B3-0D0F-4706-B696-B9A7822BF7E2_1001_3">P1Y11M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="pure" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_3">0.33</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="Installment" decimals="INF" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_2">3</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_0D6E8D90-9BF9-4416-9575-550181B14D60_5001_3">341843</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" id="id_3014833_15F28E8F-98B7-4D59-8948-17985C9DC995_2001_2">P1Y5M5D</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1001_9">4100000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1001_2">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_929362x924898" unitRef="pure" decimals="2" id="id_3014833_72596D9D-85AC-40AA-97B1-3597184A3C58_1001_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x1044748" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_2001_6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x1044748" unitRef="pure" decimals="INF" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_2001_0">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x1044748" id="id_3014833_2CC10573-7316-4D6A-9FEB-1AC36B25ABE0_2001_8">P10Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" unitRef="pure" decimals="INF" id="id_3014833_B86D4AAD-E931-4575-8099-EA275FFF8951_1001_1">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" unitRef="pure" decimals="2" id="id_3014833_1E2E4706-3A9E-4863-84D1-355BC259CFE1_1001_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" unitRef="shares" decimals="INF" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1001_0">181000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <sgmo:PurchasePlanOfferingPeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" id="id_3014833_B86D4AAD-E931-4575-8099-EA275FFF8951_1001_2">P2Y</sgmo:PurchasePlanOfferingPeriod>
  <sgmo:PurchasePlanPurchasePeriod contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" id="id_3014833_B86D4AAD-E931-4575-8099-EA275FFF8951_1001_3">P6M</sgmo:PurchasePlanPurchasePeriod>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1001_1">2.75</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1001_0">3000000</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1001_1">400000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x971461" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_3001_2">0.12</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693" id="id_3014833_19CC0830-7B6C-44CE-B1EE-3C35601D4800_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues recognized under the agreement with Sigma for the years
 ended December&amp;#xA0;31, 2013, 2012 and 2011, were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December 31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenue related to Sigma Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Royalty revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 License fee and milestone revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_4001_1">0.09</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1001_3">2175000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1001_2">1351000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1001_1">824000</us-gaap:RoyaltyRevenue>
  <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" id="id_3014833_1E71C97D-B34B-406B-A604-D1F8FF3A00A2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenues recognized under the agreement with Shire for the years
 ended December&amp;#xA0;31, 2013 and 2012, were as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year ended&lt;br /&gt;
 December 31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues related to Shire Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Amortization of upfront fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_5001_0">0.68</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1001_3">16453000</us-gaap:ContractsRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-6" id="id_3014833_9BE2A0EF-046F-40DE-97FC-25FD70B0F1A6_1001_1">0</us-gaap:RoyaltyRevenue>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" id="id_3014833_24A9F027-A68A-4949-AC89-4853D7720B74_1001_0">P6Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1001_2">14286000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1001_1">2167000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_DB1DEDBF-B075-438E-880C-6D1F4E09CB08_1001_0">14200000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8E58C979-920E-423A-B1B0-09E6A3BB26E2_1002_1">213500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8E58C979-920E-423A-B1B0-09E6A3BB26E2_1002_4">8500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="Product" decimals="-6" id="id_3014833_9BE2A0EF-046F-40DE-97FC-25FD70B0F1A6_1001_0">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_8E58C979-920E-423A-B1B0-09E6A3BB26E2_1002_2">33500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive contextRef="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959" unitRef="iso4217_USD" decimals="-6" id="id_3014833_8E58C979-920E-423A-B1B0-09E6A3BB26E2_1002_3">180000000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" id="id_3014833_907436F7-2E18-47C1-A4C6-7265043EB89B_1001_1">P6Y5M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="shares" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_13">52741000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockDividendsShares contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_3014833_41A51777-B557-4068-8627-C5800A37D5FE_2_0">0</us-gaap:StockDividendsShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7BCC4C84-4B6C-4753-8D50-0EA1194D648D_2_0">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_17">-8082000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_12">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6006_16">1219000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_2_2">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_3">21655000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_13">-14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_2_1">153000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6006_24">-22250000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_6">-123000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_19">91428000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A54E4C6D-F128-4B06-AC04-82E700E91984_2_1">500000</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_2">3469000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_9">-22198000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_476984C0-8990-4CE9-84D7-96D371A455FD_2_0">5400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_11">-141000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_12">3414000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_10">-66000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_11">-22264000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6006_18">457000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6006_20">5338000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A54E4C6D-F128-4B06-AC04-82E700E91984_2_2">400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_23">723000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6006_22">14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_2_5">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_2_3">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_20">103470000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_58B81B06-131B-4DBF-BDA7-EE88E8AF1DB0_2_3">227000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_15">800000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_6">12144000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_29">1676000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="INF" id="id_3014833_682624C4-68BB-48C9-8100-F8EF6C359CBB_2_2">1000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_16">11134000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_14">-1503000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_6DD4FFC5-8A13-4AE9-AF85-02F098514F1F_2_1">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_5">5338000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_30">4913000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_28">1676000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_24">11319000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_5">31709000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_59B82ABD-705A-4462-A7A3-FC7A15047D7C_2_4">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_3">660000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_2_2">5338000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_8">43853000</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_6B1D4AA8-906F-4446-AB44-33C8F73FD40F_2_4">889000</us-gaap:AmortizationOfDebtDiscountPremium>
  <sgmo:RentalExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3014833_CBEE8630-30BE-4666-B35B-713000DFEF15_2_0">600000</sgmo:RentalExpenses>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_791185EF-A6D6-43AE-B823-CA056F4A7E0F_2_1">18186000</sgmo:CollaborationAgreements>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_7585E592-E971-4766-9D0D-CE2E3324E167_2_0">2.51</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_923497x921516" unitRef="pure" decimals="INF" id="id_3014833_A534DA7E-1824-4B96-B58C-98890B20C09E_1002_0">1.00</us-gaap:ConcentrationRiskPercentage1>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AE3ACBB-5758-4F75-B0BF-3535AFE6B7DD_1001_1">1100000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AE3ACBB-5758-4F75-B0BF-3535AFE6B7DD_1001_0">1100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_3014833_5AF1170E-D1A9-42C5-BEC4-B457528B097E_1001_0">800000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_1002_1">1200000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_889FD87F-1495-4CF2-95B7-DF321A44B556_2002_0">1200000</sgmo:ResearchGrantRevenue>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x998276_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_3014833_46099742-376E-4708-B01E-618D0ABE95A9_1002_0">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_3014833_C9597BB3-8A9A-4AFA-958F-CEE3BBE101AB_1002_0">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1005_0">0.0134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1005_2">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1005_1">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1004_0">-0.0030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1004_2">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1004_1">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1004_0">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_929362x924898" unitRef="pure" decimals="4" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1004_2">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_929362x924898" id="id_3014833_D8382660-61DF-44E6-A72A-6B530CC96D36_1004_1">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1003_0">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_930809x929710" unitRef="pure" decimals="4" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1003_2">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_930809x929710" id="id_3014833_B283DF40-CB45-4245-B768-54106C06B0D8_1003_1">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_1002_1">2446000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_3014833_27CEE26E-BF43-4D75-992F-B3893A6A9BA6_2002_0">2892000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x923434" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6005_22">14000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6004_23">-22264000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6001_19">175375</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6001_17">328355</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6001_16">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6001_18">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6003_16">1216000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6003_18">455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_3014833_19205C46-0E00-43FA-AE4B-10534C0BEB98_6003_20">5338000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_928576x1237588" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_485707D0-B437-48E9-B57A-6804A8C88B49_1002_1">-0.52</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_928576x1237588" unitRef="iso4217_USD" decimals="-3" id="id_3014833_485707D0-B437-48E9-B57A-6804A8C88B49_1002_0">-27446000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_929038x929867" unitRef="shares" decimals="INF" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1002_0">486750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_929038x929867" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1002_1">5.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_929038x929867" unitRef="iso4217_USD" decimals="-5" id="id_3014833_A5C4349D-8D5F-41AE-9ABD-49F1B4A8DFB4_1002_9">100000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_929362x924898" unitRef="pure" decimals="2" id="id_3014833_72596D9D-85AC-40AA-97B1-3597184A3C58_1002_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_930809x929710" unitRef="pure" decimals="2" id="id_3014833_1E2E4706-3A9E-4863-84D1-355BC259CFE1_1002_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_930809x929710" unitRef="shares" decimals="INF" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1002_0">175000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_930809x929710" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_9693291A-3457-47A7-A97A-D1368F6818E9_1002_1">2.61</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1002_0">4700000</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_3014833_B608488A-89BA-40DE-867C-35B25BEF750D_1002_1">600000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x971461" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_3002_2">0.22</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x982693" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_4002_1">0.11</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1002_3">2288000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1002_2">1000000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_3014833_BA7249A7-5748-4BE4-B36F-053ECD49F971_1002_1">1288000</us-gaap:RoyaltyRevenue>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959" unitRef="pure" decimals="INF" id="id_3014833_10C12CCD-02B8-4745-85E7-7D696888A892_5002_0">0.51</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1002_3">11012000</us-gaap:ContractsRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1002_2">9026000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_3014833_CEA67B26-3C16-478A-93B4-40B02B9394D9_1002_1">1986000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_3014833_DB1DEDBF-B075-438E-880C-6D1F4E09CB08_1002_0">7700000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_1_3">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_1_0">4623000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_1_2">-6885000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_1_1">11528000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_5_3">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_5_0">3243000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_5_2">-7268000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_5_1">10526000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_6_3">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_6_0">4574000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_6_2">-5728000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_6_1">10318000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_2_3">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_2_0">6934000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_2_2">-5450000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_2_1">12402000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_7_3">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_7_0">4907000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_7_2">-5790000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_7_1">10709000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_3_3">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_3_0">5707000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_3_2">-6145000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_3_1">11866000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_92_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_8_3">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_8_0">8931000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_8_2">-3478000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_8_1">12300000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-K0008_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_4_3">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-K0008_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_4_0">6869000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-K0008_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_4_2">-8144000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-K0008_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3014833_574B80EE-F7B2-4D6D-A738-800EF40FBAF7_4_1">15043000</us-gaap:OperatingExpenses>
  <context id="eol_PE72223---1310-K0008_STD_92_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_92_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_91_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_91_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x971461">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgrosciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_929038x929867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_928576x1237588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x932953_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_926437x923140_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x998276_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0_923497x921516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x971461">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgrosciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_930809x1044748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x929867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x926520_930809x1044748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_929038x926520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_928576x1237588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x975231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x960261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x949918">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeEightMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1139642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1124646">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1097982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1053915">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFiveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1048263">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1014875">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927225x1002418">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x998276_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514_926233x928673_926634x1247035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">sgmo:TherapeuticForBetathalassemiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0_923497x921516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x971461">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgrosciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_933025x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_929038x929867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x932953_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_926437x923140_929362x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x998276_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0_923497x921516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20130923_0_932980x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-24</startDate>
      <endDate>2013-09-23</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20130923_0_926607x960063_932980x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sgmo:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-24</startDate>
      <endDate>2013-09-23</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20120331_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-03-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20130531_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20120131_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20100131_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20091031_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20091031_0_926233x1007904_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:UpfrontLicenseFeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20091031_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20070731_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-07-01</startDate>
      <endDate>2007-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20070131_0_925277x998276_926233x931915">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20051031_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20051031_0_926437x932953_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20051031_0_926437x923140_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_31_20051031_0_926233x928673_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_30_20120630_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-06-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_30_20110430_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_3_20140108_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-06</startDate>
      <endDate>2014-01-08</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20140108_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-08</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20140108_0_926233x1246051_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:SickleCellDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-08</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20140108_0_926233x1246050_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:BetaThalassemiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-08</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x929710">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_930809x1044748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929039x930113">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_929038x929867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x932359_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x924099_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sgmo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sgmo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sgmo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928628x1054008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sgmo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588_931868x1237605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgmo:CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588_931868x1237600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgmo:CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_928576x1237588">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x975231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x960261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x949918">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeEightMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1139642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1124646">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1097982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1053915">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFiveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1048263">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1014875">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_927225x1002418">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0_925277x998276">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_929038x929867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x932359_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x929831_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x925851_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099_929790x925736_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_928628x924099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20111231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20101231_0_927592x923434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20100630_0_925277x998276_926233x931915">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20110430_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20140201_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2014-02-01</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20091031_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20091031_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20091031_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20070131_0_925277x998276">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:MichaelJFoxFoundationForParkinsonsResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2007-01-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20061031_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-K0008_STD_0_20051031_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Program">
    <measure>sgmo:Program</measure>
  </unit>
  <unit id="Targets">
    <measure>sgmo:Targets</measure>
  </unit>
  <unit id="Segments">
    <measure>sgmo:Segments</measure>
  </unit>
  <unit id="Installment">
    <measure>sgmo:Installment</measure>
  </unit>
  <unit id="Product">
    <measure>sgmo:Product</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sgmo-20131231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:sgmo="http://sangamo.com/20131231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://sangamo.com/20131231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome" id="Role_StatementOfOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>107 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock">
        <link:definition>110 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <link:definition>111 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>113 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
        <link:definition>114 - Disclosure - Acquisition of Ceregene</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>115 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
        <link:definition>116 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>117 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>118 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>119 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>120 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>121 - Disclosure - Quarterly Financial Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>122 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>123 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables">
        <link:definition>124 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
        <link:definition>125 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>126 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
        <link:definition>128 - Disclosure - Acquisition of Ceregene (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>129 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables">
        <link:definition>130 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>133 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>134 - Disclosure - Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>135 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities" id="DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities">
        <link:definition>136 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation" id="DisclosureFairValueMeasurementAdditionalInformation">
        <link:definition>137 - Disclosure - Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability" id="DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability">
        <link:definition>138 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical" id="DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical">
        <link:definition>139 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments" id="DisclosureMarketableSecuritiesScheduleOfInvestments">
        <link:definition>140 - Disclosure - Marketable Securities - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation" id="DisclosureMarketableSecuritiesAdditionalInformation">
        <link:definition>141 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense" id="DisclosureStockBasedCompensationStockBasedCompensationExpense">
        <link:definition>142 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>143 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions" id="DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions">
        <link:definition>144 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights" id="DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights">
        <link:definition>145 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
        <link:definition>146 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
        <link:definition>147 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation">
        <link:definition>148 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation">
        <link:definition>149 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation">
        <link:definition>150 - Disclosure - Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - HIV - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation">
        <link:definition>151 - Disclosure - Major Customers, Partnerships and Strategic Alliances - CHDI Foundation, Inc. - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation">
        <link:definition>152 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Juvenile Diabetes Research Foundation International - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation">
        <link:definition>153 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Michael J. Fox Foundation for Parkinson's Research - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation" id="DisclosureAcquisitionOfCeregeneAdditionalInformation">
        <link:definition>154 - Disclosure - Acquisition of Ceregene - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred" id="DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred">
        <link:definition>155 - Disclosure - Acquisition of Ceregene - Summary of Estimated Fair Value of Consideration Transferred (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired" id="DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired">
        <link:definition>156 - Disclosure - Acquisition of Ceregene - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues" id="DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues">
        <link:definition>157 - Disclosure - Acquisition of Ceregene - Summary of Assets, Estimated Fair Values (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation" id="DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation">
        <link:definition>158 - Disclosure - Acquisition of Ceregene - Schedule of Supplemental Pro Forma Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment" id="DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment">
        <link:definition>159 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>160 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation" id="DisclosureCommitmentsAdditionalInformation">
        <link:definition>161 - Disclosure - Commitments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations" id="DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations">
        <link:definition>162 - Disclosure - Commitments - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>163 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity" id="DisclosureStockholdersEquitySummaryOfStockOptionActivity">
        <link:definition>164 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding" id="DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding">
        <link:definition>165 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" id="DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity">
        <link:definition>166 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>167 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets" id="DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets">
        <link:definition>168 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits">
        <link:definition>169 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities">
        <link:definition>170 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation" id="DisclosureEmployeeBenefitPlanAdditionalInformation">
        <link:definition>171 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData" id="DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData">
        <link:definition>172 - Disclosure - Quarterly Financial Data - Summary of Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation" id="DisclosureSubsequentEventAdditionalInformation">
        <link:definition>173 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sgmo-20131231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sgmo-20131231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sgmo-20131231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sgmo-20131231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedClinicalTrialExpense" id="sgmo_AccruedClinicalTrialExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalMilestonePaymentUnderAgreement" id="sgmo_AdditionalMilestonePaymentUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateNumberOfGeneTargets" id="sgmo_AggregateNumberOfGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementDate" id="sgmo_AgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementToReceive" id="sgmo_AgreementToReceive" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualFeesRelatedToAgreement" id="sgmo_AnnualFeesRelatedToAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" id="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" id="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" id="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" id="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BetaThalassemiaMember" id="sgmo_BetaThalassemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionContingentConsiderationEarnoutPayment" id="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionProFormaInformationLineItems" id="sgmo_BusinessAcquisitionProFormaInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionProFormaInformationTable" id="sgmo_BusinessAcquisitionProFormaInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CaliforniaInstituteForRegenerativeMedicineMember" id="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashEquivalentMaturityPeriodHighlyLiquidInvestment" id="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CeregeneIncMember" id="sgmo_CeregeneIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" id="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" id="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChdiFoundationIncMember" id="sgmo_ChdiFoundationIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreementRelatedCostsAndExpenses" id="sgmo_CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreements" id="sgmo_CollaborationAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockExchangeRatio" id="sgmo_CommonStockExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentConsiderationLiabilityMember" id="sgmo_ContingentConsiderationLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentConsiderationPolicyTextBlock" id="sgmo_ContingentConsiderationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractualAgreementTerminationDate" id="sgmo_ContractualAgreementTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedResearch" id="sgmo_DeferredTaxAssetsCapitalizedResearch" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" id="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredUpfrontContractFeeRevenue" id="sgmo_DeferredUpfrontContractFeeRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="sgmo_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DowAgrosciencesLlcMember" id="sgmo_DowAgrosciencesLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DowAgroSciencesMember" id="sgmo_DowAgroSciencesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" id="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployersMatchingContributionPercentageTowardsEmployeesContribution" id="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EscrowLiability" id="sgmo_EscrowLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpectedAmountToBeReceivedForResearchAndDevelopment" id="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueMeasurementsDisclosureTextBlock" id="sgmo_FairValueMeasurementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalResearchTaxCreditCarryforwardExpirationYear" id="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FeeDue" id="sgmo_FeeDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FundingReceivedFromResearchGrant" id="sgmo_FundingReceivedFromResearchGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FundsDueUnderAgreement" id="sgmo_FundsDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrantFundingAmount" id="sgmo_GrantFundingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrantFundingAmountMaximumUnderAmendedAgreement" id="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesLineItems" id="sgmo_IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesTable" id="sgmo_IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxExpense" id="sgmo_IncomeTaxExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInEscrowLiabilities" id="sgmo_IncreaseDecreaseInEscrowLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InitialResearchTermOfAgreement" id="sgmo_InitialResearchTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestmentsMaturityDatesAvailableForSaleSecurities" id="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JuvenileDiabetesResearchFoundationInternationalMember" id="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MichaelJFoxFoundationForParkinsonsResearchMember" id="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentsPayable" id="sgmo_MilestonePaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromIssuancePublicOffering" id="sgmo_NetProceedsFromIssuancePublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" id="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAdditionalGeneTargets" id="sgmo_NumberOfAdditionalGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfGeneTargets" id="sgmo_NumberOfGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfInitialGeneTargets" id="sgmo_NumberOfInitialGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfResearchProgram" id="sgmo_NumberOfResearchProgram" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OneTimeLicenseFeeEarned" id="sgmo_OneTimeLicenseFeeEarned" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsExpirationYear" id="sgmo_OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PostAmendmentFundsDueUnderAgreement" id="sgmo_PostAmendmentFundsDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialRoyaltyPaymentsToEntity" id="sgmo_PotentialRoyaltyPaymentsToEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" id="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsReceivedForWorkPerformedUnderAgreement" id="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" id="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchasePlanOfferingPeriod" id="sgmo_PurchasePlanOfferingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchasePlanPurchasePeriod" id="sgmo_PurchasePlanPurchasePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeEightMember" id="sgmo_RangeEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeFiveMember" id="sgmo_RangeFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeFourMember" id="sgmo_RangeFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeNineMember" id="sgmo_RangeNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeOneMember" id="sgmo_RangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeSevenMember" id="sgmo_RangeSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeSixMember" id="sgmo_RangeSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeTenMember" id="sgmo_RangeTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeThreeMember" id="sgmo_RangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeTwoMember" id="sgmo_RangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RecentlyAccountingPronouncementsPolicyTextBlock" id="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReducedRoyaltyRate" id="sgmo_ReducedRoyaltyRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RentalExpenses" id="sgmo_RentalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchGrantRevenue" id="sgmo_ResearchGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchServiceRevenueUnderCollaborationAgreement" id="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedCashAndCashEquivalent" id="sgmo_RestrictedCashAndCashEquivalent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyRevenuesExpectedToBeReceived" id="sgmo_RoyaltyRevenuesExpectedToBeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShireAgMember" id="sgmo_ShireAgMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SickleCellDiseaseMember" id="sgmo_SickleCellDiseaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SigmaAldrichCorporationMember" id="sgmo_SigmaAldrichCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SpecifiedStockholderOwnershipPercentage" id="sgmo_SpecifiedStockholderOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" id="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockSplitRatioOnCommonStock" id="sgmo_StockSplitRatioOnCommonStock" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TherapeuticForBetathalassemiaMember" id="sgmo_TherapeuticForBetathalassemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandThirteenStockIncentivePlanMember" id="sgmo_TwoThousandThirteenStockIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnderwritersMember" id="sgmo_UnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontLicenseFee" id="sgmo_UpfrontLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontLicenseFeesMember" id="sgmo_UpfrontLicenseFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sgmo-20131231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData" roleURI="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EscrowLiability" xlink:label="sgmo_EscrowLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sgmo_EscrowLiability" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="sgmo_CollaborationAgreements" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncreaseDecreaseInEscrowLiabilities" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sgmo_IncreaseDecreaseInEscrowLiabilities" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RoyaltyRevenue" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_LicensesRevenue" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_Goodwill" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.0800" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsCapitalizedResearch" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sgmo_DeferredTaxAssetsCapitalizedResearch" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredRevenue" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="1.0900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AccruedClinicalTrialExpense" xlink:label="sgmo_AccruedClinicalTrialExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="sgmo_AccruedClinicalTrialExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sgmo-20131231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData" roleURI="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgrosciencesLlcMember" xlink:label="sgmo_DowAgrosciencesLlcMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RestrictedCashAndCashEquivalent" xlink:label="sgmo_RestrictedCashAndCashEquivalent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_RestrictedCashAndCashEquivalent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgrosciencesLlcMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:label="sgmo_ContingentConsiderationLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="sgmo_ContingentConsiderationLiabilityMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:label="us-gaap_TypeOfDeferredCompensationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:label="us-gaap_TypeOfDeferredCompensationDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_TypeOfDeferredCompensationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_TypeOfDeferredCompensationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TherapeuticForBetathalassemiaMember" xlink:label="sgmo_TherapeuticForBetathalassemiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="sgmo_TherapeuticForBetathalassemiaMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundsDueUnderAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ContractualAgreementTerminationDate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundingReceivedFromResearchGrant" xlink:label="sgmo_FundingReceivedFromResearchGrant"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundingReceivedFromResearchGrant" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_AdditionalFundingAgreementTermsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationTable" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="sgmo_BusinessAcquisitionProFormaInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_BusinessAcquisitionProFormaInformationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CommonStockExchangeRatio" xlink:label="sgmo_CommonStockExchangeRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:label="sgmo_PurchasePlanOfferingPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:label="sgmo_PurchasePlanPurchasePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="us-gaap_StockDividendsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockSplitRatioOnCommonStock" xlink:label="sgmo_StockSplitRatioOnCommonStock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sgmo_UnderwritersMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockExchangeRatio" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockSplitRatioOnCommonStock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanOfferingPeriod" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanPurchasePeriod" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockDividendsShares" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeEightMember" xlink:label="sgmo_RangeEightMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFiveMember" xlink:label="sgmo_RangeFiveMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFourMember" xlink:label="sgmo_RangeFourMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeNineMember" xlink:label="sgmo_RangeNineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeOneMember" xlink:label="sgmo_RangeOneMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSevenMember" xlink:label="sgmo_RangeSevenMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSixMember" xlink:label="sgmo_RangeSixMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTenMember" xlink:label="sgmo_RangeTenMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeThreeMember" xlink:label="sgmo_RangeThreeMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTwoMember" xlink:label="sgmo_RangeTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeOneMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTwoMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeThreeMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFourMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFiveMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSixMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSevenMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeEightMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeNineMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTenMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.1600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.1100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesLineItems" xlink:label="sgmo_IncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesTable" xlink:label="sgmo_IncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxExpense" xlink:label="sgmo_IncomeTaxExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BetaThalassemiaMember" xlink:label="sgmo_BetaThalassemiaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MilestonePaymentsPayable" xlink:label="sgmo_MilestonePaymentsPayable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfResearchProgram" xlink:label="sgmo_NumberOfResearchProgram"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SickleCellDiseaseMember" xlink:label="sgmo_SickleCellDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_BetaThalassemiaMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_SickleCellDiseaseMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_MilestonePaymentsPayable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sgmo-20131231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3014833_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3014833_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US" id="id_3014833_925277_1_1">Accounts Notes Loans And Financing Receivables By Legal Entity Of Counterparty Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US" id="id_3014833_925277_2_1">Legal Entity of Counterparty, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3014833_935297_1_1">Accounts Payable And Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3014833_935297_2_1">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3014833_935297_6_1">Total accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_927100_1_1">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_927100_2_1">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_3014833_934728_1_1">Accounts Payable And Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_3014833_934728_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3014833_933775_1_1">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3014833_933775_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_3014833_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_3014833_938700_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AccruedClinicalTrialExpense" xlink:label="sgmo_AccruedClinicalTrialExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AccruedClinicalTrialExpense_lbl" xml:lang="en-US" id="id_3014833_1041541_3_1">Accrued clinical trial expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AccruedClinicalTrialExpense_lbl" xml:lang="en-US" id="id_3014833_1041541_1_1">Accrued Clinical Trial Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AccruedClinicalTrialExpense_lbl" xml:lang="en-US" id="id_3014833_1041541_2_1">Accrued clinical trial expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AccruedClinicalTrialExpense" xlink:to="sgmo_AccruedClinicalTrialExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" id="id_3014833_934751_1_1">Accrued Employee Benefits Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" id="id_3014833_934751_2_1">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_3014833_933907_1_1">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_3014833_933907_2_1">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_933479_1_1">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_933479_14_1">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_936191_1_1">Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_936191_2_1">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3014833_934223_1_1">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3014833_934223_2_1">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_3014833_923434_1_1">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_3014833_923434_2_1">Accumulated Other Comprehensive Income/ (Loss) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember_lbl" xml:lang="en-US" id="id_3014833_931915_1_1">Additional Funding Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember_lbl" xml:lang="en-US" id="id_3014833_931915_2_1">Additional Funding Agreement Terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFundingAgreementTermsMember" xlink:to="us-gaap_AdditionalFundingAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_977420_3_1">Additional milestone payment under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_977420_1_1">Additional Milestone Payment Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_977420_2_1">Funding available under the amended agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3014833_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3014833_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_3014833_932586_1_1">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_3014833_932586_2_1">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_3014833_935944_1_1">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_3014833_935944_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_929248_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xml:lang="en-US" id="id_3014833_1248200_3_1">Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xml:lang="en-US" id="id_3014833_1248200_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xml:lang="en-US" id="id_3014833_1248200_2_1">Potential amount eligible to receive for certain Shire milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xml:lang="en-US" id="id_3014833_1248201_3_1">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xml:lang="en-US" id="id_3014833_1248201_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xml:lang="en-US" id="id_3014833_1248201_2_1">Potential amount to be funded for achievement of specified commercialization and sales milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_3014833_1200730_3_1">Aggregate additional revenue recognition milestone method revenue to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_3014833_1200730_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue To Be Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_3014833_1200730_2_1">Potential amount to be funded for certain Shire milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_3014833_1200731_3_1">Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_3014833_1200731_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue To Be Recognized On Acceptance Of Application</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_3014833_1200731_2_1">IND or CTA submission amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_971460_3_1">Aggregate number of gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_971460_1_1">Aggregate Number Of Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_971460_2_1">Aggregate number of gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateNumberOfGeneTargets" xlink:to="sgmo_AggregateNumberOfGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_3014833_1012685_3_1">Agreement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_3014833_1012685_1_1">Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_3014833_1012685_2_1">Agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AgreementDate" xlink:to="sgmo_AgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_3014833_1059161_3_1">Agreement to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_3014833_1059161_1_1">Agreement To Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_3014833_1059161_2_1">Agreement to receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AgreementToReceive" xlink:to="sgmo_AgreementToReceive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3014833_940280_1_1">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3014833_940280_2_1">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3014833_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3014833_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_3014833_940746_1_1">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_3014833_940746_2_1">Amortization of premium / discount on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_3014833_1131664_3_1">Annual fees related to agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_3014833_1131664_1_1">Annual Fees Related To Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_3014833_1131664_2_1">Annual fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AnnualFeesRelatedToAgreement" xlink:to="sgmo_AnnualFeesRelatedToAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3014833_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3014833_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3014833_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3014833_928450_2_1">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3014833_928450_12_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3014833_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3014833_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3014833_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3014833_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_3014833_938194_1_1">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_3014833_938194_2_1">Total cash equivalents and available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" id="id_3014833_937265_1_1">Available For Sale Securities Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" id="id_3014833_937265_2_1">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xml:lang="en-US" id="id_3014833_939687_1_1">Available For Sale Securities Gross Realized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xml:lang="en-US" id="id_3014833_939687_2_1">Realized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1196717_3_1">Available for sale securities gross unrealized gains accumulated in investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1196717_1_1">Available For Sale Securities Gross Unrealized Gains Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1196717_2_1">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1155293_3_1">Available for sale securities gross unrealized loss accumulated in investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1155293_1_1">Available For Sale Securities Gross Unrealized Loss Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1155293_2_1">Material unrealized losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_3014833_1155293_14_1">Gross Unrealized (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo_lbl" xml:lang="en-US" id="id_3014833_1009087_3_1">Available for sale securities maturity percentage in next twelve months and year two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo_lbl" xml:lang="en-US" id="id_3014833_1009087_1_1">Available For Sale Securities Maturity Percentage In Next Twelve Months And Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo_lbl" xml:lang="en-US" id="id_3014833_1009087_2_1">Available for sale securities maturity percentage in twelve and twenty four months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" xlink:to="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths_lbl" xml:lang="en-US" id="id_3014833_1002766_3_1">Available for sale securities maturity percentage next twelve months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths_lbl" xml:lang="en-US" id="id_3014833_1002766_1_1">Available For Sale Securities Maturity Percentage Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths_lbl" xml:lang="en-US" id="id_3014833_1002766_2_1">Available for sale securities maturity percentage next twelve months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" xlink:to="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xml:lang="en-US" id="id_3014833_927011_1_1">Availableforsale Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xml:lang="en-US" id="id_3014833_927011_2_1">Available-for-sale securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_3014833_923573_1_1">Available For Sale Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_3014833_923573_2_1">Schedule of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_3014833_929038_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_3014833_929038_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_930060_1_1">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_930060_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BetaThalassemiaMember" xlink:label="sgmo_BetaThalassemiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_BetaThalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1246050_3_1">Beta Thalassemia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_BetaThalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1246050_1_1">Beta Thalassemia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_BetaThalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1246050_2_1">Beta-thalassemia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BetaThalassemiaMember" xlink:to="sgmo_BetaThalassemiaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_3014833_926379_1_1">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_3014833_926379_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_3014833_928576_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_3014833_928576_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment_lbl" xml:lang="en-US" id="id_3014833_1025974_3_1">Business Acquisition Contingent Consideration Earnout Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment_lbl" xml:lang="en-US" id="id_3014833_1025974_1_1">Business Acquisition Contingent Consideration Earnout Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment_lbl" xml:lang="en-US" id="id_3014833_1025974_2_1">Contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="id_3014833_938730_1_1">Business Acquisition Cost Of Acquired Entity Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="id_3014833_938730_2_1">Acquisition-related transaction expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xml:lang="en-US" id="id_3014833_923961_1_1">Business Acquisition Date Of Acquisition Agreement 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xml:lang="en-US" id="id_3014833_923961_2_1">Acquisition date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_3014833_928408_1_1">Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_3014833_928408_2_1">Common stock, transferred, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_3014833_932380_1_1">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_3014833_932380_2_1">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xml:lang="en-US" id="id_3014833_926228_1_1">Business Acquisition Pro Forma Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xml:lang="en-US" id="id_3014833_926228_2_1">Basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems_lbl" xml:lang="en-US" id="id_3014833_947879_3_1">Business Acquisition Pro Forma Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems_lbl" xml:lang="en-US" id="id_3014833_947879_1_1">Business Acquisition Pro Forma Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems_lbl" xml:lang="en-US" id="id_3014833_947879_2_1">Business Acquisition Pro Forma Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="sgmo_BusinessAcquisitionProFormaInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationTable" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable_lbl" xml:lang="en-US" id="id_3014833_1118308_3_1">Business Acquisition Pro Forma Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable_lbl" xml:lang="en-US" id="id_3014833_1118308_1_1">Business Acquisition Pro Forma Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable_lbl" xml:lang="en-US" id="id_3014833_1118308_2_1">Business Acquisition Pro Forma Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BusinessAcquisitionProFormaInformationTable" xlink:to="sgmo_BusinessAcquisitionProFormaInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_3014833_930487_1_1">Business Acquisition Pro Forma Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_3014833_930487_2_1">Schedule of Supplemental Pro Forma Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_934859_1_1">Business Acquisitions Pro Forma Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_934859_2_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_3014833_933298_1_1">Business Combination Consideration Transferred 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_3014833_933298_6_1">Total purchase consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" id="id_3014833_935953_1_1">Business Combination Consideration Transferred Equity Interests Issued And Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" id="id_3014833_935953_2_1">Common stock, transferred, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" id="id_3014833_935953_12_1">Sangamo shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" id="id_3014833_937655_1_1">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" id="id_3014833_937655_2_1">Change in fair value of contingent consideration liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" id="id_3014833_937655_12_1">Change in fair value of contingent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" id="id_3014833_934900_1_1">Business Combination Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" id="id_3014833_934900_2_1">Contingent consideration liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" id="id_3014833_934900_12_1">Fair value liability for contingent consideration recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_928687_1_1">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_928687_2_1">Acquisition of Ceregene</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_3014833_939543_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_3014833_939543_6_1">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="id_3014833_938941_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="id_3014833_938941_2_1">Cash and equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US" id="id_3014833_938234_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US" id="id_3014833_938234_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" id="id_3014833_935958_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" id="id_3014833_935958_14_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3014833_933901_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3014833_933901_14_1">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US" id="id_3014833_937352_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US" id="id_3014833_937352_2_1">Identifiable intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US" id="id_3014833_937352_12_1">Value of Intangible Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" id="id_3014833_935270_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" id="id_3014833_935270_19_1">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="id_3014833_939149_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="id_3014833_939149_6_1">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_3014833_932588_1_1">Business Combinations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_3014833_932588_2_1">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_lbl" xml:lang="en-US" id="id_3014833_938053_1_1">Business Combination Separately Recognized Transactions Expenses And Losses Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_lbl" xml:lang="en-US" id="id_3014833_938053_2_1">Acquisition related operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" id="id_3014833_924193_1_1">Business Combinations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" id="id_3014833_924193_2_1">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_3014833_1137514_3_1">California institute for regenerative medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_3014833_1137514_1_1">California Institute For Regenerative Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_3014833_1137514_2_1">California Institute for Regenerative Medicine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" id="id_3014833_926634_1_1">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" id="id_3014833_926634_2_1">Project [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_938283_4_1">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_938283_5_1">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_938600_6_1">Net increase / (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928679_1_1">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928679_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xml:lang="en-US" id="id_3014833_1193188_3_1">Cash Equivalent Maturity Period Highly Liquid Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xml:lang="en-US" id="id_3014833_1193188_1_1">Cash Equivalent Maturity Period Highly Liquid Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xml:lang="en-US" id="id_3014833_1193188_2_1">Liquid investments purchased with original maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_3014833_932792_1_1">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_3014833_932792_2_1">Cash equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_925504_1_1">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_925504_2_1">Supplemental disclosures of noncash investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CeregeneIncMember_lbl" xml:lang="en-US" id="id_3014833_1237588_3_1">Ceregene, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CeregeneIncMember_lbl" xml:lang="en-US" id="id_3014833_1237588_1_1">Ceregene Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CeregeneIncMember_lbl" xml:lang="en-US" id="id_3014833_1237588_2_1">Ceregene, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CeregeneIncMember" xlink:to="sgmo_CeregeneIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237600_3_1">Cere One Hundred And Ten Treatment Of Alzheimer Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237600_1_1">Cere One Hundred And Ten Treatment Of Alzheimer Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237600_2_1">CERE-110 for the treatment of Alzheimer's disease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237605_3_1">Cere One Hundred And Twenty Treatment Of Parkinson Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237605_1_1">Cere One Hundred And Twenty Treatment Of Parkinson Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1237605_2_1">CERE-120 for the treatment of Parkinson's disease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_3014833_1019175_3_1">CHDI Foundation, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_3014833_1019175_1_1">Chdi Foundation Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_3014833_1019175_2_1">CHDI Foundation, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ChdiFoundationIncMember" xlink:to="sgmo_ChdiFoundationIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3014833_932584_1_1">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3014833_932584_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_3014833_1116705_3_1">Collaboration agreement related costs and expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_3014833_1116705_1_1">Collaboration Agreement Related Costs And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_3014833_1116705_2_1">Collaboration agreement related costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_3014833_959148_3_1">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_3014833_959148_1_1">Collaboration Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_3014833_959148_2_1">Collaboration agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreements" xlink:to="sgmo_CollaborationAgreements_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1200732_3_1">Collaboration and license agreements number of products approved under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1200732_1_1">Collaboration And License Agreements Number Of Products Approved Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1200732_2_1">Number of products approved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_924261_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_924261_2_1">Major Customers, Partnerships and Strategic Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_3014833_936604_1_1">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_3014833_936604_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_930041_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_930041_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_923322_1_1">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_923322_2_1">Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CommonStockExchangeRatio" xlink:label="sgmo_CommonStockExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xml:lang="en-US" id="id_3014833_958667_3_1">Common Stock Exchange Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xml:lang="en-US" id="id_3014833_958667_1_1">Common Stock Exchange Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xml:lang="en-US" id="id_3014833_958667_2_1">Share of common stock subject to a stock option or stock appreciation right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CommonStockExchangeRatio" xlink:to="sgmo_CommonStockExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3014833_930643_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3014833_930643_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3014833_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3014833_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3014833_925763_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3014833_925763_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3014833_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3014833_935685_2_1">Common stock, $0.01 par value; 80,000,000 shares authorized, 62,243,892 and 53,058,525 shares issued and outstanding at December 31, 2013 and 2012, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_929610_1_1">Compensation And Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_929610_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3014833_933343_1_1">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3014833_933343_2_1">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3014833_933343_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_3014833_931347_1_1">Concentration Risk Percentage 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_3014833_931347_2_1">Percentage of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:label="sgmo_ContingentConsiderationLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xml:lang="en-US" id="id_3014833_1054008_3_1">Contingent Consideration Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xml:lang="en-US" id="id_3014833_1054008_1_1">Contingent Consideration Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ContingentConsiderationLiabilityMember_lbl" xml:lang="en-US" id="id_3014833_1054008_2_1">Contingent consideration liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContingentConsiderationLiabilityMember" xlink:to="sgmo_ContingentConsiderationLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContingentConsiderationPolicyTextBlock" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1027315_3_1">Contingent Consideration Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1027315_1_1">Contingent Consideration Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1027315_2_1">Contingent Consideration Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContingentConsiderationPolicyTextBlock" xlink:to="sgmo_ContingentConsiderationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US" id="id_3014833_933360_1_1">Contracts Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US" id="id_3014833_933360_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_3014833_1080300_3_1">Contractual agreement termination date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_3014833_1080300_1_1">Contractual Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_3014833_1080300_2_1">Contractual agreement termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContractualAgreementTerminationDate" xlink:to="sgmo_ContractualAgreementTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_3014833_933025_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_3014833_933025_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3014833_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3014833_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US" id="id_3014833_929362_1_1">Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US" id="id_3014833_929362_2_1">Type of Deferred Compensation [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_3014833_933631_1_1">Deferred Income Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_3014833_933631_2_1">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_3014833_935716_1_1">Deferred Rent Credit Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_3014833_935716_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_3014833_935260_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_3014833_935260_14_1">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_3014833_935460_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_3014833_935460_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_3014833_936354_1_1">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_3014833_936354_2_1">Deferred revenue, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xml:lang="en-US" id="id_3014833_926795_1_1">Deferred Tax Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetDomain_lbl" xml:lang="en-US" id="id_3014833_926795_2_1">Deferred Tax Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_DeferredTaxAssetDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsCapitalizedResearch" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch_lbl" xml:lang="en-US" id="id_3014833_1107141_3_1">Deferred tax assets capitalized research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch_lbl" xml:lang="en-US" id="id_3014833_1107141_1_1">Deferred Tax Assets Capitalized Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch_lbl" xml:lang="en-US" id="id_3014833_1107141_2_1">Capitalized research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredTaxAssetsCapitalizedResearch" xlink:to="sgmo_DeferredTaxAssetsCapitalizedResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_3014833_937966_1_1">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_3014833_937966_6_1">Total deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_3014833_938851_1_1">Deferred Tax Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_3014833_938851_6_1">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" id="id_3014833_932278_1_1">Deferred Tax Assets Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" id="id_3014833_932278_2_1">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3014833_937710_1_1">Deferred Tax Assets Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3014833_937710_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_3014833_940324_1_1">Deferred Tax Assets Operating Loss Carryforwards Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_3014833_940324_2_1">Deferred tax assets, net operating loss carryforwards for federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_3014833_937819_1_1">Deferred Tax Assets Operating Loss Carryforwards State And Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_3014833_937819_2_1">Deferred tax assets, net operating loss carryforwards for state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_3014833_940635_1_1">Deferred Tax Assets Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_3014833_940635_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_3014833_939013_1_1">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_3014833_939013_2_1">Federal research tax credit carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_3014833_939013_12_1">Research and development tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal_lbl" xml:lang="en-US" id="id_3014833_1101703_3_1">Deferred tax assets tax credit carry forwards research state and local.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal_lbl" xml:lang="en-US" id="id_3014833_1101703_1_1">Deferred Tax Assets Tax Credit Carry Forwards Research State And Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal_lbl" xml:lang="en-US" id="id_3014833_1101703_2_1">State research tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_3014833_937363_1_1">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_3014833_937363_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3014833_934093_1_1">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3014833_934093_2_1">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3014833_934093_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_3014833_935540_1_1">Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_3014833_935540_6_1">Total deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="id_3014833_934517_1_1">Deferred Tax Liabilities Goodwill And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="id_3014833_934517_2_1">Net deferred tax liability related to intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" xml:lang="en-US" id="id_3014833_934406_1_1">Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" xml:lang="en-US" id="id_3014833_934406_2_1">Goodwill related to deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_3014833_1068074_3_1">Deferred upfront contract fee revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_3014833_1068074_1_1">Deferred Upfront Contract Fee Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_3014833_1068074_2_1">Amortization of upfront fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredUpfrontContractFeeRevenue" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="id_3014833_937081_1_1">Defined Contribution Plan Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="id_3014833_937081_2_1">Aggregate employers contributions to defined contribution plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" id="id_3014833_927902_1_1">Defined Contribution Plan Employer Matching Contribution Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" id="id_3014833_927902_2_1">Defined contribution plan, employer's matching contribution percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" id="id_3014833_937473_1_1">Defined Contribution Plan Maximum Annual Contributions Per Employee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" id="id_3014833_937473_2_1">Defined contribution plan, maximum employer's contribution per employee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3014833_939791_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3014833_939791_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3014833_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3014833_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_3014833_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_3014833_923166_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:label="sgmo_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3014833_951207_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3014833_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3014833_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="sgmo_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3014833_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3014833_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3014833_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3014833_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3014833_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3014833_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3014833_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3014833_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgrosciencesLlcMember" xlink:label="sgmo_DowAgrosciencesLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DowAgrosciencesLlcMember_lbl" xml:lang="en-US" id="id_3014833_971461_3_1">Dow AgroSciences LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DowAgrosciencesLlcMember_lbl" xml:lang="en-US" id="id_3014833_971461_1_1">Dow Agrosciences Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DowAgrosciencesLlcMember_lbl" xml:lang="en-US" id="id_3014833_971461_2_1">Dow AgroSciences LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DowAgrosciencesLlcMember" xlink:to="sgmo_DowAgrosciencesLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_3014833_1094419_3_1">Dow AgroSciences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_3014833_1094419_1_1">Dow Agro Sciences [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_3014833_1094419_2_1">Dow AgroSciences [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DowAgroSciencesMember" xlink:to="sgmo_DowAgroSciencesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3014833_929231_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3014833_929231_2_1">Basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3014833_929231_12_1">Net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_931897_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_3014833_925166_1_1">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_3014833_925166_2_1">Statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" id="id_3014833_939187_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" id="id_3014833_939187_2_1">Capitalized stock-based employee compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3014833_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3014833_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_3014833_929567_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_3014833_929567_2_1">Weighted-average period of unvested stock options and RSU</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_3014833_938597_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_3014833_938597_2_1">Total compensation cost related to unvested stock options and RSU</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_3014833_929710_1_1">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_3014833_929710_2_1">2010 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_3014833_924898_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_3014833_924898_2_1">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xml:lang="en-US" id="id_3014833_972416_3_1">Employee stock purchase plan rights weighted average estimated fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xml:lang="en-US" id="id_3014833_972416_1_1">Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xml:lang="en-US" id="id_3014833_972416_2_1">Weighted-average estimated fair value of shares purchased under ESPP plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution" xlink:label="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution_lbl" xml:lang="en-US" id="id_3014833_957581_3_1">Employers matching contribution percentage towards employees contribution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution_lbl" xml:lang="en-US" id="id_3014833_957581_1_1">Employers Matching Contribution Percentage Towards Employees Contribution</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution_lbl" xml:lang="en-US" id="id_3014833_957581_2_1">Employers matching contribution percentage towards employees contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution" xlink:to="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3014833_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3014833_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_3014833_921942_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_3014833_921942_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3014833_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3014833_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_3014833_921993_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_3014833_921993_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3014833_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3014833_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_3014833_922027_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_3014833_922027_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_3014833_922003_1_1">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_3014833_922003_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_3014833_928802_1_1">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_3014833_928802_2_1">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3014833_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3014833_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3014833_927325_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3014833_927325_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_3014833_931848_1_1">Equity Issuance Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_3014833_931848_2_1">Public offering price of common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuancePerShareAmount" xlink:to="us-gaap_EquityIssuancePerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl" xml:lang="en-US" id="id_3014833_934007_1_1">Escrow Deposit Disbursements Related To Property Acquisition 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl" xml:lang="en-US" id="id_3014833_934007_2_1">Purchase price deposited in escrow account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EscrowLiability" xlink:label="sgmo_EscrowLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_EscrowLiability_lbl" xml:lang="en-US" id="id_3014833_1060980_3_1">Escrow Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_EscrowLiability_lbl" xml:lang="en-US" id="id_3014833_1060980_1_1">Escrow Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_EscrowLiability_lbl" xml:lang="en-US" id="id_3014833_1060980_2_1">Escrow liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EscrowLiability" xlink:to="sgmo_EscrowLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_3014833_1054426_3_1">Expected amount to be received for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_3014833_1054426_1_1">Expected Amount To Be Received For Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_3014833_1054426_2_1">Expected amount to be received for research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926674_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926674_2_1">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3014833_929790_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3014833_929790_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3014833_930808_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3014833_930808_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3014833_925736_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3014833_925736_2_1">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3014833_925851_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3014833_925851_2_1">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3014833_929831_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3014833_929831_2_1">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_3014833_927992_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_3014833_927992_2_1">Schedule of Fair Value of Contingent Consideration Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_924053_1_1">Fair Value Measurement Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_924053_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FairValueMeasurementsDisclosureTextBlock" xlink:label="sgmo_FairValueMeasurementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FairValueMeasurementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_1006339_3_1">Fair Value Measurements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FairValueMeasurementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_1006339_1_1">Fair Value Measurements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FairValueMeasurementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_1006339_2_1">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FairValueMeasurementsDisclosureTextBlock" xlink:to="sgmo_FairValueMeasurementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3014833_930398_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3014833_930398_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_931594_1_1">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_931594_2_1">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_3014833_934561_1_1">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_3014833_934561_4_1">Fair value at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_3014833_934561_5_1">Fair value on date of acquisition (October 1, 2013)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1096239_3_1">Federal research tax credit carryforward expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1096239_1_1">Federal Research Tax Credit Carryforward Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1096239_2_1">Tax credit carryforward, expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_3014833_1109820_3_1">Fee due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_3014833_1109820_1_1">Fee Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_3014833_1109820_2_1">Fee due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FeeDue" xlink:to="sgmo_FeeDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_3014833_931868_1_1">Finite Lived Intangible Assets By Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_3014833_931868_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_3014833_924740_1_1">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_3014833_924740_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundingReceivedFromResearchGrant" xlink:label="sgmo_FundingReceivedFromResearchGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FundingReceivedFromResearchGrant_lbl" xml:lang="en-US" id="id_3014833_1041136_3_1">Funding received from research grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FundingReceivedFromResearchGrant_lbl" xml:lang="en-US" id="id_3014833_1041136_1_1">Funding Received From Research Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FundingReceivedFromResearchGrant_lbl" xml:lang="en-US" id="id_3014833_1041136_2_1">Funding received from research grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FundingReceivedFromResearchGrant" xlink:to="sgmo_FundingReceivedFromResearchGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1139773_3_1">Funds due under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1139773_1_1">Funds Due Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1139773_2_1">Funds due under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FundsDueUnderAgreement" xlink:to="sgmo_FundsDueUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3014833_932226_1_1">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3014833_932226_2_1">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_3014833_935202_1_1">Gain Loss On Disposition Of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_3014833_935202_2_1">Write-off of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_3014833_933543_1_1">Gain Loss On Sale Of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_3014833_933543_14_1">Net loss on disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3014833_937408_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3014833_937408_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3014833_925832_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3014833_925832_2_1">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_3014833_937181_1_1">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_3014833_937181_2_1">Excess of consideration transferred over the fair values assigned to assets acquired and liabilities assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_3014833_937181_12_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US" id="id_3014833_939832_1_1">Goodwill And Intangible Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US" id="id_3014833_939832_2_1">Intangible assets impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928249_1_1">Goodwill And Intangible Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928249_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="id_3014833_940040_1_1">Goodwill Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="id_3014833_940040_2_1">Goodwill impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_932020_1_1">Goodwill Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3014833_932020_2_1">Changes in the Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_3014833_942370_3_1">Grant funding amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_3014833_942370_1_1">Grant Funding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_3014833_942370_2_1">Funds due under the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_GrantFundingAmount" xlink:to="sgmo_GrantFundingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_3014833_989402_3_1">Grant funding amount maximum under amended agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_3014833_989402_1_1">Grant Funding Amount Maximum Under Amended Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_3014833_989402_2_1">Grant funding amount maximum under amended agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3014833_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3014833_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3014833_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3014833_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3014833_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3014833_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_932322_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_932322_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_929775_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_929775_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesLineItems" xlink:label="sgmo_IncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3014833_1064540_3_1">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3014833_1064540_1_1">Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3014833_1064540_2_1">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesTable" xlink:label="sgmo_IncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_3014833_1100017_3_1">Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_3014833_1100017_1_1">Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_IncomeTaxesTable_lbl" xml:lang="en-US" id="id_3014833_1100017_2_1">Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxesTable" xlink:to="sgmo_IncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxExpense" xlink:label="sgmo_IncomeTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_IncomeTaxExpense_lbl" xml:lang="en-US" id="id_3014833_951847_3_1">Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_IncomeTaxExpense_lbl" xml:lang="en-US" id="id_3014833_951847_1_1">Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_IncomeTaxExpense_lbl" xml:lang="en-US" id="id_3014833_951847_2_1">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxExpense" xlink:to="sgmo_IncomeTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_932576_1_1">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_932576_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_3014833_935454_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_3014833_935454_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_3014833_935362_1_1">Increase Decrease In Accrued Interest Receivable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_3014833_935362_14_1">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_3014833_938117_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_3014833_938117_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_3014833_937388_1_1">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_3014833_937388_2_1">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncreaseDecreaseInEscrowLiabilities" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities_lbl" xml:lang="en-US" id="id_3014833_1220397_3_1">Increase Decrease In Escrow Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities_lbl" xml:lang="en-US" id="id_3014833_1220397_1_1">Increase Decrease In Escrow Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities_lbl" xml:lang="en-US" id="id_3014833_1220397_2_1">Escrow liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncreaseDecreaseInEscrowLiabilities" xlink:to="sgmo_IncreaseDecreaseInEscrowLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3014833_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3014833_924543_2_1">Net changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_3014833_938317_1_1">Increase Decrease In Other Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_3014833_938317_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_3014833_933216_1_1">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_3014833_933216_14_1">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_3014833_936295_1_1">Increase Decrease In Restricted Cash For Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_3014833_936295_14_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="id_3014833_938819_1_1">Indefinite Lived Intangible Assets Excluding Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="id_3014833_938819_2_1">Intangible assets, in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsMember_lbl" xml:lang="en-US" id="id_3014833_930113_1_1">Indefinitelived Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsMember_lbl" xml:lang="en-US" id="id_3014833_930113_2_1">Indefinite-lived assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_3014833_1008271_3_1">Initial research term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_3014833_1008271_1_1">Initial Research Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_3014833_1008271_2_1">Research program to develop laboratory research reagents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InitialResearchTermOfAgreement" xlink:to="sgmo_InitialResearchTermOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_3014833_929780_1_1">In Process Research And Development Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_3014833_929780_2_1">Intangible Assets - In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_3014833_940810_1_1">Interest Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_3014833_940810_2_1">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_3014833_931696_1_1">Investments Debt And Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_3014833_931696_2_1">Investments, Debt and Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_931985_1_1">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_931985_2_1">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_3014833_1065501_3_1">Investments maturity dates available for sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_3014833_1065501_1_1">Investments Maturity Dates Available For Sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_3014833_1065501_2_1">Investments maturity period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentsScheduleAbstract" xlink:label="invest_InvestmentsScheduleAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentsScheduleAbstract_lbl" xml:lang="en-US" id="id_3014833_923041_1_1">Investments Schedule [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentsScheduleAbstract_lbl" xml:lang="en-US" id="id_3014833_923041_2_1">Investments Schedule [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentsScheduleAbstract" xlink:to="invest_InvestmentsScheduleAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3014833_932040_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3014833_932040_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3014833_932609_1_1">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3014833_932609_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_3014833_1044992_3_1">The juvenile diabetes research foundation international.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_3014833_1044992_1_1">Juvenile Diabetes Research Foundation International [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_3014833_1044992_2_1">Juvenile Diabetes Research Foundation International [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3014833_923325_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3014833_923325_2_1">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xml:lang="en-US" id="id_3014833_931651_1_1">Legal Entity Type Of Counterparty [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xml:lang="en-US" id="id_3014833_931651_2_1">Legal Entity Type of Counterparty [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3014833_936129_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3014833_936129_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_925364_1_1">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_925364_2_1">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_935778_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_924388_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3014833_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3014833_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3014833_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3014833_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_3014833_936528_1_1">Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_3014833_936528_2_1">Total contingent consideration liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_3014833_928673_1_1">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_3014833_928673_2_1">License agreement terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_3014833_940734_1_1">License Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_3014833_940734_2_1">Upfront license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_3014833_934341_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_3014833_934341_2_1">License fee and milestone revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_3014833_934341_12_1">Revenue attributable to research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_3014833_928628_1_1">Major Types Of Debt And Equity Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_3014833_928628_2_1">Major Types of Debt and Equity Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_3014833_928856_1_1">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_3014833_928856_2_1">Major Types of Debt and Equity Securities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" id="id_3014833_939545_1_1">Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" id="id_3014833_939545_6_1">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_3014833_936967_1_1">Marketable Securities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_3014833_936967_2_1">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_3014833_937619_1_1">Marketable Securities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_3014833_937619_2_1">Marketable securities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" id="id_3014833_928519_1_1">Marketable Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" id="id_3014833_928519_2_1">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3014833_923140_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3014833_923140_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember_lbl" xml:lang="en-US" id="id_3014833_998276_3_1">Michael J Fox foundation for Parkinson's research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember_lbl" xml:lang="en-US" id="id_3014833_998276_1_1">Michael J Fox Foundation For Parkinsons Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember_lbl" xml:lang="en-US" id="id_3014833_998276_2_1">Michael J. Fox Foundation for Parkinson's Research [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" xlink:to="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MilestonePaymentsPayable" xlink:label="sgmo_MilestonePaymentsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_MilestonePaymentsPayable_lbl" xml:lang="en-US" id="id_3014833_1067937_3_1">Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_MilestonePaymentsPayable_lbl" xml:lang="en-US" id="id_3014833_1067937_1_1">Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_MilestonePaymentsPayable_lbl" xml:lang="en-US" id="id_3014833_1067937_2_1">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestonePaymentsPayable" xlink:to="sgmo_MilestonePaymentsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3014833_932953_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3014833_932953_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_3014833_963942_3_1">Minimum sublicense annual fees specific reckoning period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_3014833_963942_1_1">Minimum Sublicense Annual Fees Specific Reckoning Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_3014833_963942_2_1">Minimum sublicense annual fees specific reckoning period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_3014833_932359_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_3014833_932359_2_1">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3014833_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3014833_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_924600_2_1">Financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3014833_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3014833_939292_6_1">Net cash provided by / (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_924425_2_1">Investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3014833_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3014833_928832_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3014833_930909_2_1">Operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_935636_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_935636_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US" id="id_3014833_1003822_3_1">Net proceeds from issuance public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US" id="id_3014833_1003822_1_1">Net Proceeds From Issuance Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US" id="id_3014833_1003822_2_1">Net proceeds from issuance under public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NetProceedsFromIssuancePublicOffering" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" xlink:label="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_3014833_1232532_3_1">Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Common Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_3014833_1232532_1_1">Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Common Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_3014833_1232532_2_1">Fair value of shares of common stock issued pursuant to the acquisition of Ceregene Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" xlink:to="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_3014833_935626_1_1">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_3014833_935626_2_1">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1105034_3_1">Number of additional gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1105034_1_1">Number Of Additional Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1105034_2_1">Number of additional gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfAdditionalGeneTargets" xlink:to="sgmo_NumberOfAdditionalGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1009088_3_1">Number of gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1009088_1_1">Number Of Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1009088_2_1">Number of gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfGeneTargets" xlink:to="sgmo_NumberOfGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1131802_3_1">Number of initial gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1131802_1_1">Number Of Initial Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_3014833_1131802_2_1">Number of initial gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfInitialGeneTargets" xlink:to="sgmo_NumberOfInitialGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_3014833_923679_1_1">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_3014833_923679_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfResearchProgram" xlink:label="sgmo_NumberOfResearchProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfResearchProgram_lbl" xml:lang="en-US" id="id_3014833_1246055_3_1">Number Of Research Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfResearchProgram_lbl" xml:lang="en-US" id="id_3014833_1246055_1_1">Number Of Research Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfResearchProgram_lbl" xml:lang="en-US" id="id_3014833_1246055_2_1">Number of research programs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfResearchProgram" xlink:to="sgmo_NumberOfResearchProgram_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_3014833_1119987_3_1">One time license fee earned.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_3014833_1119987_1_1">One Time License Fee Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_3014833_1119987_2_1">One-time license fee earned on exercise of option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OneTimeLicenseFeeEarned" xlink:to="sgmo_OneTimeLicenseFeeEarned_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3014833_940683_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3014833_940683_2_1">Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3014833_940683_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3014833_927909_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3014833_927909_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3014833_934856_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3014833_933732_1_1">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3014833_933732_6_1">Total minimum payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3014833_936689_1_1">Operating Leases Future Minimum Payments Due Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3014833_936689_2_1">2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_3014833_935061_1_1">Operating Leases Future Minimum Payments Due In Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_3014833_935061_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3014833_934077_1_1">Operating Leases Future Minimum Payments Due In Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3014833_934077_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3014833_936161_1_1">Operating Leases Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3014833_936161_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3014833_933250_1_1">Operating Leases Future Minimum Payments Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3014833_933250_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_3014833_934235_1_1">Operating Leases Future Minimum Payments Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_3014833_934235_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1065117_3_1">Operating loss carryforwards expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1065117_1_1">Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_3014833_1065117_2_1">Operating loss carryforwards, expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OperatingLossCarryforwardsExpirationYear" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3014833_1056949_3_1">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3014833_1056949_1_1">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3014833_1056949_2_1">Organization and Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3014833_1017727_3_1">Organization and summary of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3014833_1017727_1_1">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3014833_1017727_2_1">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3014833_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3014833_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_3014833_927054_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_3014833_927054_2_1">Organization and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" id="id_3014833_939846_1_1">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" id="id_3014833_939846_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3014833_939944_1_1">Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3014833_939944_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3014833_927247_1_1">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3014833_927247_2_1">Comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3014833_936748_1_1">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3014833_936748_2_1">Change in unrealized gain on available-for-sale securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3014833_936748_12_1">Net unrealized gain (loss) on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xml:lang="en-US" id="id_3014833_936998_1_1">Other Than Temporary Impairment Losses Investments Availableforsale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xml:lang="en-US" id="id_3014833_936998_2_1">Other-than-temporary impairments of available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_3014833_930715_1_1">Payables And Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_3014833_930715_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_935396_1_1">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_935396_14_1">Taxes paid related to net share settlement of equity awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US" id="id_3014833_933854_1_1">Payments To Acquire Businesses Net Of Cash Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US" id="id_3014833_933854_14_1">Acquistion of Ceregene, Inc., net of cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" id="id_3014833_933553_1_1">Payments To Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" id="id_3014833_933553_14_1">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3014833_936514_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_930605_1_1">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_930605_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_3014833_1136308_3_1">Percentage of royalties to be received from sublicensing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_3014833_1136308_1_1">Percentage Of Royalties To Be Received From Sublicensing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_3014833_1136308_2_1">Percentage of royalties to be received from sublicensing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_3014833_930809_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_3014833_930809_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_3014833_931386_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_3014833_931386_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1026774_3_1">Post amendment funds due under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1026774_1_1">Post Amendment Funds Due Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1026774_2_1">Funds due under agreement as per amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PostAmendmentFundsDueUnderAgreement" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_3014833_1200734_3_1">Potential Royalty Payments To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_3014833_1200734_1_1">Potential Royalty Payments To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_3014833_1200734_2_1">Receivables from sale against the grant funded to entity from sale of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PotentialRoyaltyPaymentsToEntity" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_929540_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_929540_2_1">Preferred shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_3014833_937707_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_3014833_937707_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts_lbl" xml:lang="en-US" id="id_3014833_1091865_3_1">Proceeds From Issuance Initial Public Offering Net Of Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts_lbl" xml:lang="en-US" id="id_3014833_1091865_1_1">Proceeds From Issuance Initial Public Offering Net Of Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts_lbl" xml:lang="en-US" id="id_3014833_1091865_2_1">Proceeds from public offering of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" xlink:to="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_3014833_938994_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_3014833_938994_2_1">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl" xml:lang="en-US" id="id_3014833_937104_1_1">Proceeds From Sale Of Held To Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl" xml:lang="en-US" id="id_3014833_937104_2_1">Maturities of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xml:lang="en-US" id="id_3014833_937312_1_1">Proceeds From Sale Of Investment Projects</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xml:lang="en-US" id="id_3014833_937312_2_1">Proceeds from sales of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1085939_3_1">Proceeds received for work performed under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1085939_1_1">Proceeds Received For Work Performed Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_3014833_1085939_2_1">Received for work performed under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" id="id_3014833_929576_1_1">Project [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" id="id_3014833_929576_2_1">Project [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3014833_928864_1_1">Property Plant And Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3014833_928864_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3014833_929865_1_1">Property Plant And Equipment By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3014833_929865_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_925725_1_1">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_925725_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" id="id_3014833_934752_1_1">Property Plant And Equipment Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US" id="id_3014833_934752_2_1">Disposition of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3014833_938855_1_1">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3014833_938855_2_1">Property and equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3014833_925379_1_1">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3014833_925379_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3014833_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3014833_940861_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3014833_940861_6_1">Property and equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928618_1_1">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_928618_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3014833_925467_1_1">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3014833_925467_2_1">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3014833_930445_1_1">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3014833_930445_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3014833_928464_1_1">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3014833_928464_2_1">Estimated useful lives of related assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_3014833_1072861_3_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_3014833_1072861_1_1">Property Plant And Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_3014833_1072861_2_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:label="sgmo_PurchasePlanOfferingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xml:lang="en-US" id="id_3014833_1027734_3_1">Purchase plan offering period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xml:lang="en-US" id="id_3014833_1027734_1_1">Purchase Plan Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xml:lang="en-US" id="id_3014833_1027734_2_1">Purchase plan offering period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PurchasePlanOfferingPeriod" xlink:to="sgmo_PurchasePlanOfferingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:label="sgmo_PurchasePlanPurchasePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xml:lang="en-US" id="id_3014833_1060185_3_1">Purchase plan purchase period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xml:lang="en-US" id="id_3014833_1060185_1_1">Purchase Plan Purchase Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xml:lang="en-US" id="id_3014833_1060185_2_1">Purchase plan purchase period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PurchasePlanPurchasePeriod" xlink:to="sgmo_PurchasePlanPurchasePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_928965_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_3014833_928965_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_3014833_926885_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_3014833_926885_2_1">Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3014833_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3014833_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeEightMember" xlink:label="sgmo_RangeEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeEightMember_lbl" xml:lang="en-US" id="id_3014833_949918_3_1">Range eight.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeEightMember_lbl" xml:lang="en-US" id="id_3014833_949918_1_1">Range Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeEightMember_lbl" xml:lang="en-US" id="id_3014833_949918_2_1">Range 8 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeEightMember" xlink:to="sgmo_RangeEightMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFiveMember" xlink:label="sgmo_RangeFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeFiveMember_lbl" xml:lang="en-US" id="id_3014833_1053915_3_1">Range five.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeFiveMember_lbl" xml:lang="en-US" id="id_3014833_1053915_1_1">Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeFiveMember_lbl" xml:lang="en-US" id="id_3014833_1053915_2_1">Range 5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeFiveMember" xlink:to="sgmo_RangeFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFourMember" xlink:label="sgmo_RangeFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeFourMember_lbl" xml:lang="en-US" id="id_3014833_1124646_3_1">Range four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeFourMember_lbl" xml:lang="en-US" id="id_3014833_1124646_1_1">Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeFourMember_lbl" xml:lang="en-US" id="id_3014833_1124646_2_1">Range 4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeFourMember" xlink:to="sgmo_RangeFourMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3014833_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3014833_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeNineMember" xlink:label="sgmo_RangeNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeNineMember_lbl" xml:lang="en-US" id="id_3014833_1097982_3_1">Range nine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeNineMember_lbl" xml:lang="en-US" id="id_3014833_1097982_1_1">Range Nine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeNineMember_lbl" xml:lang="en-US" id="id_3014833_1097982_2_1">Range 9 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeNineMember" xlink:to="sgmo_RangeNineMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeOneMember" xlink:label="sgmo_RangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeOneMember_lbl" xml:lang="en-US" id="id_3014833_960261_3_1">Range one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeOneMember_lbl" xml:lang="en-US" id="id_3014833_960261_1_1">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeOneMember_lbl" xml:lang="en-US" id="id_3014833_960261_2_1">Range 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeOneMember" xlink:to="sgmo_RangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSevenMember" xlink:label="sgmo_RangeSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeSevenMember_lbl" xml:lang="en-US" id="id_3014833_1002418_3_1">Range seven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeSevenMember_lbl" xml:lang="en-US" id="id_3014833_1002418_1_1">Range Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeSevenMember_lbl" xml:lang="en-US" id="id_3014833_1002418_2_1">Range 7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeSevenMember" xlink:to="sgmo_RangeSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSixMember" xlink:label="sgmo_RangeSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeSixMember_lbl" xml:lang="en-US" id="id_3014833_1048263_3_1">Range six.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeSixMember_lbl" xml:lang="en-US" id="id_3014833_1048263_1_1">Range Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeSixMember_lbl" xml:lang="en-US" id="id_3014833_1048263_2_1">Range 6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeSixMember" xlink:to="sgmo_RangeSixMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTenMember" xlink:label="sgmo_RangeTenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeTenMember_lbl" xml:lang="en-US" id="id_3014833_1139642_3_1">Range ten.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeTenMember_lbl" xml:lang="en-US" id="id_3014833_1139642_1_1">Range Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeTenMember_lbl" xml:lang="en-US" id="id_3014833_1139642_2_1">Range 10 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeTenMember" xlink:to="sgmo_RangeTenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeThreeMember" xlink:label="sgmo_RangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeThreeMember_lbl" xml:lang="en-US" id="id_3014833_1014875_3_1">Range three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeThreeMember_lbl" xml:lang="en-US" id="id_3014833_1014875_1_1">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeThreeMember_lbl" xml:lang="en-US" id="id_3014833_1014875_2_1">Range 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeThreeMember" xlink:to="sgmo_RangeThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTwoMember" xlink:label="sgmo_RangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RangeTwoMember_lbl" xml:lang="en-US" id="id_3014833_975231_3_1">Range two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RangeTwoMember_lbl" xml:lang="en-US" id="id_3014833_975231_1_1">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RangeTwoMember_lbl" xml:lang="en-US" id="id_3014833_975231_2_1">Range 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeTwoMember" xlink:to="sgmo_RangeTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RecentlyAccountingPronouncementsPolicyTextBlock" xlink:label="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1135182_3_1">Recently Accounting Pronouncements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1135182_1_1">Recently Accounting Pronouncements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_1135182_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock" xlink:to="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_3014833_1070754_3_1">Reduced royalty rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_3014833_1070754_1_1">Reduced Royalty Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_3014833_1070754_2_1">Reduced royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ReducedRoyaltyRate" xlink:to="sgmo_ReducedRoyaltyRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_3014833_932122_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_3014833_932122_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_3014833_926607_1_1">Related Party Transactions By Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_3014833_926607_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RentalExpenses" xlink:label="sgmo_RentalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RentalExpenses_lbl" xml:lang="en-US" id="id_3014833_958810_3_1">Rental expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RentalExpenses_lbl" xml:lang="en-US" id="id_3014833_958810_1_1">Rental Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RentalExpenses_lbl" xml:lang="en-US" id="id_3014833_958810_2_1">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RentalExpenses" xlink:to="sgmo_RentalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_3014833_924049_1_1">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_3014833_924049_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_3014833_924247_1_1">Research And Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_3014833_924247_2_1">Research and Development [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_3014833_926233_1_1">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_3014833_926233_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_3014833_932671_1_1">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_3014833_932671_2_1">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_3014833_924269_1_1">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_3014833_924269_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3014833_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3014833_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3014833_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3014833_928963_2_1">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3014833_929876_1_1">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3014833_929876_2_1">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="id_3014833_939864_1_1">Research And Development In Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="id_3014833_939864_2_1">Estimated fair values of in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_3014833_981565_3_1">Research grant revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_3014833_981565_1_1">Research Grant Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_3014833_981565_2_1">Revenues under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_3014833_981565_12_1">Revenues under the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchGrantRevenue" xlink:to="sgmo_ResearchGrantRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_3014833_1048214_3_1">Research service revenue under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_3014833_1048214_1_1">Research Service Revenue Under Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_3014833_1048214_2_1">Research services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RestrictedCashAndCashEquivalent" xlink:label="sgmo_RestrictedCashAndCashEquivalent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RestrictedCashAndCashEquivalent_lbl" xml:lang="en-US" id="id_3014833_1117425_3_1">Restricted Cash And Cash Equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RestrictedCashAndCashEquivalent_lbl" xml:lang="en-US" id="id_3014833_1117425_1_1">Restricted Cash And Cash Equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RestrictedCashAndCashEquivalent_lbl" xml:lang="en-US" id="id_3014833_1117425_2_1">Restricted cash and cash equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RestrictedCashAndCashEquivalent" xlink:to="sgmo_RestrictedCashAndCashEquivalent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_937648_1_1">Restricted Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3014833_937648_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_3014833_929867_1_1">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_3014833_929867_2_1">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3014833_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3014833_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_3014833_929313_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_3014833_929313_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_3014833_934838_1_1">Revenue From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_3014833_934838_2_1">Research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_3014833_933653_1_1">Revenue From Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_3014833_933653_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_924259_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_924259_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3014833_933119_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3014833_933119_2_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3014833_933119_6_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_3014833_929243_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_3014833_929243_2_1">Revenues related to Shire Collaboration :</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_3014833_929243_12_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_3014833_936050_1_1">Royalty Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_3014833_936050_2_1">Royalty revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_3014833_936050_12_1">Royalty revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_3014833_1116860_3_1">Royalty revenues expected to be received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_3014833_1116860_1_1">Royalty Revenues Expected To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_3014833_1116860_2_1">Royalty revenues expected to be received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_3014833_931930_1_1">Sale Of Stock Number Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_3014833_931930_2_1">Sale of stock, number of shares issued in transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US" id="id_3014833_927102_1_1">Sales Revenue Services Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US" id="id_3014833_927102_2_1">Revenue related to Sigma Collaboration :</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_923280_1_1">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_923280_2_1">Summary of Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_3014833_926059_1_1">Schedule Of Available For Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_3014833_926059_2_1">Schedule of Available-for-sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_3014833_929659_1_1">Schedule Of Available For Sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_3014833_929659_2_1">Schedule of Available-for-sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_3014833_930653_1_1">Schedule Of Business Acquisitions By Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_3014833_930653_2_1">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US" id="id_3014833_928526_1_1">Schedule Of Business Acquisitions By Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US" id="id_3014833_928526_2_1">Summary of Estimated Fair Value of Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_928783_1_1">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_928783_2_1">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_931404_1_1">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_931404_2_1">Schedule of Company's Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3014833_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3014833_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_lbl" xml:lang="en-US" id="id_3014833_924422_1_1">Schedule Of Finite Lived Intangible Assets Acquired As Part Of Business Combination [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_lbl" xml:lang="en-US" id="id_3014833_924422_2_1">Summary of Assets, Estimated Fair Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926102_1_1">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926102_2_1">Summary of Future Minimum Payments under Contractual Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3014833_931140_1_1">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3014833_931140_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_928012_1_1">Schedule Of Quarterly Financial Information Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_928012_2_1">Summary of Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_925884_1_1">Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_925884_2_1">Summary of Estimated Fair Value of Net Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_3014833_931043_1_1">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_3014833_931043_2_1">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_929345_1_1">Schedule Of Revenue Sources Health Care Organization Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_929345_2_1">Revenues Recognized under Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3014833_930578_1_1">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3014833_930578_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_923393_1_1">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_923393_2_1">Summary of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" id="id_3014833_927738_1_1">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" id="id_3014833_927738_2_1">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" id="id_3014833_925396_1_1">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" id="id_3014833_925396_2_1">Summary of Stock Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_924843_1_1">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_924843_2_1">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926594_1_1">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_926594_2_1">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_931898_1_1">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3014833_931898_2_1">Assumptions Used for Estimating Fair Value of Employee Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_3014833_925438_1_1">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_3014833_925438_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_930875_1_1">Segment Reporting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3014833_930875_2_1">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xml:lang="en-US" id="id_3014833_931790_1_1">Selected Quarterly Financial Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xml:lang="en-US" id="id_3014833_931790_2_1">Selected Quarterly Financial Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_938471_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_3014833_927053_1_1">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_3014833_927053_2_1">Stock options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US" id="id_3014833_925350_1_1">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US" id="id_3014833_925350_2_1">Share based vesting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_953031_3_1">Share based compensation arrangement by share based payment award equity instruments other than option outstanding aggregate intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_953031_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_953031_2_1">RSUs outstanding at December 31, 2013, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_3014833_923243_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_3014833_923243_14_1">RSUs forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_3014833_923430_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_3014833_923430_2_1">Restricted stock units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_3014833_923430_12_1">RSUs awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3014833_929533_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3014833_929533_2_1">Grant date fair value of restricted stock units issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_3014833_925843_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_3014833_925843_4_1">RSUs outstanding at December 31, 2013</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_3014833_925843_5_1">RSUs outstanding at December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" id="id_3014833_923394_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" id="id_3014833_923394_2_1">RSUs outstanding at December, 31, 2013, Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" id="id_3014833_1038137_3_1">Share based compensation arrangement by share based payment award equity instruments other than options released in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" id="id_3014833_1038137_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" id="id_3014833_1038137_14_1">RSUs released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_970179_3_1">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_970179_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_970179_2_1">RSUs vested and expected to vest at December 31, 2013, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_997670_3_1">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_997670_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_997670_2_1">RSUs vested and expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_3014833_1107546_3_1">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_3014833_1107546_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_3014833_1107546_2_1">RSUs vested and expected to vest at December 31, 2013, Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_1134232_3_1">Share based compensation arrangement by share based payment award equity instruments other than options vest in period intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_1134232_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vest In Period Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_1134232_2_1">Aggregate value of shares vested in period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_3014833_928648_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_3014833_928648_2_1">Expected dividend yield of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_3014833_926378_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_3014833_926378_2_1">Expected life of option (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_3014833_925061_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_3014833_925061_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3014833_924177_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3014833_924177_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3014833_926498_1_1">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3014833_926498_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_923350_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_923350_2_1">Additional shares authorized under 2004 plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_929330_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_3014833_929330_2_1">Stock reserved for issuance under plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_972125_3_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_972125_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_972125_2_1">Annual increase in number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3014833_1142766_3_1">Share based compensation arrangement by share based payment award number of shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3014833_1142766_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3014833_1142766_2_1">Shares reserved for issuance of future awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xml:lang="en-US" id="id_3014833_1024473_3_1">Share based compensation arrangement by share based payment award number of vesting installment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xml:lang="en-US" id="id_3014833_1024473_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xml:lang="en-US" id="id_3014833_1024473_2_1">Share-based compensation arrangement by share-based payment award, number of vesting installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_3014833_939053_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_3014833_939053_2_1">Aggregate intrinsic values exercisable options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_3014833_939053_12_1">Options exercisable at December 31, 2013, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3014833_924337_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3014833_924337_4_1">Options exercisable at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_930255_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_930255_2_1">Options exercisable at December 31, 2013, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3014833_930128_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3014833_930128_2_1">Options exercisable at December, 31, 2013, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_938409_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_938409_2_1">Intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" id="id_3014833_1155536_3_1">Share based compensation arrangement by share based payment award options expiration term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" id="id_3014833_1155536_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" id="id_3014833_1155536_2_1">Stock options expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_3014833_931512_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_3014833_931512_14_1">Options canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_3014833_929506_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_3014833_929506_2_1">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3014833_928357_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3014833_928357_2_1">Weighted-average estimated fair value per share of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm_lbl" xml:lang="en-US" id="id_3014833_1109760_3_1">Share based compensation arrangement by share based payment award options maximum term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm_lbl" xml:lang="en-US" id="id_3014833_1109760_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm_lbl" xml:lang="en-US" id="id_3014833_1109760_2_1">Stock option maximum term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xml:lang="en-US" id="id_3014833_1002798_3_1">Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xml:lang="en-US" id="id_3014833_1002798_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xml:lang="en-US" id="id_3014833_1002798_2_1">Stock option maximum term for specified stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_939707_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_939707_2_1">Aggregate intrinsic values outstanding options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_939707_12_1">Options outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_928127_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_928127_4_1">Options outstanding at December 31, 2013</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_928127_5_1">Options outstanding at December 31, 2012</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_928127_2_1">Stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_927714_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_927714_4_1">Options outstanding, Weighted-Average Exercise per Share Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_927714_5_1">Options outstanding, Weighted-Average Exercise per Share Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3014833_925836_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3014833_925836_2_1">Options outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_940227_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_940227_2_1">Options vested and expected to vest, aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_938271_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3014833_938271_4_1">Options vested and expected to vest at December 31, 2013, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_929888_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3014833_929888_4_1">Options vested and expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_928214_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_928214_4_1">Options vested and expected to vest at December 31, 2013, Weighted-Average Exercise Per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3014833_930352_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3014833_930352_2_1">Options vested and expected to vest at December, 31, 2013, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_3014833_927305_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_3014833_927305_2_1">Percent of fair value per share of common stock on option grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xml:lang="en-US" id="id_3014833_941914_3_1">Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xml:lang="en-US" id="id_3014833_941914_1_1">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xml:lang="en-US" id="id_3014833_941914_2_1">Purchase price of common stock percent under stock incentive plans for specified stockholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage_lbl" xml:lang="en-US" id="id_3014833_1147285_3_1">Share based compensation arrangement by share based payment award vesting percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage_lbl" xml:lang="en-US" id="id_3014833_1147285_1_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage_lbl" xml:lang="en-US" id="id_3014833_1147285_2_1">Stock options granted vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion_lbl" xml:lang="en-US" id="id_3014833_942371_3_1">Share based compensation arrangement by share based payment award vesting portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion_lbl" xml:lang="en-US" id="id_3014833_942371_1_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion_lbl" xml:lang="en-US" id="id_3014833_942371_2_1">Share-based compensation arrangement by share-based payment award, vesting portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary_lbl" xml:lang="en-US" id="id_3014833_1010454_3_1">Share based compensation arrangement by share based payment award vesting portion on second anniversary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary_lbl" xml:lang="en-US" id="id_3014833_1010454_1_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Portion On Second Anniversary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary_lbl" xml:lang="en-US" id="id_3014833_1010454_2_1">Share-based compensation arrangement by share-based payment award, vesting portion on second anniversary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary_lbl" xml:lang="en-US" id="id_3014833_1054020_3_1">Share based compensation arrangement by share based payment award vesting portion on third anniversary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary_lbl" xml:lang="en-US" id="id_3014833_1054020_1_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Portion On Third Anniversary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary_lbl" xml:lang="en-US" id="id_3014833_1054020_2_1">Share-based compensation arrangement by share-based payment award, vesting portion on third anniversary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_3014833_928585_1_1">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_3014833_928585_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_929456_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_929456_2_1">Options exercised, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_925340_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_925340_2_1">Options canceled, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_927283_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_927283_2_1">Options granted, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3014833_923943_1_1">Share Based Compensation Option And Incentive Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3014833_923943_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" id="id_3014833_927225_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" id="id_3014833_927225_2_1">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" id="id_3014833_932925_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" id="id_3014833_932925_2_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" id="id_3014833_928414_1_1">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" id="id_3014833_928414_2_1">Options Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" id="id_3014833_931435_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" id="id_3014833_931435_2_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" id="id_3014833_930052_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" id="id_3014833_930052_2_1">Lower Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" id="id_3014833_930466_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" id="id_3014833_930466_2_1">Options Exercisable Number of Shares of common stock subject to options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" id="id_3014833_924548_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" id="id_3014833_924548_2_1">Options Outstanding and Exercisable Number of Shares of common stock subject to options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3014833_923731_1_1">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3014833_923731_2_1">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" id="id_3014833_932326_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" id="id_3014833_932326_2_1">Upper Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_923726_1_1">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_923726_4_1">Ending Balances, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_3014833_923726_5_1">Beginning Balances, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_3014833_992959_3_1">Shire AG [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_3014833_992959_1_1">Shire Ag [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_3014833_992959_2_1">Shire AG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShireAgMember" xlink:to="sgmo_ShireAgMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SickleCellDiseaseMember" xlink:label="sgmo_SickleCellDiseaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1246051_3_1">Sickle Cell Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1246051_1_1">Sickle Cell Disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_SickleCellDiseaseMember_lbl" xml:lang="en-US" id="id_3014833_1246051_2_1">Sickle cell disease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SickleCellDiseaseMember" xlink:to="sgmo_SickleCellDiseaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_3014833_982693_3_1">Sigma-Aldrich corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_3014833_982693_1_1">Sigma Aldrich Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_3014833_982693_2_1">Sigma-Aldrich Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SigmaAldrichCorporationMember" xlink:to="sgmo_SigmaAldrichCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_3014833_1041542_3_1">Specified stockholder ownership percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_3014833_1041542_1_1">Specified Stockholder Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_3014833_1041542_2_1">Specified stockholder ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SpecifiedStockholderOwnershipPercentage" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3014833_932980_1_1">Statement Class Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3014833_932980_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3014833_927592_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3014833_927592_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_3014833_923497_1_1">Statement Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_3014833_923497_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_3014833_926570_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_3014833_926570_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3014833_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3014833_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3014833_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3014833_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_3014833_932352_1_1">Statement Of Income And Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_3014833_932352_2_1">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_926289_1_1">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_926289_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_3014833_926771_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_3014833_926771_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="us-gaap_StockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockDividendsShares_lbl" xml:lang="en-US" id="id_3014833_927365_1_1">Stock Dividends Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockDividendsShares_lbl" xml:lang="en-US" id="id_3014833_927365_2_1">Shares withheld from issuance in order to pay employee taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockDividendsShares" xlink:to="us-gaap_StockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_934682_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_934682_4_1">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_934682_5_1">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3014833_934682_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3014833_925186_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_927127_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3014833_927127_2_1">Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_3014833_929323_1_1">Stock Issued During Period Shares Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_3014833_929323_2_1">Issuance of common stock in connection with acquisition of Ceregene, Inc., shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_3014833_929402_1_1">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_3014833_929402_2_1">Issuance of common stock under employee stock purchase plan, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3014833_932873_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3014833_932873_2_1">Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3014833_932873_12_1">Public offering, common stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_931010_1_1">Stock Issued During Period Shares Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_931010_2_1">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_3014833_930668_1_1">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_3014833_930668_14_1">Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="id_3014833_934876_1_1">Stock Issued During Period Value Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="id_3014833_934876_2_1">Issuance of common stock in connection with acquisition of Ceregene, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_3014833_935852_1_1">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_3014833_935852_2_1">Issuance of common stock under employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_3014833_936512_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_3014833_936512_2_1">Common stock, valued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_3014833_936512_12_1">Issuance of common stock in connection with underwritten public offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_933029_1_1">Stock Issued During Period Value Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_3014833_933029_2_1">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_1080468_3_1">Stock issued under employee stock purchase plans average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_1080468_1_1">Stock Issued Under Employee Stock Purchase Plans Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xml:lang="en-US" id="id_3014833_1080468_2_1">Stock issued under employee stock purchase plans, average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_3014833_926520_1_1">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_3014833_926520_2_1">Stock Option Activity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockSplitRatioOnCommonStock" xlink:label="sgmo_StockSplitRatioOnCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_StockSplitRatioOnCommonStock_lbl" xml:lang="en-US" id="id_3014833_1222426_3_1">Stock Split Ratio On Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_StockSplitRatioOnCommonStock_lbl" xml:lang="en-US" id="id_3014833_1222426_1_1">Stock Split Ratio On Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_StockSplitRatioOnCommonStock_lbl" xml:lang="en-US" id="id_3014833_1222426_2_1">Fixed ratio shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_StockSplitRatioOnCommonStock" xlink:to="sgmo_StockSplitRatioOnCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_3014833_924078_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_3014833_924078_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_3014833_931597_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_3014833_931597_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_3014833_925770_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_3014833_925770_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_3014833_929519_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_3014833_929519_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_3014833_930713_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_3014833_930713_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_3014833_932504_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_3014833_932504_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_3014833_929873_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_3014833_929873_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xml:lang="en-US" id="id_3014833_927397_1_1">Summary Of Positions For Which Significant Change In Unrecognized Tax Benefits Is Reasonably Possible [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xml:lang="en-US" id="id_3014833_927397_2_1">Summary of Activity Related to Company's Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3014833_931202_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3014833_931202_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TherapeuticForBetathalassemiaMember" xlink:label="sgmo_TherapeuticForBetathalassemiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_TherapeuticForBetathalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1247035_3_1">Therapeutic for beta-thalassemia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_TherapeuticForBetathalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1247035_1_1">Therapeutic For Betathalassemia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_TherapeuticForBetathalassemiaMember_lbl" xml:lang="en-US" id="id_3014833_1247035_2_1">Therapeutic for beta-thalassemia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TherapeuticForBetathalassemiaMember" xlink:to="sgmo_TherapeuticForBetathalassemiaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3014833_921927_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3014833_921927_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_3014833_1044748_3_1">Two Thousand Thirteen Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_3014833_1044748_1_1">Two Thousand Thirteen Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_3014833_1044748_2_1">2013 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:label="us-gaap_TypeOfDeferredCompensationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfDeferredCompensationDomain_lbl" xml:lang="en-US" id="id_3014833_927710_1_1">Type Of Deferred Compensation [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfDeferredCompensationDomain_lbl" xml:lang="en-US" id="id_3014833_927710_2_1">Type of Deferred Compensation, All Types [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfDeferredCompensationDomain" xlink:to="us-gaap_TypeOfDeferredCompensationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_3014833_960063_3_1">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_3014833_960063_1_1">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_3014833_960063_2_1">Underwriters [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UnderwritersMember" xlink:to="sgmo_UnderwritersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3014833_934467_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3014833_934467_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3014833_934467_5_1">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_937306_1_1">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_937306_14_1">Reductions for tax positions of prior years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_3014833_934772_1_1">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_3014833_934772_2_1">Accrued interest and/or penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_933309_1_1">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_933309_2_1">Additions based on tax positions related to the current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_933112_1_1">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3014833_933112_2_1">Additions for tax positions of prior years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xml:lang="en-US" id="id_3014833_933156_1_1">Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xml:lang="en-US" id="id_3014833_933156_2_1">Total payments for the employees' tax obligations to taxing authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_3014833_1065069_3_1">Upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_3014833_1065069_1_1">Upfront License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_3014833_1065069_2_1">Upfront license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFee" xlink:to="sgmo_UpfrontLicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_3014833_1007904_3_1">Upfront license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_3014833_1007904_1_1">Upfront License Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_3014833_1007904_2_1">Upfront license fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFeesMember" xlink:to="sgmo_UpfrontLicenseFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_3014833_921516_1_1">U S</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_3014833_921516_2_1">U.S [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3014833_924099_1_1">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3014833_924099_2_1">U.S. government sponsored entity debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xml:lang="en-US" id="id_3014833_929039_1_1">Valuation Allowance By Deferred Tax Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl" xml:lang="en-US" id="id_3014833_929039_2_1">Valuation Allowance by Deferred Tax Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_3014833_935310_1_1">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_3014833_935310_2_1">Increase in deferred tax assets valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_3014833_927104_1_1">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_3014833_927104_2_1">Shares used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xml:lang="en-US" id="id_3014833_932388_1_1">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xml:lang="en-US" id="id_3014833_932388_2_1">Shares subject to repurchase rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sgmo-20131231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 50b48541-4ad6-4acc-adff-4debd479dff8 -->
<!-- Creation date: 2014-02-24T17:35:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical" roleURI="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMarketableSecuritiesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations" roleURI="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits" roleURI="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities" roleURI="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData" roleURI="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:label="sgmo_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EscrowLiability" xlink:label="sgmo_EscrowLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sgmo_EscrowLiability" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_CollaborationAgreements" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncreaseDecreaseInEscrowLiabilities" xlink:label="sgmo_IncreaseDecreaseInEscrowLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" xlink:label="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" xlink:label="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sgmo_IncreaseDecreaseInEscrowLiabilities" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgrosciencesLlcMember" xlink:label="sgmo_DowAgrosciencesLlcMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RestrictedCashAndCashEquivalent" xlink:label="sgmo_RestrictedCashAndCashEquivalent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_RestrictedCashAndCashEquivalent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgrosciencesLlcMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContingentConsiderationLiabilityMember" xlink:label="sgmo_ContingentConsiderationLiabilityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="sgmo_ContingentConsiderationLiabilityMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentsScheduleAbstract" xlink:label="invest_InvestmentsScheduleAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentsScheduleAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" xlink:label="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:label="us-gaap_TypeOfDeferredCompensationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_TypeOfDeferredCompensationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TherapeuticForBetathalassemiaMember" xlink:label="sgmo_TherapeuticForBetathalassemiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="sgmo_TherapeuticForBetathalassemiaMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundsDueUnderAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ContractualAgreementTerminationDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FundingReceivedFromResearchGrant" xlink:label="sgmo_FundingReceivedFromResearchGrant"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" xlink:label="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_MichaelJFoxFoundationForParkinsonsResearchMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundingReceivedFromResearchGrant" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_AdditionalFundingAgreementTermsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" xlink:label="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" xlink:label="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTenTreatmentOfAlzheimerDiseaseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sgmo_CereOneHundredAndTwentyTreatmentOfParkinsonDiseaseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:label="sgmo_BusinessAcquisitionProFormaInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BusinessAcquisitionProFormaInformationTable" xlink:label="sgmo_BusinessAcquisitionProFormaInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CeregeneIncMember" xlink:label="sgmo_CeregeneIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionProFormaInformationLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionProFormaInformationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionProFormaInformationTable" xlink:to="sgmo_BusinessAcquisitionProFormaInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="sgmo_BusinessAcquisitionProFormaInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RentalExpenses" xlink:label="sgmo_RentalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sgmo_RentalExpenses" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_CommonStockExchangeRatio" xlink:label="sgmo_CommonStockExchangeRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:label="sgmo_PurchasePlanOfferingPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:label="sgmo_PurchasePlanPurchasePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="us-gaap_StockDividendsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_StockSplitRatioOnCommonStock" xlink:label="sgmo_StockSplitRatioOnCommonStock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sgmo_UnderwritersMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockExchangeRatio" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockSplitRatioOnCommonStock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanOfferingPeriod" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanPurchasePeriod" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockDividendsShares" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeEightMember" xlink:label="sgmo_RangeEightMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFiveMember" xlink:label="sgmo_RangeFiveMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeFourMember" xlink:label="sgmo_RangeFourMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeNineMember" xlink:label="sgmo_RangeNineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeOneMember" xlink:label="sgmo_RangeOneMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSevenMember" xlink:label="sgmo_RangeSevenMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeSixMember" xlink:label="sgmo_RangeSixMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTenMember" xlink:label="sgmo_RangeTenMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeThreeMember" xlink:label="sgmo_RangeThreeMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RangeTwoMember" xlink:label="sgmo_RangeTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeOneMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTwoMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeThreeMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFourMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFiveMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSixMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSevenMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeEightMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeNineMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTenMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesLineItems" xlink:label="sgmo_IncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxesTable" xlink:label="sgmo_IncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_IncomeTaxExpense" xlink:label="sgmo_IncomeTaxExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sgmo_IncomeTaxesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="sgmo_IncomeTaxesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_DeferredTaxAssetsCapitalizedResearch" xlink:label="sgmo_DeferredTaxAssetsCapitalizedResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sgmo_DeferredTaxAssetsCapitalizedResearch" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_AccruedClinicalTrialExpense" xlink:label="sgmo_AccruedClinicalTrialExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sgmo_AccruedClinicalTrialExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution" xlink:label="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_BetaThalassemiaMember" xlink:label="sgmo_BetaThalassemiaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_MilestonePaymentsPayable" xlink:label="sgmo_MilestonePaymentsPayable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_NumberOfResearchProgram" xlink:label="sgmo_NumberOfResearchProgram"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SickleCellDiseaseMember" xlink:label="sgmo_SickleCellDiseaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_BetaThalassemiaMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_SickleCellDiseaseMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_MilestonePaymentsPayable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ContingentConsiderationPolicyTextBlock" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_RecentlyAccountingPronouncementsPolicyTextBlock" xlink:label="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sgmo_ContingentConsiderationPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sgmo_RecentlyAccountingPronouncementsPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_FairValueMeasurementsDisclosureTextBlock" xlink:label="sgmo_FairValueMeasurementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sgmo_FairValueMeasurementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20131231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g657040g38k71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657040g38k71.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0H>4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````Z````F`````&`&<`,P`X
M`&L`-P`Q`````0`````````````````````````!``````````````)@````
MZ``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!X$````!````<````"L`
M``%0```X<```!V4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``K`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#O\B][3<]O3+K?3>X`-=6WU/SO4J8;&[]S_P#2-6EZE?\`I1][5F9=
M>,_.=8>J68MK!M=0RQ@$`UW.W56M?_@_SFL_PUBOXG]'K#;?M0:`/7<6DOC\
M\^DUM?\`FI*:H=6:WEV&\.!TKWUDNUV[F?I=GT7[]CW,1L1S"PV/K^RVDD%A
M<UQB?I;OY?TE6&5C$$CJ[8W:RZC3EVS^;&WVHE&?A5,_2]1JOW`.#K'U-,1X
M5MK^E]-)3=]2O_2C[VI>I7_I1][4X)(!`:0=00?]B?W?NC[_`/8DIY3_`)RY
M[SZCOJ[F[W1)VP3'&[:0I_\`.;J/IFK_`)O9OI\;-H(U^*S6YF)M'_9E:?/;
M7_Y%/]LQ/_GRM_S:_P#R*2F__P`X\[_YW<W2-8\#+>ZE9]9^HV1ZGU>S7;=6
MRT2#$2TCZ*#TK)QWY[&U_62SJ3BU\8CFM`=[?I_HQN_1?SBW'..GO/T6^/@D
MIRF_6GJC1M;T#.`'\D=OBH.^LF>7%Y^KN:7&=WM&LC;[A^=[?:MAKC/TSW\?
M!-N/[Y_%)3)N:_(QF&ZIK1:T.?18)+9#7>E8W]YGT7),O+#+&L!UUU)UB?I.
M/[K4Q<=H]YY/CY)MQ_?/XI*?_]#TIPRO4=LJ86:['&U[7<#0L;6[\_=]!Z)6
MTELV@M>>6M<]P']LAF[_`#%B9K^BV]0?==DWLOK<:G-8^^L`M?6YP/I5-]MF
MVNKZ?I/_`,'^^M7IKFG`H.,]U].P>G;<][K'#]ZQUK&V;OZZ2E@,LO(=B5"L
MMU=ZI))GZ&ST?H[?Y2C&:&3]CJ+R#+1:>Y/MW>A^<W;N5.R[I[?49]KR&.!=
MJVRXEIAP=MFM^[;O_E^__BTYMZ?L`=?>6LW'<7W_`.#/N]WI^[T]B2G3J#C6
M#:TUO[L:]S@/#W0Q3VL\7_>Y9F/F85+G9#<FVUK@0/4=:]FCMKBP&K;]-NU7
M<?/KR7N93JYLR'![?HN]-W\Y6W\\)*>9;A==VB?JSTP>0L9_Z33_`&/KD?\`
MB:Z9V_PC/_22PV6?4W:(ZIU6(TE[O_>=/ZGU.C_E3JG(_.=_Z014]BS!PJ;/
M4HPZ*GB0VRNH,=!T/N9M=[D9S3I[/S1^]X?UDSMNXR-9['_S%)VV1(_-;W\O
MZJ2EPTS]#Q_>\/ZR;:?W/^J_\DDW;/'CW\OZJ;V^'X_^8I*9;3M'L[G][R_E
M)MI_<_ZK_P`DD=NT:=SW^'\E-[?#\?\`S%)3_]'T.Q_7!<[T_LSJ@\[=S;@[
M9(VM=MWMWM;^?_A/W*U9H=9Z+/M36F^/TAK:[9/\C>-ZP\OT?VHZ?L>[;D?3
M]7U./?.WV>G_`*3_`,`6CT39Z%WI^E'JF?L^[;.UGT_M'NW_`-3V)*2AW5MK
M@7T3!V$56P#[=FYN_P!WY^Y,;.L;AM&/M(,N+;9!_P`&-L>YO[_O6(?LVT_T
M&(L^EZ\_2;N_E_Z_HT>[T/1Q]WV/;O,?SW\K^:V>_P!;^NDIU7OZJ)+#09B`
MYEHC0;OH_2]^Y6*GO],>N`;),[&NV\^WZ8_=5#H_I^MD^EZ7^#W>COW?G_SO
MVC_P/TUI^[^5_P!%)3RC7?7K:)S.F3WCU/\`WG5WIEGUA:Z[]K9&)966M]'[
M-ND.EV_U/4JK]FQ<PS]G[1_0>/\`NZG_`%#_`+H_^SB*GLMW\IOX?^13N=Q[
MF\#P\/ZJXS]0_P"Z/_LXE^H?]T?_`&<24]F':_2;W\/#^JFW?RF?A_Y%<;^H
M?]T?_9Q,?L$'^@_^SB2GM-QVC4=_S?A_)3;CXC_-_P#,4+&_H>/MC;Z;=NWZ
M,;6?0]3])M_XSWJ>O^L(*?_9`#A"24T$(0``````50````$!````#P!!`&0`
M;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H
M`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@``0`!
M`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!
M`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P/_P``1"`#H`F`#`1$``A$!`Q$!_]T`!`!,_\0`
MN@`!``(#`0$!`0$```````````8'"`D*!00#`@$!`0$!`0``````````````
M```!`@,0```%`P$`#`D'!@H)`@0'`0,$!08'``$""!$2$Q0551=7E]<8F)-4
MU18F5M;8"2'1TY34IQDQ0>$B9)9AD2.C=)6EM398,M(S)+2%-PH:H5-10E(T
M0R4U=K8G*+<1`0`"`@("`0,#!0$!`0$````!$5$2(0(Q82)!D5)QH4+P@0,3
M(S*QP?'_V@`,`P$``A$#$0`_`.UG6,EJJW`:ZDHJ9@LJ"@^X/*X)0V_;$U`L
M).<;V4"JIDG%CAP-&%3]UL=SP!%VA3=,KXY6M>U:Z^6>WAC7@AZC8$;+W;S4
M=PJJ#'L5.:6$UGHK7$<[>'<CS?TCC$&2@J;D`4'><:<<-P`MF"G%QPE(_F5"
MMAF#B-D")>)KA.8CA\F,[RK9>X%*2B[5N%,'EB3#U'(\2)2\Z#IJT;7<-F&7
M04%BCM<Z4$>&.]KGP$/=]F_!FZ8GKV,4J,<ESGC+RF1/DZKL7K$MNE[N@JA-
MV&X'7<$MG1^R+B+[JE<B.G.%QCK"XWU,L216F?&!/F=P!R`3BP8HPP8X6&]L
M[,1=1'U(F9BT9+:@=3[D8CG5T!Z&`5.,8ZFQS&A",?(:^*_'%'DI8);'1U(<
MTTD$,'!T,4X6''X/2TLP=+BXF"X!.^>QBKJE]JGEL&A(W(6(\M-J1'09>IQE
M2>"A-]TFFTE-7-6;RK%L8OB^(2>B%BR<*42G"[U`B`+CNHNXE<<!A11PQ!,L
M37%-Q?-KSJ*4"@4%6SB&;%A28`B&!@0\)%L@!D@R>(N9L0WFTU;$M@5P!M<;
M,QF-?&V%L/UKY;&Q\M6/,?JD^)8%R=J)D(@QH/2H8=B6V2.;)4D]XOETIIA/
M24F04!JM@5ILYPFW*PG.6+D5K(91''"#!*FU"Q'(`J?+#6MNNXZQ<W#,S-12
M./;5G,*5(<C)S84%S-.(-R3$G!$76@DGL6JZF4NLD+!T-A)2F>G+QQ(\SCBZ
MN$`E-95A%U.3]WQ+$L,;;LCK%03VFUPPF.;5VWK36B3K<4B%EU<P%;S]5VV`
MVE)Y`%-.K!20E`HG)+?;"69Q+G".10,P0(@%C>0&ZA8WMG:]Y/GK_7U(_DKA
MBR#J20B[0$3%)7/-=LK$"1NFQH89*7ABN)S@TM-=ZN%0576:3,W%@,7?8N18
M,8,<'`L/D*&/D+:V`0=F.O/]?4N5:-A[/1\R(RGH8<RY)2\?2-)!%[9J,;X-
MY/83B5-1Z&H/AC)Y<HVT<.V+)!4!<]N9S.*!#&VV,F<\L=M9XBOU_P#B7-Q_
M99`^HV0RT2YKJY*CS(2^O.\1ON)B)+'9*.DP@LAV?YPBWCQM?C%T*I=)40F^
M`4#,'P5TZIFL0;$[!XF]O@UB_'"W->>7PQ]*$GODSBK.EZK:X><B5H)=1:.S
MK;)`(9-06)CC)'F5>;Y'@@(^3NR7$"<+G+A#7#)F!]L8M?(N!D&F(CQ&2)G_
M`./\OJ%U%&$A0X!=:BJO<ZV%PX_&H9B]/L4T^O,K-;":#<;Y7$%&(FULHM-)
M>5MDJIG#QTQ@F7/@CA`9VMBUC^Q<_P!?1G-`*N_SZ9)"1(:Z>="BS)9=#21'
M(I("4W3JVV2*:WU!-.#DD-/2T<:^(RH,%B,7`PP$Q"ML[.=LLKXFN*PU%\VO
MNHI0*!0*!0*!0*!0*!0*!0:B<B4C,K4._I0(-`[B5#DN?TUG+*4&YCA]]/K.
M*4?D_C-^I80A)-!CQ:4A1C2.=#L9V5PG@!NA6XV&[=.)B(].?,3,OG!U)SV7
MBG!T*DIHYP<HYT134B+;+M8>5CR4;9J@:6X]2"ZO#Q!C$7>G.P`$0J@G4S%:
M-D<A"=U`,UC@:$:Q?@N:\INMZDYM0I"FD1Q*0R$V6OB_R"/'I-)2!G^10R"<
MG&(_D!JMQ08F9H\&<L-<PJ*"BM*2)@$-E;`J"(5S!%:Q4+M,3-^'^1Q-FH=^
MB--+1W@>4SC?,:D%5>R":C84##]`C<W%BK$C75UK%CM9*(E7RD.PP'=12DM*
MS4"0EQBF(6=L!PTQ$?0B>TT\TLM2'*=M.#A1)N<JN_R^4A*CS6<8U:98>*'2
M/"R@96605;HS13R:=EBKXY%,`UP-4.@WOL99YY9!WLXC;C@YFN>6P^%W$XG?
M#L3NQW@[W=CHC1B.)S@;RR3=P<2VUDI26@>#L[6S(;DI&1<=QO:UPMC:W_)6
M)XF::CQ"RZBE!K[U31*[IEFECM!LXIR=ON"I8L&\U@RYB8;`5Q'[#X!%WM@9
MN6!$,/Y)+##W3BXIHF$,%D8W07<[9AB;ZS43^K':)F?[*V>TJ:G&P@F5?!_&
M2*0O3],4>@KRXVFFW4R.6E&ZR_DE@#'%TW'KO!&+2`*GE,CBDIDQ0APRP(!0
M4H,:R-"*ZX^A,]OW6^_Y7G5*;L.F78<:<3LIYJK;*OB:X\/F9#-H1(['JTM#
M&3+<>T6DV\PR*\]RQ%.)GS5EXL$$:V1\0,MIMD1'.5F9J%+CN%^M'*>WDR\%
M)95PW//;U:KH,M7$P8651)T:0L>::^5(63`B65EEPI^QN`8&(`XV.8%@_P!6
M^%KQQ$_URSF?U_\`CU%A]:C$1Y$$XU@8EQP,MR+ZXSSAYA$4+A!45]&LD/,J
MW0+-TH3+%TO.1`@4T`2^8AVP9G>PID83*V53BOZRM]OZ_1$9*U-R"V(::ZPP
MYG>K]D=8;[B<YLT)'S$24$DZV\A,TXH1>?3<(M-J=S.)U;%S+)`882S<"P]S
M*J#B6V^5CK%\QPDS-<3RS7TTYV-6G96`Q%R35_4"[5U$.Y`BA`*J,I-1BBD%
M0CF+AAODB;#M>X8F.SCEL7V+[-KUGM_']&X^OZLF:RI0*#2;%T!RFG1UIG>H
M*O=A'7>YH$3[)3=(KSB-)A]+;DBG5J4WHBNP()")OLX"L!D\L;$A"A>X>.1@
M0WM]SMUF8OLYQ$U$K>(:FI>(KD)I3E<;B3U&ZFTB<BXK#0;B.W':W%N9GI')
MMP%RI=E*"[95*HZ03,GQRI]"24O(4#/:F-]8@8S6.>%VGCEX8FI*>A&4<L1>
M@YXV7F-/;[KE@NG-0&/&^T%MGNU<0<6LK#1*/FV@LEM-3B*L$Y$55-I`QG$`
M8WC<Q@8`:Q?A+G]V3LW9N9]:$WJH+X:<NOE1@L97-C,O%1,)J@\@&[@:R4VJ
M'O8HI7*F%@.XY/#<K"88Y8X_K;&S?,<=XQ;4WK[IFG66B@4"@QOU>%%,_IME
MHFC%3!U3,MP$$F4*XF<QS(F:NFVN#CB3#%-7PSPV;9[3'+*V&S\EZUU_]0G;
MQ+!9>BB:H-="ZXV<Z[H2^AP/JKEE&1FF@&'RT$(L478246W"+:%>)$48-(6#
MS9Q,B7#*ES65QCF!,(#;8BAZN)\YC_\`6*F)G])2);U12L:E%^MIN/+S4*>9
M,JI*:!)38)!-UH28TPFL=;)X'%"8@B^3;ZJEFE<T6'45-<LH$B61NY,J&!G@
M.UBHFEGM-OEMJ.U`*9F%0$9<';"`L)9PP;=TF@M$,I)3J2)?4&JO-?A9L1AB
MA.!-$9Q0$=#S0@6P<4PSP1VU\PPA@+M8YX+GA>>LDVR54XR6"IE!T5XN0L?-
MIDNB$G&(7B!OIRBF#JK@0#:$7,BB/]1,AA`I!8.V%KB8Y#F1,2X%PQIUORO:
MN(9W5AHH%`H,`M8$5.R8I+AQEM<%+`S4HQU#%KNA;'<A4BQE0V<A4LD/!+&;
M@=AA7DA[H..E`"CE0A\L!<<A;![I;+?6:B?[,]HN8A5Y1TS!`X#C5A70]7$R
M%5YZKP1T!+CY#45Q(&:N#B<""_@5(VGC'%9Q+;A)YB_[V-@C"%3&.-R][AY#
M"7B?ISPG,?7+P$'5!+_!+5-J+Z-+H"9-CD;:RBH26U!90D!EF0HY,L45M7'B
MI+:#L(XXN0]OW!-3T(\IE<@QR!FV)4?(1K&/H;3GZK_TZRQ-#YFN0D&1%A#3
MTE)#D8'.-!L2H#G:AMOR&F)#+/D"Q=G)!W)N*S*.W%'.FU=7#4C`H)@E<`'(
M0N#.T1$14+$S,S;Y6L(B@:V3%VGFV5`J>94HEG:$Q"3B3E=#7PU]BF!3,TBG
MA%)$7#)H^3'"01`<DX0ONIBV()@(2P@2?_)_)GO6&B@__]#O#=K_`$)E"$0E
M@@]3F2A@.(!=I1K(S^##Q+Y!8B6/#,5JN,),SRN-;<\3.060MK97PME;'+8"
M'\NS)XCF7NYZA.K"BTAKV>L,2*G%TIYLJ85H@5'%,@`9Z?\`4H2V@HY0P0'M
M<5-CLF.(".3-"!B!Y97#SQR_6QOL6V$3,>$F+\I$DS#&J"E)B&B-.64E&14\
MDDI"4G::Y^)IZ8F)Q8,F03R)0"+<`"I,D5!P#"#PQMAAAC;&UK6M0IZ'+LR>
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MXH%`H%`H%`H%`H%`H%`H%!\Y8V5.8""%#)<U@"8,%!<RPP8^`1HF-F6-EA,@
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MQQ&FY/$31MX[VS+E78`#?<TTF$-M`LD<*^.P/AE:_P"K;9OLWJ1UF(YA9[1?
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ME?!NOR736<&WM-F_KKTT%FL]BAV;D[%1/@HN*3@(5=@@HF0!HUF;W`6R-G8&
M^(>>.VV<L=FW_P`:D]9N.%CM%3<H3VW-/W/65\&Z_)=76<)M[.VYI^YZRO@W
M7Y+IK.#;V=MS3]SUE?!NOR736<&WL[;FG[GK*^#=?DNFLX-O9VW-/W/65\&Z
M_)=-9P;>SMN:?N>LKX-U^2Z:S@V]IS'^I*-I363+?8$E><JR33!EDR1*9+P`
M@287-$B0QO+,\4*@WP#-*`.%[6ROELB6^38V;V57T+]K?X75>,U#ZZ9^DJ+<
MY6,OJ!_".V"-@>.8C#&')847$R-B(+;!4$QPL)G;.V6>TQ^2VS>^Q:I'F5^D
M*YX75>,U#ZZ9^DJI<Y.%U7C-0^NF?I*%SDX75>,U#ZZ9^DH7.3A=5XS4/KIG
MZ2A<Y.%U7C-0^NF?I*%SDX75>,U#ZZ9^DH7.3A=5XS4/KIGZ2A<Y.%U7C-0^
MNF?I*%SE_]+L)^)-%D^33I&D.-=,LF%8PF-R'6Q@VCAEVJC"R>11.72:LOQJ
M5>B";(KS;,OI!(F"5AR8P0F>.>068@0`@HN"5ZU$\QPY@Y/G-6D9#TE0'!<9
MZFHAD-E:E-8$5Z@-+*OKCD5$'QE!D08R5DLVV[JB67LO'LXZ1#J78Z2LH&;@
ME#@1P"P=@!\#!B-Q%3,S/#=%\-J;3NI3X>\/15):KJDD1#=D%2&0E76PJ+S-
M8:>W5E'=KV1W&T%"0KR^<EPD^6$33\2)5P`I1HJ;*E@#^:A8046P:$[14VP]
MT^1_IP0(`U+:Z9ZU#:P$_0P]UPDRM.S"<^J>?#CZDAD,%SBI-GAOA&=C>?@[
MIGN24;+%`04X<AF70BH.1K,3`R.(")F;B(CE4KP2]5++T5Z=84.N:27`_=47
MQ$':[H5TBJ^HUV`.@;24"R3+F3](4P:HDY_-YUL<VV4C$,\*+@K&S-E(Z4*C
M%[[`V)8O%S^C<=\&1_K[YT,-@@]7(_UV1XWE*;(RDE*DM065YSQV[VW);@-"
M17DZU]=<RN\4F.T16(IA)3'/F!#)4#"V5@+X7+`H9[>?3:O59*!0*"'2)EEA
M'[ZSPRRPSP9SGRQRQO?'+'+%$/7QRQRML7ME:]MFU[4(\PYN$)RZDAH)^"!R
MA)\9)4=J#49EVNNLN17ZNO\`<H/X=\HFD<1_H2VPVXAD#!M,#L:-V+JJE8)1
MQMCAD+A;=JF'3B^RMXDFB3-%FG32[)C$Q<+E5OB'?#YAV%XT)Y"*RZ&5U]L9
M,;[(@Q2.89X';IY1^L>3<[GL@;;8S@RK7$_6VN=A,7,QB6^!Z*)+0/H<1D!D
M%AGLY8HC=@PY$J0H"Y65)3F=P9(<9QFFJ(P@@PPBG(DG+9/-1,999W#L:,&1
M,MIAGE:L>90UX*./PX?AY*0J5EF_I'CMAW(I`N]Q#"E-6JB6W#O<!2&)8V#,
M&U:8]0S[N=,AAXVOA=2$O;''##8Q'F6@IO/V3X6T=ZJ-%LJ@SRWG8AR/H+U+
M12LSX1P0)->;7DO5KII:&HHP6ND+R\2NV$+4&34AB^-C5Q[DW0%@-CL7MC:-
M\7$PL9\-B#6UIF^(5J&).K-E:XF]\0C66FZ:W<UI"6TV85F1434^?3(MCYJ-
M`FX@[O-)7E$Z"E&D?)..%!TTV+NH5\,=O@3ZQBF8L+-5'TX?$225*5&?#D\O
M+6!-\YGXRU+L)Y"GY[@QY8,9SN)Z:;95:)E9615*'X[0FXHH:(<3CN11'S*`
MA'4\`QE@8Q$\QQ]&_P`JL%`H%`H%`H%`H%`H%`H%!S*?]QC(7F)V.OY>X/"O
M:$_)EM=MO'D/_AML[&_/_6NG^.:MGM%TYE.T'^W7\)^FNN\,Z':#_;K^$_33
M>#0[0?[=?PGZ:;P:':#_`&Z_A/TTW@T.T'^W7\)^FF\&AV@_VZ_A/TTW@T.T
M'^W7\)^FF\&AV@_VZ_A/TTW@T.T'^W7\)^FF\&AV@_VZ_A/TTW@T.T'^W7\)
M^FF\&AV@_P!NOX3]--X-#M!_MU_"?IIO!H=H/]NOX3]--X-#M!_MU_"?IIO!
MH=H/]NOX3]--X-#M!_MU_"?IIO!H=H/]NOX3]--X-#M!_MU_"?IIO!H=H/\`
M;K^$_33>#0[0?[=?PGZ:;P:':#_;K^$_33>#0[0?[=?PGZ:;P:':#_;K^$_3
M3>#0[0?[=?PGZ:;P:':#_;K^$_33>#0[0?[=?PGZ:;P:':#_`&Z_A/TTW@T.
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M"4!#OEM`L,<5+<^;9$MZ%XD:,58P8U(W9;8AS!MJ[/QC-O-Y-167BV7`&>#7
MT?%`32Y8A8HM\*&<SGZFV,BF!1!+Y""9Y7)?U0QV:4]-C\B-L0(\X.C)SPJR
M\D?)I1<M-))/LANY-\H:((F20WQR^2>2R2B1X8("^&%MSP%RM;\MZ+<W?U5X
M+\/K1&+%F<)8Z7(7*11F^;2:&QTUDI24C%)$LEIZ'Y[IN*8$4,I;IR14LN3R
M/%A`C&14*P5\KA[.-Q<W=\L@8LB:-(08R)&<0L9LQRP6Y@8P16FTDHJCHQ'(
MZ:&/'C&)4KAA84ZH'C`@YD<2^8Q@<3(03/+/*^5R>5A4"@4"@_(<`$R",6,@
MA&"Y@(0`<`</`4$<$7"X8H(P0ELL!`A,,KXY8Y6O:]K[%Z"(91O'>:<ST?-A
M,O-)CT(`!@I>360\DYC@E4(PURP+/)7(W+-D(NVC8J=AB2Q`M@1%S`ML!97P
MN'\8QG&^".S6]A'S(Q0(Y44M8CU#Q:B#BCL170R9M.1%1FIEB%B3744=//C@
M%1R.``I<$83`/+''/*UP\:08@9DGN"*7"\2YY1%AI^Y2<S4O$[F`B>>X35<C
M/2EM:3\,-JL"MY-=AT8@&+EN18_D$:MC<<`#,,)JN-IN.<--!<B`B.$%&6TI
MRI`2XE$58-*<:":Q/(:^FX'P#&)%;1CN&(Q0V%;$<N+:V8>6.5MF@\!U1=&;
M[.E5)[QVQ7DHD"F!`B?=31;[A.DR(:VCN4,D5-*Z><'+E,'&WD]0L'AE;"QT
MB7'V-U!#RQ",IFGJ`D5[F)-1H.A])D@VJ*:X;D%,C1ED'N:6UH8<PL+!AUE4
M4)>&5%8P:%$,F,C%QA\Q,LL\LKY7O<#9T]0$RI"<<N,V#H?:4KO$4^.[I.;,
M:,M!D)TC*IBQM4&<;T2D4HY%P52-VW4QD9,BW&$_6SV;_+1;GQ?"X*(4"@4"
M@4"@4"@4"@4"@4&KKXDV@F#];_(QRRI;V4N3'E%\W/,YQ'D#<?/3S$X8X1WD
M6,;[W3S3*[CMMC<]KGL;.VOL:ZQY-ICQ#5W^`EH@]5YKZ1%SR;6JA-^V(/P$
MM$'JO-?2(N>3:5!OVQ!^`EH@]5YKZ1%SR;2H-^V(/P$M$'JO-?2(N>3:5!OV
MQ!^`EH@]5YKZ1%SR;2H-^V(/P$M$'JO-?2(N>3:5!OVQ!^`EH@]5YKZ1%SR;
M2H-^V(/P$M$'JO-?2(N>3:5!OVQ"5/7_`+?_`$'([F4TY';4UB)Q?>6]\^4M
M;,[.[)Y0<;^7Q3KVSV!Q<K?P?D_-4B+A9[]K\0BOX"6B#U7FOI$7/)M6H3?M
MB#\!+1!ZKS7TB+GDVE0;]L0?@):(/5>:^D1<\FTJ#?MB#\!+1!ZKS7TB+GDV
ME0;]L0?@):(/5>:^D1<\FTJ#?MB#\!+1!ZKS7TB+GDVE0;]L0?@):(/5>:^D
M1<\FTJ#?MB$J97_;_P"@Y8<R8G+#:FL-.,;]WQGREK9;8W%/-C@_R^2=:V&R
M.%C;^'\GYZDQ4+'?M?B$5_`2T0>J\U](BYY-JU";]L0?@):(/5>:^D1<\FTJ
M#?MB#\!+1!ZKS7TB+GDVE0;]L0?@):(/5>:^D1<\FTJ#?MB#\!+1!ZKS7TB+
MGDVE0;]L0?@):(/5>:^D1<\FTJ#?MB#\!+1!ZKS7TB+GDVE0;]L0?@):(/5>
M:^D1<\FTJ#?MB$O0_P#M_=!9UMN]0.-J:\5!*"2,DK#E,6PMOD:,F0S7\C=.
MV3&U##Q_)_H_EJ3',+'?MSQ"(?@):(/5>:^D1<\FU:A-^V(/P$M$'JO-?2(N
M>3:5!OVQ!^`EH@]5YKZ1%SR;2H-^V(/P$M$'JO-?2(N>3:5!OVQ!^`EH@]5Y
MKZ1%SR;2H-^V(/P$M$'JO-?2(N>3:5!OVQ#);2Q\,+3YHZD%8DV&6_))9T+K
M-4&(?S<SF57$0N@*:VWG`:P!)&"0.`1NZBV"M\1;7V<<+9X['ZUZ5$)/;MVB
MIAGUP0J\6*'U(S]'59J<+&7T\_G';!!P(G,A@3#DN*%B6&R$"MFJ"987$PMA
M?+#;X_+;9M;9M4CS*_2%<\$*O%BA]2,_1U4J<'!"KQ8H?4C/T="IP<$*O%BA
M]2,_1T*G!P0J\6*'U(S]'0J<'!"KQ8H?4C/T="IP<$*O%BA]2,_1T*G!P0J\
M6*'U(S]'0J<'!"KQ8H?4C/T="IP__]3O#=K`0GJ(1%6#[U)Y)^`X8%FE)4C,
M$,3$QD%D)<\"Q74W`E//&X-MSR,XBY!6OE;"^-LLMD(8+!K$!#$&&<$PA`A8
M9BBBBZCM008888>-\LQ!,\I0MCAAAC:][WO>UK6M1;5`34M)"@IDT4AJ/R/+
M*B;#()Z23ULR<94SQX8QB3!)$R`,U9FC1L4WG8+$/##+/(2]L;6VWR4HY6L0
MAF.54H$?2W5+*D1'W3<#I#4K/IPH-N0N8(NY&2\I"`B;F,'EAEL97V,L;VO\
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M?0LY"63QY,O>,U"=9]"SD)9/'DR]XS4)UGT+5S(#$9S*X)W(U,*APGO_`&VZ
M:E=0Q?<=Y;RV-C:R2-M]TWW_``;&U_AJQ%LSVF%<>B?B\N=Y[41UAUK3VF\G
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M".W6@J(+H6<LI?!R;P:8)@7MJ9U#YXFN$#`X-[9"7D;&X6Y6!V;;%LMG9_-4
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M5E93.F,\"Y-/3B!80887/*V`8>%\KWM:UZ#3]\0)DZM];6C.0!M.3=))B"Y"
M+>58^AM[99M)[3<V>$B!XVMOL184DM+:Z2?3=L<1F<IY%[G[!@"+XH=A1V]A
M?"PTZ,P]H[0M5NGPJ]-(NHWX4.HS@E\,(HSQ$+)P:>]2X+G1"Z&3C58=RZ,0
M$6DQ1,"V32@Y%&R*BFE,$,R8OF7*9!TY_L\323K>UW:%_A4:3=039CC3JN:-
MV?(3V8;C1%U8?)N>Y"#=\]2JI+;G2,R822R66C)*J*81R&&0JF;N<+7-C@BE
M1;!`N/[K5RLN,_B9S_%VH!R0WI0TM:8!UO43\1'6Q%AY.*D9.;)MZ../$^*+
MLV374XU.4ED@FJYH^_1E!U#@I]BYE-([F1*$QOU\DQSRG%6G+Z^-!K";STD&
M$U-\?#^AF6=,!$=+F92F(U+XC:G262ZHN#GV)!2>W]R.(C<;Z:GAIILVKF,!
M!U+(,0,P$7%VV,HIT#Z&M5S>UMZ6HIU*-U$':X4@):G@LM8R;Q/"MIU-E=4V
MLZ$?`]B$!<\1`7$8;,F8R#"S,$A`1<@P\L[X8Q&6E`H%!X;G5A$!M.%=!!P,
M"HJ&K*P0`F66(8XB<0,',`1,L?UL<!,@;8WO;Y;6O0:E&'\7"'9$1_A^`-61
M-/#ED'5&"WC,_1^UIA;+A<VGH`?3FZYB>`JLWDI:.+R+@T7<W<44U=9`+;VO
MGEB-M1[6QJ6UKY7HG_%+TAF60]I%5G!([/:;*08P>UC[RAR3&^:><83-(I&*
MHREF.$DTVKJ[ZCQUO=1"*A'4\`44'#/`88$,(4#,6VFL^!G?%`TT/)[-V/0D
M;4`VG0M2LE0@LEGOIVEMHD8\E)SD2ZFQ6=)*PLM@NDM)8?Z8<`,I00HV6>0(
MX>1BQ>V5JEKK+T6]\372DXU)3`*KC_3V[BUI?>+*D1<BQ](T;S$B0&145*7Q
M(:>!]&"3I!-,DBCFQQ`2G\H>+%13!&QHL'D-:I4J,EWXM<-I\,2J^(ALY$]X
MQ^R(GF-%*3I#DJ,%O/J"7Y,;)C17EME%ULHT%9W,X@"Y!L`3947#_>\BXE@Q
MRXF.ZRUUFUQDOB(16]U*.$AAC*S67EO54R--;Z9$Y1I*T<2`D*+\A]VS(UL$
MMJ&VO9135-W,Y&**B4:6,":4(G9C8C"A&MS!R%*ZT\?$.5G\VH^5I*0TP^ON
M'2J)J$7&#"L=2Z\Y$-FA)U.P\1LSVDE)[O+J3=%$P!Q$!LI&%0$Q<0P*&&0P
MS&PJ4SDT_P"H:/-2;/6WA'EG.2P:CZ=<9/1M/9K*[->#+D!DG`RCD:KD0%@`
M(8JHD-\`B[8+(8`0$?#+`3+9O:PF*7G1"@4"@4"@4"@4"@4"@4&B?XUFHM]P
M#V:?,IVJ+6\[.63A/@\0$/?W`/)5O+=MU!%V=Z\,B[78V/\`:7KK_CKY6QWO
MBFB?\1:=N=MQ_6"GV2NOP8Y/Q%IVYVW']8*?9*?`Y/Q%IVYVW']8*?9*?`Y/
MQ%IVYVW']8*?9*?`Y/Q%IVYVW']8*?9*?`Y/Q%IVYVW']8*?9*?`Y/Q%IVYV
MW']8*?9*?`Y/Q%IVYVW']8*?9*?`Y?8H?$GU!JIP8^HS&YS9P?<]V,"F2=Q!
M-R"P!#VU[$[6_4"#QQM_!:I\/1R^/\1:=N=MQ_6"GV2K\#D_$6G;G;<?U@I]
MDI\#D_$6G;G;<?U@I]DI\#D_$6G;G;<?U@I]DI\#D_$6G;G;<?U@I]DI\#EO
M]T32,NRSIBC.0',KF5U;7_//?JJ;RPS,&N"I!=:(6W3(/`/"^X%$T,.VQ:WZ
MN%JYS5\>%AE54%A15_CU!_YI_<RC4[>):CS"O:K)0*!0*!0*!064TO\``TE?
MT=M?\>>J3YZM1XE6M5DH%`H%`H%`H+*</_3>/?Z0YO[U$J1YEK^,*UJLE`H%
M`H%`H%!__];M^U/0?;4?!;\A?SJ&97GH`A88N(-&`<9<MF@.A$=&!%7;IDZF
M`N!MKF:)8@JD+F2USB:9'!L,%EG83%`Q\UFZ'1-<VGLK#DM2:6;3R;;L;,F1
MW*T8,I3;9EBRFTP5`JDNHDVEJ0G1F?3KD5DZ7%(YJ>`FY&=L&:#'#"&PI#"-
M'^%;JOF:3HB>FOK7:'J*:NG)PCNV&F,U(4:4>!F'H7+!8M]ZOI<1;IIU3-I!
MX@4,"D<\3ES60&UN<#Q$'W=>(6\).YO@[><7PM(\^&G;45O+S">!UV<M/)%8
MQPKOR57S)N\.3CE.`L1W/SSWCNO#PVVWMNVTMNFY8+Y+YM&X@^"KR4ZG(WU&
M]I7A[D^U6ZF=3OF;R-\%\+]HIN,5`\R/.'E54>#_`#.\R]VX2WB-PAOG:[U+
M;GMA$S<S*?2DTF7X7$N%]1,SZ@]&&J%`TXG-30:,).K3>D$M":T<5SI!<^6#
MD./A7(=*"-QQ#W4S)@<OECE@.>-C#7'QPN&"$_5;;2X-BL.$XF8T78NYTO\`
M':"*$GJ#Y>QP(^ZW:JBBC'%5?6S``0!>QI14#(F>(0>.(1<*^`(=MH'C41:]
M`H%!XSC2/.!O+R#OC>G#:,J)&^]RW?>W"1$<GOC<-U!W;<=VVVTV^&VV-C;6
M_+0:_%3X>J6O0YH'AI<DX8VBZ*6^WVTKGRS/N2,2\EI.F-V:;5#``+%V#91X
M,J%'5FJXYV%6KE\@K%OY3;;XQE-;>>/*@(T^$>0C>+LHC2W;IG1TI./:?[HT
MEQSHD:\7S^Y4>`M1,3SHFDYME%MR[F2E95<B?%0*4<.`(R!@(?,\+C@&1PK@
M"J-N;9/J>AOA%;?"SRH;CYYZ_(LUR;V\R=TX-Y-(]AQA\E^[>=N&_.&N2;?7
M#>U"WMPAN6\!=PW0:I?_`,8=N+X6S^:$-$&.F34%*3`TOP3J\:FC^($^*RK,
M?8;@GF(W[&B"FRC+!N2UI&D05LM-YG$=.R*M]KAC"&<#9[(84*V52EV]).B?
M#4E64&.BK.H.?D,Y))737"4`,D)J0A9I$8W9;*EZ,9U>)%YDLYA=V,D/]SKL
M6HZ4.JD33>22H9+(<LEVN,)AD+Q"ZW;\.WSIU*+6H;E@WCPOK)T_:MO-#D_W
MUO?D*TJKVF7D_P"'_/<ONOG3PWPWPKO+'>.Y;SWF8VV^L1?%*%5OA%+HS(26
MNW-4J@UU1'TLM[3/9:)1:<L5622-J;*:AU11<2<FRRCJ9YH/),`&:ZN@%U(F
M(:3S0PG"...>1:ZB_3,?0QI"6=&[1EIGG9!9;X2I.F9QS41(LB'L8;1&4L/1
M'0";H;**@%I!?2?=I!*2%B*D%\+%QDXH)O<84[GC8Q>I,VSAHA0*!0*!0*!0
M*!0*!0*#G.^/YI+U-ZH^R;V<F@FNOS&Y=_/'A%W-IJ[P\YN1KS>W'SA4T[?^
M^O-\]MMQV^Y;G;;[&WQV==;YH^/\I<Y_X2_Q-N:%M=+D:^TU:OLO_/\`(_"7
M^)MS0MKI<C7VFI?8_P"?Y'X2_P`3;FA;72Y&OM-2^Q_S_(_"7^)MS0MKI<C7
MVFI?8_Y_D?A+_$VYH6UTN1K[34OL?\_R/PE_B;<T+:Z7(U]IJ7V/^?Y'X2_Q
M-N:%M=+D:^TU+['_`#_(_"7^)MS0MKI<C7VFI?8_Y_D]-8^$!\45"43"4I0X
MV`3I7<=V#PF&,AL<=W`",A[`@3HRPRV0AL;_`"7^39V*7VD^'Y/,_"7^)MS0
MMKI<C7VFI?8_Y_D?A+_$VYH6UTN1K[34OL?\_P`C\)?XFW-"VNER-?::E]C_
M`)_D?A+_`!-N:%M=+D:^TU+['_/\C\)?XFW-"VNER-?::E]C_G^3J"^';$LG
M09HYA^+)C2"R#)#7Y0/.-))JZ:O%RG#<I/=Q)&YJJ.9.)QK=T%7*B7W,3+:9
M9WPRV,L<K6OZN?:KFIX9K496%%7^/4'_`)I_<RC4[>):CS"O:K)0*!0*!0*!
M064TO\#25_1VU_QYZI/GJU'B5:U62@4"@4"@4"@LIP_]-X]_I#F_O42I'F6O
MXPK6JR4"@4"@4"@4'__7[PW:?D8F(1LQ6JRG&$)@/=2S=K_764(4$QR"WMB1
M"1XU?V*A@-C?.XF0F9:X=\<;6MGMKWQ"'\.:A.;"&NG9[^[G1>#AS4)S80UT
M[/?W<Z'!PYJ$YL(:Z=GO[N=#@X<U"<V$-=.SW]W.AP<.:A.;"&NG9[^[G0X.
M'-0G-A#73L]_=SH</D(NJ?%`',<M&,.W##.*!'+;SH]\+[NF'S*::M:U].GR
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MA#73L]_=SH<*]?F<J*W!7G6Q8:3-[[^WA_\`Z$=Y+=]UWGOK_;:;A-TW/<P_
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M&3@IR>K,-=Y)T>[52^V#X9."G)ZLPUWDG1[M5+[8/AE(6H6?B>OD#:`SX:.J
MP6^MZ%>T6[#.Z[H2,!#_`,B%ILPSSVA;//+Y+VV-C9_-4F>U<PL:WPCW!3D]
M68:[R3H]VJK?;"?#)P4Y/5F&N\DZ/=JI?;!\,G!3D]68:[R3H]VJE]L'PR<%
M.3U9AKO).CW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,G!3D]68:[R3H]VJE]L'PR
M<%.3U9AKO).CW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,I*D@/\`+H;E*I[.AH=+
M/!IMELSVBG8+O/``<?,E?=L=-F.!?=A<LK?K6OMMC8M4OM<<+&O-(UP4Y/5F
M&N\DZ/=JJWVPGPR<%.3U9AKO).CW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,G!3D
M]68:[R3H]VJE]L'PR<%.3U9AKO).CW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,G!
M3D]68:[R3H]VJE]L'PR<%.3U9AKO).CW:J7VP?#*2J`#_&;;>)'&=#02*3$4
M[HYOM%.S#?68YK(0];=\M-EPQ]Q,7OC^K:VU_)>I?:YXY7XUZ1K@IR>K,-=Y
M)T>[55OMA/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X9."G)ZLP
MUWDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X9."G)Z
MLPUWDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&7__0[V7"N712Y/`L4NHJZP>X
M)04W=K%0CRID2.J.T-'L@Q<"!`JGIQ@R8&V@F>(`&>Y!##7#!$"KB<P-T\;F
M-.+/I"&/Z?SI1-EXN&PWCLM,^=CMNRL7+AY9J6-G#NK"=9`_;)+W[C_O&X7O
M8S@(#@.5G`8N(R`"8!64+($<(,8+*[:4L+Y!BX6SPRO@(Y\<\+WQRM\F5K7M
M^>U$Y?KO=S<;H7[NJ'M30Y1]TN$TRT%0<SE<:(GHB7B7R/',&@O*&0.)HV`2
M`O8FFKYP\-MS)G#'^3#RO;9V;[%K7O8<OSP<HHCN,L3!SH5W63;9%W&4KS27
M;;FWE)34$8DH;^NX+)N>[*248#W+$:X^.Y[;+"V.6.5R\I)O=S<;H7[NJ'M3
M1.4?9P"_8B-D,IHXA>SG>&[!!(9T$83&SP7-TL&/FX1\`LL[[.UO<//:_GME
M^>R0GM12@^<V;+$"ID\='"*DR1<8V;,CYV#!+EBX>0PXXPF6QC@$"%A?+*]_
MDM:U!1D,ZIM.&HDRMDH*G",98/MHDDJ3@3V*\$5P**.F+P8@J&J*">0-"G"R
M8L8`YW+&,L+`C[6^TROL7HLQ,>5YB&RH1@N4%,EPS1O$;(H6$&#P,&<2V.&1
MC(N#EE80;$OB)C?.^-K[2V5MG8V;41]%!6TBR]'$3M@X\GZZ"J*W4]V,)C'S
MP!137123KD][->.V,CFTYO$E93+C+KP>B85MGF#8(O@:L./F$7P$%P%6LF@K
M-+F&.5J67?!J8XM\RDPV:SY!=C7X(70>"F@_5)RI#35^&S"8$W3W"R@SU$/>
MY8V,:`WOMA@P\1`KYEKB_HLRB%`H/G-FRQ`J9/'1PBI,D7&-FS(^=@P2Y8N'
MD,..,)EL8X!`A87RRO?Y+6M0>`RGJTI':3<?K"<:.[V6[T<BX&NZ&^>`4D1?
M1%(#$RGJJ4H%LLRYPB<+YVS#$PO?'+&^S:@D]`H%`H%`H%`H%`H-;'Q"]4S6
MTT\D/G,@J:WYZ^?^\N#C9,KO;S<\RM\[MOO_`$]VX>#VNU_)M+[/Y;5T_P`<
M3-L=YJN&MC\4R+/4-S?ULC_-7326+]'XID6>H;F_K9'^:FDE^C\4R+/4-S?U
MLC_-322_1^*9%GJ&YOZV1_FII)?H_%,BSU#<W];(_P`U-)+]'XID6>H;F_K9
M'^:FDE^C\4R+/4-S?ULC_-322_1^*9%GJ&YOZV1_FII)?I)7A\6F)W*XE%;`
MCQU%@CN]-J`*L(N8F&]B)4IEMLL+;6^VR`O>W\%ZD=)B*)[7/A&OQ3(L]0W-
M_6R/\U722_1^*9%GJ&YOZV1_FII)?H_%,BSU#<W];(_S4TDOT?BF19ZAN;^M
MD?YJ:27Z/Q3(L]0W-_6R/\U-)+],\X7E-*FJ-&U)J(0-)B8Y>&-[$3@H(YD#
M@9?56^-N@I?^2RW0PE9YVV/R8Y6M?Y=FLS%32PM*H+"BK_'J#_S3^YE&IV\2
MU'F%>U62@4"@4"@4"@LII?X&DK^CMK_CSU2?/5J/$JUJLE`H%`H%`H%!93A_
MZ;Q[_2'-_>HE2/,M?QA6M5DH%`H%`H%`H/_1[O7=_B"+O_WVH?\`_,I%JQXD
MPU23)\.:4I+U'ZFI623T1-Y$FDH[C*6[\5U[AR6N$US0^G:74>'7VC)[3*H!
M6,TB4$\L_-_8J:R9Q/)1+$NG@#6%&R6MJ;FS1=J*CLI+CZ+!,^0O/8T?;QY7
M33<I/9>DM#D*9(#<;:;>H&/4]C+8>,&:>&?'2P@XXHX3D.'6XKCVL1(!#JF)
MI`^'37\/:33:>TGR0*X,=O`QG(;(:J*NKJK'#CB1TA*VHQMN$-EL93TYW7SL
M#S<OR""X2Y2RFR5#!''*"J)-4-E">0=LX9DMC0@YFAIZF^#&^H,5'3I"<<%N
M]FIR>=<(+<;[HCUG0D6?J\9"LC6'(*;LD.,SRUNI4(7(X;-XFS.U-#F+VEHQ
MM5?AH3RHH3S3S"C#)]<5'6R5=VNSSU<)5P:NTQNRI)SX4,=0QA?@E]$&<;R2
M'NG!%BURD@)N!A%"!P!+D]R"`6MLPH'TINF%953'FZ2;'?R2AQZS&\D3.^I+
M<Z[.4<-UHPPS(Z48@(9Y1J@(+SCHXZFL?=0ZV?4TT<PIKQP45(Q'QP,W6C.I
MI6RNC7&O@)A@<6'*HEMU#S"S$)*;D5E`@/<(7'`4.Q@D9#$M;*ULK6RMLVM?
MY*2D)+44H(C(``QEAO8L6!%,&##1<@````>8HPXPJ,=#"!!"#MEF(*)GE:V.
M-K7O>]]BU"/,./Z*F]J[RB4`S$B-J*=X[<T&Z$HGE22%S3M,<(21`#,BR3F8
M'.VDV&04!(B%TSONK-6%E7-JK9SNZ<D]'WJ46C!DV0SQCIQ]<LU&=$)<M)FA
M^3).<^IN>V*RI=U5(C>=K;9^O".@XY%<:/&#TA:+E`B^'&<E9780+Q)JJ>77
MG.;/(Y\#:I*D<%*$K`ADOR]/0X_M6#JG%^<GQ&1H05Y:T^M=Q)[5U51[\0"8
MXD8DR-V4%<_)#7=+BG5[1]9R2F18"Z6+&E!JJ#?;0IBV`)4N:WGGCD)JO_XA
M$FZ75<FK_$Z9IM`GHE,<PZO="K^1G4Q!=00C268O=4XZ*'#(TC1.,N*+NC)/
M663("<O#A"!YG%MJ)J9<I;(-((XAX,K$_P#E+)@3I1BUIS%IV(LS5FZHT-:X
M)608GD`Z_->LE&([9A?1W!SE:*;OR$W.<FV4$-\S:]%T%##4EW%M$E\(T,,+
MB,4#Q#)'TF_HJMI/2:,FFNRF]8GU'OA4?^@CX5\32PZ%),U31T]$R06O*LIH
M4_NEVJT2-XMJ"7LF0Y"9@TXR*!C<^N)QNULQ+IZANXA<?JC2@Z=0I/3]"*D;
M-:KI+=D)3AJR22&E1=8OQ&XT,SNSEN9T-4A7@J9F@8,R:RW<THO72`3/+R(I
MKZ?BGJ9DJ<&P,II[+`<7++64#6J=KZI];J3I^#F&8Y"D>%]12I%KU5R6JUA)
M^EYY(46,RS$CA/27X/V193;+Z="8",RU)O%\%@LK&QQ#60I:YL0(D546QV94
M>3LZH\CME(TYZOCZ$_-8.A<K(S52&;KHB%\PNA*+<F1#G84:6-0SE=[N/6=H
MJ>G".;%#6<T9OJ10,YA8K=2*"9B:PGT:15J&C9]QHZ45RZQ%(1+^(5KP@`%+
M><FSV]VJE:06RQM07(Z1.-MV+BLB*K;'74Y'-);M503JN<.Y%+!*>>.!,,,O
M'[*)4)+U+D([T4<,,/5XUY7AR%]`3L79"!*ZZ7LIR,@C2F25]1Q=494<V$@=
M$.L]DY'RKM'?)95<[B!%"3@".5@B0P8XN<.M4(3`8,,4.^V#%PP$#RV+VVV&
M>-LL;[&5K96V<;_GMLU7-_=`H%`H%`H%`H%!RQ_]R[(?F%V*OY?<>%>T=_\`
M-?';;QY!OX]KOS_UK?2:M)Z[.6/M#?MU_"W^>M[II)VAOVZ_A;_/3<TD[0W[
M=?PM_GIN:2=H;]NOX6_STW-).T-^W7\+?YZ;FDG:&_;K^%O\]-S23M#?MU_"
MW^>FYI)VAOVZ_A;_`#TW-).T-^W7\+?YZ;FDG:&_;K^%O\]-S23M#?MU_"W^
M>FYI)VAOVZ_A;_/3<TD[0W[=?PM_GIN:2=H;]NOX6_STW-)=D?PJ'#YUZ"('
M7]TW7?\`RH?K[.VVV]9FD0E^7\^QO;8I=\LS%338941845?X]0?^:?W,HU.W
MB6H\PKVJR4"@4"@4"@4%E-+_``-)7]';7_'GJD^>K4>)5K59*!0*!0*!0*"R
MG#_TWCW^D.;^]1*D>9:_C"M:K)0*!0*!0*!0?__2[9Y2'AAD+L86>"TPF?B.
M[%0[>SH<J.WKCIH##>1$4T%BKJ1/(8L`J*)0+//#9MB*.'C>]KY6M>Q/E-?1
MRHZ3>=B#.DUF^T%2S7T<J.DWG8@SI-9OM!2S7T<J.DWG8@SI-9OM!2S7T<J.
MDWG8@SI-9OM!2S7T<J.DWG8@SI-9OM!2S7T_W&4M)N.>&?*M!&=PQ`Q<+"R0
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M$^"`MWW#8W3>X>WV=KAL:ZS$7;,QV^EL7>0G0MZBZ'OX]-GVJM7U2N_LY"="
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M2X>0$)/WZ<,*)S>*0DN0HGE-]J!L4<7<P\=T&%SSRV<LKWNVZY37MA[_`)[Q
MSSLPUTQQ?[6TVC)KVPF4?R9%*([DE45)@AHJ1*[_`-W'Y7HU&VF[)ATN%_)%
MW0*-EMAA<;?)C?8V=F_R;-ZD]HF/*QUF_"&^>\<\[,-=,<7^UM7:,IKVP>>\
M<\[,-=,<7^UM-HR:]L'GO'/.S#73'%_M;3:,FO;!Y[QSSLPUTQQ?[6TVC)KV
MP>>\<\[,-=,<7^UM-HR:]L'GO'/.S#73'%_M;3:,FO;!Y[QSSLPUTQQ?[6TV
MC)KVP>>\<\[,-=,<7^UM-HR:]L)PW9/B@BU'PFFIAAH(ZL`H>"<#RNQMGOC(
MF;-"F+;H&Z,P@=SP$QO_`"F6.SL_)LU)F+CE8ZS4\(/Y[QSSLPUTQQ?[6U=H
MRFO;!Y[QSSLPUTQQ?[6TVC)KVP>>\<\[,-=,<7^UM-HR:]L'GO'/.S#73'%_
MM;3:,FO;!Y[QSSLPUTQQ?[6TVC)KVP>>\<\[,-=,<7^UM-HR:]L'GO'/.S#7
M3'%_M;3:,FO;!Y[QSSLPUTQQ?[6TVC)KVPG"S)\4&V2SD@O,,-"**4,NYGR_
M*[&V.X8G%#,<M?=<W1B`+N@5[7_4RRV/R7V+U+BYY76:B*0?SWCGG9AKICB_
MVMJ[1E->V#SWCGG9AKICB_VMIM&37M@\]XYYV8:Z8XO]K:;1DU[8//>.>=F&
MNF.+_:VFT9->V#SWCGG9AKICB_VMIM&37M@\]XYYV8:Z8XO]K:;1DU[8//>.
M>=F&NF.+_:VFT9->V#SWCGG9AKICB_VMIM&37MA__]/OL4%`DE$C2BHF0RA$
MF#F.9,"WO;`(+"VS>^Q:U\LLKW^3''&U\LLKVM:U[WM:@_+%4+98XY6"4;6R
MM;*VV2%;#+8O;9MML<B5LL;_`/QM>UKVHEOZX2+_`/MG_P"JE3['0LX2+_\`
MMG_ZJ5/L="SA(O\`^V?_`*J5/L="SA(O_P"V?_JI4^QT+.$B_P#[9_\`JI4^
MQT+1YI*`0J>8PVIV^63E>&&.0B>HX8VMYWKF.%LA1"V(>&..-K6^6]K8VML?
M)L59(E,*BE`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!2,R/E19?FYO!;*HW
M"7"^Z[YQ3<M\[SX+W/:<(@B[&X[ZRV=IL?Z5MG\U:ZQ=\,]IJE(\N3B]=DKP
M;:^R5O6,,[3DY<G%Z[)7@VU]DIK&#:<G+DXO79*\&VOLE-8P;3DY<G%Z[)7@
MVU]DIK&#:<G+DXO79*\&VOLE-8P;3DY<G%Z[)7@VU]DIK&#:<G+DXO79*\&V
MOLE-8P;3DY<G%Z[)7@VU]DIK&#:<I@_9@4$=V*R<D/%(`3B^\=[A89H!C''=
MDTF.+L##@C"Y[8<7*_RY7V-G8M\EMBI'6X\+,S:'\N3B]=DKP;:^R5=8PFTY
M>B%+3X'#P&`<08P0EML&*$G(@@>>/_U89X)]\<K?PVO4UC!M.7Z<JK]X^_LM
M&\G4UC"W.3E5?O'W]EHWDZFL8+G)RJOWC[^RT;R=36,%SDY57[Q]_9:-Y.IK
M&"YR<JK]X^_LM&\G4UC!<Y3*/Y`=RV[DE+5%;?1$UO\`W<#>"8#M]Q3#I@+^
M5+D@AL=J,%C?Y,K;.QL7^39M4F(B")FT-Y57[Q]_9:-Y.JZQ@N<G*J_>/O[+
M1O)U-8P7.3E5?O'W]EHWDZFL8+G)RJOWC[^RT;R=36,%SDY57[Q]_9:-Y.IK
M&"YR<JK]X^_LM&\G4UC!<Y.55^\??V6C>3J:Q@N<G*J_>/O[+1O)U-8P7.4X
M;K]=AYJ/A2-*NZG4<%#S3AMXIN&]\CALT$8ON89/`(;=,`\;?RF.6QL?)L5)
MB+A8F:E!^55^\??V6C>3JNL82YR<JK]X^_LM&\G4UC!<Y.55^\??V6C>3J:Q
M@N<G*J_>/O[+1O)U-8P7.3E5?O'W]EHWDZFL8+G)RJOWC[^RT;R=36,%SDY5
M7[Q]_9:-Y.IK&"YR<JK]X^_LM&\G4UC!<Y3A9?KL*,EG*Y=5W-151EW`^8WB
MFY;OB34,P"UMRS)Y`!;F%:UOU,<=G\M]F]2HN5N:B4'Y57[Q]_9:-Y.JZQA+
MG)RJOWC[^RT;R=36,%SDY57[Q]_9:-Y.IK&"YR<JK]X^_LM&\G4UC!<Y.55^
M\??V6C>3J:Q@N<G*J_>/O[+1O)U-8P7.3E5?O'W]EHWDZFL8+G)RJOWC[^RT
M;R=36,%SE__4[O'CCB(MQB`):V8(S\,9"@YVMD$+D4CY^J!6X@>6SAG<L?)A
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MUJ`+2`#@J2.TG#`9QLK3-94DQ@(X&Q(#9@J1G>WB26TY``=P!YL*#I743?Y!
M;POB"7#L<!%R!-!F0QD6]6VL$B;D&4B*&8!>0@L=1Z]&0+#+RNDZ6FV:FB74
MLZ<52"PY48O*2]9N)*1D*MAG"26+BK8*(>'!N(0=W"LZ]/,[S\_I50FW,YAN
MQNI<GS&.F8D28?D)7*OG):AIEOAS2RVIC,J95(9C?3I175AL!(RL2&,860<@
MQ<[&S8.5G",ZVG_^EFO_`-RO3_\`F*[24A):BE!#9&Q?&<>OO",1$8&2<V:Z
M,8]&<=A+MX)\9(AZS3$7;!!BBW1L%ZY>YK:XY9;A;+8M>_R4&CF"M6TCLMBI
MC.E:8-51K5D1GO0)&,^0K/3?@)IGV.+,D]H,7O9ZQ"KM"#C#8?,"2H87C0.!
M@B:/F\"":$$14D0^-<W>-S'KAZVI;7?/4H_#]U"ZF8VCXO!,($[XX0Y.*=-Z
MF+-ZY@S]3$>QJ<5U>)DJ+TY+8#>>B0&OYA"AO%4/AERN(1@EA8Y;(,E1<1]7
MOOC7PYI/%T)Z@6F6<$9Z<)#U82X313B6\C"DN3M`D>Z;YZ7+NQZL@FBI0353
MUIVLG(^EH)@ZI'+@%"ADWO,UGD3`6NOF/JR+T)?$6-:S70J-Q1A7.-`AXD:$
MU,];2'FX7^D'FPZU4TFB-%ZJ"O%,9IK3E5NA9D#)U*33#B3;@'[9%U,?<1-A
M:3UKZH;!5]0.LEUZGY(,ZLY8@YOQ/JSF+3O%<80P@0F(UTA%T]._!GFW%((\
MDQ3(+B>B_(JPF#G3A>YTD3*)YG`N7PPO_*T)J*X4B]_BNGI+`U(1JP(Q4VRB
MEH]UP->,)M;3Z<:B[$I\:9V*_!,G:ZFGA%J*VF"W'.KLM3R;:@4=ZP>$,$`L
M3)0IF.':RS6F0N@*59)?\^:L$![/AS.E$:<5:!%5LI:XK&U`BA*3_P!.&;D>
MQY,+F!,PRAETK]M^'L\+6N8,?KY[.7RU4EAL=U(ZQ6CI`F37OAJD>+N&A'51
M-#74M-SFC73J#%#YB=A:J5F%R#`0EQLQ`TIB0GH8:&(-TU2$=)_(RL!!8#`B
M8#Y6M&JBZI?;T^)DYX6'R`<#)2UU`<FL35)!8TMSA*Q>(X5B9/AY=0B30;[D
MDE@Z='6GM\\_N&12[8*.`IA8:Z>:X0<.>0=A<B5:PROQ0TY6U=*&G1OQ!PXP
M$.<36GMQ2H4?"QYT(KS3&'D[5QW&HWQC`5K`1(@K=\4,RL&'F64;'+W&P3,R
MNYC"+->+5DE?%T6#S-U*+Q>!F*^U>`V#"4DD<H(GYR3-'SF:DPR@Y8R4%-:?
M*7IV0E=+(Q9=K&EA?--M!>A.R0"*,3&-7"SQI9KXY?U+'Q?RT=-V*3+8BB-Y
ME=#X@MY:B'`6B>?7$\&"(Q&P^C+&2F]##_1-/BB=EF3W:=2S]BR0J(K.*E#9
M`4F</%S&TMDLCKY;D6\MDG,@(;D3L#8:>X$=,6R&!\H.0/8$E4D`?*X'2!G`
M,R2-X@&,;"`B8XYAY[..5K7M>JR]B@4"@4"@4"@4'-]_W!<A68G9'V1]QX5Y
M>_\`YMKMMX\B_P##;9V-^?\`K77_`!S6SGWB9JG-]V@\?'OYRW^M76X8UD[0
M>/CW\Y;_`%J7!K)V@\?'OYRW^M2X-9.T'CX]_.6_UJ7!K)V@\?'OYRW^M2X-
M9.T'CX]_.6_UJ7!K)V@\?'OYRW^M2X-9.T'CX]_.6_UJ7!K)V@\?'OYRW^M2
MX-9.T'CX]_.6_P!:EP:RZTM$BQYP:4(,6MOM^$605,;?9V=MMCAW'9V?S_Z-
M<Y\RU'#*>H%`H%`H+"BK_'J#_P`T_N91J=O$M1YA7M5DH%`H%`H%`H+*:7^!
MI*_H[:_X\]4GSU:CQ*M:K)0*!0*!0*!064X?^F\>_P!(<W]ZB5(\RU_&%:U6
M2@4"@4"@4"@__]7N3=A-[V7HQV[A:N65WP?L%?%FJ^&.`G)M(5[Y"8W?>=Q<
M+A6RMM;7POMKVOL[%KXY:BN>/HG.4XWF^_6-I?N4L>W]3C"\H:^XR.26@^;3
MU-M!82L%)+6B>YM=U)*FDKB(="445>05Y%DI.76\O)!X'$4L>(F2YH#.VS@)
MCLWV5Q@Y?JQHX4(V;1-H,HZT$5ODCBVI!$_-9T*(XZHY5Q2<[C5U%35I)/JJ
MLL+[C6#9\Z;-#C&31LR(*+GEGGEE=Q@2W>;[]8VE^Y2Q[?4XP<F\WWZQM+]R
MECV^IQ@?P*FO<P'D`*ZD`L$-;<Q3"6T#I=2!"S_5$$(&%!WJQ$`YCA>^Y9C%
M3`>&>Q?(/.UKXW<8.7M(B7=&3\4_=]\XAFU(8(6^`F(FX'5(V=+AF!!AS1@X
M;``,8X#&11,A38N.0PGZXF5J@]:@4'B.5"+.EN.!LG#BPG$W&B*J$:4&\KGV
M^OD2RN0'3QSB&O)0Y541%@L$8OF6.%A0S!8;'$0/+'/&U[!A6A_#M@9/6#+K
M<:Y,DGOTRZ=/[FRD25Y7<C\>@`&F202DI1*TR*JKYY@I[02WX`*I'B@`(>:J
M:-CB&Q11,[9XEN4>.?##TTF&_);$)*4VHD3RB>4U96A-(FQ^`PPW5I<D)&E-
M=5V/&QM3.-IJ&U5\HV_;X%P=[E<C9K`J&7P'SQN+E,T_X?.G!*>Q-X)R,YBJ
M>E36O:@D../.4P8BQO2:\6&[X^?RD@,DX`8()*-("4^#YM72@<L4TPIB7-8`
MAYYB[HHVE.]/FDJ.],V6\8R=LS9LM/;WFDS8P>4O/5[QM'+8P4L%$HBL9KN-
M2/!)I=+Q!#*$A3`ALR13P[%"XH9>^8>0F;09?T#PTIR1($F-AW3S$JA+B\G.
MJ66Q#,Y2!&C%D5TD"B<FC.A>:[;52Q,@Y%U*22Q54/I5TXVJ`A6WR(+G?+.X
MOZ/U+Z"813E.7A$%9EYM,Z<<)3,2!$B#+#M)P^=<$TH:@A2.[$^/\S@Z.EKC
M@Q53)R^(5K$`50;(Z&6Q,[`EA:V(ATU1A"#ND%[,0JLEUV36_$3:=(BFKBJ)
M85+A%E78#$P)%Q`\,28Q=O9;4SG:][F1?U[[%_DH7;'5L?#*TT-YP"*A\U,C
MT;6$O+$[IL2/2:7\JPBDRFMO-3D,TZ`HC**R:QU<8!YJN:B6"5"B@`6-X8"A
MX8B8[:ZC:4FD'X?D'22V'8QUE?FA)8\AOR7'[)C,9\O.]H-F2S$X*B.JR&W7
MTDH)LD67FRHB(N`)4+.V)I.+&3014P%B;,6$%O<$T,0@%(+R?J"<E)F$Y+'`
M.RC&C)E9ZM>))*50&>"PKK3N8*6J`I8ZL>:),J2.C%;E;J.!,OD;L.(%AG87
M*JV'\,2"XQOD984G:JVTKVCAG1*57R.I:3<EE-CN.'`$X(X:269-*I@%/;S$
MSR-E2!`,/$CD24SP9@$>YH7+*4NTO<(?#7TWMQ'CDI'QJ8(M=,:)T@(Z=*,<
MS&^6Y*;H2I7=IF0)((2*\K*9HV_R[L?QO-:SX3P,9$%#8S(7*8VVE6DVEG<D
MIP2.E)J0`84#8"6GDTX$TK*)Q753(1$L&6#,*2LHC&5!44!L`K9#&!Q!!AQ+
MWSSRRRRO>Y'H4"@4"@4"@4"@TB_&1^':H:^.SEO&;^1KDHY7MU__`*XO('G'
MY]<E^T_(_61P3P/YG7\:W??7_P"'N?\`*:ZWS4FT1YBVD7_QW'!_G>OW<LNO
MJM5.?V3>/Q_K['_CN.#_`#O7[N677U2IS^QO'X_U]C_QW'!_G>OW<LNOJE3G
M]C>/Q_K['_CN.#_.]?NY9=?5*G/[&\?C_7V/_'<<'^=Z_=RRZ^J5.?V-X_'^
MOL?^.XX/\[U^[EEU]4J<_L;Q^/\`7V/_`!W'!_G>OW<LNOJE3G]C>/Q_K['_
M`([C@_SO7[N677U2IS^QO'X_U]DA=?\`VWS@;"^?0^W3<]O'>O\`O79KR+;K
MODD7.?[#M`&-IM-\;7_3OL[&S\FSL6D7,7:SVB)_\H]_X[C@_P`[U^[EEU]5
M:G/[)O'X_P!?9OVTS0P-IX@6+X3,.KSW&CAL`-T1V<"^;G#N0)DR8W]P'=77
MN#=M8QM=SWX8V-KL[?Y=BU8F;F97K1"@4"@4%A15_CU!_P":?W,HU.WB6H\P
MKVJR4"@4"@4"@4%E-+_`TE?T=M?\>>J3YZM1XE6M5DH%`H%`H%`H+*</_3>/
M?Z0YO[U$J1YEK^,*UJLE`H%`H%`H%!__UN[EZ-9SN(RBF6\\@FIDCC&3>.Z-
M5)<>>9X<J,0#.%Q5(4/(B*$0.&`;[G_IACY6O0_LC/F3+W/=]VK8^UT6XP>9
M,O<]WW:MC[70N,'F3+W/=]VK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[7
M0N,'F3+W/=]VK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3+W/=]
MVK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3+W/=]VK8^UT+C!YD
MR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3+W/=]VK8^UT+C!YDR]SW?=JV/M=
M"XP>9,O<]WW:MC[70N,'F3+W/=]VK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW
M:MC[70N,'F3+W/=]VK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3
M+W/=]VK8^UT+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3+W/=]VK8^UT
M+C!YDR]SW?=JV/M="XP>9,O<]WW:MC[70N,'F3+W/=]VK8^UT+C!YDR]SW?=
MJV/M="XPKQ^(3N2>"O.N6>$]\;^WA_\`U0T3NX;EO/?7^V4`]SW3=`_R;.SM
M?E_)5B)^DI,]?K"O=RQYQ?N:97E2K7;*7TP;ECSB_<TRO*E*[9+Z8-RQYQ?N
M:97E2E=LE],&Y8\XOW-,KRI2NV2^F#<L><7[FF5Y4I7;)?3!N6/.+]S3*\J4
MKMDOI@W+'G%^YIE>5*5VR7TP;ECSB_<TRO*E*[9+Z82%UIRLGKY\HOR?OU6"
MWKOLUR0LXSNNZ$BXH'\L*I89Y[0MGAC\MK;&QL?FI$=JXDF>M\PCVY8\XOW-
M,KRI2NV2^F#<L><7[FF5Y4I7;)?3!N6/.+]S3*\J4KMDOI@W+'G%^YIE>5*5
MVR7TP;ECSB_<TRO*E*[9+Z8-RQYQ?N:97E2E=LE],&Y8\XOW-,KRI2NV2^F$
MA:B<K*"^0*($G[R5A=];T-<D+.+;EN9(P*/_`"P2EGGAMRV&>/R6OL[.Q^>D
MQVKF2)ZWQ"/;ECSB_<TRO*E*[9+Z8-RQYQ?N:97E2E=LE],&Y8\XOW-,KRI2
MNV2^F#<L><7[FF5Y4I7;)?3!N6/.+]S3*\J4KMDOI@W+'G%^YIE>5*5VR7TP
M;ECSB_<TRO*E*[9+Z8-RQYQ?N:97E2E=LE],)*DIBR80W*:3Y0W!+(AIMULM
MR0LX+?F`XX^!*VXXJ66!C<1<<K_K7MM=G9M2NUQRL3UYJ$:W+'G%^YIE>5*5
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MQ3+/@I&SOGFJ&`C-B28IV(6&NN*IIUN/"=HC<4)?$MCCXA4#FF\_E&:6^R4S
M3=!\@P2(11@^`GBN1V$=0WK(3=!7C.[V#X*OB.2*&2^\0112ABG]C^RQ]%'Q
MR8JSTIZ<G5K*<DAF9'?SB>C/E";$&$U5-@EB.S*37P68K9>;T1$I+:"4N&8V
M(IAW,LF!'102>5C1NP5LL\J43"VV9\7O3K"3GEQ`U+:G'&_=^:H=1T:,4V7T
MYC,1/C$M!Q-K'UR*C(S65G*H2"82?.TD63ENY?`VNFS-@\2^.5K;*BEP*?QH
MM(Y-/3S"0U=2CU62S1SD"36>Q(%=;J=4`L;?@Q8!TSP131,R<>IQLJ!OW$,0
MP.;P("!#B@AXC@[HHILTC*3&%,K`:<I1>Z4IZQ^^$<LO-9T(HV0R<K)AK;6P
M&#W3`(<`<$7#,(<`;`,<N.'F$+A@)AEC:(G5`H%!YBTJET)&5EPW@,(41DP^
MJF@RV.&9@0NG%138^`&`H@(>0V08-[8VRSQQOEL;-[6^6@Q0*:VHF-L[1>^;
MHSZ*(FN<)L#Q3OU.;0!AK`NJ%%R>"(TF^E>11#"*,YOC@&<DT97L&H7PPQVX
M%\C&):\^E]B3%$82.4<(LIQP$@'V6HR017!'PV<$<[':0*E@*S]**>2I8D99
M:8,MDL#"IAGD1`R-@6S%QN*'MB*R>NL?2I'K<S=[MU"Q(GMD"2VK#AY;*O=#
M6R"1)KT5>!D!GKHR";4^`%,0S@**:N=L`"G$2QDX<S`*%C`X1:G#T4C4_#9S
M%^FE]Y-M@(S$D`W'F+D?;TCU&;SP/$8M:DPFUQG*1=X*&!I!`93KL8SW]B0/
MX!D#1C(K8CB`;'%)*LZ@X$;C=:KO<,WQ"A--][KYD.A9DIF);=>6X[G8;S56
MSRT`FN'<KBX[;>@HVUVUMG\MJ)2&-?6%I;>DAO"*FM/48+;\8;*:\CN=%)NI
M.N$48CP0U)SH;J(+(@H:"OHV;:2\U$V,GFC5DXB*6,'-P"-E<QBU.$V2Y^@A
M;:@C\19KB178X2SBW!7FER0SC[4"<.8.!C!"$<119%2,%G(N)B)8K<:P]\,K
M9;78O:]$I7"QJG9W*1IH9C`*%)::6I`]+A4G*T>NUL.%E,DI$K+/.D^L+!A-
M/'<U5'5%8E9$WR4RR`)*@X()C/#,8+#,M>5S,&4XQE9//J\72,PY)2DM0R25
M-38+O;[Q3TY4Q`!,Y)I\ZW5!1+$U#$L8#$N")EB);#/'+8V+VO<C7NU/BMQ`
MOIK9>SB@G5#&L(.^6%*%D+46]V7&QB&KOA.DA<B+'!<4F)+;W>+.0#\CH`R2
M`J+2*GD-\B!6%%#Q$QO4MK7WRS`3-4,,W0CKA>KT;,1D`)5DR'TV\JO:/&OD
MY'3%KU6F.LB-T8)X*1$^55#R)F9)E\A@E7`H*'8X3*&-T+AU*6+E*\6X/DQ&
M&4E,#&2RB9DM&H\R>+=L^2R/B5P/9*QAI74;+X*9B2$Q&N/D7L%8+*V>VVM[
M7HB-I>HG3\MMMTO)%G2'%=H,84H"]G6ER<R3[;9XQ\?>Q$)TKI1;%2V^*=,_
MR86)L4&XF?ZN.S?Y*%/K/SU!B6DLI>4YGB=.0Y)&WM'2R?D5GE$E_&-V+E]P
M92B86`R;I&W<V%AM2.8^6W%PML;.5K7"V*!0*!0*!0*#4%\5G5JZ-+?(-YMI
MC44?/KE1W[YSE%8UN/FQR=;WWCP6MHVY[IYPB;KM]TV=KAM=KL7VW7_'%VY]
MYF*IJ"_%KD_U8BG^J79[;UTT_5BYP?BUR?ZL13_5+L]MZ:?J7.#\6N3_`%8B
MG^J79[;TT_4N<'XM<G^K$4_U2[/;>FGZES@_%KD_U8BG^J79[;TT_4N<'XM<
MG^K$4_U2[/;>FGZES@_%KD_U8BG^J79[;TT_4N<'XM<G^K$4_P!4NSVWII^I
M<X>RX/C#2TY%<VM'FI$(1H[N&ZAE$9X8%\=[E02F&YXC/P<2VR&!:]]G._ZU
M[_DM\E(Z1'')/:9^CQOQ:Y/]6(I_JEV>V]-/U+G#<G`DB'Y9AV/Y'5`$\JH.
M]`!5S1=*#,`IP0H@XX5\2@9LT>,X!;`5MBV8HE]G\]8GB::6]4"@4"@4%A15
M_CU!_P":?W,HU.WB6H\PKVJR4"@4"@4"@4%E-+_`TE?T=M?\>>J3YZM1XE6M
M5DH%`H%`H%`H+*</_3>/?Z0YO[U$J1YEK^,*UJLE`H%`H%`H%!__T.V;5Z+-
M`>FZ5<-/9!64):.(A!,;>#>-I!)T$2"LOI"6\%QGCKPY9&\]&XR3:BH(V!G.
MP0JH6`PRMEMMK<,3]4Z+/S5T5H[>^'?$#?/'6*9;F)^$Y@898J6DR*=ZJI=_
ML+@*1!DHZ*]54ZI!*1L\H899*V8)O:C&C9K&XE7]6D`72J_]26K33%*.E[X7
MDG_#B4HM=AA\ZA9!6A@([93G:98L7$48S9S*2`D-%7!'83+'T?=DU-*9F0U;
M:GBUBE\Q`G]Q.'WH>U0G_P#MZH8TQ)D"N\?40BRLK.)P1<73T^SN*%AM0$L+
M@"L=#WYB!EEFT5<B-83=LL]ZBAX_DMM;/JOU5[I\T!:J$_7K!,AR!IX>0<<M
MGXE6N2;%MQ+9`@.D)C.>#<A8W%C[,Y9'1<[$U=S-,44@+M;B6,$MM>V-\;7O
M9F+E/I_9--0^C743!6MO6G(=X[^(E*L5:K5)+?D;+V@>;\XY".+XA9<X7CK4
M(DEM\&L4!#.N(0HEG3`(P!)-V^0`9FYHP$5A](;\_ANZ=UC2OHPA:%G"@F&B
MNH"8X%M998STQD'%EJ;V=JZ]#C7!=@24C%57))'7LL#&9<#>N_+C;B(*%M!<
MTI+.2H%`H(X\$PTM-)THQ&V&1U6;BVF$\1,[!AW-'TPT5+V$$O:]L,+BBVV;
M_FM\M!HU8WPFA(\:7PTU-FM0HA2S""4@D]3JT>EA^N9%P-F-)SXC)TF&FWG"
MYE9KBA<J2^7R"P221*V!/;;C8,"VYU*\-[?^E)H.@C74Z]/V,+O&)XW8^,8?
M"HGK0DR%$&8$QSG)&E9Y.R!%%*>`P)%%*$VI'J^F1F-D1WP*(I`9AB;]``N(
M#A=1M%W[9#R[\/20&]).HQXP3"L8#1X<?GPJI!B:)D%1:C&*N8KHME5V.J5F
ML5*FR!=MME34F>HE2!`P>R#+F\,L@Q!+887M<1/BYRGI;0H_7Q/3<?DHQJPE
M*-!/B)NS5BL,IQJ""YRR:S#?PZFE!C*R&2+EC*2HN%KS\VP,@@0[98@ADPCH
M>6UMC1+XXPUCRE#[HT"1VQL)60M+#F7'5IKUN0.W(TD^13R"HLNTEZJY:G!M
M.V($I,CB02LC'5N/7LF)IQLI!0FMB'"1,N")<#$6X1J[E=C1^'1J74H&>;`*
M1NT;7G_X=GPVV+BXW"X$YOAM.4-'K7%,O^$Y);BFCYO()$FW`R$A'#Q,H8#*
MD,Q[&\,1`\`KJ3:/W7V?T$2Y-DCOR4WMI]C*&V+)>H/00N+NFT1R,IV)IYCZ
M5U1[')!D%ZB-E-&92HL.=/>)9*3DPF)EOE(10;'L-TR#"`)<>+9_Z==.JS$D
M2:HX^7&6VQDF3Y\U./QH,=!5BR$C*[!E-6.&VVABGDLIB$U!5<@/<$;<PLLB
M-Q+Y;&5\=BJDSX5;\,F")_T],B2H_E%#-L^(4Q;9R?IO8KQ=$:/^76<S$=H%
MDQQ(S\D6*FTW&\\44HM`!@ML8Y<XM@)(-@SH^65L,<4$U+$IL:/-8SCT@(/P
M_73%K`94=+,_/-Z2K/!N6$Y>,\DROJ\<^I?@N/H]1FX<41WXNI2@41P\U$R5
M)D<\AC%\\LL0K5&KB[MXLT:'=5`*$16(@CC`?4`@ZFM>4E1/*123HOY.VDS-
M4>I@Y(91NS=%LEM1Q$9`CUY,8).,J@20'=PIAPAB"5OC<03.XB8SP_<30#J*
M;VJ65I%P:!^03RWJ-?VI^$Y4`E6,FQ$[:>#VB`S'Z>AS)'RQ'JO/:XDMC!3-
MH@B<E+YU'4F]8ML!E!@KX6%Q40HYDZ`=7:ZGSX/J&@=WNVTPPCI530R\?3[I
MJCQZ-R8]-TJK#IR6&#BS(S:$4M))3S[GNJM-/.)BJ6P2$[(HIG+&1\"V*C:.
M*2"1/AY:S912(:=.H5NC3,JKND]VZ:)JCZ%WYI^B17;`YN;7D_6ZZ,%1[1.M
ML$?-TL!>2";I,M$-#.%W"WP3I#$R%<+$`7'T='J$5%)(B.2'Q,8C%$I/*C8F
MSO"1K$4N4!"$Q,J.YA;_`#%L\+[<;:8[KELY;%MG8JL/5H%`H%`H%!S#_P#<
M>LN<'?V-N1F()6E;@[M#><G)C'KO??`.^^0W@?AOS41U7@KA3>QK>V[[GN^]
MA=IMMSSV-]9JRHGS+F&Y%]</^4'59W?)>]D*WM.$TZ_E!R+ZX?\`*#JL[ODO
M>R%-IP:=?R@Y%]</^4'59W?)>]D*;3@TZ_E!R+ZX?\H.JSN^2][(4VG!IU_*
M#D7UP_Y0=5G=\E[V0IM.#3K^4'(OKA_R@ZK.[Y+WLA3:<&G7\H.1?7#_`)0=
M5G=\E[V0IM.#3K^4'(OKA_R@ZK.[Y+WLA3:<&G7\H?2;@O760,"%#VCC5H2-
M!;7=2QO3K,1<P'M\,1,-T!&9V`F&W#SME;9M;9QO:_Y+U-Y-.OY/FY%]</\`
ME!U6=WR7O9"KM.#3K^4.RS00ENI%T=:?4I\-QP-!V$6"3`76TZD92;[B1CUC
MQ^^1-615<L44TXWCAEC>X8P6&=K7M?8^6IY8F*FF7E$*!0*!06%%7^/4'_FG
M]S*-3MXEJ/,*]JLE`H%`H%`H%!932_P-)7]';7_'GJD^>K4>)5K59*!0*!0*
M!0*"RG#_`--X]_I#F_O42I'F6OXPK6JR4"@4"@4"@4'_T>\-VO\`0F4(1"6"
M#U.9*&`X@%VE&LC/X,/$OD%B)8\,Q6JXPDS/*XUMSQ,Y!9"VME?"V5L<M@(?
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ML*%'+LR>(YE[N>H3JPH4<NS)XCF7NYZA.K"A2N9`?;.>O!.Y%9A3^#-_[;=-
M-6H8QNV_=Y;&QM8V!VFY[T_AV=M_!5B:9GK,JX]$_&)<[L.HCJ\K6_I-)/1/
MQB7.[#J(ZO*;^C23T3\8ESNPZB.KRF_HTD]$_&)<[L.HCJ\IOZ-)/1/QB7.[
M#J(ZO*;^C23T3\8ESNPZB.KRF_HTD]$_&)<[L.HCJ\IOZ-)/1/QB7.[#J(ZO
M*;^C24D=J\T7,X5!;PM+Q3`[O38+YZ9=0XV0>]B18I?9$M'(=LMO<OMOR6V-
MG8J1VJ*HGK,RC?HGXQ+G=AU$=7E7?T:2>B?C$N=V'41U>4W]&DGHGXQ+G=AU
M$=7E-_1I)Z)^,2YW8=1'5Y3?T:2>B?C$N=V'41U>4W]&DGHGXQ+G=AU$=7E-
M_1I)Z)^,2YW8=1'5Y3?T:2DC27FBV7"GK>=I>-X$M][)?#3+J'!R$WR2,E+;
M`EXY$MCM+F-M^2^SL;%2>UQ5$=9B4;]$_&)<[L.HCJ\J[^C23T3\8ESNPZB.
MKRF_HTD]$_&)<[L.HCJ\IOZ-)/1/QB7.[#J(ZO*;^C23T3\8ESNPZB.KRF_H
MTD]$_&)<[L.HCJ\IOZ-)/1/QB7.[#J(ZO*;^C23T3\8ESNPZB.KRF_HTE*$=
MQ-!+070C98R^-DX0TP/`Q;3-J'PQ*\'F!QKWR#O'.5Q=UL-L6V+X[&Q^>I/;
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M40`D`*,&&,<&"`%-"@E0\\K9F!0RH&8F6.%KWL'AEE?Y+7O0?10*!0*!0*!0
M*!0?B9,ER9<<V;'!*E"H(IDT:,BX`%RQ<##(4<<<<7+$,$$$/&^6665[8XXV
MO>]]B@_L,0,8,,8$3`4(7#$0(4/+',,0//&V6`@>>-[XYX9XWM>U[7O:]KT'
M]T"@4&%>L"?(W@_D[Y07H*T/.?SMX(W-/<9_A#@7S9W_`+/`":H[EO3A8'8W
M;:;;=?U=G8RV.G2)FZACM-5RPK[?&G#GG,_N_(WLU6].V&=HR=OC3ASSF?W?
MD;V:IIVP;1D[?&G#GG,_N_(WLU33M@VC)V^-.'/.9_=^1O9JFG;!M&3M\:<.
M><S^[\C>S5-.V#:,G;XTX<\YG]WY&]FJ:=L&T9.WQIPYYS/[OR-[-4T[8-HR
M=OC3ASSF?W?D;V:IIVP;1E+7W\0C2VJ.I5/(LU"YI@^\=[9!-:2BH=]R3B8(
MVU+BM4`0/8,!YVOLXVV;_+\MK[-2.G:O!/:+XE$NWQIPYYS/[OR-[-5=.V#:
M,LCFI()5\-Q(=C6<9]5;ZZ4Q/)2CB(J%+&RN>6>&(MBQ_`J<!V<L+VV!`\,O
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M_#+U%*<=/)Q1^\\E:`$E$>#37%9MKZ*(X=3$.-\X,264(V252F!E.4Q@![`B
MXW%+BB!Y;..>5KR?#77S#06S=;&JF;YV^%3'[@<\D,GLFZD(RT>ZM`\7*YTT
M.6=11MZO=O+I!SG@#94K(I9-CF!4Y44M^8BV!4'8,'EC>^6663#51$=I9^)G
MQ7YCFA@Z*60J)\'%UK61&GQ5`YR3&H4=(+D8"?I:;DL%H74F62,2,JFVKYX8
MLO/)1&6`E3!0S`,7([TVE[8+37S_`&8RZ#-1VJ[$SIZ@@C*+4-P"0^"6\-2;
M@CISM56.**ZM`2T]F`;4B;Y0W4W7H1D$91(EK!GKG14LL@X#@!)V"B+94P+,
M1S/UM92=\1C6@Q(.AYHZ>$W2JVV]&_P=F'\0)Y&9J+S8[7`?%;[H>;?<$=,M
M4,2N<5UKAY-:Q(L2S6C1D]B9,"Y#*`@@H.Y+*BYO*F%/XE4J1+..J[52R6FC
M"/C49"?PC2K9;#MR7G"P8O6M1T/''6LJR@AIZVW5%8)-\N(.`&"$>(9FC=P+
MBBVQVUKBN*]RZ,-!TNZDI@AYQG]54881G*C+E5Z,`/(NVC[))2*RT8-'4V5*
M1-CJKI>BJS?.U!7`M\)IA2,Y`'2XU\+XA9!X8UB:^C-:B%`H(=(F66$?OK/#
M++#/!G.?+'+&]\<L<L40]?'+'*VQ>V5KVV;7M0CS#3RSM4R[IX^&;\-^=T=W
MH*JP(\B718#JU3QL`'2OD(0?,4L]@NQ\8!D1#;D(K$<O-R)2R;R#P$S&(E3@
M8@>>66-\8U7,PK@'7+JU2E_25+TQN-/C+35.`S9?3@3F0QHX=;\9:1.\]J;=
MTZQ],C.<SN)28A,ISQ*(DE,W4V4XZ=`=A@]8R!8N4L'<M1S$>7VLO7CJ:5%^
M&I&Y4X7<($_ZJM2NF<QI*.M`%!5X!28?!G^S>?SK?`"[>0N$&N-#Z6:>HJFF
MX)O!R]CD3+D[6`,#$J.4.8/Q`=3)Z.V7#3\D].8^J-QZKH>@&<I&><;128C>
M`4R5XC?,GI*S%*E'K]<;`E-$?J@P,TEH'5@P&8Q&4,<50M8:Q?`T6HOU3^T_
M6MK3DB0HX@)C3=%*0;!?OQ&X_=6H5-B)*=Y64$'2.BP(O,-Z,YIW=P38;[G&
M/28>05O&PQM)W^0-BA%KVQ`#Q%1C"+1O\2+4V@,EFR'J*F9D$FW./PZ4_5BB
MCQU`!<V=BF03T\0E"K4:C60E610?/PV^LYC+!"YK:H232:S?`>^1=.Q%"LLU
MCQ&4FT[ZD98U%S;I$#F-2Q6'1!_Q/-54')ZJ;3(W2',?;J#\-&4GF4S>A2'G
MI($5Y.H@J/LX1,BH"J:3<\2F&TRN)82]Q,1$36$W^(Z@-&)]2J=K0DYNQ)J:
MAN/65%C`?\*+SZ.(FH#3DHC2`I&DB:-.",$LV2UE?>&+P!#5T?<4U=5P4HH$
M0-BXYB!8B.8I749:E]5;?*.&/5G5<C$UN7_BM:C=+!>4Y09""K\@;!CL6>78
MDV;:2=50$CAF6`V*E)#3(*^(B,F;?8``,X9WVHF(Q]%JQ+JXU>3A)T&0NC3!
M&[8(@/\`^(<TI-G).B8DX",TL_1U),"M9EOF.6^8<V2"TCCFQDDVGK&6!A43
ML#!4]D4QV<2N01*B+FF-IKXK\\D$>>WLPY!2I$CY7TYMN:H4<\I1?%C*P9Q-
MR:H6#`8LD!-6,9E=;PO$3>:+[-.$P5?82&X+YH(H@F`!3(3#%:ZQPETF_$-U
M/QZ:ER+XRG".M4QQ(U%:0X$;,TQ\TH;0#;7!FN/IF>;[&.&'%)2!`AU]V<4<
MD&^GB*RJF(Y4ZJ@`"%Q3N.X&!4?6&:;]D.?'O\';5@[-0Z*G-"<4_25K)3''
MBVEYAJ80]VPQI336BZ+&XL?,A,Y'<*ZU22>?422>KF`TY5&'!#OA@'A:SZ)Q
MM%>&!\V-R'--[SBI(T<J!(B=?6BW6>Y]6D1M60'2[6*I1PTM+:FX&#(,B,S%
MUJ"<T%T&:AT=*3U8&R:H'RZJ<*XB"X8;)<N;RR'2]9DW17/$.-QY']Q@=SP4
MP42%V1&K98+T(R%,MM+JE+"I&<JK-G:KSE%#X,&R(!IMY@HAA%4$?$+$QE<8
MQN]$J_U8\J?Q)M5C'@EM2KA-<.3>OSY\.:<]995O,^.D9*!TKO\`C)NQ:MHC
M9.62W6NGG&PCJI(II`'P<6-U3)<1L]@P':XA,-:ZQ=>WMZ^YGU+IS%UIZ7Y0
MU5Q(TBT>?#A?LSNM2-Q.V&V;U"KDS<M#*$BA@D'$^<S#?:#83FX504TV2$/K
MPRTKE!#(IC.UBAH1$<37U>M"6LW6PN:CX\AJ-64AC0=#2MH^B9^(2RIP.W`3
ML8RK"D8+;FE11/OZ9&C.!YV)JB\,QFT6;+;4$=1`3LR5['CPM\2XF(J_J\](
MU<?$*.:-(NU9J4QLU:0I(?+S5'^TXTB>)4^5(JA&)%.66^M+D6-^5I$16],K
MC6%A*13+A!&%`'()P6U3"MQ<Q1LA475.@"+G8GOZ,X[?20MY.5*>C%:+L3''
MDD"M_)?3W&WT]8)+>2"/ED.B9*I8YB/<IG>^9;=-SO?9QJL)U0<QW_<;2%9A
M]CC9'W'A7M"__-M=MO'D._CV-^?^M=/\<U;/;KM3F.[0F/CO\Y739G_7[.T)
MCX[_`#E-C_7[.T)CX[_.4V/]?L[0F/CO\Y38_P!?L[0F/CO\Y38_U^SM"8^.
M_P`Y38_U^SM"8^._SE-C_7[.T)CX[_.4V/\`7[.T)CX[_.4V/]?L[0F/CO\`
M.4V/]?MV0:#%GSAT>Z?UJV>WX1810QM]G9VVR>/X[.S^?_1K,\E5PRYJ(4"@
M4"@L**O\>H/_`#3^YE&IV\2U'F%>U62@4"@4"@4"@LII?X&DK^CMK_CSU2?/
M5J/$JUJLE`H%`H%`H%!93A_Z;Q[_`$AS?WJ)4CS+7\85K59*!0*!0*!0*#__
MU.\&1HUC^7F>IQ_*#.;S^9"T81C:LU74F%EA"43+=7$US(0YM..8"%QQ4EPH
MQ0Z7OE:]PS!</.VQEC:]!$U;3Q`ZZJHZZJP[&II:0)-#FE(5?,U!!/DY="*7
M(X2;8T7(@C#/K>5]RNJ"7S.9!VMC<2]K6M0N5/L[X?.A^/G<8?S)TJP<V7L9
M.O8\(ZTF/T$LOXBR,A'6P]RY=3Q*W-E$QPMY3-$QB866!2Q<T-A@'C883;%N
M<O4/:%M':B?BM3-Z;XFR/0BWCS1B@P"TD\I=CM52LH[[;:+@4P`#P0<\E<WG
M@4$Q$`"$-#9X8XYBYWR%SSRH!\_"@T>R;/#5ER08L93N9+"TW,S3@PH)5V<C
M"QPS49BR*Y9`0W$A`!V#'*F0\7.,FY$=KO',GC:V>&6SL5*7:64[JTD:8'P%
M(P#O@*)W&!+C?9[5DL%69"$;">;>CP(,)@I2X&(3OB9*LC$$.Z1L6QR3LP\,
MB]P\L,;VJ7.7N0+IQ@O2\RC4=:?8O:<3,D\X#SJ/MYH)^\"1]R*1--3CRX?R
MS$&,'5,PG(Y0O<47//.P!4(.U[8!X8V$S,^5UT0H%!^0X`)D$8L9!",%S`0@
M`X`X>`H(X(N%PQ01@A+98"!"897QRQRM>U[7V+T&(DBZ$M,3ZBR2(E0HL9L-
M(DLH!1GOU=@YC1Y';O7F3BOI"VMLPTMDV<;MFW7:72>#U$+('(2Y(R+<N(7,
MV!,!%B9CE=2U`\'.1X,R0W%#,4KS_CDH3(1Z^5J.V@J/!AD4\48PGDF8YCR.
M.M-<H1',"9@AD1P,`L\\KXVM?*][DN<OS*P'!1)^.&5"<+1*4D]VIQA'=<CE
M8Y9P#\<R0;!WL;2W"[PD;!PK2<9+_P`F(`9,"!9X?JWQO;Y*%_3Z/&3-,&FE
M%C]S1,CZ>(,28K>AX14>,9ID2L$A'[L4Q12XPJBYF85;X3<7CPHQ0+/(8T6%
M$RR"PO>^SC;8+<^;Y2Q!AV(VJ0:*4V(LCAN)D?HZ\WF&G(+';*.09*`Z;EKN
M=#:)-/3"Y=MH[CN2!N?+$\003FY8;KCGM<=@CX3\$P@J(N#;4X;BI1;H;',1
MB&@'X\:)Q%#C4V;('S<>X)1A($(XL<T>2BHPB38/>&8I8+.X5\@\+V%OD9NG
MJ`8Z4"RM'T'0^Q54F8339139L:,ML*!4TCMA09*09+'41%(F0#"4S%<VD%L\
M<K9`)AH4KA?$`3,.Y;G+\G)IST]O*1428'?!$-.J6FSF0$;DHN2,&0N2*WQ$
MO*^:8(B/930S3E2LT[.][@7`-!W!O?9PV*%SE^:SIMTZN+&2,'!`<++N$QF$
M4W+V*S%C&4\94--NQJS=,R1B=0A[/@P@6/#V)9J>^LBN[9[E?';Y;(N<IDWH
MSC=I`-(LU(^9#8+,%$4VTQ2[>:B"B@,IN+8B8,LH#2"32!8-N(BN,B$LS14G
M8$`QD4!OGCE<+#:D4HM:-M.HJ`XDZ/XKCB$7,OD7,3!DN(8GAU!?R`*]!$T1
MWGT@XNQXYF^9,.NR07P50E)-4":J$%B&<`'PM;&Q;E"(+T$0;##1E1IK97.<
M@)L,MG.3<I?9L/B-]>268A`(#2:!*+XWC*.H>;S*;9;`84JG$6\#C<T;'''S
M&'%R$H7+)=O1'%+1CW*(VG&,>MB*<TE40,XQ;S+;:+'N2$N8&0EM%R9::FEF
MWDDK`9T;$T6N6W$QB-G83'*V66R1Y+0@6#(^2G$AL*&(G9"(\"8B<[4=H1TS
MVTE.A/&+#DQB#B3T9')%%LF*4,B!9!&<!<,@Q,L;VVN5[7`GP+!B3(0$N)<,
M1.FRL61B[<+2<GQTSR<A%V\32@4(H@@/0NCAN0)&*HA8,F&5Q,V`P*AXA8XV
M#QMC8MSEYR+IMTZMK)_9MR`X60,Y6",@RCDBQ8QDK*203E\[FPG]D10@+O$(
MU<3*XF*COFV>VOMMG9O1+G+TY!@>#I:5$5;E6&8IDU:;A12(-Y7D&.V@\U1!
M(+0.198)(I]QHZD;2RBL7SN&9#`S#P'PO?'.V5K[%"WSK>GR!'*[V7(3CA"(
M5]_1L63R4=/A;C5F*KO8)-),6-I11EN4\BCK36+)AK&PA<,B.!@");;86M?Y
M:+<Y?.Z-..GI\-)!8+T@>&7>Q&JHB+#893HB]D+[2;BN,:&/#*B"W%9#-HZ.
MHBG3`@V0Y<$,7(43+.^6VRO>XN<KA``!+`@EBP(1<N7"#````#P"!`!"PL&$
M""$';'`,(/#&V...-K6M:VQ:B/UH-9OQ%="T!:T^1[EQ9KA=O)KR@^:_`+H=
M3;X/\\?,CAK?7FRH$-^[[\U2FTW?;[GN66TV-MGLZZ_5)F8\-9WX%V@;F;D+
MI0E3V@K50;]\?L?@7:!N9N0NE"5/:"E0;]\?L?@7:!N9N0NE"5/:"E0;]\?L
M?@7:!N9N0NE"5/:"E0;]\?L?@7:!N9N0NE"5/:"E0;]\?L?@7:!N9N0NE"5/
M:"E0;]\?L?@7:!N9N0NE"5/:"E0;]\?L?@7:!N9N0NE"5/:"E0;]\?LE;X^`
MY\/))="HGHT-R!P:7WEO;:2Q*IK'^53B@XVP/DXQ+Y_RXF7Y[['Y/S5(B)@G
MOVM%/P+M`W,W(72A*GM!5J#?OC]FR:)H60H2CAH11'C=6DME,9(#0VXGG!5=
M7-%$X(44;`(924\C)\YG80;*^W%$RROL_EJL3<S=+$X(5>+%#ZD9^CH5.#@A
M5XL4/J1GZ.A4X."%7BQ0^I&?HZ%3@X(5>+%#ZD9^CH5.#@A5XL4/J1GZ.A4X
M3Z+TY0`?2&*.1.`A8<)[804J.&'CMD=0QQVV>>%L;;.5[6M\OY;U.WB5B.4!
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M0J<'!"KQ8H?4C/T="IP__]7O#=K`0GJ(1%6#[U)Y)^`X8%FE)4C,$,3$QD%D
M)<\"Q74W`E//&X-MSR,XBY!6OE;"^-LLMD(?R$LGCR9>\9J$ZSZ+9R$LGCR9
M>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G
M(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QF
MH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)
MX\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L
M^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9
M>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G
M(2R>/)E[QFH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QF
MH3K/H6<A+)X\F7O&:A.L^A9R$LGCR9>\9J$ZSZ%G(2R>/)E[QFH3K/H6<A+)
MX\F7O&:A.L^A:N9`8C.97!.Y&IA4.$]_[;=-2NH8ON.\MY;&QM9)&V^Z;[_@
MV-K_``U8BV9[3"N/1/Q>7.\]J(ZPZUI[3>3T3\7ESO/:B.L.FGLWD]$_%Y<[
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M,ZA\\37"!@<&]LA+R-C<+<K`[-MBV6SL_FJ3UYB+6.TS:+^B?B\N=Y[41UAU
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M$T-Z297U1@QWG*XL99L`,*/PW1DS!'"(^I/9<;X!AN3%M/#)/S3\GA8W:UDX
MS<>Y?<?U-TW3`L1<TP64/C3QD;=?PSFDPXR\]3_Q#23:4U7'&0PDL:`2+B7D
MQG;58+A,M7Q?"@4>Y=PI5@L1$<,8=M&KXBVMEL82_"Z_^O3-%<^(%IF%8;'<
M["E!!=:S-;1U(+NGY)NE.TF#**GI<1G`H2TG%1C""6NE!-$TWAPC61VY3=K8
M7N6N-^KLU*EAUIR^,K%,P)<2,-WM1<:>H:4-'BIJR"32:*K&X7)%B2DXT\!D
MF'P#=3<Z>IC%VZ(>$.#(^2.$4QR#N>N?N&1SEK/6OTM;E_BY:-8YBZ%'7J3F
M9F18^I<@YC3H$SVPE2A)1#%H/8TJI15=;ZDW8Z$4U=LA+*`>"R-#$2@H(1:X
MQ@(`*]LKK-9FZAYI'XI<2HD]ZM6Q*+C830TY:>8OTP24TIL3U%9<8LAE-2+<
M$7$0%+1T(FK&7!D?R$+8I(*.7-FCX8ULL0\J6:S499[P7/T0ZE6`6D^$WF6>
MS,'5EAOC'L$Q=;ZHD.)O',T]=;CE:[J2T-U-5QI!O#:F""F2*'`;98Y9!VQS
MQO>I,5Y7%1"@4$0D%\(,9,%[R2Z1#(38CUH.5\.,4D6R.'`D%IHIU>5Q"A3#
M+',T9P3R`EPP[7M?/.UL;7^6@U8H>N;56U6GIGU%SK#<,(.F;5&[XH:9%"8#
MP>:]-,'X3_<H##:^_%%51B+(?B>?5%9.(+@2:`E")(ZACF#D=#"$J-5',1/+
MY@?BOHRZ4TIOE$B254E@SE)<^QLXVHHPO)SGEU558J:CG/-H"(D!MDP1G/FK
MN)"QQ41\")\HG@8F@C(A3,F9&!6:^>5_*WQ/=):2UXX>EU^0E-KR'&Z-,1Q9
M0XDD-8)Q;%*ZXCS/)2#,XA%`%Y-FS9V)!Y/S&/;&5AD\WGCAD7+BC86TUE>T
M::JXLEV8Y2A%A%I`6'+"QY51)*<@T;O)+C1NNI*%;MLF7A)"HDDVBLO$X1<H
M)T)/(&30]B(8@XM@\-SN(*:^V_\`%:&R._$@;CLC(DGO?1L[%!'A=LD%$_B-
MJ$3UE\+T-QH"3&-!"7**SDG)'`;AO(#',`H.I%K[%[Y7J7Y77_S[3F./BRP:
M:A*%9#EL@\DAUO33W'&H:9B<6QG(\FL?3VR)$+&+I;HE%U-Y!4P&DUC9Q,/[
MWS,Y9F]ZD!S(@.!?"XMUD]9M>2C\1O2\FS/E!F:\]SCJ*2TQX/6W"FQB^C\9
MMJ3)11$-<BYN+LF%T3)F%3$C!N$L72+AFQ;&#65\,MSQMMJMIK-6^5M_$ITG
MN-T'D')UNQM(%DF65MK2L\HZ>C6AB2TV!RJP?F4S&,GJR.`UWIA'2:WCYL]<
ML-L"DB)@R5N8`!$$Q6:R\%"^*-I35R;E-J8TQL?-N1>BS.`G2'`LM,U7=\:.
MY](L:L%RL%*6&J">>EI$>[C()R*4(8"GS9HU@'D"'GLXV6:R]8Q\2G344;;8
M5QP)F\Z';([RAU,B$K!<H*4U`RRPVL0?#ACU2C-+;AUPD%X%GJQ14P$SPWCF
MFF<#5S%B]LQ<!4HGA\3C3KNA:1#,B-Y/@,SI1*:E[*QYK22%(^!8]+X4/E4_
M)OX-D5-%,#N\?!##1PA!'`,O98@AELPLL1+BI\?5?REJ<Q.Z8)DU#-^-9-:1
MR+X_DYUEF+.,?.B*7(>4F`RSKK*@FT5>*@*&:"K[B%AB=+7%"OLB!VRL,"*'
M@*YIAVS-=&I%IE]+#MU(Q5"R=$FL='3"<:/^(WH^E)3CV1W'#RQ,[/:,I,IU
M-0L.:2G4@-U1+!J*(?.7*'"6U&`W,;`7"+4<UY9`Q#KSC"2U.!X_)%'B]I,E
MB!H6G)QG8IBV2U^+V(W)K;PJHRUYT.I4;Q`=GMMW'4M0LFV50P3H!<KMCX16
M][;-2O+_`%C?$:TTR.JNM(9X\KK9A"9SBD%I"I\(RH?+S8R&D[T^/W(YX#NG
M-4X/+B4DO58))^6:3@+D+<Z`9!Q$)9V,T*EXX?Q+M.1EK(BTGI,W*CN7IB=<
M"%X6382?IF<"DJ,5F%Y&>384HYLEXJ1+-ML`Z76#!C+.Y:Y(P%<,03/.V%"I
M6`X-=>GYM3.G08IGWU9T&7/'S!7'"5C1[FX[8LDRRG)ZM&$9R`_04;)O-)_/
MHBKDLB*<:%Q$QN>*XCW!R,@6$%35IGISU3QKJE(.M>BA*D<5FMM4R3$M_.N.
MW.SF1(>`*RY&^;5(R7U\D3+O)+3E=JF@30A>ULRN5P;BX8V'"OD)BF25$*!0
M:&/C<Z@'O!?9D\SGBN-+SIY:.$>!E(=.X0X$Y)]Y[YW#/#=MZ\+B[39_T=TR
MV/RUU_Q_5CO%TT,?B`S;SQ/C]Y3_`--73C#&L^S\0&;>>)\?O*?^FIQ@UGV?
MB`S;SQ/C]Y3_`--3C!K/L_$!FWGB?'[RG_IJ<8-9]GX@,V\\3X_>4_\`34XP
M:S[/Q`9MYXGQ^\I_Z:G&#6?9^(#-O/$^/WE/_34XP:S[/Q`9MYXGQ^\I_P"F
MIQ@UGV[!Y5_QZO?\K_N9.KEU\0W/F5>U62@4"@4"@4%A15_CU!_YI_<RC4[>
M):CS"O:K)0*!0*!0*!064TO\#25_1VU_QYZI/GJU'B5:U62@4"@4"@4"@LIP
M_P#3>/?Z0YO[U$J1YEK^,*UJLE`H%`H%`H%!_]?LRU]Z9EW6%I3D33TVW.DL
MY9>JY$JL5<2X3.'TPD'',S1[)YT$P5(7Q-"9J1!F"E0KXWV,!AL<LOU;7HL3
M4VUB-+X&B3%DP,64(]F,F?*M/7>V=3Z4WG&TCI`&/(-:JE)SE1=.D?B%G`NX
M6+)SOEE84,C^U3BIP4Q;,0GB+A<424UM<>$.B3X/6J9H/'3>4>^H2#UN'M)A
M'7TWHC06U'[T2GNJ)>M9JR&4.K[Y7E%=4$LVMISH?(.69(F6`*DTY,QP#&-#
MCB"8J-HYX3^)/A/S[![L@5PLZ7(?6@&Q\.QU?#YF0NYF^]`A3+<5Y%=,I$'_
M`!EDEF0\++>3@62I08!5V``28(N>-A1!,+!J-HF_U8VN;X;VLE.EIO:=HG.Q
M@"T\O@K,W0])4^22Q'VH1\:NJ2_(R6_"$;**`=*")\G$FNK@*A,D?W8#(L)C
MD-CA^H)91M'GVM.2/@6.1R)\@I[3GE$3<B;!^'ZA0H>66^XL!"[FT,1Z)'H1
MJ1K-I=1E4%(D!,,#96$0U$N?3!Q,!@Q,[A;011MZ;5-!FFQTZ8HL?+7>K:A)
ML.=^S`Z)56BT%*,T+C=5%1SM]H)JHX'.XYV>;T>SD?2VJ-\8<\=Q$)%1`<@,
M=[W,8&#1FLS-LWJ(4"@C+T:"!(+.=C"=A+A-K/=LKS0<J;NPQ;A!`<J6:1ED
MEO@MF$8`WVG'1`]N'ECGCMMG&]KVM>@UDM#X?LXB$=-\0S-JA;<EZ8M)[TCM
M\QHT4>$AF=,#_4(9N&+"J7-DF&)-<[77$J.C9`B,-=$;*((X!R>&9JX5KYAY
M1JXYXY3N$-"3OBM<@$9?FAONQLZ9I8U(O>-DY-BL^VW`L-#4,DN[;M=[+H\F
MKZ8;7V8X'R=R#5"*:3`/D"Y<+,D"/<4QE4F?/#$9>^"<UAQXA6R+IT^R&Z&'
M"8,%NR^I;2L+-+,74A-?CI?+<?;*:Y";F"KL!](EWB>(#6NL*::IE,@=W+XB
M`897E+LVN03!O(H>G8YYT><W+7/SQG+<^!.!O-GSL;S.0?-?;\+JO#/!_FGN
MN_=@INN^-KO?#:;;.HPN+_"MC,WJ!8.H5SOY>57(P=1D[3W@B(Z,7;R*\"LL
M/)!DIDL)^6R5E<PX4Z%I*;!%?1S-L@,1%0*XN]P;Y?)*7;BE0)7PG9'8\3*$
M)QAJK1V^QI<TG11I!U-BK\$YN1=>3,BYM/5G7?$.CWEL@G1.]'0RWR>1S`:D
M7=1$N&,&<PPR,%<,15&WUI?QSX<:59*4D!"E')%1!M?6G36TCD<F2(HY(Z5I
MZ:$`M!/A_(R*]`!5#)P%(+PSNX,MSR*<);%T\Q<OMAU&W_Q1(_PJ%[D\;<-/
MJ=#,CZ9X(8&J!N03$#1BY,9LKCA:A8NDR)\4Q_2NMR,L-5WJ$>Q_*"LFMT8F
M@-C$0V8`-*`N=P+[=1MZY8KMKX<,_P"LMPS`%JG6Y4;C,PTHPO`<4NV8HI@%
MM.(%X1],B9,Y,T/#T62E*C?=S50SC13PE\596">+AR5SA,F&7``P'#+<15-C
M>G[X>UH:6H*<5U+3ZSA(8E.8I*&9VFO3DIPA'SK$E:%TJ'K8'$=8F>33Y9SI
MH:7B>-*V1D?$\#B`2Q*%L2]C`E9F;8[%?@RD<8V`CX[J,4;BIVFW"#T1Q)46
M$B)Q+=R+K&MK)9,G;P47VN$#Q1NO`D13C*"-;(-1+E\Q+G`;#;B'*7;TV.F8
MAF60M.$M0W.DLL)SOF5&+(#!N_(VB)9CYL-M)>C(%:!4<)AK\L2&IK)Y+-&A
MSYC/->+8'!!KA!AE`\<-BIQ]&*3,^'Q*9['3TCZ@]2S8E)AZ4FB&DPA'\>0"
M8B-"">I")5&&6_)DE&W%-,R++W<+8::R=&(@$C"&3"438@^TOC8,,.+>(1-'
M^&(Z$AX:'U4&:([)INC./H`8Y=\MB"5IH:BGTDP6TDILJ;!-2VE3<(C!PG+Y
MHJ,;66TK-]=WD&)F`6-9"#[[`4;>>%(L[X)Q6+HYE&*(CE&%HU2G0RUMCLJ8
M&QI?.I6J0LVU>1VR]_-*6IJ1IV2"4ELXRW6\(V5<`BA-P^MI1R^8IP$<+;BJ
M-GIY_"`>W(G,L(VEG2Z:;DP3F<GPN&<T:.(N4B)\.*,V7'*RMPB&@ZHT16CY
M>9^;)+*+6/!'AS!:XIDLIY*>)BXX2C;QPLE(^$R@M;5&BZD4QS0O(JD;5M/S
MG>ZSJ(T[92U-11ZP2WFDV#+VB&8DV5F(*P'%(Y%F$SIS-327&"F+NZ*!4.^Z
M9%J4;<4OW2-HA<&FN9YUF%6D*.SF,TIS;)'HZA&'5>#(T,.!"6'$K*$M.IGG
MI9E%'4Y@=@2]@44E))"0B0X)2PF93,8;+/"I,W$0V&T0H%!SO_'MT<:D=6G9
M2[/:<V#_`)@<NGG=YR.DLVMR\ZN1W@#>6^`1=^[IYMG=TV-C<]KCL_Z5JWUO
MFBX^KG@_!Q^)'ZNQATI)OV2M7)?0_!Q^)'ZNQATI)OV2ER7T/P<?B1^KL8=*
M2;]DI<E]#\''XD?J[&'2DF_9*7)?0_!Q^)'ZNQATI)OV2ER7T/P<?B1^KL8=
M*2;]DI<E]#\''XD?J[&'2DF_9*7)?0_!Q^)'ZNQATI)OV2ER7T=O$J_X]7O^
M5_W,G5.OB&)\RKVJR4"@4"@4"@L**O\`'J#_`,T_N91J=O$M1YA7M5DH%`H%
M`H%`H+*:7^!I*_H[:_X\]4GSU:CQ*M:K)0*!0*!0*!064X?^F\>_TAS?WJ)4
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MRD+4+/Q/7R!M`9\-'58+?6]"O:+=AG==T)&`A_Y$+39AGGM"V>>7R7ML;&S^
M:I,]JYA8UOA'N"G)ZLPUWDG1[M56^V$^&3@IR>K,-=Y)T>[52^V#X9."G)ZL
MPUWDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X9."G)
MZLPUWDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X925
M)`?Y=#<I5/9T-#I9X--LMF>T4[!=YX`#CYDK[MCILQP+[L+EE;]:U]ML;%JE
M]KCA8UYI&N"G)ZLPUWDG1[M56^V$^&3@IR>K,-=Y)T>[52^V#X9."G)ZLPUW
MDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X9."G)ZLP
MUWDG1[M5+[8/ADX*<GJS#7>2='NU4OM@^&3@IR>K,-=Y)T>[52^V#X9250`?
MXS;;Q(XSH:"128BG='-]HIV8;ZS'-9"'K;OEILN&/N)B]\?U;6VOY+U+[7/'
M*_&O2-<%.3U9AKO).CW:JM]L)\,G!3D]68:[R3H]VJE]L'PR<%.3U9AKO).C
MW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,G!3D]68:[R3H]VJE]L'PR<%.3U9AKO)
M.CW:J7VP?#)P4Y/5F&N\DZ/=JI?;!\,G!3D]68:[R3H]VJE]L'PR_]'OO.G2
M::3-J*B;+$$\@6'.GSYT<(J3)$RH68YHV;-#YA@%BQ8`/+,03/+'###&][WM
M:U!CHAZS='SG!<YAM:KM-;A+LDMB=>8Z'.D7JP+1)YK26VL#;G%(.DQ@@%LG
M$N$B%A#=PL+G3@`&SNHH>.1:G#T.UOI3X'\XNTWI[\W^$^!>'>6B..!^&-Z[
M^X)X3\Y-Y<)[R_EMPV^Z[E^OM=K\M"IPD*]J)T_-9MM=Y.>=(<;C0>X1D9EN
MI>DYDI#;=X)/<KFQ6NN*"V73%\(K8?#=,B@HML-OCMMC9M1*2PE)D;J3$SE%
M.D%D'XS#2SZX)(I)UH)IB!HB5D9P5%C-W`'Q&_BEIN9,:Q@Q<QN(-PL[9Y6V
MN6P'E\M,.\G/+#RLQIR2<Z7GVUN3G_\`7?-?_&_"OFS_`(F__+O_`+K_`.^_
MW?\`VOZE!^3MF^%F`PDN5'W+T7LJ,%P)&'1)'=K_`&HVV$L`N,I8^WADMX+*
ML3;R@$ND;[L2R!,9V-!?KA;;'Y:%)^CK"0X4I-7D!43EQ#62)541UE'/%E-*
M54T\#@9)**:HDA1R9XB<+B8B!#!9Y!B896RQO>U[7H/1H%`H*A$GZ%L`YE$"
MDUH'\]/),8_-Y1(5RZVHQB7+MLP[A+.U+2+G5),,W;904W@!D%<<0,/*V.%\
MK7QHM3PGK1=;??;4;#X:2D$LM5Y-Y%=;96``C``*JWW$FEE=&4@038)<V"$>
M3C@8N.(H>`F-L]C+'&^S:Q'DQY([)E=LV>4>KY=RMJ[A>C4LJE2YXJ#YP1V\
MW!'CS3=Q42I,UNJ$\FL?(B9;3<Q!"V60>68>6&>0?0]I`9$;)!5??[J0V>B'
MG`W&J35'`H%TPB9<CO6B3;:R&"8,YX!B*:^OJ1<F4"M?;C&!L,,;7RRM:@E]
M`H(!)\HL*&68?D*3'""UF<F*;81SZV8)J1\$LHO-THK*;1;,LD$E`]?A-SN(
MF5MGB%<,*XULQ,L`L<\\1Y3^@Q=D?6UI"AY[G(WE;4G#,</E-,()53;3V?S?
M;2BECN@H$?;V*IBKG2H*;BKD!L1P,A\P\<P;[?9VMKWL6IGQ"]DE^,M=<Z\R
MD5T(:J[&NAM1S.)O$%$L:549O/H1PA,U:4"@(F8A=,<XC34[$1KVVABY$;:7
MON>6P1+*!0*!0*!0*!0*!0*#!#6S-"=$/)GP@E\)></GGN7_`.8V3]QX)\U-
MT_*1.;MNG">/_P!.UVOY]GY.O^/K=N?>:I@?VT&[ZK6_>/'R'733W/V8V]';
M0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<_8V
M]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<
M_8V]';0;OJM;]X\?(=-/<_8V])"Z]=S=<Z^?7/,RQ'?V]?\`=?.K$SN6]B1<
MG_M_-TOM]OO?;?Z%MC9V/EV-F\C_`!U%7/V)[W/A'NV@W?5:W[QX^0ZNGN?L
M;>CMH-WU6M^\>/D.FGN?L;>CMH-WU6M^\>/D.FGN?L;>CMH-WU6M^\>/D.FG
MN?L;>CMH-WU6M^\>/D.FGN?L;>CMH-WU6M^\>/D.FGN?L;>CMH-WU6M^\>/D
M.FGN?L;>DA:FNYNMA?(+GF98]O'?7^Z^=6);==\DC!/_`&_FZ8VFTWQMO]"^
MSL;'R;.S:3_CN*N?L1WJ?"/=M!N^JUOWCQ\AU=/<_8V]';0;OJM;]X\?(=-/
M<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(
M=-/<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X\?(=-/<_8V]';0;OJM;]X
M\?(=-/<_8V])*DZ\FZEH;E1?,NP_G$&FA[Y\Z\0MY\'#CC[.X^;HF^-VW;8_
MT\-KL;/RU/\`7S$W/V6.]7PC7;0;OJM;]X\?(=73W/V3;T=M!N^JUOWCQ\AT
MT]S]C;T=M!N^JUOWCQ\ATT]S]C;T=M!N^JUOWCQ\ATT]S]C;T=M!N^JUOWCQ
M\ATT]S]C;T=M!N^JUOWCQ\ATT]S]C;TMV(IU3);45=.()'!N:02`.B9\*6/[
MIB./<"V&TL0)[GL7ML[.SEL__"L]NM+$VOFLJLIP_P#3>/?Z0YO[U$J1YEK^
M,*UJLE`H%`H%`H%!_]+J-^-^R95?WPYIB1(K0W.Z\BJW'+@DAFLK(WB['?#[
M=?*(KR(B(MB&&1T7*R.5WT:#"O;(0@6'QO;/&]PLY+77RU<?$?G/X;T^?#!U
M/-G0PB1>I2<CQ+"VU2XS@I4:CR:,:D=5VF8);92\L!,-)$;XI=9R2!#+>,G,
M#8XA*QFQ<7`D(,"^BQ$QVBU-3R"UIM'T.LO2NX-'<]R*3UEN(RH&$?0L]=-^
MGD#-:A@P"RT28XK/.!PG7F7NH(:EGFJAJ5L,0QP0LB^&X;)DL?7#&--+,!FP
M1\*]HN(8A%+BAG4]K=2=59*>=/)R:&%$$M*J0F&%9/5((:)QO)[@CDX.:*@M
M\%..!%0[YX#7SN.6,!6F%^O;]'6#I'4C\E1HS,&OV:)`T=J\5'T5&6X]BUZ0
M^==LC);I%;SXPP@!TI9QJLJ-#RP06[V)Y*!TW<>P=[W&"$R&OISG]VIO10TS
M!K_MD7DVEUM#&5''23K],@-]61LQCN*R3?FH]9;HX24<+9#V4RJH`5-DLK![
MK@8P"%"O;.V&53Z-3_[1)RYM2.&S_P!OK+VJ!+(A:/HWT>G&_*"L^&N,X(YC
MZ7'1I$CA.C<]):2,DJ!8H85QB)PDCCG`1\"B@$+>UB^=["9,'Y5YMLA^".TI
M!9GPWX.29!2%YO9FE64E]CMYS%CA);18O<<H.Y;CTJ9)*`HILD4,ML\":)`Y
MVPW$@8`PMAC;&U(3MY;8JK)05]++^PBN+I%DP1OKSMM'[(=#RQ:C63CJLYG.
M(VT4ZK`MUO)B:4/GSZVMBE,2I4(($7/,<7&UL;_DH.79LZ==<&EL.09%EV'6
MLKB:^-*>J:.9_4(,79*E%WJ.HMX-N9-1$6/:7&49B=K`,9021G.KQZ2Q3#RV
MG`!#$BN8^-@0!18W,Q/CZ+[:R@:5IHT21>IK>MG3TW(.@'2FYYS=39<&NT)G
M2](044,;!G:<6C%[(/']/[=:">%D"=D1;-(V`HX^PE;8(W=3,!#Z3+](K@K4
MA%"?#$H0RK:C"TN2?J2^*^V59A.)RO"T/MYJFRVMUZP25-Q<M[VCAJ-Y<FEI
M-AQ$%T\5#-*2BO7QS/#$C!,L")KG^RIH@+ZKFY#`2B@SCJH7GVY)!^'Y>58H
M4XPUPM=YL1Y$]1[;3I^<:Y(<UN=VHPAA[-Q34"+R1FH=+M<T02]^!E,"%\\\
MR\7X6#&\`3Q(LM:<U"2I(UV!I\X:S_B#L*=\.7+4,V49)TWL#.7G3"C%)@$%
M]/(QG&[E6V2CADU,C8@J'RJGF4)*6!<4H$`29CFJ\*'`)ZZ7*P]-?*W,VI6%
MT!)TS*I6-I1%CC6-*[A1IZ8^HN4R1T_([4@%PI"XX9#O$::U,$P*0TI?0W$C
M;\L'@*;%-[J(KEN@TX:?K2/*>M%_:@#,ROP,YJ:<[$CEC2H_I(/1`AQ(TLX;
MDAKBQY%*HK%V#P>9D)!P-8JN!$R+E<F(4!'#*B&BXQ)GQ2FM+BA(3?\`B2ZA
MD4SC-$R,I_9S8NWE%Y%M6[!18!NWWPQ4M(A,\Q)0N5TM/AIJPI,?-ANAD!YK
M0Z.2-B#8[S.BF3+ZD_\`F$,>,HM6'-7GQ1D.3X-G.7"<_,73>DQO'[$TX3+*
MJ#-F*%`:ZWG0T`74U&(M1RDA9'U@(F;$6E5.+`8B"99YVQ"$OB*N(Y8SMV&]
M5L5:<G9I^DB8IIC46,]*_P`+='('T1MZAI)C:[T0'EJ149:A^^6G(Q:0$1JN
M9*1F\TW@X&:<)J`*?BG"&#.]\@+9EXN)B,H9)8VK.00--B^HK&HW1;%>6D)&
M-118HC:\M1YI@ZAVU+;NLX5!X%V$NI4K.EV*T=D&\=0"$JI:LFG6\>-$+E,S
M@9G"BQ7/UY6LIRQ*G;U57$9;&KN)D(.1]6,,R2>;2-KAEM#/H)&*7,0A*2DM
MMJR:IZ<DM$>;M0059DIC1("C@98X;]-W&%%VSZI7Q4RD"ZJP]+R1&J,6G<U&
MK'U;1BD3KJ7+!?$155;4'%2G#:ONS\Y+GH\VQJQ8:,FR850`W^28BD51M_#B
MC%,A2F"F!1>+]_V;]-"!!U).E")$AZRL[)N<"05=J2-*#Y8<G1LZW0FI;^=1
M!OY+#6F7#&3;C([>+E4_!35\AAUX$I@J8##@G`QLZQ/F>&75$*!0*!0*!0<^
MGQVI#LPNRSLCV`X5Y;_RY;7;;QY(?X?EVN_/_6NO^+^3'>+ISZ]H;'Q_'PE_
MGKK;GK!VAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7
M^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL':&Q\?Q\)?Y
MZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI
M9K!VAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EF
ML':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P
M=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!V
MAL?'\?"7^>EFL':&Q\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL':&
MQ\?Q\)?YZ6:P=H;'Q_'PE_GI9K!VAL?'\?"7^>EFL-JOPJY+L^I`E8I8Q8?>
M#.13&Q;+;;7=5K,/9_+_``5GMX6(INWK"K*</_3>/?Z0YO[U$J1YEK^,*UJL
ME`H%`H%`H%!__]/O#=LE1RP1"(+Z?[*90JG@.(FA.UU(3<$4`RN06)D0C@L'
MR>1O`OD/A82X=LK87SQV=C9M00_M&:>^?:&ND]D>7*+4X.T9I[Y]H:Z3V1Y<
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M!^KFGU7=BJHI#XT\#)QC>.]Q,)#B,MCEN2:3`%V`1U\$7#8'"RM\N-MG8V;?
M)?9J1VBN96>LWX0_?4'^N>GKI*A[VDJ[1E->V#?4'^N>GKI*A[VDIM&37M@W
MU!_KGIZZ2H>]I*;1DU[8-]0?ZYZ>NDJ'O:2FT9->V#?4'^N>GKI*A[VDIM&3
M7M@WU!_KGIZZ2H>]I*;1DU[8-]0?ZYZ>NDJ'O:2FT9->V$P82YI]2'8E**N^
M-/`*<7W]O@3.0XC,XX[JFG``MD$!?&%SV1Q<;?)C?8V=F_R6V:D]HKB5CK-^
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M`[YXVO\`+:U_DV:;1DU[8>EY[QSSLPUTQQ?[6TVC)KVPG"S)\4&V2SD@O,,-
M"**4,NYGR_*[&V.X8G%#,<M?=<W1B`+N@5[7_4RRV/R7V+U+BYY76:B*0?SW
MCGG9AKICB_VMJ[1E->V#SWCGG9AKICB_VMIM&37M@\]XYYV8:Z8XO]K:;1DU
M[8//>.>=F&NF.+_:VFT9->V#SWCGG9AKICB_VMIM&37M@\]XYYV8:Z8XO]K:
G;1DU[8//>.>=F&NF.+_:VFT9->V#SWCGG9AKICB_VMIM&37MA__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g657040g51t67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657040g51t67.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Q>4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!;@```E`````&`&<`-0`Q
M`'0`-@`W`````0`````````````````````````!``````````````)0```!
M;@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"<(````!````<````$4`
M``%0``!:D```":8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!%`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE.=?32_(M=96RQVX`%[0X@!K#M;O#MK?<J&3E],Q;W
MTVXN[8P6.?5CBP`$.?\`1K87_18M:S&N-KW-+"UY!$R"-`R/SMWT4PHR@(!8
M!\7?W)*<G(SNE8Q=]HQ#6T.VL>,=KVN[;@ZMI:QKG>UGJ?32=F]-8UMAPG^B
MZMUIM&*TAH:0S:YC0;=[_=LVL_P:U7593&N=+=`28+NWR2%.48=+==>7?W)*
M<VK)Z;;>VAN*6O<YS/?C!K06`/.]^S:UNQWL?_UOZ:M-JIKMJ?76RMXL`W,8
MUIATAS?:`K/H91$$LCXN_N2;BVE["\M#6N#CMDDQ,#7^4DIMI)))*4DDDDI_
M_]#U5)9E=N7;6RTY!8;6M?L:UD-W`/VC>USO;*JCJQ=FG!9?D/M;9Z3G-IK-
M8=MLL.ZV/;L]%V])3I=3OIHHK-SQ6VR^BILS[G/M8QE?M_TCCM1OLU'[@6#^
MW<2QC3;DY#8:RTMLQ2=NX_HG';2]F[>S\QR=WU@Q@`?MF001N$8Q^C+:_5_F
M?YO>[_R"2G=^S4?N!+[-1^X%FXN8_+K-N/EV.8UQ82ZIK#(`=]&VMNYON^G]
M!6\2V[UC38\V@MWM<0&D0=I;[/:Y)2?[-0="P0>4OLU'[@14DE(OLU'[@2^S
M4?N!"S'W!S&56>D"'.<X-#B8V@-]_M_/_=0!]K)`&4^3I]"O_P`@DIN?9J/W
M`AX=^/:;VT/#A3::G@3[7@,+V>[^LL=O7-S7O;;E%E8L+GMH8X14=C]NP.W;
MG?S:C_S@PFAKQFW;;07EPQN"!Q;^AW>I[/\`P-)3T:2QL7J'VPV#'S+7>B0+
M-U(9!=.V/5J9O^C^:CN?EL:YXR7.+`70YC(,#=M=M:UW_224_P#_T?0*7>G3
M578VQKZZV,>/2L=#FM:UWN96YCN/S'(60,FRP/IR[\=@:&&H8SWMTWG?^DJ^
MG[Z_^V5>RL/*MR&W49C\=H:&NK:UK@8>'[AZ@<WWLW5/]G_%^G_A`'I?4C4P
M#JMPMK>XBW95JUVS]';5L]-^S9]/_A$E-1E><VIU;NH9%I.C7NQGM+1KK^AJ
M8Y]GT?SE(57^FYISLPO<019Z+P6@`MVL:*/=NW;_`-*C?LGJKJVMLZO=O'TG
M,KK;,%KP(VG;^>W_`(M$?TS/?6&GJ=WJ"P6>H&5M@#U(J:QC&LV>^O?ZOJ_S
M22F++3L:+#8]X`#G>E=J?^VD;$!?DFQK7!C:RTES7,U+MWM%K6._-0OV9U+2
M>JWQ,OBND=VD>G^B]GL&SW>HM)H(:`3N(&KN)/BDI=))))34S3M?6XAQ;M<"
M6M<^"2R-*VO=^:J_JL\+/^V;?_22TU2S,+,OO;;CYUF*T,V.K:UCP3NW;V^J
MUVU_YCOI_P#GSU4IK9-EMM#F466TVG;MM]&YT0YKG>WTV_38'5JMC4YE%[++
M.HY636T$/JLQW@&=Y:[<RK=[=S?^VU<LZ9U%X:!U.T1Z@+MC`2U[JGUCV!C-
M]+:GL;9L_P`-8HNZ7U3;L;U6W8YCVOW5L+I=6ZNNRNQ@K>QS+7^O_8_P:2F9
MO!Y]4_&J[_TDHN>',<UK;"YS2UH]*T22(&KJVM_SE(],ZE$,ZK<V`0V:Z7:%
MM;6[MU6YSV.8]_TO\*KF+3=2QS;KW9#B]SFN<&M+6N.YE7Z-K?;5]#_2?OI*
M?__2]57&_P",.SJ5/U8R*K`ZZNYU8?=0S:VK997;OO?ZWJUU/V;?4KKL_P"%
M]-=DL[KO6NF=%Z?9E]2=^BC:VD`.?:X_X"FH_P`Z]W_4?I+?T22G.^J+^IW_
M`%>Z<2#C,JHJKVY%</>UC6L]9L6N=LM_P?K-KM_PGI+7<SJHM.RZ@U%Q,.K=
MN:V/:WVV!K_<I=.ZEA=4PZ\W!M;=CVB6N;V\6/;]*NQGT;*W^^M64E(<<98!
M^TOK>8$>FTMUCW_3?9_91DDDE*22224I"R&Y#F`8[VL=.I>W<(^3FHJH=7R>
MK8V.Q_2<-F?>7AKZK+10`R'$V>HYEF[WAC=B2GSWJ_1^LV9O5+:,',L^KIS6
M/ZET]A<U^7:#NR<KI^,\67.Q'/\`3>]K+_UG_!/_`$?ZGZ,VOJ/I6#UJP]S"
M*3Z9ACR/8ZQGJ>]K?]'O_P"N*'2,_(S<8_;*J\;.J<696)78+?2=.ZH.L#6?
MSM#JK_H?X17DE-0,ZGO83;3L!!L`K=)'Y[6S9_FHF.W,!/VE];A``%;2W67>
M[W.?^9Z;4=))3__3]4/"X?Z\^E_S8RMWVGU9J]/[5M_TU/J;-WZ3Z/T_2_MK
MPY))3]`?5CTOV'TSTOM4_9Z/4]';Z>_:S?ZGI_\`3]3]+Z:U[O5]7(C[9'J,
MV[-FW=M_[3[_`/`_0]7U?T7K?]?7S0DDI^G<#U?4?ZGVGZ(C[1Z<?2L^AZ/Y
MVW;_`-:]'_"^LKJ^54DE/U4DOE5))3]5*KU#^9;_`#_TA_1OI<.^E_P:^7TD
ME/MO5/\`EW_UJ_IT_P!$C['PS_P/_N5_UU=57]#*_IO\T[Z7/?\`HO\`PW^C
M7S0DDI^E?T_J&/MT;M(]+9$]OSO2_K?IO34+=_JF#G1+)]/9MG8__KGT?Y[_
M`(3T5\VI)*?_V3A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'``(``V`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O
M8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"
M`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P/_P``1"`%N`E`#`1$``A$!`Q$!_]T`!`!*_\0`J@`!``$%`0$!
M`0$```````````@%!@<)"@0+`@,!`0$!`0$!`````````````````0(#!!``
M``8#``$`!0<(!@@""`<``@,$!08'``$("1$2$]=8(105%AB8&525U5>7>#F9
M(M2UMA>W,4$R(],V=@IW&D)5-SBHN.AI46%QLR5UUA$!`0`"`00!!0$!`0`#
M`0````$1`A(A,5%A4D%Q(C(3`X&1\$)B,__:``P#`0`"$0,1`#\`[^,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@0N[3Z0EM&Q:!0BG65EE'1O0,Q-KBE&22:
M5&15E5HV=9(IK:4[(0*$KD?`:KB:`YQ7$IC"SUZH:1`684-8$TMWZ+YM[(4(
M_'Q2DOUJ0=1JI1V19Z_8U4@G/0+TX21C&M4^@Q2EA50IUB>I*SC"91L6T3<S
MM!.R"]`T:<H,![;?2:QB[WZ=(J'X:?C^^#KGG]F,9_J..,\)SV^5/PT_']\'
M7//[,8S_`%''&>#GM\J?AI^/[X.N>?V8QG^HXXSP<]OE3\-/Q_?!USS^S&,_
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M<\_LQC/]1QQG@Y[?*GX:?C^^#KGG]F,9_J..,\'/;Y4_#3\?WP=<\_LQC/\`
M4<<9X.>WRI^&GX_O@ZYY_9C&?ZCCC/!SV^5/PT_']\'7//[,8S_4<<9X.>WR
MI^&GX_O@ZYY_9C&?ZCCC/!SV^5/PT_']\'7//[,8S_4<<9X.>WRI^&GX_O@Z
MYY_9C&?ZCCC/!SV^5/PT_']\'7//[,8S_4<<9X.>WRI^&GX_O@ZYY_9C&?ZC
MCC/!SV^5/PT_']\'7//[,8S_`%''&>#GM\J\2SQW\\1POZ5YX;Y'R+8:$T*U
MAL+FF1.=;JD;D5LH10I%"T"@RN+#9U&TY9:QN?VAP3*TVA%;T'TZ%I=8LWV^
MO5+GB;HJQ;.(LND.@TL?1]+<ZN,<:;`<HH2-#$K2A,Q0+%]9WA$6HXPXYC:Y
MXC:5R9>V[&9IK?6M<G"+V(2=[Y]KAKITL[)V8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`__0[^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:N>@B2UWDIYI`
ML#M26R<6=:/#.4<(9A3:ZKKJY"9UK@B*$+9:=8K:C1)S#`ZT(97H#O>]:UZ-
M:_M_PV_3_J1N;<C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`C/6I)
M:7R?B/3A]D:]\%NQ+L((A>A<7%NA(\./!/#O>P;^BA3!S]EO6M;U\],]/I].
MO1C;NZ:_K?NVHYE3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__]'OXP&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&!J]O?\`B5\^_N-=5?Y^<>YK7]O^&WZ?]2)S
M;D8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$;*\_B<MG[A\U_^8*N
MLQMW=->U^[:9F5,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__TN_C`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8&KV]_P")7S[^XUU5_GYQ[FM?V_X;?I_U(G-N
M1@,!@,#G+Z^/[7KSIBB.7.=O(+<$ZO.^Y6X29UBSO7%)!BE)4>B4+CW2=2H]
M#"1N)R5*!.<!N('L.UH&U0#>_;#3%GXN<XEZNNO&RVZ](FJ;TM&ZJ["\B+F^
M3KH.8(N?.8X==C[42]5%#J@CS#&ZZ#*'+_")()Q(=4TODJ9MV-7\^"G(&L4G
M;$<(OV.B;GKLSC.NO;K7EJCRYU9:%LT+`%5&7_7,)Z<2G)J/N>PHH@8H-/92
MA0D*G%A:BMN9SJ8C+6J2T2=?HO8%:DTL02])32U(G*=.A=+);F=%\Q?R6QNQ
MKZ>ZHJ3G3HFV:WAUOHJ&GO1D&B*!SJV)V:I<VUH<$RG0G0I[61**+7<D3T[@
M)T4@1^E9HLU&(E0;>77&#AB9MF5J>9KH"X.:.(W^SZ.FRV`3Q/8E?,A$B0-[
M*Y*BFMW<E);BE`G?FQU0ATJ`2'6Q>R]?6M>C0M>G?IFULG0_SDNTE[(L/5J$
MQ;BSLRPC?*S8G63=$6*I3E$OYY9J=BUGTB8JGP2@'1Y9'70*09]A@WM&?I:H
M2_\`\>C4Z3CT=OUBV>E_++6/RUG#"7-B^2&)TK+*RH%AIKHOH6WIGS!!;XA#
M1!XZR/TCF+&\K'QA-^M"M,Y)T;$\H2XHH7NJL1?S/UC@%IO;GF`)R\OICJS-
M<RW,DR_LT>5FD)+R[6/1\2@EHRIYMZV4M!0>C&AL9/\`$]?=2A4K(,A2K2UZ
M21UO3I$R/:TUP-6!(`B,+$+6CAZ(QRF,G"YL6Q&?+C6>H1TK-[>HJ\*12\KK
MF6*V*W2=+"GU>Z6<_KB6UJJ^&%1N5K3'R2.:Q42)*>8%,VFI#/G(U!1`1C#.
M7?HO"YDEG5F"D/("VV7:,LHZSJ"N/G&X&"IU-YLD*M`B,'CFM7)G#;4:]L+M
M&WQT0@=4;AO1*IO4;*.3F^N'UA;).]G9?ICJEUQ,RYC^'%?D/CG<CD<JK2B+
MRB]9DPHQ_+N.=QM$T5^XS%"[M+8]5HR.:=<K"]2%F"[>N:<GV-*(:-4`(M^R
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M+GO<7>(J_D.>MZ5$+B@JB0#^00`B)-EO2K-;-I.ERDET'Y+HQ1MRV%SS'>?[
M\O2W*^KN/V@>PU9'&UV1KX8Y(G)<]2!:Z;7@"Q((P6B(*/V>1[56L<$Q",H\
M8Q^SMV[S'5)IF9S,):\N](5]UO1,`Z!K#Z5*B%@(%RA*WOR=.D?F5R9G=PC[
M\QO*5*J6IBE[2]M2@D0BC323@@":4,90P"W9<S*676V5G_#)@,!@1LKS^)RV
M?N'S7_Y@JZS&W=TU[7[MIF94P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]/O
MXP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!J]O?\`B5\^_N-=5?Y^<>YK7]O^
M&WZ?]2)S;D8#`8#`YU:4H?RKTET7TATLLYZYQN"V+ZD(DP)I++P7MFX9634I
MU]6ZZAC8F;#C6F/)4R5)HW1AHS3P(4NC/Z9(AF8DVEMPZVZ629N(DG8?%=^3
M"\_)K9:=KBI#3U?Q`DHZKR!2<G:@VQQU$JB:I$[@VE#MK9D[^;HO2PSY!E>@
MS0?1Z=:N+G:^DFTQIZJSG?@7H%;%_#:U$)(C\\XF?8LY7F$4F+"!"G:VJ`$K
M-1D?S3>I$86?&U(-:![/0M^IO6_5%ZVF+^/HY3\_:L<I4+Y`..K,L2D(-7]'
MSSFBQNI'>[B[TDT]7MLJBM;SB01Y3.H@.O&Y$4XO,]#%FHTEL/U[-M)=C=FG
M&G)?5)`DLZ?0MUVDO7.$@/+/RQ:W8O'[U2U,IV!3-UT]@LA()DCR!A;-MK$X
M'G.(A.`TZD(3BRCM""#U?2/6MZU\OHUN[2V8B:6:[9JL]M<9M-A\5=%43S#5
ME5P.;VTQQ5$F1QV/QBN6A[61^:,+V4)^7LC4C)-^8MR97[`1P1^H(P00^CU]
M^E9TLAKMC:6U9$#Y(M^/>0*D.B7%-'M5K7_CLC'-;^K)?`&NV[/:9\Y/RM*A
M:?FX3E+-IM5A&%9O8`"WK8?1ZWR;DES+Z.4XV?7+2/?/-]K\F<B\R\ZVNZ0*
M-3VR/)A)K=CZI9.SH=!D<>3P[2-L?'J_VXYK<J?=&Y4OT82<B`-</VFQ`].B
M#"3,V8DGURZ2R[6SPRE5M*&=J\T=P<*UA$ZUBMQUA9]1W4]7W'+YF'156W]9
M,E*,?C4DLMQ\;54B,?B&=H.;U0TYAI9#AH>]DE")4[/LF99]4SQNNU[-AW'/
M($IB%@RZ;2G@2G.8'I-3,Q@C1/6;IN9WQ+Y)*)`H9R=$Q]I>2CV:%P9Q;P+1
M'C4J#74HS110=B*.4;RR=>S.VW_ZSU2R\8_/5B\J\.TA0MLD,Z:P()JR-R`A
MA=`/345N4VY/9HUA2N991):G?T+(DWM/0'6@&^L'T[]7T[NLQ)*SO9MM;.R.
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MY;^G.XKB17NKBS`YKS*Z@BECL.'SUDKPN2J4.U2Y6(F.J$AJ[V0TX#%!0?7.
M"4-2<XW&WFKSDVUL[1Y>EN*NMNHHIQI>EBT-4CQ;7-X9]&+"Y75W6[LC!9$%
MDS$R,:!>R6[%TB8$9EQ2UE&NTFVH,1%@/*")09L@TA4LMQ;";:SE)>E^KP6;
MXZK5LCQ^=#TW6?*%.\MVQ<EHUC(TD&9[V?[4&ZL$'?8XY_24^LR1MX4PWE$`
M+B%.F0A&FT7OTZUHPT7IG'\;,=2;2;2VYB<C?RQ:Q/D1Z0Z3-3L!=8V=R5'Z
M:BRK;R`3R;,T3HV*U0%S0!.,Y&UE$HQ_[_8M^MO>M:#O_5K%Y6LYG&3ZY5WQ
M7<U6=R1Q;7-'W`G9$D]CC[83DZ)H^[EOC:4GD<W?'MLT6Y%$DE'&#;UI8AZ#
MK>@"%ZN]^G6_0UF)BF]FVUL[-B>5@P&`P(V5Y_$Y;/W#YK_\P5=9C;NZ:]K]
MVTS,J8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'__4[^,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@:O;W_`(E?/O[C757^?G'N:U_;_AM^G_4B<VY&`P&`P&`P
M&`P&`P&!:TP@\*L)E,CD^B$7G$>-/)5&L,PC[3)64U2G];YNH,:WI(M0C/(]
M<7J#V7L0?3OT;UZ<+V[$/@\*KUE+CD!B$7@\>*/.5%,,/C[3&F4I2H]7YPH+
M:V5(B0@//]0/KCT7H0O1KT[WZ,'?NNG"&`P&`P&`P&`P&`P&`P&!&RO/XG+9
M^X?-?_F"KK,;=W37M?NVF9E3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__]7O
MXP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!J]O?\`B5\^_N-=5?Y^<>YK7]O^
M&WZ?]2)S;D8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$:J[$$7D[;
MPA%K8BN#I@(P.MZV(L)_04`T0(>M?*#1VTYGJ;W_`+7LQ>C_`&=^C&W>.FOZ
MW[MIV94P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_UN_C`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8&O'O2H;.<C*9Z@HF.'SFV^7GJ6*UM8(S2B'.X:/LEM:V
MNXZXCIQZM"E#-_9QYI?X^%09[!0\,)*48?0I]8*7%RO>650:3Z2I?H5F$Z5;
M.6MY7HA')Y)"U^S&*QH,[)#A)7%@GU?/(44NAKZV+"Q%')EZ0@7IUH0/7+$`
M8NLLO9RLL[QG/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!AJY>@Z7Y
M^CXI';]B1N%I3/9%M;:X+@GR>3+U)@R4+-#HBATJD\P?W)0#929"V)%2M09K
M80%BWK?H6R=UDM[1^.&ZKLEXF]P]D77%G"`R^]6J%0>HZLD!11<MJCG.OCI"
M\1)#-R"AG%LUC61*)BXO[ZV`,.^BPC0H3!_.$IX0\[<W+IVDC9#D#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`_]?OXP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P(T7#QCR1T&[DR&[^::.M22$`***D\WK&(/TG"F(`:`I%N2+FHQ\$W@T;O
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MMY15[L\:W`,$XA[(F\-X\Y[C$OAO*O0LJBDD9:RC2!YCTDCU1R]W8GQI7$(0
M'HG-I=$92@@T&]#+-+"+6];UC!-KF=6?X)XM_',O@\-7+>)^;52Q;%(ZK5J3
MZJBQARA2H:$9QYYQ@D&Q#-.-'L0M[^7>]^G&"[7RNO\`"L\;GP0<T?LGBGZ/
MQB'+;R?A6>-SX(.:/V3Q3]'XQ#EMY/PK/&Y\$'-'[)XI^C\8ARV\GX5GC<^"
M#FC]D\4_1^,0Y;>3\*SQN?!!S1^R>*?H_&(<MO)^%9XW/@@YH_9/%/T?C$.6
MWD_"L\;GP0<T?LGBGZ/QB'+;R?A6>-SX(.:/V3Q3]'XQ#EMY/PK/&Y\$'-'[
M)XI^C\8ARV\GX5GC<^"#FC]D\4_1^,0Y;>3\*SQN?!!S1^R>*?H_&(<MO)^%
M9XW/@@YH_9/%/T?C$.6WEEJHN(^/*#?_`*UTOS#1-92O01`+E4/K"(,TG3E&
M%B*,(22%,U!>$:<TL6]#+*.``?IWZ=;RI;;WJ46$,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@?_0[^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@0V\B_P##X[M_<VZ>_P`DIQA9WGW26KG_`-GL#_Z,B_\`8B'!
M>]7GA#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__
MT>_C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$-O
M(O\`P^.[?W-NGO\`)*<86=Y]TEJY_P#9[`_^C(O_`&(AP7O5YX0P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]+OXP&`P&`P&`P&
M`P&`P&`P&!K$ZZ@([A[:XKJ=TL>[H'#7FCNUY:])J3NZT*0<GMZB,@Y#11PU
MZ>ZME$6=75,U$2E?HD@\TPH&U(]Z#K>]Y&IVJ_\`\.JK?U_=^?S">Q??'C!R
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M'%4J-.0D27MWLE2)22DR5*F\@G8)"=,G(`$H@@@@JX0EDDDEAT$(0ZT$(=:U
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MI$60:.((-+*'M,#>P[WK6"]HV=Y63`8#`8#`8#`8#`8#`8#`_]/OXP&`P&`P
M&`P&`P&`P&`P&!`.W_XD?#7[M'??]Z^(\GU:GZU/S*R8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$`Z@_B1]R_NT<
M"?WK[<R?5J_K$_,K)@,!@,!@,!@,!@,!@,!@?__4[^,!@,!@,!@,!@,!@,!@
M,!@0#M_^)'PU^[1WW_>OB/)]6I^M3\RLF`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!`.H/XD?<O[M'`G]Z^W,GU:O
MZQ/S*R8#`8#`8#`8#`8#`8#`8'__U>_C`8#`8#`8#`8#`8#`8#`8'.K?GF"\
M=4:\A=`/K]T&<V-O/E:=M4]<)BFG;YTHAED2J:\RHF*,'MX*O&XNQRM55;^`
M2AO*5HTXD&_;&E^V3^UF6YK<7HZ&FET1O;4V/3<,XQO=V]&Z(1J4:QO4#1KT
MQ:M*,]`XD)7!"<(@T.Q$GE%G%"](1A"+6]:K"H8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`HDED+3$8X_RQ^.4)F.,
M,CK(7I0D;G%W5$-+*A/<G$Y,TLZ1>[N:@I&F&("=*0<I/%K0"BQC$$.PY^>=
MO+MX\YMY%KV7Q:_SGE-T=77$-+4O\WJ"]@'S6S8U-^FD#U&"DBBL25;&-&KM
M5@!I6Y@1(3?G_I+.'HA1LF9ZMW6\9T=$.5@P&`P&`P&`P&`P&`P&`P/_UN_C
M`8#`8#`8#`8#`8#`8#`8'!#W;P3J2_\`<-PREB68H<'ZCM"K[_5-XR!&!7P1
MR`ID-Z*A@$6(L\2MXKJ7&Z^39?RZT/?R"WF?JZR_AEWO9IR,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?@PLLXLPDX
ML!I1H!%FE&!",LPL8=A&68`6MA&`8=[UO6];UO6\#@F\6_")D.\]UB5,L;#M
M1#C>7W79:(I60+T*HPV*MQJF%QA@]!"2I4;L1A=R=:];8M$;]7TAUL6LSNZ[
M7\/N[W,TY&`P&`P&`P&`P&`P&`P&!__7[^,!@,!@,!@,!@,!@,!@,!@1,F?)
ML/F?9E'=AKA)OK12]-7%5R!&)+H:M6LL9X@Y\?>B5N_3I,3&6%+*4@RO1ZYV
MW\(M""$H83"YZ6)9X0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P(EUUR=#Z[Z^Z2ZU;?FQDHZ+@%&Q%X+]AH"MN65
M*DE[,Y*PFA+#HXF1L*F/%#V(8QZVS`#H(`AUL9<])$M,(8#`8#`8#`8#`8#`
M8#`8'__0[1ND.RZCYI<8Q#GY)-;(N.>I%J^O:&IV-&3BVIBW-QH2'!\*90JF
MYFBT1;SM["H?7]>TLI(PB`)5[0.P87'_`(CR#L;LU9ZRA%X]DZ!(8+TITTHZ
MVK)O?@%>C7H^DD49ALS8TQ_I]/I"G<U8/1_Z?^K5XWPF=?+]_:][7^`*,??"
MB'NFQQOA,Z^3[7O:_P``48^^%$/=-CC?!G7R?:][7^`*,??"B'NFQQO@SKY/
MM>]K_`%&/OA1#W38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z^3[7O:_P!1C[X40]
MTV.-\&=?)]KWM?X`HQ]\*(>Z;'&^#.OD^U[VO\`48^^%$/=-CC?!G7R?:][7
M^`*,??"B'NFQQO@SKY/M>]K_``!1C[X40]TV.-\&=?)]KWM?X`HQ]\*(>Z;'
M&^#.OD^U[VO\`48^^%$/=-CC?!G7R?:][7^`*,??"B'NFQQO@SKY/M>]K_`%
M&/OA1#W38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z^3[7O:_P!1C[X40]TV.-\&=
M?)]KWM?X`HQ]\*(>Z;'&^#.OD^U[VO\``%&/OA1#W38XWP9U\GVO>U_@"C'W
MPHA[IL<;X,Z^3[7O:_P!1C[X40]TV.-\&=?)]KWM?X`HQ]\*(>Z;'&^#.OD^
MU[VO\`48^^%$/=-CC?!G7R?:][7^`*,??"B'NFQQO@SKY/M>]K_`%&/OA1#W
M38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z^7^;[`[3+ULPSQ_,9Q9>MC,*0]?08Y
M<:`/](9:,I=6;:B-5##KT%A.4IRA#WK0S`!](M.-\&=?+*E#=W5[;<_+I*P8
M/87-?0AS<K=&RG[J2L"-3.FYK`(;RZU!.HJ^R6O;:;&@)8C%(6AR-<4I`=G*
M49!>MBU.W=K'UES$XL(8#`8#`8#`8#`8#`8#`8#`8$';Y[NKVI)^925?0>PN
ME.A"6Y(Z.=/TJE8%BF"MSH`(V9UM^=2I]C5>U*V.X3`F)@N[D4XJB!:.3(SR
M]Z%MW[+CZVXC%>NP.TS-:,+\?S&269K0RREW7T&)7%`%_2`6L*0UFY(BE0`[
M]!@25*@H(];T`P8?0+=XWPSG7R_W[7O:_P``48^^%$/=-CC?!G7R?:][7^`*
M,??"B'NFQQO@SKY/M>]K_`%&/OA1#W38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z
M^3[7O:_P!1C[X40]TV.-\&=?)]KWM?X`HQ]\*(>Z;'&^#.OD^U[VO\`48^^%
M$/=-CC?!G7R?:][7^`*,??"B'NFQQO@SKY/M>]K_``!1C[X40]TV.-\&=?)]
MKWM?X`HQ]\*(>Z;'&^#.OD^U[VO\`48^^%$/=-CC?!G7R?:][7^`*,??"B'N
MFQQO@SKY/M>]K_`%&/OA1#W38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z^3[7O:_
MP!1C[X40]TV.-\&=?)]KWM?X`HQ]\*(>Z;'&^#.OD^U[VO\``%&/OA1#W38X
MWP9U\GVO>U_@"C'WPHA[IL<;X,Z^3[7O:_P!1C[X40]TV.-\&=?)]KWM?X`H
MQ]\*(>Z;'&^#.OD^U[VO\`48^^%$/=-CC?!G7R?:][7^`*,??"B'NFQQO@SK
MY/M>]K_`%&/OA1#W38XWP9U\GVO>U_@"C'WPHA[IL<;X,Z^3[7O:_P``48^^
M%$/=-CC?!G7R_`^QNS4?JJ%OCV3KTA8O2H31?K:LG!^&5Z-^GZ-12:&PQC4G
M^GT>@*AS2`]'_I_ZMN-\+G7RD-S?V74?2SC)X<PI)K6]QP)(B7V%0UQ1HR#V
MU#FYQ-$0WOAK*)4XLTIB+@=K04[ZP+W9E.&((`JO:"T#(N/_`!__T>DSA)O2
MV9$95VO)2@.=H]AR!SL@;XK*.&MC=+E.JYNHBK&4Y8`M2AC$2KE(A/,("`H*
MAW6K%0P[&;Z=;UG3+.]ZX^D3SS3!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,"+_7]/`M^D)26SKQQBTJ\3'VG1MB(=%EOE;7%!D:E[A$J:5>]>T+(T
MY)M)')/H6BW!I4J4AOI*.'K)9F-:W%GA//G&U!7ISS0]W#0A;!W'3-7VH)M#
MZ?5;Q6%"&.6B0A](A[]5)MW]GKT[W_L_Z=YS=+TMC,V$,!@,!@,!@,!@,!@,
M!@,##/1UJ"HOGF^+N`A"YCIRF;0M0+:+T^JX"KV$/DM"A%Z!`WZJO;1[/?HW
MK_:_TZPLZV1`SD"G@5!2$6+>%XY/:5AIB+3O*Q%VBS'RR;BG*-,]S>5.RO6O
M:&$;<E.TC:GV+9;>TIDR0KT%$@UG23$<]KFWPE!E9,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@0,[M;TM9Q&*]KQHH#9:/'D@;+(`^)"C@+9)2YKJA
M;KWJQZ.1@,4KHQ+:Y5KCRR!`-"G=T2-4`.AE>G>=ITRWI>N/I7__TNF#QI_P
M_N.OW>:Q_NRASIKVC&_[;?=-_*R8#`8#`T@^1CI7OGCY$LL"'6=S-(&.PK.9
M*[Y]I'=.SY]M^:O,E6$D-\>TM23]&VKUS>E]H:I5EIRR!#]D2$&CE!!0\[6S
MPZ:37;IBJ'>?7/D$9.MN=..X"_\`*M?V#-.,8;=ULR"T6"7+H:CM@MXF[%8;
M1&G-EDNU!,;$X14(6LD91YGJ[%L9X_6#ZJW;,GI9KKQNV+C*Y.B.I.[JVM?@
M#F*)2_F8=P=,,=LCL2Q!P>:2&LM.\*3(7MF51%M+EC4])VDQE$849[09HSE`
M]#UZ@-:#BV])]4DULVN+B)#^.WK^WNCE_3M37Y'(`WV]R?<!U32R4U4)Z+KV
M<>H8](4[PRM\C5KGIM6A61I5M26:9H.PFE;T40+UR066W,O=-M9,6=JBUV3T
M%Y0>?KWJ*%Q*9\?JX+T]T`MJ6ERW6!66ID,2;')7H^.'V.J+?DZ-2H1-:DHM
M8<W!.T:>`8RR@A%H.I;M+.RZS2R]+F1)-V\B%=<G-D<I_N.T(PX]5$L;=(9&
MQ497-B.,?DK7,IE+T<14P5F4('!W6`:8PQ:V[>N9O9!J8PS>@Z/3ECN<=^Z<
M;MUUGXKNL#RF<>5A8CK7TRELY:R(]/#*NE-D[J:QS*>BUB$N!C6HB+Y9FHYJ
M-$N2-P(,*4&%&G)4VR3=FG`"49L+E(33:S.%>Z$\E?)/,<SEE;VI-G]-8D/8
M&"3KH1'(/*I/('!BD"!X=BG1G(:6P]*M;FEJ8E*ES4[.+3-I6@?.#"Q&E!&N
MTB33:]9.BIRWR+<HQ.EJBO<,[=I;#;\5G-E,M<"A4MF$YL1Y1;5ENS(Q0AG:
M#Y"!T85:$Y,X`5$IPHE8/8&B"<,`!.4Q*<-LV8[/5.O(/S#6U#0KH>:RJ3,$
M.L9[612"QERK^:(+4E$S;7ETCSE#FVKUS*FF7TZWO;,H3G>U2EI0;"`>SO9'
M$F&,S&2:VW'U6.\^4[BV-5M7UJR>R'J,Q2RU]F,<=T_U_.&I[(E51M87*:PY
MZ85;$6YM$H3C-*2(TII?I<UJ@DE)LX1I?K.4Z+PVS9A2(AU>"U.O>>6B$7@2
MTU1<_*KK;C-S_(Z7?$$XDJPN1/"<N<JK"6HP%Q4#:C(`F&T'&@]<2,8PA/"I
M+,*9ZSJ8QK<SKE;S!YD_'_)GJNFAHMMX.264ZH(\V2D^O9PCA<?D[NI,3,T7
MF<H5L9+5&9`YZ*V=I.>/UDJ783U6R"1:'MRA_/;KT8O5>8JK(MV#T+SO.X;.
M44'ILAL:667Q2K;7F,J?)HD6#;)DB<XPQ11>8@C*)R),"VN@0_,W(D`3B##2
MS0;R<IFQ>%XRY7[R_P!W02/\2N'4/374\7LN+(['E,:#9[73\CJK:E02X$M[
M+`FJLOHLR2O,F),*-'Z$R4XP98A;$(1:<T_$O3-J77\N,C/%#^1+E_H?_$IO
MA4EE#',*ABZJ<6!7%AP24P2PF.&)$A2P4H!&7UN(4.K.,E05_31B4"*$H(T:
M$O:@CVEFTJ76S&>S'%?^6_A:S[*K"K8=:CFO>[@.;FN"O2F#3!LAKG+G5*VJ
MT4`-E;@SIFE/.!!>$I1J'8][3+%!:0\1:H82=N4Z=5NFTEN&RK*P8#`8#`M*
M??\`(LU_Z2D?]CK,+.\5WQT?P^.$OW-N8?\`)*#YR=;WOW3)PA@,!@,!@,!@
M,!@,!@,!@0V\B_\`#X[M_<VZ>_R2G&%G>?=0H#_R+"O^DHY_8Z/.KE>]7;A#
M`8#`8#`8&@CH;IGR<T)?7.O/[99')-N6AT/-AI6.O8K3MB-CC&ZT:E`QR6Q9
M>YK+(5`9H^TI"C-Z'[,8U`$BP9/K[2&`WFW:63HZR:66XLD5=]ZW[^M7M_KG
MG&@IYR%6T,YQ5UT%`KO.-S83H]I)M$T3IL!#BPR$92Y6E<2E`C?2G("`LPO0
M=;^7&;FR8..LUUMEZKJM/J+OB2][37C3GV1<TQE17?+$>O9S>K2A,V=&M_?]
M.<58G]J(<&25I53,UKG66E#3C&G-VF3$"]?8Q[].,WEB))KQY7/=,;QN=?//
M<7*$*OJ3Q)NA<K<7:31B4,[&:K.CACU%W4U`:YQS;@H5.1+2YI=E&Z(4&FFI
MCA&$[-.T7HXRZW,RSOKQVL:\>;/+%;,F\B5M\LWS%X:S4PY=`7SSW0%AL32Y
M-*O=B4U*Q$(8E*7%:_."%T722*N"$&QEITPOI16D`4#8#QZ+DVN;+V;NDX3:
M=\,_<U^39F,YNL&_.NGICAS8T=C3[FN+*H1#92M2G`;CD.H>E6M;<;*'(2XX
MCYT)0L%L!'H+U\@1;UH2;=,WRS=.LFOAL*UTC4.^@G;F$4D.*N!BJ#=Z.[*H
M:'5,TH*V#)4<3&]'R=0D+C^CBWA>4$2?2C9P2A;,V'00BWK69G'U9Q<9^B,-
M>^3;E6]Y?*ZNIB=R%[EQ#'/3H7*#*]EZ.OINZ01F<W*1`@\V<V,,9D(X^4WC
M/'ZQ@25)(/73[/+WZVYREZ1KA9UL1[XI\A;/'/&MS/T3V)9KK)+&M=]L:'MF
MVF)#?+`LV4--RV/%XZP16!U\Q`4.[DFCK"D(&-.C++#H`!J#-&&^L9)?QEO=
M=M?SLUG1+J*^1'E.64=/N@4DY>FR%55(T4+LIE>X'-F^QX5-W-U;&)JAKS6V
MF$Z8CD#J\/"9.G+3)%!1IA@O5,]!1VR[F8RSQN9/J4KY#.8+QU:Z=DE$F@[[
M1\4-GUIQ2WH)*ZOE$0@1*(YR,FB]IE;8B&='"VXCVYAY`C=D%&%;."7[8KUT
MLI=;,>W[H_R#\UW\BF#U$'B<QZ+0V$K[-4S>SJPGE8P=ZK5JV5IUGD<ELS8F
MEB<XXV:/+$>/9Q9Y98]&;*]GH0@I92ZV*+1?DIY1Z'LAAJR`2B9(Y1-FEVD%
M8CG593ROV:VF!B3&+'=XK5XEC$UHY,D0(R##AA#LL[910QA+$$`MZ3:4NFTF
M;$]<K)@,!@,!@,"$'DL_A_=B_N\V=_=E=DV[5K3]M?N__]/I@\:?\/[CK]WF
ML?[LH<Z:]HQO^VWW3?RLF`P&`P.<2W%O6*WR<2#HVS.%;XO.J^=VYR@7)$>@
MZJ(@BJ%>K&45(;D7J'I>3I<^2#91AR(.D_KIP&)=#'[5N(&+%SRSAUG'AB;=
M;W7Y<7'+EW!Y(N<KCZ#Y<E`N>7#A9M03ABFC@-&5!+9!.+0?TL&D#A%7]O6C
MD;(7)4^]Z('L@S1NA?+K0M!69VF9TP3;CI9+URJG:GCPU9O4/C6KBN:SFK%R
MQ3\>N.*S1YK63.<<-K-C.9&A7&$@97IV%)6X;HY-^B0FA,-.4:$8#8M[%O+=
M>NL^AKMC7?-ZMMO.?,%(<H04^NJ)A">&QU>\K)(]F#<79^?9+(W`!1:U^DLD
MD"YS?7QT/*(`#0U!X]%%`"67H!8=!UJ23LYVW:YJ&_D%IRS[/O+QP2.`0MYE
M3'5'6K+-[&<FLHDQ-$8FG3H`'/KL(TXH1:$L10M;V'0Q?)_HS.TMNK6MDFV?
M#^#31]B[\R,HZ!7P)>.HP\%IJ\9+$4ID9C.59(KB8',UA;SS#1+"'K<6"L$(
M0"PZ^;#,!L?H'L(KC\L^C,_GC/7+3UW%3OD7Z3C_`%I5T[K?L6<34-ZKWJFV
M>&.E9L?%HN;&5_8U<'$!"D7)Y).K4-]EL0$8]'K$X=E*58RCR%H!9LVN>[IK
M=)QLLQC_`*VRH*&M(?E%ZHN917[GNM)CQ-'ZVB4W/)1::7B9Z=F8Y;&D!YI^
MC_G>B$8MFZV`)7H!_2%_HRXO*WZ8<\SA)GKEK<K7DV90KQL\GP"^.6NQU%L5
ME95U2R)2SE%VC3?T!SW*G2<JW**/:-F=)*V%+&*:ISM"4&E[.VB`D`;ZI9@R
MC0S'XS,K=VEWMEF/;)$JJSR&$UCXM^J[NJ61]!7%R=/+D7W15#%N.J+7<819
M!C(RP63C;TBO;*_3R)QR+DGG%)MFK/GJD@1X@&`6GEOR_&TSKG>2XE2,NN-=
M`=97;XR;I=>5YS63!6W1EJR::Q:9JHV\OT,A!#1$T\-FD\2MZ@Q%'G)[7LQA
MQ"$(U*A((@O^F(7JBRW-NMPS,2;S/T9WL*FK0=O+C0%XMT+>%52Q;DF?0F03
MLL!&F-KE;I+9"K0,2@P9X3]KU29848$(2Q:]0?IWOT:WZ&+RE^B9G"SZY<\W
M.$5Z0ZK\7=-\.UCRK+E31/;Y5RDKJ$Q='3JMCD49[(=E<HD3LITH(=X_,8\O
M"<W_`#(T.U"UK)$)+LT1Y9&LS-UQAUN-=[M;]&\=!&;UI7R\VQ:!?/\`8=AT
MUU)5=.P=LM*%?0ZF-5RYPTEH;'U;8)JYP2&-#<@3MBD_>M:$H/T(@*<LX1@M
M%ZZS:W'=SZ723/6-?[!Q7UFQ<"T`I;Z.=I%9O-'D66=3/%!/BIK:GNQJ[8Y*
MZ+M$,^UJHUL6*UZ=2#9:8>AFJ$9I_L@C."!.?,7$Z?5KEKRO7I8E="J[Z$ZF
MZ]O?M![YKG_.4"3<(S#F."PVTBV5LM:T9T[N[O(]NRN*-2Y8<UH$/ST2$!ZP
MS6E!9*+V&S-;."EO6VW'T2V36:YS<L`*>.>D@\%^(^MT=,R<JP*0ZZA,[MF-
MDDMA3K!(R58,\>G"1/OJK0%DI"D;@G/.,`,8@^T#ZWH%\F3%QKT^J\IRWN>E
MCIHS;B8#`8#`M*??\BS7_I*1_P!CK,+.\5WQT?P^.$OW-N8?\DH/G)UO>_=,
MG"&`P&`P&`P&`P&`P&`P&!#;R+_P^.[?W-NGO\DIQA9WGW4*`_\`(L*_Z2CG
M]CH\ZN5[U=N$,!@,!@,!@<QW-4W[)KWI_H7L&_?'!TK9=V6XO+BD$''UL%)C
MU.4FUB3_`$3`XQ](NA9BE>H"E("O6!+)TJ$DT;KT&*E6S,3.;>+M>-DUFTPS
MO$/&A";Y\C/?]E=;<ZF2^JI&JIQ;1\HD+H]-30\*@0LINF!K$9%Y&UJE>TYC
M<G*4:/#O10P:UK0=[WZ;QSMMF)=\:ZS6]7][6\=1W2GE;LN76_!K(0<Q'\CQ
MV/,LNA<R=H&SR*;MK_#6O<"<'.,.B)[7-9D<-<S#T`O4(,^;%C%O^B#0IQSM
MU[$VQI,7KENNJ:I:XHNO(O4]21%J@M>0Q`)MC<89@G_,V].8H/6J3!GJSE2]
MP7N"]4:I5*U)IRI6I-,..,,-&(>]]G.VVYO=H)!XZ;@MFEO)6TN4/<Z]N5=Y
M$;DZGX[F"\YO;G!8\-KNF?(1((^[!4CVW-,X1!-;PGG"*`28>`\P/K)M>KC%
MLV\Y=.<ET\8ZH^(N).Q93XDYM%W^DG]!?R/N)=U""HS#FU!().P;VU)G4ID3
M:6+@%FC&X+3DZ88]*32DF_9`-&,H!LQ>/;KE>6O.=>F$P(+673_4?;E^7Y,>
M<IUS/!+J\:%B<ZP-78[FSKGIOESM.8F)O.ES='U!BB+.:E0I<%!#>;O:S;>W
MZ4#T5L\!>KUMMQ]$MDUDSFY7[X\9/T[7U$0#B.P>(;.KQ94T$LN+32Y'-TB:
M6JU0@))<YQER@BE$J5*YV^31Y=$I"H"36BB#%)ZD9X]!V#=USC&$VQGE-FO]
M+PWU?&>*_%;)3*ON]-*.29QU"?=%8TS)6.)=%,D;N>U7EV8Y97BEQ5F-BIY:
MF=J*'\U*V:K-+=0!T$LOYP:3G%QJURUY;]>^$FF^K>C:]Y9ZYMKBBINV8)T%
M<<]J51(W?JF0UK([_G$.B7SU))Y'`XKI<XLS')T+`]'I0B7:.<EI>M;3>L>0
MF]2XN+C.4S+=9M9A2N8>?;B'TKV!<<\Y^ZVL&G+:X1?H1'(WUO+X8*Z+><?G
MZ5(ZU&_N4:=]M$!7S`#:L2-Z,XXGYD@4%*1B)":$`$ES;CI@MF-9+,Y^BQ*?
MY<ZYG5;=H\U51&NHZSX\EG+[G&:5KSMI=$BYE&;]^L#<I0PFMUK(^NZELI]0
MP(UZ32@9WS0&U)`S0&#ULT:2XLG9;=<ZVXY9^B_>'^>WYSMKD!-<]">2ALL;
MF1B6I#91=MD0$_ERK7A'6)\>6AK`QN<!R*3Q23KV9(W)&UM`$"<D2;2H9Z4@
MW8DG69E3:]-L68KHZS;D8#`8#`8#`A!Y+/X?W8O[O-G?W979-NU:T_;7[O_4
MZ8/&G_#^XZ_=YK'^[*'.FO:,;_MM]TW\K)@,!@,!@,!@,!@,!@,#R_/D6ENF
MWYXE^D=I1+M(/G!7SW:()H2!+-)?7]OM*$\>@;,]7U-#WK7I].!ZL!@,#%%*
MT?57.M>,]44M#D,#KUA4.JMIC3<K=%R9(I>W-4\.IVE;RO<G(X:MR6FF;]H<
M/U?6]4/H#K0=),=(MMMS>[*^$,#S$K$BDQ22G5)U!J([2=842>4:8D/$46>$
MA2``A"(.V2:$>@BUH7JBUOT>C>L#TX#`8#`8#`M*??\`(LU_Z2D?]CK,+.\5
MWQT?P^.$OW-N8?\`)*#YR=;WOW3)PA@,!@,!@,!@,!@,!@,!@0V\B_\`#X[M
M_<VZ>_R2G&%G>?=0H#_R+"O^DHY_8Z/.KE>]7;A#`8#`8#`8#`8#`8'E3+D2
MW:G2-8E5[1JC$*S2904?M*M)"`1R-3HH8_8*B@FAV(L7H&'0M>G7RZP/5@,!
M@>82Q(!44A&J3@6GDFJ"$8CR@JCB"!%@//*3[%HTPDD9P-#%K6PAV+6M[^76
M!Z<!@,!@,!@,!@,!@,"$'DL_A_=B_N\V=_=E=DV[5K3]M?N__]7I@\:?\/[C
MK]WFL?[LH<Z:]HQO^VWW3?RLF`P&`P&!SO>9.YA5SU)PK%9QU+T)RYSY,6JZ
M3;CEO/L^G4.D.DK6FC`X\N&AA#5)3WI40]&$IR_:M#AL@E4=Z@2]"&9K&UZS
MKT=?\YG7;I+4GZUZ!D%;<L5'(.)C[$[ZK::NMFKE/1_7_1R"LU$7U'I-IJ-;
M)7);0A,<FKYM2^%KD+2C(9"0$D(!F"/V5Z@AW/28ZI9FWETOIYVGR]Q!;Q.3
MU2LI.3:GZ^\S>8H_0S-+FI\.E5[#/&)MC3!8:=I*;U,?<&H`U>W+;;H00E&E
MEISQ:+V<Y=,X.'Y<<]&"._\`MOR'55PS.;$6<W?96LY@L.#L;G/66Y*TM)J9
MXH\.C$>A?XTA,C+F3(#GYV.,8%Z`THDYO];YWHTTD>@Z6[8[+KKK=I,YB65H
M]^7E7`>?JA,Y"^?=J=%*YX='>>T=XQETAT/B$#,5J'"<RRZ4T73-`FY0QI]+
M"DA+:$T0RST^S`&%E[.N;TF.K,UES>7XQC]#Y7W1LYV[(L.Q>;G.$WYPX[0M
MDM^B5-D-RQG<39X]$,\9=XW9S9%W,@QI>"BEBHO?T4?K1:<&@F'`."?DY=+T
MZQ>'762]*G%R5>MN="PM]L*R^>GGGV..SRD<:<1268Q^2RB=5:\,Z)S8)E)F
M1@]I]0GQ=[<7MV=48-4DWO01;%K033;+GZ,[22XERUX\RL@NI.^O*O/9(^2V
M/"A3'".**TED,=U<:F5>1`AIDJNQC8'*@$C5QY_/G"(AY3*4^O62KC-&AUO7
ML]Y)UNS5Z:Z3_K`?-U?V%./)R[0Z@^MNSY[S)QV0,GH&07!TE/K)BMCW0M*<
MD"6HF9I6?,H^L1QI5ZWTK\X)4>J:WJ@ZV4+:,PV3]NEN(MLX==9FHF\)WQ5-
ME=`OK/TSY*.[HCT$5W"]12GN?XS;EO+Z>GD/1RV+;@D>E3?JO9M%RF*2RX]R
M9ER(Y[:TVFLD`!%IRQ:/,FMS>NUSEK:7'328PM&Z.A75%9WE5D<U\@_2E.6M
M1-SNR?DRHHUT!)&Z(RQ2E=I.27$2JB5B=6V01XM4@0)3"DQ2=.D+.V8;Z0>M
MZ6?VZDG33\9B]W2_4S19W0'$U:--U2"PZHMJTZ%AH;%E%=.(:YL^(2]_BC:>
M]/4=6D(U089+25QHCO9Z3>A$H$(K9(?5V7K?>=>[E<3:X[9:;^<.8+!E7D1[
M`Y[?N^_(VY5_RB7S9*H,!7U4^JG&7'V)!FF=R)HLCYRPG,[XQ&.1@DQ9")&V
MBVB%LLP9@]^TS,G6S-=+9PUO&9J+Q5\53(NZ>VH)UIY*.[N=11SII9$J!K^D
M+<MY%$'-F/D3\@6LYS2P5[93&QH&Q62W)TY7KM9(2SQ_T1ZUL1<S^5SM>ZXO
M'6ZZ2]&UVJU9M+^:+HZJFL!Q42ZJY2KSI5:A`8':)#8%=RD^IC5J1&$8@)/K
M"UI%YZTW6@&GJ@%[&$8?4&'4Z;6,7K_G+XK<9FG,P&`P&`P+2GW_`"+-?^DI
M'_8ZS"SO%=\='\/CA+]S;F'_`"2@^<G6][]TR<(8#`8#`8#`8#`8#`8#`8$-
MO(O_``^.[?W-NGO\DIQA9WGW4*`_\BPK_I*.?V.CSJY7O5VX0P&`P&`P&`P&
M`P+#M.;$UI6-C6.H(TI3U_`Y?-CTPO:>JH)BD?<7TT@7LM"-]!H$&P[]76Q?
M+\GRX6=;(TE<+T?&IIXKXA:MP7Q=U#+Y_.;A[)O:XJ7M!WIV6/CJYOLZ3NCM
M+I.SI%+@Y1DR$HT2I0F$$03U"(@T/I]F#69D_'NZ;7&^)/2(=-+^FT/CV\A_
M9P.A^KR*YFL5=FOD)HMJ\I]+[%C,$BDE"D%:X9`O7ICF"0RLXSV"<YLTD$$L
M@_>MFDB3&[SUQ;FK<<M-<3/U7UPS<5*2>@[@FE:^13MR]^J6'Q^3V<6?4MOV
M;:C_`%O5LZ#`X^MEDF@VY77$=;"W^#V,,M`TK4C^YJ"TB@P19B@`A*-67I;F
MYP;2YF=9-<HT\N]O=/U_R+TS25_W%9#W.+6XQF'5W(-W/LYE;A/SB"8L[(YO
M#V>>.3JIDH7F)KF,]<W@*4@.0:;5YX1A+-3!#);BRWZ+=9=I9/KBIPVY*I%!
MJ[\"_9ZUX?'^?J7'G6B;'D;L[*G1]F\<ZDHUDU,ULI<G!2>XR9V+.8EKD48J
M$;L;B<,X9@31Z,R_"LR9O^FOT=%&;<C`8#`8#`8#`8#`8$(/)9_#^[%_=YL[
M^[*[)MVK6G[:_=__UNF#QI_P_N.OW>:Q_NRASIKVC&_[;?=-_*R8#`8#`8&O
MGH?D"9W%VOQ-TXRRB,-44YD_Q9^MT?=`NNY"_P#U]CA#2T_5SYHA/;1?-E1>
M]J?G)R?U2_1L'M-_T=2S-E;FV-=IY8K[ZX=MKI2Z^=+FKO[.]@M=,MTY97RB
MNKF.62*FW\4T2%HP3+Z&C2)Y*=9(Q@UH1294D+*,&G)W\X!ZOR2RVRFNTDLN
M?^(T-7B$M)HXC7<[MUOUZRV]!^S578%(S>/QES;:^0R!J2EML59I%%/FQJA@
M0;;E*S0TJ+Z0(;C!$>SVK`5L`W'IC/7+7.<LXZ8PSU>W'G:?8_%EYT;T]:G/
M;5;,^>((ZUP33$<G".I(:""/3&_&)7MTEY:V?/1DO5MYX5)OLMA0;$6806,&
MAD;66RRU)MKKM+)<*+:7'?><^>^4^K&^T.8&ON7GELLB+2-I-8K-%S-/XA/-
MKFTE`<:7Z]AH'%"QJ1#4'DI2`J%BC>R0)0D%[&Q>E^I-M9RF+QJRU/C`O.8\
MW]ZM]FVO63OU7WN\5V[S5YC;;*6BEH,CK%\3*XG%HV!<0YRY>VM;4<N*"L4)
M@*3=&$%F`%LD:@UQN+UZTYS.N)TC<C7$94PJO('#5JDA8LB4,B\95JTNC`IE
M2EA8T+4>I3A-"$W1!YJ38@:%K0O5WKTZ].:8:5*BB%H5MVYY9^:J^D2>O[*Z
M5KF.=0<V39[^DCF9$LD32_0N7R[V("W#T?5>SI.F(WLHHPS0D?K>R,+"`L.9
MTNT;N+KI;VBY>#.,/(?QBTP2J4\_XP7TBGGBB5VH>UQBVU5NSK3\X%G2AZ.E
M#CI$V+IB<V%%)4AZDH)!1*4@L0=@+]&TFTZ=,&VVNW7%REIXZ>0)GQI7=Y0V
M;2B,2M;:73]G7DT*XL%U"E;H]-F6$M3:T.6G9"@-^F4HXL8,_P!D$PC6C0Z"
M8+T;WEUF,IMMRQ]EI<J\!$4KTAV3?=DHZLGJR_[J(LRK%P(T!TEM=M.ELC<%
M2`]V?F4!K2XJ%;LF$+Z./&4(:4(]B].@>A)BVEVS-9/HV9Y6$$*6Y4F-9]S=
MH]3.TBC*^(=+,E"MD4CS<)TW)&$ZIZ\0P]Y,D(5+>0UZ+<ER41J7YLH/W[+>
MO7T`7R9).MK=VSKKKX4CCOD"9\X7KW+:LFE$8?FCJ>ZD5F1%M8@NNG*.M*8Z
M6GC02/;@A2IOI$0I&`.OFPSRO04+?K?+K6),6U-MLS6>$>*@0K;J\S/3EP(P
M'FPOEGF2O>7R7+1.B$2Z=SI_#;3DB2G["2-<9'$RQP(5@UHW9)IY6Q#"$1.A
MR==K6KT_SD\UN-S3F8#`8#`8%I3[_D6:_P#24C_L=9A9WBN^.C^'QPE^YMS#
M_DE!\Y.M[W[IDX0P&`P&`P&`P&`P&`P&`P(;>1?^'QW;^YMT]_DE.,+.\^ZA
M0'_D6%?])1S^QT>=7*]ZNW"&`P&`P&`P&`P&!8]FPI+95;6#72XWV"&?0>60
MI8=_O->Q2RIA7L2@WTDC+._W9*_>_P"@((OD^3>M_+A9TN7.-3O._1?:/B/A
M/&=?3R+5185!7Y.:0Z79)^=*0)75)5\ND<D2P`Y6P(')W*2Z'(8ZI,`7HHLT
M"3U0&@+U[(6)+=<.MLUWY8Z6)R+N2N_;,Y>NWEFXIOQPT0.4T<GK.GD%,1&S
M8REA;NU+F$AD(=PO05Q0(<AC;::FT4E(,4`,T5L.MAT+6[BV67#/+6662YRF
MM&N>9&R\(L'*"A]939:T\DM7/)TF)"N^KADC04X16QCZ4`:8#G]"C<RMJ`ZV
M3H_V&_E!Z_\`1RXZ8],Y_+E[:V+Y\04EN/Q_\S\YH[`AT>Z)YJ8E+#'K-++?
M-1%T8Y:E6LEEQ!2>4V"D!4<DS*K),];2/9HE*`H`@!*--R77\9/JU-\;6XZ5
M2NGZD?@N?A8\>9+@3(W^LYK5-IV,\,J4XIL+BG'-9-+"\2#VRPLH]L;I4:XK
MTZ'VA@1[/&``@#-V4':__759?_Z;?_.K?GFG(P&`P&`P&`P&`P&!"#R6?P_N
MQ?W>;._NRNR;=JUI^VOW?__7Z6?'&=IJY(KBJ5X@%3'G)3)^:;&:=B#\[99S
M1\B<8*Y$+2@C,T5],-S8D=DN];V$Y`XIS@?T#`[SIKVC._[5.;*P8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`PITA9$9J&@;CLN8+"T4>AU<2UW6B&
M/0#59H&=42W-"$/JC&H=7QS.)1(R`!$8H5J"RP!$,80[7I+5DS9$C>+H'(ZL
MXZY-K&8HAMLNKCFBB('*6XP(P&()'$*MBL??$1@!A",(TKFW&E[UO6MZV'Y=
M9R=;WJ2^$,!@,!@,!@,!@,!@,!@,"-':,#D=I\==95C#D0W*76/S1>\#BS<6
M$8S%\CE]6RJ/L:(L``B&(:IS<2B]:UK>][%\FL+.\1RYOLB,V]0-.67#UA:V
M/3&N(D[HA`'H9J0T;.E)<6A<'U0#3NK&YDG(EA`PA,3JTYA8PA&`0==9UDKE
M9BV,UX0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!!GR.':=>2+'JE`
M(!LQZ-4QCFFN6G0@_.WJ<WA(FZ"MI"(H0R]&_0[<YJW95O>]!)0-R@X?]`L6
M\FW:MZ?M'__0ZY;]XZL8RV'/I7D6>Q2M;BE2-I;KAKVR&MW=J0Z#0QY%IKC:
M^7ZCQFI-7UBQEL]"9%*&@I6::C++2KD*XDLG1*6SL=+,5C$N0^0\@/L%_#M8
MJU9(AE'JV+L9C/9U0BQB!I4W&/-,,CM\U4`UH80J$A!H-"]40?3KT[US])PG
MR?OZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/\`
M?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^
MLWD#^!:#_?`B'NMQS]'"?(^LWD#^!:#_`'P(A[K<<_1PGR/K-Y`_@6@_WP(A
M[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`
M_@6@_P!\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'
M/T<)\CZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/\`?`B'NMQS]'"?(^LWD#^!
M:#_?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"
M?(^LWD#^!:#_`'P(A[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_W
MP(A[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_P!\"(>ZW'/T<)\C
MZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/T<)\G^"DWD&V$6B^%H'
M[3T;]3VW8<4+)]?T?T?:F%5.H-`7ZW^UL)8Q:U\N@[W\FW/T<)\E1@W&UZW3
M8<*M#M^2UXGB=9R-MG%:\JTHX2)_K@J<M`R%\9F]T6+*F:+/%L/T+<P_.&MK
M3L[2Q(G`DM4(*TP!8@RVW[+,:]N[:=D#`8#`8#`8#`8#`8#`8#`8#`U8SGC:
M]:6L.:VAQ!):\41.S)&Y3BRN5;K<)$P5P;.7<9Z^33>E[%BK-*7BIWZ:.8OG
M#HUJ&=V8EK@<8J"%$8,P0K+9]BXV[]U.#)O(-H(=&<+0/VGHUZ_L>PXH83Z_
MH_I>R,-J=.:,OUO]G8BP"WKY=AUOY-7GZ3A/D_WZS>0/X%H/]\"(>ZW'/T<)
M\CZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/\`?`B'NMQS]'"?(^LWD#^!:#_?
M`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^L
MWD#^!:#_`'P(A[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_WP(A[
MK<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_P!\"(>ZW'/T<)\CZS>0
M/X%H/]\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/
MT<)\CZS>0/X%H/\`?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^LWD#^!:
M#_?`B'NMQS]'"?(^LWD#^!:#_?`B'NMQS]'"?(^LWD#^!:#_`'P(A[K<<_1P
MGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_WP(A[K<<_1PGR/K-Y`_@6@_WP
M(A[K<<_1PGR/K-Y`_@6@_P!\"(>ZW'/T<)\CZS>0/X%H/]\"(>ZW'/T<)\CZ
MS>0/X%H/]\"(>ZW'/T<)\GX,D/D//#[!!P[6*16<(!1"M][&8R&=*(P80;5.
M)C-3#V[?-4X-[&(*=(>:/0?5"'T[].G/T<)\F3J"XZL8NV&SI7KJ>Q2RKBBJ
M-V;J>KVMVMW::0Y\0R%%MKDB^(:D)FY-8-BR9L]*9;*'<I(:4C,,2H4*$DP[
M1V;;>Z]),1__T>_C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8'_TN_C`8&@F6]D]I=>=,=15'R!:5'\C<Z\82HFL+:Z5N.*(;"?Y;<(
M'%8TND8CD??G5LA[/'FEX;CT1PU(M*-#`4;H_8E9:4F-XDDSWJ8=?=6R/F/E
M*;7+W_T!0%DIX=8YT5BUH\VMSJX);(9W1LC(8@PF09O$Z&:N-RDRYQ3FM+0(
M](%"2G4[&`'S@99,9O2*[5WE!YILV)]%/RELN:JI3RO6KS<-S4]==2R2L[C8
M*S9XXY2G4P00E\#H;VUNC2U&"3_-E`S=#,(T<`GYRGV;<IQO18U-^8_B6];L
MK.CH+(;'`\7,W*SZHG$EK&2QBK[!?&IOVND$-BDS=R4Y#O)(X:`Q&KV45MNV
MX`^;$JSCAE!,F5NMCTV_Y?N/*6LB=P*1FW'(6*GY6U0:]+JK^FII-Z(HJ8O"
MU*W)(S:5E,:,]N97L"]6!.<G3%K3"56AIA:TI+&2%DFMJ:W0%C.,"YMNVVX,
MM:UKM#*/LFQH>XBT4[,BMQCL#>I-'UHM$':(<VL]2C)'OU#/4.)W\@O1OTY6
M7-+4/E/[_CT,\>]\6';O,M[QGM&Y&2JY!S'%:_\`JA?$-9WJ8/\`%!S*.&,T
MM6&.R)NW'AC,5JD9*,A2J2)S"QZ/V<3,NEUG68O1N9O_`,L?*/.UDSNLY*GN
MB<JJ=2QY;?LQIZFYA9M=\^))4`PYC-N.7QU*<ABPUJ<OU]$EZ5'Z]/J;![4(
MRPW+$UM5Z_O*%R]0+A"V<W_%.YWF;5$1T(F:>=ZPD5OJX]S^H$5[&[9>)@`!
M)'*U,*,$9IP.-^4HH8M`]'J^L)+7B@/E2Y3L0/)VV@ZT&O?:LGL&*4&"3UE(
M(^*1+*UU'=R!S7?/@A`@CRGZTH_F*\.S4ZSUQ^H+_=F>JR<;U],/]P=YL+AR
M;Y+T/.$UED7O#B^,H8_*Y(4S":A1B92+0%C6?%W%>!0G=O9H4B@(C@E^J6/T
M>CT^G0LBR=9E='XD<%HBAN8S;6A_1]U6E.N5ZGNV<:HRBI=::IIC[Q#4)LAL
M6;N<>0HHO'&L]Y0.!QVA*0&%@(,'[$)?J;%4QG+"78WF?@5.4GQ;>_.D7=KK
M@?5UR1B/?3^X!.US8@K5.Y/S%8S6UB:-MQR>]&V1-7S%JCZC1IJTY(OV`DX*
M86\F5FN<RKBHOR!(NBO(23"HW<UR5;6+7R^^SESY2O+DL53+')R8Y?\`1ZNZ
M06_-"D<R3LQ25PTD"A#H#8(;<=OY3-&BT+,3LO.)^;3AB86'$8>@=K>;H38D
M\'5]<]#R"FIFR\YSZP0K=M@8M&+,6I`%J5HW$.R=G')"$97HV8:<`G_>8R<:
MN?HSS!<=\QV1;]/SM1;4@LZCM15=8,.KFJY!,U[7%I1"V&>CGAB]%LEC0PB-
M,$G0?2:]<K2`)4*0DE!.'H>@LDUMZM@E16O`KUK&"7%5S\3)Z]LB,M<MB+Z0
M2H2Z<&9W3A4)AG(UA1"U`M)];92A,>66>G/`,HP(1@$'59[.<[G3K/S`]0U9
MU#T?2MG\N.K3SCT;==5(Z`L&H7AN/GS+5+)&I<!*BL"-R9*J2NSNSRH"-*6=
MI(`2Q,$1RPLLT0BYU;LUF)6P:M?,-SD[\+T%V9:A$@ARZ]G-;`XU3$,9W6Q[
M%DUO,+^[15_A$`865&!?(0#=64P](I/"D)VD4I='C*4'EDB93C<V,IU=Y3^4
M;5J+HFVFY9942-Y/9%;_`-!578M;OL+N2MV].A='$D3M!G36AJ37!,RJO8Z2
MJ#]:,)V69LLST!RY3C>C!)?GA\>NY#IB4RJVT"=WCXWJN9(II&P3([=*\M:!
MG-BE.J4+4L<)S(PR`S3<#V*8"`]9Z0DJC`:V/4RO&L\U;Y3.4[<YQLSIF,J;
M0(BM.S0BN+(@3A5DJ.N2,V`O=V9B:8@?6K"F?'E:\/#L_I2"?FNSR`&#,"<8
M5M.IT3<IQN</!67D<IKI=CZ/@,!.N;GJ]:8J5]G,@AU]T>[PRRX*Q+6!>;'K
M-35U*3-(Y8T-RK:94%(-0'V^C4X#@E@4EB$,8QX85J'R@493'(/&UA],]!RR
MXWOI%FLHB)7$@H=5#5UE2"O7%V-4MA]60<MT%'Y`M$)(Q-25(28)X<?9""`L
M2C>@Q;,VXB97&W=E#=S1R>O=,'S)L=ZLEYL&LJ`63$EL'L*#2((#QITLAC:T
MU2)*!<%(?HH033/0:F.),T`XDTL%2S"9.$,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,""7D>[50\#\KRZ^M104\EOTQ'X'6<(VI,1)Y/8LR5&(V!$X*B0#4EM:
M`@A0O5`)U[<].D&45L!A@1A+)FX0IKI9Y8X_/:M>;G[5X.U(Y7)X"=8_'KA"
M4T441B,RQT:POL:@4\0/[C/7J;MS0K,`UZ5$JTBMPT$/M5!6PB,G5?Q^DJ25
M_P#ECY1YVLF=UG)4]T3E53J6/+;]F-/4W,+-KOGQ)*@&',9MQR^.I3D,6&M3
ME^OHDO2H_7I]38/:A&6&Y2:VJY>WE+Y'Y]DD%B$HD,UETEM>EVZ]:A9ZJ@$@
ML==;,->G8ML9$D!3QPE28\/[NFV:XDD#T20%K3'*C#BRR][QDDM?VCGE*XTD
MO(`^WDUB."&E"7PR&GD.,;<P6`78@5Y3:56A,'1@6NSA.5BE24(A(E]N6:E-
M"JT;\UT(\+)QN<?5>_*_>](]:2>P*[B+/;58V[5R1G=YO2]^UC(JCM-FC<BU
MO<?E?U9D!8M+8\\:]78#B#C1DZ-)V>`G2A/[4680!\D7:/2-/=R<@<L4]?%)
M<W0B^J[M233*VKLAK/)XW&7.#M4@?&KYZI?)1$T21.]"CX&P@&UA/K+%Q>_2
M,7JEBBR3%M2/=.Y(MQCS/6U@=>=!Q;IR8VM/'")54]<LUC\]57&O5K#`-L<K
MV#1N4RI$[+631`TZI;IR*2B4;*(V(*DTHHT8S>D:[:-\B=AWXX>;^Q8UT//*
MVJ:@X-0\@H9_E%/)'J0<\'*J[M4ZR]#J&4-K,O<Y`CE<-&0N;W,1^M*DF]E[
M&#T>T>5LQQZ,FRWS(+J.M+QWT^[1FQ.A(C?7,S;:=MW3&N?9LCL"Q5+E2+7.
M(9,*>K*'*#F4Y7(W@S:V4LR0I8"-I%6P^DD!.M[9..<LL\O>1B/2^3^2&[IU
M?%JR6D>;&:M9ON@YWRN12T]YNB[E&YX\NB(2PWV$QL]PEQ<7-/`%RV$U*6E+
M$7H`56@Z92Z]ICJSI1WE\XOZ#OF&\^5_(+$+DUFLCL\53+I56DEBE:VJ;'D"
MMPDC17\N>24Y;^N80-BPLT\)`&Y0H2&%)52@8BM&,EUL6',_-IQQ#I4<PE1W
MI6:1TVS5=+1NUJ^Y[G,KJ:?V\W+SVURK:N)DB)`5.I<C5IAZTF;B3_G0-:&F
M$>`01;9.-2*\G'0=B\J\)]#]`5,>SIK#K>-QYRC"A^:P/322K=)U%8ZI&L:S
M#2"U80M[P=Z@1"UK1GJBWZ?1Z-U),V1JEE?=/DDXJJ3FSL3IV3<[=%\CW<*G
M062CA$">ZJN"FT5OQQ#(D+\U!"]N<7DZ%B"H.(/T;L0U9X"0!+2@/&H3QK$N
M9.[95U!Y3^7^5;+<Z<DR.XK0LR+1,BP+'B5#U3(+065-`%)`%94TLU8V[2-,
M68_F1I:@?KJ#%128XD\PD))Y`S+EF:V]7OL'RH\55Q3=#=`O%FN#G4'21TD2
M53,8W$)*]`>'*+-;HO=&58QDMX),WR#;@SG-1;>-%M:-YUI'LK1N_1IDXW-G
MU1B6>??@9#&I"[*`="!E<+?'AKL*IMT-,06?6S.P*6Q&\3>P6<W1;)$X:@7/
M"9.-0K<0*-J3?8Z(V<`P`)E>-2XMOR-4-6$.IN8QV+WST`5?D%!9]7L'-M'S
MJVY(^5X)`T.ADN7(6MO1I(XW)T+XG&84Y*$BL/\`O`^QV(HW0*F*C+T1Y!J^
ML_D;G7IWF;JUUI&!V+U16%<.$RU0B*U'Q\`K<9,S2:EY)`Y<8W*H2K<W-"6,
M]V)WL\@I(#:<8B%@3\BR=;+&2.C/,%QWS'9%OT_.U%M2"SJ.U%5U@PZN:KD$
MS7M<6E$+89Z.>&+T6R6-#"(TP2=!])KURM(`E0I"24$X>AZ"R36WJV"5%:\"
MO6L8)<57/Q,GKVR(RURV(OI!*A+IP9G=.%0F&<C6%$+4"TGUME*$QY99Z<\`
MRC`A&`0=5GLR+@,!@?_3[^,!@<T<VYEZ5XXZ%[B(3\/(/(OPGWC9Z:]I%!FB
M1PPB<0&UCI"*;N3?(H9,2MAD[`9-U0SDNB2E!"8E"A4Z4ISP'ICXWF63KBQ$
M2(>*SM-7XMI+`D](*ZVMU@\H0>Y(+0+/:,2C,N<JF0UM'X&CB$9L&-/HF."3
M%O\`;JCVXPQ2F4IOHPL8"P'C(+VQT7E,^L)C5GR;+IU6/D#G#1R;W/#KNM3@
M6Z>=8?->S^HF>XYC8CM+XF]B:JNC#*Y360.+:W)Y.F1C2.[BI3(]:/&`K1.C
M3_23/;K,9?V>^(>HE,*_[?ML25&XB6\A2B&N71Z8#[#P"K!*B9JOVX*'38I"
M$MW$2<P+=#TV;6CV85L/HV(0-">#,SLB@^>/N^ZPLCM"H;-Y@[FZ.J_H[HVS
M;BKA1R[UZSU)S_8$8L=R0.@&.\8`]39IC[!)FDU$44K<W9`H&IV2`L`3$R9,
M<,N9TN8Z6+BJQQ4<66G25=1Y6-V/Y=F]606)GO13@N&XFU.YQ*,1XZ0NJHDA
M<K$I$0F$M4GA`:/_`'I@]:WL65CZY<W=1>+GH3D6C/&OUOS]SDM0]M4E/W9I
MZVJAHD46T]6K3DXD4M3/WTDI<I9N#GR9DAH4R5$8G5E&`"Z!-,V,U$4`N8[-
M\LW:6]%Q6_PI?E=]6]W_`%PY[[<Z!HSL"?K9W"E/'?5*&GX)(T4W;G%-+:VZ
M"K]QFL=0'H$0'43?MQ<DRI(8BT8'0#231!+)F8G7K&'^D:LMO[<['07*]=72
MW#IWQ6TK3=N5S0G3E+U79,$KPYR6J7>`VS:M^,,C@=BFM#`\I2DSDP:+5IR]
MD*"A:)!L`"SMF^6:'!D=+]YV\,G;_CVYDL>P*KXDF]E1ISYZ<);&D=I?5M6K
MBL(?G1,^.!XVJ5*$\@K)0<)62(L:@2\LTQ*G!L_21X3M=I;UJ]D/(';DXHKS
M>KYWSDH@ED]JFUA+J;K=LGL/EWTH(Z/N2Q;%BY2G<6QK-?HB6YD(74TX"1()
MR*/TE&<GT`T;R9F=>JY;^IGR*I7CE>L$\(ZND?-K5P%6U6EU_P`D7W#*,=6'
MKUM:6=D=Q7U/`R%H>@UJ@9TGL%!Z=4K:]!"`1`3=_/25`F/^Y8R7\(]E0_PT
M>/BK&>CW"3=!\<]II.D9M2R61Q@I^?(G$[HZ/?"4K"YB=]LZ]:[,]@M:THDH
MXQ2)*:+6BMGAV3CZ+F<K<]$N)KS=TIU%W^DOY^I624?7]N>(&P><7QQE3[%7
MQ15]OS^S;(5HH;("8^\&K5SNV1V1)7`\:0@:4.A[*T=[4(M:?5,R3&?J@DW\
MR>0FY^.>7O%;+N)5-3)Z,N*#O-D=4.]AP5TJ3=>02821^U)8$WM"U2^O4OD*
M!]*").5HTT9NSM'%D:/,VD>ES,W;+8:;R=T"=U_YO['!6J[<.ZBYCJ2`4%(!
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MYV=)3%'NSGH4-KPN-;D$W<6Y>1'6)P?W!H2E(DZD\@XLL8P'``400I5O)F3C
M,LP;XXZ"_P`0/^WG<SZG5F-O'5(2V,]*J=N,5.)JV3J.;Z3B;4C=-:>1[>5&
MYO%UY)1K7I<6`]/LWU]!$`P3P9GYL0O_`#1Y'ZJKOR[/O-<0DD(LZ]^VVZS:
MI<XW(X(AFDYI!8Z'FS1UK1R<'%P;6&5+6=1O1&UVD:\&MFZ(#I7[(.WDS/QR
M\W('(G3R#J?L>[I#373D9KR[N!7RM:U<.K;QCUSW6[SLUU1)2XO+'4N6/JF+
MJUAS8>H0M@CA(D3>82+9A!AHTQ(MF)U^K^-*\*]61JM_`RPR"G75`Z<GV;=T
MBZ$1G/L.._PS:I,]J'*.K7,TB1')W/:].((P`;A+#0"_HB"$?R8\&9G9.WQ_
M<VW;3W>_EJMNR(&MB]==#6?0[Y3<F4.D?7)IPTQ1KMP$A6(D;4[+W-N`V#DZ
M$(PKB$HQ"/\`0#0M@,]5Y2V8U;ALK)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@:V?*_QA+NZ./)-4=:OK='[9C,MB-L52L>SOF\?53>"JU(T[0^&[2+0E)'ID
M<ER4DP98B2%II!INME`&':KK<5I+ONDNT^X+VX[DLO\`%/\`X!=&5/TC2<^Z
M9Z;)G52K8I+X569S6C<$[#)D[N%V?(_\V2A7)FXE8Z')`I"4I0EAGH,U/^-R
MR9_+HJUO\*7Y7?5O=_UPY[[<Z!HSL"?K9W"E/'?5*&GX)(T4W;G%-+:VZ"K]
MQFL=0'H$0'43?MQ<DRI(8BT8'0#231!+)F8G7K$_Z_X[LZ#>17@>QXK3C[$.
M?J'\<AE&.Y[O-H_,3JVEY!CBG::X<7[3M])RUV:D"DM.-R0IC$2C0=F`$`O?
MJA)GI?.6LH7B\[5>?'I=,`)JYY9;?B7E]D7:T'KM)9$:A\JM"J4$#88:G-A-
M@LTB/;H7(EQCBL6-RE0J3*R#6SURP:-&G]=AKE,^L-HWC9H8;5?]E=!27F7N
M&K)LXU$V5<.U>U^G$5V2B3M0I2W2%;!V".BELKD"1G8U[.2I3N:L99&PC&6G
M`7LX[0D9MZ8S&%/*GS5>$[[\XJZ,B?$"3N:EJ=K*W&&RJF>G.J2(T^NTN:I&
MS1Q&\-MHF+VE2)D<WU*\D#,;51>CT`=@$`X(1@5=;TLSBK8Z&J?J)_0>-#KV
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M'?([2ME1R1-38:!]T!`:T2!]2I1F.'S,HP1NA%B$#6Q:>3,_#J_<RXZZ.#(/
M^WH>]5@K)9^**L.;NHUXWZ($):C7IJ4Y\95@'D1C^#Z8"!Y@[L4(UJTO+V-+
MO?K;T85L;P9GY^VFCE.<'5W">>^I.BZJZ*G_`!#%N[)78M.**QOZDT'.+/>[
MG;<R;X=-H7S4^,;9T86@B"L2@Y(VN+L46`T)ZK>]%+CDQL:OUD[X=6/ECIFS
M.A/'GTS3E.153-[*F\6C2.*Q5&M:FY4\*FZPX>]K""%CVO;&LD9+6V'F_P"]
M/+];V?JA](]A#O5<]>EC43.*`\B7D(Y[Y6X,L[CD'(_/-6'TJ1?UT3^Y8#-Y
M+,X_3T70LFV.N83"C37EJ<)$)*:>`X[9I0%&R"S%)!0#A'3NUTUMN>K.DLBG
M:?$7?O=MZ53QB\]BUOW+'*:4P=YATRAK&J@4[JZ$N$1U#K&;Y,O)6-L-=U[Z
M<<L7Z#\TVC)2[`,1FE!9`Z629QAA&LO&5U!2M$^%RK54-33"3<X]ANMX]#FQ
MU\CYS+63!*94MEPPFKG!R0!?QQM(L*2J!-NEGM5Q)NTWM2ME#&QV+M+R9\,X
MYZ#.L;_N%'O53JQ)>P*)B,0YF<!N,5#_`(G/Z;FVY8>Z-;.88\A,9!!F;\V)
MS!N?S`D1QA9GK;`#8P/)F?@P7)J5\BU=5'XU*N1P+J]70<!Y18H)>=6<?71"
M*:N1!T4E;0MK*1,["W)F)<EK]`G"F"8H0NNV\@PH\PX6M>IHUX,S.S%L8\=W
M9++XM*.YV74P\&W##/)FQ7%(HMJ91-X/35@W2R0*54X%*%CXB0/#<),I+.]H
M(8%QX3-#$G"+8@Z?0S.6?2>QO)W0)W7_`)O['!6J[<.ZBYCJ2`4%(!NT9+)L
M25LO+JJ"O+,V$F/05S6)%+M!1F&N!:-/[3T"]?9?H'CRF9C5,3Q.4S9G/?CS
MYFIRXXJIA%E0B+25'*HJL6M3BJ9U3C8<P>T9!ZQD7N;6<,YK<R#?]T>9ZOM/
M5%Z!Z$'5B;=;6Q+"&`P/_]3OXP&`P&`P&`P&`P&!$>^."N->GI2@G%^\X59:
M$S;6XEG32N21PD<A$T)33#TC6M>$0T:]S;D1IY@B"%)AI1&S3/9A#ZX_266S
MM4CH/!856428H%7,2C<$A$70@;(W$(@R-T=C;$W@&,T*-I96E.D;D"?VIHA[
M"46'0AC$+?I%O>]D75@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0<C/C0X`AME)K?B_(5#LMAH7D4B;7
MY'`6<)30_P#M]*BGEE8QDCCS*YHU8=')CDJ0DQ*=K1A.P#UH6%S?*<>$,!@,
M!@,!@,!@,!@,#__5[^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@?_6[^,!@,!@,!@,!@,"*LJ[LXA@DD?(;-^R.58;+XPYJV62125=
M"U''I)'GE`:(A<TOC$[R]&Z-+FB/!L!I"@HLTL>MZ$'6]87%\*!^(OX^/CMX
MV^\]27_^XP8OBI4Q661:=QMCF4(DL?F40D[8D>HW*XJ\MTAC<A9EY03T+LQO
MK0I6-;LV+2!Z&4>G-,*,!O6PBWK>$7!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1PZNZNI7B^E91>][R@J.0Z.%:(1(
MB-%*9',)&I*.&T0V&M`SB!O<G>QD"T23H0"BB@&*%!A*4D\\LLEMQ$-?&5Y:
M:%\D\3=R8X255UWQ0U<?*Z.D$@1NC^".`6[*;9E$G$*5JW+XP<G.(+6G$I2C
M6M>/V"@L)9B0]5)<KMK=?LVLY65O2V6Q>!1>03:;2!GBD0BC.X2"2R60."9J
M9&)D:DQBQR=75R6&%)42%$E*$,PP8M!"'7IW@<_'*7_<4<U=&]A2[G>0L!M5
M5J_O:..<ZW%)W+29+/WLH8D)Z"=(%`"T\&-F*[81Q\0S1@&$04ZO9*HTLO<R
MW=+)ET496#`8#`8#`8#`8#`8#`8#`8#`_]?OXP&`P&`P&`P&`P/E8>5/^)'V
M_P#O+VQ_>MPS-[N^OZQ`/(KZI_BL_AN<0?NT5/\`W4;\U.SCM^U3\RLF`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.&K_N
M;.>NS@W#'NAI?)5UB\@E)$$9KE!'D"A"QT/(%R=(0[,TR9RE"LH;I.G1-\X)
MDAN_0OW[-O%\W^;(R!YKKI9C'U<R%16[9-#63$+>J&7O$$L:"/!#Y%Y0QGZ)
M6MZTG0BS"S"S`FI5[<O2FF)UB-06:E6I33"#RS"C!@%&^_2OHM^+3S)TIW=3
M3H?9C]$*>Z!J>+*7VYHB\O*5BC2R.,:(:AWMF$KGI8#0X(%.0,YR)-.&?'S/
M26I&,@296IU*X[:V7TY7O-!YG)1W=*G*B:,<':*<BQ)Y]&@ZV>VO-ZOC2J]9
M++Y:G])9Z2&HE1.CF1E-UK?K:`N6A^=_-R$$M;UUQUO=I%J*HK)OFR8A4-0Q
M!XG=C3MX(8XO%V,C1RUP6G:$888888(I*@;D"4HQ0L6*#"DJ)*48>>8646,8
M8WVZU]3CQ^T1=7-7)E1TWT#<;A>%H1%CTG?):NW\X):23Q^V00=G>%1!3Y)&
M.&)1!0I7%R$-:K+*];>B2?8IB-N%N;F1,S"&`P&`P&`P&`P&`P&`P&`P/__0
M[^,!@,!@,#5N_=7V\WOCR@3+6+2=$[.*0C0V,@8M$IEAQ)6A"V9Z1"T`&O3O
M_7O.\_SUQ'&[[94K[7=R?ES!^8D__$Q_/4Y['VN[D_+F#\Q)_P#B8_GJ<]C[
M7=R?ES!^8D__`!,?SU.>SYZWD*?7"3]R=7R)U$4-R>KVL5Q7"(*T22)2JD2P
MTW990=[T6#8Q?)K7^C//MTVL]O9IUTUOI#K,M/H4^/;IZU(QPWRA'6I6R@;6
M6B:Z;4(#F8DXX*9+'4916C#1&:V8/0`_+O?^G/3KIK=9?3Q[[[3?:>TQ?M=W
M)^7,'YB3_P#$R_SU9Y['VN[D_+F#\Q)_^)C^>ISV/M=W)^7,'YB3_P#$Q_/4
MY[)G\U69*;0BC\[RLY$<L;Y#MM3"1(P(B])M-J%3Z!E@$+0Q^U/%\O\`^&<]
M]9K9ATTMLS5L]Y6Q-:)XOZAN6N%Z5JGU94C8,SA[FM;T;LE;Y"Q1Y:M:UI[8
MX%'H%X$RHL(_9'`&4/T>@81!].MX;DS9$+>4^J+.<^B457.?45:=BTVHYH>[
MIM&V8O%H)'#^<ITTOD23,4+F$NJMS,KDQ%-X^\.JLAK7I4SZ0!F,5^TVDT+6
MXMDQVZI*U#Y!JKMZ9U=&4];7M`(W?J=[5<YVM9D&9HY7-]D,<:4S4T4%-12Y
MYFC&:Z0E`I>&TJ4LL=.<VY,8:F`;Z-!W4LPL*.^4VB9+N*/J2LNC450R6U=T
M@MZ$=ZO1-M+0^U39ZIK-MBTH?CY5]8_F;M-BT[<!];6EQC:9:M*2JW%,J`I(
M(F5XW_K*;3W?64AO^Q>?(]7MTO3M3,G41FZK)30UG2T[4FO\.VBR6=^FDY=I
M4W:`R2-H=!ITOS!*O6DJT9VUB=*FV0I/J8Z94FH?(-5=O3.KHRGK:]H!&[]3
MO:KG.UK,@S-'*YOLACC2F:FB@IJ*7/,T8S72$H%+PVE2EECISFW)C#4P#?1H
M.Q9A6*I[IKRV([.['15E>,0HR%PV>V"W]`36&L*.KY_$*U<3F^5.T+*89A(K
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M:%R97UE<B1)UK>X(E`A%G$G%B_\`R$`6M"#O0M:WI_/4_ILXG?(]XY'GEM]6
MVA5J%>\\^/SE_NP:&K<7&JW%>?ZJ:./RI08I6K(X><9HIL<SQC,%O84RL>U'
MLCE?+?\`SX]9^KT?Y_Z\NE_9JB+,,*%L11@RQ;`87L18A`%LLXL1)Q>]AWK>
MP&E#$$6O]`@[WK?R;SD[+DA<+E5B2IA@\'87&3RV3N)#2Q,321M0N<5RC>_4
M**!Z0@+++`$1AII@@%$E`$88((`B%JR6W$[I;),WL[4_%GRQ^'?$%\H*2Q!_
MZ%GS>21-9TI9RW8V,,H_8*-5Y#%RL01HV$A62$U>H*`4:ZJP!&;Z22$I1/HU
M_P`I)U[O)O\`ZW:]/U;=/M=W)^7,'YB3_P#$R_SU9Y['VN[D_+F#\Q)_^)C^
M>ISV/M=W)^7,'YB3_P#$Q_/4Y[-H[`L.<6)E<%.P[4+FEN6'[`'U`;.4HR3C
M=A#KY`AV,>_1K_5K.%[UVB&/D>OJ8\R<B3JZX*_M47?XI/>>&XU^>T3:O:6^
M,S?I"I(#-QKR'<LUO+3G0J4.!>SQZT)-Z_M@"`,L(PEDS<,10GM*1&UA>??U
MHGKXGPY'HLA/H:&M,8;EU@3R"-COHEWZ1DAJTU,ZH44_4K"PQAB">ET5'2`K
MU19BE:4!/%QVGU9VIGMNOKBM9YIT^M[OJ&6)JR-NN)#NV"(H(WV54"=_;HRN
ML"(!#(G9W;$+2[O2`M<VR)(PO[?I<0)2@*T9KT5+&/8-Y)Z<G3]6/L:TZ`C5
M37A-$=>TIT?+J^:6FD+1EKR-R*BK='W`F7+K!:$DX4M8RF)>]QUI;G<PPG24
M\S1Q6QLG%D)C[7ALLMQ]K*%5'?\`-XU%+-54Q+;WB<`;7:EHS:C:L0M;Y#W)
MQ!*2[`.U&7M=I"[.Z2.J8^U*RC@*UY.B#1`&.F<HO<-=I`D32U5/8<AFEM7O
M/>F>QFUG9&)O2/;I!:5K'HRS(:SSNPE@U34VPRKXRD94K&A5*C-J7)=H"1`2
ML4`."7%L_P#$Z.@^DX1SJVPKZP,4XGDTL^6;@U6535K`GD]D6-*261UDSBWQ
MQJ7N;&S)43'&F-8X.+BYKV]K;TB<1BA27Z0:%4DRP=KR)4LAIJ[K=F$2MZNU
M_.$FB41NRGIO$6=ON"!O,[5Q8F(;5,S=*7:)O;-(T4Q1+4+FUO2YL5I-FB)4
M&#*,+",,\S;H2.0ZR5M0I(C/9O8R>G':[D,9AC:P*%+Y%6:9,D'5-K2KD,EC
MC<*2#>'XD99"@Y.0).$8MGZ%K0!##%O!'3TNZYYFJVZYM5<AK!^F<%A\E7`7
M)F=/$)(JD3(0Z*G:N!(YC+'PZ(@.,V`D3MI$N]&]>L5_IW@LQ<)G80P/_]'O
MXP&`P&`P-8[YR):SB]O#@G41+1"YT<%A&C'=:$S1*I6<>7H8=-(M!'Z@]>G7
MIWZ-YWG^FN(XW_.^E*^QO;?Y3$/SRN_1&/Z:G\]O3PN7)=DLZ0:]W>H"U(2A
M`":M<I(<A2%B-'HLL(U*EK*)`(PP6@AUO?R[WZ-8_IJ?SV6W]GYY_6)3O[04
M/]6Q_35?Y;/GY^0)K,9.W>JF@U6@7&MMYV&C&L:E05S:I$1(5@-G(5@-!`I3
M&;UZ0#UK6A:^7//M<[6^WKTF-=9Z0_S+3Z!GC]I)U>^(N57<J=58A*<J,KQ8
M!&ZS=&A<DP3X\C'HA<C&G$-,I+UOT#!O>]AW\F>G7_36:R>GDW_SVNVU]IJ-
M/,,T?CC$S'+*Q>5!)7MSB&F8@<3BB?7"7[8PI&@.&`KUQZ#ZV]:UZ=ZU_KR_
MTU8_GLKWV-[;_*8A^>5WZ(Q_34_GMZ/L;VW^4Q#\\KOT1C^FI_/;TF-SC5TE
MJJ+/C/)S&PQ6XO\`MS3[:U1RLG2;;<B2^@P9R5*()GM4XODUK>O1Z/ESGOM-
MK,.FLNLQ5`[?IR6]"\@=)4;`C&<F:6Q3DZ@D7-D"P]N9"WN1L:IN;QNJY,C<
M%"1"%0=KVA@"#1!#\N@[_P!&8;EQ9499-PN])[B:'ZM"HI":OO3E2R.9>RF&
M/J-QTUX7G1@K_".XXLR-;0!IDMAQAT7O;*I6+1IE`V=W!O9AFDI96HN6*^.>
M(9I3,CH!GLWD[G83G0C.)KWTO'NB;2DSLZK6:!O,)9YG`J3D]<;11V5RXA64
M%U3*GE.D:DRM9\T4*M@(*&+<YZHB\C4SU)T_PQ`^=PQNG&'FA_Z^M&P7VY`S
MR3CM!O@M0^06PK7?((15HX4-G53J26-!/FZ)W"_`;$S$K]<Y,)63[,\MQ+GZ
MMIM;\F2=.Z^1]JL!Q;D</[*LIP<XLMC3@<J?&R%OW.%>4XZJ'(E2A2$MS\G=
MH\N-)*`8>7LKV0]CUL6P!>4M_7TC9QSQ#-*9D=`,]F\G<["<Z$9Q->^EX]T3
M:4F=G5:S0-YA+/,X%2<GKC:*.RN7$*R@NJ94\ITC4F5K/FBA5L!!0Q;G/55:
M3Y9Z.A-R6?8[-2E$T)`I+2=IL,OYQBM_SJQJ`Z&O^5KV!UBL\4P=?3D=C=*Q
MC6DKJD?7%N95#PZ@=QZ4(%.B?:GBV,L\)\X6_1DVNEW?(C&Z$HN7-4`15ARS
M#KJEEY1"O9='U4Q%8$VB+C)8?#&RLXQ-$KHU$I(RQIM-Q>F\2D924TSYN&I;
M/^MDV$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#"]]P!]LJOE$8CHT`
M'(UU;%H1.2@Q,F]BC,,&;K9I1"D>A[T+Y->K\N:TLUN:SM,S$0:^QO;?Y3$/
MSRN_1&=?Z:N?\]O1]C>V_P`IB'YY7?HC']-3^>WIYEO(EGMJ-6XN+I!D#>@3
M'K5Z];(%"5&B1I2AGJE:M4>U%D)DR8@L0S#!B"```[WO>M:Q_34_GMZ<5?D[
M\D*J]7I^H2CW[6J,9',U#(9>U#5I]W"O;%7]!2E$I(1K2*^3JB-&(R#"RS%X
M@A4'AT'111?+?_3ETG9Z/\_\N/7;]FE\(1#WZ`A$+>@B%O0=;%O00!V,8O1K
MT_T0`#O>]_ZM:].<G978M*9'"9&RRZ(O3C')/''%*[L;XT*C$;DUN2,S1J96
MD4E;",LPL8?_`-!:].MZWK>]99<=869Z7L[-?%-V(F\@;<.JGQ[AL2Z6BC/\
M\<(V[+S&1-:#,A*W\]ET%3EHE!!JU$6#VCLUEB]JET+:@D`DOK_-^^O^LLZ]
MWDW_`,;+G7]6ZO[&]M_E,0_/*[]$9K^FK'\]O1]C>V_RF(?GE=^B,?TU/Y[>
MC[&]M_E,0_/*[]$8_IJ?SV]-G#$B.;6-F;E&P;4(&IN1'[+%L1>SDJ0D@W98
MMZ#L0/7!OT;WK7IUG"]W:(F=\T--.E^7Y73M?#82Y2]V#S[)DPI*N/;F;;76
M71%56C)@*%29"Y&A4&QB&+`I@>Q$$U3LLL6P!%L82RXJ#UU<`7R7S_W#R!0[
MC`U'-O0$`>)/S['9;(G5E7T';DMER9UL.JFU*EC[ND%1TB5FJ)`SB),+-8%Q
MZI`!*:F-(-)BRS,M[IPV9SL_V+U7&K06*4)%8AXWZ0YVDVTSB<GE9;_<EC\_
MR%J4M*3YB:EVA(C];NOM5`C@C)4[(UHH>AB$"IGI_P!0I@/)W8KQ6/%_*%L1
MRC&&HN-+*H&7*[SBMCR212RVHSR@M0+J8:8Y4Z^MF8J!R&4GQIG^LJA9(%A"
M,DI6!'\ZVI!LB+F=;Y9MYRJ#KCF25SBG8O"Z1F//TMZ7LV[&2WWJS96QS>*5
MQ<M@.=ES*`+JG25T[$R.?Q]\?ER%I<0R-(V*DAA*I2$HPD2,\6R_=@OE7@6^
M^3K62W;`G&!&/5M7G>J'JV`*9$[`CTZHN<WC9]G4M9T6=0L)HT%V4REG&TYJ
M`U/I"\M3BK0C4E&ITBG!;*F#UO2EO2NQN7NB:'00Z5V1S)-+!6G5I/I2XP>.
M6'`+;KY?`YHUHI@V1N6CCTQ:!Z0+VL\]`<C,VG.(.V`)OKZJ3'65%*?\)W_?
M5,>0)TGJNK*VO?LM142B'PN/O[_-:\K]KYV0L!E8LTRG8XG%GN0O$M>&E3M]
M7(V<)3>F5EEI"E7S;TG1<SIX9[IJM>LY/V09TU?L(IRL8@GYD=:4CL"KZR)#
M9TF02%=9<2FJ]XD,G<X+`FE<A=0-"C28I(B+VC*)*]H8<8>,*>I<8Q%Z^/6L
M+SH?F.MN?;QB<"9%]$Q&-5=&)3`K!<YJALEBBS8%O(F2IJ=(-#U,)-7$%$^E
MO&<XF!-]KK9N@!+$:+BW,3APA@?_TN_C`8#`8#`8#`QQ;M15M?-;2^H;>B#/
M.ZYG;.>QRB+OA&SD3@B.V$PLPLPL12I`XH%11:A&L3F%*D2HHL\@PLTL`PCM
MUCYQ/EN\2-D^.&R=R"/Z>)WRW.W@\JM++-(T<MCJT[1RL%<6.-(26E02U`E+
M'M(KT`I*]I2A'D!+-+5)4N;,.VNV?NTXY&C`D?RCRC=7:%U1>B*(BYLCF,C-
MV>M6G[-31R'QQ,:2!WF4R=P$G@9(PR`/#LX[81FFFC+3IRSE1Q!!E2V29KZ5
M_CB\<5*^..E4]=UVG*D=@R,I`X6[;K@@*32.PY&F*'H(0AT-0-DAS(-0:6TM
M)9HRDA0QF&#.5G*5)VG&VVMAN$,!@,!@,#S(T2-O3A2H$B9"E`,XP"9&04F3
MA,4GF*5!@220`+",]2<,P>]:](ABV+?IWO>\#TX#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8'&Q_W+_=?4L,D+7QE&(A)ZHY_G$81O\@M
M,HX(==#EF%)C'>%LCLW'&!:H=#UJ@"9Z;31%.*]5L&SR@MIB?:Z5TTD[_5Q^
M1*)2B>RB/PF$Q]XE<OE;PWQ^-1J/MZEU>WU[=5):-M:FIM1EFJEJY:J-"`LL
M`=B$+?HUF71]"?P]^%:`<8U.YSGI.(PZQ^E[=C#BQ3%O=T+?*8M6-?2=KTA=
MZH:"U@5K0\.+RA4&DR-R+`(E8`T2!.(:(!ARW4CEMMF].SG_`/-/X0'7C=4[
M]+\O-CW)N6W-<8IF,4$,YX?Z"<'%7OV)9ZCU!+7:K%!YX2$3@?LQ2VC]1,N-
M,V(I4?+&M=L]+W<[,0E\J@$HC\W@\B>8E,(H[(GV-2>.N*II?&)Y;3P*4#FU
MN2(TE4B6)3R]"`,`M"UO61M]27Q>W3TYT%Q945I]:U\GK^V9"W&;UL!8FU;.
MXD0!.",V8\1,2)'J$.DT2[$H&W`]<@8-`6$Z((5EI$^XX;8EZ-@F$,!@,!@,
M!@,!@,!@,!@,!@?_T^_C`8#`8#`8#`8&.+=J*MKYK:7U#;T09YW7,[9SV.41
M=\(V<B<$1VPF%F%F%B*5('%`J*+4(UB<PI4B5%%GD&%FE@&$=NL?.)\MWB1L
MGQPV3N01_3Q.^6YV\'E5I99I&CEL=6G:.5@KBQQI"2TJ"6H$I8]I%>@%)7M*
M4(\@)9I:I*ES9AVUVS]T`.4>4;J[0NJ+T11$7-D<QD9NSUJT_9J:.0^.)C20
M.\RF3N`D\#)&&0!X=G';",TTT9:=.6<J.((,+;),U]*_QQ>.*E?''2J>NZ[3
ME2.P9&4@<+=MUP0%)I'8<C3%#T$(0Z&H&R0YD&H-+:6DLT920H8S#!G*SE*D
M[3C;;6PW"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P(R]:\AT5VS3;[2-_1$F319T]=:SN:<0$<HA$F+2J$S;,86]^S--
M99$U:4C]0?JF)U!0AIU)1Z8TTDPLMES&LSQ4^$BJO'8_S"U)B_M5V7NX/<A:
M('/C60;:WU]69QQJ-M(CS*M,5[;9U*&K?K/:\)INR2S=MZ0SYO\`.3ETD7;;
M/V;S<K*GNS2U/S4Y,;XVM[TR/3>L:7AG=D:9Q:G9J<4QB-P;7)O6%G)%[>O2
M'#*.)-`,LTL>PBUL.]ZP-!=4_P#;M\;U?VFZ=,A&LDU3(#DLJK?FE_;27"'0
MZQ#%ZE6I6N+NJ5'J)3!F'82369E5D;]D?OT*SU1)("S)AOG<8=`F5@P&`P&`
MP&`P&`P&`P&`P&`P/__4[^,!@,!@,!@,!@,#'%NU%6U\UM+ZAMZ(,\[KF=LY
M['*(N^$;.1."([83"S"S"Q%*D#B@5%%J$:Q.84J1*BBSR#"S2P#".W6(M<'^
M.OFWQWU^^P:A6)S.7RUY4/$RL.8J$#O8,L]12J&Q-3N]HFYK3A8XLA5;3H$:
M9.0G+])AX@#4J%!QI;;>Z=F$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_5
M[^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_6[^,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@0#\E7<GX>/,#KTA_A?_`(O_`$9,HA$?J9]=OJ![?ZU*U"7Z
M0^L7U2FWL_F'L/6]E\Q%[7T^CUP>CTXJR9N'.K_YMK_[?_\`\5?_`--V3+?\
M_9_YMK_[?_\`\5?_`--V,G\_9_YMK_[?_P#\5?\`]-V,G\_;K!YSMO\`Q_Y[
MHF]_J_\`5/\`QKIJL+;^JOTK]/?5G_$B$,<Q^K_TY]&LWTS]#?3/S;YW\S2?
M./9^T]B5ZWJ!K%Z6QF7"&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]?OXP&`P&`P
M&`P&`P-6OE(\I%1^-FH_I9V^CYM?4V;UH*>IX"W9:EW4E[&F%,)@),/2MDKU
MD5Z]!Y^O4/<#P;2)-^T]J:GEK6NN?LU>^&CST#ZCDA/-':#S'(_>K^\K!5-9
MB1O;8K$[,VYK#5"2N75N1%I6F/3AN]MI.SC`$!#VG`!.+T.00B<4J[:XZSLZ
MC,K!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M#2MY]J5MN_?'G(Z\I2N9?:4Y4VK6#JGB<'8ULA?CFUK<UIKBN+;F\HY0),B+
M'H1@]!]`-;UZ<E:UN+U<+/X5GDC^"#I?]D\K_1^3%=>6OD_"L\D?P0=+_LGE
M?Z/QBG+7R_&_%AY'M&!)WQ)TIHT8##`%;JJ4Z,&64(L)I@0?,/6$`L1P-"WK
M7HUL>O3_`*=8Q3EKY?2HX3BLD@G$/&\(F3&YQB7PWE7GJ*RN-O20U`\QZ21Z
MHX@T/K&[(3P@/1.;2Z(S4YY0]:&6:6(.]:WK-.-[U*K"&`P&`P&`P&`P&`P&
M`P&`P&`P&`P/_]#OXP&`P&`P&`P&!JU\I'E(J/QLU']+.WT?-KZFS>M!3U/`
M6[+4NZDO8TPIA,!)AZ5LE>LBO7H//UZA[@>#:1)OVGM34\M:UUS]GS9N@^@[
M<ZDMR87A>$P<)M8DV<!+75U6BT6F1IB]>S;F)B;B_0D9(XR)-!3HD2<("$Q`
M-!#K_3O>763'2,.$'G)CB5*8XU.H3FEGD'D&#*.(.*'HPHXDTO81EFEC#H01
M!WK>MZ].L*[F?!WYQ";R)BO'?8DJ*3W4G*2,-.7&_*P%$W`24`*=OA,V<%`@
M@+M,L`0EH5Q@M:D>M:*-W]*>J)QU*Y[:XZQU6Y7,P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!%+J3EQ#T*VQ231:;/E-]
M!U&<]O%#WO%0:5O->/CZE2)7QM>8\I/)99[74R2MY"5_CSD$:1Q2@#L`B%12
M=2267'V:C^.?._&+S[12<16]#8-#I06E?ZY2V_!9HM?JSL?H"&R1U:EB&$A?
M6ED<&V"6$S-NE#!\[$<NTYC"W;VI]J0J,F6KKB9CH=RL&`P&`P&`P&`P&`P&
M`P&`P&`P&`P/_]'OXP&`P&`P&`P,57<^VS&ZLF;O14$8[)MTAI,+@41E$E)B
M$77OZDPM,E4R5^-",U*QM6C=JE)9`=J5)9.R"A%C,T:`?=PT=!^"_P`S/4EN
M3"\+P.JJ;6)-G`2UU=5MOM!:9&F+U[-N8F)N+0:2,D<9$F@IT2).$!"8@&@A
MU_IWO.*ZS;6=(Y[[JJ*94%;=C4I89#>FG-6R]\@\L3M2\MT;27Z/+36]Q+0N
M)00%K4P5!(M`,#K6AZ^7T9&Y<]6,,#=;1_@/\B5Z556EZ5HQ5?N'67%6"?0Q
M>OM)O9GC30]I"7-I4J$>T>SVY<$HP(MA];UBQZ_T^G67#-VDZ.W/QF(O(3#:
M;!57D$8(F[3&!)4#?"KFC$^;9<ZV!'"@;3EM]B(BBDZS4R8P%@#]+!T9IW3[
M]=5H"PLP];8Y[8ST;*\K)@,!@>8M:C.5*4)2M,:M1`3F+$99Y0U20M9HW:0Q
M2G"/9I`%6B!^SV/6M#]07J^GT;P/3@>)Q<6]G;U[N[KT34U-2)4XN;FXJB$+
M>W-Z$@:E:O7K5(RDR-$C3%",--,$$!8`[$+>M:WO`]!!Y*DDE2F.*4)U!19Y
M!Y!@#23R30:,*.)-+V(!A1@!:$$0=[UO6_3K`_K@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@:TNT/$_R#VP?J83"&J*RO-N5HW>-]#4\
M-'#+4:GUK.+5-#B[.*=&:VS$*%607L.G5.I4$`!Z$IZ4ST&AF&IM9]D]JU9Y
MK'H#$6"QI:AGLY9&%O:9-.&YA^JR:8NC<2%&=*!1O3B[E,*M^"3I4H2%*3R$
MZ@T8"A[+T'*RO?`8#`8#`8#`IR=X:%:]8U)71N4N;>$`E[:G7)CEZ$)N@[+$
ML1EFB4)@F:%K8=C"'TZWKT8%1P&`P&`P/(O7HFI"M=')6G0-S:D4KW!<K-`0
ME1(D9(U"I6I/,V$LE.G(+$,8Q;UH(=;WOY,"TX59$'L2#PBR(?(T+M";(9&"
M10=_%I0V$21GE+>2ZQY6WIG8A`OV)W;CP'$E#*`<(`O]C`O?`M]DED6DRJ2H
M8W)8_(%L,D`HG,$;(\MSJJBDI`S,TB%&I*G0*5!S%(`Q^1-Z[:-5HI3I&N3G
M>I[,XL0@%2R+'RE?!B)+'SILU1]IECG#RGEN,E+=%G]Q>F=BDJ^/@4[=D<?>
MG:-N*5(L,)"F4J4"DLL8AD&A"'__TN_C`8#`8#`T1RO_`)IDO_\`?O/]HJ<]
M4[1YKWJ@90P&!PN=T?\`OC],_P#C///[=5YX]_VV^[W?Y_IK]D4LRV[H^%__
M`'..9O\`P8@?]A),]FGZZ_9X/]/WV^Z5N:9,!@;+>)O^097_`-7B_L5KSC_K
MWCK_`)]K]TPUZ]$U(5KHY*TZ!N;4BE>X+E9H"$J)$C)&H5*U)YFPEDITY!8A
MC&+>M!#K>]_)G)T<O7)?3E3E]ETAV0AMZ/.TL\C5IW53UQ5L&0`62"$0U[4M
MF^`Q+F`/L1MZB/PVHTK&N,]B#0'2:B"+^D/7KQNSI9X;9ZSM?JOI"X[RD-66
M)45=TISSTJOYXW6LKJA^ETHM$NOT<*4V]*'FPT5B,&X8N.52!:EC!*%J5$$[
M1EGK]*@G[*)K/23V@E(E/6C=2/F,F+_?%365$*2L>]EKW5EH\YN<VB,[9X?Q
M+1-D*(2C3.-Y!20R"OZ%RTA/;"TRXD*PQ8O_`*0U@B"YY:Z9UZ)3S?NA^Y@>
M^@HW8L=BI<,A'$,!ZAY988HR*FHR4Z8T0JWG]/F%$KSR%3HBM5PBA+24E+3[
M"AE!!/H%[#9FR8SC'EC3J7K?IRCJ^T9OH2ID/0M5<P1NW+)H2O\`CB]>BAOE
ME)HB_/LE(LR5U7*G<%!4S*WQA-0,[HY)T6TA!)ZX]<>4#V01)+].C(D?D_15
MC^0RG']ANAFB57SCB!AN134ZJO760H4["JLFIP2J,[<PV4S-A\R=U3BK^8R<
M37[5K1G_`#7YDI#K9@QTQVZH_P!7>1?INV7NO[A@K!-YK7%@]&$5F7SS&>">
MK%;:Q4,=;KE5ZFW=]E#9"Z9<9O'6=(&3N@/;`CI"0L]K_P!VK)$KT,1OVRLF
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!&#KS_V-K/\`J!B__>-S?^?[
M,;_JU1YZ'$P&!PN=T?\`OC],_P#C///[=5YX]_VV^[W?Y_IK]D4LRV8&\'P3
M_P#O#V]_X,&?WXB>=?\`']K]G#_?]9]W4?GI>4P&!O;B7_*L9_Z?9O[.39Y;
MWKT3M$,_)O;D\HK@7JBTZQ<%++/(Q53J"-R)%[;YY$UC^L01DV9)!)RCSRE4
M.1O)CH6,!9HRQI-"T`>]>IN5J=;'^U1P+Q+STAKVPX%1]?L\TJ!G7OB"[VEH
M`5;4H-51IS0R:1SRQFD94LL]1*4#HK4*RWI6Y)E"@T)H2_7+)$6,V_5"Z,]A
M=B%T=SEWC+)/3:FBNAK5HZ/J^96NMG5!+(%4O0]E,]<P1_9KH4V(J-E]I1PJ
M5-;F[I3V-(TK=;5D)P(PE`.'%Q,V?5FZE[PZTN.ZNNY`9.*DB?/_`"7>EK4N
MC@*:LWA]L*UUS)3L<G#8O=YTHG+8V01'$7.<LQQ>TK6YF/(0+B#@I-;3F@&)
MT\U&*/=R=BQ?A:E>M[1E=3O,R[$<N;:^IJN:_P"?+2F#53CW:)AQ<@GKRV0>
M6R.T;R6KHDWJGTN+-#8WJ"G,);4E4J2]_.C"XF<+K!WYTC4]/=:2"8Q246IJ
MIFOG\B@+JL[DF_>.(W8<^Z#L(-/%PF;0&VF]C>G,JL9ZZM+@X+H[H!2IB<@E
M;]@K*]J>3$Z+Q[A9.X:YX9Z.<9-U)73P\-#9"9`QSR!4;(:SF!"(Y[7-\VAH
M26^Z'9*UI?GZMD5,[RG4;6EIRUR-6G4>U)5@$QF=&7.W5EGIN7(=R\[V"URN
M].QK'9^729M$XF=`2`Q"?+WU^N*7-D/#*9:N9=0'FUA?S/;A<C];<DY!N]E[
M/`3JI.^?HUY>4)YJ&P+40\M)+<B%'ZXEYB%?U(IG"0%,*4'7JI:B1\J,R/2H
MS1HR:YAU>.QBCU=C"4GE:08M&;UZF2M:]LIMO?:]C]`QOQ[Q_EU_AU;27NB$
M3BU':Q)I%%5@IZKAE1P6,OUB1IHAP7F.(7ZP`3B9H&,&EBX"1,6G7'[`?LH&
ML)C&<_1&6OKPZ$H*$=HMH%56/'3UR^6BO.:(M,OJ_(TM0M\NL[FWD-B26>ZP
MT;\ID"9N00MO/=A,>G8_U73U$(5AY?H-,+C./&$H^:V6[8[Y(>B&2]IS"[+D
MK?Q)RP4P3J&0Q77NI%$3;VZZ4HE$FAYT@E"!GDZ)Z/7I3/F*P:-0D(3GZ`28
M::4!]4OZ_P#7_]/OXP&`P&`P(N+^1*I<5RUP4*);H]<K4+#]%NZ()>CE1PSS
M-`#MI%L(/7'OT:WO?HUF_P"FS'\X\GV-ZD_*9?\`GE#^B,O]-C^>OL^QO4GY
M3+_SRA_1&/Z;'\]?9]C>I/RF7_GE#^B,?TV/YZ^WS0_)<P(8KY`^QXVV;/$W
ML?0UG-B(2HP)JG:9))EQ16SS0%E!&9ZH?EWH(=;W_JSC;FVO3ITUUB#V1I]+
MSQH\KUE*O'YQQ)',^4!<'SGFL7-:%*ZI"DVE*N,H33=$%#:S1`+]87R:V(6]
M:_UYVG^FTDCS;Z2[;5.'[&]2?E,O_/*']$9?Z;,_SU]GV-ZD_*9?^>4/Z(Q_
M38_GK[/L;U)^4R_\\H?T1C^FQ_/7VS/6M71JJFI>SQ@QS,2.+AMS4;=%1*L[
M2G:8A+Z"QDI4H0E^R3A^3>M[]/I^7,[;7;NU)-9B/YW-5C'>%2V33<G=9&RQ
MFTX5(X!)'*(N"9IDI$>E;4I97L#,YJT#F0@6J6M8:4$[9!@B]#V(/H%K0M97
MLL"X.7*JN>B$7.S\D=H[`&3_``V,B1\-6IFF1PA;4<@C<EKYRB3JM0.I;6X1
M]RBJ/18]DF:&0$90]"`8/6RYZY8V5\-U\"XY;;T2M"_JR(LF;1NR;6JFMK*^
MJ]46=/XN0P(DTMDK.4QJ9.V.;TU1=`B>@,CNT)7Y(G"6XE*M;%O8R_$EX5K&
M3//4ZHZ>7(UQ/L2%3&)W/5S3,&DNN%;Q.:QC]//UDQUI7Q=P=V*PC(#%T:,!
MX5YC=Z2M&#1#'H.PC/95KVX=HGHMXYT>[+0R-8KYCEC/*X$4VO)*%$^:97&)
M/A,8GZ,;>I(ED-5R*!,CBI;AZ**.6M:<S>_0#U=B6S*T[G\?U7W1-K=F:FR[
MXK@OH*!LE>7O$ZHGC5$XS;#'&65ZCD?424Q3%'B4MSFVQ]].0B,9W-L+7(M!
M(6%J2?6`(2X7NZ<=P538U#6C'Y[;L#E%"0)OJEN^I<K:4+78U8-[Q$G\$$M%
MM=(T\$O;(H=H8E--,;_HI<()AY>E&BC1`P9[K>AG#\2K69F/E:79T=7]?'V6
MY6R?0,9L)E)IC<M?90*:R4A$W.$.<9VQQ"32M0H6KX^W/Z-C.&L4%_-`D'#*
MV,^DUL(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%D6!`&*RHZ9&)$->
M!M-5I5HA-J@M,I]LC$(96M&FD*0:!O8M^G7J_+EENMS$LEF*P1]C>I/RF7_G
ME#^B,W_39G^>OL^QO4GY3+_SRA_1&/Z;'\]?9]C>I/RF7_GE#^B,?TV/YZ^V
MK^T/^W(\?EMV)-+.E3ST.7))Y(W64O@&FQXRD;`.;PJ,6*PH4IU>JS4Z71IF
M_4`(TS>M?Z1;SG>MM=9M9))V6'_Y83QN?^O.E_VH13W:Y,1>>Q_Y83QN?^O.
ME_VH13W:XQ#GLDWR[X->+>19=()K53I=JAXDL<W%G$,LG+`[H@M@G-`[;$F(
M1PEI,*5?.FXO^GL8M>IZ=>K\OIUK6\;F,;_G,5.'[&]2?E,O_/*']$9O^FS'
M\]?9]C>I/RF7_GE#^B,?TV/YZ^S[&]2?E,O_`#RA_1&/Z;'\]?:4:!$2VH43
M<GV/:=`D3(B-F"T(S9*4D!!6S!:T'0A^H#7IWZ->G><VU'F$1C,_B<F@LT9&
M^2P^9L#Q%95'74C2EL?8Z_MZAJ>6AP3BWK1R-Q;E1A)@?D](![P(>4OP9"J0
M?(0L9;WZPE\/K$9O^&U36'>[[)*SAR4+2O86AK+:B4+:^RQFB[,XC3M:.1.+
MRG1:`2,`/:ITXRBVY^BW83XV:0@[O"$Z6<7B^5%5MA!M2J>;)+8"-QHBN)RB
M?UTICKI'F$B-HI@N;X5(%WSMC:W9\<FEH4$DF)DQ8R@"T,U(^N.=*_JXN_BH
MT=(3`](6M*[CL+Z3<4RK9,MF,(AT`=BX[LEO2_1K.%B@R+9))OS@8#]F#V8+
M0M!",]F/3>):4/Y6K_D$_P"NG^&U5LE>-M=R1'*E+-9\/>:H7-;M7LZC\W84
M[6I:IO&7AF3JB5A!)98Q@$6:4,@PTD8S<Y?P'QE#Y-5=N4]=5K7GT9#[E9&R
M/R0%Q3)B,5,C<RG+EC4.$EUS$*Z:HH\(W-8!9IR3I?I(Q4B2&&'CVF)]49[8
M4@'#4-=:?N.F;,NKI2[&.[(@T0:0R&U+2)<Y3'&".Z=Q1W<&-C<;B\>CCXUJ
MW@2DUU^CCG1U4)TXW-0NV07Z!GK+A38=RI.V?I2I[)FMHO=IUSS_`$9.8A5[
ME8;^%ZMQ\N&Y9P)QLR?3WZ"AT/A6DC#74?:F".B1%[-+2KW(L9)`?4&>,]*D
M'5=$0BHI5=LVCAKXXRGH"S`VC83U(EZ=Q6G.R2'QB!L3$U&$(4.T,3B\7B*1
M,W(Q>U$1K9@MF#$8+>#/9&A1XXZ1316*1R%2^XJO<ZVNZV;VJ*<UY+V5IE]1
MO]WNKZ[63#H0)RB;S&A5C(CI,M`:QNK8Z)Q%'>@6Q"`6(#!RK]-GC=Y\;::M
M>EOIBX'%MMV\&[I1YGSO9SRY6Y';X9FVNTS/:$.L505M[:).UO%9-SJ0,W:D
MH"X9X/9_,C`I`#-SEDBBN.X+1-G3^Z4E@7'9UJVI"X1"+`FMN31'*%T@0U^Z
M2MSCRY.V-;!'8[%E!0)<<F&D943:T>Q(+&6B+4#4GJ!;GI]'_]3OXP&`P&`P
M&`P&`P/E8>5/^)'V_P#O+VQ_>MPS-[N^OZQ`/(KZI_BL_AN<0?NT5/\`W4;\
MU.SCM^U3\RLF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
C`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g657040g62s27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657040g62s27.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0XH4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!0@```F`````&`&<`-@`R
M`',`,@`W`````0`````````````````````````!``````````````)@```!
M0@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"XP````!````<````#L`
M``%0``!-<```"W``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``[`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T0=&`:6C-S-L$1ZQ)U:&?3C?^;ZOTOYS_`(/V)#I36W,G,RG0[U!6
M;/:=CM^UWM^@W>M%"=_2*_ZK_P`K$E-)G1`RL5MSLP0T,#C=)$?G>YOTG*WB
M8HQ:O2%MEPF0ZUV]W`;&[^RCI)*4DDF(!!!X.A24ULS'JS*6,-]E(+@YCZ+-
MCB8.T;F_3;^?L0+.E$W5/.=DM8T;35ZFCR)VDZ;MW_GQ6!T[!#'L%+=MGTVQ
MH='#_O[E%O2NG-;M]!I;N%D&3+A,..Z?WDE(:NE5U@L^VY-@#"TM?=NT+347
MF1]+\_?_`*5-^R&AFS[?E^\!H)NDD-'YNYOYWTWO_G%##QNE9+\NAE%<8=GV
M5P:US8!93E%CMWT_Y_?O8K;>F8#=X%#8L^E\AL]O[GM_<24F8UF/2&.L):P0
M7V.D_P!M[E)CV/$L<'#Q!E5ATKIS=P;0T;C+HTG7?_U2/7CT5.<ZIC6%\;MH
MB8X24D22224__]#U55[!D_;*#6UAQPRP7.<2'@GT_2%;1[7;O?OW(SG-8TO>
M=K6@EQ/``6>R_-RJ_7KL%#.6,#0XP?H^H7_G?U$E+9?6FTV>FQ@AUHQJ[K'M
M8PWD;A4P./J6[/\`"^DW_!V_Z)6F]0Q8:+K&4V.<6>F]P!+@0QP9NV^I[G-6
M0>E8'6^D7=)RPX6U6>IZ[3[VW$FZO/Q['?0MWN=[/S/TN-_1UF8EF%9ZG5,;
M*_:>-DB^BW'LN#VMQ*_YW:YXKMNKKR'?TBWU?3JS/TOZ/]-2E/49.>RK*JPZ
MRQ^38UUOHEP#S4PAMCF-_?W/]G^#_P"$8B5YV':\5,N8;7`.%>X!\$"S^;/O
M^@YKUR/4!AY!HRNJWEEO1Z[K!GTN-7KXY;CEA=9]+]/1D;+&,?\`\H,_1?SB
M-CUG&J%3<UMWVIU>0S/M+7N9F/`=7OKKVM93D-:[U:]E'ZMZGHW_`.#K2GHO
MVBUV=9C5;;&XY:S)@^]C[`U],L_<]-_O_P",K_X16*<K%R"X47,M+(W!C@Z)
M^CNV_O;5QN4W$?U"WJUN1;TC.S3C83VU.$>N]C+*W/\`;LR+:*&9-?Z7]'=B
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M>_)<VK%W.`:^QX+JVAWYS=K?4]G^"7*486+B6^CT_J-N1?T5U=-&+;<"#<\&
M*[=XJW6OQW8^.['KM95^C?\`X9^0C9=.+U3$_9-C0S#ON9=T^^F-]%V]_K55
M.VGT[<3(_3U^RKU,&ZS&]-GI6)*>H&=C#8VZQE-KS`J>X!TAWI^V?I_I/:U6
M%QV(_#<QW4\?*/4L3);;5?598'AF)67;75&/5N93>_VY-S+?T>3^L?Z>K5Z9
ME95N?CXV587V8]-PWL<0RYH.+]GRW5_GOLQ[_>W_`+3W^M_P+TE/_]'U*VME
MM3ZGZLL:6N'D1M*YWT^M88^S''?<&^UMM4%KA^:[5S7,_EM?_P"9K4_:3N!9
MB%Q8QS!ZT;BX[8G9_-N]GI6^_P#J*5'4=]K6VVXH:_Z/IW;G'=_-!K2UN[>D
MIAT7"R<:NV[+]M^0X$U@@AC6B&,W-^D_5SGK(ZITO#Z3GXF5T[I#[79.59;;
ME8NME%]M?V=E@I^CZ&1O=ZV]WV2GZ=U?Z?U%T=^S<-UA:=KX8.#H)>6_G>FL
M@?9S7[,VR`^'/#7$R'>ZD^X^W=^BV_N)*3=.Z)BT&QIQ6LQ[<=N.:+#ZH#9L
M?;1[S9^@=ZWOK6,.AX>'U5W2Z>BO^P68U=->34]SFV5-L]2VK*L>ZOT+<:RW
M?1^D?DV,9^CM_P`"KV<,;T;@[-LK$-DACCLY]P:'_G*CMPMS/\I6Z@PWTK(=
MP=_\[^:DIV7?5SIN7TZ_I^=C-?1D7.R'-)]_J.._U_69M?Z^_P#PC?\`!_HU
MD],Z<VS.R\=_1[,+T<J^X65OVU.=8P559>+?N8VS[7CON^T5U5_HK-E5]?Z%
M&P&XH:[;U&Y\6MDFMS3N)=MQ_<YWZ-SG;-JMN&.1:/MMC8;[B&G]&(/O;+O9
M_I$E,LKZO=.=T_&)Z?3DY73*'-PZ-&-+C6ZHXWJ%I:VF[=^>SV?S_P#.5K-Z
M7TMN?TZLOZ8_#+*J*&U9!+0&4.:]V)96Y[[;L6F^K]`^WZ;'_H_U92RVXARQ
MNS[6N],?HQ6\@CV_I-+`J^S#-?\`RG>9=H_TGD_2^A_.?];24WOK3T3I_I7]
M79TD=2S'-J9DL:XML--3Q=ZU3&_S^3C[?T;6;+[OYCU/\"K6#TUK\FCJ'V=U
M#S99=8+2))L9Z'J^BPEM60^ME.__`*YZK/70Q]F92][LVQM;:V[G%KFBL!G\
MXT[MS/:?44K!CQM.6\.]-\-VND@!NZS;O]^S_P!&)*:'4^CX?2NHX>1T[H[[
MO7R;KG9.,27TWVU&D?H?S,3)_P`-N?\`9*G_`,Y5^G]1;'2NDX^#:ZRBCT&F
MFJEC7N]1[65[ME+7DO=Z;-_T?46`UN$&UC]IW&3H?2?+_I'9_.>Y7>DMQ1FO
M+<ZVPFMP+7,<P-^A[FOL>]FY)3__TO2+,3,<X%N16`&M`W4AS@X3N>UV]O\`
M)V>WV>__`*W6'VBMS=UTAOM#CAODD.+=75G;M_1V[/8S^=I?_P`;K*B[9ZNG
MVB-9V[OWK?I;O=MW?S7_`%O_``:2DE636\5U6-L?8YH#GFE[6ZCW;MS=E>[;
M]#>B##Q!Q2P?(+.M]/O]MW;71&_=&QN[Z/LV[?\`P?\`F_TOJ+3QX]"N-T;1
M_.3N_M[OSDE(WX&%8"U]%;@>06@S"A^R>F:?JM6G'M&GP5M))379T_!KG916
MV=3#1V4OL>)J?19)T/M&OQ1DDE-5_3.GO=O?C5N=$26B8\$W[)Z9_P!Q:O\`
M-"MI)*0C#Q``!2R`(B!P$QPL0B#2PZ$?1'!Y".DDIJ?LGIFGZK5IQ[1HIT]/
MPJ'^I30RM\1N:T`P58224__9.$))300A``````!5`````0$````/`$$`9`!O
M`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!
M`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!
M`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`__``!$(`4("8`,!$0`"$0$#$0'_W0`$`$S_Q`"\
M``$``@,!``,!`0``````````"`D&!PH%`P0+`@$!`0$!`0$`````````````
M```!`@,$$```!P`"``0#`0D,!@8&!@L!`@,$!08'``@1$A,)(105%C$BE%65
M5A<8&4%1T=(CT]35-I;65V$DM'6U"G$R0K=X.?"!D3-V-\'A8D,E)F:AL?%2
MHC0UAS@:$0$!``(!`P,$`@$$`@,!`````1$",2%1$D$#$V%Q(C*!L4+PD:%2
MP='A\6)R_]H`#`,!``(1`Q$`/P#H\#N3[C>W]S>ZG6SJ=0^DR%4Z@3F/1,G.
M]B)[=86PV%/7:3(66,68FS6+M$:[.R>UV1(N"B#$$DC-P)ZQA5,2-8DDM6.F
M[F=:BRO:B$'2T@D^D];C;=V=;?92\"&8UV6ID_H4?(J+A6?EK>5>H5=^[%*`
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MSBU]Q0,/LM@M.>RN2=CJ?NS_`$>$G5/-,5BR7C/JGF9Z0SK\@Q%9J=T>6%5-
MP9-!1+Q409+K9.L;XJWNR^W?==AC,(J_9VHRNBSEJ6H\`DG7K^WI-BMZ+DK(
MM=KNL/*BVRBP2KM\<J#5)G-KB[7.5-#U#F*4;E/&\X>?KON\>W1@]RM^>ZOV
M6A*I=J%=#Y_<*R:B:O-2T%94F$;)*%=MJ[0Y<30*;>8;E-,)^>'!PIZ`NO7*
M=,LROC;Z-D;M[C73#K8C15M<VQC%?I*I9-(I+>ITS1]3?SF>*M3O$+V6-RFG
MW:084YPV2.=*3=)(,E`(8"J")3`%22WA%KL3WYF/TU^U)^K)H%6M.#=T=8OT
M/;9]M"(29+?3(*M1"D:A$NY9JA*UMRSF)%?Y@"IMWB;EN"*P%\BJ1IV63]L\
MMU>Z-W"T3H]U:4VS+*M2[A<W&FYQGT;$W\TX6L%+>)HT4J]>C77T?*^9J``)
M?34^'CXB4_AY1J29J/E:[W]QL#[481UJ]P3$\'@X3M'+3%5Q;=^L=VO5@H9;
M_$L&+I.B6ZN:+"1]L9R$LYD4&Z#L2-43+.">F1=)-RLA%Q++94AK=[LOMWT3
M8'>%6OL[4HC1(VW$H4P0]>O[ND0%S%95LK6;'K+"HNLGKDPQ=('2=(OIMN9F
MJ42+^F?X<N4\;C.'N]A?<]Z*=4[M9<WW[?HG/KW4H:KV&:JJ]-TJP3/T>XED
M5()]$M*G3)XUC(9"*75=ECOFSQJ!`5>%03.0QF2:V\1XU&]V'V[],U?/L1H'
M:.C6S2=3;1*]$AH6+N;N+FG,Y&(2\;`JV\M8"F0UO5:.DRJ0C^0:R[=RH5NJ
MV(X$$N,GC<9P^U/^ZCT&J^S*X%.]@XQAI;;10R-XU&BZDXIT?IOU!>)5H\GJ
MC2C.,JC+&TEFJK1PW<329VSI,R*OD4*)09/&XSACC_N2GG?;?N!6=7W#%V77
M_K5UTHVOV"D0=$V%WM>9DD&GU6P6V[S+:JOJ1:*Y(Q9%%63"`<R$SY5&Y5&:
M)@$[H8Z3IU97BGND]!NQ6Q1N!8QV/K%XUB:A'%@@ZPTKU\BV\['LXGZX_2@K
M-/U.*J4U,1D8151W'-7ZL@U%JY(LB0[5P5)DNMG6Q/WA#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.!SM:_P"Y_P!\82^^XK+9%E?4&4PWV[K)'-;RGIMLU:KZI=*^
M^A'<T4*DO%%D:0[GE$HIR0B3I1B*BQD44$G*QP(:9;DG3/JL5+[G?5FJX#UF
MW';;8[R-YVAR^N:;1LP3K5YU+0CL96I1]LFBLZMEU/LUKEX&LM7P`O,A&(,!
M3\BAA2]0I.5G%S8V5:O<#Z;4OKI4^V5AWNH-\`OCIE'TF^L&]@G36R8?.GK)
M.NUVIP,+)W>7M+9W%NTW44A&GD61V;@'"*0H+>08N<8ZL-E/=!Z'PN%UCLA*
M=A(-GDETMDM1*I*J5/136N>N4`NHVG:S'9<G3CZHM,PJJ7^MH?10.V*=,R@%
M*JF)F3QN<8952O<-Z7:#U]N_::J]@*<[PG-':\=H5VDFUBKBU*ED7;)@G"6>
MI66$B+O"STB^DVJ+%BO&D>2"KI$K9-454P,,7.,=6I:E[O'M\78FNF@=SF0/
M@V=+ZQK;:=POL34GU+H3>2KT2,V]C[9DT(^?++O;4P!!BS3<2#E)?U4D#I$4
M.1D\;V9OAON<]$NRFPKX)B'8FL7_`%9.*?S3:ML(&\1S69CHIO\`-RBU8M$[
M5HJH6U6-;%4.X1C'[M9$J"PG(7T%O(R76SK8K>NWO1QO5OK19]CV:W8YV7MT
MQW+U3#<T@L.B]ERR!;T.A2-6)9&=FF[_`);-&7N^8QT\+EX=LW/%3*2[=*/>
MNCE6<#,M>.:D)U]]U/%^X/=FN9EU@[.8G>,/1PRSV2VT&9R;L93-R=Z'`S:I
ME9RN6>]9]4LP^PK"N/V1EVRCLTKZB;@Y$3H^*J#*76R=8W]GONP^WIJFP0V$
MT+LS59[1[+/.JM5FP5O08RH6ZR-%DVQH.G:A,5"/R^VRKIVJ5!JA&S+I1ZN8
M$FX*J"!>7*>-YP\S7?=X]NC![E;\]U?LM"52[4*Z'S^X5DU$U>:EH*RI,(V2
M4*[;5VARXF@4V\PW*:83\\.#A3T!=>N4Z99E?&WT3O7NT0]SM;1JH_CK+`NZ
M6I=JU*,'17,3/Q#B#&=AG[)ZW$Q'$=*LCIJ)JD$0.DH!@^Z'*RYULV]UOW+7
MW3"H^Y!;>L7530>J#XUDD+M4LGONHUO?ZG4JEH\YF5CM:T9=6,S27#2-F:\N
MZ!%H[?JG9&(HM\L0%SH3+?C,XSU6V:G[F?23$:%C&BZKMS&J0O8&A0FG93%M
MJG>[K<;+1I^#C[#'V0*1G58M]J8PXQLFD)W2[1-L50#D]03$.`7+/C;Z/0G/
M<FZ-UO&LJ["S78NEL\6VFSJ4S.]$!I9G4!)6AO&S,L]A9P[.!<.J0[BV=?>?
M.?74HTK)9'T5Q36,0AABYLQU:$/[X7M7IT]2\J=N:P6%1LB]478C0=A"XMI5
MLBV67<.<\_1W]OVU>(+Q-/ZN>,+$BX-Z(.15`2!,Q?';LD-M7N*=-.O<)FMA
MU':X]A&;!3?TC9L-2J&AZC(6O/ACV,J6\LH;+*C<YEO4#Q\D@J62<-T69BG^
M"@B!@"I);Z-.:YWAA+$VZ`W[K1V$P9/*>U/86"I'S]]J.L3TEKU..L_86"GY
M8-1K3O[%Z&TD(YRV,K:4XJ/8R"147:Z1R&;+#'.8^6]^\?[:N96Z>H=Z[25R
MO6ZJZK<,6M,&XI&K.7-9T*ARS"#M+"PJ,*&[;0D`PEI`J"4\Z.E`/#HN/EGJ
MP-'0HS,7QV[++FSEN\;H.VBZ+IHZ12<M7394B[=RW7(55!=!=(QDUD5DS`8I
MBB)3%$!`?#E9?-P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`__]"\RB>T_EG8
MWW*_<>VWN7UQGK)37%WZU3_5N[O[KH=)BY51CG\VSTE]`CG=WK'UPK"9@(1-
M8))-<J!TR@D!045\\QRWY8DQ6INQ&3=S<F[+^\53LTZ>:1OM6]S+#J36<IU*
MG3=7AZ/2'4%AUQS2V_;^0FY!,8M[$J:`_69LO`'DLO&H(MTQ*\%5N[F9C7KP
MSKKGTYW>%[)^RG;KWB,VC5^N?1NXTG59:<C8MVTR_4?L)(,X.+EBJKN%(ZPI
MRC@A&RR)3"14?O3@(#X.Q;,;=?5'.:]OOMQ(]"NX=,@<,D'%[B/>2O';NDY#
M+NX:$7V/$8A"BM&A:FHX<G@EV4T@1=9JBN8H.$H]1-)-1844E"YF9U]$L_<!
M5[1^X)[?FER-+Z+;+DENIVUX9<JWG&C.:FUV76*U29="3MSV.ID2Y<N([[.C
M(B1DW=NSN9!%-<R"15"@BH28EY9C:LK[`]I/<-Z^=E$,)U/$*'9_;LW7+I][
MI3.*8364Z!<;+?XRMP5O0@IJ0%I/.&<@UD2(-E%%4VZY/.)%"G*0G22SZJ]*
MEUI[CZ-TIZD^U=)](-3S"[X)V9@[EH_9^8=T9EA-=HU?U"Z7%[I&8W1C.*2]
MLNDRPM*R0LFC,BX^(G]545Q(F^C69F[92PE^F.Y/F?\`S!;U3#)1U8.S;%!I
MUZD58N&5D]0CTL^MYB,:G(*+BNJW3L:K,P('.D`//3,!?4*`@[IF?CU8YI=.
M]PBGYOT&PR+I';Z"P)A[;./9K=H[IW$X:GK37N#$5")K;BB[?:]<1ED:3C,)
M`,4TG;IN1)`KU=?S'6$/Y!U/QZWURU_UDZ2]JJ1D/L,UVT8I;XJ8ZQ=@>V$_
MO+-9./.?-(.YZM;9BJ2\^*3XY0CYZ*<IKMU$?5`4U"B/AY@#CL6S.W59Q[W.
M+Z]NW2,:=B6=6/4[M&[=C=P^R%439JS;N$J]E._EW#5)Z[9H*?+(>`B'G#P\
M?'[@"(*FN,]6A++3^W7N-]R>F6@W?JM>>HG6#IOH4QMTI*[38:&[TS4]);-X
MLE/KE?I-3F)]Y"1D8_CBF7=.%BM5FCAP<%?F$6Z"A>DEZ]:KJ<=:.Z4!T@[*
M^TV3H_I-STC8NR\Y<ZWVC!S2DNMSBD3.GTVZ$UBQWR0G"332V1\36`23BS-5
M904!('CZR7R1WT7,S-LK,J/T_P!+@/<[["Z38LWD;9F2OMN4C#Z+K$_&1DDU
ML][C$*]`6"&9NG2KEXA-S48P7^<()2`NB<Q3B8AOB9STGW03R/HIV8K71'V1
M:*^P"R16E8%[D=;UW>H0(Z'3L%"H!>P^DV-U<[6H@[$YHXE--$K*J%.LH5L1
ML0P!Z9"%=FLS.W7T:S[Q8Q[F/9YWN6=WS,>XUJG*EV]:7++ZC1HO"(+HZ?K/
M$7R+)2;)&.TB$U.\[*Y++KO72)7BCELV%5P_`IDUDB.I/&<=DU>SG4WL;<.R
M_O.VZLY):9FM=@.@U'SC&9AHFQ%GH5ZBJ"PC)"KP)CO2'/+-G[8Z0IJ@GXF`
M/`1\0\7=)9C7[O3ANG^SP=^_Y=F3AL2DX>+ZOXCH4/V37C(J)CTLOMMHZZY)
M'N$;DFU51-]3F]%:S8KJ$*N*TD9PJH85%3'.[&9^?5T3\K!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`Y,]K]H6W]F-`]WS3[1D=DB=?4U>H:OT?N$D_.6`ODK5:Q
M.R<E`I59_(N:+:H>XNX]O#JC-QZI6QGH&(=,@J^:8Y=)MCQZ]&9[=F';Z;WS
MI/WUN.!=P:Y%EZ,,^NFUYQTH)0(S?<>U^!O%FF9)S%T.VG4AW697-25(5NFQ
M%,6[!ND99<A2(I."9F+,^K[%UZ:Z3D.+^W1O'6_JAV.L57ZN=M-8WG2^L>JS
M^<3/99:$T23:I?:^.B:LX2ICN6;+5DLBTAFISR#5221*`%`CA5$9YEOHW1V/
M+VFT'=_;P]R)KT.V`:KUUN_9:+T+J^Q>T:P=@TJOJM)9TRJ:^C3$91I"*60R
M[(SM2)*\4D&RC!CYW`$5]9J)C%F4`>UF2:_`=2?<V[.:QC,C@SSW`^W'4%KA
MF`6Z=9(:C&GS^\D.G;FL75',A7H?6K\X?/'QV,HX30(+!=9T*R94/FG=9C.L
MEX9?%QEWU&B>ZIULNU#[66KW/>P75JBZ+9(K88[`6[:U93G$U$4'/H>C-<"?
MMZ3#S#(+0072#E!LYD`4(J0#"FJ)G?N<>-_Q3Z@^IFNU_MW[%-TA<9D(6B]<
M>K>PTG;Y:*BHF/B\SLT]U@"NQL'9$6:B1FSF2O$@Y0(!$U"'>K*F\?$QS"[)
MGIMUZH06+HUVX'VF.R>7L\*M[S6&WN2V;L)!9F0&!;7<\R:7:IO"3-3;%=JM
MY4[UBFLX01*H"RZ3=3TRG4\B9WH9GESTPF5J^,=BNW_>+(MZB\)T_#Z??O;+
M['8U*/M0:Q<;*91I.@R>D054@[JG`3$H9C,KH2K22!%L=55)LN7S>14IR%)T
MDLSZH:T;K[V^V;K7[>WMU2W2#6,2LO4/LOGNE[!V2M3BBQ^00M0SFRW.3?V+
M(+5%3SB4O%ONR5E%4R+)N`I/?`3G635.Y0-9DMN4CY?ICN3YG_S!;U3#)1U8
M.S;%!IUZD58N&5D]0CTL^MYB,:G(*+BNJW3L:K,P('.D`//3,!?4*`@[IF?C
MU7!]4\_N=.]O7K;E=HK[Z#T*J]-,>S^Q55^"*4G$7.#Q&NUR7K[T/5%!)]'S
M;51LI]^)"J$'[[P^/+Z,W]K?JYXL*ION,?LHJQ[6-+Z"ZO4-*M$)I.>WW>M?
ML>>4W&Z51]2VFWW>?G6B)YZ4M-E=H4NW*,3MD&:;Q%P)UVR;LR1$59Z8;N/+
MRREG.8!N/MY=V^N'8&F]==9[C8C1?;6HW15(<4C*Y+Z52;KFL]`O8VU.*A/S
MD4#>%MK6&`JKMJN4C8DD^,J(BF";LF99C.+E%JN>W'V?8X1TH:W/`5P7NGO4
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M\@HDK`OF/@LDN@*H&2.4?`/,'B[+;,[=?1FMHZ,=AGW3+WUJHAU_FW&H]EN\
M^E7_`!=D$5"FL>I9H;9*M<*A,P3XSGU7D(@T6DGK))94@H**KB0A5%#@9W3,
MSIU=)V&PTI7<4Q^OSC):-FH++<_AI>.<@!7#"4C*G$,I!DN4HF*"S5V@=,P`
M(AYBCRL7FMI<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/__1[^.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!JW8
M\1R/L+0Y+,=OSJIZC0)=9HZ?5:Y1#:8BSO6"GK,)%NFX**C&38J"(HN4#)KI
M"(^0X>(^(EQPUOUXZ:]7^J!+`/7O%ZAFK^V?+%L\_')/Y:VV%!D)C,&,U<K(
M^F;7)QD<8XBV:K/#MFXF$4R%\1X6VWFI-<(<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`__TN_C@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?_T^_C@.`X#@.`X#@.
M!7'IDU,H>Z=U.@$):31@I#J%VSD7\*D_=)Q+Z0CM"ZYHQ[]Y&D5!FY>L47JQ
M$53D,=(JIP*(`8WC/5K_`!JQSE9.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?P"B8J&1!0@JD
M(FH=(#%%0B:IE"I*&)X^8I%#(G`HB'@(D'P^X/`_O@.!_!E$R&3*=0A#+'%-
M$IC%*950$U%A33`1`3G!)(QO`/$?*41^X`\#^^`X#@.`X#@.`X#@.`X#@.`X
M'__4[^.`X#@.`X#@.`X%:&H_^;+U"_\`!MV__P"\;K5R>K4_6_=9?RLG`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`J"V_%*EL7=2BY+D,OK=;L5-GZSV7
M[:Z5!;OO*</6*BE.*O<UQ"'KB6C_`&'AK-O%BAEU'#-!D@6+IT0].FFD9ZP$
MT:EQ'Q0_9[1*1%MJYC&>4+[4:W[I_8_J\H.@773Y6OL"H5+>=/>:8HXD)>U3
M3=VE-9VBX-78\64*HW,JP8%B4U4G+08[]F6Q'=W<YF$JN4M:/E@]H;-W(U+I
MZ:74>6M'$6#G*<PM>ZSFMA#`X6NCN+<937$P0KWU))R>9<^B,@5$@JB,3^,)
MAW22UB,ZKZE*:6M48;5HG*-;</I+*)2RA6DW47#VD:S8:VZGVL=8X1\]AVS)
M\LU.=P:*?J*-DGKTB!'J]3IGIPINS@:=F_MSW':QP;M@C:'G6C";5<K)V$[+
M[38*+K$T_?4.:>2=&^E]J;G8J?\`4IQ0TCZL8QKAS,U"ME0!!0[,8UZ\I?=A
M^[W8?+)_NE/4ZA8Y)Y-T<;YK<KU]I).YAH.CTJUYG6=$MD#54(ST*]5K)7HU
M>159R;L\BW?'.W:F8(BFH[6))G#'^QGN#ZS1>PU\PK)@Z[*7&E:;UURVLX[H
M<O99'<]N_3H7/WMCT_.:W5K!&K,\\QJ&OQW<R91@_,+>!DEEUH]`K91<2=,U
M_$Y[D>AK[G<:O0\Z;VBA9UV;A.MTW1X_)NPUDU6V-BVNKT?0M2KND5:H/L/K
MS&AS5@>/203]PNXD8B&554?,7+E%J1DPE3UXW+?-KVOL)'RE;R>NX1AVMWG$
M6+UH[MC_`%6XVZNL:E86<Z=NH=*J5^LM(.TD;+D$SIV\>D,H0&R1"E5J63IW
M:(E\<@NQ7?SMC5+_`'/;8N,S7KGTTE,X',=_VK(34>>O=D[=(V>P0S7,KW5H
MIU*28U*,,K\^V>H*_))E42.F)R'BYQ(K\G]*[A;/5.C3O/=7M\CNN67#W%2U
M^2;2CBL5CM6_Z<:=&TBGQ^F5V"2B(&7C]EIM9>0[PXM@1924NN];D2$H)@7I
M+>R3^;>X'3VM1]RSN>SM$K/9/1:+@6AYU5;9+NV+6&G9+KI"*IYD$9)O$F=/
ML,OJKD(:3:D%OZ<VHJ"P^H!C<)CB>KZOMJ]FZ90T.Q&"VWM3"=L/T257)NPB
M&M4"_+=D922C=4J$?!;-74%LV7O,LX5I_82J3CUK$()F<L82S1A$T`;^D;B%
MG%P];M]HT?MG83I*E3,\[2[7FUTQGO'+O,OQJ\V?JQ=I:>I%CZK0L)<IE#3]
M;ZK/A:4]6;DF[0ZKU5T4TF95FV6(=10HG25_G4S:IJPQ'MGPN@24SHNK.;3V
M_P`AT2PW"WZ.G><RO.3UFZDLU!O#([ZMQ.BWFG_9=O7I.3L$7(@[7:GE&"@&
M=%=*B^K977+N]V'T>5Z:6/4:%CD/F?<UQIM-J["B2=S>7>E77-<[ONDH3T](
MSWHP<E6[K!Y7,@$8W:$<0JRS5,S^0`%%!&.6AW.]]A.R%@]J[>+35<LJV#[7
MW"^W>7Q=<F+6KJ56A'W53MG]A(S0%'Z:M8M3B[4MVK)O5&!8LL$[;D9>E(`L
M+I!V7$GE/7#8^-]G-?-6.M63X-0\M@Y/<-2]QV"/)Z;:]:M\/2/U;NS=P@T+
M,`R5BGKG<3VQ$':B\.I+QS=JX>IE9.6;%DFQ4)9R3?N66YKE/6B:GI'K=U^M
M6P2?:BM7_2-YMDLVPZI7'J3I*V16:LUTJ4Y4I^7D-4N+99Q7RKOTC-8YLL"@
M.W?H-W#)X]:EQ2]:U;4?;X_3?I%:+E.K7GK-:M)D:M!?7XAU0Y&<H\S88&-2
M-,'2L,?/04<NU!P=3TEDWR9S%*GX%(6IZX5J=0)O4JQ#Y)MF-0O9MCE,!T%M
MM^[/.NREGV>2S33MZ^P&9SN6R635[9K9*S8S#EW"6%U,3-7;LH!S$.6Z9E57
M"B`)QJ]KW2WJ7;;M;8<[ZK_4*1@T3KW=N8"=R1DU?WN6H629*TQASL4Q,:@X
M4<14W?;TUCV9&B,;##$LEG3\I1=D2:J+KDQ.O7HTOK/;?MQ8JQ5JU4C930MA
MR+W(,GZI;$\CUKNXS[0V]IC\^NU7D:X5=LI+P].N%4T9JG/13A=[(1ZR9R(.
MU0!-948G\89%JON1ZQ3]3UFG4[.H>X(]=+CG>=7^CP63=CKU==CMDU3L_O>B
MFRB[4&H3&<YZWJD#H:!(AG83/WTT\:J%<!&-E6SM5DFO#*;GV@MF,W#N<&89
MO59JY1_?3IM@\:A<+YHJ<%;9?LKE/4Z"3GIIP\?7!M04H%?2DT`3KT4E'_+L
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M*P<!P'`<!P'`<!P'`<!P'`<#_]7OXX#@.`X#@.`X#@5H:C_YLO4+_P`&W;__
M`+QNM7)ZM3];]UE_*R<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"%D7T>
MHU<T;1=+J.N]BZ;+:OI:VL7V&K6IG95JP6Q9G#Q7B\C5H1TX/$MX&OLHU!J*
MXIMX]LF@GY2%`.%S]&<LNH^-,)&M2B$=.?-U3LU=^W$4)YYV8@;+H%6T&G3\
MBY)X`"T&,+I<F5!A]ZBFIZ1_OA3^^&:QNV=(<2ML38V*AKU79J<[!NNT,9>:
MA=)2N7JD;.^KS.H/K+2;`Q`IHEI(5)NM%N6"J;EDZ8/G**R2A51`!ENB$Q^N
M0^2/<:=35WM-<EH&UP$U.7:XS5NN\TC=E9AQ8WDE:YQP[D57;EQ.N!0(3R-6
M"0IMVJ*#9%%%,GU8S8^MF7VKKJTZMS+.86R9G0JEFR;%*8<(31JO2FT,TA$%
M)I,H.1=E0@6X*K``&4$##\!'A<]<L?OO4;&](A>S\#9F$\JQ[>0,56]E%G/.
M6B[^*AJ(VSI@E`*%(8(%5.MM2E$Z93&,L(G']P`&;T0*UGIKVUEMW[%7K)[6
MWIDCMNE4&ZY_ME>[5[SG,9D456LQRK-Y1*]=/ZO57>);_;F[;/'!V[V==+&F
M6;AHP=+L&S!'PBYF(G,VZA4"&UB=UBFW?9L^5M]ZC=-O6=T;3)B!RJ\7^/3A
MF[BSV"F$362([L32`:)32#%=DSFRIF,^1<**JG/4RV]FV1TW*'&D.:@V?-UM
M6TV?URX&?/U7P.;E98V"B)-RR*J`%8L3,:XU*1`GWA!((_$3"/"-'Z;TNS?4
M-.MVK.KWNM%L&ATJD9[H;/)]>M&9QMUJ>>O[I(5>/EW%45C[$R68FT&63^9C
MG[%SZ3LP%4*;P-PN6=0'5W%JA*X)(TVI)5!IUHJMSI>1U^O.%&->@:]?(N"B
M+`U=1X^J>6<+M:ZW.#A=0[@S@5%E#J*JG,(SRU)%>WIUE@9C2Y6#K,W$-]>[
M'Y_VKO\`7F5A=DK4[KV;SK6WP#]6(4(JFE`N;PR2FWL<4P-W,F0%!`">*8C-
M2)F<:I,YL=$W=RA)M=&SZE7S.HB2C91RQ925,T61J$S/P-ECD1!O/LD)JC1S
MQD"X#\DY2.=+P%0_F&>F&`;?U=IFYW/-]$E+CJM`O.50>B5FI6G*+NO2I9*`
MU-:C.;G%/UDF3Y-ZVD7&<Q)R>)`.B9N/E,'G-XB7#SZ%TYPO,QQ8]0@YQHXP
MB?U&WU"0DK7/V&9F;IM+&:::?<[]/V![)SMYM-O7L3UTZ>2#E5473@3AX%*F
M0@R^Q4.HV-T>(ZV0=?83R+#JE/6BR9&1Q/.7*C25N-#O^<SBL\JH033:2]<T
MJ4`A#^0J:YTSE_\`=@'!F]6IZ3[<G7>@6[*[37W>M?)87H%BT7$Z%)ZO;)7-
M<JD[;#W"%L,-3J6^=JQ;6MO6]V=BBW<`X4CP(DBS4;MBG0.P9O5MJB]1\:SN
M8R^<K4=.(O\`()SL18Z49W/.W:3:5[17I]HNLKOTS@`2!']ED5C,B'^\9(G]
M,@>`%$!FH8[7T1MD3:\*D<$A7=ESO,6/;$\S24.UVV]3M&-<^U.R5#;9VRQV
MU8A`R=KG*6VM</(%=U1TJTC5?68N3`Z5CFZ01<\Y31Q#(=$BNL<+C78R^'U"
M[R53M]9OUK92,@\4=15MD;#\G`-+-*,(R;L9Z?4IAM"ISCYHVD)@6`/W**3A
MPHF6I;US&R(G(J;"XQ&X,Q1D"Y]$Y@SR)FW4?G4E2TUA5$Z:W14DQ("AY`(1
M("BOY?,*GW_AX\)]6JKMU!R6ZYIC6:?,7FH%Z\HUU/%+Y0[E*5?2L\6K=-7S
MUNYA[8U%11W]4I3QQ'23=ZBZ92+9<X+H''RB4N6-J]%L-/D:V2(JZ(U(ZV",
M[!OM*2T&P+:_([C%3L;/MM0D;\]6=OGMD!6(;M"D43,Q0C$4F2#=)LBBDF,U
M]M7IAGK?0Y+2ZQH6\4*>M)*4II+2D:U/PL+K$Q0H.-K$):M`8&([.^M[JLPS
M..D91DHP>2;-HBFY45](@E&61S_4?&K-.7RQ2L=.*R>C[]AG96SJ)3SM%);3
M^NK#*X_,G31$@`1I#,$<<A1=,R_>/#D6\X^"H@`S6RZCD5-I.AZUI\$C()VK
M:Y"FR5Y5<OSN&2[JB5)G2J^,:S,0"1Q$X-BF54"B/JJ>)Q\!'A$1);HM%7LG
M<#,=#EW'Z`NR.S9OV"A&-+LDE!7J&O\`$P=#;WZ"F0/!'B#U&0M^2P\XV#YA
M[\^M*2#=RW1212%P7/'=M=+I_37L*A`W?3=TU./8:?B^NPQ=*T=2QJP-RPB_
M,M)I:\.JG$L!:Q[NSQC4\F@/G*^1;)IB)0#Q$9;DT3(J;J$UD<]:T)!:0Q/3
MTM=HIF+]1DDWN25!OV;$7DDB%,$C'_9C29,GH&\"^L=-3Q\4P`29:U[,8K8]
MY:8M3FLA",,^KO8++M;UQO)N'_U&P5C%Y1?4*96(.,;QCN/EE979ZM5SOTWS
MAHW)$(.SE%98$D%"RXRDSPAP'`<!P'`<!P'`<!P'`<!P/__6[^.`X#@.`X#@
M.`X%:&H_^;+U"_\`!MV__P"\;K5R>K4_6_=9?RLG`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`B_W-[#/.J?6O2-\CZNUNCNA_
M8_T:T\E581M)?:B^U:F*>I)H,9)5M\FE8C.`\$3^<R0$'P`WF`LZI0<(<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`__U^_C@.`X#@.`
MX#@.!6AJ/_FR]0O_``;=O_\`O&ZU<GJU/UOW67\K)P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*TO>"_\NGL1_P#XD_[\\RX6
M<K+>$.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?_]#O
MXX#@.`X#@.`X#@5H:C_YLO4+_P`&W;__`+QNM7)ZM3];]UE_*R<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#G/_Y@[OU!=<L4
M1ZO3^5VR><=DZS%SU6T.-E8EK78IYF.JTBQ6.#?L'1!D'+U./9M!`R0^4/J"
M?C]P>2MZS/7*UCV_NY\7WZZXPW9&OYI9\NK5CL]JK]?A[7)1<K(2S*IR`0KV
M>;N8@`;`Q5G6[QH4A@`X*,SB/P$O*S9BX38X0X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@?_1[^.`X#@.`X#@.`X%:&H_^;+U"_\`!MV_
M_P"\;K5R>K4_6_=9?RLG`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`YN_^9ZP,=(Z&U;:(YD9:9ZZ:[`2TB\`I3_*T+3$QH,\C
MX>`*$%S<W5:/Y@,)0*B8#%'Q`Q)6]+UPN)Z"X&'5_I=UGPA5D6/E\^R*ILK8
MV*4Q"A?9AB%DT-8I#@!R`[O,S(*@4WWP>?P'X\K-N;:EWPAP'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`__]+OXX#@.`X#@.`X#@5H:C_Y
MLO4+_P`&W;__`+QNM7)ZM3];]UE_*R<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<#7VIY?2MGH<]FFB0Z4]3K*6-"7BEA\J;D8
MB7CYZ.,(^!@\S65BT%B^("'F3#Q`0X..&P>`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.!__T^_C@.`X#@.`X#@.!6AJ/_FR]0O_``;=
MO_\`O&ZU<GJU/UOW67\K)P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<#_U._C@.`X#@.`X#@.!P>]HO<3]R"J>\,..U^>SPVJY[J=OZJ8
M<]D\R8*(JYKV'T'/I&H/K!%I.4$Y.4E8*.KKL7!?(!0,KY/O5/'F?5UDGC]'
M=^F4Q$TR&4.L8A"E,LH"8**F*4`%10$4TD@.<0\1\I2E\1^``'PYIR?WP'`_
MA11-%-1990B221#**JJ&*1--,A1,=10YA`I"$*`B(B(``!P(:.O<%ZE#+O82
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MF22@W_GCY%,BQ4E7+K.EY.F,SA-SA#@.`X#@.`X#@4F;)VO[SH=UM3B>J#?+
M-\ZT8!4*RCM.>SU<<U&<_2R[3;R,_BN7;(VEWD9/:XVJ)D9A7YYHG"PJTBA&
MR'E74!5%);PU^,DSS5I?7_?LS[,Y=`ZWE$PO)UJ:.^CWK"39*Q%GJ-HA72D=
M9Z/=J\Z'YZM7.J2Z*C208KAYDEB>8AE$CIJ',\-T<!P'`<!P'`<#Z,I*1D)&
M2,U-2+&(AXAB[E):6E';=A&1<8P;J.W\C(OW:B35DQ9-4CJK+*G*FFF43&$`
M`1X%"'7OW!^WU)83O8'M5&TS1.A5RT:RL\XW*GT";S?6*)CX2WTV@[_>LK%_
M/)OL+MJ2?KJJD4+8(N.63EU$G$>J)&[%QGT:N,XG*_)@_8RK%E*1;UI)1DDT
M;/XZ18.47C%^Q>(D<-'K)VW.HW=-'3=0ITU"&,0Y#`8HB`@/#+[?`<!P'`<!
MP'`A3[A.XVK`.JNA7/,[:PJVURBU?I^#,G5-)HCZ_;!8)IFG4LR@J.:6A3SL
MO>P;.&(*`OY8ELHM)JD.@Q5()9SUX:-ZE]O=RB[92NLO?^$H-+[$W6!&6R_0
MLV5?!D>W+1<0C)6^E1AI0"JUS7Z,'JJ/(L1^4F(\OS\8(D(Y;-%EG)TN;KPM
M(X0X#@.`X#@.`X%8?N+[IV2H<GUXR/IE=:$Q[&ZIH#EVO2+S0EKO!KXS6F0*
MZ#HEPDFD[%.J#2J6LY:)G=D37=2S]ZWCF0`Y5`0?2+,8MO#;?3_MX]WA:XY+
ML%.;8_VIR`C0=0RY*05D(">KT@X7:5_8<?FWB;=U;\DMZC<Q4ES)@\AGX'CI
M`A%R)G<.LZ4Z<R]$X>$.`X#@.`X#@.!2IV`[5=YF?<O08'IZWRG=\*Z_9Y7W
M>[Y?9X!S4I(^J2IOJ88Y0=I:RK]J]UN2I*R<P*+E@6)@BJM&\B/G?)&(DMX7
M\9)E9SUT[#9QV@RF"UO,7D@,/)K/XB<KM@8FAKI0+G!.!86O/=`K:QSNZS=J
ME*D,V?,U1'P$"JI&5;JHK*"S#>7"'`<!P'`<!P'`<!P/_]7OXX#@.`X#@.`X
M#@<\VV="BVW_`)@7K+V4"$*>D+=<[9L5I<*MP.WD],PHS+*8I47!A]--W$$U
M&CND2^`J>+`1#X>(DGJW+^%CH9Y6#@.!S^]SNUM,U"N66]:2XDICJ!7[.O2L
MAQJJNI!>1[KW]A)#77ECMT;"C\]<\6^UX&BJE5FXJL[<Y0/*/2.V:L6B3>NN
M9Y7A+<?C/V>YGG4#W&=\KL1/:#M],Z,451JU4J>%YCGK*_WN!KRB1/E(VTR9
M+#5J%2I=JV\`%A'MIU)O]Z4ZQ3E.D%N_:)X3UN:^MNO7+MSTXQO2]O4[O4/9
M<SSRH2LY;\X[#Y*M6F]H@VB)`^S[>\4ZQVEJM.V%7TXUBR-5'(/WKM)(!*8_
M@:?)?619IK>DSEN#VG>N=:SNI7W;+EG-$H>]]D7+6TVRG4NM1==KF1T8GJ.J
MCB]7BH]HR:QOT5!S\]8ED$D32UE<.5UO4*DV$DLLN3REZ9Z)`]Q>K=@NR-3V
M3#9EA1.RN(R#VSXK?'B"JL85X\;@WL6:W]NU`'$UE&G19!C9EH`BHD4R;QOY
M';5`X.?N3I?HWSU0[)P/:/)&=]90KZEW.!F)*@[#E\RJFK8<GUVK`W0N="F5
M$@(1V6/<N$W,>^(4J4K$.VCY(`2<D`,M6?[)*\(<!P'`<!P(%=^>S%CP^@53
M-\@?1B?9?L9/.<WQ()-J2384[TV8/+YM5BBS>8'=4QVL*&D5$SE.D]E%&#$Q
M1^<`.)+;).5Z3-O$;3ZOXMF648-4\LHB+MU%PJ3Y[-V*;=&E+==+K/O7$U<-
M"N<VOYG<[<+M8GSB0D72IA,JX6,!?*0I"%N/&LY\D(-NKMCZ$[3-=R,UBY"4
MQ&\#'I=V<M@VKE[\[78Q`C"-[14>&:$4.EHN51I0"RMVY!^T-514\Y#/F+-4
M%Z]8NO\`UJVFO6"#MD!!VJL2\=8*U9H>,L%>GH=XA(1$W!S+)&1B9>+?M3J-
MGT=),'*:R"R9C$52.4Q1$!`>0>QP'`<!P'`<"HGN/HS3LIOT)T-B9!0N/U5I
M7-'[LRC%04_M%7I!8)+-NKR$@@856JVF*-"S-M3+Z:GV2129B?R3!B\LF?LN
M?'KZK-)BEU:W5<D6G%18P[F("-1C08M1B3Q1FHM/I2D>"7R@L/E1]'TO)Z8)
M_>^'E^'&<<LXRK,Z_3LMT*VR!ZB75TX4ZK['/NV/4*UR2JJH8WHCDCJ5?]4Y
M^47$WGJEB12<2&>+.#^LEZ+J$%17R1I`68XX:YGU6Z\B'`<!P'`<#XEUT6R*
MSERLDW;MTE%UUUU")(H(I$%1599502D323(41,81```/$>!4#UPO</W1[0O^
MVMG63D<;S%Q:,XZ2UE8!-%.&"RQH#1.T+]LMYB.['J#EDM&59?P*#&GD]9,O
MJ2RY@LUN,ELE\9SZIH]J>K=(['9E-4JPIOHY4[AE8*W9Z\Y-%W#/KQ`N`DJG
MHE"G$/!U`V^I3"1'31PF(?$IDE`40452.SGI4ZRYC7G2?LC=-`3N77?L.>-C
M^U^`)1;6^'8-2Q<-L6?RAG#:B=AJ$Q^]1-7;RBR.C,-&WB6!LB#MBH5)/Y7U
M9QT:Z7K.$]>$.`X#@.`X&K=MV.B]?<DT':M+E/I%'S:LR-GGG1">L\719)@5
MI$Q+,!!62GYZ1418QS-/Q6>/G**"8&44*`A!SH+6IJTJZ)V7WA@U_65[&C&R
M-AB%54W[;&\IB!<JYGUXJJXHHE;QM&BGHN)M=$A/K-H=/GJ@J%%OZ=NMG6GE
M-NDX9)W%ZO62WEJ.V83,,Z3V5PYY(V3&[B[!<(=\=\BD6RY/HR3,2.IC)M18
MM",99N`^HW4*@^0\'+1'Q<SZI.E^B0'53LG6^TN2L="B8A]4+3$3$M1-9S*:
M625LN3ZU4U2,;MGM@,D1(JZ\._,"K-V4A$I.,<-GJ102<$Y&K_PDCPAP'`<!
MP'`@MWV[-3^`9E`5'*AC'G9#L!8%,NP6,E2'<QL1-KLC/+7JUE:))K*J4G'*
MMZLW(!Y?*Z63:L`$%7J7BQ;<3E>DZWB,\ZHXUG&48+6<PI_S<JG'?/2MLMLX
MM\]<-"O]C=*S%TTNZ2QQ,O+6Z[6%TN]>K&'R%,H"*14T$D4B7'C<)GRZH8[_
M`%6S=&=AE>[.40TI-YA8D(YIW3R.MM%W:UPHL2D1FP["TJ%;"!%-<QR-#S2:
M12"I8JLDJV$P.FC(PKUZPU_ZW^%KM6M%=N]9KUSJ$U'62J6R$B[)6K##NDGL
M3.0,VR0DHF6C7B)C).F,@P<IJI*%$0.0X"'(/>X#@.`X#@.`X#@.!__6[^.`
MX#@.`X#@.`X'\"FF*A5A3(*I"*)D5$I14(FJ9,RJ93^'F*10R)!,`#X")`\?
MN!P/[X#@0P[T7B9A<=C\NI\VZKM^[(W*+PJM3T8Y(VF:M!V*,F;#K=[AE3)+
M>C,4#$ZO8Y>/4$H$^IM6I#'(*A3<<V19W[*KNC.85WM;W;N>Q*5QJSZX^W^V
M@</ZXU%`I5*I^EY&O-DW<RS9B=1%13'<^%@@Q!4@^B\G$W"9@6:E$O3>XQI.
M(SKQ=O6_TZ(.<U<H?OK>X=6*OVAZ^=,U'YUJ91GL!M^V-$%4CL)6]+J"OBM1
ML12'(L#"IIE&T+-50.W</',0L)?%L`AK2SSF>%NM\+9RG9U`[,,)A.$DFDB"
MR*R;93X*`)3$.0OCXAX^`@(&\!#G?;7,>?6XJ[B+DF%CB$'S8Q%V;Y`!,7X&
M`!,4/.F;_P"T01_^GGGXKMS%8BM:_0[[HN;)YBN;U>RV&:>^[&4YD!C1BM7Q
M52LIY1MDLV04(2/L\3:;C]D$G2I!&28RHI>)OIZ?D7KCNU.+E/C:-QS7`*>6
MZZ;.JQ<>\E65=KT3%Q<G8[;=+7*%6-$T^CU&!:R%AMMIE"ME#(LF+=94$4E5
ME/(@BJJ2)C*EW2/?ER^A6%_#O:YA%4]`'!$('5NSTW'Z*V<D-_JZ-F@,"ZZ]
MEJ+`>L3XJ$3M+UTV-]XHB!P$`UXWULASQ+?X2<Z_^[E@FMLV[ZZH1-"@%EFS
M536:E?(?5L%CGCUT1DS:6R]-(ZI7C+$W#I0$R/[M4ZO#JJ&(DD]46,"?)99U
M]#I>.5KB"Z+E%%RV62<-W"2:Z"Z"A%45T52`HDLBJF)B*)*$,`E,`B`@/B'(
M/EX#@<.;KW1ZGV5]Q[;=&/)G6KD0?]#G7U555(T:RQNJ2JBCN4AO24%,'NGV
MM,\[(*B`K'0,Q;B<R3)("]?:\;;_`-F?=UVFNO9TQ]1]WCY@C1DX>@=H_1(3
MS"<!`IS`'D./Q_[(C_[.7W-?5C3987881G8XES'NDD5TW")RD]4I5$C`JF)1
M*<I@,4Z*I!\#`/B`@/.4N'2]8KA]M=JYI"W;G`ZL^4F,$Z]]D']$Q1TL91?[
M)?7:35="TS'(Q^JY4/(5O)+_`&YRQCP],`CD5AC/44^0\$YZ]&KQ,\MZ=F^[
MN2=95#0$LG(WG1OHR5D6H-7?UN,4K-5<K.VK:ZZ5<KC-URBYC37+QBNDU<R\
M@@ZEE6ZR,4UD'""J)4EO2)];PJE__P"@/*B3*<,=+J8=T,@9!1JV[9:ZHZ(T
M\I_(FF_<=(6E,4FO6\B9D33)(X!$PE?G*4HGUX_69^Z_Q<?9:7UW[YXAV$DX
M:HMEI/.M'L,>XDZU2KLYKCAO?H^/;?,RLEDN@4^=M&::PRBT2F5=HP<NZE(Q
MN`'D63$3`7F;+.EA]9PFOPAP(U=Q.RE7Z?\`6/9^R-N32=1>5TM]-LHI5P5J
M%AM#M5"%I=6(X,8OHJVBWR;&/*</$2"X\W@/AX<+)FX<A_MM]VVM_3L<W9YU
M>2U._P!\LFB:K./O31D+'?+6]![*R:B)#BDV8-VY4&4<V2\$&<8T;MDBE31*
M4/1[?C=>G+C[LLVZ\.M_K5JK*XUU&,4=%.Y3+ZC41.`^<GD()DR_']W[H!_T
M\Y[ZXK6ER^KW.Q7--JZ_:;7=3=IP=/2JDG.3-M(]&)?T8M80-86.AQ$TF9-6
M#G:"^C4Y5H]*8#-EFA3_`!`H@.)>9>&^N99R^QT=T'1=8Z>]:=+UI(Q-$O.,
MT.RV=RHR",7F7<K`M'3>RNHH#'"'>6J/.C)+,O'_`%-5T9'X>3PY%O-1=[+>
MZMB>%.IR,K",#>!K,F_K]DT.VZ#%Y9A<%:XETJQF*<&@JQ%RMUZM,&\1.C)M
MJ95K22'<IJ-I!1H[(+<;);QPG'/*)>>>_1E5WM+.`;0."VD%Q;)J166]H)=W
M>7*YU#E=IP$5V"Z\]9L^EP03`IDBJVMFLX$3%*F!@("CQMXQ?Y.DYS/X7%8;
MV.R?L/$RK[.9YR:9K*[-E=Z'9HF0J>CT"2?MOFV3"Z4B=09SL+]0;@91DZ%(
M\?)H%%=DX<H""HPQ_LWIP'`H!_YA#O0CU:ZOU;%8.3?L+EVJGGU.G',*Y^6F
M8C#H#Z8KKKABX24!=D^M+&9:0"1_`IOEI-XJB<JS<H\=,S/#6LSG'*.O1+M5
M5K-4ZB-5<-&<.QC8QA%Q\>"39G',&2"35DP:MD0(DV;-&Z14TR%`"D*4"@`>
M'/5B;3,>;KK;+RZ2\XN#*Z5>.DFZI5%P:H$=E\P&-ZGIE#U!^(^(*>'_`+?'
MGFVF*[2YBN/OQ62YMIG4;L-G#D(O=F/97+,6I$:U`P&U"B;C<86O;7E$ZB5P
MV0=UU#-V;^WIJKB)(M_5D'A1*":@'7CZK,YO99C=;M4,XJ=AOE^LL)3:74XI
MW-V6T621:Q$'!Q+%,573^2D7JB39JW2('W3&#Q$0`/$1`!@IGV[WMLFRJ<!B
MA5J16(85@%J^['Z[-XK;;#&*)"=M-P&2T/&NP&I0;%T8Q?(A<HJGR/IB)Q;>
M7R^>^-YO2'3TZ_9ZV!^]1CVNNU4Y2JP,I%(J',_L'7/1Y'?0K3`BAQ&4M&=V
M#,\3WA9@@T`%7"U>I]B1:`"AESIHD!8[QOIUGT.G'%^JWZBWRE:?4("_YS:Z
M_>*1:H].5KEKJTJSFX":CU#'3!U'2<>LNU<D*LF=,X%-XIJ$,0P`8I@"#+.`
MX')=[ZGN*5NN=M,`Z;J.!6I&7OZ[MFQII*%,TDM+D4%%\=J\ZEZI!&-ID8X+
M93HJ$426?OHI8/*9F/CK2SSF>%LOAM9RGGT\[-1\VG`2;.1*L@N+13X*`8IT
MS"41`0`?`0$H_'G?;65YI<5>/&R$?8XE%ZW,5=F^0#S%\0'P\Y0\Z9O#_M%$
M?_IYYN*[\Q5X$$.-^Z70(W+EP\>R^$Z/8.RE.:(J*1X5_%E:Y&X]M<@5L/I1
M%G1L-L5J)5U@\)=@Z!/Q$T6GY;<=.ZS/C9>$_MIW'-\`IHW;2II>/8.9)K`5
MZ&B(N1L5ONMJD$W"L53Z-4H1L]GK9:90C54Z3-F@H<J**JZGIMT5E4X84O:+
M[\V64:PR$.[K^#U0S85TT(#5NSTW'Z&V<$,8$4K-!8'UV[*T6`%0`_E$T[0]
M<MS>)%$0.`AS7C?6R'VEO\)18%[MV`:RP2D+M]'S^!57CV@:K5[S&:K@[=](
MN/E$&EDO\?%UBVY:F+H`(5[>*Q58M85$R(NE%3^D$LL^QTO2<K5D%T7**+EL
MLDX;N$DUT%T%"*HKHJD!1)9%5,3$424(8!*8!$!`?$.0?+P'`X<;K[I=5[#^
MYEL5S4D#*5&G@XP[KVN=9,\8AFM8F3*62Q11B*>D+_5;@T&7<+>4JQXU*-;'
M$P,PYT]JZYN>4]W7::Z]G2?U#WN/E?D6R[T#LWZ)$S#Z@&`HG`/(H`>(^/E'
MX_Z0YOW->SEI<+)9N)9V"*79+E252<HF](QB@<GWY?@(^("!DU`'P']\!YQE
MP[*V?;C:*T.U=SNOM-<#(]?\&W]I!9&H7S'8TB?O-*A])U[%8%R7Q;N*WFMQ
MM!%VB28__A@S2D;X%*Q*4)TS<<+>)GE(3LUW1RCK&4L/.IREST1U`+6AKGU7
M<P+%U%UA-PJP)<[_`&VVS%=HN8T8\FB=NG)3<BT%^NDLA&HOW21VW$F;B<I]
M;PJ<4_Y@+)TIHD,<G4T'!I`4#-@[8ZTH\3:`!O$@OD>DJM+&;`X>3T0FOIXG
M^X_$G@<=>-[S/W/XN/LM"Z]=^<-WY]7JP5Q(9MH5I:.G=7J-U=UUW&7Y*.*(
MR*^4:33YNRYCJ(-4R&758Q4LK.L6?E6D(YCX^0,V6<PYF8F[P'`<!P'`<#__
MU^_C@.`X#@.`X#@.`X#@.!1QW_WF(AM"VS2'3MN6G],\*FJ.T>F6(=!SOV_L
M8&W69BFD7S>2:SS&:Y`@0X#Y_1O:Z?E#XB._;G7-XB;<2=TOO:QPEY@'1G#:
M[/M@0OM\@W6V::H?S?.*7W97RV@2S&1,;[T[RL,YMM"^)?O?2C2``F\/.;&<
MYJWMZ+">!^=9_P`Q[UXOV4>XU==AFVD@XH'9.NTNX4&Q+?,N&AWM'HE1SJX5
M09!8QB&DZ[(5Y!U\L7P!M&RC(`#RB',WEVTOXM;^VOW2DZE,,,[M,JX-\L*)
M8ERNN)O6:D$B94C&.;Q%5`/`!\?^L`A_IYZ?:W\IB\O/[WMX_*<.RO%^[5`S
M7*[+H.FV-.)SZG5I[9K%**>9P9DPC6HKG^2;)^*[Z0=&`J+9LD!EG*ZA$DRF
M4.4!GN:\UC2VW#?G2?,+X['0NW&\0SZ"WKM"K"2HTB7\3.\(PNNE?#C.#H)G
M,H$?,041++2]I]+TRNK9+/A,42(H>7@[W'$X<^?N9=K;5VZ[>W+`NN2T@_A,
MEJ\CA;FUMEWS)\RO#VV29>P!*'\FY$A1L\7$0U7/+"F1XBVCI))H8S61.=3K
MIIG-RY[;>,BW'VF='ZX.*U:L*SWK50>L>P9/'QY[E6:DR+(*72ON%S,$;J>\
MRR![S:'I9,!0D0FW;Y\W550$72Y50$F=M/&K-_)N#M5[8V)[<,AI6.,8KK7V
M@8,WRU6VK-81C"MYR1626\T+LE/C$FL!JU.G/4%O()R*"D@#4YBMW*7Q*;,M
MG#7/2\(*^USVIN5`TN<Z?[#"FHKF"O\`.9%(YK\V9]!83O$3!RET80&=R;PP
M.U.N_8"F0DG-U)%0?DX&5:?36'E82T0Q96]YP?2WK_<=#/(CP;3!)VBL6.LJ
MNG#%*Q0,O!*/6ASINF:<O'N(\[IL=)1%0CAN5P)R"4Y3`8`\!`?CP/R/-:S#
M3^JVZ7C*+PQ>U33<@N4A79=`2JH&*]BW'BUDF)S`47<+.QYTGC)<OBD[8N4U
M2"8BA1',MES.7?IM/HZ0O;+[R#:8V*B9B0.C.1@)-7B1U@\WJ)>0/4)XF`?(
MI_UBC^\//7KM-]?J\?N:72_1T@Z'W2M;#)ZMEF+(MK!VIWN35S+K['/$1>Q4
M-,+QYWEIUFYHI$763SW%:N"T]*'],X.#H-V`>"KU(><?<U\;]6_;N>>(EC3Z
MWCWM_P#4]9"2G'S;-<,HUAN5\N\V(/[3<9@HO[7?[]85""52=ONBVMZ\D'`$
M^_=R;[TTBAYB$##=N;EQ_M-4OW;K5I[L/H&&1NTXI'ZK>]BM6-VZPV&/B=`-
M*S2C+-?TD/8AR^;NV^4Y>QB:U$1BB3R$308>==LZ,NX];M/;_'&6+O)LZ^NK
M%RZ\]BNM54L&49Q4(');(R>Q#_*STZM1L+6Y6'5-"6"HRU4CV(5X3Q3ED*`>
M1(4'#8$U$_%(Y.<K,7%:ESURJC[Y>VI#8=3+7V*Z84KY2LUARAH>W=0X)_)0
M])N<34ECS9M.Z^)1+AO)8IOF;D35DHA6MJL2N?1%-HFD\$"/$N.E_5>;S^7=
M.SVUNWI^SV2FBK%95+E=:7`4^QLKXO'Q\0YU3)[^2<+G6C2,5%`G%QMM!]59
MBNV9LU31:DLM??+-D463EHF"S%PG/7"R/D%4'O:]>+WV9]MS?Z%F3*2F;Q`M
MZKI<+6HL7!G5J0SJTQ5EGX%%FV\RLJ^7K#1ZLQ:%(H9S)(MR$+YQ*(2M:W%C
M\V7']5L.076,ML`[71^763+(-4E#$(\9^<!.F<H#Y1.3[I1'[@_#[@CRZ;76
MYCIOK-IBNTSV].YS*X5^O2[.5$5#@B8_\L'F*?R("8I@\WB`^(_'_3SU=-]<
MQXK+IMB\K0M9O1^^6C5;I94U'8Y37F-;U#O78&A3%9.:$HY+(9KUK1D4C"4L
MQO$M&'=V%N`IJHTM@X3$0^JH#SS;3%P]&EZ>7JV+[I_;N$Z=]1+O*,)1]$:?
MJ,3,Y%AR$"F0LFSOEDKTDW9V5J/G21CF-$8%/)G7,`D(JW12*4YU4R&29N$G
M3JYRNJ%MI&0Z=`=E^VO5FGZ?ECXM?IN:RDH20M$;UBI$(V0:L$\WI%F++UJ?
M6C3^#I^_62+85E#JKI.Q5,=%QUV]OISPQ/<ZX]:Z\M%Q'`^Q.?LZIIV89QJ^
M=R40V/#QEFK$+/1"$6\9I&CWM<4<-5%(90C0R9VKEB=!9#P(=(Y#%*(<726S
MASN]H\`T#VP]?R+2\FOLZ'7>P6E*@9%H%L?R%ELW5:]6=V=^RQO2YARJ>3TW
MJ%K;M%1LNTE%'+R#<@#ELLE,(QS];6?+I>?0XS9QZQT2]?=EB]]R*H:C'1;F
MO.II&3B[14WZZ+F3I%^J<S(U+0J+*.&PBW<R-,NT&_C55DO%%<S;U4Q%,Y!'
M*5N;@<</_-8=>+W)_JT]H86/D9:@5J+LV07EPV(X79T^6E99M9:7(OTR&43:
M-+2961:&<F(FF5PS;(G.)UVY.2NFEYCG"Z0]I9K#+RQAWL@X"KRSQ$A2&5'T
MF#M10H?>@8?`J*X_=`/@!O\`IYT]K?%\;PS[OM^4S.7<YTK[6,7D3"O#21%(
M]RQ;*.?47*"0MS(E4.=0QC>4I2%^(B(_#P\>=M]<S+S:W%2&ZV+J=T-\=]WY
M9NZ_03ES2U95TFAI!(44K*#YQ](V7M(HP52$X'OSJ.^S=17,<IBU=F[=D3*6
M8$QO,]-Z3'JK_P#>D[K*Q.C9%T_R/RSVCQ,JVUS0V3KU0K4,[5K\XPQMM+@U
M>)J3$U6K6_0N36.52!NC(1$,Z4,<O\D;>FN;*QM<:UXOM(6'%\4T6$Z\:WUU
MJ]0[0:`T?66-[)2J*MMOFTV1K'OK/.MK38[0V>V&GR8QK-9]'M6+PL(J!%4T
M4&J_IE=W?2S\LY)OY=.%QO9[H;UF[9QH'TR@,XO0(_SN*CM="!"F[1194!*H
MWE*UH$6W+*B"#E,BIV+[YR+=&(4'#58H>'.?'6<K]+PI#Q#9MD]N'MQ<L0WR
M7;R\:NFPT;2+5"Q@1=/["8A.OB5A/MQ%U[U_E*5NN,OVI!TMNT`R4]6V;]\N
M+MW'1CIY>9;CKZ_^U[3T]/I]'4%R(<#\Y[_F,NO%\R/W'M`U>:822M`[&PE/
MN^?V1<HK,W3FK4BJ42XUH'Q"E2^I5R:@2J_+"!5$(Y^R$WF`Y3FS>772],-9
M^VQW.E:58(O.[1*N#))NFQ8=RNL)O4;`<I2MS"<?$5$/N!^^40_T\]'M;Y_&
M\N'O>WB^4X=GV.]WL^S#*+-H>GV(L5G].KKJQSTB;S.EF[9DW*8B$:S3$7$E
M+R*XD;,VB(&7>.E4T$BF4.0HO<UYK&ES9&_NE&4WD4K]VQWN#5A.Q/:!Q%34
ME4Y`Z3IWAF)P7SOZ&.O3-TF1)(KBGP<DK)V)1)-('MMEY$YO433;B7B[7M.'
M/-[DG;&V]R.W-\P?KJ+]_5\JKJ^%$M\>\<-90+.M:Y-;L,:@KLQ.#=&[MHB#
MK!I4"_-)LH5\#4YVDJ?S=--<YN6=MI))8M_]IK1NMCRKVO#\UZT47K%K62,(
MO[:5BK-$9)6XP;Q9=BVN8WN4;_;FV._J"!D9'ZVY>O6JJJ(&<N"JE,&=M/&D
MW\FV^U7MBXGMQW^EXXSB^MG9U@RD3UO9,WA&,/'V5XZ16!2`VRD1R+:NZU2Y
MP5/EWZ<D@I(E:G,5LZ2*8Y%)+9PUS,7A!GVM^UERHNDS74#8H1Q17$3?+!DR
M^;N':KV(P??:_"3-S+2<_DW?@HMUWW.@0;ZP49$3&;0KN/<1[$PQTC#M&:XZ
M6<'7K+_]QT+<B/.F(XLQ$RD2=PX:$E(Y]'&=-#@FZ;%>ME6QG#8X@8".$05\
MQ!\!\#`'`_(YW7&M.ZF;YH&,WYD]K>C9%<7T"]-Z:C7YD6*P+1%ABS>8WS$)
M9(A5!^Q6*8R;ADY3.41*8!'/67ZN_3:?1T*>V)WC6L+2,K\](G2G8DJ39T0Z
MWQ4%/R@58GB/CY%0#S!_I_\`7SUZ;3?7ZO'[FGAM]'3+<>ZMHALBK^?8\Q:V
MWM!M,I^C7KQ7792NF*=H>LEGDYHEM0`%#)9UCM81<V*<6,7TS(,R,P-Z[QN4
MW'?7#?MW//$2QSJF93T'ZJN&TW9G9J3CE.MFBZII=@(*]EO-E5&3N^I:?9@2
M.NO)W"_6AV^D54$A4,=TZ*V;E\@))AANW-<@1M:O7=#7K-O]VPYIK>(-]:NN
MQ7#&;%9)Z%C](CCN3U_)&&ER<"J],9EDV61T1$,8TOS$,9\V<NE6ZQ7[I!3M
M/;SKC+%WFNW#KDZA7?KGV*ZRUZ9R/+J74,NFD9"LV''D:=6(V`JT]#+@SL-.
ME:Q%QK>NN4&3DI3HF*W!)TT417`A04`H<K,7#6<]<JR^]OMF0&4TN^=@NEE'
M^FI194[IL742NJ/XW-M3AZZ9:2>6_%8:"4;2.*]@J:D`R-?D*LHP]1VU`K=%
M)\L#@R7$Q?U7GUQMW_\`:8?MD=PR]FLH"OSUG<W&V4^LU*U5R^22+1I,:IC=
MT--,*1=K"U8IMF"6B0<U5):MVY-HDDU-.0YGZ*+9K)M&Z:S%PG/59OR!P,5N
MEXI^<UR1M]\LT+4:S$I>K(3<_(-XV/;AX#Y$_7<'("KA80\J21/,JJ?P*0IC
M"`<#Y:?<:MH-9A[G29Z,L]5L#0'T+/0[DCN.D6HJ'2%5LNG\#`19(Q#`/@8A
MRB4P`("''`R7@?_0[^.`X#@.`X#@.`X'\F,4A3'.8I"$*)C&,(%*4I0\3&,8
M?`"E*`>(B/W.!\#-ZSD6J#Z/=MG[)R0%&SQFNDZ:N$Q$0!1!P@<Z2I!$/NE$
M0X$>.T78-GUYS<)N/B`NFHW.5;T/$,O;NDVTGI>I32#@T'`I*&,!V->BD&ZT
MI/R7@*4/`,7CU3Q*CY3#^G/DMCB_:;L)CW0%O.*Z)5Z3:GO:;W"-.:I*(1=U
ML4U9U;;8X%P9/P39):UH9R0<3%@J5:/JC54K?Q3CO`.FWXZ^/K4G6^7I'4[S
MFIP(B=W^EV0=\NO]LP/7X\`9RJ1Y.FW!HV(O8,XO31JX2@+M73&5;F,[C%7!
MBN&PJD1D&2BS58?26-PLMES'YA_8[KULO13LC;L6U*.-"W_,YX@MY)B+@82U
MP*P_,P%PJ[Y9%`\A6;3%&*NW.8A%4_.9%=-)RDLBGF6ZW/J[=-I]%ZO53)>Q
MW?GKW/7JL6*T4/&\)F:^]9VB%>/8F9N^^10-;)6&T4];>1083(DRM)9V8%"^
M,R]CO*!OEU!+Z/*>Y9K>'FL^+.WJPS(O?9]R3HUK2N<=E)AOV8H4)(D9RE>T
M9G'Q=T7A"+E*>2J6HPD6WFOJKA`GP/-)3:!1$Q11*8?.'':76XKM)KOKF(_/
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M^5:OW.KRB8>"<E7;1$M)R$?I@/B($>1KY)0`_>-R)PRG@<A?_,MX3G.KW/'C
MY]3XA+LK6\ET;5-"N97H1IGN&4MY%0E9JTVS1;+&GK)8+K,N4JXH<2&3%F[;
M&,)5TO2>/EG'I&M=O'&>+7(_A6F36*:8UDUE'L0+5VI'3C)PFLV7:KMEQ352
M>M5"E607:+IF(H0Q0.0?$!#Q#PY?;V\;]&_<U\M<>KHWT3!?<$I>/4;OS2-,
MT7&MFM]!%?.:A7Y)2+4K6#/7#*<A*S9(E<CA@O8;\M&-Y^40=IJ>F*[5JL0@
MM3$+TQ\DMG/HXRSV[-+.G_EHRK^^#N?9W`M;Z(=XGU55'8:V:FU/L@$8PH4K
M1K_'R\?-5(NQ1,(U9U-UGKVSPK1E*R;!C'NXABLN[53?@3TPXYLO5V\9S$<J
MYMO9WJ=#V/'+GF^B465?0KY20C)"NRJ;69KT>+87$_$R35!>)LM2\KMNLE*,
M5W,:NBNBJDL=-5,YN\]SIAPV]O-SGH[2O9FR*9RGH=G$E89Z`GYK9Y:;W-VK
M5YN-LD%&M;XE&IP42TGHA=U&23II7(9F+T4%%$D7YUT2G4*F!S<MKFY:QCHM
M3Y!S"=:;EGO1/W5%^F[N<3K2%KTO5*MDU:.RDD8N4P[LG58_L1FZ<>\3BPBO
MD<>V.@2%)C4%%RN"+6=7R%53,LL6VS$GJUB];Z?^73WR,G`_-U]Z;`J.;MCV
M$VSKI04JSEK/9+9F]PA8-)\Z*\TR@14"IM6F,HAHV795FEDT:<<1+L`4*V1E
M$`4#T_G2H(RZ]/)TUVZ^-YPBCT!V+4(#0H7*<NA7UROU_GXZNYM4$3*^C+V^
MPNVT9%,G2R?P81";Y4J[YR82IM61%EC"!2"/.FGN>,LK/N>WY65;)VDCO<D]
MIJ9?7'$NRM].%@GS7#;4E&T1:*79]'DV;!M8;<2F6^'F81*(=IQB+-L0C9-9
MK&H($*)?3\0;:YU\YSZLZ;2[73:?9K;;_<3U#W@,BRC/Y>APC#N/USL5@M]9
MJM!^;2C.QU%GH1FWNR%`J\DZ?RB.OU0:VPD2UYLY=C-QWU!:/*19LFP5QKMB
MNETY[-/0^\[]KR-%ZGNF+NE/)V^P>:MRZ@HKG]7JENLZC)NW;VF5LY(]I`.3
M-W:2PH*_ZXN0Q"H)*JJ))G[7W.CC/:ZOT0\MHZ&8YEG.;-GRDFVSVB5"CMY)
M9,$59!"IU^/@4GRJ)3'*DH[38`H8H"(%$WAXCSBTUQVMP&`[2]<=DZ_60R:#
M'4:+,5YC)*>;QK]F*F22IEK0\J:P_.5&WL&,FAXD4#UFA?$A@\2B67%RJ']D
M/M?7=84WO$G$T)-(JC+,-.OU+>-9-F^IFENX!7%MOK!"/V;=)P+:]8^ULCU9
MN=9N=Y=!$#F4%4I+;+<PQ9)E?UR(T=V:CL;E.N^W(]AH*,LF&-,MN\UK$/+M
MR.62]$KM??S]B<`!EFQV[V.CXT[EJX3607:N44UDE4E4R*%+.9CE^5!ON(V?
M%K1'!)0ZT3!6Z%@KI64BO',N,#'6R(96B,ITU.FCHULYM]=A99K\X4J9#'35
M1<^0B;@@<FTNMCKKM-IE</[;43OO=Z`F>M6;OIJ*KT33W<IN^@-#K(K5O,&J
M)F*E;B7Q?*FG:]0>^6+:%`3'3CQD')2F^6'G:;YUFM]>7#;3QVN^/LRJ;]QW
MW/?:MU.*S1'5G.HX=6DF4+3L]V&&9VZL&JD(@A'1M996$B<??:X6#BFQ4&J3
M*60;D3*7Q24*3R!C?6Z7,_5O2Z^YK_\`IAG8S?;AV]W&=]R+!<\M4C$VZ&SU
MCOE`K_K7>=Z]Z51J/#T<4Y]"%8EDTLMN,%3VTC!65PT;,7C@[MFIZ+QJJARZ
M;X-M,S"<_M8674>\7N$Y!:+;,HPL5A=>_3/(DL4BTC;/:H-"*7A:@E38&343
ME['$NIF4:'>/6B"K-FP#^4635<-"JZWWS,8<]=+KFUVU\Y-*9_>=SBJM<@RK
MMC/Q?SS#K!HS=EJ*2+55XXF>M&^@SQ[<JV=HU;.';MF=K.Q<FN!0,";:,6-Y
M1\?A9<7KPO,L]4L_;:WB*[&=*<)T..MZ-]<L:RYSBP7%,KI)2TV3)YB1S>8M
MCAJ_2;R#0]S7K`3*9%TDE1;R"9Q(4#`'(;<IR\(IT][VBYEK73^)QJY4V*M6
M@:_K=1HN'2;Y)<7F>WOZ?/VRQ:.P78.&TFD%5RVJSZAD"&%"15.BQ<!Z3D1"
MR>5D67QSL_.0M%3NN&:"U9S#-Y'248JPL-<EOEGC2-ME8>'%S7KE5W;I%`)>
MI6N.*5RP>I`9!RW4`Q1'X\S/QKM^VOW=$O5_'^Q_??KK.Z)6[%::#CF%S4(\
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M6[[:)6UUPKGZM64V"5<C4H\7R"9W_P`VZ,EX$1$RC?;*37QCJ,YS5S2^\:I6
M^GG86C]T2N!K4;J]";P<[+HLWRS-7L;U3LU?WCKB5[].8OURR&J1-?DZ>[64
M(+?Z2W*DL7T!6\US)-I5DMQCTO\`Q71O3[9`7VI5:\U211EZO<ZY"6RMRS8P
M&;RD!8HQK,0\B@8!$#(O8YXFJ4?W2F#D1D?`Y(?^91PW.-DLF7IT>H1"'9"B
M9/:]2NU\*9TW?2&-1U@95.CYR\8L4%AL<[;[]+/S0)CE,JU4CG+<GP>^`/'.
M?I&M=O'':UQ_XW?Y[%-/:R+DLA!NHR06B;!'/$5V+QBX:N#(.6LBS7(FX;.F
M+M(Q%4U"E.F8#`(`("''M[>.TOHWOKY:V>KI&N'7[OU%X90^_E(T_0\<UBST
M91?&JS6)AS#J5["9)W'3#*/LC("F9NYK5E8UM//T72:I2M1CFRI?%L)0ZX^3
MRLY]'"6>W9K_`(^K1=(]\[?MTQ77^C?>N0K3V.V&ES6<0O8K[/-:I9<UN3@2
MGK<CJ<#6&"%>L-!).,VK>4=1T<SE(]B=9X`2"A`;GXRV7J[^,YU1RK^Q=H>G
M36Q8Q=\YT"BS4C%R*3B/=0<B9A8X&/1;.G,Y79=DBXAK=4C,W3=TE*1R[N.7
M:KI+IK'24(<WHUWF(X;>WFYEZ.S'V5,?GLLZ*5"P6:P0<],;S:Y[>U"UN>86
M>#A8ZY1E>A8"&:3D2^D(EZY3KU4:.'I6Q_3;2#E=`?,=(ZA^6US<M8QT6T<R
M.83%;GG/0CW7TNJ;Z;:U5AH>OW^,QVNJLY!%A*8GV\J#77XJ/C5B('B6[?,>
MRV0HU2*156!P5">5]$!*JORVS$GK%Q;F^F/^?_IT]\B'`Y2?<%>:9[AG>2F8
M!0+7+1%$R?;S8EG<&W;B]J$W?8&K+S/:77]"BC%%E-Q&:U!^YKS1B]$I'!V+
MQDV505FQ5#4DFOEZ^AGKX^F,UT]9?FM/QW/:AE]!BDH6GTB$9P$#'(D13*BR
M9I^7SG*W1;M_7<JB953TTTT_4./E*4O@4,VY&><#_]'OXX#@.`X#@.!$7M+W
M.RSJTW@8.9:6+1]DO:+L<OP3-6K29TZ^&:#Z;J439.G;&+JE)B51_P#Q&PS#
MEE$,2`(&6,L*:*CGI.3Z^BNJ5F.\_9)19[K.UJ]8:*^,!F6*]4WK=.UI,3&*
MJDWO?9*SP"ER?RY2F%-;[(L*JBF(?>+KAX*<Z3V_^U9N\_QC&0]O/J[*KH2-
MVR=EK4RFJ1TI/;C/VW<9YX[!3U5'3V5UF>N3MR==41%0IC>F8#&+Y?((EYJ:
MZ]F?/;N^L_\`;QZC(NSRL)U[SBDR_E*5.:S*$#*YMN4@%\"LYG.%:M*,BB8A
M3B"*I/,H0IQ\3E`08U_ZGEO_`-JTG>NK&[TJP'T3`.T&BGN$51IC/JS6^S4K
M-=AJA7:I,+D>OX2D6VV/U]:S563=MFOS3YI,2'S"+%LDX:N$FZ*9'ABYUY7S
MMZ;3_9)_VA[IBF0U^0ZTWB(L6:=VKH_D]$UUSIKN.?N>Q\^V(/SUSQJ_1Q$:
M_=J%5XQ0$&,`W^7F:ZP(8SYB50[AZYY;>6;Y<M]+/QO1>7R!P'`I>]Y[VM(?
MW$L++.T)C%QO:3(8Y^^R>?<J)1Z=QB#&%]+Y/8I$_E1".GE"&5BEW`@E&RP@
M?U$6[EZ)Y8UKMC[-H>T1$9.A[<V`9538M.+6J-#-4M<K+M`&\U#;BS>NT]SB
MK(S4(D[:3T;JAI0ATER@HFF5(`\4P(/-3IBQG;KM97/)[VG1@'\[#N:;!@[T
M*<OU=I-&CF"1/J-LLEVFFD!`UA@3Q*+ES,R+U(J9?N%$/.;P*4PAUWQMIF\L
M>U;KOX^BUAQU#=^WEDM/F:I2PV/$1Q"CX][@G7AC&!+1NT4ZLTEC4[!V$H%=
M6`H*Z[3F*3A5ZQ2*4]KKY"LO%-ZT8*EY8Z='2;9MS_"-O8#$[SU$N%"[X=/-
MA:R^:VF!@7M'W>1F7$[3+Q39A1.1@<&[ARR;@2W//+@S6;LJ=ICP2RT;)>@U
MG77U$[6:<,YQ+_N8QG$^\_\`2]CHMWGQ/OYAL'L^/RJ2#DP!&WW/7\BQ<VS-
M;<@7RR%=L+=J<#*-SF+ZT>^!--&28G37(4@F.DG"RSE]GOMT]I7>OJSI_7.Y
M?*,7%IB_J5$M+AM\RK1M)@P4>TNW-O(7YHJ3"3_D7R:!DU'<4Y=-?,!%S<$N
M+ES9>TQ[FURZ1GL?1#O$QE(6JX7<GM">7-\*C^5Z[/E)5PV2:W,B'K'G>OL[
M(KIJQ-B9E,G71=>FZ`T2JR=HIQEK;K?K?^?_`)=A+)ZSDF;21CG;9_'OVR#U
M@_9+I.F;UFZ2(NU=M'2!U$'+9R@H4Z:A#&(<A@$!$!X8<T/:%DTOOO,VBM7H
MOD@(C.?;HBH4CAH\52DZX7N+%6H\7Z8J&*[BIR^20L'?I@#44U5"K%$"K"-G
MZ[_PO_3^?Z:<]W7VFLLK/:S'/<0B*RS-U\<[=FTKWNH3)JDE'Q=>/=(D]AV@
M621/*O4I]N8R%S30*#A`5!DB@<%WR[;..K4VN+/5TE:W3:SMV1/D&Q&<BU7B
M5'T0LEZ:J(IF:>;R(')XIBBNW$!*)?O1`"B'-ZWQV<MIY1QHTOVSFNC^[UC5
M9B(2/=4^LNG78'78=PS0>1;:IYG-LUXKZQ'+%.V<,[Q=5&$-\NJ42.DU5Q\I
MR(+@&O=D\M;/5?;VOAM%V,CD%8R&UTWI9O$K96?7&]VUVGT([#MG[4;EU<UR
M=C9&//U@F9V>:R\3+T>VQCMVVIK2=;/(:6C3J560;/2ECRGQ>ES&I?*7IU_M
M#:N[C??9/W%Y`[`]2B^L=VLOFO630J<NM1P:6.8.@T[-=/8Z7D9-[&1B$Q(I
M)Z#GHNW$C".'(*%%\DM$R+U;+,\59,]/3_7+J@IMSJ.B56`O-"LT'<J;:8QM
M,UNTUJ39S,#.13PGJ-G\7*,%5VCQLJ7[AB'$/$!`?B`AR,J"/?\`NB$_MF24
M[NGB+:6;]A>GOEM*ZM56486RR9+#RR=HDC0<DAXN&MFRB714L<0H4#BF07X$
M26751)R5O2^C;GM7>[I5NX-;H>5;2M'5;L#+U]PM4K,V(1A1>P+6O-REFWU7
M`RATJQJL,1%12?J*BBBJ'I*/8\[F/-XM[9C'9FSE>#PCF.]G"G5K7;!;)#4Z
MY&6!Q9<P[<P5DK4_$EDXV4-JW;)]^F2*F4GZJI%"OT:["M7""Z2AW"*AP,<`
M*<#ZOZZ'&V_WG]-6=0_;4SKVQ_>-2E[*!9+$]<R_2E^E5KG'/S)Z_H;I[`C;
M\KE'+DRCP^BU/-G4P2.<JG%.7KZJS@#F>%<HML2=6]MLZ_VNG]PWKU7MER>3
MD'$8U?G/'J-'GG2*H"[=1!3T%#>(#YO`GWO_`$`'.WMWKXUPWG^7JYIO:,]J
MF`T'0.[EZMR<JUSNJN6N%Y5;ZT_6B+74]19V"KZC,W+/+(@`N:]<L?E*]!%:
M2"'F$CEVJW/YBD=(FQ=9-MIZ.OG;KK?5:58\*7[FL-2Z^[C'TN/]P'+Z%&MK
M*>>;#"8YWWPJ%<.XJ@ZO+0<<1X[KDPQ=R2D>K.0Y5)K/+0MZ8_/03SZ._G76
MKTLE]/Z>)[?_`+C`]=-@A?;\[@:1+`ZE'#^(PRX;')L&.I9K-0P)IO>N78>0
M<O5&KF9:D504IMI(Y=QUICG3;Y9TLDXCC*RX]#%N>G7^W2/PRX\_=-QG2_:W
M]P6C>Y_UF^2KF<[C..:_KC%9LY&BQ>I3:175CA-%8Q@IO1SO<FL:,BNZ;^=S
M'V!HXD">*Z3%LM/7EN7.MGJZ..E7>?).[-'D9JF$>T_1Z8,<QU?&[*Y:J6_/
M):3;"YCU_F&@@PM=)L**9UH6PQ_GCI5N41**:Z:[=&V67%Y9^LX:B]X^7DX3
MVR>WSR*25667S9E#O"(D7.8(.PW*L0%D4.5N('^71KTFZ.J(_P`F5,IA/]X!
MN"<Q#C,>@&%]XN@^ZXO<D6K24O6SR-RK=[;1!5YK-='K669O3\^LT.JLN49!
MNRI$+'MG2"2C=)W&/'#/Q(8QE>7?KMLFELFM>#[`V'1?43-^R_5S181C7>TE
M(WM[^F)(5DG*EBJCJM1"F/6>N//327DLSL-;4=NH=8Y""+M=^4Y$E@52)).C
M6]S9VPU'[W73JFV?/KA:W;9A%L6,3(6=*:6`B*<*#!LL]<.SN#"`)),P2.)A
M$?`2!\?ASOK9OI9LX]=-Y=6(^WC[>6S]:NC'7+L1DJ:-0[GL4+)L9H&:.K#U
M[5LVT9RVD$^MVM&.4JP0%GHT7&NFB[A/UJG:E0>H%\R*X+\9,SZNVVWY6>CT
M]MZYU':\KJW=[I<YT+-TL^LME=VBGU1B\3[!]%M;AG+DFE,J768U-29F*/"6
M!X[&]YBND^1=Q;L\E6DQ;JGB)E+TQ>/Z,=>G/]K,?;+]RVC]TZ[8\NMUJH).
MTF+KD@=-AZ9-QSVGZ0T;E.1EKV/N$7KCZ]1K(BD"KE)$RIX=VIZ*@F049N',
M];,I9TEQT66Z#0ZGJ=$N>:7R&;6&DZ!5IZEVZ">`(M9BMV:+=0TU'+^40.4C
MN/>*$\Q1`Q?'Q*("`#PCC#ZJ[3M/L5=UMCZ9WZ(LFK==K7,IZ-6(9IY"V>SY
MPZ370B=DR%DLL2.D[["P$6:.LU:*=/ZP>),5HJFO'D^=29S)RZ7%DOH[)\FU
MG.MTSJIZSDULBKOGMWBDIBMV2'5,=J]:G,=%9!=%8B+R.E(YXBHV>LG*:+MD
M[14073363.0IBS"C+WO[+88+0NII(5(_F:XO[AMMB7(`N(-KQ5,2HH5@4A24
M3`KPT5,RQDQ#P6\I#^00#S>.M.;]JEF9_,>][HOM$4CNYTWRE#$HN+B>P/7/
M):Q!83*@@R@TKQ0H.N,$4<>L3EP=%NTBI)NV!>%4<J@E#RIS>!TF[M\*F+&]
M=L7Z)5>TK&90I[<O7O+*;$M8@]1S9K3-9JZC4S*7@MO9>JCN<79HYPFD]86=
MCJJDK\TDX*54A_#P#R>3FITQ8QMUME<YWO9=%A?6:!<TN!%YHD]>*_1Z1%QJ
M)325LL5TG&\)!UM@D`E%RXE'[LGE#[B92BH80(0Q@Z[XVTSZQCVK==[KZ+9Y
M3J*E[>.85J8K-(2V3KROB]!R#W`.OC>'5L#+6ZI3:7'5%_V4H%<53`JFLT]J
MQ.M*L4$6_P!IX'S$'R/V$>;G+'3HZ3;-Q?X1YW+%+_TSO.=][.GND(6^A7"%
MAQJ^SR\JXF:?HU#L`,752P7M@Z9$!>S5FUMU46U/U-P<99K+&;-9U3Z@=&7?
MW,O2\]S&,_\`,_\`,7H]&^\.*]^,+KVU8],-RJ.$DX^]T%W(-'-JS2XH)$&5
MJUC;H>DH8J2AO49/0230DF1TW"0`4XD+DLLY?#[@'3>G=\>J^E]=+8LWC'MC
M8I3-!M2R(K&I6DP'J/*?9R%(0ZXM$'HF:OTTO!1Q%NG2!1**OB`EQ<N;KVCO
M<^N?3%.P=%.\K20@*;@UI?9X>Z22:CB;ZY2"4N[:IP^A@F4ZL_@T[**@,'9&
M8+EKXN"-G0?1U(]XBDZ9:VDMG?\`MV%,GK.29M)&.=MG\>_;(/6#]DNDZ9O6
M;I(B[5VT=('40<MG*"A3IJ$,8AR&`0$0'AAS:]G6<7>/=TGZS=!16B(]_P"V
MM',F[XH`BY@(S=+-?XZ)$%_%-U'2>E%1261`!2<>L=$Y3>8P#J?KM_!ZZ?RT
M;[RWM+9NV[%9=[B%9K#,V-!LV7RW?JA,VR:3`,[+>:^G>]M91S4"JJHO:V9P
M2V)MR&4,(A*F()C23CF,=8WKM<6>KI*T&MU/<\=<(Q@QLI%R$(1_`N&1D%V1
MD3-2+("R50$R!VCIIX>F)!$ABB40^'.FM\=G*SRCC/)[:3?2?=TP2H0<&W<U
MUI.*[?KT6+3YB*:4#)I".E3NK`W(14J,?<K*,?74_.4"N%Y`"@/E(H8FO=FN
M==NZ^WM?#:5=18,8IN'6:G]/]L<R\?U3T"ZB;H[N<8=N%SZ9;K,H/VZ6$.9^
M::RS!QE][;NW+>K%ETWL6\1=NJI+-74<LR(/+%G6-2^4^O\`:)4=JVD^R/L\
MVWT-)#]5NZ6*,E='H4.1VWI4ZTL,O&UQUV9ZJQKMP_6K5CB9:29I7[-E'"RK
M(7*"K5=VU682(6V69XIB])S/]=*ZB:#?Z3J=-K>AYQ:H.[4>WQ+.=K-IK<BW
ME(6:B9!`CAH\9/6QSIJ$42.'B4?`Y#>)3`!@$`B<*)O?WZ#SW8C$:UVOQ1C*
M%[%=1O6MK0*PY=1]JMN5Q[U*Q6&*@GL>F:0"V4.19!/PATA]9(Q'I&Y%'+A$
MO)6M;CIW93[4'N_UWME4L_RCL#*1-=WZ9CU6-)O":36&I78=2$1/]43AFI#@
MVJ&R0S=$#SM7/Y$UC"+Z',X8*>1K<8Q?0LZW'HO?X9<S/LW,XZV]C[3?;(JD
M_O#1MW[D$5'0)"Z&8O/=6O*WF9!`X>H20%O!Q*!EO`#IHNCI@(%6.!K?UT_G
M^UO[;_Q_3IFY$.!__]+OXX#@.`X#@0][J]JV_5?+6,I`03:];3I<^EG6"9@J
M[.U"[:+),W3Q)S-+H>+J+H--BVBTM8I$``K.,;&`#`NLW(=);<3D[V\*W<(Q
ME[79.Q:7H]@4TWL'J"K64US795JDG)6!\DF7Y.L5MN"9253,:B0?E8&":@FT
M8M2`<P*.5%UU>\UFL^KE=KM]DY:_`%.4GWG[@?N!R6D;.:U<HD#^3#[G[WC^
MY_I^[]WF<KAYTG6BE(;^3\/A]WP^Y_[>64PTU9(,I04^\\/N_N?P\U+_`+,V
M(4[WC58U.O#"3HRL7(1D@UGZA<ZO).*_>L]M\4J#J"NU#M+`4Y.LVJ">D*JW
M=('#Q\!34*HB=1,VK)M,5);K<RIG^WOVVMNM-K;UUWQXR4[+8='1;J1L31HG
M$QNZY1(+'C:IN%?B?5.#.1=.FXQUK8MP,VBK`4?2$K5VS+SSV76XKO++)M.%
MEW('`<"$&E=&JE8=-G=QQ76-<ZI[+;OE#7VWX>^I:U?TYQ'HI-(Z2TS*]/I>
MB9;;+!',2"@C,?26\UZ(@DH\41*5("YZ8L5X].J:[[+]V+MO6D=C+EV2Q[K1
M,S%$ZP/[]5<<K4=<MH;H/*MK6T037(,XSR(F:O2DS.*S57+XLF9=W]4DFJR9
M#,S#<;8__);K+C'Y>J\"W12;^.44\@&42#XCX?=(/P^/_0/$K-4M+N6G2*UZ
M;A4_#)6'I;VNK&SR&=59^@RDH3&NP!J%=="OF0M(>33%@ED^^5R$EI:+8^/R
M<=96SUL5("2R?D68Z^BZWR__`*B-?0;J+D6C]%^GE_E8&7SG:8S&X%U7]SR*
MP2&8[+$-GQGKF,\;U45V3VQ0XQSH@A%319.(4(H)%FAP,8HZFLNLRFVUFVV.
M,K'_`&L=E[#:MFFNP?9O1ZW:]/R'7[#FCVE*UMK%ZYGT1#KN5JNOK5G@F]6I
M&C+7^H+QTQ$3<!6(6,>-%CF*J[5%4C3'W:N.EG"NWWV.F4I77-;]SW"Z^F_O
MV*L6E?[-TUJV3^7U?!%3)Q;N9E&Z:9BOY*E,7`MW:JR:PEAQ3<F,0D0D4R6Z
MV;19C:76LV]J7LZWS6?S'K>I8WEEZS=BJS(W7IK999R99UG5ACXA6UVSK@^<
MN%E54X)2O$<RU5;JG]6.^0D8GXD;M"AK;63%GZUF6V6;?O&!^[]&/,>[T==N
MP,,Q%=WH?76ZU]J1$3)E=7[IIJ%2[:9TU6%/S@:3F72;AJU,)/,8R)2F,)$P
M`LU]9WB^D^E_OHZ1%T*_<JXLV>-8NRU6UPBB#ID_:-I2$L%?G6(IKM7K%XDL
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M!7<35K=8NON5=5NQ:`WWL9UU]P;H]7JSHKZ&9O)/9<HT.]6$,KV9`ABJN(^V
MVF#I$[7+0DU\_GGXMT)?]7>I%#.,61N7.=IQA(OL]A,QUGS#4>QO0YE<\>V^
MN,4K:\HF-S36'RW3DV3QJ6><7O"):OV[-+@XBH!9X_.,7"L+1("D9%J_*Y42
M`=[:S&9.K&NV;)M>BZ3KM<)#1\&R>\S>@9_K3^YT*OV)YHF7P,G6\\N7UJ/2
M>EEZO`3D]9I:.BW*"Y0])T[,L)P,)TFXB+=+#5Z5R$=W.F5<Z&]X&=(8-Y*J
M]-^[]G):<=G*NZ5K[SK3VBAWZ#QDVHLTS,8]/=M9E9JO"+H%;E3;/&Z`>="+
M<>IK2S/CM^M-LV>>O[S_`)CI/]NOM'<=WSVVYGM:C4>R'7>6B:;J3YFS2C8_
M18":8*R&;;;!1J(B@QBM*@V:P.VZ?@FQGXZ2:D`$D$Q&676V5.EDLX5:])2#
MUV]T/9L1$OR\.W[)]IZ#"QGJ`",16^U^?9]W:SH4BF*0WR#!MC,O'-S&$P@H
MZ\@F,=0!-?\`"?2EYOUD_P#2_P!W'",J['9[(YAL54;6RIOW;&4;I_-OXB:K
M]@B517A;74;-"NH^PU&VP3DPJ,I..<MGK8PF\B@%,8#9)<*;N\%*W;K;G-+Q
MO)/<)[(6+2=XN3#/<'S32ZKU9OIHR.9E*^OUSO-[F.O+C1I;-<NJZZDC(O7#
MM>6<*$8L".Q=/`55LSF8Y7\<6[3\5MG5_#\XZ]X%GF-9DHM(5.IP@HK3L@H"
M\Y;[%*N7$S;KM9W7B8SRTW*SR#N3D%1'[YTY/Y?`@%`)UE^J9SU1;[E=?+%?
M&M;T3(9AK2>R>'3#F\8/?7!5BLFTX9MZ$W0[@1J8B\IF.HPI#P\^Q$1`[58K
MA,`<-T#EUC,27QO'15Q+7O)>\ON'];;G.XS`JH6_VZ=K:[;G=]KU;M'T&SU+
MLG$YE;,VNA7C)9M8SYSI5:E(Y%59'T5"J$<(%*1?X37GK&MNFO2^K;%DC-2Z
M/;GU9@>MNMRV4=7M>U`V<ZI`;1+S>S=>LM>R;<BU$A:?49APCHV:26HV-96)
MBUHVX1%18RBB"3EF7YA`IVTQQP:WREEY78]A,&S;L]BVBX+KL(2?S[3*XZKT
M\S_DRNVHG,FZBYR(<*)J@QGZY,-F\A'N0*86SULDH`")?#D)<7+B\Z\T_L/T
M][)WGKBUGB,.Y'2@[R:PNT.SKQM4[,]8YMRR>DSFX(BNN$K1K3'+-B$(HJHM
M6WSAJLV,5S%.!-O7\]?&_M.$V_&S:?I>?NZK;;,TOW(?;DT1S06KOZ1V6ZZZ
M)`0\-*D3).5&^R-;G*\I6YM`B@((6K.M'9&9NT_,*17\>8/$Q/B.%XL0O]C7
M6FV@8C9F)3BH\G*=@&ROQ.<_G;R5@SE;KW.1OIF*4$C-+!U9=+J%+_\`>/!.
M;_KAXZVYE[Q,8S.U6-]@.G68[[9JSI9YR_Y#N%*CEX6H[QBMC;T_3(NO.G(O
MG%3EEI"+GZI>J6K(#\S]'L45+1J3@3+)(IJF,<<KGICT5-Z3E%PW_NA0^IVF
M=S-1[$8;C#2'T3MC"WC/NMM5KLS9S2T?:,:PD\EDV+T:=>R-D.S"6M;479&*
M592:M54S+2HG3LEN<<%NLQ;/R]%_LM'H/HU1`I">!$O%#R`7RE*4OWI2`'WH
M$\H?``^'$Z,WJJ"V;Y_I+NQ>YM+143Q^]/JS2^[U*;_>L%*G\PC`4[LS$MBG
M`&UOQE9Z1*P"FFJ>7J!UO,7UXYJ<%GJLO^-_A"7J/UOZ^[I*^XU%W?)J\\C:
MU[JO:IM295C'*TVU4I]`QV7PSV4SBZ5)>%ME(7+-QCCR.H=\S5,(&\P@(G+R
MZR67,]3?:RZXOHFCT4OW8^L=PMXZM:CN3VVY'0J)6KSAM>VU,M\WS0ZK.N/E
MIJZ5O9(ME2F\M2*)8SC#R3&=;6>R(.E6QUWR+=9LHYS9BX]%S+K+ZLM]X3H`
MKW9ZYA8\Q;A%]JNO;ASI?7NU1Y$4II[+Q8(R$SFXNU!(46%Y1CDBM@4,5-"8
M;,UCCZ)5R*OK.5ULXO%4V>V+W27R(*EOS(SB*Z^;;>8O,NXN8?RJ<5A6].74
M=6(_?(2-="0M9C'DN]9-[@F`D^9AI!G).`.YCE!/O:3:3>?RQUE\+_"WKWAZ
M%$/J3U;V"30`S7+NRL33K4Y.8Q$B9KV,H]PPZSM%#$*(I`[LUI@#><1\`!$0
M\!$P>$U_:96_KLF+[?=UD;YTLZVRLX!0M$%E\'F]V\BJ:Q!O^0BXRC0#)G2$
MQ/2-=*6_$I0$WD*(%$1$/$<_1;R\'2.C%5L&H3VY8KKVQ=5-AM_RI[[9\1D*
M4XK&FO&*#9DPE])RG4:3HN86BQL(YN#=*7"*;2XH^":CI1(H)\&>\5[]+J8Y
M[+]S+QV)TOL-<>Q^3==)J:H/5&0T&HXU6F=OU))NZJVN;G`H8_GF?Q,K6JV(
M.:S4W#TLD=<QI21142!1F/+C;'_Y+=9TG[+N[A$IOX\ZOD*91(H@8?#Q\2"`
M_=_?\!XE9JDR2<+=*IS7>NKR':3_`%'[947>9/%ZW*,OJM<QCL"US"]:1?\`
M&EHER55L7(]KK<#+S\2R(9-K%R["2:E2*D_1$BSUG#6MSZ]8T+T9Z>XY?NCG
M3R]F8S="V9CAE)?PF\9!8)'*MBB@DFOUE*-4NU641=V&#;_.BW-&S*<G%+)>
M/J-#>/@&IK+(SMM9MMCA8M[5VS]BM<RK48WL_HE5M.I95K-CS:2I1:RWB-:S
MMC"O'BM?'7;)!H5>BW]Y>*FXC9>(EZ]6(2+<L5A,"CI8RQ6N/NU<=+%<?ON=
M,WE7<U[W.<3JZ,K<LF;,:MVLI2#5)5IK/7]Z5O!NIF68^FJG)R-.9G39NSJI
M+%"'.FZ4$J400IDOC<Q9^4\;_#9WM/=E2Y[-9YUE5L*EFZU[I3WMZZ5VI\X*
MLZI$C%Q2MJNG6R0=J.'+MTQ;UT',[6".#?,1S>.E8LYS$:-$T][ZR8NOZUF6
MV7R_:<L']VQG^ACNGE&_M&;@RMQZU25@9%8I',,A?.@6WT?M;6F*P$\Z:C^=
MA9)VT33.7_6V[<Z7@H0IB!-?\I]%_P"OW_MT<J)1%DAE$5T8^;@)Z,,DLW<H
MH2$7+Q$HU$BB*[=8BK9['R#)<2F(<IDU$SB`@(#S**K],ZNTOI+F&DZSE7<O
ML3U)Z_T:$F;;/957DL9UG,*RV`@>C"936-XRO1YZG*3$TX*A&P,1)HQZT@Z2
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M^@S6%$`%O#J"KK2S/CM^M-LW7RG[S^G1_P"W-V@N^UT>YY!N;IJY['==)"#K
M-]G&S1&,;:M2+$R=.\OW..BFYCM8T+]&1;MK*MD!]!K9(F232(DAZ"999=;9
M4S+)M.*JYZJD/UV]V[7,M.95A&/^RG8:H-&P%($:>M]T,HKG=.K+I>8I$RM8
MNTX2ZB6QR`/HN71VH#XG.`W_`!GTJ^M^L_KHZ8^90X'_T^_C@.`X#@.!SU76
MXJ]C>\>V:M(.#/*3UQD9?JKB48H<%6,?.5YRR>]C;VV0,*J2$_8=$12K!UTQ
M(J5C4P3'X+*%YU]O7G9CW+B36)CU!$O@E\`_<_\`0.;K$29J[9,03^`?<+\?
MA_Z?N<Q6HWC$1:2R7Q\OP+X_'_H_]7[G,9;^CP9]BDF4X`!?W>5*CW:D"!ZG
MP#]W[G-1BHO7%$O@K\`^/CSI&*KXVJYONOMWR[M_7$C_`%GKA:/KEU3:HN%E
M['U^LPMX3>:HX2;$7.Y12I1S3K,#)*@C+P;-8I?$G,^Y,ZY]8W[=QMX^E_U'
M4(R>M))FTD6#E%XP?M4'K)XV4*JW=-'21%VSE!4@B15%=%0IBF`1`Q1`0YP=
M7VN`X'/][\ON61?43'(CKC0[0XB-T[',58^2EH-T1.=RS$G+E6)MUV;*)B=S
M&V.U@FXAH%<"D,BJ#UZDH5:/3*HZ9DO#6LMS4*>B?92N152IL+3%FL1`0,/&
M1<+&1P@DU81S%ND@T;H$+]PJ228`(CXB8?B(B(B//5B6=.'EN9M;>71%FF^M
M+?#(-'ZR:JZB!"^L(AYS_`!#S"`!YA'P^Z/QYQVTQ72;9Z(6[U4$.U';O&>M
M49(E0K>2Y[JG9'7Y5%%-Z$#(W3/KOUUP2'51*LF*TE+2VAV:PI-U#I%$E3*8
M1_E$Q#%OHZ:],U`W4.K%B]E]')-WS#0M<VCJ>]@*5B/<6+T2:5L\KGHLG00V
M8]AJ:R;IE1K52JZTF6!?0K%(4&L4+5,I7*Y_FF[6^-^BW\Y9C\FS]1U.1Q#4
M*AWEQE/[3JP%<80.[TVNKHN4-VZUKN!F72\6FDJ1K+Z'EB3U:P5)P"@'<@+N
M-`YDI`2\Z;:9F9RYZ;?X;+[8.:SO<,QBY^%=0.B93K5(;24<[!-.3K5UH=WA
M"K(G.W<I^F]AY^"D@`Z2I/OTE1*<H?$.<F^'&IU.J,4[C.ZG3OKOJE,T.S=.
M=U2W?I!IM6M<1=X!6.4DUK_E+>-L<')OXZ3:QMC8&B;(HDY6\@V!VV4\1\2<
MUK^6MU7?\=M=\<\I^^X9V5QCNGB'MM;-E,\@^FC=[LIH-UIBB;IK9:%*:%@M
MTL&FYM9DW;5D[;3%=CI"/;2!$P%$_KE$#"`D'DT_;4LQKO\`9>/T;E7T[THZ
M?3<G(H2\E,=6^OTK(RS43F;2CZ0R:I.W<BW,J=10R#UPL94@F,8PE,'B(C\>
M0O-<NWNM>Z52-B[NU#JY4YTC_&.LEM^K69TT725A-%[&1*IV*1G"J8J)OH+&
M!5619IB)2*V(R[@0.#)FH._;QY]3:6:=.:LMZH=J5"MX]PTE1,FJ5'Q*"@"4
MQ1*01*8/N&`0'][X\[[:RO-+8MZBM.C+Q$HB!TBK^4!$"_`!$P!X_#P^'CSC
M=<.OE+%1<3TQK/N6V7L#L=IOMXH.=LNT^,57';;G;MO%W.<IG1M'3(V6DZ5<
M`5<*5)C8.Q>L6T&\FS3.X]*!172`#J(KI<[UKI/QDZ=?_;4^<R=R]O3L.]]O
M_5[#.V/'+VG8M#Z'ZO:7CB0D)6E(KF?6_KU9YUR)S/[CE:SCU&*JIS*.XQ9,
MP^@55DT+O2]?&L[S,\I/NW=U0VEKU'[)H8)(+IM>L':>[R+S(P%4$X[#>RMD
M,\EYO.&R:RI48K.-X=HK/8-LAX(L+<=PT21*651`C?7QZS@UV\IC_*)2>\?C
M&7;A[>F]U_3K?2\\7JT(CH677V]VB%I</6]EJ9U'.=H(VBP/H^-B'USE'!JX
M!Q4]4Z,RHFD4RIR!SG6]>8J-ZA]I&-9J/2[W'I:3094ZU5`G67N3)IME':4?
M79.4>1D7H$J5HV67C&V>;]`).0`J/F2A;0]-YS$$IC]-KY:S9B3&VVG^W^OL
MS;4[36)GW;F6K9798VP5C1V/M=Z&RL$4Z\["41T:_P!YSJ,D&QVQF[@2V+(9
M_P`Z0+_?*-7)?,44C%+R3]=_X:O.LQW_`/#I-T"_4_+*-;M*T&?CZM1Z'7)>
MV6RQRBH(1\+7X)BM(RD@Y/X"82-VC<Q@*4#'.;P*4!,(`.4Y<.U7]SAKV\[I
MZAV!FE'D21<0SK&*O)G3*IGV)P\C\W%1J":9E$4[!=97QF9]8AU`5>F2;E.9
M!FW\.WM>.+GEGWI9)/1TD=9NT:GR#-JJ_!PT6(GYDCG`Y/B`>!B@/CX#\?NA
M\>:VTSU<]=L)5;?O-$SK(-`VRWODFE5SJF3ERG#E4("RS2$CE7H1[(IO_?R<
MFJD1LU1*`G7<JD3*`F,`#QX=/VO1577O9;0W+(,LT/6MEUK(.P3WKC<FLNQS
M"96K#.M[AMNXV_ME,6&Y/8]RC,7EEGFNW-H5")%=FV44@45A5\Y6XM\?RZYD
MZ8Z,%R/;)#L-FFS]1>Y54B4>P6.'=8]V4HJY`0C+BR>,A^S.MU($DV9R5K1H
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M.#<6;0NA3`(AY3%3!<WI"4#'\R_KI_/]K?VW_C^EF/N@=]ZI[>/56V[)(`QE
M=&FS'I.*4UTH`_:?2)9DY/'.7K8AR+GK%3;(J2DJ<ID_,U;?+D4*X<MP-BM:
MS-<SOMY=J&;R#"35M#RP6^WV.8O6@6V65(:?N>@VQ^>6M=IGEB$3%22E)-8W
M@'AY4$2)HD`$TB%#U:37PDCA[GEYVUU"8?V33FXEHPD717(>D0B2JA@,<@"4
M``H&_P"MX!^\/.>VG9==FA>_*J.JU;+.JT`8KNQ]P-;J>8O&J94US,<;KK]O
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M7=M-43BZ])`JDH8_U.0.D3P.4H\SQ<>N6OK.*LL]K1^Z6P34(=9PDLSK7;#L
MQ'1B2`G])FC,Z7)7639E(951-,Z=DM;XR@$`A?4,81+YQ,8;M^VS,XU^R#/O
MV>Y1%=4,D@^L='LKB)VGL@P.TL4O#J>28S/"G;Q>&M=I:N"F\T?8[J*#J&AU
M@*)FX$?.R&36:(>>=,R7AJ2W-D1`Z+=EJ]&5.GQ-.5:1$#!1<5%PL7&B"+..
MC6#9!NR:-4RCXE2003*4/$1$?#Q$1'Q'GJQ+)).CRYLO7ET-YOO;2XPR35^L
MFHX42(3UA$/,?Q*'_6$`^(^/[OW><=M<7,=)ME"'?Z,IVO[9Y?UN@9E>&A\A
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M\BA2@[A[#7Y3XE,`>=%7P$`\1#G)OAQJ]1ZNR<5GN1U+Z\:=7-(MO2#L(3<>
ME&CU:UP-TA92&0GG>B9$U96*!?/X*;:O9R)=Q-F*FJHB!+"Z:*`'F,4-Z]=-
MM>QO^.VN_?E9/W;[&9%W0HWMI['DLRWDUWO;HF<WBNJ(R3>P4*4O'5FX6K2\
MULZ+IHV29SE:B):-+((F\1]0Z8IB8H'$)IUVG^O0VZ:[_P"O5<ST7GY"V=).
MG5IEO'ZK9>K'7N?D_$3&'ZA,Y)49%[XB<I3B/S+DWQ$`']\.96\US$^[U[HM
M(U#N52^H-5FDI''^NMO2G]'<MS%/$7WL+"*&)$PCM<IC%>5_&5S',"0^5->R
M^<QRG"/;'-K3Q\IE-IMX6S_46%]3.U1_0BW3.6$2'*GX@"OB4Q3%\!*8/B40
M$!_=YZ-M<QYY<5<5#:G&WF'1\3I`N)0$P%\`\3#X>(^`>`?'PYP\<5UFV50Y
MNET%[F=R[.:-9-$O&<YA&=B,.R;.[-GCDL?:K96>DKK2Y"\KUJ<<(_)P3.2[
M$ZY/,6TJDF_527J8+(D#U"&#%ZUUE\9.C5]*=W/VY^Q[GHQJ-BG;'@.L+66_
M]%=6ML@\E)(&0O59:]]<+=99!9=Q(VBBNY$'$0NY4,J]8.$RBH!UVS1'>E_Q
MK&\S/*<^K<?6#:&'3[LRCD+UT5GU<[9WIRI0VP%'Z5A?:*S+JO'E;:`'WL5G
M?8E\8ZK1`G^K1UQ*9,A$R2_WK?3QZ^AIMYS'^43)]W'$,MWSV_>PM1U6U4V@
M,X6K%NU%T"]V*$J%?I^L5MRFIFSEQ:;"_C(J#^TMG<HP!U#KD,LA+J($\QU2
ME-BM:]+%+/3?LZWA\^Z3>X_*2BR,"W@S]8.Y$@`NU4TJ39YI&ICH,^V;?.'3
M)0-S@8B=!0$%%48*<D#>)2J"8-[?EKKMZI)X[;:?[-G;Q;J_9?=&AM?RZ2;6
M&HWFO>T;I5;LL4LY5C++'ZIVK>Y8RLS,%2"86LKD%X="GX)I@*)0,8"CYC<D
M_7?^"\Z3[_TZ?.9#@?_4[^.`X#@.!YDU*MX*&EIQV191I#1C^5=)MBD.X4;Q
MS55VN1`BJB*9EC)HB!0,<I1-X>(@'QX','T;=.W'7/'K!**)*S-^JC?5[`ND
M)O(YL>O/'>H6-V/F(0?5=SEN<**?#P`YQ\!'[H^G3IIK]G'>_GM]UF=1?%`$
MOC^]R4B25:E"$*GXF^X`>/\`^_F+.6HW"PGRII``'\/A^X/AS.&GD3,V50AO
M$_C\!_=_T<8+PT/:)$A@5'S!_P!KP^/[O-R,5&.X/"B"OQ#Q^^_^GG2,5#C4
M6$?8X2>K\HGZ\7.Q<E#2*/B7P682C-9D\2\#@<O\HW7,'Q`0^/W.7[IG%E]5
MN_MGW&6O70'J+-SRGKSK/#:/49IR(&*J\EL^C"4*1?.2&.<R;U\\K1UERCY1
M(L<P>4GAY0\CU7FIR<(<#\T?WX,I['Y][C6W6CL`,A*Q.IS[VUX=;2@Y4K,G
MC+=8(ZEUF!74_P!7:R&?Q":$7+,R@FH203.Z,04WB*Z^;R[:XQ,(E=2>T<SC
MUB8Q$H_6^@+*D3;J'4,)69A.'@D;[H@D;Q^]'[@?<_>YU]O?'2N?N^WF6SEU
M&95WKIE$S9_I%DFEQ@X&+2>';QY1>2LL]7,FVBH*$8D,4\A.3LDNDT9MRB'J
MN%B%\0`1$.^V,9>63:WQ]5+>&>]OV]ZQ]T-BW>=BF,_6MEN<6YV/";"W:HI+
MUVJM%("FPM<MQH]6P5N8HE75%M'N$S'8N%#'5=M''J#X>2VRW,ZO;-=;K)*[
MY,9V+KYW_P"L<;?Z8I%:3B6VTZ3@[!79QJ@JH1M*,UHBWT&ZPQCKE83L0JLL
MR?-A,<H'+ZB*BB)TE3USLLKEM8M+?TEV+5^@M]E9*3CLF!.]=;[5+G\SJY=9
M[<^7&IMSNC`0TA*YU*>M!OE0*FEZJ`)HD!)$/#O[5SG6N7NSC>>O]K1/93WM
MJW5V_IA(/3BAF\BIMV&-5E2F(ACND3*R=QI<4B0#"C'YAJJJYDRG,`),+*P0
M3+Y$?AS]S7QVL]&];Y:R^K4D)6Z9[9'<WL+C]K48UCK%V7KND=R\`GE46Z:5
M8G\\BB3/9K'DSID(X=-ZK%*HV*(;$(5!E#*"F!U'!U1&:W&9Z+M/*2^O"M+3
MKE99K5^F&`Q;0RW8&81O/=O78<17,[B^T_>Q:*JW7?-9EFFF9U".\3S.8A2.
MC>4X-H8B:P^4$C^#6];LNWZR?Q_$=;^A93?*KT_MF(=9IYO4M&K'7J2R[#+'
M+J"FC`6:"SX]5S^3=NDTU`:*L7C1J?YCTU2H*%!04U`+Y#9,]<U^4+?Z=H&5
M:':J1HT)/4_2J399*&ML'/IK-I^&LT8\43D$7_JF.<SHCH@F]4#'(L`@<IC%
M,!ASP[]+/HMIZ,]UWD2Y8U2T21DGK<R*:*JA_`KI(OD("A1^`>;]P0_<'_IY
MZ=/<\I);U>3W?;QUG"Y#LY[D$[BO7&R,,F<24OMM\JDU'TE.#%59_38D6B;.
MP:@].W`QF#:HI/R?(J'^"TLJV3`#%]7RO<Z3IRS[<SMU_5%7V8/?9L?7N3H/
M4WMM*1DAUQ4.UJM`U%1BQBIG$E'2Q_DD+4XCFC=*S9ZYD5Q%V\=@:2C#+'<G
M<+-B"BGYI7JVUSUG+K.]Q+I_&]W.LLY2("0:PNLU)U'ZMUST9L='YJEZ_4R&
ME*=+L9(/,"$7.'`6#PY1,06;LR@%,=-,0TYRXKEU/M1NS>`2D'>$7](T%`TA
M2M$A2>K'V+,-IH,HFF[7;H>J5U$S56N,4A*,"F,"J/@CYA`P&YZ99[FF,.-E
M]OW.G^HZ+\2E:;[LGME+4O9B$)*Z;19S&-Q3CTFAG55VW.9((2:MD,S\/DVZ
MK.]5]I:X)(_F(5LLR$_F`1`?-9S*[9Q<SA4S0[Y>IOJ*Y]OJYOV]=[;0VU0'
MMU7U6.7*5=.MSZ3A]+[S%G3(5ZI!R'5B*F;,C)'*0ZS]BLH<2G^/->7XX]4\
M?SS..7Q=!+%4^Y?N0Z=HV<QZ1L?K^L1MCIP1XJ_9UCUXZ=YX;#L!2C#*F.HR
M-=-6L3>RQ[=7[]9M&OA^`HCY7&GUM+GR^T_M/C_F#\K[(:U[=EPB.O7STBQK
MMQKUUVZH0A%SV&X8]6&LM(RC2+10`ZDBWKMF3BYIZS*`*+-(TYRF,*0HK8K6
MF)>K\YRI6N8I<\QL$&Z4;/62I3@)#"4JR8&`3HJ>'W2'\/\`U#\>-;=;F.MD
MVF*Z0.C?=QI9&,:R>21D)%MZ*+ANJIY5$U0`H&`?WP\?_4/W>>O7>;1XM]+I
M?H_KW9O<6O$E0JGA&,OY-&+KUWJEPU>],&X.8EI;*HY86R@YX"ZZ3B+?.HZ4
M2:3DD@H10B2J,>0WQ,LGSC[O:.WLZ_Y6]?1<I[*'O>F[I.6G6/M&Z@X7LVQC
M%7%'NC)!I!PV[1T4T7=RS<T,U2;QD'I$1'MC.UVK,J;.2:D67;(-_EU$1Y2M
M[:XZSAM[WG,#EL\+2?<KQZ(7/>NO[0E/[&PD(V3^=T[K!89%LG-K/2$`AY"8
MRF7.E+,C'.0B345U%CBFV3(&M;XV;,8\I=>_]JL)[LXGF&@8AV^H[U696Q>P
M-+B_^AJE,I>L)MS5O'ZY4$_/XINT9NBN#2;$AR'\DO&,E2E\Y"B'?W)-M<ST
M<O;S-KK>+T7E^ZMUS<]G.M>>]EL%3B[3N'526C>S6`.2%;NXK0JP5E&3%ZSM
M8S@AB.('3J.Q243(0"G</F3(GG(0QQYY_J[3UEXJO?5^Z>4VYED?:6">MY7&
M.L'6R>[ZS<.\$1:S>VW=I*X3U$Q^<>-#%3:V-UJ$W:5E&PF,*,E6TCF(()@8
M-;;9DP::XSGOAOCV$\ZE$,7=:++K+OT(.IQ&:LI-VB9!Q(Z)9YR7V7>I9)42
ME3DHY[+6ZMQY5B>)$G\*]1_ZY#@5MT\=>T3GRO>J?/\`FF\K[(#N6+[)-_/3
M75U.BIT6B+1I%SPU%TQ60D)6Y1]D1(!DF,]=6"+)=F[4$H/VD=Z!/$S!3QYU
MUTQB]W-U@6Y3V,VII(-'2_T99PF+]L4P^"?WP>+E,GQ^)0_ZP!]T/]/W=Z;W
M6_1/<TF\^KJHZG]RX"7KS6;<6%JT8,V)G\@]=.TF[1FS:HBX=.G3A8Q4F[=N
M@0QSG,(%*4!$1`.>K,LSGH\=EEPJV[*>\1VAKG>JL]DL/DG52K&;TQS0,JK]
MVKJ4I7[QF-BDXN:M\S+0<PW(NT0U>0A&:YG#,S"41C&C`A5TE4?./DWMSGT>
MOV]9XXO6NUKVT_<:RGW(<&;Z93$D*MHE8.SA-DRA>0*_E*!9W":YFRR#@R39
M66J%F2:*N(F0!(A5TR*(J`1TW<))R5-M;+]%)W;S,UO;N[H2D16VPQ/5?O#)
M3NA9^S02*VK^7]DX]%NIHM'9>0?E8R(T5@*$I'("*9!=F,T:(@1`XCV]K;%\
M?2N?N3RUSZS^FQO;<[%MLD[U2F:/'PH9]W+AE$R-3*$*PB.Q>75]=]"2A`4.
MFDU/I>5QCR/<F)XJ.'T!'$\#&4\0>[,7RGJGMW.MGK$@.ZF71O3SW"<J[SQZ
M*++&NW1Z_P!7^S8F^439536#M$V^#:RJ!R@L@UF4XC[/2;D3)M62/\LJ)E'(
M`//6XOT=+^6MGK%<_<#>J1])T2TV&8;$0[:]G*YD]6."RRH1W33VW[%*7+2;
M8S=@(%0B+YVA)*M$_2!-"4:E#RG7!`P%L_+?KQ_Z,8TQ.?\`VZ1/;VS.=S+J
M=FZ-PC%8>]Z,ZN>YWV+=$%-_$6O=+K/ZL]KDD02)@5]3FEL0A3@!0`H1P!\?
M#Q'-N;:G&)V<!?OI9;V,S_W'-WL?8,',DCI]B=6W';8@@Z)69O'$3$B:)#P!
MUA420=4F!9MXJ3:E,)T9!!14WG*NFLMFNVN,3",/4;M+,9!8&,+*OU_H2[E$
MC54R@B5H8QR%!$WW1!,?^R/W`^Y^]SM[?N8Z5R]WV_+\IRZB<N[UTZ@YI(:1
M8I==2'@H])P5E'%%U+34DY,BVB*_!,BB!W\Y/R:Z31H@'AZBZQ0$0+XF#MMC
MQMR\TESA3'UZ]\/MQUF[DZQM=NCVUGI.R:`PD=GQ"99,$%DZ[`-B5^L1%0M)
MF1)J`FJ%4$R,XU0RBC%R8IE';=8ZQU.>2VYN7MFNMUF'>WE.J]=^_P#UD:76
MG.(K4,)W&G2L',PTLV*4ZC"3;+P]JI=MB?545B9^(6.LT>MQ.)D5B>=)0Q!3
M5-7.RR_5RU1R%TZ6:YJO0C19-_(-<A%*X=<K3+*^9W>NLUI>N?L<8%A'Q=O\
M\?%4@7Q_`A2K-P32+Z20&'O[5SG7UCE[NO&\]>?NM+]E'>D4VNT],9)ZF+?)
M)(=<PMN=3^4)BNF33Y6P5!F0YU%5&F6Z@H[13$3"5O%SD:@4"E3*'.>^OCM9
M.&];Y:S;U:)@(BF^U]W+['XI<3,ZQUA[!U;0^YW7B>.@@V:5R1H<8K,=C<7;
M.5U"?,C4XXJ<[%M`.1!G$G^)A6<'Y-;C,]%VGE)9RK^O%RM;W2^I_7Z)*W2[
M(OZQH?:G1VOH+'3CNXON,NXR(Q.AS[=$ACH)X9E4_'HNUDQ,FC#)D4\2D1'R
MM;^VW:+M.DU],_\`$=<%QS6Z5CJW9L?Z\3K&GZ!7<&ELVQ*R2Z!%8^M6R'H"
M]8SN8D$2I+)`WB91LT6/_)*D*!/$4E"AZ9LGKU?DZ:=2=%RK3+I1-1B)VL:A
M2K7+0]SBI\5BST?:(]\H61,]75.HHZ75=`*I7)3J$<E.54ASD.4PX=^9]%I?
M1KNF]@'L=4;3)'3=(G(FW<*'$"ND@\0`Q1^YYRA\#!]WGJ]OW,R2\O+[OMX_
M*<+L.PGN/SN']<YU3*5GDUMETKLU'9VSBT`D'-<229@G/:1((??)I1M*:NR*
M(F4*=->45:(F3.113RO<N)TY8]N9VF?U0Z]FCWV;-ULEJ;U<[;2K>8ZUN%"P
M%,T8(IHVL>*2$E(*N2N;$O&MT%K70GLD^55D5G)%Y5DHL9R599,AVYO-+W>K
M;7/6<NN;W`.HE:[W=7YR@1<LQC+_`!AHS4^NVI1S@JBU&UNMHFEJ';H:79'.
M8L9)&4^4=*HF-ZD>\4.G_*`D<NG.=/LY<?TQN>R&"6*E:HQ>TO2(\\UF6O5T
MIA8S^=;%1)`K.3=-4DE2J1,Q!6B-0EXX`.)FQP1^_,8@CSTZX]S3JX;2^WOT
MX]'11UJLU2]U'VUG=&W5-K)SERJ=FP'L$A'`F16)UV@N"0\G;HI`GD2CWCJ6
M8QUOAB#]Z@D\:"("`>`^:SF5WXLL5+Y[=-'C^H]L]N^ZRB<-V^IFU5/V\)!U
M$%2;.G=4U#_6JYO<454#N6\*YZMIS-G0?*%,Z66@G"YR%4-\->7XX]4\?SSZ
M<O,Z.S-1[=^Y->IK)TFX8=3=.I"U+0BS#]&:]<>A]#'+<C7C%Q2.0&]QW>;A
M)MBW5`AE62#LR?E,V^\<:?>_TM_;KZ3_`)KK/YE#@?_5[^.`X#@.!X-JB5IZ
ML6.#;*)(N)F!F(E!9?S^BDM(Q[AFDHMZ93G](AU@$WE`1\`^`#P.5CI//F/U
MJP)NN15N]A\GHE;DVRX%*LUF*M7F%;FFJQ""($5;2T6LF8O_`&1+X#\>>K3]
M-?LX;_OM]UC56GBE!/[_`/>_=_\`U_=XL2-]P5D`I2?R@?N?N_\`1S#4K8;:
MU`!`#U/#X?N&_P#KY+%?1D+2!B&_E/W!_=XD,M36&Q`8#_?_`'?']WFI$J.U
MLG`$%/O_`-_]W[OW>;D916N\X@BB[766(D@BFJLJJH8"D232(8ZBAS#X`!"$
M*(B/[@!R]D6_^U+#.(;V[.IAW+0S)2SY6ST8J)O6\3(:G+R^E-7/E6$QTRO6
MML(L!`$Q"`IY2")0`1\;U7FK!^$.!![O_P!"\;]PK!)K&-49I1LRW*XELQTQ
ME'MWEGR^Y^D4K:=AQ5.W.\BWWI$0E8TRR:,DS\2"9)8C=P@67%R_,Z[A]/-N
MZ.;=8\*W6N&B+#$&%]`3[$%UZI?JHNNLE$W.F2RJ*`2D#*`@8/B4CAHX(HV<
MIHN454B8=I<]8Z7_`&+/;!MVQY`CVT[#'?KTYJK(DZOYW+D/\K)R+0R\5*;+
M--%@+\P2-\CB.K(*^8`.9V^`@>#%<W77:],\1Q]R3KX\U7![N?7[&HF^KRF9
MWS/)G1TGRC5_2:G:8*<L\D@43G4(>`AGSV3!PW(`G*)D@^]*8/N>/AOW/':>
M69Y,^U=M;C%\5Q?MCN[7T1Z@]9NX4"PG'>&:-2UVO=?.$$WSM2)A6-VLL35.
MU=0A4TUG!;#G%91;(6ALV3,,Q442+%(+J-2%;GCI+&[<[76_PGG[XG7$-NZN
M4ONIB`,[+I/5-!75H>4K:Z#]#1>NMIC6JNHP[.08F.WE(M*L@A8F;CU%$TFS
M!S\N`G=>(R7QLVB29SK?53/[:LGLE:[@YQV:DZ7<8FB9[6[0WM.8QT2!^Q]^
MR;6:&*\1I$!A\X^K5KMN'-II&-DOGH,)>8=O8Y$S*,=)D5$-[[>>,3I$UUFL
MQ;UJ<WO"GZP>X[8.E>?YUJ4[(VY#2-`S9TXA:3HT(?.&V^4MI7:[/Z')3M,8
M1E39(ZS6*O$R,)*+LI5ZWE54DT`\BJS?,F>9<-2^.>L>1[+'2/8;[V@V;W`N
MU:I[+<65_P!$B(F;DHTT4E9MW0D9:BWZ:KD(JR8DCZ9CT>23K$<5-%-F,@X<
M)-DTRQ20\7$Z2EN<='5CR,N>KWMO9KC.]%6<]@>O\5$0G;2EP_D?,O\`5XQE
MOE9B6::+&JSK]11!FTO4*S;`E!2CCP(JD!8]XH5L#5=A+&]=L=+P_/\`4:E?
MX30"4)*LVB.TYC:RT\M-&'DF]Q;W0DJ$*%7-7SMRRQ+`$S_J@LQ2]<7'\F)/
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MJG3!MFV[8Y7$DFOK$`.]].AM6[<=[>VO435I^*E3Y7GMB<6R/I]N8U>QY7<,
MI?\`5SLDTJ3*9J3.1LUNJJ,_"/&TS`F.5J:QK%!QZHF!&37.<]%\L8F,N@GV
M7NB,CTHZN)+WV$/![%L2L39;?"/"-C2M&J<0U<HY_F\DZ0*`JR<*WDWTK)IB
M8X-IR<?($.HDDF<9?^$JW\Q2G*8ARE.0Y1*8I@`Q3%,'@8IBCX@)1`?`0'A'
M#?[ZGLDO,@DKAW2ZAU(JN./U5[!M6.UF/\I\D>'*"DK?J7%-"#Y\R?+`9Q)L
M42__`)=5.=9(H18F)&YL===L]+RH4Z!]?-S[3=G\\P[`G2D7;+<\54F;,NV5
M=05&IL:4'%EO-D3(8B8QE=8CYTTS'(=X\.@T2$5G"9#76V7I5WFMGY<.PGO5
M[>?5_KUUJB,O?V.H5BGQ\$\!.TZ9:8&%G;=8E?,^LMRL$S,.X\LG9YR:<'>/
M%B>4A%50*F5-(J9"]]-IX^.W#R[>7E-I.KG#]K+JO!ZKWKD\O5F)A>LCF^F6
M3/-<H+UR@_K%DI;Z`?T[1J1:V0"V0L%(MP,E$ER'.B#L"HJ@8BHIFXXGE9GH
M[[;7PEQU=TO3GL#);_3]#ZU=FXF`_60R&)2INWU@[)(M5V'/[,T?1-;VZG1;
MDGI/L^UB*;N"/F8%-]&FDWL8L4`21.LQCI6>UG#CPWSKSL?4?L'LW3"(J\Y8
M*+0)R,M69Z796\N7-*EUKUF?.UIEQV._$C9)E5:A2)AZO!RTH[(":K]DLBW3
M,!``.FON8GCZIMIY;3>.FGHOVBRSK5TWQKKCVVLD_3+CF.:-Z2-AGZC+SN7:
MA3F9W3&N.,5TK/E+Y3M"J;&MKMXIDW+(-[(+=D!WD4S.<$PYXL]%M\K;.',#
M'="]-M>;=?\`(>LMJLUHSWL3LLA6+OF5HB)BNNW.[=:;!JL=5+18T9:NQ%JH
M.6.\=NIKM*Q\LB19`RJZR+,SHS=N36),5?*W,_UAW>]:<'J_63",QPJH*'=Q
M.=U=I$.)A=%-N\LU@7.K)6RWR2*/\BG*V^T/GDFZ*3P3*NZ,4@`0"@&67N[=
MB67]C,LN>+;-4(R\YO?8E2'LE=E"']-='U$W#1ZR=(F3>1<S$/T$G3%ZV.DZ
M9.T4UD3D4(4P%EQ<Q^:G[I'M;ZY[;.N?29;ZA=L%NT@]/CVPD9`FVEVR8'<F
MI]P*V(#2$T*$:!XKH!Y$)!`@NV@>GZJ3?-CKKMG[IB>Q1[=MX[Q7NTV'0G$K
M'=0\R>-`N[7[])KJE[*5"4A<G:K&,03U[TSI2%E]+SC\AZ+,P$^HE5)J;7&/
M1G>3G_)+SWJ>L&#P"4N5W?\`+J?H4`516%A7UMK<78%!*4?38(P1Y!*46173
M(`>F1$W@4/$`^]\0[;>.^O6R5PT\]=NDMC#O9'Q[8J5U^T?MA@\0^9]AL0WZ
M<KSJF2IW<'![[DSC/,VG;W@%J7<%3;-W4D15O)UY^L13Z)/@T<F+\NLN"G'6
M9E[NV^TEDOZNF3M%F>8^[I[=DH&3RH)RULB$-'PZ>ET?I%AS+?LZ<O?I<'9F
MZOJN*G9(*T,WU7L21BG68I.'I2@8Q2&%_:<7KPY$\1C.S&K:1D,DPIDSF-US
M73:]=&\A=R1M'F+?IF":-`'T#.>O1-#D*G2--U>!>M%@<1"\RQ9)('%NY7`Z
MOICTVW\]<2=69I-+FW\719[L'93JOVAZ*Z-E#J9O,9I25BS>W?H@L.3:G!:M
M#*4#0ZI/WMA*U\U.7<U\"4-.7;I3GJ_12G,+A)ZJW3,<>>,^C4Z7.8JDZB^W
M)?.P?N*)4RX6:9T7JUTZ/5H^"LEB:-E&"W7!*Q2.Q=>,I%\G%QT5<K5MK6PM
M)ZSN6J(H##NGPJ'24>LTC6SQS,]3RS)<.VGD909]P/H-CGN'8+*XSJ:'TB:9
M'7FLQTN.8-7=FS.Y`AZ3>8B_7%(SZ&D"D*A+1AE4DI)H'E\Z2Z;=P@JZW%?F
M?]P^GFW='-NL>%;K7#1%AB#"^@)]B"Z]4OU47762B;G3)95%`)2!E`0,'Q*1
MPT<$4;.4T7**J1,.TN>L=,_L:^V%;=;Q9'MMV*5>JU1(913K%GTR4Y&KM=L1
MY#RVR3K5QY?6^7*1=C6A5#[TAG3XH>51FL/77:],\1Q]R3K->:K"]VK`,<A=
M#<2F77O/)W0@?J-92CU"TP4[9WZ)3J^?U*_"O7TF5PU](X@)D@^!#!^X/AOW
M?':>4OY,^S=I?&R^*ZCVR).X]">HG6;MC%LI1[U_U&F>GW.SIB7YP*PT0ML]
M%4SM=48AD595*Q4JKHLV-R:MRBK+5I--RLF9W$I#SGC\96[<[76_PG3[XG6<
MVR=;Z?W<Q,K>P:=U2CGFAMG->41=I:5UTM#-FXTR%3?-!.C(LHJO`6QQZYC*
MI((M'8H%,HY`12W6S:)B7.M]5-?MLR>T4_N%GW9N4I=SB*)GM6M3*[9;&0X+
M=DKMC^LTQ-S!Z9&87./JU;[-A2-A81\F60A"R\RX=Q1#M8Q=$BHCK?;SQ9.D
M377PEEO6IZ^[4;J'[D5UZ:9S6M2GW\\G9];S9O,0-7T.O-\ZG-QIL.PHCV]R
ML]4F<#`!(:E1(*'>0LF*,LZ:22Z:**0^==+,F>5ENO#QO9=Z1;3=NSVQ>X'V
MM4D)>XLK_I$?7I:88NH\]RW-ZZFZ%IUL@XUX1LI'47)8GZE4(5,J0-E7#EZ5
M`J*<<AZB].F2W/7#JCY$4$^]+[-T#W[J:VW8HVBZUVWHT#\JR%4S6,A=MKD8
MF=1I2;6]4])!C:F"?BG!S"Q@3(`@R>&!H**["6-Z[8Z7A^?"_I6AT[0W.>2%
M5M4%J$%:CU%U2UX>2;7%A<6TE]*-7#P/H!*!.!*?ZN#4$A5.J($`HB(`,X=+
MBSKP[N^M_M2,.N'35>^=E)N&?=@KY5H]YK4Y99./1@\UKI""XK^5PLF[<$C6
M<97A=&5E%DS@F^FEEE/.HD1N)>VF_7.W+S>Y)C&O#DH[(8=0X'M-`-,2LM*T
MBMR]_JK63:4Z7A+C!0DE)69C'D:S2T<M)PK5E(NU/2.DY,"8G\Q3%$!$.9]R
M:YEUL=?;NWC9M+'=5U1O,ITNU^#Z3:+*NW/7[2GDD;I/>IIRLY+2)9J@YE9K
MJ/8IIVHHIZ44P05D,^5=J"HYBTW$,FH<\>R2/+,?9B7RF?\`**D?>DZN7'KW
MVMKO9W&J99[71NY;IAG>@4BA5Z2L4VAV5KD0X5ITE#0$.W7</'NL5%@NB"#9
M$RBTE&NG#@_BJ3FM-_"]>"Z^<G_:-I^SQJTOT\A=PLW9M.8@\NWFQ4NUP]IS
M=F.PY=C-TJE=?UB[5;?9S.W,_/XSK2Y&S!C*MYR'90R!H8B82)UB*EY-LVW;
M'*]))K+UB(W?VJ4;9^S?<SNKU#V.:B+_``N79W9VFAI0EZ8T6Z9I8\@L'3SL
M3&4Y.:K+)*V6[.ZM:ZR^CYB`55:L`GU?!8[LQ1:SQSST7RQB8RO#]D_H5*=*
MNLBDMH$*X@M>V<\+.6&OR*922]'H\"W?$H%(F0`1].QD"9D)J82`"?*2DRLR
M'S@S(J=;_LEN>>5R_(AP/__6[^.`X#@.`X'*A.U1?KAVF[)=<WJ/T^+C]"F-
MSR1/Q,5M(8YOD[,7AJ2)!4A%5&E*T=S8:\<OW_HECD0$PE43$W?VMNGCV<O=
MG6;=TAZY:0`$_P"4\/N?N_\`[/\`HYTPYMSQ%N`"E\%?WO\`M?\`U\EBLS1N
M(>4/Y7]S_P#B_A'DPN>[ZKRX`)1_E@\/^GQ_]/N<N$RUQ-VT!`W\K^_^[PC1
M5FLX&!3Q4#[@_N_^@AS0ACM9+5I#*&Q'/3&-I'8.SQ.)T<2>H8\?(7PZT?.V
ME0$O%0C"A4XDE/.U`#P3:QAS#]SF?<N-;U^C7MS.T[3JZ^Z33X+/:94:#5VQ
MF59H]8@*?769C^H9I!5J*:0L0V,IY2^H9"/9)D$?`/'P\?#GE=V3\!P'`A1W
MGZ!]>/<&R<<NWBNN#.8I5S(4+1*X=JPO^<3;HB)',C5Y=RT>H"TDDVZ:;Z/=
M(N&#Y,A!42]5%!5$LMG#551]K?#4:U`5+:]#W?LU5ZQ"1->@,_U71`K>+0<3
M#,DHYC&1V!8C$9-C3J+;QR)&Q$9.%DA*W*!/,/B83#/9L#LE8L=Z"=4-3O\`
MD&79SG$I$5=2J9-2LXH]7J"%HUJY*HU?*:9%0E;C8U)Q]9O4DP(J1)(_H-"*
MN#%]-$X@)UO6]&H^N6>UO-NLV/X611M,-,\RRI4*3<+@5RG/O8FOM8^?E7B:
MY?*NI8)3YATN!B@4QUS?>@'P#I)ARNWE;6*]&+!)=<MGMG0JPJJO,LE*O8MM
MZ>2+H#*IP>>,)^+C=9Z]K/'*GF<I9-8;;&R%=2\%5"UF:!L)O)&`',68OT=)
M?*9]4]=XZP89V6C(5AL5$;6)[5GBDC3K9%2\_3-"I$BL!`6?4G1Z3*UZ]5)P
MX%),5OD)!`CCTR`J4X%*`05\]D_:Z86W#]<1IV]]M+MI\=1)J<PR)ON_664K
M=?U>JQXSN;NEV<2E7GEG23ML2T\4YUU*H`)A.*8F*02WRV[K/'/61LSVQME8
M[%DH7>.%)K';+4Z#V4)!)$*V;U:YZDUFJQME7CV_J"*R?Z:<UFK$[5`A1^=M
M)_,'Q*(KRGT[+-^0.!5SV?\`::Z[]C^PU![80\Y<<#[$TAX=RZU'(HW.UI>W
M"6,)$1DC8HG1Z/?:LO;JPQ*)8F<*P"28F],P*',V9BW8:\NF+PVK7O;:ZGH3
M#&V:E39[L_?&`G.A>.V%RL7823;K'*!`7AJYH3V4SRH&2*'\D2#A8Q%'_P"[
M(7A,WAH7OK9*9]O.GG3>HL(B(1L.OUOL?HM:KS%C'Q5>Q?K+)M+I7592)CB-
MVS-C;-Z9U*.9D43!)TDU>@4#?+'`MDS<)GQEM9?V,R"I=DLNF*/+/7L.\7.P
MG:E<8)8&MISZ]0#M&6IU^J,BF8BT;9:G.M47;94AB^84Q24\R2BA#;QGI7.7
M%S&Y^BG8*T]A,:=DUB.CX[?<-O<[B&[LXYI\M"K:93HZ,=%NU415324;U;3J
M19(NQQQ0*7Y9K,?*B)C(G$>?'2\NMQS.'W]9Z*8!JMW>ZLV97;(=ADT$6TOK
M&"W^SY'<K$B@`$3"YIU5\WJ^A*D0*5$BM@C919%%,A$S$*0@%(J^[I=3J7U/
M>]?=^7O6W:]3K%JA.J_:4^SZE/71&7Z[=JHL^:2RZ4,4L73:^I!7[Z$MZL=%
MLW#DZP"LL?T$`)J6V]3$Q<3KRN?Z\SL[.XY2OM9*&GKA66\OG-UL)BB0+)=\
MJL,MF=SLJ28F.9%O8K/4G;U(AC&,1-<I3&$0$1R-T<#XET$7**S9RBDX;N$E
M$%T%TR*HKHJD%-5%9)0#$424(80,40$!`?`>!4%4/9>Z[Y1MNI:[U^U/>>M,
M1L*4<%TS7!IZBTN($6*Z[I>,JUY=T";UC/:C*OW2CMS$UV=B6_S8(&2%-%HT
M01F&KM;C*8F9]!^GV3RQ[/6L%I$S>UU4G#O4-+;OMAUI\X2`@@N\U75WMST!
M8QE2`H)?J()^I]\!0'E2VWU0T6T2O:S[C&GV.(70=4SJ?C+?K%".T"E4BU=<
MTZQ0&H;>TBEB?ZF*E.KM0I$4N*?\HW?&?-3^44SDYK66YK.UQ)KZUXW:^HW&
MJ2E.[@X*Q!WN?74DK,!7FOBG^FG''I$W&IX3,&3'R.AM4,T^;@%%B*EC;,S9
M.">0!6$VMIF?5-;BXO%6P9O?*5MN7TC4:>JC.T+6:'6[G7G+MJD)9:I7*#;3
M<45^T.*Q`]>,E`!9`XF`AC'(;]WG-KZ(<ROMJ8$U7D39#;-YZTQDT]5D)JH]
M?=BLE-SQZZ77!==1CFLR%IH%2];XE,$%&Q8&`WB/WX%,6RV>I>O,5N*9)']*
MN_4AE=:DKM*4#2<XK7=7)IV[W:?OES4V?KRZ7H79JMMK+=962?JR6E]<K&X9
M'#U46B"<N5%%-)NB4A',N5XDO\.BOD0X&G]XP/(NS666G&-QI$/H&<W!H#:7
M@9A(W\FLD;U6,M$OD#I/X6>B7(`LS?-5$G358H'3.4>%EQUBNK`O9UQG#LWC
M<7<[]VKOF*0<A+/(G'C:DTR2BN"R\JXG'/VQ'`*YE-PT=VM*NSG5//2[]!5(
MB"(H@B@F0)A?+KG'5-NGX-U)ZC4VP7"CY#B^&U2EP$Q9[7;Z_1ZU7'+""A&3
MN6FYVPV5G&EFY'Y1BDLLNX<KK+&*`^(B/*F;5?71&R+6_);EL%C9NHJQ]I-B
MTGLD[AI,@)2,)7=#DV['*X*13%58Q)"#Q>N5MHX(82F370.02AY>;FMDE8WL
MNV)Z/AI\PXZ8]PH&2BDSDZY]XM!CZ5H$,@4PL<W[5246+/.-)BV;<A@:QFWM
MH<M:L'@4I#SJ<0[,8#KNC*3:>L76YF+S%KFI8[ENV4F3SG6*%6;]29=3YEY7
MK%%MWK0D@4ZRR$S'*>4CJ'L#%RN9=K(M%$'S1P/JHJIJ@!PRJ%$G[8.*2[7[
M-/=A[>JY>*+ADID2O9_2W5/4B'!B@>#&?>R+K54X@K;S(`DG9"#Z)Q*)A'P$
M+F]SIG.(B![9SR5S#4&^4SBJ@2E$CM#Z':`X.F!U;-:NFDXO8NLMZ7,0$P!:
M]=8KK+*+N%"D<*(Q3%(X"5,@)+Q*M]9_*]_D0X$).]70#KQ[A.4IYAO$`[^9
MA7#J3H6AUI5K'7[.YMV@5!R^K<LY:/4#L9%-),KZ.=(KL'I4DS*)>JB@JDPL
MMG#6%2]KG#B5N#JNX:'O/:&N5R(C(.#HFOZ.I#8Q"Q40P;Q<=%QN!8W%Y9BR
ML2PCFI$&Z$A!R`HHE`H''[O!Y=HS/L]8LEZ$=2]1NF*99G.=V%O7!HV-4C.*
M95:0A9]@O:R55RJI1D77H^*;')(7619F7*FF;T&:*R_E$J(\?8G6];T:VP+/
MJOGW6W),*3,SFXO.LII^;NU7"1%V\]]GJRQ@I20=HKI@5<9UR@JNL!R`!S+&
M\2_'PYUQXX<KMY6UB'0V>E^O>M7+H/9%U9#-4ZI.[9U!EGRX+JQV4-[)%0^G
MX*X4<>"SA+%K3;XQ>"\QE3C69U!J'@2+'G/:8OT=)<S/JG?O'5W"^RC"%;:]
M14)R5JSA1[3;K"RT]2=)HSY44SJNZ3I5*DZ_>:J9PHBF9=-D_10=^F4JY%2`
M!>0_I75VG]J^%NV&ZRK6-S[;7W4J]29>V8-$7?=K%.P%>UVE,@LF;.PB8QK!
MN+4I]K(9H0"S:\H4@JBH0H*E3,2YO=9C/ZQNOVR=FCMIQ1A?XI5LC';%5J1V
M+)!-B`@VJELU)K+PFQUUDB!C%63<[9G]@L3A8H%\SNR*>8H?>F.O=/I>8LJY
M`X%8?:SVH^N_:'>\W[3H3%PP_L9G,E'NT=:RAE05IJQH1+-=G"JV*$T6EWNG
MR-EK)%2&B9I2.-)1XH(>50P-F@-S4VN,>C8]>]MCJHE)QMFUJKV?M3=XM0J[
M2Y]M;M8.P+MFY33,FDYA*E>G+W,:@JAYQ,F$)`QA$U!\Q2@8"B!,UHWW`;!2
MT)?J=TQJ$/!126D;33MMOE:@XUC&PM=P[K!9X/55Y!_'1:*2+%"T[%"U*#9D
M%,A'7S+D0-X-U/"R9N$SB7:LR["9-3NR65V"@3SA]'A*I-)&!LT&Y%C:*1<(
M5VA+U*]5&51$KB(M=/L+1N_CW*8@9-P@7Q\2B8!Z8]*YRXN8VWT1WJY;?D,M
M!;`DQ2[`X!>)'$=Q%@@@TCIRZ5V$A)N&TB!8I>'R,!K&?VB*L39(I"%:&DE6
M8?%L<.<N.CK>\XK(-3Z0X+J-Y<ZNE&VS+-@?-TFDIJ^(7:Q95<["V0*FFW2N
M9JN\;5_01:H)%20//L)-1LB7TT3)D\2BELX3[JK.\'4NH]3!PGM"%_VS6Z\U
MUAEUZ[.CLVC2-U9S?6OM,P'(+.@,&@A#4Z&)%WN2K[H3LXM!5<Y@%50X((IA
MJ6VR6]#$Q<1<EUBFI^8P^DM+;*NY^W4H+#E-NLC\`*\M5IQZU3F5V"WN"`4@
M%&X2E/5E"^!0**;PH@'E$.9&^^`X'__7[^.`X#@.`X%6'N>=/[7N5-JN\8;%
MIO\`LCU[1FGM>KI%",S;-F$P1!Q?<3=O3F(BE)S!HYO)5U=QYD6L^R1(;TT7
M;E0+KM=;+#$LNMX4S9GKD/=8)I/0RSM-(ZKEB_C)1LM&SM?FXU<[*:K5DAW0
M$>PED@)%%1J^9KE*LV<)F(8/$/CZIM-IF//9=;B\M]QMS``*'J_'P#_M#^]R
MX_V1E*5V^]_]]^]_VN!]=U=?$!_EO_YOW?\`U<#!I:X^(&\5?N^/_:X1HZZZ
M#&0D7)3,S)LXN(BVCA_(R3]PFU9L635,RSARY<*F(FB@BD43&,80``#CI,U9
M+>DY6"^TYU7L5MM'Z^NO0;R&;2E9?5KJ53)EHHTE(G.+4DV4M&X3;%R!7+"=
MUQD@W;PJ"A$EF59(*AP$TH<B7FWV\K]'HUU\9CU]5^/,*<!P'`<#1G9+L=DG
M4S&+KONX6)6L9O0VC->9D6T8_F9!P[E9%I"P</%Q48@X=O92<FY!NT;E\"I%
M46`RJB213J$+);TCA=[$^]K.=TNXE!L$W7GE%ZVYC,NE\4SB4>-EW#6W/&Z\
M275M%%D=2.D[ZYB7:[=@D119C7T')TFIE5SKOG&O;L\NJ[Z7PLG+H(Z^=AV%
MHAHMRWD$UB.&Z)P$%2F`P&*4?W##^X//18\LM;#L^JT2#[Q]"I2UW2JTA!&.
M[6R;R8M=ABZW'.8!IE$)&R$661E';9NHJK.SD2Z]$Q@()6@G$P&3(4_'><.V
MES-EMWZ?\'\AE/TV9'Z94D5C*?I(IOD*BX\WRZIC?6?*"2_E'R&^X;P'P\>8
MQ>S3QI/M!UNB$16>[UD`&$ACH,VFB522E'QBF3(#>+AXZ5=RLN]556(1-!JB
MLLJH<I"%,8Q0&"NGVT:=(YK*1N;NH!Y".8JC[MJCJ&DF:[.:I&?;_P!I;/:.
MOM8GV*RI%X&1D:35I1R#!RE\PD9%0H^F)#E/J\2>IS;5Q?,AP'`J^]S'W4\*
M]M2BQ+N],9F]:]?8R9=97E$`BHW4L!HCTF[B9LMF71/%56IL)%V@DNL/S#]4
M5!!JT<>FL*4MPUKKY?9R9]-?<FMVZ=A]2UC=9EN]V3495@H\D4P%G$Q-,AC.
M$JCG]+CSJJ_1*94$GJP(-0.HLJY<+.G*J[E=14W?V;,6?Y.?O:V8Q^KINRG9
M&DVQ:B#LBA3ID'P]0#?=`/B7P$>;NKE*]?I+L>2U_LI[@R5AU/.JJO)['AS!
MK`6&[5V"DY";C.L.:JS$LUBY&0:G>E58+M61W!`,J*D6HB<`!L7G#;]J[S]=
M5E1^P6"IIIJJ;=D*:2PJ`DH?2:85-4453H*@F<TT!3BDNF8AO`1\IRB`_$!Y
MDYX0>]P&UY9V:ZM:?URRC0*+I^JZ:O1H:GU.CVB*M\I'6"+TBFV%A:II"LO)
M%2NP=-<Q1)1R^>^BW2(T\/$ZAB)*63CL9PDUU+FD++2-!L$49NK5GV\;,PJK
MIL`^E)-:G<WM(LTV0_JJ$<)V#0ZS-/TU2`0BR3DIP`WF\YUY)Q$I>0.`X'-%
M[Q/OPUCJ<>_=6NKP.+'VB9MP@;9?7L8):9B#F39-W9S,DY1#T[MH+>+>D4;(
MII*1#!94AW*KA1%9@,M;UUSUO"NOVR^W%;EL^B(1H]6)*)NW\A9%9205?SDQ
M:YJ0<2]FL5@DG2AWDM/6&;>KO';I4QCKK+"?[@@`>K3%UF'G]R;3>Y=!].U*
M-D8L7+UZBFS1;'<.'"RA2I(H(IBJJJJ<P^4J::91$1'X``<EU27T?<]KS=\1
MBO;\ZJQLIL^41KV-QJNNUX5_HM19R58AWRK]S!PLQ'N)=->'<PD49)DJ@<`(
M@JV.D4QBD\P^>2]G?;FI[N.P>!M3J)NMOR!LHCYA63<:53$3I`0/$XJ$4FBF
M3\@?$?'P\.$5H=P[+E^J;QUBVNEV>OWFF=4:OVBOFN7>K2#:P5"#IERR5I7&
M]+7LT6HZ@WMAO5A08IH1:"RSLQ6HF.F0HD\^I+.J7K,>JV*A-)EA1J6PL8D-
M8653KK2>,F4Y4S3+:'9HR@IE5<O5"D%\0_@!EEC`'W3F'[X<JRS@.!XEEL<'
M3JY/VZS23>&K=6A)6QV&7=^<&L5!P;%>3EI)R*9%%`;L6#514_E*8?*4?`!'
M@<,'NE^_9!]K;5"8!@L9/1_49C9(YUJEAG&BD+8][2B9%%VRAUH53S/X#)TW
MS1-RLP<^E(31`*1XDV2!1HHEGE,\.GA9K<7\EI'4_M/$7>M0K]C*(JI.&;4Y
M/26*)0*=),0```?#R^`\]6)9'CZRXK?G<+1:^OCN:&D9R*@'SSMMTB2@K%+2
M32(90$DR[;XS-N9M6:=+(_14(N"B7JRSLA@,@W(H8P@F!Q#E[G2.OMW.W\5<
MNW[!X&\217:;?D#I!Q\S\NLWTJF+I+_)F5([]%1.:,17Y4Z!P4\HCY!(8#>'
M@/.>+V;?4<]D^NK)(5WF^8JT0*;RBLYU.C()`;R**>45%9TA`-Z:1C>'C_U2
MB/W`'D%8=/\`IQ.[J-\IY"DC.S7<1EH5#%=L\1;V.C8WT"L^5Z7JK)@(E5)6
MYF=.VBF,AZ9&K]VX:.2BH5<%#ZO37%)UM[2+IN9#@.!H;LQV5R'J+B]PWS<[
M"XK6<TI*/^JOV45(SDBY?3$BUAH2(BXJ+0<.GDC,2[Y%NB`@1(AE/.JHFD4Z
MA2R9N(X:]]][*8[J]R*%8K!6EZ)UVRZ8?*X9GLH[:NG;&U/D'$,;5-`5:B9@
M^T"1A'BS9DBF=9C`-W*B#4ZRQUW[G7MV>75?<UOAB?RZ"\![",;-$1SA"035
M*NBD8!!4#`8#%`?`?`>>BS/V>65L.<U?.X#O-T?D[C;ZO3"$J';%^><M5BBJ
M_&_2F]'H+)]'&<S+QDQ*HZD9-BN!_,*I0:&*4/(=40X;SAVTXV6Q?K`8-Y1/
M^FW(O(5)%8Q_TDTWRE1<^/RZHF^M>`)+^4?(;[AO#X>/,XO9IY$GV>ZXQ#91
MT\W;)#`5)19)HPT"KRTJ^],R9/0BH6*DWLO,/5552)IMVB"RZJIRD(0QS%*,
M%>WMGT1WDOTS*5H69B7,-1M<U%U$RI"-)*DT7=^R-ML^&U.T19#$&-G5:G7I
M-8C8Q/,V])P7[WS>!M7I)#FV^BWWF0X#@5G>Y1[H^#^VKG\5,:*SF;KJ-ZCY
MQ?*,FKQ%6CRWN(,S!N^>3-H69.H>H5F.=RK8'3M8J[H2G'Y5HZ.0R82UK76U
MR1=3O<SMW8'L[J.Q[F_9CK6F.HQHBLV,HW@JWG\`J\^R6<TABNJL,-5*P,BX
M4]'SG7>/'*KQVJNY6.H/;V;+F>KG[VMZ6?JZ:LGV9I-L&@E=D4*JFF/@"@#]
MT`^(>`_Z>=+'*5[_`$SV?&Z[VA[]L[#H.?TR6<WSKJP59V:\5Z%DIN4)@$`^
M!RTC9A\Q=&(6+?-D`](JB9S-S^!O."A"<-I^5=Y^NJR@_8'!4R%44V[(DTSF
M4(0Y])II"'.D<4E2%,::`#&34*)3`'Q`P>`_'F<7L(3=_K]C6_\`537NO]"O
MM1U'3-3BXBJ42CYQ8(.\64UT/9:_)UB9?1D"ZDU(.OUF90:23^3>`W:,6B(J
M&5*;TP-9+F&<)"=1)E"QU;6)^+=&D*RZWO18.N293"9G*_H\)!Y=<I&.$?#S
M,W6G4B=-YP^]64\ZA1,4X&%>:3I(EER!P/_0[^.`X#@.`X#@5!=WO;"_3!;)
MKL+U=LT'D_8>4214NU;L:+S]"^]BR;D:M5-`90Z#B4J%^;M44D6]LC&[AT9!
M$K=\U?(@GZ&M=KKP63:8V4>7.^W/!IYO2^S^>6WKE;UG(LV1=#11"@61P0PE
M`U$UV-,YS>YH*_`2$;2!7Q/,!5FR1_$@=Y[FE^E<;[>TXZQG#._H.VZ3EJ]1
M<MUR%41<-UBK(*IF#Q*=)5,QDSD,'W!`?#G3GAS?RXNX`4PBL``4!$1$?```
M`\?$1$?@``'(-2M=A1O-L3SK)HBS;;ICDP$;YYCT,XOUD2,8YR>M-C$">%IT
M:EZ9C*OIIY',4"%,918I0\>9VWTU]>K>NFVWIT6P]3/:6MMOGX/7._"%<<L8
M=RVEZ;U*KTHWME'82;<2N&4WO%G31+%:7/Q;P"J-X./`U;:+(E446DS"`I\-
M][O]G;76:<<]W0"4I2%*0A2D(0H%*4H`4I2E#P*4I0\`*4H!X``?<YA7]<!P
M'`<!P-=ZUE&>[IFMTR'5JO'7/.]!@7E;M=;E4S':248\*`CY5$S$<,WS-P0C
MAJZ1.FX:.DDUD3D53(<!+CK'YH7NI>V1I7MM;FI7W/U*T85>WDE)XAJ*A`.,
MK$ME@46J5J<-FK-FQT*KHK)%>)ID31=HF3=H%*10R2.;,.TLVC.^A?=V2IKM
MC2+C+"FDT(!6$@[<>1-5HB!?O55%#%*51`@"(B(_$H>/[_AZ/;]R68V>?W?;
MQ?+7A.:Y=@H;=+0'9BA[8O6];Q1>(A>J%)RJ<C9S=)UA#S#W]-MEC:8A&75:
M'=[!"2#FN01)>(,U619-7CA%1LZ*0^=KKMY;9^RZ:[:XF.EY_P!?1U<PO3W>
MWD(E+0?N(]HC(S;%M*0K?1LPZUR4E$M9!$CMHTG8QMBE3='D6[=8I'*9@:G*
ML40\J8@)>8\JN(R>-Z:[8J=E]J?<`[).D$4?*_:4FD=:*.G)+>H4P_ZVMB-H
MEX]J=+Q(8K=RFX#Q\Q%B"'CQFF)V2AQ[#,\PV)F8^CL9121M4L6PW6WVB>EK
M;=[Q809-X\)JUVJ>=/922<),VI$FZ`'39,D2@DU001`$P@V_P'`<"N7W-?;I
MS/W'>ODCF5G,TKFFU<K^?Q33A0,HZH]R4;$*+:0]`AW#ZEV<&R3689@4XG1`
MBZ0`Z;-U"2QK7;%^C\T?5\JVCIYNUGR[2X&1H6L9985(Z6CEA,*2ADA*LSDH
MQZGX-YFMS[!1-TR>(B9!XT6353,)3`/)+=;F.MDVF+Q5W75;W)8"OYP\G[J_
M42>5IBF16'373^HRTJ)1281$614Z157<JZ$J:0F$J9?-YSB4A3F+ZI[FMUMK
MR7VMIM)$T.AL?,VSM?28S,.V>C0ET[81^G2/:JQ]17M(TNI4S5X@MDU7)AMD
M[9LXUZ@+4NEP,M*T[U6ZK!RNH>.6*Z*V%4#<;9,67K>722V677\9Q_K_`)=&
M2G33LBBDR2CO<1VU;TC_`.OKV;'^N4ZZ=H^)/`K=1CFU?29+^`&`3F36*/B'
MW@>`^:>53$9`VZ06.;*]9:SW([4:;69(%FTC1VDKDV2UB1C5B)D48NY3'<II
M.F$]0/4*<[:QM@,FH``4#%\XO*KB=DTZ?4*OG]5KM'I,#&5>H5&%CJ[6:Y"M
M4V,3"0D0U291L9'M$0*F@U:-42D*4/W`^/B/QY!D?`<!P.:GWXO9X/VXJ[[M
MAUPKQ#]F*'!@%YI\<0$U=PHL$Q5,DFP:I(',^U*L-$"IQOWQ5)5@460^HLFQ
M($L;UVQTO#AUQ78+3AEX0FHY1XV31=@VG(H_J('$$%?36!1`X%,D[;&*("40
M`?@)1_T73>Z7Z-;Z3>8]70JAWU@[GCC?,8C1:K2K1ML0]I(W*V6.,KT%G-0F
M&*C&[Z'+R4M(1K1%Q78!PN$4U]4KF2F3MFR!#F,;R^C;;6R27K7FUTVFUN+B
M+1?:RR*TZ8RW3*,'[D]G<RP;'K=6+!ACO/*WET]ATE1=693E@L50K4QJ>)VB
M2D[%5M%CI5RY.SG56(QDNP%%N0XK'YQMDMFO#IBV2[3\EO).G?8TKY83^X-L
MIX@S;TT$0QWKF$ZDY$I`%P>;4SA5DLF!O,($^0*/Q#Q,/@/FGE4Q&>5+I7!-
MI6LSNQ[;NO960J4M'V2"C=<GJ7&T:.M,8H5S'3I<\R:AYG4IE>'?E!Q'EF6T
MM\BX3273-\RBFN5;:O3LFCR!P'`^)=!%RBLV<HI.&[A)1!=!=,BJ*Z*I!351
M624`Q%$E"&$#%$!`0'P'@?G[^^K[.[WIY<Y3M)UXKJJ_5>^S:9[-78XIUU,(
MO$Z[6_\`PE1L4ICI9E8GAR_2'7B*<>Z5^FK>F`L#.LV.NNV>EY5A]+.VLWC%
MD95J7D%AK;M=)-FHHJ;R,53*%`$!\1\`0/\`]G]PH_#][G7V_<Q^-<_=]O/Y
M3E</J'8'(NVSB)R>[;-4,]SC,F\C:)"3=VYJSMEDW2:J<W7,RC:+7V+XEDF3
M98$VYGGSAN@X:I2H1K8_\J"A`WO==KBWI/[<]-=M9Y37K?Z="O2?&NR/83K%
MB^W67N[W!HMHO%0(K<*/>J%@(J1EO@922K%F=0S2Q=?J_8DJ;.3,*L^@A?IJ
MNE89RV5467$_JFY>5;LDO1*>'Z>]@RE(2S>X!MCTGS)#*GJ64==*DY.S`">H
M@5>1S*W@F[.(&\%O*)2@(?R8^'B+RJ8C=V.]4\XQZX36G!+WS3]@L,*-8E=<
MUNT&MEU"JB_2E1JD&BS90E1IM;5DVZ;A=G"14:B[612.X!4R*(IRW/*_2),<
M!P'`UOL&19WO687?'-9K$?<<ZT2OO*U:Z[)$$R#Z.>`4Q54%B"5=A)QSI--T
MR=HF(Y9O$4ET3D53(<!+CJ_,^]TOVS=.]MK=5JR^^J6G$+J[?RV(ZL9H<B,S
M#).#*&JED=-T$F#+1*HB9,C]%/R$<I"D\1(1)<$DL\.VNV9]6U>A7>"0JSEG
M2;G+"G\D0OR<@[<`1-=HD`>(JJ',4I%$"!]]_H^/[_AZ/;]S,\;R\_N^WB^6
MO";=M["16V6TO9^C[2_KFL8T_KL)U=HF/SD;,[[.5:'F9!OMMB85!&&O0PKS
M:H*PN8."+,1)V2B+%BY=M3H."E4SM=;Y7/'"ZZ[:XULZ7G_7T=6T3TZWQ>(+
M(PON(]H3IR[1"0AT-&R[K=(2,4V>IE<M6L]%I8E3WPR+=NL!'*2A6BA5BB`D
M3$!(&/*KB=F1QG37:U56!K5[@'9)XW;D+]08TJE=:J*C*JE6*<Q#NU,3LTS'
MLUD0,F<K5TDY`#>9-=,P`/&:8G9*3'\0S_#X:6BZ0RE%7UFEAL-SMMHG96UW
M:[V,S1NP-.6RTSKIY*2CLC-HFB@EYR-&3<A4&J*"!2IA!MS@.`X%?'N2^WKE
MWN,]>I/);J+>OWJ`%]8<;TY-F5S)Y]=SL_1355`OE<2%1L`))-YJ.`Y2NVY"
M*$$CINU615=;BOS/=IQ?;NF.[V3*=4KTC0M4S6;]%TW/ZORC]N4_J1L_`R'D
M21G*M8F7E<,GB7BDY;J`8/`?$"YELN9R[=-I]%U/4SW(8*!SUY.7J060<55B
M7YN-0,"LE)/B@5)C&Q2!SI@Y>2[HQ$D/,)2><X"<Q"@8Q?7/<UNMM>3;VK-I
M)ZIM]%!E[5VTS]?/NSU_:W_MR31#]II#J5*U'3:U0+A'QD[H.)C;YR1HVGT%
MQ4<OB#N:D\535;.5#OFRZ;M-MYQ4X6SI9?RO+I);++/QG'HZ/E^G_8A,C4D9
MW]V$?(J`O#V+)<$GE%VX>'B1L=M1806C@?C_`"A_7+_]C]^>7TB8C)6W32S2
MR:[+2^WO9N]03L11?U>'E\WR:'E8X_I>M'R$ME6=56_I$<`4Y#G93C(13.(!
MX&`#\>57$2\I=,JF=5.NT2C0$95:?4XAE!5NNPS4C.,AXF.1*W:,FC=,/`J:
M29/B(^)SF$3&$3"(C!DW`<#_T>_C@.`X#@.`X#@>)8JU7+?#/J[;:_"6BOR:
M7HR4%8HIA-PT@CY@-Z3Z,DT'+)VEYB@/E4(8/$.!`JS^TW[=5I?+R*G5/.ZH
MZ<>J97]%CBTXRW%18HE,N5ED=AI+)-T7Q\2*E3!5,WWQ3`/QXXX7-]7BP_L_
M^W'$&;BMUGA[25N`E*CI%_US56RH"X^9#YQKI=_MC9^)#B)2BN102(B*1?!(
M1(+-O-,XX3QS[,,UR6OH5+*L\HV9U5KY/EJSGU2@*97V_D3*D3T(:N1\;')>
M1(@%#RIAX%``^X'"<LYX#@.`X#@.`X#@1[[2]8,@[B8C<\"V^NDL%(N++R`N
MB#=*>J\ZV*H:%N%1DW#=U]&M-?<J>JU<`0Y1`3HK$5;JK(J%EQ<N6?J-_P`L
M%+TWM!-6/M9HE/T'K90+!\]0ZU4%IAI9-L:E,#F);Z`S6:M242`02.1.79M7
MCY=XNFJW06*V,5XI,-W?ITY==E*SV@YM#I5[.J/3Z#7VY$TT(.E5J%JL.BFC
MY_2(E&03)@R3(EZAO*`$`"^8?#[H\KFS#@.`X#@.`X#@5">[5[3^>^Y/EC5Q
M$N(2@]E,_:+#EVHNV1OE)%B)EG"^<Z"LQ;+R;VD2;I8RJ"J9%G,,],+EN10B
MCMJ[EC6NV/LAE[2/L(T?J.V<[#V]B<^V;?I,HH5NI'9(W#,<GBQ`/%RQ0GXQ
M)G9=`>B(@I)':^E')?R+(1$RSA9(NVV>DX='S)DRC6J#&.:-6#)L0$FS-DW2
M:M6Z8"(@F@W0(1)(@"/W"@`<K#[7`<!P'`<!P'`Y=_=W_P"7_7[:Z@CV,Z?2
M%#SW4KG,M4]II%M<NZ[1[4L[4307U"%>0D++J1=O3$?5FVPMQ2F"@9V0Q9`%
MBR$L=-=\=*M`]NCVHNN/M_Y1"U^/K-9TW:79$I*_[A9ZO%NK++3ITO!:/J)Y
M!)^\IE*C!.9-G'ME@$X"*SDZSA0Z@I&;MG[+2.5DX#@.`X#@.!CUMJ58OM8L
M%*NM?A[74+7#R%?LM:L$>VE82>A)5LHSDHJ5C7B:K5ZQ>M53)J)J%$IBCX#P
M..K0?^5KG)/N$FK0-<A:[TIFY@UFDOG'3YULM+B#.@</<SKS-Q%NX:=<&$PH
M1LV\<E!LS'U'2#EPAY'DPZ>?3KRZP<'ZS8+UEID'0\,RNF9W`P,0SAT5(&#8
M-YR319H)H_.V2R"B:=LTR]%/U'3U^X<.G*PB=0YC"(\K%MK>O"'`<!P'`<!P
M(Y]K.JV,]S<2MF";K6BV&E6A(B[=RV.FUL%3L;--<L+<JA*G17-#V>!5<',@
MMY%$E$SJ-W":S59=%0LN+ERX=1/^6"E:=V;FK-VMT6HW[KA0+*9W0JI45)=I
M9-L8I'^9B2:$V4;MD:'7B)G3)*,6CQ^Y>K)K-TEDFXD=JS#=WZ='7;3,_H><
M1"-?SVDU&AP+=-%%O"4RMPU7B$$6Y3$;I(QL&R8LDDT"&$"%*0`*`B`>'*YL
MNX#@.`X#@.`X%2ONN^U-EWN3960Y#1E&[(4*)=IY'K!VQ_3,CZB[[]'M]^42
M4>2E`EWZYSE,4JKJ&=K&=M2G`[MJ\EC6NV/L@5[2?L"5/J<[/M_<5M0=AW%9
M)5O3Z`V:A:\ORYJN55)677^O1K9K<KZZ:J^0BYV9640`G^6%=8Q'2:1=ML])
MPZ5&#!C%LVT=&,FD='LTBH-&+!LBS9M42?\`41;-6Y$T$$B_N%*4`#E8?;X#
M@.`X#@?_TN_C@.`X#@.`X#@.`X#@.`X#@.`X&O--NCJAUPDVT9-WZIY)JQ]!
MRHHFF!%TG*@J>9+[[S%%```/N?'EUF:SM?&91^_67G?S9B?PMY_!S?A.['R7
ML?K+SOYLQ/X6\_@X\)W/DO8_67G?S9B?PMY_!QX3N?)>Q^LO._FS$_A;S^#C
MPG<^2]C]9>=_-F)_"WG\''A.Y\E['ZR\[^;,3^%O/X./"=SY+V/UEYW\V8G\
M+>?P<>$[GR7L?K+SOYLQ/X6\_@X\)W/DO8_67G?S9B?PMY_!QX3N?)>S2FF]
MZK;1)9A'-*)77Y'D<#TRCF1DDS$,+E=#R%!(/`2^"(#^_P"(\L]N7U/DO9K;
M]I'=_P#+:J_E67_B\OQ3N?)>Q^TCN_\`EM5?RK+_`,7CXIW/DO8_:1W?_+:J
M_E67_B\?%.Y\E['[2.[_`.6U5_*LO_%X^*=SY+V/VD=W_P`MJK^59?\`B\?%
M.Y\E['[2.[_Y;57\JR_\7CXIW/DO8_:1W?\`RVJOY5E_XO'Q3N?)>Q^TCN_^
M6U5_*LO_`!>/BG<^2]C]I'=_\MJK^59?^+Q\4[GR7LDQ6>UMAG:_#3*M4AD%
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M>Q^TCN_^6U5_*LO_`!>/BG<^2]C]I'=_\MJK^59?^+Q\4[GR7L?M([O_`);5
M7\JR_P#%X^*=SY+V/VD=W_RVJOY5E_XO'Q3N?)>Q^TCN_P#EM5?RK+_Q>/BG
M<^2]C]I'=_\`+:J_E67_`(O'Q3N?)>Q^TCN_^6U5_*LO_%X^*=SY+V/VD=W_
M`,MJK^59?^+Q\4[GR7LS[..^=NN]@/#.J%7&*18YR]]9O)2:B@F05;I@3RJ!
MY?*8%A_T_#DOMR>I\E[-[?K+SOYLQ/X6\_@Y/"=SY+V/UEYW\V8G\+>?P<>$
M[GR7L?K+SOYLQ/X6\_@X\)W/DO8_67G?S9B?PMY_!QX3N?)>Q^LO._FS$_A;
MS^#CPG<^2]C]9>=_-F)_"WG\''A.Y\E['ZR\[^;,3^%O/X./"=SY+V/UEYW\
MV8G\+>?P<>$[GR7L?K+SOYLQ/X6\_@X\)W/DO9I33>]5MHDLPCFE$KK\CR.!
MZ91S(R29B&%RNAY"@D'@)?!$!_?\1Y9[<OJ?)>S6W[2.[_Y;57\JR_\`%Y?B
MG<^2]C]I'=_\MJK^59?^+Q\4[GR7L?M([O\`Y;57\JR_\7CXIW/DO8_:1W?_
M`"VJOY5E_P"+Q\4[GR7L?M([O_EM5?RK+_Q>/BG<^2]C]I'=_P#+:J_E67_B
M\?%.Y\E['[2.[_Y;57\JR_\`%X^*=SY+V/VD=W_RVJOY5E_XO'Q3N?)>Q^TC
MN_\`EM5?RK+_`,7CXIW/DO99CD5W=:1FM.O+YBWC7=FB$Y)=BU445;MCG663
M%-)1;P4.0`3\?$?C\><MIBV.DN9*V/R*_]/OXX#@.`X#@.`X#@.`X#@.`X$*
M^\L'ND_G6>-,-0W!THAL$"\U%KUSM^0TG8'.5H4^]%D4JE-;?9JE0_5^V*D(
M9PBJ](X5;%/Z13"`APLQZL:ZVD-M4=@.HTW8MKD,XQAMN=(MU2UMV]C-?MFV
M,;2XS2=A-Y:0Y8>JR"V-NX.=9$:%9NTEI-9N[;KE(S(H[%Z)!=B?[`(__$$=
M_LTAS>G+G[G$^Z`%BAAL4%*P82TU!?562[+ZQ77I8V=C07()!=14@9%P#-ZD
M`^)%/(82#\0^/-N4Z(6=-H2T/'NS6.SZWK5Y4I^[[3D\)$7*V)3$$A5ZE:6[
M*#74CRQC45)QJV;>07?G`Q@.<!#[X>9U]>OJWOCITG"=O-N9P*L=;[8K57N!
M!MFVQ5:(S#,KYEN"Z%DRM@JR,W;K/NL3++/KP6,<NC6%9IF$_8\_3*JW2]%%
MN[G`6,7T3"GBW\N>CK-?QXZWJM.YMR.!%#L?9[FM=.O.+4ZVR>>EVR]VME;+
MQ7T(U>T1U0H&>6*\R4'55)AE(Q\5-VM[&M6@OS(+*,F0N3H%!?TE$\WTC>N,
M;6SAO3/*9)42#7@9"_731$PE';R-E[ZO!/K!&QKE-OZ<$>5A(*!-+LV+DBIT
M5WI%WWD6\BJZ@$((6=/5FW/HC[V(_M/"?[A#_B#WF]>$5WZ;)V:R[!G&-PUK
MFJ/!S-(T+2K7-UH6*%DF&M-F*%6HJJQ4H_9OR0S9U(7KYQZNBE\T9)F1)-1,
MJBAN+S)EJ8FMVQFMVU6$>UR!8PLA99RWN6)GA?M!9`BOK;QNL^<N62+\\)&0
M\>NI&LEDVI50;D5631*=83K&.H:QFW-SAD/*-1;W>Y;,L;T6]0*35:=KM9>N
MH4'Y#*,$99<4V4<[?HD,0Z[%B\=$663`Q1433,4#%\?$,[7$M76>6TC[=!SN
M>ICD7<KJV@7X[N*3;2K2VGK2D8O-E5154L$4VBJ]&NH`ZH`JG\DW7^0!)0O@
MEYTP4&R8]2V7_&1M+E0X$!;-V%4C.SC%LGI,"A0H2\5?K_-9P$Q`%E9*TW6N
MN[`M?B1JK@TVZ2A+?*UJ`*9(B:3?SR0G$XD,4G.[?ESTX=9I^''7&4^N=')8
M;GG]A:G_`+ACO]F)SG>:*X[GVQ6ANZ,8S1V*K-LMK>ETGJI8\@"P58LY,7;2
M*D_M3C4TX==T>R/4:W?YRG54AT4TD&GJ3`G,H*9RIXS^7/1UFOX<=>5IW-N1
MP(E]A;'<Y+3>OF%U2XS&=1^N2.CS-TN572C?M<6KYE5V4J>JUA_+L9-E`O[/
M,3S3UY`K=5T@P:N"-Q265(X1S>9&]<8VMG#?U`J,E2*^6OR-ZM^A?+O'*S&=
MO2D$ZLB,>OZ9D(EY)0,'7T)9*/.!RHN'"!WITA*"ZRQRBH:QFW/HS;E1I'LK
MJ,EB77W:-=AH]I*S.<9I<;?#Q\@"XQKJ6A(1X\C$Y3Y4Z;D(H'R:8NA3,0X-
MP.(&*/Q"6XEK6L\MI&F:4U<9OK.<UF[;YV#O-XNS.6:N?M!7:\3%=!G$Z?)V
MR10@@BJ$UB:?]!9Q2[M@A%OVJH(H`@Z5>',<QYQ>:MZRXDPEM:?[,6/_`'#+
M_P##W'-3F,*P[-,_9VMV"P?+F=_0H.6F?E"F\AG7TQ@X>_+E/Y3^0RWH>4!\
M!\/'[G-W@G6R-#X37KG-5;.M8M.LW.>FKK48RV6.L>2N(Y^?[70B$NUB(2%)
M`FD89E6%'J1&BZ#TKIR1$1=G7%0WA-<XEM:VLENLUG1)/FF3@1`F9FQWW0]G
M9.[II-:JN035-ID/6<D9-36.:E[)1JU>I&VSBIX.;EW[=N%J19LVZ7H,4R,U
MU%B.#*%%/'6V];B-])->DS>Z1N=3D?9\^HEEB9V1M$58:;6)R,LTNR:QTM8H
M^6A&+]G.RD>RCXEFPD9=LX*X711:-4DE5#%*DF4`(&IQ&;,6S#,N5&"Z??(O
M+\[NVB3)B?3J969BPKI&4(D+Q2.9*KM8Y$YQ*474F[*FW1+X^)U52E#XCR6X
MEJZSRLB//4S29BQL[YGEOTB#U.Y4!_6IAU;X"4@Y6/DH;0J\WG1007@5EVB2
M5?NK:=BD$1.HHDP8MA,<WG`>9TN<RW-:WUQBR8E678#_`&Z6_P!PR'^TL.7;
MAA(/:=0A,4R32-:L1D_I&=TRP6MR@=9-`T@K$1R[IE$-U%#%*+V9?D2:-R^/
MB==8A0^(AS%N):LF;(B;T/V&PV]AJ&2W_8*UM^A97*4VPO;_`%::K,Y$S%>U
MBIM+,+5LZJ[ETP10JFCL[/!M6YE%E4(N-9B=0_J%'DUO,SU;WF,63$6`<TYG
M`KX:4NT#W7DZ,;<=T/3F.*UW9D:T>\HC$FM#_6;+$.8U5M]%#SU4\7%)-_D/
M'R`EXAYOCS&/RQFNF9X9\9G*P?FW,X$#^WD%:&]LZ_2E;UW7*0EH>]4+*;)#
M4ZVI0\&K5Y2O7N6?JM6(Q;D6TTY=Q"'F=><QO(3R@'AS&WIU]733&-NDZ1-F
MOQ`P$'$P@RDO-_28]K'_`%>P/"R$Y)`U1*B#V6?E1;@]D'`$\RJOD**AQ$PA
MXCS3"+/8C^T\)_N$/^(/>;UX15],S-CONA[.R=W32:U5<@FJ;3(>LY(R:FL<
MU+V2C5J]2-MG%3P<W+OV[<+4BS9MTO08ID9KJ+$<&4**<ZVWK<1OI)KTF;W2
M-SJ<C[/GU$LL3.R-HBK#3:Q.1EFEV36.EK%'RT(Q?LYV4CV4?$LV$C+MG!7"
MZ*+1JDDJH8I4DR@!`U.(S9BV89ERHTAV#N%CIN>)*5%\E$62V7G-,VB;`NS0
MD4JROI6@5RD*V;Z>Z`6KU>":SBCE!)8#(J.$TRJ%,F)BCG:XG1K62WKQAE]&
MHTA2C2A'.A7N\-)!.-%NWO#R"DE8EVT!Z60=Q[^,@(=\)9H'"(K(+'5;H&;E
M^7(B!U`-9,>J6Y])&P.5#@0/A+K)V"H,MPN^HZS7&<W=[6UA(3.H6,>TFDP%
M:O[^EQ$1:&2M3G5))Q*E9)_4W,D<3BZ66*T!J5$GDYYZ>5M=,8OC)$\.='->
MOG#.0>]+J\E&36B5]VEG"CX)')6E??Z69M&.G$B^BZ2UL\3.0ZEAG6+51BW$
MS<7!3.?,V.BY!)9/S;_M7HTXB*?5`=CWBNW>ES>S;#6F6+=Z8RS.:UJQY&M]
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M8B8I(&,H`<&.N(P:T^Y'@]?T+K_1V<;J$LWW:;T*O_4EL6W2"FZ)*T&%?/W$
M59J%,94WN+6><RC+Y1Q&N6S-_&(JIO7*169BJB,7JVO0NT5+D]4N.0V^]TE6
M[*;]><=S:`JE=TANNHZHV)9_MTO4KC,V*!1K1]"CZ7;59DYV#H8IU%F3(U45
M=-GZ:(P^:R]T^O%7CW\DO8[S8D(JZZ9GLBCG.';KJ\DSL^-2C*#U-->'S#-K
M?+D@Z--2*3.0E_0^D(NA,E\T)R'*48K`">X%B+[L1BF#UXUBMC+><1<;70]-
MJU0O]AITE%O;/F,#36K=]"4J0BE8:T,-'%\M.'?)1<(5CZ,B=NHY0`1BXM>M
M5^Y>:Q&0U'0-3O$'-3-UT[9,RJ\3A^;[;?9FY6#*=,T.G3$%1\HBJ58-FL\M
M38VC+$L"[.'<,$731RZ14&..W6.,,A?]Y.K4?GN<ZB?42O:AK=DG*5G)H.EZ
M'8K-:;W6F\ZO.Y\QH4!4I*^(Z'%J5B0;*P"\8E,`_:J,P;"Z#T1&+U;FR'8,
MZW>AQ>E998#V.H2SV<BT7CF%L%9E6,S6)R1K-E@+!5K9%05JJ]CKMAB7+)]'
M23)H^:.4#IJI$,'APG#9G`<!P-7ZGEY-1BXN.#0-0SIQ$R)I!"8RRXK5*4<@
MJT79+L)0#-)&-EHY5%<1!-PV4%%4I54C)JE*<`_O'\AH^&4*,SK/F+YI`Q[Z
M?FG;N8EY*PV*QVBW3TE:[C<+58YER\E[#:K?:IEY(R+URJ=5P[<G-\"^4I1R
MQ7L3_8!'_P"(([_9I#F].6/<XGW0:YT<6!4#-JQFJ%L;U=)XDG=+];=)G`>N
MSO!4L]UD/J<XJV$Y2_+LU'7Q31#Q!,OP`>23"VVXRSWE0X$>9'JWC,SG6C9I
M,UD):&U62T&9N,P_437MKR8T>8DYN7E&=D]`LA&OHAW(E)$J(B48U%HV(CX`
MB7DQ,6->5S+V2`;(BW;H-Q66<"@BDB+AR8IW"XI$*05ESE*0IUE?+YC"!0`3
M"/P#E9?-P-6ZOCU.V2(@XVU_7&+VJ61G<:;:*I/R=6MM/M3%E(1:,Y7IZ)70
M=-'*D3+NV:Z1_5;.FCI5%=)1,YBC+,K+9P]G/Z&RSR$6AFEANEI4=R*\J^F[
MY:I6W3SQZN@U:CXO9-8Z3%FDV9)$3:M$F[1/RB<J8***'.DP6Y1[[$?VGA/]
MPA_Q![S>O"(:7_+*UHKBNR4HYL$+8JBXD'%9M52G7U=L4.68;I-)IFB^9']-
MU&3+5!,CEJY37;JBDFIY`522.2V2X66S/9E57KK:J0;*!:/YR419F=J#(V2:
MD+!-/%W[YS(NUWTK)K+NES'=.S^0GB5%!/RI(D32(0A4Z);FY>_RCQK%7H6V
MP$W5K)'-Y>OV.*D(.;BG93&;2,5*-563]DN!#$/Z3EJL8@B42F`!\0$!\!Y.
M>A+9<SEA-#RJ+H#@5V5IT2PE3C`AH]K<[S.69E%1A56ZH-V35^X%)5Q_JB1?
MFW(.'OD)Y?6\#J`=)CU6[9](V?RH<#2[O`,S?T2P9\]A3NHNSR5CFI:765(:
MTJSMGLSZWOIQ*P^B#Y&5:V!\*[54!_U;TDBD`")E*&<3%C7E<RMS@'@``(B8
M0``$P^'B/A^Z/E`"^(_Z``.:96'9Y_86I_[ACO\`9B<YWFC4S_JMC,IF%KRF
M1KJCR%NDQ;[)/3ZZZ1[NO9[I<I*_R=F1MGRX23><96N3%RQ7*/BS]%$B8`FD
M0H3$QAKRN94BB@(%`!,)A```3&\OF,(!X"8?*!2^(_Z``.5E_O`U1J^,T[86
ME9)95+#$3=(L);72+C3+%)U.XU&>&-?PCMW"SL2LDL#:5@I5TR>LW!5V+UJN
M8BR)_`@EEF6I;,LCH5(99_`%@6<Y;[*8SQW(O)R\VB5MMBD'KPQ144<R<JNJ
M*+=)-,B:+9N1!H@F0"II%#Q\4Z);EFG*CRIV#AK/"3-:L48QFZ_88J0@YV&D
MVZ3R-EX:6:+,).,D&BQ3HNF+]DX.DJF<!*=,XE$/`>%1[H753/<^L=,L$?9M
M9L#?-$I%#-*S=-/M%LK-#1DX!U554X5E+.UGKWY:M/EV+<TFX?G;-U1!,2B!
M1+F21;M;+TC?=I_LQ8_]PR__``]QS4YC*MPY"J%,0Y2G(<HD.0X`8IRF`0,4
MQ1`0,4P#X"`_=YT&FZ)AE3SAY&FK$U?D(&"([2K=)>7B??TJN(.T5VWR<7!.
M'1B&CV39R=-HV<G<-V1!*"!$_33\F9K)PU=K><9;FYIDX&G;5B-6LMH>75E,
MW:D6F6C6$18)B@6R2K*EECHHZIHI&?9(&6C)!U%D<*IMW@H%?(HJ"D58$_*4
M,W66Y]5FUDQZ-AU2L0M)JU:IE;:&85VHP$-6(!B=PY>&90L!'-HJ*:&=O%5W
MCHS=BT3(*BJAU#^'F,83"(\LF))$MS;;R]_E&(W6D0-_B6<%94EW40UL-9LJ
MC!)?TFT@]J<ZPLD0UE$O*<KZ+"7C$%%FYP]-<$P*?Q*(@,LSRLMG6/I-LWJ+
M&\H:'&QB<78TJJ]IJQXTJ3)C(0;R683::<BR02*DZ<QS]@)FJH^!T2N%RAX@
MJ(<8ZY,W&/1*G`?[=+?[AD/]I8<FW"))Z/FU7U6"85FXH.GL"QME-N*L6BY]
M!G+2-$L\7<(!C-(B10DE"!/PK59PT.'I.2I`10!()BCCE9<=8\YGCU!C-,:Z
MU#PR4);T*-)9XY4ARH1T;*UJ0GHNR)(R\:V0(@]>1$K&"9DN/@HW([<D`1*L
M8.,=<F;C'HV?RH<#`B9M6$]0=:^5)Y]LWE!89LLL+LXQXUB.L,C9VR16'E\A
M7@2LHJ(K>/B)!`OA\.3'7/JN;C'HSWE0X&!7K-JQHJ]%<61)XJIG5^A])K0L
MW9V@)6>#CYB,8*O`*4WS;,K6=<`9$?`#&$H^/PY+,K+9EGO*B(78C^T\)_N$
M/^(/>:UX$&[5B-6LMH>75E,W:D6F6C6$18)B@6R2K*EECHHZIHI&?9(&6C)!
MU%D<*IMW@H%?(HJ"D58$_*4%UEN?59M9,>C8=4K$+2:M6J96VAF%=J,!#5B`
M8G<.7AF4+`1S:*BFAG;Q5=XZ,W8M$R"HJH=0_AYC&$PB/+)B21+<VV\O?Y1B
MUVI=;T2K2]-MT>,G7YQ%%%\U(Z>,'!3M72#]B\92,<NUD(V2C9!JDY;.6ZJ:
M[=PD11,Q3E`0EDLQ26RYG+RJ/GS6C?4E$K1>[4ZE$X]!=Y=[;)655!O%_.BT
M08-W)DX^/\3R"IEE$42+N1$GK'4!)("),>JVY](S[E0X$?9'K5GC]_,*HOKQ
M#U^R6(ULLM$@[K-QE&G+$M)MIE]).(%%<0CSRTJU*X>)L5&B#M<RBBI#**JF
M/GQC7G>G=(+FF5]&/4=MH_4O/J<ZLEVJ"4K6818MCSNURM*N$4YB+"E-LUHF
MQ0ZJ3MN11W'$3=('!1J_9G5:N4EFRRJ1_-O^U>C3]8V'BN`4G#27=Y7I"XVF
MV:99&ULT;0=#L[ZW7:YS<?!QM7ACRDFZ!!DRCH"LPS5@Q81[9FP;((^8B/JJ
M+**9:MR__]7KHB/:YZBPO>&2]P5G4[";?I$'KSRN+*NM1&-GDZT-0DKLQJIF
MP"G9WM=450,8[E1F158[DC<CKRKE87RN,>C,NUW6_0NR>C]:XUC?9C-LCR>V
MVW8[C8J5*PK31G.H0,`A6\885UA9:;<:TYB(]2USDF_6>HCZ#ABR]%,RQBJM
MQ+C/=$1ST)[!9Z?0VN:W.#U*$K7<G'.\^.-]GLB,7/7:_*5^4KO8O/KW,T;/
M6$)36TZ^_P#S%!2[&'>$^N2:IG30?(JLM%S$A]&S[M=?[IU*WI3,,>8WK$M(
MUEY9LD2VJPGBT:)I683F>QTFTTT^/^67M,.[=(O7;$L$V:BFL9!%TJ9`%EZG
M3JU?I/3'<WE:[16W-I+/V6Y2/?2D=TNKCV>DI(:VBM3<9Z_95+5;1%V\(=_#
MM[]7*/;8%Z5B#@4HZ826*KYQ.F2+F=.V'FS/3[LI1\RZJY9GEB6N5%S_`##0
M&&]U.M]C-5ZGRVA]BK_)5BV*[:]U7&8)QI#ZK%O+NVOI"#8O8LRZTZ1P8'@H
M%;\&9U?-USZB=A.NDG[?$FUBLWO`8/TYL_47:VY[[+U=2"^U=VZ\6E;1J,?[
M"6!.\HQ;7('Z7TIR,*HNHY0\')"BH)!;+EYU,ZB]E,0#K=IU'@\LTN^X???<
M2"Q9G-WV9I478\][H]C9/::S-5:_%H]E2C;U3FD!!H.F;R+^272?R*)'93)(
MJK#,N639/TLV&L6[K3I%L?45*T0G=3M5V]W"!@+#89.OUC]87$MTSR$I&</Y
M:%9N;,:LR%_A4WKI9K#(O5$WSXB*9E"H'&>4LNJN-6O%XS=V=L/#&4TCM/O.
MRU\(5VL[(2J:5;1G8$DB*S-G\M,@V,(ND2@H1-0?`%#_`'>5+<X2GX0X#@.`
MX'UW+1J\3]%VV;NDO,!_2<HIKI^<H"`&\BI3%\P`(^`^'C\>!]'Z!!?B6)_)
MS/\`F>7-[IB=CZ!!?B6)_)S/^9XS>YB=CZ!!?B6)_)S/^9XS>YB=CZ!!?B6)
M_)S/^9XS>YB=CZ!!?B6)_)S/^9XS>YB=CZ!!?B6)_)S/^9XS>YB=CZ!!?B6)
M_)S/^9XS>YB=CZ!!?B6)_)S/^9XS>YB=CZ!!?B6)_)S/^9XS>YB=GTW-0J3P
MQ3NZO771RE\A3N82-7,4OB(^4IE6QA`OB(CX?<\>,WN8G9]?["4C\S:K_=Z(
M_H?&;W,3L?82D?F;5?[O1']#XS>YB=C["4C\S:K_`'>B/Z'QF]S$['V$I'YF
MU7^[T1_0^,WN8G8^PE(_,VJ_W>B/Z'QF]S$['V$I'YFU7^[T1_0^,WN8G8^P
ME(_,VJ_W>B/Z'QF]S$['V$I'YFU7^[T1_0^,WN8G8^PE(_,VJ_W>B/Z'QF]S
M$[/13KE>13(DE`PR2290(FFG%L2)D*4/`"D(5`"E*`?<`/AQF]S$[/[^@07X
MEB?R<S_F>,WN8G8^@07XEB?R<S_F>,WN8G8^@07XEB?R<S_F>,WN8G8^@07X
MEB?R<S_F>,WN8G8^@07XEB?R<S_F>,WN8G8^@07XEB?R<S_F>,WN8G8^@07X
MEB?R<S_F>,WN8G8^@07XEB?R<S_F>,WN8G9_)Z]`*%,0\'#G(<HD.0\8R,4Y
M3`(&*8HH"!BF`?`0'X"'&;W,3L\W["4C\S:K_=Z(_H?&;W,3L?82D?F;5?[O
M1']#XS>YB=C["4C\S:K_`'>B/Z'QF]S$['V$I'YFU7^[T1_0^,WN8G8^PE(_
M,VJ_W>B/Z'QF]S$['V$I'YFU7^[T1_0^,WN8G8^PE(_,VJ_W>B/Z'QF]S$['
MV$I'YFU7^[T1_0^,WN8G8^PE(_,VJ_W>B/Z'QF]S$[/G;TZHM%/5:U6N-E?*
M)/4;P<8BIY1$!$OG3:E-Y1$`^'W/AQF]S$[/N_0(+\2Q/Y.9_P`SQF]S$['T
M""_$L3^3F?\`,\9O<Q.Q]`@OQ+$_DYG_`#/&;W,3L?0(+\2Q/Y.9_P`SQF]S
M$['T""_$L3^3F?\`,\9O<Q.Q]`@OQ+$_DYG_`#/&;W,3L?0(+\2Q/Y.9_P`S
MQF]S$['T""_$L3^3F?\`,\9O<Q.Q]`@OQ+$_DYG_`#/&;W,3L^FYJ%2>&*=W
M5ZZZ.4OD*=S"1JYBE\1'RE,JV,(%\1$?#[GCQF]S$[/K_82D?F;5?[O1']#X
MS>YB=C["4C\S:K_=Z(_H?&;W,3L?82D?F;5?[O1']#XS>YB=C["4C\S:K_=Z
M(_H?&;W,3L?82D?F;5?[O1']#XS>YB=C["4C\S:K_=Z(_H?&;W,3L?82D?F;
M5?[O1']#XS>YB=C["4C\S:K_`'>B/Z'QF]S$['V$I'YFU7^[T1_0^,WN8G9D
M35HU8MTF;%LW9M&Y`30:M44V[=$@"(@1)!$I$TR`(_<``#D5]C@?_];OXX&C
MMM[&91UY0I*FFR-O3=Z/9GM/HL!0<JU?9+=:+%&5:?N\FPB:5CE)OMN<$C*C
M5I&0<K_)`V;M6BAU%"@`>)9,LAQ[:,QWVCM-&R.V-+A4G<C,PIGR+.4B)",G
MJ[).(>P5VQ5V?81-DJ]D@I1JH@\CI)HU>M5"^"B1?$/$EF.6T.`X#@.!AE_O
M4-F]8<VZ?9V9_%M).MQ*K:H5&S7F>,YM-EB*K&J-ZU4(N:GW3)O)32*CU=)N
M=)@R(JZ<&3;HJJ$#,^`X#@.`X&L]4UREXS7F=EN_VO6924RWKT7&T+-=(UNV
MR\RY8R,F1C#T3)ZG=KM+'3C8ATY5,VCU2(-VYU%#$(41X.6`5/M5BM_<8.G0
M;(ZN33L=$WR?S23A8B0*V4@\U8MW%TE+,TE$8V:JB,#)OFL2Z3?-$EVDT[18
MN$TG!P)PN+U>IV)_L`C_`/$$=_LTAS>G+G[G$^Z#7.CBUG2-CS31[3I-*I-K
M9S]HR&>95K18ENUDFZM<F9%HH]9M5%WS)JTDDE2-UDQ79J.&Y'39=N8X+MUD
MTYF7*V626SI6S.5#@1OO_:_'LQO+7.+:GKY+?)+*MX1A7.MG8^\L+,NUA$K&
M_2J-AH^46.N6]2*A5?6>A&.W8LO(H1?TSI*E)+9.C4UMF9C'WB0[-TD^:-7J
M!7)$7C9!TB1XS=QSLB3A(JR974?((-G[%R4AP`Z*Z::R1O$IRE,`@%9?9X&"
MZ)I=&RBNC:M`L#:O0QI!C#LSG;OI&1EYN45%&,@:_!1#60G;'/R2A1!NQ8-G
M+M;RF$B9@*;PF<+);TCZ&;ZS2]6:2CJHGM**D&[293$3=<]T',++&KN$C+-1
M>U/3*O4;.@V>(D$R*QF@(K%*(D,;P'B7)99RT7V(_M/"?[A#_B#WF]>$1#O&
ME4W.D8L]KE'#=U.NEF4#"Q$+/6JSS[IL@+ETA`U.J1DW9IL[1O\`?K?*M%01
M(("?R@(>-MDY62WAZ50N,!>8<D[7%I!5B+A=FJE+04]699D\:B4'#*3@+/&P
M\]%/$?.`F2<MDE``P#X>`AQ+E++.E91RAP-.P^]Y=89YM7X2;F)15[)N(9C/
MLJ1?%Z$_EVJJC=>,C]+)61SM^_(X1,F"2,H<YE"B4`$P>',^4K5UVDS8W%S3
M)P-/7_=L]S&8C8.W_;QN^F7#)C$*060ZY<HN4DI$CQ1E#QT[3:-/PCV=728+
M'!BFX,\`B8F%,"^`\S=I.5FMO68_WC:$/*MIR*CIADE)(-)1FW?-D9B'EZ]*
MI(N4RJIDD8*?8QDW$/"E,`*-W;=!PD;Q*<A3`(<J+'L\_L+4_P#<,=_LQ.8O
M-&F+;VYQFD7TF96!':`N[@LVM&0T)UA[-6I.P,JTI$(V&5JLM5<AFH2V0D&M
M8&!7;Z,<NV;<SQ`#JE%4GFF9PU-;9GIC[Q)GE9.!KO2-7H.21+"8OL\,2C,2
MJ$%`1K")F[-9K/.N45W*,'4Z?5HV:MELFCM&JJWRD:R=.`0145$@)IG,66R<
MK);P^7.M-J.JPSV=IZT^+6,EUX"58VFEW7/;%$3+9FPD58Z7J6@U^KVF*<_(
M2C=8H.&:?G26(<OB40'B7)99RS_E0X&A8+LUB]FO)\]@+-+R\V2PR]0"794'
M1%L\6MU?!R$[4FFM!4_T5O;3#JLUD7,<C,G>(N$CHG3!4HD"9G#7C9,X;<M/
M]F+'_N&7_P"'N.6<QE6Z(@4!,80`H`(B(CX``!\1$1'X``!SH-/UW><OMDXQ
M@:[,S,H>5=/&,//(4>^%HDV\8%<G=-H/2%JREGTTL0K-7RE:R:PG$@@7S"',
M^46Z[29L;AYI#@:]O>ITC-S0Z%JDI$LC8%'A(*!KU9M-VM,R6-237DW$94Z3
M"V&ROF46BNF9TX3:&0;`H053D\Y?&6R<K);PRFO6"(M4-'V""=B]B91'UV;D
MS=TS4.0%#I*$69OD&SUFX063,11)9--5)0HE.4I@$..4LQ<5[/*,2NEVA*!"
MC/V!"S+QI7!&RGV5I%TOL@B8R+AP+AQ#42OV29;QZ238PJ.CH%;)#Y0.<ICD
M`TMPLEO2/'S;5*=K4,6Q4@UH=0:S6,?L96P9_?Z.RF8Z8:_/1DG7E[S6*X2Q
MQCQF)5"N6'S"'D.01.'G)XI9>L+K=>EY2SP'^W2W^X9#_:6')MPC=&S]@,SZ
M_P`0VL&H+WB-@'"+UPM.UC(];TJ%AT&"L>@LK9Y;,Z/;V%2377E$2-AE%&8.
MS><$/4%)7R8MDY:FMVX9S1KS"Z)7T;+`,KA'QR[ERU(VO.>7_+[`55HIZ:IE
MJGI=9J5J;MCF^*2RC,J*Y?ODS&+\>$LPS#E0X&L\QV/--E:6U]F5K9VQI1;S
M/YO:UF;62:!$7.L@T/,0YRR;)B=T5)!^@LBZ0!5F[;K)K-U54CE.,EEX6RS&
M8V9RH<#6=KV/-*/?LUR^UVMG#7O7U;*CG4`X:R2JMC5J$:A+6`I'S9DO&1GR
M;-TGZ8O5VP.5E"HH>HL8$QF9TBR6RV3I&S.5$0NQ']IX3_<(?\0>\UKP(17#
M<\QHDXXK=AG)'ZPPC6LS--H*HW.W)5B'?'7392UQ?5*O3D?3(MV+544G$JJS
M1.5,QBF$I1$%VD6:VS,C;?-(<#$+K?:GGD4C,V^7)%,W<@VB(Y)-H_E)68EW
MOG%I#P,%#M)";GI=R5(YDVK-NNX,0AC`3RE,(2V3E9+>(^.E7ZM:`Q>OZX>;
M*2-?#&R+*R5.V4B;8/`01=`D]KMUA*_/M04;N"'(=1L4BA3>)1'X\2REEG+,
M^5#@:D:;GF3^W+4IA.23Z8;S:U97?LJA<W=/0L[8WIN:RMH3>O*4%*R-EOY-
M2/-)@\36_DS)@?[WF?*9QE?&XRVWS2+S<_V7.\`Z<4#5-4F)&#I4'#TV'>O8
M>J6^\S"TQ>;S&4*HQ$14:%`V>X6"4L%PL[!@V;,&#E8ZSDOWH%`Q@\V_[5Z-
M)F1F\-VTQ^QP616*#'0E6.W:DOD%"9V')]*SFSO+8RK=MMLFX?TC4JO1[LPK
MD5`4F1<N)$T>+8J*(J`8R0&.7+6'_]?H\K/1GO\`QGN^V+N'+]JB/.H$A$R*
M#/)R6ZX+O'->=40E?B<N5S)>*3H4+'P5T`LS]4;N5%5S-P<F`'KIQZ<]6LSQ
MQCJD?WPJM]M^Y^W1$YM=7>:VH_8S93,M#:U&+NX5(OZE?98JSU:O3OA!O"OT
M3&9$^:$$R*N2F`#'`I1$XJJJ5=7W.\YS7--`F(FO,*YW6[:1W?[1=-E-#I>4
M:;N,M!)73'=2T&:QY.KS-4R37:A86LO#LE`:UMC))1\4Z6749I&<%]>C<=TD
MJY1,>]M^'V_L=*W;`;?VR[&,+/>LSO>V,X%3'5LD[-V"AYM*Z"C+DU.S99G4
MU%1D4[E)-U\L-=C/._7/'I+NCNQSY8G5\-&J$EL*75G*3V;<'O5>[>XMVQ@L
MZ=(WO4*Y+6KJK5^M6RW*E5T]Z3DXW0'V./=0K"["*4=/0"1KQ&[=)=1HLB8X
M[WUP\'<6=]?]K-_SRR;G1NO=SJM_Q2+Z<3FCW?L'$VB#RB,SO,G4%)X;7*K.
MM\_U%G8=)2LD=;&SGY^2EC@LPEQ!D#,I1.)T2/-<:[2_<$OT<6_*Z],:E(ZH
M#NTU>WZNAMG2>#I.".57\7:L9%O-9;9<&7DJJ"M=>C'L!<VJP,U"M)EXJ$@8
MGHC/3[:[C>G/:7-,XE2:)-9C/]*@6[78_J&RW:M=@9JS[A76TS)/FE]F)Y[3
M-XC(F&^:O3&,EI@ITYQC\R[\/2;(#UCV>TEK;*RW>Q"SW77HKW`8;6V33H%3
M("TZK"RR]3+2LO2Q57%J=6'K:F6BC6>]OY8EU<"@];K&4D$ITZ;1%--%_:ST
M_P"K+.W=/M+\GNU;&,YJK;1.NM3QO1.NZ]6T#2H2MTO1J_UUIUM?3=.JD+.L
M*]+O9:PP;5"0^8:.SN&A3-C`4BZY57=)_BZ!^5DX#@1N[16U&L9XW:K7+L=F
M_P!I)QG#DT'K%B;G=[_6#)HN9,YGE40Q#L,A%U^508G:+R;BLK(M3*D\'+50
MZ:H%C37MU9P]IO67-B6_,_L9:ZP?5:749FU51_6M9G\>/L-NE:':M&C;*M(6
MZIW75Z^G'VFR0SIR04)U^J95LT5`6C<7EO\`[$_V`1_^(([_`&:0YO3ES]SB
M?=71HMJ=T:@7:YL*[.6Y_5*I8+"PJE8BI"<L5F?Q$4Z?LJ_!Q$4W=R,C*S#E
M`C=!)%,YSJ*``!S;E)FR*U>O63]CL%UW#+!?:-3G,1I-$MV7;58,NE;;;'ZV
MB3,S:^P,-INC1[BCQ"->CBWZ7ML;\T5V^:(/+8DDHX`/346S)98Z;77:7%X_
M^EKG-N1P(I[)7;!*=DNG4[&04S(PE8L>VKV688QCUW%5Y&6QV:C(M:<D&Z"C
M2)2DI)4K=N9P=,%ES`F3Q.(!S-YU;GZ[I6<TP<"'_9N-L41?NLVR,J;9=`J&
M/Z+;WE[KU,AGEIML-&WC,[12(S0H"FQI%I:U+U&4EBHNFT<BYE"1TDY5;(+&
M3,F.;S*WKQM,]:]3K7<[Q<IK6EY>6UNQ9VPEJDCFE@V;)5L=M<@5U7S.[<BW
MKDAF&1S#J&CYA1-%!RYB"^?P,!%EBAYN)GKV-I)CC+SNQ']IX3_<(?\`$'O.
MFO#"M75"RU/VRJZ>[@[G*TQSDUWS9S8:!5I"]V7.;%+6"LV%C.IU")AK)+NX
MV=:1!TE'#:,D4T73%L5TCZ!Q,$O3:7TPWKUULSURV!ADW;I^JS3^V+VUX0+I
M9&M5D+U4BT>U25-;+()P;^7K7V:IZ\>LY\%1*"T8S6,3P$R8>/+KG'5-L2S#
M='-,O!M46\FZO9(6.>#'2$O`S$6PD`,H06#Q_'N&C5X!T@%4@M5U2G\2@)@\
MOP^/)>*3F(5YU;;O%0O7K.X:O:_1[+4$*+0-)SY?)G2F7-(.N1+F-LM@;:BM
M0GM<>,UE&"8QZT=9R>N@9/Q:@L*Q0Q+?QG7+I9,[7,L^_P#X_P#A/+G1S.!'
M_>8:8F'V#'B(F2E"0_8"FS,N:.8NGQ8N':UVYH.9:1,V25!C&MUG21%%U?*D
M0RA0$P"8/'.W^/W:U_R^R0'-,K#<\_L+4_\`<,=_LQ.<[S1H30:[8'O<?K%9
MV<%,NZU`8QVLBYVPMHQZO!PLG8IWK0M7XZ6EDD#L(U_.I0+XS-%90BCHK)<4
MP,"*GEGK&Y^FT^L_\I6\K!P(8=BFM@JNX]=MO"HW2XT&BUS<*%</T>U>3OEN
MHDEJ;7.5JQI491(&.FK%9$(@E%?Q3H(^/DGC=&:\Q6QT!<#S-YE;UZS:9ZLQ
MZP6R]V^,UA]:Y+3)VKLM6+'9%8M>S3]$U[GL\#*LL?OW\G4%,^RUZBU1U*0L
MK5HNX@V:RS5N3_WI`(J=/5-I)C&,X2>YIDX$`^F5O=YIE&0=9KEFVQQ&HY]%
MN*';))7(=!#.'[RN#*'D-&1V52OI95+PUV4;A()"C-+RR[B0`BK<5P6\F=>)
M,=73>9MVEF$WK3_9BQ_[AE_^'N.:G,<U5>C0$E:\]OE7AG@1\Q9*9:(")?BH
M=$&,E,0CZ.8O!62`RB0-G3@A_,4!,7R^(?'F[UEBRXLOU14HEXN)G.!4V!K^
MPT=]`MZ]3]0S>6R5VUS2OU^O4N?;OI-CICFA*04@(6!G'-V)XJSJHKM?+Y6H
M']?RXEN=9U;LGY7,^G7_`,)O<Z.9P(MWEV[S[L+"Z?,UFY3]*F<??Y^66I-*
MM.A2%3L3&X(V4R4C7*7#S]G0C+<P73*#ILT40!>+(1R8GB@/,7IMG'3#<ZZX
MSURD97YDEAAH^:3CIB)2DD`<HQ]@C5X>9;HG,8$?J$2[`KR-753`#^@N5-=(
M#`54A%`,0NF+TZ/8Y1XMD257KL^@@FHLLM"RB2**1#**JJJ,5R)IIID`3G4.
M<0```!$1'P#@G,:RZX1<G!]>,&A)N.?P\S#XQET7+Q$HS<1\G%R<?1X-H_CI
M%@[31=,7[%TB=)9%4A5$E"B4P`("',Z_KK]FM^NVWW35P'^W2W^X9#_:6'&W
M#+)>\%=L%LZI[/7:K!3-FL$I7&*$9!5^,>S,S(K$L4*N=%A&1R#EZ\5*BD8X
ME3(80*41^X`\Y[?K6].FTRE9S3!P-.=@K/=JAC&B3>:0,I9=&^SZL/0(F)BG
M\RL:ZV9PWK56D'S*-0<.RU^$G)=![*./*";.,;KKJF(DD<Y9>.G+6LELSPAM
MU>RK8NNFV1E,L5#JS#+]`P6HU@LSE\M;KG`Q.C]?6[&NQ\_?92:HU3^B6'4Z
M%9BIF<K"J1ZO6"%%05U``V9+*UM9M,YZY_M99S;F<"HSL!F_9G5;OV&UO/,W
MJAE\RD,QA,+7O$E<JIH;UWUTE4=BE9+/8$E%EXF6BM<OTZ]KGS2K]LWEHZ/1
M^XB)5#8LMMN'76ZR:RW_`%5K%9F@LM<K]B"-EH4)^$BIH(>?CG<1.Q(2K!!\
M$;-1+]%N^BY9CZ_I.6ZR9%4%B&(<I3%$`VYWE%WL1_:>$_W"'_$'O-:\(K!@
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MI32\5V=L\+(R".<W!S29=-Q9YN6"]HZ62'"@JQMB:/0?J`K)A)^NN=)1`7'B
M4V->DFMERWO,V[2S"7G-L+B'\%GEHZ+9I`:BCL'V36?9/8"RF%5*_P!TT:M6
MG.]1@M0H=HB8G,:M=+>@W@;S28YPNZ0C7"*!"^*_D1\ZA?-O^U>C3B,EZ1L]
M%LE5N=HV%M>K4UJVS:+$=6]!WW.VM([`K=>Y>OT,`<7*%DZC2K=6'TG>F4TT
M1+)1$/+R,!'Q:T@@=8?64RU?H__0[^.`X#@:RNN1TR_W;'=`L;9\M8\+MUDN
M^?K-7ZS5JTGK5F]RRF76DFJ8>G)MU*??)%,B2GWI%CD5#[XA>#/+9"RZ+9(Z
M[A9)!%,OF4664(DDF7[GF.H<2D(7Q'[HCP/Z443134664(DDD0RBJJABD333
M(43'44.80*0A"@(B(B```<#XFCMJ_;(/6+EN]9NDB+MG;19-PV<(J!YDUD%T
M3'262.4?$#%$0$.!]C@.`X#@.`X#@.!K35J;*7FL)PL2NP;NBRC1\*DBJX1;
M^D@BZ3.4#MFKM3U!%</`/)X>'C\>:UN*SM+M,1'']6V\_C6J?ATQ_47-><8^
M.]X?JVWG\:U3\.F/ZBX\X?'>\/U;;S^-:I^'3']1<></CO>'ZMMY_&M4_#IC
M^HN/.'QWO#]6V\_C6J?ATQ_47'G#X[WA^K;>?QK5/PZ8_J+CSA\=[P_5MO/X
MUJGX=,?U%QYP^.]X?JVWG\:U3\.F/ZBX\X?'>\/U;;S^-:I^'3']1<></CO>
M-$:KT>UB\S$=(1-ASQNBTC`9*%D9:R(JF5!TX7\Q"MJD[(*?D5#XB8!\?'X<
MU/<UGI4^.]XU=^SHVW\Z<L_+=M_P1R_)KVI\>W>'[.C;?SIRS\MVW_!''R:]
MJ?'MWA^SHVW\Z<L_+=M_P1Q\FO:GQ[=X?LZ-M_.G+/RW;?\`!''R:]J?'MWA
M^SHVW\Z<L_+=M_P1Q\FO:GQ[=X?LZ-M_.G+/RW;?\$<?)KVI\>W>'[.C;?SI
MRS\MVW_!''R:]J?'MWA^SHVW\Z<L_+=M_P`$<?)KVI\>W>'[.C;?SIRS\MVW
M_!''R:]J?'MWB5%5ZLZ#!UN#AW<Q35',;&-&2ZC>0FSH'502*F<R)E:\BH9,
M1#X")2CX?N<SYQ?CO>,@_5MO/XUJGX=,?U%R></CO>'ZMMY_&M4_#IC^HN/.
M'QWO#]6V\_C6J?ATQ_47'G#X[WA^K;>?QK5/PZ8_J+CSA\=[P_5MO/XUJGX=
M,?U%QYP^.]X?JVWG\:U3\.F/ZBX\X?'>\/U;;S^-:I^'3']1<></CO>'ZMMY
M_&M4_#IC^HN/.'QWO'F376&_2,/+1Z$O4"+/XQ^R1,J_FBI%5=-54$S*&)`'
M."8'.'B(%$?#[@#R^</CO>(E?LZ-M_.G+/RW;?\`!'-?)KVJ?'MWA^SHVW\Z
M<L_+=M_P1Q\FO:GQ[=X?LZ-M_.G+/RW;?\$<?)KVI\>W>'[.C;?SIRS\MVW_
M``1Q\FO:GQ[=X?LZ-M_.G+/RW;?\$<?)KVI\>W>'[.C;?SIRS\MVW_!''R:]
MJ?'MWA^SHVW\Z<L_+=M_P1Q\FO:GQ[=X?LZ-M_.G+/RW;?\`!''R:]J?'MWA
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M-5Z/:Q>9B.D(FPYXW1:1@,E"R,M9$53*@Z<+^8A6U2=D%/R*A\1,`^/C\.:G
MN:STJ?'>\:N_9T;;^=.6?ENV_P"".7Y->U/CV[P_9T;;^=.6?ENV_P""./DU
M[4^/;O#]G1MOYTY9^6[;_@CCY->U/CV[P_9T;;^=.6?ENV_X(X^37M3X]N\/
MV=&V_G3EGY;MO^"./DU[4^/;O#]G1MOYTY9^6[;_`((X^37M3X]N\/V=&V_G
M3EGY;MO^"./DU[4^/;O#]G1MOYTY9^6[;_@CCY->U/CV[P_9T;;^=.6?ENV_
MX(X^37M3X]N\6IXQ2I7.LMI-(FW$>ZEJW"IQSYQ%*N%X]5<BRR@G:*NVK%RH
MEY5`^)TDQ\?W.<=KFVNLF)(V=R*__]'H\K/N4=J9GW?;%T'=]4CM^OL7$R*B
M.M$C+<E9V+)A1"6QIJ<E8W+D*"ZSV<F@+#-V:;9%R#MVD`/%7118J3/5KQGC
MG/5LKW4:EJ.BS72?/,=O5AH>AV#<M@G:/(P<])P;-WHN9].^Q>I9>QLX1KMI
M]4JJVBTV,"1:K"9)=F*I!#[[BFOKE$7MCVEE^W]+ZZWO'[)9Z50\?E.B6]:P
MW@)Z:@9-MLW8CN#C..U'#;:$>M&G<JT&DAH"MCB'?K%(\<0RRB)?Y!0Q9,7J
MF%M'=+L;5ZSW"W_.H;%RX+TCODQ3;EGMSKMVDM;V=KGE.IMTU:9JFAPE_A:?
ME!X]K;5&D$V>UNT_4UV`J.56!%R@F22=)ZU'KO?N78C<NMW?-S1FN.0_7K$[
M[$X3-UJVU^^I;5<'L4URZT7*^QUN;65"KTEO`REV:MV%=?5A\ZE46BYUY",,
MHD4!))CN^'OG8+=8J%[GE'H\1FM:"+USI'`WR6GHF]6-QIE/T>M9!#2T-/L/
MT@,X)FJ/SS*.6*S9MV#RO)NFKEJJ[<_/$=R?XMKRNTR'4.V=NHFIY!B:-USK
M%O;=K\(EGD+:\WH5CTOLOMNWXA`,GE5-:[-#U3,J=<'K=^DC%-6\FHU=O?FG
M+M46PMQC..J2FKZYV2PW/8)KJ&S]8(K2;=HZD%3+#5>M/8[2G5RKR-.?6%W`
MTSJEGNOV+6+IH$;(1RWK?3+6X;!$(G?'21/_`*H%3$OHAO&]K>VG85M[8V@9
MW:<ZRYYL'8'M=E.E5B<S[66U<M%@PK/^U];7D)VE2UWIETBJA*JXZ>8:5J7!
M*:@YP60.W2HLUT59V:Q)Y-M-NRMQHMJ[`T+)J+G$/I.G>Z&SZOTRQ6`+Q+U)
M"5F^G&5;_9]:TJ!-="2=AD8FGUZ6:(1$"^K3%\JVCTO,T.=V]4)CC[/]M7=O
MLIGT7L>8S5>Q2V;_`))VMZ@]?F5NCH#1*3C%\K';^QYU$U2U*5QY:;S:J18*
MPC=G"<G'I3EB*B=FDX*=1-T1$@Q/XPEEU?V36[E>NRF+[B;.Y?0.O5]I4,2[
M956+'1Z;=*CI&95G1*V]"EVV\Z3.5NPPZTJ\8/DAFGS=<&Z3A(R?K&02J7'3
M"8O"'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/_2[^.!KBX9
M12;W<<EOEECG#RRXC:K!=,[>)2+YHC$V"T9[;\NF73IFV72:RJ3BFWF2;E2<
ME43346*J4`43(8HSRT?$]&NLD!3=0H,!G1(2L;)V!B.S^A,HR<GFZLWLD%HE
M,U2,L"3OZB9S%1C:ZT&-<EBFAD8PI"*)%0!-=8IRYKS;WT+ZXZ-?+5>K)"78
MJ6AV"M6W4<\A-2T6NX_J]LIZ<"A7;+I640MD94:WRS1K5XY%P9RS,G)(L4"/
MB.2I$`!FO%UCV[.KNTV/0K#>*[>3-]7DX&R:13:[K6FU3-KK=ZNPB8JOZ#8L
MXKMICJ9)WF+BX!@B2059&4,9BV7.!G+=!9,9K:]PZIXG>R[*6R5I\['?9[+[
M)IYT;%.M#3<KC@5D*`JU!L_3)#)1/V19"H1H")77D-ZWG\X\&7^Z!U1PG4G.
MV.KY2_M"?L)0\ZSC42N)J<;DEJSDLI=)W.AB@92+8:O.5.>OTB^9R<:+602>
MF06!8%&S<R8S>C7[KHKBS^(K+60L.\R5HIUT?7VLZE*=B=GE-;A)Z5IJF>RZ
M,7H4C<W4_&UZ6IBIV3B);J)1BHG,X%#YLQG`C-?,'1'KNUS+,LH@XJ^U.NXU
MI5\UG,9FHZWIU=T"H773I'2'][?L-*C;4C>W+>RIZU/M7:+J07(LT?BF?S>1
M,2C-9#;^FN`W>)T&*FZQ,I*Z1MT+V0E[!!W6XUJW0>WUNI4VC0&B46V0$W'6
M"B3D55J'',R?2G#5$Z(+D4(<CMT589KZ=<Z4X%7*A]D/HEIL0.]KSSL38K;<
MK_<[;H5TV+*K#4;+0[C<[U.33RQV$]>>T.(109++_3DV#!-F5`&P"D(S6Z:M
ME%)IM\U'2H".<-;=L;ZI2-^?JR+YTA*.Z15VE.KIVS%PNHSC"M(%DFD8K<B8
M*F#SG\3B(\(V/P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/
M_]/OXX#@.`X#@>=,2\97XB4GIIZWC(:$CGTO+23LX)-8^,C6RKQ^]<J#\$V[
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M4FV=B:?B+^AUI_`7?0-$U%]/,L[RW,X1E/7FUI5.-1F+?+MD9>6KU>B:]5(U
MT@=_(24BQ9I*.FR`*&<N6Z*M23+!L_[I8QI3G&(ZNA=&\UMEQUO.XNOV"J.J
M[8*/?\,B)R4U"F:5#2RS9_5YZLJUYRT,F0CI-=P!#(G4;*$7,,6-%[%[B\'1
M;#C\70,DU#36-S[=Z1U3O*T#5#O'D-.Y=0--L-A+5D&LKX2\\[GJ:U-'MUO2
M(\ATY!?Q34;`41)RLF2/ZB::GD.GZA"']-4OD4)YR@;R*%\1\IR^/@(?N#PC
M^^`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?_4[^.`X#@.`X'UGK)G
M),W<=(M&S^/?MEV3]@]02=,WK-TD=!TT=M5R*(.6SE!0Q%$SE,0Y#"`@(#P(
MM]7>CW53I:TO++K%CL'E*.DS+2>NIXV5M$Z[FWT>5X6,0,_ML[8'["&B`D7/
MR<<U40CV8N%110(*AQ,6VWFM&[;T)5V/7=YV%.]HTR[VRE=8E.O=YA8Y5:W8
M?LW6^3["R+"^"9<Y&4U7[(UVLL7)17F*G)PII!FN(%<E.6++P^2X=-])T*G]
M\D+/>*4TNO=7JK3\/66A(J<"LTV\1&*:1G,_8BD>K'DWM6=6/0!=-$/_`.J(
MR;^50QE#?"IGAC]YZ?\`8V,L6XJX5J60PU;[29;GN>:J?3:5;)Z>SR=I&;N<
ME6OV9DKMBAXVT?4Z<JW,$+,"T12D&!5?FS)+JHEBYGJ]:H]/MFZ[7].3ZK7_
M`"UA0K)AW7[$+9#;/4K18YJL(]<(*8IE*NE,7IE@K#.<<RM-G3(/XE^+-#YQ
MDBLBZ(159+E3,O+SZQT/MN==I]'[;9UH%?B-"U#L(M9;U&NHR3&$O76F;R7&
MJ#(Y1:@14,J:Y4NXYDYLU7ED2^DQ<R+AJH0Z#UUR+GIAO/L5AFK6_5L*[`89
M::%$:;B$)L-+"M:E$S[^BW2C[6UH:UC8.I*K/&\_6IZ)L670;QF]21>I&13<
MMU$!]<JJ527I94<8KHGKU$B,DT:C:1FDIV7IW9K=.S.@2-HJ5DC,@NDKV3K-
MRJ>ATB'AH:<>VRN0U6B;#%?1'ZKI\]74KZ8N@`CU=-.+F=NCRXWHKV"@*#2G
M;;6LGL>X47OMI'=I&8E:3:H',[*YTFEZQ1I*G.(",L4I9*VVCV.LN'#4Q'\B
M<AF**2JJWG47X,SMTPMA3!0$TP6,0ZH$*"ITTS))G4`H><R:1E%C)D,;Q$"B
M<X@'P\1^[RLO[X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!__5[^.`
MX#@.`X#@?7;NVKL%A:.6[D&[A9HN+=9-8$'3<WD7;+"F8WIN$#_`Y#>!BC\!
M`.!&+6.V5,S'14,@A:%KNU:J6HH:!.T3%:>TL\G3:,^?2D7#V:Y2T].U2J5]
MO8I.#?-XMFK(C)R:C)?Y5JJ5)0Q2R9;OJ^@5VTU2H6\AI.MLKLRC',-$WJ(D
M:-:DW4JB55"#E*M:&\9.15C1.84E6*R!7!%2B7RCX>/",H<RD8S4*B[D6+58
MZK%`B3EVW04.M)KJMHU$J:JA3&5D'*!TT"@'BJ<ABE\1`0X'\I2T4LL=LC)Q
MZKA)J+U1ND\;*+)L@77:B[.D503D:@Z:JI^H(>3U$S%\?$H@`?TUE(Q\P+*L
MI%B\BSI*+DDFKMNX8'11$Y55BO$E#MS))"F8#&`W@42CX_<'@81/ZUG=8L65
M569LS5"<VV?FJOEK9LUDI1O;9RO46SZ7+LVTG%,GL4P(UI%-DGP+/%VZ"I6W
MI)G.L=),XQRPG1-P"E[3@.(0]8^U-EVISHTO++%FR11,_P`RS"J%DK)H;QH6
M,E'$TC]M[!6:\BT#Y0AW-@(J9P4$!25+CI:\#".VV/\`8R\;GGV;/)Q>>Z^W
M5:CW0TQ$A&,)1XVG+74W$Y3W7S3@U@JR-TH4]"B]`B11DH5VD4HE3`YA99AD
MFA;Y6,_U#`LJ69N)N;WK1[;F[!S%O8\R%1DZEBNC[:X=V-N9879$G\)G*K5%
M,A/4%9TF<?!,!$1CI::MOE8RJVX=3GK-Q.R>W;:SQ!H6(>QXJU*;D,CU77F4
MO86JRQ7!(YQ$96X0*0H`L8[M)0H"0IN"3.6]N$.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.!__];OXX#@.`X#@>)98=6PURP0"$O*U]:<A)6'1GH)Q\I-
MPBLFP79)R\.[\IOE96-.N"S=3P'R+$*/A\.!4#[0_M97CVT6&_M[GV'<[5^F
M*TUV3C(IA"RM>K<,E64YU-2VNXV6GITYKS<B32:<B9(XE31CT"&<._`IDI(U
MMMG'1M=:T3G5;NOV@T+0,FVFXY;V8IV$3E!TC$\9T_>3PMFR.J62DV?++S6L
MDKUSM]2,IZ[27A7Z\8G"NC2CTBKQ)9+R&',B-6]Q]+O.S;I?^T/4#<]AJFQ]
M5,MA>IM>=]:KEM<I1)T&6GO-+S15E0H&Z,.O&NS=GDX21<2\NZA2'00:&/+)
M_2A3:%GIB^K/<`ZHVJ6[)]7[#VPS4NGW3#?;?ZU1KK0;I!N+A4H3M+2K_87,
MW.P\]*%D*O);!55Q4=-9E,33+,CM1VV.V(]/ZA+><=T<I3J%;(7H;>K14L.D
M(G:M$[JZ):.R"CC(9>\;#I_6>#[WZ$_:5MY15G4!>-1S3]$D="RR%)92#-A9
M*^19-LBX&242>O1<_EST?<-@HL,'L,]4J_H^LX5:.Z/7_2^PF`T_HUL/6&NR
MN4U*!90MY"A]5;TQ<6[3ZW.3;.M35C9PL<NWGRQ#CR-7BOS":PSU^N&Q]XP[
MJI;)/HML->Z+2LAU]HO979#:!5'71ZZ3%D:5.Z]>]L91<XMUP'+9368C.YS=
M7,&^`CBL,VJ$PDWE5D$0]%X82WK,]6[W-^N[^T^X1W1SND6'4+/D51D>HO5:
MDUZNO;')VFRY0D\F=&>0\=$D<.'$7<>RMK3KTPN0PE19T(JRH)D;F'A.T:2Q
MCK5VWZDZUU%?NHZ@6JO/<.M'332K9DT5H]HG"33J*L.U9QNNP%EH.0:LXQKL
M\5.H2$J1)-B@]OBIEB`F<@`7,N6B>J>00T7JWM1#$]/-PS_L!C<OJT=W>VJQ
MX5?*E$NM$>=1]ZKEEG-$V"6BF$!MQM)U^76D8*RLW=AC6I)0&Q9!DM*HLWCL
M7_+KT>9U]QI*/L7MF,7747:8'MGDO9:W27=;?9#";U"0\I.O\7[',;;;[OMC
MV#C:[M$/I>ASC.3@9UDYG8Z&:+E9G=12D@V8O78O^77HZ6^5@X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X'__U^_C@.`X#@.`X#@.`X#@.`X#@:!ZQ_\`
MR>B__D#_`&RUW_\`UC_^3W_S?O?_`/:__P!,OSN__2_ZIPMY;^X0X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
<.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g657040g80k35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657040g80k35.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0VT4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!C0```@8````&`&<`.``P
M`&L`,P`U`````0`````````````````````````!``````````````(&```!
MC0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"Q<````!````<````%8`
M``%0``!PX```"OL`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!6`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TW,Q!EUM8;'U['M?+#$[>Q_ZMO_";%E9/0?18;ZKLS)+/3C$JN;6'
M.80WU&FS9L?_`(6[]+^D?^D_G%KMS,-UOHMOK-I)`K#VETMW!_LG=[-C]R+S
MJ$E/-CI5S8:!U-SQ6*V/LNHB:M]E)L].QWO_`#?6=4__``?JJ3,*Y@>TT]1(
MN:&/8ZV@UPQS7[W-=?[?5<'_`&CZ'VGUK]_YGI=&H6U5W5/IM:'U6-+'L<)#
MFN&US7#^4U)3SOV4L:RFNO++W57ZNRJ1:Y^03O%WZ5WOK:RB['OQ_4]'_M[U
M(VX]-NX3FUTN!.QF1C0\N..]HWOR'/\`5;]FJ8S^19?_`*=;@Z3TL;8Q*1M<
M'MAC='`L.]NGTOT5:;]C])ESAAT@O.YY%;1N/\N![DE.6_'JR+2PW96.[(F]
M[V74@UN:X6FNW])8]_V9]-=7Z*NVGT/T""<.\4/H9]O]M;*A&1C[S6T^JRVN
MQUOTK'5>C=;:QGZ.W_KJV?V+TC3]3I(:(:#6T@#3VC3Z/M2_8O2`W9]BHVCM
MZ;?'=^[^\DIR#@/=<R<?*J98XRUN14:@XVLO8YU>]KW.V6Y+:F5_]I?9;^D^
MS>D5^-ZU@N^RY1%A#B*;:75ESG_:-_NN9_)W^SW^C2M)O1NDL]3;B5`6[?4;
ML&T[)]/V?1]N]R-BX.%AAPQ**Z`^-PK:&@QQ.U)3CUX62,%^&ZOJ#V@L<VU]
MM'K>VQUOMM99M^E_X#_A%+#Z0+:S6]N7B.V5L>][V.<]K7/N]ME+[?TF]S6W
M/?\`SE:W4DE-#IW2:\`N<W(R+R1`]>PO`D,#MK?H^[TF?^B_YVU7TDDE/__0
M]#IIS1FAYQL-M(?8?487>MJ;=CX]+;OLW,];])_IU<PY^R43SZ;./ZH5"G$8
M.H"S]E,K.^P_:]U9/N-Q]3:W])^GW_\`LPK^&(Q*!$16S3^R$E)DDDDE*222
M24I))))2DDDDE*2247O96PO>=K6ZDE)2K+&UM+WF`(&@),D[1HU#Q7Y+Z0[)
MK%5A_,!W0/-P]J@WW.&1DQ6!_-,<1[9&KG_F^M_U'_;B?!S*\[&;DU->UCBX
M-%C2QWM)9]!WN_-24__1[S'Q<=O4O5&'EML]2T^NYX]($F[<[8,CZ%F]SJ?T
M/L]:K^:_P>GA_P!$H_XMG//T0LO[5C5Y8>;<XEAR"6EKC40QV1ZC7>S;[-C_
M`++_`,']F1NF=1LRNGX]F/C6M8ZMNUUXV=MNK6>K9])O[G_%_HTE.HAOR<>M
MVRRUC'1.US@#'S0`+7.#K'N=W#6M<T?YHAWT=WT[;$&ND-S['@6R^L-?#6M:
M3WM]71_J?F_O_HTE-UM['"6AQ'CM</RM0K\ZO'H??<U[&,B20."8GG:W^VB2
M29]-_P!X^/[Z#>QC:'1A^H-!Z8V:CC][\UJ2FQ7=5:TNK<'`':[Q!_<</S7_
M`,ARE(\4"S%KL<;`P5W&!ZS8WP#NY+7;O=^:]#D4@#(I8!QZK1[/SF^\0YU/
MM=_Q7_"I*;0LK)<`X$L(:X2-"8(:[_/8H^O3P'M)\`9/YW8?U'JK06>K>X'&
M:[U-37J[_K^K/TOL1#:YSME;C8Z8)K`#!_7L?O\`^A^D_P"#24OE9^/B-K=<
M2!;8VILP/<[CZ99N_JL_2(;1DY#O4L:*P)-+=#L_-]5[O=ON_<8SV,4VX3'N
M9;E`6VUG=7,EK#_P>[\__A?_`#A6DE(F8[&O-AEUAGW.U(!)=M;_`"?<BI))
M*?_2]&MN;7U6JI^<YCKFEU>%M9#@UK_4=ZGI^K_+_G?\&B8N7C#&I#KF;@QL
MRX3,#E&R:[K*'LHM]"TCV6[0^#_4=])0PZ,JEM@R<DY1<_<QQ8UFUL-'I?H_
MI^X.?O\`Y:2F7VS$_P!,S_.";[;B3'K,XGD(ZI.Q>HG*]5N<6T;P[T/28?9^
M=4;/I_VTE)_MF)_IF?YP3'-Q`"3<R!X$'\B.@9563:P#'O\`L[@02[8'R.[8
M>DI?[9B?Z9G^<$OMF)_IF?YP3X]=U=09=;Z]@+B;-H;(+BYC=K/;[&>Q$.H\
M/-)379D8#7/+'UM+C+R"!)/?^4I_;,3_`$S/\X(>+CYM3IR,LY`U]OIM8-8V
M_1]WM5I)2'[9B?Z9G^<$OMF)_IF?YP4,FC,LL:ZC*]!@C<STVOF#/TG?1W(U
M+;&5,9:_U+&M`?9`;N<![G[!]'<DIA]LQ/\`3,_S@B,>RQH>P[FG@C@IK6O?
M6YM;_3>?HO`!@_U7(&)1FU&<G*^TRT"/3:P;N[QL_P"I24__T_3QE,-_H;+)
MV[M^P[>8V[OWD!O5L8[0ZO(8YY+0UV/=,C^K4YNW^6KJ22FD[JE3>*<EPVN<
M"*+-2W\SW,;[W?F*7[3QP)+,C36/L]Y/$]JE;224@KS*K+?2#;`X@.#C6\-(
M(G^=+/3:[_@WN]12LO;6YC7->=[M@+6N<`8W2\M'M9_+14DE-3(Z@RBTU&B^
MP@!VZNISVZ]M[1MW*+>J5DC]7R0-"2:'Z2'._=_-V_FJZDDIIGJF,`8KR'%O
M(&/=X3_HE9;8UU;;`';7`.`+2'01/NK<-[7?R7-4TDE-;[<S[-]I]*XM!#?3
M%9+]3LGTV_FH0ZM63'V;*'T?\`_\[^S^9^>KR22FBSJU+FAQHR6DS[3CVSIV
M^AM]RD_JN*SZ;+P):`XT702X[6M_FE<224__U/55BL=E%IFO(#MCC[;+HF![
M6>M3]+=]#U%\WI)*?I`_;P\.VWN<"3L-KMI.YFQOMQ?H._\`)_X-2L=E[&!U
M=Y$.#B++-T39M?-=/N_J^FQZ^;4DE/TDUV<Y]LU6LU?Q;81NV\5[L?Z.YUFS
M9^C]E:L55-@$W90=#26G>0-3H"ZIJ^94DE/TVRE@]3]8RR"V""'Z?1]U?Z+^
M<_J)CCL+Q^LY8=K&CHY]T_HMG^?_`-;7S*DDI^FCCM.[]9RQJ"8#ON;^B3LI
M8`[]/E.!;^<'Z"?S?T?T_P#IKYD224_3)HK-A(R,P'>XQ#]LZ[A_-?S?[G_@
M:MXK0V@!K[+!+O==._Z1YWM8[^I_(7RVDDI^JDE\JI)*?__9`#A"24T$(0``
M````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<```
M`!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`
M.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("
M`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`&-`@8#
M`1$``A$!`Q$!_]T`!`!!_\0`E0`!``("`P$!`0````````````<(!@D$!0H#
M`@$!`0$!`0`````````````````!`@,0```&`P``!0,"!`,&!`4%``(#!`4&
M!P`!"!$2$Q0)%187(1@B5MB9(R0E,28V>+@903)",U$UIV@I-$4G1S@1`0$!
M``$%`0`#`0`#`0`````!$2$Q05$"$F%Q@2*1H;%",O_:``P#`0`"$0,1`#\`
M]_&`P&!YO:LO'Y8_D8BEM];\>7]4O/-$QJ=6'$^:J(DU.Q2<N?0C77QP$*=\
ML6Q922H600,P=2C4I9C6<`I&I":48#11(5A\Y;SUF2SE-%\]K=]JDO!_(T&K
M2O\`GCOKKMGGKS;*^7+6"SX+S[%:E2+#)7+V--&WR41F1J)DF0&.3(F.7N):
M0D.D"H)BLW1A1))S>SFP*^.[.+NT^<>7.U+OA'6U1]@))XQ53>S'44<I*<PJ
MU((U(W\^,2V(0M2=%CX\\)7$A&D,!HQ2><H`=ZI84Z@L8R66SJIM\:WRZ])3
MM#W"[=<R9AE;74W.=B].TL>UQ*,Q008;2<TL2"6(RJ=1MN;_`*VN/?$K&66`
MS1B@KU2_#Q]T#Q:M]9QB)*P^4WY!_P#M>_(M?UEV-&S.B>:+*YWBT(=R*V@B
M1#&4]B3FKVJ6-+A'DS`2QO"L+9*U:81BD@[9)O\`$4+^$`L;POS-D[+5PCLC
MMNA.J.(:[M3LGF[M^#=?RQ3`Y#`*UKF(P6R:I"<Q(G1//$QD#>70)[2P*UP=
MN(W$.R1)4YQ19(3!Z4IB9++D='\B7RP=(<^=W_:E+B;%?(O)`.=E'=RO43:7
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M$A3`$$HT8R"-*U);>A\S?;CHN;4/;O3O/'/':5W=%7-S_P!W490L%:IC073E
M$O-91A9;4C<TND!=<6+!*U>I"U0-<HE+FVIM*2DV])`;4CUM;XE!`2R6S)E1
M%(9K\V5;\GF?(G(>E*'E"-IKI'T#,N&]<_L+1$V&H=-*6:OC4WW0E7#L@V7L
M$),..5ISCC"23$YH2UBD00;,<K_G<Q@?3/S/7-5_8?',U@#:<\\-V9Q'2O6%
M_08,69G:9PN%6S9DUKY_G0)`E0&2/:VM3'%B&I0IC?:*!H30BT66<8>!I/69
M?.ME?/W6EEVG\H'7?/0IBQR/GVMZ!Y^LRJ$S.UL!@-J[*CT?>'%](EK<F^I/
M[8\EN>SD_J*#B-%F!V5X!\,=TS_,O=@W9O3'6<X[1K+XY^(I;"J>GSS2CMT9
M=W0\SAZ*QQUC694D40AD11""._@P/,F62/1/J!7A,)%I:DUK90/7'@DF;6"T
MYT[VESAU\_<*=FV7".A%-@\\S2\N:>E8E7#/5CV]KX"2Z_=$)L.NV,XV*H7%
M*A:3G`L2'U"R0%%A$:ITKV%",EFQKIXA[L[(ZM@M)2:3_,ER74]I6M+!QH/-
M$BY^J-;993ONR'2#QR,@])V9EI[M/TR%*K;P@1@,V6YDZ#H>_`0F_K5]9-_S
M6]CY3.FYQR'Q!;=X5@YQQGLEE<ZPCD*<9<C`MC*%TG5K0J'+G![)/`))IO:H
M\]+58]G"++\"/#SA%L.\M8]9MQ!/Q?\`2-L]'.MJ.TQ[GY:ZYB\62-;00R4+
M6[[7,EA<A4+CQ_5I(ADOMG5;'GE"F,*0J0)_:*#23/2-'LL>@R+[23L^7<'6
MUX</]@\MV-/9@WC^/"ZE2VF+:`JBK+[FE;A7(W%3!YRX3!*T%/A40D@PD:.+
M4*CB4I2!Q-%X>*4O!)++Y46DWR!]V?\`:N[;^28J7(H,A?K8B!O$,*<Z[A)Y
ML)H15T+!ZZ*DDG"O8S54I?)LQR58F\7'9Q18$0%J;00J0>1VU<GU(ECC7HB^
M[6O6G&!R^:/D+H4I_4B=GWGFOJ0JYFG\S;&V,N4ED$=:'ACD:EV;5K.VMYZE
M0>21L19*0P6PZ#K?@_LLDE_S4>?*#\J73?-_92.$<[%MKG0')<+IRU.[`[BK
M,]N1C';-L1*-HH8F='5&I7,SH?"Y&W*48V\9!N].QIPQ""EUH*T]?66<]5E_
ME3Z_O2J)?\?\3YIZ-KB@HQU5-YTSR>YIW$X5-(2VQ=%&8:_1B2*!S(29O2M?
MIO)@M&`5I=&A4`\P]^`=8J>LEW8Q/B+L#J<_OQQXZM/IN@.[Z]>.=G"[0W50
M<3C49-J5\;98BC1$5F>H,[.\3]H\`,WL!)AIR\1JU(;H917F+&+)FR+(?)!U
MC?M9S[E/C_D744;.E^RYC,6E@L*;-.Y%&JCKNLV1'(K#GAT;\!DO;VB:5NST
M1"@L]((I$J]0L0O3Q22<V](Z"AR_E?H>V9E7_3LR@77'/RZGY),HYU;'(E6%
M+RRN;+9TCFK20>5U,R/"`Z0L[@6CT$I2WM2T`!')AFJ@Z]R26Y/\WIQ5?ZJ[
MSZ7E/P'NG=SS,6E1THEK>Y)&3,"XA&4[2%VA]_SF!,)^XB2V`C(@)8RR)R1`
MVF\AHP;,'K8Q;%MV,GUG95;I'Y4^PZ9ZI^/EI13&/BH2=\;<8=%]6-RB$1`2
MA8GNB[]U'8\H0/AK5IQC@-FR)KVG3I3TZ4DT&M!T'0Q>+5GK++Y3K._D9Z@%
M\V-6\G0R5,B7DMUL&04T_M&XC&EKE(;`@//4:M^?;(E*MK,D;>%G=+.9D8@%
M*"P^HC,UK7D'L0V\GS/G>ZT/"O7][WASC\C=B6-)FYVE7._6O7M456N2QIA:
M262$U)!(B^0=N6(FU`F2/2AM<G8\9BA6`T]3H6@FB$'6M:)9)8J73GR+=63"
MO/A!D#]-V92Z=K61<\<Z%.+A,33`E;3#7M0B8"&LDAI+*BPTJ<O6A#;M)QF[
M_4>][QX7)_K\>B>2R-CAT<?Y=)G).S1N+,CK(Y"[J_/I*U,;&A/<W9R4[+`8
M9I.A0)3#1^4(M^4._#6]Y6'G*^*7Y2.HND^KW:`]2$MC'5W4U8SV^N(D((RQ
M,*E)#J_MZ<0QTA9R]J3$NCT["CK"J5^9Q,4GB0L@%83-`6`$=)6_;UDG'5^N
MHYI\M])]A<D\YL_>U7*&SM28WXBASI^U&O\`RU4SU(QQ^6)$+L2J4JE<O-7-
MLG*2:-">C$$:?9@O/Y_+IR2>MEN=$\IKI[QC7>,:X*D/0T3E\G=OC!G]SCL=
MOJ&%QEO5]&*KHLB&P>>@83$3IM$S,#(D:DY[1L\Q`J$C&:,OSFBWA,F;^JUA
M^5WI-Z^(6!6RPJFPOY`IUTNU<4)49\880ITM_CLI0(Y.IAAK6-B"M6U2C+$8
MGVG`0F7K0[UX^4(1MX7YGUG9^.KNV.K(!W[*.4C?D9HKCZ!0'FNJ)R.P;IIZ
MLG]!8-BNA+<V2A.W[>!,`D#@^*#CG,*8D[9"<HD8"B0@UKRB26;C<-\?,NG\
MZHMRE-@]@55VVJ<["?\`4>N&G81&X)$4,>1,\;;_`+($VQ9Q<VUP=F60)7!4
M<KV9HT05X"A!UHD.]UF]>C4OU'-/EOI/L+DGG-G[VJY0V=J3&_$4.=/VHU_Y
M:J9ZD8X_+$B%V)5*52N7FKFV3E)-&A/1B"-/LP7G\_EU.6I/6RW.B<[VOSY`
M66X.5OC.IZYZS7=96!4\PO+H7L"050U%QV%U2TRJ3,+`[PVF2SED=.D3HX-F
MVX!2GUDPE*<C0]``J.4I'XDDRW.'41J[/D3HSJM-\>7071-=6K*>HJ*LF6<>
M=BM=(1R%NT9L^NFAS=Y&Q6733.M##'5,SL3>8XA+3&#`+6DP-G&^Y.+1%R6;
M(@JNY3\Q%@]O]#\5D_(75#6Z<_UQ6EAK+`-Y$KM4@DY-CM[<O(:TT>"K(4-9
MK3IQT$1HE9^CMA\=!!X^&G)_G)<21\S/R*]8<W6A7-,<1C9%4WAE*V-U?T>%
MTB[/*`-5&PUP0-+7ZNW=&M(:DBQ2WO`UAA/I+`!`EV`8`F>(U/62\U8[OWO*
M;PGC#DGI_EV4(6A%T1?/,;0!P<61CD>SZTN-M=79W9#T;PC7)D#P$DLHDXP`
M`*DAY0P:V`6A:PDG-E;D<K+0]\E'573M>=P<K<RTMU;57(\'N"I+.F<OLNW(
M+7TLC"!ZA9RQ2UE*%4Y4-1:,;N4CTB)`!<2$1QH=^48O`.XU),ML0O4'R`]?
M,[3\I57RN^J1ZJ7\C\;2SH2I^LZ1A\=;XDW3W=9RF1LD#E[,R*GF!.CLC<6P
M*LA*5L_6BVU4!28=ZGHIGE;)_G]1'R/V=U-?C=SN]2#YL>/&6;6TJK<;GSB?
M051[L4N02YQ:TYE3!4)GU"O^[%RQ;],+$6D+-]T:'82]"\`X_M;)-_S4R=DS
MCY8J&ZGYDJ.+]V5C]K]GW;9,+@!(^6("<944?80(7YE2O*E:H5K)L:C:'LE&
M(WU$9AHT^S1;WL?AIRD^;+PLNSWIV13/?/`?&UR7C%[?(M&DND9I=DK8ZJB\
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M-=66;=$'3US8LH8?6D$0`?(QN#6K0*3FE1]?2R>"5TN:I"I5H##%:0AO&W$&
M"\$2M:E]%4;4O%JS^$,!@,!@,#__T/?Q@,!@>;*I:+^7'X\H;:W'W)%#TU>]
M'2:?V+(N<>@W^X(U"%O/K%8BK:Q*@L"NI&80[S,<2<5)BT!3:G5!-5[.$(P\
MDPI,7.8W;ZWFWE.MZ<-]R,"/@WJFLK-B?2/=/'33.6.TT]@GM\!BO1<2MI&N
M#-XJTNJ)K:VF.J8O]1.01\]4G1%C2C"K4[`I)`68)9S.SDP.B.[>TNU.;^H^
MT:-A7(M1<>)IZ]U=13/;T:O"<SNTYXT)6$Z4R:7P@A/%T4=9DR%,J2%ZV%42
M>DT5Z0P*CS2R;)+)>6K@[X:NXSJ$YX@[3&(_&)2ON+I:M^ER"+`B@S!\I7U9
M]730+DD<D<@*3N1[:5"EI@D"4PU=O:S8?2\WE\&-?4Y6IN7XS^KY3R]\S551
M.O8]]Q]?=75Y9W/+.7-(:W('^`QJXX'+%BI6H,=2&^)"1QQ@4#+2+A)C=[+T
M6$'FV$.V=4GM-]6X7G#X^N0^61-=@T]S#5\)MQ)#B&U9)H^R-YLKVK&T:)>F
MYED3PJ4_1Q/1XC"5`TYZ8I2`6@G"V7K]*S;;WX:-8=\)775Z5)UY->A^DIC1
M]O\`8E@SB>V3S_#_`,?32M)*<SOKC(J=:YE*DVEQAJ%C>3]"3`0G:"VI-E^G
MH!P1AU,:^I,R=$TN'Q^=7]"UC\-\.ZII:&RH/)TFGL9ZHC<DF$!E;"OKAM:&
M"(5T[FE%.JE--3GZ+QA$:M))">J`M"9LW6][T8-X-DOMB;C?C>D]'=VVO.N2
MJ@B%7\K7-\>,WIN9QB#.\:B\==.CSI-)U,77KX&H<$@TOC&?IZ<IT2)O3),/
M/T,0-'JA#8?6SGKJ*H)RE\C//G!O#E61"EJ'Z'0U"RV*R=4<06ZNJE0TVB4_
M3"6/,-<X5:LG:9!%6=Y8TCX(PW1JO200QD:$6<$*DD8V6U&=$?$59UOO_=<M
MM*@*Z^.RLNJN:T=%13EZIK`9;:;&2>M\C8)HRW?*54."UU^!3%I#&"`)6UI*
M2%GI5RL'E2F;&H5,+[=.=9Q(X9\UUD<HF?'7(.9Z,BZ)XK5%S_,>Y]="1YWB
M+W4VFE!"7]V14NE;R[+!+I)"0*"E)YJ<HDPP\P0$J86P:"Y/\[NI]A_QHOD*
M[NI58;#VJ;<<5W\2[=PE)7>0.K(!;+7]'/))MU9WJ(`<?K@T\HB#EI2K4E%[
M2Z-5#+";H8?#3$^N+YU'OQ4_&ST;PUV7U>^6(Z!F=".==PRL.=;"725E<Y$Y
MU[$GL*V'Q=\92%&G]M5PB*FDM(QJ4Y:<0D/E3;VFT1K21?;VED\I\[,YHZN@
MW:%8_(OQ)#X;<5@,U*/7.=W\\S*:(:V%9U9'2$^;1Y;#YT[E"8663-\GV5LX
M2\8"?*B2>`1A]<.R2S,K`:;YC[3Z1Z^>^[.S*RA7.ZBO.=YS1?-O-$6LAEM9
M]9W.>_5ON2=3^QF`LJ)JEJML=3F\LM'Y0G@.*&(M)[3?O1LDR)+^*+X\8US9
MQ?SQ$>B^=:42].URYSUZD$L.B%;328-CR==<[E\#=DECMZ!T6*'-IC*]J&D/
M)6B-0^D64`0!$Z"%#VNVYT6X[M@UXSWGYS;N>:_H.U[(:91%Y&FK3H^-))'7
MDV9FE<(3TQIAN`]-L=EQB0[U6MR4@,3D*"O(9Y`F[-+J3-Y4HXJYPZ<D/?E_
M?(1T/1\<Y-+L*AXK0,7H%DLZ)VO('XQGD#`_NUHV))J_(!#3G8H$73H6KT33
M5(4"DPDX!?HA&HBVS))5E/E6YRG76/`W0-#U?&&F763-&F(B@[0\N#.T)=OC
M#8,3D/NRWA]/2MK4J2-K6H&`X9I>_P!-@UOQ'X;M3UN65"7??'UM71\0C_QU
M2\.9#K7%5G-$.8(6!ZC\;8DJFL+#I]\D3:F>%RM%'DB1J9(>MV3O1H2S?2"`
MOS;&#6YV67/;4/<Q1KLR#6A47USX<.0*6:6EQ9V&3WC`+@HY1/X?'E:#<?E$
MI9DD=A;:^N+B>R*E.C4I"L`U19PR1#V$8O$7.>:J'"OA@ZTZ(;.U;3Z0Z.FW
M-MB]EV?+G&94E"/QW/X0]UNSF#4TVPS>2(]NQIQ,4,<5"4HI"=L:9&029K>U
M'FWIB_4F9&4,_P`=775V5)\/5;=84E"Y2@X]G5EQ7HQ@D4SKZ5QYSIM.V1YA
MJE9M`G=UB>3AW%&5&A4)"O<*M*&\1Q@=:-!CP;-]K%VJ?X`<N7OE,%='-%3Q
M.I>.I]QR&O;,88"X,#`PK+Y:K-<WQH=EE=>](5!&5#4R(DEQ0I1:`:<>`6P^
MNI$-W3=]<O5E_P`DO*71-CV+R5V'QZ"&O/1_&TRFSBV5U.W;<<8;8K>T8^DC
M<_A@)*/_`";0^*&Q%M.D&J&E3!(<%9FU`#2R0&B6<R]'$YL:?D[OZ\WZT^PV
M*,<B\\HJO>:_8.2X+.(-;LCF<P?A+TJRRIM9+&W.J!&4V-J[>D*5$L+"(PI/
MZJ4&RU`U;DOS)QU:L&KC?Y:J^X<E'Q%QCG6EY13KL^2R+QOMI1>,99V)IJ>;
M6HNL5XV^TN>$^QU$I,4NJWQ.3DF%I250"2R5(R/7,<]&M]=^M6!ZN^*6Y+7N
MUQ;8JSMD@I]F^&,7%<3F;K(&!L5KK^@\Y>Y57"=='CW(+LE;U"UO:5AR[T]H
MR=C$'9GF!O6,2>TS^V)\Z?&_VA'+<^-"]KBC#$JLJ&](]_\`1?:3HFFD66:8
M)3T,SP:(5^<U[(>U8Y6!QC-?(`>1N$I^GE``2;Y?)K>V="^T_P!.S(YV^4?C
MLWO+GWF?FJL.CZ8[+NBYKCKR['>\(;7#E2CI>K$D8)"584$DXD;O./M]"C1A
M3E-.BRS#4)A^QBTJTF)<F^MRV\OO9WQV=@T+3_Q",G.-?Q#HN=<#/MBRJR6I
M=8S'6<=>7Z:IVAS4I&=\E?MEIK-M_6.!2<X*09_MTY8S22Q&>73P;-]M[IIZ
M>6?+AUEQGTG1*KB^NZ+G]HM4.KJ+.K+TW`INC6PB6.R\NXU+T:80SEMB0J&-
M^FO18/74J?K8AE%[]N/'*3YEEU6:9?#AU=S=,.&;MYKZ)GG4$KY"LN),+/5%
MB:K>MV6-\_.#>K16>R0U^&:W@%];;$I;:)(J/&8,AQ./"/U@B]1B_4NRQLY[
M$YCN&WN^/B[O>"L"%SK7F.2=0.-PO"E^9FU6P)+-@$$88>8A:%ZPAS?A+W-C
M4@&%&4=LC0-",\H1!WMX27)[0?>8[A7?,=#.OTS`A'1+/P$JH5?)MOS,!Q*L
MLV[97-`,X8T)9I^-2;C[J2;[P)&TOF%L'G\^MZT[F_YSOJD</^+"Y&'Y<7.Z
MCDS.7P@U6O,^SHJPZ>64T]1U7/J]C\/>`*XYM4<_E&-<O"KD*%4`@A&2$@LG
MSB%Y0;9ROU/G.[Y]5<G]<)/DNM+JNM^$Z*[1JN=<_5]5K6RW38]6QI`P2)A7
M(G)S?F]IG#;(E8'!.%!M($S20GSE*!^4W>O$.Q+,RUM3X;_-*:L']IN?D.I^
M,E;9+U08O6E.32&S**O#*L;6Y6JE1HX.RL30TN:MW,/(-($3LT82`F"%O0M>
M%9N=J@SL3F.X;>[X^+N]X*P(7.M>8Y)U`XW"\*7YF;5;`DLV`01AAYB%H7K"
M'-^$O<V-2`8491VR-`T(SRA$'>YX67)[1@O<W,/4;7UK0WR'<5QV&VA;E65I
M**(M2AIW*TT$16Y3CXXNLF:$48FRX&FN.R:/2MY5*@"6F`3F&B3F;%L"<Y,K
M$LRRL+H;GOM/I;O.NN\>UJHA?,$>YRK*;0/GKG2-6:QW+*BY19B5T8IO/IQ/
MHL23%C-*(LXF)"B4F@;-UI/XDD"(.&K%LDR5-]+<QW##?E6[/ZD?V!"EIFXZ
M2HR%P&0E/S,J7ND@A#.R(Y$E4Q].L,>FPI(>B,T`U0266;K7B#>];UE[IO\`
MF1K^4_%%U=U%UCW+TI==^3SE))=2Q=15?1BLS*WGA\ZY62,J./DM$Q$88[(V
M1LE*!H1GJFL(@'&+!*!GZ%O8!BF-?4DDD0\N^/+Y$$7Q>5QQ^;6\<G-E<N]V
M,5@4][BSH*UMD_YZBCE*9:S.JM\4NVM,"T4DDJE*!`LU[Q,@&GT$O82]EENQ
ML^M;G^8+I^0Z?V2>Q=1<45YS]6H(RZ+R)W%^D(O:SD=)DZML+:V`489VI$K+
M3."0]28-5L?D*VG"'>M['KPO+-SM5>^P.`U_4_R0<@VY8M0P:U^6ZSIJXHK:
M2"<FQIU;BY5(4KH?"0;AKNH$XO/INYB<T)Q*<P"<P.A"$'R^.19<E\J_Z^-N
MV*EL'Y<X3SM5T;@G,O77%:Z%43!(O)HRS0XZ_CZ;?((J3?:JIU)/@YCJ]2%3
ML2O9!#:,LP0S3`^0H(6=5^O_`,[UU$7*E*=[<[UW0U?J_ADXXDTGJ!F@K*9>
M*R[:&2V"X/$3V@"&Q1+"H<X/2>4EJDFEP#`+S%(%(-;"=Y]:%@MEWFMDG<O,
M=PW=UK\9MKUVP(7:$\V7;8<TMMQ5/S,U*&*/R"-QIN:U2)N<5B9<^&G*VTX.
MRD8#C`:#K8M:UO65F7)4<_(+S?U;KJWD?O;D""1&\9USFR6;7TVY_ELW::U.
MGL(LAI4(-K(G.'X!;"RO;9M>KV(:T[0`F^U&$H\L"@@R++,LJN$"XK[7N%L^
M6'IKH2M(545Z]O<I2#GFF><8W8K!-PQ),UTO((0PAF%D(#"XBH<)&^FM^M*"
ME/H%"VI,-TG*V26!Y79/F3I$36O\,R]#\8E*LE`\Y55"/DGK!IH"2_D6,.$0
MB<U*LJ'/C"9.7(=G$+$S.\*0(]K%.Q*%9B92<2`P'G."3C/^GUSST7/4?'W)
M+A[M^1&:WM`DBCE[KGF.G*B:%>Y#'E#\H>8TP,29[$6TH5Z]R8'N)O#?I4@7
M#+],M:E*.(&/RA%LF\3RQ#X8.%>IN*)!V@GZ;<$,J-L2?5FGKFR$T@:'=58\
M1K5FF$4;Y.Y-Z)8J=F%6J8SFT0B'+05FQ#%Z@C#`F&;0]K+F-Z>5DP&`P&`P
M&!__T??Q@,!@,!@,!@,#48Q_)4_N_P`ESAR']A,'[>1N<GI)AN\M2Y%N:SJ^
M$UE&[IE-<*3#U>F338C@KT<C+)TG"J,=TP@A.$'82Q3NUG^=[N_=OE_YF;I*
MNBJ&N^IY2X!=K@C4:4Q#GF92!JL&74)(%3';<4@3HDW[1]<X2D0G.BT_8B6T
MAM*$(:H)X=I]-/FLLF_RM\G0QNA;^E,MN?Q.3T["N@Y1,:RJ&8S6-4S2-A>Z
M^T[(NA<VHO5A3,XZ;5HA)M%*G,@M`H,-2@+!YQ-/FNYD/R<\UQRX5].JD%O+
MS6.VZ_I*5V>S5:_.E)P^?6PUQ1SK-!(K03;%'DZ6;"F:!.D-)$?LLTW0E`2"
M!%G#NI\U^JT^3?FVV+NA-&Q-NN/ZI:4TMB"U+8;Q4TF9Z=M9WHYDE#U:2FO[
M(6%@97]KB8H@L2&G!\FSE>@:)"84+U=-/F]4`=R_(W9_,W0K?2T3:^:(8U`J
MUBL9MEG5]DS2HX_=S^\O4P:E53U+/44465E%Y-'4\83'+G"2.Q*<H;LF#M.$
MGSJ0S5DU9J4?(73L#M6M:BG$1MMB=;*?ZD@S?/"(2-UIQ'95UH&U9`X&ELE*
MO`WS%8Y'O"5.-R8"'5E3'J``4*R1><(+J96*5S\I?+UDS=BAR-/;L4;)3JZ"
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M23A#7;V6B$KT$0M-/FI^YH[-J[J%TFD8C,9MNM9[`VR*21]KB\JV>ZNG(X3.
M]._V3/FEG>-FE/$0DQK`N*)4)SAF)STPBE12<P181U+,:?6_YF;8+ZI>J:7&
M<COS<A[TE'("&CF)VMYLZF4Q)NNQPJAOM0.U:-YJL:=N:DX7A:!0H0D'DD'`
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M3RH1`6)U98'0@W0P!2&"(5:(:?-2VL^0KGQ#=4HI=21:@00F5N%>2^XBZIF*
MB@(S9K1"PV&[5L]VVG;S8\W2UKAPPK%`#?*C(\X21J`GB"5NIES4.H?E]X^5
M069S]>9<$6;(S"(#9T9;)O4<IA+]<%9VI-6ZNJYL.GT$H+:BI;#I;-'A(A)6
MF&HRT^U19JKVY`O5R:OS5VZ!O:,=$U\58D5CL_B:+ZR[Q];'[*B2V'R5O=64
M\!*P&TQQBQK>6PX)H#$SDUK%[6L+'XD*3/`6@UF\*@SWY#([2=X=<1&Y6A0B
MJSGAKXN+C;Q!8Q))A/I%*.KWNRXR!L61UJ.7*'4I$_1)N*1E-R3W.PJ3?$)X
M_3#J-9N8YA/RA<]'0,Z4ZAW06IR5=BGG@KGG5+R0[HI5:Z6&!LDR/D5DF&>>
M%)JN!?71.!JHMO*;];]0X!VO1RZGS5V*DM**777$2M.$?7`QB9-GU)M(DT;?
M(A(T6RE*A`N;7V,R1"VO;*[-;DD.3J"#R0B":4+R[$#81")T5WZ?ZM>.>+5Y
M!KALJ:16.GZ?N5YJMQ>V)>T)-00AJ@CY,`N@DSFX(=NJT\+2,[T-;`7IM1+C
M?5]P4F2JRR;*J+RI\O-56G7D.=N@&"74O)7VO[[L@^:K:TFS/0T@8>>'Z3BL
MQ/74U=A.:R5ND%A+*4X.I:<!Q6S-G%IS#3"Q$@FK?6]ES.8>UZ>ZO6RQD@C9
M9L,EL.9(;+W.$7#74@K*6K(!8I#HH@%BL;4_%!"]0N7%,JOVRI.8,PD9.RU1
M:<P181U+,:OZ:^8N=V+'&1JD]8PV(6T[=S5#134R'C>_H$ZYGM'IIYYO.NB$
M!,?1N9K_`!F81![:5Y9@S4B-T1IS#"]DK22M36OG_BQ#E\E3^C^3%%R"5`F`
M?/(7!HI%XNXU2Y%N:/K-_K&07>TUTG4>Z^A*&D^OVI.A$1I/M6%[5:!Z_P#"
M,@#>4^>-[L+AWR9VC*.TWSGA<Q<QQ)B9NB9+1FJFG=MR2N^KG6(LCHYL;5?T
M18)[&X[7MB0Z6'(`.3<R,"I>Z*FDX(B#3C@F`+:?/&L9CGR&=F-\>6=)SZL^
M:G#C]IZ^?^8Y2"(O-FM%\Q!A+Z44<TL=EJ4CSIY@L@3I)4>A4+4"8PD\\A1O
M97I>47E:?,Z;REIR^2I_1_)BBY!*@3`/GD+@T4B\7<:I<BW-'UF_UC(+O::Z
M3J/=?0E#2?7[4G0B(TGVK"]JM`]?^$9`&\GSQO=ATV^0+L`R*='=0U%S]2<F
MXXY;GUKQ.5))39$P9^A[6C'/[NN9+KLBN4**+*:ZCK1'EK(Z;;&]X5#6.A#8
M:,0DPQD%&C)Q+>5P.J.L)+6-=4.=S_#H]9UN=6V)$:UH=GF[RZ1*"%*)1#WZ
MQ%TXL!V;&MU?D$2BD%C*Q<J(1I37!0;Z1!0-"&(0*DG76&![&MJ@*Y=G3N6D
MBHO/AVO'JDIY#S`X+[P0]2/TKCJB1M)=/PL9#79$8>T!#2Z%N3?)DJ`A,!L,
M4E+E"<>A!&;T=')?E?YCC\*KR6I([?DN=;&*O<"*LX?2\G=K6BKSS*XQQMO.
M,V%"3MH5D(?J\')B358%XRDXTQ8S23C`"(V<T^:XB#Y=.15D"LNR50;H8HO6
MT3I>Q@"D=+S5E>;%JR_YVWUI6%I53&UJ(M_G$'?YJX:1`4$)@'C$6(99)A8B
M1FS5^:R/7RB<Y`@\GDJV-7VU3J,6_'*(,YY=J5EK?T6\VC-(R?-X1'&2KE!0
M5R@$P@J-0](5AQY"+Z<E.&<:2,H9>KJ?-=-(/ECY:9(K64@1MMRR>06>YVPS
M)JJC]9K@V]#G:B75O8K@9YW`GYP8G-D?X*\NJ9,:V$[5.:\9P!-Z=86+0\FK
M\WE@%Y_)D[U`XW$JC59CM]J@UJ\.0!CB<?:W^%SUH:>N$*=8-ZG.YZ:T-HG,
M'N2B&EO2DD'%N"E.D<O:Z$>I3M)-[K"PSY%N<YQ?)?/S7NRD+^MGLSJ%BGKW
M6TD:Z=D]TUPS+'VPZ<CUF&D#CSA8$-0M:P*HCS`2'J$1Q*10I-#H`JF7-8';
MOR&1WGSH>]X#;[0H3U/4]7\M2=I>X5&)),+!>)KTA:5BUBC8]QUG.6'.J$ER
MB[?I,4A1B6;&H-_0[?I@U-6>NR6.0'Y2.=Q0;[FW$.@03G=XF\ZE\]?AJ0&=
M$G6J1#RK%.9BZQ(.-5?3RJ[."^#7[4:1EH-_QF!/_P`'+J?-075?S#U2NJ)M
MGMLQ*Q3)2^RGI]Y3PBGJ<LF5R*'\_<\7`\5TX7):484ISGZ`,S0W%H-O.W`)
M"@MQ..))2>8HPHN:M]:L?_W+>=5%ZQ#G)G06;(K3L=75:ZL6IBAZ96VV365L
M0U\G;=>T+>37Q.WNE,Q%@C:W[@=1C*4-2HG2<249QI0#*F7-;!\(8#`8#`8#
M`8#`8#`8'__2]_&`P&`P&`P&`P-+S5\)7/K2*+6&38MKF=11_I+74CCT6=,9
MH8;([)/LQ3/W<:ZFC)H.G4J1Z:SPL2@TEJ"M-;B]>H>,8S//,:^K_2P<,^.*
M$PQ\J=\2V1*5IM3V%VI83>0>U-)9;LL[36/JR3MRP18O,0FA0GT>D`@?QJ-%
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M3+D+`\EHF-'96NQ&6\6F61&2NC>0M4Q]I:$UWK"4ZM(2<?Y$Q8Q`%O8@[&]6
MM.FOB\Z<N&33*)]&2._ZPIYIXH*Y*@+E8L_YDL*9-*1%>%,6E'XS#TM*,(&2
M;50WL]._2WY7-DR1YEC>Z"1*$)"<(L8OU)TZMBU1?%;6E/3*$S9CL9_.71+I
MH_J,UF0P:M83$C96KH%RH`V'QR)UY&HI'HA`T3$O"J1)B$YRLHPG03U*D8S#
MAL3Z=<W?$C2IM?5W5TRF\QE\*@_.W2W.2Q")(TM"Y_CO2UBL=CO,E"O(+5::
M))#75A)TUB`4:3Y]!,-`+8?+MA]58_FCCTZB9U.[=L&][2Z6N:<Q"%UB.R;7
M10-K<8]5-=.,F=8C!F%KK^)Q1K*!MUEJQ<[+C@'*WAQ'[DX01^.MU+=[*M&?
M%2L=I7+T$HZXMIWYSFG64B[">N:D,`IQFCZRQWJW172F:E=EAAZZU#8PBEY9
M&C4Y;F1L].3Y0B)$+S:F+]?G+.7'XSF5,H)EU<]!6G4ER,71_4G0D)MN'LM>
MNKG&P=<R#;Y:M:+HI/(S+X=)X<I"0B"0)6C]T4I;4JD`P&%_JP^OQQ3_`(R$
MT6@U90>A>K.AJ/1PBN'ZK)@%+JL[/8+AC\PG#U8\QDD\@=K0.5P4NT'^:2AV
M6BD;<WHUH1.)A8]&D@)*+8?7F/Q&_BSA%6N4&!S]T/T-0,3:*LIFG+1C=?/,
M)"XW;#:&=I$\P`Z2SAUA2V80R3F*)6O3.CC&%3.-:VJC$H`$!%YM,/K>L8!:
M?PV4E:8!.KG-E?WLDOSJ6[V1_E%44Q;$<1D]9R\B73R&.E<6_"IS#7Q/&UJ)
M.-A<QIRG!N5$^MH0@F'$FL/JLY=/BFJ4^L.I*F8)R_1>+]/4'0-!N9;+$X.S
MEPQIH4F=@0R1A9(NSQJ*`=):JGJE0M2IF]"W$&@UI,047OR!8?71GYOQY,`[
M2M.1)[\O!JHNZIO-+1L[EIB<(BRUG,K&L2`AKN:NCY*V^*DVPLB4C;`_4%,;
MV^Z9S'G05(BMAUZ.ZF_G*NE8?"O1]50*P(/';`4$G2B"Q:L(Y*T7/?)#-)6R
M`Q22L<LTQV4L;*)(!T&*9.<:0%R84Q"Y$/9"0L8R2EH?>9,7ZJ>^8N&'WCX=
M4PVG;5=Q5B38]XVO?#`HCL%B\5FSW8D08X_%H]"8#$8VVLM91Z*/C4F<4+>R
M>S0%[)6C4://6A%JI;O5V]N_'O#K<LJY;*<K"DS0NN66<4RQS;$36UGI&51Q
M38$AL"+I$)QXM'*"9LLD(TZ\1G\2<HL(B?$6]Y,6>V8QN=?&VPR2?3VX8;>5
MCU1=+_T>'I6`6;$6*!.[E6<E5T"U\Z22+)F"=1Z5Q661&5P5"9M82O1;-]<T
M.RQ@T7X#8?7YPD.1\UW[&:Q=(I4?6EP+)&74L(KN+/=F&Q"7/*:?-MGK99*[
MPD\H<HT:N>7N2QUX$UKFLH@IN(:D)9+:0E-V6(%39WB3NB.;"+ZD7/$P33Y^
MKV4<Y72BN*,.3,TL3XG>A;B,J@LABKTW/Z12GTW2",3!63[DG8%*0S832]^8
M.L$N:J7_`-J*GG.I^?J6ETXE\E@]%P?J^OCD_M&IK<)JP]9L[^R2LQ6M("?]
M"<XLFD!AC:>G`/>CR@#'KQU@WND[B+X]*RXC-F"^).K-)GR4M,<BQ3VBI'G^
MH7%%$HH486W('592E9P)PFCXZ'""I=')X/6#5K`:-)*3>8P(Q;J'5GQ'4NNC
M?'S>?-Y87+>..FI'T5#9VE;VE,[2Q#+NAGCHZ0U1*T@/%*HAJN9*T&BQAWM0
MG$UE'%^`S#M#F+]=6!.?PE<^NVG>P%=C6OOJ)RZ5#U2FZ+!,9H4)HLXBS")X
MB/;Z7*F@*="G;6(G<?3G":]KB&X6M@/#L``A8?5_I-DF^-=%-+3:Y',.G[]E
ME),=_-G3;%SG*/QM(XXPVPS2PB<-A##9[W!5]R,E9HI,G`>5&4CV2B+*U[<(
MM)]:*RIOYRPJ(_%BI:I&B:IEUG;\WYS:.D7[J=KYC!#JJBT+46>Y6HYW*T%2
MJ;,\5'9<PB##/G+ZAII6.FTBD],1L8=%E:+W,6^WYRPAS^$KGUVT[V`KL:U]
M]1.72H>J4W18)C-"A-%G$681/$1[?2Y4T!3H4[:Q$[CZ<X37M<0W"UL!X=@`
M$+#ZO].7T7\.L<O4-L1B/]9=%4[3-RV++[KE]'0P<"60G=R39H=FN421M=':
M+&39!$)@8_+CW^,ENFFQV,6G_P#L>8.P,)[9V7LZ0Y/BO1=6P>OS9C,JLD=3
M2^'V-3UHUB8R,\NK6P(,W+V9D?F1$O:'*,J6]0QNZUM7-BA$-$J;5IQ'D!X@
M&"I+BMRGXT&YRA))[ST_T"]=+H[N8>BFOJ]T5059.6*SHW#G6O6M&P5Z?$3*
MC::M!"7Y<V&Q8MF^GJ4ZL6SA&&`*,+F+]?G#]1KXPJ^C2R!/?Y7L21RZ.LG9
MVIU-90DC"J1VQ.^VR(458U@R;Z*U,#(U+H^&$)"6I"W(DZ(E$`I/L/E*T(3#
M?Q7'J#XJWIRYU+B-)3.3R2P6/EK@3C9B3'J8O%#Q0/D[J2%VNY6>G?',0FYO
MF@XP6XJ=)AA,3>LD*`4`P8]`$PGMSRG+_M<-RYMD<QDG3]V/W5;U><+Z`;>L
MM,M4-,WC4PK:`.U4P5A:Z^;8(34YE?(*ZD#@WKV4UH&D=1N"@\[6A[)T2P^O
MSAB-D?#S65C5,TUHZW/.7AS52RWI[9TTL6N*&M=9:4]O)W2.\XL-4P3>LES!
M7]A-OL24;`ZQ8IG,:6TH";8%!8`:"P^OQFTA^+&`+HG:\7C5P61&39\/BA7&
M)&L(8Y?((.Z\,M\=05H[*U<D3*BIRMD.XR0<\"<`:VH-$,6M_P`6\8?3Y5/\
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M]0B=J5')8"R35DECFK,9)`UM:-8@`N5%C`>2>(K3#ZJ<]?&1'FWHRM^F8G=T
MZB<UI9#5->4]'6EAC:.NX/SI7<*D$/D'/Q,':BVEA5Q6S37_`&YN:P!2=6A7
MHDFVWV91`2L8;QF+O<_1FT(?4<4CUS34ZP['1CD2A^E:HEK(6+$SI*7MVCK>
MNTRM[2T'.$=C"Y$VJ#DR8DA0<D$:`/E'K*S?Q,N`P&`P&`P&`P&`P&!__]/W
M\8#`8#`8#`8#`8#`8#`8#`8#`8%3^W;Y=>;>:YY:<<=HFS2](MAD7A2B;1^5
M2QA/EL[FT>AC*A'%X6>BD,B<U9[YL*%$6K0$*%OI`4K$:;9RHDLFUJ;J?Y$^
MX+=<*UI&/I:$C5R2CM7IKDM_GEDU5*$K>A:*.Y?9>@T4M55?`.AI@BCDY+4N
MQS<M:@RMX1B-2A`(Q*8,W1$:R=>V,#D?R==/V?3M?QU)(^7J%E\@Y<['M*U9
M_9()LVQ6=OG.]VS7G$R#T(:1/F%SBDI>!Q@^2F&JE#TJ:25"7TR%(2CO4:?,
M3A:]HWFQ?#_\>5B5]=+Q`+#D;=\9*6:V,ZZ<Y&\R!ML<^HH_*_N!S-DK&O6E
M/+E(@+'DQ2J,VZ(BE*0T0-J]J278DGU=1K#.H^MJ3N7H"7)Y3`+'H!T^8"(\
ML2&$R9FGKY:Y8;E@G.\:+657(=3D,3AL3AZR0)W%`Q:;%@%JM8NT(TG8RQB&
M3)YQ*'QM?)ET?UY;D6:+0KJN&FL[AJR>VC#/LUI=8]**K51":)(ZW1"2KY+9
M$@46PU.C.(W2I\;V)A`@?B#$PTWI&E:)2I[>LC7[V9T5TI0$H^8*Q2;#L1VY
M]E\E<N9DJ9LDD@TX\UW&=R]6<VHVQH,:0X#41>,3Z3RMUCKQMNTBT2[JF=2,
M8_`7E>6I)_GR[/Y+N\YI!.GJF,@-I6:S(.#*;H^Y9I!8,SVD[L]YV%9L[KA_
ML*N+7>(4T.T0;8PP\OL;@ZEG296VE[5N@PDF;%L8M"3B_J1>\;X<R+^NZZ6G
MHF>R&IJ[J6C+*B3)0W;JCFBT^?8XOA)<^7RYDYULF.-E-]7)[@;5X3B?,X.9
MJHK8V7T@*@EE:))TF/CT6^UW*;*^6J\IGUA=M"V!1T;HF:<PM[1T9/*L`POS
MCQ55%A,+,AHT4P21J4JY98RPE(L:#FQ4:N5.!J;_`-\[S8\D_P#F8B?Y"_D(
MMQAOZB9`1.K'@LEXDH/GN^KCJ6O8_9ZR/VO=5NRVL95<506@N@S*Y0UCB4.Y
MU:'5>2*2J6PD*EQ&`D?CYA:+)Q?U9B[KHH^U[M[7G'3_`'5>G.,+IACY^5\K
ML%)VS8=?IFJKK<JR&2)EZ6:H/7!@'.[5CW8LT5)%YZI$XM[$@0[3+-$D[$:$
MDEF9$S]`W?><T^`YOO6:.[]%;QE_///LF?)''I`LKY_7.,CGM:$&2,F01XU(
MIB:B<,2W2Q0--Z0$P7`P(2P`UZ>G9,_UGZUVMMVVA2K'WQ#!*I4SLS#SSRU9
MT2J7]\5H]H0AH>'KIW=?RB6ZZ-8)17=A5K*GM`H2$[BR(U&%>D2Z5'&GD>)`
MBWG&R.:?(YT`U])2QC:'+G%!641[?KWA_P#;R[))(LZLE(;`30I/N_X\K+FS
M<SC9F]=+MNR)JVPC2+(XWK!&.!9X-'%DR9_2D$#^2SM.J*`H>&-4L@UO6C8[
MSWS8KK:5LP*52A,AC7.G0$@AS/4HTS9<L0,`J6&?YU4]*W31<7B:Q$G`@4^@
M!:8U?F:N\V_)%T'/[+94K0Z<@\\Q>)59QG.YW7G2DGE!<NMA]ZE"<HD,>I^Q
M(._+VM(AAGH[:V9<1')*6\ONP%'!3D&;$6U/E#/+W6'7-5.$`,D\EK6Q**N_
MMKY`*49&B1-]@NES1EUKZ1]%V+&7Y5/G&;&QY1%&U17&F9.PD-)84S3Z>RU6
MA[T`@U9*X+9\K7:%>T[$;NN&(<ZSIOO#@.;=;UE$JQBUE0W\=2:$R*I([M'/
MGB13R;GR:%'([6T[NFTA2%2@3-YI)1QF@^X,:GS/_+F3GLGH.9R&+4I-[5IR
MPGFKN]_BS4BO3D97*(O7<QAG0]RK/N&HY6A/GDVV)T:4<9%I006YGI'=@<T@
MU*8H8A:.&3_Q6:M?RHW\CL!#,'9!0<SK68W9U;2#5R?`29&/L*N/VU1FY7YO
MGTW5J9@N9EZ>4G5'K;JBTPH26Q"_MAA"@\>QZ.:?*+(K\FW=\OC\M3QB4\1V
MC+E'QO2;Y`XFV4W'YTY.<2>8O8]3%NM#3DA9;,E(6N!-?R9Z1$*`$(%RA["G
MV(HL"0XM:T^9^]6UW@WJR3]EH;XN=`"/E<]EVPE@7.(T#>K*D+Y'8A!(K^1)
M7(G<U:<A=B7&T71S0H0D)TOM"FL98]&B_P`8=9LSCNTL<^]V=Q1CD>OT%6R2
MEGI%17Q1M/>%@RR_8[:5E639#PR6=?;4^P,I_:[/C*9,DD,9JHD`'%44H5HU
M`Q_J<$T&TD;LF\^66]F_('T!:;+=4;AT_I>BX%7%D?'HP!KM2\2YLZNGZF[)
M;SW;[Q+8%(FB9,K81!DZ*2F,NTNF94%V8TSN<>>0(($^B23A-5,_)]U-=G2+
MU788G5-?U1+;`ZOIJ+.+W&7)OF-*OO/R&5`C=CSQZD5KI6RT4*]YC_\`O0P-
MK"RFL:)2G&%8+0#CC6GS,U93XF>X[B[OBEO3VTE=1,A-=.\"K=O@-=I9)I]4
MO`((U2.0W0ZJY0)*N#7%S*WC2Z$D%HBP@9TX_54*CM#$!$]IF-O&5DP&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&!_]3W\8#`8#`8#`8#`8#`8#`8#`8#`8&)SF!0
M6SXH\0.RX7$[#@\B))32"&3F.,\MBCZG3*TZ].0\1U_1N#0YDD+DA1P`GDC"
M$TH`]:T(.MZ##8QSY0D).C"B&4A4,140AV<7Z%GQBM88P'1%]=XH"!NSU&#6
MIE2#8'9T@Q8690I2;*./:0Z2#$)/KT\&WRZUTYDYM?&2*1EZY\H]XC<#?G^5
M0>/NE3P-P9(;)Y6Z+GR4R.*-*M@.01U^DKTZ*5C@L1EDJ%BI0::<,9A@Q;+M
M\LLDE0U/,JZU4$OJ^NY54NFMF8]5=)(5&GRNM,D<&A,CS/J$N;8JC6FMA,;$
MPD2?VWHI=IRME!#LL/@1P2Z-I0I.>D*I^K2DBFQ66X%*4NOXF!.HMJ-@92H[
M:)Y`6C19MBL)<:;@HGL6MN:4+>FT4<'1!7E&WR_<-I*F*YD\LFU>U%6$$F<]
M.TIG,NAL!BD8D\T4!,]8)\L?V1I0NLC.";_%H2PTX6A?KX^.#;Y'BDJ8D318
M<?D%15@^L-NN"=VM=D>(#%'-HL]U2(6IK2N5AMJUI/1S5P3-C$A3EG.0%)@"
M$9!>MZ`27H(V^7W0TU4#6CG[<V556[<WVN`PNTD*&#1A(CLHLYB!%S2Y^F3M
M99,Q`;&2PMPM.(5.A(`Z3[_PM:!@V^6(N'+?,KNJ@"UVYTHES6U0SL\>JU6X
M5%7ZU56K!'B=IV!C@"A3'C38<SL9&_(C3-VTQ*8'\)80Z_3"[?+C2'D[EB76
M4*YI7S30$GN`:YH=!6O(:;KIZLH3E'T"%J8'$4Z<HXIE&US(UM:9,C.]UZB9
M.G*++V$!8-:&WRSTFHZI3EV,416->D%7"-29;A9,+C99=IF+674<6&6,`#:$
M,W&KCP=(#=N>E6S$6O0%XE?PX36$O_+/,<K201!*><J'DJ&KF9OCE9(W^H:^
M>4E=1YI3:1-;#!$[C'E),19FU'KTDZ5OTG()*_A`'0?TPNWRRM;2M.N57%4>
MZ537#K3!+(V1LNI76$QMSK;4?9C4I[2R"A"]M41HQK;5"$DP@@2;991A0!!U
MH0=;T3>_=AL8Y.Y9A,/D]>0SFF@(C`)NH:E<S@\8INNF"'RY4Q*P.#&ID\9:
MHXD97]0S+RPGI!JR#1)S@Z&7L(M>.%V^6:*:6IQ;8Z.XUE35HKMUN1[;F^U%
M,$BQ]CH6_:;:+:!'.#6H<G3(]H]^ELH"H(/2_A\/+^F$V]-X82Z<F<KOC*XQ
MIZYGY^=XZ[SQQM-V8'2FJY<&5SLYW)0IG:QG%J5QLU"MGCHG;$Q:AW,+$X'@
M3E!&:+18-:+M\LU?*6IR32Z(V!)*FK.0SROR24T#FSY!(L[2Z$ITYIAR<B(R
M1>U*'F-DD'&B&`*,XD(1"WO6M;WO":^)-&THG3LJ0BGZM(21N62>>QU*37\3
M+3L,ZFP'PJ9S1E(`T!+:Y9+BY.Y!<W$C1:Q>%Q4Z/,,T>;YR[?+]-U'TLT$Q
ME,TU!5[6GA4(=JSAI#=`(FB)B5;OP&TM\KZ,E)FDH##"'D#.D"K:4NBD"C24
MG1A0O2!Y1M\NI8.<>>HI'D$2B]#TS&XHU3=HLQKC#!5\(9X\VV1'UZ=U8;!0
M,K<QIFU'-V1T2%*4;L64%>F4%`,+-",.MZ&WRYY=&4^BFLEM%CK*OHQ;DM9S
MV1\M^.P:(-MI+D)I`B2@*YP%C,?7`*/QT,HM4:>2$8=>(!:_39-4-I#XQ&*B
M)C9=HQ:ZG0RUY?3DFI.(3-'1W.D)0P]@EDA8Y4]RV1PFMZRAT/M:RGA\BS4-
M>[/248%A*`LG:<(!#\TQJ^VKE\M<Y0+D?GRJ^<:R^H&0NJ8R!@;%KL-,-W>5
MBA:L>9!(G<2-.D1_5I+(W-6X*M$E%$Z/4CT``0>`=5+=NNY;><^>V9H6Q]GH
MFFFIA<ZS'2SBR-M80A"T.%.&*GM:.IEK:E8RD2JLQK9,Y';83`":]FN"D?H>
M8\W8QM\OF]<V\ZR-_:)7(:#I9^E$?86>*L,D>JL@SH_LD8CJTARC\<:'A<Q'
MN+:PL3BF+/1HR3`)TIQ81E@"(.MZ&WR_JSF_G=PDLWFB^A:773&S(ZXP^R)8
MLJV#J9+8,2>$WLW>+3=].8ANDKCKHDUZ2E"O-4)CR_X1@$'],&WRR"(4W4%>
MO*B1P&JJW@\A5Q:+P96^Q"#1B-/*J$P="!LA</4.C*UHEQT6B#:6%.UMXA[2
M-Y`=%D%EAUX834D8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_U??Q@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_6]_&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!_]?V4]<]L0OD=16#&[5S9]MS>VG!Y!$8%5*&**I&J8XDZ0MN
MF;X#4QED0;UQS0.>MA21L2'J'-T6K"B2"/3]=0G+)K^3#NZE(;=?,M!*F^PG
M2P.I6\IVB:=NB@$R2OVIQB4FF$95W`"0NC$[P<Z9(80^$-:/216X'JV5<`:<
ML*4X8!ERU"<<^5"IY#`)1:?X,Z/;*_:'B,16&R`]KI)[.N"=3RP6FMJ^@-;1
MJ&WG*)AJ53M]>2CFXM_;F%+MOT-0>>0`.35^?U<GGN_X?TA`EDYB31+HN<Q3
M2:5O-(3/FI&S3:!V#7S\KCDNB,F1-3H_,@G%K<4GCHYO<%Z%0086:0H,`/6\
MJ68G/"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/__0]7_R:\<VKV+`Z_BE='4L
MM0L<A]1\9+?AZM>O9ECI(86)KM:L;$CJMMF\`FE<-36Z:,(;E2?ZVWN1Q'K$
MJ"DP\E:];B*E?Q0.1%R\O7<AZIO)^F=2V/5=@7(MF4D;'--9[G5?/QE)IGAC
M0CBZQ8QN\NTG+,=B52Y6C,1.3J`H)9ZSUM,/KBS$+MWPU31*YAFB6TZ#@=B5
MFW5"72"^F.<P5;#))+Z7Z%8^@([9O1$%8YJ)HF4M<E#%]$V6V>R(;TC@N/)V
M9L\*<MA]-I'('/#_`,[0&=HYO+&>:V7<-V6CT!9[Y&65;'(B&:VB]@7J6:(,
M;DZ/;FAC<;9D*)O3B4JCE*GVPE!NPC.$`-2W44=,UI#H]T)R!<C$@<&FQY7U
M"RPF1R)!(Y,F"\Q,SGN]`FL*]F+>`L!S>=]$2;&':7Q&(@(A;WOQWL3O&P7"
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__1]_&`P&`P*;=9?\;<0?\`.2Q?]/G1
M.%G=<G"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!_]+T5_-=.Y-"V"@CF.ZUT&:T
M3C-9;)JFCMZ2_FR>6LVQB1U"$J4UU:C$EU&ETNJ`QV$H(CK\K3-BSZQIR,T9
M](UK4K7KWX5VL'LGH:5=<_'2MC;7V''::>)!5\3B#:^PA[A,<Z?,MKE:3V`_
MSJXG&/&ML/>UD>E#@P$#9-ATDC(F*0NA@=EC(TE+),OE3N+==7AN'5.-LZQN
MU_CES4YS3,/D,GBNT'1:Z\ES:=]OP"K;*^VM*BS#^9U9\`>).S_26@MK(;4+
M0!>6F`>$"T1<GAZ!_C/G\CGU*VIM?/)):L#A75'1-<T9:4KDY\Z>)[2D/G:A
MOA[L.?K1J'*>I&I6):T$/*I0L4+R6T)@U!WCH>ZQ>K\]43*;G=#<8PL^HI*C
M@J3K"/N**XC9-`#8PZN0N=[[,&P)HNGE!MAIEI9BHT&SCVHI)O:86]&;"(O8
MQ.[8KA#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8&E!H1T?8W5U\UG8"*]+1N65=0OS9'XK7U
M[W7#VNKZ,B=+4.K>;$EC9%[8A4/A]>LTHDYB8D02=N+R\N.DZ,A49H_9$:YS
M\7&XOC:."33N>N&-REBR(5_UO'&6&-\OG,UL);'F9ZXDXUG3DTH'^?/\FD6F
MP^72]S7Z($K$46H7&[`$.A>&5+V7IPA@,#__T_=Y8%75Q:[6VLMF0:+3QI9W
M]DE34WRIE0/25ND4<<DSNRNZ,M<2=I.L1+T8!:$'P\X/,6/S%C&`090L8V1Q
M/:%3@SM:Y2P*Q+V%0L;TBH]D7"1J&\2UH./)&8VJQ(%1I&S"=@'LDP8/'RBW
MK8=>5#8@G+D1)$4C9),O4'JY844Q-99<H5*B-)E*F1%@2Z"]J%";7IF#4Z-$
M,'\.][U^F!VS8UMC*WHVEF;D+2U-R<M(WMC8D3H&]"E)#H!*9&B2EE)DJ<H&
MO`(`!"$.OTUK`J)UE_QMQ!_SDL7_`$^=$X6=UR<(8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%
M9ND^A!4PV1F)PB.AL?H.W5;M&Z(J8M9M`&5R1M;1.#I(98[A`;J)59`T(@KY
M(]&!'[1'H)*8M2X*42-263?X0!7'QH<^MPI)/KJ8";AZ)M1VW+KNN+;A*(<;
M,I4>6$LEN9F*-2)`E88!#T6@ML>;!B4FHFTD'KGJ50U"DYA]7MT7`J&C:IH5
ME?H]4D.10UJE$F-F4B(2K79R/>I0<PQ^+C>G%>]N#FX*EOV[%6Y$'8C=Z`G1
ME`#K6@ZPFZEC`8#`_]3V<=7=H5WR5NOF^4Q*R+"E=EJG@R,PJK(ZFD<F.CL3
M=(<V364F)%KFTDC;XX=/&HK1!1ABQ:M<$Z=.4,1FQ`+)K&U/R$4$EN"$U`8@
MM<.YV]US#6NS#ZNDZ"IV^R+=@A=EUM5[Y*G-.B6-LZE<)5)EA:?:(:9*)62G
M5GIU0MD:&5@K+\G-,.\!DUJ**LZ*9*V:%K(R129.%=,JYMMR62N?M-:0J%5.
MDC,SD#W)Y3-90]I]-I!R5&68EV)0:844`0M#%M:$OF#]%P(V?04B2-B=NE<O
M@4HC$T8E$9F4*GD"?ED9F,.E;&H&=I`]L3R@,+,](T].:#83233"A@'L68A_
MK+_C;B#_`)R6+_I\Z)P3NN3A#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$#="7]&^?X>WNZYI=)
MI.ID]E0FH*GC&R!32W+(<$2Q:T0R,EJ1!2I`[2H#UCDYJA%MS(TIE+@M-*2I
MS!Z+)K!>;J`D4)=)1>=X.[9-NH;=;VHF?2%K`>*)UQ%F_6E+'15-D+_.M9JN
MARHP9AIH_(LDCP,]V7ZT<<40E%O:=%L\(8#`8#`__]7U7_*#R!;_`%S"ZR8J
MI9Z6?3HK)]K%?Y//DL3F,'=W.10C3/;%1VK"4Q\LA[]`VMN<Q."!,,C;RB4Z
M](X"Q(E";*UZW&#OO!W5LUMKEMZL;HV$3N)\U2BF9ZQ6HNC,C9^A2':"UZT1
M&V84%,TN`*RET>OE^;U;BX/+VF/=&M*[JD:<DS82%18V<\*VLWPWV@TN?WHP
MR_FBK)U6I-*N-5)*;K"6Q&O[9L:CNAV2]H];72<;&_J5"R7K6YB''`;1'N9S
M>C=59H%1Q0$Z(#%^FUOC;GR6\^P&PR[%D4;DEG73>UK]"6.IA2)U00ILE5HO
M9:S<;B!+X>>]',,:8V]$B+4*O3/5C)&>,LO9FP:K-J(NJ*BA"/H;C&XB")+J
M=.O6$?8%IYL_GZB,";2^=[[(`%-7BB3FUX@6^FVE>*LAJ*5[WH0MF;$89L8E
MZQL5PA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@1#>5W0;GVO'*Q)V>X')B5*-DC47CZ(;S-;$F[T
M8)+%:ZKZ-D"TLD\XE[GY4R!$3^HA[$8:(H@HXXL2:@WGJD9ROF2_J7I8AO/Z
M!F#-])B$"1+0/D2Y;K-P+1J1U-!''8=)W:7O2A,4JFLF)`4)_<RP)R-`:D"`
MD);>TZ+H80P&`P&`P/_6]_&`P&`P*;=9?\;<0?\`.2Q?]/G1.%G=<G"&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P(XMFV8#1\!?K+LM^*CT3CQ2?W*GVZIP<7%Q<%1+<R1V.LC<2J=
MY+*I*[JB4+6UH23USBN/*3IRC#3`AV.JK=&U)/K5L-KZVZ=CVX_/6U._H>=:
M/5*4JY'S=7\F)`B6ND@&B,4-[OT-8;*46&1N!9RA*R(Q?16P?HA<%;F6^(O7
MA#`8#`8#`8'_U_2U\P5EW/7K)1YU66K)X7'DZZ72VS(94LY@L)OV3,,8DE3)
M$4ZKA'8:33#8C#5VY"I^L1SW[;I:N>V@:D[:(I02;*UZH`FO7MD%W9R=:U2=
M=2FY(?9%G<R5G.*K3Q6M8)#HQ&+BH%EEK/'9W4FRWRY72WK_`);)$DC:Y"V:
M3,L,;%'M%NMI$)YJLN=98J%'>\NIBXM01>NJY-(4_85-\VV1?D^-15IY>.9!
M:O:U=4=-SJZ2$Q4*:$,PH5,71E2HGS3@!&N8A+2Q!4^ML1<G/#>]\=MH3>R:
MKM]MFD[<[63U!U5T)2$$M5[$PGOMA5S7,T&@BCT^N<7;VB/OKRUD*3&=4X)4
MJ<*XYL$<,&C1F;W6*Z;JB=RE1T-QC`3:6LQ#%$/6$?=$UW*G6G!U@\+A\[WV
M8*.-S2BME9=!3R4-886(:N()6_SI3=A5;#LD1PG?EL5PA@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@87
M8MBP>I(/)K)LF3-<.@T.:SWF221Y/V0@;4!&P@UO>@!,4*E:I08`A,F(`:I5
MJ32R22S#3``$%-*DKF==*SUCZ=Z2BKA$XO#WQ0\\F\XR(OR'U\@VG,1ME^W,
MRF!V49T/)VY4=MM:SMFE0%K4>W+_`-8/7G@+>.(O_A#`8%+K+[/:HC8<FK&M
MZ7M:_9'7KC%6>S5=?.501*+0>231O2/$8KXR6W;:=5,$HM>0,SH@5)(XSGKE
M@27-$)6)(%60(PN?J>J8N6&7O!D\[A7UM(F"ZO,;D$;E;*MC,TA$QC2\UJE$
M*FL9<0@6L,GCKH0,E00+SECUY#B##DYI)Q@LQ*^$,!@?_]#W&W;SA0W2+/'V
M&^*BKVVFF*R-KE<<1SZ),<I*9GIJ<4+B%0W:>4*SVI+E]/`F<"0>!3@A$8E4
M!,(,&6(LMG1VPZ)I`R?,MKF4W50[2C;,1'([9(Z\B(I\P1Y,5LA.PLLQ$T;D
M34S)R-[`!*0I+(`#]-!UK";V[.O1<Y\]MJ*QVUNHBFD#=<2D:VW$"*L(0E16
MFL-$<,Q78Z4AC+(FZDP2@S8C',*H>]C%X[_7?B7;Y9_#H7#J[C+/"J_B<9@L
M-CR;:)@B4.86N,1EC1[.-4;2,["R)4+4V)MGG#'LLDH`/.,6_#QWO>$5<ZR_
MXVX@_P"<EB_Z?.B<+.ZY.$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8K.9S#ZSA\DL"P)(SP^$P]G6O\
MGD[^M);V=E9V\D1ZM<N5GB"`LHL`?TU^HABWH(=;%O6MA2&!P&7=<V%"^C+P
MCCY#*:KIV^Y^8.>I*2L;7AR>_3]-IZ,OR-*!`+(G`$HMF0V,*BMF1%.>)<NU
MI[/"G9R].(V$80P&!`?0G2U3<RPE9-++>58CM;(21N"11`9*+-L%^7`6C:8I
M7D#;AB?99)'CZ:H]!.G+\N@)SC3!EDDG&`+):\HMQ=1,TEZ&N:O.@7>;\VTR
ME<5/5U5UN\27G6HNI:\[0N:#-Z6L7^W6.?=)1HM8VTL6F/DL<((`4A),7M*A
M^&G,+(*!&\XXZM^_Q066KO>A;-Z*D+U7ZVPKTZ"F,DM&-59(FZ7P.OYS7D*K
MB@#XQ'96SJE[))TCI'J<;I!MQ0'J6]>-\V>E4*4YA2@U&?:99&S_`"LF`P/_
MT?:+U-V94W)!$(!83=/Y*^V"I=11V)5G"G><R<Z/QEPBS?,Y<>UM)8ADQ^*'
M31J+/%X[/4*W%*E3%G*%!9>RR:PLKY&.7%-KL=3(I'-%RI^D-90A//TE83XV
MI$%C7-%FB:U76KY9'T`,>9)U.(N_H5*1"I,+\@UA*<\9*HT!`AE8^T_)503E
M!93:*N)WXP5E'Q-Z5DL%[I67`BMH/;Y/VRL8O&*@<&TER%8\DEDQ=R$[<E;@
M&"4%[$=XA)+,&%I\WHM-1EZU]T1`]6#7*IY$V)Y%*88_LLHCSO$9A#IO!WQ9
M&IC"YC%']*B>8[)HV^-YJ=2F/*U_L"8#8RAEF"%F(7ZR_P"-N(/^<EB_Z?.B
M<$[KDX0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P,>ELMB\"B\@FTVD#/%(A%&=PD$EDL@<$S4R,3(U)C%C
MDZNKDL,*2HD*)*4(9A@Q:"$.O'>!0B-01][BET3N>YXR[1KF*"OB.7<]4-*T
M*QL>+5D;<:%1'NA+ZBZ\))B-O0&!"KA$.7$Z-;O$#P[EZ<Q)$307I_+8QA#`
MK0Y=:TR3;!-(QIS?[(L=-(&R/3%KK.+O,R9:K4NBA,G+,MR;-J;[&K<XOWA0
M]-[HY)WA2`P/M49^Q:#LN*\W,T]4=<_7HSSG>L]XOKR'S15`IC,I%SHW'61:
M>FE8L2S%WIY^G4T`X1V*I?2`@;W4Z*(3%:OU5R!<I2`)]0<3KRN1!Z3K&O9+
M(IS'(HWZL29-D;:)I9+F$3O8,O01-F0,3&ED,M<-GO"U&C2MP3=)M&`2^\-/
M4^E[A0>8834JX#`8#`8'_]+U1_*3RA=74<3J=)2\2J:2/4-DYJ@A]F$XG]16
MC5DD>9+`0QRUJ@MNN69]>V(N($-:\Z0M0T^_J:3VRE,/WC:00IE:];)U1<#D
M#OB0=(4=*KGD/.]X431Q-$*HV@7VG8]=R-;;4/B+&QVGU5/JXCW/CU'[8N@Q
M\TX+H>V.4I2L#($!&@^DK,,7%#9E\J],/Q`7NR+@2V,NW,]1R>L3:*D=;1.K
MUMS**RO&U:*Z(8+K8[6O]%,BGA_B+\HC+";&4X&X^5*D29V4&F+E9)"1&!B_
M4;:^+Z"G="P"R16F[Q-SLZ[+^MSH2>)("<]K(+&7RT'TI4GB43<Y&A:7QZ:8
M\QMJ,C:U2A0&JU&C3=IRM"T'*S;O1%75%7-:3H;C&U@2JRS75SZPC[(;$U5D
MS%56"4@OG>^R=+FZLCG8<,;GD6F\(A+"48%`AF&BV+Q-'O8G=L5PA@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,#')?+XK`(O()O.)$S1*'Q1I6OLED\B<4K2QL3,VD#4KW-T<EII*5$C2D%[$
M,8Q:#K6L"BL2B4H[8E$?M^WX^\13EV*/#?)Z&H:3MZEJ>[;>VI26NCM^7Y'5
MQ92I$SHE11:V%PM:7H2$6BGEY*^I^R1,Y>G\KD6G;E:4C#UD^MB:,<%B2)4B
M;Q.[ZJ]$*MU<SM)FID:490#G%\D#NJ%HI&WHB3UJLW>@$E#'O6L(Z>LK5*N>
M%O,KA\7L"$I].+LS1<^XZUE->KWSVJ%*<@EQ,"E6HU.BHBL5K/(4%Q3,ZY1I
M.;X%E@V4<,O16VM"[6B-U"CM@V]=%^VC**M7O`US)4""L.+*J;%:HY0Q*D0$
MNU*]RD4C?F`Q(G3G2Z;29,BV(1@42([9XQQG1+<<H$N4H*IDO2Y<#MRWZOD;
M_.6![C\4=HC7<8F4A6E+"'.+UZY2F3H53M#4Z<E*SOCL8O>TOIF*23TQRI1H
M0WKG193"&`P&`P&`P/_3]_&`P&`P*;=9?\;<0?\`.2Q?]/G1.%G=<G"&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&!A5CV/!*A@LHLRS94S0B!0MI4/<GE,@5@1-30VI_*$1IYHO$9IQYQ@"2""
MPC/4J#`$E`&:,`!!J*:K#E';-^0]VL?FOIAWHFOK'CBZLZA=JW%6E<MRM*H"
MI;^E.G'VYG&O&ZQ5S$6:2YQF"Q0,F/CO@4J<TQC\+2-DC72<5LKN>H['M=:Q
MM\?Z'L"E((2D6E2]HJEBA"6<R\XX8/;$$V5+V*7+86U%DZ$`W;,A2.PMB\Q+
M@G%K6\J?T^DFL9EI6$Q-BC47MZ\5K4^1FH4;'`0J[6GY3N1'RE1;A9LSEDC1
MH6+VS"E`L='^6O:+1YR@G9J@U6M3@/'5QGNHI99RRW8S=\HC,PHR<HV9BBU4
M1F.2&'+VYD0&E+WA1-[`0S0QZEBV3KO\NI1)26MK^FDA3F$J-'J=F#QB:XY'
M(_#X\PQ*)LC3&8M%F9KCD:C;"WI&ABC\?9$)#8S,C*U("B$+8TM3<E+(3)R0
M`*))+"``=!UK6$=S@,!@,!@,!@,#_]3TW_+A:_0%8L=*J*5M.4P./`<Y));7
M:*:?::#T6L8&&3U4W,TW@E>7`5Z-L0""JI(I)D;$UJ$:A:X.[*2J.VW&K"C9
M6O7.Z'P=&],S+H>EE%"=-/W1QLJ2<YV=**4KVEHE%Z3AG(,QJ=FD\XL6])!)
M(H[SJO;PN1X*5.T#8TLJ$O))/3)!-ZA'[A4(9,NQ35A[_P"PR(YSJF/Z:<7\
M[N*G.<;0F,Y,@%.:1\9.MO\`9]>T#*]UVC10Y,C#&$<*F2UJ;R)EI^&!]CIZ
MP2D1@U*?1K)SQT;Q?C^M.P[)K:XV6R)LNL]SI'JCH"@6&T79LB[6]V%#JQF(
MF^-OLA*A+6PQ!7)&Y$K^DN2IN;V].I7-IIFTY1@C`ZK%[,8ZHL-T4]#<8UR.
MJ[+2-2#K"/NQ5L*DD.U6#F>/G>^S=L;<K)F9\S$\E[6B`()S(2G\Z<WP.WK0
M-C$[MBN$,!@,!@,!@,!@,!@,!@,!@?%2I3HTYZM6>2E2)235*I4I-`0G3)R`
M"-////-$$LDDDL.Q"$+>@A#K>][\,"KTN[BXW@SF-ADW45$(Y,#S>$026A$'
MJ:G;"7ZNPI86QNKE*E8]AV'6@E(Q[$,8`ZUL0P:V7+X8QKO.B%XM%Q-BZ2L(
M8A;T4HK_`(ZZQE#&<'6S=[,#,45,ZA!90RB!&%;,<@>X!Y=D^IYR_,,-]CJ%
M`2]LW)G9SV8I$#:,G5,-L9$I),UYPGF&SV;1%,U!]'^/9:\Q(>'_`,@B]&_X
M>#/U^_W>OB86@O''79;-HS0MIQ_CFO),$_8-AT:'>H);4L&BV#SAWKW6B-&>
M._3V/RC\HS]?'7=M1MX?&:5YU=77@'>S5,MXWZ?.8TFP:-]<*^81*JY3"6_1
M0R?+H9[D66?L0?1$;H6MX,J.YK\E%%"D-:P&@)'770MHV/+W2*:KAIN&$P"3
MQ(+3#)-,SW:8-,O&6^L"923&#D:<"I$2(]<,)(=['H0=#+UO1GZ#INY&>T:1
MKZV^8%M:M5YS^0UK'9@EN*$3@ANE#%35KW6`IQ9&1"G</9+X[4+B0$X(O`M0
M85YM>&]X,Z\KK80P&`P&`P&`P&`P&`P&`P&`P&`P&`P*ZVYUKSC1;ZDB-FVU
M&6:>.#>4[-E:-.G*:6JZM1YIY"=S:*K@Z"1V(ZMZE0F,++.3MAI9AA8@!WL6
MMZPLEK6E?72W3K39\S[*I(K4SY;YKF.^:Y=5#_)3:_A4W9G!M5*NA>DI;(AQ
M>6R".MW/%ODQ>/FGIV%S<FANC,Q%[0PI4+>HLDZ7JV)/5HO=7<]RF?\`6LNK
M^!JA)W!*:XT>KEKL0C*D02FJ(Q^OU3\V;E4[LIU<E@"&HM"T%*7-Q.()2H!&
M;T$=3OPI)RSP0TR2TD'6MZQ:>('!*<%UI.F[GL&76[8D5UI4G7-EHWY+9M*Y
MA]1MM28E)5-44:S28K7_`)2M)2#W<K:Y/%M[1L>E%XP5E<IU#XTXHK-MZ!0H
MV>.5%0"1PQ;;BMEV,)#:(F-/LF8$S7]<6F`(1GN:I`D--'K_`!M:\=ZJ8Z-G
M:KRF[]4\_>Y8=2L9;HZI<+"Y\0L$)FCV^RUR3+$Z=ID]P&*'I$7'8Z6H*-]M
M'$"%2>X)]"VZFI!"3#'#/JUJBM*;C@XE5<&C$`CA[HO?EC7%FA&TD.;^["+,
M=I"\#3%@/>9"[F%!$K7JAG*U(@ZV:8/>M;PB0,!@,!@,!@,!@,!@?__5]O-_
M\L\^=2-$;9+]J>%V>AB#\DD,;U*F)O=%#0K)7MJUQ1(U2H@T\IDDY342D=T.
MA>U=$6O14`&'0?*66SHPU9PCQDX6>TW4LY@I$ZV6%YB4A9+"W7L=!*6=[@1+
M0GA3DV.I:("A"IBB=@0EM^RMATE`D*"7Y=`#K0VYF\,E;N/^4&AMM1F:^:J)
M;VB\5&E5QMB.J80G06@?I2-<`4Z2%L@2),$IR-,5@"K":$"PXU0'6CS3#!#;
MY2Q7E<5_4D.9*\JV$Q6NH'&DYB5@AT)8&R,QIG(/4'+%(6]F9TR1`F$K6J##
MSA!!H1QY@S![$,0A;(K5UE_QMQ!_SDL7_3YT3A9W7)PA@,!@,!@,!@,!@55L
M_IYR@EM"I>%<X7Q?4O1UTPV>]FU2Y<[,K-'HW)I+*XHR`<5MY]`4P>K<UCI#
M%V_20$K0%E!`(8P['H.%S]1N1\@U5Q:<N<`Z4ATLXP>$D&36"U+NF[$Y=9F*
M5L:I_/C8$T:=JLZ)M@E2^:<TIF@HE&DIYP0[V2$SPWK!GCEV^NZH%*-E%T94
M'2O1IJD._9N%9TN_1>#+![#H16D=O7L?3E-N!1GF#XF)I`>`O6_$>PZP9Y?K
M[P[[GOEU&J9Y[Y[:S!B"%XN*S)/=DT)`+SZ`-55M2,L)AX?1UH(MZ*L0[9NQ
M"!_A:#HP8X?L7,]]3,&_S!VY;R@@P98U,7Y\A5:\^1!1X;V(P`70]DM*[D(/
MUV`&DLX(\"]_Q^H9H)@1L[1]B/CVY#5*$RZ=5("\'--XB"Y]*3.P.F%@SMCT
M=[C>[ZE5AIR1E*->H2$HLLI*/6O0`5H(=!&WRM)$(%!:^;M-$"A<3A#3H!)>
MFN(1QGC3=HM/ZOMR](F9&B3:`1ZP_)KR^`?.+P\/'>$99@,!@,#7?W]5!<T*
MH^R7FD*RORO:/E5DS2VH+:CA"&Z,GU^XTG84:5N*\<_:'J.K4+$[NR5>>0<2
M+6@)O4U_$`.]%GC6L'G"`2GK]ZY[M/E:J+:X+BU.7A,GV9HUUZH['CE;K%/,
MELQ:*)4'(]E(7J"Q1^F+/<4<-$-M:VDW<2>U&RCR5.TJM-&KQN\ML*JZ^J*$
MT(70=,I+OKU*;Y%%V\ELK^XR-I;PB.UMXGG+CZXO]A)DY)("]F_93S.59A@Q
M"T@(*!O>JSQ>BT54W+5=Y1?4RJ*>QFP(X%:I:UBZ..1*PUG>D(_2<H](F[>P
M.D:DS2?K92UL<"4R]&<'99Y)8];#HB2\!@,!@,!@,!@5)HWL:MKYN:^J6C"-
MY0O5)OFD+>^.2<94?M1A;7!9"YK*:^7C)**=V^N[CCKY$'H!0C=HG-M`,8M`
M6)];+G1:E0Y-R12B1JUZ)*K<AFEMR50J()4KS""_5/+1$&&!-5#)*WYAZ+T+
M80_KO],(CRP+OI:ICD2:U+>J^LU#D5H]N(L"?Q2&'+R=C.+T<B*D;LVC5%;&
MG,UY@:%KQ+%K_P!._`.3*;?J^%UL*XI+/(PVU7IK8GPN?Z=4RV*JV>4*&U)&
MW-O=V\:M*YH9`H>$@$1J<1H%6U)?I[%YP^(_'65->587DWO#K5\@5R1L85Q#
M:Y+S8Q+(\D`N4)M*P)TA\G8F4MT$`@6MF;2[."3O>@F;"+>M8,Q@\:Z332R?
MIX&TT?TDF*&\.+,MG4EI]WA,`:S&LA8<>O4/<T61]:X,YXTP"DRIO2+2E1B@
MOT=C#HT19<_7;6S/;[C+RWM-/<_-=JI535I:MDTFN-BJZ.MCAM0L+^C&@U&)
MU*E2@*9*`P1Q34(CQ4E!T/?@=LD3/++9>1<[O728N`NE85_;:Q-'AK%DO897
M<%=1U88:B,E:5,VLLCHV33-,D)VI*;SQ*F$:@6BS3B2=;$2$CC5)&+=C#0Y$
MW':S!:[^M<`JTCE&:Q*JQG9TFB`$C:T#']Y3I<>E$87ZNC%3BI/T,8]>IL&P
M``&`0+D^KH#/R+4+>[HFM@I?J043]9W0-V6*@;"G=$>WKDS)!Y3/'"N8\F-2
MJC`Z+0,Z8(1#V+6M#\!:+JR($R<L\Y4`@D"E0`DM0H`4`)YY:?U=IRSCM!T8
M:`C9P_)H6]Z#YQ>'AX[PCQU.W541247%+R,^%F-GT#<C<M=H\\E=RV"TBFKE
M)VEQF$U9&"DW6C6>WI\:A./7C>G%BBSK'3`%JG(+@>TA,<<G].F<Y]<MO_&"
M^/78MY1O&VH3+WMZFM5-4RY7IZ'0J63KF[B*I=Q1:@C+B\W`XQUOC4DO24LS
M"%L/D;@HV]ZVJ$C9D")J,7JU9F\;%^-UQ=-U5R8Q7S+#J6=C["V_?1N4;,D[
M>K4UVA1Z):Z_D]OO40B\X-5.:\TQ6Z.,72Q)9K92=,F4!)`I&MJ<=EBVZ.1Y
MG<7UW:&%F:W:4K4KC)G1N:T*%QD;@A;DK.B7OJU,04I=UJ-I0D)2C5`C!EIB
M0%AWH``AT1W.`P&`P&`P&`P&`P&`P/_6]J/3W8])<C((DLMU9,C54U5.&F)B
MK^O9C9$C&R,"V.HI=+UC-#6AV6((G#12MNVO5FZ#XFK4Z9.!0L4IDQI9+7(9
M^S>99)<T!Y^BUNQ65VW9%?'VG'(?&%>WU>3`0,+)*&^1R/;<`\J*))#'I"E6
M-87':8UR3&;,3A,`'8M#+F]D3M?R3<RN,0F5BJ=7:P5M#2DWA8\DYQO1G@DW
M7N,W;JY9&*IY.?`=M=MR223%U(1MK?'!N2M=L6QDEB+`,81E_M9VE+PK?H2"
M$6+5KRN=H\)[D<6<DSU'9'#91&9=#GI9')=#YA#9@U,<KB4KC#\WG)%J!P1I
MU!)I?CY=@$`0B68A#K+_`(VX@_YR6+_I\Z)PL[KDX0P&`P&`P&!'UD6S5E-Q
MXV6V[94"JV*D[$$V26)+X_"V(`PA\VR]NLC<&U#ZOEW_`.7S^;?C_LP=58A]
MPQZ7ZV3SO1O1/29Q@O22OL+K<VN*P,-$(T&E15OW^X5)7T@9R-E^8Y1'UCX,
M(-^!91IG@7LN>:_6Q?(-8_H^0',O+3&H\!'>L*==3V0!)ORB\@2RM<^5Y%GS
M>M;#O?J2M$3O?CKU_P#9@X45NOE^T8!>LONRXWOJ'K*J%'/,;:Y?*&CI*G^1
M(Y$U4,F%D2:0M,N:ZVEO,)#A63,P/2=<F`Z*'D`#3UFUBD[6_`,7>R;N5>86
MF)]1.]P-'$<>Y>B9-($Q,AQ7.-)RB5S&P%$Y"\G218]US+)J_.#B"-`"0-R=
M%6U1@-:+T,0?TP6\=6UC*R^6CR1'&)@G%"4%%$GFD:,!LXLE0,\L@XPK6_.`
MH\:8P(!;UK0MEBUKQ\N_`*ZH.O.;'FS#:<CENQB7V4ED[A"W6+0CZG-U,>E;
M0>L2/##*UL2;WEJB+BRKFY2G6@<STGLU*8XD[R&E&`"7*[FW;J>JO7-#6P4%
M>UW.3PD.5E$U$S0`Q"AT2=[?2=WD=F6/6D5:U9QNP^0LY>'>P"]3?@6$P0!G
MZRI^DMEG5<5*8'6*,^S7!C8'-OJFU)XW0,EJ='4;:-VC<UGM>L]WLK4X1=*J
M4:4GLJ>1(CU279:4X\DP"C".IJ-QO]S(?3[XAU.PI3ZR'<9:ZCLJ:V>1I.+W
MNW(+Z_3*J*B,$<1O2?1`D[;H)OB9L6B_`.MEX[,48(1U""Q0O\QZ"K%RK9.^
M.JM/74*YU<HB[JH^:4M)8F5ZGLEO.R#E3@WZ4%&K%R-M;PK3T^ME)TA0QD['
M'AVEKTU,+,>6QP9.EKYIMF0-WLUD1J@BBB&9\6Z4*CP/CF\6#2%A3M.X@+4!
M*])"\HD`BR0>9,(>S!F#^F6OU9$2>L"*P>YQ9@RPLT<:5T^89HX0:SW0^.G-
M:G;X?,J^#%%+:\OREKT)Q$W%HDZD!YY.B0$&;*PBEO1'(<_-H)937-BUPFR&
MQ+(@:J\6CJ?KGI>4!E],L2O;I.Z^C,^GK7U`]Q`%FE-J=B=$B)J3MYK(Y.`M
M:`I]#>%EYY1%1W$]M1CMI-TW*Z4H:LXP\PN3))Z@AO8?15^2%RLS:U.;!I_'
M62PN>:CC[.%JCZQU85J`:PU$)K4(/:$IOI99*B+;QFM@=K<P<]7F\MTAN"GH
M)8SVT-FF9L=)6Q)G58A:M*E"[2!,<?K8BTVE:LPSRZ_3SCWO_P`<J;8@"]_C
M?YENN,Z;&R*%4]*4D>BD7;YQ5:)H95CA'H`-N402)V/&%K>X0FY8%%UC.D&E
M9)4W.J)/Z`1)M)S=:-"):B*HY&C^/M(Y1"^J1K>KJQ>W-,<=UISY&UC31KJH
M3)?:(7*_X,H5N\IYX=O1\0&.:A2]PH`?XSGI`(P",,7KTJW4+Y<YA;IFAN^O
M:]BR.3NK@MF:*81!X=2FE\<I.G4C72C:-G>M1=\4O:9Q&(2L:<[9P1!%YM^4
M&]5-O1D5K<S4A=SRW2"SX3]SN[2V:9V]7]R2YE]NW:5*%NDWH1Y_:4QO^95&
M"\XP",_B\/-X:UK0VQEC]4,#D=8$4XO;WE+7R5FCD?2-D?F4TB;ND:(F<UG,
M21),8M(6::)?:B9DX3#"W`)JDH(BSQ&%F&!&3]<.IZ3KZDV]V:Z_3RQ.C>UI
M"]P#++*LJRE`E*<C:<K:1=94NERYL)T5O^(I,824,7\0@[%^N#=88P<JTS&;
M$#:;0CL4$R`\NK^$Y?>EZO4=^I/6ENEXMP9ZLAP@PD0M.!OI)-MNTB;Q#Z)9
M?IE^4NWH[.UN;*GNIY;GZ?I)VH<FILTT(A12Y+EK=&%#I4H6Z"I:JWGT2:ER
MGUU0_P#,'DF*/)X`\_D"$.AN.@Z$I=UFG*\_HZK6^.+)"?6@(E6)-H3"=EQM
M#(V!&C#`W::3!K!)[!=4T?>&M&M5&BVL6N0D^P*!CV<89@EYUK9ICAKHNC7W
MF!=47.G(]-KJ5DB)ML"PVKL:]K-EMG5+*F=LC]U1E]89#Q7#2'ITFAK0@DR;
MSO*).1+&A(J%OR#5!.BVR[RV>QCD[EB$SU3:L-YIY_B5H+71R?%ED1BFZZ89
MZK>WDQ6:[O"F8-4<22$]T=37`\2E0-1LX\1YFQB%L8O&IM\I5=X)!Y`ZIWY^
MAL4>WQ(A$UI7EWCS0Y.J9L&<)2-N3N*U&<L)0B4"V9LD(]%['O8O#Q_7",E3
M)DZ-.0D2$$I4B4DI,E2IB@$)TR<@`2B""""@A+)))+#H(0AUH(0ZUK6O#`^V
M`P&`P/BH4IT9!JI6>2E3$`V8>H4&@(()+#^HC#3C1!++`'7^W>]ZUK`AU5T!
M5OWI8E7Q^0@G%KU;$%,SF-7PHOZY,6I$!I9GIM9U9`1IVALE,C;I&W'-C:N6
M)%*PA<2>`/MQ;."7%&>E.L+J?H_6M.T12B8R_+O;)#N9T!:$K(;[;J^J%SH9
M&4UAS!=3SQ.X!6$=>VG:A2!\<Y+I4W'B(3HFIZ=`J6M/%DZW>&IFE.<N_P"C
M"%%-VQPM#>U)TT5[7W,<%G5N6;'7CFUMH*O$C<VQA3!64RO4#17,$&B84"J4
M-KCK<ND;BW%&'$*Q^@()JV7OCT3<@TY(>>N7:$HZ6N4?=Y/5571&#OSI%"#T
ML97.K`U$(5JEA2J43:>F:3#R][(+$G)V`OPUY`^'AE8MVVK'80P&`P&`P&`P
M&`P&`P&`P/_7]2WRH\RW?T5&Z=.H^NH%+I-!I.I4-$U-M*Q*1O"FY>^2BN?M
MFQ*LLJ#IW9$7$6PAF7#E;6X-RW9P2FYP2EF'MFB3)6O6XEHWFV\W*^OCUMJ8
MS"+3)VYLY[O^O;SF9FCVQ;,K/M6&T*T$RV.1I*W)DIC2\R6N798J)V<AVE+/
M)`6'?FWH%39E:S&#XH>HF(:1]B17/E/**@64'+X'5$%NGHN;5#T%<-$='QZZ
MFVS['_+;)+9C3@5,(9U$91)$RV:+4XW(T:A<H3)4@-S&OJ-N?$U&6-25?V>K
MMP^*%V3>/0UQ=#2N.P5Z>)+#H,IM!_*5MD(8)*_,<8=)&5'V%N2`5+AMC>!4
MX"4&%D%EB!K=9OXC+JBM?:]#<8V=]_V8H^H]81]F_'JJ5>K5Z'R<[7V3]5;H
MG[`/M7D?L?,(_P!P+Q&<;OR_Q_I%G=L5RLF`P&!#]M=`TA0Z!&X7':L%KD#H
M(13&BE$B;FY[DBH._+IOBD=&<)_E;J8/^$"1N3*E)@OT"#>_TP9;T0&9U';]
MCZV3S7RC9$J1'#T6ELOHI4HY8J[8#`Z\BLIGE\>D?13D2#0O4"(JO@)%!>OX
M%>O-K>%SS7X+HGJVS/;GWCU@?!&@T!GOZUY(@S=6S>H+'Y=`;WBX+).LZU7+
MTO#8MK8\*%'C%O6M`"$(O4&SPYC;SUQ%RTJ*M>3,M8166%##L=\]!S;[SM`]
M0FT(\8U%XWK(Y%.QC",P1H@?5M`"(6Q:#K!MO"P+;<U=R:JS[HKQ_)MRO=M+
MR\LSW3X=V<&7I6)6N;UQ<(+A^W7<O4B<6TY.2!!L_P!<T&PE[%A&/4_<K_;*
ME]$MH*\*B8VHI&)KD5P-U=1XJ7G*MF;-(8(S'[(ED]0;;2@!&H&]M+.7OU@!
M($>,)X22V9W:K^^K=E<BNNL>0NBY7S;4G,%EORBT[07.$IG;Y()Q0]23B-JD
M%<2U8Y-5:L4==+W>S"$9S6VG//HM[>Z!-.5)"QZ4Q9YG5G'(3J;T9`Y'SY`N
MRK::&SD%^U6!<WI%53CJ*[Z=D+:B>^?Y@_3FP:GLB0(9)&8@@4QI[$TJVI6M
MD+$N5'^*8\@)@O'.-GBBI8N\U;^(9NID%C192S%,;RKFSVJ7R.1I23P*0'O;
M\V_25BAP]8H`MGE^B9O8-;\?'QWNLNLJ/GJB*#(?4])4Y6E4:E)R%3*CX!"H
M_%E\K5-GO=-BJ4N30@2N$D5-H'%0%.8M-/&0`X80;"$6]87;>J8L(8#`8#`8
M#`8#`8#`^1Y!*DDY,I)*4)U!1A!Y!Y8#23R30;+-).*,T(!A1@!;"((M;UO6
M_#>!0USY:GE!N+C-N&WYAAC>L5JWB4\H3M0Y!YQFZU8L,7N2ROC6XEP>>;)H
MYF'&>"J/IU48/.'LU<P*#Q;5`+N]4M4CU1";=?W6LWYDD=-=`15O)<)G0=GE
M(&R<MR$6PDFR6(+6]:OC-K5T)9O91,DC2QR:MCWHH\Q.J\Z8`L_XL[A#`8#`
MZQZ>F:-LSM(I$[-C!'V!L7O3Z^O2]*U,S*S-24U<YNSLYKC2$3<V-R(@9QYY
MPP%$E`$,8M!UO>!56$=T\WSV2Q.,M4CG++^1%I#=5\KG]+7165;6LO5IAJT*
M*L;/L.`1FOYPL=B"]C;B6]R.-=2O`U"%22()@BY5O<(^1YY*8DY2I.*3ITY1
MAYYYY@"B2"2@;,-..-,V$!918`[$(0MZUK6O'>!AY]E5REFC76RF?PI/8CVV
M&O3+`3Y4Q$S1W9DY2@X]V:XL8O"^+VPDE(:,9Y1`R@A*'O8O`._`(B)ZTI%V
MK9;;$'=YC;4,12K<(TJI2J+5N1S62;3>G<O:(F.M89)G@YK"G5E:-=]DA94Q
MAH0GJRM^/@7+T2`78SXHL5)!4U06>-C51G4B,ME0&`-];-Z@TKSIHTO*73TB
MS/N,\S_#$4GC2@@@6O$XTL.]"V1'0'[K*6UJ)<UU]35,VD;+RTI#-.IG([BC
M2:`Z0E&&O:XR$-%<G#EXW`T106LE6-$`LGS[<!;,T$LO#/Q0BP5E@.<C<;>>
M00!=%MLB6J6>,1=L1-[RI2E$+I/]]^P43HYP*-+$-&62J2$)]F"V,!V]%[+(
MP;]KU&_8###K28AWE'X1*5-D('?I=\6W@XMLK*+5CU)_JMH*'XAJ^C$*!B1E
M)@)D+;Y=#3%$C#H6B[>R#''H6SNI%JF&\4J$+36Y:A6W3+M:1LY+Y7J#:88T
MRYDYNBRPY.7>4T*.UL&W\SRP9I,#O?N'A24<V!&2=5E*+YZK;GJ/NK1!$3HN
M?)6ZZDEC6/,791*;.M68"3%I5$PL>:.&OJ4C>S""@E$@_P`)"W)0@2($Z5&4
M2G+%NIPPA@,!@,!@,!@,!@,!@,!@,!@?_]#W\8#`8#`IMUE_QMQ!_P`Y+%_T
M^=$X6=UR<(CBT+AJFDXT=,;@LB$5C%B=B+V^SJ3L\8;CU`0;,"B1'NZM+IP<
M3M:\"DQ'J*#A[T$`!"WK6QU5*?NW'B2-A[ES[0DYFT;TE$<7=EZJ_P!J/.R7
MU"="2JCI;:[2&UY&TJ1#T(I='(2^-R@D`AEJ=AV#8RYYK!;>C=^)8NWRCJ/H
MZVF./O;V"/(:5^.JCK)4/+BZKDS@XH&I^LQCCUNWTI0D-S.H$<_M7XZ;"#!!
MTI&3K9?J#CM$U<VT_3<1ASS95.\O*:FL=Y)?$X%UX(@-]T392E+'MJ4V+:RU
MPMJT3V9^4>3_`!W94XN:4D0A&(O4#Z(A;^I(J(GJT]]7.M\N//;5&C&8PEM@
ME1,MD/[ZBD)BQ":4XKK8F3]&V]S9D;>4I($B+A:0]2<>4?I40$@2=0+G9PI-
MS0R32QMV%*;;Z*6ID[LSO+/7+#=TTKBLV92RA1#3I11RJUD&62II5KT7N5:*
M0+'A*K$<82:6-)O2<(U,4FKV`S5:QN4R@\0EKA&#E:F-+Y-&F5^6QY0O"G`N
M/8U3JB5'M)RP*0K1HTXBQ&:*!YM[\NO`C+\!@1U:%OU32<9W,[ALB#5=%/>I
MVPN0SZ4LL4:E+JLT9M"SHECVL1%+WEPV4(*9&3LQ2H'KRE@$+],&;T<BM;4K
M*Y8HCG51V#"[-AB\TU.DE,"DS/+&$Y4GT#:I%IT8UBU&!<CV:'1Q`AZ.)%OR
MC"'?Z8.C/<!@,!@,!@,!@,"N'1U]K*3:H4UQ*')[%M:U94;#:TA3C*2(-&SU
MC<PNTMD\KGTY.:9#N%5W"HHQ*EKFY%MKDI\_H)4R50J5$%"+)J*H1TO:T9N^
M`4%TW"*EB\BNQNE;I24QI>T76=QN3+8>SN$J?(1)8],89`YA'9"1#6I6YH7!
M,0Y,[HF0*]"-1*"2TYXSC8L8HOJC$<=D<O5W/4Z6)P]Y(CDNE"BQ8>1'8M(5
M7M/:L4C>S7@+:R/*GWY'II5)I1X_6+\`[\X?$CY%]`T,=.816!-VU$;95FQ4
MB=UO7A=DPT<YL&$*4#RZIIE"(D%ZV_RN*J&N.N"D#B@3J$@R$"@S1FP$&;"7
M+X8V7U3STHA$JLAOM..O4*@\B*B,M?([IRDA;#)CCDA`&1P1L*!Q<2W#1JXK
M0P:)WLO0];%X:\=Z&5DA=YUN?.817:9PDBN2V+%")K$C4=>6*LBJZ.*4#RYI
MU:^?)HH;`X\K.1,*D84;DY)%HM^D'1/G4)PFDQ7"Z''G'I&IW>2S:I^A)`15
M\O+11IV:><^EJQO^#30\2%.7-*/$Z5["+:+]KI05LU^C03FPX@LPH\XX@)Y6
M%YB'FSI#H;EZ6,<)NRO[NZ;Y]=X,FG3-U7#J7<TMEU>S*E*X144Z6JZ--B,4
MAD3(UI=&K'>*M")P++\FEL=)'ZJO<7)>G59*MNL1W;2B^[:6HZRK!9S7M,UP
MEH13/G<D^QVT2E&F<I9&)`CNYVB"./,AQQY:DMT7M[MZR(XLM$,7I^>IF=:F
M#<QM0R?0EB3TYZ<`?(R6\3*?N-A1Q,O@KZ8@?#_M$,,0)G95*'`AP1H"#%25
M:6@T!:8:`T?M_(</[8B!VZS=(')#3(!SM!K/)DB-/$40+>LJU8&XQ#1R/:]X
MDCH*D*;D+-)-IQ*`DMJ5&O2Z&`L0EV]#$$`X0-VS5/3]LU%)&"%NM22*$EPR
M'/DTHP5?2@VP;ED\*F"6;RB`Q&X5UPQZ$0N+6`UL*9D*2/,1>`*@*5):M402
MHT8F$R53&X)I*.K:(<.8X'9_1<ZO:RK6J]Z1GK^5!423S*Q0V;0^2N:JV7.?
M5.NBL53UT;'CGA*(I:.2OKPG2IV,_9)@3PQ>EWLV\$U`SAL"-V4KF-L.#]&8
ML7&"&DZU9RAK]V$%*K1G2225:R/356S_`"E20N,\RI2U#"`WTS2BRSB2#"JR
MQ,KE'G(<`=ZL?:?AL]KM_EXI^]Q&UT!EP,SK-!%(RM25<GM(^7[4.Q04!6RS
M1"WLH8=C!Y1B$(1=J8TD1BB!Q3NZ&,1Y$[)&Y(SI71(RMJ9Q3-#>4<0@:TZT
ME,!22W(B%)@"2`BT46`P6@AUH6_$C(<!@,"L%S=9UG44A2ULWII);][/"0M7
M'J`I]N3RVSER50(L*5XD:82U!':QAQFS?-M_E;@R,OE`/0%(S0Z+V7/^(A!S
M;:W2ZE-(.UGIG35X%00X,O&U8NZY75.@`V,Y*'H6>'I&E[Z$>$XA%B-9P)FB
M$%&@V6:W._D+7"&R=%\D"!"U(436UHDC:V-J1,@;FY`F)1H4"%&2!.D1(DB<
M!:=*D2IRPEEEEA"```Z"'6M:UK".7@,!@,!@,!@,!@,!@,!@,!@,!@?_T?3_
M`/+'=/2-.1^FW"BY])H+$]NS\]W$OJAJJ&9W<@9V>2U@WQ>2,-8VN!2=/ZP9
M7"0JRI.B8"1/!ZE8TI?.!&K5^:5KUSNYX>F[^-ZJX22-5G0"Q.;NEN4KLN!O
M:J]K!P89'8C]7M:TC*6Z4J7>5.\C=D;-)%MCB5,+4VIVH]&0?LEQ&X#]+9(R
M9?+6FQ?(]V:6P<ZI5UZQY^<>[*BYXL]'-2JLKHM@XU6W#U_75#R1$P%H49"*
M0QMEB%@J"6_[T$\*MO[(<8>I&3HU%HN3GCHW9<$V_9%K5U<+1:<H#8$GHSJ*
M^>?"K+^WV.,J+&8:QEFD;#*7-IBR=!%27[3:O`@<A-B1$B$X(3O33D_Q`U6:
M\N/:UE]!7STM+H-4FNT9]>%<?(/:>F:+Q^Z)?#JOK>%0-LL2.4?!:V3M4ZA3
M)&I#?@J\DCDI?##@/#,Q(586WU!&^DIRW,D[=&Q/XOY_\@73D#.C,ML;H2)T
M"XVE:"=ON]D=**M2Y8NC1JU3H"K+@MV\)TBG3,^10I&1'3"HO2JHX"];ZXG1
MN$!06W6)[9/Y6JYAXVG-*/LBZ6F4&Z=NZ]XL\KHXPQ>Z#N-ULMFS:[FA*5SB
M)VL^V[?UFQR.(BEXC$[4KLQA*!M*((670=D@V2W>.R[TLI>LK(OJ`S&QN&8]
M/'EYA#:M=;RL,FDIH74#HE0/"LJ#Z9'^4/<G)>T:MN3)C%T9;U*`TUP+'[HP
MLL\9=3>.J6-6->8X7+GX'.2@N6M$GTUQ&"*[9@Y:F81G:I,5J4GR)*!:QQHT
M*8TPW:`X9YOB5Y-#WL6MX/[=^5,K;,G$$8ATP41"WZ*D/$YGAED1\0X!)3&U
MZ4'0\F+%-YCG+C4SFB1)MKDYI"40%HC=?^P(`Q_;H=S/HS[,ESKJB8!N<MDF
M`@AD/_/"K3+*XKM0E`.1N\Q_$.S(FY@3F&F:;0MCCK8B@A]SKS^8(X\L@)?+
MX-F\&1CK*JDU9N<33K[&DY]URH5AP^;&-[P<?&HC7*:B%$6GT<3N9+>1]852
MZ/J!E*5)NF_Q2E%+"<,?V]]2J89+E&JRH%DL-))@)8&T;O.Q)1#'^':4)=&/
M<ND>N>(@^1&3#2B.WIK1M3VE"8`&OJ`M#%L!>&0$K;[W-X,G41JH0UNHB:<Z
MRW4F;S,R;M,ZVWO`E3=!H^.OBV&0Q,#J!O`6M7N;6L$G-4#VE",HLLXG#'M;
MZF%"98(1=`%6,*2%[@I6CK%40DN(;/2;-+EA^R$SZ?)`)O7T$:,LM*(>B]["
M'6Q:T7A1>V9$OK/Y$N?[)Z.DM-0RIE7,0H;#)E8+>ZE1%CZ".DDN7VS'ZOGK
MY(VB*5M.)RSG1`:`;VF5.+ZP,CBB0"+-"J\\7M<8=SVHMZSNH^MY[SM:G-0V
MAXAU9L,BN*$4O.IIS_*;89)7(3TZ-S9FV_(D&U;@B-5G?39$_L,G0I$ONFI&
ML*//;_:$"])K9P3'KT%.8*[+;3KC=?-$1)16%"VRFGU%(9M/!H'8A?)&"<.%
MRO*:#Q'3@:@/1L@V=W6)P)U!9[JK]R4-)4X=#N"]!*89+F59?T=23%TDP'"'
M3:.THWH"XE%@*$INXVX1B03F6-\I<#22C2QN(C47Z&Z$%.$0->(X\,@)@=DZ
MF\&DZJ\I,9'(Y$T[)+JX2PNN$T8L.2`;WA,IFCB['QE;.8ZM4+G%.I"B;'9.
MA+V@*!Z8@&*-&C^F._B"SCH;,(VJZJNDB02:3@?&6PF6)<VHY+7C,2:C$"%P
M]K>*%D,)7,*@E*()ZA_:GQU$)2:(I63_`((2!OXR(FK7X$W@TS4W=;RY/#XF
MGC3K"3CJU2PBQ7$IO>$1TVG+:U5JW.>I8M/=@*C-,JUF:P*$2?12(LD)A1I&
M.BY]0J(9+(2Y6WT`XHY;)PR<U^#;LC8IFP;+-3GEQ^)R^)[C[['XP$Q-KQ1D
MG>!@!#`,0@#$'9=_&0$TG&2YS!;!-E-P*GJNXB3#F%K.O"W"H,Y)`('9M/>Y
MU6Z*9I(!9TN6)7@>QNLD;75:6>20H*,*4$%&A(Q[?,-1FPF85ZN)LAXC$]DV
MY;*02"];TD;ZO=]J4ZGT4TP?;'<9@SL`=I2RM-")>F:0I0^WTFT1O9>RZR$F
M@ZA(G,%LH,*0FSBLHB3!H%(%2YX6J8O&2$#LU%HFQ.L<3T(%>VM^6IAK1E#7
M&)U1A8CM@%O6#52.@/CVJ*71Z&KZ7ISG9EEM?6RON04&L*LV!PI^Z7Q^93X_
M*F>X4J6.O+B8XN2':14U24"-Q<X\[,[:H+(5)4PT!XE\OI".>+7L7H:G+VNJ
MJN?:-9.<(V[-=3PFGGP^RIN]/KK#)57*(R6V8XU35`(U5\!A4_D:9CB36C5)
MSU;SMP4'IS$Y:/0WBR+U(X-"6]K5,:"'Q9"R+5IKBL9T<?:4S6K<%"@2P]>J
M;R4@$AZTY6+9HS1@V,1F]BWO8OUPC)PA"`(0`"$``!T$(0ZT$(0AUX!"$.O#
M00AUKPUK7^S`_6`P&`P*;6!QZRCE[U;_`#G-G;F&\7Q3]3DDD@[6B=JQM9R"
M$(/->])KS4D.L<Y44`))KVF$S3,I.`)25\3%A\FR[YZ,1)ZVL2D30,_;%1FU
MNTE"](OI.H/KED\TN(`^/^?F)P&_5C4$(0=A$?N3MYD=2;WY`R!3O7CL9O1=
M:*2Z*3R/-4N@\GCTSBCZD*7L<GBCTVR*//*$X.A$K6IZ:%*QM<4AH=^(3"31
M@%K_`&;PC(<!@,!@,!@4\E_<=&M<B<8!6*B3=+6LV':2.%8<VLI=H/+"M%HG
M8$T^EB1<@JRI/-I26+U)=(&(L03`["(6Q!ULN7^F)C@O9'0A9^K0G#?R!6:W
MT=EUU0SVDFW03N@$$L1R2:7T\LP(?78U&@B`>BAS,M7I_/YDLFUL.A"'$64I
MZB*CH-@5QRI8*S1!(ZK-NLD<DP#W"4S1]'H6CI+/9D[GN$LGDI5>??K.;PM6
MKC?'^(W>O#!;;U2WA#`8#`8#`8#`8#`8#`8#`8#`8#`8'__2]M/1?)//G5[9
M%&N^:X9YT7"7LI[C"Q6)0C=6GU'!F7/K,0Z(34ZW<;F)+$F2/+?L>TSBE+"$
MT.Q%E#+++9T2+NG:N^Y:SEX(-'D\CIJ-R2'56Y)$(4>X'%I>ACC;(V".)4FR
M42!K=&^(MA(R0E^0):(H(-!T'"(A;>'>/VAIM1A;.;J?1,UVB3_E1K(A3.%%
M,2T;R=(V]*X)_;[+3H6N2J#'-(G3:)(2.9@E9(`*!;-V7;Y376-6UU2\)9JX
MJB&1ZOX+'@J],\7C#<0UM*,QQ7*7-R5:((#K9ZYT<UARE4H,V,]2I-&::,9@
MQ"V3JU(=@_'3RPIO>A;2:X]9D/F_0G9+(.Y'>!]`WW"B9LJ_!UUN1;D-ICMD
MM[/''E-N/%$$KF8AN6$I#U)(#`EJ#="C4MY_ALPYNYAH_D>M_P`2<^PU1!*_
M^X7J5_0E,NF\U-V_R(PDYZ<-O5@2252`0EYQ`1B+VJ]'0_,((-"$+>ZEMO-3
MYA#`8#`8#`8#`8'6/+*S2-K6L<A:6Q]97(G:9Q:'E`E=&M>G%L(MD+6]:4>D
M5$[$'6]A,`(/CK7Z8'V;FYO:$*5L:4")K;4)($R)N;DI")"C3EZ\"R$J1,`I
M.G)+U^@0@#H.M?[-8'-P&`P&`P&`P&`P&`P&`P&`P&`P&`P*;R?ANF%#V\32
MHEDZY<L9\4:7.LVYKD_XZ)?'/0!`TZS.L#T+Y1UD.F_'7BIDD6=E/@'00F!U
MXZV75.>WHEVW#N;I*QN=JTST!!':>T*PJS)%%Y?SO;BI&]7W5S,%F=YW6+M-
MX0Z)Y,H5!1.*IOBC![9`L4#+3GB+`0;%F:KST]4KI5=(S&7)/CYE,#E,:60Q
MR:;#K#K%FG#:QJ2I_'"O43D3B?5D^*SG`D>DY0!M6RA"4;T<(HL.Q[+.O5M)
M%TY>8PB`G^.GKX)X@["0)?/N`DR$)PM>!8EJA%V\Z+2$FA[UZ@R4R@T(/'8"
MC!:T#=9R>7R%=/8[P,)47XC;&08Q^F$^X^GX#$4)6_`&MG*C*EB-_K@)O4,\
M?$I,<;Z8![]/S:``P9/+ACC7R%3<("W>T>7*`;SB0^\35W7%AW_+B#O4WH0&
M6<6!*:>BB7P)_71JN&+];%^GH^'ZX.'Y'PI`IH'0^CK2O/JD1@2Q*V"WYZ6S
M54J.UH?JZ5T53K15U+OB3?J"`6!X8G0TLK?EV:+>QC&-\1;N)P^)0)@;HI!H
MM'(7%V@D*9IC<39&R.L#6G#K6@D-S.SI4;<B)#K7Z!++"'7_`,,(R/`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`__3]_&!5"2=M\V1+H9CY<?IXK26\^J$#62A
M!#IHJB39)WMN:7F,0E_L5+'SH$PS>6LKP2L;6I4XE+%!!A/B`(E:$*HN7-80
MU?)#QZ[QV<S$BQ9>AAM>)@J7^9R&A^A(K#EPCI@@@"%OA,JDU5M$?LQ\>)DZ
M)V]O;HVI=E[B>;KVI)H?$6AE66IZYZSOR#(K'J:4%2N)+7%[9=K-MCTP.C8_
M1IV5L4CCLCC,F;6:4162,+PA-3+6YR1)%J4T&PF%!_3Q)T0-UE_QMQ!_SDL7
M_3YT3A9W7)PA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8;
M8->0:UX>\U_9448YO"9"!&6^1>2("'1E=`-[@D=D.EJ%2$9)WM'-`0H+\=>(
M#2@BUX;UK>!6Y-\?7$B-6C7)N7J;*5MZU&XHCOLUM$),N;U)2U"J+T,`@Z.2
MJR`&`WX?PC#K>OUUA=OE</"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M!__4]_&!I(N7EKJIT^3>!WC3<+C=<Q!8_15ZL.[6.Q'M3&;)J2+MM2-$OK^Z
MZ-?"W)@<K=-"RK4$9>V8+>H$V$MAYBT`V01(YW:V?.56E@^,3K]C3-JN(M=>
MUBUTJX<^3F-4B3TU=EKU+T5=-#]+1VX"YXH_)C,Z.=),;A73,K8T*0G2P_:I
MP+"J\J=$2<-B_4;?.':3LFFJ^M1PMTIA:K`O3H^ZNB'R&Q=^4RF/5X7:4C`L
M:(0WR52UL8GY0TLK>G,7JBT:<@YT4*=E!V5Y!BK-1WU17CHFZ&XQL8=J66K:
ME_6$?:2JG5*X=NL&P\'.]]E;?&Y(3#")F%Y,VB$,0CGLY/YU!O@3K6P:`)W;
M%<(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]7W\8#`8#`IMUE_QMQ!_P`Y+%_T
M^=$X6=UR<(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_UO?Q@?D0@@"(8Q!```=B
M$(6]!"$(=>(A"%OPT$(=:\=[W_LP/+_"OD5[/97:PJPLNTV".7S8]N<YUY&8
MW*JGCCO#:H:+HMVH:R?KSI&>0E]-@ENT7'&:P@`2E.ZX3M]16,ZY:`LMQ4)A
M1NR<-U/"MRV/;M?6ZTVN[M\KFM$]-7GSNNGK7'DT426$WU;*=(V.7F1]`J5M
MC8[*V9P(3.1238$H7-*HT466#P!JLU&'9=U1]FM3F:/%P#I&3JZGZ1CED3MR
MKGD7JJTXHU0T^DKB8M.J&<5K34KADD.(>)DW)CT;6O6KDYIX@FD@V2?Z8G=+
M_P"^VDOY'[)_MT?(/_3#@RG[[:2_D?LG^W1\@_\`3#@RG[[:2_D?LG^W1\@_
M],.#*?OMI+^1^R?[='R#_P!,.#*?OMI+^1^R?[='R#_TPX,I^^VDOY'[)_MT
M?(/_`$PX,I^^VDOY'[)_MT?(/_3#@RG[[:2_D?LG^W1\@_\`3#@RG[[:2_D?
MLG^W1\@_],.#*?OMI+^1^R?[='R#_P!,.#*BV\N_&5JI2X'.C*MZWDEV-U6V
M`OIZ.O7QV]\D,S_::.)NZBOF5V/<^=V!M);'66EI"#QJ%R(@)1@MF'D@\3`B
M3F;T2E^^VDOY'[)_MT?(/_3#@RG[[:2_D?LG^W1\@_\`3#@RG[[:2_D?LG^W
M1\@_],.#*?OMI+^1^R?[='R#_P!,.#*?OMI+^1^R?[='R#_TPX,I^^VDOY'[
M)_MT?(/_`$PX,I^^VDOY'[)_MT?(/_3#@RG[[:2_D?LG^W1\@_\`3#@RG[[:
M2_D?LG^W1\@_],.#*?OMI+^1^R?[='R#_P!,.#*?OMI+^1^R?[='R#_TPX,J
M+::[\97*!D*[FJWK>/SW<IL4@]L:/CM[Y.0ABR.Q94CKE:$QNYW>TON7:N4[
M4K4:THV,*@\>C"R3-")+&>$I?OMI+^1^R?[='R#_`-,.#*?OMI+^1^R?[='R
M#_TPX,I^^VDOY'[)_MT?(/\`TPX,I^^VDOY'[)_MT?(/_3#@RG[[:2_D?LG^
MW1\@_P#3#@RG[[:2_D?LG^W1\@_],.#*?OMI+^1^R?[='R#_`-,.#*?OMI+^
M1^R?[='R#_TPX,I^^VDOY'[)_MT?(/\`TPX,I^^VDOY'[)_MT?(/_3#@RHMB
MG?C*HLRV4,LJWK9#6;?]B?B5X2_';WR-Q??=L"DZ>?52B.=UBTGZ9(`EE$>N
ME1^8O>]@]4/\>AB4OWVTE_(_9/\`;H^0?^F'!E/WVTE_(_9/]NCY!_Z8<&4_
M?;27\C]D_P!NCY!_Z8<&4_?;27\C]D_VZ/D'_IAP93]]M)?R/V3_`&Z/D'_I
MAP93]]M)?R/V3_;H^0?^F'!E/WVTE_(_9/\`;H^0?^F'!E/WVTE_(_9/]NCY
M!_Z8<&4_?;27\C]D_P!NCY!_Z8<&4_?;27\C]D_VZ/D'_IAP946N_?C*7==?
MMC15O6Y])K*MN!?8,B-^.WOG3RU6FW2RC4]/,J`@SG<ER,;'^).LY/5C*0J2
M`&MJ;1IZ88B2U0SC]2E^^VDOY'[)_MT?(/\`TPX,I^^VDOY'[)_MT?(/_3#@
MRG[[:2_D?LG^W1\@_P#3#@RG[[:2_D?LG^W1\@_],.#*?OMI+^1^R?[='R#_
M`-,.#*?OMI+^1^R?[='R#_TPX,I^^VDOY'[)_MT?(/\`TPX,I^^VDOY'[)_M
MT?(/_3#@RG[[:2_D?LG^W1\@_P#3#@RG[[:2_D?LG^W1\@_],.#*P^5=ID29
MPK:+4;6_2B^5RBXJICS^.PN'>S*ZBC36KM-FA)9K\XS:RZ2@<*C@V2%&+%)*
MA<Y%@":6'00&BV$L0SROSA#`8#`__]?W\8#`H5#OC'X?@Z*V&EIHIC6,=QDM
M[=)F&0.TCD+0RQQJ4QIV;(C7Z9W=U0J\BS9*XJD>TB1H$DTC=BRSDXB@ID9:
M8NU:VI:@K2BH*U5K4<.:8-"&8YR5HF)H">(L3@].*EW>G5>M6GJW)W>7EV6G
M*5BU6<>J5*#1&&F#'O>\)U21@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]#W
M\8#`8&OUV[F>VZ_^DZ&)YFMM<[4!S<5T''C$JN..,GOD"N5S6(M$>JF%Q]4_
M&F-\D=88:G;U[HN0+#50A@.;2"2P*3BYQ+J"1?*#(F-HM&.650+=7MZUC:?-
MM<KX"V6R59$,/*Z#3.$S6*3[`;8-%U2"3U+3T2D4CDS(-H]RB):R]%F'DK$Z
M@<U?GQ>&%D_,&>UU:_6-/N9G"$'NU$45TW3#6?<,><V>84?T#:2*JHM,K5E@
M8FA1TD").#RWNDG\4\@1-#.LT<%4H-`(C&GSSU;!>-^G$775'-]R(8PFBQ9T
MRL>#*"&66H+#A+TX5I.7V"N4GK6QVQN9D-AUT_KF(P]I>2T*(*Q.+Q]$'A^M
M2S%I\(8#`8#`8#`IQ>?6:RE^B.6Z%_#,RDC?TK-G.':M[ZS&V:O86L;8)8DV
MVT^AM4Z2^23(TB!:W['3:A;0(5?K[<_6+TC-+)LM5R;ODN<XU/)%'N@^<G^A
MHJ&CNB^C(6YN\]1R*PQU1S>_-K/(7^XJG+B3(XTM][)W,"J.",<7E(Y^7:?2
M@*K6R=1<\5&D)^6I]$6POUO<RN<"KD<X=Z$F$X9+'1RA^8>GX=SDX]"SJL$-
M8?:;<[.<9:RV!SCB%Y"Y:5KWQ)H'TTHDP)NFGSXJP_%7?Y76,L>H'(JT9JQE
MY=*5)T9%$4:MMCN-L?*BN4Z1)8X:_.[%'8T&&V$R*X]Y'=A/*4:3@6)C4ZM4
M49L8:EF-C&$,!@,!@,!@4Y[NZS6<3\WSKH-+3,RNTJ$MYB];'8H\QN-HFQ,`
M/_SB7R-_5#4,<9+-V$HQ0WMKTN":8#0$1@=B$$LFW-1A>7<TYHZ\F:#/?-+^
M=2;C;U$T27=KC/$K"]2VR+[,0E,I5,U0=$ERJW(S"3',H$C5I7I&L0C)5Z)1
M*0HSQ:BR;.O+"'#Y(W=O>ZVTFYWE4BKVY>Y'3D*O[;;)6P(8(6S,,M<*T=;!
M>QK-'R90\++"B,A+:FI"V'M[@V-P%(W5-LX!8AG[V=_"OD2U+^E$-0&TPK9J
MCDW0UT\GP6\#K":53B_7Q0<.>Y?/6=VK`#`2;'H6J%$GAM:74+VL6+7)O\AK
M>F*.*.V,XW>6RW*R8#`8#`8#`PVPI6X0>&2"6-,&E]E.3*BTJ1P6!`CIDODA
MPE!)`4#&&62&*1SW.O6]06U;BE*"4`6_/O>M!V&LD'R56/(>5:'ZBKODU7)&
M"T:9L2^K&.DER(8'6]*02N`)#EC8]6RXUVXMKW/982I,^AM@V]M(5B2*-GJT
MA16C11K)MFN=8/R<FQV`V?;,`YUL*U(-4W'-6]23)"V.C%%I9&':X(K-;&CD
M%F**5*&].Q(HI6\(,=9.L2?5')K+<402&U::;Z6#.VIAEO<*R+6-Q!`?P3,E
MS?V6-J!JR?N2-I:]KA8Y53-K/W&?7WL^7S"9$$0_0/;:9VQM$A4^YVX!.!I"
M;4SKST7YPA@,!@,!@,!@:RHA\@5C6/&>D%$#XVM579%']%0/G:/U'(97&T$E
MD3C.8Y74BU/;&=XFCG<;J2!QY%.QK'!64ID7MFI(%2;HLXX:-/&LZ<NFA/R2
M.<_9:M2QNA'9\M*47KT-4<WK>%3ACF:5$R\OQI_<[0G-53U8DAL<LUF42C<=
M86HU1ID(-=9`$E4-*),?K33Y_7ZAOR&6I:G,].7W5W(SHY/-I2WH1JDL;G5P
M-$#KRD(ESQ.K(A\AE-P765!Y.Q1I<_%P`(D2,#<<CVO5&)MN&R$HEQ@R;9J[
MW-=X,_2U`4[T!'V!\BS+<->QBP&Z.R0CT7EG321L(<`(56PA`4K`5LW?HJBM
M>@L(\AY7B68'>5+,N)NPA@,!@,!@,"C;OV>O:.O)=RL=0%FB*BO+MA]*M]@E
MK(XLW91<!E]=Q04*JN$,ZYV>G]6Z'SS9>E3D>S&A<$@4Q2106=[DHN<;JLR;
MY.;"1-]IQ&P>8`5ST)%XGS-((!4Q-MD6`F?WKK>Q%E95'75COK7`XZLJJTDS
MXGTK>F(]"N&D:?46D*%*8H9N35^9YX3;&.Z9G-9)VG#(URA:9TVY--JINCD"
M<I-"DTSN5TMAH<G%F4IDC8N>H[!HJ1M(6IVN.='%5MH,&J,1$GE>R'4SIRE#
MBOJW]W=9S"<'0ILA3G`K;F]//8(K8#=;5<21XA`&@Y7**LM-J9(RDG\'6A>@
M)P+OIJ`PMP2JTIA(1IQ;$+,7`PA@?__1]_&`P&!4&P^4#)?<UO7M%[9EU;V#
M:')K7RNVO$<;FM0JK].S32QILV67&U"W>Q&2YO<K%-]`L[6TY8D90_UWL6L+
MO&*M\X_%@R4>HK=JEMUN-OUS5IMC/D?@#G5-=0H+W8-IP1ZK*96984OBB8F6
MV3-WF#REU1*'!Z4K59WOQCV;K80ZR8M]OQC:#X=*SU#M1J27[=$Q=H9#:+K2
M@98_H:R5+:0K;G"Q]6I5D-2L1D',BEC-Y<J(3`>-R)$N"ZMZ%,G\A'HA,QA]
M?B]_*G,L<Y5KI\@[')GR:NLSLB=6]/9>_M\;8U$CL*QW;ZO)G%#&8:S1^)11
MFT:`LE(W-Z,HA.04'S;-.$:<94MU9?"&`P&`P&`P*]W+SVS7+8/-M@.<A<V9
M9S=;#I;#(WH$J50FDK@Z5K-ZU,:74U1O1J1$4AFYJG0R?$>S2`!W_#O>%ES6
MOI@^)YU2.MR'3#K"96"T]$SQEEUY:D%1U=][V"PM-A1N;"K53:.D9\W::Z$T
M1\3`E9TB@IL;6M8;I*F+,WH>3%^NG";S/C?@1M]K[<%:MFEP13=\GZA0T0GU
M$RH2R]*2ZJ5E/N]K-C_N/&30HTN/.*EQ2M@ENT29_4FK=:WH>R,8;QT=UQ=\
M>]=<9R"Q9BQ2QQG<QL)DB4-.?%L#J:N"&R#09PD[NR-XF&GX/!6%ZEST]S%>
MX2&0+$YC@^+AEFF>GHO0-U+=;`,(8#`8#`8#`KWU=SVS=6\Z6WSK()"YQ-EM
MN)J(FXR-F2I5KHT)U"I*J$K1)5N])#S@B2ZUH)F_+X;PLN756K3X$FU@=>ZZ
M\9^I))&I"S,+#%ZZA;W458V5':F8D;>0GE9=;FSA$X&Q1[L-?[@]W=D99#H>
M2>%+[CVQ)9>AO&8D7?"T&)I/D&D&Z6R%$R\B6A35KLKV-,C6.\^DM2I'<*H^
M4B/'Z9"B=O#XJ<7(XC^(*HX7IZT'?AH;S:QB(?'=!(AT@7>I-F6$YQ)HNBUN
ME(;1+@1$Q0&)]`7=$5<*LFP4KJ4P%RUR3.;:[.*Q$UJ5@TS<[NJM85O8QEA*
M&\8V%X0P&`P&`P&`P-0,N^)TA^H+D+G1FZ3F+-7O)*188DCSU6\`GD/MJ1@.
M*-B\DL^`RTE=$Y$;"!;4&-B-4G4HBE*D1^R]F@*$"8U]<VXLNW\2HSJ%ZTJ*
M:VI(9M,>RF&9L]LW`HC<=8WT1TKHF.\_HU;/&68!$<;4D9B$73&HT)("T@5&
MS=Z"'1@LJ;S/QF\HY/CTH/XY/42QY2[XZEB"61H)*)"/4R4(*=E=.@2/GGWX
MH"3&V5F+-B3^(M'E!#_Y-[P;U_5L,(8#`8#`8#`8&N2UOCX#8,%[$A<7OZQ:
ML-[,MB,65.Y'$&]K`]L34Q06`0-V@+*K]=,IVP2YI@!0'$WU2E!J98H3>/HF
M"T*8U]=..C*>9.(0\_3&+S)[M+\B'5W33K1E6,#955<U%$JZA,DF;1-I:0PQ
MBM6UI9?=25QBS*%0:(G1F]-@1;$(1H]Y4MU!4^^+%++N:ZBY?9NBIK&*_K*X
MK2N1]0'P>&RIBMEUL2U9K;39&K*B+\$Y@DL-AK_.5/I-2LM0WN(B"#59!HB0
M:#,7ZYMQLNK2+/D)@,3B,DE?WP]1UF2M*V5:C4?AH'C:/6RB#RHM%4J*.,1)
M*70"@)D919!8"]:"'65EG.`P&`P&`P&!5Z9\TE2;HC72C//WR)3E%R]97-+$
M6@:FEP1LA5A3B%3TJ?DA<0F:5OD:>(.GT0D-`)(<`P7J:W^FL+O&*9\X?%B*
MAWJLAOW2,IMB(5S;:N^EL>?ZNKIADMEW(.)3B+M5@6O:C,GW8MA/+(=.SW`C
M;HN5!TK2)-:T$I.`O4Q;[;O"RDGXM;W^4]=3)EN>VZUDW6!-&C42FK7HB'2^
MKW2A6<MMC3C#Y"04J&M)>CDX-NJ)<2<B<$0ST)Y9B50:`53>G#+^4>5V7EN/
M6.E3S1\L28W%9[K;UES%X8XA$4KM,G5@CL7%]`A,!8X]$HHS)V6*I`Z(3IQG
MGJ=G*%!YQIN]Z%NK580P/__2]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&!_]/W\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_U/?Q@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_5]_&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!_];W\8&%2VRJY@)B$F=3^%0HUS`>8VE2V5,4<,<"THB@J3$(
M'A>C$K`G$>#1FR]"T#8P^/AXZP.+%;7JV=.!S1"+*@$R=4R(QQ4-D5F,=D+@
M0WDGITQJ\Y$T.*Q24B*4K"BQ&B#H`1F@#O?B(.MAG^!^##"R2S#CC`%%%`$8
M::8(("RRP!V(9A@Q;T$``!UO>][WK6M:P/PF4IUB<A6D/)5)%1)2E*J3&@/3
MJ4YX`FD'D'E"$6<2<6+0@B#O81!WK>M^&!]L!@,!@,#H4$JC#JM-;&N1L+DX
MDA-$<WH'AO6+2@D#T6>(U*G4&'EA),%H(][#KRBWX;_7`[5&M1N*8M8WJTJY
M(=Y_15(SRE28WTS!%&>F>0,90_(:`0=^&]^`M;UO]=8'\&M1%JR6\:M*!>H)
M.4IT0U!059Z=.(H"@\E-L>CC22!G`T,00["'8PZWO7CK`_2M6E0)CUJY2G1(
MTI0SU*M6<6G3)R2]>8PX\\X0"B2@!UX[$+>M:U@?8(@C"$8!!&`8=""(.]""
M((M>(1!%KQT((M;\=;U_MP/U@,!@<98M1MZ<2I>K3(4H!DEC4K#RDR<)BD\M
M,G+$<<,!81GJ3@%@UO?B(8M!UX[WK6!R<!@,!@,!@<5.M1JQJRDBM*J,;U7L
MEY:<\HX:)9[=.K]HK`6,0DRKVBLHWTQ^4?IF@%X>`M;V'*P&!U7UUD]$Y1]8
M:O03./T=0?\`4$GHD.^CP)=M9QGK>0IQ]T8$OT!;T;Z@M!\OCO6L#E!7H1K3
M6T"U(-Q(3EJSF\*DD2TE*<,99*DU+H>SRTYIA8@A'L.@BWK>M;\=8'YTY-^S
M5Q&EZ+9S8`LQR)TJ(V:WEG%"/),7%^?SI`&D`V,.S-!T(&M[U^F!Q&B0L#^$
M\;$^,[T!,(L*D30YHG(*<1NA;*">)&>=HH1F@"V'0O#Q\-^'^S`YJ9>A6F*R
MD:U(K-0*-I%Q2922>8B5:``W:96`H8Q)E&BS`B\@]!%Y1:WX>&\`D7H5^U6D
M*U(LVA5FH%NDBDE1M&N("6,Y$JT2,?MU9(#0[$6/P&'0M;WK]=8`Y>A3*D2)
M0M2$+7$1X6](<I)*5+Q)2=J%042<8PFJA)B-;&9H&A>0&O'?AK]<#EX#`8#`
MXIZU$E-2$JE:5,<O.VF0E'J"B35B@)1AXB$A9@PC4'!(*&/80:V+0`[WX>&M
MX'*P&`P&`P([GUO5/5(6H=HV?7=;`?E!B1C%/IK&H<%Y5$Z+V<F:A2%S;M.*
M@K1H?,`GSB#YM>.OUU@9\F4IUB<A6D/)5)%1)2E*J3&@/3J4YX`FD'D'E"$6
M<2<6+0@B#O81!WK>M^&!]L#B"7H0+2FT:U(!Q/3F*R6\2DD*TY*2,!9RDI+L
M>CS$Y1A@0B'H.PAWO6M[\=X'%^NLGLD[E]8:OIRQ06D2+_J"3V2I4:>)*4F3
MJO6]`]08I#LL(`BV+8];#K7C^F!RSUJ)*:D)5*TJ8Y>=M,A*/4%$FK%`2C#Q
M$)"S!A&H."04,>P@UL6@!WOP\-;P.N%)8X!W^@"D#(%]V((=,@G5`%WV(:?2
ML`?INS]+/,-*+1FM>3]2]^;_`&?K@=@:O0IU:-`>M2$KG`*D2!$:I)+5K@HP
M`,5B1IAC"<I"E+,"(S8-"\FA:V+PUO6`,7H2EB=N-6I"W!64<>E0F*20+%)*
M;R>X.3I1#T><4G]0/G$$.]`\VO'P\=8'%=GUD822U+X\-3,G.-]`D]V<$C<2
M:=Y!&>B6:L.)`,WR`WORZWO?AK>__#`_1#TS*M-PDKLV*0NX#C&G9"]*=IT+
M3`]108W;+-%I:`@O^(>RO-H.OUWX:P.SP&!QE*U&B]O[Q6E2>[5%(DON3RB/
M<K#_`#>@D3^J,'K*CO)OR%A\1B\-^&L#DX#`XJ1:B7E".0JTJTD!QZ89J104
MI*"H2FC(4D",)&,`3DYY8@&!WOS`&'>MZUO6!RL!@?_7]E__`.0?_P"S;_ZV
MX7C]:_+N_/?[SJI_.O\`V_?=_MBN;[<_*?WG]C>W_*M&_4O;_>'^+]V>KZ/M
M_0_A]G[CS_KY<B]N-=;%/S'^^:E?PC_VZONO]I_77U#\._=/V]]O?E_AWW?W
MI]H_ZE]9^I>T^B^?_`]#ZEX_Q>3!VNZV*_\`Y!__`+-O_K;E3C]0E\EL+>)Y
MQ@TL<_\`NX+@1/:.?+%/I^GUG04"2*H_)V=XD*FS*062.-RVSN:BW=)O4A;$
M8ECO])V$_:4[1)V@Q9U:86NZ.G*DI0FN>;*RD%!QZ87]>,BC5H\P4S<5=TE=
M2UFIF"R=IW7E77[273DUI%&^6$XC;T<5C4+#'IFZM#H6W.#87[I<>:R7K5AW
M'ICY%'V*O=N&V'9T0=JDIKX@K`'3#72<`3Q.?6'U))D\4ZQCDR+>*R7V5I%&
MDBM2<I;&UY0'QY2``QB(]'6L)DZ?RQV=]N]EUW?YC>\6O>Y<U<NH>NX6^<KH
M>6XVYP=#25:4O=LVYF,J":O59,;K8LOLI/"$#N3[68#,DQQWMP`0$I%.CADS
M^G34?U1\CTFC#Q'W2R[A)1ROH?XU(_$[9<:GA[](4<+Z0FTXC?4*>-N$IY,J
M6`KFR%E,Z$9Q14>?TT.5&C2[?'`.O6V+([J/W[\H$"9@N46GEM=#S*4UW\G\
M2C,"L.I*Z2I6R0<D6%'6'G&9->X#5T,=GJP9RQO"Y0-,L./12L911"5*#>@&
M!<F>O_IL1^/FV[FGUJW)'E=J7CT1SLR5O43[&[HZ$HYMHB8MM[R!PG)=LU7'
MFEJJNI4DJC+&UM[2O-_R"@R.JEGTX2I1KR#PESCRT1<LUJ:W6]QJNC$=BCK<
MC%\B%CO5BP:"<23FLNCXW6#I<=]I'&<6MV\=MTCU@U,T1)[0NRIB.;T(%C(8
MC:@*-#3:-$:MZ_PL1"[\[&@G/-;M(93>?/"%JY=LZ;\^,=`<A127-%[=<`Z$
MO=`CJ.PX\V43)FN(MOVPWQ\9+"B*C0G@IX/=ANFC"![*)D?2Y(S-&_K99:\B
MY_.M+I&56KRG,ATG9_.5V)[2:)"SQJJ&]^>>+>]Z)ESI'HO14.=`N*IR;)3I
ML:4BEO<RG=,(I1H1PG3KPDF7WSU-87._:**=RN_)3<0^>>P5]C\OS3CR(.5`
M4N[QB;+X_2#%#YY(:TC^YP9*X.$@U`W*3K`(F",:E>:!$$K^(9-GAFD/Z!^2
M11V6YPE4Z*HA`([,7-I;JL75W+E,(>.;6NB4[W&K"CBJ.\=/$6;I>OF1ONOK
M#A<B5&%T*''C8Z1OVWJN3/7$<QSICY+HW5+*_++(N:RG^WN#^<[^F3NNH&OE
MTBH"<2?H^*5M=3Q5<$K^H&(A]70^D'E>^"CCPB>E`5S?M=L`D^AHAN3/7?Q^
M[UZ@[X;(Q7">@KFO]^IY>HZ$*A?2-H\VJX)/Y_,X@HKY+3,3E$7KGC/I1QFT
M.7:<W4;<IW`:Y.L`:902%P1&)B3'`9.Z<8ITGWJW?(16E?V4LLI\A4G5U='7
MNLZXJM8R5O'&AVHUA=;.GCR*=<Z$K'V!-UKF*E),M2VLA<&W986@Z->X&8DP
M9,6F^0N=1[H[XVG*P*6V^3F,SFS^1GR,&)8E+&E[7MC3V=1ICLH/B4@9&B6M
M0VHIH5#5%+$*<Y,6G,&8$(0[WA)Q5&B^CODH8%9%@QN565;TAGZOY6(A'Z,?
MZ@@""&L"CFD^7+^55T:^SJSC<V52%_5-1*76W-U7%RA,:4G*"`_?NAN5SU7I
MXDZ2-^WW;=EWKTK=C%(IO3-=0J9W7R@IJU63<5@Q=T<YM!F%Q@%;0DUZBK+)
M4@@*ESO&VQLBA@@-YKRN_P#,02S\;6<K)@5NE'[O?OM5]E_MN_&/U-O]E]T?
MD[[[^C^FD^J^Z^D_[O\`U/UO7]OY/\+R^GY_U\V%X8AW#>L]YEY_FU\Q%151
M+/63&Z2*6)[1,E!0'D`2B4,7C$3'&S2`[E,ME2Q*V(PJS"TXU*LH.Q!UO8M"
M3;C6#QM:A7.]FQ"!K^G.>[JL;N5%9LLL0N$V^U3Z+Q/N<M9(IJQ+0(&E_<7Q
MDKJS:JVGC@RDH`(T2V#MZ1'K9CB7ZD:O/;HW#53^YSZRX_G#\#_;_P!,W])_
M%/Y!^L_6?=)_#ZC]W_Y+Z9[+U?\`VO\`%]7R?^GQRL\=DOM/W#Z[Y]=^C>V^
MLC^VOI/OO7^WOIS=Z7USWG^']9^K>[\WM_\``]OZ/A_'Y\(\C$JJ6_ZW77%(
MXS#I_*JBZ@^:E[!8,8`U.9WXQG56=\M<W@5WM;8).8KW`[0JAM7,[PM*+"C`
MH960WU=Z/'D=)9Q_"9:,F/10?D:BWR$._/EUM%/=.](VSRRMLIQ-A)L77<T/
M#;#*YY@V;6R"7K+4@IS#;5+'/3F[N<>2-)B61&BTL'HT@Q0[ESYS>4?49`5T
M!MAS9H;2#O8TF=8+VJUV3.YUS+>'//95+))C"+&?PG]2VI%Y5*N:^KF23R)N
M0-D>-5+EZI6-:D<&?6AE&:+']LVY&<*-K([X\;9YSHZ0Q"5\W</6))?D7?*^
MY_F-6ZEX&'EYB(2U[/W=;"(FT6_<$FZ`0EK6O11KNY'*6Y4;ZFP'!$82[S+>
MZ#Z*B7R`5M#>GXZ&CKKK6V_DAXPN6Y44L<W>$/9LNZ_8I9-K+>OLHRO9I)5]
M2*I315QE,K,A?T\>=M.<>3``3ZI)PTQ;G'Y5W.2G?G8GY">;HWPUS;;'-M?L
M]"6NS]*/<LJ6<T_%[16%1R)K837<P1R]&WJYE?U630M2I7N*].-R-2&K#2EJ
MQ(9HS9+N7:^O14.H=/UYVH?V9S5>U]67/%=*G<-.=:5E:4E>EM?L]=15.?#^
M>K3AR+[=HVQXK<25W7OJ]2]1T_R*2EII^TGCL(G294@OG0/:39U0JBB>5WT@
MGK=V'5=:PKED%%MD@H"7\/NB"`_?EXR6_P`-3N+@"3(D:UX<5D@*F)8&EW0:
M:/I1WK?XI,F*A"OGY.G*K3[(WTIT"BE`^%^CNI#(TGHBARV8-OT%TFEKVLZM
M1-6J#"YIH_.8&];5NS>(\UX=QI=&D*"4OB0$N3QW3DX]B=AR+K"<12!VS:;Y
M,(?VCSM6<.YC:*$8U-'/M#3>IZ@F'0"JP;B;Z==I%$%<$2RIQ=R7)7*-K&4`
M"PF(UI:Q.`L9,_IB,1ZE^1A?$EBV*V#T%*KQ<^;>A9+TW7U@\>A1P/C^\HZ.
M.D4TW4XCCU/L;Y8`E"I4K2$LX7*>J'YJ3C?@IU&P:1JAD_IQH3:?4U_0WG2/
MS=-<4A7I>P[A@+;<TNKF"2)^'%7GB:U5B63U'.G;F.BG1""-3QQ]D1(#($PG
MA<##6G:IR3A.+V.)JO59WM\C4#I'BFNJ(F%B1MD0<NUT&-*[(K2Q7<B9]*I[
M$?8W;5.V,U1OB6]I6\,-<Q9"F2(FK;G`E)*!0-YT^NFTXMI7*YZ[=>OD/FV$
M.QZ"$>PZ\P0BV,(1>'\6@BV$&Q!UO_9O>M>/_P`-97-^L#!K%_)7VHN_$GV-
M]\>LB^F_D7Z_]J>W]V3]2]]]L_ZOZWL?4]#T_P"'UO+YOX?'`Z`7YS^_X;Y/
MQ/\`BW[9!^0?-]X??_WC[-Z]3[-\/]W?MGZA].\OO?\`->C[GQ_B]+"\-5M6
M`7&69W*;=Y/*FNR2K-;-,PKU"[BBX.3=PV'`A8H<.1;&[@ID[87K8_I&]-^Y
M9MT^I:TM];6HOC.B5?CS-M$XB9BJC=4"X4!<TW*I,90YX.0BAI4*CA<BU2FU
M0Q1G5&%=%!DA<5T+P3!BX"](=>T]G@N?VOA#?W"?2%?Y"_#7U_[R;/8_9OWO
M](_'OND/UGW?UO\`SOWE[+W/MO)_D?5]+S_P^?*G#4?W35UU2+Y(:7N:BVN1
MK[%YOXCMFX((THPJTD9M&0,5]5(SRFAWUTV2)L"LMNHY-(FMM"</S(G0Y*XZ
M"+2/(LS,OEJ;=H'T/U'Q;PKR35W/UYRPR#TYTYU3+6YE50:L5D/MJ16#<M>\
MGKY"]6O,Z\:1*X)+WYPD+BQI'$QT/3@1GEIS2-^?1J9+;:E_J:0F=():VZ=F
M]-O,LLFP>*:T;BJ(Z(XXO6RH5*K58'B;JIY!N3;GY[D9=M<S7\FL(HQO<!'M
M;4H.)$U+P'&)2S/1$XX_7)Z(C]/2F<_*2EMKF23./:%JQGF`?(21JJ";6=<,
M/N([BBEVZ/IJ]Z"8X<Y&,@Z[N(!/U5S^N("C1-R@T\6_$?B\I/\`YYX=MU@^
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M*HKR8K!<J5X[5>?1M5S.,*I?SY6[S8J8]M3L*!U`DD3B0J+VN/+/%H@7+U_&
M57C9/3MJU2\)$MX=@VQ1<#?N$;=LFVY7SHCIZPJXNX[HY&VW?6D6CS%04.6R
MB%PF&J0216VE-3P9%G!K1)CUZU.>>E,+,WHF*4=0?*TDZ/Z/1UV2XR$,%/Z7
M_&=%OU=SMR8)C3T/J"0/'-<_C)S!QP0P!F\UE0&]Q/5KKC.+?G%4='0LR!26
MF+`Y3/7(^LO>;?Z`KGG=C:[]ZMM8AI^07B=4EN2RN7(;4LJK>2N\1L-;;1L&
M./K*+Q^9MD!DBLH6Q/<+,;8RJ,*0&JG@L)@"1QX?;\Y_(A*H6S0HJ]+HA[C`
MJ4^3N0.$_8Z9J,V867+>5+G;8WS49+S9+3SZQ)U4LC.M!5D,B)JW(D>S1E:"
M</2H#DSU=J^]8=ZN<F;W@<EN^*W$M2<2N/.O-40YP1O-#="Q2T(743STQ(;*
MLY?4S^[Q@V.R%^DB9:+4HCOV*G:2A[+6[4>8\9,13!K*Z1I^)J8D9.NB>:J;
M7V)\C\^C,\I3G8BYI18'29/8,M.JBK9:TOU16MMGB+]%%XW)N2`2->I;LXU.
M6Y$Z(UYRW+7,N?M3Y`X"0HE%N6/:O.-GH(M\=Y,#IJ.<[Q^3TY81-SN-/-'6
M3_.;)E%22]NBTIC5@RMQ8DR/3^V[9#$Y*0D"L]Q+4!)D[)J@T[^1:XKNN3DY
MEN*9Q=PXXL)KC]A6V5&88!TM6%W_`-855-:M>CA+8PI9S7.`<-)Y2484A"F%
M]05)QJ!#4!+58.))?+__T/?Q@85+:UKF?&(3IU`(5-36P!Y;:;+8JQ2,QO+5
M"*$I+0C>$"P20"@1`-F:+V'0]@#X^/AK`XL5JBK8*X'.\(K6`0UU4HC&Y0YQ
M6'1V/.![><>G4FH#EK0W(U)J(U2C*,$4(6P"&4`6]>(0[T&?X#`8#`K%'N,>
M7(G=*WH>.TM$&JXESS)9*9,$Q;AYDLIFB90CF<N:6$U>9&6.7S%*L.+=G9$B
M3N+F$XS2DXWU!^)=N9O"SN$,!@,!@,!@,!@,!@=2PL++%V5JC<;:F]B8&)O2
MM3,S-24E"VM;:A)`G1H4*-.`LA,F3$%Z"``=:UK6L#ML!@,!@,#A.#:W.Z,Y
MO=4")S0*/3]="X)2%J,_TC0'E>LF4@,),],XL(P^8._`0=;U^NM8'0I()!T"
MDA:AAL41+$IH#TRM)'6A.I3G%[\Q9Q!Y*,!I)H!:\="#O6];_P!F#65X#`8#
M`8#`8#`8#`8&#12M('!GR?22(QAL87VTI,GF5A.:`LP"F5RA)'V>*IGIU$,P
M83%I,>8$236PZ#KTDX->'CX[V&<X#`8#`8#`8$<3ZG:CM834.T:LKBR1L)IA
M[&*?0B,S$3,<=LO9QS4*0MCCMN--V4'S")\FQ>77C_LU@2"F3)T:<A(D()2I
M$I)29*E3%`(3IDY``E$$$$%!"62226'00A#K00AUK6M>&!]L!@,!@,!@,!@,
M!@,!@,!@,"L4ZXPY<LNV&R\9U2T0D=HM:V+.0)0M+<0?4G2#*`*H0[25D2KT
M\=ESM##RPB:53JD6*&WRZTF&7K7AA=O3651[FND8F&??;D#2-!]I7`TWU83@
MD=I$%XEEJL,HCTQ99*[O0G<;L<G:WR*H-D-FC@M):0CV84ND8S"!C:__T??Q
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_2]_&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&!_]/W\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8'_U/?Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_5]_&`P&`P(LG=
MWU'6$HK>%6#848B,LMZ2&1&M6![<BTCC+Y"4TN;R8@:B!>.]A`C:3`;.,V6G
M]V:F2^?W*Q(2<,8'6W6_/5L*YXDAMD-9FJY2-;Q(5D@2ND/;5$3>VM`[,\_C
MCC+$3*CE-<.B=Q+TFD#>-0TJ=[T(H\99A(S"Y8^LFZTYUAU=US;$BM%F05[;
M490S:OI(6A?EY$@A*Z/(99N:^R;6E8YM4-;(TZ)ESD[+2$S>U)CRQK3B-##X
MC*R)1T/2Z6UFNDCY^TZLQY`1].CH"',X@]:KC[A+D3&.0DH#(PFE+A$FI2[)
MF@U:!S4M1`UA1`TP=FX,N:D]*_(5CX\1XDAY`O8T3.O6J%4<D*%C/(?!.840
M&>3K6M/&I"M(VTF^\3(%:E0W:&3M4`G2E/LTCN<!@8RJF470S%AKY6](B)I)
MXS+)DP1T8AZ<'6+P5TA;)+WI*#0-EB1,#K8K&0?O8M;T-R)\-;UO>]!DV!AM
M<V#$+9KV"6I7SO\`7X%9D-B]@PA^]@YM7UN(3-D0R.-._P!+>T3:\MOU)F<B
M3O;JTZ=43Y_(:6`>A!T&98&"V!9U?U4SHW^Q9<R1!I<7Z/1=M5O*L*?ZE(I6
M^MT:CK*W)]:&J7N+L^.Z9.442`8O,;K>]:#K8M!@SYTM1D;M-#2SY8K0WV0O
M4,:`MB-3.PDB1WE`=#BL==Y*2W&15BE4L+%H;2TK5R=R<P"T)*0:'>M[+E='
M)NN>=(=)4\1DEFMS8_*'MT81IQLTG4(D"ME="&!T7/3RC8U#*P1M%)5'TD;P
MN4)VGZP4<@TIVL(.(+&5*K)9M?R2=3.LX_+F1YGE=L\2?9S&6U8%8XQ5LG2R
M7((D:]:)T,A$H>E,$==%IQ#]P$"38Q@"`PH1A$91WK#GN63&'P&/V6V+Y7/6
MEM>8DW?2Y$E(=T[U&5TU8T0'=:S)F5(_OL);3WM`UJ%!3FM92MKR"#$G^-A<
MKOZLZ(I>ZW*0M-73]IE[A&"4*UR)1$.:4*AF=%3BA:I.P*'-`A32R&NRUH5D
MI'IJ&M:51R8T!2@8BQ:T,L2>P/R&2-H79N(>4R4:UU0:*?XY(8HY:/9G5:S*
MQB990UL[P!$<K0&#2*=D:3KT@BU289R8XDX9'<X&,QZ91>6*I4BCCTB=U<(D
MQL-EA"00Q#8I00S,L@.95VA`!H"TMED2%1O0?-KTU(/U\?'6@[ER<$;0W+W5
MP.]N@;$2IP7'^F:;Z"-$0-2I.](@!AQGIDEB%Y0!$+?AX:UO?Z8'30N81RPX
M=$Y_#W'ZQ$IS&6&819V]HN;_`*I'),UI7ID<?8.B5$YHO>MBTHWT5!))Y?F\
MI@`#UL.@R;`Z9:_(6]W9&0\AY,6R#ZE[`Y%')"YM"?Z4E`K5?6Y`W-:MAC/J
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M'9$@:I`P.99)VM'HER5,L2FZ$4<468$0-!V>`P.F1/R%P=WMD((>2UL?^F^_
M.6QR0MC0H^JI1JTOT20.+6D89-Z10-Z4_35*OV1O@6H](S>@;#N<!@8S]Y1?
M[Q_'WUI%]Z?;/WE]N^8?U#[7^J?1/K7D\GI^R^K?X'CYO'S_`/AX?K@9-@,#
M&2IE%SYBOKXIZ1&31LC+3,G".A$/Z@EB[ZZ/3(T/1H/)Z>D2]UCJX@O>A;WL
M:8?CK6O#>PY$JD[!"8Q(YG*G-.RQ>(L+Q)Y(\J]&;2M+`P-ZAU>'-3HDLT[:
M=`W)##1^0(A>4&_#6]_I@<>&2YFGT2CDVCNGG3#*V9O?V;[BC$FA;YMM=$Q:
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M\8#`8#`PN6P*)2\UM='R(Q&1R"-%.!D1<I0PH7@3`N7^S-.-0'J"3%:`I8H;
M$VU/MQEC-`2'6]_IK`UK<5\^6O$9M<D;L2KEL%YU<6*(,2:DK*EK%=T833EC
M@=1-^CZ7E#LHD<M54HVIF!8A3)7Y26$LE&UD)6QJ&@5$"C5O[RZ6-<Y=%U70
MO%Y,?K-CL6Q*N^.UQXVL.N72=1UF:XK.)=".>B]RD#^LVJ9G.%-,FIM2@D86
M\2M<N2&HE"$A3[79)PV;?Y<V"<BW17;W&:8(0@E-9D=`\Y]!N/0RZ6MA4A3(
MJ%H.FZV6PEQBQWFD[I+Y;+:03)2U!0?IA<1>C"35.E*+1"L;&2WMR)+KCZ=-
MDTC@[#,*0?I]RTXS!G?G-G4,\DBE6UYV"US!KD465J];?V0N26G&RSFU20<F
M<R5!@1E'$%GAT-X136O#MR1A_J2,*FEN;J?D\M+5=`LVI*V'Z8HIRST/;%P\
MC,T=;RC%OUQ#,V:5QM@=TH1!*11>,IV\X.P!`2$;.?*$F_X^NCA?DD,IC2E[
M=W*.21GLB6,4VI*,N/4JIXZ"JVRD#HX'N-7RM58(TD1ACEKZ7:0!,Z4M<;%`
M@4L#JN7)F+]1DZCA7HE9%ZZ%':XK>MIDU<W=Y4I''R++HQ$'JIRKLL2CYW3:
M18HCBI^;(2<X1R%3!A4B@&CFB*G2D1C4A)2&J"P$V/E"^%;48%J:0R?FZ-V'
M3Y\DG1R3CUZEE*02,QN>2>,T^S1;HI$P5K%V^H8D]P]P@#T#>VI2Y/1()`.0
M)0;?/.DT79YY6K+YBLMLX8X<I&1P2.6JJY[@U!,O0%!+'YG!%KM::]Y^=:U?
MJ^VXOY8(>_M[+9:]KDJ9*[B(:'8<>+(4#`6=XZ)O-JL\]^/NVYK7%IIWBOXP
M[2Q!R;U.U\O,1\P;W9+0]WSZX+'L+G:/0=Y=ST!4=DE11I[9FQMD2<M.G80I
MS$;<I*;PA"(;_P"VRSL&FUUUU$EC\>B['(YBRVC1DPCISN6T%J65-#KQK>72
MUR:'1VT'36M+A[`MWOT3`&J`A]$/FV/0=U)<JL%KQ"^Y%T7)0*N7Y)(Z`:;3
MJBU(ZGJZ7<\P5NNJTX`Q5LYQZX>A'N33ANM!\5U?+H.THV1I1H4^@I(BW'JC
M7,GVK<AB\9UY<&YN=^A7*EFRFH3%&E9*IC7L?,D]X1":,\--)OA4]V/-+%57
MO%7M,,ZSN:)/.)V:Y'1AM$N4KQ.#FE,((+4%K"Q+.J6IA0]C-MU]<3FJ(VR1
M<J_N<^6*I9)<RJ&!E<$U@-%M=:EVS8S@C*&F5K7NO8+=3,]E'J`[-=S4NDI(
MS32Q`#4WB(V<>8K8;+.>Z^A,19&>GI%U13_4#1;A4A:M#@#%4-,55!D-4[@W
MJI)*\/"F2TTA;4HD^R6L$+=!IQJBU"/1*J+L=1P'RI<-#3,EWGK6^,+<P\\0
MJEWPB36@UVDT22;160J'D#[0;:A0HM4C1R(A>O*3QDE,RIAEJ$!0&A$!J+&>
M+94`.GQ]VP_QBUUS[74>=+!::<L$GG=V6R5@/60>Z7GL;IJY8_+(DM$Y[)AL
MM*A,ZCIQ3X7M.J3`4'H]'@UM62(:LU\AO--FWNZUN]UU7;78KM$(C933&4\H
M?(-N$16?2@^(*(W*Y;')>VHY:S)$.X^,)<OKR0L5@1X`C@-_N`K![3B7.Z(G
M/C6<-MT6W,7[F"M[JJR5WI9-DKJMV]U^R,%B2BT:RYS1Q&Z%#?(B@H5<BIF8
MU[-$IH'HLI>2.8'NS7[I6`.S!O3E]*IX[N^&OC&1;E8Q6\[0;F&(A8>N5EKN
M*"2UY&FCEF)5)*:F;/=@36._I'NS8^XK1MI_A&)&0\B>GDS3R6,D8V)<X'YF
MO7GFHI?5MEN1KA-7RLJI,CU\*%T>>9$S.A%/LD)6U$XM");[0#50DMCZ@4>V
MW)2&1:R."?8Q'NOU1:M%LJO*+ARW'*$ML2(I:)U:S['Q/&;OCK%8K<\I^E)!
M5?7M'V7=EX2%S3?3%CR>74</D907=^&7,Y6%Z.3+TX1)D@3AL6.[TY;L&W(5
M`X?1$4:4+5#ZAZ`K]M9V1V9X(@CA<RJ]MAL$98\62K9RF=O*-1Z3$^S](M`4
M6'PV6'0=Z$N=4.RCAU[BMDS`<8YR@EG<N)+D4RZ,<K`?(9%X"Z*91SQ5</%:
M3?%7W7V6F>89:<5>%!R5:6F/,4/*E]3:/="$WKC?WE!,>^/?IYF3<VM3RS-S
MJNKJI>7HK&9,SS"O'$SG*4T])W!\LHZ.RV?Q!XL!O%*4YY8@NT4)VOEP=Z:G
MP*1`02HT79RM+RM2EL<PS&VK)FU-`7L-A`8$]-Q*$R-L?GCG""2R]Y%Z_-2)
MN4OI[5I@:=3=--EKDR"$V^X,7M`=Z;F&.Z-);+C.>V.9;-O6?M*^),1+K%CZ
M@;H!(1;DJ2/J#?<=<\LV9(&P`]N+>Y`)4UG6S^8(TD0?,(K1`1>J<6$5257^
M1\031AD$S9DG--=W'S<1.KY(J7F@V9QZO8+`CK+BO-JZO[8C#66';%"D,.FL
M&F9836LDB318Y[,<&%,8<J/UN+O[RZ:9\D=1LJB_G")5DSS=7=M<=MTRVI3;
M4:6X$;%?VJ>6P*?2%_E1RUY=HKL<%<2%^P@62$!XDXQHS0G'&D#9PY*_B"W#
M;6A+RII.'/\`+XS><HLYUZE4SUB(E#K4[Y0EAP&*4D4TB3:EIR2`2&5(V\AI
M.V7'"DC>!W(.$XJE)0"[/+^4AP-:D*!!YV\0AC8[OBEY<HB:;'2OD<<Y5%*)
M@?!'.%'6XP,;K[Y2!/'%5L0Z1`7,A>]$ONTQ"HXE04%(8$F_\=7\8B9C,O98
M7"X+%&A'"N0:ZB%P6+!90AD+;;-['3IP`_V%.T29.CD<>M28DQM0L<DLQ3H9
MZ#>ME/",CT4PST+T=I8'!UFK(B@=B*PC,T<'KJWM.R[EKTXJHI(XVI$[+Z`N
MB2<QREZ+MY([UM+TU7US,"?9,;N<1MB^N*%2,('-)L@X2Q]H+\?-D+[%IIKO
MR(L%LU7&RZ;3681,Y4T6`SRW5?\`'EC58?\`<R!V;8^=8J5LLYY;0%FN#*2)
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M98E-@6#9%N09,N4.9KB]R5.UE*'A`E"D,T:+?^K+\:\LV%2EP1J9SBNV-.;K
MD)CI=3/"':,O$A8W*!7K8+XS0=>O"J/DK@TN];2=@]F:0-2C**CFDZD1(R$0
M#!;J$9AQ!;\H8;?C@JFA)<R?ZZ[*9Y]=A\JCSDY=;'7&@F0J+BDG;5:8IU`3
M"WAV:'#6Y%LE%"U3(2WL`SFXTPXL:M!>W-:]XB/+[.WT3#;KK&G&5V8I9S*L
M<8A%H<L='.%-+)"YLWMS^G!!'(ZJW=N4A3)3_3TD*=C7%#HQ>A2%&#>O*G5:
M<1=05#7T2ED7B$4/O>B:IXR(JAM.GB):P/LRK1BZ"K.\8<OE+D$EQ-9#JRNU
M4%.K7$D`<%VDYN_`96Q%EME_AVN_C^G%?3ILV?43'TY2438JRCSA5TQE,0;0
MVQ+VBG/M95>+^AE'FCCC+(K805R\TMS"09HZ0J75!HU>B2E#)OZCF.?'MT\T
M$<V-+VT-CDMKNI^7(G&I2U3"OG(7-\HI^4.#W9:B/RR>0][L-O\`N=,>6+3M
M$R!.$N#OZ4]@2H""%&%V<I#7?'Y;B-A3.4%B3!%;'FC-V<EO*0IID0Q.MLM$
MVZ>A=H4U7<YF3,>X2!<QR>KV-R8DBH(5>XBD=3P$`3[&(L9-1M+?C^LI[)LI
MTC')<3KV%RVWC)E7=!LDLHB0Q2$G#HZHJY:9'*ZPE+"IJ5&V()3#79P$*'O3
M3)XZ<<2J9%IAJQP*V79Y;S*Q,FI,8:F.>1Y*T2".1^(-;DZM+R:\QF2O6HDS
M'R5=%CW=V=9EIC;I$:J1$C?=@<E&D_K#V;H>C1UA(N`P&`P&`P&`P&`P&`P/
M_]?W\8#`8#`UX=J="V945E\^0.!RIPAC79K'=3S)'R/\IW+U[)]'UWJKPL2%
MOK6CSONQN;%7WHK$K=#23$9`BR2QB`(T'F+)U8(Z_(&@I0E<V6EJ4V6\%?A]
M"A<=5_$N6V[:RQ*W<[)$9(]=&V[$$4`D"YI0^W3QJ0*VQ_T\>#>!,:,*HQ+%
MS5B$78;.]21Q;XQ2]VRN&QHU.T3JRX^S0I?'(/,E]3L=RH8>\L89UJ?*E9<5
MD:%*N<$30I:&]Y7IT1JKS:6#15,_4&LWR&,-J+(DTU8WMZ!\3]`T)75@H%TH
MK>RD*:%W4CFBQ`8W2>H+!FD522P@4-5)U:,Q:,]N4$;\Q9I!R<\V+BQLVZOA
MT#G\DK-[CLBU+6:7T1'6=`6)K+#*6*]E;\F1S]L.5+DX"(A`TL"ERU^--\IR
M9!$W`THLX6BBS*F*VP7Y5^>['9Y>\15J>UA3%"XG9,>`.>T!LN35Y+9='80"
M6/JY'<BUNIM/''B4(E+LBG)L<=$C8I+&%,:L"H0)YJ_-2E67>,"N%XI>.UQ7
MT]E[Q<0KW-&KCSM53K$(&T\UV;6U56Q))%,DUD;:I#'B9!:3::S'QK3X8[I=
M[%HL@?\`!E3'RMGY":)IZ]$=#20U4ID)4@JJ+2AU2RRJ&\N*/]TO3>Q0%O'"
MY'8K':TN]8]Z0*7(Z/Q]V3M3>N*4J#`E@4>B,M82@^2ZO%86@Q92%]LVK`;'
MI=19#BBJ<Q?>JV.W=6?/+PR0Y&V6RX[C3@19]PQTD!LH&PHC&Q<)PV>%(F4F
M%35^?U&C5\C#Y&72W7NYJ]FT/9*PD'3)BBLFV+PYZL`$8H:MN890<B5/C?:*
MF*K9&H>+B7#;QHCST+LB.($(Y&(G_'&>$]HN[$;@_*JY3<ZWH.]&V;.D8=J-
M]Y2'W>WL#)`X)9SI/_N3\Q_C%='"(A9+*6%.G?3703PN`C$E``)BD%3/WA\[
M+Z4ET[YUY2M[G9T10/?6$LY\^V76SH25+EL5A%WQD4O3C>X>QS9H0'R9"U'D
ME&E$/1B8I1Y]`..!H(A#.;J-7;N5WYGD5IU=U0\PB;S*'.-(%UQ+:^31FEF>
MR4]]--T.,>CT@3W!;AD&@DJB9?/<H6.9ZN3DI%#04E/3DZ4'EI#8N;S$DU5\
M@4"O3[;5TU55NV8P'KF-JLN30X-8OS-33L^6-+ZJVW2D;99:M5,]L4M@[@<Y
M*H:5)6Y*QEA==*3$1R<PZIB,DORT\U.!LXVTM<ODB6+Q.736.?9S_2TP>[$8
MH//HE7+X8S1*/VVNE,-6JWF;MREL3RY)'3G1N,,.(#L1!Q0)J_-8S>7R8.<&
MIZ^'=OH2TJUL6`Q#I6+QITLC\4R.#M?1]+\OV'U.R5U(BJ\MF1/#NB=*I@PG
ML;@A`)FV$>F[:\#AZI)+2>O,Y3%,_D4KBL6]_26U6UA5+8S8^5TT,M86-)*.
MC+I*4EO(;3=JXD**<J[?W4K(S.K524M&MTZOZ%6@41U:1Z!QGL_>5,9?1G<T
M`Z,ED(B]5P.PGQ')H&[S^2S3WE8'0FND#'8=KU"X,KV\M-D.I\J?-6E3[HTD
MF1@A]:51>RUI*XQ%O9VAF.!,[XNN`=/5W7LH+J]OK&W)N]0>NHZ*(V3]WNR%
MDJ1]G!DW<[V&[@J!G?G&:L!K.D@8F<;TH;]A<BEYNO53$C.$E\M7)8=S1ZU%
M]FP^,P61P*]+%JTJ.Q9\6R9$F:(<-I`VJ%LA6I&S3P[+2UPC3S24:,@&Q:+`
M7OR;-,%F+.X0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!_]#W\8#`8#`@&9_C#]QE$_<'UG\L?8%\?C7VOK?0_MCW50_D
MOZQY?\'WOK?0O9^?]?#UO+_XX7M5/+\_;%^5[6^I?N7_`"]]3K_[X_`?Y`^J
M_1/QRL\WN_M3_0OL#[#\WUKZM_E_<^W]M_J/M<B\\($=O^V']G/_`--_-'[9
M?P6@^^/L?]PW[8_MO]GK=]M?>OTO_+_D_P#9_P#2O:^Z_P`SZ?TGW'^O?3<<
M'^O[2+!_VH?E-N^N?NA_*WW?R-]4_,/USWOW?[JZ/V]>\]S_`*#[;Z;]=]Y]
M#_TKTO3]?_/^ZP<I7M/\9B^2GF_=C;9R9"30=UAJ,M&%P5?4)6>%`)U.L<U2
M)(R,ZYKK(B9`AA0`+C%Z!5+AF&)`I0@5WNG_`,U7!'^QW['9_H_[P/IWW'2?
M[7??_FCU?I7WJR?AG]JGW_\`[E_8?UWVWA[_`/C^D>V]]_IGTO(O*P/+_P"U
M/\PQ/\6?F7\@_3.Z?H'Y0^[/7\GYGY3_`'8?5?O/_>7ZG^:OMCVWU#_$]S]5
M]M_E/2P7<9%9_P"VK]S8/J_Y[^[_`*Y3OY5_&GY<_!7W?]51_@O\[_9W^Z?U
MWWOL?'U?\+Z3[#[B_P!']GE2;B$7_P#83]D4-]7_`"E]+_#5_?@_Z1]W_>/L
M_P!V?)/UG[:^U/\`>;\O_N=_'/V=[7_->Z\WD_P_4R+SRC=3_P!O7[+L#[E_
M<=[OZ3UK^6?R-^2?R7]9^S>9OW"?<GWS_J7UWZ!]F?3/8_Z/Z?J_3?\`*^3!
MRR;K\5;E6/-5-2%2E?T$7=:`F<,\</O-HL!6N5\M1(E6XUU):/3O;XWP9AJW
M;&IDR):TJ6]V/"2F3JFU[$U*PB?^&4HBZ')^-+@,EU6=".,)*KKC@NC7"KFU
M&RWPNDP*H8PUFL.9V)V?FEI?U33H0W%,G7+4A!PA@`><`(3!#O7P;?V<_C65
M>Y_=)^:/SE%OJ7U[\I?OA_/'XP??L+[<_P#WWV?X2^M>Q]A_N7]K_6?7_P`K
M]6P<NPCO[+/R#`/M;]T'UOW5;_D?VG[BOHOW-^8YE^./W;_4?\;[I_-7UOW'
MUK]?)YOJW^A^VP<\L?#^QO[:LKUOW*?BSZ&\_9WUO\P_AS[0_,D&^\/VY?<'
M^YGT+\E?1?0\O^+]&_\`D'^A>O@YX=[TC^PK[1N+\X??_P!G_N*Z._)_L/N'
MT_R3_P!LNW?S+[?Z#_K'VS^S7[@]K[/_`!?KGI>A_F/)@FO@;^SK[8E/O/W8
M?EW\C5U]L?7OSG^[W[B^TK3_``O^)/N3_?/[,_'7WU[7Q_T?Z9]S?7/\7ZY@
MY61YM_;I^2E'XK_)?W]^!XU]>_)/WS]>^U/SA>GN_NW\B?[U_D7\Q_=OUCWO
M^-ZGE\O^#Z65+K##?VL?NC3>Z_-?W!^9=^S]Y^6?VO\`[FOQX?X>U]S_`/QO
M^1?LKU/)Y/\`0_KWCY?]Y<B\XF:NOQA[&S?QC^3/_P#6#K^0OH7J^^_)_P!P
MQ?[L]?U?_P"L_P#]/]1\O\'T[U_#*GA;#"&`P&`P&`P&`P&`P&`P&`P&`P&`
<P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g657040g97x50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657040g97x50.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0[B4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!70```F`````&`&<`.0`W
M`'@`-0`P`````0`````````````````````````!``````````````)@```!
M70`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#$8````!````<````$``
M``%0``!4````#"H`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!``'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T;J=KVD"NPUO96^P'=M:'`L:Q]_\`P.KMV_V*S=F8U+Q6]\VD;A4T
M%[RW]_TJP^S9_*VJCCO8]]HKB180]P[EWZ0._P`UZ+TDL-5AK9Z37.W"OPGV
M[O\`KNWU?[:2F+^O]*J<!D6NQ`XPU^579CL)YVMMRZZ:G._MJY9E8U1(LL:T
MM`+@3P#]$N_=W*KUC8_%.,^IE[+]+&6P6^F"WU';7ML:[ENS<S^<659C`9.#
MT^G`K-==;S6^XN=746AK/:W_``]M?Z+Z?Z3_`$5O\XDIWV9-#W^FUXWD2&'0
MD#DAKD5<_G?M'$->ZEO4/M%C6O?7NK<Q@U.RK?9Z>UN^RN^NWZ:NU=/Z=D-M
MQLG&IN+==[V-<Y['3MM>YPW^KN:]CW_OU^JDITU"VVNFLV6&&M^9UT:UK1[G
M.<[Z#&KG[,H?5Z^W%IMMS/6:Q^+AY%H&PGU*J\;$O>++[?6MKK;Z#_4]+]+=
MZEG\TJF1]8>K4Y%IM;2YS!6:L1U;FO#K6-HJOK]2ZF^VBS/=;CL99A5O_5[_
M`--3ZF.DIWS=U>]N['HJQFF"TY+BY\1^?11[&?\`L2LKJ_UGJZ%0YOUDLJJ&
M02W$^QFQUKP`/5<:GL_0^FYWT_6V?F?\9J=&ZD[J.*;'AHL80UQKW%C@6ML9
M;7ZK*W;+&/\`^$V?0]6U5/K7TSJ?4<.IO3<IF);59N<]]`O)!&R*]S+74>X[
M_4KK24X.)]?OJUE.+:CU-M+1^DOVO=54W_27/J?;Z=;?WWHEOUNR6SF='Z3F
M]2PJB\#-NR&T8]@!VNLJ=>7^K5_H[-B;!^HW4<L$];^L.9G8YEMN'18^FIT&
M'TW_`*1^ZO;[7UUUXZ-G_4__`!>OS`^_#:V^ZPM%=#KFM=8&E[JZZ<9[:FV-
M96]WITL24]'T;J)ZGTRC.+&5.N:2^NNUE[6.!+'U_:*/T5FQS?S5=5+I&'TS
M!P*\;I=;:L.O<&,;/,GU-V_])OW_`$_45U)3_]#N<"UC:&/VN:ZRUM)W#:=X
M&SZ+OS&N;Z;%9Z.[]+E5>XBES6-<1`(AU@VN_/V>IL4>H$C+:T$!OJ8[]?WM
MUOM_ZYZ;&*_B,:S&J:SC:#\2?<2?ZR2FMU"MS[6`';NK<T.[@[JK-O\`::S_
M`*"JY[+7BG[,\U9)LVU6]FM(WW[Q^>WTZOH-]_J>G^9ZBU,BAM]>TG:X'<QX
M@EKA^<W=_F_U%3<+ZA^EK<3H":@7M)\F_P`ZW^U_VXDIK9F+F9EE%CK_`$FX
M[S:::`??IM:QUUGT.7,_FU<PO4?DNL<WTXK#7MD'4N>YGT?Y/N_ZXLFSI/6.
MH9ANNS+:<*NR:,6@.QQ`^C]KN=MRK-W^$KJ_1_Z.RI;]%(I86SN<XESWP`7.
M/?3_`#&_R$E/*_6EQQ^LUY+WN)IQWY=`+PSVX[;?M6/BM;O]>[(]:C'NKR,>
M_P#0YGJ8W\S92_.?@8K:,O';C69%N`QK/2M8`]]6.&,:ZIE;,?[1?U#IF1]B
MZKZ=WVKT/L./^S[O5H7<9F#B9M?IY-3;0)VEPDM)&W<QWTF?V5A6?5&UN*::
M<IE[R3L.95ZE3&@?H-F#0_%P'V8N0]UU%UV+;9L]+'_P-22D7U=J99UW)NNM
M&5E8U1J;E4LVLL8]_P!H-UMV.[[.^VSU68WV1_J^A9TZW)I]+[2NFOM;32^Y
MVHK:7$?`*MTSI.#TN@U8E<.L<7WW.ULML<7/LNR+?I6V/>][O_/?Z-6WL:]C
MF/$M<"'#Q!24U'!U'3KK'NBUS'66/'9Q'YO]3Z+%F_5N^G)]5EN'91DXSMI?
M;!:\`^R[%>W]&['=_@7U_P#5JY?TO+MJ^S_:_P!`(VAS)=I]$/+75^HBX_3*
M\+&=7BR;7D%]I@.=K^=L#?8QOT6,_P"K24M3%/5+J@#MO:+=&$#>/8=UFYWO
M>UO[C&?VT'HW7\?JF'3DEAQWWD[:7>XM!+_1]6Q@])EME=?OIW?H;_U7^>K1
MCDG$P[<K)+_1I;N:2"]T1]+;7[MONV_2?_I/567T?"RW=3LR/L_H]/LFZUEI
M#7NS):?M%>-0Y]5>[]+ZV]E'J/\`1O\`TMOJ7)*?_]'T+J-&2_)]2BISR*2W
M=+-N[W>F6M<]K_5J_P"HN6C6(K:(VP![3V\M%)))2E"VOU&%FYS)CW,,'0[D
M/,S,7!QWY678*J:_I//F=K6M:/<][G>UC&?35%F7UO.;NQ<9G3Z3]&S,E]I$
M?3^Q4.9Z?_7LMEW^EQZTE.C15Z-8KWNL@D[GG<X[B7\_VD19E?3>JG6_J]Q/
MA330P?\`@U.4[_IH@Z;E#CJ>5\8QS^7$24W+&>I6YFXMW"-S3!'P5;]G'_N7
MD3X[QS/]1!?T[JG^!ZM</^-JH>/_``.FA$JIZRP0_+HMCN<=S2?BYN3M_P#`
MTE-Y)4FOZPUT.JQK&^(L>P_YOHW?]6B^IF]Z6?*PG\M34E-A,1((F)[H3;,D
M\U!OQ?\`W-4OT[I!VL&D$$N/GV9M24TRWJ5FS&#&4U,;#[G0\/C:W:RO>US6
MN_X3^HK.%B,P\9E##NV-:"[B2T!GT1[6>UOT&HP$"/RITE/_TO2[NIX5&,_*
MNL+,>MGJ/L+7;0P#=O/M^CM6;_SV^JO_`)8U?]+_`,BKE_1:,C$LP[KKGX]M
M?HO9N`EA&S;O:QK_`*/\I8M_U"^J]#0XX^2^2!%=MKB)_.AKTE,[?K%]4,GJ
M6/F6]398['&W&H.[8VUYV&_9M]U[F.]&O_1_I/\`2+H?M5(<&DD$D-$M<!)T
M`G:N>J_Q?_5DBNYM-[3[;&[KK001#V[F.=^;^ZY;HP!ZC7ONM?M<'[26P2-1
M.UC4E,CGXH=L+CNDB-CN6G:[\U/3FXU\^DXF!N,M<W28GWM:D<+#))-%9)U)
M+&ZG[E%O3NGLR!E,Q:6Y(9Z0N%;0_83N-7J;=_I[OS$E+T=0P<EN['R*[FCD
MUN#O/\TGP1?5KW!FX;CV[K(O^IGU5OV[NEX]9;P:&"@_YV+Z+D"SZD?52NHO
M9@>D]GN;=0ZT7M=V?7=4_P"T;TE.Y=E8U#=]UK:V_O.(`0G=3Z<QGJ/R:FLF
M-Q>`)G;](E8F!]5_J]9>7Y.)D9]K6^U_5-][6MT;MJ;E[Z6\?FL]57F_5'ZK
M->7CI&'N/C161_FENU)3HG+Q_1%X>'5.B'-EP,B6_0W*#.HXCW;6N=,@:L>!
MKQJ6(>'T;I6#0[&Q,6JK'=8ZXU-:-@>[Z3V,/M9_817]/P'L<Q^-4YCP6N:6
M-(((AS7"/SDE-+KS^J5U47=.L8WT;"^^M\@65['C;Z_\W3L<[UOTG\YZ?I^K
M4JW[1MP[L-H?NKN>[&]$N#IN)W55!_\`.4N97ZSW^ST=E'Z+_!^I=S^DXMF`
M**&C&9C,/V=E3?8R![(QZOI;=OL;7[_]$L7&Z7DU9[+*WX]F17^BKRWML8\-
M<YK[]F/74RBK_B_7M^UO_P`-C[$E/__9.$))300A``````!5`````0$````/
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`
M(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`
M"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#
M`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`5T"8`,!$0`"$0$#$0'_W0`$
M`$S_Q`"\``$``@,!`0$!`0$`````````"`D&!PH%!`,""P$!`0$!`0$`````
M```````````!`@,$$```!@(!!`$"`P4""@4$"14!`@,$!08`!P@1$A,)%"$5
M(A8*,4$C%Q@REU%A)"765UB8V!I"4E56U_!Q,R:!4W,G=[<X>!F1H;%B<H*R
MTS2TU#6U9I:'QRA(B#D1`0$``@("`@$$`@("`@,````!$0(A,5$206%Q(C(#
M$X%"L5+PD:%BP='A_]H`#`,!``(1`Q$`/P#OXP&`P-=7W<&I=5IHK;/VCKK7
M"+DA56ZM]NU:IZ:Z9U?CE41/89..*J0R_P"`!*(@)_I^W`]FEWVB[(@TK/KN
MZ5.^UI=91LC8:78X>TP:SA$J9UD$I:#>/F"BR1%2"8H*"8H&`1#ZA@99@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,"$>ZMO;LF^1M*XK<?).@4>P.-3S&]MJ;7V339[8;&JT9"V-:-3JM2
MJ/"V^@HSERO%F*_.H[?2R3.(CHI4XMW:SA`A"S&,UH.Q\K]^Z%Y)Z[T_N.(F
M-[2,IQ7V;L69JO%?3CL?S-:ZKNB+B(>[LXJXVV4?T=BVU8H`/6#^TK,U)IS\
M1D=ZY68IJ1<9F8WD;V":2E+!HJM:\KVV]P2?(O4,=OC6_P#+'7[B:;&U4^E8
M*+7MMH7E)"#+4&40:PMU'99`$%"&$&Q"J/E$&JM3%Y?5KKGQIK95NUU!15=V
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M(N5US?;`WA7\6W5=RRK\%`:-G*:2BI1BOKV!SXTUKJV7F&E:[M65I&IK?7*!
MN7>%=IB,GIK4=SLS>`=M("Y6,\RUG%UHIK;8I27<1,9*,X,DBD,@LV[5_$,5
MB>P/95H?6EMVK7+'3]\+P6CMJTS3FV]EU_4TO8]=4FY;&B:&_H3=Q*0[MW-V
M`EHDMC1L6DC#Q\D_:R"Q/F-FS=RR<.ABLJ8\]M2JUN\2,S3-QU.\4395#U$^
MTM8Z,W2VW-7[:D/$V#6<)6X6*GI:O21;G"3!'23@\HBVCVZ#E22.R(U7,F,-
MYZ1WM5MZQ-M=0D+;Z=9->7)UK[8VO=A1#6#O%#MZ$%`VMO$SS&.DYN'7)+5"
MUQ<LR=L'SUD[82")TUA-WE(3INO`8#`8#`8#`8#`8#`8'__0[^,!@0<YU[DV
M'K^CZ]U5I*51@-Z\E]B-M2:^MBS!M,)ZTA6\!-W7:&W5H9X4S.4/0-=UE\>/
M17ZMUIYW')+`9)0Y1=\''-O2/NO.$?%O727RVNF:1<;H\`JUFVOL^`B=E;@O
M$L=N1!]/779=P92MKGI63,!E%>]P5N0RABHI))B"8=,3PQ=K?EJG?VEHWCG!
MW7F!Q3CHC3VX=1U27V#;JU4FY*UK+D12:+$R$Y8-:;AI4.#*NSSR6@&[I"$L
M!D"3,#(G061=`W*L@I-I,9^5UVO&MZ7,4^SQUVJ56N<0"P1-NKD)9XL')/$X
M".GXQK*L@72ZCXU@;.R]Q?W&ZAF&F1X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`U_2MI4/84E=86I6)G*3>NK0^
MIUVA>BK:6KLZR$#`B_CW2:+DK-^W,59HZ*4S9TD/<D<W:<"W%3.6P,BF!#G=
M?';94[O"B\EM`;+J>N]KUK7M@T_;XG8]&F-A:YV9K"<L$9;(^,F(JOW:A3\#
M9J3:&"KR(DV;XP`5^[;N$%DEP%,N>+*_;7?'O9L9O>H<A-K[2JUYNT9Q^NVF
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M(V'45=E^,W9H/7SUNFY1=S"YGAE%^X%;0M#+D+J"%WC567&CE=L`-@[GB;!K
M*0F=WMC3L)2*_M"ITF^QMZ@:,VA-CQ='*D5P_K+IS#?<W8I@Z`K8J(S.+CEM
M.2X;2#VN\I()._,BFY%<N=5<G6;D]>7Z55GKJ.XNLW-.<I%EQ&6<R:G'E<4W
MI3-R)A*)]41%`WDJ9Z8MR'X%);WG-EVAQ:*:>4G]I<?=P4B`O^NDMA:]1L6B
MZQ.U1>N;+J#F=B`NE0N\+9'K=9-NYCW#$RQ'"9U%$2D.)<)'<;-+*:4JMGBG
M=.XZTQ_9KD[LJL=QLTX;3=5.S&$@H6.&SLE+)8EKE<D$8@4U9H0CB*,0:M2L
MTP:^5<5(K"&`P&`P&`P&`P&`P&!__]'OXP&!4_SGG[4_YE>NZ@4NE_<)6*L&
M^=T62Y2-CB(>'C]55W7C73U^KK**?-AD;#8UYS>5=DT",EO*BG'#Y$3HJJ+M
MK/W0O[=DI\Z.34F_:=+[$T3NK7]>(FI/WK4NQZ=!IK*I()*2]GITS"1I%5EU
M$4$4SO7Q`,8YRD*'U$0#ZXO56<65M[@;M)CN?AOQPV-&P$W664SJJM1Z,18?
MMAI),:JW-457Q5H:0E8IY%S"T"9XP<(.%$W+%PBJ`AW]`Y.MXM2VPA@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?DNN@U06=.E
MDFS9LDHNX<+J$10001(*BJRRJ@E32223*)C&,(`4`ZC],"IKDE[I.$O'UR]K
M\-<7V];LS.=!6`T\DRG85BY+W%*65OKQXQIQ4BJD%-4K!U).T#AT.@&:FMJ9
M5+7'WX<J]I2B\'QVX_4^LE6$_P`=-RRM>W[D5$`4%-9$L26L1"2@D()S%/&N
M2AT$`$0`1'4TGS6;M?AK1SR3]Y6RUD5$H#E(R9O>\S(]:XWJ4V)*FAY5!*29
MCM:19#E`Y#%[EG1S'-T)U$>TN:QI])G9@LG<_<E"J.59P_/!DFBH'R'8UO;O
MVPBB_8)"IO6L2:,$ICJ`4H)G[0-^$.@ATRXT^C]7V\)I['O8AKJ1!I*;RV%&
M22?:J:.O-4K$FN)3)"D`J,+E4WI_$<AAZ?AZ=W0X?B`#`]=;\'M9\L1KG-SD
M'7^0[[E%%V=FPV?8#Q9;<5C%-X^KW*/CXR(BG,38JVR%!@YCYEM#)*.2I@D<
MCKJX0,BL5,Y->L]?7X8NUFV?EUD<+><NKN9%,^9`JI5C9D$S0/>-:2#Q)24B
MU!!)-69@E!\:D]4W#H_8F[(0IT3&*FX32.8@'X;:W6_3KKM-ORFWF6C`8#`8
M#`8#`8'@6:U5>EP[JPW&R0%3@&0%%Y.6:8CH&':`;J!1=2<HX:LD`,(?3O.'
M7`K?W7[C?7MHXZ[6;WQ$7*2;D.<\?K1FXN*1@)W!VIV%L+:GJ*&,40`H2/=^
MP1``$!S7K?GA,^%4VWOU27'6MKK-=0Z+N=Y(!1*E(W&U151$JH`/XOM5<C+X
MDX2ZA].K]$1`?KT_9C&L[V:FNU_U0[=?JO-E)2!CM.*5">Q0',)6RETLC)\*
M?U[2C(?%=H`?_P"V^)T_Q9FW7XRUZ7RGWQ-_4Z<3-SV&'I?(;7-MXPSLY*M(
MF/M;B<9;'U0@=X=-LW<V6UM(JK6&J(*O%0`ZJT,O'M$NJKEXDD4YRS,+I8Z5
M8Z1CY>/8RT2^9RD5*,VLC&2<<Z0>Q\C'O4".63YB];'5;.V;MLJ51)5,QB*$
M,!BB("`Y6'V8#`8#`8#`8#`8'__2[^,!@5:>TW2F]K5J^O<C>,6QZ]K3=O%*
MO[EO;-]9:HG<6=MU[(:Y=RUSUVSB%T';4LI<)JD0:*:ZJ1RMDR**I_QR(XS9
MS%F.KTW-0[6SOE'IEXCR@1A<ZI7;6Q*50BQ2L[%$,Y=L4JR8F35`$7A0`Q1$
M#?M#.KDB;S'C-P[6?Z2XJ:1VJ[T1:.1MFOC*Q;H851M=Y"BT+6VL[)=98D=6
MG3^(;O'=ILR$-%***/&9$V+IR4JH+'1`V=KB<-:29MLZ6M:JUS7=/:PUSJ6H
M(F;U36%%J6O:T@8J1#I0--@6%=B2*%1(FD"H,(Y/N[2@`FZ]`S#3/<!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"O[G-[(./O!*
MMH#?9%:X[5GFPJ4;2M1<-W%ULBJIC(LWDCU!=*JUI1V'8:0=$$5.ARM472Q!
M1RR9%.I^.'M7]L#@EDY'VX>&G%^7%%S#:D:-I9M+S$.*@*-5WVNR2,?.V)XJ
MF7J=S;'K`A%1*LR8`B<"!K.LZ[2S[X66\??2]P0T0U9.)+6BF[K4W\*CBR[I
M=IVMJNL4J9EDTJ0@WCJ"2/,X()B)KQKI<I![#KJ!U$9=K3"SZM5.K4N*0@J=
M6J_4X1J`%;0U:AHZ"BFY0#H!4(^+;-6B(``=.A2!F59!@,"-G*?1]NY#ZN?Z
MNK.QX763&PG.TM,W(:U8['EG4`LD9)W&5TDI98%C69!X0XE-(>)VX1(/5#PJ
M`"@76R7-B69F,JG(_P!#&NTO+]TY#W1YU\?@^WT:#C?'T[_+Y?D3DMYN_J7M
M[?'V]!Z]W4.G3^V^&/Z_MO/5?IOU%J*ZP&P:?OSD-7K96URO(N9J\Q0X1XD[
M``(L107-%F6SN)>HB=%RR7250=(*&25`Z9C%-+_);QB+-)+G-20WY[+N%'&0
M)"-V=OFMN++"B=H^K-6$]OLI9!L`%<,I%&N-U8B%DBF`?(D]69`0W4.A?H&9
M];><<-951;(_4[\+:Q\E&B:WVS>72'<5+[HM4JHP<'*!A_"ZC9BZ.TTC"```
MF;`;Z_4O^%B?.T:QM>M4([5^JWDQ.H%.XKP#8O7^&,W?IF<``ZB'XC-:]5>_
MJ'^`"Y,Z>:OIM]-)2?ZJ[DN8Y_LW'K12"?4?&$DSV`\,`?N`YVVQ8\##_C`H
M8SIXJ_U[>8\$GZJOE\!NJFA.-RA.O]DD'L]$W3_[LVV5P$?_`+W)G7Q3^N^6
M>5K]5]O!HLD:X<3]4V%N4>JZ-:NENIRRI>XHB5)S*)WHC<1)U#J*2G0>@]!_
M9DS/"_U_:XKB)^HKX%<E)*.J.Q9&?XM7I\FD1-+<*T0&MWK]0Z1!91FTHMT:
M)9D)Y!'SSK6"2,!1`HB82E&YC-UL7V(+H.D$7359)RV<I)KMW""A%D%T%B`H
MBLBLF)DU4E4S`8IBB(&`>H?3#+FB]N'O48\6K%/<?^-CN.D]HP9W<5=KR9JR
MEB5:?:N`0=UNMQ\@1S%KRL4JF=&1=NT5T6RW<@DD98ACIZQ),[$EVN)TXS=[
M<X>2_(F?>6#9NU+?87+MPY<%"4G)"3%J#DYC&19F?+*DCVY"F[2)-2((ID`"
MD(4H``9N]^.(Z3^/6=\U%)V^>OU!6?/'3Q4PB(J.EU5SB(_M_$J8PYG-O=='
MRY`P/=K%7LEVL<'3Z=`S%IM=GE6,%7*W7XYW+SD[-2;E-G'143%L$EWLA(/G
M2I4TD4B&.<Y@``$<#_5/];&H]J:'X(<7-1;L?KO=G4C5$'&6=!TN+ES7A75=
MR4/25U^]0BJM`@'K2#,*9CH]8_\`AF,GVB.W"\VU-_"&`P&`P&`P&`P/_]/O
MXP&!$3FCR)U]H/3=A;61-6UW[9L+8:'J#3,`BC+W[<EYFH=TQ85.J5D#&</V
MA3NBJRKY0@1\1'`HZ>*I($,;"QI?C9KV=U'QUT'JBT/D9.RZQTKJS7MBDFZA
MU4)"=I=&@JW+/D553J**HNW\:HH4QC&,8#`(B(YUG$CE;FVM0\CK2STENGB=
MRFL[94-6:CN.QJ/N6QH(NW0ZZU]NRBJ0#?94JW;$.1.H5:_UZ"+..S!TC(MT
ML\-T007$,[3C+6GS%ND=(Q\Q'L)>(?LI6*E6361C)..=(/H^1CWR!'+)^P>M
MCJMGC)XV5*HDJF8Q%"&`Q1$!`<PT^W`\2QV6N4Z#DK/;I^$JU:A6QGDQ8;'*
ML8.#B6A3%(9U)2TFNU8,6Q3G`!.JH0H"(!U^N!3]M;W<<;V%AE-=<3]?;CYV
M[7C^Y(U=XZTJ<FJ@T==W:C]UO_VIXDK%N1Z]C^&CYQK^$W4P=INED^UPCM,[
MA_4$<CQ56U9QVTMPOJ#TGEAY/8,[4K7?$"'.`"G*I6-S;3@JB00$`5IC`?H;
MZ&Z@4''DX:MF/5-[@MN`<^ZO9R9B1V<`?0U"O&X35I5)PLM\SK`0\3JV"6\*
M(E%(AF92CWF3`4R``FU-M9\)\?;6<W^G&W=9?,>R\Z4+,HLH5PI^8-?6V4\[
ME),4D55CO]E/#&433'L`X@8Q2_0/I],>_/1.&G);].CS!J`'D-:[]TO+O10*
MDX(M*;$HC]=$YSG7:MW#"K6!!<O>B@8"K+(D./41$HIE[[[RSI+,Y:;L.C?=
MQPR$\LTEN39ZU&"LX^;KG8\MN2D>$%SJJR$A4H>:M35DV!0ACG4DXI`2E,(F
MZ%./6STIRVOH7]0%RSU^Y;1>]*E2-Z0R*X)R#TT>CK._%!/HDJ5.3K#`U1`4
MA*)A(I`^0QP$!5*`_1Z2])G$7$K>ZGC+L7C=N*[:PM1J)O2IZVLDS5-7[68-
MXV3D+4C'JI0X0;A!XZKES11DSE6%JT>"^,V2,=5LF3KTQZW,GP>TQ5F?&??]
M-Y0:/U]N^CJ%+$W:$1=O8H7*;EW6;"V$6ECJTD<A4^K^`F45FYC=A2K%(54@
M>-0@C+,6QJ7+>^01=W?S0XS<>9="J[,VG%(;!>MB/(S4].C9_9>XI=NL"?QG
M$9J;7,5:=@N6;M19,B;G[<#43J%`5`Z]<+B_X1Y>\^-IV-(XZ>X"<G+.F=0Z
M+2?VW.:.X_U=4XE04;N73"V;/F=NLHXZ9E`4,-/.X24*4O@-W&%.XOA/T_.S
M&3[0]FTTX5FVK/@SKR/=`7XFMY./WQM>7AR'#O!22V_'V+4D;+NT@$"';H4U
MLEW@(E<F+TZWUOE/;7[?D2,]A$F5T\F^9.H(.0<H@9M%T#B$BSKD4NHL1<Z0
M_GG>E[L$NBW*=1`AQ>-3'3*D8Q`.53RO3[/>?]7\$=^R"H)"[@^1/&C<*O\`
M&,I7]I<<K;KH%Q$B8HD8W366Y)$(@A3H]!%>OR8]%3F^O:0@/6^3VGAD3/G#
MR1IY56VXO7]M*6<)=4T9[BWMW2^Z:J_.GW=ZXMMKV;C7?8TBJ29E"IC"..T1
M*F"ASC]9ZWPN=;_LW1I_G]Q9W)/HT-CL4NN-N&+T<Z/WA$2>F=Q-E@$.])M1
M=@-X20LB!`,4P.X89)@H0Q3)KG*(#D7'S\)F80P&`P&`P&`P&`P&`P&`P&`P
M&!5SS2YP;`JU\8<.^$]19;CYI72)%^^26$%M?<<*:\0(!=G[CE0(K'QBA"ND
ME(R+<B!G)E$CJD."[)I(U</FX8>KG7/'>S.M^;OLKWD[S"M+H)VV;RV"FI)$
M@9QP0@KM];PTDHZ3@$&`%*W0D#A]P%NF!$?AMC?#(M^/A%I^0,!@,!@,!@<A
M_P"H"]M>Q]-[.?\`";23V0K*L=3X29VQ962OQ7LRZND<26B*FB]1,5ZSA&5=
M7;N70('(=\H\!%0022,5:S::_'ZEFEV^>'&/9+=9+<^5D;%+O)-RJ<QQ\Z@^
M(G</]E)`O:DF4`^@=`S-VM[KM-9KQ(QS,J8#`8#`8%IG#SW&\YN%&OYW5&KM
MC,[!K62AY..@*EL2,&TM==R$BCX2V#7;\[II*5UZP'JHBR,LO#>814.R.H(F
MS4N.XSMK+^4$ZK4MP\H=OQ50H]<LFT=M[+G5&T+7H1NM)S4U)NA7>N.SR'$$
MFS9`BKARY74(BW034774*0IS@MNU62:S'PZ3N,?Z67?]T8P]BY3[LI^EF;]H
MD\=4*@,C;)OD:=4@&&,FY@Z\11HV10-]#F8.IMO_`-50W[,88N_B+3*E^EM]
M?T,DB:S;*Y07-X4R9G`+W?7D%%J]A^XR:3.'U8G(()+%_";J]4/T^I3%'&(G
MO6Y7WZ??U!T"+"4N^OYUG&-PZ+2]VY`WVOLC"`=1%=XWM5>9$'H'7\/9EQ])
M[[>4.KOQE_3!Z6>G+;&]0EW[%8Q1;PNV.6.QFYETC"4Q%#4BXS4(L!1*/4%3
MBG_A_=E]+X3WVORVSH;V>>@GB>Z62T-7Z_J9RXZHO+77M%6QQ/+(>,4%"N[,
MO&2UV=-A2Z@9,3G[@$?PB(XQ]PQM?BKJ>+'./BES7A9V=XQ[EKVT6]6-'DL\
M>S8V"NV.NC*@Y&-4F:K;X>OV1@V?F9+%174:@@J9$X$.82CTA99W$K\(8#`8
M#`8#`8#`_]3OGF)B*KT1*3\]),8:#@XY],3,Q*.D6,;%148V5>R,E(O7)TV[
M-BQ9H'5654,4B:91,80`!'`JT6YI<A>2R*Q^&.L*_2=02)0+!\LN1S:7+%VZ
M-5.9$]ETMQYA',/>+E#JME"N8R4L\G5(]X``HD@[;B45+):6S7OM]NF^,=7U
MC8Y7:-MLUIWAR#M#0[.W;]VHX:2MX>,%G!WBE7J#)FV9US5VNVSI01;5ZNM(
M^-3`"F4(LL`K&W)(Q=K?PDME9?,\9M)!HZ8/VK=\Q?-UV;UD\02<M'C1RD9%
MRU=-EBG1<-W")S$.0Y1*<HB`@(#@0Z@N/&WN.:[MSPCW)'ZTICEXM*.>,VWJ
MV_V9QV*^<.3.GH:]*QG(#8NC222SA<ZC>#DW-?364!0D-W`/7-U\.DW_`.T8
MI4_:AM39UMB>-5&T%2HKE-8)ZT5:$OMGVLD\X3S[FCL(]U;Y?7FWX^(C;OM>
MS08/#F<T>*@DIYB=LX3>.6R;=1T.,8[:Q.\\-RI^L.`W1-1UYY_[GOG,RU1[
MQ.4B->2:B^K>,-(?$`WA_)^B:7))M))RV25,W4?6*1FG+Y$A!6#N`>MR96/T
M>@4365<8T_6]+JE`J<:7MCZS2Z]$UB`9!V)IC\6(A6C)@@(II%`1*F`B!0Z_
MLR(R[`8#`8#`KVYN\'^(N_:/:+KN'3$U+6V+CCN4KOI"I2#O>CE8H%0:H1:-
M4BI&0NZZ8J=$FDHTD6:(&,<2)@!E"ZUMG$J62N%S;E'8:]V3;*Q$,-BQL%&R
MSI.OMML4TM!V"$/Y3E:#9JLG)2Z$;))]IDS^-P<B@D[^U,3"D3M(YK<O3C[!
MZSQ2N%VU5NZSF@-%7J/DK<WG'#64E$:7?J]$F7,X0C(=I(RCI&Z0D?\`!.@U
M;.'*\@@Q(D3\1^N=YF9:UO.%X4]M;EIS$_R>CEMW"/C6_*8I[7),H]/F'M:(
M62,DI]@@9)K*0'&>`?`<PIO'I)2X'2`ITV\,L)5"\YK;VW=I/NMKZ9X\Z:X_
M14C%ZFH<15UIUU]QM=B,9W-7>\3!C'.K.WV^3SF3N-XGEU%#&.\E7SMP83#^
M/I],W))TYVV]U6#O[V0[!4N8ZLU'7C:GE)&87KT"OL*HA8]_75VU,Z4<2E'T
M-*S]/A*#41:1CEPA9-A3,,P=,DU%V[1<B1S$-37S4&JU)R-\M#)OR=Y=R&\Y
MYK:W$E.Z@T_+<DN1<NM`IS!UDJFK`<29W5^DZ#8SQ"0MWBQ7$^V!<HB4G:4S
M8M7\1=#PXDM&Q2EJI&E-!\D-*1YV[:QR0;HUENVG5V2517!@5*`EMJ.'\?\`
M=2B][U&K11)55/JH8AP3$Q#-S\U.K(RQJVW&L42#=62W3+."AFAT$3NW9CF.
MX>/%B-F$9'-$"+/968E':A$&C)JFL[=N#E213.H8I1",DS8M6\@Y>%TYOSC>
M=Q!7>*M\]06NYJ[J^[URRGH[UE#6]C]JC[!<7=-N<$$LF=1G(MV3U$GE((D<
M(+(IN*LMG5?!7M=<ON,D0I!\5=N:\O\`J6$E7,C4N.O).O6Q^[K\`[,FY<Z^
MHG(VN6IQ::S7(YR*P0B<Y7+0$:BJFU\GQ4$REQ=?%;F\O<39XN<MZ+R6K;Y,
MS1+6NY:=/SE+VSH.RV.!D-@:WNE;7%*29.48USUGJQ*,S(R4+-MT2LY>'=MW
M28$\ADT\M8_]-A[NY(Z#XVUT+7OG;U`U1"*$5,R7N=DCHAY+F0,F59"`AU5A
MF;$\3%4O5!BW<+``]>WIA%;%@]R^O;*!TN*/$SFCR_!0`-'6W6FAK?7]7/$P
M,)#J+7&UQS2;9)`H)0!0T(9$>[^V`]H&N/-7#0]H]D7MLF"E<:Z]1EDK#1PA
MY6HWRZ2EI>`"Q$#MU'C&.B->+M%"AWBJW.!5""8""8!(83L3R5IRR>S;W4U!
M$SF=]8Z'QTT0<K+06L]T6M-%`15`RBQJK;IH$02!$QE.[H*9.AC="F*(W&OE
M&JHW]1ENVBSA8#>?"V-C9)`&Q)*-9W*VZXFVAN@$=N2PUPIUF<"`F$3I(*&3
M^@=AEOKWA9IF9REJP#1_OYX2[/791>PD=BZ(EW/:FJ[N5?)9*>1R?H":2-BI
M"\W)E1,<>T5WD6R1)^TYBEZF!Z7X)5R-#V+0-I5QG<-:W6J7^JR`=65BIT_%
MV2&<"``)TR2,0Z=M?,D(]#IB8#D-]#``ATS"O496BO24_.U5A,,'=CK#6%>V
M&&07*=_#M+&60/!.'Z`?B02E213D41'^V")^G[,#WL!@,!@,!@0^Y4;POM3_
M`"SHSCPRB;!RCW,A))4)":15>5/550C0(C:]];3*V*<[.B4GY":3-N8/+/SR
M[2-;%.*JQD2_\/;XI\3-><4J9)Q5><R-TV3>I,]KW5N^WE2>;*W/?7BCAS(V
MBWS`^5Q\5-V]7"-C"*"SBVZ@II`)SK*JD2FP&`P&`P&`P&!S->[WTDWGG#<V
M'*+C%*P9-WQ]3956]:UM,FA!Q>S(VOF.6LRM9L;HA8Z$N<>R<'9+IR2R,<]:
M)-NB[11N<7<LRWKMCB].2*_^IWV4ZU?#'V/A+R'D%P6.AY:%KR8VJP[TP`3"
M$KJ].X1@I"`_A4\WC,/T`1R8K?MKY9S0_2U[1]B@@:!X:[1C2.`(8IKVO4M8
M>,JA0,!ET]D66J+("4O]HIB@8!^G3K],8I[Z^5A.HOTO?/>[%*[VA=M%:58^
M4J:K&0M$S?+0!#)%4,LC'4R#=UI5,AC=@@:93.)BCT+V]#&83WGA:'J#]*GQ
MOK3-![R#Y/[8O[U)0%W#;6\'4-30`$Z%'X3A6RI;1E':13=0,LFNR.H7Z@5,
M<N(S?Y*L=UGZEO39Q_;,_+I_1UCDF'8#J<WGL!/8KB1<)"("K(P]\LKVH)G,
M/]I)O&MT!_\`:\N/IGWO_9,AIMGUVZ/BC_9[_P`/-91D<WZ%8UF=T]7#)H($
M`"-V41`+MW3@Y2)@!$4$3G'H`%*/T#+C:_#.8JIY_>Y+UBP.J[=64*3K_E_8
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M?/5G#U01'ZCW*#]<7?:_*S36?#3[I\]?*"J]=N7:@_M.Y746,/[_`.TH8P_M
MS.;>ZWB>'RY!T.?IEX78[WV/_>:BA)A2H32>QB;8>MTW`1):]*%BD*U'23@O
M:T!T]O2,<NV1.(J*`T5.0H@DH8FHQOT_T+\KD8#`8#`8#`8#`__5ZQO85)J[
M.G>/7"UNL8L)R'L]EO6\4DA$QWG'#0J4!8+G4W`)&*JBPVCL6S5.M/NXQ2N(
M21DDOQ=1#+)FR&<2WY;T111;HI-VZ2:"""9$4442%21112*!$TDDR`4B::9"
M@!2@```!T#.CD_7`8#`U_>=?LMB(HPMFD7RU(416)/4UF<[!E<`5_"$=:9!N
MJ60?U@4_HO%I&0;2!1,B]^2U.=L8O_+"-V\?Z9N;4+K5!TOR:G%EB);6%DJ2
M)(:8U%?:<=-]KF^T%2.%G]CFZ'--4'#,$!33%-,S<X&0543,LS,$MERD1PJW
M?8.0G&K7.Q+NS:1>S&P6?7>WXAD7Q-HK<6H[?/:MVFU;LS)(JQ[%:\U!\X:(
M'*!B,ED1`3E$IS<G6]\=)480P&`P&`P&!$KF'?\`C)KO7+!_R7I,)LV.L4T6
MJT'6*FMFVV[OLBZO6+U\TJ.N:$,9*/INR.V4>LL)DRI(-&Z)W#E=N@F=8C-G
M1C/X4>5+U+T7;2MFW)LB(EN,-ONTRWL.O=+Z/G6IX714$R/Y*W'V"=GDK0M:
MMF+MR).)UQ%.(V$;OP,E&($(G\E?KK=L<L;>N?TKHZS'RT378*+GIPUFFXV(
MCF$M8SL$(I2>D6C1)N[F5HUJHJU8K22Z9ECI)&\1#G$"`!0``,M8[]@-U6O7
MCJL:&N%7UY<[!*Q<5(7ZRLGLJO3:@[6.2SV"HPK9JX9S-Y9L?I%H/CMV/G-W
MK*@!`*8LQ\H$1GK-@;+;9>J[6D&4IQGKUA@;9!:^BY.8<WWD)LDD&12?W!RN
MV4Y396>Y6%*P2;Y-A%-7)8U)#M'M(F'@-5]O_:SJGTJG:]K\?4Z'5:[2ZO%)
M%1C:[58:.@(5BD4I2`5K&1;=JS1ZE('42D`1Z?7KD1D^$::W]L5_JO5TS<(M
M6(9OPF:366LU8TG"]8JRE[O-<HWYTM2+1RQ<JU>EEL0RLB0B[<QVC10H*I=?
M(6B%<K\!K:(('\M<.2^^VSYU+UIJQO*48G#O2M&T"?\`+<3#:^BJGK[6R,JM
M.'D)UXA%NA+&Q+-PM)A)=%<\W/A4N-5Z>DH*QO-J;)D8^P;7F(A2"*:'(HE5
MZ/6W+AD\<U>K%60:NY$7CJ-;*OY)RDB+I9`A&;6,CTVT:WO7")`X$!^47$66
MY,OAEH)Q0M#7VG2<)8M9\A8*DQ=JY!Q5SIS]"4JLG'6KR0HTVGM9)F*+V.2=
MR3B=B'2C<ZD6)E$SRS+>NWJ]'@Q3M!Q^Y;OJ?>W'W5T)SBJT#`7LVU+);K-O
MZP[\UR_4>1R.TM:[/WS]XVU&HPE@8+L)ZO"Y.2`=?&[%5FCAHIF+Q<5ON9G2
MZ#(A@,#$KI0*)LB%6K>Q*54K[77'7Y$!=*W#VF%7ZAT'S1<XS?,5>H!_TDQP
M*9.4GH<XG;C:2,YH\'W'"_J@==`M>*YL.M))UV?1*2H\F_*K#)J]A2%-#/&*
M"`"906JYOPCN;V)ASM7?47/3U-;:9S#>7LNME9!V*%?V'1Y`\WJO9;5B)E@C
MWJ+MLI"3A4RB90\1.L2.T0Z*_'`@IJFWF;3#-S*F]P!]EU_L?L>#8N[)&*C(
MCE!#TW3UT90Q'<?58FQ0<)%06L[`RCG;QV9D)K.R,@L95<46J=@?*_0H``-M
M?TXGP2\NP_.+9@,!@,#Q[!,IUZ"EYU5A*RI(B.>2'VN"8GDYN3,U0.L2-AXY
M,Q3OY5^<H)-T0$OD6.4O4.O7`T]I74SFG.+=LF\BQEMU[9=,I+8,^WZN$8>'
MB1>A2=55=VL'G2H>M(V150:)E!)-])N9"6423=23D!+?_AOG"&`P&`P&`P&`
MP/G>/&D>T=/W[INQ8L6Z[QZ]>+I-FC-HV2,LY=.G*QB(MV[=$ACG.<P%(4!$
M1``P.:/G;^HQU+HR5F*)QL@(;9]B8+J,_P`^V)625JBBZ'5-P:#K$8>*E)EG
MWB()/7#]B@<2=R::Z1BG'6)K^ZDFVW[9PH,Y9^\CG;;K$Q+0]^6^EQ#F/^0H
MWIOY<K+`2N0!=F9@YK$2SDCD*T<]HG4>*G,8O41`P="MKK,>L:TUMS[*Y[%[
M(^=]K%0;!RSY"2A%!`10>[CV2Z:D$`Z?PFCFT*M40Z?N(0H9GWOTWZ:^$?;+
MOC<5Q7!S:=CVZP.2F.<CB9FW\HN0RG3O$BSY=PJ43]/K]?K^_'OMY7TU\,+6
MNEM7ZBK8YDPB/4?\O<%__!.7)[;>5]9X?"I89Y8!!6:E3@/4!`T@[$!`?H/4
M/+T'J`Y/:^:8GAY)SG4,)U#F4./U$QS"8P_^<QA$1R*ZQ_TZ/JNL]PV1!\^-
M]4]W$ZWH8'><=8&R1A$AV#>'#=1!+9Z<?*-3G6J-);+F5AWA"D^5."DY;+`$
M>8%=2.>^WQ%[7LL](W&GV`H2-^A0;:)Y(>!11OM>J0+)>*N3H5$#@CMBJMSQ
MGYM,9!(R*4FDY;2K;O*8RKE%(K4UQEF;6?AR,;A_3S>T'5\O+MZ]I:$W)6H]
MTZ396S6>Q*(LG*,TE1*U=I5>U6"LW1-5TCT.*(1Z@ICU*)AZ`(YQ6_?5"V9]
M8/L9@E5D7W!SE.L9NH=-0T/I#8-A1$R8B4PHN(""DT'"8B'X3IF,4P?4!$,8
MK7MKY>8Q]:_L.D3=C?@ORZ((CTZO>.NVHTG7_P!TD:FU3Z?7]O7IC%/:>4@-
M?>D/VF[**BM"<0+W"-E3=#K[!G:%K(S<@'[#*K,-@6RN2HE+^WM(W.<P?4I1
MQBI[Z^5HW&[]+-R6N+YA)<G=RT#3%<(\;J/Z[0DEMGWEZP+V*.FB3P5(&H0C
MMP7JD1S\F4(B;^(*"H!V&N&;_)XCKLX7<%../`C5X:NX]4T(=N_4;.[C=ILS
M.4V)L249_+^')W>SH,6"DJ>/!^N5FV3208,"+*%;((@HIW5BVWM,+"&`P&`P
M&`P&`P/_UNKK;_8U]DU#^6D)U)W@]L+[`L99+HU)5-]:X_-R2"":8KB+\URA
M!5.J<I`^,F"0&$5A+K7O_";?M_RD+FW,P&`P&`P-,^NOR(N^=4>B(?8X[GCL
M'\OE(8ID")S.C^/=GM((=@]A1/L2=FC+``%'Y)E.[J;N,;G>ZZ_&OX6/Y`P&
M`P&`P,.V%L"EZHHMNV9L:QQU1H=#KTK:K=9I90Z<="0$(S5?R4@Y%(BJZA4&
MR)A*FD0ZRI^A$R&.8I1"JK5B&PN3&YB<R-OP<U1JO"P%@IW$;2=@:H,YZBZX
MMRL4M:-P[*:=#KL=N;B:PC("11C=:O`)E9'$[MV^[-ZSYJ;7_6)FYIS,#\U5
M4D$E%UU$T444SJK+*G*FDDDF43J***'$"$3(0!$1$0``#J.!#B;Y^\5X76\O
MM4FQQG*HSN\IK:NGKU=L4G(;-O<3\<CBO:A9%C$AV@)G;HB`/H8SN,(KW>5R
MF4AS%JXO3?*&VZXSU"7=5Z86#4]5:TX]XLT=LF.2AK-2(A!B:1?M[;$QCR:3
M8RL:W((+MT%G)@.'843&Z!@^<*])3V7VB\K*DXO\2]J;9AAZD9["V/*QNBJ+
M))*F.5M-0"5C935QL$,<G:H'^;&:QPZE$J?T-E]:<3O9C[OEQST%!V>=X<:3
ML]=?MS(.JFRW=+-I5=BY1$'L<^D)N@.J^[*Y;"=N8!0\0F4`1`Z8&ZO6F=/-
M;$XW\TM4)VV)TU:^,UNXBWFY2IF\/&!3H!]JRV39&2K@&L;LG7+0*\M+`R:&
MZC(MV!>@$(10YS`0%EG9B?%6,H6RK.GT1&-;+7W,E8(ES/0,>A,QRSZ;@V9F
M9'DU$-$W)G$E$M3R+<%'*)3HIBNF!C!WEZY$!DN;JNJMM[/UOR$)7'=:%QLF
MTZ&V7J)!_98BY0E#2<RECT=8HAJ[EWS/D30XM$HKQZ)@)+)G`Z:+8_:DK5QF
M<)NZPV72MQZ^J6T-=3C:QTF[PS6=KTNV[BE<LW(&*=)P@H!5F<@Q<IG;NFZI
M2K-G*2B2A2G(8H1+,<-0\J..\7R"UI+,HHL=7=UU.+F9[C[MTB9F=HU#MA%B
M9>IVN"L3%(TU&QQ9UJU"6:H&\,I'%4:N$U4CB099F+K<7Z2>XD\IFG)*KV6-
MLM1D=5;XU)(Q-3WWIJ;7;.Y"B6V2BB2<?)0DHS779VK6]S9E4>5R<;F%"29$
M-U!-=%PBES;_`.$M<!@,!@4]<T?3QJKE?+R-ZB-M[8H6QG*CER@M9+3/[9HH
MKN/&=9$M;N<VM-P;90Z(%33C)5HR:D'H1J8A$TR[UWL^.&;KESI\A_4AS;XV
MK+SR%#4VM4XU87;>[:67?VA9D1NH99!V_K)&;&\0ZS9),JJJQ6"C-N;Z`Y-T
M[AZ3?6LW6QUQ>O[DH'*OBMK39\BN4]W:L#TG:#02E2<,=D5`J,;8Q=-"F.+$
M\V'AE4D##WIM9!(!^N<MIBUN7,3/S*F!#&']@O$>Q\L7'"2M[=B['R,8QLV^
MDZ=`QDW+QL2ZK;)S)3]>E+>QCEJFRM<-'LU5'<:=X#MJ*9DU2$6#QX7%QGX<
MBOM&NVY*G[4MXO.0/(_E+P)I=ACJPKQEVWK![LB_ZL>P=1K<)"HR!X6EVBGS
M<;%VPS([J3_+P2#J#GEETW#!WYC."9O;IK^V8F6RN#GZCVXZ+M4MICFW:2<J
M=70QW#.H\GM2UN4C+LY3;H`9C]XJEY@-6R5P@W0=J/RWL?$3C90ISKA(=Y3%
M92Z9Z7PZI]]_JTVLY0CDN2*.O99P<2$8;6I%WI#8I?,*)5%[.\@5Z4V(?\)_
MXDF4P$-U,`=#=MS&?3;PGM<N7.@*YQ[VAR9KVT]>['U9JRDV"Z35FU[<X6ZP
M2Z,)$*RJ,<A+TY6QI&>2PE320(D1=4YUB=B9^H`-3%SA4+ZXOU!_'7F99F6H
M]U0;+C)NN9D`8TYK-V9.8UGL%P[<*$C86`NKQC"FA;>L7L2)'2:*)'RYB$9N
M%UU2MB3+5TL=".5@P&`P&`P&!6'[FE]NM?6/RX<Z1^X_G5#7K!9^:)`II)/7
M2=OK9]NK-RF`0%-'599@SCI^,&H*B3\8%Q^.UF,S/3_+Y<N7<@Y4<NUUW;MP
M?N466.=994YOH'4QA,8P_N`/_8S/;OTV78VLB]IT/(/UFR'P'A8Y5)1R0[DB
MOQ#D`CENF<ZY')19B'9X@%,ABE,(%+]-7J98F,V1JTX%*80*<#@'T`X`8`-_
MA$H&`#=O7]G4`'I^X/V9AM_.![U9JMGNLXPK%-KD];;)*JBA%UZLP\A/3DDN
M!3'%%A$Q3=V_>*@0HCVIIF'H`C@Z[6Z<;?0O[*>1AFKX^DEM&55=RBBM9N03
MQ;6ZJ!%/&=58E(792&RG!$D#]P'"&!$X_A!3N`>EPS=Y'3UPE_38<2^/4C$7
MKD;.N^5NP8MVWD6,).PI:MIF+=("DLB1S0224P[NPMURF*<)E\M&.TQ`%(X,
MN(Q=[>G1JQ8,8MDSC(QFTCHV/:H,6$>Q;HM&3%DU2*@U:,VC<B:#9JV0(4B:
M9"E(0H````!E8?5@,!@,!@,!@,!@,!@,!@,!@,#_U^K;>_\`_P!*^/O_`,QK
ME5_\?G#W-:_N_P`&W[/\M:<I["\3W#P*H45+.(]]=>4\S*R3-!ZNR)+U/7?&
M?D#<)AHZ.U5(LX;I3+2+5\(E,BLH0I5/PCT'5[C&O6U^DU,K)@,#XY!!PZ8/
M6S1V>/=.&CE!L_32(LHR<+(G31=D14_AJG;*&`X%-^$PEZ#],"#WK(O;?8_`
M?BW9DK&XMKHFKHRM3=A>/74DZE+/2'C^EVIPO(/3J/7IQL<`Z`%E1\BI0`X@
M`FZ9->HUOQM4G?7N]!=AR^8&8)L7$+S:VXR="!>QP^&0INK;(S?O$Q33.51>
M+GFX)";N[VI4CE'L,4`Q>ZW\:_A83D#`8#`8#`I#YK0NP_8%:N0G%RJW.X:Q
MT)HB&2JENE*D_9UNQ[DY22E3KFS:77_S`[C)5U%ZMTO'3<'(OO`1%27GY!(G
M<*$88%[)DSZXXY:TX+->1`V:1)<%N5D=6"\?M?L=EFY8N(.772Y9?.D/SDOI
M`K-0SQWK"+B1$BZR:XQ#XPLQ;&,N5XH;6OMSE-_7C&&K&>O-;5;1%"K58XR[
MRIOM`IS^GQ[K>M=U%LYR&RMKM)N()<MH;/Y=1E>6U1L'0.QA2?/Y.$LUB4<H
M0;Q1BG$-7I&Z),XN?MJV7/,]5T.='%31[1.5U5JLI4N+4C;YFGU>W0+W8/(V
MR5=O(+V-/3\<E*!#:BK#R,*)HJZ;\L4.:#;JJJ(D;M3F%7JBY'*WK/E5+LC8
M5RU)NJ?A=C'HFL[LWT[1)6+9:OFG3B_\0M+S)SM(_B9QZI,C$M8N-Y([#2EH
M<CRS,Q<N(U*1=/S`FB#A<"_"Q/B#Q'N$^6L["W,60:NX:$>P6K=/A8IF=I^E
M*1.+_.D((%9)VL:VWFRN3_*L,T\!11V]$2I=B1"@.^-?RY[7/$Z7&U?3L8S0
M2*#-,.A2_P#0#_!_YLQ=B:LY5U?'&2[?BI_4/^H7_!D]E]6F-@:(A)N.>LGD
M6U>-7;==LY;.6R2[=PW73,DL@NBJ0Z:J*R9Q*8I@$IBB("`YJ;,W5S[\E>,,
MIQ3EH&\T^PVN`TY6;"$I!SL*J]D[MQ&LLH_24+L?6*AQ7>S&I74D8/S73EA5
M9/6:JJB)"+^-=K;,\QO7;/%[_P"6K]MK25UHDSMF!G8'3-KC][:LJO-V%J21
MIRH:WV^YGV#W47/G2_P9-FE"16P2&*FZ?,3`649R"I"@X,?Y1\M3O_'_`)$[
M?5CR"6A=];KXJV**7J"\K]YV.A2#QSB-@=>;SJLJA5N1^MJ8JJDE&NZW+3AF
MUJB&<;U:1T<^43'^+Y!$FTXE7U9&$+=[3KKC'O#77.&/KC^7U_5:/;-/\LDJ
MT4%I]MHV<DH2V5G;:D*(]UH:\?[?!N7;ENV*,DC7[!+JMRK"06ZF=I\NFE[U
M7!,GK.29M)&.=MG\>_;(/6#]DNDZ9O6;I(B[5VT=('40<MG*"A3IJ$,8AR&`
M0$0',*^G`8#`8$?^3G)[3'#[4$]O7?EG<5'6]=?0<9(RS."F[(]&1L4JVAHA
MFUAZ\PDI1TJY>NB@(E2$B9`,<XE*41PLEO$5V^QWE=:*QP!WIR,];^S=:2FT
M*:EJO:5VL%$C*'?;%'ZXLRT.\?V6QU27BIU%J^7H2H/A4FV!5T85HY5(!#(%
M$BWA9.<6*N/5Q[%=N<>/3]R0YJ;^=;IY7S\%ROM43`Q,O<7=CD&3.;J.HR)J
MRUKFTYV1HM()<)M\N\-XW+9LHN4S=F!W1S*R=-;27:2*RM__`*@?VC[4G(RM
MZJD]6Z36NT@2,JNOM(U>O;5V<JE)N1CXV&F)&P_S'<M+>X>G^-\5!I"R_P`@
M`$K)$#$$TS5]-5@7!W].1O6OS&LN2.Z.9=_T]LJ7/7=@W.@ZPA)1+8K63?2+
M.UR-:M&VG=Y2(><(]2(62'[1((F>^3\:H)@HI<)=^YAZ/,CV^7O5^[O9[I;?
MFN^.V]*5I&>U/'<:=%;OH$*ZB9%Y,3]>B;"^<,W+=23NZ05"=7F5BK&$Y>TB
MC=9!MW)'9)KQ,+%=ES7IMTWQDXUV+F!Q;XM<;FW-;6M6F$Z9"<=(E!U%2\U1
MJG9K;'.K1JK7R$[7$J,]M[)F>9\K%5NLLDJ11,`.=-PS^JVXO2K'DU^GEX*R
M]!;\@N-7/VEZ:U'8VBLS`3&Z+;1;OIF3;*=`33KNWFMEIZL;#MAZ@91S]^<`
M;J4Q^O[&&IO>K.6[O3+3M>\2=$\V=&:PWIPQYM<I;Q$3FQ:!J74>SIJ:@-DU
M^C456/A*E:9B]5NJ5<[1S.SZH.462;A-)%XK\EZ9,O5JAMS9<8BOGUP\$>&W
MN=U[N^9N8L^+?+77U_<2CV(XW0K:M:MF=8W"+CE*C8G.I;0[L$,0\3:V<PP<
MHUIS`-T&Z;$7!#+N?,K.UMNN/#15G]4/LRXG<K]:T9_(\FIRAW._P%8JW)GB
M;(6^V%A6,G.Q2)K)+Q[.9B)"F.8AFL95RSG7L*V`R*BR+YPW;'448I[:V/\`
M0Y:(':M6S91RX>G;MT4#O'8HBZ=G23*F9RY%LBV;BX7$O>?QIID[A'M*4.@!
MIR?1@,!@,!@?DN@BY16;.44G#=PDH@N@NF15%=%4@IJHK)*`8BJ2I#"4Q3`(
M&`>@X'-CS!_32\9-WW>1V?QNV/-\5+5)OU9Q]5H^LH[`U8><,X,^%Y`UMU/U
MN9IH.7IA,9!K(+1K8O0K9DD0OC&8:F]ZO,5:S?Z:W?-&)\O:?);AG7=<-7WA
M/<+9+;=KIV3-1PLN*J4""E1K"#QR)Q,+4LHDD)OV'Z@!LU.>,9+O)ST]J!]*
M?"93[A783>UZY4WL&2H-X/BEH>\%9Q3\X&(T7F[9:=ZVZELXGSB4#K.'K4HD
M`1`0$2AFO2?.LD9_LOQM<_\`GTN=XL?I^_7OKC76OY+<G'M'8.X2UV#=79:X
M;*O-EK[6T_$24EV;*"BIN#ISY@1X(E[56#DGX>TISE_$;%DS<=+[;7NKE-9:
M-TMI6.+$:>U'K/5<8"";86.NZ-6:8V.BD``FFLE7HR/*N!>G7J?N$1^H_7"-
MI8#`8#`8#`8#`8#`8#`8#`8#`8#`8'__T.KK=Q4G7LFTN9-<GG@N#W(0KUJ8
MBH'\5KWUQJ&,724[/`<G?3793E[N\H]@].ANN:U[_P`&W[?\J\N?TK8&'*/2
MVXX64<LX?@'J=[R<O$>S*F0LQ4]S;MUIH:Z(RSA;N%%E%Z)C[_(MQ2[!^4R*
M"QA1,)1;7%AI,Z[?:Y+-N1@,",O,Z]S&M>*'(2X5H3A;6&J+A'TD$^_R'O=C
MBEZU1DD_&`G[UK=,,B!TZ?4W[0_:$O5:UF=HU+POTRSXL6WDIQ2K91-KW4UL
MT_.Z]4,H`BE%WWC_`*X+:6A$054%%!QLFJS<F'>!%!/)GZ@(`4YYIU8UOS9?
ME(;@XNG"\@/8E14RE124WWJ+;S9#H83^#8_%W3M1=NA4664752=V#43\2]`!
M$ABF(G_9,4N;W5G[=5D^0,!@,!@:,Y/;:>:$XV\@-X1K*+E)33^EMH;-B(F;
M=_!B)B8H]*F[)$0\B\!=J9NTEY*-2;',50A^BOX3`;H.%G-D0JX\4)QJ;54C
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M4U>QUDDN/7#JJV2OZ*JK*`?QXMW<>K<X/[M((.W+-`Y5`6("I1."M;\3Z0>X
MQ4AYR+Y'5&V7V*8NIR"CB\M-G/E&C9=S)[>Y0%2M>IX1-^9DDY_*FO-%MH1>
M.:`8J;2275533*50!S4\F]Q,1U!:VJ3=BQ;`"10[2%_Z(?N#,;7EC6-^M&":
M9"_A```/_+_V<QU^6^)^7W"W3$.G:'_U`QFF?IXLE&)K)F`Q0$!#I^S_`,OV
MCEE/QTA[O;6T19J]-1,K'-I"-E(]['OV3I$JS9XQ>MU&SMJX2.`E50<-U#%.
M40Z&*(@/[<WK6*Y4Z/Q;HKS<$QQGG&CYJ`V/=&@Y).-G;#$)3#RRZOMV\^&F
MP[6TAI)LG<K)$3<?+Q::+U)RU\48R3%,X)]H6\5TES)5@6G:)(P;;U[\TD;"
M9_([EW;I&O2]?"**@I#2^R>,K_0VX9]60/+`64_F'8-9P<BL0J)#)+)>8?*8
M@9#_`+1T/Y'-Y\K%1L[%R4),L6LG$3#!Y%2L:^1(X92$;(-U&CYB\;J`9-=J
M[:K&34(8!*8AA`?H.!J'UR7&2J53N_"N[+OU;SQ`=1%=J$E(F45&[\8;:[L2
MG&ZX,7BG47JL+4Z\XJ,H`G463EZPX44$2N$C'Y68N';.<;>5D^$,!@,"N_VT
M5_6%E];G,>.V^Y,RIB&D[/-)/$T$7+EK=:]\:>UBJR;N!(DX??S*CHDJ*0G2
M\JA@)Y$^[O++TUK^Z*-_TN^H-0V[B?S!F)4SN9NVR]@-M/;+B5'*[#XNJ6.N
MT5:RVBWT>Z3DV@3SJ\3Y%7*2K=4#-$RD`HH%4.C6]YBV,GK8]<.F>)FU.!1Y
MTNN=3[ZL,7:KLPG=W$C]@S5JAG](E8B9B92TR2PLG#)U3(<P-V[/X2I2`55!
M0JQP.9S;<J]>"FZ/3SHWV`5/ACP7XX_GO8,DRN$7.\N_FI7EC!V*LP$G,2$5
M`72\RLG.K0<D6,5CW+^OA'Q3A^JU2;)O4E?,FX6S:S-J&&P?9KSV]7_M3WW0
M.2DG.<LM7;9EHZVQ&N*Q.6PS&J:NEEI23I$QH2L2Y%(BESE9K@*LYN*(V.SE
M7<<L5=^HH4DKC.*OK-M9CMX/.#C9=^1_OGTA<;_PTVG(\9=G63C#&2U@D==7
M9C5=BQ!M8U*9LCV_V%E&OX)"5H2KL\1/1WRB@E'U[PN!3(8RN/DEQIWRE-R)
MXZ>L/W;<M]J&HG*C<%$W'I*'I>H5I9%G4W&B;F1*2L;""::G;6)%J_G7Q)Q-
MVBHDTD&24GV?(8(+I"J[,XI+MK.N%>'/_P#3G6?B-IB4Y`ZYY,4W8.N=7P9Y
MO:,5MZ&E==2#5,99NU;*T]2KN+<UF"3*S]!J:/45CW8+AU07<'7(DC,+-\W&
M'\>JVO["@]K;ZV[KZ;X0T2O\?.&FV;Q?M6ZABG%^V/<:M:=)2,O3I&$V3;&=
M_FV"J-A=0RL\"=P*M&ND31\A&E<+.$00VZG;SOTU5,VY0.4&V>13S6VTATA$
M<2=NO'MJBJ587,%>W,%>*`Y3J%*D3,DH6W7)62KCH&T>W<BN99DN3J42'+B&
M^,8^6F>0?N3Y2K[XV7O+2?+_`)1:WF3;-))4WBGL_6M?3UY7*8[^*5.J.4D+
MW:*]).(1(1043>5MDL]1#Y/R"NE!`&2:SB8=3/I]]K&T/9>VVD2Z\;4=3,=/
MPU&C);84)<7<[6;9L.61?ELD*S@I6NQ$A6CE(Q*_19`\ECLFRP).')CBDHM9
M<L;:^ORNVRLF`P&`P&!#3GUN+9NB>,-\V)J:/,XM<>:-8#,@P)*%IL3*.?BR
M-Q/'K)+MG'V8AB]@KIJ-TU5"J+$.D0Y1WI)=I+TEXBNG30^L9Q]NONX=^..2
MNV95-O)2ELW(WV(_;M7RH)G781%*=0;>%CXQ!RF/C2>)/%B"`]%0(($#=_LZ
MDQ&)Z?-Y6H53D7QK1B6;.FW"MQT&5$5(]K#5Z6B8DJ`=W4[1!"#:LRI?PQ#\
M``'4HA^[.=UV^8U[:^6]:_9J[:X].5K,Y%3\:KV]KV(?MGZ`&,4#>-0[910$
MEB@/XB'[3E'Z"`#DLL[:>YD#`8#`^*2DHZ&CWTO+OV45%1;-S(2<G).D&,?'
M,&:)W#Q\^>NE$FS1FT;IF4554,4B9"B8P@`".!$&P\WM4-Y`6VOVLKMV+9))
M.)VV420JZE/B2'3^2=B6PS$]&,)"8)'G2=>-,WQ"MUTSJ.4^\`'<TMYZ9NTB
M+1.<>ZY]VXD*_':Z/6))D\?,DH:LVFQO:DFY(P/78"UW1C97M8C+@^1FFZRZ
MCF/38-&Z2RZB8I@E\C7]<\L^USTTU"\T>8+R*J^Q9&XZACZ=+QTPLI"?RNFI
M$%:Y"RZD?*6)Q(DN<0Y8W9L9P1)NB116+<+->AFI!>I`@](OM6=0?,'E/K9R
MMKZQDIV\KT[77>(NW[!I4EH!9^I53LJ?\ZILX6,N,G$,K$V464"&AF_BD$W2
MCLC9L]%J]%]DP:?RNG8'7*5WY&U.H:]2C;0VH]ID*#;YN]L&-DDFS5_"+LH-
M[3*_9)"(F&<@W*4K%.1?(N#G`Z'QTE7),76RX7,LRE'0]CTO9L0XFZ1.)S+)
MD]&,DDCLY&)E8B3!HTD/MLY!33..G(.1&/D&[@$';=%44%TU`*)#E,.<87MF
M^`P&`P&`P&`P&!__T>I2L21=J\[>6NTD3'5@--5O4G$.KKD`A6CF?KD;([TV
MR^3$P>==1.7W%"Q"AOPID7@U2E[QZB&M/FIOU(P-A1X_:&_?:;0["DT?,+9P
M%XS4`@NP1=?"@+B//%G*L"]/(NT:.GBXKJH_A\A@*IVC^`V3;O\`PNO[=?RW
M1Q/M[O87%GC5?GZBZSZ\:`TW;WBSH.CE5W9==5R:<*.`\[GHN=9Z(G_B*?B$
M?Q&_:/2=1SVXMGVW_A#`B!S-8J62F:4UW\95TPV9S!XAU:>11157%6KQ>_Z+
M?[2V6*D;N*S?U^E.6ZXF*HEX%C^4OC$XAG;IO3ME,DHM3/8QO2L2"RQVN[.-
MVD-MU`#''P?*U7:=@:LV4R12[0)WQR%AJ2YS@(F-]Q`!^A2@$U[J[=2OSJ;P
MVK_8U2'Y%3MZ_P`L..-JUU,($\96[C9W&FRDV)KM54HD*8[Z0UQM.[`)P,)C
M(Q291+VD*(-NX:_ML\+4\RI@,!@,"M#V`*H['OO$3BR_3*YJFV-G6?<&THI4
M169V367&2$C+:E6)1@(@WD(67W1;*3\Y)P"C99HDHB<AO*'2R9L,XEK>V=')
M$ECQ06@*VMK2D<E>3VN]$J$<M$-$TFZ46*J4+"O#K&7K%0V"XUH^Y#4*K)IK
MBBTCX&ZQK:,;%*@Q(V1(4@9]8W[WQ,I*5&I5JA5:N4BF0D=6JC4(.+K58KT0
MW(TBX2!A&2,=%14>V)^%%HQ8MR)IE_<4H9IED6$>!:JQ`W>KV2F6J-1F:O;H
M&8K%DAW!EB-Y6!GX]Q%3$:N=NHBX(B^CW:B1A3.0X%,/:(#T'"JL>/.IZ3K/
MD3R49U"RUV>9.=E5V.0B8`YC_P`OH>KZUI<#7M=R9E7#E?[A6(IL0G0Y@'PJ
M)B/XA$<W/VIM>9E<K44R%9H].@?A+_Y=/\><[VU&Q2AT`.F8+V_K"/Q6`!3'
MKEG;6K2>Q44SQ[CN`/[!O_L#_BS6K-5?<?=8ZZ'FMNNUO[#4)FVO==:KLS'6
MTE7V;^PP$A5Y._5>-VU$RKY1R:-<(QEA>0I%&B:"Q4W:I#'[5>A][?"2WUQC
MA/ZA:EUSK*B4K6=+JD?%TC739DVI4(Z4>3H5\L;YO@N&DC87,K+*2#?Y*@E=
M*KJ.>IS"*@B(YE6QL(8$7%2C6_8YQ7GH5-4)#9.@>4&MKLDV[?\`+:G4I/3N
MPZM+2954S$%I4[3YVB!R&*NFM9#%#JFHKTQO\.FO6RUS,J8#`8%-GOJUENK<
M/K9VGKW1=&N6RK5.7;4JDM2:!`3%IM4W68K8$++N@CJY`MGLK+$C9ABQ>+E3
M14!%!N=8P`5(3EE:UQ+RI[X4>NCF=I+B9[G=>N-1[*U<_P!S0.N7/%^*B-B5
M6F3<VK5W&VK21*,G$)]Q'0K=G"V*":32:RK/YJ/R(T%TUDSF0>6K9;JJ2XK>
MC/E+R/Y!AJ/;=IUEQ_D8Z$87[84?:=RZLV1NM>GR+F-4<W&N:>HEPE[F[CI?
M[XV%M(RQ6$0HHX+_`)>JH8$S3#5VDCI)KWIY]0'KRW%Q\W!LS;5TK-Z1V57%
M]*DW7N>'AH"<VG5).*G8*21:P-:J`NE8:70:K*$<N0B@,LFFY(8JI"&N(Q[;
M7*RF0XZ\*.6G+W7G,:L;!B;]O[AT><U2X<:KVC"24=`/ER680INTXFO*OWR4
MA7G%LEE&[)5PRZG=N$W":Z?<D%9S9,?"./O0YIP'%;@AN&NUV_P$+O;<4&SU
MGK^L(V&-;W<L->'WVB[6^-@R.RSZ4?"TE.4!*211\361.V#R%4,3)5UF;/#E
M$]=.KV]S::JY:;.U[:J#P#]:I2;OV+;H2OFE+;O3D6YL5:E5FD*LV".-99'\
MT1\`Q43!8L9!5&OH$=JMGC]5=Q(Z;>/FKK^-'MQ;^R:$YZ\1.1VJ:=+-;3H_
M;6Q^,M:IT3-(.]KZTB:Y-2[&D/FSJR3+MYMF+9(QLDS5C3MU@>-W_P##:K1Y
M`&YRQ=?7%BJ?T[[FW-ZO9>&WQOG2;XO";EO3K.A>=O\`Y&E7LWK5UJ&:N<#$
M-WDL,4BHP5GK48C(L$Y4\,Z269*,3J/4#-C2<-;3VXG;,_7/LGE!RW]NVX]H
M>OB7D=%<=KGM.F;,WE$V",I+"+9:"J\VU:-:G-51N$TU4FK*Q([CX]A"*]Z"
M[SO%R@B@=VB^2XFO*T'?7ZBRJZMM<J\L'K8WR>&J5J=52.O^TC,->K%F(Z2E
M31K=FI(T*RH1SYVG$K.T4"R'F**:@E`WC,?+GZ9FGC9^6OOU07`B.=M&"W&W
M?6N6=EEG4W<I"N5G53Q@WL<L8WW&?=H1=WB']D6=&11,Z>&;D>JEZCXE#$*4
M[)Z7RZ&N.')_0_+?6L=MOCSLFO[*I$@<&RSZ'551D8.4!!%RM`VF`?I-)RKV
M!LBN0ZC)^W;N`3.4X%%,Y#&K-EG;?>$,!@,!@?DN@BY16;.44G#=PDH@N@NF
M15%=%4@IJHK)*`8BB2A#"4Q3`("`]!P(M2?!WB-+.5W;CC]K9HX<'.HJI"09
M:Y_$4,<ZBB9*^K&)HG.=0QA$@%'N$1_;]<U[[3_9/67X>*XX,:$13*G66%KI
M2:70[=*`MLH^;M5P*L3Y#5M;36=NV.)%A`2IE*GT_84!$1&_V;?*>D1+BW5M
MXP;IDH9_(M9,C%&-?JR*A%F8VVARK^66%X]30<F`9!J=)R"H.`.B@_3,LUZB
MJZ\G3C?5CG6K<T%TG**+A`X*(.$DUT5"]>U1)4@*)G#J`#T,0P#G!U?K@,#P
M+/::Y2X-]9;9-QM>@8TA#O965=),V:'E4(B@GY%3!Y'#E=0J:21>Y154Q2$*
M8Q@`4F>(*=]H;7VKR`N#>IJV8(K4UAO=@-7H%2IP(TNR5K6%D-(0DC*GE/B;
M&G9Z35CV,BW%F^CXI-4H+@5PFV,@OVUUDDORY;6VX^&KFBL8T7C9EV[92-N@
M=W$C+)KXK].$3<M"*.J-3_L-3EGX,'$@5NO"S:;ITJ?O,F9PBX01\1$]I\MG
MMPV!(UO;C&H0E.2&1DKDVKA=DN%G35&;?LU/G%N$)7$Y9M-UM*Q.%R^))^V5
M7C`(D/88/(?-Z[Y)Y4!>L.C<R[7;+Q"<KI.RKZCHY2U*K0>UI+8<;!-[79)A
MA=$GM;4KZ46R?1<RW=H&;NG<BD3QNT"MBJIB=$<Z>V;[=.N]TQ/7MTH:2X8P
MENFFG('\XV2LVA2SW)'\MHS"]XJC\K=B&NW\M+N+-'Q]F=V4R=>(DW=(ODD"
MQS5JD=`PD,4K;>RX9DS&B.<.K7&K]DZDE5X/84SJ5:7BY*W[-@W[I*V0=G6?
MJ,?`:<BV;*'IL(XBF*<<]>]\0"$+,OTT'"2IB+(-=L_/)9ADO&!Q3]>5S8>V
MH"T,*BQ@455J\R3N:TI,[+85JW3IV%6GT5;%,M=C>:L'^S,)4K%Y\1=[\EA)
MR2YW"Q&W.)(3COA<O$RT9/1C&9AG[63BI)NF[8/V2Q%VKINJ'4BJ*I!$IBC^
MP?W@("`]!`0SETV]'`8#`8#`8#`8'__2ZA.'0GD:YR"MQS-EPNG-SFM(M7[-
MT#MO)Q=6Y)[%UC"/4EO.Y$2?9*$W2+T/V"5,#)@5(2%#IKTSOW_AX^G;(TK]
M6]M_)^84;HLX"Q6>C,%G?=\1&B<7N+]<D'9UWJAFHF:)['M]L.HF7L30$3]#
MF,)CYC;NMSK6-J<3ZJM1>+/&JD.4%&KBG:`TW57#9;RBJW6KVNJY$*H*BNFB
ML*B2C,2F[R%-U#Z@`_3.DZCEMS;?MO\`PA@0ZYQ2K^CZ9A=X,".7"7&K<6F^
M0MCCVQ#F/(ZZUKL"%?;;0`R1%54E&NIW<VZ2,4AP\[=,#%$@F#)MTWI^YG_)
MYRB?G9P2L+!TW4B)[0G-FOHRC)RBJVF59.3XE6V$8IK-U#?/:.(VKOGJ)@[T
M`!N)@$#&)W8U[:O[;^6'\GR*Q=WX47IBT55E:9S9T^S;O&Y#E59QFU86\:0L
M)5G:9#_'CW<-LM0BI#@*2Z@)D_"H*:A-;=,Z=W\+;\PT8#`8#`K'Y-NC27/_
M`(=P\.HH22K''7F):+8HFH<$R4NP6SBW7HV*<HB((G&<N+!J[2-]52_95`*'
M8900NO9?VW\M_P"=')"F;Y$W@B&Q=B08T`=7:NL4Q$OJV1F^NM[N<35UI=O9
M)M&;HUS?CJYR!ZM-*1C:;K+EB]1C2G<R,>1P8S9\R":V`P&!2VP%32/LGY!T
MV2$6D)OZLZ_WY0>[H1LY=QL4CK_8[4BGX4E9,9Z)1="D4/*#<_>;J7\6;G,L
M-NM:G7R0YL57A]J1GM"RU*>N,2C*099M*'<M(I&&JBMB@HJU6(9:4)]O?RE=
MAYA20;0J)C2$J#50J)2)IKN$,;<<M:\V18G$2T?,QK"5BWC60C9)DUD(Y^R6
M3<,WK%Z@1RT=M7"1C)KMG2"A3IG*(E.4P"`]!S%_^%LR]3J'^$,B8OA\#QR0
MA!^H?0!^N6+./RCEM2PH-(YT)E"AT3/^\`_84?\`&&;UC%KFLI&P9B^<[TKW
M!6^3JE6F.0\5#*3L3,248@[TIPNUW<+]O0;":+71^=1+'=[=%MD5#B=H_.T6
M;]%@!9+-;7EN3&LSW_\`M<UK3EZONO?&GJ9K6$2#5]^XM2')"R2%IAY".N\*
MTGKA"5C6#(A6\RK$,"V!,)5PHBHBZ,X1;D506*F4?+$LQ*G/D9,")6_S+UC>
M_`W9D,9TVL$;R@)JEZY05.5J[U]NK6%_@[=`RZ7:=%:/>3L%!ODNX`$LC&-1
M*8!^@YWZC>GS/I;=F&C`8#`IR]W>R-[5KA59JGQ.7WH]Y#6>\ZTC(QGQD<RR
MFUJO6)";>.WMJF4J<DZOD'0WZ\%]I4?1Q4#JR3YJU,L5%98!E:UQGGIS06/E
MQ[O-IV&;]2F[G-#:[5V3K!U2G4!N)M0JW=;]6K)7?N39&/VU&3#:I6&QN:PL
MH9%R5V=1\LP6;+G<20*H*SGIO&O[HUOZR]C//6[[68FJ^P6=D-*/=8ZMLVA7
M$O+Q[R3A?%,GCUM?+3,]%F6(OKUS&.$U8^;`CABBP09]_B0(*R#JE_5KPZ!?
MU%&C9'??&K0]D6ONC-9:`H&T$++N/>=_83MCME)K]N"O56J.M7QM,@;)9;?'
M3RLTX5DHJ*3^3)*M8T_<1LBX72M9TN+?+2/Z;FDM=36GGEIVD[FT?N_7%!N^
MMQ&ZZ^JFQJ_=YN7F6=L;P<A.K7>K5QNE6T8Z!?M4X]%61%E+H/O&L=N=)P[0
MW^+A##F1^GPY45C84!ORE["?<\K`2>O^WM\2.U'[6EV&[M:J$-9JIJ^.J;B4
MN$G/2ER;14A%'>HR9T5E'K=(C!@BW[UV%F\ZZ;_X-^R/??M#Y2:.XGT[4M`T
MYQ!JO&O8L=SBT*TH=7<Z]LS)=&TTA>&JCAW&)VJI5=\O/UMK&QC!['N6:[E^
M+@7R#4!.[+)K,_*O7F-ZK.4/ITWU3.<W'"0=[?X[:5V'`7F'L"CP&5OU[$'L
MC=N:@;7B6IDU7M8LC>94A7,U%$,U>H.U3.6[`ZQ$C3&%FTVF+VL:Y^\B(GWL
M^OV'K?`M\]DMUZGVK4-I[=XF69]%5[;KZMM(&S4U=_6D57I8>]5^NSMR;O`<
M-78-%$`**Y4)(C9B>]I)ZWGI87Z.?6?L+@5JO:%_WV>&;\@N1LM7I:WU&OGB
MW,-K2L549]6NT]N^A#J03B65>6=XY?\`VT?MR)?C-4!4(U!51(SMMGKI#G>E
M']5W,_V8;<V)RW]A$-(P/&.3BM:)\/\`==CCM):JKE^J2*,#;4ZY>[Q:8-EL
M*K+6R!>*SD5#MFKDTP0?F.UXXR""[A9[2<1MCVL^J/1'*35%7W;P:C-24SE#
MK:AL-B:I@M3(4YG7=_ZEKK-FI&P$978`Y*Q+$18K-R5Z63:+L7'>C&.3BS<I
M*-5AKM9Q>E`/$[DO9>%R]']D/&*'>Q.JE+S"Z*]D/$F*6<H5VH7!\,@O7[G7
M(9VX7=5VE;*8)OG]4673(2K6QB_@RK*QJZ;5:-V9XK_08I=O@-@TZIWVIO?N
M=6N]9@;?6I+PK-ON$!98MK,PSWX[DB3A#Y<<]34[%"E.7NZ&`!`0S3BR;`8#
M`8#`8#`J*WE8HG>&U9-S",PDF3%%IK&HOQ>LU&4JZ"7=(KR\8P.@=S)-Y&?F
M0226073;/$V[8`4`Q@`_?6>NO+EM9:MHC6?V^.CV'?Y?@LFK/R"':*GQD$T>
M\0_=W]G7IG!U?;@,"H+D[LVQ;.W<:F.2*Q^F=$;&@B6&7@WY#.9*7F-9SAUY
MQT[8IN9%".A)ZPDA79FYVP10$='654,HL,5UTF)GY<]KGAH"9DBHQ#JD52WU
M)Y`4"5HE@IL9(,PC['+4)G*1#Z<1HVPY&SLX9ZM'5DDA$M7S1$KE%4")KO$5
MA%R._EEC+VT04HTE@H\>[?ZWVY;8QVPLB=3M[:XT'=C5Q`Q,,^2JP,#V.[)+
MS4$@Y55.W8(MY!!0KA\X3=J?"?D;AINA=^7U1O*.]771Z,U(KP5N?[#L\1KS
M7MUB(XYX$UNEJ+$&A[@HN]CF3</%)5]\#UBF+,#N60MGQ9=M9\K-;4GOZ7M\
M3<O+L;#(ZHC:O:X&(K<R\AGEEDY")K[1*4)(,6,4^@XYK*RCD\\\\2IUVS5-
M(R13)&,F<5\^\QPOK?E89!04168EE!P3%*.BH\AR-6B(J'`HJJJ.'"RJRQU'
M#IV[=+'6765.=9=8YE%#&.8QAY7GFNCU%$TUDSI*ID525(9-1-0I3IJ)G`2G
M(<A@$IR&*/00$.@A@<[&_6=[M6^-AHW-M<XB1I;PUVIT9^5JX$$Q.QK4+$V%
M6IDOU??5YP4TAL!RV7LBXO6Q(EH@S8'6764%KWF,3%<[W5B_"%5WK9S/Z)^/
M92U(I9NZT(E@_+;IS7U".:XYO4`Z=4T"UJ,92DU=6\E%L@`KU10\HLH0$`;G
M4QO.<M:U8GG-HP&`P&`P&`P/_]/IOXFOH_7NH=Z(6(Z-?K&LN6G/=0\@]6,H
M5G3VG+#=EP3EY%<AE>X$H>5%4PE`!\10ZE[^[-Z],[\[?^D?G3&7-ZJ]<46:
M8.(B_P#LTY!"ZD8I[WI2;2I\P-UV;>EU82#<I#.0=4_B>E(ME41Z"W^W`F/8
M0@$+CN_FNG5_$6GE*4A2E*4"E*`%*4H`!2E`.@%*`=````/H&=7!_6`P,?ME
M7A;O5;-2[&T!_7K=7YFKSS$P]I7L+/QSF*E&AAZ#T!PQ=J$$>G[\*K75GYDW
MKUX(<AY]55S>^"N]ZMJ3:\F*:@RBU<IEVM_`/?3R3:G5*9-(S"2-:7150#M^
MV)K!VE`!SE.+'6\^T\S_`/J27*LRRTOQ!AV[T6BTUSDXX%`ACN2(/D:Y.RMZ
M>,G'QTU0,!F-3542*H'C%RFGU$H]#!O;IC3N_A;?F&C`8#`8%76S6"K+V7MI
M-%!19"R<%VC"2<K%%5&-5I6_I-Q"(1QS`(,%)LE_D#/`+T^8$>U[NOQB=-:]
MU-OVS\I&9MS535]E+S&K-!T2?,H^'<SK3[Z2.Z:S2*=<C6DY5K/9*[5)5TI=
MV)GE]J55G_S6U&4KJ16SV/0:,2"F[:+N+M>.A:S@,!@0)Y[\:+5N^CU+8VGE
M6L=R*X_S;R\:G=.3>%O9FCIJ1M=-7RB_D3(G$W^);$1[C"4"NT$`%1),RI\L
MN%F.KT@M,;_UORJXE[`B9]L>OV.L$6K6P*5:3L:[;M;V!V=2G6^'F5Y:C7R6
MKI4XN7>IG<LXH';IL"B":C8YU3(ZLEC-SK9_\+"?5OLY_8_7]Q%=V%R965;:
M-I$&=583^=5G6HTE=BEEC*"*BJBL3%H&,<>HJ"/=U'KG+6<1UVOZMORL(-:6
M@$Z^8O3_`,X!_P#7Z]<O*98%9;^R9-U1%P0.@#_T@_P#_CRS7EF[*/.>W,Y-
MN,II#6-MB(K8<Q#NW]VO#UP8]<T)KGL33G-C7!PU!4Z,HFW=D1A(P@&?R4DY
M;)-TEEUVK9UOJ?9K/:Y^%3VEV$D%8VWJ*,?7BD76UZ\>48MRVO1VL"WXQ^NE
M18=P7':%B+#-H6*G+?NU6T]@M$#+/'*RJJ8NA6=(JCETOG_S*^_U>Z[O'\KI
M[D=M6.81-WWZSH32IP,9".*U&U306JZHA4=,PD?7'DG.+0)96+,[F5$2O7!5
M"221C&,<#")C;O"T#(R8$->9;I*%8<9;E,%61H]$YI<:;/L*9;D\JM;KH748
M.(G54@$R@QB%^FX5*0.5-44(Y9PKT*"8JIYVZ;T[_P`+@\PT8#`Q:\SDQ6*5
M<++7:P]N]@KU6L$Y!4R-=H,)"W3$3$NW\96&#YRFJV9/9]ZW(T254*8B9U0,
M8!`!#`_SZN8/L[L<?S7U=S@J.F]O<0^=&L):/H?(O0=ZD)I_0]D:_A$$"1:*
M[F8CJM8X)&:@&@Q,W#.8=-`Q#L9!BM\Q!9P?.76:\69X7_<5?:IP;]B',[0,
M9<.$NR:AR%3B;;(\:MR7ZDP%F1;0\)%3TY,+-+)$.0DXJ/11CGQF[DK9_',W
MHJC\ANH<3FN6;K9+SPJD]TG':V-/:-NEG)Z8F]OGY^\;*M4.,SIBBBZ=5K=5
M`0U.R;?D]ZZ.Q;Q<\R?:?*TDD"JB?[1;E14'Q/#%"7MK6_IG/2:7L[UGMR@?
MIUN/E&W.HXK&S-8M^-<9=*W,OF;F6[(T[NM1-/<*D4=%6E("-D6)UDD5!.E]
MN4`3"4AP&WI)^^M/^H:J\M>*WJ^YL>PW2NNZ3LG<F^K-"7;7U$LBDC)P4QKG
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M%``Z9@.4!#3G,_';BQX4>N[C#QSYH67?\Y[5.+59U%QGV56-EZ;L>K.1FG[7
M?=LT*-E7$E.5FZUV"N!Y*KM']>%*"F$RHO"R9G3E!!JX;K%/F?\`+I;;,>JR
M;F_[L-KSURV1QDX<J0VH-F/(#66U.*&_[&>MW.J<LJ/)QQ)JQ5.@1-QIKNH5
M^?MYS+QU=6=+/RRDC$O(CN83*S9`ERS-?FHU\9^%?%#WA[5UMSC6AZ3JB9J$
MF_KGL1XKP<99X)ML/9ZP3DQ#[+J<]5++6+%`H[<6>F</GBBY7)7,>N0ZKUVB
M[7<NUMNO"N'W9J1<9SAL.O\`C+K^P:[UGZ\..NB=*V&>J-TLC&2:4O[A7W$`
MFA+S4B_DV:,7-;>8P22YB/';MZFJ]<G<E.!BRM:]<]UUG\//6]Q6KNP=J<R*
M`_GKWKOG5J+6ECF]/;$:5VV:XD$)]G6]A*76782$>Z+:;):9HA9=15X"A&SZ
M0>F2_`N0J5<[;UX6YH((MD46S9%)NW;I)H((()D21012(":2**28%(FDF0H%
M*4H```'0,K+]<!@,!@,!@1,Y1;<"KPG\NJZ^%.X6UGU=J,GR#>1@ZVJL*+ET
MV2,)WB\A,%25;-RMDU5R!WJ%#R`D53>FN;F],;7X^6G>*FJEWUG&\O2*!!U/
MN:QI7`HNR25H5CQ8*>)=5,B[EM6(U3^"N9%N!#NR))HMET7Q%=;WX369N5BN
M<G0P,#V?=TM;Z_M=X61:+DKD2J_!.1?EBHT%.]-!%24E#(N/ML4@LL4[I<$E
M3(H%.<"'$`*-DS9$O$RI`LIY>)<1+(YZ8S=46O0+J7L\%M2;U[^?Z$",RD6(
M<M$(T8]I(E,1V_:HKRRWQUO_`$3E)%VX5)W<F/4O7]PY"ST-J[7<9,A1:PA6
M;`A'["3JT^AKN/%VS/7)PMJJ=DB;A4IJHE'SP\:XD7=@<.&@*F*V^,9;);),
MU9+5PVCN*FJ]'B$^PBD;9M*0:QY+1MRT-4)"[SSYG$$A3N$9!Q\A:#9*QY?`
M#=LH`G0`I5U'!P%4W*[7;MTDD26S*F`P&!"SF=:M`ZUJ,3?MNZYH%\L1G[2O
MU%"X5R(FE"@J\34<K+*2+8Z9(>+4=@8`<K-6`OG2"*KEH#D7!-:RVXEX2XG.
M.4`H7GPY@;A6I!WK2"J=#U\_935HK])T=OJ)2_*5E@V;&P[,B;A_+U.LN8./
M82:@MT73-@Q?*PJOAE5P[`2U=?OEGVY^EY3=PW>-T';1=%TU=(I.&SENJ1=N
MX;KD*JBN@LD8R:R*R9@,4Q1$IBB`@/3.;;]L!@,!@,!@,#__U+M+P5W-Z,Y4
M:J^6XB8[DC[3+SQKEYWSN&;>-HF[^4=;UQL98KU)9J*7SJ?(R\:W[%DA/).4
MT2F\I@*.O]:?[S\)]<A&S.R<[^)^MH]LV85KC]Q_WCNTL:T3;_&:V2XR%%T-
MK9)LR3*7[4C'TM[=4DE`Z>0BHI)AVE5Z37LV_;?M)'.CD^-^_813![*2CUI&
MQD:T<OY&1?N46;!@P9HG<.WKUVX.FW:M&K=,RBBBABD(0HF,(``C@?44Q3E*
M8I@,4P`8IBB`E,40Z@8HAU`0$!^@X']8$3.,&L:KN#C-["./MT%)M2[3R9Y@
M46<<22#=!C&Q>VXR-ODG,-DCJ))M2QSK9*KTKCO3.+HAG0'*<P&#E>Z[2_MJ
M.FFK_9=Z5[TK3UE.Y;V>_P!KA-PW)8SK^*_-5."^^9.1?*L7*B3E]'3EMGH]
M8JG57XYET5![Q[3YK:YFJ22;;_\`GROWS(8#`8#`JRWRR>Z]]BNHKS(>*2KO
M(_C;/:)A2$44*]IUXT/:[5N@5A;B(I.HK8M1O[\JRQ0*9HYK#8@]P.B]FM>T
MVYU_%24S;FA;JW3VQ:H34U!>1:4-4M4RRCV;M+.P5DT=L"-K<!-UZB1\54H.
MIQ#Z.?.UY=K)2SZ15,_%2,(V6=2G5%T@QS:)I8#`8#`YZ?8_KBC;\Y5TK07&
M&O.8SF!?(9_&[JV95G4M$0%$TVO'QK>4N&X&$++0@RCZ!83;1Q7GJI5OGR22
M$<!UC)@DW6XF)W6]>LW]LK/:"OSLX?U*I:GLW%%QM+7VOH&(I]6N_&6R,+.@
M\@*ZQ1C(T%==VA]%W-D_+&-4S*J+G\:[@QNTW7-2S&+&;,VV;<ME_P!:&\7H
M'91?";FHYE"?'2,V?:9^Q,4UW:1E$@4G9BPLX55!(Q>U95LNX(B;^U]!`<OZ
M4];\[1F>KZUSNW1>8*4VEK:C\>-+-G:JUBA+#=B7K<EJCC-E/AHPC>F'4J50
M!58Y1<"_<KN40*`%2,(FZ3V\0NNOG-?QN'UU4RN5*IQW&?4%&G;RIM22NLQ;
M-V["NLO7(J;FD7:B&S=@5(Y98F]I*@=11KD1+*`VCEW1U0`Q5WP.(U-O+X(K
MUD/7%HBHC8&U0ONIK#)16T>2+F3C')=J\J=T0\PN^@HK9TPHNO#QNA:<D1N>
M)K$>4J)#E.14#G%-RF/;Z6FS%BJM09M#S\[7ZNP.8K-B:8DXZ$9G,DEU*U:&
M>KMD3&31)U`A/V%#]G0,C+TH^3C99`747(,9)L!Q3%Q'NT'B`*`0B@IBJW44
M3`X)J%-TZ]>A@']@A@?=@0RYUBE*:>HVODUD/O6VN4?#_74#&+`8PSAI#DYJ
MN=M,<4$TU52(M]>5Z:>N52!WMV;-98HE%/N";=-Z?N7#9S:,!@,"-O)?5W%W
M:%(?U'D[#:L<5O9K174#-_L%U78"6DW5R1>)LZE3;3)K,)EE9Y$Z:J\>C&.2
M/@<(^5`/(GW`69G2DCUD:5]=?"B$Y?\`+_C1S,W#N[1^E*S?Z-L.FV])RU@]
M;.:ZXA;[:%(N'D*E0R7&TRR-:9-(N58M4F,@!E$45G!SB*4C6UMQ+$%/0+.;
M0YA>Q7G%S&)LF]4K5[.Z6+8TQHI2SR%AKTW.<D)[9!Z'%S/R';.-<EU?6JRZ
M;-7B<>5?H@@DD9NW$Z*B+OQ)%PT+[$^'7.'FYR&]7^V-1T*VUO5:JJ,1.[<D
M*W.5;;>U-=6&(B+O1J_KRSUU`$+/1K$\<`R41>OG,@C%OETT4D$NX[Z9Q9)M
ME,SDA9.%^C])L^*6SYNE:/U_R#HVQ-'ZUU/0VL?1I*TQUA@35ZQU#3U;K4<@
MT:6-4MU009)-$"=9*0;D(4RJQ"FJ3.<JO/0_4_5Y*1^V-H<%:WMVF[5BV+#6
M.W*EOJU)R&S8R!)++34/..:_#S,C5$8NUOF`!\ID0@$<QIVXD1,13S28:V]O
MEX/L`]WMOX?>Q#3G&"0UVCKK0<38ZJMO_<.RZ?9IS\W4"YM:T]4M6F4:F]^:
MK$T9L]D&[QP5I*+.91LHW*V+\8Q5V2:YEK-/;7QLUO['>->F.5W':N3'-=QJ
M.5?.-?:IUAMIE`ZUV?`769@8RZ'M"L4BG:7<C4UJ\F1=G#RL%-(`#E%14AT^
MU-36XME4(,O2ZIQ^U;MKGC[*JE7M!Z4UZT:3E>X<Z0O<K+VR\V*5>1T-4]>?
MS$L%OVN_I<#8I]^W15/]YL$T1!5PH=1B5#R!,->V<2+)*'!^N'VK5/3'K8:\
M9MM\:+=K#B17M\:&V8K+P]CG=:0]P&MV-S74;`_DW<U?*[9VUU9RJQ)5NFVE
MD5U5DBQSLC1<+QTGZIFY^52.K]F<H/0Y[$>1^M:@G%\E*]5*]2)?>HN8>;@$
M=@ZJEV=/NS:ZQ`JRDA(URU5U38GQ3O1-,M63L[L5BN&Q55`G2\;2+?.1/`">
MY5:G]C'L,XTVMOOFK>P;CGIUUIK3=?K3IO?V,A4;]HBV3[:37<R@,7-AJTCJ
M%XD,<@0SDSQ,R'3S)`FK?+.<767X=!7KYHE]U?P:XDZXVA#R-=V!1>/NK*G:
MJ]+N474E`2L#48N-4A':C=R\0(K$)MRM_$10Q403!,.G;T"QF]W"86$,!@,!
M@,#&;E:HVCU:<MDN"QV$&Q4>*HMB`HZ=*`)4FK%HF(E!1X_=J$12*(@!E%`#
MJ&63-D2W$M5&Q*-HV+:P=2R@N]@7R9$QVG8+ADH5Z846X+-7D97I(\)"1#98
MR:,@S=,0:LP(FN1<A%$^_&L^HY?NOVMSIU5CJ36(:KQ0JG:0[%%K\ER<RKQ^
MY`.]Y)OUCB8Z\A).S'774$1$ZJAASA;FY=I,,ER!@1RY8.FK'1EG>/';&/;-
MIO7ZRLE+&*$-'`38=6Z/II,[QB5>+;FZ&5(*I.H=/Q$Z>0NM/W1-NE.-A!1@
MRL1*\U-!MY6^14-+?RD5@GM1?/8B.)*`W94QR_"3N,])04>W;330R#)DE'@K
MY2+IM%#N>W_+E]O9X:\E;CKQ"\ZXKM3I+>Q3.R'EJE9"Q,F[.3E(B95M%7A7
MIHFENXNO,'$8&JGB*D:@X=&0:%!ZJZ.HN*9LW7VN;6IMB<1/&H<_&A@CS;-U
M18:['R<O7(5I9:))$V'%`M/PS*=.\DX8D?!6QBA$1CP'+\K-E*E:H`<055!%
M8Q,W^._%6;^8GG6+37+I",K)4YN-L,#(_)*SE8ETD\9JJLG:\>_;"HD8WB>1
MT@U5;.43]JK=PD=)0I5"&*'/KMM[V`P&!#CFYHQ[NS4[(*_$NY>W4*RL+A"L
M8L\0G+S3!LFLA8:FV^_HKP;QK98]0$UFKPIFRQDDS"0ZB:91UK<5+,Q$'6VH
MN2=YLMFL!TYZHIR<5"5N.D+M16=;1B(YG\PAE)2JRTE]P?S$7*K/GZ+ABN_9
M.D7Y$%0+V)^'I=]6/6K'])LXZLPEFUA$F>GC-0V]>CQ1WSMV^53@WU<K6P:W
M%I.GRSATJUKE:O+.+2$ZAA[&0?L#Z!ROET;FR#\G#A!J@LZ=+)-FS9)1PX<.
M%"(H-T$2&466664,5-))),HF,8P@!0`1$>F!7UH7VA\.>3G)R\<4M'['&_7^
MA5!_<']CAV:2FN9YM$2L3$3<93;:+OLM4E#.)I$ZQFJ)V9T>]1!=8J:@D+99
M,V<+"L(8#`8'_]6Y"0V#I>4X1WO7NQ99C%[#YJ[M]@EHTC4B.9EI,3^V#<D-
MW;1U\:O2<>D[-6+)5)YM7O@.Q6*1&PBR2046<KH`KJ8]<4N??,ZF$LM-[(#<
M'*ZH;&/)HV(MN]5G"J_L[$*"*+J17V9LWD;+3KQ4&Y4D4ON:T&T4.B4A`243
M$``OU`&GR;]?Y3]S;DKO]LMF-4_7)RXE"**)BZU4[K(F2(D<PENDS#TXZ8@L
M=,@)JDGA*<0'O*01$@&,``,V_;6]/W:IN:W<MWNO*$\:+)N&KNEU9RV<(F`Z
M2[=>#8JHK)'+U*=-5,X&*(?00'*S>ZS3"*YX6\Q%&XJ>["Q6AS+J13#?.XX)
MDTB%O\].Y*U<'^+5?KU=K7E*LDC-6&U6%!JR+VB07SLHB'XC=>>W==I_I^&E
M]6\@:);X/@SLW7<FWEY;B5S'UOPKVBDRBHYC!2EAV=KIIQJN7Y,0:K/`/4F=
MJVE"R\8];F2178QI^PID#`8;>9^$DLVN?F9='.9#`8#`8%:_L325J,APVY`.
M$A4JVDN54(PV`N42I!$U+D%KC8G&QC8'+@1$P1L)L3:M?6=D[1(#?O6,)01Z
MY9Q8=S:?3=^='(P&`P&!'CE3O*'XZ:(V#M68?I1_Y?@9-6/6%>N`\(]1C'K]
M9[%1EIG:W&661@HEBZDRQ)7B3B2(R.@B/><.E7O$13]7F@Y'7^CEM_[):$4W
M[RU7:;HV,\44>.%*Q6K$1>8UKJN(4DUW4BRK]%K,N!A;*J**DE'KP3G.'9VY
MGF]UK;_K.HLSRL&`P&`P(>;(TM*2NW+'>Y#7T+MFMW.L46HA\B;;1=UUI%03
MBY-+Q&5-K**0\9)P&PZY;U2.2%F8Y9*0(FL<CCQ-S-UZXHC=,T*BIVHEIW/Q
M3)K-^_FEA5N]7U+3K8VE'%KLR)5G=HO-`D]J3>OX:F!$L)()V14;J))O7[(J
M:3$H_)F+)Q5;KXJV=W*6A[&TBTVJ^:8<:RKUB"7LBE@DV=0V$YGY5B%*@K)8
MW<R[>OORFW14FHMO*2C*'?-B&053(^`@WGY[1L*24/LGGQQ=U]!0J4P7CW`;
M'Y)[-FG"@%9TUC=Z!?=":G8)$$#E<V.[3%EL"[4G0!190+M41`13[L;7J.FG
M5JV#,J8#`8'.W^I8UO<;'P?UOMFJ19YMCQXY'4/9%VCTR*`9&I/XBR5`)85T
M@5.FBTM,[%MU0!(P%1>&6$Q2HB!I6].[%6'K4U'!^PV-]Z/'+3M_<:WUER4V
M5J#9FL;J2ONI5C3JV^W9M;8T3`R566<P+D7$[66S2&?I?(0.@1NKV@?L`!GE
MJW'K:NF],WJDV9ZPYGEHE>MG4795?W1-ZH1UV]J;6?83*-<UF79XFD+I%S$<
MW90TW+&V"F4&;%Y)H)`U,;Y)O(!2V3#&VWMA1A[K>$L55?8Q>>1NPMHUCB-I
MC9-.HMQUCNB+9H/I60WU6U:E%6%NPUMK1R\W!/SR:C1Q,R4\RC42QZ[ANY7<
MF5.BD[E;UO&%YG/3ANR]I?"O1MNXV<DZ%L?D#QZD8F[:@Y!TRP19J?>=@P,1
M&1]\BW,C49&:CZ1(V:?A6L@7QBLM"2[!N@KV)><<O;$OK;F<*-?1YNZV6CW2
M;LD-RN:-KC;6Q=0[/HVQ:O4EV[:N;/W;1YNAJWB6AVM=5EZF[M-E>T:9M,BJ
MS<DC%W?W!=@)$%DFV2=M[3]*VOFMH;A=[Y;++ZBT_P`CE:COC@ML>7K%RE4:
M7(R;5[5[7*-H6]QD7&RKZLI6J*0G:/XV<TR7<MF3]J)3$,WD45E;VS+=?CBO
M3Y;^P'A_Z'ZK7>)&C^,5]0=VG7=MW!KF/A73J0U<-JL$U/0S-&WWR\762O$L
M[4L<`4TJDW!VO'Q)V@)?A412(Z)+MS:I@YZ\MN>?-KTY,;QR5X_3VL&U%Y5Z
MDEG>RTZC/T>N[HUQ;Z+MTE>L4)69DI%&U>JUFD(9FXD$C.(V5=24>9JH55)T
M09\-22;<5/7U'6*&YE>W[F)S;T_6YB`XOZ\T-2]!ZL%W&&AT$A:PFIZC5(9)
M%T@*ZJ1JUJN6DE6YE!=L2/&95A(4Z:9K.TVXUD^6VO=]P"W$]V;7/9%Q>BZS
M:[5K_6D]K7DAJ2U/FL?"[)TU)0=BK-A<N!?R<*A)1\G0+9)P4\T3?-'QXP6R
MT>8KM`3"OE-;_K6>>F?97%7@YP4;U3:?L*XZVA[('>[UE=;*[JU+)S''MC:*
MK!2-BU4DQK5_M$I89"(G6#QPY%HW:@[E72P(,$UU%`50VS;TSKAY[YM6\VN=
M*/%34FHGT9K*2KUO?US<UYO\%5[)9Y6J1RLH!(?5#^/(^>,9=NU5^.W;R3B8
M*WZNW#-NBBY!%DNN)G*_;*P8#`8#`8$).:=C,>`IFMVCA0CFWS*TR_1;$3=N
M5HFK?%6*@>.%K*F<-U91^@KW'8/$2F:_B(41*H7I_'.;6-^I&$<4:LG*;`E9
MTZ2:C"APB;5BND*:*1K%/B[C5EOAM"%8-W;.*8.T5P238*G.Y`7+3J5LJ-_D
MO$B:3E8EG)T,!@1WY8%*7C[L=_\`Y1YH*.C+*T*S3;+NU'U;GXF<9H-$'[AG
M&KNG3A@5),CI=NT,<X`LLBEW*DUI^Z)MU5-DO6I"R,G,M'0\DA-!++O&1X[2
MEZH<_*-WE>(@6*3LM:N$"O&Q/G$C<H?<&R*SE`BKE06XF6-WSAQ<=>Y^3W)S
M0N\+E1T9:$J<G1'TA43IU])_+Q$]%%C)2%;S[&9L0#+OF5F@)]RZ1>-P9`N$
MB=R0A%5.X.&V^TMCU:_QZ7658=PF]M4S/7:F:GVI!`R)8DEJLQE8B1D$(]_*
M2[A[*+QZ:L:T7N-9<WZU/2*.S1BCY5VY:L&B2"9!4,.]?Y/:XO%<]OXO66R\
M.JK1>P9'4VW*!%1<B">NMKOQJ$CKQI1;-0XU&Y3RC5Y!WB`0L[QW'!+QQ(YR
ME)1\<5HJ^8NUWSD5SQR)0N^N9GY8UN+CX6[YQ=#`8&)WJY1.OJC.W&;!PI'P
M3(7)FK(B:C^2=JJIM(V(C4E5$4E9.9DG"+5L0YR$,NL0#&*`B8+)FXA;CE1-
ML7E]<K["Q<O/\@S56M2<]!3"-(K%57<2"U7G7B:2$U)2M78QCV'@4V[M19A$
MRSE^LO&HIK/CDD5/`P[363J.=M^:G=P1WM#75O?Z0^GE9>8;V\C^NS\PPN,-
M/6R/-4()LZ8V"-OSN3M+"V5XT$L4C=^Z4<O(--L[2`R0+"GSWG.?AK6R\9Y6
M+YAIS4_J:N6]VT3Q.USH>A2KN`?\I[':X:VS$<[6921]::Z:5M]:JXV<-E$E
MTFUHDK9&-7P`/:O'>=LH!DG!RC+TWI,U4U^G(X30ELV_7.9S_E90J%9=;V.8
M@*MH&KV2G2^T;I&RD/)5RRGV-7)1\H^JE+G&<D="-*5DN^?J$.Z149_';++I
M/E=[\8=W>5S:VVMM*M:AI[VWV94QD4CD:1L8W.F#^:E%@.9O',2JF*45#$3,
MHH8?HDB0YQZ@7H-UEVN(ELDS7JZ_V!6-FU>/MU2?@]BWY1*<A^PCR.>)E(9S
M&23<IU/BR#03@!R=1`0$#%$Q#%,*RRXI++,QFF17_]:TGDII2KZ-YNJ:0VFY
MDJ_HC?CK83+6E_9%*$MK2M<I=SZ_V5&W'7TE)>6.AKKQ>]@=?@7JX`)DRUW8
M,6LN@H@P4,0U/K_S_P`B?FJ-$P'%OES5M'P$M/V6.K?KGTM4&%HL:D8W>S9-
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M7%C>,RQQY795/X^L4]G7ERH"RJ5EM$,S<%*HT,FB^EOS?G_S+J"PR8#`8#`T
M+RETRAR'XX;PT@HL5HYV=K&X5.&DC++MQA+/(PSHM3L2+ALHDN@ZK=F(T?HG
M*8!*JW*/UZ=,+.*A[Q<V^MNW25.MTRT<PVP(QLO1]Q5&12*UF:'NFBK#6=J4
MF:9!]6SZ`N4<Z3(/0$W+447"0F163.;K+F9<]IBV)!X9,!@,"G?W>.2M^%M@
M(]<N$H1S*-$9ILE986)(_CR.V#F5;%@I&IV&1M+T*TWD3HIQ[R'<M.TZ_P`D
M0+XCK^W9K7]^OY6\12L8XBXU>%.R4AEF#-6)4CO#]O/&*-TSL#L/C_Y/\(S4
M2"EV?@[.G;].F&7H8#`8#`8#`8#`TIZY(Q*X1?)/E`NFDNZY%\BKNRJ4J(]Z
MZNF>/+@W'[6[-L;M`I("3EZ)/V5B4@BFH%F4<`(BX,(\KS:[=219)A#`8#`\
M&TU:N7BLV&F7&#B[/4K9"2E;L];G&2$E#3T!-LEXV7AY:/=$4;/HZ28.5$5D
ME"F(HF<2B`@.!_GFZNW7R7]5/L3YXPG"RHK6[3NH]D6]]M?0\NW>2Q)WCU1[
MQ+M:S,N5EP?W%!'6<1=4NRQ,U%UV+=Z+UZFXCS/2YGJNN)MK,]NUGC_[)N*6
M_N(#KFLQV''4;3]6CES;36NBQ64GJFRQR<>$M3;0U;%<*N9Y-W*M4F";(K@T
MQ\QL+(JPN4BFTYV67#B1WA";Y]^/L[V>;CC)JR^O8=BQ:T>9V0Z"IUS5&AZP
MXBH()QY#"M)2Z2<S:IA:1.R9(.I%T]E#&,BF4#@AGNNLQIKR[G.!7"S77`/C
M33..FN7\A/HPJS^P7"XRR96\E>+[/B@I8K.O'I*K-HELM\9%LR9IF.#6/:H)
M'575*HX5TY6YN7)-IWAOZW^/'.G0/'V5Y';3Y3[^O_(#?M$GYS02U5JE=UNS
ML->:ZX:4;<)9.0LER7FXR3=2[AQ(P[]MXBJ.A[#"B`GRZ6VRW'#0_,?4^Q/T
M\W/76>P.(.Q9NU5'9&KW\L@RVG#Q<B29KJEU=,[AJ2WKPS:):3\<@E!PKXDD
MQ)%OTEUR"0B1DBJ+.B?KG+JPE[5P$]H_!?C-N?EC'T.(U'LVTU&V5"#V5LLV
MNT(K><0_L5'E=>Q-I2GZ>O9I#\PM)R#*R(?_`#PV*90K8#^,4KVQSK;(_CW-
M\8N3W*WA$KQVXC-*L$U;=EZ[:[`A9N=8U!@YU!7ONLNY8Q3]R"3)N>/NL97W
M*C<.@JQS9PFF4YQ*D=36R7-5I>K"^W/T_<3N:%6YY4K8^O=-Z1Y11[+6&Q#T
M&560VVML`A:<^=:X8-SK+S58\E*82I7W?]O*27,F1TJLFHDFG#6WZK,=IHJ^
MT?U:^RC6.P>*K;:L-*3FX:L_JL3JG<3*]::)<K"Y'SU2$978[>+BDY-U9V;,
M4$V$L9^93L!-(YA[!9E9]=M>5*7#[]-7M_:6SDMB<V8&D<9]2L';1930&F;M
M*7>VV4S!,A#L%+C*W'9[2H5Z653!5RY)/2\BH4ZJ*"3`12728:N_AT9<:/35
MZ\N)>T8;=.F](.H_9M9^2-6M%DV%L.WJUI5]'/XF0<P\9/V9[")/7L=)*HF7
M4;*K)D'^$9/J;N89NUO"T3*R8#`8#`8%8_,!<DGN:N0CDI@:MJ/%*("8.OD?
MO)^?%1-N@JTG47BHH))"`%C%Q3[#"=9'\`*=OX_VVN>_;?/#DX*U'81E?,9X
MSV0M$*G=?)%R#5I3:<\:(F%X9-R*29Y-4Q.YNS#J<W8B5/L$V?Y.Y^%TZJ7^
M<VS`8$5^:EM@:IQKV8A87I6K.[Q)-:$1^"]DEY/^8"Y*U(QK-E'LWSM5RM!/
MG9P,5(WB*F90>@$$0UI,[1-KB53EQ_G$G<-):DLL.U=V^BK-XZ3K+BEF^!=$
MT635:#M@0PW>'HGFDX\J`HFD6,>JP60!L=%)1H9-+NXHP<R/6#I#EU/.KQ-R
M$W6=DI!%0<A<Z]),';YP_P#D+1M;K-H\$*I5Y6T3DO84DWJ;-/XT!&Q;9)(Z
M")N]WC;6;<WMTU_DNG72*NF/1KJO6E[K5ZM&P;)>@IMBI4JE%.DXI"L3GY@G
M7U5C%WD>U0C9=S'QEKB3/E$TY)N+R*63\:A5R'34D_CDLORUM_+M99A=_P`:
MJ.IL#D-K,*ZDM'0.KF$;LRU/XN(:L&/Q'<7;(&!HLN^CV;&+E)&)M9"FC':B
M!9!2(3>I]ZG>Y<+ZWN-?NN>O-RN_S@ZF`P,/OM+C-@U24J<NHN@UD18N$7;;
MQBYCI2(DF<U"RC8JQ%$3KQDQ'H."%4*9,XI]IP$HB`V7%R69X41Z_P!=VW7^
MA[?QS5KK%[LFM'M55V!,D<P,:"8I`MX;H^"3[FL<3\DE8R,2[E3!%HQ/PU%W
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M15;<*)KLJSJ/DBQV_I%LIX0315&I6U"U#(J?P@Z'7EE#"3N(`]HAVUGV\Q)G
M8_$??]OKE8C[!NJ+VW*4V#0CVL[:H1*GSLXX18MTY!VZ;5IJM70D9IXV\QC"
MDGVG,!/(5,H=.NN^L^'';7:_*.?%_;,MIC:1*Y/BZ95JQ29*W;(MV10AHF5*
MX,R92PH'.3XSJ*?F\;D>@B+4R@=ICE3[=[ZS:9^6-;B_2[;/.[O_U^SGF;PA
MTCSJUQ$ZWW0G:XY"N6%.S5>X:^G$:Q>JR_49.8B80AIQQ&RZ"<;9H!\NPD&Z
MK99-9!0#E!-PBW71++9TT+RG3)2N<_#>_F#QL-J:PY*<;Y%90I00-9`2UOOF
MA)E5*D02N0AM36LA2J*&`_FZ)D`W<8=:]I?VU(#-N2+FT&2M@Y>>O6`406<1
MD/N'=6SGI"I%5;%=U'BYN"IPRSH>@*-_CR6RB*)*`;M!4A2&*83E$N=_AO3_
M`&_#P>!D2O6^+&O:<L<B@:_G-L:T:&24.JE]LUIN/8%"B2HG.BVZ(DBZZB4A
M2I(ID*`%(FF0"D+=?VQ-_P!U2X>.VL>T=/WSA%HR9-UW;QTX4*D@V:MDC+.'
M"ZIQ`B:**1!,8PCT`H"(Y66OO6Q64)/@1II]:(=)RCO6!O\`O.Q1$RB1\62:
M<G]@73=KIG,I.BJ%?%=QNR016*H`E,G^#H!0`H<G:]I5:3T5J+CEKZ,U7I"A
M06N:#$.9!\SKT"DOX32$JZ.\DI)^]>KNY.6DWJY^JCETNLN8I2D[^PA"E);G
MMMG`8#`8#`8%1-O<1''?V$7:"DT7=5UYS6H-`NM%D7"1TZ;.\I]:IW.J[:KK
M-VD0&$-=KCIF)ID@DV6%,TS]E>+(^1=)P!M:WFQ-IG67PE[FW,P&`P,$V3K6
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M=-M[S&%FJ6K%V6'?%ML09`SD).M_'>*#-L/CIF.*K8%"`4HB(_0<#-L(AGR9
MG9W:=FHW"W5<I.M=A[P=1;_:UAJ2RC:3TYQ=8329=K7^0G$2G+59B[1+%S5*
MLJ;HX7FY+S-RF!BN=+.UQ,?+>D_VO46K:_H-,U71ZGK;7=<C*A1*+`1=6J58
MAD1;QD'`PS1)C&Q[1,QCJ"1!NB4!.<QU5#=3G,8YC&'#3+\!@,!@,#F6]O/K
MZWMKW?4/[9.!*'S=WZX9,W>]M2MXU:6#:%4A84:Y+3S2"35_]:$9&@I_9K'!
M)E(K(Q*8.&@@]3/YY?+>MF/6H)\=-6ZSXV:[WWS;Y`ZK1I/J'YOZJK,A;N(5
MA1LTUL&N[R:[)CPJ52IM39-:^;[-`7>OS,G5)Y=]$H_E-\P5.9-VDD!7_"WG
M$G[HT9QX]MOK&X)[:Y*[\XD\6.3DC=-WQ4+#5&A;$D]14/6M%KL2_!TXK=;=
MTUU;YN`@99^@BX7!5&<6`\>@B50.JJYIF+=;9,U([2OZDKG)O*[+UW6G"/3^
MSGBBJ`Q>N:;>;*VV;)(B=,KE.%CG<K(R]K5(4PF.>.@U`:D_&J7L*8<N4NDG
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M?*>S+;KC!1-LF@O**TUJB*B;&R>(2YY4Q!&&9/@2\294`OQVQ+C;]KAMV`$E
MO?>-2UQ:MRZGE]11FU:EJJ4Y>USCQ3]4TA@TM4E]N&[W.P0U`UQ=[/&,(AH[
MD"%LJY)!=LQ7.F4H$$^1UZF<<KNHKT1>P:W\PM4U'E9<ME<C>*JL\@F^Y"4+
MD7$GDJ]48V*=K5R7:16V'-FMD&[9()H)"R9Q+M(`5,BS?"':OC#/M,<=NYUH
MU19-6S)OY?`T;HM4/.X7=+>%NF5)/S.G2JSIRKV$#N44.=0X_4QA$1'-.3Z,
M!@,!@,!@5O\`,J$7B=D4>Z%02.RG:TK5G`?@,+IW!2KF339*,Q?L@DEG3*=5
M\9%C),D4DEEW)CE2(4.O\=XL<MYS*^CBK;(^HWF3J2YVD=";`9-G->*B>-;Q
MJMFA3._,6/;,:]70$T[&.#?Y6)5V[H62)4E>XY2J-YF2^%TO.%C&<G0P&!3)
M[+=G!>G<1H>%FG,=!1TK'J7"R,(V2:$KMSGH&YM*>L>WJ0LM'-PB)%N@B"+-
M,7:DH_1226*Z0,B';^.<6^7/>S.$'3T+4W*>JP=9W-%1-;W'0_&XL;!,\46Q
MU!Y$3)"6J9BX]N^LCYE5A:QTF+=S*+.CRLE*"HHF(&1`VO+/,SCI\-=USS0U
MLM$1B&SJALJ+.JUBU75Q5=5J?HS>+HJ3FRM*BO5$']4B#LW#Q:./(I12CM%$
MYTBG`Q@4*,SQRQ.Z6SD\J5.*F%==TL\RI`OH&+J?W2U34@1-A:5-,:]C3R:,
M<"+Z`DZ^F[%$B+[Y<L_*X3(V2$[0]PF8O_X4Z`4X^:-K5?G'DM+WZ>9,)J\S
M4^Z(\F5'P,DFL1!N#I-&+9JC6(1-%H*""1$/EE<+_B4744/PVN;].VLQ.DN,
MRI@>=&3$1-H*.H:4CI=LBX4:*N(Q\V?H).D0**S915JJJF1PD!P[B"(&+U#J
M'UP/1P,-F]=:^LT]#6JR42FV"T5PR!J]9)NL0DM/0)FKL'[8T-,/V+B0BS-W
MX`NF*"A.Q;\8=#?7`\;8JOW%2H4QNW5=/;);(.4<=@)';QM<HTQ&V^>E)5,Z
MI%#13H\8VAP%,JH_.EVI3E!(RAR!LO`U]M?5M%W=K6\:BV;7V=HH.Q:U*U.U
MP3Y,IT7T1+M3ME_&<2B=J^;"8%FSA/M6;.4R*IF*H0I@#_.IY^>O/;GJ`Y/U
MO8S*DU3>O&F6M3I]J^=VK1X6_P"OK3$]XN'NHMRUIZBLR:V=I%+>'Y)2L3R*
M9!D8I1NX1538S&.?AUE]ICY7_P##S3'HWYY0&L-RZ@;07$GD<5=!6:U/K/?T
MCI[:-<ML:LBYDHR,JH6-!"SU9=9L"K*2BHX$7#,X`?P.2KMT;/C$8OM,YZ7]
MAI?9<(5)U0.1=X%(G\0C3836+V`R<I"4>B9GJI8URD3_``'+WB`!^S]^;]I\
MZ1S];\;*K>1:3U/:<TM*V.DV>==(LUIR2H:+UO$_<TTQ;'3=INA.W),B@W3.
MY!L<Z('/^(05\A0[:]=..W?:[_7KJ1?4"CO9@51EWE/K+J4%QW><9%Q"LE7P
MK=_4_E^2<W=U^O7KUSSWNX=YU'__T._C`K^]F59E7/%:<VU6&3F0NG%:YT?E
M96&;0OD<2#72LT2=V1`)(%$BKE2WZ7<6:%*FF<BAC2(=HB/X3.N5G/'EF\1+
M1D_$Q<["OF\G#S4<REHF29J`LTD(R2;)/&#YJJ7\*K=VU6(H0P?0Q3`.=7)'
M*WJ,V?.G@<[5274>R"7*2L,S)J$*@@F_U)'V9VLX3,43J"(4TB9.T0[14'J`
MA^S&_P`-:=;,2]?SD\AQ.UM-G=N'XV>:VS<"NW@J&>K)7'<NP;2B9\9518YW
MQ4I<H+&$YNY4##U'KUS6O[8F_P"ZOJYPRUA<:-4T_2'IX[8G*.Y57B]1Y%(2
M`K".MPNEH>YVY(3JI&\NO]5-K!82@3N4,:*`"AU'J#:XBZ3]7U%K53K$)2*M
M6J76F1(VN5&OPU8K\<F(BFPA(".;144R3$?J)&K!HFF'7Z]"YS:9!@,!@,!@
M,!@:9W[H?7O)'5\]JK9,>Y<0TL9G)1,S%/7,1::5;H5P21JE]I-@8*MY.MW*
MHS**3Q@];*$4353[3=R1U$SB7"N'BOO*T2T=$\>N13*>IG+W65-:([*@+7!*
M0;?9[>N.$:O([MU5+()%K%^U[;I---V=S#K*!%N'Q&KM%HJ)$AZ:W/Y9VUQ<
MS]J9>5@P&`P&`P&!`+?W/FL:#VA7JFXUE==IZ[<LY=C?-F:9%+8[G5-]CW*B
M;&C7JCUYH[D85Y*M4C*IJ.G;9<PE,5)LL"2YDJU)E4GS5]N<EM*DW;3FH:I(
MZEJ-PA):LVB[7\C)WN&3JLJV7BI]E5-3Q[_QT'[@R44+]ZLTDQ1+'K&50!%S
MX3E-37Y4F-Y2=V5(&K#$LRT@7M-KVLH2I5059V=EM?TV8:VQG1H`XMX]C+!(
MV^*"Q6*QNFS:':OFZSM$G0462YI/;UR:PKV[>9FG7=R:[DN1=+/X).G2VK(E
M@XT?K@VI6Z]IK,59-C.73E28@%9YJ(.E&;9DG+2[Q11%1R@[!50FUQ*ZX=N;
M4I6D-:77;6Q)0L/3:'`O)^:=_P`(SI9-N!4V<5$ME54/N4_.R*J+&.9D-YGK
M]PBW2`5%"@,MQRYR6V2=O0X':3M]'HMIW=NF)4C.1W)N:;;'VC&.E"+KZZK3
M=)PTU)HMD=-)(B4?J&C.$FCL"@8'5A<RCP3&%U].7?+KUQ.D[L(8#`8#`8#`
MT9R8TJGR+T%MK2(V!*GN]D4B<K,/=#UYC:EZ/8'K0_Y>NL=!R#E@B[F*E-$0
MD&8D<M'"+INFH@X06(18A9<7*J7B-Z@>(OK]F+#R8Y';B+R`W"[;H1DEOKDT
M^KL)5*NF]29Q*:D#&V^9G&D3/2B:2;,)"1EY%\5MT:M5$$SK%6F%NUO$G"`_
MLCU1^G@V(5O.ON2>F>.>YI@!E:WL_AZ5SL9F64(LHFUD+KK_`$3#7&F.4@DF
M8JKK')#2RQRB8'Z8G[A<-3W\<)<Z?_\`HZ^='!S7WKMV/['&_*V=CE8L'U\/
M=4]1;RV+(UV[R=BK*36I[#7G+!*-X-FLWBTT52RZRK-FBL=4RPD6!])<R^V%
M>'KU]#EC;:HY:V[<FF(37?)%K<;M3^&LGO=6,V73JA',XY1M#;%LNOXXTS2;
MB4T@Y\;)W+1<@B51`7J,>H!4/(PMVYF+PW/P`_3Y<D^(W(/5V^)SFE#1#.K;
M"B;9?]9Z@@+G&06P82#1EE6U=DY12<J<>[CY!>249JMG$,=N@Q>./'U$?&=@
MN\LQAT-\K>.7%GDEJN5K?+?7^OKIJ^NMWUB>2E]=!7TJ0BV:&&3LL5?6LC!S
ME!51CTS`XD&,BQ4!N!BG4\?4,K$MG3CX]U?L(H>ZX#2GK4];<G^?-'5:)AHN
MY1.AX^QS3"X/ZHL,#0-.5,\='+KW2LUAA$IR:RS`9-A)NUV1P5459GZYOATU
MF,[5(?U_^F+D+R.G]+;)Y\TN&T1Q<T61H_TSPMA8U"*D;+))BQ._G]L0Y/,Z
M;2%R>Q#9Q9I&=6=VJQ>$&:I&$>BS32N$NV,X[=BY2E(4I"%*0A"@4I2@!2E*
M4.A2E*'0"E*`=``/V97-_6`P&`P&`P&!H3DCK!7:>KY:*C6:3VRPIR6*L-E?
M`4C^3CB*>6%7.N02"TGF"BS10@F(0PJE$X]H#FM-O7;+.TS/M5A7;)\YF!%)
M"492"3OR@^15=1,K\UFH*[==<4"$62E45&Z3KN<-O&Q!=K'LT4UE>\.]<HG-
M2N781[1E&[/KLD+HB3=`+=7B,'$=)J&*[4%S(QPN&B48HDR8*KN5&JKEJ5-,
M7'\%LJW$_*_Q^*Z3?RS]SRZU@1HJX:1]S>*III'\"L`$44@KQ3B;3!TZF'C%
MLS!*);_(7`YO(W34("A`.<A!G]>R^T1JV)RKV?;XULQIL`;7D7+L:0LZ>JO!
M?VO[=>)UW$+%2=)(-$8!PU8LE"][;O=)+K)J)N$S)@!MZ_QR<VY8N]LX5I5J
M#0BHV8;;'[I=<HRNN-NF6=LB6"NNF]BLLY4MH/I=\BG,I0TJTL(*C(G772CW
M;EN[`QC("DAOZ1_5BB8^.;P[;;\$2QUVOE;KU#>E0B3H24?"L7+R79,732FM
M(NP:_7BZQ7?E-4693QBD@]:O!.BX!%#(?Y:9L.U0ES5RHZQY5-7SN28HT-:D
M*GB;U<5I9Z]@6+N*A5XY$++/O)FPV`K9^Y.F]DI,(]PJ5<'!16+>$Y\+-^&/
M`B\1NS87DCR,F[))6N$06>4ZFSKEI\=O*RT76@2LCNO,WCYC5UH,(CQMFPF&
M344[#/!2.W%-?GOO,8CIKKCM<IG)M%3>.RKY!W:!H]5>C5&;NL+VA:TA'QTH
M[EG*4J,6K`QK>98/HQ%.(1%-P\.)#K&^:V`@IE*?R=--9<Y9VMG3P[?:[+=N
M,=X>RCUC%R$?*(PKJ<?R["I15OA(BV0833=%^Z<,XMLXLD5\J"605.W:.Y/R
MH?PD%0[9B:[SP<[:_;0%6NEDU"U2V]4M(;*?TM>N(UZ6B%J\QU7,S$U+SE8C
MJ/&2-;VP]H]O0)$+RK@WRS1BJ#%%9<I3!W."DUMC;$G:3]/-Z;VH7,=A)298
M7;VJ[OI1ZZ:G?QTJ],TV)2U(]FHFC,2%@N.O4YF.U]&0BCIKYW]D)$QH_,2*
MFY.H)TR9VTL_#4N4JU+A6"U<;HWFF4I5S1Y9-K,01S6%O*-%`#XHP9(,L@O/
M.)!0Q4VJ#(BZ[M8Y$T2'4.4HX5CM*@9-5](WVVL2,K=86R#!O%F49O#4ZJ,U
M3KQU50?,R`BX<KNE5'TDL4ROF?+>(JJC9JT[`V/@8_9K96:;%K35KG8NOQ:`
M&[WDJ\1:)',4HF!%`%3`=RY.`?@23`ZAQ^A2B(],LEO1;)VKPY,<@>)^\M87
M+2FQ*`\W9K^[Q;F'GH1]$EBXM4ARB+62CI"6%M,0\W%.@*X8/VJ*;MBZ3370
M.10A3!N?QWY8_LDZ<R_'CUP:AXG;X'D`TV,^L<%69"S+5&I[!KU/")AX6;1?
M1[!E:+`_!XI)2<7$.Q(,G&$@71UR^1(4"&.D;6O\<UN<FW\UVGKZKC=+Q6S-
MZ0LLYT1(N+)1EY)]"2[JEW1(:&A((`W6DH)Y)??CQ2[UFD[2,LT465<E(H43
M$'N#KJW2=V.<UV^(GIIC@NW@Y*.LVUY1G,KL5$GC>GQ15%(KY:*A54!F9-;Q
MFD6Z9B]3-DTB)*"``=0Z?<F;&W\F>-6]?X_FK%LY.C__T>_C`\R:AHNQPTM7
MIQDC)0L[&/X:7CG("9N_BY1JJRD&2X%,4PHNFBYTS``@/:8?K@5'^OE](K\-
MM$0LPZ5>2^NJO(Z7EEG':+L)/15HGM-2#=\<A2`K(-'=$.DX4$`,HL0QA#J(
MYTUZC&_[JS6YO6SCFIP0KR#8KF92G.1EW6.0$C.(ZJ0.B)^HRSY3J'F38*63
M84,W,8![1662`0$>@A-_A=?EKSUON'#G@;Q,6?***R0Z/HR<N9<1%V6:1BDD
M9I)^!OXB<DA*IK$<D.`*$7*<IP`P"&77J)O^[9FYV8[!]B/&:J?A4BM$Z5WS
MR(EB'**I$;;;%:GH/6QN@&`J#A>MW.[BF<X#W%04`O00$<SOW&M>K5K694P&
M`P&`P&`P&!#;FEQIDM_:^A[!K-2"KG)73$\RV%Q[V#+G>,$X>SQSY@XGZ//2
MT4DK)_RXV[7&:U?L33QN&ZK)V#@4%%VK<2%GB]-$:*Y$U_<BEDJ,Q7YG5.\]
M<+IQVW="WA5D2]Z^DE#"1N]*HQ56B[C1)XI07AK)$J.8B6:G*9)4JH*HI=)9
M7.ZV?A(?*R8#`8#`I_\`9YSS2T935]::#Y":QU]R4C;34WEEBK-&&L3^$H$C
M&23Y]X6[FJ6NLM+`Y46C5P;/4A<FBU5%$4Q54;B:MZS/-G#G9MD/=-K3EHV2
M37-/M-@V',2=DN^S=.4#EA$1<E-3DB]D;%8;<]V;<]1:J@4)617.Y.5!)./%
M182@DB'X!-M64O2]CO\`8B4RGPB^SK@)D72E)TS#1&X'S9;HX\,BZ6I;5GH"
MF0LLU*9)P_4=V-W&"<3F2-V"&#./PO,XO^H"_P`PR.KR+?,M1:YFQ:J6G3VO
MK*I:ML[2:M7*#I*-WCO9+P]8A95J07,/6@;Q+@Q4W!$V;M(%,,W;PNEO=\TQ
MP_U)#((P;>NUJ+-&4K5^J==P23JTWBTR*A659UUK*EQH).[);K%(*%3213#^
MT8[ETJFB19<DMQS6)+M337$K9NY[33-_<VEFJ+JKSA;MI_B'!+L)'66G9=,>
MZK6G:TR@9V3=&\JVU-Y$W7D)6H"04.:,:JKI)R1^=MOX=.)Q%H.0,!@,!@,!
M@,!@0+]E?"V.Y[\0]D\?A/",KB^2;VC54[9'T['P%;V=`HNR5J8F5JZFZD31
M8I/W+5P`-GI2HN3'^.L8A2"67%RI'UM^ECXZ#Q[@J[N#<NQT^2JJ2LG9-C:U
M?QBFN(Z5=%(!*U#TZTUHC^>JL,F7M!VLM%R;]?N7$6J9BLTIAKWN>.E37)#]
M.E[`=+LW4=IVJ:JY25ML]3=P%]HTPGKC;$$T(\,NH23J%KM=;B'JSI4I?PD=
M6==ND8`;K(E*8"3#4WGR[2M$-=_7O@M1H2VQDGQNY'3?'Y2H]9J3;[-F=7;"
M3JCRL5NX2SIZLH2U2;%X@TFEVSM4ZIU3F;N5#*`H<=.=QGZ<=_#/E1R>8>[#
M2],YH[8VAR%GN/.RMB<*8RS:S(X5J8W:TRFPZ0R?6YNTAZQ]ZK!)E>0D'[IZ
MW2D@8P:3A?S(11DPS\NED];AZ_L]YKK\YM\<E&&S]FSE$]?'"6V&HD1JRE3:
M,3:.4^]D)*:A:]",#J`\;OGEHFJG+/B3+EF]8T^HQYW1&II)X5-ZIK,2>:MB
M_3J^N-]QXU/8.9&UZHE5]M<CHA-OKJI+(/2N-=:)=OFT]'$`95X_E$'>QGS9
MH_\`$Y67<)13&/%17SK.2%L9WN;ATO96#`8#`8#`8#`8#`@WR(XGO+L^D+[J
M218UR\NS?*EH=^==O"6.0.^@U5)=)ZD#@T'-)M8<IA`B!FSQP4IE/"H=9P?I
MKOCBSAC;3/,[5[;'FK;J)7XVRZ),U)DHE+5V+/(QZ01!G4O7X*,C8^&F6IW,
M'*'7-%G8@#%RL('63*(!Y4P-UF-NJYW,^'TP.XM<2K!T$A,LU!<2%Q82Q4W*
M:PEA-CNU)&"F07[S*`W39MD(\#"3QE4!1,INU'H+%,O,?;OIXQJ)7[LR72O(
MTNUKLE2*2%/G(QRJZKEE*W2\P*0JZZRCE-WU*5$I4CF**9E3(W%3+4EFV0?8
M\LC+T$\E%;>9QK!NG,5>.D+M2+M!,7SARU9SD/''4BY)LH"JQVZBQ"2$<HH8
MZ*@E`?(QCYX.^,/EU=QCY5[6<2;77M!O7'-JU39ED'UC=H(Z?D%5I,RRS6IU
M.V$=S`11^A@<)1<6U2%!DBDZ%7RE(&;OK/EJ:V_"W70G`O5&H)6'O%J%MM7:
M\.X^X,KU,UV)@TXR4581S-V_B(*+`Z7RU3QJ2J;F07D'B"A"J)K%5\BBG+;>
M[<?#I-9$Y\PT8&*7&&J4I#.75PKD/98V#;O)@&LM"L)OP"T:+*+JLFK]!8A7
M9FY3$#M[3&`>WKT'+,_!Q\J_J-MJSW#<<$2RTVF!1*75ZNZHVO:T5TDI6[?>
M'5F086!-=RI]BLSR(2@F<5'.4V,6#1.0DET^TP>`^[IB6Y8FW7#Z(VX7G::,
M#&7&S/+=`W^QU]@XIL1$P$*E#J+3K9ZG+UM\WB"65NZUX=K]X$CUP^!1M&*I
MNB*%%0P:NLUEL[B9MXJ6-;HU5TPWD+/,6*8GI)=N:)9O))LR6E%4%EOF)UZM
MPL!&MG$I,3*K-$/`BDNZ>K-TP3*'0"9SNUV;DD:D=5%/6NS-=7I6.95FN;(O
MYZ8MIZ(,W"L0MCFX:R3L!L\[%!\2"5VF=Y"&0E58U`$!:R"OXWJK%-^O%3.R
M!@4VV)"5Y0;BO;2R;,KU&CJP\DHRF1=G>IMT%B(2;IDPC8N.4=L2G=N2-15?
M."`HL4QBAV'#L*7O/T:S$<?WV\MLHZ"-2(1*)O7&F.V!&%%/Y=UU/>+"[LIC
M%(8"O$*Y+O6TDZ.J4>HHHBDU[@#J3^SD]L];X7UQ.=<J).2LWH+?MHY`<=M>
M>RI#CJ:P)$J%DX;^Q71#2!U:#F!13A8V5H^X+5'QLAK=9_+-`EF$E".E97RK
M%73+V@3MY;6VW-=M9ZR8U1$]:.S=\>F3G]2^,7(>QU.7X[\LFU72);:-="VS
M3,D[M3X]=H.[Z'9S-X]F=O&VA@:"G%5TF9TX\RJK@A@:LS#GJX;N-IF=N\_*
MYF!__]+OXP&!4)PT,D[KO(B:CCE/7+!S@YIR=:433`B*S)'D7?H>:=MU"]2.
M6\C<HJ4<D5`QP."W_1_L%WKTSOW_`(9OQG8H67V#<L[+/B+B<U5H'C70->(F
M$2$@Z/M.<VS=;P];(=P@HM=;C0F*+EQ]`4)7&R0``HF$V=NVI^V?EA/$J':T
MB7Y=:BAOE)U'4?,G:\+2H]9$J+2$K^R*QKOD&M`0HE.<3P<+8=S/VS4!`OA3
M3\)0[$BB.M>F=^Y^&7:E<(1OLWN#9=Q\9Q<N"=,/&-G!2=)DFN=_WC[PI%'6
M_B=]>_F>R^<5#Z"$DU%?]C?I-NUU_;_E:9F5,!@,!@,!@,!@,",O(;A_H'D\
MBP=[3I)#W:O1K^.H^VZE(OZ5N+70OP.H#JC;*K:["SP@M7XE=E:BNK'+.4R&
M7;+%`2B7*"323YB<7&8TO=>H+[RWI-?CR)UCD?QUB*[+7R=AF/:B4NY]#2EE
MA+4ROJ38"BJZIQ;(SF#@98K5@H;XP:FWEFZR\RMY:;WOJ+D#6%K;J"]0UTB6
M3Y6)FV[,SEC8*K.-Q$'-=NE4EF["STNR->G56/E6;1X0H@84^TQ1'<LO3%EG
M<;<PA@,"OKDEZV^._(#^:5N95]IKK>VSVD$W<[TBV\A/6:!5A',`0SZ#@Y2;
M2K\7(2=?@?M;ARR39NS-7"H^;O,)AK4VL_#6NG_3GP@UK"QI+9KI?=%U3[',
MY>=DSM@>K3DH<3J.W(U9C+M:HU9JN%3F(B9JNKV"4%EESE\@B[7RL4JE*UKJ
M"K&AZ35:5K*F1""CI2/K<-"5"N1Z""8G7>+H1S>/CT"D3*)E%3@'TZB8?VCD
M3M&M/E#:=WV!6C\&=?0_(M^P=.F=OW5-V>1I7%G7:C4QFZS5YMV-K5J'9]K2
M=B4HP5/:2ZZ!>X7KA@4"F-F[>&II_P!KA)KC=PM;Z[MP[_W_`&I#>W*J2:R3
M0+ZXCW,=0=0P,L?JMKSCO0G[R20U]546I2HNY-11S9)XWD4D'QTSIM4,7-[;
MZF)TG=A#`8#`8#`8#`8#`8#`8#`TSK+COH_3%LVM>M5:PJ-#M^\K.6Z;=L-<
MC",9+8%J*[F7X3EC6*8?F/AD+%(.!,`%`5WJZ@@)U3F$9J-&[/5[P8W];]=7
M:_\`'ZD)R^N-FV;;Z#>H1;.CPUWOUR/75K3.[4AZLWBV.RW<\[J,8J[5ERN5
MW`M`344,BJNDJPLVL^4^RE*0I2$*4A"%`I2E`"E*4H="E*4.@%*4`Z``?LPC
M^L!@,!@,!@,!@,!@,#\5VZ#I%1NZ01<MUB&36073(LBJF8.AB*)*%,0Y#!^T
M!`0'`U)+\>M#3WR!F-+ZKD%7:*C=RY7H-6%XL@LY%XNB=Z6+*[\2[H144+W]
M#F$1-UZCE]MO-2R7N/3BM)Z:@URNX74NLXET5NFT*ZC:)5V3D&J0%!)M\AM%
MIK>!/L#H3N[0Z?LQ[7S3$\-E)HI(AVHI)I%^@=J9"D#H4`*7Z%``_"4.@?X`
MR*_3`8#`8$?-U[3LM(D:M6JBUA`F+&SG9564LL?(R42VCX(\4U5:(L8Z4A%G
M,@Z<329@-\D"HII#W)G\A1)O77VSEG:V==M':NUC$*.7NXJ%`T^L[,I`R5*F
MHF3F+=_*V=C4&"=MA_M<<XFIL=6KPS.Z.6[)XU:/B1322?H`T=-U4`2NV9<6
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M(K"9DE#NW[-"32047@G*CP0=L7"0E$X`JA_8*;N[:WVF,_JCEM/6YQQ6O-F;
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M](RS&H5B?M#U$ICD,JTK\4[EG"13IHN%"F41:"`"5-00Z_0IA^@A5KP)KSNM
M\,.,K>37(ZFYS3M,O=E<D*!2N+;LJ+2V';5P$%%?)YK+:'1A4Z_Q!'NZ!UZ!
MTG48VYVV9)3GGY)]E%.77[2,.07#Z\5`BPE*(FLW'':]:N$#']W0#$%Y7-^6
M!P`"(]P,C=`_"8<SMW&M?VW\L,X3NRVR@[9W(0I2(;^Y0<C=JQ)2=1*>I#L^
M;U_KYX4W<**@2VNZ#$O.],"D/\CN^IA,8UUZ3?M[>VDDX7EWZY[M\E!B*V]=
MRZE?N>J_RG</L3B7O6V)P0$22.0\?(W'4\*NKW&`"N&;<W3H`F(WZBZ?[3Z6
MRYA3`8#`8#`8#`8#`8#`B%O#@_H?>=J+LI^QN&L=RI1R,2ENW1UUGM3[0<13
M8QCM(FQ358<H1M^@V9SF%&/L;*8CTA,(D1#J/4N?CX1IEM#\[](2Z)M5;$J'
M-*@R3$[-:O<DK%6M`[6I$FU7[HV3C=FZ5T5+TN^U][&=4'K20JC&3(\(FX3?
M*)J*H)ZFUGVGKK?I\+Z^\X:D9)S<N!#ZT114RFD%N/O)/5&Q9=J<2`<1:P>W
M6?'-:30(8W8/B5\XG`>B0D`#C??Z3TGQL_LVZ>2L8@Z>V?US\KX]@BX2327K
MUVX87AW\8YC^1VYA*YRM7GOX"90,*;1L]4-]0*!C=H&>\\)Z?_:/E3W+RMFC
M>:I^N7D8K%N.\(Z5O.T.)-`\OC`W\:1@7/(.9ML0W6,7HF"D<9QT,43HI_B`
MKW^CT_\`M'LM=>>Q3:IA*9'CMQ$K*RB21G,FZL7*';GQTEN]TX;Q,2;4FJZR
M\=)@":/DD+.DF`BH=,1Z)A/:_"S76=\L^@O6II":?LK#R7LFQ.95G9K%=H)<
MAIF.E-61SP%@7%2$X^5")J>BV8$.FF!%7,`]?`5$G>Y.8!,.;SVUG'4PG]#0
ML-7(F-@*]$QD#!0[)O'1$+#,&L7$Q4>T3*BU81L<Q209L639$@$322(4A"@`
M``!A'IX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8&)6VBU2\MV#:T1))(L6\,_C%R.GT<_CW9VZK119E)1;IE(M16;+F34`BI2J
M$'H8!#IEELZ2R7M_*=%KC6GR-&BV0Q,#)QLQ&KI,E#F<@6=3=%DG@NW@NEG$
MBX4>**G66%4YU3=QQ,/7&;G)B8PA=)UJV:@L.O8Y,(.]7J2?RS76U+@UGD8Z
MM\BP9"P=6BU/9!$&FOM=42.FB2D^\(M*NNPJ;)BD^?NFC%]J[YF$UUQ>:DK3
MM1BA.LMB[/EDM@[4;HN2Q\L9HHRJ5`0D&S="0A-7559P\1KC%<$3`O).%'<]
M(%4,1R].V*W:M\--UX#`IA]H_-WE!I[9_&OAIPDK-)<\FN6"-_<UV\[0!!*G
M4J#I$0:1<K1)I)RE!/[<Z*@X42(^2>-D2H$(9HX4=(E*:DG-O2AV]:#]U%^&
M<B_89?\`V&MM>NUC+OV?$&G:+VW77S%LX2=D?2$%J?>5`,Q;$52$X($@W"J!
M2%,"0]1(5,^5OK\2?Y9_QZ]0/`579E6LN_;!R5W+0;M'L'D2OM5S9=,2+`TK
MT59M[_6`@*UL"(7:K+&(\*E,`5$3%5`XE[PS?]>=<SFN=_ELVLXD=)FE?5_Z
M^./[IM*ZGXG:>AY5NB4C.?FH%2_SZ"8G36*HVL6P7EJF4U!.F4P*%<`?Z?VL
MPU;;W4\4DDD$DT$$DT442%2212(5-)),A0*1--,@`0A"%```````,(_3`8'_
MU._C`^&4C&$U&2,/*M4GT7+,7<9),EP$47C!^W4:O&JP%$HBDX;JF(;H(#T'
M`J.X!N)%+B9JFHS+I9Y,ZA_._'^55=]WSP>\>-BVW1YR2(*$(I\\$Z`453&`
M?(8>\#'`P'-TUZC&_P"ZLA>$7N_L-XK5:!ZBXTGJW>^\=A.Q,)4&-9O,0PTK
M180P%_$J^MMEE))Z@`CXP1K;D1`3^/IG?X:UZM8=Z^45Z]Q;I6IY,JJ=FX\3
MVP.-UO(N8BBZMBT9>K!KQ:6462451<%M$="-I=-0AA*HD_(;Z=>@:UZB;_NK
M+]GB:?YB^O*E)H(/"QFU]Z;KE&JR153(PNO.,&U=<)2Q!^HIA'7#>D,4#=.T
M%5TQZ@;M`9O\&G^U6P9AHP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!&OCZS_-RUXWW
M+.&TM*[/L4Q%4F1;B<[.,T?2K!-0^L8V%ZJG2!A:&Y7-I<+`4JSEU/"10PHM
MFJ:`24P&`P*J_;AP`D>=_'1HEK.:=4[DUHN8<;,XYW2/EUX!VUM:*+;[Q4%9
MQJH@[AV=U91Z*:3Q)9`[&6:L71E!10525+K<7Z4;\9^:=4/1V,#.>U'GWQ(Y
M/T/X5.W;K/DOJ0_+;5E-VA%.74%,1JDM/ZEEIF&J\M+Q+H6[>:M32512[DC.
M171,L*-6?4PZ'))+96U=8ITB6V1QSWD=S"1Z;R6BE)#7UH=V)JS(F:PQD0A+
MVJ-@)([_`+UDVJ@`1$IQ1.)R"8!Z3&MSBRN%S9>9AL[B9;K,YK%BU;>DU$KE
MJ&40KKOSN`<++0CHBYX,QEBF,1PFU(U5024((D.U31-U$3=1F\F9M.JNEXQ>
MXEEF&S`8'__5[^,!@5(<;VH5/:_.O5ITQ;GIO,6X7!@AV"FDI"[_`-=:RY`?
M<&Y2G40\;RU;(F"*"F/XW"*IS@54QP#>O59W^+]-A\$X_P#.VY>;O(1P4BB4
MSN"O\;*2L8GD4)1^,=:^WS_B=&$>TBV];_=$E$DP*4!:$[NXX?3-N;6IQKK&
M!Z7;?E/E#["-=%3.FR3Y"4/;\("H]##%[CXZZB<2QDRB1,3-E-AU&?.4P`<H
MF,<O>)BF(36GRSO_`*WZ9'QT8J[&]@/(G8"X?YFXW:/UAQYK8"!5P_.VY7P[
MVVTJ"@=OPCEI\3KL@)=#G.`B<3%*)`--NVIQK/M:+F0P&`P&`P&`P&`P&`P&
M`P(5;4Y`;B?[\7XS\:J1KNPWBJ:O@MO[7O6V[)9(6AT.O76P6>L:VJ[*+IT#
M-3UGNEZD:1-..P5H]M&1T8*ZAUSN$41+CC->K:.8NO=)Q%>BN2[C\B;4&E&O
M6P*GJFK[?W]6]?51M*2D.XV':+9K_5*R](U.X=0SHZ-BM+"OL"D;KE5.0[5Q
MXQC/2/&Q>;NR*WL;;E9K##74M6:9RW]=>D*K+G8S,@I*4#EU.ZDC[[,KOV%I
M1CY"991]Z=*P3I!--HB/B,NB[*`@>+(M'RLF`P&`P&`P&`P&`P&`P,;N5M@*
M!4+5>[4^+&5>E5N<MMDDC)J*ECX"N1;J8F'QDD2G55*TCF:B@E*`F-V]``1P
M(3:EWUROV:IJ[8;_`%AQ\HNJ=KJP-AA=;VO;EI:<BHK5-I(BO!W"49MJ,\HZ
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MA5[_`$6?C+52[K7XBU5.RPSDCR)GZ[/,$).'EXUTG^!=E(,'*:J9@_:4P?L'
M",FP&`P&`P&`P&`P&`P&`P&`P&`P&`P&!\[PZJ31THAV>9-NN='R#T3\I$S&
M3[Q^G0G>`=?\6!&OA.D5#AIQ(1*0Z8)\9-#$`BA>U0O;JRJ@(*%$`$%.O]KK
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MG5"1>.W;QK"Q2(D</W)I`?G>-XX3(+8%"D`$^_Q@*(I",WO4SFM:3NXX34SF
MV8#`_];OXP&!56Y;#4?8[R0A`2[6.VN-7&?;;54@&(0]AJ5KWAJBV`J0ICIJ
M.0@8JL_Q3@D<R8$('D!,?%K3NIMU&Q/5JX:CQ#BXM10GYJKV\.5D/LAL?_\`
M6++8X<GMN25K2F2F_&61=NY(KH!'\*C=PD=/^$9/,M7X_#7BQT8SV2\H(EB8
MCI"Q\5>'=SECMB(`G$6%O?\`EK43,I`Z('4/(2M?A&"R?F,0P-T"]I!+^(=:
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M/HF>`U_/-W5>JO-9UJL3')'UJ[:J=;1FK:X1KM#X82&GQO56,Y<UARY4DW43
MKQRC7NXZQ'@B@#U9GWJ'3&5L&5DP&`P&`P&`P&`P&`P&!ANQJ-";0U[>]:67
MY/Y<V)3;11I_X2PMGGV2VPCZ`E?B.``PH.?@R"GC/T'M/T']V!5"7A=R@LSO
MB;4MG4_B%9DN*6S])3$9RTCY^XLM^W+5>D)-1U$50VK7FD'\?5)^UH)$/+?%
MV(K$`[6661:]JGB3C69SVRWC_P`&;]J&YTFNVVITS96M];[KV5M6E;-F.6W)
M[[Y#$M=AV!:JD_C^)3RJR&A(V^5X]Z5B';UM.H-%T/-(I(D7=J,TA;_[>IKO
M@ILBLZV]>M!G;%13CQ4MNZ9;:3N%DIXQ9F(V;H/D/JB/&@_,JK?[C*-YS;K!
MPX+(DCDB-D7)RG54(FDL,]OET;Q%Y(PA>#FL]NFT9':E]?R28T>[ZWMUYF]B
M[TD*KHNV<=]>/+-29[6]3B=,L2TR\/)6>:,[/;B2,P@BB04VH"<1;.?MF_''
MAM?M/4;UT5NR2E`D9;A]J&W:]O[^%=32Z4M*6/7$+4`<41=_68]R\C%Y:*\S
M@7I8U040(;QG.'8`M[:3+P"W+3)S5%[J2M1MTS3J]R<H%BH$;R7Y"\68@U;W
M'R2E][T"P0&T=&U"5LKIW7F3HD=,04C"JQRQE@7:N`.P3!X,SE9MHK7;/4VG
MM=:Y8U2N49"IU:-C%*C4+)9+C6*\]!,7$E&05LN#*,M-DC$)!=7Q/I!LV=NB
MCY%$DS&$A:RVQ@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6>Z0L9M.;9+3CHI6X
MVL[X%54<KBV;IV,:M*A!G7<@DN+=$DGXA,?L/V%ZCVCTZ8G8Q3C5=Z_>]-U1
M_5H1_!0%="2U]&-7;6.;LG3?7,FZI)9.N+PTY9H64JDD,$*L<[9R+UJX:F*8
MBQP_$-O=(WOD#`K0W1[8.*^C-J[`U/9HW>UF>ZD:N'6V+KK316P-B:XUN6.C
M*E,SQ+3:ZQ&/DDAJD9?H)274;).48LTPT2<G366*GA<5I#4W,OB[MK8]Q@M3
M<AM53+&P6\FTM6W=G8V$;8*-?KE\:-D*KL&H3R\/:X**M<M_FE=C(,FZ@K+)
M)&)YG"`I=>+K+_BQS]=I;,?AJ??VT]>66#MK$A8;2-)D-DV+5%_W7.Q;%K(\
M+>9E3GH:9HL3MMI+QA2ON*O(&05:(IO3+(1KQE+(`51LC+I+ML^U^*U-)>XV
MSZ56<UM7AO#[MW'7ZI8;K;]N;E>T^W%AVKTBU`BK]*P=8&L2DA%,I%:N-58M
MRE&NCI).'+(B2AQ$3=<S[;7NK==9>(N=R!@,!@?_U^_C`8%7&XWD:\]EVLFD
M,\(\DX+@]N,-A-&R:*WV-&P;VT4MJ?[HX*LHJR7L)8.WF:(BFCYDV"Q^JH$+
MXM:]_P"$V_;_`)>KPH,V@>4GL*I2"YV!9"]\?]P-ZR`B1F9*^Z1BJ2_N[)#S
MG(F>TS^HWC-T8B:8*.(<QS=QSF,,V[JS]NK7?'=0)[?OL*NDDJ,E9%N7)==J
MS9/_`,B4J&MM"Z40I]>B2@4B9&=7&POD'8%#J,T=^8PB8PCFM.JSO_K^&X_5
M3,QLKPAUBV2D4G5H@;1N2(VA&G5'[O6-LGW+?9K8E;L;);H^BYME9)A90R+D
M/,H@NDN!E4UDUE,-WM8GA#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`\^7BF,[%2<)*(
MF<1DQ'O8J1;E7<-C+L9!LHT=HE<M54'3<RK=8Q0.F<BA.O4I@$`'`J=HVYH_
MAMOK9.D;W<&<9QNU5IC3<I'/Y!O4VGY0D]D7O95)U+5H&/KK&K.Y'PTO5WQ7
MS9I$OW[R1=QI$Q6<*F,YU>?\1.N?-3>@N8/&NQZSG]NQ>VJX>C52!L-BM+UV
M23C9FMLJG*NH"T,IRHR#!K;8RPU^Q,SQSN*58EDD9`2-C(`LHF0\Q<9QPOSC
MY8',<KZ=LK5FN]A<<+[7;9!;%N#RMMK2VC5Y92)/`M916R0[FIOU(>7;7*.D
M&)&BD2[(W?$7,*7B\IDRC=9+G+.ULQCM4OQJKRNQ+GRVV@Q1L>U*"?EA8K;.
M$KM;92U<3VG8-,:OC=JUN)09RL@K>./N^./MX;QZZ[A!ZR(Z)'2C5$56:#K+
MZZV\;%VVDF=?AO\`G>%'![E5M'7E=N>HZEMU*%K\Y%6NU.T)5CL24@:M6(..
MU];K?L^"7@ME_G1NB+:&?.7<F+EVYC"+&$>X@C;,:W,2;WVF*V&7T?<`5YN5
ME)VL;JML3/#`!8:7;N2N]I^GV1M4UEUZI'6>.>7LSZS15:5<G%DUD'3E!$#&
M+VB4Z@&YNGM5KE;KE?I]?@ZG5(6+K=8K,3'P-=KT&Q;1D-!PD2T28Q<3%1S-
M-%HQCX]D@1)%%,I2)IE`I0``PCVL!@,!@?_0[^,!@4+Z!A.1W%^&M[/87`;D
M-L#8]RO=FL&V^0NMKOQDV0\W;8SS\Q]NO;UO,;_K6T&]:2JXH$B(IS$(GAF0
M$CVS-/L*0^IM).C;7V_VB7'$_7>];-R4V/RIV=JA;0M1L^D*9I2E:ZM=L@K!
MMFP-:CL*[WEO>=A0]*/,TREH@C<U4(V*).3+Y`%W!W`M#J'0&6YN23$QEHYB
MWWCQ!V!NFCRG&K;N^J-M7>.W=ZZGV=Q]BH2UO99UNS8<Y?YG6>U(.T6NL):Y
ML-`?6#[='S+QZG6Y.$;-S&<LW*2K<;-L3&"Z^V+*ROC3K3?<KS+7Y"M^.M^X
MGZPM&K[%"[NBMC;!U/)R6_[8DO54]13Z^KM0;`V?!P5OH$<UDT5[#(O64L>.
M6)'"1=#M\$MS<R+.)BW*W;(A@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#4>R-*4?9C
MMA,RK(D3;(M$6+&[0L;7AMJ$,H1Z5Q`%EIF$F!-"KFD%%?CF()$W/:N3M5*!
MLLMB695=[9]<-_M>Q;#K.I-M5%X=7^PL=LV:+L<M:T;S"['B:8S8OX*(CX"/
M8JGCKIM"D5:TN),LR0$7`2XF8F74:*&U-N;F<%G'%Y:^V;ZQ-LW*7F[)I&6K
M/'N3=PU<A]B4:T35GNVH^1_Y>8P]=;%M"5:L#"Z4M\6C,%X@EJC'#.P)-%B%
M\*BZ#1TQ6S'Z;R3.9[3I8UP3XI!P]T!'ZQE+(PN^P;#;;AM';M\C()C66%SV
M=?I8\G/RS*`C$&D=&QT>Q3:1C0J2"`':1Z2ATR*'.&8:MS4PRHHD445(DF15
M7M\JA4RE44[?H7R'``,?M`?IUZ],(_3`8#`8#`8'_]'OXP&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__]+OXP&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&!X,!9(JSHOW<,JJZ8L)5U$!(>$Y&$BX8D1!XM
M$NC`"4DQ;.U#MC+I"*?R6ZI`$>P1P/>P&`P&`P&`P&`P/__3[^,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,#\EED6R*KAPJDW;MTE%EUUE")(HHI$%1555502D
M323(41,81```.HX$;[US)XH:T%=*[\B].0;UL/:O$FO]<D)Y,>HA]:_%/WTV
M(`("`B#?H`_3-37:]2IF3Y10M/N1]?M:,9)KM^6MCA,0*HA5M<;`7`HB*?3M
M>S-=A(Q<.U3N$4ES@':(#^+H4;_7OX3VB.E@]_/$N/4%&!UIOR?$H_5PM`4.
M&9*`*)3@*!UM@NWQA*J;L,!VZ?02B)1,'01?U['M&F)W]0Y1VY#C6N+]KEC@
MDF8A9S9\17B&6%82K)F.PIEG$J2;?\93@41.?\(E*'X\O]?VGM]-;27ZB:P'
M7(,5Q.AV;?Q%`Z4AN9[)K&6[SB8Y%VVLHDA$A()0`@IF$!`1[AZ@`7^O[/;Z
M8Q)_J']GG,D,3QJH3),"B"Q)&^6&4.<_7J4R:C:$B"I%`OT$!*<1'Z]0_9C^
MN>3V^GCF_40;F+U__MVUC]/_`-Z;5_@_]SQ_7/)[7+[8[]11M!(Z@R_&B@OD
MQ*`(DCK[88LY#]?Q&44<P<P54HE^@`!2"`_7J/[,?U_:VX9`R_4:V)!<32G$
MJ%>M?&8`18;H?1B_E$Q>PXN7&L99,4R@`]2^+J(B'X@Z?5_7]DVS\,L8?J.Z
M\=`QI;B1,LG/E,!$H[=3&30,@!$Q*H9PYU?$*$5%03`)`2,```#W#U$"S^O[
M)<_#8L?^HJX_G44++Z`W$R3`@"B>-EJ5*G.?NZ&*HFZE(<J1`+]0,!CB(_3H
M'[<GI?*Y;/B_U!G"-^)RO:9R,@NP$A[Y*C4-PDH8XB!P2&&VE*JB"/3J(G(3
MJ`AT`1Z@#^O8]HV]!>\7UURQRDD=IVZJ@955,5)[56P7)"$30!4BY@K$%8U!
M274_A%`"B<#AU,4I/QX]-D]HW57?:UZ\K0*01G*6@-O,#02?F)G:Z@``]*8R
M/E&VUV$!`2`4?*!^T4!Z`KV"(9/7;PTWO6N97$:XBD2K\H>/DXX6\78RC]Q:
M^7D0,X,8B":L8%@"0056,00*0Z93&Z?0,F+X&^(2R5VS-OFUR>A;`S[$E/EP
MDHQE6W8N4QD#^=@NNEV+%*(D'KT,`#TR#VL!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@>!:+56:3!O[-<+!#5>NQA"*2$W/R32)BV9552((@N]>JHMR
M'<.%2)IE$W<HH<I"@)A`!#4C5U;=S@"@Q\_KK4I^T0)+-7<!LK9:/G35`%(I
MR5"4UG0W+1/L42>$2LTG\@Y#H0Q&P&DB_P#+>31HU8-6S%BV;LF3)NBT9LVB
M*;9JT:MDRHMVS9NB4B*#=!$@$(0@`4I0````#"/HP&`P&`P&`P&`P/_4[^,!
M@,!@,!@,!@,!@,!@,!@,!@,!@:HVOO73FBX8)_;^RZ=KV-4(<[0;+-LV+^3\
M1BE43A8?R'EYQPF)P$4F:"Z@!U'MZ`(Y9+>H*A=S>]WC[4A=1^F=>W?;LBF5
M0J$Q,'2UU45#B82(JHK2+67M;@I0#R&35BF@F*)2@<!$PDW/X[\UF[3XBJ';
M?NBYK[#4=(U2Q5'3L,OY$B,:%56#R3%L;IV%7L-R"SR*;LH%^JS+X(B(CT*4
M/IFY_'K'.[[(P(4GG]S+62??9N2.]8]XL1="6FCW2:I+=10Q?#X)F<63ID20
M?VID*LB0"E$2AVE$0OZ=?"S-SX2@U_Z0N<-S*V5LD7K;5B"BA!6+=;VVDGJ3
M<0`QU2-=?,;LD=;L_LI'62$3]`.)`ZF!_9K%]:F+3?T],DH"*^P^3K%H/X1<
MQ=,UFXD`-U.;O*A/3EOC13Z)@'031INIC#]``OXI?YO&J^GVD[6?03Q+C2IJ
M6?8V];2Z*F4IR(SU+K\8<_8EY%`:MJ.\D2"94AA*'S1`I#]H]Q@[\Q_9?"^L
M;V@_2WZ^HGM^X:KLUGZ>7K]\VCL-OW^3IV]WY:L->Z>'_H].G7K^+NR>^WD]
M8VI%^J_U_0YBF:<9Z<L)6X-0^ZS%UG2^,!3$#&+-VB0*=Q_"#JL("J/4>IOQ
M&ZSWV\KB>&:L?7;P:CVX-D.*^EU$P.8X&?TR.E%^I_J("ZDR.W0E#]Q1/VE_
M<`8]MO)B>'O1W!#A3%^;XW$WCNK\CQ^3[EJ"B3/3Q=_;X?N\&^^/U\@]WC[>
M_H'=U[2])[;>:8GA]RO"'A@LDHB?B1QF`BJ9TS"EHG5Z"H%.42F%-="KIK(J
M``_0Y#%,4?J`@/UQ[7S58T/KUX-C^WBAHD?_`.75=_\`T/+[;>4Q/#Q9'UK<
M#)1<CASQ5U`FH1(J(%CZX6(0$A3G.`F;1*[)L=414'J<Q!.(=`$>A0`'MMY7
M$85)^I?UW2YG9W?&.II"\3.DM]MLFPH4I"G2\(BT)#W!@1@H!/J!T`3,4WX@
M$#?7'MMY&O)/TH^N%^*0MM&2T,"8'`Y8W;>WU0<"82B4ROW>\RIBBGV_3QB0
M/J/7K].CWV\IB-52OH-X%2()`U)N>#%,JH'-%[&:JF7%0"`0ROWJLS!2BAVB
M).P"`/</<!OITOOLGK&HIK].EQ17*8*[NCD+%G%N8I#34CK>?*5T(F[%C$8Z
M]K8G;E`0ZI`8IAZ#_$#K]'O?"X:;L'Z;6H.E#&K'+6R0Z8JI"0L]IV+LARH%
M0$JR9CQ^Q:J!U5'/XRG[0`A/P"4P_CR_V?1AI.6_3D[OBE4WE)Y/ZY=OFY4E
MFKB4JENJ:R3H5C$6`CF)?6=9`B;4>XBA0$QSCV"4H?CQ[_1A\`>H3V[ZP[S:
MQY8QH(($538I4+DCNVGO0;-R%:-$3(/*U7&3155F/:"9'*B290$GDZ=.Z^VO
MS!]Y=+?J,M7B*E=O5YNC9J*YS.%-MZ/OH"1JHBJ10&6SI=:3>@Z$O\-,K=10
MQ2F(<A0-VFF=#EZ"/*W]0QK(#?FO0MCV+\0BXK>;0E9LXN/C-U#*"`:7")\Y
MS>8IDP0_]*HF!2`;\9#,:>1["7NN]E>OA'^<W`1!NFT%4SX"ZNWUK%4J+045
MGOD4M#FVIM5$60F%0YDQ*F)BG$O:'8;.)Y5E<%^I4A6:_P!OV1P\L]>?M@*1
MY]AVPTDU_+X`4[QB)[7E:69`J<Q>B9W"HE3-W=QOV"]?L2.J_P"HRX02YDD;
M%0^1%/7,H0JJ[NG4B9BTR*+^,%0<0NQ74FH"*7\10/A`(!U`GD'H`O6B2%4]
MX?K3LY4RK[\?51VH0#`RM>K]ILC%Z)"JH520CJ=*PB9T^G;T%U^,_P!"=W4,
MF*),U;V,\#+D=%*#Y>\>P7<'!-NUF]H56K.W"QG!6J:"#2T2,,Y6<++'`$TR
MD$Z@#U*`A]<8O@21JFV-67L$AH^RJ!<@7[?`-4N5=L0+=Y%%">(8B1>`IWD1
M.(=.O4""/[AR#/\``8#`8#`8#`8#`8#`8#`8#`T#?^4O'[6<^%-M&T:ZKL!0
MAE&VKJB$CL7;C],BA$CJ1>I=>L;1LF5(150I!%M%J@!S`4?J(`)<5B".T.1&
MSB%+JK2Q-302YRD#8G)A4C9^9L<3=LK6M$T"?=7&=1*!>U1I9IVA/2&'J!#D
MZ&,.&=531,'&SK&\7^PV+<.QH\YEXVU7U9FI&51PH7M..NJ!$-8VA4`Z21S(
M%?L8_P"_.FG:D_DGPE\@C+>>$,!@,!@,!@,!@,!@?__5[^,!@,!@,!@,!@,!
M@,!@,!@,!@1\Y"<I=&\7:P%GW->8ZME=(N3P=?1`\E;+.LU*`G;5ZNL_)(/A
M\IB)G7,5-FW,H45UDBCW99+>HELCG'Y0>[K=&Q#OZWQSA":6J*@JH!;)5..L
M&S91L;J3R$%9-Y6J@"Z)Q`R;9-\[2.`'2?$'Z9UG\<G;-V\*ZM7<<.7/-:V/
M)ZJ5;86U9&0>"G.[.N,F^4@D5RJ%%<)G8-L=E8+.VX+"<6I'*SPQ>HIHF_9F
MK9JG-7/:(]",0W!I+\D]ON9)Q^!1>EZB0!BP(<@G-XW5XL\<J]?(+=2E430A
MV9R@!@(N/<!BXO\`)XBS7RMYT]P.XB:)*T5UWHBC-I=EV'1LUCCSW:UD<%$I
MCND+'<5IR58*JJE[Q*U402*/T(0I0`H8NVU[JS76=1+G,M&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P/(F*_`V)M\.P0D1.L^BI?BS$:SDVW:NF*2Q?`]172Z+)
M")3!T_$4>@_3`T79.'_$RY"H:V\8./5E45$#'7G=,:YE''D*W^*14KE[7%ET
MUTFWX"'*8#D*``40Z8$?++ZG/71:Q5&4XFZR:BL("?\`+9+!30`0;_&_AEJ$
MY!@B`I_40)V@*G\3^W^++F^1H&Q>AKUIS8]8[4%MJ/U2'I7=N[+<@`)E.!B_
M^MEDLX]%Q,`F_>`E#M$H=0%FC05B_3><&Y7R*0FQ>2M97\)4T$F]SUY*1I%`
M6,H9==M*:L7D5CF2-X^A7B90`I1Z=>[NOM1C2/Z?YS41`-0>P;DOK9)(S@&J
M:":BXMTC-R-6J8&K%RHY1%%N0$U!*4@*I@!0!,`Q[?1.'K)^JCV8TT#C0O<3
MN&>%,OE;IWZ(V`Z1,X5*5NLW.6;VYL0B+1%L0#)="G*53J)4R&$3BS/`]=+B
MO[]:D)4ZC[#>/=O:)O"C\785#C$1=-`:G2\CA\3CW;9A%8JA2#X4G0%,/4YE
M.O4IWZ?`]=%A^H=J)3=\WP8VB9NLFT#Y"4U'B^(BH;NE`^-$:Z*1%V5,.XH^
M%0"G#M1(;KVS@>REOKWYP8+FF>#O$B]@U=&+XJ3M9O5%)-J82))C'FN&[GR;
M<R1C"J8[D4Q,D42@F!^G5P/81YH>XFOA'_F[U(PDX*RC@5_R?RPU8F"R*1BB
M!"@S>W;[4IVJE`#KB<%1`PD+]!`KCRO'E[8^Q'V%1A0)9?3AN1JZ5$QFY*OR
M(H-S:F0*!0[W+R/HK0K-<5!$`2,41$H`8!'KT!C[,3RR)M['.6IFZ!GGJ4Y9
MH.S)$%PBUM&O';9)80_&FBZ569*N$RF_8<R*8B'U[0_9EQ/^QC[9)&^Q+D*J
MW$TQZL.;3%WY#`"$8GJ>6;^$`+V'%TZO<*J"AC"/4GA$```_$/7H$Q]P_P`O
M2)["-].3@W8^KKF^=XMU3:E?M]+Q3$S@P"")7DFZVC\=@V,IT`ZQP$J9>IA`
M>G3(G^7U,N:/-F6^2E&>J/>WRT6RBR1)KD%QBKC14X="IIB_E[^W2_&H8`,"
M955"EZF`A@`<O^5X\O;:<B/9!-)-P8>MZC559RBF"JNP^<%%0)&.'"8"0ZS;
M7NI=AC((L%!$')4UDS&$.B(J`/>5QY./+VVDC[4+$4#JU7@7JA)<"^,'MNW[
MNV18]4!(8SQA'U;2$<Z53==%/&C(%*9,.SR@8?(6<'#U$=$\Z+*<5;YSQA*@
MBY.91>-X\<6-?U(S!)0.X6<?-[UM7(Y1;P*&$I7"K,#F2`.I`4ZJ"1D$?P8U
MF_1,7;NR>1?(E50YCKH;EWI=W%2=B<QCG^=J?7;S7>EW_P"(WX!6K9Q1+U(D
M)"&,4Q<I)ZZU3J[4$$%7U-KBAZQK7D!88#7U1@*;#&7`@)^<\978^.9G7$@=
M!.)!.(?M'",_P&`P&`P&`P&`P&`P&`P/_];OXP&`P&`P&`P&`P&`P&`P&!_P
MQ@*`F,(%*4!,8QA``*`!U$1$?H``&!13SK]PU9U@I,:MXMK1-YOZ'R&$WM%0
MK>4HM0=!W)'1K*(@JTN\XV,`B*P]T2W,!0ZO!%5)+IKIGFLW;PY^Z3KCDSSE
MVZ]2@6MPW%L69.B[LEGFWZKEG"1YU#))/[)8I)4D978-J`"1NF8Z9.A01;)&
M/V)#TS-9],<UT5\2_2YI;4Z<7;N0KAINZ_I)I.#5@R:Z.J()[W%.)"12Z;>0
MNQT.@D\DF";%8AA[F`&`IPY[;V]=-S7RNABXN,A(YG$0L<PB(F.;IM(^,BVC
M=A',6J)>U)LS9-$TFS5ND4.A2$*4I0_8&<VGWX#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8'_U^_C`8#`8#`8#`8#`8#`8#`\'\TUKNLI33\.0:88I;:*LBU2+6NZ':V$
MIIPZJI"Q:0P;U)WWK"0OQS@?KV]1P.7;V0>TZ6W*M,Z/XZ3$C!:C2.ZC+A>F
MO<QF=G>);QJ,8=4`*^AJ*<4NHB`I.I0ANU4$VXF16]'\?\>.=NW.[9XB.?`O
MUL;$Y>R+>YV920U_HA@\`C^X&:@68N)VS@Z+Z%H"#M$[9RLDH@=%Q(JE.S9J
M=2@5PJ0R`/Y-IK^23/X=;FF=(:MX_4>-UWJ2H1=0K$<4IC(L4N]_+/>PI%I>
M?E5A4D9V8<@4/(Y<J**"4"D`0(4A2\+;>W3&&U\@8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`TK
M?MY5S7S=](OX.T3$+#N%&TY-03%@Y:1:K=0$WA/"[DF3Z0.P^HK`V26Z=IB$
M[U2BGFII;\LW:1LJJ6JO7BLP%RJ4LTG:Q:(EA.P,RQ.8[22BI-LF[9.T1.4B
MA2JH*@(E.4IR#U*8H&`0#/7#3(,!@,!@?__0[^,!@,!@,!@,!@,!@,!@,#B;
MY6\LMG6?=_+Z-IEYEXW76Z-DA&6./8."$)::MK-1]4:8BJZ`HN6L>ZK[5('"
M*!R$=(@1);R)D`N>G768UXYCA=KG;%91ZX.)FLN1VV6#S<^PJ'`4.!E&B"&N
MG]_KT+L+:MA4.@9A6X6LGDDK-^7#JKIE>O$DB'7[P:M#BL951LWVLG$Y762W
MEV2P$!!U2#B:S68F/@:]`Q[2)A86):(L(R*C&")&[-@P9MR)H-FK9!,"D(4`
M``#/-WS79Z^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&!Y<S+LH&+>2\BH*;1FF4Q^WM%15110B#=L
MB4QB%.X=.52))E$0[E#@'4.N63-Q#I$O9G-&A:1D4T]Q5VQTROK(@X+:&Q$+
M(P:HF,7L4D&$3W2Y"^,1,/QD'8ATZ``YK^NV9E8]Y+BQE:?(F*N5.<;`U1*5
M*U4Q=,H5RP$?.I%"S'7,+9%S'HLQ:$39`_*9,.Y4QCE()A`G[,>O4O9=N\=,
M--)4MEJB<@KK98]-23,^?.'$FX#RO)9^LLZ>K"(_7O6=N#G-^P.HYKG,LB<8
MN:A=P$Y0T+6\EN3C;:).4:UFDW!>\ZGL*4+8)V%7J^R'\E,V>K?<8:/E2,5*
MU>0?/2BZ,BF+.8231ZD;'[;_`":6W,AKM)K,U:%-;ZU'7RM'$M=HQM&/%&B1
M+`1)^ZJR!GPE!N9_:FC1>O1R/XP\BB[E--`!ZJF('USGZ[>&O:>7TR>Z];PJ
M[$LK8`CX^2D4HAG873"01K"TDX.5)NW"P';!&%1<*'*4CD5`:&.8"@KW"!1>
MM\+[1M7,J8'_T>_C`8#`8#`8#`8#`8#`8&D^26RB:>T#N/9WG^,YIFNK7,Q2
M@&`ACSR40Y2KS<AC`(%4=SJS=(HB`]#'#+)FR);B6N/WB9Z_M_<NI!"2K$1^
M4M:E=F2E]K6U!RA7B^)42O&]>:@!7]PF$^TX>)H'QTU@`CERV[BF'T;;37\N
M.NMV_#J7XH<"-!<2(Q%Q3($+-L19KX9C:5K;M7MK="H0`=-H7HG\6J0RIQ$/
MC,@(=0@$!RJX.0%,X;;7;OIUFLU_*:^9:,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#4F[OA'U\[;
M/G0LTW4_32IK`IXOXK2WPDGVBIU``(*3`PF#_I$`2_OS6O:;=.5SW]<TZG%5
M)CJRARJ3^Y2Z36"9J-%@45;)D**<@[$$NH%,D500)U'_`-(8O^'.EOII]UG6
M>^_U$N/7FI1M'\!Z86?V(_;7`8H+8:N/@;O85E97;,[ATY!LZ*L9$'[Y<ZRJ
M('*F90PJ=`4,8PZQ<R8^&+M,[<_*6.A-QW?=.JY*8N&L:E-54SIXF\F*L*\=
M)MD1<F2"2(R>J/6[QL"!!$K7S(CV]!*H/4"C+,68O)+;+PV]JO46OY6&L;B)
M"%9TI9RY;-G1(=HQE7;PJ?>J1\V40(NV4ZCT`%2"<_3Z?3H(MMK,>362Y\-4
M<EN+-YM^B;A6HO9,A5Z[(QSMK$&7B4I)1KYDC$`PHE?,/(CT'Z$`2"`?OQ-Y
MGKD];,7X4][;Y$*43U?3>J=U;;6LE[J]`LVM&LQ(.7(2LY/5A!W6&X-1?+*O
M'#XYVR/4W>HH83%.81$W4;B:ZV_2R^VW$^76?J.W1%_U5K6\P$N%@A+A0JA9
MHF<!91?[O'SD!'R361,LL(K**/$7(',)_P`?<8>[\77/.ZMAX'__TN_C`8#`
M8#`8#`8#`8#`8&$;$UQ2MLU1[1MB0#6TU"3>0[V5KK]1R6,EE(&88ST8WE$6
MJ[<7\>G+1J"JK543-W()^-8BB1CD-9;.8=LKCXZ/B&#.+BF+.,C(YJ@RCXZ/
M;(LF#!DU3*BV:,V;8B;=JU;HD`A$R%*0A0````#(/LP&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP-.<@-0I;WU!==5FM,U1G=G8LQA[I7BI*3-5L$-*,9ZOSK-NN9-!\1A,QB!U
MVIS$3>-O(@<Q2*&'++BRI9F8KB#Y_P#J%VOJ)W*[2?;RN.^]JTN7<34ZN_U_
M*2%06ADC(3,(4R%>"4E*F4D48JSA<S5Y'`Z.**JB!"`Y6Z>OM^O/)-YKG3UX
M:Z9;W!+CS3(%:ZMD[A:/M[5"-/($15*[D@3!-#PG,!_#U<%[1``*).@@``(#
MG67C[<L?JO'$=&'')U(:*X[MH"4GB/Y)U#)J':L%2*F>N71`$J1$B&`%E#%[
M2]``W3I^_P"HY+,V,RX?KQ:8[R=PNV;=L$SRJP<ML:&84.D.C"C.N8Q-DD=W
M8!C?&50XRCEWV)%$>A2(]>OXA`%LS.%DN%C4M;I=Q4D:D[@DW:CD4F[<LS()
M@]64/]`#PH$5!,I0^H].X0`/\.<Y)G.6[;C&%$?-[B;'S&P=;T&WLJ?'T.T[
M0C9UV14&SL82YR?PXULJV2DF($4)9CI-VJR9C]IE@()2`=10P])9M.F.=;Q>
M5HW%+7\[Q7XW--66C<=DG:]59&X2M,<"FTAI1NQM4\_LC>$/(,EQ4<Q\&\D5
MDVA$_"D1`P$,F;M*8.=US>)EO/'A(KACRJ;<@2[0H<J\1?7[2TG7$)U\V212
M3FJK=$IT:78'*2!P10E7J]4E&SHB:::)E&?E(!05\:>=]?6\=-:6V9K_T^_C
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&,P-RJ]GE+I"0$TRE9775F:TV[L6
MICF7K=H?4ZI[!:0LB!B%*1ZO2[U$2)0*)@^._2'KU$0`,C(JFIT\:A#]2$5#
ML.4W5-3N\:@=!'\"G8/:/[!Z#TP/^@8IA,!3%,)#=IP`0$2&$I3@4P!_9,)#
M@/0?W"`_OP!3%.4IR&*<AR@8IBB!BF*8.I3%,'4#%,`]0$/VX'@RMC:1,G6H
ME5E./5[1,NX-LXB(&6EXV(<,ZY,V=1Y:I./:.&%5B5F<*9NBZ?J((+2#EJU(
M8R[E$A@_"WW2JT&NR=MN,XQK];A3,RRLN_.8K1B:0>,X]D5P*9%#D,X>/T4R
MAV_45"_N'K@?3'6%I)25FC",IMD>K/F;!Z]E8.4BHF0.]A8Z=*ZKLL_;(,+'
M'-FTD1%=RS4600>)K-CF*LBJ0H>X8Q2!U,8I0$Q2@)A`H"8Y@(0O4>GXCG,`
M`'[Q'I@?U@,#2UBW[KBKW'\B2SZ23L)7L<P613BG)FS=>529KLA5>'!-#PJH
M/DSB<HF`I1'KT$.F:FELS\,W:2X^7M;*VY4]4IPRUJ"4!*<7=H-#QK,CP$S,
MB-SKF<%,X0.0@%<EZ=H'$?K],:ZW;HNTUQEDM7N<%;:JSN<8X40@'K=X[3=2
M:?V\46K!PY;.7#HJY@*W13,T.;O,/;XP[NO3)99<?*RRS/PR%H\9R#=)XP=-
MGK1<O>BZ:+I.6ZQ/^LDNB8Z2A?\`&`B&17TX#`8#`8#`8#`8#`_A55)!,ZRR
MA$4DBF.HJJ<J::9"AU,<YSB!2%*`=1$1Z!@>-#6:NV,7H5^=B)O[<L1N_-$R
M#61(T74()R(KJ-%52)JB4!'M$>H=,MEG<267JL!9;TU9(VH*2SM`JV<TJXA`
MBQ@[&D/W1HJJ@X:B[6ATV!1350.'>*OC'I]#"'3+Z[8SCA/:9QGEFLQ<JC7G
MK:-G[/`0C]X@9RT:R\LQC5G2!5/$91`KQ='R@"G4.A>HCT'_``#DDMZBYD[K
M(4E4ETDUD5$UD5DR*I*I'*HDJDH4#IJ)J$$2G3.40$!`1`0'(K\W;QHP;J.W
MSINR:HAW+.7:Z3=ND7KT[E%EC$3('4?VB(8'F1-D@;`R<R-?EH^>9-%UVJSF
M%=H2:(.VR9%5FI%6:BJ:C@A%2_A`1'\0?X<N+.S,O33]&Y':\V%:&M2KQ+`,
MD\3>*H+/8Q!JR,FQ;*NUC"K\Y18O<DD/:`I]1']O3+=+)FLS>6XC9LI?J7"3
MJ%9F;/#1,XZ:(OFT?)OD6*CALX7<-D#HJ.C)(*G57:J%!,#BH/;_`&>@AUF+
M9F3A<R7&>66@(&`#%$#%,`"4P"`@("'4!`0^@@(9%?\`<#&;E<JOKVJS]WNL
MTRKE3J\8YF;!.R)CD8Q46S)Y'3UT=,BARHHD^HB!1'_%@9()BE$H&,4HG-VD
M`1`!.8"F.)2@/]HP$((]`_<`C^[`_P">5/Q^;R$\/9Y?+WE\?C[>[R=_7M[.
MWZ]>O3I@?][B@8""8H',4QBEZAW&*02@8P%_:)2B<`$?W=0_PX&O-1;0K&[-
M4ZNW'3!D"U';VNJ9M"I)S#9-A,_EB]UN*M,(,FP3<.B-)`D9,H`X2*JJ5)41
M*!S?01%XX?W"[1I]G&'/5G<A:&$Q<MAT`9FO0DO*P<-:]53=KJU\C+-+M61V
M-;^Q6VE2,0*KPZ22TF@#=(QU%$P,&P`,4PF`IBF$ANTX`(")#"4IP*8`_LF$
MAP'H/[A`?WX`IBG*4Y#%.0Y0,4Q1`Q3%,'4IBF#J!BF`>H"'[<#^L!@?.[47
M2:N56J'RG*;=91NV`Y$Q<+D3,9%`%%3III^50`+W&,4H=>HB`8%94!RJX_6>
MFMKS8=C1T<X<(2#!W#/2`5\24*]7&;;RY7P%68RJ<F51-=N8J0MA2!+L+V"&
M=O7;XZ<LSYO*O[D5P=U[RU9GV;0=3:)>1<1'O582Z7F"*\D5@#O7,2-)'F0/
M)MTU@,<I%E3)IF#\!0ZYJ^O$VF:DNT_;>&G..G$CF37F]/O]DV91G3>NR:SQ
M36<A7[`W5C:\V>JI1R+B>557(W>G8I%510\;W^&8I5%$S"/9<_&3'S)RM9D[
MNRE]:2NS6GE<7*N>8\JW(F*YV<@Q\Z#MD1%$3$.Y052.0"E^H@7Z#F<8OK\'
MQGY?S8X:,V!J>#MU$ED&=Q?-A?C+R;]-.55$2%63<?'.;Y22:R1NT""4H`/T
M```,3BXLX+BS/RYVO8=L;:M>:51AL*?F64LK<J2A^;73+PP";D]Q8-PE&LBD
M'3N8"5-R)>@G`INH`/:.:VQ->#29VY6>^RJWW2U4OC]IKCQ?:5!;<WEL>H:W
MJB#U82MD%9U147*DFNY4`@E19-#*G,4%#=H="$.<Q2#G-UFU62;6?,3H]7OK
MWM'!>G;1E-I[00VUNS=TW69*^V2+0<MZY'15*:3;>JUN`!XTC73IK'N+/)N#
M+G:-!.+L">+JF*BG+:Y=?\</_]2^OB-Q`U)L_BAQBV7>;+R7G+ML/CSI:\W"
M:_K4YDQGWBTVW6]:G[!*?;8??,?$Q_W"6D%E?`U00;)=_:FF0@%*&YK,3A-M
M]IM9+\I#?T#\>_\`M'DO_OQ<VO\`B%R^NOA/?;R?T#\>_P#M'DO_`+\7-K_B
M%QZZ^#WV\G]`_'O_`+1Y+_[\7-K_`(A<>NO@]]O*C;W/5B0XA?TW?T\[4Y'4
M+^8?\X?S?\CE/R3NOW7\I_RL^P=G\P-K6K[9\'\S/>OQ/!YO,'E[_&GV6:Z^
M&]=K<Y4:_P!5?*3_`&F.0O\`?9LW_2C'K/#63^JOE)_M,<A?[[-F_P"E&/6>
M#)_57RD_VF.0O]]FS?\`2C'K/!D_JKY2?[3'(7^^S9O^E&/6>#)_57RD_P!I
MCD+_`'V;-_THQZSP9/ZJ^4G^TQR%_OLV;_I1CUG@R?U5\I/]ICD+_?9LW_2C
M'K/!D_JKY2?[3'(7^^S9O^E&/6>#)_57RD_VF.0O]]FS?]*,>L\&3^JOE)_M
M,<A?[[-F_P"E&/6>#*5G!W;F[-S\M-$:MV3O[D38:+=KRUA;-")\@MSP1Y*,
M59/5CMRR]<O,1.,!,HB4?(V<HJ!TZ`;H(X]=?"6V2NN?^@?CW_VCR7_WXN;7
M_$+D]=?#G[[>3^@?CW_VCR7_`-^+FU_Q"X]=?![[>3^@?CW_`-H\E_\`?BYM
M?\0N/77P>^WD_H'X]_\`:/)?_?BYM?\`$+CUU\'OMY;*X-T2*U1R%Y9:UJLY
ML>0ID72>,MDBHG8>W-J[?6BIFRJ;V;3SF+F-M7.[3D:E*)0#,%4$'*;<1;E-
MV`;J(XLDO#6;9+>UGN04_P"PN%$E89_F?7([CY4!AN1W-#AGNQQ>6'\MX>/O
M&C*C:N$"O(2@64[:68WD\@Y=:?OT](,'3,&$P:7%5%=R_D'"01K/7+TX[B[L
MUCSBUCLJOZ(U[K37.K=Q2WP+MK.O:1ID/-\<"<-;WJ:L5&>>PIB[OM5F;;=E
MH4HPCAO'5*)BH*/4;).UFB+A`9X:,UWZ]KIK[4FNZ6[TX9E%3WKOT=JCD;!Z
M;E--,KY>N4-!O^N+$[G99383QOK;9SZ"!6R.EUK(L\A9IFHXCUQ5;O?"H,_\
MMUZ@XX[3A-I:IN^\>*^K-AI,-6:>IM!+4&6I*W7N*%KU_OG;EQL5S84A_.+1
M-5GK;0[74Y20<T+[JHXLM9,Q`2QZ;!X09\5\M>X=V76>F^+:C/7M8@+AKG>6
M]=P<A)J/=0!IR5B)WBGS:U=5IJ:GT7"C^ZNV$EMZN1;-`%G2D;&J%11(DS9B
M1(9Y1%U-PPMNXN*4?*5GC!2:+!VW@UQNCW54E7VJ'_\`4SNV"L5?V4GM5R+!
MV^9%G&U22?M&4Y:U8F9>/+4X1>D2;M_D87//?RE'*<.+)'6&>L5<XOU,VB)C
ME'JC=UIXD1J>F(-K>:2VX;IZME(=U6$IYOIF2M.M=^/64\>.D95&&DG,$9XW
M=K+$8*J$S]L&?^O*]W'7DC`7/45#D&3?C%SP@]/:ZG9.LV6&T/L'>.XV%VXY
M4*M+R"SN-C9G5]%64C6TS&`#"OJ)JM8URFR!N)V#V\5<[KEK:&.O:(RNZWR;
MHSIM7:V]Q\@COSVAO",4I];Y28F3<^66(J;R%$0/UZA]!RLLRP.=+GG[#.,.
MA>7=FI-NGK/^<:8K1%K;%QU+G5R,'JU;@+"P*#UPV9-7Z3NO2#-4BC=18@@I
MT[OIG;2_IPY[:;6YC5_(SWF\(]OHU)C6T-S,`A'<TL]=SM"C&S42/$&)&_A"
M/MDH[.*AFI@^J0=.H=>GUZ32>MN6M]+MC"0D%[@^!]FX[1&L*CN]O`WN0A(J
MN2,5=*M;:<U8)211=6)=>S34&TI_QQ**S4PA("/>J!@[B?C%)G?-Z++-,2<K
M$.&"<6PU+9MJHR;:3@+"HX?QC^.?H/HEW!5AHY%>38.FRJK)8KAX=PD90IA`
M?C!]>@9/Y+G:1G28EM?7QAW'L79%PGXNVS2,E%1]=7D&R!8J-9JI/#RL:@W_
M`,J8M6RBB:#914G13N,?N`PB(AUR[ZS63$--K;S7]_SUO_\`43_+;Y$7^6/S
M9]G\/VU+YGPOC>7M^9W]_D[_`/I=,>L]/;Y/:^^/A_')_<FQM;VV$B:A--XN
M.DJRF^5*:(C'ZX/PE))NJL5:1:NR@46Z20`3MZ`("/UZ_1IK-I<PWVLO%9IR
M.N=GA].UFTU2<>PKY_+UY1T]8*E177CY2!E%E$0.D4R904=&1/U+TZ"3\(_X
M9I)=K+%WM]997\ZANE@EN-]BLTS-2+N:BXJ^*!-NW:SB0*:.:/7C5P#@W54I
MV8&*!.@B)0('3&TGO)(:V^EORUYQ)O>P[I9+.2S6J5G86(@&X$:R*B;GLDG\
M@E\1P#@Z?RN\C5DX+T$XE$#_`%`1`.E_DDDF(FEMMS>&8->2\NYW8YUBUJ\?
M*1!K8%8:235XY:2+4K4Y&LM(.0.1ZU?$9+HN%0*0J'5(@!W=>IAGI/7VS\'O
M^K&&Y;WN[7NMYQE7[=)NXYZ^C4Y5$Z,:\?MRLU7;ED0ZHL4W"Y#"LS4^GC'J
M!?I]?IF9K=IF-7:2XKV-@[2IFL&C%W;Y%=D64.Y3CD6T>^?K/%&9$CN"$^*@
MHBB)"KD^JITP'N^@_0>DFMVZ6[2=L#W%MF9IVKXS85(C6$PUF!B5".Y+Y(I1
MT;.,Q<,)-1FW,D*P&5.DD)3+$`JBI?H8.H9K77.V*FVV)F,(J]I3Y`\>K8VL
MCR/0G6C*59S3M3PQ[!G(Q?\`GN$EU?(=)!HQ!-)`ZIQ,5,!35^H``@%L]-YC
MI)??6^59FB/9)PQX]V"\Q.T^0]%A6;V,:.5"PRDO>UT96"6<=6(LZ#%6AX1Z
MHTD51\?8!SF2`G03]I<U_),XQVG\<VYXX:6HGM0X!#R;5N#WD"U955U>;Q-M
MYI[K?;K5J+-^6PN8E=4CN@(K-@>*+HE#R%(=,QP[@`0$,M_9CYP33;WSCAM_
M>W/'B+O+94.OKWD;JB6C4ZU$1C%20M;*L'5<KNWLBXZLK2>'?$62+)$*J442
MG)XQ`Q>I#=&G&O/:?R2YZ6!\I+?77>IZ*SI%FBIN*_,;4C:3K<RUDVQV\-7W
MS0J0/XQXND8!)($,(=3=?H/4/WY_CYMM7^3J1]2*\;)<)'+RSRT;&-V5=L4B
M,G,R"#!LFK6;9+R#7O?/UR)D763B0)]3AWB82_L'IDO'\A)G^-7EIGVP<'N.
MD5=J]LG>\(X.>1824-&T6*L6Q5WDB9%1C,-BNJ9%3,.R530:MC=SITW3'L,7
MN[P`HZ_DF;+%_CEQ<Q$C2?N:X0Z]W,_G95WM5*JI-K`VC95IKY-=%0CTY!8%
M.Q).)R:!1;]2C_D_X5``.G8/=EVYUQ\FO\=FV?A(YCSUXB\P>0[)C3MZU6/C
M;#,0D''(W=1[KEZ$2S;-R.R,R7II`).G[H2+J((HG5.HJH!"@)AZ8GZ=/M-M
M=KMUPMBW[O.0U6^IM2H#>+<2ATT'SUBLV%VS)"`4S"(B$TFZJ2B8R"A3&#QG
M(J0B).@]JGUQIK[9M7;;UQ(E5%*R"\7'+RS5%E*K,6BLDS;+"Y;M'ZB"9W;9
M!P8A!620<"8I3B`=P!USFVC-S=TP^Y!<3][ZDAJM7KE9;;KR>;U"O6=.*&,?
M6YHU,_K9".9M)6,C9'[JV3!J[6%)-LX$BAE4BE%0I9Q8B+<N*<_*S7(7:M/X
MMZH^_P`MQNT7K;CQKG:,#JF?CJ+]L=[0;;;I$=5XZ=EM=5UPM5YZ*16;MWZ4
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MS3?&P-=<D=9[$N^SW;FEV"082C&GT6K3:;"<GC,;;81GUDW;1(S=`#C/VL3X
MCZ0F]#..356_*]9I.L+!R7FKMH:I4Y&&C:S!:NG=0:90D&\57()-O'U4CS;<
M;:72K($41,X<*.>T0<`<]2\X3`PA@,"J3>O!GAYORXWRT["X_P!*L#N[V"14
M5L*4<W:/Y"SP,0A%RM@?F;=HK'?.HH0.8!`KCL!P("LJH<W2=25C/.8PG\MU
M'BCPP=MM>Q$56H)DZD5ZU755W"C",8IN5Y`S,KUTNY4:MU^WH8#=0*4_TZ`&
M;G.V/B1B_MS>ZV'Q0VV3=&IKG+R3-5I,N1DVZK$Z9OELET$B"BFHF("8O:@!
M1Z_V?W@/0<;3%F%UN942*#M*,H;K9#"]R:,<0+X\D%4%5?C`XAV"589G<'.;
MKW*-F\@LLH<?[""`?L`HCF[,],2IHU?:?'^1G#NX1E&)QX1*8(`T.U\:3@B!
M@[BF13!,2'-^[Z_0<Q9MCMJ77/31G+S8/'VV::F8NQ-H!4A8U[\M-]\)=%4$
M2>9%7PN$SD*JW53`Q1Z#VF*`A]0RZZV7GHMEZ[<L?K,V\1A[(N-6RKIL2=V^
M[>\A9?5&NZ=/R*U@+"5_93BP:P8V-FU='>C&_EHEA0E2.4R(E*1B4H"`&ZAS
MO,M]LNW6)-<<1_HAYS'_U>HS@1_\A;A;_P#--XY__$_3LZ3J?AC;]VWY2SRL
MF`P.9']1G_\`X<__`.PG_P#0_+'33Y<R65T,!@,!@,!@,!@,"=/K,_\`EZ\7
MO_A.8_\`[.DL,[=5WY9EQ,!@,#5_&7_Y7_,#_P""SB3_`/G?(W,;=ND_;%A.
M957;9X;VS*66PGIFR/7:UIYYR6/5&MGTIR4?V5M6C/W`P2%A?16_XV+>SB,6
M*17:S9NW;J.`.9-,A!`H.5_3]O#^Q^XO_6?ZT?[B>4G_`!&9.5_3]GV/W%_Z
MS_6C_<3RD_XC,<GZ?L^Q^XO_`%G^M'^XGE)_Q&8Y/T_9]C]Q?^L_UH_W$\I/
M^(S')^G[/L?N+_UG^M'^XGE)_P`1F.3]/V?8_<7_`*S_`%H_W$\I/^(S')^G
M[<J_+G4?N\E_9UR'F=#-=PK;'=NM1EM=]XGM=JZAXSS;E'1VK6\6T;R.Q;H^
MJBGQ8=!HA(MI>:>%4DF[A0I")`5-*<Y;EU]9ET)<!J;[VX8L$',K:O%!]3.K
M(DG'VNJN;ANYFP(!/,U0D-*NM<:T%\D@4"`[=/IA193N,IWC_$->6+Z_&5XF
M5EQH^Y[UZ<L-X\^+AL;1&@KUL:KW+7^L7CZS5V-1"%"?BX,:<XCG$J_-&L32
M+-C6FQE2`JL**"B1CF*!@*7IK9)S6I>%9+OTZ>RUDV6=+<4+J=)`@G.5I8=>
M/W)B@(!T19L;BY=N#_7^RF0QO\67VGDS$2MP\6>2/'T2&W;HO:FKVBS@S1K+
M7&DST/`/W)3F(*,;8G#((*3.)BCT^.X4ZAT$/H(#ES+\J\C5?(?>VC_N1-0;
M?V+KAK-(+M9R,J5MF8>%GFKI($7#6>@VKLD/-MED@`IDW2"Q!``^GT#"69[3
MHU![D>=FF%'Z]=OU1FG,BQ0CW+JSZZJKQ<4&ZYUTQ`8IE#$%7J8"F.8IA,!0
M$>IA,8R_J[2::SJ,B;^Z;F,A>$=AG::@=65*:3L"BZ])EB-G,H58%SK+M&ML
M;)%376`3'(GXR?40*!0Z`%^/7X3^O7.?EXVV?<USJW"Y8/+#<Z/%.XQH[9,U
MZ]KBM(&31=J>7J9.6;S**AVZ@=4Q,40_ZX&#Z9)^GHNFM[C5UT]J7L"V!!-:
MQ:.2UM<0#(C%-K%1,%1:PT2)&M4V;$H$J]5AA,#=!(.G41ZFZG'J<1,*22YG
M:^LQC'#7$?S]YLQ4$ZK,;RGWBQKSU)X@[AFVPK`E'.49%,R+Y-9J1X"1R.TC
MB50!#\0#T'&,W/RN)C&.&U-,^UKGMH=TY7HF_)55M(`S)+1MMK-+NC6628%.
M5HF[<66NR,JD*/D,(*-W*"W4Y_Q_C/W+,]I-9.HFMQF]Z&P-7[&8W7=FEJUM
M`J1I$5G]-G7U#FT7,NFJ@]F5&\FVM\5*/"(.E@!`@1Z9Q/\`VR=.HV\S#/\`
M7)<RIY6OW1<0-Y[*9VN;5V)JZ*,C7H\[>Z4Q69%@W:>`9,Y_R$\MYG;8CQPX
M43[4P450*`BF0YO&#7].N/EC;3:W/PE)RS]P_KKOM8K04;?"]KDX:3?N5XYG
MJ7<T6]%LY:))`5NXLVO8*.'R*IAU*+@O]D!']@9G276W+6^MVQB*^MN?J#XQ
M#1IM)Z3T8O8)(\4^A#;#VS*%9Q;%O\QPO%N8VB5IPX>R+F-`Z!FZKB8:%3.V
M*)VYP,)2VS]7M*LT_3C901MOE/R`WA\UML;:-IEX)\N@X5J#.05A:255J*GP
MU0J,0+*!6<M"JF`BZJ"CGH(]5!$1'+G+4UFO4:^H&IMJ;7D#1.K=:;`V5*D.
MDF>,H%-L=RD"J+F*1$AF5=C9%R4ZQS`!0$O4PB`!D:;I>\%>;D:U5>R/#GE2
MP9-P`R[M[Q[VVU:HE,8I"F5<+U%-),#',``(B'41`,9GE$?[11[K1W96%TI]
MHJ#XPG*5G:*_+5]V8R?3R%*WEFC181)U#J'3Z=?KA7@-'SV/5%=@\=,EQ(*8
MK-'"K944S"`F(*B)R'[#"4.H=>@],H].9L]EL?@&PV&<GA;=_P`;[S+/Y3X_
MDZ=_@^<X7\7?VAU[>G7I@9]J[0>\=WO1CM.:?V;M)V13Q+)T&CV2UD:FZ`8P
MOEX2->-V*9"B`F.L8A"%^IA`/KDS@3$7]1'LD;Q`S:G$O8QF8$$_A0=5)S+]
M`.*?0*^WLBL\)^XO]D&W=V_BZ=H@.3VGE,Q"796H=K:9G1J^W=:WS6%BZ*')
M"W^I3M1DETDA*4[ALTG6+%9TU_B%$%4P.F8IBB!A`0$;G/2I)<6>=?)GC1=*
M8^UU8U[O'0<M$_:-6WI"2N50D5FZR"47$1\.1XWF8D?.1,$"1+EFKY"E`.X.
MI1OQ8S=9;FSE_I(4&0MLM1J;*7Z$CJS>9*JU]_<JY$2"TK%0-I>1+1Q/PT;)
MN&[1>08QDJHJBDL=),RA"`82@(YP1H+D)'\WGDS7C<4[9Q5KM?)&.BVM'D)K
MS;ETF7,R+H!9*UYUKC9]"9,HPC+J"J;E%PJ97ZE.4OX<+,?*/?V/W%_ZS_6C
M_<3RD_XC,G*_I^S['[B_]9_K1_N)Y2?\1F.3]/V?8_<7_K/]:/\`<3RD_P"(
MS')^G[/L?N+_`-9_K1_N)Y2?\1F.3]/V?8_<7_K/]:/]Q/*3_B,QR?I^S['[
MB_\`6?ZT?[B>4G_$9CD_3]J<?=I0?;;9N-FFF$L_TSL:31Y14MY3H?@SJ+DG
M`[LC[:GJ_<B+*;4D9#:6P#)5%I'.':3GP-$%RO5VA@<$(4Y%%RNOKFM;<"=7
M?J:(H84TIL:'K.O/*@=2/YP6""V&\>-"%(!C+EAVMQWVQ511$Q2-E9"+*H?^
MV(``*%<K?1UBZO;[4;4F%3W3+Z_F]C_'*:Q/=7URQU>D@Z$A`.C"QELM-PG1
M;D4`P@JN[`QRB`>,H@(FKFS"6DF\/%2<N[Z_%BH]Y).>WIW?'8ME'2W;W"!>
MOC2'IU$`P**-B\A)72EG2LSFUKV2KV^S3,XRA(H?N"U?"V3CV76B6+9N!CK,
M(DL@#9$>G<#=(G7J(".>F:RS&.7GMN>T8N1;S8V];=4M0ZUV`Q6TGMUJ>22=
M'.*TG57"JI"62NBD0?&OT!T=5J!CI'33[T3!_!\AK..YRO'E.*.U3:>.,>Z3
MXOEAYV0C:G!1,[7+-,$A_P`X/(R")%.+$R<O1?QC.86(B0ATE/"@N0O<*I3D
M#OQF62;1<8O%5]ZDI^V+WL2]?U8P-0IA;E9HEUK-E&S1I`D<];"LQ=HR<X+-
MC$/G,^@N1,6[8SA#PD,0QSB?H&\V92R<8O+T]N\9=K<=EYT=;.7$I7"JJ.QK
MKQ=4SN'1<E%86\:[6%?S1_0_5$IA`"$'M+^$H!EFTLB684#[;?[WYG;8-QVT
M<E>PL24P6*O@N'ZK*I0*2GR3N5)R2;JJF(R!!JL82D*;S`F)0*8>H9SWMV_3
MKG[==)KI/;;'TZC/33Z^^)?'^JJNE*A"7/E_IV:F8Z[;,F&[I1VUB;A*3SRB
M3E-AG#QS$P;&2JB!V8N03/)%?M)!(%Q;>(!Y[:W7$^&IM[\K_P#,*__6Z.^/
ME6]A>D=!Z0TPZX74&PNM1:@UKK!S/M^6E3CD)Q>@TR%JBTPA'J:U>*,$9-2)
M%8J)E53)%.!1.80[AU-L23!=9;;[-O\`YF]@?^PM1_\`?`J'_A;CW^D])_V/
MS-[`_P#86H_^^!4/_"W'O]'I/^Q^9O8'_L+4?_?`J'_A;CW^CTG_`&5>^R/@
M?[$>?G\F?A<<->:M_E-_,3R_*Y%U:X???SW^1>SL\56K7V[[9^31Z]?/YOD!
M_8[/Q6;^8NLFN>57W_+\>R#_`+E:Q_O6KF7WGBM9GD_Y?CV0?]RM8_WK5S'O
M/%,SR?\`+\>R#_N5K'^]:N8]YXIF>3_E^/9!_P!RM8_WK5S'O/%,SR?\OQ[(
M/^Y6L?[UJYCWGBF9Y/\`E^/9!_W*UC_>M7,>\\4S/)_R_'L@_P"Y6L?[UJYC
MWGBF9Y/^7X]D'_<K6/\`>M7,>\\4S/)_R_'L@_[E:Q_O6KF/>>*9GD_Y?CV0
M?]RM8_WK5S'O/%,SRWSQ@],/L:XZ[_U9NY?5&M;:CK>T(6-2MI;JK4*I+E1;
M.6_Q"2IX^4*Q$WR.O>+=7IT_L_7'O/!<68RZ"OS-[`_]A:C_`.^!4/\`PMS/
MO],>D_['YF]@?^PM1_\`?`J'_A;CW^CTG_8_,WL#_P!A:C_[X%0_\+<>_P!'
MI/\`L?F;V!_["U'_`-\"H?\`A;CW^CTG_9MOA[0N0+#;?(C;6]M55_4)]BUO
M1M6JM;A-G1FT%'*>MQVNO,R;V6BX&O),074O+8B2)D3"/88>X?V!+<W*XQ),
MK`\@8#`8#`8#`8#`8#`8#`\Z6B(F?C'T+.Q<=-0\FW4:243+,FTE&2#14.U5
MJ^8/$EFKMNJ7Z&(H0Q3!^T,"KS=WI:]=F\7;J6?:*::TGW9U#JS.F9=]KI,#
M*%`#&)58PRU"(<3AW]WVCO$W41$>INNO:^5S4!+#^F:XON7`&JG(/?4*U[S"
M*-A;Z]LSCQ]B8%*#F-JU23`X*`<1-XN@E,`=`$HB:^]\&6._\LCHO_:=VS__
M``A3_P#\=CWO@R]R#_3,<9FZXFLO(?>LLU\S8P(P;&@5Y?P$.87B8N7]>LZ8
MK+IB4$C^+M2,`B8B@#T![WP9;WK?Z=;U[P94RR;C?-R$@%`Q[)LJ):F5$JPJ
M"90*A2ZJ0!.0?&/8!0[`Z@`&ZFR>],MF?_0)>L[_`%.VW^]_9W^DV/>F:T;L
MS].-P>MC=TKKZV[MU1*G\HLBL;3#7&N-S*',<A7<5:H!U.O$6Y1`I`)+H'$H
M?B,8W4<>],JK-U?IK^451,Z>Z0V]JW<<6B!SHQMB1EM5W!P(B84T6S%R-LJ:
MHE*'0QUIIJ`C]0+TZ]-3>?*Y5FWOU0^Q?72[AO/<1]MR1FQ3F.I1(IAL]!0I
M`,81;KZWD;6DX,8I?PE()CB/0.G40#+[3R9:Q9>OSG>_=)-$.&'*E-581*0[
MW0&U(UJ`E*8X^5[(U9JR;AT+]!44*`CT`/J(!ES/(G5HGT(^P7;[Q!6WTJKZ
M$K9Q*96;VI:8\TBHB!^U8K&I4P]IL?S2A]2$?(QZ2G_MH!]<GM#+H+XK?I^.
M'>CS1UAW,O,\F[PS.5<0M[?\LZS;."IE`!:Z[B7[PTH0#&.!B3$E*-E`$H^`
MAB]<Q=JF5WU2IM0H$"QJM$JE;I58C""G&URI0477(&/3'IU(QAX=JSCVA!Z?
ML33*&91DF!YTK$1,\P<14Y%QTS%NR>-W&RK)M(L'2?\`U'#-XDLW6)_B,40P
M(QVW@GPJO:XO+;Q,XZ33\RPK'DW&G*`E+*G$[E4Q5I9K`H2*Z)UGBBADSJF3
M,J<3B`FZ#ES9\CRZWZ^N#%1DTIFO\0^.C&4;_5L^/J*D/G#0X"`@LS/(0SKX
M;@.G3RI=BG:(AUZ"("S?(EG&1<;"L&L5#QS&)BV*)6[&-C&C=@P9H$Z]J#5F
MU32;MT2]?H4A0*'^#(/NP,#V1JW6VX:J^H^UJ'4=C4^2#_+*W=*_%V.(54`I
MB)N2LI5LY10>M^\1273`JR)^AB&*8`'`J,J?HIXBZXY9ZRY,ZU<V:MUW7MC6
MN1]&2A_S52G=L8MG"M1DX*<EG@6:`:UBQG0E`:N591-9=HDF04$NX@Z]KC"Y
M77YE#`8#`8#`8#`8#`8&*7NO/;;2;?5HR:5K<G8ZQ/0<;8D&C=^O`2$K%NF+
M&;18.P,T?*Q+I<C@J*H"DJ*?:<!*(AEEQ<CG5BN+/)SAQL2[<FN4==U5O+4#
MU^91>O:(9[(M4CK-17Y:RUVEZ;.UABN%8>E#MD#QQW98Q<Z:PH@W^0X)VF_M
MF9PYW3&,1%:KVS4/+79>S;-Q,KLO3KOK^T05M2FF!)B"K\LYFF<@@#$D/,*%
M:.GR:\:FH91)J0A2=Q5!/Y1*.Y>.V++,</#F>1/.""VO3JY8M<I('5MM:C;(
MMY3/(F:K;B::H2:\:O&+.749(BQ$X$*]22;BH8I?)T-UQ_@XYY9GS_\`8O'V
M"!BM45>C3(7HRK>,8-V=>=(.4I%-0A4%!4*!RF726#N*)>OU`!R2>OE<>WC$
M9F2U\Z+KJB)`M?B$;8ZBV;=)K<93[8=RS7$$&WF<`B],0Q2E`W8(EZ!U'H7]
M^N)U.6>[STV=P(X3WC2SB\/[U(5Y?<6Z+$WF[.\@U/)%,#(MS-&<='.E4B*F
M:,TU3@*@]!4,(F$`S%Q,UJW-DG4B:T#Q.VGJ_>DMOK6%ND6<V6EEJ4W&DD2J
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M6$[B=CT82%024515D96]).%*G')'62,5`XKJ$7.3QI^1003'7]F+C'Z3^N2<
M[?J38U[4N5]0Y,6!URXU13:38:=$L;-68PZT3-*66`=N'C<D]"3L=*RT',(M
M7K`Z2P-US*-U!(#A%$RA"9K6^V<=.>TFN/*Q!MSFTWM<QJA8RQ$"^@T_C+I+
M(%8.`^.8.AR`=%--4O7]AB?3K^_K],37%XO)G,YB$CKG*]:<OZEQ_P!1/&=R
M9W=FX<2TH$@DL6BEC/E.B$<.A$Y05E6J*X(I`8JPBCU#\(#CC,U^22^MV2@V
MMO#?^N2N"'GHUK!O`$BCUX_.@5),Y>AC*`9<`_8/[1S4FM3-\HM\;=IP4GSW
MXSA1)A&\;?GKQ+)6,U<,6:"&UT^JTNWOSVQJL@719PQ($%#I_(,``\314)^-
M(HEQ_)CUPUI+GZ?_T._C`8#`8#`8#`8&M=F[GT]I2-B)K<FU]:ZEA[#-MZU`
M2VS;U5Z'&SEC=MW#MK`1#ZU2D4UDIMRU9JJ)M$3G7.FD<P%$"F$`^MQM?5K.
M!J-I=[*H#6L;`F82N4*QN+C74(&[6&S&5)7(&HRZLB6/LDS8#H'!BU9*++NQ
M(8$BFZ#@Q?#WVULJSV9L-=9V6ON[!4FT4]M<$VF8Y>9K+.=0>.81W88Q)R=[
M"MIEM'N%&JCDB9'!$%#)B8"&$`_.H7*H;"K,/=*#:JW>*=8F@/Z_;*A.1=EK
M,XQ%0Z0/8>>A73V+DV@JI&*"B"IR=Q1#KU`<#),!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,#%;O>Z1K*JS-[V1<JKKZD5UNF[L%RN]AB*I5
M8)JLY09HN9FPSSQA$1;=5XY32*==8A3**%*`]Q@`0P^-WYHJ8ID+L>(W5J65
MUY8YZ.JM>OD;L>G/J9/6>8>$CHFN0MH:S*L'*3TI(*E0;,T%U'"ZQ@(0AC"`
M8,7PSYK9ZT^L,S465A@WELKD9!35AK#668.+#`PUH7FVU9EIF%1<'DHN,L3F
MLR2;!==(B3L\>Y*D8XH*@4/DIMVIFQJU&7/7MNK%[I\T5T:&M=-GXJT5J6*Q
M?.8QZ:,G81V^BWY6<DR6;JBDJ?QKI'3-T,4P`&3X#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`PO8&N:!M>JR5&V=2ZQ?Z;,`A]SJ]PA(ZP0;TS58CEJJO&R;=
MRU,NT<IE424[>])0H&*(&`!QT/,U?I[5&DJX-1T_KBDZQK!G:K]6"HM:B*S&
MN'ZP%*J^=-HAJU([>J$(4HJJ]ZG84I>O:4`!FT:/Y<\0:5RTI\;%RE@G=>7^
MIJ/W.OMIU,C96P51>4(V3EH]S'O?\WV.KSI&:(/HUST35,@DJF=%PBDL36NU
MUZ2R7MSZ[7])//"P,7U1A=R<;K?%23A1NTV'*I7^C7:)144.7[DZBXB!G6J)
MBH@4?&U?+CW")>@@`&-TO\N98S-)+F+*..WI@T3HGBG):70G'CO>MG<0=PL'
M)M%@D[N\9LVN+*/:_,5=.5554;5J&6<+-5F!E4QEV#EPFY.4%RE1YS:RS#5F
M<Y:!0]-V^MUWJ*3YE<HX>X:4KKDKO\AZ>@IFI36P3M3"#-K;IF34%.#C5>A3
MND&8//,7N2*9/J58F[_)F)-9/RN-T/Q(XT\8FB[70FE:%K)1XR;QTA+5^&3-
M9)5BU'N0:S%KD3OK-,))G_%T=.U>I_Q#U-]<YVVM/__1[^,!@,!@,!@,!@0`
MYE7ZB:NW!P@O6SK'#5&B0^Y-KMYZR6-8C6!CPFN,FXX>/2DG:I3-T"2,B]2;
M)@IT!154I/J)@#"SJJYYC1M:WS%SM9:52TU3BMR#]G:DSI2,2KDS0Y")K+W@
MU:J[>]R:\BY%BQEJ;$V/D5$3EFK<B1-LFL_,29:$(#Q)56-9_P#>&M(G9O(R
M:3]A>L;#2[&ORJV>?A[P9<.HML>J1U[NBM4W#7]B;FH4X\3^#"0$WHQK)7V-
M7$3EB?,BW7$ID3G`<<>%E7KU4M6L+-R1XMVW4I])Q5'O#+>FDZ$C8XJU0D+I
MGD*XGY60K]>F8)LA"G9UG>=6N0E:-Q`8Z/D6")DDR^(RI+\59QE9,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"F'G18-Z$V9S7?T+;VYJ#%\=O
M6M2>2FJ8+7LFE'5I_OJOW#E_)HN)]J,(^6M;>8CM=Q,?(0:BXQ\BQ$OR6RJB
M;15"-3''Y8;O)CN"MAS4T`PV?L'8475U/6/L[7-KW*BML56)V1M7E+8(F^O/
MB09J.H\I:"^J(>36KD:\BV+#RN4V0QZ*Y?&\DQ^FM>VC2)[]_/'1'(IBTL^R
M=D>QW24ENN5H=94H>O;CKJ_:79UO6>Q]65@KRR3%$!&IUL8]XK(S<]--+;!/
M7)I-=,&9B%^YX:U@=G\E86Q^QC7$W`6F5Y7K::X#\$:Q<$&2\.AM#8]EM?+>
MJQ'("K3#SI&(M5=1W9IL*3.8XMX9PD[;*@(-^AGDX_3X6'>O5G9M*[`Y$<4[
M%IU;1M3B9"J\A=!T<EKB+Q$1FN-JMG=<V)7(BQ5QHWA@/"[NHLS-N&I@3=()
MVYOU*8@E4,2\XN5IV5DP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P-#<J+//TGC
M#R.N=5DW$):*CH;;]GK<RT\8NHF?@-?6&5AY-L"Q%4OD,)%HFJ3N*8O<0.H"
M'TP15O3N56\-'T?:&WX6$Y&;]T2RKW#2JT>/Y45R4T+=9??^\MZQ&F+Y&:YG
M+]J:F[$D==Q,#=X24<.[!#.V2LJ3Q1DA\9=R9M&L2\?*1&PN;F]-<QF^;*_T
M)K6;J_#:L05BY5O8;=LZ21!1]16>V;1'Z'CI+433\[*T?4DPPF%#6`]8+*/G
M/VQOV"0ST!CKGMBSWF]N?5MR]A$GLRD4NRZ]T!R"T+IW2\17;M,)V)Q.[YH_
M&2-U]79U)IIX705Z<M.Z2SDW*)&FI2",Z<Q[&/F$6;9PX>3'3TH3F?<;K/<?
M86Y:YL-,G9;FQ':(=25%M-XAM9WF)E^)NX]QL;6Q=;/TI1[9>*BR>0!XR0@A
MCXE1K8H]-P62<-FY4W@QW^&1\3^=]\W],\;$[_I6L:RKW+;C;:N0VGW=;VI)
M;#FF"&NW&HFMUJ]^CGNM*,QB7#@NXV#F)<L73\BS=JL#@C=8Q4P%F,K+<K+_
MTN_C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`U5O;^7_\`)#<G
M\V?E?RK_`)5;#_F9\+[A\S^7_P"49?\`.?Q/M'^=?E?ESY/C^+_E'?T\?X^W
M`U;R!_I\_I[KG\Z/N'\E?SWQ?^T_%_,OR_S3_/?4O\B?/^7_`/U@^-_-C\N_
M*Z_@\'D^3_`\N%F<_:+?(_\`H._G-LC^</\`,_[E]IU+_4Y^4?YZ?R`^R_)=
M?RI_JB_)/_O3_;_@]WR_O?X/R]X?O?\`F;X^19G#]]M_T*?GOF=_,+^9WR?C
M:@_J>^P?SR_)'\S?@Z5_D7^5/R=_D']37V_\B?EK\K_^M'?\#XO\?NP3/&&<
M1?\`3=Y.//Y\_J._,']6G_O*?U`_SV_,O\_?Z;-H_"^%^=_I^2?Y-?F'Q^#_
M`-7?O'F\W^=?/@YY_#XN/7]$W=P`_DK]]Z?TI;7_`*/OF?GOM_D!X^/'\R/O
>OY@_%]V[OR;V?>/\N[O-\?\`#Y\>"Y_5E8SE9?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWRAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">$ 128,212<span></span></td>
        <td class="nump">$ 73,262<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="nump">12<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">128,224<span></span></td>
        <td class="nump">73,288<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">18,836<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">18,836<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Estimated Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">121,278<span></span></td>
        <td class="nump">54,426<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="nump">12<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">$ 121,290<span></span></td>
        <td class="nump">$ 54,452<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized gains accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized loss accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesAmortizedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Ceregene - Summary of Estimated Fair Value of Consideration Transferred (Detail) (Ceregene, Inc. [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ceregene, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Sangamo shares of common stock</a></td>
        <td class="nump">$ 1,200<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment', window );">Contingent earn-out</a></td>
        <td class="nump">1,510<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
        <td class="nump">$ 2,710<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Acquisition Contingent Consideration Earnout Payment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_BusinessAcquisitionContingentConsiderationEarnoutPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferred1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EISAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) (Dow AgroSciences [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2005</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
        <td class="nump">$ 6,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum sublicense annual fees specific reckoning period</a></td>
        <td class="text">11 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
        <td class="nump">25,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue attributable to research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="nump">4,700,000<span></span></td>
        <td class="nump">4,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">900,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">License agreement terms [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
        <td class="nump">250,000.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
        <td class="nump">$ 3.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual fees related to agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AnnualFeesRelatedToAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fee due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FeeDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InitialResearchTermOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum sublicense annual fees specific reckoning period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One time license fee earned.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_OneTimeLicenseFeeEarned</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalties to be received from sublicensing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>21
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"PL7U]4P(``(<J```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VD]OVC`8!O#[I'V'R->)
M&/^)Z2:@A_TY;I76?0`O>8&()(YLMX-O/R>TU50Q*E2D/A<BB.WWP8??Z9E?
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MF3DD2`X%DD.#Y"A`<AB0'#.0'%<@.3Z"Y!!3E"`HH@H44@6*J0(%58&BJD!A
M5:"X*E!@%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP*15:%(JM"
MD56AR*I09%4HLBH4616*K`I%5H4BJT:15:/(JE%DU2BR:A19-8JL&D56C2*K
M1I%5H\A:H,A:H,A:H,A:H,A:H,A:H,A:H,A:H,A:H,A:H,AJ4&0U*+(:%%D-
MBJP&15:#(JM!D=6@R&I09#4HLLY09)VAR#I[*UECJOD1'S]??Q?C,2_TS$+<
M-Q0NW`TY'/K2Y(WU5/V,/A4B+Q[@W[-/Y4AUP1OO^I"*DY[.OX7'9N2P>]*G
M@\C'FIZZD<<ZAD\34^GR_('/2HXTU#HKJH[,YF.-=/D7``#__P,`4$L#!!0`
M!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N
M'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/
MH&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1
MRF%HT9,9J&7<E.4]AK\>4"T\U<%J"`=[!ZH^^CSYLK<T36]X+^9]8I=.C$">
M$SO+=N5#9@NIS]NHFD++28,5\YS3$<G[(F,#GB;:7$_T_[8X<2)+B=!(X/,\
MWXIS0.OK@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@`
M```A``LABONU`@``5BH``!H`"`%X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<R"B!`$HH``!````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````+R:RVK;
M0!2&]X6^@YA]+,_M3%(B9Q,*V;;I`PA[;)G8DM%,+W[[#FY1'&C_=B'^C4$2
M'ATT_WS?T>7^X<?Q4'V+8]H/?:/T8JFJV*^'S;[?->K+\\>;6U6EW/:;]C#T
ML5'GF-3#ZOV[^T_QT.;RI]3M3ZDJH_2I45W.IP]UG=9=/+9I,9QB7XYLA_'8
MYK(Y[NI3NWYI=[$VRZ74X_48:O5FS.IITZCQ:6-$5<_G4SGUOP<?MMO].CX.
MZZ_'V.<_G*/^/HPOJ8LQET';<1=SHZ9=J;X<,;(H-:OZ+^5H=CD:E>,,N1QG
M8#F!74Y`Y8@EER,6EE/6$C7*<HO*84<')D>SE[G&R_R./%7F#DV59E-'0^H8
MQ[XZ#ET=RTZRA5&V;`A:"$%7E$ZECENBR7*>78Y'Y7BV(CQ4A&<KPD-%")O*
M`JD<9N5.RN=#Z6:G1O#7-@P+.;HPN<)V@D`G:+8Q-3;FK%&9[A%>TS+M^GW;
MH*&B#%M1!BK*L!5EH*(L6U$6*LJR%67A0G=L13FH*,=6E(.*\FQ%>:@H87-'
M('>$366!5&9'!R>'+5`/!1K8B@A0$6SH0.9H]K71\-IHMCXUU*=A^\I`7UEZ
M=&!V+!LZ%E+'L7WEH*\\6Q`>"D+8*TOPRF(WI@8VIHYM+`>-Y=F]CL>]#EL2
M`B41V-D),#MA5DFDKAWCYG,>RWO"ZT<HU[O1DQ1VD&&.V42&0-:SSM/TE`(\
MN(`R-VR9&RASPY:Y@3*W[.A8F!W'EKF#,O=LF7LH<\T&LH9`MFP&6@A!QY:Y
M@S+W;)E[*'-A9T=@=H0M"8&2"+-*(I>/A^*KKRZ;]>47!YC\<@;&EPUBR&$]
MZ_3\3TL!':[9#M?8X>RYLG"R+)O#%@;9L\'G(?@\&WP>@X_,'-C?!'9#$28>
MUV^^!EW]!```__\#`%!+`P04``8`"````"$``XS<DVT%``"?%0``#P```'AL
M+W=O<FMB;V]K+GAM;)28VT[C2!"&[U?:=XA\OQ.?$Q`P`@:T2,L,J[!P:?78
M'=*+#YEV&\@^_98[B?/;;5OD*BDG_;L.7Y6[??;U(TLG;UR6HLC/+>>+;4UX
M'A>)R%_.K7\>;_^86Y-2L3QA:9'S<VO#2^OKQ>^_G;T7\O5G4;Q.2"`OSZV5
M4NO3Z;2,5SQCY9=BS7/Z95G(C"DRY<NT7$O.DG+%N<K2J6O;X31C(K>V"J?R
M,QK%<BEB_JV(JXSG:BLB><H4N5^NQ+JT+LZ6(N5/VX@F;+W^SC+R^R.U)BDK
MU4TB%$_.K8#,XIVW+LAJ?56)E'X]\6S/FEXT03[(2<*7K$K5(X6W5Z=\N;[K
MAO4_ZU0\"?Y>'A;5YN3C6>1)\5[_E5*[:2R/''C7/SV+1*WH=]NVFVM_<O&R
M4ON+)#\%?9U!NH_^G.0ZO'U&(JI4=),KH3;17;[-OBBHA'76[R@RQYK(4T%?
MY%WBU(ZCRC4EL4A%PBA%T15+61[S:%$O+4%BYH&&>X1&],!`!E5TL@<]62AR
MJ*YW&17+Z,>:@XH/OOBCOK15KHL,5"CQ35:"(U06"G,[0V<T%9\,Z9JU\@O.
MS+K._)`O+!?_:>!UL1=5EC&YJ3.S$!#2#&.:=V5NF9#1$TLK'MUS5E92YQ>7
MA^#%27?Y/9.O7+&?*>'!XTH*)6@N'"B;S6"U8W>74]KBURM6$F54!YH4I8X'
M!6CL-!5Q#%#OV;^%C*ZK4A49=3J!)55.7^H)$"%DLQ/4,6"]C']5HB3OB[Q.
MX#67_(7GR-><NO;@B,'I@Z1!)ZG9=-^1V+KF%`*9MQJNA]`L$TJSC8M<O*D!
MI$[?JDB3.O0;NJG:X&)L+,?`\(ZF>\:C1_;1JM@<V74,["[CN*CJ!GQ@&UWV
M.EZZ*"NJX5]X=\3.,;B[R=9IL>$\NJ(T+X6*'FC(X'+$SC&X^[NB0G.9;J);
MD=-T$BR-OC&%%9\C>C1S.R-N4?TL^:^*BA3=O'5*A<RY!G/CG4=EULU>S]@Y
M0N<:T/7W'E6$V@F;Z`31<PWT>GNP1P4!=`T`!UJQ1P>9=`TFQSL2LW."?&X?
MGC@F!UJRQR$DUC6([>_,'AD$UC6`I?FT;]">M4BK:]#:TZ<]&LBK9_"*[=JS
M&)'U#&3'N[95%$36,Y`=ZKNM1X`^[6)@='D&M.--1(@U3>1A><GH]'%_$Y71
M]G$(.HZ-#4#;KD\)19<);11;.R</BTW&YW06\8HG%6T^#X&U"FYPVQ]8M-/!
MFGFMXAOD]L^'G0X^XAP;6]LS,.X7VB4(A[>/M2>CDZ&A4;.]#AGRL6)D?%)G
MZQ'J8%R^`?60/Y=E665KU,&)Y1M,#^D\ZTT\ZB#2OH'T^`C%WG#H='+8E?@&
MT^-*M+:!T4>HR>BD>ER(PFF$'+L5G('UN!+-X$;)1ZS).,HE"N<@A#/-[\%Z
M;`])3=H(!<@U&4=Y1-$<A!#LP`![/$<432/DU$?%9EL:&&@//42-%@D0)#(Z
MH0WI&%,VP.J3<90.#C7'1B(#`^UQC]I-@H,V,-@>5(KKB0W)#EHZ!MD#&XW=
MN0QT'!O)#@RR!X3,)U&`8)/1239N6?93FO;)N]<!X%"(7),QHK.+ICXDW5:*
MCHL1Z#@V.A0:7.L!V3ZO[)^O.<-'HT-'Q0/6H8%UG]#!,_`H1*S)Z$0VKH,X
MAL@U&4<)(8TA-BP9':'6-L\H&D:&[1$:4+=T]L]Z?;2E<S8#'8<.U9!J@^JV
MT.$=PV6LQ)L`H1"A)J,3V/@6%#/D.&0U,RTTL.X].C8<@4<SA(B,CD>#>UE-
M$NI@AF8FU9V39..*[C70<1RD<::IGNI13B_Q8I;&]':Q_JB/CMK;Z?[=ZL7_
M````__\#`%!+`P04``8`"````"$`_=[_A$\$```;#P``&````'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;)1778^K-A!]K]3_@'@/8+X3);FZ@+:]4BM553^>
M"7$2M(`1)IO=?]\Q0\!VFFSV93<PA\.9,V,/7G][KROCC7:\9,W&))9C&K0I
MV+YLCAOS[[]>%K%I\#YO]GG%&KHQ/R@WOVU__FE]8=TK/U':&\#0\(UYZOMV
M9=N\.-$ZYQ9K:0.1`^OJO(?+[FCSMJ/Y?GBHKFS7<4*[SLO&1(95]PP'.QS*
M@F:L.->TZ9&DHU7>@WY^*EM^9:N+9^CJO'L]MXN"U2U0[,JJ[#\&4M.HB]6/
M8\.Z?%=!WN_$SXLK]W!Q0U^71<<X._06T-DH]#;GI;VT@6F[WI>0@;#=Z.AA
M8WXGJXR$IKU=#P;]4](+EWX;_,0NOW3E_K>RH>`VU$E48,?8JX#^V(M;\+!]
M\_3+4($_.F-/#_FYZO]DEU]I>3SU4.X`,A*)K?8?&>4%.`HTEAL(IH)5(`#^
M&G4I6@,<R=^'_Y=RWY\VIA=:0>1X!.#&CO+^I124IE&<><_J?Q%$1BHD<4<2
M']2/<==RXX`$X><L-BH:$LSR/M^N.W8QH&O@G;S-10^2%3!?,T,=4Z[W4H4<
M!<EWP3)P018<ZO.VC<*U_0:6%B,D00BLB`E"5$1Z10C_!&LFW;!![J09G-`U
M>U#3_Z_&5:)X2),8J0*26XBK(M);A!>HD.P6$L431$G#4]-X+%^`H6TD^Z+E
M1#O8E2`$BC@YK-4@_121/4(HXN$U<@T>BQ?@C0G.3,IB1Q./D&CH'9>$DF=#
M<JD<)S&)M=0R.1X2,M,KJF&U/:]:@#756LLF"`E1M1]HO9#*8<\/M8)E<MAW
MG3FL:`Z_HEF`-<U:#R<(N6HFGJ=6(E7B)-23RN0X@2WLCNSH*[(%6.WN6).5
M(`3*//60U@+IIXCL$4+Q7`QN:5=\W-T"K'GNJYXF"$'/O7"I+]U4B9-(:@7<
M"94X=,J='67Y%=D"K,G6^C=!",HF7NS,JPH7I1)WB:^EG2EQW_'G5E3<)K!Y
MRW:+(?3YACX\I26@M40R8OQA@8:Z_"EZMZ>RAQ`U"3&MGNX9@K--V1+U<31B
MT/[`B;UYI:']"L#WXD!;,YD*"(D_.Z!J%T/K>>TXXA3M<T,.TA*"&-2^<,/(
MT4J3:@B72$V-3:\BO"!VY^U7E2^FUO/R<<8I\C5G$W*=@^)3)I[;=O1=CBY"
M+;-,>3BZIUD,K.<UXWB3-2_G6HZ6RR,0+`]=;3FF1$6X;J@A,A7A!5$POT6U
M7,RNY^7CI%/DS[Z,\A&S');JPK%\K:52\<$-&]8,T,J2Z8"[UHL))FE_<KO!
MN:?DH"E(X`PB)(XK-EA&FK^I"G`C7W-!G&(D!B<@\RO0?SRCX"=\3;LC36E5
M<:-@9W'^(.#>=!?/1HDX&PVGFRD`1Y,V/]+?\^Y8-MRHZ`$>=:P(#.[P<(,7
M/6N'+^8=Z^%0,OP\P2&4PK>Y8P'XP%A_O1#'I^E8N_T/``#__P,`4$L#!!0`
M!@`(````(0"V$!RKB@,``!X-```9````>&PO=V]R:W-H965T<R]S:&5E=#4R
M+GAM;)R778^B,!2&[S?9_T"X'SY$1(TZ&45TDMUDL]F/ZPI5FP%*VCK._/L]
MI<H,U:'.WJC`T[?M>\ZAQ\G]2Y%;SYAQ0LNI[3N>;>$RI1DI=U/[]Z_D;FA;
M7*`R0SDM\=1^Q=R^GWW],CE2]L3W&`L+%$H^M?="5&/7Y>D>%X@[M,(E/-E2
M5B`!EVSG\HIAE-6#BMSM>=[`+1`I;:4P9K=HT.V6I#BFZ:'`I5`B#.=(P/KY
MGE3\K%:DM\@5B#T=JKN4%A5(;$A.Q&LM:EM%.G[<E92A30[[?O'[*#UKUQ<7
M\@5)&>5T*QR0<]5"+_<\<D<N*,TF&8$=2-LMAK=3^\$?KR/;G4UJ?_X0?.3O
M?EM\3X\K1K)OI,1@-H1)!F!#Z9-$'S-Y"P:[%Z.3.@`_F)7A+3KDXB<]KC'9
M[05$.X0-R7V-L]<8\Q0,!1FG%TJEE.:P`/BT"B(S`PQ!+_7WD61B/[6#@1-&
M7N`#;FTP%PF1DK:5'KB@Q5\%^2<I)=([B<#W2<3O.;UAZ(>#3Z@$)Q7X/JOX
MSC`,^X-A=/M:^B<5&/'_&QJ<1*!(SB+!K:ZXRN$Z8#$2:#9A]&A!$8"'O$*R
MI/PQ"->1\CX,%<1(#GJ0H^JQ$`4.Z?4\B\+^Q'V&G$A/S%PQH-DPO3:QN"2B
M,&PS\;69-&9YC8G:.LDEHZUF=4D$VD3K2R0:-O.XX&AC*R2=;FL`972]`,ZN
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M-P5F.[S`><ZME!YDK]F#V9J[J@V>^V,X4*'_U.XO_#&<J[+#;1Y`>UJA'?Z.
MV(Z4W,KQ%B0]1_:`3#6XZD+0JC["-U1`8UK_W,/_$`Q'M><`O*54G"_D!,T_
MF]D_````__\#`%!+`P04``8`"````"$`@AW%[G`#``#,"P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6R<5MMNHS`0?5]I_P'Q7L"YD41)JG:K[E;:
ME5:KO3P[8()5P,AVFO;O=X8AA)"&IGU)`CD^<\Z,/9[%]7.>.4]"&ZF*I<N\
MP'5$$:E8%INE^^?W_=74=8SE1<PS58BE^R*,>[WZ_&FQ4_K1I$)8!Q@*LW13
M:\NY[YLH%3DWGBI%`?\D2N?<PJ/>^*;4@L?5HCSS!T$P\7,N"Y<8YOH2#I4D
M,A)W*MKFHK!$HD7&+>@WJ2S-GBV/+J'+N7[<EE>1RDN@6,M,VI>*U'7R:/ZP
M*93FZPQ\/[,1C_;<U<,)?2XCK8Q*K`=T/@D]]3SS9SXPK1:Q!`>8=D>+9.G>
ML/DM"UU_M:@2]%>*G6G]=DRJ=E^UC+_+0D"VH4Y8@;52CPA]B/$5+/9/5M]7
M%?BIG5@D?)O97VKW3<A-:J'<8W"$QN;QRYTP$604:+S!&)DBE8$`^'1RB5L#
M,L*?J^^=C&VZ=(<3;QP&0P9P9RV,O9=(Z3K1UEB5_R,0JZF(9%"3P'=-PB;>
M:#`.IQ>P^*2H,GC'+5\MM-HYL&L@IBDY[D$V!^:],]+1>#UG%3PBR0VR+%W8
M[N#"0'V>5N%XMO"?(*=1C;DE#'PV&-8@?%#32`(9;4FO)WD?&<$8&9..4F[I
M13O,X/4PP_>$03!4K24^G`0-+T4FS*B%F32((X,`:1O$G(_.[J:]45RT=,%=
MD[YP<D@@*2!,6!6`C:?C(#AH/%(`T;H*AG`J^E.-B[H*#KDE!829T!:`\.<$
M3#XB`!=U!0R;%),`PI``!D?LK(+P6$&_=01W(X\ZD0ES0?GQ5F@=N?[("'YK
MXQ'F@LBS]T1&<-?SN..9,'6V,==G]AN#S76YYPK=#7TX2U3H&E3'A@OQ?'#L
M/*V$XWE[>[<SZE?'!R[L^*]!)&+8IP';TOLU4#,[UC#M:B!0G8A9GXA.R[NL
M\3#J:\<BNIVG!M4B^EH/PR;5RD3_]J_0W:UP<K-0WQM57>?<#OQ0R\-+_N00
M=%M.#=I[[RO`A]H>>Z7OA0>;]7$X:GQ]&M[5^&"J.DE`>%)\`M&]<Q!&-PX-
M531SY$)OQ!>19<:)U!8')@8U:]XVP]S-H!K'FC]@EBKY1OS@>B,+XV0B@:6!
M%T)U-$UC]&!564TT:V5ABJI^IC`U"Y@+`@_`B5)V_X#S7C.'K_X#``#__P,`
M4$L#!!0`!@`(````(0"LUY;1=0(``(0&```9````>&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;)156V^;,!1^G[3_8/F]&$("+0I4C:)LE39IFG9Y=HP)5C!&
MMG/IO]\Q3F@N6Y>^!!R^\UV.#V;ZN)<-VG)MA&IS'`4A1KQEJA3M*L<_?RSN
M[C$REK8E;53+<_S"#7XL/GZ8[I1>FYISBX"A-3FNK>TR0@RKN:0F4!UOX4FE
MM*06EGI%3*<Y+?LBV9!1&"9$4M%BSY#I6SA450G&YXIM)&^M)]&\H1;\FUIT
MYL@FV2UTDNKUIKMC2G9`L12-L"\]*4:29<^K5FFZ;"#W/AI3=N3N%U?T4C"M
MC*IL`'3$&[W._$`>"#`5TU)``M=VI'F5XZ<HFZ68%-.^/[\$WYF3>V1JM?ND
M1?E%M!R:#=OD-F"IU-I!GTOW%Q23J^I%OP'?-"IY13>-_:YVG[E8U19V>P*!
M7*ZL?)ESPZ"A0!.,)HZ)J08,P"^2PDT&-(3N^^M.E+;.<9P$DS2,(X"C)3=V
M(1PE1FQCK)*_/2@Z4'F2T8$$K@>2*`G&HTEZ?P,+\8[Z@'-J:3'5:H=@:$#3
M=-2-8)0!LTN60'_^G@PBN9HG5]27`MK`;FR+-!U-R19:R`Z8V34F&A`$Q`<'
MH'KI(/ZO`U=T[B`>#_2]R=DUY-7BF8'XW,#;T1TXQ\#]&CVY5/:8\0DF&;R=
M*0/D-/K;R@X,@W/"FB;AP.LS>\P-RC!VMRL[\'GF>!Q?*'M,V@]#!*?3\/@L
M</(>60>^E+ULM<<D7G82_4,V?8^L`U_*3H8XOL\>X]..TBM9?Y#X]ZRC*_Z5
MZI5H#6IX!6,3!BET2_MCQ"^LZOII7BH+KW]_6\-IS^%E"P,`5TK9X\(=5,/W
MH_@#``#__P,`4$L#!!0`!@`(````(0`B6L`W3@,``'H*```9````>&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;)16VX[:,!!]K]1_B/(.P;D00,!JMZMM5VJE
MJNKEV20.6)O$D6V6W;_OV!-"$I;;"Q!R?,Z<F?'8\[NW(G=>F51<E`N7#$>N
MP\I$I+Q<+]P_OY\&$]=1FI8IS47)%NX[4^[=\O.G^4[(%[5A3#O`4*J%N]&Z
MFGF>2C:LH&HH*E;"FTS(@FIXE&M/59+1U"XJ<L\?C<9>07GI(L-,7L,ALHPG
M[%$DVX*5&DDDRZF&^-6&5VK/5B37T!54OFRK02**"BA6/.?ZW9*Z3I',GM>E
MD'25@^\W$M)DSVT?CN@+GDBA1*:'0.=AH,>>I][4`Z;E/.7@P*3=D2Q;N/=D
M]D`BUUO.;8+^<K93K=^.VHC=5\G3[[QDD&VHDZG`2H@7`WU.S5^PV#M:_60K
M\%,Z*<OH-M>_Q.X;X^N-AG)'X,@8FZ7OCTPED%&@&?HVC$3D$`!\.@4WK0$9
MH6_V>\=3O5FXP7@8Q:.``-Q9,:6?N*%TG62KM"C^(8B8H!H2OR:![YJ$^$-_
M$I%H?)G%PXBLP4>JZ7(NQ<Z!K@%-55'3@V0&S,99>-(91&/6W)M%=BF@%93C
M=1G'P=Q[A10F->8!,;`#&HS?(#P0;R(`U7X$`53HX]SN(S"+NA$$84-O@WQ`
MR,06MJT7=/7.ZQ@P5*OE(AZ/>D*("5N8<8/H.`5(V^EY90->N&"BR5\X:6C1
M(4)B6P`23:+F=4<5JGF]J@%W5>-Q/[&(N<+O^!9E`[Z4:<1<H1S?HFS`7<_!
M4:H1$V*O3S].M)GVK:UTOKP&W!4-^WV%$-3T3VR>Z2V:!MS5#,*#%^PIQ(RQ
MIR;Q(:9.3Q'8H-=[M>BN\%&":TPM?+*926]>G4^R17>%@^A@"1W7(%0.HNC$
MYB6].75!&:=/>_M&_51;1ABW-M>#N)62;JY[`\N,Z,L#DN!4Z@1PZ*':^7YR
MF0D^F![&2U??C)FK^YK@4&KK!E%_@M2@VODD/)7RFT:7.9#[[=TJ9FT903@S
M_9@<F@$]XQ4`3\B"R37[PO)<.8G8FN.=0*F:?_'J\0!7#]^>,<T+./DKNF8_
MJ%SS4CDYRV#I:!B#M,2[`SYH4=DC;"4TG/GVYP;N>`Q.V-$0P)D0>O]@;B?-
MK7'Y'P``__\#`%!+`P04``8`"````"$`WO)F<<X"```O"```&0```'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6R455UOVC`4?9^T_V#YO?D"$HH(55G5K=(F
M3=,^GHWC)%;C.+)-:?_]KFU(2;H">P$"YYYSS[GF>GGS+!KTQ)3FLLUQ'$08
ML9;*@K=5CG_]O+^:8Z0-:0O2R);E^(5I?+/Z^&&YD^I1UXP9!`RMSG%M3+<(
M0TUK)H@.9,=:^*642A`#CZH*=:<8*5R1:,(DBM)0$-YBS[!0EW#(LN24W4FZ
M%:PUGD2QAACH7]>\TP<V02^A$T0];KLK*D4'%!O><//B2#$2=/%0M5*130.^
MG^,IH0=N]_"&7G"JI):E"8`N](V^]7P=7H?`M%H6'!S8V)%B98YOX\4ZCG"X
M6KJ`?G.VTT>?D:[E[K/BQ5?>,D@;YF0GL)'RT4(?"OL5%(=OJN_=!+XK5+"2
M;!OS0^Z^,%[5!L8]`T?6V*)XN6.:0J)`$R0SRT1E`PW`*Q+<'@U(A#R[]QTO
M3)WC21K,LF@2`QQMF#;WW%)B1+?:2/''@^(]E2=)]B3POB>)DR"9S^)9>IXE
M]!TY@W?$D-52R1V"4P.:NB/V#,8+8+;.IN\Z`TNVYM86N5)`:QC'TRK+ILOP
M"2*D>\S:8^`?T&.2'A&">-\!J(X[F,"$_IWMH0-;-.Q@,F[`0^9NL,=ZDZ'>
M:1T+AFD=N<C2J/?ATEA[S/0(D_:(@5.`'#L]K6S!.083?7Y9-NMYO;+'9&X"
M\3Q[;6P@"^,\EK4C/A^P+1K+O]KR\AYS@?%TV,%IXQ9\+G*/N4`Y^Q]E"QY[
M'D?N,:F//)V^$[E=_*-_U?G(;=%8/AM-W&,N,'X][.!TY!9\+G*/N4`9%O'`
M_&EIAQZ['H>^!_F#GDS&H?N][=>:8*IBGUC3:$3EUN[D&&;5?^OOBS7<%XE;
M#/T/L*X[4K%O1%6\U:AA)91&009G7/F%[Q^,[-S>V4@#B]I]K.%B9K`6HP#`
MI93F\&"OE/ZJ7_T%``#__P,`4$L#!!0`!@`(````(0#YBTC&OP(``"L'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)1576^;,!1]G[3_8/F]?`8(
M49*J2=6MTB9-TSZ>'6/`*F!D.TW[[W>-$Q(G6]KE@6`X]_C<<Z\O\]N7MD'/
M3"HNN@4.O0`CUE%1\*Y:X)\_'FZF&"E-NH(THF,+_,H4OEU^_##?"?FD:L8T
M`H9.+7"M=3_S?45KUA+EB9YU\*84LB4:EK+R52\9*8:@MO&C($C]EO`.6X:9
M?`^'*$M.V;V@VY9UVI)(UA`-^E7->W5@:^E[Z%HBG[;]#15M#Q0;WG#].I!B
MU-+98]4)238-Y/T23@@]<`^+"_J64RF4*+4'=+X5>IES[N<^,"WG!8<,C.U(
MLG*![\+9.L7^<C[X\XNSG3JY1ZH6NT^2%U]XQ\!L*),IP$:()P-]+,PC"/8O
MHA^&`GR3J&`EV3;ZN]A]9KRJ-50[@81,7K/B]9XI"H8"C1<EAHF*!@3`%;7<
M=`880EZ&_QTO=+W`<>HE61"'`$<;IO0#-Y08T:W2HOUM0>&>RI)$>Y(8U._?
M1UXT3<(D?9O%MXJ&!.^))LNY%#L$30-[JIZ8%@QGP'S(S.H8<_U7JI"C(;DS
M+`,79*&@/,_++)O._6?PE.XQ*XN!$S%B0A>Q/B!,*4#>J!$R/]<80PW_[OY!
MD@DZE^3NM[J$1"YB?8F(DQ'B:`3O3C5>UV;`"PSDHQ59.AEY!TM7%C,YP:0N
M8GT-X6@#DE-MIL9O^V>"`'>R?Y;EKH*5Q5S3>`WA:(1S<*KQNG\&[/J7!V?2
M+"0;>O$F#O(\<P%K!Q!ED\G17D=8^C_"#-@5%D^/#6,+:S&Y519X21(XO[,^
M@+%F*(_P8XM:F79HV3/=,EFQ-6L:A:C8FH$4PC;C4SLK5S`KA\GBCR]@5O6D
M8E^)K'BG4,-*"`V\##R2=MK9A1;]<*0V0L.4&FYK^"@Q&`&0"$:E$/JP,(=X
M_,PM_P```/__`P!02P,$%``&``@````A`/3[ZF>J`P``J@P``!D```!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&ULE)==;]HP%(;O)^T_1+DOB?-!``%52=5M
MTB9-TSZN36+`:A)'MBGMO]^Q'4(<:*`W+8E?'YYS7N?D,+]_+0OGA7!!6;5P
MT<AW'5)E+*?5=N'^^?UT-W$=(7&5XX)59.&^$>'>+S]_FA\8?Q8[0J0#$2JQ
M<'=2UC//$]F.E%B,6$TJ6-DP7F()EWSKB9H3G.M-9>$%OC_V2DPKUT28\5MB
ML,V&9N219?N25-($X:3`$OC%CM;B&*W,;@E78OZ\K^\R5M808DT+*M]T4-<I
ML]FW;<4X7A>0]RN*<':,K2_.PI<TXTRPC1Q!.,^`GN<\]:8>1%K.<PH9J+([
MG&P6[@.:I2AVO>5<%^@O)0?1^>R('3M\X33_3BL"U0:?E`-KQIZ5]%NN;L%F
M[VSWDW;@)W=RLL'[0OYBAZ^$;G<2[(XA(Y78+'][)"*#BD*84:`Q,E8``/QU
M2JJ.!E0$O^K_!YK+W<(-QZ,X\4,$<F=-A'RB*J3K9'LA6?G/B)"":H,$39`0
MZ)OU8!1,8A2/KT?Q#)%.\!%+O)QS=G#@U,!WBAJK,XAF$%EE%KV;&="H/0]J
MD]X*:@%VO"R3B3_W7J"$6:-9&0T\`:TFL!7IN2*,6XD'?"TDI-Z'#,'$R^4_
M0JI--F08M>%U'BLCF>@RJ\32S@T+`"KS<0"U"9SN5""9H!Z!T40=S=A6I$,*
MBQ&"=!F'BZ/$"Q?2;=U))CU_5D:3:'^C:9#TP*SE:/J.=7"6NE3J?%VW3FVR
MZ<).?..=T8PUW5T8![W*IM9Z,(U/V5E5&]M\PU538ILKF81V659&8[A0Y/?M
MM);CZ+3;HDH^0J7$?:K^23<:L*SUNP\VI+#8U$NMUS&N.ZHV77L6C&:(<4AA
M,4YMQF%7E;A?O]-I,:?-:(RK8>!/;-/3[C*<M5,OM*@0]*QNZ8:QM+K/=7K*
M#%<C&BK:H,3FN_`RN&XM,GU\N,\UHD%.$^>RQ.94;;IS!*_4T33UX5Z'C"C2
M[20>GQY+7>;46HZFT]9^FTOUZMNY3&>WN7I/Y0H-M?^&;4AB\T%MNWRW-6.D
M=EU[=AO19?,:3A/GLL3F[+TTKOA[_K8X?Y>I:0V2,"\S!"-3ZV`#9ZW[T6G=
MD)G1T$Q.)>%;DI*B$$[&]FKL"^#8M'?-2+I",Q@O8'[KW4]A5-7WO78!)L4:
M;\D/S+>T$DY!-A#2'R6`Q,VL:2XDJ_4\LV829D3]<0>_"0@,+OX(Q!O&Y/%"
M3;/MKXSE?P```/__`P!02P,$%``&``@````A`%O'%G5]`P``3@P``!D```!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&ULG)==;YLP%(;O)^T_(.[+9P@)2E(U
M(6R5-FF:]G'M@`E6`2/;:=I_OV,<:"`)M+LIP3Q^\7G/,3Y=W+\4N?:,&2>T
M7.JV8>D:+F.:D'*_U'__BNYFNL8%*A.4TQ(O]5?,]?O5YT^+(V5//,-8:*!0
M\J6>"5$%ILGC#!>(&[3")3Q)*2N0@%NV-WG%,$KJ245N.I8U-0M$2ETI!.P]
M&C1-28Q#&A\*7`HEPG".!*R?9Z3BC5H1OT>N0.SI4-W%M*A`8D=R(EYK45TK
MXN!Q7U*&=CG$_6)/4-QHUS<7\@6)&>4T%0;(F6JAES'/S;D)2JM%0B`":;O&
M<+K4'^P@FNGF:E'[\X?@(S_[K?&,'K\PDGPC)0:S(4TR`3M*GR3ZF,@AF&Q>
MS([J!/Q@6H)3=,C%3WK\BLD^$Y!M#P*2<07):XAY#(:"C.%X4BFF.2P`_FH%
MD94!AJ"7^GHDB<B6NCLU/-]R;<"U'>8B(E)2U^(#%[3XJR#[)*5$G),(7$\B
MMO-A$?<D`M=&Q#9FGC>9SOSW+V5R4H$9C8IC.#//]J8?"&AZ4H%KJS+FAJF<
MK1,5(H%6"T:/&A0_>,<K)+>2'8!@DR'E9YNS6RF#7$F1!ZE2:T$V.)39\\J?
MS!;F,]1&?&+6BH&=W3+368_9-(PL!2D<-@-OD^RN[+8AFBF1&JAKP(0@VT@A
M_^>17J_!)B`)]P)RK>Z;UY?,?-Y%-I>(/^DQX27C>EV9[27B]YR+KB#>VX([
M1D`-GQLA4^["UAXV1$Y:ZO"6-GN^UTO%6C%0Y"TS[0:R&27"46([2D1#1,<)
M6&K?B<G-SU-3&G(2.'8>Y=SIQKE6S)`3HT0X2FQ'B6B(Z#@!49\[,5P+$N[5
M@NOW'%`,O/]F+8P2X2BQ'24B17CU-\F=6\Y;S7;BAT_?>?SOVQ-R4L\'KU\)
MBAGR01&^6F'7Q7!T]G:4B(:(C@?^_W@@)_4]<+M1K!4SJ2.TC-Z7:],\O5DI
MX2BQ'26B(:+C@FP]SP[$X9T@X5[TD_Y.4,Q0!8P2H2+FUQW<=I_V#@_H[^0:
MK[]?1:[Z-]46%)CM\0;G.==B>I"]F0-O;4=5V[BV`SBJX<3MC8=V`.<QC)OM
M`VCG*K3'WQ';DY)K.4Y!TC)DT\140ZAN!*WJ\W9'!31R]<\,^G8,38!E`)Q2
M*IH;^8+V/X'5/P```/__`P!02P,$%``&``@````A`)9QABB<`P``A@T``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-3`N>&ULG)==CZ,V%(;O*_4_(.X7<,)'
M$B59;0+3KM1*5=6/:P><Q!K`R'8F,_^^QSBPV.S"3.=B$O#C%[_G'.R3[>?7
MJG1>"!>4U3L7>8'KD#IG!:TO._?OOYX^K5Q'2%P7N&0UV;EO1+B?]S__M+TS
M_BRNA$@'%&JQ<Z]2-AO?%_F55%AXK"$UC)P9K["$2W[Q1<,)+MI)5>DO@B#V
M*TQK5RML^'LTV/E,<Y*R_%:16FH13DHL8?WB2AO1J57Y>^0JS)]OS:><50U(
MG&A)Y5LKZCI5OOEZJ1G'IQ)\OZ(0YYUV>S&2KVC.F6!GZ8&<KQ<Z]KSVUSXH
M[;<%!0<J[`XGYYW[!6TRA%Q_OVT#]`\E=S'X[H@KN__":?$;K0E$&_*D,G!B
M[%FA7PMU"R;[H]E/;0;^X$Y!SOA6RC_9_5="+U<)Z8[`D3*V*=Y2(G*(*,AX
MBT@IY:R$!<!_IZ*J-"`B^+7]O--"7G?N,O:B)%@BP)T3$?*)*DG7R6]"LNI?
M#;6.>I'%0P0^'R(H\L)%E*P^HK)\J,!S.Y6%MUA%*(KGU^)K7VV84BSQ?LO9
MW8':@Y6+!JM*1AM0[N*CW?01^U'`(%)*Y(M2:;4@%@*R_+)/0K3U7R`S^8,Y
MC)EXM3*9HV;@Y>MU+)6T(U2JU*.SP0T?//7&(-A#8]]/>+=^!5OK7P;FV@[?
M8<*%R1S'C$6D8V(9F2+9&$F^Q<GP""7Q?H\*WKD@WL<V1DOST0?-A$/&)(ZS
M1#I+9%.$X0\6,O2GBC/\X<O;Y5)-@M=TZ&%M9>&@F2F?LT0Z2V13A.$3/`U]
M3M>J@LT\)J&=1\VLVS<1>=;H48].N$]GB6R*,+S%'_&F8,O;,C$K\*"9J/46
M!G%LN]/C4^YFB6R*,-PE'W&G8-M=:+G3S'#U26@QQS$3FRKI+)%-$89#U0E9
M!\02CN'I&E63+*>AM<T=-#-T:KDX:N*1:80B^RR85<BF",/E^O^X5)-LEY:'
M@V:F7,X2:4>H<W7A65'(NM'!OMY7@^$10=H^GLIVEN4RL%T^H"F;\TC:(\HH
M\E!@_-F^WTN;,5#MPJ"<I\L8.M-QANW]Z`%->M<Z$TCZ4.FV[#GO6K"COQUO
MVJQNAW6?5Q%^(4=2EL+)V4VUN@BVSOZN;L./J@UO&^E^`+K@!E_([YA?:"V<
MDIQA:N`EL/%SW4?K"\F:MG,Z,0G];_OU"K]W"/1F@0?PF3'97:A.O?\%M?\/
M``#__P,`4$L#!!0`!@`(````(0!6KZ(;]00``,$6```9````>&PO=V]R:W-H
M965T<R]S:&5E=#0Y+GAM;)R8;X^J.!3&WV^RWX'P_@(5%37JS872W9OL)IO-
M_GF-6)4,4`,XSGS[/:6`M-QIG7TSCO37AYZGI^VQVZ]O16Z]TJK.6+FSD>/9
M%BU3=LS*\\[^^R_R965;=9.4QR1G)=W9[[2VO^Y__FE[9]5+?:&TL4"AK'?V
MI6FN&]>MTPLMDMIA5UI"RXE51=+`U^KLUM>*)L>V4Y&[,\];ND62E;90V%3/
M:+#3*4LI9NFMH&4C1"J:)PV,O[YDU[I7*])GY(JD>KE=OZ2LN(+$(<NSYKT5
MM:TBW7P_EZQ*#CG$_8;F2=IKMU\F\D665JQFI\8!.5<,=!KSVEV[H+3?'C.(
M@-MN5?2TL[^A#4$KV]UO6X/^R>B]'OUOU1=V_Z7*CK]E)06W89[X#!P8>^'H
M]R-_!)W=26_2SL`?E76DI^26-W^R^Z\T.U\:F.X%1,0#VQS?,:U3<!1DG-F"
M*Z4LAP'`7ZO(>&J`(\E;^WG/CLUE9_M+9Q%X/@+<.M"Z(1F7M*WT5C>L^%=`
MJ),2(K-.!#X[$02O6RW08OD)%;]3@<]>!02?',*\ZPR?_S\.B+@U8SF(H-G3
M<;C"V7:B<-(D^VW%[A9D/WA77Q.^EM`&E/L9$GX.<_;1E,%<<9%O7*75@MFH
M(<]>]\%LO75?(3?2C@D%`TM[8):KE<Q$/<-3@0OC_L&C$Y*[Q#W1=R&C!RX$
M.40*TS6.],<YV`?$824@WY/?'`IF$;3QSM%\MI"!Z`<B2!D^GC(S626>$K[R
M(C)%@H>SD@F0OF,3^'3//UR0O1F\$RR]\<RME5&&@H$$?\RN'$=D)+"1B(T$
MT1&2$S#4SSO!.^ULL'N(,O"5&0T%HW/"2.`I$?B*X_&46<J.$QTA>0$9H'KA
MPV:O7R*\D^S%$BEC#`4#XQC\4L88&0EL)&(C072$Y`1L@:H3YO7!.YG6AV!T
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MP+$A^H,#<5K=*R8_F@2DS0PC@KM7S=OM!*D;:JQO)DKS8RN2@^<UEI(-`3PS
MF"`J,VEYS-4?6OS*`)S2FF!$L%DE-B-$B\B&\%)+,>2)_4(4:(;EH:OBNN5A
M1#`R(K$9(5I$-H078"-##)DARC4I,_S)\M#5=)T11@2C'N%GA^<H/^CBH7FT
M8\E'.M$BL@F\_AJ9\.1!*JHVR8SI0:HK[3HSC`B&^T"^V$2=[JEU>MPU:]8B
MOU'\>+D*,\2-H;B(*FAUIA'-\]I*V8W?!LY@GQJ>BIO*$&W@<@CN>)3GF-]@
MMG>00P-<(%Z3,_T]J<Y965LY/8&DY_"]J!)7D.)+PZ[M#<^!-7!UV/Y[@:MB
M"M=.G@/PB;&F_P(O=H?+Y_U_````__\#`%!+`P04``8`"````"$`9)FXE0X$
M```_#P``&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R45]&.HDH0?;_)
M_@/A?8`&!37B9I2=>S?9338W=W>?$5HE`S2AVW'F[V\UC2S5.,CXH`*G#^=4
M%5W4^O-KD1LOM.89*T.36(YIT#)A:58>0_/G?T\/"]/@(B[3.&<E#<TWRLW/
MFT]_K2^L?N8G2H4!#"4/S9,0U<JV>7*B1<PM5M$2KAQ87<0"#NNCS:N:QFFS
MJ,AMUW%\NXBSTE0,JWH*!SL<LH1&+#D7M!2*I*9Y+$`_/V45O[(5R12Z(JZ?
MS]5#PHH**/99GHFWAM0TBF3U]5BR.M[GX/N5S.+DRMT<#.B++*D99P=A`9VM
MA`X]+^VE#4R;=9J!`QEVHZ:'T'PDJXC,37NS;@+T*Z,7WOMO\!.[_%UGZ;>L
MI!!MR)/,P)ZQ9PG]FLI3L-@>K'YJ,O"C-E)ZB,^Y^)==_J'9\20@W7-P)(VM
MTK>(\@0B"C26V\A(6`X"X-LH,ED:$)'XM?F]9*DXA:;G6_/`\0C`C3WEXBF3
ME*:1G+E@Q6\%(E)41^*V)#-0KZZ[GC5SY\%B`HNM%#4&HUC$FW7-+@94#=R3
M5[&L0;("9NG,A_@H'9W7]ZR"/$GR*%E"$\H=EG/(S\O&#Q9K^P5BFK28[1!#
M,&)W14C7DC;JG;!!;R<:0M$7?3L-5VT2++5=6;?J!'!W8EU-R!#AS3$D&D)Z
MAI%8#XN5$9Z]6SM7T7(15$E/H^\'6,)682!IG0\?(W9W$=$8`KF`VTP/N02'
M)H2H4^8&,ZQMJS!SOZD6!U_<C5V,WKF(Y$*`I\N58%VNEN^MPK1R%];"09_Y
MEP=/LZ`6@-8N!EIVHC$$,N-_Q(P$8S,^T<THS(BVW5U$-(9`Z@.L?EK]RT7W
MZE]AQES<141C".1"MO+>/CF^Y4@PSH'KZSE0F+:@B#5;XL^7!WU30@L":X8*
MT/$&%1BA!4O+Q3=P^PN0U>5'K$JP9C70GN:MPJ!$!4OM<;F!66@\T2W,GQZ"
M/!#H8=/SU:!U%WK"6A"RH9EH(=TNX>.0S_HA;SN<U!F:W0H/9Y7T5V"#LC=.
M+DBB.FE_1_;)H$$KT*C!NY"HO=5M%FQ!]M">A6D[`U&==[PUMJ#;(IK([^Y#
MHE$(MB+[:,_*^/9`5-?M9V.X/[2@;H-8X)8#E:%O$/H*#^I-PT08XUJ$H()#
MK-@AQ/(##B5:?Z"TQWE+%`@E::$)WMT$:;TVN@GZ\\*!C<BV.SU5JDFC5`6#
MG6&LD[?5IB#=<XZ3Z0S?'^0\@W8&?[@5J'E%O<X7M#[2'<US;B3L+&<1%]ZL
MNK/=G/3HRA=A[?Q6SD_-!-1=@/&EBH_T>UP?LY(;.3T`I6,%H*I6`Y`Z$*QJ
MAH@]$S"X-']/,*A2>'UW+``?&!/7`[BQ+0>O9@K9_`\``/__`P!02P,$%``&
M``@````A``LZT4':`P``FPX``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&ULE%==CZ)(%'W?9/X#X5VP4$"-.FFE>W>2W60RF=UY1BB5-%"&*MON?[_W
M4LAXBVZD?5"!<P_GW'OK:_GUM<BM%U[)3)0KFSECV^)E(M*L/*SL?W\^C6:V
M)55<IG$N2KZRW[BTOZZ__+&\B.I9'CE7%C"4<F4?E3HM7%<F1U[$TA$G7L*3
MO:B*6,%E=7#EJ>)Q6@<5N>N-QX%;Q%EI:X9%-81#[/=9PB.1G`M>*DU2\3Q6
MH%\>LY.\LA7)$+HBKI[/IU$BBA-0[+(\4V\UJ6T5R>+;H115O,O!]RN;QLF5
MN[[HT!=94@DI]LH!.E<+[7J>NW,7F-;+-`,'F':KXON5_<`6$9O:[GI9)^B_
MC%_DS7]+'L7ESRI+_\Y*#MF&.F$%=D(\(_1;BK<@V.U$/]45^%Y9*=_'YUS]
M$)>_>'8X*BBW#X[0V")]B[A,(*-`XW@^,B4B!P'P;149M@9D)'ZM?R]9JHXK
M>Q(X?CB>,(!;.R[54X:4MI6<I1+%+PUB#94F\1J2*:AOGGN.-_.9']QG<;6B
MVF`4JWB]K,3%@JZ!=\I3C#W(%L",S@+(C];1>OW(*GA$D@=D6=G0[A`NH3XO
MZV#F+]T7R&G28#9=#*.([16!"43:Z.:&"WI;T9"*6]'OE^&J#<&H[<JZT3>`
MNQ7K&4*ZB(GA)NI"PEG+0L1.J%C,\/3#WKF*QB#HDAN-01"V_'5V-AH#16M]
M!!2QO8N(^A#$!;QF>,H1O+(A1:TR+YQ2;1N-\8.Z6\;TX;;O8?3!0R(7$CQ<
M+H*IW(`9]=YH#+RZM60F^RXBZD,0]0%5/ZQE,.A>RVA,GXN[B*@/05R$U$7_
M*$4PK8$7F#70F*9E?&=,/^QQ9/38]K,!T2<"B%5<Z&]FT7ZK"#:LAL8`V&@,
M*=3,;+@!F*@?0SS,/^,!P:8'LUP:TY:+T7)-'T<38]23@+GCS<G'ZP1$),!W
M0H*?![<!Q"J#%6YXO6HT-1NPWY.]GHP;$*F88>\^).J%4`NX-MZTW+`Y@ND5
MM7]=:4"]5C1/#R3J9:%6<"V]L=(_>IA>><GBTIDI&E#3>X%SO_=HQ&CRSNQB
MM&M$0_I?0@WCJCO<L%ZCB>'.?,'>6<A]<\(8`HKN@*@1:(!/&$$T'4=>:$X:
ML(U'4%.YF>/368.,Z7KD;6D$<R;AX\C8T.'A8#"K=JC/`GJK7/#JP+<\SZ65
MB#/N\SW8M;1WVS/(@X>;3./^!L\F>-]M'\#1X!0?^#]Q=<A*:>5\#Y1C)X3]
M0:4/%_I"B5.]0=\)!8>"^N\1#H$<ML9C!\![(=3U`E_0'BO7_P,``/__`P!0
M2P,$%``&``@````A`($I?X,2!0``OA8``!D```!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&ULE)A=;ZLX$(;O5]K_@+@_(8:$A"C)48GI[I'.2JO5?EQ3XB2H
M@".@3?OO=P8#Q0ZUZ4T2X/6+'\_8GGC[_2W/K%=65BDO=C:9S6V+%0D_IL5Y
M9__S]^.WM6U5=5P<XXP7;&>_L\K^OO_UE^V-E\_5A;':`H>BVMF7NKYN'*=*
M+BR/JQF_L@*>G'B9QS5<EF>GNI8L/C:-\LQQYW/?R>.TL(7#IISBP4^G-&&4
M)R\Y*VIA4K(LKJ'_U26]5IU;GDRQR^/R^>7Z+>'Y%2R>TBRMWQM3V\J3S8]S
MP<OX*0/N-[*(D\Z[N;BSS].DY!4_U3.P<T1'[YD#)W#`:;\]ID"`PVZ5[+2S
M'\@F<HGM[+?-`/V;LELU^&U5%W[[K4R//]."P6A#G#`"3YP_H_3'$6]!8^>N
M]6,3@3]+Z\A.\4M6_\5OO[/T?*DAW$L@0K#-\9VR*H$1!9N9NT2GA&?0`?BT
M\A13`T8D?FN^;^FQONQLSY\M5W./@-QZ8E7]F**E;24O5<WS_X2H(>I-W-8$
MOEL3`C\G-O;:QO#=-2:S]7*Y\->KZ5U8M"[0HG-Q9^YZ29:^&<01@]*,,8WK
M>+\M^<V"Q`7LZAKC-"`;<.X&5PQ%/]R?C38,,YH\H,O.AAD'`UE!BKSN`6WK
MO$)8DU83CFG6LN;0:3"*:$R[&Q_&1&X2=0I,(6#JP2`\0[#Q;.GZCV+L?_?>
M4-P`[QXH4/MZ+_&#N=PY>J]Q9474O?GC1=ZRETA`D#W3@5`L`8D;0R!_'?0O
M:@;[,$%#1S2!&I+!RR4"R.`A`>;:`G).'QIL!%-V$`D_4`8Q%!KX[*/E*VA&
M!34J(IU"X@2F(:>>#\4[&]*@[_OR(P&:N(1"HL,S*JA0K)JYZ;IKV,.47(TD
MA3=?#!42GO\5/!0K>"M/#DXH-#H^HX(:%9%.(?&M9+YI:8J-3&DJ-#I.HX(:
M%9%.(7%B@318^O5IBF(YCGZ@QE%H='R=`G<(97^@W;./B:!,XDBGD,B"KY"A
M6"5;*!DJ-#JR3H%D2FO:/?N<3*>0R`B43].#UJA5-G5U:46+9FE0'A[ZAY_V
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M`:]AUHJ*0^94:P.B*TM:3J.$MBZ"<SV>Q#H7F1+KB>F4HOJ0*96=/B2Z$J6E
M-$IH[X+%A%JF]P_'=BR9#ZN*Z7RB!I'YE'(@)+I"I>4S2FCO,LJG:R_QN5^J
MA1JUO-C>_=%J-;JUQRRAK:1-TF!LI=6ZR)!*031MI77O"Z/57"V,6I&6UEC[
MT-9%_+,D"_QC>;?R2)H5['%#B<`5QW_B:"IGY9D=6)955L)?\&@/B[?^;G_L
M^.#A@8UR/R0;.$:ZOT_AF'+L?N1NHL;'Z8W@]/`:G]D?<7E.B\K*V`FZ,)_A
M65TISA_%1<VOS0':$Z_AW+#Y>8%S8@8'5_,9B$^<U]T%'D_U)\_[_P$``/__
M`P!02P,$%``&``@````A``((O^#/`P``Q@T``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&ULE%?;CJ,X$'U?:?\!\3X!0X`D2C*:@'IWI!UIM=K+LP-.
M@AHPLIU.]]]OV28$FQZ2O'0'ZM3)J8M=E?77][IRW@CC)6TV+IKYKD.:G!9E
M<]RX__S]\F7A.ES@IL`5;<C&_2#<_;K]]9?UA;)7?B)$.,#0\(U[$J)=>1[/
M3Z3&?$9;TH#E0%F-!3RRH\=;1G"AG.K*"WP_]FI<-JYF6+%'..CA4.8DH_FY
M)HW0)(Q46(!^?BI;?F6K\T?H:LQ>S^V7G-8M4.S+JA0?BM1UZGSU_=A0AO<5
MQ/V.YCB_<JN'$7U=YHQR>A`SH/.TT'',2V_I`=-V7900@4R[P\AAXWY#JPS-
M76^[5@GZMR07/OCL\!.]_,;*XH^R(9!MJ).LP)[25PG]7LA7X.R-O%]4!?YD
M3D$.^%R)O^CE=U(>3P+*'4%$,K!5\9$1GD-&@6861)(IIQ4(@+].7<K6@(S@
M=_7_4A;BM''#>!8E?H@`[NP)%R^EI'2=_,P%K?_3(-11:9*@(YF#^LX>S()%
MA*+X/HNG%:D`,RSP=LWHQ8&N@>_D+98]B%;`?(U,Z^AC_5FH$*,D^299%!=$
MP:$^;]O$3];>&^0T[S`[C8$CT6.0B4BO")E`29L-7GB@MQ<-J;!%AU#4S\MQ
MU2B=3(WAW!2P&T,"$Y&.$6%D0K(Q)%GT$".,T`QC6KX$;UP@[],7)6'/J_*U
MTQ@H8X^)341Z%Y%-(0SU\#7/%T$Z0?</%";^+3LZ"HV9BN(N(IM"&%'`^1M&
M,5T#"39K$"R79H9W&I.H0Q"@V#H%Z=",E@NK/IDV?QZ[H3M^1K<$F[I#W[=T
M:TRL=*-Y8"M+A_:E']C"M?D!X<DSPB78%(Y\Z[SM-*83'L\CZU"DAAWYR#K2
MF;8_H%Q.<^NJO'_K2">[X>V6T9C/%:@CD=Y%9%,(HW&69A33#2_!9O[#T;VN
M,7/5.%93I5?;3R^D;`IAZ$9PP0_3/RU<H4WE46)W3@>:2OQ]2#8),4.0\^SI
M#D)Z"IIWIMU"'6@R%,TS`<DF6<Q0Y)0;A'*G&GHF#H?7N(^0!NE&6@36;$X[
M<W?.@X4U-3+#?1G>S*9N.=X>UZV'H:G[QJS'%=*@3E@8C;8:P^[;%V_6^>NX
MX^3F;@J'NCTA7*+-]A]?G+`Q2]!U5-G'(S7MGV1\Z(]B_]:36KE>I_6V61-V
M)"FI*N[D]"Q790071O]6K_$[N<:K1;PWP!;=XB/Y@=FQ;+A3D0.X^K,$YB33
M>[A^$+15N]V>"MB?U<<3_%XBL$7Z,P`?*!77![GI][_`MO\#``#__P,`4$L#
M!!0`!@`(````(0!><!3:^00``,@7```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;)R86V^S.!"&[U?:_X"X_P+.L8F2?"KAK%UIM=K#-25.@AIP!+1I
M__V.,238I`S=7K3-Y/&+/:\/>-8_/]*S]D[S(F'91B<C4]=H%K-]DATW^M]_
MN3^>=*THHVP?G5E&-_HG+?2?VU]_65]9_EJ<*"TU4,B*C7XJR\O*,(KX1-.H
M&+$+S>";`\O3J(2/^=$H+CF-]E6C]&R,37-NI%&2Z4)AE0_18(=#$E.;Q6\I
MS4HADM-S5$+_BU-R*1JU-!XBET;YZ]OE1\S2"TB\).>D_*Q$=2V-5\$Q8WGT
M<H9Q?Y!I%#?:U8>.?)K$.2O8H1R!G"$ZVAWSTE@:H+1=[Q,8`4^[EM/#1G\F
MJY!,=&.[KA+T3T*O1>M_K3BQJY<G^]^2C$*VP2?NP`MCKQP-]CP$C8U.:[=R
MX(]<V]-#]'8N_V17GR;'4PEVSV!$?&"K_:=-BQ@R"C*C\8PKQ>P,'8#?6IKP
MJ0$9B3ZJO]=D7YXV^F0^FBW,"0%<>Z%%Z29<4M?BMZ)DZ;\"(K64$!G7(A/H
M??W]>#1^FI'9_!LJTZ8K/`EU7Z:C!3&7DP7:%T.,JTJ3'971=IVSJP9S#WI>
M7"(^D\F*@'*3(#&<6\J^RABDBJL\<YF-#JL&DE&`S>];Z-C:>`=KXIJQN@R1
MB5U#<!^XK-T$[K+SIR>YD=,P32-7#7A-X*ZB/-AOB$8C4`.A"%2^&I"Z6_[`
M6RE_CR=6DR9.\S0US[&:P+UK8WEXNRZQ4#)@"P1ZV$J^,D+G$:,\RGW$*#I>
MEU%4_"XQF<EC"KJ(.J;P`4+N?9$L@&7U#0LX+5F@!G9JP!:!=GYG"V5(S@#&
M'<!X`QA_`!,,8,)^1LHQ;#[?R#&GI1RK@9T:L$5`[)M\Z3MJP&T"[5D^D2>6
M]XB9RHP_@`D&,&$_(V4/MF<I>WR3G7YY"C6;!6\%YTUK6<^7RF*S!`-=N2W]
MN3S<'4K8*.&@A(L2'DKX*!&@1-A'2);,'U@R@?.O?__FK38Z[$WW="\7<L(M
MP?19@A(V2C@/"*+TQ'W`R'WU4,)'B0`EPCY",F6AF-)O!J=5,Y;R`"W!])F!
M$K8@%M5;#;R^5S_R8QQ4Q&V+D!EY(.*A(CY*!"@1]A&2&?P*U'XS[#>#T[(9
M"Z*<D99@YE4BY\OIDB=33N2NC<S,,5EV$+N-3/GWJH@CB![3793P4,)'B0`E
MPCY",F.IF,%/$'R[XJU44Y3SP1),3[)V*&$+HC9V,B<3Y5QV4`D7)3R4\%$B
M0(FPCY`<X9<E:7T,LZ1JIGJB;-Q6#?69@B,VCC@XXN*(AR,^C@0X$M:(F&BS
M:NG?-Q#9'7Y?&[Y[$7&]:Q_L"Z)<LZP:ZG5%Z/0@=JTR$X,P1\14MDD'?XZ+
M(QZ.^#@2X$C8B\BF\$M=VY2!2T;<!65SU(.>"*@G\SL<L6M$>#-69UA5DW!P
M&1='/!SQ<23`D;`7D>WA]\'_88^X1DKVF.HI`S4^?A3UVH,B-J[BX(B+(UZ-
MM-_YY!<57R(F#]Y"`HD04TG6X(7/KY,BK!&%35&Q2VE^I#MZ/A=:S-YXT9+/
MTUOT5E!]GO+ZDA*WR`K*:]VX3590,.O&/;*"(E@W;HU7UB/]W7@%EWK@C=N#
MH8YZB8[T]R@_)EFAG>D!NFR.>+$R%Y58\:%DEZH.^<)*J*!6_YZ@8DZA"F".
M`#XP5C8?^`-N-?CM?P```/__`P!02P,$%``&``@````A``:A48+1!```MQ4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#@N>&ULE)A;;ZLX$(#?5]K_@'@_
M`9,`393DJ%RZ>Z2STFJUEV=*G`05<`2T:?_]CAF2>J"UTSZDN7Q,_,T,,/'Z
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M]L%(BJUV;PEO<\@HA)EYOHR4BQ(6`(]65<C6@(QDK_W_<['KCAM['LS\T)TS
MP*U'WG8/A0QI6_ESVXGJ/X38$`J#>$,0^#\$8?YLX?GAW5>BS(<H\+V7*-[,
MN_.9'YC7XJ!7GZ8DZ[+MNA%G"WH/5MZ>,MG);`6197X"R#+:7#/V6<(@4S+(
MO8RRL>&D@<-;J/++-O3<M?,"E<D')D(&'J],<'='F7@:AU$BN1"R5/*K4^4-
M!YRN8I!L5>SC@E_6+V&Y_DO4"-]0%QMZHZ7$4\8;+79*S'V*I%,D?$\*$8+Z
MJT*R4HM/._DB)@^"GE63OARM,D)FH3)TD;&12(Q$JB.()RQD[#F'CM074!ZT
ML2&9[\VU#*E%A`SQ9",F_H"A41(CD>H(8@K5^[JI/(B:AMZXHLB$_8D8N/T?
MM8B1(+F@1&(D4AU!/`/JJ:^DA*G?W!U5*4(FZ/V\^4=^2.C\C$2J(XA?2/WD
MF6GN6'D0]0R].:U!A(R/HO(.13^/\7.=I9%(=02QE"/1Z$YAMI0'C2T7U")"
M1K4()Z93)J!1$B.1Z@ABNJ2F^GZ5\-APM+8(F:%?_0\;%A$U":,@B9%(=001
M9'`]_7HM^Z/&JN-3<X`T(O&`8#HP&:-9(2'((OS@#$\IXE.$VLH1X<N=RW"P
M4&\IH3NJ231`6EN,@[8+NLQ^@DF&($C@Y9KV=DJ()8U!5>4XH:CJ6Y?A\$$4
MV?CL'""M(L;1((DY2JI%J*6<)13+VT8AAA,(/"HSPOC..4`:E=B,)&8DU2+4
M%A:CVAIJ*FEZDD[OGPPAM2='9V`\()I$)&8DU2+44DX32DT-ECA[J)T;L-'=
M,9*_\R`5&H78C"1F)-4BU%+.%(KEC9V+DXBA<W7C2G^AB9D12<Q(JD6HK9PM
M%%M#37$246L:>N^_A7J%B"&$G>OU5WUZK8P'0E/UQ(RD6H1*RK'B=DD<0E3)
M@$TD=9/*4$HCDC`CDFH1:BEG"\7RQL;%B<30N+JQ9;`U(@DS(JD6(;:P(T5L
M]8W;T_22.VW<`<+?9*,Y/QX^U/6L&9'[:)]?[]`/]\EP`ZCBS8''O"Q;*Q?/
M<@_,@Q]4UW>O^W/WGMP6&;T?P[Y=O\GE7#^`;;-3=N!_9,VAJ%NKY'L(Z<Y"
MN`HWN/&&+SIQZK>='D4'&V;]TR-LD'+8S'%G`.^%Z"XOX(N=ZY;K]G\```#_
M_P,`4$L#!!0`!@`(````(0`]D6'8^0(``)4(```9````>&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;)267X^B,!3%WS?9[T#Z/A100(TX4<GL3K*;;#;[Y[E"
MD6:`DK:.,]]^;ZDP`J[CO"B4P^GOGEY;E_<O96$]4R$9KR+DV@ZR:)7PE%7[
M"/W^]7`W0Y94I$I)P2L:H5<JT?WJ\Z?ED8LGF5.J+'"H9(1RI>H%QC+):4FD
MS6M:P9.,BY(HN!5[+&M!2=J\5!;8<YP`EX15R#@LQ"T>/,M80F.>'$I:*6,B
M:$$4\,N<U;)U*Y-;[$HBG@[U7<++&BQVK&#JM3%%5IDL'O<5%V170-TO[I0D
MK7=S,[(O62*XY)FRP0X;T''-<SS'X+1:I@PJT+%;@F816KN+.$1XM6SR^</H
M49Y=6S+GQR^"I=]812%L6":]`#O.G[3T,=5#\#(>O?W0+,`/8:4T(X="_>3'
MKY3M<P6K[4-!NJY%^AI3F4"@8&-[OG9*>`$`\&F53'<&!$)>FN\C2U4>H4E@
M^Z$S<4%N[:A4#TQ;(BLY2,7+OT;DGJR,B7<RF0+]Z;EG>S/?]8/W7;`A:@J,
MB2*KI>!'"YH&YI0UT2WH+L"YK<QP=+7^KU2H49NLM4N$H-NA"@G+\[P*9^$2
M/T.FR4FS&6O<OF+;*G2`VC8^&\#`VT%#%.?0EY>A9=-BS=:Z;LP`>'>PW@!D
MK)CX?4D\EH2S3M*#G?1A=<(3Z,#KT/HET)TQ3F9O_DTZ&Z.!1>OJ"#J"1K%]
M5Q%?4_2J@&ENCUR+(P01=63N9)#QQFC"IEG\8.XXS@#^7!`$\'P@B'N"J59T
M#CUT^(G=CJ[%??1P%+S1P/1=></@C2(PQ6GT-S33V=<L>O#!1^"U>`@_[T(Q
M76,TU^"-PL!/+\%?L^C!AQ^!U^(!_'P0V\9H3-.X%]"V1G"E.C@F]#27%0;>
M'`-FERRIV-,M+0II)?R@MW@/%K4;[4Z?M:?WE\'X!DZE9@_'W0,X%6JRI]^)
MV+-*6@7-P-*Q0^@'8<X5<Z-XW>S-.Z[@/&@N<SC^*>R*C@WBC'/5WL#$N/M#
ML?H'``#__P,`4$L#!!0`!@`(````(0!D(W5/D`(``%`&```9````>&PO=V]R
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M/W-15A:J/05#SM<J?\FX81`HT$2CJ6-BJ@8!\(FD<)T!@=!G_WT4N:U2/)Y%
MTWD\3@".]MS8>^$H,6('8Y7\'4#)B2J0C$XD$U!_VA]%H\4TF<[>9B%!D3>8
M44LW:ZV.")H&WFE:ZEHP60%SYRSHZ+W^SRIX="1WCL5S@0L#Y7G:S)?)FCQ!
MINR$V08,3$2/&2!V'<(%Z&BSLP<$]/:B(8IST?\N0Z?-@0?:QO%`VS5F=(G8
M72/&TTM(=@V9+WK(A?[QI7X7^AB:\G4?[A#@SO*;Q(,$MP$#=>PSGO4*?*2[
M-Q'9:X@+%_":]U?!@5,,$?7*YLM!QMN`6?K^B:/Y0/GE[L`73+_C[\[^W0V*
MPV2'QI=<EWS'Z]H@I@YN:A-X8_\T7"A;N%#\^)%^`P:ZI27_2G4I&H-J7L!1
MD`D3K,.5$!96M;[=]LK"*/N?%=S<'!HZC@!<*&6[A;MT^O^"S1\```#__P,`
M4$L#!!0`!@`(````(0#QTZZ<X`(``/T'```9````>&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;)Q5RV[;,!"\%^@_$+Q';\L/6`[B!FD#M$!1]'&F)4HB(HH"
M2<?)WW=)RK+LQ&G<BVUY9V=V=LG5\OJ)-^B12L5$F^'0"S"B;2X*UE89_O7S
M[FJ&D=*D+4@C6IKA9ZKP]>KCA^5.R`=54ZH1,+0JP[76W<+W55Y33I0G.MI"
MI!22$PV/LO)5)RDI;!)O_"@(4I\3UF+'L)#OX1!ER7)Z*_(MIZUV))(V1$/]
MJF:=VK/Q_#UTG,B';7>5"]X!Q88U3#];4HQXOKBO6B')I@'?3V%"\CVW?7A!
MSUDNA1*E]H#.=X6^]#SWYSXPK98%`P>F[4C2,L,WX6(=!MA?+6V#?C.Z4Z/?
M2-5B]UFRXBMK*70;YF0FL!'BP4#O"_,7)/LOLN_L!+Y+5-"2;!O]0^R^4%;5
M&L8]`4?&V*)XOJ4JAXX"C1=-#%,N&B@`/A%GYFA`1\B3_=ZQ0M<9CE-O,@WB
M$.!H0Y6^8X82HWRKM.!_'"CLJ1Q)U)/`=T\21EXTFX23]-\LOJO(&KPEFJR6
M4NP0G!K05!TQ9S!<`+-QEIQU!I9,SHU)LJF`5C".Q]5T'B_]1VAAWF/6#@,W
M8,!$`\('\:$"4#VM((8)O=[;?04FZ;B".!GH;9%K!YG9P8[UXO_1,TDPM9&;
M)`A/!!TF&6'2`7'D&"!CQV\[->`,1[;+41">NG3AJ0W#B7I=$`;Z?D$#'@E.
M!DK75A=.K&":SH;HD</T$D$#'@D>FN8$7;@7G)T1G%XB:,`CP>G@P0FZL!.<
M!O,A>N30K/;1O7E[A@8\$CQX<((NW`O&9V8XOT30@(W@X?(EP:E-AW&JR?S0
M]2.;L%4O\&G1I[JG;GN0.[+Q+#U<(Z?LMK!;4IS*BGZB3:-0+K9FPX9P\(9_
MW?9?P_:/[#4?`K!\.U+1;T16K%6HH26D!MX4#J]TZ]L]:-'9+;(1&M:N_5G#
M:Y;"D@L\`)="Z/V#>4$,+^[57P```/__`P!02P,$%``&``@````A`"005L*-
M!````!$``!D```!X;"]W;W)K<VAE971S+W-H965T-S$N>&ULG%C;CJ,X$'U?
M:?\!\=X!<R=*,IK<;RNM5K.[SS1Q$M2`(Z`[W7^_99P0JNB9=#8/(?@<'\IU
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MA0')<?5W'U->QI!0D.E9KE2*10H!P+>6);(R("'1>WT])[OJ.-1MK^?ZILV`
MKCWSLIHG4E+7XM>R$MF_BL0N4DK$NHC8$/T%MWI6X#+7>T#%N:C`M5'Y<@@0
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MN^U2_%LHR%U8#?^'N[(7+,+MPK=(WL>*`^MD,SE(VB=W&=.[C-E=QOPN8W&7
ML;S+6-UEK.\R-G<9VU\QD*V0=F3KKR>K9`]U*)K&*M<FU3U6'+]>";W`(V4[
M:</P9B:]IVW8"VU2*[,V['ATG9VWX2"TR5*V:,-.2)^]1+#KDV>OVK!M.62-
M7[=ARV$VP3<(9YY+%HYM&V>P8[DE#AD&6X('#)-L:MAM@M<OFK'B>+5AS#7I
MP"8(9X%'9N<4X99CDF5HAG#F6N3Y<X1;MFGBA6Z!<-,W;XFIXU]BW&9$?X5Q
MUR+QK]NX:P8VT=^T<<<.7&+L%N$><V[Q(^-@._:`<9*-C0MONLHW15$3[2E@
M#JG7"<(A+E)P4X2[CDOT9PCW@H#TGR/<=EHOCCJ^!<)=G\:_)#BMBQ7"?<LC
MOJX1;GD>?;%L,,&R/)*A+2+8KM]*`;(.=M`/6"?9V#K7(<O<6''">LX]F3U&
M:FI"<;*232F.I\R,PD1^CG"_9^*//WLB<WB!.D"\))[E'7Q%<1+0FN`.\7I#
M<1(?G$EESIM\^K?XE)'JQ*FV_QDO#GS"T[348O$J3Y,6^-"TJH/NF/5ALPQ[
M7M*^A@-PW6XT`!Q`3]&!_Q$5AR0OM93O0=+L^;`N%.H(JVXJ<:HWNL^B@J-G
M_?,(_S1PV.R;/2#OA:BN-_!@H_GO8O0?````__\#`%!+`P04``8`"````"$`
M'LTH?]\"``!-"0``&0```'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6R45EUO
MFS`4?9^T_V#YO7PFH40A5:.J6Z5-FJ9]/#M@@A7`R'::]M_OVB8T0)N1EX#)
M\3GWGGNY9G7W4I7HF0K)>)U@W_$PHG7*,U;O$OS[U^/-+492D3HC):]I@E^I
MQ'?KSY]61R[VLJ!4(6"H98(+I9JEZ\JTH!61#F]H#?_D7%1$P5+L7-D(2C*S
MJ2K=P/,6;D58C2W#4DSAX'G.4OK`TT-%:V5)!"V)@OAEP1IY8JO2*705$?M#
M<Y/RJ@&*+2N9>C6D&%7I\FE7<T&V)>3]XL](>N(VBQ%]Q5+!)<^5`W2N#72<
M<^S&+C"M5QF##+3M2-`\P??^<N.'V%VOC$%_&#W*LWLD"W[\(ECVC=44W(8Z
MZ0IL.=]KZ%.F'\%F=[3[T53@AT`9S<FA5#_Y\2MENT)!N>>0D4YLF;T^4)F"
MHT#C!'/-E/(2`H!?5#'=&N`(>3'7(\M4D>!PX<PC+_0!CK94JD>F*3%*#U+Q
MZJ\%^2V5)0E:$KBV)/[<F07SZ'8"BVLC,@D^$$76*\&/"+H&-&5#=`_Z2V#6
MF<T^S`Q2TGON]2:S%=`2RO&\CH/YRGT&"],6LWD/L^@P+LAW,8#N>0SONWK2
MUN"^=A1Z':^);S/&Q$'487K:X37:&JRU=86U$9O3`W1FQ.W[0K-KA#08F@2?
M\\8=K]6V&/CMM#^P%\HYW5X-3C`8V+'&(WLM9F8*'W11]6Q=7*.IP7W-13S,
MUF(BJ_E6[YYH=(VH!O=%X]#ODK$66TR;:!PZ'Y16C_FS=^AR_VKP4/?-1*MK
M,1-*&U^CK,'_:RJ+F:#LPQ"=GK1!#[,>NMV"K-V1\S90>D7V!Q/KLML&/10.
M!V5N05.ROFI4^78.77Z-6]`4<3UM)O<9G(?C1AM9;D&Q>:W&EML#T9X7#=G1
M[T3L6"U127,8#YX3P200]CBT"\4;,YNW7,$Q9FX+^&RA,"L]!\`YY^JTT`=N
M]R&T_@<``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T
M:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z'
M'FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+
MT@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2
M"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VX
MB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?
MB8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7
M,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-
MK2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F
M?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPX
MVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"
M8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT
M_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R
M:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#
M$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X
M9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<
M*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,
MKG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX
M15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DW
MQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(
MGIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q
M7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9
M>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"
MG$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY
M&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HP
MF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%
MRI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8G
MB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<)
M:G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])
M`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^
M@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJ
MF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"
M5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)
MLI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI
M9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*
M6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_
M@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"V
MENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]
M</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"```
M`"$`V0TGX88+``#E9@``#0```'AL+W-T>6QE<RYX;6S,77MOX\81_[]`O@/!
M:XL&J"V)HBS)L1R<9+,]X'(-<@Y:H"D*2J)LUGRH%'5GI^AWS\SR-2N)Y%):
M:ATA9Y'BSOSFN;,/DC??O_B>]L6)-FX83/3>95?7G&`1+MW@<:+__&!=C'1M
M$]O!TO;"P)GHK\Y&__[VF]_=;.)7S_G\Y#BQ!B2"S41_BN/U=:>S63PYOKVY
M#-=.`+^LPLBW8SB,'CN;=>38RPTV\KV.T>U>=7S;#?2$PK6_$"'BV]'S=GVQ
M"/VU';MSUW/C5T9+U_S%]8?'((SLN0=07WJFO<AHLX,]\KZ[B,)-N(HO@5PG
M7*W<A;./<MP9=X#2[4VP]2T_WFB+<!O$$]W(3VG)+Q^6$_U*UQ*19^$20/SQ
MO]LP_N[WR9]W?W[WKOOO;[_[YT_.\E^__&G_MU^^U3L9&T(3;%!-\[);219^
M3BAW4@EN;U9A0`09@YI06]?/0?@UL/`W<`80#R^[O=G\JGVQ/3C30WB+T`LC
M+08K@WSL3&#[3G+%S/;<>>3B92O;=[W7Y+2!)YACI-?Y+I@)3W82#N?E,T<T
MF4PCA,')U,<S5"8?1++Q9+5,]G\.R,3Q&M3S.D5_'"\F1;5<TGCM^\6>#D_A
ME=N*\(D>YQ/=LB"']+I=5"LU6$O,QK,N\#L;LZO!V23K6WUK*%4RSA?W[88,
M^Y9,5=8PM-X/[\ZF3OG,RJ1+T_"Y(@`#3JX670C=BO@>6O@YAY^<N4-KQV*,
M*I?T6>@5N?'!]9V-]LGYJOT4^G:`BJ6=&KN:ZY,YQVN'/.<"\EFT3#YW7M1E
ME>KEU$8L2;?/IL=*MO;Y[%=?,AU6/G5A:Q\5:.BJ6YH0948#"^L-Q+OK>?D8
MIF]BE0]G;F]@.!4[46#!@99^?WA=0XT?P,@/G;N37%=S]6-DO_8,5NF*-=B$
MGKM$%(\S-K)(*[O9U;TUNV=\"3)1%"5$+6LV;('H_70\DX]T-A[+)FI8\)%,
M]/T`/Y*)6O#?3)I.T[[=E`4RIZ?%+LX$="^'X_%XU+L:C49CL]\S3:;D>>K1
M;K!T7AR<')"FIGT$`T`P[H_&5P8`Z9HCQNJL"/H`8#@8C`:]L6'"_RR3MX]`
MMDX'NFJK$@2*K$H0*+(JJW,Z$C)_&BDP+Z<X5@D"158E"!19=2@Y`P^56Y4@
M4&15@D"155F9+3%68;Y;<:P2!(JL2A`HLJJTXC/-P+#(H-BJ!($BJQ($Y[9J
M-JR:W=];;$)MOS(KKX_92`[&CO,P6L)B8;8"UL/18W+N]L9S5C&,$B/W\0G_
MQN$:_IV'<0Q+:[<W2]=^#`/;@Z^=K$7VMZ(E+#[".N-$CY_<Q3,PXV8D$KP)
MB[8XY#YK8H5O#LWNT!P85\D@2A)KWUFZ6W]?NISW05\!-:)NZP4G.@QR)JD[
M%/.K';1":C[!%LS4S-*"#<`G,I<0;"%#QF*M051&TD),1M)`4$;20E1&")U#
MP95I<AEN8=U[U\"6->IVDVE=43[5!`GP`QYS&`1ILZ_/VB8'-%K;IJFLD%_V
M8F-JX(=5K`<DK6FQ+V=-@P-2UK00E9'WF\RZ'/%\.@'3\P$D._KF+C\.!C!*
M&F9X=I)@FI]PN2E9<!).=X?%K25/I`8*S;JK3(8=->W+((-)$TDR8+5MJHR8
M]M?0_2\<S_N,'?(_5GD-`%-=MS<O*[)=!?80X7X.W`V#7V$^.?V:]/?)`>BX
MK)%1VDBSUVOO]=/6GSN1Q386,1;L+,Y;%T=35J@4Q^\]]S'P'399IR=D?HS"
MV%G$;.,3FV<OP],OP=-+"8G@.86_6<(?]"2LCU/XPV3002."7I3R!^<2YB_3
M'W"+5^K48`+JU%5X9"*`(7^&`(R@`@%N24MU`.ZI`@$,I3($X*`%`H!3X16G
MQ$&/9#/P@8(E\&^+)>283$J.98M2EJ5?X%\AI<6EWY/43/(M.'JA9CBH`'`2
MR[(4JRK%$+-#I!4J@(,*%5C0Z\KI\GIE.5^90DC2!0R%1B`-5&E$GE>2G`L\
M"P#5&IE*K$.(4V`J4@T!X"B!0`P!NU348U#4`U-O4-0%4PA<'WS&F*#>P/60
MBC``'B514=0)/:['.*,:"`15&9)X@Z$J15(,JG)D80I#58HD$%1E2&H)52F2
M8E"5(XDI5*5(`@$THB1#4DNH2I$4@ZH<69BBKRI%$@BJ,B2Q1+_E%-FATZ;)
M)"J9/QV,CIH_U5Y6M1.IO;)!$]@]:YZ,GI*1(]B"C:7(4!IO`K2SN5/M*8S<
M7V&0B3<#+F`RU8ETO'DT=A?TS-?(7C\X+S`43=:=7E;E<[V`))O?V'5&'F$I
MIH(_3*[K6A/FTO5S`I;3%5$K.1O4UT[,[W@&/[E=ZR&U('!R1S4&#`O5&-#>
M*0;I;B@I3*&3S"`*>Z=L=Z%J@@Y3+%=8H%A,/C79K-97*7-41CKA#:>Y`H9/
M5&^"><7J&@X/I4I"O0W7R6F7T#PERT;WME,R\3#\*N1@K?2$*F,+1^IBHK^)
MV)*857!PKDQR`Q*D.N9DD>?L^13N3E,G.<V__=V9D:JNQ&)K&;6]6J-TK.&M
M24EG"5U&IZI2;QNWTM[X.*4E=Q[M*8V4N%1IU6Y^N'`23'@4/MMXUG`<)+O3
MW<>CVKLHHMHB)8^*9@:NB681"Q\1XR?:NP8T[X`9/,'R\BC:-=TK-60B>IUK
M&62JISH&>6%+ZZPFF:J4.3Q+:6>DS7.?I@O'M?F^"1KQ=,2#*54%M89X6+&'
M`U5V-K2';L.+CE5:&UA:TV&9W^.J>56AT8KK48N>/PK/,1':Q*>,,D"XL4.*
M;:A795.U<A!">?,F$+Z19%8_Q]TJT".Z?Z-BMUN594M[@29^U2,S#6\GFS8S
M8MNXC[`I5:N4]$KSAWC/7J_'TLQ7D_BD.%]SYA65;FF/IJ2T*Q5-&AKJ$<?T
M*#0-MA%!)\ST&F0`W`8TJCJIP41PO[VH9_OE5:^ST45/\84VD;%Z:4:BULX"
MI7#.[,RA3I/M%("]`>1.*_X^JWPG@8:/](-'$'?_H%UH[Q=(-!]08E\PW[H>
MW&V/6P1PE\=BNX%;A:?)R71=OHI6/D(P<(:2T(+2H2FMO%[$L3"E!<[;E!:P
M3RJ4/DA+:,%-:(UIP21P2@OW914RFE";-\4%35):O.X'@KHW#]F1[6`L<*'(
M(K@HK<*.H#DB8Q]$;DJKL",8CM("D9O2*NP("`DM$Y@TI578$:Q`:8&[-:65
MV]'$=%KH?B"H^ZN#=N1]%;<;B>"BM`H[\K[:%_152JNP(^^K*')37(4=@2K1
MEPD_-*55V)'/$Z9@GJ`R%G;D=3\0U/UN1N4]WA#T^(1*83OX1G2$A8:(CA(J
MA=5X+^\+>GE"I;`7[]^FH'\G5`I+`3TBD0D_B$N4VZC/:]<4U.[47F99EW<8
M[&=$8,`#61=;#UXB$.(K"-AV.BR6B4"X/BM$Z<E9/&LSN#LZ)\3'`W:C(H3N
M7]:>'=AQ&+UJN(4N)\<;?2!([B]AF.N(IX##!1%`?X47-L"[(#302Z(AWH>Q
MHFI")H\%7CT]08ME:*!U@H;W/QQA-$$#K1,R?%+%^DF$S(=@O<TMQ.=2[+I%
M2'QT@V=GR7L.KV&<K!&A],G9QI&=^Q\?4CB^$2*"]]3G-/@4D3R*-GL`0%I_
M?H);Z#,E8J5-8@>K?Q&>?]O&1(WLQK:BW\4]"B)$'MP8'GV2!3&/`V`)D0AA
M6VM.8B>C"-+XNQT%&"U<Z.[X:(E$Q29AJ/Z7+\7S%9C>8WRE"7OR0CX>`/4N
MG96]]>*'_,>)7GS_@3U4")PIO>I']TL8,Q(3O?C^$9_6!%$,\QR0;CYNX`E`
M\%?;1NY$_]_]=#B^N[>,BU%W.KHP^\[@8CR8WET,S-GT[LX:=XWN[/^@,GS_
MRS6\0.2$]ZNP]\#`-N&>>;WQX"TL42IL"OYS<6ZBDX,$/GM$"\"&'0R9$)U-
M_GZ:V]\```#__P,`4$L#!!0`!@`(````(0#W9&+*'X4``&RV`0`4````>&PO
M<VAA<F5D4W1R:6YG<RYX;6S<G=UN',F5Y^\7V'=("/*V!)`4/Z1NJ=ON08FB
MVK3UP651[?$,]B)9E23+7:RB*ZNDIJ_\#KLW"^P"C7V4?A0_R?[^YT1$1F96
M471[?+$+>'JHRLB($^?[*R)__2\_7D^+C]6BGLQGOWFPM[/[H*AFH_EX,KO\
MS8,/9Z^WGS\HZF4Y&Y?3^:SZS8/;JG[P+]_^Y__TZ[I>%KP[JW_SX&JYO/GZ
MR9-Z=%5=E_7._*::\>1BOK@NE_QS<?FDOEE4Y;B^JJKE]?3)_N[NET^NR\GL
M03&:KV;+WSQX]O3%_H-B-9O\>54=^D\O#IX^^/;7]>3;7R^_?34?K:ZKV;(`
MCN)HMIPL;XOCF2\`W,6C#\-7Q</'OWZR_/;73_2*O[:W7[R=SY97->^,JW'W
M\:MJM%,<[&T5^[M[!]V'KZOSG6+7'S[M/OS=:L:;N^O?3,`.U@/[[X/S>KDH
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M-:WJNI@OKZK%ITE=%?5--9I<3.[6-_L].`)KE'7-TE_W'I?UE6F_D?ZH_KR:
M?"RGU6S90_C;<O%#M2S/IP!2C5:+R7+2)][Q;%F!NF6QJ$85,S&ZNR`DD1ZN
M[QARLJANRLFXJ'Y$X=?]54Y983$9B:B"NKO">V&L`$03"=]W=\S9?(FHW3UF
M[8ZWBME\MAU>[,YZLL!$+;`A,B?"Y8TT)J]4/?8`4^7L<B)T.H1;Q62V?;.8
MCT1T<(@.'#EEQM7':CJWJ;H+?C>?CS]-ICVMY2BX:^OKGQT&I$TGY?ED:B3N
M<4PBX$UY:^R@S9:CT6(%/;(7N[#RG@T9S:]%UG(I`VN(NKZ9SF^KJCBO9M7%
MI,]Z1_5H,?^4YNZ)^:OJHH+88]#VL9JM>BS7)O8=('8GNI/8"+A4&P3&V9C5
MD['TC/84%]@,Y[+\<?,HAS9.LD;(I*PF2W%6[9(;`1FM&?S%SS_]_%.7%*;G
MKN930*Z_,$9=WO;H''1B[3KQX>[.[EYQ@V%&/ZRJ;XKGNUO8(_U?4;N^+%?+
MJ_EB\I=JO%5\N;^U__1@Z_F+?0/QV<'6[K/G6\_VG\7!$YD4^`;>F3=ZMBB7
M!=Y3=7V.!$</R@9A^/>W)!<HP>4$@>AA=S`>P[#S&7(M[;$]F:$=;B;(>7?[
M<.+J>C4US3R&XT:3GGCF0TP#0^/KFT5U!>>R.K+*OS<PFF&L@]TN"#TBVR;O
M\^:==N4$PX5?6BTG^%&/-]F9(<:X,E_N_05F<89IFH"UDWEM""PV.Y)MGDC<
MT-U=>UB//>XUW!GD7D,S!NJ/SZQPVC=6]:)XCZHV@;VG/:Y^'%4WRP+O$C,.
MG@M,>_E+S73/^SIUU;7&0,^GT_)\'G1+>;FHC'0]^XQ1=)-Q*8>T]]@9+BC(
MWM.`"[S@:'-[ZB#-+Y&]RR2AQ.7&FE487T]FYB)+9'NTN<("2I2*BW(2](H(
M@S:-BC5JP9ZP^W9D;2%A!G9WC3=SK.G%8GY=A+%HZNX8-Y8NT<6C@(#':ZWV
MNVI93)FR.\7+LL8/-,Q,IBLY)IA\&UD`HNN\[CO!RUS5C):N0K^L;"_GOV"R
MEE9H\SG"F"DN0\B&L/;@SJAV6-ULCDWQE3:'O/F;/?\T#WE[#_-I>P_3-@O4
MV+$IY&(`<[8W'![<H=,2&ZYF)!.F,F#%)4F$0O[)QW*"^$VK;9("VS6N\1W>
M;WOA=7QR!YG:-OD(YQ$_<@.ACEN!0E!,OTPIF2!U69.-I'"H^/>W9HY[287,
MWIX$>WOH]G;S*YGAQ=>2X;W76)?0-GJ=KD^*1^+HQQNG>4F,/IM)1808#)_)
M?(S$KKO=W?=?V8I>R^=>5:!L@9ZI,4.BV707\-E,O@M<]6FRO"*^P_WZ1!RU
MK&;%C4>2\PL\68`UY2-=*"MH$X[F=5^I_Y.7B]ON(FCCLJL;-E?]6"U&BE<!
MWS<_O]&NW5DU3==&!$Y=#.=\/.FZOV.O_Y&+_OT[%A&+*D8P#O_-BM"M!`,W
M1/WW1]YGI]H$W5`N^C9F`\4URJ*K[M)M`9)^ZEEY&;BN&GRDD8^E#:_ODP,@
M[W27N/4\G\[XN,FNF'[NO>[XGKFXYSJ]]S9R^QI6+D?H[>!%P_Z')$,($*LM
MF:>=+CG^PR:.*.LNT-EQ%T,'GQD?I_WL>W=8M4-EE<B/?=KH9#>N)YGKR<<-
M.8?QGU9U"'F7<\)`?,01><'&S>)7N5R6Q8HN5>,>WC'UJPKOB/C'%+,YK=?*
M6?[%?NAB:)`]DW[CU>O)ZKIX4HQ)72NO=6\QB:ZD7N#EFSG.A4\IL+LYI"X@
MA\EIV>@[@Z+[)"4$!]H*3[R6E<IP9@E#<VJC&TY^H:<Q3CK).GO!0^;U.29;
M4&QQ%YFZ^SV>?<1*2*_<0<J3H'<MO+N7KGI+5MHSF4+]O5XAQS>JJG&(*N01
MWG^Y@:D'X[2>=D@FWUC8\Z?]5&]KBV0+[\$J"=\,_TB6:ER<W\*PCP+Z'T/U
M/FZ[^`]9@L_@OX6:CDLC!&.<Y%>:E4S[G=SIXIR5/X)@2P<O*D_9!%&O+0@G
MJ;V<>C*#!91SE>A\*A?C7I#6IEQ:M@-7=^=KT7?A29,6.M:].)F-""GP!,#W
MN/*_A7#74](V1NT[TNZF0-<-W")=&EU;M@`C4&+KPG#'VY4R;YO>&ZYN;ARK
M*"6I-ER`%7Z:WB#_;4"O8YN>=GC=BNR-9#9)S@GFY,*6N$UR=I<%!":'A:2O
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M%Z6ZK"8$-X_^[?5)_7@'MB*>6RJ?6B)#`3I;(=#$]I1!R\33U9AT8E/F$3Q7
MJ^O2$![Q!JD53]"K<$GQ:S7%<B$CX**:8;[)F;.L7KQ!+UZ7(\,U4`0`]?_'
M*PL_$W:)0Z=3,(N8::HF?Q[4&V]#[#E6%5(AE-`7K;"LC`UR<$T_K2,^<5Q<
MV-B0C0KSH(I*9^*(NN<:1T:'@*'4-KTM/LT7/QC=8(%BMK(:`?NE?>1R>UE!
M[APDMOLGHFW@OB)HMXVBL.93<O?*\"TF0A<;;`BQ(Y`$K;]W7=XFU-201CG-
M6QC?P]AZ1:\%Q!"=+6-([<$49(XFH04Z3>A6H5Z!>W&+SH;?ZQ5EZ;J^6$U]
MS2BW(J\AVO&/2`*H<7?M*8.4C7*SD8BS!6FR+'$`,8C92%6;)4G9^FIR@\BM
MK+H<I;CP=+$QDN5))26Y;0PF%4$=5^?++/O5L-%Y-9V`H8!KT;P-*.#)W\NL
MG"WG!B34L4Q"7H72S\\_Q=K/5J'VH$O?OA!M5=^8QO;,;GOO1"WK-RYJ=':]
MY8P!4<HQT$$FL;DP5&@7&?KAH2F&'-MTM9BO+J_4VO.LP8#QEU27WE^45JW/
M."03K5"22NN(D5C:9+>A=A"H?T#:=HHL/Q<7%0?.YDMQ84,AJ76D!Z+!E3=>
MX6<7XH/`F%NR*&"@G,*PQVC-B"SCI4+&0[.F*6W\!)7*%#ZUU%+2BWI+<APU
MB]Y?S2[*CU@H=/56OK0IR_-5C=)&30LM7IB^%0*#O!NM&CFV41T-TRBA3_/5
M%&M0%=*2U7BG>+U:`.>"P(Z593V32Y]1+0A!T_A@P@PW(=YRY\;*^EN.JXTY
M`]_<W5`/U!+L@65,FAH_4J2)EF`TIXR-<@D"Q3*6']N(EX[Z7-#9I@ZZK^L;
MS,!O'MR(ZQ<?JP??1K5JGI4*YNT$1?$H_MNR/>\Q@=1A?_XI=++M%!\L126R
M8N=E"5,YBJ89]SB*^?F2W'DVM]N[1MN+%BB=ZUH=#S)]XH7#H].C[;V]7?,(
MC&_PFRW@ETD;3/]R5:&Q%S87_JCYU(\&KQZ#$QBS928@1UF<6/YM'_-.`4I^
M!1@LX=X()>UJ<W<PA881`;<2_A/:5Z93=,R*-P`3@22:6$PNKZ"%A1^"-9`8
M\[R2FT``R8^"<O"]DS=.MYS_.$$YR251K=!(7Y<750SN+^2\C,)#4[X1_[9/
M]P#:.\`07$WH"S&%$PR_S8MN%&<)=9G?(;#"EFU*]S-A$/WOA/],GM#3^!?5
M].G1W'W`OP3P0O-<PSI[^F7QFH*<#SF#"'7QKOI4G,[9OYY>E-<3C)O/H!^>
MV,3+;\'GQ\G'X,-F2_YSEEO/\#U/`Q\*8RCWJ5P`-0T+!&?&0_2:7>*'"H'G
M:/!9$"H`SQH_5><S2W4BF<*!D-!WG?<SID#F6,@]4VC0.%1X#5Y[MVP+.1HY
MJHI9K28@MQ9'`\A<&<.;_!$CEALX;33!*(@9S6FKT4.S\M)]/_CRNOP!_X9$
MB5R.H"\)KZ]#`MXV6E)C&/E&"3%6WHJE/CT6@V9"P%IP$WL!D,498GOT?H6[
M/G"1<86(SV9*%N><:H;;:$=T@LS]'F6H4HO<VC6C1A10`1&Y*VV<+TO]"?4*
MTFA:9!,RJ9/QI%P086PE%6=COZOH-_YS\68"RM6F4EY@GPK<%^K4B5C@WS3!
M(NRS./?N/<>GQ0E*0@%\X)&F,?AEM%183B($]]W6\4>PK'%30*U0R+>Y/NJ5
M6@/SB[&5@XQ;!@UK$,ZQ,Y(>V.PL*'HT&!X^+L[F-X1=SW>?;15K`81^P\-F
ME!@(0SRAJUK>>^(Y,4#@.W?:!+)2L837A$>DYAAPC6IVC:C-++W-KI6)-`2&
MABU8-K%52#<JZ$<G;Z4&*<6)Q&@KK+4-EO&T'CRTT@*R:V4I;IE)$ZJ$1:GV
M(-;"7I'\"`@;J=/=NQD&5+\R982>*QHXU;AY]U8O0QL>%'+H)4CKU_LFHA#4
MAG2EQ.ZSG7^R.G@MP9.S&C6&+TO^6IP/%^0]A7+:C`RH;9F"+*.2P9']NAUS
M;!;3U$&%"+.+5;1T5HD,X$3J2^I<X2G027'$.H1_HW@)HLNY4="+W'O7$?!]
MDC&75J`1GRX*Z)YH]HW1/JF]C,:(#:Z@YZC432*%ZK)LZH[4!3&;>;[!/Z_4
MP29?7ZR'+\IS24]'\U6N)H%*:ZW;24_Z4[;-_CB"%5@)*]'+1$8O)*;HV2@Z
MYPH_`^Q-.:M`\VL>'36<8G)/DQU9#%P4]HFLJ1%7U"4TH8F2!*L.)B":UCX<
M."#.($?$@ASCI790MD,?-;\(%;UXS2`E_&&9,4W=E+A,U%BL4F"KUN`,XJC6
M4+^7^+(+,CQX$-0XT/<22OXED]<)*+>*#\/B3/G2%8F[SD,'*Z:Q4,FS'](J
M/4(,$"[,O"-%E@.,KJO*13HH2198"S:8P\M+5`X:H*#M\:#`P9DJ\22AIK[M
MW:C!',%`R\FTZ/C*3X.!$S[E^>O5\)ZO)44N?6:MOK'Z+:SW]O*VJ;D.-_9=
MQXU8-DL]XE`'"JTM:&C1%*HU;2TBN\19-L2IJZI`B,Z7R:G`4#4I72\Y@YD_
MK_`#4/[."-@,98Q@P3G![<+:P..SR8PN)V/7<GI-3T,!EL&@7'0O%RDFISM"
M0I<5HH5$*7KUY0`^L*HHK6UZ]LPP#$E27^?FILT>AL]8*MAC<Y)SR5-LBC^A
ME)`8HPQY=LSI!!]H0@@)8Y..F%2?VKF<I!D%;3Z86AN.)JJ.KH\2+I=_;TUP
MVG&&6R2M2P;R++1!:YQT,#(@9Y3__6DUO@3[;B%LX]NHOAE)L6O\.K+@;=`:
MK?,1'XGS!BG;"9>.R>_AD%K'##"RF.G7M)VUN\DC.8&'TKN$AM))LCPB5_6C
MTJ*"T0.8SFX)US!OH,24EJ"W?>9D:?;L&8+&861#WOIK*\U(TGD^$#-N[<)!
M.PK+XNG*`GWPU:.[@2AHLR2#B:^&-FQAWD!DA;3+>J5XCJR\<\I4M)+;(']%
MF4(\=W2O"QDZ4>&^@1"$1D:IVBE.\PZT%J<K\_WQCFXTR\/DXN`BD!H:G_",
MGF7DRR)(^";2&J#DMQ+9LLUPR@0&-\%,^762]%?S<4]X7DL;?"_8B[>FN2T6
MZ5F\,V8>E8O%K?F)(>P0=AHJ(MAX&:YP@KG18)C(K)'(TC5+./#N`DN-Q@,G
MV8^?.:&@2'E!C*Y@*1>],9N!4<$&>ZOI::<\D2SM3I%IY"PA9/!A>X%9+!"%
MS#V1K(!N9+(H$#:#56P1N-*@R+4K895A32%:M9`]DUIWN)K$BW8^91%1KY6T
MZZBR+'%KQ1./,D?(6<!U-):9#=XBJG<%<5W^"5IA'*1/+/3)+;MT-YM6,<TD
ML$U3N7*6&C.]+B>GH!"*P)*H!6E`WF.JDYAZ$5+E1ZT]_-(:I7C81G7P*ZU!
M+&'9P\P\X,3`,1NZ/G8HBF6/D13,DU(&$M],4HADE!K:-@WN\B&ES"#E5.'X
MAJQXH:3[\>V4)I=>Y&GTM=WN%8^:X-\].>AYH;,&5G6@LO0:$B@)7;E'05<O
MOI7)"RR?-Z;\<H"-V='X`<($]07A@X>G!H!E==M&Q6T@Y@CC#F">.1/Y&L)(
MW#.K*0NHNDK!?Y2$$(,U?2BCR0)C+@Z1*Z%B&W6^F*KI*Q-!#"\;*A'6E.:6
MW6(-Y95[7':JA1'U4P]AUZ5RPA`LI%K(E?/Q4UF$_]ZIQ%IXB19$].L.$LJ4
M(771:-<JC%<%HB)HV`8C*,:0SV0>E+P/41E5/':/@<?\!H%!,,5R.XN"]X&J
M)DCU]`Y86%#+#$FAZD?Z[_'#QR0YS.K(TLZ1!!V8<D-J[IKFO)C\*-Y5I<>=
M`$_'NV:SO&BTBPR6G\YAFW/EJHC.F4W&RS'JG"QIZ>`-?J`DJC,T;=0L;\E0
M6-XK&+"Z6-WP+HJT5O5>=@#FMU=1U942.^8/+$@+GZ\6=92#1**(PRV\]]GD
MFAXMW+CV!+CU""@1#,'";7!T`7`QORTIVDE..9FPLC)K>+$RI0I%5$GU0D&'
MJT@7+K]]JZ+?#=UI1Z$S9=`01-(Q82]1CX^].5;\.QA^*-[-=RC`[^Z^V-X[
MV$KXS#CT;W_]'VEZ2O>BJ:B4AK:6(OWS@4J5S?:XE_O]YR1BOW5%A3XPX<IX
M4<5X^`JN(%VC;`8*H2I^1QH=%S56&:@U&!L'/B@XI^6X#`RLS4)\TZZ.7=.G
ME%2)7./AF.*3I&2,C$IP;+68GD!6I:*D+IKL6:A5Y4N0R,*(A[H`;0$`/N&T
MCX,E?DS.,0+;=ML%6YA*J^.%QXSHN1ZX:/%$<I7-`L2*#9,T`V)_7FD:(WJ<
MF8(<`A]*]XZ7MNNA.9&LN=0G:Q*Q!S\OY&O6(B2W8OA`#1R@7F!KBZ',(.:+
MQ`ZJ3)H4&^\X,QT700*"2`CEB9"#JH1P;%4SQD?K0**QXBZY22*C>4+4`%A)
MLY(P7&"!R9$*WJ!3E&.4,C+CII0B)RFFV'=L;I!*:1IIY;A!V:PBU(-@8>RC
M`;ZA;B3'C!T'48]K.6\F*@J=,E$V$5I=%R6`#_X"/63WT>MS%->ENUU%8-6X
MQ:L2K]B\SI68<L-;;5/=>"5"5OY*6#[DC.!UZL&B9:!/)LO&!:2;0BI-;.ZD
MI.X1COS[9"25@E%W-("QN#YI>XFIJ&3)$!8BJ`HQFXA@`6Y0L'D=YAY*UA/[
MQJ8=#1LXI9F6V:QB]<]1AQOJ4IEB1B8KI#H(5:.4S#NVE+[D)*JBI`^YUT`V
M*[%F1AQ%":$3+T?;\MN__?7_=(L1P;W`W"HS2&-5S'A#C:B<NFNBI.15;)':
M\G1$@$5^FGEAC;E3^!0*[E&Z\3K$\_'=#&X/1<:AYR5[M=%?09;B7)1NW/)_
MT]U72.<)'+"D;".OQGE:'E+431ZI,<I44D1OTH0EZLF+#>XO74V`DW,>5.[,
M)W,%EH\0V;1\(!0^4YH,VSC6>3*_T6&$A"O#))Y/ZO_1]\/W1YQ"1.!3V/\-
M2F*R&&_?$`S>9D//3KHC#<6:07[=+&_.^$:>E(`]1PZ3+$K$V_M[=#0\\>5G
M%0DY%)1--^-MEM.T&5@0M$L`%)P5U5Q#2E,&+8*+-AFKP!XB)C'#+Z56$XQY
M%`P"V[O8E+5@%U&G)Z\A-%EUN3UG%LR?>QIU,AT"/V\\:Z;;:OL[TJ,PA%4<
MUSD]C=V*;-K8G<B5L>Z%KI?L1]9*?"6Z;L`$V,\9>Z?X@V4@Z5&TG,P=;SH.
MW;>(=B>Y,3%BZ3*^K94Y5"%N-A[J\5K@J>[OUFP4N<\#&>/<"`1,Q0U,PQ-S
M),QKS!9LHI&(3HR408L%;QP#L^@F#@13(V9:-9RQT9V1;YB<ET`$M[&M^,Z$
M,)K]Q!=MKK"DR!"IKG#D<`V]9HQT?'=]_MLMK4+;"[Z2#QE\MU4\LC^MBSRP
MD9K1]H/SZ*6M4-<2MA"\:&`RCS<9ET[\LORV:1N;WK9IKK`:#];4J5IJ84HP
MQ#4OI/:"H[PFI/)LHR)9]U.,<>W,'A'DZ$I>2U"#3)GT8&WH!/8U,VJNC(*9
M>X;Y(<LRQ9C)EV!R@A`SDD'U-).Y&\5$L(3Z!<@SF/I=X?-8+Q#Z-;A!7C%#
ML')+Q6O@H0EFC/L:Z)N^0@?"G?W@N^6`,4]+>`-K>YS9N(`]*KT-06TY(WJ:
M=F-;0`5<M3AMQ)-8/KA[8,V)9*K-75[>)PN*#%DPK$Y8"^=0^CQI$E79]"9(
MI$?4@2&=*$G`IL6,0:!`S'EYD$VKMD?>(L.ZA,(94$9I3VLIFL)TM4+_"&!(
MQ61B"'<FT3-?7CM/8"`>Z^[9L15(B*"8ZCP9P^T:N"=*=72OBF'*&R4?O&L/
MW,H+ELJ_X$E8A-FB-D@9!W8E"5(DJ+ZNJQ)X9:^M&.+H[!$_5/N,2=+DL8\7
M^C39%+-EVTH@MI``>:+?IRTZ1K)$BJ"F'79JMTUY?[-4K<:F]7IV3_4$,K]L
MA3`KQ#-(",%OH+U!V,#1*&@?WWF,,RF>2!%<4M21=@V`"::F:P$L$+Y8DJN'
MOE?>GZ*KY'2C3&#L."U:S10L'8V3R^MR>S`=4\Z\@@U3\AL5K$>/C<]?X0,/
M+A?I0$;QYLUA\>C58/B8N6\$&GIB7'SY_%=;Q8M?V2M[^_S-DW25#0VS1,#6
M*Q/A@<,2F';Q30?,'$:'8S!L+?ALCT7V]GS%_?U?]9=HPY`O2!(FPL$?*8JU
M76\5[(VV*G''?#&;E-BMT*]A#')J)UY5)8"3W^I4A^J;CPZ/3]\ZP@Y_^^J8
M7#9$-X\['F#1SVV4[3UC!T\/M(WG`7%LIX>ISC:Z?NAIE#XQ["NH':[2*HXV
MWRYVETZ0`@Q\AJ)3R!/8K&BME+N$B2TMU$!UL8<Q%I\<HH`2CT@)I>:;QF%1
M8N"*"RZ#/HJ^)VVGX78N?X!72HN:^MW"A$XR]'L]YZP]%YVA,&N/NU3L4B^L
MC:QUSNO6'W<R21$J&[=V-YX+\V*T1#7Q2:=E564DNP@O2R7D=HY&'ZM?H9+(
M]4O1""OVK_$*,.R?8/H3\9<G8WREA)R(7VF4._5YI)7B5&C1NHZA,1D$9LH4
MR8XU>?[-9#\4;BVZ].:OYDB)U>O4TJ27*8+YU2*LO1&WYD8$&X`!AU+R!Q&D
MD(=>R9O;Q(!=SA_:M0`OK2`E?)/I,HGKCLN-K+?O)3X*VE<6MWD_LK^).[Q*
MX:.Y?R`:=#^"Z>41J=30'1YO2G"BNA!PSBI/K,8A?N=&R,0Q`J3%1IEZN1K]
M$+*$CTZ''[B=0"S3>3/V/+5X4[;N*%[7,+0CI">A#Z\XX?Q-H;A7@6]RRV*Z
MJE6;E7/H!DONX8Y5:ILLJ00\1TI`!@8MU.G@K93S4TM"R-V%W)]@M%="T$3J
M84VIL6?7SDA=,)55LS6%=10(%'9ET[7=>7C)@[>7TY+K(X8CRHK\$C*?2G((
M*L[8579,">#M;^A`J55B&5IYHE*2%-KI'`Q#1>P;_\FA*]B.RP3QJ*7M)O4/
MVQ?J5%/65$3EP$Q`(=P=)A63A[X;L;]>S+U.@\#3N&I0(!2F#7IZJWX8#55#
MC/G]<%Y078IW=6%`Q)!Y)0E&@6QOYL`"PAA5*><,;-"FH3[WU-N8:[`KLF$T
MY5'!"I>""?W-1K4_>3.)I?3XP\X0MI'3JVZWVTE%EQB6A,VB($+S88A`K(D&
M.CK#(8KLC;<T:^J5ZFPE-7VG`RYMX@--WO`6L2*1OB#=XVIW:9YA>W4C(4DJ
M2-7IZ1;<"J5@#UR>$%S`):JTV(&*?.[/]H8']"K%7M,9V<*OE&V"^&91;4<1
MBEG[?!-B.<LPMR1RK3Z;ST)1PG<6I-9T<E2ZQN`LKQ5[`D@`'_MO!][-K&/!
MQ[/MDW"MYVENGC)?I*N1LXE"<T!F7>_3+!SL/?[Z\<GI?RFO;[YYA?6'H<T#
M@:OA:79Q+F8++;@5;0QB]16!\-0(+QQQW-.L-O$#+9?CN7=RPHNFH^IZKAX*
MWD*.USM-<#*1$.'\L?10J&+G[@2<&!9":7@0U$BZ%:J=A^*[X2`PM_UZ^PY:
M3EL)75160+#J+//&HTC.^F`R0AN0FLZ"C76G'OI=K<@1#P:LY:[9ZDRH:G1W
M+LB4Q]A\<.436ZI/).OX,$'F/S=SE)X$14*5E;1R5,?FD+L1FO:D^X0[E.W2
M-+GV9(^M<P`[TWK?CR^&@X'>20(ZSE?+E,>0CR8,P5%9"X>R+/J?Y2!`"K,+
M;>?5\I-Z^<(#O6LT%,\<^MD1QK!G1%M"9JEAM<DI%E-QUMH39'U8;F-/B,FE
MDS"UAY30(IQR-BRS8-LJ"X0D$O(Q_;#O>>RL;%.SV['F=CYNP9M;P<ILGB,E
M`*/3XT%.7/\PL%E9+``H%IE7YFOVS[YVM4*\[)<]WDC>8JI!][^%,^Q,&27<
M7#T_U7[AM^,FCR/JSK9'(T?!M58ZQ2!BMEK7PC$,H&\Z\R6^\32%D=\DVN^>
M8<_KU<Q.D7;#\)D*%"V^X\?_GU@N'1!Q1E,'0H>W_E'62BO<A[-ZENNP:5SD
MS^S:H#?A(NC>!9P?4HZG>Q34?9)#;(STN.N9*#(AA9R['G9D#::5#RR_`3,R
MV^9&UY@:[&D.\X)0'`A04PN+>36X+1@78T58$_#\1@I$(V2I$7LS$3B.8[N@
MG=GBP1WS[QK@I>]<(<<MM*:4OK,[1A!F/*(U$T/J:GIAU&5`?W.F>ET9:L?6
MGA!(&-*S3(VI0TGJ9:4>CY$^RL2MDV#Y^:T-I[S:E$@%'"1TC99$_J+@>Y]&
M1B'^S#@$&Z`)\C,6EC'WTIS9X_.0!-[^5*E?$J6@XSK6UXK/JS,2%VJ6CBZ\
M7%9YH$GU0]1U,)JNBVS3!BI@%5X@Q*`,R9)6D`HHE5[#KM"';_I)OK.Z0`+>
M__;7_Q5[%OBE;3\R-"3\_.VO_SN%Q-[,3\M/G.Q09U[B9P"&2YPE!29F&MX#
MC6EIFMU,FL)]`]B]`%'_@.&Q7W-JMR)U[4-XILO%XXY26SV<Z<U03<4TP1\*
ML5E.6U-$6]`U`=`EPVKN"4%5'?BT5L3H`AC=_+(D_#3*++Y_$TZMHO<-&9N6
M(^JT$`E*G>N\+F(P(YX0X7A=,9""6%RK2')(%J*GF#&&L@UDBGM(JM4A9H]2
M'?`CM>(M+?)ZE8?[9!TXI9T[6=H5<_C+;D\S+$TN8L+`2D\F$!]#KWZJTY/D
MP/=S:Z?K!I"P'W1<#O!G9@)M'WIWW1)Q?T2,ED?JZ7!=5/6&0S'-#=5=!GEI
M)<X9XW1X1A%:R+$D-D&Y<3S'<3U6^YR<,$&47@I$B)*\3;UB0?-W=A]+K:2*
MT52J$C1:)J1URSMIO3BQ2R2\M_'>9*&,R#KV7P-`@FP35+0FW!,J:8+F9HJQ
M7>-`")[U]6>7BU,2Z\+=0W$U*O'\4[X+V&%(KJM)2`^7K-.1NWG'UH<V-LZ&
MW^T@8A^A2L/`JZ9-3/MY&@DWSL-@4F8>3LEV*$VG$N=VW"+G7F/F+HYOD<A:
MLP(<^(EJ?Q8?1$*$5.[F/7#5@K*",9V48S%D-7![Y2![&<8JV"(&?^QY7]CS
MK:><6'[^Y5/J)EM[SY]N'3S]TO3&<_VUM?>"SR0UD=?TMB<0P\J20&O/HD2Y
M=Y4+IJ&2.H%K?T>'/-*Y>N@)]GD8-%&L**,S^%I%+'`*^/&<D7)FF0;W!^5D
M_?#I\*B%3U[EG\J+]TXY2&'4[4<`MEVAAN`=:H5P(L!NY;\8R:)V"8$)+OD_
MQ)?=B%J68WJ-#Z-_V#$"M.>8Y_VE[)-3^W%!"D!\:<B*+:D0I`WV+933RB-V
M*0Z-RM/L$8RNH)Q2]\3;&S3];B>T>^,3^$56/:(=SPJ^G+58Z4XW9QG-_'HP
M?(E^L$])9.W3>P?;N^!,B&H^V1#,XR,_#;^_O_OXZ^(TTD"X'81C28`V!:]>
M_'R/)ZIGV=F1]ZR\6#NYW#PI^.H3:CV`M:;I`M*'%"J*'RR$[K1@@T`??$(6
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MYIII(6/H_)B<1HXIG`%ZYAW#1NL<0\5I9/NW.5&Q()'+1-8TZ1ZO$=P_&X-K
M*/Y+_:?2E=GLF>Y5T.4A1+R5TAPG<O3DX+FY-]C-4$E`>QOG^03"4#8K5<4+
M^E2XGKAW<^4;E8J+O:^Y]*BTVX>9)AQS9B4R+F)G*Q!*\^H`?'!$S=S:!6_^
M=2<7WPQ^/X-OML".6&)3]1D16#76MP+=P4#$-Z7$7HNK0[C_=?%?_?1U`U8/
M'MDDA]7OYO)#V(U[T)S3IG#CW9Y>FT./`8526G#84AUA@CMU3&&5W"FWMBO%
M6M%(V1;T;MS![0;X#[Y69[_PR>#&]U[J.D=]M3%@-:A,0+'SXT9Q8?J<4ZZM
M0E`_6,Q1+\Y9S9KM%H\F.]4.]7,*X5AC:(R2I%;%G;*"A\Q>3"Q[*?CV<4]Y
M_$'IX6S&\$*@1HO,N5^9=D!I3R89;@JG%$T.(@FU1[%P.WI/)@`NA.]2)VXC
MT'9]0GZD%E8/#!-:/_]^D`6+<5+4'[@E\<^[5N8UPX:2XJ:B"!&OM$$O>.&H
M\N4O_T6/,6B*C#)D01^X#WK09[.Z80ROB)(8R<7D1YM<+V8]`EZJQ*+"6+AO
M,?]B/X,O@V@.4'S1#H>B8;LP`!`$L28-5EG9W`4W0\U_('B,T_7>P_-)5U3D
M=U0ZUV9:64=/+*,N)7+#&N$4LDY"F$UD>6FSVZ\;W'B1D*V[?89GC'6$/@/K
MR9C0D+=-2_&K.2`(ZPTAHSXHN/PTWU;B)M[3H!<CWEO(/I]HN'V+PG4M1V="
M7#_6/6;L,ES;%G@=U45RBB8IO_/9DQI^#BR:LF!@T!9\<939XY&E<AI%.N0&
MG=G!=4U](&H3$B?N0AR[^&<G/)MC2)BD(Z>(<N\:$I"(28B+Q$0`JDR.@[)W
MEY@=[CU@N&15OR184W8C[!-;Z!<-:`/PGPD#CGE02H&DXJXD%S8I>V*,N7'A
MQ(S<D\"=-L*R4VG=;%`7R)[ZZ5CA3-F9U_-/L?[6:,0N=>YTZ7YR".K<FDIN
MIK*?WE(?MI[9W<8/>&0/PT<O'_>L\,]KOE[7.)_<$JK3DFL^LHM#]_-/W^M:
M@I]_>NL)),N[==TO4XF</5S[>]'[%D08?M`=/K#"20_ZM[C:Z7H<NRRS^^+#
M[@\__\0)SW6[MECN[[A-ISOQAFG?W/&EQSZB>P@1]T7W5=53&LN0+'P%/])5
M-N9?XF;N7G89#]HDB?BZHI3$?Z,KFEIHL?A(+GG^YJXW2SGIF#S*&E%%$E9+
MI69E_*5@!8B\%1,1_>/N(D;4]QDL:75)^_R3#'B[3O#_;)DB\X\C>E!?[CL<
M)'I&%="0[1])^`]U?#=9T]2;TG+LXDINDO`O5_%:P\8>J60]P]?5V2.+/^=?
MIZ!$2LGHKG-)?EE=G%(!3VCB4X"<[KC.6BU0UE8JY@))_TMSK.E%@-W"K!H0
MVO92C2/8C5"B,C!D_+%3DH18%?&T=D_3#YOFFJPHKBUEFA6)X1<(EO$J?V8%
MF^B01PHF80V><RI_R&2U9\[FC+/<_C.K'\7KF'?LE9?89^?.K0,V[G<SM_16
MEBW23N--"Y9-B>Y%VHS9XFR7;<S!9^K70M8)$K@9;"_=#`8!<1'4'X:N$44\
M[Q#GOX%;E207<=3XT=7-?\1[\LQ<]\EK928D&+PL)\7U98Z-1P$-!3D[F<)P
MSK^YD])K66UBWK$,ACQD9CTUWQUZ;'<H>1'KE6X$'^`('9'/HK]OF"XH^UR&
MY$`9$CZ.\/NCL\'+-T?%\.CPP^GQV9I/(9Q)55M9U&OGB+U0':/\8'PL&=KU
M=<Q'2YY8$Z$$/TL"\!GW@Y2@O@74_PZ+FGZ[F/F.H\N]O.6']$W!WG!2M;WA
M]C6[JNX1\2@T=O:.68I!@J?37:`O!MT1AZJ]9G6$G@,S^'C'A5.]T6=^VV=G
MTL]3H0M6#_">VS$PR]0;=X"M7Y\G;R[OHIN0?GHB1VHYL*Q$JO%2/\VS._Z1
M8VR[%4(L#X##H+[Y[%:Z<`==*`M)^LCE2Z%[-(<Z^&KW5U$)Y)QZ-U,:<-[;
M&5SGF5*/-%7I\P64U.R"1W<WHDJ0T@GWU%+4XROSKBP4I63Q)1`=_!*(+.4:
M<":Q2>5=!TFK`-UL>8N0K181Q%0UNAO(=NI8U,G1'>N=\<(_8K1U5]QE'5C&
M&W=C6)&>,/9WU41Z:OM5^C".OD`J^L86^^(TG(;PPP%#E40]F#R)5\UL_B#I
M.WU2YJE]4F9X]O[P]]LO!\.C5\7A^[<G1^^&]GF9KL1(23:AEZM+3M[SU34_
M563^\)HO!*9&@<PT!I:3Z4N-"ZEP;[AM,NF?TY]FV([Z):<>_*8Y/@=E]ZW-
M6N#>NYXB_O`N5WGXU8#<3Y*5+84^>-WBF>`XR"?R[A0WC^@.3/[#O;V=_9]_
MXGRI+@J-A5<55F(7O$\4^C(HI%&@)FW?*Z/[I%(9^SO/OW+^W%P?)*<3+EC.
M6"_V?BR:`SEI<SHK<>\]/=MY&AV<_Y`=[>V\>!YW!,-*MX(Z9#V_U#CG@72>
M0TYY$JVX/]X%37T;T!-3I0&\>D&8'H.&+B])@M)Z.1!KUQ;@6;&C::I9>Y8B
M!3;Q-,5[OU:E\WL3]D@U64Y).\R/033PFU5E')Y^'@K1TH:[2$K3FSW7.9O:
M:;!%Q#+1;Y5V\F1RW)>C#``2#V>'(Z*K;=EG95CK6!47[%F_?O8.4VDX"$U=
M(6W5#\=.D$8<78W+)DF?E)6AH;RWM(Y_":YU=SFD5M^029=RSV(PS96VH!=L
M0$C)Q<TJ%!/D[7C'\1O:*7I\)43V!+@)*;.ID.IXFBEU9_AI#O:0>0^=(KRK
MEN<[^R^VBH<'.U]Y^P-_[7=:'_K-1XE18MZQS9@=SG,RY'P$>KS;.T/D6OQT
MA";UDF#P%`NY4>I7UT[7GP+J2N7>SK/=[;V=Y\^[#W[5_6%WYZNGC#QXVG_P
MXF![?V>OE^([BJK9#O_`G$YG,VGF%_2<\&<[!U]N\Y\>-&C*71X\6_/@X`4/
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M0TE?1Y.!&5)6T_<)1VJ1F]@%I-W96Y^;/$R>LJHZ`V8X44$L?!U&H<'KU`%+
M(2MV`'\F`'AF`<#;P>_>GQ:''P@$WAZ=#H%V<'KVCK]^>WPR+.PCDV>G@[.C
M[XX/B\&;-\>#=X?]KTD>TN)0GH>;>W59@8X[T4O4W55[G%#Q)MR/E][QYGZ[
M?(`^=*SIY^^KP6/^K7W+$'%+WS(TR7XU*2]G6//)J`?*,1^C](LAI4,0#;%[
M]%J`'2E2R1ROFD\XMK8GL.-I@'3QAW\?,^V"SV+JCGG?!CR=/COJ'1'Y6L80
M=CU/LPP)*=VLXC7/]!E,VY*<F^;`0?\;CC:(;]/$?9LO@CLTIX,.AB,#K`1C
M=E0T')PVW:*/FBW39R[SSW&EG;41U0"O:F@\&-'TN_;@4XV[@4ZI;AV4\)L_
M]!'$F7]XTS^JXF5PJ&!E'W9"Y*]&P/#-%2[6X6HD:]6V',KYE*^D\$&N^=*.
M.[_&7U.=]OOCXRW]A_\>_ZNAYU^]N)H6#W`'A\2.&\<U6\O%#NGDNRS)'=A:
MS:[DY_%IJ_D-AX$GI9VET$=/`Y,Y0R2P2YK*+N"3;!6CE_@C`!6]WM*^-,6#
MR.$V\+<K.];"';-&OT#=XM%O7SW6'D$=+UBA8E:MP'5^=48<+&\VL:6<*OY/
MO5X(`=D<HB=?U++Y,5LG_JQUI,(@#9]+`Y](/GV-\QG-N<;2ZOO6$-/F:H))
M'SJ(97LKI)A_C:9D5IJ2N8\7':9N@KR(G^$(OL#D)YG2`AOXTVIDT-6A`2'I
M`DX"SOEB.M[^1(D9*^ZW$&V?DR<7!8-\,RA^*L)V(`#]C#0["6,<;%@BMF2O
MD:1$5%0!T86Y(7F)!HV2R[7Q4/?KK!W!;HN.4-!&T!F_1":.FL2BF9@M3!A3
M>V9-DXL[.9)H_=!0RCZL(*+JRF3LSS79B7+:7+-C@+FOXA\$D(OA-?O6'=N]
M\.;#^DII`JRM:@"*?0!`;5UOXEJE8M/>0G0F-LT=1#9R39^*#"<^%AS@Y06[
M[I1<I[XT]VJQNE16%8)ZH/?H^!T?_F.!(V3FIN*E0VJ[=OK^S#*TK<&'9P.$
M#0FBH\OY;`VHZ<:27*R%ZYSNOCI@)LTDFLI7R!KDTX9-W$J"396P-%5V):E_
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M_MH"Z33M3`/R6^UX1\+?4"4MD$*73(T@CP_WX9U$\G96Z+/LTKE+3@I&0:9L
M)>56\Q3'<PQ"Q>&72XY@D8W1V8-0D-7)',<74`>.)LD4CHC6^G@3U5[7',BH
M)*ZQ+F`Y<!0ZH`D(&U<1Q09S2<CU$1[L)]IB2U8[Z1`KK=AM;Q9ZZPH&D1"4
MTG6G4V(,CCNTN_F:%["&[9:6A-3,O^V).D$-:LT<$[#04+P!/TTCO8G/Y^O(
MVO(J,JM;2+/;M`6N74R*3Z[S,'QJP>[#B?(N+Z.Y*%J\<L_ELUV$8!@S8;RV
MN64\RK\A<;VTAT<H2C\9:NP2'1YG=WR`I`>N54S3JN&BC&BK&OD*!!/3B>O5
MRY(QO!@QV[Y\J+!T:!GRT[VJM^#L**Z!OW1FPON`,R%^F_YV+W#]&]Z'Y)-F
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M#?#INHI%I9-MPFD`/)BDI*9Z*NZL85.J_=B<ID]5\&6W!#>E?\&=W5O.6VI>
MQ%"@"_!-]%X3>YO$HP4ON<]%;6"A_;E.=X7Z:0&\W;XJ1-#5/HV<)^Z+ZX!?
M(497C2-XBK+TM0KSC)MS<MH/U?UXU-#,@=3%>+N<ZI2B<OL&<HBJ3(23G/5A
M97-P4I!DH,KS(=IU@V:=4]11(S%_VSLT\B7&:U@[MF]%CS'(B!1%]U(SU`_;
M#W51`AZ_M71]C!12P$DA1`ES"Q6VTB?+G854=IH;K'0$.XHI3(<#]T+"8A^#
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M%!8>2!H>1MS,W+K),/PW-3W:I$>FWT>VS4W`IU/<2Z>O6^CNX%R]PGG$51A$
M(<+#2-8?:@GT'U[5Q)-:_-1^:M=C[[TRHGUJH@IM5^TGO*6N`T;6$TT(0"Z)
M*%X@`N35.%TW9RA7B.A\.4MV]LBMTS!FQ@NMSSY$W:C\L9GYX1@4D(L6+OS(
MW#O$9'Z;^U1/*,#R:G@Q_*0LLD%=)7]YQ6UZA=VPJK!!$FC/82*Z:!.8![@,
M*C32K2&9(5U!D&59UUWWY]A7R`_K7I,**\4CRN0`$A<8Q?H%#N'[%Y;E+04`
M\!E91=9\+W.*906O):$@(TPY7@Q!JIEBI4"/)79ZJYH2XHW@M+"HIG&82V-.
M8M,3,`1AG6JM$C8X,7A"^$JBRZCY-44]E"T)I36:1D!1O:)W+N=E<V17NA9E
M8.Y1,Z22\FMU<4PY&?@1ZQ>Y@+T]&JAHO^,(T41:3+[!69:`Y;'HU]XP3"=R
MX]C"^=+0@)%/C>XXC:F((PO>]KM"-5MX^M0Z5P40[LHO5)$H((P:L,<XRCG!
MSK>3HRE-:PFP>L9]0GH`N<+]KL9<!-O"I2;&I7I38->R,W<BU_C>V7N-_+9G
MNU@/$R6)$4ONS?H#PGB-(&)FYV8]$4D"=1#4D]&MC4I4H]$<@1+FI+JW3NN(
M]?44SN7EA#0""GJ)A=^M9?$5N\.FJX?"YP%%,OSJW2K[.RTQG1\2K^"B5&IU
MXA]R=%7G4'UK^'#K;K6[*A)LU\X.NB^,G)+?6X!(FHL>@%Z0O-T]$CWRV%QR
M*YBF"216B;[^7O`K/I%Y@W:PFNIE'+^&V(WJGW#FR-L3J,"[VG-EXCB>FQII
M#<'RHV*'BT:#OJ_.14@@Q^0U0M_Z;+#J6VL5S'J4_&E:F*'@S;2P7L[!)^IB
ML3".JZA;-OUB=6NON9FA%?)/PG:1<U:G6"`:>-&+N>[%`FZH=-D:,]EZGC1%
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MP?F;][3"1N3)!E8@D'T=-(I(/ET_0QVF'RT;$;^`*26;E3@7?2^ZZIEDGO'.
MB#K?>6#W*:!;*FO`6E4`L,A$*Q[9,BM\S]O:(H4J5IHPDL>$KT^26#=S*5U<
M(=FHNUT=ZN81*$<YLS"'![-*.NLFB;>XK@=BIG7(A-45-?@(31X\H64$*386
MC@,^GD4@%F`SYJ,_/"82WU$U'.()'!)&IB\Y#C#>Z]=FI$QP(:BG".KH`!3$
M\R00[MV^4R5E5\J#QBQN)7+-UK,F$3-""$EE-^##O#:JT=@?`X05FUDK^ZY=
MSMIO6=WQ7]TTSF\7T2;$\?Z$#BI7,UP\*V(JM<1".BPN03,W]E8K.4<B4WNU
M,Y&=)"0>MH0809\#)^DZ*:TTS=FKZ;0<$2Q[K!#D.A[@BTY\(#GTX*?'---`
M`SD;K;EVH1)[T^9,:0,?'2Y9R27<(K)R[#=O>MD'%`GKSNX+A`?)B3K-P%3:
M)+D!+[6\4$UBU%J%!<Q-(ZK\B<D@[%H(V3#12>;CSK^F0'9:SL</N%,LE:2G
M?8B-E.680AALP\%-)&+HDF+'"F,AX4].\,6GA#T7MHD5I7I_1\&B3(3@.<6A
M**Y#"IH"U0Y</&'>M!E*@5^C5I'Z+&<=.M0=2^X$4$J\S&0A"'@`46I612XJ
M9*!EFWFJ.NRR<5'JU,,SU[O4U(X'^,JKXNAHKFW'7:FR=?:`N2O#"*XV))3I
M$4#>N"NG23)+K==ZQ#_^R."J5F>:YL(SHQ59BQ,%=3(E&<BR<UHS)"Y5X$YS
M4\4-,>DH#9=3'+%@<,OLJ%&@G?KM6D>E:LU;M^G9C$6X`[%K96RP<]9W"`(3
M=@KF51;"<0LC//-#GF#"D!"0?O.0!U\8)`)#P@[L8!&$C43IRG*],%\X(!OU
MA7#4SC.0UCF$ZS\\)[")PQI^'OYG2K:%H6#>^86)X>QJ&.):\"C>3,;OV87Y
M9XC'BVNE\N].@HMN#*^=08:0232]K*7BXLWU:#L4^-3%M0.[4(LK2D(MWJC\
MD*(K?O@,M1B7H1L,-]/7"TZ8?8(J7E7W\*]['5+GA^+J#E_IIVOJC^'A(E]C
M+7M)7):[GWHFR.:GW2JU,OKSSD^MX0-Z=UTVNGH*U".O5Q$5$+Z:Q<03P;B4
MB2;3OCZ-K4B>.YCB4\L[&-.TWA`UH1\DR4J^&^]L[8NVT"NY*M'BJ<DN/L\^
M$*T`1=732A0Q%X2JT!+X2X;BY/*,RP*X?>$(CP3MA$T-)W-P?W/VK;-9R[<T
MT9!RWJR%%6)/*NCIV3O$*O9V%EO(&W4P@`K,?^BL<^(7K.,W.N+&>F0$0N52
M>V617C.K5"ST[EK?ZSPH(=P7I\QW,5,)#E_O$^P%$B1GY3.E(V,\_#-Y6Z-G
M)O=A7G9+&/_=-..+]>/T#$O_T7&^6*W8&%E3L)8J+I8$1'PFV?HLR^JDO=B=
M'MIZ.IQ^7$':3P::UE*K='&=A:6$Q!(Q>,YY'T/ED($YO0X#<)Z'^##8P[&D
MF(B]ZYRD'J:.0GZHMCZ%89759?Y%/N%KSP>`#U/>!%$E^!ACO':QE6>ALS:?
M<H@L>H(T0+ZLM:2=:*RAG>CT._/`W_U"B'2JVKE390Z:&XM(S]D1AF7F'%GW
M[9@\H0CKK.J7KX5&I]6;UFGDHZ0<DU6X6*>20J2W2CW@L'@EDJ;*^LP?JU.R
MX]!*.163]+7Z97J--KHH\FC"-84(JU&,QY1D'TX@-Z\`?/K*T;_SBN7HS9=0
MDTMW#UL_!3!K+K!*.+BL2!N)_-I6F%#]FL0'\JWZER$Y/_0";]<+DT:^S1="
M(6,I$UNT!JI*RF/V/3^"5Q@6JA(^Y4NYT\45]NK\['RUX<KH$?Z.E8,W7,%'
M)>3;X\F`1'J*4N=;+E`4EA4U2E[E>T4F5U4HNZ5`9=27/"6-#]Z`5NA<WYPD
M)HC,AV_+APHG*ZBB:9F%"1J*=R64V-0U4DJR:%@49=,&,79D5_PZJ@J(\,J<
MC4F.]R_``&W<%,:@3`DP4GS5MP`+P(U#<8S):!>^-!VMEG1.=S"(YUJT!\<%
M21DOIX2*E?$AOM/=\3FC\2"6_?\>Y_/NG(!>B3<I.(SL->[XSV&#`-,-(K/2
MC(,=R(*G!!#YG64YVC_Q7#@]1'%U8H?$.FD`8VV+:1Y][\Z=>7P(\^MKLR%A
M5N^TE22&(EO:]+`W$:'NB63)T)^KSA5KR6[LK!SW-C%X?^D`R8\):)]H/GP"
M27"8@F-:`LP7-*_X:*IDL.%YFE5+!),ZT4*CV5VIW?YYJ]!O#&_:`+3'Q"`^
MFIRX0-$LG5;MMVHLRSJ5[1A%/<:3\!HKL@YA6CO[&;-)D4'>\>5_2\'*B[GB
ME7MC;ZQD@<&Z??9\@M^[YKU(J.S2<'^2:XW.MN1Z*6(PGQG$*N>'1>3BYD;E
M7YE*[N'RZ_6X:A%=72XIFO-UMZTKBV*#8%$>EQ=F>8[)$08JU1ZO,`*2ZVI\
M]1HWK?FL3%3S=NIRY7IU$2]9TW%'404Q&>+X4#.=R5-XI3!`?:6T<#:%`[V;
M,.N*G)YFDV&I.+Y6NQ*).'D4?Q;VE>]A@?,M&^A?QG>$.84ORU-2K0VOM!2?
M#(,JO+5FD!4CF,]XRCM9FRE#2?C52I5R1RO]13$*9C>S'I^*>4SE>[&<,Z">
MH.O,+O'`EF,Q"%E!?*5"&2HSX:8HOWM]HQVE"*T?;R(0F)RTP^QDZUN=.>_<
M^R3>]QGSCY;^LK7W6#G-EE-O64:E%7S2*(1\HDW9I6ZV&;6Y/K$V\CK(K)9P
MO>Q+<[N['5/[N9+1<<29V-51H_U'*W>5&.(5@#J*R;GK7*[8((,`>6U#:C&B
M>RM/3`6$1*:`.-:^50*BI[QQ3UU5!8NG6WLU;$H")5.YC)3BWCPE7:FRU.;9
MG&E`?0A#+!"LTIK%`F7?`#H/NW?<PMI+TLO6#MF2G)':[\!VYJ-*2$D!)?OQ
M\6`HJ5M\&C%$QJNG7I]BI5F&*ON-ZB)FS$=7PSG,4#\@Q4V4&&7NSZ?6K+AP
MSC1I=BRH\E,E557("$4BVQ>F3IOR.F0GY7-P!I8&SQF[8GONYX[YZITD<`_(
MFYXF\NE\K?*C#ZW<T2NAD0J4Q-7JC1LK&H[B%Q9F^_XZ'.GI,9D[:#]_43?I
MWZIKX^T(L(Q^H8E>E-<F7C6`9X6*E/%8XUE7([,06#0#\`"OWOV<18R6GO[E
M\;5\*5"TX3#"4U%C4@'-F'ML\7$[0+DQM:YNN/XU!<U00LKTRC%68RB7:(5O
MX"X>11\M_;#U[#%^Q+E:E19OC.9&7,3>'E*J*I-;"[Z!4F7TF4JRF]A>19Y'
MN/*/+XUY&@LJK"`1$*#M.+%-:[&%`MDL%ZXN6!?->0K'=V![Q,D\G^)\`I>!
MXV9N.<EGLC)1JJ]7XPXJIB>W6]ZDG;!5;DCX%V\\W#7M,3>Y&U)/O;1AE$]R
M$?\A%O8J0)'&3@P(';8PM):T@@-]F4'G*TQ<QYL>5=$)B1-7G@#57*[B+ZTK
MPT%\O<<KQU7;:0YTDY%DY+0;>J3<!^4E0Y*'"IFBY,RN:V9ZSUIUC#=_?+&S
M3P_3Y\]&SQ^/-K?WMG_8?K;=G>'B^S]=CGY[>_*'V3GIE?_RNW-A"I=^_^[[
MYT6175NW*#+_F\4\&J"$N$JS3MZOG/VJ[!JYA;FA38;>Y@_4%M&#%>>[]-+]
MJT.Z*9P>W99:LH6M:Y?LIJL)>(-@62?;F[DS_,7B=TGQ$=X_G7)'XH5WSXB_
M\XO11"-!TFTP5770OBA:;Z-D@<^V1^N&\HZ\R-VF-4`[;)<]6Z=;13KE[R2B
M(#^XJ2.E^5"U`(0\5Z)=ZE*]-[I/G?228OZBNULR"Y+CZ$J9-@!*--:H#./Q
M3U'Q:ZI<+N$I*[%>[S*35,7C"RL(97HEPV8M,/2.61U`$6ZLK-(::5`5'&\I
M`%!Z/(#:6<4JFHZI6L8MDQXDD:$-965([DB0)JU\#F2/O'".#0$X57LIWLVJ
M41"(Y$38UVP(J8$Q1S=/`DP!;(X!:;A+FJ!B+9V]MAZK$Q<FDU<J0Q.&P1CQ
M[1W%0V/.Z2`-A(U*;KL%AFY7I^02.T;`HUV#9<2WC6!M@E<T^'"UM?$E>L)%
M;08XB4*:^O]=_N?XN^__-/NK*JG^Y7>K=W['O[03T]K?0K2K^N7B,36T_LJ!
MQ0G4JV#O#,#HZ:L):3YVL4B\_IT-?/D]JWUW_.ZL-^4_9KIA5F-^H8."H\`5
MT&%\X,B[8-44#N%F-;W;G4(&X,.+R3&=0_C.,2IX#0U=@I@BZLIM"LZ^G&UL
M\EP'L05=ILMS`/%WI4%U44*&>4%)\B5:5C4R=Y^O9_CK<,P%#.%1@%S'Y\!8
MR.PM;"PA6(='(;N@&%^CC6_7LH#1^#";-F>)&TOY@'E$IKBY2.7+.X=HXAJ7
MJO<?(]6V>X=B"X-7TL>A@K5V,9S98M=?C+PDO-_6?<G/Z7N_&YUEOTTT6G-B
M,?.\?;2,>7WY=CHFKT=[X"`@P"?>M9PF,V)>S.^6QM[.P]]:F\,5N[I^=,>Q
M!$\\H0TD(JOCVR['@ZG6\,6V8V/>&0![]76O,X`21%)JOUC60.*>#@!-X5RO
MAN+F[,6<,)%[US'%CX+;(M.NS%=>]7K*_K!<XQ;I.VF*8'6-Q.IB0>R=M*;3
M7K/PYG2%Q[E9%:?,)@HV^3C2.KB_^CI`^K5@EH+4CH"S*KKWV*5.4]`5.9XL
M:V85>B%K!FL:C`=Y>EKL75V-ZC-3`P:%>\1B2A5"[NZ?*QFN/01/E`I(]]5'
ME7"$PE!SM$S!>)9#I33IDXZY(CNCA`Y-MCH8.;/3MQ3\OJ=]*6FTW(B=E#(8
M=*4VN1#$NLD^ZPYYE\16R[)4%`08Z=Y9E![`"*]*XWM5<59#N`YJRI6F&BWQ
M.AE+"-79*U6/I^6=D0Q'6HCIQKPK!.QL+-D.F,ZN0&:EL0?8'=9C^7<EW*3A
MVN]06!6C2'=J0HT]9;`#@V@I[,LRD^)($Z#?H$KR-9Q>R6D&D%!I<M9L\LIH
M'="'%."NX*$)5C?;HUUM;Y<'XA,9/RI-78>C_5^A?$4"N>@AWQ@+B28SQ(YN
M`%3YQL1Q?0F\"^KHU`UM8&>0)0&_K.6`U0-IFS5*DT5)VI!U)`D=U[#&7JO2
MP3>1Q;D_N$5298W;!,\A9\>.C@?,14']V2-BT>H2L6\-ZP$%J^LETZZS]E?2
M2R,5HX)>M9D>R+4^]=-PC?`@E`/8;M<@N_Q>9^/BT/1;4Q^:2R:B":Y.J+J/
MPQ&_BQI)"9')`O.NJ,C@EU"@0RT#;.6Z^NTT;K&"Q,N33M+N$%`HF8;CL58N
M*Y!.^\J!]1&'R7BA7&=3[;N/!8.?K,O`-ND1Q/C-L3YV:\/L4+/8(+,GY78I
MF@<`U:\.?C'XQLZ12`FNU,'K:^[ZV)S,WAAOJ"[$:+>^$XTD#$DPF(@E^"6?
MMO?V;0=JL[KVI:7[&[V.O80S>J\][+WEP^/U.\34(:]!LG00Q$L/-GJ]?Y_U
MX=9.29PG[8^SPY)<\$)L4O9L=6E2=H.)Y=9:R]+.[M[_F+P]_R.:G^$:,<B*
MF(U3*`,KF[*HUE;T#!?WN`LVRV*M$BM:LWZ&4MEA6BQ;.6Y6SN06$>S"N3(D
MWL&O(2[A##>9^YT%679"Y=CK3FNFK47<F0R+2\8%$C!9P/+*M?>1B\.<"^1N
MEQ*T#BH0C9`]1B$8'N`LXR75`+M'(]@+8A`+!(YI15EFD<NJT<G+JY;PC&19
MWHQK!DWT]WBBC$<.KW]FM<,9V=+=F&TV8YS-:WA0#<^N(4[<$R&R!W?+P&A`
M`('WK.)UY7+RFQ><O-)-OZ,EI?CAXI,J"END8JP3%T:JR8$44[1$[C%_^>**
MFL59<?\M$'K5O]KI0-<;G,BR#J=]M1UA_"!J%/VI!Z5*#-N]L(+R8?3G64G-
MGNO=*K4WU`LL78I_M9#$WSEVPRS\9OK9K\+4%);H(42ZH%&[,9:S([WR,D5%
M.`K=Y"D4LZ/J8F\A!73[#DJFY?@Z<AJNYBP?I7VLI);5AJE,E=0Z\1G0YYS:
M/MB>6>#``9</_Y);%#2Z)!K",<ZX[0VOAA\G`!#,0PIKR<*HD&&N7AAXC-"C
M2X%[1HZ9BC/W&"3GK?&BT8[&"!"8"'$DL]"9/,RTAF`9O"#AI\\B&R-WU/([
MR]C0X?0]V<!&4L1_!?S4F5[0L2E47Y:LG5`;.C4.E1\G(7`L37KV8#=&@='N
MUF!U`FMZ"^JQLZ_]EEK'N>7@`<:*GR_7ES5DGIU43G$]?4EMY2^&+^><E0H_
M(\L($)$N']P"OH[>5".UW[YMNAF#;%8J:)R</-ZLQU`H]?3O7;R7;!R.+F8"
MF9(LZ2+OH:ZA>`<F97YO=YF:.$'=T4H,%5$7_*PK$N*H0UM-72XJ_'$LL%+&
MF4_)4I1-#2S,5//AC/5:3Z%X[''83"N_<*>HX9./!,)C&:'S%$1F>3D!1-`O
M9@`C8N")>9T8-0>72Q,EOJ`]ZC4(R:^MJP[[CP9IY48;1#AE&C_#4,E<F+YT
M%!=.Y4L4JT_M`X,6M)/.+"V%-71%O$]4TT#I6,D,F&:PI!/=SI:/5)L%-(E7
M#2)P9FVZ"]CJ5DUUXLO21$Z_8"G'T@4-/$7J0ZN=P4T5?'&@>S&NWG!^8>^>
MLQ?M,$YR.GJ\-;:]>QT6H2?)`S5D41N:(V;KF2]C9M!%=U9+`6J#MT;)\!IF
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M96Y)D\[Q29?_KVE2;Z".D@\78J+J3,P63_/HQ^W1#^G]:IQ0L4.`)%L]BQ4;
MWL?U00$_3A[-(9X;S!KW1=*UT+*R1T5<,RDPME=Y;5M,C9E?GMD)2F,^QG^G
MD\F-!7%RJ9Q$/CSPBZF4-\)_-9P+SV4R62_!Z$1$A<TBO*IMQU7/X2NRC.M2
M[9&8.]@(!]4U\G(-2"%/9T2:FW!B^)F0L-](TWA'M8$D25*@LT+BX)G:>I45
MJ$)`HT4<'M;GP?!8V&Y,B]6E!SW\?19IA$*]C"NLLF=&F7M?H2@C"#=VM.\\
MLFU[T]493AKPBX+*H/9=)B0YG^$X$R_;1A=@3IWG&>NA]I6FKR]UJP>=>.D5
MQ6VS%\!U;-9GWZ&&!0?!EHQ1?#YXATSB:5O]LQU"_1H1>U!Z$DX)1[K-XG_B
MS^*5:YEVI:,F[36Q`\V6"`ERR:XNVTI2"A'!UT;12G@B7<3H_7+S&%8-!AT`
MHT\,>0EV9?B(P^B0FAFT_JR[.,6UGT78Q4A#&FM:ZX13:Z,EHM@4IF*R@2A5
M.+2S&Q==$Y^KY\%^08AO<+]6P3*TS!R)D6*E3SNK"*DG:,@Y7P'(;8<60""K
M!::<>5R:]_+MA.CKU=L$K23`HAB<A3&K5!+(*'C*#.4Q,8\$0BU@$0P!L59?
MMA-B+-37OB9WP-M%@*7I,OMSEB-X%"KIBL3@=-)SP^:3AD>2MB1YB+5</^X`
M26REX[SZPF5D^T,F_8#/(5GV+#,;,QSGY.0]O*K'(8:A,A<&!5R5WF1VOR<K
MA+TW;:.+`H\OW(*#=$F8D;4NMLPXZ2[(WN*V/?PV]L!,]F*_;QG6<\?D6N%N
MNEY5TCJD5NIE+!@I[^*]K2;LL"S9ZP`!F@J[H!.+LJ$A'O"WB=^YKF<I3ZZ!
M-JD8&[!)XGBZG=MUOPCE*07'$L8BRZ=BLB(#)Y@4]I,R91!'=4D)S$<1S28&
M@)Z)[>Y:@%09[TC!-PP:?A"LSG,^1BWTZ)`1.ZEIQ&;,?1TJ1.93UX;5+-;@
MFMC*7EBT%NE1FBRTLHF#L^>U%N8E^JA(BW!JJ;@0E$N<*=^=8=(HQJZ"]<80
MK.R'0#1GU)>XB9%["8;88[O7O__MOWYP;Y%!9?)2'6%HH`2DWDW__K?_8PJ&
M>E&KBR/,CY8`P4<WZXA:#L0)["4.EYG,XE6V^%T2S,&&&(VCW8ZZG?;UC+VX
MZ$WS%'AIE"`)E?T1IF%Q!&BT*IK*JD7%T\#5.2"LE!:%G:S:('1CUE4=2738
M!D0AYXSZ;@*J'C/8Q66B'O<D5-I_A5GMSHV;D9IY]JM0_^IT0@&)O#K*,SY)
MSFBXILZ!D8[+2/!2HPBW/@(O;;%%7W5;`=F(U',_5X6<.N@,>%V>'=WW35A$
MWGM*R5H3'J(XWF!92D6V&##KPX7%7G1P2&;^83B9%5G#UYQ<;.JM=WTY%):_
M-!9#0)EE_FJ5OM8:QV+,>:5:]B4X46_+)K<FH!!RNP]5ZV-5.S>SS(1JFF+"
M@'46]>Z=Z<\(BH\?MD6M'S]T<*T]V:6=TX\?LLODXP?9KN>7'S^`OA\_6/CU
MXP=,ZDGOLM"E]3O+#Q_V[B5<6KN_O-$/QSU"H5?M#S[?,T(3C.X=2GO+H?;B
M[M"/:^V/H"VCD$NB7%YZ(4+!VR27G9O=<\W=@_<MH7EW[_GN]M[!SR-=,[A-
M<O/NT^UG!W/GD<10Z-1G0));3V".72=;`NS7N*`6'D;5+SO/U*[G\151G4L)
M.BWHU?%O^KLG!)[HFCUE*>O>>'FC!9:!MS@+TC.\>RDT@/<=GD8@1-)%XX=W
MQ'YH5[*TOGQWK7?U91]1UI8?WNT=W]:BF1*G2[GRV:EA1$K^^[JW(;,E>N[\
MCB711Z5H$G^H;#)_8156+)&52(D6(,>#L)]-[E>:UUR8^$"E>+ICY%;2EF8'
MM;PUI`>D0I5?56"\<O:*"WD-=Y!YOHH>%;.-*`+IG5SUR%`?SN\I$'*V4MXX
M.V)*(<DUE/#`*&'S^=.G.P?"_OWVD),9)5YVKK%9N&ZR%7+D"G["4.=H;P@&
MPJO)F8.@./'+'H'V'G5.&+5XU$J)_>W1\U(3$#FU.=^LT^C.QBG98C#:*<6W
M#DY_)@W2`T\<:K_X]Z$J4^$268*FRJ_BR6$X(99MC+/KH1RHI3T[MCWF$CJ`
M*QVFLLA2ARQX`XJ-)YK7J61X*#OD[Q-^+B=Y[)<#B]7W[BK(NDQ[G,87VA^1
M[M$\N??$#<]FF^U;^U5)Q#?&A2][IH1X,\SZ&G1\:.C(9;";__KGYT^VN`<6
M5<%X\\'/[:R[!*+<W6;SMX_95%:#)>SM?F=+>(;%Q8>17C3QZY8P0)/3-!PM
M*1WOT@CWT9FZ8D&T7MY]EGW\Q./%,`?I%Z(?7!ZHOX^@G;X]E*#M5\1($U&(
M2=JETY7X!E%3]!*UZA,=HA]"9"Q(;E4^J+Q&8'-TM*_`0.3?ABL)YWQ[?_G.
MJM]]'="8,YXT3DWWL/MV@"CLNQ=B`,;@Z&2+JI0OR9R,UN^LO,1])9\W$>,S
MKVWS1K!0UJ7</LW&"-K#4UC.+37N?E"4!O<!2)E`M*F;$<IE:9Z=-6[U$]'G
ML2_C%_(J!N"8U?(#T9&4J6QZ;:Q>_TCF?G'9^#V._F\W'4MD(@V:.0R8!%'5
M2?.$3F_=>U@ZX?70Q?!$94UP*HPB4VQ:K!;'!"XG:+QTUG5)6%L`ARV.LMR7
M0%FH794ZS@K%^A*)YG5<C::A&S\<6I7GH]MC:5\DF+AZ3]!0SEFYD+Q4!S%U
MCKH:H]W9<%IH]IA&X[&-AF/7"2YZ>#[E@K)`=%M,%%]Y"13TI6I*X`&#=GA(
MR.:UF0KA(5EHB="[GM;+JD#A1WLX/:+J7`4\1*XY!ZMH@$EW;GS0*#G0RZB=
M4<"YSAIPS5657=8"+8D*?R]V[BAC1G@PJ`!CWHUC/GT''%2V.<Q$Y!#6HFA;
M=FDN=8R94F3-C(V:*#N3]]#1:+G=B#Z)[LVYA['3:5;IW=<?+A&0_I2PPR%V
MO5*2S#E)X8EH66@N\M20E?^PC,.SFJDEYV!,;W[LN&]0^ZY6)HCX*C1W:G@&
MZY1W8,9Y^J3,-`-]@#%EAQ0DEZW!)6QX0,J?$TIE\H*K@W:%H/HL?>,!*0_.
MB7T7DC;\Q=-@^O4/\@L9U;DFLQB@?3!6J_KG@?&5.%/`T?=18.7JGP"2$3:Y
MQL`#,DXX;]@_2OS5A8_AC-]RDMC"VMT,YMQH)G/S<MZ&YGI!$8S+]RM<ID7C
M%.$-`I"_6$"H,_8F.A^WPQ%\BO.O+JJU,<VC#V*0%$-;Z',PPJ]I,4,R$9?$
MN]P0:OP>!&!M$5,/[73T-0@2D0[P0ETGZ;/0R3NI$V`:Z\0GACA"N\2[(B;J
M8>WW*?:3D$0Y(<?.:`58^",2)_582E')D'P5XZ]E1540`%<XLKPG^1;B*YO:
M_!A"/4W"DEKV$7./9D=O$*/(6\#CG--,-<\BL4Y_O@^H4:$A;)[@&NI4%$Z?
M(&QG[R8R7)K-_/H<3C`8'20\/D?T>S$:J$5+T]6/'XAJV,UEL7Z3OVBND2@G
M-Q2%R.[GD=9BF?GU>:'\2_[43MZ'M^_WQFW94@7=`3:/LGDC'#'7D32&1>S?
M.0X<I4IBV[B]<=T2>ZS]`!(]O9+J6>E'[;YN##!GM;!X</8*'_X?2,,APQM"
M@G.NX%9;656,`DXJ%YO5N=@1:>X.@Z\@&7762=;PG3%>D[G90>$(W">]<SM%
MOUCSTU<1&FV-Z;1+N2)^C9)$TK%)U2P?"@)IUD*4XH+V2]8C*ED5-VZB-Z@1
MB_P0\CE2@$55YNWU]42!+7RN`=_<A:_<8.'`"2"7.[P'UMY#HWVN-L`C4!\;
M[*,F`B=I=&X036S9@==5?H+LG-4%LT[O_RI.D>F^"]U,PX!)T`ZRKU;CH;-J
M#8U"5-I+"+)\.,/K)JTD#UU.-TLT>(\"TI17&4.,60/V`^]G%IZTSFHB6%?B
MO,26:HS#*9U8<L2N!H86QP<MH3SX`4ATJ`34D#8]\KXY.0^0C%##4+-#SDN]
M9%U'8UA],3Z=U&-V4UA?3@\M>""@Z^#R96%V/!@3:'.V,16.1>-ZV^2[":G.
M*>5DZ+@0/OY-M]A.""2[SV838IL:#:^5O$5?EB5I.>2R,N0MI<^$TI.*+!L`
M?H\:MC'8S]XCSUW)VTWGM\N$?_KN\ONZ)+P6PV#6G=&BCT=+G;&H^G7H$N5`
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MVQ?&Z7JT]@'9O?C&"#FU#WZ2"&]_)`;FYD@_=M&)CO4>/X\,]5KD@=(])V\O
M^I$^#-VE75!ZG)3E7DWGTNKR??QPJVOK\SX]LG+@?CGBTNJ#M>6[=Q_.^^ZZ
MK<R=,.2AF+>\[);TCRS2S[+R>C"9.U!LVI-8;O(AC4D0I#AAS0<2`EFL/0EE
ML^F2W0'S<+K"BCA`)2EI@O%EI4#4).G*)E]7HAFW%S_TM^9N&K)6'0E#<2PS
M9RL(0<<8];W+EE]3@@\")^TU<I^QJNUF&P-KNF:V!SP>`J7[_(H_N%ER%IH=
MK+`3-BO.SBB@Z<ZK6W?I\5WL$5O^1M4VM%FDA<_F3B_@IM$7H=?+*W.$2T5K
MXH(.WKO599G`]T'QP9JN44?JFO6U0`1A,&)2'@3WQB-.O(Z!3#LI#,A($C<4
M/6U3B6J6#EQKA^#0R0R$=#3L;/2\_I*C"+ZLI;2K36QDP2M[RHP5G.,=O,Y#
M/-QE"S;=JW8.%RZ,T#YPJ8PR(5=S^S!H[..'RS,&=2[:OM/A_D^H/6Q?\*F'
M%E5(N/UFSER+=T_OW[MH*7__VW]^_$!WT+6[[:C\N%&]L#'TP@.N:O,1N,6C
M5Z[,U1[K>03]W9OB[NT-?!QIA(U>W)T1-M;*"_>&IKA?K>'^G8$I'MQ+(]R[
M_:`GM>C?_S!/0;??ASTI<HO.=*OEE8W;]WJ#["$00#$YDUQ'XEJ5?F;"5B%I
MHU%HNXGM!W-??X@X0_$5I]EX<&_Y_MT[H^$I1DM[^R]F:,\HO9)/.#)/(CE?
M#Y*T0.DW6T\#:E;:1>!8=WO?3/C:60WA^):=D>B,!L;'AJTM3Q>)19'#L<U5
M?\K&%B%*>W47@]E`]K+L&MTB[?%W7J&?+7S'@BWRQV*V3DY8PJG^@]Y#:?")
M)7S<'A5`LC*-O1D9^0&_NW$?FH$`.;UHIR(#$VU?O*'0TLG85$4H"V<7%TKJ
M[T*`Q".`P1M2V0U"62*U((H1'8P+!W3A7(1.MBE"_H>DN4ZHX')4'K4\CB:S
M\[\<%3H7Q78PKB6[N48`1X(Y>R/=/RO"5M@VK/K:"5\G=_KD*M(P8/=U21L1
M7[.R//HJZCJT\&"CI^;91XC)5Q0(#WQ%)!P2;F%TH[4/3[5(<;B17FISFS,\
MA@H.T5,UI$OB2E@Q/()<+^U>2'.!)S=^ICYI!Y;/'$AGVH)CHC*_^$M^J/#E
M9$M:R1`IYP0BY^(6U5B6%!-SL!H#*=8NB;C6AP`JBJ"U^2D\NC'Y;3ISIS+5
M_G$]'3S"\MMC<HMRXJP7*5+?(Q=)Y$LHI]F)R9T)U59L:P,!\-5[][F=_(&1
MR(/EA^OW;<4UOVWXIR_.1LKY^=I@)EK]P['##'\ZMQ1B,^-#"Q8?`8O5)\J=
MB7*6]4/!RIG2ZZZJ68#"]E?;""J+;3?J"*'D4^\RDZI9DH.K<WZJD2HG9ID+
M?;"&,EW=Z9.X2F$SC:`:!)RLH*C79LL`P!M_4Y*K8TR\1<C':"X=YG8]VE3_
MF,?J,'$;:]PJ=EML-YEC`E-C11P(F>8440PG4F\[T(_\`6516P3!-JND&D7!
M-%3/FVD$Y=T*/-66MR[,6^R-G8COI`V##W2&2H)%-&R;AQY*&O<Y+XG@\.!'
MBEBBO1"7/?_.>([I9T(V(0R9CVL/E^\^O)-11CQ"<^5(5!1VA'Y0_(PQ;\G#
MD!O1X+)*UN7]Y?OWYH8)AL:7M&\"7EV_7<MQB5F+;1R`K3?/)L21B8+*Y48D
M%&Z/#L;_:WN_'1?$R4S0T^<Y)WRPP:9$'7$"SEJ@0K#U'+U&Y>R`3_VTN$G@
MURGQ7*%&X8/Z-H62US=^;\#2&S4H2S0FOTU<JE^"J7`RK4Z%$V7>3EL!9Q(`
MR;M+R.23IF*I6%9O*/>QV%0DT\IHU`GT,&DK9:,5$,"L4I<%;4#^:0.,I:2X
M"@1/.;N0PE0OKX;+$74G[PW3K5F@?179KEIG*CB22BD^56?C,[+1"#Y.KQXU
M%8R%>,TPX1OEU.JKLF1%+^SEVZ-]ZI>I(L<#);<ZZQ08L^)6GT:G*#8M#@J!
M444#S^LJ^C/P!!\?H6<Y/P-\I8C"4G$-.&Q`D>E9BZ)[T.=@N;KFP,U$Z0,2
M$NC.&V!S<GZ,"FZ=&T2,&JR=)"\\:E#:Y\\Y^(OV1Y<O?:BU[_W41[OVE:75
M.^MX_/OY^P\>+*^M]HQ'P;`_;P]TO=<2FHFUGYA_#K6B5\[=+FY@GWF@]ET8
M,24;QM\5^[FR/&A#3I%.77&!(-J$@2@SJ6L*93Z4"YZ-DIOV"*'K]!;O<TA2
M2=J**C0Q)"(&0%9C[CQLC'\0L8C+V*63I3F!%J#AL(^LGIC1>\T8'-V-3;[W
M@)FW;*K>A,S_86T;@,<^](]6R'870"522(R#61H`.ET7E_+9FKL.`8TSZWA&
M0DG-F`N?Z[#_P[.S7YS30YQ2$9V=>>BW@E`%E.AE80\54SDEO<6:>.@(347R
M[&[O^R+%(=@<AQ+BG5,&AQ!;`PQ>0R:CB#AQ:ICA:[%#+2TG0)9HG4&"9HO9
M>U/Q$!<?+&*`_#25QV`EJ"QWJ2H4A?FCW)-<0U*/(WQT]S'DRBUD/9@H9,O]
M88AQE]"K?RH9-+0".UW3N90B(?O]E1JJH=]-AH#C0GT0:FIK)D-2W^J2XGPC
M!.8UCI5D;-MAWUHE,R?_DFC.TM)&TSDUBHV]UOIIYBMT$04PO59@6"1+C/Y?
M$9,ER=E6*O5$Y($@-/LIRTGAE=E6.8OIUMJ=AXWK?/5A!05$2>6W(HE1B'L%
M?DG0E%/JS[YPP9%"\%H&@)IW6;(<_\`H<SN-/S;$NJJY#Z#XD./<#T":FA+L
M^_,FV6>D/R0X!0.<BC@,4^Z64)-?<J5.>TJ:.4V4A_>A5;UKV1##6P'-%?OE
M>S^2WM>)3QD(G.ID-]+3ST"<Z5!#U$K,M2BA/>79YND0*;^ON*XM3R0:O8%*
MYMNS6G];24=IU7T9%[,WQ^>C(U<]Z_<BZ)\MWAV_WNQD%)H'FWF)H&21J9><
M`Z@D0CC1]I:@G`D*"MB:["OA#Y"IH,?AZI>O!)_#J9ANX+N!H*=)'Y2309]5
MK[P7M_>'J1#CDCJZ*/A^AQXM35G[OI*G@)57$/3MZ^"<P5A**I3Y0,1NN8TA
M=Z&S(")N1_"[56H)9CJC)<`R?A\JFA?=(>N8H6]TZ,QW-1F]^->:I?AFW%4B
MB#=+)3'DOD&!9RDQ=OZ*%T'5K-%SE3:I,@/A`\?(16^L".>*A7M/7W['5H#&
MA%NNV5=']\N<,(KJA3D5?\S6WWR&K#TFL,@[CQQ&];N0Q3]W#7Z(5Z=YN3@6
MI#&@#%K#.%7\!/&$YU>SG%)39J=N?!V')7E$YGJ8T'K-%#R]94E*LL4@"!)R
MA#ZIP;45#^@=W5>(FJ$T3^78SE^(!'%9I+/U`:O5>)T$P"&T:W;A].7@T2T(
M5VI=V0E4G9%^KSG<_,5>4^SZ:`HOML9/A]X)NU5QQM&R,36QD!>?4\&0M,Y-
M'<S1JN+2&#N2^6.9/M`9AA/!D0!.&@6W7^YY!9"BJY_ZZ=+:6L^$VO9N_?.V
M[$;*3/=96/Q8G!=UR]#W26EVW"XR7I]9N:>]C^2]KIYN==4<,N/-S><O*.X<
M[8Y_'C]ZLFT5S_RX]V)[:_1D9_QHYPGW.O6=-=("T6!E896U)E)+6KL(W,P4
M$CV`LXZIX-PU"-).T&[:]@E9YYZ;=D].\A#->QO)]8H4,EPR*&&OIOWJZ*WD
M<L&=-*=5.+N\T=;;-6RG+,!'SED&J[A$7-:35%ZC,>>_9[Y.\\E_@K=MS0YW
M^^GND^<_;V^/'G$;U^.=@]'ND_&S=ED'A:2IU073SRC0,S-,G9]7.#\@2[,[
M+6@V>2?3P=.7W2,9]UY__+!Q9W7IEV_3.0^K$D>2<>9Y0AV35;!BS32S%WRT
ME#3J&$VNS6^=00\\D9P16S>U'H&3VKWU5[9P63WF^/%#]_]J$"&:5-`@O,YP
M,:=UV83'7%G/W3N_3Q._LJS#>_;O]&8SAM\Q.G']0M_=PI]+_-HU[G63T_RD
M7$[_B;#"T^XM\Y(0;FQ%0(IRZ-,R#7(`[EVOFT6**H=@:Y&5.@%&LQX2*`I=
MQZ'>SW"R=2H\;L?&@FP@!+&%N[I@\WVL]@[@QRM<(U-=R/08;0DO+]2Z1:N)
M%G>'WJMZE7R*?WK=*.;'%^.]@^V])S^/'N\\&S_;W!D_&6V-#\:CI1?/QB^V
M=@ZVMWJI?L*.PM8B\V<*:T1B`*VC*`TJK5%`T]A=<:UB3Q"`D9;':)9_*6S6
M:U2OSS%;D^*26J[4.4:RM'W^PRGN93/#S!8_3TU-)%"9:Z:*1J_!P%+3+T/#
M21*AB>G:-Y@#Q.NMB3VJD_ON2>EC?(N7*#>7\].`P^N2QIENU2IFJ)L,+FVE
M#040S#ERBD[3;:O2OATNCDB\'8U9J`'6^`1K.;N:L1/U`U`K$RL,0^>TXF@5
M+-C+?63L)=3\V(N%_]B+,/^XT2)K&%4]S^CVG)Y"2_>6'SSH9?LLW5W>Z$?!
M>7>UGUNT](!?>^M8NK^\=J]WI0+CWE\;_/5A+^9.>X^-^[UWGX%RYD('_![5
M:B&P1..+'J#T8W\&?NR!G3?[7NG]4INQ+46ZG;-]?KUBM&&<8/_%HWTZOVP_
M.QAM_\3_MN,^KUKS>+WUAFODR?Q@+6"XV1WJ`/K#"8WC9%F[TW^9W%"RC,Z\
M98S(B^]R;T3W*&R23C@Y))9CLE?O/,&X4B>L?*F0%TCG?\;%E(^.SW!EC[BR
MXT@5IK='2_X+&4[$8G+EO;OW$N_7^/&A61!'>7;,1F[D53-]I+?ZL-O"J1J?
M3G_!("D=G<_E&)!B!1_3<*(M98-:P$.L(%T-62GU,;W9C[J`]G)Z].;4+T_4
M,&^F;\]>`[KCT[/S";%H)24X(Y(:051K0O8/%@1E`6^/XZK%XZ-?\.?8=<"L
M6IY#](K-K70%W]#U>QF"59>1!A[_?H:J`4=#@JDK@-WS(%YG;GLV3L+VV]D?
MC.'UEA6/#2CBB*Q&%1?Z))N!\SXJ*X*+,:%4-+MYQ:`L#A<G@R<WKT?0K]LI
MARTGA3RU0-$Z7"L9NG`RRR)_Q4ZFG%\:&_1V74N#91CF;SO]K]O]Y8U7P*"K
MLA0,"XQ(T,"2VQU_ZA;QFKTEQ"WM%95J`E70TBE*/HRN!,9F>UVMTG:A(TMW
M>/@:X\27$]$,G`YSI[HQKDP_H;LR[K1LL%3GLXR/[_1*-U1[<F-+/,X!6'_<
MJZ<27VL9+R>_4>/P2>"MEV<!C0)\X'-Y:KV+=P8C3`K/A8!@Y9<)4_FWGVQ2
M7\JGG6L7\O8O($7R"VVV7#Y,'=PYY.IX/_D%_P<<A'\IYI>Z05:HR0J#'7#G
M^97=3TT+;L(IB4?)F<P1>JJNN-+1V0HK?LM=MYI&.U7.*,#8QV$G##I]__%#
M"S1]Z(?:XJ0ME).FL=DBL+H_+9CE1#?5L6\M)MTGD1<LN(;>&PL5(I8M]Y2-
M%VJ38AO)Y%2V;WP9#]!4F9W`(35NC0W*H#6[80U!F4(@MQ-^QL?';P_-$Y5`
MJA5ZDQ@:1HJU7EF?:J`)H^LTML@HLX"Y!'/D``C5Y+/<8<OY!HXT,?3";1-^
MB13`2]NJJ$);P&FH>GZ\#*YK6B1+Y\R-0+JJP@SC!K.30%H>I#4[XUHR.7'E
MN6:N5E]:PI:G-0BHY^`8$3ND6Y%XPQ/P:R7WBO!6TQDJWGI[`IO4D%7R;&!C
M4K8+[>6O=50MF@#16VL/UV\_2&=?B\I=*^*W'+$6INSNUOT26"G,@`=:T3PJ
M22(,B'5.N$<8G%Y"!F$8M`\H!4F['E-"*?.?/JV:7Q1!@+M8ZI3?@+DR?&NI
M14+D/W=8"R^4E1?,LD=LZ(867!<_8)_."F/3`^1G)5FS1$_0'V;$";>FOX-#
MI9L^#]$'=)*QC[KS@HKJQ"9L&(5PXATT&GY55D#BM1)'(C+/RJPT(K.>T<LZ
M])7%;>39"%L3K;*4K+#9WXOE3+7RFXN81-`6[FM@A`.>=A8%3%D,9HC1!G4*
M_-QKP=T)RC\R)?>&H&.SL0!3(;.77PPL->7@<)60-'3)=^'SM68L;,@(T$.;
MYQ>ON7TIPN\ZI_UR7TF=X10N3`%UE_LBK?_>4OJKYT;8*4DE8[]G9`6R6ME5
M'ROZX^PE55,3;KET$AFU=LGC<D7A4U3?*R>VT=*!/,JSWJS5TH>_M)"7)7AN
MY^QC,';\+BJNK>Q[7_VT\`2BO5A41VO<Q-'$UEFB_BRM[S%B)NG:OG;Q^ZE7
M"*=:+8=_73O:^W:LQ^@%P5!9N$<-O$J#X9HNT>N\Z)=1]?U9;M65N$NDNHG*
MA";)U^W]_D6@L6G^K#9M;"_G,-0-((D^4,*L*]/#_P+M5EFIYPB'N(E(OM(>
M,CZ=7/R"ZJ5RL^H`YAYW!>`=:U1@8K6%G97?K#RR]6XFK4::R]QQ5<HU]$$X
M-]H)P/"KMU$B^R*E#&Z3?ZL2.>BE>_C;R7-NZXHF23T_R@&G89(TQH6C>BHB
M\BZ-JQ-[)0I1GHDI2_HE.V0]<S,JP3PA1[))"9JS7O)@JEY>B>)EO^;SYIO:
MW]T=[:96`'N2#KTM/9W\.^K9YA7KPI"&['9Q"49`7\JM]%SEM;ZFZQ_.KF-E
MD7+5T3Q:IY`(OO;#Z-^>6G/!_]V>2O)0P6SLBA3UW7<K(#/#]A/XW=O)ROCD
M)85;;Z!2,CW#7S%ODG'I+BX:VD2J*^]N_JH+<PT$855=_.CREP.:9\W(!T9;
MZ*WV^K'DQ0K^:RM=/(J_N3P:6EGO-&ONME^WQX;'CQY?WV@;_>[_^_;5@`KW
M(AT/A/R22.Y`FXORY<"'OVPQ!&Z7&NO>!".CV^O3:(-*)-;X:5"-A%;J]OH<
M=2\N#F_GC$%2^4ZQ=<P6E$A)@]35(8,52C+:/JOYM''6:)^8&K7>!``U1R96
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M#'9T>^[;2L.<-U*2JO.>%Z4+51\'`K88Z.3N#^>2?GPMG+]9'T[V>AJW:,V;
M[YN[P]]5RFAE<L]&*[5C8-Y+4H%5/OD/L*Y'U_&)6B'M&O3RG]7VY"):/C!/
MJ=240<LW&<BX^=J#X/!O<^L?,0&_'S32CV`!H+;:6M$/#E]>\2NDDQG]AP.M
MT#!AW3GX^"63#`!E8#7MMI[BL5975AGF.+:4<)`6]RD+E_:X$*+TS)^SYR?R
M#XU6;_R<97T)F`R!;W(6[;J^<-[/.YZ!17RE$QL8^8L/<>V:0RS/OQ"8GWB(
M7VW>+SG$SB*^ZB%V1O[B0UR_YA#+\W_N(7ZU>;_D$#N+^*J'V!GY"PYQ6'8C
MWS]3/Z_&*SF]LP49V]4'E88A!:.R8ZN7I%04Z<&?E2<ZN=_?7ZL>5`-^S5GQ
M82+>WY#7?#21#1/&3"M%:S\AJN2T?3[L^.Z"I')QYWGF&4WC?-NW[DYL9_OA
M0I>3R="V9*:7HQ\F9#M<^];2$SX;"+L4U;4`N1WLQ@SYLT5W.^,\D'XFFM?0
M#RN.KL8D@)_U'+/?K`VKUN0W\S[FKPI-`O+*,>SKDID#F<EB^FNEJM73)[O)
M*GCH%G&"5?,6:GG3.\Y/'U-!>1]1=B9_GJ+%VJ4&PS/L+=[4<UGH2G`[7<&,
MEFN=4J)B:9JM,WE71^*:C;<G;+;H4)P&NKDFA',M`94H373E-Y?#BBJO+;LQ
MUS40/22B$O>OPJJJ:`-FK=KMVNVEHT5&1R<<6N>,S%.)?R#&D"IONU>,SI7-
M<R'RV8Q_'D1&8]T$^]JS690Y(V=-0"Y\RJ.QU1,N@DDRQ*H*$MVZ2C)`]AF6
MYN0Z[4BD\D@2K9):;,D1K@DFFEP-3KRRL#]MH$3>NB[%"6%$;W=Z,/=(KFZ0
M,3.,=/S)(;JC.AP9%8'7KALGDR*`X.&K$OQC,]%^B/TD]XSE+_0#1SU(#([(
M.#-O?%^<61X_VU:P3_W%VZ52*+&X-?=B[*0"QMH9^2P92`8YY?H>6=:/)L83
MF$YQ^AO.HWS11KNBRF%F!&`9=005U4KKV[FK^6;5&/B(LK(XX+7A`UY$5%\A
M*%QQJ<*/#->?6V0V;Z#G-$W>G1']!$P:"%F'4+3_XMK&35]<O>&+J_<7OT@;
M8%_CVL/%+^;-K#T8?''!<62<_PKQ;>K8+,!='<_-,;]_5&G[+>Y^7KS\L]GY
MZNBIG\*V*G3:Q1Q,+E[C/&Y_YD+?VZ-U>K*I1JI]2)!2R>7MSQUI5R7_U'*#
M^S-9C"*%"@XA2''=OC5ER+0(S(L%_OC<);+JIV91^<OA3117=5RC\W]INYKF
M.&X<^E?F-GN0LK9E.\EEJV1%WK7+*:LD.7O8DZ(HCLJ.I-)H-LG^^GT/'R0;
M)+M[VO+-UI!H?H`@"#P`4LT)$;K-*>?6\V@Z6!1ZWUB'M"IWBL7FO$T56!4%
M2.\=.04-$N3J'5F_;"N?'^X0SP_XD@'2"*^-&W.24*&&%,40?H;5G/)8P2<.
M0CL3\$7&;TY2:H%C:8U?3+`:6A="BSLVQ6UT\:L58Q-83[0*HN4*T+VN2YQM
MY@CL'3D>.L@=_OG?^AB="D@TE5&/E$*0#,'8=)@DI<?JSD,;-V6A&O=2H3$#
M+5.(N[:G+M$H=#3EE.&\*O"1=4S3Q.8*%`="H`P:JOHMG6P"`*EWK@_[62Q,
M`<ESN?CD^[C+;[>?TX]55'WCG*9K/A)Z9Q%4%XE1%/7;>S;`R8Z;%OD_H"[O
M*6JL$O0GP^JDBO_V3JX1JJ(6AQ.8FY&)3*8#V:&GU5#QU2=/+1NFP8XEN6&D
M_1I"B%BZ]$`T5`K>E*F$<EJ&V/F1^.2'Z(#$`YDQW<!8?02D`SA'`%3G&-(J
M0KYA>ZOVR2K9J0JB?,^TVD!3EJ(=\2_W"'A'RFUL@BG(Z6$0EP?7JYL1T$9W
M08*K1/S[K@';#`QJ0GIC,R(==W&F-HSK$!0[DQ,X\/\2Q_SRTZVDR]`G6*2S
MAM[=3&#Q&B$AR&$9V[OXN'C0('8!@X#ETEU)\T7QK([]#_,@XT]+.>=H-_?S
M_NI?;WZ:PSEM]AA`).;C(6"J0/"-0*EM<^DHO?A(8R#T+IPL1?>;`H`5Q5U$
M3Z9R`AN#7^S.BRNW/O\#@0A@2XVB,HW"X?7&5!+X0?(\VE0S-%JH>Y`I!30C
MU(S&.)1V?0HO2*!1-<KG;4XCTE<DUT`3RD<!JL%L[DK#:!E^=V04%Q3PK.PJ
M_-/MK$O77>.O-R(,^APFP(N[*R3@N!1MOHK&\0G&C5I\$)L`CAGW^E&SHP^O
M)ZA1M!I7^Q-Y#U4AWY%[NUM@]H>X!OXDVN(ID?JFLH%$M+<XK/M50O1I-D+.
MA)M?J&;&[P6.D:O6F3FV7;H_;[<`^S!CW0\(I$#6\B(V),-N@+J!8J.9QC#W
M&;NWA.S4WI9OW2K&O[RAJZRR7S*:N-#_9#5E>9.).J3I+7\WL(\=;6XH+O_$
M(Y&&"GY[TR&*Z1/Y@"]L_&E".BS=YQ^!J+\`C.,M@F%O_RP@52(&X$7[A$OG
M]@:XU?00GK'-"ZCNL,MU?H;"=\1CQ1TX]!.Q.I?@8Z<?UQS5VY-DJ+C'B>4+
MAKI6NF'D&HX$2Y<BKN$4>C!CV=I:Q"M$_]T02EE2'K.S'"/Q")&7+&];.F5A
MM_&8!8V1IN3(MFJ\CA'"_I'J*2YF`R5>,)""(9'4U0J4E0;!U`_I!%4LWIJ#
MO*U.XZ^X;N*CU(B9U$:8$)-H0Y2P*[=(]8T`DDC+%WT"%SA\=Q7+@[038F*O
MZ`X>:H,.,O+8/D7>2#$'Z+J260ZKB1?*U>;R'@\72_05>V;?;;E!V-+K&\9X
MRP8G/IS0HX\D*6<*YO4MBI\LV&L_[1Y9AI'D\F"A<ZWA%"UB;;Q?SK73,X@4
M7R.G^H[A$BD0Z7D5A#M^\G@JW+@%V."\X&MW]*_^YA0##W0UA&(6.X^G$<\S
M:969M0"'`@WNA/X4G]AQLFDA"Q2R?DJ%3",>Z>CX]'C_*;P5-`]2<`SR;AQ^
M_M]O5WA4W..B\'0H/8FKE)YU*)57SA2ED24L("O345#+%[(IFT]:D5:CEG'T
MP$U?!1P-SD*G36;X]NWAW1#6)R81R@K"@#6D:>P:\9XB^@F\E"Y[*T&I1.'1
M:XR3$9N^TW1#+!V4J'9-:<C0@5P;M-]PX"A6SG_#S=#%I`((P`@C`AAHZ:7^
MW&\^&'5>E<57-8!6GCN40DUKJ^M-&E<!D2W;W[?J,\>]@+L,)8X@9F.[?]\C
MU<@^TIJ38)L4K[%K"W!8//13VK-[PGKXA4)`+PI-*XY;FV?%7QCCQ!;/[.SJ
M[IL5ZGI)7;VXO!]HW/B#:XP<>#VN@A/MP*H%(LZ`QA:@>7B<NCUD!A9#G(+(
MNJT9"8$4'*VWW@D*L4B4J9MXK?A50^D)%F(8@&"&5BTPFY?-EQ^7@1<8SLOE
MU17L.&)&HBFYJ-AS-S0_Q_YG9G0R$_:-UX+V41N"@,BEK%%$(B=J[Y23TT%0
M7!8*&(VHBJ@HJB-&FKH1ULR?8]CLJI;S&E=;T[AYEM(9R>24+5<YY3D$MUEI
MX[>#]H?S.QB^=;27G1"'=N?L=4<XA5RV*6Y*'00Z@/BM[CQW("'!6XJ$8<04
M7U&29*ER9B$FRJJ>2;X?-H9HPI<TAGTEEF\M*`FO1EUDD:*\**F8B6!'1;60
MOK!1XYQURC)6*0K6"KW8*"^D!S/)R?&5XTI'+_!92(,@8Y9$40*<T\SJ3(Z=
M2C@]>\'7-[<#C'8EO*$G@R35`$NSCMQ+;,#2CP]_[:-$.Y.+P7XCX`G.!R[A
M7\%R>H]J@0.D^5%N0_)L_I1H[M&["2?!9R2BT8H:BK>A;"A-2O7\SZ4DFA7R
MRDM:[@N&^;4*?8[QXR85PL.R-'"9)>_F_7,6M$V`5WW\&[B[KBTK0.M\ZT?X
M9$JUSZ*(PXF+GS`7!(XE-A')<R#`*MG6E\B%64+?DUZZ,.<\0'+\YTW,UIF<
MQB@SX,+Q9$*HR%K`Z\@V^G^ZN%V9T/,;)_7Z^D^<#UDKE\_A.[''^NDW!U[O
M+?Z6I1PO1"@JV&-(CO96#QO?;1T[UN8+A;D5<\XE_#J2">\9?'T#*[9:$C`O
ME?UT>N(T`Y!6&0LR+.5ZV!LFE.T#;F8U*!F=./V1WO9%<7MU>KO0(K.;D84Z
MF#MG^6=`ZC["EH6P?K+?8'IQ+*=H;C'LR@M;UC;N7/EJL!01EDT,O'MQ1N93
M$38U$"ENMP2_7:%`60DV%?ZW=I9[0,NZHHQ14A;\R-//U=&''N%[_A4@G5L*
M]^-_@8I*?0O&S?LZWZT*$L?/9OY-)T;V2H6VFJK:9UD&K"5,I-[J4&V$I$1=
M"EYM2->,U&P)-HH""[4-25'%QABJ]O!*]$Z;M=1E*#-3@"PHB:U]BYS+T.`;
ML9\VQ+;4!ZM;*F>]-./*R(U1OT**UX^TJ+3\J1>YG_E2N!1Y-KJPO9G]#N(\
MO-^(C%DUOM^E4XJU7?H5\]U;5;C/8X=#@-D4FKXZX0,&N3]3%8]7[2H>/D%1
MREB*:C;QWE*EN^(1:%WR%85D>H]`:ND*'NL--K%\N_+'V(1.AILXL<Z:)>0!
MJ5$N)6>4'P&\V;]X*YMKALQR&FMPFC+$PJ2,IRERX\*1>=YZ'QI^<W7@J.@.
M'MO;H8882/ZV63U]V01%.]?.7/:]QJ)\R30,0M\+D?#1=0[[8XW&DAVL4.NM
MA8+W40PV,=]86=L3@W:/RV:N<+'`.W^BLTQ+2.YV[0S2&TT;UJA1-X.E[*8\
MU+LTOT\&5QS?T!LX(UQ4BX!>G5+/&S5O^S:^+]1IL4,K(3G^&:QK0PE/$B+<
M_.ESJ_GO>OL]]AF7)Q-'Y]WUKT@6]\8>Z55L@$_(5N*Q)U"2K08\7/VX!KH9
M(TD9;E$IQ;8,*SQ.[,,=+V,E.=EX_:U9-%`R4@5?.[Q$R>70]SB#M4&_BBB?
M=OB)$CKH6E77EH$E2^Q.'(L2>MXGE*14BCN2$)LX<J7SHD_G.ULAF!IMB9ZU
M8W64TLL^)1_1LT1H;+&_[1/RVRJ'5+UH2F(=T7=]0CZBB7M%Z7P_32=?GQQ/
M>ZFQCCV3O8=;K!(W=C9_6MP6KVJ5ALS^GHWZ6=UO-JR"VGH.:(:^#0P.#=VZ
M"N69TZE2Y*73KI=BM0,CPVUI!RF!Z0XJEX7[959H:U*+YM-0+;]@9)U#,[)&
M2U2#A1.=K<W`N<4RP4CN!Q?K8G_;@,J8@]D:XAGOCL?(9"RPL'V@IYB-8+&L
M;,"@D2RS`YR1NDI;-:#C1U)"1GY#N\$H!8=8!K%(Q2&IGPKT`T.DU41AE8`?
MCR#,7O44W^,2AFL8-M5Z&,R\E\S>=&+$L:SA_'@>__C:"D33+B*593ASK.,O
MD&N#6<:.W`^IEK);M_,V^5F#KRI`P7$^7FHU#OH-7+RH@48WNI:C-];H71T#
M_AVF^C@:R^(YJ7U'PCEM[,+,FY-?G)L^<XBZFMTK7WUM/WX*CBZ+42X7+#BH
MK!9)5",,U%8MDGY2,)(F[R;\""'XJ-J!TS)LIJZ\R!LV0OC^1[LQ+<'#K1[\
M9),<?"`2'AFK>Z&+,<>A^GPJ<9=%N?>6XJ=I.:1$C+![:YWB('N93H?LT&TU
MM?UG,'N))Z-%H4PU^I_#G^%R@/&E2N%YEHL;'4L%XQFW4M7'#WI/\WJR^E$?
M++"3U>XA@9<_L>IK<04!((+5L0(3U$,8"8O.+]\DCP'%(-G*\8Z$JW#.T-OL
MIO(XH%>Q6)E//C8\:Q0PJ]O^?;-Y^,?_`0``__\#`%!+`P04``8`"````"$`
MWU>G)XD"``#;!@``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)2576_:
M,!2&[R?M/UB^;YP/D@(B5(6JVZ1-FJ9]7!O'(5;C.+)-:?_]CFU*":R,<@$Q
M>?SF?8^/G=G-DVS1(]=&J*[$211CQ#NF*M&M2_SKY_W5&"-C:5?15G6\Q,_<
MX)OYQP^SK=(/IN'<(E#H3(D;:_LI(88U7%(3J9YW<*=66E(+0[TFIM><5GZ2
M;$D:QP615'0X*$SU)1JJK@7C=XIM).]L$-&\I1;\FT;TYD5-LDOD)-4/F_Z*
M*=F#Q$JTPCY[48PDFWY9=TK350NYGY(192_:?G`B+P73RJC:1B!'@M'3S!,R
M(:`TGU4"$KBR(\WK$M\FTV6!R7SFZ_-;\*TYN$:F4=M/6E1?1<>AV+!,;@%6
M2CTX]$OE_H+)Y&3VO5^`[QI5O*:;UOY0V\]<K!L+JYU#()=K6CW?<<.@H"`3
MI;E38JH%`_"-I'"=`06A3_YW*RK;E#@KHOPZSA+`T8H;>R^<)$9L8ZR2?P*4
M[*2"2+H3R<#][GX:I>,\R8O_JY#@R`>\HY;.9UIM$30-/-/TU+5@,@5EERR#
M^OP[&41R<V[=)#\5:`.K\3B_CF?D$2K(=LCB%$F'Q/*4R/(]0L#>WB,D?[]'
M-PFR8/3J,=G+^QB+@(P.D&)(+,\1`XOPG$.+Y\OGX!*#]JNUH^(L`C+QM8VC
M^,CY\LW;`U.0[')3#CXRE0VKL0A(X4V-X_`9(LNSR,`<-/[EYAQ\9&XT?/(B
M(,%<D::C;#PY*NKR$,FS.!_GZ1L=5[S'G(./S+W*ADX+R%ESA\@;YL+Y%+9O
M3]?\&]5KT1G4\AHZ*8ZN(:`.IU,86-7[;;I2%DX5?]G`2X3#'HXC@&NE[,O`
MG7_[U]+\+P```/__`P!02P,$%``&``@````A`&J^^^WH!0``G1@``!@```!X
M;"]W;W)K<VAE971S+W-H965T,BYX;6R465UOJS@0?5]I_P/BO0&;ST1-KRY4
M=_=*>Z75:C^>*2$):@@1T-OVW^_8XV)[:%-X:9O,\7!F/#/'N+=?7IJ3\[/J
M^KH];UVV\EVG.I?MKCX?MNX_?W^[25VG'XKSKCBUYVKKOE:]^^7NUU]NG]ON
ML3]6U>"`AW._=8_#<-EX7E\>JZ;H5^VE.H-EWW9-,<#'[N#UEZXJ=G)1<_*X
M[\=>4]1G%SULNCD^VOV^+JO[MGQJJO.`3KKJ5`S`OS_6E_[-6U/.<=<4W>/3
MY:9LFPNX>*A/]?`JG;I.4VZ^'\YM5SR<(.X7%A;EFV_Y8>*^J<NN[=O]L`)W
M'A*=QKSVUAYXNKO=U1"!2+O35?NM^Y5M\B!RO;M;F:!_Z^JY-_YV^F/[_%M7
M[_ZHSQ5D&_9)[,!#VSX*Z/>=^`H6>Y/5W^0._-DYNVI?/)V&O]KGWZOZ<!Q@
MNR.(2`2VV;W>5WT)&04W*RYIE.T)",!/IZE%:4!&BA?Y^[G>#<>M&\2K*/$#
M!G#GH>J';[5PZ3KE4S^TS7\(8H+4Z(0K)P&P5W:^XFG$HOAS+QXRD@'>%T-Q
M=]NUSPY4#3RSOQ2B!MD&/+\?$;`0V*\"+)<`V1ZVX>==$-QZ/R%SI8)D"('"
M'R'<1N131!"-$`]HC=P@8I.;R'H`>W>=HUA$.(:C>QE&AI!49E?$E1M?6`0@
M(2:!ZP\68"!H1![$Y,$("0T(0>37$!8U<#*?F@!O78ARW)0@(=00DLA-93Y+
M*3'3SEF<K,?U%BTHY_FT!)C02D>WN%4(B26ME,><T,Y->PBL]7J+5KR$E@`3
M6CI:I(604+6`?JBTYJ:5K?TQ)(M2LH22`-N40NT6*2$$,Q6P2+<4<C+-(>,Z
M((N4$*S9TT"`"2DVQHJD$()Y"B.Z>::5KW7%69362R@),*%$QD^&$+5UG&0Q
M?[/J3OF`%H-!-#]5$DV(32:G\+AUD1E;DU3FR@6:N:]76]EBR^8YSF)S,(1T
M6$J/6Q<+:YWPA`!R"Q"G0:Q+SZ8FINSLXF(XDRUJVC%6E\*HFD_C6"<%B]X"
M@-:FFKM-38S=^=1P2%O4=)4H:HA!:BSTB3UGECT*-7.;&!GS\R203>=]2'HO
M4QA%,$UH(R@[>!HU0\=@<UPT\\6QB;8HF9^9PBAN44KV/5?V.=P6#7XVG?RA
M'I1J8\WA3H=PKCRH@:=;V$[8HM'/IK,_(IN5*<Q8;6E`4II;B)1'QKG-YK9(
M`1A.<*CEL4@B';1*V-N4UQA=2*I-KT%L>D0-9O;#5!8B*@L,,9C",$A)BG/;
M[K,/&I8369A'4*ZRY2'2#\`\*@P2#-A:CS),HF7G8:+76QGDBP1"H@DQ\N!,
M890P);191_-[^V]36R00?"H0]-"3*0SFC/.4;'INVP-?AV83$\-ZMCQP'.VF
M/$2DXC.%40T+U42Z)K<`:?+1(9(3?;C^AB+19#>I+B@,,HO-<[XJ,]06M*>I
MH2MVRA:)@GA_):(0D0F6*8Q*&;P\VT?-7-EGB`)?)`H239)&14%AL`62D%#/
M1_/G+;!(&OA4&F*2EDQA5-K6C$_(H1,%2&+CS=#>T47*P'&DFTT0DQK/%,;:
ML4F'OB,-&F,3)-KP22_@O#>EBQX?,XX8BR"MNFL0BYZXN3"'B%"&!.K^.DVY
MRJZ^6$\I5`:%P>J+N4X/=JQECHQ)8]-;I`O!],7!./8K6HC!P@IYP'W2-KGR
M@H@@6*=&Y]CD%BE#,%6&F`Y@A<%'WP0^9\:)2.4-W2@(3Z+(","F1_1AGN@'
M4YV(Z316&-Q:-ME9]*"45X=HDQ,#>[9X!0)-ZHU,C$QA,#&,LX21H9-;B#A,
M/WJWASM;B]O,Q$W5(B:EE4G/T&!XGQ7ZTQ.QA7CO1(RWP7A9VE3=H<JKTZEW
MRO9)W/1R\#Q^B[?0&=MD7%PJDN]SN)V6WWNC`2Z'+\6A^E%TA_K<.Z=J#R[]
ME9@''5XOXX>AO<B[S(=V@&MA^><1_@U0P:6EOP+POFV'MP_B`GO\Q\+=_P``
M`/__`P!02P,$%``&``@````A`//&VT;\`@``J`@``!D```!X;"]W;W)K<VAE
M971S+W-H965T-S`N>&ULG%9=;YLP%'V?M/]@^;T82$F:**1J@KI5VJ1IVL>S
M`R98!8QLIVG__:YQH,&T2;47$ON>>SCG^MIF>?M<E>B)2<5%'>/`\S%B=2HR
M7N]B_/O7_=4-1DK3.J.EJ%F,7YC"MZO/GY8'(1]5P9A&P%"K&!=:-PM"5%JP
MBBI/-*R&2"YD134,Y8ZH1C*:M4E524+?GY**\AI;AH7\"(?(<YZR1*3[BM7:
MDDA64@WZ5<$;U;%5Z4?H*BH?]\U5*JH&*+:\Y/JE)<6H2A</NUI(NBW!]W-P
M3=..NQV,Z"N>2J%$KCV@(U;HV/.<S`DPK989!P>F[$BR/,9WP2*98;):MO7Y
MP]E!G?Q'JA"'+Y)GWWC-H-BP3&8!MD(\&NA#9J8@F8RR[]L%^"%1QG*Z+_5/
M<?C*^*[0L-H1&#*^%ME+PE0*!04:+XP,4RI*$`!/5''3&5`0^MS^'GBFBQA/
MIEXT\R<!P-&6*7W/#25&Z5YI4?VUH.!(94G"(\DUJ#_&0R^\B8)H>IF%6$6M
MP81JNEI*<4#0-/!.U5#3@L$"F#MG5D?O]3VKX-&0W!F6&$.W@PL%R_.TF@<W
M2_($-4V/F/48$PP1FPYA"FAHDY,)`GI[T5"*4]%O+T.GS8"-MHYU;2>`NQ<;
M.D+&B$DTA"1CR.S5\$#L9"C65'@"'7A>M$D"W(G&*'0DK"T&%JWW,1V*W%Q$
M).<0`Q?PFM.2?\R%28HQE*I7.`_F0XUKBXFF;=?XGF-R8\/P["D<D\DYQ,`"
M;#77PO6[F[CK'I/D6`A]QX+%]!9\1^'&QL]Y.(<8>)B./5QN)I/D>G#VWMIB
M9NTJ!)'O6-P,PKX;3FSX;8<#_;/_T6^27/W.EEU;S%$_"'0E;BX!X/XP;[$,
MK_:M>GLSV(.S8G+'-JPL%4K%WISZ(52MG^TOI+O0'#G._!HNJO98)WT`+HJ&
M[MAW*G>\5JAD.5#ZW@QZ0MJKQ@ZT:-KC>BLT7!'MWP*^"!@<E+!M,,J%T-T`
M7DSZ;XS5/P```/__`P!02P,$%``&``@````A`!L(^KL2`P``Q`@``!D```!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&ULE)9=;YLP%(;O)^T_(.X+&`()*$G5
M4'6;M$G3M(]K!TRP"AC93M/^^QW;"0%G:].;-MCO>?.<#^PL;Y_;QGDB7%#6
MK5SD!:Y#NH*5M-NMW%\_'VX6KB,D[DK<L(ZLW!<BW-OUQP_+`^./HB9$.N#0
MB95;2]EGOB^*FK18>*PG'>Q4C+=8PB/?^:+G!)<ZJ&W\,`@2O\6T<XU#QJ_Q
M8%5%"W+/BGU+.FE,.&FP!'Y1TUZ<W-KB&KL6\\=]?U.PM@>++6VH?-&FKM,6
MV9==QSC>-I#W,YKAXN2M'R[L6UIP)E@E/;#S#>AESJF?^N"T7I84,E!E=SBI
M5NX=RO+4]==+79_?E!S$Z+,C:G;XQ&GYE78$B@UM4@W8,O:HI%]*M03!_D7T
M@V[`=^Z4I,+[1OY@A\^$[FH)W8XA(9575K[<$U%`0<'&"V/E5+`&`."OTU(U
M&5`0_*S_'V@IZY4;)5X\#R($<F=+A'R@RM)UBKV0K/UC1.AH94S"HTD$],?]
MT`L7,8J3MUU\0Z03O,<2KY><'1P8&OA.T6,U@B@#9Y59`O7Y=V:0DHJY4T$Z
M%-0"NO&T3M%\Z3]!"8NC9F,T\`(,FG"JR"\543Q(?.`;("%U&S)Z$U(%32&C
MV6"O\]@8R4*76266CQ8F`%"9,<#KU5%BZ/`H\Q@EUC<;S6RDL13Y:XH)&YA<
MSZ;$*Q?2'+H2H]1B,YJY[FL4A';;IMNS,_>$"N;Z>BHEMJC"P*(RFIFFFH?6
MM.7CW03]9XR2]S`IL<V$+":C,4PQLHCS\6X8+8;829WF[V%28IO):L_&:`P3
M"BWB?+R;GE^'"9*ZM$9'PNO#KL13I%EZ'@GSFAD-S,TP=(E%G9\DZBP9M7["
ME4ZYU%'U]BF@@J9\<1@-K3!\1F,&?A8M[#Y.M@-TCC9TYM8PAVI+^([DI&F$
M4["]NA%"&-AAU5Q6&Y3!R0.WA+6>PR6FU_UA`RZ1'N_(-\QWM!-.0RJP#+PY
MC#LWUY!YD*S71]V62;@^],<:?BT0.-,"#\058_+TH"ZZX??'^B\```#__P,`
M4$L#!!0`!@`(````(0!?Q.-U)P,``#X)```9````>&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;)Q66V^;,!1^G[3_@'@OUY"0**0JH&Z55FF:=GEVP`2K@)'M
M-.V_WS$.!,R65GU)@/.=C^_<?-C>OM25\8P9)[2)3-=R3`,W&<U)<XC,7S_O
M;T+3X`(U.:IH@R/S%7/S=O?YT_9$V1,O,18&,#0\,DLAVHUM\ZS$->(6;7$#
MEH*R&@FX90>;MPRCO'.J*]MSG*5=(]*8BF'#WL-!BX)D.*79L<:-4"0,5TB`
M?EZ2EO=L=?8>NAJQIV-[D]&Z!8H]J8AX[4A-H\XV#X>&,K2O(.X7=X&RGKN[
MF='7)&.4TT)80&<KH?.8U_;:!J;=-B<0@4R[P7`1F7?N)@U->[?M\O.;X!,?
M71N\I*<OC.3?2(,AV5`F68`]I4\2^I#+1^!LS[SONP)\9T:."W2LQ`]Z^HK)
MH110[0`"DG%M\M<4\PP2"C26%TBFC%8@`'Z-FLC.@(2@E^[_1')11J:_M(*5
MX[L`-_:8BWLB*4TC.W)!ZS\*Y)ZI%(EW)EF`^K/=L[PP<(/EVRRV4M0%F"*!
M=EM&3P8T#;R3MTBVH+L!YCXRI6.(]7^A0HR2Y$ZR=%P0!8?R/._6[G)K/T-.
MLS,F5AB8B`'C3A%)CY`)E+3IZ($->@?1D`I=M`]%_7<Y>HW2::K17TP%Q'.(
M-T4D<X0?3"'I'+(*!\@D#'\:QG7Y$@Q],TK?(EP-O%V^8H6!,@XIUHJ0O(E(
MKR$FZN$UXR)<5R_!D0FI&90%SEI3KS"KKGV\E5Z<9&H.G*EW.C:[X?H2^$0T
MC-M8M&SWMSM'.FGB7>WUL<(LE/BUUEC)V.H&OB9];`W"2UHFRI<?42Z==.7:
MU,4*HY3/M"5C:W#I8S6?8Z.WO`S"1/CJ(\*EDRY<F\588:#N0T\M-4C20^2)
M=.-YVKRDO7G$,)1F$H/<XZ-3\GJO2["N76N(6&%4K_MNJ.L>F^>C`*M.OJ&?
ME-$H*-%JCZECOL;L@!-<5=S(Z%'N*!=Z='BJUF<,Z[-;-O9@@/75H@-^1.Q`
M&FY4N`!7QUI!KS*U`-6-H&UWJ.ZI@,7579;PG8+A^'8L`!>4BOY&KMCARV?W
M%P``__\#`%!+`P04``8`"````"$`($P%.9H+```/5@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6R<W-MNVT@2!N#[!?8=!-V/))(Z&G8&X?D(+!9[
MN%9DVA9BF8:D)).WGVYVDU85V_W+SD424Q]+9%>1;)9DWO[YU^%Y]+,^GO;-
MR]W8F<S&H_IEU]SO7Q[OQO_]3_S'>CPZG;<O]]OGYJ6^&_^N3^,_O_SS'[>_
MFN/WTU-=GT<BPLOI;OQT/K_>3*>GW5-]V)XFS6O](EYY:(Z'[5G\>'R<GEZ/
M]?:^7>GP/'5GL^7TL-V_C%6$F^,U,9J'A_VN#IO=CT/]<E9!CO7S]BRV__2T
M?SUUT0Z[:\(=ML?O/U[_V#6'5Q'BV_YY?_[=!AV/#KN;[/&E.6Z_/8O]_LN9
M;W==[/:'0?C#?G=L3LW#>2+"3=6&#O=Y,]U,1:0OM_=[L0=RV$?'^N%N_-6Y
MJ>;.>/KEMAV@_^WK7Z>+_X].3\VOY+B_+_<OM1AMD2>9@6]-\UW2[%XN$BM/
M!VO';0;^=1S=UP_;'\_G?S>_TGK_^'06Z5Z(/9([=G/_.ZQ/.S&B(LS$7<A(
MN^99;(#X>W38R](0([+]ZV[LBC?>WY^?[L;><K)8S3Q'\-&W^G2.]S+D>+3[
M<3HWA_\KU.Y1'\330>9]$,>=N.N%LUA^((IXOW93EGT4=SYQYK./Q%CI&.+?
M;G>\R=Q=K-8?V1]Q<+1;(O[MHGQ\4#8ZB/A7!W$WDY4SVWBKZT?6$071;HHC
MQOC#VS)5R6YK)]R>MU]NC\VOD3@@13I/KUMY>#LW,G)7-2K'?1V]5T:B?F24
MKS+,W5B,DJB0DZC]GU]6F_GM]*>HUYTV_M`X5`2=D,4IPX9\0=0M>'N?Y7I-
MH\2=Z:(DW8*WE=@;IYWH5LGX@IPO*/B"DB^H+A9,Q6CW0RX.,#+DY@.T&UFI
MY<AVF^9W"][VQJ4#$`R%MZ`D')(5&\9($;$3%REE8>(K3#(T;'M3*#(H<B@*
M*,JAX.-6#<G%N)$LBV.)9%D>6)XXANW9EFN1;/,%`5\0\@616G"9.&>VI/F/
MKS#)T*PV*QHG'9KEBAWWV="L-JS8\BM,,33+%=NO\@I3V0U)HKB,D23:DR<U
M21Y?$/`%(5\0J07JHBI/@7&WX/(P9'N==*8[1Z1\0<87Y-V"R[`LN87);&@!
ME)WIWKJZ6$"&4ESIR%#*XV$N%MJ'5*XECIN+D]!RR3;35T:\;W^B8N,30!%"
M$4$10Y%`D4*109%#44!10E'9!$F\F,21Q-L3+G4[!^V3N9[-:,WYRBS;:<9B
MUOZA(E#"4A(A%!$4,10)%"D4&10Y%`44)12539"$BQDW2?AU5SZY%DW\RF''
ML:^,):T!%"$4D1*JO%8S1U88+:\8QDB@2*'(H,BA**`HH:AL@B1>=A+XO02>
M\LBU:.+7,S8_]Y6Q)1Z*$(I(B4U[7G%FDP6;I,0P0@)%"D4&10Y%`44)1643
M).WBMO83:9=K\;2S&P-?&5O:H0BAB)18M6E?;M0%A1WP,$@"10I%!D4.10%%
M"45E$R3SLB?QB=2WJ_'<>W3(?8ULR<<DQ"3")-9$71(VABM"@H.DF&28Y)@4
MF)285%9"JT`V.CY^WG=4?T3<45],]=B]HZ^1M0I4'`L)<90(DQB31).%JA1V
M%4OIJ[/)FK53,OP..28%)B4FE970_,NFR&7^[3-\1_50:-[92/@:69(:8!)B
M$F$28Y(8R)KW7%(#8A/<#),<DP*3$I/*2F@!R([*90%<-^.7[>;!%(#?W&ND
MCZC9A!U3@7[=4B@A)A$F,28))BDF&28Y)@4F)2:5E=`:$!D8U`#N[SAR-3X5
M8/-N7Z/NK#IQU#U_]_>@)%1,:TE`$NDWM42),4DP23'),,DQ*3`I,:FLA):$
M;!%]XK2@.DOT^L#:CK[\8%/4#<F.PU!@0G26&6(281)CDF"28I)ADF-28%)B
M4ED)+039.N*%X,Q$"L%,0;6<2"4XK!?C.\.^U-H9G!*&B%UZ0T,<1B),8DP2
M3%),,DQR`Q&??=,#H#`B=B]6&A`;F\I*:#7(?M)E-8`B4.TG6@2#VP1#CVK!
M-C%P#(B.1HA)A$F,26(@*_YA8VI`;)\R3'),"DQ*3"HKH24@>TN7)7#EA%&U
MI&@I#.X<;'VK]EL%@0-)B$F$28Q)@DF*289)KDD_D7;9P!4X1HE)926T"&2;
MZ;((P'E`=:5H\MGAX#NVUI5./B0ACA)A$F.2&(CAMA%N<&:(PT8FQZ3`I,2D
MLA)2`"[O'MH+H.7L5L'AMXL:D7DA/<<'F(281)C$F"2:Z';17-W8T.U-B7%-
M),/OE&-28%)B4ED)S?_G^H:NH6_H\%M&C:QU@/N&.$J$28Q)HHEN,*\,'VFG
M.$J&28Y)@4F)264EM`S$*9U<!ZZ;#+AR-7XZ8'>`OD9J7.=SP[@&FE@J)<0D
MPB3&),$DQ23#),>DP*3$I+(26@:?:R*ZAB:BR^\1-9JK3W;I^37H7WS['()=
M/$-,(DQB3!),4DPR3'),"DQ*3"HKH04@#D%R'@#3`<G9\>^R^W[?5>CRX%Z[
M[!8X,*!!`0SC,!+A*#$F"28I)ADF.28%)B4FE970`N#]0E``ACZARSH7OORE
M`]XGY,<_)"&.$F$28Y)@DIH(;W5D)D1W.\>DP*3$I+(26@"\3P@*P-`>='EG
MR(6=OP"3$),(DQB3!)/41-;L;)29$"\`.#(%CE)B4ED)+8"/M09=0VN0MS5\
MC2XO`6RP`DQ"3"),8DP23%),LI[(W\1ALZ&\?_'="4^!28E)924T\;PA"(Y\
M0R/095GU7874W'^],<[]+\G2($(21'_N2(^C2!-+@<68))BDF&28Y)@4F)28
M5%9"LR\[7)>=P"OO`%5CC'0$W4%#2"%5!8NE^`5`D6::P<"%';80DPB3&),$
MDQ23#),<DP*3$I/*2D@=R.\*?Z(.VM7XG0!O"&FD.P'.;.4-ZT`;RY$<8A)A
M$F.28))BDF&28U)@4F)260FM@\\U!CU#8]#E'2&-]/E@;KPL$+,V?2$X),34
MDXVTL!13C$F"28I)ADF.28%)B4EE);0,>&/0/BGP#`U!CYWJ?8TL60DP"3&)
M,(DQ23!),<DPR3$I-%%'CK>1%U)Z'2V)F*^7JP43%1&+]LCJ8]#<?ZX;Z!FZ
M@1YO"FEDK0$5QT)"'"7"),8DP23%),,DQZ301/^*C#OA7R<I"5A,YFSL*_*Z
M.UG,-Y=_WB[:M!A$'@;S`OS=0D^NQN8%'FO^^1I9,AU@$F(281)CDF"28I)A
MDF-2]$3>9++&6]F_^.Y-9F4EM`!X9U#>(%Q1`(8.H<<VU/=@^R_`),0DPB3&
M),$DQ23#),>DZ$G;99CPH2W[URTU8!M]6@.\.2AK8(D?J&!H$GJ\2>AUK3#S
MC@3]Z^_N2(A)A$F,28))BDF&28Y)@4F)264EM`9X?_#*&C#T"?F7[7Q/(?49
MX6S"GS(0]*];:J`+\2Z)<)08DP23%),,DQR3`I,2D\I*:`WP5N%US2+/T#+T
M>,M0(^MD0,6QD!!'B3"),4DP23'),,DQ*33I^RNRF=I/[=MOWI6$F.Z9*R+$
MX^,N8]`B^%S'T#-T##W>,=1([8FS7#G>V[14?850"WVJH'L9DM77XA%?]/6H
M7_G=DT2,28))BDF&28Y)@4F)264E)/GSS[4)V]7X[0!+K:^1^F5P58&LC`--
M;&<`$L54Z1$.$F.28))BDF&28U)@4F)260FM@L\U"<43&(<WA;Q)J)$EQ0$F
M(281)C$FB2;JC.5NW,UBPXHV)<19N*O5DMT(9?B-<DP*3$I,Y',RW__:ABH#
M]1Q,]2S#0WU\K(/Z^?DTVC4_Y#,NY0'<+^V?O_EU+A^CQY;[SDW8/F^++8^<
M&_$HP:%/Q',\3<M]]\8WQ0_<F\"T/'1OQ.._1/QI_\;B<9ROV\>ZVAX?]R^G
MT7/]('9E-I%/B3RJ!WJJ'\[-:_ODQF_-63R(L_WODWCP:BV>%R8>6S(>/33-
MN?M!OD'_*-<O?P,``/__`P!02P,$%``&``@````A`+V-]AZ-!```;Q(``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-C,N>&ULG)A;;ZLX$,??5]KO@'@O8.Y$
M28X.5-T]TAYIM=K+,R%.@@HX`M*TWW[''G+QD+:D+[GQ]S\_C\<SF/FWU[HR
M7GC;E:)9F,QR3(,WA5B7S79A_O/WTT-L&EV?-^N\$@U?F&^\,[\M?_UE?A3M
M<[?CO#?`H>D6YJ[O]S/;[HH=K_/.$GO>P)6-:.N\AZ_MUN[V+<_7:E!=V:[C
MA':=EXV)#K-VBH?8;,J"/XKB4/.F1Y.65WD/_-VNW'<GM[J88E?G[?-A_U"(
M>@\6J[(J^S=E:AIU,?NQ;42;KRJ8]ROS\^+DK;Z,[.NR:$4G-KT%=C:"CN><
MV(D-3LOYNH09R+`;+=\LS.]LEKF>:2_G*D#_EOS877TVNITX_M:6ZS_*AD.T
M89WD"JR$>);2'VOY$PRV1Z.?U`K\V1IKOLD/5?^7./[.R^VNA^4.8$9R8K/U
MVR/O"H@HV%AN()T*40$`O!IU*5,#(I*_JO=CN>YW"],+K2!R/`9R8\6[_JF4
MEJ91'+I>U/^AB`U6:.(.)O`^F+CNW2;>8`+O)Q//\MT@BB>@V#@M%:7'O,^7
M\U8<#4@]`._VN4QD-@/G4WAP,N>`O1<O")0T^2Y=E!>$HH-%?EG&OC.W7V!A
MBD&3H@;VU5G#=$5V4LCU!+PS(X2-,GJ0"+>7\(0D!^E(S/'U/TS'&E=79&.%
M%YPE&B0$[WY(.0@RZBHF;G#Q5[%-4>-?:<(S@5)D'RDT1C"YGU$.6I@0B/.Z
MQ3Y9N10UH5KYA,6^YU/&:T4,EUERR0^-$7;5->/'BRS%.IL_RCO4(!MC+($"
M3.*'"B`\S_!"K[&%][!),66C<4,-LCVPB`7,]0@<2B;`1??`23&%(_^<HN8$
M%T-F)H0-%1/89#<E5>;S'2P'Z8RQ3_9GBAIDA)(3Q"'9X]FU@J:FMKC)5QCE
M(,I(XXB:@='QP\0CL\A0,2&.#,K>_8%4HR@EB5,ZB!`SB!TG\4BV9H-D"N>-
MMN+#-OMX-S-L`'JIH>5P$"6JUH26.X)$DRF0LKC?G94,6X(.>:D76+,'$4(R
M9D5D%MD@F$(IJ_O]E-@3=,I(W[XI0Q%2^E9$4B(;KD^!!,T7(.4HFI<QA401
M0L;6*)!X&5X_*][RKH\R3LA);`YZ($D=3)7UPD3&R*+;6[NLI:Q6@!AI+_)>
M;`+@N,_$`>EPJ;*^`([VS.0FPTB7F<@X;C=Q0"!297UB#*UXE(V3NPW[4KM1
MHT@V!F0ITT%TG6YQ0`I^=E-TF8Z^Z#?:SH1%O]%W1C>.;-Q6XH!4JNR&Z"+1
M2-T;O>=S4C6*1I46HD&D1Y44@NR&Z#W2&]WG\]L-]T;WH7<\Z2"*5/<)0CA^
MZ>4J&P374WF/4C824M@GQ%..(O$,Z79W433T<C_V2<'*!L$4RB^U'SC1CRGI
MAA]$&$N?.1'=1X/@(TH\]^.)MN;MEF>\JCJC$`=YIF>P3.=?\7E#"L\;U.'<
M/E^`X_X^W_*?>;LMF\ZH^`:&.M"S3:/%!P;XI1=[=:!<B1X.^NKC#A[L<#@`
M.Q:(-T+TIR_R"'M^5+3\'P``__\#`%!+`P04``8`"````"$`^_B07MH(```W
M+P``&0```'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R<FEMOVS84Q]\'[#L8
M>J^L*T4%<89V1;<"&S`,NSPKMAP+M2U#4IKVVX_DH43RB!+I]2'-Y<_#<_V)
MDO7XT[?+>?.U[OJFO>Z".(R"37W=MX?F^K(+_O[KTSL:;/JANAZJ<WNM=\'W
MN@]^>OKQA\>WMOO2G^IZV#`+UWX7G(;A]K#=]OM3?:GZL+W55_:78]M=JH']
MV+UL^UM75P>QZ'+>)E%$MI>JN09@X:'SL=$>C\V^_MCN7R_U=0`C77VN!N9_
M?VIN_6CMLO<Q=ZFZ+Z^W=_OV<F,FGIMS,WP71H/-9?_P^>7:=M7SF<7]+<ZJ
M_6A;_#`S?VGV7=NWQR%DYK;@Z#SF<EMNF:6GQT/#(N!IWW3U<1>\CQ\^T"+8
M/CV*!/W3U&^]]OVF/[5OOW3-X;?F6K-LLSKQ"CRW[1<N_7S@OV*+M[/5GT0%
M_N@VA_I8O9Z'/]NW7^OFY32P<N<L(A[8P^'[Q[K?LXPR,V&2<TO[]LP<8%\W
MEX:W!LM(]4W\_]8<AM,N2$F8%U$:,_GFN>Z'3PTW&6SVK_W07OX%42Q-@9%$
M&F'_2R-)%F9)7E`/*UOP2`3XL1JJI\>N?=NPKF%[]K>*]V#\P"R/D8$?4ZQ+
MH;(8N9'WW,HN8.W.HNA9?;X^49(\;K^RG.ZEY@-HV-=)$T^*+?-F<HFYH;MD
M3_*X,Q?SG7G2N2L?X!?Z-LH18YO4W(9'GBW6=-R.+V+5TX*@))W"``]`DVD:
M,BD,#YA$#]3/`[YH%[`HIS12DDWVP0/0$"A$%N6ZPO"`Q7N_!WP1]B!''H!&
MSP'-59X,'\C<AY1-Z'K9^2+L@\HR9`$TD(6<1E&9+C1<\7\\X(NP!P7*`FA*
M40<24E4F(P'\*J&-X'K@7(RWI6A;T.C)5ZDQ=B[-G?T:D"]RC0!H/#R(6:7]
M@Q=J''V)HI<BR'H2YEFI_U.Y,C(1<SIY%T&HD1]%A/T`X($?*;LP3'\W=T:X
M\RM"#)A;QX`4P00D<4*SA0Z,_Q<+Q2J4!:*BA"&4(KT5:+$PAS%3Z47@J7"C
M0*S";JB&EVYPT[M`PJ`DF1I5LQH6(GJX8$.BVD&Z`**I+]7?30\0#]=Q$%M`
M6*@+GMP91'H-5'[,S2TH=%\48^#<^E51BGR<N`N(L8V(,R:`:)S%3'6I&3X"
MHB/W0#EC!N<4`)%KYP1QT(\"8A5N?37C4'TI@M:/XR1+Z<+\)0B"GDX`YXPT
MS#`@3+,#EGYL*18.!`EGF\9B/PR(53@7JLUE+KCI$0/KN;`@T0V"!,Y^9B[4
MH$LG0.1L"8XL+0WKS9AP-0J_F+4"B/0JJ`P9D\#O2_3-/5L!$+<.`F':;(4E
M)^Y"86)!(<$@D*(Q]PNG@01AT)%ZP)]1]!D'A,E=`!OG8;(4,F*?9]YM#)P5
M'T3``4+B7!M2L_:(@IX^6&BH[2!;'T1Z`])B`<9\VG`+NB=0K$)S0%2RP0TI
MFDX#<:841BI2"Q$]?+`1$5-`F!X;(F/'5/OQ,$4P7&]%H4;1%RHV&3U`4"^"
MDICA6R#H/@ZDP+=U"DB1CQ-,H_>!(P-<C3(PHT`*HG$8TZ4.1!!T[`SP6\=`
M"B+GSHA\?B.8V@BH^DI6'T30^V544FTZS.(C"'KZ8('A#`,IB/3BTT(-B.F&
MA8@>(V@CHNIRF0J=B*NIL!#1PP<;$564T@<0N1HB0S!<;T6A1D-0J&L=["Q%
M>A%4@HP29!8*NC$@5KD>%$B1CQ-W@3`#QAG#.,.`%(VYSQ:.Q1FBH"/W0#]C
MY]EI0)@<X9^'BSMS3FE'0+\1S/@J5/WY(T(0C7<%:98GBA1F]1$%/9VPT'#&
M`=Y$S%.]^K101S;3#0L2W3.8V9"HVEQ.@H[$I(BB3#W+,7VP(-'#!QL2,0<R
M$#E[$='0T8L6"E(5FXP>1'H15(+,\"T8].``$&[].)"!R,.)_"X2"C6>!=5A
MD`$IFG*OGI\8X><(@^NY%VJT\XP#4C3NO'0ISA'[_$90K$(>S#@@1?*N(,HC
MU1YF\`B"GBY88#BC0`XBO?9TZ1%%SE28B.X)%*MP)E23RR[@IL=G`V0E$Q8>
M>KA@XR&&0`ZBL1V6[DIRA$)'(UH02%6+R^!!I-=`Y<=L!`L#W1#(`6_K$)`B
M'R?NPF!NP>#L,"!%8^Y5:<SH$0(=J0>JK9\%<A`Y-B8(>W[S)U;AQE?7>:B]
M%,D[@BR/DP4&$`1`3Q]L=\/JCDOZ`"*]])0N/!\D%AJZ!U"LPJE0/2[=X*8G
M!A2DU(AM]`&QX-##!QL.5:=)'T#DZ@=.*^UHN-Z(A*M1\-K'D7)C$.DU4/DQ
MH[<@T,T``G1;9X`4^3AQ%P6)A8(S!DC1F'JZ%#Y"H"/W@+YU"!`0P<[LHV+%
M9S/QB'N>$VCCWXP"(`(*T+*,DB4?$`(]?;"@<'82("#2BT^I0H61BL("1/<$
MBE5H$+13%PR"%$$JBHRE8@&(A06('C[8@(@I($R/=X@D7/K$JD`L7&]%H4;1
M:TTNHP<&ZD58F(/"`D$W!L0JUW,!*?)Q@FG\05AP-<K`#`-2-`YCN3`(!:*@
M(_=`OW4,")-CU>,X+-6MBMG\B'U^,UC8&(@Y($70_"G)TVPI?$1!3Q\L-)QQ
MH`"17GU*U828J;`@T6,&;4A4;2XG04=B0HJ4+#PA*BQ(]/#!AD05I?0!1-"+
M-"3J*9Z1!8IHN-Z+0HVF@"K+L+,4Z450"3(WMV#0S0$*&%P_#DB1CQ-WD9`"
MY(QIG'%`BB#W<1+&"Y-`$0<=R>=JE'SMF"F3#R*Y=19J;U.:J><\TXZ!?D-(
M^2KDPNS)@!0!")*HY`_&[)]1401"3R<L0)R10)A&3PCI`A2I!8KN*12K<"Y4
MH\MR`#DA%W%$62J6<F&AHH<3-BIB%+`WG'G5IIZ(\,D(WE^&UWLO=?=2_UR?
MS_UFW[[R=Y-C]AKB]-OIO>GWB7CS>?H#>VWY5KW4OU?=2W/M-^?ZR)9&(;\P
M=?#B,_PPM#?Q\O!S.[`7EL6W)_:">LU>P8U")CZV[3#^P%^MGEYY?_H/``#_
M_P,`4$L#!!0`!@`(````(0"E/M=,]0,``%(.```9````>&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;)276X^;.A2%WRN=_X!XGX"Y$R6I"FA.*[72T=&Y/!-P
M$C2`(TPF,_^^VVQ"L:%D\C*9))]7UMK>OK#Y_%:5VBMM>,'JK4Y6IJ[1.F-Y
M41^W^K__/#\%NL;;M,[3DM5TJ[]3KG_>_?%I<V7-"S]1VFJ@4/.M?FK;\]HP
M>':B5<I7[$QK^.;`FBIMX6US-/BYH6G>#:I*PS)-SZC2HM918=U\1(,=#D5&
M$Y9=*EJW*-+0,FW!/S\59WY3J[*/R%5I\W(Y/V6L.H/$OBB+]KT3U;4J6W\[
MUJQ)]R7D?B-.FMVTNS<3^:K(&L;9H5V!G(%&IYE#(S1`:;?)"T@@RJXU]+#5
MOY!U0AS=V&VZ`OU7T"L?_:_Q$[O^V13Y]Z*F4&V8)S$#>\9>!/HM%Q_!8&,R
M^KF;@;\:+:>']%*V?[/K5UH<3RU,MPN)1+!U_IY0GD%%069EN4(I8R48@+]:
M58C6@(JD;]WKM<C;TU:WO97KFS8!7-M3WCX70E+7L@MO6?4_0J270A&K%X'7
M7L2R'A:Q>Q%G$"'6R@I<XGKWK1@8JZM2DK;I;M.PJP:M!\;Y.16-3-:@?"L/
MAAD*]KMZ0:&$R!>ATFE!*3A,\NLN",V-\0H3D_5,A`RLJX$A,A'?"#$+0C89
M?6"`W\$TU%$U;4-GS,_IS:,8)'LDIB,[B*:,)1/QE+!=&4FFB!\,B)0#IG2<
M8]F_@+<ZB`_U\WQOT.T*%B$#\_B+D8GX+I$L$9)[^)FQ>]$ZSF]7UFT6Q"!8
M0V.'GB][C)!92G&72)8(*04X'J=8G@,!RW,0A$H71\AXW2H@INWYKK(28B06
M\B5+A.3>>\2]@&7WSJ@SL8.00?=V:+FF:GX,.,$T73(&7!@_4I"L^X]8%[!J
M/53:!AFT_F0[)'!LF8B16"K\$B&Y%_>#T;ZYW#8"5MP':ML@T[NW[&G7(+!D
M?HF0S(>/F!>P;#X(E5TQ0N;6\Y[MN<J:CF5B9E4D2,SGD]P3V.K'M1<;S_WM
MOQNEYE`:).HA#`+='P1*TK@GYFWVIY;P!WOA>(\;&E%.(@ZX41=];`LE>"R.
M3X(@5$^R'AJ;"$+EI(IG(.5$2181.8PX]QX/@Z>E'$8Q$1&$Y#!JA\U`BDZR
MB,AAQ"FHA/E`C^'9*8?Y=?;C#DL0\O&`<'Q?F;JX!\9I)T%08QZ1@P"C!KE_
M2L.-?+KHU?VVA_H@5N"I1T4/S+OLUPK^T#R"0?!JCY?6BC9'&M.RY%K&+N+:
M3J",PZ?X2!&)1XKNH6#X`F[TY_1(?Z3-L:BY5M(###57/IRS#3X3X)N6G;LK
MXIZU<)?O_CW!LQN%RZBY`OC`6'M[(YXZAJ?!W4\```#__P,`4$L#!!0`!@`(
M````(0!-)%^=.00``$D0```9````>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM
M;)Q8VXZC.!!]'VG_`?$^`9,+(4HR:D"],]*LM%KMY9F`DZ`&'&'2Z?[[J:((
MC0U-DGU)`CX^G%-5=N&LO[WEF?'*2YF*8F.RB6T:O(A%DA:'C?G/W\]?EZ8A
MJZA(HDP4?&.^<VE^V_[V97T1Y8L\<EX9P%#(C7FLJM/*LF1\Y'DD)^+$"QC9
MBS*/*K@L#Y8\E3Q*ZDEY9CFVO;#R*"U,8EB5]W"(_3Z->2CB<\Z+BDA*GD45
MZ)?']"2O;'E\#UT>E2_GT]=8Y">@V*596KW7I*:1QZL?AT*4T2X#WV]L%L57
M[OJB1Y^G<2FDV%<3H+-(:-^S9WD6,&W720H.,.Q&R?<;\XFM0N::UG9=!^C?
ME%]DY[<AC^+R>YDF/]."0[0A3YB!G1`O"/V1X"V8;/5F/]<9^+,T$KZ/SEGU
ME[A\Y^GA6$&ZY^`(C:V2]Y#+&"(*-!-GCDRQR$``?!IYBJ4!$8G>ZN]+FE3'
MC3E=3.:N/64`-W9<5L\I4II&?):5R/\C$&NHB,1I2&:@OAEW)LYRSN:+VRP6
M*:H-AE$5;=>EN!A0-?!,>8JP!MD*F*_.2$?K]3.KX!%)GI!E8T*Y@PL)^7G=
M>K:]MEXAIG&#\?L8IB*"*P(#B+1AYX8%>EO1$(JNZ.$T7+4A&+5=67VZ`=RM
M6$<3TD=,YRHD[$/<90M1Q$X?$8M@J(Z.-L_6PN03!I+5ZE^T3Z[C%MQ$A&,(
M13T\YOY0(WAC0FA:99ZMQ=8GC%L7B58B`8W!9SM?<Q:.(13=L*[NUXU@7?=4
MC:E/F/F"A$^F,W4\H/$Q[6,(1?OB$>T(5K7/O(]*K.O!)PQ)9[#KV*ZM+\^@
MBUDN';;H04*"#%M4#+BJ`=Q4IK#ICJ]3G*0:\6PMR#YA&B,SV&-Z(H,N9#X;
M0(1=!/,P%)U@*#ZP?VN;XVT?.$GWH>T>/F'(AV.3#WTQ$&8XVK0]CB$4'][_
M\8&3=!_:<O0)T^3#&_9!F#$?8PC%!X,B>CPA]2S=B:LN7[\!=65ZMK:.@@&0
M%I%P%**:P>[V<'4QZHGJ'NOI9@A$>7$]K[^6@X:'(`NW7@4J2]A`NB'Y<*M:
MP6[8L3*^T!GU3L4"TZK?;T"-OKFZ2*G+-9!A?;1"1B&J!>R(]UN@_JE:T/LT
MZS=9CVGM,!@`?02Y,='G^8"H)B`6#YA`M+8NF-[V&(%F@_VZ'?R\88]"5/'8
M'^_/`'53-0-ZN\!W='`X4B'!;4@X"E$M8(>\WP+U4\AN^[K3?]EC8TVW60<W
M(>$HBVH!N^/]%JB7=K/0?_N`DQEF8?B5KQD<21&>[#[/(HFGDQL=;')>'GC`
MLTP:L3CCJ<R!XFWOMB?&)P>/!-I]'T^2>-]J!^`@=XH._(^H/*2%-#*^!TI[
MXD)ME704I(M*G.KCU$Y4<(2K?Q[AR,[A(&-/`+P7HKI>X`/:/P&VOP```/__
M`P!02P,$%``&``@````A`,&86XC"`P``D@P``!D```!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&ULE%==;YM*$'VO=/\#XCV&Y<,8RW95B')OI5:JJGO;9PQK
M&P58Q*[CY-_?V1V,V75,G1?',&>/SYP9ALGJ\VM=62^TXR5KUC:9N;9%FYP5
M9;-?V__]^_2PL"TNLJ;(*M;0M?U&N?UY\]>GU8EUS_Q`J;"`H>%K^R!$NW0<
MGA]HG?$9:VD#D1WKZDS`9;=W>-O1K%"'ZLKQ7'?NU%G9V,BP[.[A8+M=F=-'
MEA]KV@@DZ6B5"=#/#V7+SVQU?@]=G77/Q_8A9W4+%-NR*L6;(K6M.E]^W3>L
MR[85Y/U*@BP_<ZN+*_JZS#O&V4[,@,Y!H=<YQT[L`--F5920@;3=ZNAN;7\A
MRY2$MK-9*8-^E?3$1]\M?F"GO[NR^%8V%-R&.LD*;!E[EM"OA;P%AYVKTT^J
M`C\ZJZ"[[%B)G^ST#RWW!P'E#B$CF=BR>'ND/`='@6;F*1DYJT``?%IU*5L#
M',E>U=]368C#VO;GLS!R?0)P:TNY>"HEI6WE1RY8_1M!1(H:2+R>Q`?U?=R;
M>8N0A/,_LSBH2"7XF(ELL^K8R8*N@=_D;29[D"R!66;F@S_O9P9JY)DO\I`Z
M"F@.Y7C9Q"1<.2]@8=YC$L3`$S!@/!V17B/\"XD#^@:1D/K'1<I#ND@_T!4D
M"%DHFV5BZ>B&)@"<&0N8=D>"P<51YD%,C%]&3##"S'5$.H70M`')_=HD>&U#
MFD-5@MBH2X*82-5U0>+`<"T=QR-HX7A0KNF"SA[KNJ^SY"%3GS_PJ^Y+$#-7
M^J(X-HT;A^=1Y`ZG-75S7=UT12785&6XDB`&O!F<G1O&IF>(?&!N='KT$5D2
MK,LB9#&DBV8AYFR6%^GA5`O[T0U5\CTV&A+39DFPKBJ(+[RH"C&HR@_G1H53
M#-_P4BMC_!%E$FPJ,[HG00PJ(]`^AE\8#G#F^9>H)HK``+W?+X4V95V8T;`>
MU.N"%X=K(%(-L5AXY)*9+LZ8^-/%)#BD]8%A]E@/0G$/Y%UUR--#IN3)$7QW
MKQ$<V&-YH6O.VAYTHYV4O^DT1C=03N;[%>(<A\]A+GC^92;UU9T:]KW`*8BN
M3\[GD;[[!B^1I_0N#%UC@"4]"-O_(0J,1DB'^"79T1#451JOAS^TX?5[(72-
MJ9'(C0Q2P!?7>^HP?J,/4!VN@+@AU;3;TY16%;=R=I3KG0?/_7`75\^$+&&-
M@#W-N)_"2JKN.T,`-L(VV]/O6;<O&VY5=`>4[BP"61WNE'@A6*OVEBT3L`NJ
MKP?8_2DL*.X,P#O&Q/E";JW#?Q.;_P$``/__`P!02P,$%``&``@````A`,/D
MK$)I!```F!$``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R46%V/JD@0
M?=]D_P/A_0H-HHY1;P;([-YD-]GLYS-BJV2`=NF><>;?;Q6-T!\N%U]4]'#Z
MG*JN+LK-UX^J=-YIPPM6;UTR\UV'UCD[%/5IZ_[UY\N7E>MPD=6'K&0UW;J?
ME+M?=S_^L+FRYI6?*14.,-1\ZYZ%N*P]C^=G6F5\QBZTAE^.K*DR`9?-R>.7
MAF:']J:J]`+?7WA55M2N9%@W4SC8\5CD-&7Y6T5K(4D:6F8"]/-S<>$WMBJ?
M0E=ES>O;Y4O.J@M0[(NR$)\MJ>M4^?K;J69-MB_!]P>99_F-N[VPZ*LB;QAG
M1S$#.D\*M3T_>4\>,.TVAP(<8-B=AAZW[C-9IV3E>KM-&Z"_"WKERF>'G]GU
MIZ8X_%+4%*(->1+9_@]:TES0`V3.=3`C>\9>\=9O\)4/B_`6@(OP?V_+/`>X
MBM<OHWZ^+?G2INVWQCG08_96BM_9]6=:G,X"5HH@#!B-]>$SI3R'-,!:LR!"
MUIR50`&O3E7@?H(P9A]277$0YZT;+F;1T@\)P)T]Y>*E0$K7R=^X8-4_$D0Z
M*DD2="3P?I6_!XO9*HKFB]5R.DO8L<![QT*"6;"*2+1X0,N\8X'W@66B(4\&
MIXU[FHELMVG8U8%=#_;Y)<,:(FL@O@59AJ0/^_]%'<*-),_(LG6A7"&@'%+_
MOO,WWCLD-^\0L43`:X\@.B*Y(3"32)HJ7WB@MI<,N5`EW]\/-V4(1F4WUEA^
MH0H)#"$V(M01J8V8]PA-*B1<E8K1#:%ZQB7C38!30A7U[&UD8HF`=/7!7.B(
MY+N(=`RA>8!E5`_CVA&\=2$^O;*EKBR6"%7[2D<D-L)PEXXA-.U0HM.U(UC7
M_J0KBR5"U4Z,?9[8$%/\&$(3OWA$/()U\<0HL%A"HK8\YV01&NX2^;OJSI0^
MAM"D+Q^1CF!#NE&2L82HTHA1DXD-,=6/(33U^-BAG(GC.Q[!AOKA,)#E*B&:
M>J.B$QMBJA]#:.J?'E&/8$.]L7`L(9IZHZ83&V*0I&,(33V!XW%Z\%NTH=\X
M3N(.HQDPM_X=C.E@%*);P,8U>?\0V>;4(S,P#I6XPZ@6`J.ZDSL8RX)<2J49
M(+H%['#3+<A^J%DP*YA(C+IV8);P'<R@KWLFL&D&B&X!&]QT"[(=:A;,,B9V
MRPS,.KZ#&?1U%FR:`:);@&@]8`'1>BT$`[$\B8C$:%DPB_D.QJ!)1R&Z!>QV
MT[,@>Z.6!:N<[?YI9\'&6!;&(+H%['K3+<@>J5DP3IN8V'TT-$H^N8.Q+-@T
M`T2W@*U/L3#M.93(AJE:"8U3)^XPZH8:-+1[+ND@B_:Y8Q$L0QB=C(BDHS2Z
M%>R#BI7QY@Q#K5D3H74RC776SL)W(3@^XTI+^73E1WX0PJ#9/S]*#W+NE?-7
M19L336A9<B=G;SC'$KBW_[8?S+N)N?\!1MQ+=J*_9LVIJ+E3TB/<ZL]P&FWD
MD"PO!+NTT]V>"1ANVX]G^`>$PF3ESP!\9$S<+G`D[_]3V?T'``#__P,`4$L#
M!!0`!@`(````(0"B#L<\,P0```\0```9````>&PO=V]R:W-H965T<R]S:&5E
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MS=VF<=!_&;WRP7^-G]CUSRI+?V8E!6]#G#`">\:>$/HCQ2%8;(Y6/S81^*O2
M4GJ(+WG]-[M^I]GQ5$.X75"$PM;I:T1Y`AX%&L-RD2EA.1@`WUJ1X=8`C\0O
MS>\U2^O35K<]P_47-@&XMJ>\?LR04M>2"Z]9\;\`D99*D%@M"?RV))9C.);K
M+S_"8K<L3L]"+,-:NL3UYFTQA:[&35%<Q[M-Q:X:[#VPG)]CW,ED#<R=?X2:
MWF/W'`:>0I('9-GJD#3@"PY1?MYYGK<QGR$R28L)QA@B(\(.@6%`VF@P8(*]
MO='@R*'1MX/9V89@M*UC#<0`</?&6HHA8X3MRI!H#/&7/40R%N(V-!8][-S=
M@9W1N`CVVL!&S_-[_L8[@<!`T'H=BLO#640TA9!4P&M4%39DX[3K<=%6!U>]
M6>B]>4FH$!B_V32$0'F$CRPT%!#X?J.1$=$40I(!CO^X#%RDREC)%@0"(]GH
MJSIN8&26:`HAZ?`^HP,7*3I\)0<#@7&:<*CV=W/WXS"%D.SW/V,_+E+M5U(W
M$)A58_\2RN-J^%'$AD.P;?A*^D3R]-N;)"5X4U`*Z'QBX")5B2WOA4!@A!)B
M.$KVA\-IRW`70YTK)<FB(9@8WATIJ\](P46J%$>1(C!2<LB(<!8132&D@!`H
M2VI$Y@MNLVJNXK:@*2'SD&@2(DO!`_##FXN(8W-8=@E1MD_0@CQ1=Y=D7'5E
MA.^.$)&,<.TA0M:!I^7'=8@S=JC#\Y5S."`")-+$,M3Y4)GWE!(02?.VL;B3
M&@0/RH&"Z7.O0:M)H527H`5-;J:IX[F](DU!Y"#`FX82WG<1(;AJ-B\$:%+*
M+"1J7W6;19:"Y^0@&BAEONCBO5\M5:/K2`L2]Q'7@2T]NHZTD-MVME%Y]T$.
MS<]GI(B#5DH-3[V2--1PV1S>FWRE#H2W0')MQOX,_2;Q]!`1%]%_B<:BH-61
MAC3/N9:P"_96%A29?K3O^QXLO)(KXP'V@SAN]A/0CIWC(_T55\>LY%I.#T"Y
M@$S7M4HT=.*A9N>FG=FS&AJQYN\)&F\*C<3"`/"!L;I[P!?TK?SN-P```/__
M`P!02P,$%``&``@````A``7,J&`A`P```PH``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#`N>&ULC%9=;YLP%'V?M/^`>"\?(9`F"JE*4+=*FS1-^WAVP(!5
MP,AVFO;?[QHG-#89R4L2N.<>GW-]G>OUPUM36Z^8<4+;V/8=S[9PF]&<M&5L
M__[U='=O6UR@-D<U;7%LOV-N/VP^?UH?*'OA%<;"`H:6QW8E1+=R79Y5N$'<
MH1UN(5)0UB`!CZQT><<PRONDIG9GGA>Y#2*MK1A6[!8.6A0DPRG-]@UNA2)A
MN$8"]/.*=/S$UF2WT#6(O>R[NXPV'5#L2$W$>T]J6TVV>BY;RM"N!M]O_AQE
M)^[^843?D(Q13@OA`)VKA(X]+]VE"TR;=4[`@2R[Q7`1VX_^*EW:[F;=U^</
MP0=^]MOB%3U\823_1EH,Q89MDANPH_1%0I]S^0J2W5'V4[\!/YB5XP+M:_&3
M'KYB4E8"=CL$0]+7*G]/,<^@H$#CS$+)E-$:!,"GU1#9&5`0]-9_'T@NJM@.
M(B=<>($/<&N'N7@BDM*VLCT7M/FK0/Z12I',CB1S4'^,SYS9?>B'T7465RGJ
M#:9(H,V:T8,%30-K\@[)%O17P'QRIG0,7O]G%3Q*DD?)TG.!"P[;\[J)POG:
M?86:9D=,HC!P(@:,KR.V)X0LH*1-SUZXH'<0#:4P10>PJ9>WXZ11)ND:`U/B
M&#(S)(X10:A#TC%D<3]`-!N!;F-:O@1#WYR5+YH'`V]?KT1A8!N'$D<Z8GL5
MD4XA-/6PS/DF3*N7X-B&TGPH"XW")0JCJ0]-_1<PNL-T"J'IAY-WNWX)-O4O
M])43A='TF^US'9)>@`SK:/HC7;\\N=</@4PR?7QTI^HBA0FC_AQ[CF%SJ\*:
MS4&@.K93",W"8FQA#OZG6TDFF1:6NH)$808+QCG9JO"4A2F$9D%.^+/_SVGI
M$FQ(CSQ#NL+,5?'UV'8BEEZ.:5J7NM;;.D8FF9J-/^Y$8187-4_$8&1+;C-/
M:5;#6,VJ!K,2;W%=<RNC>SEH?5AK>*ON``G<`?J)Z0X!F,$=*O%WQ$K2<JO&
M!:1"1T./,37%U8.@73\9=E3`].U_5G#9PC"#/`?`!:7B]"#O"</U;?,/``#_
M_P,`4$L#!!0`!@`(````(0#@A\/[!@<``#(=```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;*Q9VW+B1A!]3U7^@=+[@FZ`11EO+>A>254JM4F>92&,
MRH`H25[O_GUZ-/=ID.U-7HPY=)^>.=,]T]+<?_Y^.DZ^56U7-^>UY4QM:U*=
MRV97GY_6UE]?XT]WUJ3KB_.N.#;G:FW]J#KK\\.OO]R_-NUS=ZBJ?@(,YVYM
M'?K^LIK-NO)0G8INVERJ,_RR;]I3T</7]FG67=JJV`U.I^/,M>W%[%349XLR
MK-KW<#3[?5U685.^G*IS3TG:ZECT,/[N4%\ZSG8JWT-W*MKGE\NGLCE=@.*Q
M/M;]CX'4FIS*5?9T;MKB\0CS_N[X1<FYAR^(_E27;=,U^WX*=#,Z4#SG8!;,
M@.GA?E?##(CLD[;:KZTOSBIW;6OV<#\(]'==O7;*_Y/NT+PF;;W[K3Y7H#:L
M$UF!QZ9Y)J;9CD#@/$/>\;`"?[237;4O7H[]G\UK6M5/AQZ6>PXS(A-;[7Z$
M55>"HD`S=>>$J6R.,`#X.SG5)#5`D>+[VG(A<+WK#VO+6TSG2]MSP'SR6'5]
M7!-*:U*^='US^H<:.8R*DGB,Q!<DBU%[8!Z"PB<+ZBRG2\<.O"5`(X&`=G"$
M3^8X'FC)[.&3V;O!]&X^]Q=W;T2"^A@BP>>[(@7,'CX_-B4'EGR(1/X9"S6C
M*S<D0ECTQ<-]V[Q.H+I@;;I+06K561$2G@)41Y$4MW("DH&P?"$T:POF"\O=
M02)_>W"6\_O9-TB^DMELKMCH%EMN03*-T(8F$)E`;`*)":0FD)E`K@`SD$5H
M`VG]?VA#:(@V?%8;#DBQ7$,(;L%=0A.(3"`V@<0$4A/(3"!7`$T(*%$DA`?)
M<GV?X#E!O&!'4'+"N[O3)[JA-F3/$8FST$VVPD2(@9`((3%"$H2D",D0DJN(
MI@EL5T@3,H\/%@ZA@=J#G4@(@"N'&8VI)$R$2@B)$!(C)$%(BI`,(;F*:"K!
MD#65QC.&6`]B\$EL&`);L)#'NPN,#!%&W"U$2(20&"$)0E*$9`C)542;.ZSI
M!^9.K/6Y,P0.!3GWP#;F+HS$W!$2(21&2(*0%"$90G(5T>8."Z;-G1XK4W)N
MCJ<`<=1EH(A/^P]R*FP1$B(D0DB,D`0A*4(RA.0JHLV9=,7J43H^46*M3Y0A
MM#L:)HJ0$"$10F*$)`A)$9(A)%<1;:*0D=I$E<7M#W7YO&D@8>%0O2*`![T!
M[1@(B3Y_BKB>."BW`I$5X#K&$1)2(Q_B*67BZ&42"2->)C%"$H2D",D0DE.$
MCEI3B713_UVF@477B4&J4!*2(F"EF)7O#@V::SN>H9(T$#))9@XE&$JE(VG]
M@-EH:#)IP&ERC497CC1D[Z\DA_9O<(9R[@V#7#B7E*0P!K7E5K`I":LKJE%Z
M\D0CK5RC2XD8%W1%1`'/M8TTC;F!FJ<H6"*'Q.>22F@D?L;I:7PWF!L'1<X-
M;L775X!T@A]8`=HX:BM`(1_Z)Z&:%Q@)MW68XZU!L:<`8<5%B9BC[P]RSQ<&
M<<R)P5.$OZ(V(DZYH]R%,SV6'QCM1\Y=;L72E24-I:KL3VV>#FM+U92GD)'R
MOE[A6^:H)S/:4J65%)S2L_QVG+E1`#'S\4:7,L',*88RSD63V;%](UC.#6X%
MTR4GW:DJ^95S"03A!Y/#FEE56PIYRM'$K``:2;"06_EB:XHP%'-(TB<82CDD
MN3(,Y1P:N'092*/Z`1F(N7'P,$B.8$N>>,`*SJ)1&9BC+*J(.RZ'`O8#=ZEG
M:LP,2'&-5;"(SS,UY8XR6&8$\P/CU43.?6X%TX4D7:\J)"EA=T%>D4W>W_^0
M1SY37PH9)6R,=<L</3"^+4S(K&!,7)B(03XTL,+1"XS2BCF]6EI>8*Q.PJUD
MD:0X8G8]HG$RYISK5D1=?-)^J^*_4<RT6X<07(:-0R&MF`4DE4&G1<@=9?I'
M&(HYI!:SH.>#2+F5Y,HPE'/H2C&3YER5X>>.$=;BJ^HP2`YLZU#HK1IGCNHJ
MNKA-8ERT[!W?1NG':&Y5XM`1)')(4M'WQ,^X(XL_]XW&(6<&-[<=/1E)\S^V
M"E^;RZTG(?7$H<\06I)22$M2`8TF*;.2KQLC!T$QA]0D%?124N28<4=)GW,(
M)RE<76!YW/D4]LD/OB4;F/3#B$,P1F4W,WJSK;3BLPHQ%&$HQE""H11#&8;(
M%<ZPU0=D$Z()1*]DZ)OX4]4^5=OJ>.PF9?-"KEN@O7FX%S"]"]HL5O"Z!0A,
M?+F"5Q)7<-?FET>&1QBLX#D6>X2.O8K@J0S_`L]W*_((AW^!&ZHO[A5\`S=7
MPP%LQ-ZX,*AK]MX*7K5>X?>!_UK@C;^"MX[883-?P1LYP&<B,MQ878JGZO>B
M?:K/W>18[4%B>W@7U=([+_JE9\7ZV/1P5S74[0'N)BMXY623G-TW3<^_D`#B
MMO/A7P```/__`P!02P,$%``&``@````A`+H8#D*9!0``*!4``!D```!X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULK%C;CJ-&$'V/E']`O*\!@R\@VZNQ#<E*
M&RF*-LDS@]LV&D-;P(QG_CY5=-/TA;7955Z&\:&JNDZ=Z@N]^OQ>7*PW4M4Y
M+=>V-W%MBY09/>3E:6W__2WYM+2MNDG+0WJA)5G;'Z2V/V]^_65UH]5+?2:D
ML2!"6:_M<]-<(\>ILS,ITGI"KZ2$-T=:%6D#/ZN34U\KDAY:I^+B3%UW[A1I
M7MHL0E2-B4&/QSPC>YJ]%J1L6)"*7-(&\J_/^;7NHA79F'!%6KV\7C]EM+A"
MB.?\DC<?;5#;*K+HRZFD5?I\`=[O7I!F7>SVAQ&^R+.*UO383""<PQ(U.8=.
MZ$"DS>J0`P,LNU61X]I^\J+$"VUGLVH+]$].;K7TOU6?Z>VW*C]\S4L"U0:=
M4(%G2E_0],L!(7!V#.^D5>#/RCJ08_IZ:?ZBM]])?CHW(/<,&"&QZ/"Q)W4&
M%84PD^D,(V7T`@G`7ZO(L36@(NE[^[SEA^:\MOWY9+9P?0_,K6=2-TF.(6TK
M>ZT;6OS+C#P>B@69\B#P'`ARQ]'GCH%P7$R6LUDP7RY@]#N.\+9-&YY\Q*D[
M67ANZ#]PG'-'>'+'^R,ZK%YM^?=IDVY6%;U9T--0D?J:X@SQ(@C6U9WE+)3X
MGA"@``9YPBAK&R8CU+B&[GG;!*Z[<MY`\8S;;$T;3[78=18H+X;=ZT"L`XD$
M.,!(T`()_P=:&`5I=0EM.Z#G.=4X=!:=RUX'8AU()$#A`%VE<_!A8@U/B4X)
M=(+F5Y30ZKQE-CB]A%QSC88P$3P,)#:01$84*C`Q="HX_`]V&4:!/H4V%7F;
M;<:-[I$3)H*<@<0&DLB(0@Z&DLG=UP>-6P[=V%N.+!16>EL)H\YM;R"Q@20R
MHJ0,)913QED_@ZGT@WI@%)4+1T*%BZ_UEC`27`PD-I!$1A0N4#B=BS>;X/IY
M7PGT4[-G2,#V%UR`=@:R-Y#80!(945+%TXJTV-[/#XW5_#C"-JTV/P/9&TAL
M((F,*/F!;N/S0V,U/X;,8(V2YF>@J<^,?'@(HZFW5(WVS"A0(\U4HU@8=7V4
MB-B`*,0\B"0S8]M<VR3-.<]>MA22@0DPH(@/VQG?Y#"(RKB-"W.G/=RT5CL.
M`<$NK3V'`AA`<`Y<;<F->ZO.,5%BJ81PXQO=2AY::YDS:!JTN_74]72=N`\>
MGT32IE"#5E.#&ALL6+2#P;%,53+A47PP&QQ+I8[[Y7CJ;'>%3:.KZM9C4(#*
MOFV`NM98.VZ`60VFPP\G/'(_'>,N,BOJ?*ZU==(%!L_!P"I/W$W'\^1[K\R3
M0;W$FBP[CQL\D%A8=16,N2/7<[XT>#*7D7KBQCJ>)]^&99X,ZO5<J.VU\[C/
M`SV%5<^31V9Z+MQ0#9QT@<?IB;OQ>)YHK4U9!O5Z:F7?X9$*?!Y-66'5\V00
MUW/A&_.3O1^I)^[4$L^?6VOY=B_+S""0N9\\@6MHS1T?:"VL^AKP\$SK(-0F
M2X+'3A1DG-9X!)!J,+"O@$IB8V$'!F6-8I#OBV5KYPFHYS^P('.K0#C&G6,/
M)1W4AE=7'3P<2)G_G'K\A"&KQR`?TA-+7^`:'<RMH-;":H`CLU+[W-QT>"RW
M7>;]Y5S[#$H\;O"]5E'K@F>+.W7Y1J_0'(,G"%EI=D)1E.:'%EEI`=VM`K?J
M/T]CN*'!'O5;B*7/;ES8)W]!JA/9D<NEMC+ZBK<IL(!M5@)F5SW;(()O'9@7
M.CZ+X(-B`)]'<#@?P!<1G(0'\##:PL'&?+$+(SP]F2_V802'O0'<<R,\-IEO
MDA"NJX9>P#W6TW3`88OW6T/X-(+O<W.`K1_!UZZ)/P71$[LG<T3YX)[JFI[(
M'VEURLO:NI`C5!ZN>6!1K=A-%_O1\!9ZI@W<4+7==(8;20(?(NX$C(^4-MT/
M&-D1=YR;_P```/__`P!02P,$%``&``@````A`(^=;C&K'0``**8``!D```!X
M;"]W;W)K<VAE971S+W-H965T,38N>&ULK)W;<MPXDH;O-V+?0:'[*:G.I0K;
M$ZTJGH_%F-V]5LNRK6C+<DCJZ9FWWT01R03RIU"28^9BY/[X(Y%$`B"09)$?
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M@?[W_NZO9^??9\_?'O]*GNX_E_<_[JBU*4XF`K\_/OYAI-EG@ZCP!92.CQ%H
MG\X^WWVY^?/[2_?X5WIW__7;"X5[26=D3FS[^=_[N^=;:E$R,YDMC:7;Q^_D
M`/W_V<.]Z1K4(C?_.O[]Z_[SRS?ZU]5DMEE.ERO2G_U^]_P2WQN;YV>W?SZ_
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M+X-F>NE'X+K7F&O5(%KYDMT@&:($)`(2`TF`I$`R(#F0`D@)I`)2`VF`M$`.
M0#J7>$&C:?H_$31CAB9+FNN'@.!49T6AJ`V2(6I`(B`QD`1("B0#D@,I@)1`
M*B`UD`9("^0`I'.)%S5J0B]JXRLVO@P9]3$XW*C7EM`%5L(UU=>=0<3%]D`B
M(#&0!$@*)`.2`RF`E$`J(#60!D@+Y`"D<XD7"^KS[XB%4?NQL,1;)4SU)6<0
M#;$`$@&)@21`4B`9D!Q(`:0$4@&I@31`6B`'()U+O%A0AWY'+(S:CX4EM,9V
MQL5<75D&T1`+(!&0&$@")`62`<F!%$!*(!60&D@#I`5R`-*YQ(L%=>AWQ,*H
M_5A8XH^+A8K%(!IB`20"$@-)@*1`,B`YD`)(":0"4@-I@+1`#D`ZEWBQH`[M
MQ<+L9V;+"<UI[]S1&$-^F"SQA\Q2A6D0#6$"$@&)@21`4B`9D!Q(`:0$4@&I
M@31`6B`'()U+O#"9G;H7I_!U_2CWH\&(>H(S@^FUL:B&>""*$,6($D0IH@Q1
MCJA`5"*J$-6(&D0MH@.BSD-^>,Q65*<%?FD83?M-+:V7.0#7C*AS.)%;JX$D
M*BZX1Q0ABA$EB%)$&:(<48&H1%0AJA$UB%I$!T2=A_S(F3VKCMR2@O#.Z6_:
M[WV]N%GDQVVCXS:H)&Z`(C9_-72+&%&"*$64(<H1%8A*1!6B&E&#J$5T0-1Y
MR(^;V;?JN/W:B+,[8'?$6>1'3N7G=B;U:2YY$I,]H@A1C"A!E"+*$.6("D0E
MH@I1C:A!U"(Z(.H\Y$?.[%W_,Y&SNV`W<A9YD9NI)-'.I*!UY`!%J(H1)8A2
M1!FB'%&!J$14(:H1-8A:1`=$G8?\R)F=KANY$XL0NS%VP].CV?'NTS%EO3.I
M.HJ%@_:((D0QH@11BBA#E",J$)6(*D0UH@91B^B`J/.0'PNSTWU'+.S&V(W%
ML%=VEA4SG>HQB3LS5"0-OD<4(8H1)8A21!FB'%&!J$14(:H1-8A:1`=$G8?\
M\)C-KQN>7]Y7F7M=)@!NY(:=M1LYG1CB@N[E:2C(:XT(53&B!%&**$.4(RH0
ME8@J1#6B!E&+Z("H\Y`?.;-5=B-W8I*S.VLW/,-FVPV/SA69FX=Z8`&*4!4C
M2A"EB#)$.:("48FH0E0C:A"UB`Z(.@_YX:$K^WO"8^1J]%CD+Q%T^HA6=<>"
M[N@!%*$J1I0@2A%EB')$!:(2486H1M0@:A$=$'4>\L)#EW$_//W]\8EY$"$\
MD(XE_4A9M.B?,#$WN'>(]H@B1#&B!%&**$.4(RH0E8@J1#6B!E&+Z("H\Y`?
M%IV?.!$+3$+,+)H.&]`=HCVB"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(CH@ZCSD
MQ\+L[M]^@9G99(!S@;%H+G/33I!<<V93E6O86]6"!JEDDF8J)1N)BE<)L9AG
ME"!*I:!K7B6J,E&QK1QM%8+$%IQ0*;9$M9BK-6PE*JZQ%O.,&D%B"VILQ9:H
M%G-U]3B(BLUW8IZ0WR%T*N/$X,1\Q:Q'7H<`M+<J%7V5`8Y$Q:[':#Y!E$I!
MIV5FJ@MFHF+S.=HJ$)52T#$_5XO>2E1LOD9;#:)6"KKFU=`XB(K-=YXM/ZXF
MI?".@6XS$.Y`[Y$75T#[68\HKNQ4A"BVR+&5($JEH-,,,Y7YRD3%->9HJT!4
M2D''_%PMC2M1L?D:;36(6BGHFE<]_"`J-M]YMOP@FO2$&T1G0?/R[?[VC^M'
MFDKIXC@R:.?T8%__N)]Y7E4M0RURXK%#M+=H(9?="%&,!1-$J11T6T?EQC)1
M<>OD:*M`5&+!"E&-!1M$+18\(.J\@G[4WI<=F6%VQ"(:W=P,.T'2?G"!V%L5
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MYF+NT(;>FK!*YJI4D/@^PPYESW!A7:#]O>]`SG:"#A2L"K9!*2IN@PI1C:@1
MY)P,=I@A$&S^(`49=1[R.XS)"[VCP]@TDMMA>N3/0`NUC=G-K.K$##2HV/7(
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M4><A/XC44;T@_MID8*RHR:!'ZJJBALMNWJOFM`4:%BLP7/9610MI/LF("_;K
MVLWB<KE9P51@C0='6<*6Y(J82GV.5S@5].;M-64]49>TG`T'JR]8%6R!4CSB
M%J@LDF6U6G?7;#E8?\.J8/VMU!]HD0/;ZH.R7"UT=K=CQ6L^^7W39!'=I8WN
MF_]X_/E:]L/9=-'T`IW3YB=E9MA9E?D3ZHFVH#R0$'%!03$C,9\@2A%EB')$
MA:"`JZ6HI,O`:=>H:@0%S+>B8O,'1)V'_.":O*$.;O\(77C+,^\3CNXC"1:I
MA8<:#SNK,BG34(2M>5D91%RPW_)L+A>K*YWZC=DKFA->-YZP)>D8*1?T1@3.
M-;U7BW[+LYZHU7G.5H+5%U)]P,F2;4D+5!;9ZE<3_3N@FLL$ZV_>5'_+MH(M
M<F!;?5"6B\U"Y4PZMO.:3WYWU)G6$YT04ZKS'JD+GMK![*SJU`7/VG(O>#VB
MY9A9>"XWE_02`=4+8C;NM9Q>]R6L<B]X0WU.Q\!.V*N&*\Y&77!SMARLOV!5
M\(I36I5SS:\LLO4O)Y=J-5&SY6#]#:N"];=2?Z!)#FRKC\IB>KE6VYV.%:_Y
MY/="\LF;%$_T0B-7RRZ+:+\[S$.+A<IQ[DSW,P7E'NX>480H1I0@2A%EB')$
M!:(2486H1M0@:A$=$'4>\L/SOFSO'+.]C/SPJ)EK)RJ^MNX118AB1`FB%%&&
M*$=4("H158AJ1`VB%M$!4><A/SPFE>8N*4Z,'IMYDWGP>FZ1%YZE2F_N1"7A
M&0HRBE`5(TH0I8@R1#FB`E&)J$)4(VH0M8@.B#H/^>$Q.3@W/,YR_D2D3$DU
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M*J]&O:O)1,4UYA;1"3$J!`5J+,66J.`<*U&Q^9J1G&,C2&S!.;:L"I[C051<
M8V=1?XY^MS%I'/=">J+;]%D?-V%B,B74DZC;<'4[BYPFW5MDIBNG0ZA-5R0J
MMA6CK011*@4=\SJQDHF*S>=HJT!42D''_%(MM2M1L?D:;36(6BGHF%^IJ>4@
M*C;?>;;\N.J4V(FX8B*,$C00UQYY<>V1BJM*ET76%JG8]=@BQU:"*)6"3LLL
MU18T$Q6;S]%6@:B4@JYYY7TE*C9?HZT&48L%#X@ZKZ`?1),D><?@[',JWN#L
MD3<X>^0T_)Z6N2;4*H@JW12)BILAMLBQE2!*L6"&*,>"!:)2"CH16ZE=524J
M=K5&6PVB%@L>$'5>03]B.NGR:XLNS,4L>N0%LD=.X^^MBE8)?-X1HM@BIV""
M*,6"&:(<"Q:(2BGH1DVM_"I1L?<UVFH0M5CP@*CS"OI1>U\NAI*&L';JD;.J
MW%D5(3EGN*3OK<I]R!)1++:X91)!`?,IV_)7#&ID9Z)B\[F89U0("M18LBWI
M@A6B6FRQ^490P'R+M@Z(.K%%YOU0OR^OL\"\CD5^;GX%R^2^(*6<`V>S9UM.
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M=JP*3XVBXB!$%MFI<;6B=[`KVS%+@JV;B.W`S)"*BCW(+++3P'RB?_"3OZG^
M0BP'ZB]%Q?57;'Z8&J?P`#I+@BW0B.V`!^VH"GJA5=E&64QTFJ<[Y9+?"\GQ
M]_1"(U>]L$=F;RRIAI7:U.W,F[%,0?HSJ&#ZVHN*8Q!99*>"J\NKC;8=<ZG7
MAMWQIU0)JX(>I*)B#S*+[-2XG%RI3$'.98+U%ZP*UE^*BNNO+`JT0,VE@AXT
MK`IZT(ZJL!>2$;.'[>?"Y62NIH:.S;SFDM\+2?6>7FCDJA?V2,V%:MFP,PE2
M*GABF2@JCD%DD9T+I],YI:+5-3%F3;!Y$S$>&`BIJ-B%S"([[C>3C<J'Y6^J
MOQ#+@?I+47']%9OO)\/9^O)2_S*E9DFP!1JQ'?"@'55A-^P#:AME.=&_?>A.
MN>1W0Y-;??M"<6GDJAOV2$V&*H&VXX+!=MJ+BF,0662G@M7E$GZ_PX6H75Z?
M9Q-6!1U(1<4.9!8-PUX/@IS+!.LO6!6LOQ05UU]9]'H#U%PHZ$##JJ`#[:@*
M^Z"-.4^%>HW0L9G77/+[H,GPOJ,/]@EA=[.R[)&:"M5LL6/5B66AM>7LF&U!
M.Q5>+993_9J\F"7!UDW>Y$$J*NX$F45VT*\F5RH;D+^I_D(L!X9**2JNOV+S
M_4RX6J^NUBHC6K,DV`*-V`YXT(ZJL!?VD1IF0G7IZTYYY'="DZ%^1R<T<C41
M]LB?"'4S[9:V8+"9]J+B$$06V7E@<W5U.5.KLIA+O3;J[*KP+1ZD;,O9,%LT
MS(3ZN=J<RP3K+U@5;(%25-P"E46V!=8+:@'HA/;<@AXT8CO8"<?:"3MAK[*-
MLL(=,E?VFDM^+]39_?!-M26F\2WRI\*U2JWL6$7.OW[-W(N*8Q!99*?"^6HY
MAQ]'LB08WT1L!SQ(1<4>9!8-HU[7G[^I_D(L!^HO1<7U5VS>+@I7Z_E*M6[-
MDF`+-&([X$$[JL)>V'<$VRB;R4JMO[I3+OF]4-^M^*5[3$N\B6&1FB+5-+;C
M@L'FVXN*0Q-99">(V>656;+[:=28B[TV'.T<:7T/NI"R+7>.[`L.T\$&+M36
M<K#^0BP'^D8I*FZ"RB+;!-/+#;6`:H*:BP5=:%@5;()V5(7=TVN5Z0(>AN_8
MSFL^^?WS?;=8EGB+Q2+ZP0^WW$Y0H,GWK')^RXDH9B3F$T$!\RFKQ'R&*&<D
MY@M!`?,EJ\1\A:AF).8;00'S+:O$_`%1Q^AHWH^KR3:[:[!?FW?L#0'G2>EE
MCVA7(N'ND7E\/G0%[%7.[SHB:\M>`<=_R\F:X-A)6!5T(;4JQX7,HF$WH,=;
MSI:#]1>L"M9?8OT5%[1)XK%?]]2L";K0L"KH0BLN.+'2)WVPJJ%5]`]^.J[L
M-9>\OKC2]RIT7WS;SSF/9OQ]@D7NW"/(.4']4Z@]J^2WFQ&BF)'T]410P'S*
M*C&?(<H9B?E"4,!\R2HQ7R&J&8GY1E#`?,LJ,7]`U#$ZFO?C3;W"FWO"*^^5
MD:NX]HC>+#I,,E;EH#VB"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(CH@ZCSDQX)6
M`>^)A9&K6%A$5_YA=E_H7[OM5H.*([9'%"&*$26(4D09HAQ1@:A$5"&J$36(
M6D0'1)V'_/#HG+&9&G_I>R(K3"<SH@NO$SEUXV$G*HF<M25/64>HBA$EB%)$
M&:(<48&H1%0AJA$UB%I$!T2=A_S(F8R9N\`Z,<GU"38WT[JRR`^/NA.V$Y6$
M9RC(*$)5C"A!E"+*$.6("D0EH@I1C:A!U"(Z(.H\Y(?'Y)+<\#AKCA.1LKDJ
M9\V[LHDIR6/O$.T118AB1`FB%%&&*$=4("H158AJ1`VB%M$!4><A/RRT.O7"
M<B(61JXN1Q9)HF"W`K1'%"&*$26(4D09HAQ1@:A$5"&J/>2WG]G]N]WZ1/O9
M#(G;EWOD/$^\6PU(KA/X=(55^<^=Z_>\1*+BN2D6\XP21*D4%"?@G=J9J-A6
MCK8*06(+3J@46Z):K-6C)Y6HN,9:S!/RP_.^;,H*LRD6>>'I50[:6Y6*A7(]
M$A6['J/Y!%$J!9V6@1_HB(K-YVBK0%1*0=>\\KX2%9NO/5M^PYOD@CLNG.G^
M[;^?7/4I"N\BW2.G\7=6Y:"]1>ZC_(AB+)@@2J6@VSHJ]YF)BELG1UL%HA(+
M5HAJKZ#7TFN]F0_/0$>Y/X-;Y#Y^+TC.&0;LWJKHV2`^YPA1++98E2!*N2!M
M6V1MK%]"G(F*;>5HJQ`DML#[4FR)"EY"7(F*:ZS%/"$_%N_;:*]QHVV1NL6E
M[O[N6!6^Q24J=CVRB!]\NIROUOJE"C%KR+DA$M!Z"1I/$66(<D2%H$"-I:CX
M="I$M8?\X)@=L3LEG1@H=@/M7*K7/5*W>-3MJ)U5G7@V4E1\-I%%]O[&_&J&
MSP-Q*7>4C,3&NB[C,N6"@C)$.:)"4#`V4&,E!?D$:P_YL=';[A.QP;WUND=J
MX.C'9%AU8N!86[*]B&Q!2L!*,RPVZNY3;%7F)8_#T,%7GHH3W#(IH@Q1CJ@0
M)#5"ARA%Q356B&H/^>'1>^M?NIJO<<MMD3^B](\E=ES0;58XR;VH^"0C-D\5
M#_%8;-0]V9@+NH-JKM]-D+!*1E"**$.4(RH$B5]P0J6H^(0J1+6'_*B97?([
M)KQ^4^TNMLSGNFB[YZ;S!05<W[-*[I9%B&)&DA!/$*6(,D0YHD)0P-525-+*
M<-JUI_);6>^@?VULX,9ZW2-_1M/WW'=6=>)>']MR9[3>_+`46-$#+VJ=$;/Q
MX,!+6"57RA3KRRRRM["F$_U<9<YF@I45K"+OAR$],G1LVU$@1:7OJE5LJ[_7
M-UVL]<O(:U:\YI/?$\RVW1UONB>\[;;:NM_]>^/0)@1DH.RLRKS64\X0;JNQ
M2NX<18AB1F(^090BRA#EB`I!`5=+4<DXA-.N/97?^GJK;UK_+:\Q7>.FWR)U
M6=*)>JLZ\1ME-B_7C8@+]K\1I77>!J])UBGWF@3=/&%#$K@4J\LLLL_MT,A3
M>]><RP0K*Z2R8!BMX]Z(P9'7J_A1GME&OX2@/N63'_NQ;,-\,S&_#+G]\_GE
M\2&]N_]Z'(ZC7V@B'7\89HTI!T9T9!AJBXV^+R`J[K][1!&B&%&"*$64(<H1
M%8A*1!6B&E&#J$5T0-1YR`O=YGWIBZ/<3U\P\L.CLE<[40WA010ABA$EB%)$
M&:(<48&H1%0AJA$UB%I$!T2=A_KP7#Q_N[M[V=^\W'SZ\'#W]/5N=_?]^_/9
M[>.?/V@03.GJY/"SI[LO'\^OUU=;$VEJX*&$/;*YW)I*1H[,J4R?N=-E5M.M
MN8\^4F8UHR.ST2-S.G*<#<':@HX<EZ-P9$E'C@LC?61*1^C3ZR,>3%=TY+C>
M@3)K.K(>+;.A(\<+,92A-NC?`*N/S*C=^B<L]!$J,MK24RHQ'6WI*;4G)27&
MSH;:<SK:GE-JS^EH>TZI/:=C[?G;=/O;N"TJ,%8[53ZJIZK':OYML?UMO"N1
M1V,.75,41X-(,1P-(45P-(`4O['PT=V-K4GL8L/2'8VMN5\Q=F1#1\:L43Z8
MCHQ9H]L<6Y,'1FN4B-V:S"L>H;3JUB1-\0BE/[<FN8E'Z/[0UJ3&\0C=)MJ:
M##D>H;M%6W,O:.S(AHZ,G2DEUNG(F#6ZA;0UV7.T1N]BHR"/18W>!;.-:'.!
M9>@U+EOSDA8\0J];V9KWJ^`1>E/*UKP:!8]<DV_7H[[1;;NMN1>!9?9TQ-R(
M&SNRH2-CK4.W,.C(F#5Z`][6O-H'K=&+\+;F#3]XA%Y^1^<S-LSH]6ET9&R@
MT0NXZ,C8B*(7/=&1L3%%+Q.B(V,>T)L"M^9]1^@;O3!P:UY[A$?H)8$4GS&O
MZ9UR=&3,:WHK&1T9\YK>?D5'QKRF-RS1D3$/Z(V*6_/&)_2-7JRX-2]^PB/T
M,D7J;V->TXOVZ,B8U_2J-CHRYC6]_XN.C'E-[YBB(V,>7),'UZ-'Z`64V]WH
M$7KI)(V?,:_I[8-T9,SK/7EMWDZ';4`O1:,C8U[36[;HR)C7]&EDNA*,EIE1
M&?KT(]9#G\;<9J-'Z*N66_/-2BQ#7Y_<FF]+XI']8DHM.G:1HO>74K\>.W(]
MI\L(95_0VO6<+B3TCNRQ(W0IH=<SXQ'Z(/76?!L5C]!WJ;?F$ZEXA+Y%3><S
M%CGZFC$=&8L<?2*7CHQ%CKZY2D?&ZJ'/<V_--V#1`_I*]]9\"A:/T)>Y*0IC
MOM&'G.G(F&_T=6`Z,N8;?5N6CHS50U\FWYK/WZ(']('RK?D*+AZA[Y13WQGS
MC;YA34?&?*,/(].1,=_HL[IT9*R>:ZKG>O0(?:Y]:[[VB[[1)]JIQX_Y1I_O
MIB-COM$'H.G(F&_T^6`Z<JSG8EA'/G_Z\//FZUUU\_3U_L?SV?>[+[2NOZ0O
M.)Z?/?5[Y?X_7NRG?7Y_?*%]-"W]S\^^W=U\OGLR:A)_>7Q\X?^@$[GXZ_'I
MC^/>X=/_"P```/__`P!02P,$%``&``@````A`(2_WYIR#@``6DH``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)S;<AI)$H;O-V+?@=#]"'4W2(*P
M/6$U?>00&QNSN]<8(8NP)!2`QS-OOUE=E77(OVG`X9O1^.NLK*J_L@Y9#7SX
M_:_7E]Z?Z]U^LWW[>!5=WUSUUF^K[>/F[>O'J__\D?]V?]7;'Y9OC\N7[=OZ
MX]7?Z_W5[Y_^^8\//[:[;_OG]?K0(P]O^X]7SX?#^[C?WZ^>UZ_+_?7V??U&
M3YZVN]?E@?ZY^]K?O^_6R\>FT.M+/[ZYN>V_+C=O5]K#>'>.C^W3TV:UGFQ7
MWU_7;P?M9+=^61ZH_?OGS?N>O;VNSG'WNMQ]^_[^VVK[^DXNOFQ>-H>_&Z=7
MO=?5N/KZMMTMO[Q0O_^*!LL5^V[^`>Y?-ZO==K]].ER3N[YN*/9YU!_UR=.G
M#X\;ZH&2O;=;/WV\^AR-%X/[J_ZG#XU`_]VL?^R]_^_MG[<_BMWF<;9Y6Y/:
M-$YJ!+YLM]^4:?6H$!7N0^F\&8%_[7J/ZZ?E]Y?#O[<_RO7FZ_.!AGM(/5(=
M&S_^/5GO5Z0HN;F.A\K3:OM"#:#_]EXW*C1(D>5?S=\?F\?#\\>KY.9Z$`_O
M[B.R[WU9[P_Y1OF\ZJV^[P_;U_]IJ\CXTEYBXX7^LI?;Z^'=37*)D\0X&5@G
M(Z\E';53.YL^T-^6VCL*WIJ"-!E,P3-K')F"])=K3*[C^V$TO%6J=509T0AK
MP=50:RW/K#2R8T7_P]5Z,G?5R@,4N1$ZMU8>EHC^Q]0:#\_L+`VE[NRY8]K7
MX=E$^V1Y6'[ZL-O^Z-$20EW>OR_5@A2-(_+&<:X[;2/_6.!3Q"LOGY6;CU<T
MWA32>YJM?WZB]>I#_T^:82MC\X`V46B1LH6:3LKM1(),@ER"0H)2@DJ"6H*I
M!#,)YA(L/-`G::V^%!>_0E_E1NG+RCPP\`078K(%%YE(D$F02U!(4$I025!+
M,)5@)L%<@H4'`C%IIOP*,94;6H^]8!W<WX7J/6@;M>+;B+X-35)K8A4&D@')
M@11`2B`5D!K(%,@,R!S(PB>!V+08_`JQE1M:7&A+L$+BTF",NM2V)E9M(!F0
M'$@!I`12`:F!3(',@,R!+'P2J$U=#]1N/V?P<JNL&U%9C`=#[CR9!_?W(F*M
M$1>;`,F`Y$`*("60"D@-9`ID!F0.9.&30$.*L0LT5-:AAH;0X<.&ZN!^)#2T
M1E9#(!F0'$@!I`12`:F!3(',@,R!+'P2:$@!=(&&RCK44).X.5PW>W@*9`(D
M`Y(#*8"40"H@-9`ID!F0.9"%3P+!5,+G'Z"Z)ZZR#@4S)`BZD3@ZI=;(!AV0
M#$@.I`!2`JF`U$"F0&9`YD`6/@DTI,X'&NI#Z/4=S?1N.57!4$Y-!CHE4V?(
M%,@$2`8D!U(`*8%40&H@4R`S(',@"Y\$VJG$)Q"O6['&/)2,D4X]&\T031!E
MB')$!:(2486H#E#89W7:]B>=%S"'Y\WJV\.65G`R:M$BH>S$Y"SZS$Y'$YY5
M#RH5I("*$XM2A]RN$$=B9YT8JP&5MWM',A+Y3>:LN,8<48&H1%0AJ@W2K0\%
M4R=J7[`682C!MLKH`WB@C$:!,A:Y/K<HHZV&L<D*HR3<4#.5.I/F9.!$L9X9
M%<;*J[]T!76^&<6AY\H9L)LZ<!-*I`["%TADSLU^\&@TI#.>C8$X'H2-2E6Z
MKT*,UC9GA?%DK;CIF2O(*$=4("H158CJ`(7*J$/K!<J8,ZZOC$8#ZI3M\T#.
MCE1=/ZC5W)]#+?%DK5B&S!5DE",J$)6(*D1U@$)EU%'T`F7,R=571J.8.N4I
M(P(Y56GH&3'39A6+K#4SOI*;9C[>1Z.!B-"<+3K'H7!M8M%+AUQG8MF`BMWK
M!MS15:8X8M=L<:P!X1BHHZP_!FHOH(LT$N/$(F?.P/YH:"3B5"Q8J<IESXA3
M:\7Z9*9@?-=(?S<:B;')V3,M?S8:8`84;.7VZQ)1%59V>W<GSI0UESE66:BR
M.O_Z*I_05A^7J0KN_$-D3M!AI(O82]F*1N^X`A-CE3@%,D9!;V1DY6QU++*:
M@T'A&L&M+Q%5!@WT:`[#9;X^55.HKCH97Z"N.4C[ZFH41&XD=Y4T,@4[NS]Q
M5MS]S"`;N;&X+LNY3""_K+]@*S=N):)*5);<@;:F&\<J"[55)^<+M-4'[2!R
M-1)KM&A4&AFK$Y%KK9RV&ID%.1G>BO4F-YXIVCOF1.'J9\^E*\BH8A1()Z=)
MS5;':@P$IEP_%/BG#N.-ES`O,2B(Z8%<,U,N>*RM^D6"LV(I,H-,3$>T0H93
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M8?=N\<H0Y8@*Y]XI8YKJ?%58L`Y0&#CJ%"\#)[Y5'Z?JG7^)&YM<P(\;C<3<
MEG<JIN"IN6U\^;NZ1I3W.:63H5@Z<G;OSZ&6_47[HD8X60WR937HQ*RU!5V[
M_-4]%%\E';[X)_87G:,$N[A)6]ST26.+VEM@CN+&RFT`&1=T*&?DW!>(2D:N
M8(6H9H2SDY*N4(:?VE\:+^'^8E!PQAG>B,PN-58G)BV[]T,)KM4RKM'?T3`L
MV9<?2AB6KETV+-L*0B,J+DBAZ%8AN<G5K;Z\M2J(5)7V!I$JA^B\_:5Q(\9(
M>:;=W858:JQ.["]LY3:`#%'.R+DO$)6,G*\*4<VH)8)I)$&>Y+Y912_\#%^B
M7`F)#*(I:\=S>",O[;C@R*YB$T09HAQ1@:A$5"&J$4T1S1#-$2T"%$:CRC?\
M=5-%XVW2O*J^5&Z3NKBU_T'%G1J!4&YYT^2L>'9.$&6(<D0%HA)1A:A&-$4T
M0S1'M`A0*+?*'Z3<^G+_4K5U)N+O8)3AM*@M<N;463FU;4%&&5KEB`I$):(*
M48UHBFB&:(YH$:!0;95#_!JU=382J&U0&-LBX4X3:\723A!EB')$!:(2486H
M1C1%-$,T1[0(4*BVRBQ\M;N/8.J@*E=GC>CND,5*C96')H@R1#FB`E&)J$)4
M(YHBFB&:(UH$*-1/Y1\7Z&?2%7^Y-2@,27D1E5@K5GF"*$.4(RH0E8@J1#6B
M*:(9HCFB18!"254*X4OJG;5.1*=./H()KY'_4:P$T`11ABA'5"`J$56(:D13
M1#-$<T2+`(524E`%4I[03YF+LY=!+A%,$T`31!FB'%&!J$14(:H131'-$,T1
M+0(4Z#?X)9E9XR64U2#*N7@ZIPZY4ZZ?.>N\U5B=^(B7LV+W.:("48FH0E0C
MFB*:(9HC6ABDE0C%/Y5SG?7Y.J64B&F#`O&UU8D<V!0<'/T4F3-PNEO/C`I7
M?\=(E\[7D0^6.0/V7#O/C*:(9JZ@\2RNC>;.@-TL`C?A,,G<KWN-(?%@/#02
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M;<10?MB\YH+^/(/[[RE;^7/:J.JZ/3=6W=U>L"^_1O]P&4;`97<"`[P3,(BN
MU%B9U"&GC-\"LSYK7W0[Q`4S+NA0SLBY+QSJ<%^RE?-5(:H9.?=31#-&SM<<
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MI"?-JW]X<DM/FM`43^AW:3ZWUD^_5]-L)\+^@1K<:J^:V]*/SX/Q9Y*PI8/4
MB]9.4!]:NT`]:.O`P]V8ONS:XO]^3%_@1$Y??1NK+Z.U/8G'ZMM=^(2^ND5E
MVIY,!C=C=5>!92:#:)Q1+HQ/*%\?5ZU/*-\F;VUE'A+J)EV$HK>'A#JJYU;?
MCA7]LL_[\NMZOMQ]W;SM>R_K)PK,F^:MWT[_-I#^Q\%\UNG+]D`_Z4,73_2#
M*O0;3FOZ'NJ-^D;*TW9[X']0U7W[JU"?_@\``/__`P!02P,$%``&``@````A
M`'MB!Z2-!@``7QL``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK%G;
MCN)&$'V/E'^P_+X87X#!`E8#OBN1HFB3/'N,`6LP1K9G9_?O4^V^V-T%7B;9
MEV$X5)_J.E7=KFZO/G\KS]K7O&Z*ZK+6S<E4U_)+5NV+RW&M__4E^/2D:TV;
M7O;IN;KD:_U[WNB?-[_^LGJOZM?FE.>M!@R79JV?VO;J&D:3G?(R;2;5-;_`
M+X>J+M,6OM9'H[G6>;KO!I5GPYI.YT:9%A>=,KCU(QS5X5!DN5=E;V5^:2E)
MG9_3%N;?G(IKP]G*[!&Z,JU?WZZ?LJJ\`L5+<2[:[QVIKI69&Q\O59V^G"'N
M;Z:39IR[^X+HRR*KJZ8ZM!.@,^A$<<Q+8VD`TV:U+R`"(KM6YX>U_FRZB?FD
M&YM5)]#?1?[>#/[7FE/U'M;%_K?BDH/:D">2@9>J>B6F\9Y`,-A`HX,N`W_4
MVCX_I&_G]L_J/<J+XZF%=,\@(A*8N__NY4T&B@+-Q)H1IJPZPP3@KU86I#1`
MD?3;6K?`<;%O3VO=GD]FBZEM@KGVDC=M4!!*7<O>FK8J_Z%&)J.B)#8C<00)
MT(W8`W/G%#Z9T]G$>IJ9LSEQ.C)PS@9"];*!XXZ6S!X^/^;(A$1T4R3_C+DR
MJ)Y=>KRT33>KNGK7H.9!L>::DA5DNH2$)X9&)U)U+U.0(L+R3&C6.L0+26B@
MO+YN0*:5\15*(F,V6VQCRA8[;D'R3V@]%?!5(%"!4`4B%8A5(!D`!L@BM(&D
M_0QM"`W1AD>UY4`OEJ4(P2WX$$\%?!4(5"!4@4@%8A5(!H`D!"R<GR$$H8&%
M*Q7)7(Y\2VW(UB`J23'9"1.A#D)\A`0("1$2(21&2#)$))%@5_D9(A$:6(RP
MA0@!\%)B1F,J"1.A$D)\A`0("1$2(21&2#)$))5@RI)*MQ\`?%LAUIT8/(@M
M0Q:2/`NYB';"B`_S$.(C)$!(B)`((3%"DB$BQ0XYE6(G>ZTUFX#]!W=;0B3+
MPA!X@`RJYDF111@)61#B(R1`2(B0""$Q0I(A(LD"N42RF+/)`G09KPXR4):!
M(@[M(,@39(<0#R$^0@*$A`B)$!(C)!DB4LRDKQT^=L<#)=9RH`RA_4T7*$(\
MA/@("1`2(B1"2(R09(A(@4)%2H'2_J)+;GLJLM=M!04+#^`;`MC01]#N@I#(
M\5/$LL5#=2>0?@58IK("/&KD@#^Q3.RETH7XPH@ODP`A(4(BA,0(22A"9RVI
M1#JO_R]3QR+KQ*"A4#W4BX"58E:.U35SUM2TY<W$[PV$3#TSA\(>&G$6]5RD
M<P1G2C\4]P:<.>F9`9+%)/W<XXO+I.T?/'$Y]Y9!%CS%1)W,S*6LP(Y;P3XE
MK&X(2>G)B:&WLI2>QF=<]K23VYY:B@(!-QB6+G(6/C2EZ*:5.J68>^13<I0Y
M)]S@WI3DI)#>\@-)H:VHE!0*.="`"2%GUE1-"AMX;U+L7"&L>,Y]D]$[7086
MEM)3!.QW\B'<WTB`(!ZQBCA7OWW'LONY>GA*^)![[F6Q29/Z`;%93SM<`122
M5X"E[)0[DUE)M8TVW=ZJ%YL.=!:=V#-3R6+`AMBC60Q[XE&QQ22Y^Y@-9.XM
M6WE,)#]R+XM->MT/B,U:XZ'8%%(J6]D!=B8;.*J)UUOQ:'T&.;2R336+`1]R
MK[2Z)1-RJU'W46_%W<>R^Z4C+]B$C[CG7=8:*DW2^C^U$^1TJ?03#)+JW5DJ
M.]Z.6_V@WBD]%"_7P&<#;2E(2WF@!-QJ5.+PH4E$O16?1,P@7O7*FDM^Y%U.
M!.GF/U#TK/D?%CV%[$$+1PZ]D!>`1M:SQZV<@;QL8`\%W*JG#WMHA#[B5CU7
MC*&$0QV]K`SI^8?*=*>\.;G6U![O>$UZ<@`W/'U;!BF[A-*6[9@5-'PC07J<
M7JHTM0/P.1?=I1W[22F9@--(9:WN_R&G&9U2Q+E&IQ1S+C8EU)8FG.;>E.1<
MD6.+FBMV].QR]:6ZWCN=0#[Y\00NSM%^0B&IN@4TFAEFU5\7^HS>[J&`0\/J
M?H0^X@-[KAA#Y$T`6XA0?50Q>K-/KX[+O#[FN_Q\;K2L>B.W]M"=;%8"IJ\4
MMG,7SOQ`H.(+%\[%&/>6+AR9;N#FU"6G#?P+G!M<<C3`O\#KC&?K!KXEKSEN
MX98+EY^89VN[<.&'\6?'?0:1\`];QX6[KQOXS(5[(<`-H0:\WKBFQ_SWM#X6
MET8[YP<0<MJ=C&OZ@H1^:5D-OE0MO-CHRO$$+[)RN-V8DKNC0U6U_`MQ(%Z-
M;?X%``#__P,`4$L#!!0`!@`(````(0"C+LAZAP(``&<&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;(Q576^;,!1]G[3_8/F].)"0M"BD2E=UJ[1)
MT[2/9\=<P`K&R'::]M_O&J>(-%F7%X0OQ^?<>ZZO6=X^JX8\@;%2MSF-HPDE
MT`I=R+;*Z:^?#U?7E%C'VX(WNH6<OH"EMZN/'Y9[;;:V!G`$&5J;T]JY+F/,
MBAH4MY'NH,4OI3:*.UR:BMG.`"_Z3:IAR60R9XK+E@:&S%S"H<M2"KC78J>@
M=8'$0,,=YF]KV=E7-B4NH5/<;'?=E="J0XJ-;*1[Z4DI42)[K%IM^*;!NI_C
M&1>OW/WBA%Y)8;35I8N0CH5$3VN^83<,F5;+0F(%WG9BH,SI.L[N%I2MEKT_
MOR7L[>B=V%KO/QM9?)4MH-G8)M^`C=9;#WTL?`@WLY/=#WT#OAM20,EWC?NA
M]U]`5K7#;J=8D*\K*U[NP0HT%&FB)/5,0C>8`#Z)DOYDH"'\.:<)"LO"U3F=
MSJ-T,9G&""<;L.Y!>DI*Q,XZK?X$4-PG%;CZU.ZYXZNET7N"[4:T[;@_/'&&
MQ.=SP20\=NW!.<7CB#(6_7M:I<ELR9ZP:''`W`4,/@=,/"`8B@[*J':YL@=[
M9>^*3^4N!,8RR7F9Z;&,-WV*K7N_4+\)<:,BTB0=^$,&`3,;8>8#XJA0A%Q>
MJ`=C+^8CVE./`^@":3P7ETM[<"\]F'R(H%U#,]/D'U5BQF,I[_/-?WWVFXXE
M#Y%Q8]-D<=[8Q:ED'*<19OU^=_V^8]5#Y%CU^HUJ&.PP/0I,!9^@:2P1>N>'
M-L%Y&*+#?;)._)%]&Y]EZ_Z>8<,'G/..5_"-FTJVEC10(N4D6F`M)MP48>%T
MAYGCM&N'$]Z_UGBA`X[$Q!=>:NU>%RC,AE_$ZB\```#__P,`4$L#!!0`!@`(
M````(0`K!43Q_0H``)XW```9````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;*R;67/BNA+'WV_5_0X4[R>`629024Z)?=_W-X8X"34!IX"9S/GVIX7=$NX_
MXT#=^Q*<GUO=+76K)63\\/?O[7OLE[L_;+S=8SQUEXS'W-W:>][L7A_CDW'U
MK_MX['!<[9Y7[][.?8S_XQ[B?S_]]S\/G][^Q^'-=8\QTK`[/,;?CL>/0B)Q
M6+^YV]7ASOMP=W3GQ=MO5T?Z=_^:.'SLW=7SJ='V/>$DD[G$=K79Q7T-A?TU
M.KR7E\W:+7OKGUMW=_25[-WWU9'\/[QM/@ZL;;N^1MUVM?_Q\^.OM;?](!7?
M-^^;XS\GI?'8=EUHO.Z\_>K[._7[=RJS6K/NTS^@?KM9[[V#]W*\(W4)WU'L
M<SZ13Y"FIX?G#?5`#WML[[X\QE6JH.JI=#SQ]'`:H>G&_3R<7<<.;]YG;;]Y
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M!RDU_`[>F"-Z$O@-;99<&[T4YXN^N*F#G#$IFS)?I&:*4T5?W&2+DR5EL^7:
M#CJ<-OKB%J,.IXV^N"Z"#F>+OKC)%F>+8[/EZ@YRVC@WIHVN/*>TT1=7=I"S
MQ;DQ6QS.%GT1V+JZ@YPVSHUIXW#:Z(OK.ICF;-$7MT0PS=FB+V[L8)K31E_<
M9)33)FW3YHLYF.9LT1=7V$KXB^AI32ZOCJNGA[WW&:.=#G7S\+'2^Z940>OB
MU=A?R\SZ_*?EF=9EK45I-8]Q"BRMO`?:5/QZRCKYA\0OV@>L`YDBRJ3"$B66
MT(N^5EN6H")!58*:!'4)&A(T)6A)T):@(T%7@IX$?0D&$@PE&$DPEF`BP52"
MF01S"182+"50)KP<&&6":0@$3T'T%(1/0?P4!)!VHT%RD:T$I:W)79IF_X_<
MU6IT[G)7B@QL,CLB45F"FY0EJ$A0E:`F05V"A@1-"5H2M"7H2-"5H"=!7X*!
M!$,)1A*,)9A(,)5@)L%<@H4$2PF4`F*"R:%2)9"!Z"D(GX+X*0B@.H]@*%&I
MK$.BZI7I\E<>KJFZ%7VY.:^IZ60X$8N^C-XYFL*;"XN4C`B/0!E(!4@52`U(
M'4@#2!-("T@;2`=(%T@/2!_(`,@0R`C(&,@$R!3(#,@<R`+($HA2B&R8.88*
MPZHPK@H#JS"R"D.K0K$-Y3+M$2"7=?[=N&'0:FC/0?M/D[BX8PB$HK+;B/#(
ME(%4@%2!U(#4@32`-(&T@+2!=(!T@?2`]($,@`R!C(",@4R`3(',@,R!+(`L
M@2B%J(BHA`CCJC"P"B.K,+0J%-M0=E.JA;([ND)KZ5,2<_(5`T+?CFQ:I^4V
MUPAQLS*0"I`JD!J0.I`&D":0%I`VD`Z0+I`>D#Z0`9`AD!&0,9`)D"F0&9`Y
MD`60)1"E$-E`<PQ5":4PK@H#JS"R"D.K0K$-Y2S5T!MR5DN'<S8@].7Z+&?E
MCM<(<7_+0"I`JD!J0.I`&D":0%I`VD`Z0+I`>D#Z0`9`AD!&0,9`)D"F0&9`
MYD`60)9`E$)41%1"A'%5&%B%D5486A6*;2AGJ4#>D+-:.IRS`?$/]?5100E(
M&4@%2!5(#4@=2`-($T@+2!M(!T@72`]('\@`R!#(",@8R`3(%,@,R!S(`L@2
MB%*(BH@PK`KCJC"P"B.K,+0J%-M0@M)15BA!_7.Q._T0Y?BV6?\H>E0LZ6#B
MP@8A3>=?_JF85A+.6Y\XI\=K)YF2(;;Z.JG[\'>XLB^429U.UIQD*AV^7S'W
MN3I7@=2`U($T@#2!M("T@72`=('T@/2!#(`,?7(V@",@8]-*GT/2:(FU;&+N
M\VA-@<R`S($L@"R!*(6HB"C(`@HPNZ1LS`W","N,L\)`JR#2_JB%TIP6_?\]
MS;62<)K[Y"Q*)4.BTMP7RM`!S=E.1.:Z$>)QJ1K=3&I`ZJ;5N>I,>!HUC!`K
M:H*B%I"V:76N.AM6W3%"K+H+BGI`^J;5N6IQP#,P0JQZ"(I&0,:FU;EJ,=83
M(\2JIZ!H!F1N6IVK%F.],$*L>@F*E$)4-.W.E8O15D&Z42:Q=E5&715$02Z)
M%!0CKH+\.E<?)-B%*:8?>(?FV(4E@Q[=\9IQ$@_/I@#I!X-G\^);.,-*+*57
M*'X(@RO)12E'=+`22-$9I2ZAF9PC$J/*`K0"_ME8S1KC,-0M.FLH[3=8O6\_
MET^+[&FR0*3]EC7&]ML61=COL'K?/OVX1`QVEP4B[?>L,;;?MRC"_H#5!_V_
MSXEG:4,6B+0_LL;8_MBB"/L35N_;3SL9$?\I"T3:GUEC;']N483]!:OW[6>R
MWT3\ERP0:9^>6^FY]QBGZ<4.T),KPR(\4#R=>`KD90K0XRU?D7Y2_.<Y0,^\
MC#WC`T\?\NNLJ9P%]"@LL.`/PWU>GB31H[$O?`@M]OH7-+=4(BTN*I&/,G1$
M;;J<38O=:NEDAQI&#DSYHI0<@TH@1;\WT)4HE<HZPEJ5]9SO&J#NU5C*[K#J
M%MG..-*!AG#`R23%=K+)>B(=:+&4=:!M480#'>%`ZCXGJG67]40ZT&,IZT#?
MH@@'!L*!;%)6@R'KB71@Q%+6@;%%$0Y,A`/)K`S2E/5$.C!C*>O`W*((!Q;2
M@;3\@K9D/9$.4#T*II3U@.J181$N4#WRQ7@B)+\EQ9I`!2G0%.T$3RF2/BM(
M5SG!LXB=<-))\4"2*M(73H0K$KEZ2T72XJ(B^2BT-\H+ITKZ5W_^,G`VQ#*&
MY8M2,M4J@52&SBK.2J"(1360"JT-Z;S81=2L18Y$W2*K_D)1\CL4=B(CNMV\
MRHF6M<A.M"V*<*(32`DGQ,..[E5.]*Q%=J)O4803@\M.B!(]O,J)D;7(3HPM
MBG!B<MD)V#/Y08O.B9FUR$[,+8IP8G'9"=@X7>,$%2HS8]@+*E2&1;A!A<H7
M$VDAOZ'Q;(L>#=H]&:/&$9Y<7^Z>+CHB%D\J6+[8'QT)%RS]</[\]W)??)D+
MGN7G3*DMZA_V42T*;Z$RHC*4`BE=3$V5@4U-^:(45JS`8NCK8P:V48&K-!K&
MXH6*%4C9M4._*W`JRB%7I1,-[G;8"5$VFZPKTHD62UDGVA99[Z%L=BXZD15E
ML\NZ(IWHL91UHF]1A!.#BT[(<`Q95Z03(Y:R3HPMBG!B<I434]85Z<2,I:P3
M<XLBG%A<=$*&8\FZ(IV@BF72T!0*GFOA6213DRJ6WS03RDWI!VVO`@O1CE18
MS`X'_<K1.!<Q'O1][Z(C8D6EBO6%(W[%\E_`\7_LNW7WKV[)?7\_Q-;>3_UR
M#?UV_^G!8/OJS^G$3/#BZ94@7<+D#8?>%;K8(DTW3@\Y1`N5*>A(75!%-^AG
M&1=N9.G&Z?N[4%7,T8U3814WRO<%>G"`FL;W!7TXCC?*^0(=!2*OYPMT)(R\
MG2_0>2[R?KY`A['(Q_D"G:0BG^<+=`R*7!7S!7V$>>%.E>[0Z2/=29A>T\M1
M'ZM7M[/:OVYVA]B[^T+Q39X>5>W]UZO\?X[>!\6=7I'RCO1:U.GRC=Z#<^GI
M:?*.3B)>/._(_V@#YLVZIW\!``#__P,`4$L#!!0`!@`(````(0`5L,9NJA``
M`-A9```9````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*R<;V_;.!+&WQ]P
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M0>XN74.QSS>7-Y?DZ=.'^S7UP(;];+MZ^'C^>7+;SF_.+S]]Z`+TW_7JYR[Z
M_[/=X^9GM5W?_V/]LJ)HTSC9$?BRV7RSILV]153Y$FJ;;@3^M3V[7STLOC_M
M_[WY6:_67Q_W--PI]<AV[/;^KV*U6U)$R<W%-+6>EILG:@#]]^QY;5.#(K+X
ML_O]N;[?/WX\3R87T^MTDF9D?_9EM=N;M?5Y?K;\OMMOGO_GK";LRWF9LA?Z
M]5ZRBW1^E4Q.<)*PDUGO)+N83ZYNDCDUY,#%J;3K`OV^_^(9.Z%?=C*_F,RN
MNB`<N/:<J]&OOW9R<9VFL^QZI-4T`;M6TR_7/*ZW-UR/?KG>-#FFI1-*+3?2
M-L?<(![JXJ5+E"[OBL5^\>G#=O/SC"8S9<+N=6&7ALFM=>HSSD6IS\&W4I!R
MSWKY;-U\/*?>4W+M:-[\^)0DDP^7/RC7EVQSAS;*(O<6-K&MVT*#4@.C0:5!
MK4&C01N!2PI+'QO*_U\1&^O&QL;WZLZ#$*RI#%7N+7R50H-2`Z-!I4&M0:-!
M&P$1")K+OR(0U@VM2"))5,_OG(U=\_I,RE1P>I,^.D!*(`9(!:0&T@!I8R*"
M1`O=KPB2=4.3D5:N/@`XE=CH4)1ZDSY*0$H@!D@%I`;2`&EC(J)$3191&M[9
M_+)BK;M@^$[<,:$5.@I/HC*D-_+5"B`E$`.D`E(#:8"T,1%]IS$5?;=K;99<
MA*WEZ.76>I)Q84+[2!27F8I+;]3'!4@)Q`"I@-1`&B!M3$1<:#`A+M/T@N)X
MXBYD'<FP,)%A2558>J,^+$!*(`9(!:0&T@!I8R+"8D5]O#4?GBK66O;=D>FT
MWWAR(`60$H@!4@&I@31`VIB(CM+HB(YV&F362=PWE*]?'VQ-V6DF3M!:#9$S
MH76[GQF3:Z4\"C::];$J!ZHE2=B*1`>L<!(].#Q4G;EL-J-XL!`5B$I$!E&%
MJ$;4(&H%DGVVJBE.SV[4KDA"C'3>J2W:X/QLNYLPB@;-H\.CYJVB8?,HKI@D
M\W[&RSY8P:/[\*Z59^*DD^@5(TJD/O&2Y+IO2:=P<U^Q.U2RZ.TK^@B5:&40
M58AJ1`VB5B`9(2MW?DV$K">5](QDA&YTA'HK'XYB`JA$9!!5B&I$#:)6(!DA
M*W5^3818-,4S@Y&(T.Q*1ZBW"A$"5$X`&405HAI1@Z@52$;("J(X0B,+!.NG
M.`P.3;N;)SQO`!7VT$`9%EF5B`RB"E&-J$'4"B3[;,7."7UF;13WF1'MFF'Y
MF*E]*[?G!#NKPNFR0%0B,H@J1#6B!E$KD`R#%3<GA(&U4!R&7A[%85"GQGS2
M6X49`*A$*X.H0E0C:A"U`LDP6.D3A\'=9>F4_\AD<**)(NP[=D=C;8=\YN[_
M=1('48&H1&0058AJ1`VB5B#9?:NEXNZ/]-F:JYV"4:P0`!430"4B(Y!H)ZT<
MI[2S,Y?M9#2EI3::M/IXRE8)S=W>:CI1RJ#POFA5"U;3H$"[=;#TOJZZFVX3
MNE\O-P?C#4AC!3?1Q60$!D5=VB7J_G&]_':W(2=D-#""";6@:]/G*>NY*&D9
MS6CC[EN1S/3YE*VFL=5`8-A]2(;25YR[**03B`+7(6G57S_V+*-@!=CQ^4JB
M7><KHR3IIVT>T'`+G/;S5I&B160\ZMS+IEME%#<]6FE.&$#65_$`.I30JMH'
M,)GID[0=.9JZ8YGMK.S#A-[7%#.;?;G,GM*S`YW9;$!#&]R\F=E6_1P*S!^;
MU[<RFQK:IS:+J#@R#HFQ[M%PRWBLV2KLW:5=.&S\`C(>#8RUU3MQEP8F9=QT
M)X_BK<2.@%UII<902TP>K/P>5"`J$1E$%:(:48.H%4BFO)5`)X2!%5,\@HQH
M^^@3*9F%,V,W7/FTMPIA`%2BE4%4(:H1-8A:@608K-Z)PQ#-_)'$8*441\2A
M6&-,`16(2D0&486H1M0@:@62W=<2:Z3/J*NFC,*VDB,J$)6(C$"RG5:CQ,,T
MTDZ6-/'8.*0TAE(/^=19C:W$[&MD)796,[>[SM4!W?A+';4.)Z=IK,Y<:BQ&
M0DK`D9B-1I2$]QZ&O/3>9YV2F*J#AO$UCM(1B14=QX]U9Z[ZZF2+&FLU`#E7
M'!EKMJ*%U*]?I:_(XO%ZKK=8;W#<T&K9%*U`QVN/!-44(SGB.N'9:&S$V7L\
MX@[1TF(?6T_2:R5JC&\1V?7;PYO:D63`26/N-$R\*7<>2`-$VC&@X18X/>&M
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M%%D`Q8F;Z'4E3YS56.:RKSBL>*SUOMX\UGJ#.(_C+!+),--R2@?FN&-MYT9*
M#T9Q?@<4\B9NF<MO;Q7.L"4BXQ%N0S/JN!CKPPJY,U=-MQX(489%^:W/<[YB
M:&>!J$1D$%6(:D0-HE8@.;)6ENB43ZEG)[X3,;-^5'P84;Y&\=&"RE>,GDPB
M*A$91!6B&E&#J!5(QD<+K2[S[?/G4P.$$LSNZ#9F,D!Z9P]6?@<H$)6(#*(*
M48VH0=0*)`-DU5*<0"/SR)JK/'&([B#[#N9V42>K"!6(2D0&486H1M0@:@62
M?;::Z80^.XD5;PATRP.'/M,2-ECYR!2(2D0&486H1M0@:@6283B@\T:R`+7=
MC-57.#?FB`I$)2*#J$)4(VH0M0+)[ELY=4(6./4ELH!1D..Y59]V?@14("H1
M&8%D.ZT$.J&=K)@B)3=SB"2#S\,\H+"X#VS2KJ+=A<,6D*G#1<F^R,J[-\$]
M(=D;*W].Z(U32R+J#HG>`"IF#JFFAQ-/IT+*8!6:'OL234^'5)1[#^CP=.DJ
MRD63D3@*)9DZK.3>2FC%Z-F%DU*#5O"@A*WHUE1W`R/3-\.,-SA*45J)(8;1
M[JO3S/Z]R=GQ=W$Z+RHP3I79#2M*.7WJ\!7?:BL'QOF*)F/)%6EOL%&8)FK)
M-MXQ"83^\O&\D`EA%=+QN9RRH(IF)J-8/@<TW`+NFO-%MS)\XI:^8D#&(Y3/
MZ:`N.O41;N=%C9\31?()8*:.=3E7'#DJL5674_X/1O"HY'V]>7O2&[R5+'),
MM1YZWU$I19W$2(RULQJY%>`KAB-(B<AX-##65JS$:=K-U?>\.9VR[(DSF!&M
MFOV$23)URRWW%<,.5"`J$1E$%:(:48.H%4@.NE9"(^LYRI^4$6V8?1AF^JP4
MC/RD+1"5B`RB"E&-J$'4"B2CH`61S1.[()YX5$I1*7DDLT2?M8-5B`_["HE3
MHI5!5"&J$36(6H%D?*P:^C7SR.FJ6-6DC&2$((-ZJQ`A0&7PY:T,H@I1C:A!
MU`HD(V2U4QRAD7EDS=7VP8@ZU<^C)--GZK2W\ATL$)6(#*(*48VH0=0*),*0
M#0G%=TRDSH^,CT<4@!`?_4`N#U9]?!"5B`RB"E&-J$'4"B3C8W59G";OWI`R
M5GC1AN21C)`ZL^3!*D2(?45+#5H91!6B&E&#J!5(1N@T99FALO1(AD&=?_)@
M%<+`ON(P`#)8L4)4(VH0M0+),&B5>G@]R9SVC)=5C\1Z,M?GK&`5PL"^(M&%
M5@91A:A&U"!J!9)A&-*D[_H#E`QEJ4<R4?2!*UB%"+&O.%$`&:Q8(:H1-8A:
M@62$M,0=2134L1DCF2CZW!*L0ACZBAZ5:&4058AJ1`VB5B`9!JUCW[^PHL3-
M&,E$T4H_6/EP%(A*1`91A:A&U"!J!9(1TAIW)%%0RF8.1?>V<T0%HA*1050A
MJA$UB%J!9)^M0HRWVY$^6W.E.AC)R:'E>]9;A:$'5**5050AJA$UB%J!9!@H
M<4\)@S5786`D9X#6Z%EO%<(`J$0K@ZA"5"-J$+4"B3#,M3@]G`V=N0R#1S(;
MM$8/5GT8$)6(#*(*48VH0=0*),/PRS3H'#6H1R)1KM6]QCQ8A0BA!D4K@ZA"
M5"-J$+4"R0AI#6HWDXF[13B2,RA'YP[1PRC?UQQ1@:A$9!!5B&I$#:)6(-G]
MT[3G'+4G(WHU)O39646H0*L2D4%4(:H1-8A:@62?M=`<&6=4DW.'H@[F`84C
M:WQ+W=W09BOYO$;_`7X9K'Q(#:(*48VH0=0R<JV7D3E-8-J/=:C-@Y&(C+,B
M=#`RSHH>576/+*XFZO12LF<R"$'I/7M4X?5K7Y%?,KJ:J.-A$PR\FU:XD2'2
MXG,D>5!ASAT2(>K1P1`Y*Y4\JC<ENX^?4R*J$-6(&D0MHZ'D.4UTSE%T,A*/
M"V]@/V%E2F/?WQL:F&A#5O"TD"]HGTKWOI)KE7F&K>S[W\%*O]%9^<:'M;\.
M*%2$)SO-<"/4T;0=:X1,4BM(8RT<;6K'/[><LZR-;CLQDL\M]4OBN:\8!VQ@
MB-B]L,(A<E;V-9<0_&MU'C/^BK3_!BL<HOZ*?J+7ON+!1C2^V[(1ZF30>E]O
M-4(.D17+AX;HN)<5Z0.,L`0[%#^!8ZN1)W#>*KH9A,AX%/;["E'M4?#5(+*?
MC[2M=TUUX7&?@W2?Y7M>;;^N\M73T^YLN?EN/_5(C_\^?>BQ^P[E779S:T\"
M-*:Z9'Y%GZCL7MB`$OOQRN[U%2B94DGWG2!=DB5TG:[;4#*CDNZ)-)2D5-(M
M"5"244DWM:!D3B7SH?YDUU32A537F=%UG.R$$KH.O1XT$)V4ZM#3PJ$2JD-/
MT(9*J&WT[&BHA-I&STP&2J;DC?Y6;ZB$O-'?F@R4S&A\Z'W0H1(:'WH3<JB$
MQH=6IJ$2&A]:009*)E1"7^L8*J'HT#<MADJH/^[NJX[UA/I#7SX8JD/1H7=P
M!TJF=!WW@K_V1I<9C!I=9/`:=(G!*TQH%M"WBP:N/:%8TO=NADHHEO2=%RPI
MYNFMU6)80D+KUFHI+"GF&94,]86^(?MY^/IT^0%/=]3@07MJ[E!K/\]N/],B
M@TVZLQDQQ.V<&.*SZ]L[ISW5,-%+9K?Y8$E!)?:U,;PZO;=%)4/MHG?*;LU@
M23&?41"'VTP+(#VGP^O<933T](1JJ(0F&#V9&2JA&-/#"BJY[+M*W]5]77Q=
M_7.Q_;I^V9T]K1YH,;[J/H6P=5_F=?_8\Q^.?]GLZ8.Z=)"FCZC2%Y17].VQ
M*_L-NX?-9N__82_0?Y/YT_\%````__\#`%!+`P04``8`"````"$`^@I?W%L1
M``!$90``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RLG5U3XS@6AN^W
M:O\#Q?U`G"\@U?14$UL?_JJMK=G=ZS2$)M5`J"0]/?/O]\B6+!V]QA!F;IKF
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M[4^UWGQ[.-#IGM$1F0-;W/V9KO>WI"B%.1LWP[C=/M(`Z-^3IXU)#5)D]4?S
M\^?F[O!P?3J9G\TN1I.$S$^^KO<'L3$A3T]N?^P/VZ?_M4:)&5079&R#T,^>
M(`..$^LX[1R3\=ET/+NX;+H?\*3!->.FG\=U.;>.=`%8Q_=V>64]Z>=Q729T
M5EN1O4#O[31Q$IG_N&ZG9^/+63*;FU,TH%%"LK;]OEO?\S8]FFQ+5X?5YT^[
M[<\3NH0I`?8O*S,A)`L3U^59VWV7>:\E'B6+B?+%A+D^)>TII_9TM?S^>7PY
M_W3^.V7XK;6Y09N$6RR=A<E!$S:-018#$0,9`Q4#'8,\!D4,RAA4,:@#<$[2
M=OI29OP=^IHP1E^GS(T#@>"1F,["N:0QR&(@8B!CH&*@8Y#'H(A!&8,J!G4`
MF)ATJ8"84[I6^B=%EYO&BZ8_EIL77*R;UL9,L%T"1^F[[$PZ08%D0`00"40!
MT4!R(`60$D@%I`X)TY:N?=#6Z''D1&#"T%Q"LW$G),X$UFA([<ZD4QM(!D0`
MD4`4$`TD!U(`*8%40.J0,+7IT)G:PQELK!M1G1@WEEPPF2]Y4B\[(^>6`LF`
M""`2B`*B@>1`"B`ED`I('1*F(>78$1H::ZZA)5S#JTC#SJC3$$@&1`"10!00
M#20'4@`I@51`ZI`P#>G@C]#06',-+6$W_JM1I&%GU&D()`,B@$@@"H@&D@,I
M@)1`*B!U2)B&IN2*EU#SR=D%)>Z1DZ>)Q/6UA):F?CJ]BI=-G5&G+Y`,B``B
M@2@@&D@.I`!2`JF`U"%A^M+!@[[CV=GQ\II`7%Y+N+SC*'T[HTY>(!D0`40"
M44`TD!Q(`:0$4@&I0\+D-54,Z#NY-&7EL?G;A.(*.T3=!QD\B23V5IW&B#)$
M`I%$I!!I1#FB`E&)J$)4,\3E-I5"/%W,"!XY5R1MQ4$K+2?9C4-<ZVFLM76\
MZAQ3[^AB98@$(HE((=*(<D0%HA)1A:AFB&MM"HE8ZP]-'4E;DC"U+>)JSV*U
M.RLG;>IB^1.0(1*()"*%2"/*$16(2D05HIHAKK:I+4*UAQ>U9N,CFHX=XI+&
MA9BW\I+:6*&D@`0Z2D0*D4:4(RH0E8@J1#5#7%)30(22MMLSS=KB#75MZ1%.
M#RVB@MGIMC0[/G0.`I0BRA`)1!*10J01Y8@*1"6B"E'-$)?2U!&AE&_H9\RC
M6YE%[1ZIV9]:F@+96'F4(LH0"402D4*D$>4,\6,VZ_XCCMF6"6'.M&CB+ZRE
MJ>WIF`D%=_0DJCU3:S6EQ86_[T^B>U'FK5Q*"D02D4*D$>46M:/GRIC5?*A,
M<&$='C:WWV^V-&RZ4_9DR83V-^VNIZT)0L%:Q`0#E"8MFE('7IVK:%,J\U9>
MG<[1(8E6"I%&E%O4IXY9B_]U=>R*/E2G1>-),`5U*)`"TZFUFH[;O>51$JT@
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M>.G10'CEK'PLC2AWJ`G/E8DKCX\E*!8D=.\P.3NE'UU^)*.XQK-6YD=GU9.@
M-CP[UW%&9"Y6.YDD\^DLNM,):V'JL-=[DR[.X)B4BS4X)NUBV3$E<$/,79S7
MQL3/EBDZPCR.S]9OVY?7UE[!C=+<#N/YI$4LOSLTH%9J8TW\`]8,D7`HS._W
MA%?.T8?7B'*'>O+;E!FA8F]<^<8\FFDMHKM_ES234;R1;*98X^A7^RFB#)%`
M)!$I1!I1CJA`5"*J$-4,\20\KC0:8VGD$"T\`TFCI>+26[F[0HHH0R00240*
MD4:4(RH0E8@J1#5#7%)3FX19:J[KCVTDTUH*,M@BGL'1Y+ATCF$&=X[N#&1H
M)1!)1`J11I0C*A"5B"I$-4-<;E/Q_$URM\43E<M.HINQ15SNJ'Y?>BOGF"+*
M$`E$$I%"I!'EB`I$):(*4<T0E]L43J'<;\S!QCR:@RWBDL)BHK/RD@+*QH`$
M(HE((=*(<D0%HA)1A:AFB$E*"W,N:;`0&%:W\>3J6A1L92X1I8@R1`*11*00
M:40YH@)1B:A"5#/$I:05W!'9.3'FD7X6^:W,I;/R*$64(1*()"*%2"/*$16(
M2D05HIHAKI^I9MY_=4_:XB><,"T*-_X\\BL$K`NLU1L[I=[*30L"D42D$&E$
M.:("48FH0E1;U+.O2`MSKG)PP;]_U[6)$B5O6ULQ\0&EUO&-75=OY95N8Y&C
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M7$1[`\*%>6U:LG-W._#A(2D7:W!(.AI2S]QMA1L<4N'"#*I4OFM(E8ME;R?S
M4?1LMW9A7AL22Q]3=@VFS_L>1C1A>$UB$:W1W8RS]"A(`[C/.RO_M"!#)!SR
MX:5'`^&5L_+A-:+<(1^^\&@@?.FL?/@*4>T07L^F.F,G9'@B;<PCX4V$ZU-Z
MQ.V%!Y1:Q\`J0R00240*D4:4(RH0E8@J1#5#/*$I[8_1SYA'^EE$5W8W64WB
MJVQ)=5KC&.RT(\H0"402D4*D$>6("D0EH@I1S1"7U)3_X2WFC91L=PO"JMG<
M1(S*=#_WDB;Q!QV\E4O<%%&&2""2B!0BC2A'5"`J$56(:H:XI&8W()34[$]\
M[$LSM(B'#+:(97`2K>^6SC',X,[1G8$,K00BB4@ATHAR1`6B$E&%J&:(RVW*
M^%CNCSV:HPUVD-LB+G?\)-0YAG)WCEYN0`(=)2*%2"/*$16(2D05HIHA+O=Q
M^P93W#=PB$L:/^WT5DZ_%%&&2""2B!0BC2A'5"`J$56(:H:XI'&1_<8<C-4T
MU7E-XM*/8`Z.MD>6WLI+VCDZE*&50"01*40:48ZH0%0BJA#5#'%)37493@IO
M2-H6H^RV9A&_K455RW+:63G]4D09(H%((E*(-*(<48&H1%0AJAGBDM+URB0U
MM[4/?+EK:N)$JS*+^(P0[^HZQW"2[1R=_!E:"402D4*D$>6("D0EH@I1S1#3
M>A97;L/IVYAS22T*2H`EHA11AD@@DH@4(HTH1U0@*A%5B&J&N'['%5HFBZ.4
M=(BG9+RY[:U<_J6(,D0"D42D$&E$.:("48FH0E0SQ"4]KO::8>WE$)]1XRU?
M;^4EM;%\V9VAE4`D$2E$&E&.J$!4(JH0U0QQ2>/:R\RH'UNYSK`N<XAG<+2A
MM/167FX;R\^S&5H)1!*10J01Y8@*1"6B"E'-$)<[KLO>F%2Q]IIU)52PS!K'
MI:ZW\I)VC@YE:"40240*D4:4(RH0E8@J1#5#7%)3T;Q_F36S!5"P$^T0FQ3&
M<3GKK9Q^*:(,D4`D$2E$&E&.J$!4(JH0U0QQ2>/ZZB],"EA[S2QBD\(X+F>]
ME9>[<W0H0RN!2")2B#2B'%&!J$14(:H9XG*;`NB(#+;U4IC!%G%)XW)VUEDY
M_5)$&2*!2")2B#2B'%&!J$14(:H9XI*:FN@(26T)%4IJ$9\4XG)VUEEY20%E
M:"40240*D4:4(RH0E8@J1#5#7%)*+B:IF10^]+*'F8D4E0H6\02.*UWGZ%<%
M*:(,D4`D$2E$&E&.J$!4(JH0U0PQM>?'55^-.9?4(2YI7-!ZJRZ!$66(!"*)
M2"'2B')$!:(2486H9HA+>EQ!-L>"S"$N:5R0>2LOJ8WE$S=#*X%((E*(-*(<
M48&H1%0AJAGBDAY7D,VQ(+,HW"-`E"+*$`E$$I%"I!'EB`I$):(*4<T0UR^N
MOH;+@3E66`[QVU1<T'HKGY(V5E#0HI5`)!$I1!I1CJA`5"*J$-4,<4GC"NOC
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MC?2>EAEI35O$?2VD->UT]K60UK1AU],R)1_Z9$I?"_G0!RSZ6DAK^IQ`7PMI
M38^T^UI(:WKZVM="6M-#Q)Z6,?FTGWZ-%1V3#WVKM<^'M*:/+?>UD-;T7<&^
M%M*:OO+6TS(AK>D;7#TMY-+KD9`'O4FPQR,AI=NW3L5'DY#2]&Z`/A]2FEXU
MUM="2M.;L["%_LK!E_Y8Y-!C?T.=]]I3UWT]?YDNOM!$@QW?F'/?Q\U5UL?I
M'/:>0CJ#O2>0SE_OZ9N,%S?M1_8B89?4LNQM2:G%?`\*CX*^<40M?0=.7Y(B
M1?I:TLETD='70S`:?:MEH7M;Z"LHU$^?STTR7]S0BYXP&KW':['L;:%W=RW,
MV[30A]Y;12U]T>A56POS0JD^G\N%>3L3MM![EBA:TW+>B4U_P^)E]6U=K7;?
M-L_[D\?U/=U:1LUGZ7?M7\%H?SG8=T1\W1[HKU=094E_NH#^6LF:WLHV,J^&
MO=]N#^X7ZOJ\^_LGG_\O`````/__`P!02P,$%``&``@````A`$AS):*7#```
M0T(``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK)Q=<^(X%H;OMVK_
M`\7]!&P^0J@D4PWX^Z.VMF9WKVGB)%0'G`)ZNN??SY&E8UEZC8&9O>ET'A^=
M(UX=R3K"SN.O/W<?O=^+PW%;[I_ZSMVPWROVF_)ENW][ZO_G-_^76;]W/*WW
M+^N/<E\\]?\HCOU?G__YC\<?Y>';\;TH3CWRL#\^]=]/I\_Y8'#<O!>[]?&N
M_"SV=.6U/.S6)_KU\#8X?AZ*]4O5:/<Q<(?#Z6"WWN[[TL/\<(V/\O5UNRE6
MY>;[KMB?I)-#\;$^4?^/[]O/(WO;;:YQMUL?OGW__&53[C[)Q=?MQ_;T1^6T
MW]MMYM';OCRLOW[0Y_[IC-<;]EW]`NYWV\VA/):OISMR-Y`=Q<_\,'@8D*?G
MQY<M?0(A>^]0O#[UOSCS?#3K#YX?*X'^NRU^'!O_[QW?RQ_!8?N2;O<%J4WC
M)$;@:UE^$Z;1BT#4>`"M_6H$_G7HO12OZ^\?IW^7/\)B^_9^HN&>T"<2'VS^
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MDBW$5!!N5S;P;.#;(+!!:(/(!K$-$AND-LALD#?`@*2M]:7$^'_H*]P(?5F9
M!0,MN"7WDBVXR<H&G@U\&P0V"&T0V2"V06*#U`:9#?(&,,2DF0)BCFC:MB^H
MG)NB%2V=C=QT)Q,S\Q;21BS.=0)/39-E;5(+"L0#X@,)@(1`(B`QD`1("B0#
MDC>)H2W-?=!6Z''C0B#<T%I"2W\M)*X$RJA+[=JD5AN(!\0'$@`)@41`8B`)
MD!1(!B1O$D-M^NB&VMT9+*PK45F,A2)TOZQE=B=VQM9&W&P%Q`/B`PF`A$`B
M(#&0!$@*)`.2-XFA(>78#1H*:U-#16C'T-#PWIKUM5&M(1`/B`\D`!("B8#$
M0!(@*9`,2-XDAH:40(:&\O9_=T^B=Z>D:&C**<E8;F3%W7L)9`7$`^(#"8"$
M0"(@,9`$2`HD`Y(WB:&=*-.:6Z=NP82U*9@B<KM>"09D!<0#X@,)@(1`(B`Q
MD`1("B0#DC>)(1C--$.P1K*=WK>;;XN2)B)MI%J$'-&>4NXTA1-31TG<4;TY
M6M:D,;.=F3FS5])H3/$:T]\R\FHCGOX^D`!(""0"$@-)@*1`,B"Y)/+3&VJ+
M>N;ORUUY,?56J"FX1@TQ07%E-7:K`L$=.B-S2#QM4,NM/3,*-.H(%FI?HAJA
M8-;^.-(&[#G6GADE&G4$2[4O%<PQ/UFF#=ASKCT3,D=.%!/7KRRB"K6FA$(N
M[3_JY)Z-S3XMV8C6^MK(Q4&3WL59@;9RK:V&IWS19EP(,'*'5C"?#8SI9@<+
MKNI2V&IE=RGBB+)+[LRN1V,VZ.Q2TAK,[GC::F5W*>.(2J7[Z8,Y)#D;G.N2
MF2:B3&JFR5]:3\71A9T]$HVI5JB'?&953$MN=ZZKJH!7WO5-SE,-W7NY"CR,
MK8GILV=J6H>'O`S8JC-^J*UXWD56_/'8RN68VW3&3]BJ,WZJK3A^9L8?TV&>
MG01*LW/QS200!5TS"5INGC1W^>XI#IOLT99HU+A_*BM"'2.P8JMQ?>/U$/F,
MM/M`HP[W(5MI]Q&BF)%VGVC4X3YE*^T^0Y0SJMR;PHO:KBF\F'WN5)SD]J[?
MS8@C-WL\)!K1OE.G_\1:*9:JX8AV]MK*7I96RNK2XJTBRF5IZM@SPN=@G;D>
ML%5GE\*KNA2Q+]FER6AD;<QB-NCL4L)6G5U*K^I2QKYDEV;#F76/S]G@7)?,
M]*$T@?1Q)E7E5:7/;^7GN<UP<SX+-];V3")C/M>H,UF4E3YE],0!$+F77Y)4
M*[K/2$^X0*,.]R%;:?<1HIB1=I]HU.$^92OM/D.4,VJ9SZ)&AOD\N2,%;CP"
M$X=?]I@H1)MU/5NG0W/A7W+#AWI!72'R$/F(`D0AH@A1C"A!E"+*$.4&,M-?
M5-5-M2_<MF013O[X-KIP%#*6R:DU)Y?:BANN$'F(?$0!HA!1A"A&E"!*$66(
M<@.9DHJZ^P9)59G>E%0A,TNM[<G2J:VTI(`\M/(1!8A"1!&B&%&"*$64(<H-
M9$HJBNL;))6UN)&E"IF26G7OTJFMM*2`/+3R$06(0D01HAA1@BA%E"'*#61(
MZMJG$MT3OS(W[V^,3$FM>G.IK6I)$7F(?$0!HA!1A"A&E"!*$66(<@.9DM*&
MP\C21AUX05W1TE)7HN8QK@MHA<A#Y",*$(6((D0QH@11BBA#E!O(E%*47M=/
M>%=5:HTUE)$N>)>(5H@\1#ZB`%&(*$(4(TH0I8@R1+F!3/WL:K21BM<7172R
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MN>&YB.:XBJKRAOFJBM#F!D`B<[[>P_9465V8K[453RB/CLW%<D#S52Q/5KKX
MZNJE>0IN0]60Y@!'BCHCQ5=%2M!MBBCKC)1?BF2.GZA$;Q@_5;@VQT\B:U["
M>JL:7IB7M16KZKG*_5B.W]W,6OA\92"^)3@_XP.VTA,D1!3I8`U?]];B'G/#
MSH@)6^F(*:*L/:)UH\BYX;F(YI"*2OB&(56%<W-(ZUJZ*8,E_-*MK7BP5H@\
M1#ZB`%&(*$(4(TH0I8@R1+F!#$G%,Y.&I-5W%W_EK+/R9%:0C$A.G<#WUMUV
MJ:UJM1%YB'Q$`:(0480H1I0@2A%EB'(#F6J+^KF9P(VBJ'O;(-9Q:R^N4+,^
M1[1"Y"'R$06(0D01HAA1@BA%E"'*#61*22N&(>4%_82YE9T*Z65L.0*T0N0A
M\A$%B$)$$:(848(H190AR@UDZB?*Z#.I>'U]+KX7MF65J%DB*JL+):*RNE"?
M:RM>+7Q$`:(0480H1I0@2A%EB'*%I!*F^**R_?OBR_JX62*.)#+$KU%C$8:Z
M034\7Y]K`ZU[[9E1@/%#W?!,?:X-V$V,;A)$J6YXIC[7!NPY-]R88R(JXN:8
M7%A09`%MB*]J:I)%W^Z@/A\I*_JAK7`\:BONNJ<:FO7YS-[W*RNQ<&KW4)_K
M3K#[$%'4'M&J'..K(B;H/D64M4>T/F-^*:(YKK?5Y^(Q"GM%NZH^YX:&\#BN
M6)^KAF,C;696M>RS>WT^%C#2-[`04725^Y@;T@U0IXW=^X2M=,044795Q)P;
MGHMH#J*H4V^8G+*L-2:GJG0-E:$8%X_:T.B+`Z#S,JRT%<\>3Z$SQ;BZ>FE2
MUL'9;8B1HLY(\561$G2;(LHZ(^67(IGC)VK=&\9/5<N-RHT>/!$C<Z$85U87
M#LFT%0OML7LC/6;6`9+/#<_EK#PD8RL]2T)$47M$ZW0HYH:=$1.VTA%31%E[
M1.L\0[P&72V`YR+*<95O.LOW1W?%X:U8%A\?Q]ZF_"[>8J8*Z/FQQO(5ZX5+
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M?^Q]%*\T.8;5DWT'^4<`Y"\G]83?U_)$+^]3F4IO7],?:RCHU:FA>.SLM2Q/
M_(L(4/_YA^<_`0``__\#`%!+`P04``8`"````"$`?3](!P($``!A#P``&```
M`'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)R7:X^R.!3'WV^RWX'P?N0F*$9]
M\BCB=9/-9B^O$:J2`4IH'6>^_9Y20%MFI\Z^$>GY]>_IN=1V^N,]S[0W5)$4
M%S/=&IBZAHH8)VEQGNE__1F^C'6-T*A(H@P7:*9_(*+_F/_ZR_2&JU=R08AJ
MH%"0F7ZAM)P8!HDO*(_(`)>H`,L)5WE$X;4Z&Z2L4)34D_+,L$W3,_(H+72N
M,*F>T<"G4QJC`,?7'!64BU0HBRCX3RYI25JU/'Y&+H^JUVOY$N.\!(ECFJ7T
MHQ;5M3R>;,\%KJ)C!NM^MX91W&K7+SWY/(TK3/")#D#.X([VU^P;O@%*\VF2
MP@I8V+4*G6;Z3VMR\'1C/JWC\W>*;N3ANT8N^+:NTN20%@B"#6EB"3AB_,K0
M;<*&8++1FQW6"?B]TA)TBJX9_0/?-B@]7RADVX4%L75-DH\`D1@""C(#VV5*
M,<[``?C4\I15!@0D>J^?MS2AEYGN>`-W9#H6X-H1$1JF3%+7XBNA./^'0U8C
MQ47L1L0![QN[/;#'KN5ZWU`9-BKP[%2>=@&<K=<!SV[RM]?A-2*C1Y%OKP,Z
MJW8%GITK3Z_#;R;#LYO\[7584$8\JY"9N\RS*S%XC=0E%T0TFD\K?-.@C:$*
M2!FQ3<&:6"#=%ALOC:[\_JOZH.R8RD\F4XM!81'HF+>Y[TR--ZCRN$$6'($(
MWI&AB"Q;A-4TDPWD@94\$,H#:WE@(P]LY8%=.W#WS!(=V[=$Z]CA8<"`2';A
MA`CVPNE`ZC[OW39Z;)88/4<*S:*/V**/RS[ANR(2]!'I9U9]PO=$D;"/.-+O
MK/N(/Q)5-I\@8Q'9?H+X(K+K(U)4]GU"]O;01T9W5X3LPF;X/[++9L$>_%#X
MEFF*"UEP!K;)KCFDL"^51*`D5DHB5!)K);%1$ELEL5,2>R5Q^(H0T@IA%]+Z
M=;,R>J9#T72I\N5L<F14[X,O8VLH==E2L'O64.J?0+"[0U?27PEV;SR6YH>"
MW1D^E'.]K:X%NSN2_=](=OO>#O7\K6`?V9YDWPEVV_-L*0![$;!M3P(.`N"X
MHX<0"*F#LX&0.O;WI=YOV2PQA98I;?D+SH`?79KECE02@9)8*8E02:R5Q$9)
M;)7$KB78?_N+)>5K_VB5C0?!>*\5(9%P3A,2^74/,EI.H+3S+SCS50*51*`D
M5DHB5!)K);%1$ELEL>-$LRE!4SKW3-1=O1<!VW[HN1J`.P^+>J,`3>G<0\YS
MR:\T_'R9H^J,EBC+B!;C*[NNV+`?=J/\)K6P)G`<@U.5-+Z#&U8];G0&N.&4
MT1G]%E7GM"!:ADX@:0Y&4%P5OR/Q%XK+^BAUQ!3N-O77"UQE$1PGS0'`)XQI
M^P(_;'27X_F_````__\#`%!+`P04``8`"````"$`&<D`L18)``"P,```&```
M`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)R;46_J.!;'WU?:[X!XI\1.0@"U
M'4UB>W>D66FUVIE]II"VZ`)!A-[>^^WW.,>$G)-@T^D#M/'/)_'?Q_;?X#[^
M\F._&WTO3_6V.CR-Q4,T'I6'=;79'MZ>QG_\UTSFXU%]7ATVJUUU*)_&/\MZ
M_,OSW__V^%F=OM7O97D>081#_31^/Y^/R^FT7K^7^U7]4!W+`Y2\5J?]Z@Q_
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M!P\`KZ/]UJ8&*++ZT;Q_;C?G]Z=Q/'M(LR@6@(]>ROILMC;D>+3^J,_5_G\(
M"1<*@T@7!-Y=D,7==6-7%]Y=79D\B"2:?>'^B8L![Y=&P*]W/CPTLU$`WB\/
M</_3SUQE>+_<^6[YIM@53<^JU7GU_'BJ/D<P7$#L^KBR@T\L(?"E2[$#VDZ^
MU<?0N3;(KS9*$PNZKX;$_/XLHOAQ^AV2:>V8'!F8"SI,2IEBB)E11@TQ&67T
M$#.GC!EB%BTS!7U:D2#7N$@QC)[AO+]H8BMQ39(V?J-;CLR\27`K9,$O*'Y!
M\PNF<X$\-"1Y]Z']#VOAIS&$NG:.B-C#(I,UW9NFBXB)7G3+DY0U575+9287
M'-!=8")%EBQ8=AA"7-."M!K&8K?5-I_#764K\=8+UGIDX+55Z/H$36<62,P:
M?9(TSK(LON93@ZA@$!TDC(\@4L`DPZ5(X)H_$6PE+H5D4B"##4TC*5@K"RQ/
M&B%F+$L4K2Q2%EQ?*M_4V?@((@#,9U\7P%;B`O"I#!GHB)NY@`1*-,LB^T-%
M5,$8.D@8'T&4R/Z*$K825X*-ZAP9;*<0"U9<8#%F`A-1L:ILO.E+U9L:&Q]!
M6F_])UOC9L'IVU;BK6<34HZ,+P^00'UBF22"31HJ&$('">,CB!#@-;@0X<G1
M5N)"L%;DR&`_)S/6TT6WE`UWU2U+9CP)+J6WD\!'D+8+Z/&O-[ZIQ5O/IK3<
M0;X\<(@;**F<)7P^"`?18<1X$:J']3^=4>%?%@2Z)6H0F*/*'82-G$=SUIN%
M*_?HI`(A=#B$\2)4`FN=[I<`C1:8D';6AQF/SNJY0,C3Q"*,J#"BPXCQ(E0(
MZZPZ0MSGF@3Z,9(3DJ5U[B"<&@3+F*(MO6K*IA851G08,2W2[$VNCT%E@&[K
MRA`8$I:F4\.BUWID<$1,XC1+&5$()."US:J>`D%$NRBW[V.\]Z$J6'_528:`
M"NC&2!)$;)+/[8<$(-7U\6)&%([PRN#S?8V]UN$HQHM0':R[NE\']&)$!\DF
MP%P@=)D@15^&BZ.S:0JK!)U=%*D?QW+.-QB:$!.9@N=@IL4XQ(W(:T?0QEMS
M=7_CT8K1QE\CXUY7^/P:[J`<@OJD,DV3C&\"53B,#B/&BU`EK+OJ*&'GQO`V
M2J`G(XH(YHYS!V%S17\?Y<J'[3.OS')%MY5O3BS&BU`1K,UB(H0MM$!S1D5@
MZ9@[R#/R"X>@3C;K4Q9$A8/H,&*\"-%#_B4SV=2B*X;@&X+<0<Y+I\QK%J28
M#3%%"A.NDFZ+;Z>$%Z$2,/]XGV>00SZ2M3%WD"\E'.*&3@:?MO"4"`?18<1X
M$:H'I'EWB/B736EIG@I76X(SIH/<=!C'K+QPY1Z=5""$#H<P7H1*P&QD0`*T
MC_#:.I^^GY8(>9I8A!$51G08,5Z$"@'/V\V%.\>&K<5RHN>G)4)N]68K2M&6
M7C5EZX(*(SJ,F!9I_/3U,:@,7W*2]CL8UOR>GW8,CHB)E+"/IA:I<(0G8508
MT<'[&&\0JL*7?*0<\)$]/^V@JPR];84CO#)<O.;-7-'A*,:+4!V^9"GED*5D
M'RSE#D(=9LE\P9*]<`".EC1F?ER1^G&\F"=LBM6$F,@L32.VY3?D'AW+3AO/
M7&1@:AQPCY)E>BX1\G1QX9#+`A*E<S#5=,"H<!@=1HP7H4H,6,FPGY9#5I+9
MG]Q!+AT6R8(!A0,P'3*V%5>\NF35=5O]YH@Q7H3H8#]XY6M$6(>F%ELC!!\6
M#O)EAD-0JBP2:?\+BG`4'4:,%Z&"#!C*.P09,I1\J,0(N<00O8^A7+E;5-D`
M5[1VM&#ENJU].RV\"%6!V4AK'<([K7C(3K*1GCO(FQ88!X42\_EBSK52X2@Z
MC!@O0@5AIO(^+Q6C;X3F=,PE6QUR!V&W)[W%@Q3SI8,4]KZJUFWQ]?[L[L:+
M4`F@R_A48<>5?Q&);2T^5?"MEH.\.8%Q+CD1I6E/"R0\073X/L:+4#V8K[0I
M<<=,T?>7<.Z(KH9YC)!K+)POH^6%*W<S!2U4M++H3Q08W*.3:>,/Y0T5@=G*
M.T48L)<=SX+[SCCH#`N'H$X+^&'&285CZ#!BO`B5XTON,AYPEWRFRQV$;9R)
MA`W@PI5[NE,%0NAP".-%J`1?\I@QVD?_]MM!GB86842%$1U&C!>A0@Q8S#OF
MRP&+V=M^QPCA^)_P3W2+MGAH^#:#2X41'49,B]C]=_<YB!`)\YC^!:.AZ8+1
MVX`[!L?$1,YF?%M2.,*3,BJ,Z.!]C#<(58$9RX`*`X:RMP%/NH;2RM#[;,X1
M7ADPB`?1X2C&BU`=F+4,Z#!@*26W#PE">"80OL'(^*'!@A`SOJ52I#B1L>3;
M:TV(20S'S6*VWS$$$===&VT]\Y&!U@_X1\G6N!S.6EN'Y>G`PB%N#9$RB>=\
M5ZK"8708L0>_;S\,*H$'N_'X[[X\O95%N=O5HW7U80]MIW!>K[V*!\ISL<RE
M/9S*KA=B60Q=5V*IAJYKL81SJ_TX!@ZL-]>G[0W@O/AQ]5;^:W5ZVQ[JT:Y\
MA4>+'C*P3B<\<8Y_G*MC<[CVI3K#2?'FUW?XSX`2#M%&#P"_5M7Y\H<]T][^
MK\'S_P$``/__`P!02P,$%``&``@````A`,+;7DP9!P``-Q\``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6R<6=N.FT@0?5]I_\'BW3;=W$?CB0(HNY$V
MTFJUEV<&XS&*;2Q@,LG?;S75AJ["QDSRD&2F3Y?/J:JN`^['#]^/A\6WHF[*
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MO]7E]H_R5$"VH4ZJ`L]5]55!/V_5KV#S>K3[4U>!/^O%MMAEKX?VK^KM]Z)\
MV;=0;@\4*6$/VQ]IT>2040BSDIZ*E%<'(`!_+XZE:@W(2/:]^_>MW+;[C>7X
M*R^P'0'PQ7/1M)]*%=):Y*]-6QW_0Y#0H3"(U$%<8*_7Y4J&GO#\^U'6R*@3
MF&9M]O185V\+Z!KXS.:<J1X4#Q#YH@QY]%IO206-*LA'%:6+!2H:J,^W)R&C
MQ_4WR&FN,3%BX$@,&(I(+@B50!4V-7ZQ!KX]:4@%)^U`4:^7X\)1;:(<'9<2
MB,<021')&.%X%)*.(4'80X@,A\J8IJ_`T#=F^AR[C]OE*T8,E+%/L4\1R5U$
M.H4@[.%CS"),LU?@C06IZ9E%G#Q"@JY[EM+W):M.0@%2^@R0$H#C!=[P$80Y
MG#F3N>KY^^VC-O'\"YK=&#%`HU?)\W\7D4XAB`J?JIC.OP+3_`N']7:,&+<K
M@.>SXYN8J[X_9!9/*EEU!]6$<4`9S\N[VL29.RSOB$'FD6"Z$G,U#)FN%%=]
M'%I><(.Z<G)C3$XG6X$993&,`#RJB,&/]861L6XY,9<]QV&[4W,YM,.A#TF^
M(TIZ7K[5)D9^-"<1,]7G%P1:`:M7>EF]=DZ(`@%3W<S[/`G=+JZ!C>E8@[!I
M>#\G_>HUBMCRDQ"J0OF8T3TS5:#[T8D_M">VD4#05"GN0]))")6BW,V0,GT0
M!'JA.?9==CICC<$Z+!W))DO2KT]4`C_F>A(H?>5N\^FC%YKT/>8YL;CXI>IT
M&;`N2_KE"?:7"-<@E#TH?`=[A::GP&'#+Q:(T<D7+ILS"5D7[C!G]!$PMP^M
M24DK0YN?<K0_,^4NZXA8/7F#,#VR;7M$VEQ?.JY@-4MU`*W:\X;Q1)DK4YO/
M'"W09"Z<@!F5,'UR*<9CQUP?\S97E^(6;>5H!NV9TP9]T*3OC8ZJZ:1R](0@
M3"M="L\>".IV,?<#_Z$;:=Z5N[U?`'HB$<`(Q`(Q6/A`LG9.R')HL[Y+R;(C
MAJ-.V2MS,]C?F9!HA83U$%C/>,1@OR^EX$_.B3`!0@CNUZD&Z(8WGIL)<\G,
M=IIYAZ;C1?#GE%B#-'41N2'KJ80BX%F&`5(*D%X8#?FA])G+WJ%_S5V'AL3,
MR_ON>A^23D*H!.B#^;TC%9I58#0L->A2`0$/P&P<)A02"5>RB9I2A(!W^V`(
M0A6\RV#EV&!')A-K$"KPU(?3H9H0@+`=-^`GER!"<(2AR2A[9K#S1J<<&RWD
MD)*,-0B@-]\-[T-2#<%<"/OF"%5?")F--%/(V'R%RV=H%WICZ1DZJ@6&F)"9
M]@&N98*60_G=[%$JT1W-42K<H4WUB286ZO)WX$0'T9,RD$Q]2M=OOBY*Y70&
M\YGY1W^D"H9IIQ40E_5#P5\MD^[#^^<CX0A6I)0`EB*"/WVWT@(P)[XS4M%=
MX4SW+3YZL8WEQ8('T/#@V"E,[D/220B5P.QX9B7&MBQ<_C`G3=OU(S=B9S[1
M@,G#8,;P;&$\<Q$9ZONI]S=4MXL[!!ONL09IAY#`H6\&K(<&3,GH(>HM:&F\
M1E`1S*'GU<)!$Z:G8FA8/!4:A")"GW\SFI!UX1M?\W3[4[H>!$,IJ0)EN>\^
MUX[:Q<I@?#>I%2`(%02^L%F[)3J*GOU7))@!/!$:&JD&9M$SJW#%JCWV`!T[
M"-*M)(0;L?F9$(0;&>\PN@YF!"\RG@:I!FC&GZB#VL7K,%1:UP%!J$%"J[!6
M2QP3H%J)S:^4`NP@'$R(BO@IDW:NF+3Q!JM%($CWBBU"QC'146ZJ3`F`JJ0B
MF$?/[":T82CV8!6CKU:<BU</H)&,NY!T,@J5<L6T74CDM.O!O>.XJ=@(C34(
M+S<$W-[R$8M!H+/Z?#"IZGY3?<YU".K`^TN\WCL6]4N1%(=#L\BK5W4W*>`K
M[OZW>&\:P[UI=\FX[A?@VO*<O11?LOJE/#6+0[&#K?8J@#S4>/&)/[35N;M,
M>ZY:N+#L_KN'"^H"KNWL%8!W5=5>?E!7J_V5]]/_````__\#`%!+`P04``8`
M"````"$`,F+EEF(*``"'-```&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;*Q;76\BR15]CY3_@'A?0W^!L6RO;'=-LM)&BJ)L\LS@MHT&:`N8\<R_SZGN
M^CJW:HWIS,LP/O>#<V]=ZE0WS?6OW[>;T;=F?UBWNYMQ=C$=CYK=JGU<[YYO
MQG_\^],OE^/1X;C</2XW[:ZY&?]H#N-?;__ZE^NW=O_E\-(TQQ$R[`XWXY?C
M\?5J,CFL7IKM\G#1OC8[6)[:_79YQ)_[Y\GA==\L'[N@[6:23Z>SR7:YWHW[
M#%?[C^1HGY[6JZ9N5U^WS>[8)]DWF^41_`\OZ]>#S;9=?23==KG_\O7UEU6[
M?46*S^O-^OBC2SH>;5=7OSWOVOWR\P9U?\_*Y<KF[OZ(TF_7JWU[:)^.%T@W
MZ8G&-2\FBPDRW5X_KE&!;OMHWSS=C.^R*S6;CB>WUUV#_K-NW@[!_T>'E_;M
M;_OUX^_K78-N8YWT"GQNVR_:];='#2%X$D5_ZE;@G_O18_.T_+HY_JM]^WNS
M?GXY8KDK5*0+NWK\43>'%3J*-!=YI3.MV@T(X-_1=JU'`QU9?N]>W]:/QY>;
M<3&[J.;3(H/[Z'-S.'Y:ZY3CT>KKX=AN_]L[9295GR0W2?!JDF2SB\NJ*F>7
M<V1Y)[(PD7@UD?G%/)LNBA-QI8G#ZYGO"#Y=P7@UD1\O>-(WKUN+>GE<WE[O
MV[<1!ASM.;PN]<<ENT)BNPA]X6Y9_FQ5L!PZR9W.<C/&)Q,-/V"4OMUFU>QZ
M\@W+OS(^]PD?]GBP'GJM==I:`BH`)BC`58'E^PE5Z"RZ"OO^]Q;P9>6"LO6P
M(;4$5``09<S-3Z"LLV#PJ?%SYGC?^^B/EEL=L38/SL75$2$J1*@23/)/J$1G
MP1#.`I;Q#!FG]TIQ+JZ4"%$A0J4@<5A*>BNR0Z^=.\;VG>X-,J<:+GDY'IR3
M#:LC1(4($41[/DY0.S-!@_`'=2$(.B=',$)4B!!!U!X2[/:3K+SPF^*']Q2=
MB=D;9!&V=S85[)V38Q\A*D2(O3Y;R-UPD6G],5+P8?8Z$[,W"+//!'OGY-A'
MB`H18H_4DOWE8@AYG8C)&X3)R\W0.3GR$:)"A,AG.$"$[-__['7>3-%":(_;
MY[)9(1KLO1S)&%($,4TM06)$YCAWG#T@6:]EV/`LD7L+<9=+68$)7+C`V@?:
M7(H@KD`K4E#!B4;W^D4T#<2-KB1-YV4YU5D$*8*8IM:;@&:WDY3=6?#<SV)F
MI"MLM8&XU5(6;6#8:A=HRU+DQ35HH0EJ.-%J(TLAS1[*NY-T=R9ZR"*HCB%%
M$'/2VO)Q3D:)0DX&XN47AXX'?=S0>X@_3=4QI`ABFEIA`IIZ^2M,_KD'4R-4
M(7\#\=)+E=8'$<T_7/H(4N3%_+7&"/YY-62?,&(55N#T*]SII(QGSLM.:AU#
MBB"N0.M,4,&)X=7>8D,V$`W*7.HU)B0:E`A2Y,4TM:($-(<.BDXC^!N(!F4N
M%1L3$@U*!"GR(O[X;$?\LV$GIBX5UV`AKD$*M_=RHQ)#BB"N08CB^Z.2Q\IG
M(1X5J=W>R],TN?PVH\B+:6K]$:,R2+MS(V3!9])"W&BIW=[+5V!R^8U&D1=7
M($3Q1*-CW<L-Q(V6VNV]/$T7:"%%7DQ3Z)[^3`X[B>:Q)EJ(.RVEVWM9OG4,
M*8*XA+-D4E\@B-W#0MQI*9/>R].,E%.1%]/4FB1&>F"GC;J%,^T$+]"9N53*
MW'GY$B)(D1>7D%#*;'XY0"KS6"H-I/<$?U$PEU+IO7P)?2X$6DB1%Y>@!4NL
MPB"QSW4BL8/W$%=P*574!`9TZQA2!'$%6K*""DYL+-I;T.PA;%VV7P]Y!-4Q
MI`@B3D5"&6=%=ROA?7I=(-.SD%_.!PMA8_.C<2GDO;9>I:M+68@#O:9R$6=)
M8Q%+HX'"QL90'4.*(.:4T$%[Y#C1V5CX"@.%G340-RCJK/$*.YL,],<`KD(K
MTH='MM#>8B9ZB#H;0;4)#+P40<PI(7SZJN5$5V.1*PP4=M5`H/C>O!JOL*O)
M0'\TX0J$[G67W<..HT4LBA;"SA#4((\?WLON)74,*8*X!BT_P63H&LS&<>;E
M8V&$+!!%"W$)\OCAO7P)L2B2%Y>0$,5!1]4BUD0+<07R9.*]?`4F5W!4)2^N
M(*&)`R[@BU@1+<3\Y;'$>WG^)E?(/X28/]++(1JV`CJ1V'D,Q!7(4TGAO'P%
M$:3(BRHHA7Z^OPEUWDS30+CNLP0>8JB.(440<SI+#LM8#BV$=?,[R$(>A[R7
M95['D"*(:6HA$CM(-@5XYOY1&D$+]@\+T=HOA#@^>"]?@,D53"]Y<0%:R(("
M3JQ]+WOA3=[20-QG?\CI;T9Z+T_3!5I(D1?3U-(4T!R^4Y=&Y,).&X@[[4\3
MI@3G9?G6-E?8Z="+2T@)9CX?</E2QGII(2[!2[<IP01ZOK4/M%4I@K@$H9<G
MAB76Q-)`/"Q2UKV7Y53'D"*(:28T,:LP;N=^*&-)+)VRA;N*%'7OY0MP@192
MY,4%:+$)IOU$G[6WV)`-%/:YE,)7.B=+J8XA11"SU!H3L!Q^\Z;4F40%!N*!
MEF</&Q@.M`NT52GRHA*JLY2O\V::%@H;G2UDI[V7Y53'D"*(:0HQ[,[:@[8.
M?;`2G;80=UJ>,;R7+\'D\LU7Y,4E"*%\?Z2K6`XM%'8:#^*)+Q.]EZ=I<@5W
M?LF+:6I1$C,]Z#"GMQO9:`.%C<ZG4M!MH.]J'4.*(*Y`"U!0P8E&&[D*U+`R
M$#=:"KKW\HUV@192Y,4T$VJHI^?,+;J*I=!"W&:IYM[+DJUC2!'$_(44#C^0
M5+%,6HA+D&KNO7P))I<?'D5>7(*0R1.3$HMA92">%*GFWLO3=($64N3%-)$^
M'.C_H],ZD]B_#<2=EGI>.2_+MXXA11"7@/1A"2<ZK;T%30.!A[N8R:=2#2OG
MY6E&D"(OHHF'>(GF<$'O,G$)%@*AH`2IE-[+E1!#^FGCKD/=F/<E]$\/]T^L
M;IO]<_/0;#:'T:K]JI\,1LVWUP[N'UN^GTWM<\O24I57>NL"A<A2P=(]9!Q9
M9K!TVVADF<,R3V:[A*73I2AF`4M7GK24B,&9+,&M1`R..@E+A4IQNDA9\.PV
MMMV4)8>ENTDO&50%+$4JID0,+C43V4K$X.HN94&O<1V5LJ#7N!9)6=!K'/]3
M%O0:Y^J$I4`,;J.E+(C![:F4!;W&[:&4!;W&#96$I42O<5LC94&O<2<A8<G!
M`%\:I2Q@@"]C4A8PP%<B"4N!]\$]_90%JX![TBD+>HW[I`E+CFS]MT5R#G*L
M=G^W.[+@??"E;RH;5AO?I:8L8("O+U,6K!R^%4Q8,L3@R:"4!3']70K)+4.O
M\2Q+*@:][A]#BF+0Z_X!'VG)L=K];2]I04AR=3)$X*G!U/NCTW@:+V5!I_$`
M7,J"3N.QLI0%G<;#7;$%/]>X2^="0,+_7B]S"M?#E,#ORJL[;-#Q&]_K3WH*
MQRHF%Q%KF%QVK&!R`;%^W4=EXM8"/P-Y73XW_UCNG]>[PVC3/$$,IMTW@_O^
MAR3]'\?V%6J%'X.T1_P`I/OO"W[PT^"W!5-]@^:I;8_V#Q0V<3\ANOT?````
M__\#`%!+`P04``8`"````"$`OZ17.\`1``"/8@``&````'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;*R=6U/;2A+'W[=JOP/%^P*R#017DJU@ZWY7[>69@)-0
M!W`*.R?G?/OMD:;5,_,7@\F>EY#\U/.?UO1<6T)Y_\\_'A^.?M\\[^ZW3Q^.
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MF)]<!F=7\TORQ%,[7>WO@7Y.U.XI>*$+TF#0!0^L\4H7I)]OJS&@``_M+4UU
M8)T!MX_ZRQMKI28=:J4[?MN=!I=<E/XBM0:+L[Y_>!HWH%8=*CVT>4^'OMEW
M]?7-_N;C^^?MSR.:/ZCS[;[?J-DH6"I9[N1#[6.W?ZG74W=7*I^4S(=C*D_]
M>4=#]?>/L[.K]Z>_T_"ZU3;7:!/8%BNV4&-)R:Y=$+H@<D'L@L0%J0LR%^0N
M*%Q0NJ!R0>V"Q@6M"SH#G%)XQAA1?_XK8J1D5(RX=:\9&$%S`L(67&3M@M`%
MD0MB%R0N2%V0N2!W0>&"T@65"VH7-"YH7=`9P`H(S1)_14"4S(=C^E,&37!F
M1^!ZL%'+SFAT89NL1I,Q2D!"(!&0&$@")`62`<F!%$!*(!60&D@#I`72F<0*
M&DW4?T70E`Q-EC3;CP'!J4X;^:(VFHQ1`Q("B8#$0!(@*9`,2`ZD`%("J8#4
M0!H@+9#.)%;4J`FMJ$UOOG@94M9]<+A1KS6A%5;"%;CKSFC$Q=9`0B`1D!A(
M`B0%D@')@11`2B`5D!I(`Z0%TIG$B@7U^3?$0EG;L="$=G9&+&;.;#8:C;$`
M$@*)@,1`$B`ID`Q(#J0`4@*I@-1`&B`MD,XD5BRH0[\A%LK:CH4F=BSF3BQ&
MHS$60$(@$9`82`(D!9(!R8$40$H@%9`:2`.D!=*9Q(H%;7O?$`ME;<="$SL6
M"R<6H]$8"R`AD`A(#"0!D@+)@.1`"B`ED`I(#:0!T@+I3&+%@AKQ#;%0UG8L
M!C+K,P/]&60%9`TD!!(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@G4FLAE?'[S>T
M?&]N-STCJL)8'\Z=<2!6XT!`%"**$,6($D0IH@Q1CJA`5"*J$-6(&D0MHLY"
M=GC4X=(]Z,_?J<R5SO\<?M8?SJFT!>8(7`<:V:%S#RIBQ077B$)$$:(848(H
M190ARA$5B$I$%:(:48.H1=19R`Z=.H::H?/O@8/AU&J%1R,[/)?NR!JM)#R`
M0I:_&J,?(8H1)8A21!FB'%&!J$14(:H1-8A:1)V%[/"H$Z<9GB&%=J(RJZ]$
M2I]5S8$TH,603U8YL)7*2=(B9:`UHA!1A"A&E"!*$66(<D0%HA)1A:A&U"!J
M$746LL.BCI1F6%Z)A3Z!FK'0:,C'#[$`M`X`A8@B1#&B!%&**$.4(RH0E8@J
M1#6B!E&+J+.0'0MUI'Q#+/0)U(S%@.8RZZQ43HS&!2%SN_#.GM36VFI!NQ-C
M4^&DID.QXJDO0A0C2A"EB#)$.:("48FH0E0C:A"UB#J-AE:U(Z8.GF;$C$EM
M_^W^]K?K+34GK?H3HVI.^7_]5$`?7\U`#L@*)*"U2J^I.8\JD*C-G-QH*%82
MM;$@HQBM$D0IH@Q1CJA`5"*J$-6(&D0MHDZCJ:BI(^K_'S5]T#6C-J#9?%ST
M5^KI%86(D!&B`(;?8+6@?<08R.#,V=.'6HNL.&J1R#.*!8G6S*TQ$2W#:N9D
M_%*Q8OE,Y!GE@@PMM\9"M`RKF9/7*L6*Y2N19U0+,K3<&AO1,JQF3O:F%2N6
M[T2>D#W@U8G:[#H3`YO."N/(U@=PLX\,:$;KX1CJV<Q-8ZAGC*K;T.0M5NX-
MKL6*70\118AB01[Y1*Q8/D64(<H%>>0+L6+Y$E&%J!;DD6_$BN5;1)V%[%#3
MBOF64"MSYZ0^H!E-MA+$F3.J5X$N:$WB&.HIJYES=`RUUNRR?[9\<35W^E7$
ME9D3#4P.,5MY74HFK5R7TM=<REA&9K6<D;?^@JVL>W'K+[E^&E!&$)Q#736I
MY0:A9BNO7PU;>?UJ#_*KF]0R_+)Z+*7C[!ZK=B.SBSYY<?ANI%>Q.[)&,^J#
M1ALZB]B*K?QSEECQL`PUFI_UO3:8!;,K9P\3L8FWY6/1-OPT6JO?;B6BQ1ZD
MC.R0.=O?C*V\3N0'.5&(%3M1LOS+S5"QB=>#6K0]S="(%GO0,O(V0\=6+SEA
M]TFR>L,L.E/F3N<;T-S85&DK0IX;7+/58MPNA8@B1B(?"_+()VPE\BFBC)'(
MYX(\\@5;B7R)J&(D\K4@CWS#5B+?(NH8]?)V7*F/6'']I9//3*DXX1[0W)Q%
M8"N\T@5?V5:SO-53W14B9*UAT0QF[V`[%K&0-3#<B25F(6^W3%C+ZU3*6B^M
MY!G+>%W*6<;K4L%:7I=*UN)VPFFZ8B&O4S4+>9UJ)K7<X+6L92_OSLS=36H9
M\;.[-OEE=6W_'E_U0;</#\B:LD;D&95KK36741DBBAC)H(\%>>03MA+Y%%'&
M2.1S01[Y@JU$OD14,1+Y6I!'OF$KD6\1=8PFIBR5@CS\[*9.:&Y<!V2?W>;.
M7F6E"\ZM;;_1V89W-K45G?!X^0T118CB@^03+)@BRA#E!\D76+!$5"&J#Y)O
ML&"+J+.0/815TM,,]:^M3DK%69T&9!WISF$CK(UHR,MV&3N`5O=.NJ'*`)`/
M^D07T!OM=N8VT@;JP<O+E<4LXW4IF=1RI]R4M>PIUSE199-:;B/DK.7UJYC4
M<OTJ6<OK5S6IY?I5LY;7KX:UO"%L64NOFQ#"CF7Z$[#=CU6>UNS'KRQ%0UJ7
M,I\\IURKGDK]QUJ*1N3I,6LN*+-MB"AB))-Y+,@CG["5R*>(,D8BGPORR!=L
M)?(EHHJ1R->"//(-6XE\BZAC-+$4J7RO&==?FY^&K+$5[@'-Z<<X&TSLGK45
M=831"K)`:YIS^JF'9B"Q<D==J*WX\`Z].V(#:Y"X`RYF*Z]+"5M96JY+*5M9
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MBA6'.D(4(TH0I8@R1#FB`E&)J$)4(VH0M8@ZC28>/,]I(K1&SR\M^[V*$T@E
MW+_DP2V]TE9&;-<:O?*Z@%BQ5H0H1I0@2A%EB')$!:(2486H1M0@:A%U&DU%
MC=;KOR!J2L6)VH`H8\$MO9J/R#O\!JM77A?06N;K`B+/-<:"/#4FHF58P>L"
M8L7RF<@SR@496NXR7HB6806O"X@5RU<BSZ@69&BY-3:B95C!ZP)BQ?*=R!.R
MIV@Z/UI=Q[]<J@<:;A\9D$IU&#LXY['N2A>T]WGN#:[%BET/$46(8D&&$ZY\
M(E8LGR+*$.6"//*%6+%\B:A"5`ORR#=BQ?(MHLY"=JC?EEVD%"^$6F<7K2T]
MO"[`!;W'@[58\=V$&M%>7OW>>7#^;NYDR2,N1+.+]#4WS#%;>1U(Q(H=2%]U
M(.-"7@=RMO(Z4+"5O%90L@-TC)#[FSFM4$E!P\IMA9JMO$XT;"5.M`<YT4G!
M:2?LKJ=RA.:F7&TKWOS<7SUQ<R>?`:DMJ-%@;KI3%WQM\M%:1KY;%Z3]DNJ1
MYY>+A1.+B"V\K1P?Y$`B6M(C!Y_4_&W<G^-$)@4-*[=#Y`<Y48@5.U&R_(NM
M4+&%MQ5JD?:XV8@6.]`R\K9"QU8O.6'W2)K#K![YRKJGS)V]T8!HOF4_5^J!
M"EFI*5BBY<9AS5:2F@L118Q$/A;DD4_82N131!DCD<\%>>0+MA+Y$E'%2.1K
M01[YAJU$OD74,>KE[;BJG)D[TP3G_2]Q'/Z&D<I.NN'6R3@:D&-L,6^I"ZI'
M?*,5YBU9WNJI;C(N9*UA.;R<S]XY\UK$.M:X</M;S#I>GQ+6\OJ4LM:+2W3&
M.EZ?<M;Q^E2PEM>GDK4&GR8FZ8IUO#[5K./UJ9G4<F/7LI9W(>]$BZ80NQNK
M1**O&Q^6M:04(_3C`5G3UHB\G59;26(NU/)&(C-B)`,_%N213]A*Y%-$&2.1
MSP5YY`NV$OD24<5(Y&M!'OF&K42^1=0QFIBV5(+1C/<KRY'.1QI92TH+]*&F
M*(TS3W#ES!@KL>)%:XTH1!0ABA$EB%)$&:(<48&H1%0AJA$UB%I$G86LX:C2
MB%9X^OWK^0DM!F_\OE:O9&\D&%E[V+GS:P<KL1HCARA$%"&*$26(4D09HAQ1
M@:A$5"&J$36(6D2=A>S(T=IA1<X_L%3FT5GX-:)W2KGA5XC6B$)$$:(848(H
M190ARA$5B$I$%:(:48.H1=19R(X%K;]OB84R=X:*1O90<7Y?9J6RCJJ@\;0&
M48@H0A0C2A"EB#)$.:("48FH0E0C:A"UB#H+V>&AC8\5'B/W_\JH426=2`W(
M^&7GU0+0&E&(*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z"]EA>5O:;H%I.T;&
M[S\C6B,*$446LOU4J8K#MS#4,Z#/#(B689EI1R2[&CQ/:2VU"HQ[GYG[FT6A
M6+%\I-%0HWTW;G[`&`R'GR,7F#;0R+I)G3:0^UYK*S67RAT%3MXG%"NY(U/+
MOJ.ID_&LW\.\,KKQ,+P8D)WSG[N_-\96%$/C)IPMZ7K2RCU0A=I*9^*"<_?[
MBA$;V"TFE=EMH<XR9E_]M>@.)R+S[:;%@-1HEEN>.[\$M])6ZDLA8N6>V]=B
MQ=$-67[1YR,OW#<MN02M?Y.Z=ANH`P.W`?6:5SJ!/EX8)X[%@,R3I*!I!X87
MB]E*<CPAHH@1'I;.S=TX>?Y+P>M%[#5+(Z=7.V]EK;252D%--O)PCZQE]7WH
MU:SUTGM-$1N\U%.LB-(WM*V(NNUR6,Z@5W$:1@G;KVAJJU=2G6PEQ^(04<3(
MB/3P+>_A`\>/F^>OF]7FX6%W=+O]H;[338O0Q_<C'CXB?KV@KXC3?$EC!:[,
MZ$K_@`.NS.E*7ZU[Y6K9]=.QRX.S94<?9YJH):#Z:41/7:'ZZ>WGJ2M4/WWY
M9.+*G!P8U@C'`_I8^J=I+9*:4J+*)^VIZJF:/RV6GR@@$RXMJ*VF^#E]O7V*
M7RR[?K9P;N#Z<ME=3MF_6W9]/W'LU_/9,J0'(.@1/?-?II-7Z-G\LIR\0L_0
ME^WDE>O%^?*:5E2L9T575I-7UG1%[2NP#*W@=&5*C38=RVCRRO6".A=M8E"-
M7D"C*$YVR/G9\IK>#)DH0U?4.S9XA5Z.HC:8JH=>P*$K4V7HG2'J+U-7K@-J
MMV$-=")'7W99KB:OT-=<ENH[)A.^!1=T9:K=Z",GU,.GKJR#RZ7Z]`2JT4<D
MENH3$7B%/O:P5)]RP"OT40;RH+]R.MX0_7<`WV^^;LJ;YZ_W3[NCA\T7FH;.
M^J<*S\-_*##\8Z]?)OV\W=/_`T"S**U.]!\_;.C[3V<J6_1EN]WS/ZCJT_&_
MDOCX/P$```#__P,`4$L#!!0`!@`(````(0"YSF_\``\``&Q0```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;*R<VW+C-A*&[[=JW\'E^QU;)]M2C2<U
MEG@^L[*[UQI;'JMB6RY)DTG>?ALBFDW@IV`YV9LX\['[!X@&&@>*_/S+'R_/
M9[^OMKOUYO7V?/#I\OQL]7J_>5B_?K\]__>O_K]NSL]V^^7KP_)Y\[JZ/?]S
MM3O_Y<L___'YYV;[V^YIM=J?D<+K[O;\:;]_FUU<[.Z?5B_+W:?-V^J5KCQN
MMB_+/?US^_UB][9=+1\.3B_/%\/+RZN+E^7Z];Q1F&U/T=@\/J[O5XO-_8^7
MU>N^$=FNGI=[JO_N:?VV8[67^U/D7I;;WWZ\_>M^\_)&$M_6S^O]GP?1\[.7
M^UGT_76S77Y[IOO^8S!>WK/VX1\@_[*^WVYVF\?])Y*[:"J*]SR]F%Z0TI?/
M#VNZ`]7L9]O5X^WYU\&L'EV=7WSY?&B@_ZQ7/W>=_S_;/6U^!MOU0[I^75%K
M4YQ4!+YM-K\IT^A!(7*^`&__$(%R>_:P>ES^>-[7FY_A:OW]:4_AGM`=J1N;
M/?RY6.WNJ45)YM-PHI3N-\]4`?KOV<M:=0UJD>4?M^=#*GC]L'^Z/1]=?9I<
M7XX&9'[V;;7;^VLE>7YV_V.WW[S\MS$::*E&9*1%QJW(8/#I9C(97]U<DXK#
MDZX>BJ>_/<4['*^T(_5C[7AJD5/M27^UYW!T6F4'%)U#;0?26J>6.N`V4O_S
MT7*I79MRZ:X_>+>#:_:E_]&^W0@[FGA`;=L4>W(C7S2]Z]!9%\O]\LOG[>;G
M&64`ZC^[MZ7*)X.9TN5NVA3?=MQC_98ZK%+YJF1NS\F?NN2.!MOO7P;7EY\O
M?J<!<J]M[GIL3(LY6ZC1H&07-O!LX-L@L$%H@\@&L0T2&Z0VR&R0VZ"P06F#
MR@9U!UQ0>-H84:?^?\1(R:@8<>O>,9"@#:V`L`6[+&S@V<"W06"#T`:1#6(;
M)#9(;9#9(+=!88/2!I4-Z@XP`D*9`@(RHAS4G]MYC"@ORN*=,3(<W9@-?M?8
MJ'FB'4A7ILF\-6F#`L0#X@,)@(1`(B`QD`1("B0#D@,I@)1`*B!UEQ@QHM0,
M,5+M^L'$IF0H-U)^;P."F4T;N:+6FK11`^(!\8$$0$(@$9`82`(D!9(!R8$4
M0$H@%9"Z2XRH41,:47./*&5]"`XWZITF-*6VX1J.IM8(:HW8;0'$`^(#"8"$
M0"(@,9`$2`HD`Y(#*8"40"H@=9<8L:`^_X%8*&LS%IK0<DYB,;86!?/6J(T%
M$`^(#R0`$@*)@,1`$B`ID`Q(#J0`4@*I@-1=8L2".K01BV:9]DDMXMU#1#F:
M86G(N-ESJ%76',@"B`?$!Q(`"8%$0&(@"9`42`8D!U(`*8%40.HN,6)`JULC
M!NZ&5]9FPVO2[-`.#0]D`<0#X@,)@(1`(B`QD`1("B0#D@,I@)1`*B!UEQ@-
M3QGD`PVOK,V&;\AHVJY\YRWII*:!M19;-$9C6M=U\M?`G$N\UHCSE]]J,PE:
MTA&R2PM;H8[1>&26%K5&K!VWVDR2EG2$[-+25JAC9)>6M4:LG;?:3(J6=(3L
MTLI6J&,TOC;OK6J-6+MNM8D8'4+M]S_0(P[F9I?0J-LG$"TTLKJ`M4GRQ(IK
M[J-6@"@4QVZ[C,UVB<2*Y6/42A"EXNB0S\2*Y7/4*A"5XMB5MP91)58L7QM:
M9ES5#AA/(P[3W/YI??_;W8:&(AGUI-X1G3KHLXAF'TUK=B[R;M`@(]R`%MIJ
M+!G:0^2C5H`H%,=NZTSLV#:5Z)08HU:"*.V7M[:*F5AQ2^2H52`JT;%"5!N.
M9B#5SKD;R)Z`T3%F&[%FHVU$K$%C6A%ULJ^]DE?G?93LU8FH6-GI9R%6W`P>
M(A]1(,@A'XH5RT>(8D2)((=\*E8LGR'*$16"'/*E6+%\A:@VD!EJM0/_0*CU
MAKT[.!LT,H(XL3<*ZGA6S>LT8ERA;JWX;CQQ9.0C"@0YY$.Q8JT(48PH$>20
M3\6*Y3-$.:)"D$.^%"N6KQ#5!C)#K;;MW5!W=B$?2,]Z\]_M`0T:TH0OL1U:
MR7(^T%9&/\'!WF<UM#*CI[7HT$Z=55]-1]:LZ[.!L[L%)U4I[-6RJQ2Q%:6T
M3B-8&2]F*V>]DI/JE?9JV?7*V,I9KYRMG/4J3JI7V6MEUZOB$H^%L&:#8U4R
M^S;U*J-OOS-C*7-K2=F@T:A==LS5>2-9$>J$%'NLMAJWCAX["O(9B7P@R"$?
MLI5H18AB1B*?"'+(IVPE\AFBG)'(%X(<\B5;B7R%J&9TD#?CJHY4_G[.T@<S
MW9S5(&/6&EQ"SFJLAN_T`"W?77AJQ^NC"4K[&,/2[EN!.KA6"R1G^:&VHDF>
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M6B<J\X&V<B:RA;:B[9+T`.W8)++!<#"\MK1]]CJ6R@X'+,%)-0A92VH0:30>
M'R:U@760%K.'L_3DI-)3T>+[S]B11I`,G:&UP,[%L6-E#[""M9Q!*%E+FJ!B
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M9*R>W2`CD;6HT]GMYEIHK9'\-,Y#Y#.25!`(<LB';"7R$:*8D<@G@ASR*5N)
M?(8H9R3RA2"'?,E6(E\AJAGU)#*:(HUXNS<\:J=JQ[5!8V/>GEB/1N?:T;W3
M7;"\S,@>(A]1H)'Z(VG3[DDA.D:(8D2)1NK/<?D4'3-$.:)"(_7GN'R)CA6B
MVD#FT%9'K]V%\3NA;DYJNRM@-2NIW8VY![(62'.V<J:WA;:BG,$K0`^1CR@X
M23Y$QPA1C"@Y23Y%QPQ1CJ@X2;Y$QPI1;2`SU.K,LAOJPQYH\HGP.T%O#CN-
MH#?HG6V/FJ;4NL79A1?:RGQ*9,^U'FLUD_]P.K5^B^"S#$T?Q\=+P#+.*H6]
M6G:5(M8RDIP]_<>]6G862EC+6:^T5\NN5\9:SGKEO5IVO0K6<M:K9"UC-6'7
MJV*M8R&L6>98",WN3*D$NG-W47+2#P]4#[;GK@:]\V1+.[ZWVM9:W836(/T8
M:S"YL7_KZK.TT9IV9`*V(KGC_3UD*YD\(T9&*V.WU=5T5B)A+6<E4K:22F2,
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M1#&BY"3Y%!TS1#FBXB3Y$ATK1+6!C"$\HB6%$>J_]$3JH&+U`"6L'FX92==Z
M:C37CNZ<OF!YR60>.S:9;#(>V\M\GYV.9;+F8)AUG*DT9"VI0*21?B!EEQZS
MA[/TY*324]'B*2UC1_=L(HZ.;%&PEK,)2M:2)JC8L8V!_2R@9J=CK6!V1;(R
MNJ)[W3I2YE:?:U!W-M%6A!Q-L&`K29@>(I^1Y.-`D$,^9"N1CQ#%C$0^$>20
M3]E*Y#-$.2.1+P0YY$NV$OD*4<VH9S:AMC?B^M=2C%*QPMT@==0DZSJ[#\Y5
MZ-5*P4A$]I)JH:W4UE^T[%'ML5:S4[L>#:_LQU%L<6RGIK/.*74*3ZI3I*WT
MXRB[RO%)%4K8RME(*5L9-V>7F+&5,>CMY7;.5H:6'9:"K9SU*K65.W@5:[7!
MN[%FHYHMCM7)3%?VD;6]'3OM:12M8*%?ZZ-L&:ES;:4J*-W3;JT%6\D#%P^1
MSTCD`T$.^9"M1#Y"%#,2^4200SYE*Y'/$.6,1+X0Y)`OV4KD*T0UHX.\&6]U
MBMS=[!S2V.'<^H,?!E`;;3N5:42[&HGOQ'I:.F='>1UQ@<A#Y",*$(6((D0Q
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ME4ZO>,[4"YP]'H,!7>G3"J8S]3HDNH33&;V^W,.I$/6.:]^5`5WITXJG,_6>
M)+HDTYEZ6Q(OW$UGZB50O#"?SN:]%Q;3&;W<C0[T4O!,O?+;=V5`5_H*\:<S
M]=HHN5RT'8B^]?:V_+[*EMOOZ]?=V?/JD4;0Y>%G,-OF:W'-/_;ZYS#?-GOZ
MRAME-/I&%WW5;T4?;KA4CUL?-YL]_T,5T'XG\,O_````__\#`%!+`P04``8`
M"````"$`9^AXAT\#``#J"@``&0```'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6R45MN.FS`0?:_4?T"\ESO.14E6FZ!M*[525?7R[(`)U@)&MK/9_?N.<<)B
M:&'[D@`^<SAG9K!G<_=<E=83X8*R>FO[CF=;I$Y91NO3UO[YX^'#TK:$Q'6&
M2U:3K?U"A'VW>_]N<V'\412$2`L8:K&U"RF;M>N*M"`5%@YK2`TK.>,5EG#+
M3ZYH.,%9&U25;N!YR*TPK6W-L.9OX6!Y3E.2L/1<D5IJ$DY*+$&_*&@C;FQ5
M^A:Z"O/'<_,A954#%$=:4OG2DMI6E:X_GVK&\;$$W\]^A-,;=WLSHJ]HRIE@
MN72`SM5"QYY7[LH%IMTFH^!`I=WB)-_:]_XZ\3W;W6W:!/VBY")ZUY8HV.4C
MI]D76A/(-M1)5>#(V*."?L[4(PAV1]$/;06^<2LC.3Z7\CN[?"+T5$@H=PR.
ME+%U]I(0D4)&@<8)8L64LA($P*]54=4:D!'\W/Y?:":+K1TB)UYXH0]PZTB$
M?*"*TK;2LY"L^JU!_I5*DP17D@C47]<#)UC&?HSF65RMJ#688(EW&\XN%G0-
MO%,T6/6@OP;FFS.MH_/Z+ZO@49'<*Y:6"UP(J,_3#J%@XSY!3M,K9J\Q\$ET
M&-]$'&X(E4!%F_0>N*"W$PVI&(H.H:A_+\=-HPHR-8:1*6`_A@Q,',:(,#9)
MDC%DL>P@AHUP;"/Z9U?=;*@@Z)]>&A$*._XV;WN-@7)VJ48FXC"+2*80A@MX
MS?\70P5M;4A5IS"(5Z;&O<8L=#OYT=!"?SD.P]<<Z][I+R^]Y6NO&>(AW7WQ
MTQVDP*9HA(8MI#'P\L[84/<L(IE"&.J1J5Y]O/,-I(+F&DACIES,(I(IA.%B
M,78Q_S6K(+,6XP;2&-0V4!AX@U(=^LO!<C7XU)/^<KA`K]UIB%='?&__G&X@
M!39%(S38/O8:,Y7Z640RA3#4KTSU;VL@%3370!HSY6(6D4PA#!=P]!M%4#;F
M.ZB-,JLQ;J$K2&]"P2H:-,G!7(^&FY2:2E2R='P$YWVWQVD'>N30)W)%^(D<
M2%D**V5G-4[XT+K=4SWJ[-6HTPXKW0),&@T^D:^8GV@MK)+D$.HY"]A&N)Y5
M](UD37O^'9F$&:.]+&"F)'#2>@Z`<\;D[49-0]V4NOL#``#__P,`4$L#!!0`
M!@`(````(0!N6R.)N@(``),'```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;)1576^;,!1]G[3_8/F].)"0-"BD2E=UJ[1*T[2/9\<8L(HQLIVF_?>[
MQI1!D[7LQ>#+N>?<#_NRN7J2%7KDV@A5IS@,9ACQFJE,U$6*?_ZXO;C$R%A:
M9[12-4_Q,S?X:OOQP^:H](,I.;<(&&J3XM+:)B'$L))+:@+5\!J^Y$I+:F&K
M"V(:S6G6.LF*1+/9DD@J:NP9$CV%0^6Y8/Q&L8/DM?4DFE?40ORF%(UY89-L
M"IVD^N'07#`E&Z#8BTK8YY84(\F2NZ)6FNXKR/LI7%#VPMUN3NBE8%H9E=L`
MZ(@/]#3G-5D38-IN,@$9N+(CS?,4[\+D>HW)=M/6YY?@1S-X1Z94Q\]:9%]%
MS:'8T";7@+U2#PYZESD3.),3[]NV`=\TRGA.#Y7]KHY?N"A*"]V.(2&75Y(]
MWW##H*!`$T2Q8V*J@@!@15*XDP$%H4_M\R@R6Z8X6@7Q:C8/`8[VW-A;X2@Q
M8@=CE?SM06%'Y4FBC@2>'<E\.96$^(#:_&ZHI=N-5D<$9P8D34/="0P3(#Z?
M$&3BL#L'3C&<:8C50!,>MW$<;<@C5(YUF&N/@;7'A#V"@&BO#&K3E1W8*;O2
MNE"NO6$H\S>0D<S\?V0<.,6P]L''\;P/WRM[S&*`6?:(D3)`IB?HP-"#Y8#V
MM+8>-$$:#M5T:0=NI?OB=A:X)H,Z+,YG"1$/I=J;L8"^O'V2G-=8L[,,.QK'
M\7G-U:GF/%X%*XC[;5GG.);M+&/9?S34#?/!77&I1LO+X%U5YS=6[2QCU=7Y
M9->GJN%J[>;,.\DZQ[%L9QG+7KZ2]4/0#PG)=<$_\:HRB*F#&W`17/O>VL_>
M7>1NYFO[(MFU,YGT'V`F-K3@]U07HC:HXCE0SMK&:3]5_<:J!B*'R:@L3,/V
MM82?'X>;/W/USI6R+QL0)OWO=/L'``#__P,`4$L#!!0`!@`(````(0`]FX$I
MI`\``!93```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*R<6W/;.!*%
MW[=J_X/+[VM;E.38JCA3L<3[G36[^ZS8<J(:VW))RF3FWV^#1*L)'!J6LWF9
MB3\>'#;1``B`%#_^]M?3X\F?J^UNO7F^.1V=79R>K)[O-O?KYZ\WI__^/?C7
MU>G);K]\OE\^;IY7-Z=_KW:GOWWZYS\^_MAL_]A]6ZWV)^3PO+LY_;;?O\S.
MSW=WWU9/R]W9YF7U3$<>-MNGY9[^W'X]W[UL5\O[MM#3X[EW<7%Y_K1</Y]V
M#K/M,1Z;AX?UW6JQN?O^M'K>=R;;U>-R3_'OOJU?=NSV='>,W=-R^\?WEW_=
M;9Y>R.++^G&]_[LU/3UYNIO%7Y\WV^671[KNOT:3Y1U[MW^`_=/Z;KO9;1[V
M9V1WW@6*UWQ]?GU.3I\^WJ_I"E2UGVQ7#S>GGT>S9N*=GG_ZV%;0?]:K'[O>
MOT]VWS8_PNWZ/EL_KZBV*4\J`U\VFS^4-+Y7B`J?0^F@S4"U/;E?/2R_/^Z;
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MO@T"&X0VB&P0VR"Q06J#S`:Y#0H;E#:H;%#;H.F!<TK/(4?4HG]%CI2-RA'7
M[BT#29IGIFS."BZRL(%O@\`&H0TB&\0V2&R0VB"S06Z#P@:E#2H;U#9H>L!(
M"(T3OR(ARH9&]%ZG\4879@9N.XVZ9QQZUJ4IF1\DARP!\8$$0$(@$9`82`(D
M!9(!R8$40$H@%9`:2-,G1M)HJ/X525,V-%C2>']("-U(S93<:I$K:P?)(6M`
M?"`!D!!(!"0&D@!)@61`<B`%D!)(!:0&TO2)D36J0B-KPS,GO@TI=9L<KM1;
M36A"<4B7-_I@IFM^$'&Q!1`?2``D!!(!B8$D0%(@&9`<2`&D!%(!J8$T?6+D
M@MJ\D8MNKG"F9F;NM*B"9EHZ,NGFO.I6/P>R`.(#"8"$0"(@,9`$2`HD`Y(#
M*8"40"H@-9"F3XP<T&31R(&[XI7:K'A-NA5"6_%`%D!\(`&0$$@$)`:2`$F!
M9$!R(`60$D@%I`;2](E1\32W?4?%*[59\1T97Q^F7_,#Z0]-5^;0M.A$$UK=
M],:O:U/D'T0\?@5`0B`1D!A(`B0%D@')@11`2B`5D!I(TY&N%HWTT`!OI*<W
M-NV_K>_^N-U0_=$$>Z"_C&F]TJUBE(F9M8[TLP9DT9$)F4N*/&L>YQ]$AQ0!
M"8%$0&(@"9`42`8D!U(`*8%40&H@34<&4J26Z/]_CEH7,TD:>6/I6X)Z21G9
MG4NK:`=(5*.+J=6[1'7(G=@S"@6)EV>?,1*OGLJSUL&QJ-@^$7M&J:">EWW&
M3+QZ*L^:L.:B8OM"[!F5@GI>]ADK\>JIO+%9J[6HV+X1>T)&[QZII7%_FV*@
M&]-F%O?C5FZUD6YQ[=%$L]=+)V90<UU0[8N)RK[`A:@X=!]1@"@4Y+"/1,7V
M,:($42K(89^)BNUS1`6B4I##OA(5V]>(&@.9J5:+[G>DNENCTWJ,3W>K=@!I
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M,-NDVE#IM\DW;IAZ_Z4_BG9HW)]4'9#C`A?JF0@UY/&DU](`!:P2^U"0PSYB
ME=C'B!)&8I\*<MAGK!+['%'!2.Q+00[[BE5B7R-J&+7V9EZIEQMY_:EUCMI.
MML>:#HW[HPA,A>>Z(,VT'1>Y8'NCI=IW")^]NIOFR+OR/+AMZCB-CF'WJ)"-
MG$%%1P45L]=K=_*$;9PAI6SC#"EC+V<]Y>S%]83#=,%&SJ!*-G(&50UZV<FK
MV<N\O5LC=S/HU<N?V;35GM<[AJQNB\R8^'7(&+(.R-E@M4IZI:\V^,U1+&`D
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MPS;M"MALQVH/L]^.WY@]=UN>1H/5NZ`RVLY'!]3+GUT#"U;):.LC"AB)?2C(
M81^Q2NQC1`DCL4\%.>PS5HE]CJA@)/:E((=]Q2JQKQ$UC%I[(Z_>+]F!;EW,
MW46-QG0G.?1-G#VSRGV'TBIS#]+N=3Y[Z54K#E`L,#J)W=Q"5CE#BEAE>-DA
MQ:PRAD08H%AE>-EQI:QRQI6QRO"RX\I9Y8RK8)7A9<=5LLH95Z55[A36[/5:
M"AL6M`]KS89,41H#E'VC_7WS0BUT\'$71<7[Y)ZRL5IRA_IS:*TB)(T;GFPL
M6"7OE_F(`D;2]4-!#ON(56(?(TH8B7TJR&&?L4KL<T0%([$O!3GL*U:)?8VH
M830P<%';-?+MOB%Y2F[E5:/>@W]6R2/I!2(?48`H1!0ABA$EB%)$&:(<48&H
M1%0AJA$U!C+['O6#]^1"R:U<=*C_5%GMJ)"*D*,9+;3*?!M@;#T]]$7%\^<`
M48@H0A0C2A"EB#)$.:("48FH0E0C:C0:>/"L%HY&QNS1\JB7`UH7*Y%Z7U-Z
MT%RK>KE=:/3&"P*BDJQU]E2048BJ"%&,*$&4(LH0Y8@*1"6B"E&-J-%H*&MJ
M\Z\_"?^YK.DMQ-YB4MV6J:]1>^%JG0MR=K^NX!NO"VBO[F<E[:9#(/9\QE"0
MXXR1>/54\+J`J-@^$7M&J:">ESW!R<2KIX+7!43%]H78,RH%];SL,U;BU5/!
MZP*B8OM&[`F90S1-SXRF\\;M4LFMGMTAU3H/$WK8GYZK_0C5DJA=B,J^P(6H
M.'0?48`H%.2PCT3%]C&B!%$JR&&?B8KM<T0%HE*0P[X2%=O7B!H#F:E6FW?]
M4>*-5'=[??VENJ>W_RB7DD1X74"KS&TC3+6VEQ';9WO>AK@:6[OD`5L;ZQ/;
M.F05S<\E3%L5B8JK,WXS@(0+.0-(6>4,(&.5O%:0<P#F!I%5"X44=%Q?R2IG
M$!6K)(CZJ"`:*3@<A-GTU'YCO^FI&]2[G_M[RL4:?#KTQG-_7?"MP4=[]?:[
M=4']W'_Z83*Q<A&PPEG+X5$!1.(E+;*+:6RT-\\*(I&"P[GHWEDY*HA,5!Q$
MSO;=ZGN@%@I6.&NA%&M'F)5X<0`U(V<M-*QZ+0BS1:HMQGZ+?&,P['8DC<'P
ML$G)<<Y5,Z0&^M;R7ZMD:\[G@H("1C+U"@4YZB]BE7C%B!)&8I\*<MAGK!+[
M'%'!2.Q+00[[BE5B7R-J&+7V1EZIJYIY_:FI<.MBCC0:O?'47ZO4`NOU6\^"
M[8V6:F_&^>S5W0X_C+TKZS%.P#Y&O[!O="'[.&.*V,L94\Q>K]ZB$_9QQI2R
MCS.FC+V<,>7LU<4T-#RQCS.FDGV<,56#7G;N:O:BX5O:@3UN-^)%0XC9C.F2
MC>');L;'[5J.E8W5CCO4W[74JC>&+5;)QIR/*&`D'3\4U*L+NY5&K!+[&%'"
M2.Q300[[C%5BGR,J&(E]*<AA7[%*[&M$#:.!88N:YD"^^9L#1_^X7$T4NH1+
MM--+ZX7R6U;U%V/6B[IST?#M;8'(1Q0@"A%%B&)$":(4488H1U0@*A%5B&I$
MC8',CDNC!R12]?-W?B5`=4:[YVK4S]KTTGH1;,X%91:[0.0C"A"%B")$,:($
M48HH0Y0C*A"5B"I$-:+&0&;>'!N?[JDAO;T)F=*[D9*#N5;U?L:Y0.0C"A"%
MB")$,:($48HH0Y0C*A"5B"I$-:+&0&9:U#[B\=-T-3NS>XU&LL\P9Y6@!2(?
M46`@,TZUO?6..+O=L/YR0KV,1:'W=L/G@F0PQZ>)6F4]Z;"&!5]4/)P'8@^S
M#WNGR)Y]'/440#WBMY/1(>,B`2UT0?,IP,A:]/JBDBOJ>YGY4>OH?G[:#8CI
M&36.-WIWMP`W,M4A<\-S;/]H9JQ5=`:9`=JSGL6@RIY-^EI%MQ'UN9C1U/[T
M1<`"8Z+<.YE9%VK]:=?%:-K^./WX'V%0#B&['9H8$^@Q3"QTP==B[5X^9'OI
MH[Y&DTGWTR'[-3,N\=HDWZ@#U5N,.G"W@E9NSJ,UHCL*-[^Y(%?*624K7!]1
MP`BGBJI;&*'_5.=L7:PKZE8&5KNV?H<TUP75X.%HUUIE[KA!NV8O;M?PZB`+
M7FLK9DZ'Y]#2KH];,ZEG5M:PI9&1ZTZE)A2N:M`J61;X["4H8-3+=?>9M.[S
M4T^K[=?5?/7XN#NYVWQ7GT"CRO_T\8#U]]G&WNPS.5%KM([0='^F9JQ#1\9T
MI#TME)G0D;:)6D?H.W"?![WH^W!M9[7TMW3R0;TZ]4!,GR>SS[1.&@B6(AH*
MZ'8Z:]J)EGWBRUG3/LJT^,*;SGQJF'@&>H8XBP>/T+.^63YXA)[)S>K!([?C
MR]DMW:3P/'1CG\T'CRSHB+I58QFZ*=*1(3>ZC\^"P2-S3]7]8.5[X]DM=70\
MSYR.J"?S>(1>J:`K'4H9/;:G(T-EZ$T#BF#HR.W5[+9]%\#*SOQJ-A_BBZM9
MW7892[^XGM5#^N9JU@SQQ>ABYM.OI_'ZZ`?G,_5S<CQ"/PR?J9]]XQ'Z`?=,
M_3R;CIP?`J.O$KXLOZ[RY?;K^GEW\KAZH"Y[T0Y#V^Z[AMT?>_WBV9?-GKY'
M2&,Q?5*.OC^YHD^\7*B)R<-FL^<_U`D.7[3\]#\```#__P,`4$L#!!0`!@`(
M````(0#?"'K>3`H``(\T```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;*R;V7+BR!*&[T_$>0>"^S$@%F/"]D2Q[_M^1V/9)AJ0`^AVS]M/%E*64/ZR
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M7>(N09X>[Y\V=`;ZLL<.]O-#7*4*JIZRXHG'^_,5FF[L]^/%=NSXZKS7#ING
M]F9OT^6F1.D4_'"<G]JT\:01'9R`HZOG%/0/L2?[>?5K>QHZ[W5[\_)ZHGQG
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MO],CTEPT>N/38A+N7?)\TRVO3JO'^X/S'J.I#`V'X]M*3XQ2!>V9;[?NS='<
M@#^Z_]*-5WM1VLU#G%)/M]8CS1I^/V;O;N\3O^E&O_9LBFB3"EJ4V$+?U;7;
ML@05":H2U"2H2]"0H"E!2X*V!!T)NA+T).A+,)!@*,%(@K$$$PFF$LPDF$NP
MD&`I@3+IY<0HDTQ#('D*LJ<@?0KRIR"!--WTBHMB):AL3>W2J/Q_U*YVHVN7
M3Z7(P"]F2Q0J6_`A90DJ$E0EJ$E0EZ`A05."E@1M"3H2="7H2="78"#!4(*1
M!&,))A),)9A),)=@(<%2`J6`F&1RJE0);"!["M*G('\*$J@N,Q@H5.K[4*CZ
MUA3^3,,]51]%3R^7/36=#!9BT;71ST>F\>:")B5CPE>@#*0"I`JD!J0.I`&D
M":0%I`VD`Z0+I`>D#V0`9`AD!&0,9`)D"F0&9`YD`60)1"E$?IHYAPK3JC"O
M"A.K,+,*4ZL"N0W4,LT1H)9U_7URPJ#=T)R#YIRF<+-W^6#I%CVCJ.HV)GQE
MRD`J0*I`:D#J0!I`FD!:0-I`.D"Z0'I`^D`&0(9`1D#&0"9`ID!F0.9`%D"6
M0)1"Y*>9<ZA*:(5Y59A8A9E5F%H5R&V@NJG4`M4=W:&U];F(67C1(_3P<E'6
M=\&R+ADC/JP,I`*D"J0&I`ZD`:0)I`6D#:0#I`ND!Z0/9`!D"&0$9`QD`F0*
M9`9D#F0!9`E$*41^HCF'"M.J,*\*$ZLPLPI3JP*Y#=0L]=!/U*RV#M:L1]P5
M4/W850)2!E(!4@52`U('T@#2!-("T@;2`=(%T@/2!S(`,@0R`C(&,@$R!3(#
M,@>R`+($HA2B(B),J\*\*DRLPLPJ3*T*Y#90H+2,&"A0=XWA1B]AGUXWZY]%
MAYHE/>2%--LTK26X*PS:2;!N76*ES8-;R1"_^UHI,:DHNT:9U'F5PDJFTL'N
M7#'[>617@=2`U($T@#2!M("T@72`=('T@/2!#(`,77)Q`4=`QN8HO:9#5TL\
M"4_,?KY:4R`S(',@"R!+($HA*B+RJH`2S)*4GW.#,,T*\ZPPT<K+M'O5`F5.
MJU_?+W/M)%CF+KG(4LF0J#)WC3+TL.O/1-*RUHT17Y>J\<VD!J1NCKITG0D.
MHX8Q8D=-<-0"TC9'7;K.!EUWC!&[[H*C'I"^.>K2M7A8'A@C=CT$1R,@8W/4
MI6MQK2?&B%U/P=$,R-P<=>E:7.N%,6+72W"D%**B.>[2N;C:RBLWJB3VKLKH
MJX+(JR51@N***Z^^+MU[!18RQ&A>'1AB(7<,>AG"MPQM'1Q++M&O72X&A5BG
M+GE&^N[$B]EX%PDSLL2Y55PC6NG1S3.3LT1)5+W]=.O[.%+-1.++7S?DXC`9
MNQ&(G;M+BYII7A.[92)Q[+8A$;$[@=CT[EU<X>XUL7LF$L?N&Q(1>Q"(G<OG
MQ,/7\)K8(Q.)8X\-B8@]"<1.6QF1[^DUL6<F$L>>&Q(1>Q&(G<G>BGPOKXFM
ME`G%P571H(CHRALT7.IW,N6J?%5\;\30&#;QO4%"*"J^-TJ\^/F[M'BUI+Q!
MD_YHK`7NY/H[!I_H,V?S8*/Q4(;6\LS0SJ;%5+3$!WXDRGL)IM60^X"5'.\5
MSY=U>VXVJ536$M&J'.UR2@"-K<96_O2I[B/_9"PIH"$$6)FDF"LVV4^D@!9;
M^0+:/HH0T!$"4OF<Z,==]A,IH,=6OH"^CR($#(2`;%(V@"'[B10P8BM?P-A'
M$0(F0D`R*Y,T93^1`F9LY0N8^RA"P$(*2,NGKR7[B11`+QQ-S9M&4/19A`3%
M@XH'0O(V*6X!]&+2\QXM@H<4#3PCP@RBR,%(+S'=""S"2B?%FQMZJ_D_1`0[
M$L7[3$?2YJ(CN2@P][D3HDJZQ]!QP68K<U@.M9*E5O&L,O2$=M$"12ZJGE6@
M+Z?E5P=J?D3.1-U'OON0IN2>4%!$1IQV\RH1+3\BBVC[*$)$Q[,2(L0=JGN5
MB)X?D47T?10A8A`N0K3HX54B1GY$%C'V482(2;@(.4VZ2L3,C\@BYCZ*$+$(
M%R'G2U>)H$9E1@RKH.]&&!8A@QI5:&W*QR\>;=$CA+Y:88(:(3RX@L-9#E1J
M5J%"Q,V3&I9K]J&08,.BWOJ9AJ7-1<-R47`*E1&/$B7]/4Z8'&''"K.2%Z+B
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MZR)OYPNT)HN\GR_0@BKR<;Y`JZ'(Y_D"+64B5\5\02]#ANRITAY:0:0]"7/6
M]&N0M]6+W5D=7C;[8VQK/U,:D^?730?W]R3N/R?GC=)+OPEQ3O0[D//F*_WP
MQZ8WH,D;6FYX=IP3_Z,#F)\2/?X+``#__P,`4$L#!!0`!@`(````(0"['@$-
MQ04``,0<```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)1978^B2!1]
MWV3_`^%]A,)OHTX&*KT[R4ZRV>S',XVEDA8Q0+<]_WYO<4O@%EJ%+VTKA^LY
M]Q[J@+7^^IF=G`]1E&E^WKALY+N.."?Y+CT?-NX_?[]\6;A.6<7G77S*SV+C
M_A2E^W7[ZR_K:UZ\E4<A*@<JG,N->ZRJR\KSRN0HLK@<Y1=QAB/[O,CB"MX6
M!Z^\%"+>U2=E)R_P_9F7Q>G9Q0JK8DB-?+]/$\'SY#T3YPJ+%.(45\"_/*:7
M\E8M2X:4R^+B[?WR)<FS"Y1X34]I];,NZCI9LOI^..=%_'H"W9]L$B>WVO6;
M7ODL38J\S/?5",IY2+2O>>DM/:BT7>]24"#;[A1BOW&_L14?CUUONZX;]&\J
MKF7G?Z<\YM??BG3W1WH6T&V8DYS`:YZ_2>CWG?P(3O9Z9[_4$_BS<'9B'[^?
MJK_RZ^\B/1PK&/<4%$EAJ]U/+LH$.@IE1L%45DKR$Q"`OTZ62FM`1^+/^O6:
M[JKCQAW/1M.Y/V8`=UY%6;VDLJ3K).]EE6?_(8BI4E@D4$7@514)_!&;^+,G
M:HQ5C4E3@P6C8#%ETP%5/%15-XG'5;Q=%_G5`><![_(22Q^S%52^=0>U-/UZ
MU"[HDRSR35:I:T$G2ICQQW;F^VOO`^:2*$R(&+BL&@RCB.B&D$.097GG`P_X
M-J2AC3KI,1CC_DAO'.5).D>-0=C'!!K'/F(\I1#>A\P7#83H@)'J.B8/K7G3
M(4\"$W;Z./,UEB%B8)Y-KV<-@[JUD17!30BB`KY&5V&?ACQIXT*K6H;^F'(,
M$4-4^!.*B>Y@*(*;$$0'=+ZKP^PF"=;Y:T8($3.IKP=_I*F+;D<['="8FQ"$
M^>P9YA*L,]?<$2)&,:>LHMNQQ[Q-",)[_@QO"=9YSRFW$#'W>=^./>9M0A#>
M\MZ@LVB:G2+!.N]V/:BOQA`QL]HIBXD_7<QTGW<12[:8C"?:S'@7L8##;-FN
MP(3]\AGV$JRS7VI=1PQV75M1H]NQQUTW(0AO!DO\\+;7:,I\.M>NP5"!R!)#
MQ45V"#="J`29:!WGR+BUK_@,<]"\Y"N040K6,4"XL0J5(F.N(\5\$3`,1;+>
ML]:?>!4HT!2O`W\TTRZ32`=,-;=Q!;BOD-*7\3:</H9AE_YTKB_WS)28F+IV
M"#="J`20V94PT$SR+-O]`T/0_3XJ*58(-U:A4F34#9\&!F-W&K.^F1#4F,G7
M5JU(/@1`(QH`ZYE)![0#I^1EW@TGC^E(R6M?'3)3A*K^6R'<6(5*D-'7D3#0
M2AB8EG7)E*I*BA7"F0E"I<@<[$BQK$N8FG0:O74)0:U3M-OMB&F`0`-P'3!I
M@XB2EV'8(2_G8+^79ABA5(1&(50@XR5MBN)Z5-Q8A4@)M+0>9JGZ+-OJI$`F
M*78(-T*H%"VUS98*,&7I-'1+*9!1@CVM5976F&U@4@%`IFLKBP")IG=.,]8:
MMC9"&"#(*,`*X<8J5(*6UP/MA)%L7J$"!!FE6"'<6(5*@6]Z8AH2K4^C9R<$
M&258(3Q`2&NG-I:H`!F,G57*8B>,43!#^ZC/M,>;4/X.!BJ-`JP0;JQ")6B9
M/=!.F+D6.UF#.0JL$&Z$4"DR&H=/`X.43J-G)P0I([0NP+@.3$?YHZ.4\U,A
M'=P+Z?9F3"U("#(ZR`KAZJON5Z$2[D2U_5$NP(BU.,B:PY&J<Y\G1K410J3(
M.XSA#JK1^H*D_1@1*A#AQ[1?:Z)[(/KTS8T0*N*ID![?"^DV/=%2"D1$4'Z1
M'<*-$"I!!F;G2AZV*(TQ9LV64B"C%*QC@'!C%2I%!F9'BCDB8/^GGW$]2R&(
M\&/Z0YVJ1$!T9'*SZ7'4H`C<3,)]DDP4!Q&)TZETDOQ=;A0Q^)FN^10WL4+8
MQ*IW?+SF`.PA7>*#^!$7A_1<.B>QAU/]T1Q2K,!=*'Q3Y9=Z5^(UKV#WJ/[W
M"+N%`O8__!&`]WE>W=[(?:YF_W'[/P```/__`P!02P,$%``&``@````A`!$-
MV5..!P``K2T``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULG%K;;MLX
M$'U?8/_!\'OMZ)K8B%/4+KI;8`LL%GMY5FS9%FI;AJ0T[=_OD#.E/10SE/F2
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MZB,(GO:B/VD%_FQ&FW);O!RZO^K7W\MJM^]`[@Q&I`8VW_SX6+9KJ"BDF<2:
MQKH^``'X.3I6JC6@(L5W_>]KM>GVBW&23[+[NR0"^.BY;+M/E4HY'JU?VJX^
M_H>@2)$R26)*D@![>AY/XH<LRG)_EBDRT@/\6'3%TV-3OXZ@:^`[VW.A>C":
M0V8ULAG4QSTR8*-B/J@@'0KH%N3X]I3'=X_3;U#"-6&6B($98#`Q1ZSZB"0S
MD"GP,R1AZ#;)Q$M2!7&226K2ZW$L$?*@RZP&MKKZ@!&`RMQ.0`6!TE<5R./(
M8H"8]!K#$2L)P3A"DMLYJJ#%&(9]42FS=%HBYE[K',4/<6R5<74-N$_BAP<S
M!$806OUV@BJ($\QCFR!B<B0(T\I\O59YA8^!I!EC;A",8-XGF$*P/!=4D$TP
M,?FQSQ#C9H`<)03C>-_GZ)\**LC7B8B1.$H(QE'9GK6F^#FJ(%['N->)B"&A
MXRB>V5(CP#T(1G'6I^B76@5QBKD]%Y:(<3-`J24$XQC!$G=['7643VP"231%
M".?I\!"_WA$N__+20R"1)^;!ILCNTW1F)A]GJ=;VF[LR0D>X9@EN:[X!IS>!
M1):8QPWA/-6"?SM/M`GX>5GD>F8325Z"S2E".$\82P!/%<7G4'^:1PA"2?.9
M;=LK]CS*'I*W)%<K_^VE1+_@DE\<@R273(5**4%X*1W&,V`"H6=X))>,A7A*
M$,XSR'PB]`U>3]O""?2FA]/S(?/'<A_9O:.^[>3QO3V_)5NA(DH07D2']0P0
M&UW#([9D+<13@C"><9#[Z"C?_";0F_.;/1?F=QQD/#J*4^QO*0G$^LWJV94+
M8SJ'UU*M_M9"E/M?8-`S^,2Y[*VUH,L808RH(8&:BQ#.4QF$Q=/?FS':BMR;
M!!)Y8AXWA/,$3`!/%<6%[WM/C"!&HB>\`V-JSHDZ'&B`\"X'NG@<"2_9"PDO
M03C/(`>*AS@0@5A!3;&(YV`'BH,<2$=YA9=>;XBG`W+I#5Y0RX74N8K_!2-V
MN%%BO>,L"206=+`;Q4%NI*-\[Q@$$GD.=B.U"MT^XW643W@"O>E&[+G@1DF0
M&^DH3C%/>J=$^(XCE9+RN"&L-1.'&:DQRALE'>63G$!N$CB'1`CG&61&"9H(
M-\W+)-4DE@1B/"W,RH4QZQ8G"GFN>]-32(6V!;>^?)D@B!$T7TZ%E""<G\.$
M!@B.YB&[>B(Y#/&4()QGD`DE:![7@O==G4#T>N$Z.6((X1@A"7(@'66)WCO&
M)!`3W6J,E0MC&H-7T^%`_JU'XG(@^SB30(RH(4&J#W:@),B!=)1W.9+LA7A*
M$%;/-,B!=!07OM^=!!*ZDQ#NBG.:#A?RRYZBP5Q/HMP^=ED2R$T"RRE".,\@
M%TI5E$]V`HD\,8\;PGD&N5#:=R&'[`ARDZ!Z(@0[0UB54DAR;4'#MILZBC=G
M?O4G.$UA22"1I?IVV-]>'SZ:]8!7,\B*U,;9K[KD,U1-"<)Y!EE1.L2*",2*
M9:_R,H8S#?*C%-]D^'RWSS@)Q)@:6:FBCC<B`^$\'7;DWX2D:",P"X1C;0*)
M/`?;41ID1SK*FDD]?R<0X]E3?K`?998?R;M.C;8()O8Y)X$80:,F"BY"F."9
MPXC\@NLHWP)/()&G],;$>089488&<CV!^@L\@1A/6W`9PYDJ,[CY="Y#"[EF
MVC_N)!#M0!Q_0L<D;"2F,SA)P-@D_?N/3$79[6D?=1+(38+:$_.X(9QGD!-E
M0YR(0&X2Q'.P$V5!3J2C>#T=[8EVQ7CVVM.!>4-XAQ$-$-YE1/919R:Y#!54
M@G#A@XPH&V)$!&(%-<4BGH.-*`LR(AWE%5XR&>+I@%QZ@Q54B6S/>/]1IX[B
M1//4/NHDD%10$<)Y!AE2CD8B[T`()/(<;$AYD"'I*%[/_HPG$.-Y4165ES&\
MHD&&E#L,*;5//`G$F%I3281PGI#&[E#_5B174;ZM"(%$GIC'#>$\@SP)+K[V
MO+.W]R007>+K&SP]ETCB[5B\/'HLFUVY*@^'=K2N7]3-UQANWYE/\5;N,IHO
M8W6WTOI\!;=U]>=3\P`NRYZ+7?FE:';5J1T=RBVDO)O<P]`:O&Z+OW3U65_I
M?*X[N":K_[N':]$EW-V\FP!X6]?=SU_4A5YST?KI?P```/__`P!02P,$%``&
M``@````A``&TJ7XX`@``(04``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&ULE)3;CILP$(;O*_4=+-\OAD`.BP*KC:*T*[72JNKAVC$&K&",;"=DW[YC
MG-"DJ:KL3<#AGV_FGQE8/AUE@PY<&Z':#$=!B!%OF2I$6V7XQ_?-PP(C8VE;
MT$:U/,-OW."G_..'9:_TSM2<6P2$UF2XMK9+"3&LYI*:0'6\A2>ETI):..J*
MF$YS6@Q!LB&3,)P1246+/2'5]S!460K&UXKM)6^MAVC>4`OUFUITYDR3[!Z<
MI'JW[QZ8DAT@MJ(1]FV`8B19^E*U2M-M`[Z/44+9F3T<;O!2,*V,*FT`..(+
MO?7\2!X)D/)E(<"!:SO2O,SP<Y2N$DSRY="?GX+WYN(>F5KUG[0HOHB60[-A
M3&X`6Z5V3OI2N+\@F-Q$;X8!O&I4\)+N&_M-]9^YJ&H+TYZ"(><K+=[6W#!H
M*&""R=21F&J@`/A%4KC-@(;0XW#M16'K#,>S8#H/XPCD:,N-W0B'Q(CMC57R
MEQ=%)Y2'3$X0N)X@T2Q()M/YX@X*\14-!M?4TGRI58]@:2"GZ:A;P2@%LG,6
M0W_^[0PLN9AG%S2$@MK`-`[Y+)DLR0%:R$Z:U:TF&A4$DH\50-;W5^""KBN(
MDQ$_%+FZE?PI\:J`^+J`_UMW8F@11A?6X[\R>TURJ1D55YE!\G[K+BC#X&ZL
M8#$;\=ZZE\S]9,+QH<_MM]PO04<K_I7J2K0&-;P$8AC,826UWW%_L*H;6KU5
M%G9SN*WA4\1A$\(`Q*52]GQP;]'X<<M_`P``__\#`%!+`P04``8`"````"$`
MPEXF_(P"``!"!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R45%UO
MFS`4?9^T_V#YO1@((6T44C6+NE7:I&G:Q[-C#%C%&-E.D_S[7>/$HDE;M2^`
MS?$Y]]Q[?1>W>]FB)ZZ-4%V!DRC&B'=,E:*K"_SG]_W5-4;&TJZDK>IX@0_<
MX-OEYT^+G=*/IN'<(F#H3($;:_LY(88U7%(3J9YW\*=26E(+2UT3TVM.R^&0
M;$D:QSF15'38,\SU>SA450G&UXIM)>^L)]&\I1;B-XWHS8E-LO?02:H?M_T5
M4[('BHUHA3T,I!A)-G^H.Z7II@7?^R2C[,0]+"[HI6!:&579".B(#_32\PVY
M(<"T7)0"'+BT(\VK`M\E\U6.R7(QY.>OX#LS^D:F4;NO6I3?1<<AV5`F5X"-
M4H\.^E"Z+3A,+D[?#P7XJ5')*[IM[2^U^\9%W5BH]A0,.5_S\K#FAD%"@29*
MIXZ)J18"@">2PG4&)(3NA_=.E+8I\"2/IK-XD@`<;;BQ]\)18L2VQBKYSX.2
M(Y4G28\D\#Z2)'F4I=/9]3M8B(]H,+BFEBX76NT0-`UHFIZZ%DSFP.R<32`_
M/H[@]36KX-&1W#F6`D.WPW$#Y7E:YEFV($^04W;$K#P&G@&3!`2!:$)($,8X
MI)>3?%)V8*?LDNY"6?F-L4SZLLSD(S(.#)D9!9]GD\#KE3TF&V,"XIE!@(P-
MGG+^ME%WJ,#@+J0OG4P#OX_`8V9#`9)I$H??S^2AY<;R;\LZ\+EL'GB]K,=D
MONZOB.8?$77@<]'9F:C'G+S.SF7]7?:M+KFN^1?>M@8QM77W-(%8PVX8(7?I
M,`7"#[C"/:WY#ZIKT1G4\@J.QM$,_&H_!/S"JGZX2!MEX?(.GPW,:@[M&$<`
MKI2RIX4;,V'Z+_\#``#__P,`4$L#!!0`!@`(````(0`0.P(780(``$\%```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)2476^;,!2&[R?M/UB^+PX)
MT#0*J=I%V2JMTC3MX]HQ!["*,;*=C_[['>/$RM1.RFX`P^OGG/><8Y;W1]61
M/1@K=5_2-)E0`KW0E>R;DO[\L;F94V(=[RO>Z1Y*^@J6WJ\^?E@>M'FQ+8`C
M2.AM25OGA@5C5K2@N$WT`#U^J;51W.'2-,P.!G@U;E(=FTXF!5-<]C00%N8:
MAJYK*6"MQ4Y![P+$0,<=YF];.=@S38EK<(J;E]UP([0:$+&5G72O(Y02)19/
M3:\-WW;H^YAF7)S9X^(-7DEAM-6U2Q#'0J)O/=^Q.X:DU;*2Z,"7G1BH2_J0
M+AXSRE;+L3Z_)!SLQ3.QK3Y\-K+Z*GO`8F.;?`.V6K]XZ5/E7^%F]F;W9FS`
M-T,JJ/FN<]_UX0O(IG78[1P->5^+ZG4-5F!!$9-,<T\2NL,$\$J4]).!!>''
M\7Z0E6M+.BN2_'8R2U%.MF#=1GHD)6)GG5:_@R@]H0)D>H+@_01)BR2;YK?S
M*R@L9#0:7'/'5TNC#P2'!F/:@?L13!=(]LYF6)^01_3Z+ZOHT4,>/*6D..VX
MW6)[]JLBRY=LCS45)\UCT.`U:M*H8)A-3`G3N$SI_2*?(WNQC^R+[E-Y#"\N
MPTS?#S/[GS!>C)6Y2+[(9I$;(@=-=JF)BK\,HN1Z@UY<4G05RU9D1>2&R$&3
MCX7/TCR;Q^\A;ACLT'<%IH%/T'66"+WS0YOBOO@VGJ>'Z7@DX@><YX$W\,Q-
M(WM+.JAQZR2YQ0$VX42$A=/#.%5;[7"2Q\<6?UR`O9DD**ZU=N>%/W/Q5[CZ
M`P``__\#`%!+`P04``8`"````"$`J'"E&`4%``"Z%@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6R4F-N.HS@0AN]7VG=`W$^(3<A)24836KT[THZT
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M:;<Y)'`"Y78G%\>M^XVM0Y^YWFZC'?1O(FY%ZV^G.,O;;WER^"/)!'@;XJ0B
M\"+EJT*_']0CV.QU=C_K"/R9.P=QC-XNY5_R]KM(3N<2PAW`B=3!UH>?3Z*(
MP:-@9L(#92F6%Q``_SIIHJX&>"3ZT/_?DD-YWKK^?!(LICX#W'D11?F<*).N
M$[\5I4S_0TB?J#;"*R,^J*_6^80O`Q;,'UOQ4)$^X%-41KM-+F\.W!KXSN(:
MJ3O(UF!9G<P'__2?#(ZD]GQ3F_16H`L(Q_MN/EMLO'=P85PQ>V0@`VJ&4R+L
M$GY0(Q[HJT7"T<>+5)NH2']6F]?GV".RU!%3!PM;#X@`\,QX`6H3>+/E@3EG
MA@)D9FV&$J&-(!K!2%NC/8(*WKIPW#HZ\]F2?O,>F86.+^-+SLP`MH&%S^?-
M.A$&5WRX,`6;PE:&,&1FE3"Z&+87^;Q>)(KF8Q0IV%`43&N[>)&0`7\T[FR<
MH9'0BA!UBS'J%&RJ,R\9,O,ZD-S(@[`-0""7S4T@PE0[:]4*^PU3L"G,\,D>
M&>(VZMC01A!M*ZIM6!U3FQYE*#(VC3:":&106(<[4-.&!SLY6D$8V_G*K'`A
M66?+I7\G(YC1!^RQU;0IS<S2"B*>,RY`:&>H\U1M'GS[&%9R4N`Z65M!=H5H
MZ`Y#%:I2/5PA%G:JT,Q<AM#]\+;7;>$%_6UIP]*#J5U&F'G3HK'T51!QD)'$
M5H2ZT.@5`W5BS0=?M,IOQY6?C:$%F3IM"-4YJH.PGA;2S62$[H>ZO<Z"I=_D
M&Y4VJGVPGOXQ:RQ7(4:(A+B3R5:&*AS51UA?(S'[;P79%?;TDN845*'131Y4
M0VP`#S(9H?OA;:];PLN-'C(L0_0N(Y,#GU[_?041)U(DM"+$A=QH*`-UXCN!
M/9.UZ:UKU8EV^A&J4]7WP46;8S<@H>YD<@7U?SG^&*P0O`U\M6I>GJ@X5=Z'
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MJW;]%$>4>[;><S5H,IZ',+K4S[UZ`2:'U^@D?D3Y*<D*YR*.8'(Z64!ER''V
MB!]*>=7SK1=9PLQ0_WF&&;&`0=9T`O!1RO+S@YINUE/GW?\```#__P,`4$L#
M!!0`!@`(````(0#,ZWQH!`P``%<^```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;*Q;:V_B2A+]OM+^!\3W&["QS4-)KL#NV;W276FUVL=GAC@)&L`1
MD,G,O]]3=K^JJX<$*U^&R>FJ<IWN<I_RZ_;W'_O=X'M]/&V;P]TPN1D/!_5A
MTSQL#T]WP__\^\MOL^'@=%X?'M:[YE#?#7_6I^'O]W_]R^U;<_QV>J[K\P`1
M#J>[X?/Y_+(8C4Z;YWJ_/MTT+_4!(X_-<;\^X\_CT^CT<JS7#ZW3?C=*Q^-B
MM%]O#\,NPN+XD1C-X^-V4U?-YG5?'\Y=D&.]6Y^1_^EY^W(RT?:;CX3;KX_?
M7E]^VS3[%X3XNMUMSS_;H,/!?K/XX^G0'-=?=^#](\G6&Q.[_4.$WV\WQ^;4
M/)YO$&[4)2HYST?S$2+=WSYLP8"F?7"L'^^&RV2ABMEP='_;3M!_M_7;R?O_
MX/3<O/WMN'WX<WNH,=M8)UJ!KTWSC4S_>"`(SB/A_:5=@7\>!P_UX_IU=_Y7
M\_;W>OOT?,9RYV!$Q!8//ZOZM,&,(LQ-FE.D3;-#`OAWL-]2:6!&UC_:W[?M
MP_GY;C@I;O+I>)+`?/"U/IV_;"GD<+!Y/9V;_?\ZHT2'ZH*D.@A^=9"DN)GE
M>5;,IHARP7.B/?&K/=.;:3*>3][QR[0??J\\(O)I">-7>WZ<\*B;O'8MJO5Y
M?7][;-X&*'!,S^EE3:=+LD!@LP@=<;LLOUH5+`<%65*4NR'.3$SX":7T_3[/
MY[>C[UC^C;9929N$6Y3&@M::PE8AH#Q@!`*6!9;O$UA0%&)ACK\R@*.5!BD;
M"^-2A8#R`)8RZN834J8H*'QOXI-\RG-<=39T:MG5*;A):4TL#X$H'V%,4,F?
MP(2BH`@++\NDF/`\5]KH$A5K8JD(1/D(HX+`/I7X5F2*GHS;C,V15AKQSP/!
MH;1&QJT2B/(1EB"FQT^03M<I=CVS4WWXA*4X/'>-S-G\9WS^2VMD<Q>(\A&6
M^U3F3D5YY59#442=Y#S/E39"]%^6O#6Q5`2B?(11H1[$VS4OUPD9\[G6"*^3
M@$-IC6R"`E$^PA+$,OH)MMMZU@KIM?--D7CV&N&5$NXHULAF+Q#E(RS[!,V$
M2/_Z4FG#B%H)MT=C=:E8G(VE(R'%($Z(A.O#!9-T,H>]T!QM92!>,@&5TED9
MQTI"BD$\31(K+TTJFQS)7'F*)IWFL?PUQ(MFQD_;TCC.+?%*0HI!/'_2J"#_
M-.^Q/29:[/P5T!!G$#0YI7'T&5A'LRB*67$&)$T!@QZ;9*(5#GNQW0"3Z9A/
M]\I87:Q\7RMU5R8@Y2*!(R>$X#ZARULE40UV&P.QR@^IE,[*3'(E(<4@GB:I
M5C#O?2I?BY]?-U8/_:40K:^U<OD+2%%W1-/35A?/GZ0JR#])LAMW,?+AUB#1
MJN=ST!"K_6G8"QM'O_:MHZ&EF!7G0&H6<D!!7+O[:%'$7'FU'W:2B;:Z6/O6
MQF1?.3<#*09Q0B1P'J%W:I^LN=)BH5L(>?R:2NFL3$Z5A!2#6)II1&U[-95M
M(,[`0+QRPK;265D&$E(,X@P">>UY%9M:W?6G.^C+5L;J4N4X&T=(!^]N9=#E
MK6)6G%`@Q)<K)Y5Z:R!>.0&5TEFY-'4L=Q6LF!5/,Z*WLSG=KKGVI$VEX!J(
MET[89SHK1T$*+K/B%#Y'<-.HX`;]V<I872P=H:Z5<S,<%8,X(03_^*9#2Q5L
M.@;BI1-0*9V5R:F2D&(03Y.DS-L;Z93M63I:%#V]2JU.^B=RV&TZ*T?!.AI(
M,2M.(::YTUF/=C.5DJLAVB*\K3]L-YV5R;>2D&(0IT`*%ZQ"KX8YI4#!UM]!
MG,$LZ$%+[0@KQ\`Z&D@Q*\Z`)-)C\,Y.J075KY4.PB9GCE:F`JHDI!C$<II$
M!+68M+W8Y?1:1SZ+!G+S4QH(VYPKC5G045;&*K.\E(&XHVOC.(E`4]_)W$JG
MF<75I(/\B950)2'%()Y3((NMSNLN]YW\I$1.-.3/K(;X!(F9U5;^S$8=7<_)
M69`^?;AD)V0=U$0'L9D54*4=/2O%()Y31`;I^N>=6;6JYU9=0_ZL:@@I7JI7
M;>7/:M31-8^<0:![?FU<>04QD:)H(.P,'H>PGW)69CXJ"2D&<0X14=0;Q[44
MI"A.K+;Y%,)^REDY"M;10(I9<0H14>QU,3&1FF@@O@AA9^*L3+J5A!2#.(.(
M)O:X%3"1BF@@GG_8EC@KE[^.Y:ZL%;/B^9-Z>=L+G0C]5H`"!3N/ACB#L"N9
M6"O'0$"*63$&640_Z=;-E>=`&Z;-WROX>="`K(P5XMLS.SPIG(TE)"'%($[H
M*BW-I)8:"'5@DTQ"*J6S<FGJ6-[E'+/B:9**!963C`%>._%:#;TN*],0*YQY
MH*RELW($K*.!%+/B!$@%0P(]"J<34_XL<N[ZI/8VZ"K35A<+Q]J8["OG9B#%
M($Z(%-`C=%F.,ZV7_KQKB!=.0*4TCJY**@DI!O$T,0=^FK3E]-.MC"+Q/<=`
MO'1<;]6N1NFLS+16$E(,XA0BTINDTQX7<YF47@-Q"JZ1T12$SE;.T;!2#.(4
M(M+;9]NTPNOVFKP0VZ:VNEC]UL9D7V4"4@SBA$CV/E[]6B3]ZM<0K_ZP:\NL
ME4M30(I9\31)V[PTV\XSQYE_[;9)<8+:UQ`O'"%/ULH1$)#*?(@1R#]';]LP
M@=YF07>S,D:7ZL;96#X24@SB?*Z26^KM@FDWD%\W(9/2&;DLI=HR*YXE*5M0
M-OWN@.52;PW$"R=LE9V5HR#UEEEQ"B1O`84>.PZ=*]T*N!TGF8O*L5KJK,(S
MP41R-]DK"2D&<4)7Z6TN]=9`?N4(*J6S<O-NA=I`BEGQ-"-ZVT^L<JFW!N*E
M$_;XSLKD6TE(,8A3B.DMDKERS\RMV+JBP'N\P8-N8W5QT]&1_-(1D'*10)L3
M(F7SSH7+K5JN==`3*P/YI2.HE,[*S;N.Y;HWQ:QXFJ1L7IJ]KPYS"L35RD!^
MY:3CL,EW5HZ!CN5=WS(KSH!T+&#09].A,(%:I>.@,U[EVNIBY5@;1TA`RD4*
M*Z<(Y/=RY;36?-X-Q"LGH%(Z*YNFA!2#V+P7@:I2Y9"Z77G&MF&"_+5L8M+L
MU6TZ#CM\X^B*I)*08A#//Z*W_2Y2"JFW!N(4P@[?6;DED'K+K#B%S]';(J*W
MZ3AHBU?&ZE+I.QM'R,JT@12SXH2NTMM"ZJV!>.D'5$IG97*J)*08Q-/$'(1;
M3L_2H4A!]6N(ET[8V136RE$0D&)6G,+GZ&T1U=N@KUP9*R1H3VA!2(AKY=P,
M1\4@3N@JO2VDWAJ(ETY`I716)J=*0HI!/$V2MD"M^G7Y^!9'E(Z&>.D$C7-I
M'/V-TSH:5O2I3QN^M>HH=)_N=)^+[.OC4UW6N]UIL&E>Z;.<68H//2RLOQDJ
M)HLEBA!1@Q%L)_B<:!(=R3#2/O81/CE&8M&618'CM`V/\"G@T[958F2*D6DT
M@QE&8M&6.8Z#5B3"!R/4#<9&<!PT8+$1'"<:;9G/P:=]!!UFC1'J'2+1BC&R
M;K^Q"GT*^G2K?0(G1E*,Q(ZSS,=@&AO!)3LRB!XGQW'0`D1RRW&<:+1EC@K!
M94',!Q6"2[/8""H$5T.Q$51(--HRPW%PKRSB@Q&ZY1H;P7%PES,V@N/@YF%L
M!'40/<XRFR*#Z,IAA&Y[Q:*A0G"G*3:".HA'F\`'CX,B/A/XX#&+'%EF6&W<
M1Y<C>!Z"XT17.\-JX^%!S`>K'8^6(@.\*!'QF2`:GO3'1K`^>%(=&\$JX.EI
M;`2K@(>2L1',-1[VR9%EFBR6>#%,CN`5/V0=S2T%T^Z)>GAFI<@Z&FV99HME
M=!7P/AA\HO66@BE>GHKE!J9X)RDV`J9XU2<V@@K!*S1R9)D@-[R1*T?P<OB"
M7NN.C2`W7'#%1I!;]]9_.#L)<HL>9YG,L`K1>L,(O5P;.PZJ"N^S1D925&\T
MVA(G8]0#B47YX^#18^/0L3C+!&<4WNN/Y(01^C0D-H(ZP]<8L1'4&;YSB(V@
MSJ+'P?>ZR[@''&*1J)1C.)U^$7R)4HG6'6V:$?L5RB1:)2B2-L[(%@D^ZWU9
M/]7_6!^?MH?38%<_HK\8MR],';L/@[L_SLT+>F=\W-N<\4%O^]]G?,!=XV7:
M,3VI>6R:L_D#4S>RGX3?_Q\``/__`P!02P,$%``&``@````A`*+^1)!>!@``
M/!H``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK%E;;^I&$'ZOU/]@
M^?T`OD&P@"K@NUJIJD[;9\<8L((QLIV3<_Y]9[T7>W?`(>IY2<+'[#<[W\SN
MSFY6OWTOS]JWO&Z*ZK+6C<E,U_)+5NV+RW&M__TU^/*D:TV;7O;IN;KD:_U'
MWNB_;7[]9?5>U:_-*<];#1@NS5H_M>W5G4Z;[)27:3.IKOD%OCE4=9FV\+$^
M3IMKG:?[;E!YGIJSV7Q:IL5%IPQN_0A'=3@46>Y5V5N97UI*4N?GM(7Y-Z?B
MVG"V,GN$KDSKU[?KEZPJKT#Q4IR+]D='JFMEYL;'2U6G+V>(^[MAIQGG[CX@
M^K+(ZJJI#NT$Z*9THCCFY70Y!:;-:E]`!$1VK<X/:_W9<!-CH4\WJTZ@?XK\
MO1G\K36GZCVLB_WOQ24'M2%/)`,O5?5*3.,]@6#P%(T.N@S\66O[_)"^G=N_
MJO<H+XZG%M+M0$0D,'?_P\N;#!0%FHGI$*:L.L,$X*=6%J0T0)'T^UHWP7&Q
M;T]KW9I/G,7,,L!<>\F;-B@(I:YE;TU;E?]2(X-141*+D=B"!.A&[(&Y<PJ_
MF5-G8CXYAC,G3D<&SME`J%XV<-S1DMG#[\\Y,B`1W13)'V.NIE3/+CU>VJ:;
M55V]:U#SH%AS3<D*,EQ"PA-#HQ.INI<I2!%A>28T:QWBA20T4%[?-L[264V_
M04EDS&:+;0S98L<M2/X)K:<"O@H$*A"J0*0"L0HD`V`*L@AM(&D_0QM"0[3A
M46TYT(ME*D)P"S[$4P%?!0(5"%4@4H%8!9(!(`D!"^=G"$%H8.$.B\28RY%O
MJ0W9&D0E*28[82+408B/D``A(4(BA,0(28:()!+L*C]#)$(#BQ&V$"&`LU0D
MV#*C,96$B5`)(3Y"`H2$"(D0$B,D&2*22C!EI)+I3,1^^O".0X@ZG7A\6X;`
M)MHK9SS)];431GR8AQ`?(0%"0H1$"(D1D@P1219(-Y+%<"8+&'#[B.0;+QDH
MRT`1FYZB9!?=(<1#B(^0`"$A0B*$Q`A)AH@4\T*)>3Q08BT'RA!ZQG>!(L1#
MB(^0`"$A0B*$Q`A)AH@4*&EB\1G;);<]%=GKMH*"A4/HA@`6G*7TA"4D<OP4
M,2UQL.P$TJ\`4UT!'C6RP9]8)M92.8E]8<2728"0$"$10F*$)!2ALY94@G7[
M_U4B)+)*%!FJ))!>`*P2-;+-KI<Q9X8E[R.^^%X()&@Y$@IDQ%$DB$C3!(Z4
M5B`6WW/:1-`"(BE(^C=)PAL%!9TKKZC.7!:+029LWZ(X'&,IQ[[C5K`Y"2NL
MX$TK4SG)?&9ES3JAK9FIQ!]P@V&](F?A36=JZ4<WK=0IQ=PCGY*MS#GA!O>F
M)"<%K#Z3%&*N)(5"-G0>0F['G*E)80/AE[!".GF&L.+EY#/(MKL,+,R%3!SP
M(=`<WB<.N=6H^ZBWXNYCV?W<4&X-"1]RS[TL-NE@AUOM!RN`-KS0;/'I;`T*
MR2O`5+;'';?Z8`4PKOXH]ME`>]&)[1A*%@/VO34J8_B0^ZBWXM'%LGO34KJC
MY"/WLMBD%?Z$V*QS'HI-(:6RE1U@9["!HYIXO16/UF<0JVQ#S6+`AT":QBK[
M$?<1Y^J[D5AVO[3E=97P$?>\RUJ3AGJH-;VG?[*',%A;/DP!A:1ZM]7[QHX-
M),\>]Y7RF!44;Y\"2F])09K*@1+T`T?HPX<F$?56?!(Q@]BB4W?.Y"/O<B)`
M`BD1'^PPQ%S9SBED#?HV<MT%*X!&XO>XE3V0EPWLH8!;]?1A#XW01]RJYXHQ
ME'"HHY>5(8V^6J+FG+SG:8^WN>3BJPK&;A!#=1Q3:<AV;"`T>B-!>IQ>VDO4
M#L#G7'27MJTGM$VS64IEK;8;(:<9G5+TT)1BSL6FA!K2A-/<FY*<*W)747/%
M[IM=KKY65ZC:FU>280?)KCS#_81"4G4+:#0SS*I_)_/A0;I;%CT4<&A8W8_0
M1WQ@SQ5CB#R!LX4(FP=5C#YITS?3,J^/^2X_GQLMJ][(<S5T)YN5@.E;^G;N
MPJ47"!3<>W+A/G0#7[IPG<!XM'2A^\<XO-4_FS?P+7G#OX6;+KSL89ZMY<)K
M%L:?;?<9A,!?;&T7'G9NX(X++QN`3T7$\'9_38_Y'VE]+"Z-=LX/(-:L.ZYJ
M^OI//[2LSEZJ%E[MNY([P7]I<GBVF)%'H4-5M?P#<2#^[[/Y#P``__\#`%!+
M`P04``8`"````"$`2EL[<,H9``"'AP``&0```'AL+W=O<FMS:&5E=',O<VAE
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M]]_WU-H4)Q.!WPZ'WXTT_V00%;Z`TLDQ`NWCV:?]Y]L_OCWO#C^S_?V7K\\4
M[AF=D3FQY:>_U_NG.VI1,C.:S(REN\,W<H#^_^SAWG0-:I';O]Z?3ZCB^T_/
M7]^?3^>CV=7E=$SRL]_V3\_)O3%Y?G;WQ]/SX>'_.M'8FNJ,3*T1^FN-C$>+
MV2R:+ZY>;X241T_HKS6R&$63V=7B+9[,K1'Z:XW0B;WR+*YL6?K[ZV=!X^IX
M%O37&IE*<P::\-J6H[]<>;C-Q]15CC6-2<=%WM[J8VJ?SHST@(EC)N#RF,-N
M_H,]F#@Q"Y6-N%H)]R_TF3''V_Q'W][2:T(><+C'3KS'HW%T.3<]/U228SR6
M(+_>]XMN`!['\_KV^?;#N\?#SS.:)"F,3S]NS90[7AK+/)([3_JQ_=+0IC%M
MK'PT9MZ?4WD:M4\T'_WY8;:X>G?Q)\TA=U9S@YJQKUBQPDP8QNQ:@UB#1(-4
M@TR#7(-"@U*#2H-:@T:#C0:M!EL-=@ZXH/#T,:(Q\D_$R)@Q,>+6O6$@09NH
M@+""BZPUB#5(-$@UR#3(-2@T*#6H-*@U:#38:-!JL-5@YP`O(#3S_!,!,6;H
MRN<,FFA\Z4?@IM.8:VL_LN:^9-5+^B@!B8$D0%(@&9`<2`&D!%(!J8$T0#9`
M6B!;(#N7>$&CN?^?")HQ0Y,ES?Q]0&:+A1^2&RL*1:V7]%$#$@-)@*1`,B`Y
MD`)(":0"4@-I@&R`M$"V0'8N\:)&3>A%;7B%R9<AHSX&AQOUQA):X/3ABB:1
M'ZY5+^)B:R`QD`1("B0#D@,I@)1`*B`UD`;(!D@+9`MDYQ(O%M3GO5AT:X61
M66V'PV(*^F'I2-3M#<RE?@5D#20&D@!)@61`<B`%D!)(!:0&T@#9`&F!;('L
M7.+%@):-7@S"#6_4?L-;TNVDC@T/9`TD!I(`28%D0'(@!9`22`6D!M(`V0!I
M@6R![%SB-3RM;=_0\$;M-WQ'IM?]\FO5$YF:)F-U)5EWHHBV7<[\-?/GK[@7
M\?R5]+:9I$"ROI1K6BW:\U[$A@HP5/9$#,&)5+TA$453M0&H>Q'7UO2VF6QZ
M(H:@MK8W)*)HJJ;];2]BV[O>-A$O^G3]>$/TC=J/?D?<Z`-9=T2%6BWVXE[$
M/B=@*`62]:6<YIBHKI;W(C9=@*$22-67<DQ/U3ZB[D5LN@%#&R!M7\HUK?K^
MMA>QZ9UKR`NB25Z\(8I'N1]&B]PX(EI;1)%DGV)$"19,$652T&F$R;4_`>2B
MXAH+M%4BJJ2@8WXZ]<W7HF+S#=K:(&JEH&M>]>FMJ-C\SK/E!]'LDC%C<5R%
M/'^]O_O]YD`S)8D&KHQ3RDS8?$6WUZ9E/%=Y8S):-&J]V`):6U4D%]`848*V
M4D29%'1;1^T`<U&QJP7:*A%56+!&U&#!#:(6"VX1[;R"?M3,5MJ-VD!T*`'6
MAZ?;>7OAZ=!DVD=L9;*(%#%"TGYP*5A;U<R-6%?008G8XE9.$65H*T=48,%2
M4,#5BFV1>W*UGZI+<BTJ=K41\XPV@L06-$XKMD053=6582LJ-K\3\X3\4)L=
M^!M";3?L[DCLT(0VA4XSJ#EO9?*_)OJT^^A5<()K4;'KL473RV.>\GJ\H)6!
MFI(2UM`$\++Q%(UG@IR"$V4^MZKHZNC"?#11"Z'B5?67@Y7I)60E*FZ"6M>O
MS[]Y5?T;L>R<K*Z_%177OT6T\Y#?H4QRX`T=RN82W`[5H8AZ3!_-*%(3[6IL
M"P9COA85GTULT:2+YG@\OJ;;D?XE-.%B[M"&WIJR2N:J3)#X/L$.9<\P.G:H
M\9@NA[X#!=L).E"R*M@&E:BX#6I$#:*-(.=DL,/T@6#S6RG(:.<AO\.8#,8;
M.HQ->+@=ID/^#!2I0;HR6=E7S$"]BEV/;4$:_M(,4:06S8E53=U83*_5U2`5
M)]A\)DC,#W29SB\[!T6C*[4]*H;JARY;#E:F0UJ)BKVL$36(-H*<<]'F6U&Q
M^2VBG8?\'F/R+6Z/<5);;UA4=ED;;]5B$SG^S*/6URLJ83J263[U\Q.T]%I4
M?)*Q11$-F+Y@%*E`)ES0'?H#':EW@LUG7-#S"^<>>X[=W+,8P<QC#;O5P]F5
M@W7I0%>B8B=K1`VBC2!I*7"B%16;WR+:><CO1R9]Y/:C$\M<FVUR9YX.3=UE
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M9Z$NN`5;#M9?LBIXQ:G$)6Z"VB);_VQTJ:XN#5L.UK]A5;#^5NH/-,F6;751
MH2>:KM1V9\>*EWSR>R'U5:\7=JLQ?E;RU4\H3HR=8_<4YV<+-4!N6$53;M]=
M8-*TEJ0GKJ481R9&E"!*$66(<D0%HA)1A:A&U"#:(&H1;1'M/.0'TN1KW:7+
MB>FD2^^Z2Q1SF3(AI$MV'YQHIC)M*U%Q+-:(8D0)HA11ABA'5"`J$56(:D0-
MH@VB%M$6T<Y#?GA,TLT-C[/K.1$IFZZ3R?/&S/@4*??Y'D1K1#&B!%&**$.4
M(RH0E8@J1#6B!M$&48MHBVCG(3\L)DOGAN5$++JDGC=J+)*UR\K<,S$#2=`:
M48PH090BRA#EB`I$):(*48VH0;1!U"+:(MIYR(\%71Z]6#A#Y/59PHFQHM9)
M':+!R5/6RJK,>.WG.LP"6!7=C195-%,KX5A4;#Y!E"+*$.6("HL<[TM!XA=X
M7XDM444SM8ZN1<7>-X@VB%I$6T0[BSKO_7";C-H;AEZ7@/.&7H=FWM-;,[4<
M6M%](],AZ,$#:09HK+55S=RE>S13R\U85-Q8"2,9[*F@0(T9J[P:]0([%Q77
M6%CD/$E1"@K46(DM4<$YUJ+B&AM&<HX;06(+6K5E5?`<MZ+B&G<6=>?H=QN3
M`WM#M^E29EZWZ1!U&ZYN->F0TZ1KB_SGQ69J_1^+BFTE:"M%E$E!:;]([_%S
M4;'Y`FV5B"HIZ)B?J>5X+2HVWZ"M#:)6"CKFYVIJV8J*S>\\6WY<3:;H#7'M
M$DM>7#ODQ;5#7EP[I.*J-B'QI%>QZXE%CJT4428%G9:9J2<^<E&Q^0)ME8@J
M*>B:5][7HF+S#=K:(&JQX!;1SBOH!9$>^GA+$(]R_UIMD1M$BYR&7UND@J@R
M'[&HN!D2M)4BRK!@CJC`@B6B2@HZ$9NK754M*G:U05L;1"T6W"+:>07]B-':
MQAMVO[3H,C?1U:++(B^0G<H+9(?<Y_UL00<E%CD%4T09%LP1%5BP1%1)03=J
M:N57BTJB!N>X0?,M%MPBVGD%_:B9',GK)\NID:MQUB%G5;FRJA-K8JMR'NZ+
M$25BBULF%21-"BN&C&WY*P8ULG-1L?E"S#,J!05JK-B6+&YJ1(W88O,;00'S
M+=K:(MJ)+3+OA_IM>1VZLPVA[I#9!/=[G6BNE\FVH-F>]2H(SUI4W`RQ133%
MF!L%D_%D`4](L(3&QLNV4[$=4&6B8@]RB_K;HE>JNQ2OJK\4RX'Z*U%Q_36;
MMXGRZWFD'&A8$6R`C9@..-`.JG3F?&M5MDTF]+H"=5_TE$M^)]39JW":A)Z2
M@$YH4U;NACO2]\]77##83FM1<0ABBVC;8#KA>#RAIVS5;)UP,7=J@1Z>LBKH
M0B8J=B&WR-XPBT;7T:7[/[65+-A"T)N254%O*E&Q-[5%H09IN%C0A0VK@BZT
M@RKLE;87=#<5IZ-([:=V;.8EE_Q>:?)L;[@*VK2<DTB==DA-C<JI%:M.3(W6
MEMRWB&U!.S7.Y^/97-E.6!)LW?15'F2BXFZ06V2G@>E(__:D>%7]I5@.S$R5
MJ+C^FLWW4^,8GH5F2;`%-F([X$$[J,)>V$7*-DHTTFF>W2F7_%ZHTY8GYD;,
M3YI;L[0\\Q\FF*M-W<JJ3CS%*"J.06R1G0JN+Z\7VG;"I5X:=L=?]:2L"D8J
M$Q5[D%MDI\;9Z%IE"@HN$ZR_9%6P_DI47']M4:`%&BX5]&##JJ`'[:`*>Z&-
M>C<7SD93-37LV,Q++OF]\&W9U"EF4RU2<Z%:-JQ8=6(N[,S38I)C$-N"=BX<
MCZ>4BE;7Q(0UP>9-7^5")BIV(;?(COO%2-^>+EY5?RF6`U-1)2JNOV;S=J5\
M=7FI?R31L"38`ANQ'?"@'51A-^Q"91ME-M*/X>].N>1WP[=E9Z>8G;5(388J
M@;;B@L%V6HN*8Q!;9*>"^>4,?DK"A5X:=G8NM)X''<C8ENPM<XOZN5`/@H++
M!.LO616LOQ(5-T!MT<L-T'"AH`,;5@4=:`=5V`>[QNS;1*\1=FSF)9?\/FAR
MMV]8%G:I7C>33(DF<T%64Z'*GJ]8=6(JM+;<J;!#=BJ\ICN*$Y4/3*QMDP$*
M[9A[VP%5)GYR)\@MLH-^/KI6V8#B5?678CE0?R4JKK]F\]U,.+^:7U^I%FA8
M$FR!C=@.>-`.JK`7=JW9SX3JTK<[Y9'7"4UJ^@V=\"CW,W06^1.A;J85%PPV
MTUI4'(+8(CL/+*ZO+R=J599PJ9=&73<3LBKH028J]B"WJ!_U^A'/@LL$ZR]9
M%:R_$A777UMD6^`JHA;0G9!+!3W8L"KH03NH@DYH5;91YKA#9C,ON>3W0G+I
M+;W0R%4O[)`_%5ZIU,K*/"%A)LSP5"@JCD%LD9T*I_/9%'ZGQQ*J(C`5BNV`
M*A,5>Y!;U(]Z77_QJOI+L1RHOQ(5UU^S>;LHG%]-YZIU&Y8$6V`CM@,>M(,J
M[(5=/&VC+$9SM?[:G7+)[X745[U>^$OWF")C177.#JDI4DUC*RX8;+ZUJ#@T
ML45V@IA<7D]HR>ZG41,N]M)PM'.D]3WH0L:VG-6B1?UTL-`7:BX3K+]D5;#^
M2E3<!+5%M@G&EPMJ`=4$#1<+NK!A5="%=E"%W;-K3MLJXPB>R]ZQG9=\\OOG
MVVZQF.ZF.V*'**?.+;>R*I-F?WG:6K/*^5DAHH21F$\%!<QGK!+S.:*"D9@O
M!07,5ZP2\S6BAI&8WP@*F&]9)>:WB':,CN;]N.J[%K\V[^#-#.IXI@?,Y(Q6
M%IF<32C<74$W+\(%N_E_^&>%K`F.G91501<RJW)<R"WJ=P-ZO!5L.5A_R:I@
M_1767W/!K@EF0S\T:5@3=&'#JJ`+K;C@Q$J?]-:J^E;1OSW9<64ON>3W19-S
M=C>ENB^^[I>%],@WS#T=\N:>'CDG"+\LM+9H;\V35HPH821]/144,)^Q2LSG
MB`I&8KX4%#!?L4K,UX@:1F)^(RA@OF65F-\BVC$ZFO?C35W0BW?XKD!DY&IQ
MTR'Z31F'9V55#EHCBA$EB%)$&:(<48&H1%0AJA$UB#:(6D1;1#L/^;'0N?%N
M[+WY-TXT%=@@2<^97:OET`VK:`SV5P)]+T<T'-LUHAA1@BA%E"'*$16(2D05
MHAI1@VB#J$6T1;3SD!_(MV67(\PN,Z)43Q^<2+_,9R4J"8^U)2\8C5&5($H1
M98AR1`6B$E&%J$;4(-H@:A%M$>T\Y(?')-!>N,:=F/ZZU)N;@XUL-D[RIBM$
M:T0QH@11BBA#E",J$)6(*D0UH@;1!E&+:(MHYR$O+/0(IA^6<"R.<O]2Q$@V
MIBM$:T0QH@11BBA#E",J$)6(*D0UHL9#?OO1`L_KUB?:S\A5^W6($L@\GZSH
M^4FC,CGE?B*"AY'65F5R?KT*7G$1BXK-)V*>48HHDX*.>?@)BJC85H&V2D%B
M"TZH$ENBBJ[4Y;$6%=?8B'E"?GA,,L"==4Z$I\L=N%.-^=%/%PNN;H5H;9&*
MA7(]%A7;2M!6BBB3@D[+P`]"1,7F"[15(JJDH&M>>5^+BLTWGBV_X77:1&]I
M7O6J6-I$PW"QV11WN`!:VX*4B61?8T2)1<[02Q%E4M!M'95KRT7%-19HJT14
M8<$:4>,5]%M:)S).='',6,QLXD'V02M!<LXP8-=61<./SSE&E(@M5J6(,B[H
M)N4B_?[57%1LJT!;I:"`]Y78$A6\?[46%=?8B'E"?BS,WOH-TTVW%?>FFPZI
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M/%W@G*BI>X`)%W0'U53_%CYEE3NH[`D)RE%5("H%B5\#40/SM13D<VP\Y$=-
M;[E/#"K<9\\ZY*:/!05<7[-*[L[$B!)&LO!($66(<D0%HE)0P-5*5-RD-:+&
M0UXKS_4.^I?&QM&*OS&TR)_1]#W>E56=N+?$MIP9C0MV-U;&EW-ZP$*M,Q+6
M!"]E*:ODMQ,9UI=;1#/H\5<X(_T<7\%F@I65K**K<S^D<>A(_8Y*W\6IV99M
M@NA*OX>Y8<5+/OD]@53>ZD_WA-?=QID;,ZHK=,@=AU9UXA8RJ^1.18PH8>2,
M0T09HAQ1@:@4Y`1#WW&J1-6/0T2-A_S6-QMU=^UM6O\U;W"DCS5#>W=(79;4
M$^DK6_#$;V+9O%PD8B[8#05:YRT6^IK$I=QK$G3SE`U)X#(N*-7E%M$M23OR
MU-ZUX#+!RDJI+!A&VYK>B,&1UZGXT9')0O_HO3GE4Q?[[BO9W5=U'_:/7_:K
M_;=O3V=WAS_,%[#'EV9D]]Q^GWLR67ZD^T'4R]01>@/=TKQ$;>C(E(X<6QG*
M1'3D>)G31Z+YTMQW0FL?HZOE1SH_/$+WAZC,U>"1!1TY#F.HYYJ.'-,AZ@A]
MB?SC8"WTA?)C]U#Z&W/Z0W73R0^=^\>([`\:HC89;)+9<G>\`NF*J:6&&HKR
MADN3,L&&HESATF0"AXY,Z,C0:5"FA8X,6:,$XM)D6-`:I3B6)J>!1RAAL33I
M"#Q"B06J9^@(95Z7)NF$92@!NS2Y)SQ">5BJ9^A,*2M(1X;.E%)6=&3(&B5G
MER8OA?706W4HRD/UK*>3I?D9/Y:A'^0OS<_M\0C]<'YI?BF/1^@W[TOS(W<\
M<D.^W0SZ1@GQY6KP""7!*3Z#7E/KF(0KUD/)03HRU`;T+J-E,]@&]$JCI7E7
M`UJCUQ@MS4N*AHXLZ,C0D*57J="1H2%+K^R@UCG>U5=CA%X+04>&/*!W/BW-
MFRO0`WKUT]*\P`*/T.N>EN9E3D-'%G1DR&MZOPP=&?*:WF-"T1[RFMZ504>&
M/*!W8RW-NSO0`WI%UM*\P@./T&NQEN:E5T-'%G1DR&MZZ0X=&?*:WN1"O7?(
M:WI;"!T9\N"&/+@9/$*O$ENN!H_0Z\.6YN5@Z#6]1XJ.#'F])J_->X8&RI#7
MYN4U0T=H+`QZL*-K1_?"0=6IZ`-=RY@^)X7&Z'-;2_-]+3Q"7\I:FN]@X1'Z
MHM72?*\*CZPG<PK"T!1/+Z*CH3!TI%DLS0?2T-AFL32?2<,#+8VWH<9L:;0-
M-25](H_\'6I*^N8:'1FJHU@LS2?@L/)RL30?@L,#%8VG(:\J&DU#7M%W`:E]
MA[RBK\K1D:$ZDL72?/<.*T\72_/U.SR0T7@9\BJCT3+D%7T,D?K#D%?T*3TZ
M,E3'S6)Y,WA@M5BN!@^L:3P,>;6FT3#D%7WND?KOD%?TL4`Z<O3JHN_T3Q_>
M_;C]LJ]O'[_<?W\Z^[;_3(O$R^/G"Q_OOYC]0O>/9_LB_]\.S\^'!UI'GI]]
MW=]^VM.WDB_-&^$_'P[/_`]JVHN?A\??G[[N]\\?_E\`````__\#`%!+`P04
M``8`"````"$`!D>YK68.``!+2P``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6RLG-MR&DD2AN\W8M^!X'XD<9)0A^4)"^CS.69WKS%"%F%)*`"/9]Y^
ML[HJ.[LRH82\>V.LC\R_D\JJK$/3?/K]KY?GWI_KW7ZS?;WK#RZN^KWUZVK[
ML'G]=M?_UQ_^;]-^;W]8OCXLG[>OZ[O^W^M]__?/__S'IY_;W??]TWI]Z('"
MZ_ZN_W0XO'F7E_O5T_IEN;_8OJU?X9W'[>YE>8`_=]\N]V^[]?*A<7IYOAQ>
M75U?OBPWKWVMX.W.T=@^/FY6Z_EV]>-E_7K0(KOU\_(`\>^?-F][5'M9G2/W
MLMQ]__'VVVK[\@827S?/F\/?C6B_][+RHF^OV]WRZS-\[K\&X^4*M9L_A/S+
M9K7;[K>/APN0N]2!RL]\>WE["4J?/SULX!.H9N_MUH]W_2\#KQZ-^I>?/S4-
M]._-^N>^\__>_FG[,]AM'M+-ZQI:&_*D,O!UN_VN3*,'A<#Y4GC[30;*7>]A
M_;C\\7RHMS_#]>;;TP'2/8%/I#Z8]_#W?+U?08N"S,5PHI16VV<(`/[MO6Q4
MUX`66?YUUQ_"A3</AZ>[_NCZ8G)S-1J`>>_K>G_P-TJRWUO]V!^V+__11@,C
MI45&1F3<BH"<PQZ4FXO"J[GHS<5@?'6M+NEPNS9N-ZV;^S+0QYO+P"M^-J?^
MK;&'5V,/5W3$,X!L-1<80/,8#W=$`WA;>\!_SHII@&VK_G->5)`%?0V(_KRH
MH$&U![7L60D98`NK_[@N=:E[7=.)Y\O#\O.GW?9G#RH#--S^;:GJS,!3(MA]
M=:NW'?I4?X:.K%2^*)F[/OA#5]W#(/SS\^1Z\NGR3Q@X*V-S+VT&ML4,+=0H
M4;)S#A8<^!P$'(0<1!S$'"0<I!QD'.0<%!R4'%0<U!UP">EI<P1=]?^1(R6C
M<H2M>X^`DC9D"4$+=)ESL.#`YR#@(.0@XB#F(.$@Y2#C(.>@X*#DH.*@[@`K
M(5`)1$)&4(N.UWP<(\H+JGMGC`Q'4[O![[6-FC_:@71MF\Q:DS8I@BP$\04)
M!`D%B02)!4D$207)!,D%*00I!:D$J;O$RA$489$CU:X?+&Q*!FHC5/(V(9-K
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M*!T+H420M/5R2&>M$4KG0J@0I&R]NM)LS%2M$4K772$KB>K`P,IB9TX[/&U6
MW^^W,.Y@'W:DSHY@6VLVNTK%SFXC#(O[SGB7:&[0F,KQ0B)?.@82A>38;1NV
MYX[("ALGEEJ)1"DY=N79PC<C*Y3/I58A42D=*XEJR]%.I-HK=\\MCB0,#K/:
MC.FM-2SC,<Y[=60$21S#U-LIM;?VB)@9*W4N1E:\ULS)"N47$OD2!80<\B%9
MH7PD42Q10L@AGY(5RF<2Y1(5A!SR)5FA?"51;2$[U6H7_H%4ZTV[E6J-1E82
M)WQ7H(X&U:B&?N%*=6N%GV9!CHA\B0)"#OF0K%`KDBB6*"'DD$_)"N4SB7*)
M"D(.^9*L4+Z2J+:0G6JUF^^F^M?*LSD3Z`YVC88P,5!NAZQ8SM0)+_2`]P;[
M,:LAJXP+HP6G0NHP]/IVQ.9:'PV<W2TX*Z3PJ!8/*4(KZ,&=1F`5+T8K9US)
M67&E1[5X7!E:.>/*T<H95W%67.51*QY7A5<\E<(:#4Z%9/=M=>;1[=OOS%CF
MB*3;B372-[.:E<ALT*).2N7T9*S&[>RW0$="/J+F7EDC'Q!RR(=H15J11#$B
MDD\(.>13M"+Y3*(<$<D7A!SR)5J1?"51C:B1M_.JSD^Z>?VUFJ54V))2(VO6
M&ER)FJ6MAE"4:%#+'F#DNPM/XWASLD`9'VM8<N5`':FJFNF\?FBLH/+CQ!"A
M(VRX*/"AJ$;G!)&@EC.(5`:1H:,SB)P<.Z'REBA0RQE$B5J4B0H=3V6B1I]3
MF;#[HSI+ZO;'=^J,/GJREDL:676F18X6F(.(Z@LC&DH+B7Q$-%(#0@[Y$*U(
M/I(H1D3R"2&'?(I6))])E",B^8*00[Y$*Y*O)*H1':DSZJCJ`WDU)UO=^4.C
M$;S0B)NPPZ79P%A!+LF*=_:YL8*E$@[HA42^1,%9\J%TC"2*)4K.DD^E8R91
M+E%QEGPI'2N):@O90U@=0G53K::4X;7Z_DCO`Z<4^B@+>A2FZ%[=X%?%VLKM
MD)VGS-#*6<CFQ@JV2RB_0$==R`;#P?"&:?OH=:J4F76'B=,908A:%$%DT'C<
M3&H#=G06HX?SZHFQ<D]I*6GAY\_0$:*GH<.GM)P<.U9\@!6HY6R"$K6H"2IT
MI"3<LIUNC5ZGFL'NC.HPK=L9WYE/]-F;U>O,<1R5S-F@18XVF*,5E<R%1#XB
MD@\(.>1#M"+Y2*(8$<DGA!SR*5J1?"91CHCD"T(.^1*M2+Z2J$;4R%MY'1X[
M"OUPD6E4['6K04/8=-`HF+"A.#-6(ZL4\5$P1RU5^/"+14.^45N@EMZH#893
MJ#SV.9Z/)J>V:KKNH)4SJ/"LH")C-<9Q:`<4XZ6<`25HY0PH12M+B[=2AE;6
MJ!?5":TL+9Z7`JV<<97&RCY/X7%5J$79&[*SDAI-3@5E=VRPL@H6WY#]L7V#
M'GOTC!]"Q2/CH9)A/5NC[L+86`'J=%#>7'.THN]>+23R$5$I"`@YY$.T(OE(
MHA@1R2>$'/(I6I%\)E&.B.0+0@[Y$JU(OI*H1G2DD$&'MO+MGJ"&RISE5:.Q
M-6]/V'W0F7%T+POF*$\S\D(B7Z+@+/E0.D82Q1(E9\FGTC&3*)>H.$N^E(Z5
M1+6%[*$-P^PCJ5;F+-4:L3T06R#-5([!\;W)25MU]T#&L8-\B8*SY$/I&$D4
M2Y2<)9]*QTRB7*+B+/E2.E82U1:R4ZW.++O+SF8/-+F`E<`[XUL?=G87H&HI
M`NE\9]N#5I!56FO(4F[D82H@*SZG+5!+3_[#VUOVQ0/?&*A;(23#+Q:@C#.D
M\*@6#RE"+:O(\>D_/JK%XTI0RQE7>E2+QY6AEC.N_*@6CZM`+6=<)6HY4UBA
MUJD4UBAS*H5V=U;GF+P[#R;-E^G.W]*KE10O:!J]<V?+.+Y7T(Q6YU`''<WB
M;#(=L1-:'RVLUN29"=#*N6`,T8HFSPB1U<JRV^K(1\X@$M1R!I&B%061(7(&
MD:.5,X@"K9Q!E,8*7O!TH4+'DZFHT>)4`':/A`"L'OE.657F;"[5R%H.M\A1
MUN:J$*OIE;:N"XE\1+2@#`@YY$.T(OE(HA@1R2>$'/(I6I%\)E&.B.0+0@[Y
M$JU(OI*H1G1D.:S.;__W2J-/@:U9U!P,PU!KIRQY/VJHK=3$WEH->3F8&ZON
MX2$ZFOWR=#IBM]1]=+)&(9<.4,<90$A:.+XB='1.1#$Y.CY?@EK.(%+2PB`R
M='0&D9.C(X@"M9Q!E*A%Y:Y"QY.IJ-'I5"KL2@,?QNJ1[U0:9<XJC496I6F1
MHPGF0V-%@VDAD8^(QFI`R"$?HA7)1Q+%B$@^(>203]&*Y#.)<D0D7Q!RR)=H
M1?*51#6B(Y7F8R?#:HG"\VJ.@:%F4+$0=Z2,XWN+%ZW5F3$7QK&#?(F"L^1#
MZ1A)%$N4G"6?2L=,HERBXBSY4CI6$M46LH:P>KC-&L*_=$>J4;%'MD%J.J,>
M(.Y(H96SDLU1GBK9`AUU)9N,QWS[X:/3J4JF#X91QQE`B%H40&20N2'%KQZC
MA_/JR5E73TFKG4W0$:I@IW79"CXGQXX5GU<+U'(V08E:U`05.K8YX/<":G0Z
MU0IV5X35K=45W;.)VA*PJF-0=S8AY&B".5I1P5Q(Y".B>AP0<LB':$7RD40Q
M(I)/"#GD4[0B^4RB'!')%X0<\B5:D7PE48U(SB8CR+Z5UU\K,4J%E1B-U':=
M!@'O@[/F\N\>^1DKM=$B+3ZJ%ZBE=VHWH^$UOQV%%J=V:J;JZ,C=$U]X5DR1
ML3*WHWC(\5D!)6AE56M>*5*TLCX<OV*&5O`9.TTI:I-I`DN+7[%`+6=<I;%R
M)Z]"K39Y4_8=AAHM3L5DERNHEZ);=P]^SKL;I6XP\7ZMD57&6M1I4]Y:<Z,U
MHALN"XE\1%0(`D(.^1"M2#Z2*$9$\@DAAWR*5B2?290C(OF"D$.^1"N2KR12
M/RBCT@$O,-?J?.L?B-&_K?&RWGU;S];/S_O>:OM#_?@++*T^?VJQ_F6:>NK5
M\(0+*+`WX"=KOC3?E&3\'G[*IIE8.1]Z]5'[$?STS3']L?=%A\Z%QE[=U&_.
M)U[=G$1Q?NW5S=>+&$^G'CS()S]8>NO!@V!'^.#*4\\2R7?RJ:>>*))O%%-/
M/5<DWRBG7G7LVN6M5QV[-CR*Y*EGCZ12,/74@U?RC7#JP5.11_BM!X_0'>%P
M"?4DEGPGGGKJ>2SY1C+UU%-9\HW[J7=_](W9U)L=?6,^]>")4:DTO_7@6<(C
M'*)5CZ7)=_RIIQY.@S<NVX3#3QF]+;^ML^7NV^9UWWM>/T)OOVK.M7?ZQY#T
M'P=ST_WK]@`_8@0S-/S4#/QHU1J>!;]2-W4>M]L#_J$NT/X,UN?_`@``__\#
M`%!+`P04``8`"````"$`Y*W*]?L+``#J/```&0```'AL+W=O<FMS:&5E=',O
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MWSY._RY^!/GV[?U$PSVF.Q(W-G_YM<J/&_(HJ;ESQD+3IOB@#M"_G=U63`WR
MR/KG8]<AP]N7T_MC=SBY&T_[PP&)=[[DQY.W%2J[G<VWXZG8_4\*#90JJ62H
ME(PJ)=.[P:@_$2I:FM'5TC;]LFWJY6P\&%]J.5$MZ5>U')#G6DQ-50.:]JK!
M53V\5\WH]\8>BOZ4-R?^<UT?!SP6`ST85_5RP/X7_[FUGS1FLI]Z\)I]V9,S
MIYR(J_5I_?1P*'YT*+JIV\?/M5@K!O,!:>$I*(>CFI3GYB1-1J'E6:AY[-(`
MT70[4B!]?QI/I@^][S3Y-TIF@3(#4V+)$F*F"[4K&[@V\&S@VR"P06B#R`:Q
M#1(;I#;(:J!'KJW\2[/A[_"O4"/\RYY9,-`.=RQGL@0W6=G`M8%G`]\&@0U"
M&T0VB&V0V""U058#AC,I0L"90PK1YO62YZ9H12MC;6XZX['IK(64$6MO-8$G
MILBR$JD<"L0%X@'Q@01`0B`1D!A(`B0%DM6)X5N*??"M\,>-"X%00VL)K>V5
M(\>3F>G*A1)J\W8E4GD;B`O$`^(#"8"$0"(@,9`$2`HDJQ/#VW3KAK?;9["0
M+IW*SE@H0EM;Y69G;"VXRTJ(FZV`N$`\(#Z0`$@()`(2`TF`I$"R.C%\2'/,
M\*'<NNZFU*#=G:*AZ4Y)1C+'$CO/$L@*B`O$`^(#"8"$0"(@,9`$2`HDJQ/#
M=Y12&;YK=YB0-AVFB,PD2X<!60%Q@7A`?"`!D!!(!"0&D@!)@61U8CA,E%R8
M)Y63[?2^W7Q=%!2(E`0T.')(^9#,DH02TX^2.,-J8U]6I!;9`VL!74FA$=FK
MA;\EY%9"'/X>$!](`"0$$@&)@21`4B"9)/+N#6_3NO;7O2V4F-Z6I.[MBM0<
M"=Z60B.GS&N=_F!H;F=N=;UR=*66B5^1%D-!I4@DT&3(2NG"ZCJKC2JU3.**
MM!A**D7*D)6(I]5U5IM5:HD80R7J#6.L&B*`2DD.@5+<'!6%'-HLJ]D\&YD^
M7K(0+>Z5D`,CU2CE6)F<JZ0H<Q2W/W3ZEC&/!8SXLHWYC<9LJ:!1RNY2R!9E
MEYS9O37T$0NT=BEN-&9W*6F4LKN4LD7EI>GDWAR2C`7.=<F<)B1E3)/:;GW]
M`BJJ;"NF%1I18EM-C)F5WB^YW;FNJFI3:=>[FJL:.E,9^_<C:UP\UDPE2V4>
MYJ7/4JWV`RW%81=:]D<C:RY'W*;5?LQ2K?83+<7V4]/^B`Z6[$F@?';.OCD)
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M'7"^1BWJ`Y;2ND)$$2.M/M:H17W"4EI]BBACU!#/HBC&`;GYM$8<\,@55O=V
M;&_T"Y:JYU[6/K34,KQWK!"YB#Q$/J(`48@H0A0C2A"EB#(#F=$@JNJZ\R_L
M8D+<VL44HJ2Z6@_IL8VYM2[%(9IH>%\MMRM$+B(/D8\H0!0BBA#%B!)$*:+,
M0*9+1=U==VDM.[S@756QU]<4B>JG.0-`*T0N(@^1CRA`%"**$,6($D0IHLQ`
MIBM%45UWY07_R1J<AH;C=C%02*?!2T0K1"XB#Y&/*$`4(HH0Q8@21"FBS$"F
M_T2E6_=?;2K>D"K)>MEP:[V$+C/0)86VB'`ZD-#K`!0/*R5UX;1'2_%`>HA\
M1`&B$%&$*$:4($H190HUG/LX]F'"_^7\4HNYXBI4/_K1J,WY2NK\X8\6J/RN
M-3/R$06ZX9G3'BW`:B)4$R-*=,,SQSM:@#5GAAHC(!S*ZXR`:%]02G'+^4(#
M37/*SZKMSIG8-;IJ:*;_4"1H*>ZZJ]"(UOB:>BM!\934T$AX[6?4/JH/$(7-
M%NVL_RJ+,:I/$*7-%JTZ*[MDT1S7VXIQ!XMQA8RC%P?2&&YH.!['5:G7FX[+
MZHUI,[4*&8_54WL]^K9ZGZ6T^@!1V&S1.O*(N&&KQ9BEM,4$4=ILT3I@SKCA
M.8OFN-JU_H5XQ:)>[$<0KU/KD'3)4O6J`#<O+:7C5:JG>!7+DY7U>JK!I3A5
M7=1/[`*T%"K4;"FZRE*,:A-$::NE[)(E<_Q$&5M/0"Z,GZQZZYF&6&AI_*RX
MA/56-;P0EY64'C^E?B3'[VYF+7R>LB^.H]I"$C0'W%#'3,CW0L):U]1:W"-N
MV&HQ9BFM/D&4-ENTGJUGW/"<17-(_Z9R7>R--+"BCJJ<,;97Q`5+U0/3<MA2
MR_"PKA"YB#Q$/J(`48@H0A0C2A"EB#(#F<X7970]GLJSS_$=N>?&=UL<59#7
M:B5&E,A7(^),K7UYJ:6TMZ&X=U'*0^0C"A"%B")$,:($48HH,Y#I;5%IV]Y6
M1X47%C)9HQL+&93M2WH24ZYM>N%?(7(1>8A\1`&B$%&$*$:4($H1908R77E;
M)>]@)<](+WA+1"M$+B(/D8\H0!0BBA#%B!)$*:+,0*;_1'5]9BI>7\D[LD8W
MIF55MG,X+Y64V.CU.F!GH2LE=:&2UU*LWD/D(PH0A8@B1#&B!%&**%.(;INZ
M:CA?O);YUYU?:C&+286D27F,HE&;\Y74^4I>"U1^UYH9^8@"W?!,):\%6$V$
M:F)$B6YXII+7`JPY,]288R+J\'I`M"_((@67V0;K7B@DDA\]S:&29ZEZ`H*5
M@99B]:Y"9B4_LRL$)25^:IVP$C0?U0>(0H4LBU:-&2DI\7/>8HSJ$T2I0I9%
MZQXS)25^&BV:XTI)Z"WC*L2MH)+(JABL3BV'JJ'1*5CDM)0>5Z7>F#8SJZ[V
MN"$)ZWNVU?LLI?>T`%&HT*C58L0-6RW&+*4M)HC2JRQFW/"<17-<19%[0[S*
MFKB^4XF7(FBHS7B%2IZE+L2KTJ4S+U<U;*ZO/77U[!PN%V]?&^?I$B`*6RU%
M5UF*46V"*&VUE%VR9(X?S;Y;QD^(6W$ID167=B5/GZB5#2_$927%CG950RM*
MK-,GC]6?F[-J'$%]P`UUX(3-%JVCI8@;MEJ,64JK3Q"ES18M%XJO_$H7GK,H
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MQ8G_H$[UJJ^4G_X$``#__P,`4$L#!!0`!@`(````(0"F,JM0;`T``+U"```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*R<6W/B2@['W[=JOP/%^PG8
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MY[=JO_[\"M?]PQNM-^B[_D6XWVTW^^I0/1VOP-U`+U1>\V0P&8"G^]O'+5R!
MDKVW+Y_N^I^\Z6H4]`?WM[5`_]V6WP_6S[W#2_4]W6\?%]NW$M2&?5([\+FJ
MOBC3_%$A&#P0HY-Z!_ZU[SV63^NOK\=_5]^S<OO\<H3M#N&*U(5-'W_.RL,&
M%`4W5WZH/&VJ5U@`_-O;;55H@"+K'W=]'R;>/AY?[OK!]54X'@8>F/<^EX=C
MLE4N^[W-U\.QVOU/&WG&E782&">CQ@FXZ[`'S_6D\+^9].;*&PVOU90=PZ[-
M,(A=,ZQ[FHFQA_^-_?B2:3S8A'IYZH>+)O)01?6#&>$-KT9^.+ZI=>RX*`^N
M0<]&6]!]61[*K7XPLX6T9UUSP0;IN<[LU$!'21UTL_5Q?7^[K[[W()/A^@[O
M:W4N>%,/G&"XZ4F;`#P5?Q!XRLLGY>:N#_L(H76`I/EV'TZ\V\$W"/2-L7F0
M-LPB0@L5U<KMC(.8@X2#E(.,@YR#@H,Y!PL.EARL+#``:1M]8>=_A[[*C=(7
ME7E`0(+[KMP16N"0&0<Q!PD'*0<9!SD'!0=S#A8<+#E86<`1$]+C=XBIW,"Q
M:`7KZ&;LJO>@;=3!VT3TM6L2-2:-PH+$@B2"I()D@N2"%(+,!5D(LA1D91-'
M;#@,?H?8R@T<+G#4-T*&$Q:K#\:H2^W&I%%;D%B01)!4D$R07)!"D+D@"T&6
M@JQLXJ@-E^ZHW7Z[Q^-66=>BHA@/ANB*0)V=D2`S06)!$D%203)!<D$*0>:"
M+`19"K*RB2,8!)0CV"_>N)0;5TE#8&(K8`.6^XT1;L!,D%B01)!4D$R07)!"
MD+D@"T&6@JQLXH@[9N)V1Z.R=C4TQ(I&06:"Q((D@J2"9(+D@A2"S`59"+(4
M9&431S#5?<DRZFH,4=2MG1KH:J?)R-).D)D@L2")(*D@F2"Y((4@<T$6@BP%
M6=G$T0ZJ>4>[;L&4M2N8(;J#J8\^06:"Q((D@J2"9(+D@A0V<2Y4M1_.E>HS
MJXZ2X\MV\^6A@B,'*LD6!0(HJDVIK;RX"M2.H>6KV]+:*B)$QYCOW;C'V,Q8
MC6#.YK`+>.$>DQ6>=HE$J4291+E$A4%Z]:Y@JJJVTZI%&&@Q&V5T$0ZU!J[S
M0?5O():C3(/HFEN4T5:A7S<S_M!C=X#8>`8#G"R1DZ429310M4G@F15#.1F@
MY\)QXTJD:N4/2*1+:T<BC4(H39H8\/V1&RF1ZFJ5D/9ML46UQ@J7'M-`1(E$
MJ4291+E$A8-<951E^P%E3"%L!X]&\+2'E!GQ[(A4TZ[R$0*&]).9UEBA##$-
M1)1(E$J4291+5#C(5495H1]0QA2MMC(:^7;,C'A5'ZGG"1?$3)N5SYJMV/@*
MAG4^WGB3$8O0!"TZ]R&E-:'H&2%K`_D"<G2O%S"&QVD3-T4*M#BU`'</5&%K
M[X&Z%_CPU*?U]+</.360'?\:L3AE!U:D>MD+XK2Q0GUB,]`?U]*/)Q.V-PEZ
MAN0_G0$I6M%].I,H=R>['H^'7&6SP%.3N2JK"M=6^<P-Q!3$=J1KQ"*=Q5ZD
MVML+(EU;!:1`;`8&SM7PR$K0ZE1DU;?\E!:!6Y=)E!LTTKL9<G6;);9OI:NN
M*H<_H*ZIGFUU-7(BU^-G9^29@9V7/R,KO/S8H"9R??:4)\$QCOQ\_A2M:-\R
MB7(V63`6VIK+.#69JZTJES^@K:ZN87/QXA\\C5CDLD5%:`59=3IW9V2%[F.#
MS($<A-?LO$G0H'/74NDYHX$X68[(D8ZG28%6IV9T!59ENBWPKQ7CIMBW==?(
MB>D1/S,CK^D2.G5OK%"*V`PT,>W!">FF<(*>':UD3`O/&0ZD,,\-&HWJHW\2
ML+D*'')J+D=QG[<_W8=Q;>[>Z`P*K#Z'4)>.:#5JTB.6*$%$[E.),D3D*Y>H
M0%3[<F6`\'0"[XP,RIS)H!'+;+8WD:^M`CC1.S+;6$&!T408#M25C@?O'`Z9
M[P1-8(K3OE.THN3(Y'0Y6IG*[L;W6'U1H,6IV5QY(18=>7\IKWWEA:FN$<MK
MUE%'9B`TG!W*S-`]I5IL$*0:#1Q-6(V9X$`[X8()VYZ4%H&;FN%`FC%OFS$<
M\GH+!YZ:T15?=3GVH7HFMDU31`'RH(0#X9T4;Q`I(UM/'$AI&4N4(+)3O'%/
M8AE$OG(<2*A`U)+BJJ6Q9?BU&-2-D7U/5RFOZDP[2,(A?QO56)W+?.T+JE%+
M5M[VQ.C+WGZ?WWD3M')\B7L.6M%V9XB<@7P1.5IU+J)`*\>7M0@W4E4;T;5%
M?U7OD/_GNC'U/(2?$QHY$=P@2VIK9?K-;N,KH'=Y8XD21'8$-^XI@@TB7SD.
M)%0@:HE@U0?8\IQ)9-TV.*&J40@+H5M$P$Z7R-=6*I7(2BICW-/A%9N!\-0%
MKSF1*"7W:)5)JURBPD%NX*@JWE:F;MROU8=Q>I<_Q(7R3<2-1BJ*&RG"(7LX
M&)F!YW+;^++OZAI!WT?N@Y`='0FZMW.HY?ZB?<$B2%:#:#]R]'4F:YN!M"[[
M='?%_UA7Y,NNR"`G.[45H/85F.PT5G0#B-$7H021G9V->Q)+^,IQ(/DJ$+5D
MIRK>>0QZX0??2/!-"T"[^&"04^.$0];91<;J7-(V'88E*S_:8YS1COJ6L#2^
M[%!J"4MM!>LBI5L&^GP1.5X0;$N3>N(F5Q@K]<29K*RSRHE4Z(N[M^BR^TOM
MQJU##;(CF%#[RG0$HQ7=`&*)$D0D8BI1AHA\Y0YRM8#3I"5<\:.!%W_(3)4J
M^F9+EQE.V+.X![2R;SRLHXC(!B-E)E$L42)1*E$F42Y1(=%<HH5$2XE6#G+%
MAW`5XNL'S1_\C)]Z2,EJ'42094U*A$/>$Y$5J6U\39I4C:55(E$J4291+E$A
MT5RBA41+B58.<M56G<.)D[F[A%*W'ZZN1O9'`8R5A682Q1(E$J4291+E$A42
MS25:2+24:.4@5TK5G]A2GM%/MS-V"1H81#5))-%,HEBB1*)4HDRB7*)"HKE$
M"XF6$JT<Y.JG6@!;OU]J0@/EA=V`-+)NLY&Q.E,1&*LSGS8@*SPM$HE2B3*)
M<HD*B>82+21:2K0R2"OABJ\ZEO]??-/W6!6:*OQA/QSQ&T2'L%U!F[N_MAJ=
M_$"#\0P&I'OC&5%*\W=,EI&O$Y]Q(`/T7)!G1'.)%C30>&8=S)(,T,W*<>-N
MDVH^[&TZ<\;H7L4Y8S1B71M[;!<%QLJN25JVJ,V*%ZNQ\07E5JW`.&!OZ21H
M8/=P8K+THB5EK59\23G.B$L*69M?H$'GDN8T&6[=@I`5;GS^);HW3ZQO^+LM
M*S0X-;\;%*H[LX.B[O`O>&L>GMR(LU(CMZ'RF#P1#CRU/)/!QCW=SF(ST+P_
MX_-:.$''IUJ6VG&*5IW39V2%NY.[TWLA:Q0+'-(Y_1RMZ+H6$BW=N<(;EF(K
M'')J+G>+55MH;_&9O#==I'T.:^3FO<<.HR@P5F?ROK%"96,ST+Q++Y1-S.NJ
M[&\*[Y8<;QQW6&6T2)P^=Z</64%?7#3[7/I=2+1TI_*OV6FV.C>7LZ^C<UWW
M19^PK+VX-8]!+(_YPSD<V+DK,[2B&VULD'KB0]LIGK+30,O*>@"ALQFM.A>1
MD56SZ08Y[T"%_'./!0ZT\TP\BIFCE973B.BREP9U7_:*!K9?MAL!<-D?R&Q5
MB[+RUB!H3%"9B%#["O3YC%;T""^6*$%$[E-"'>XSM"+WN40%(G(_EVB!B'PM
M)5HAJGVY*L/N.RK_4F\!I:807R-VK+)'/)$9J.HZ2A>>"#-C53^8QV\EBF=_
M,?K2M4/@W;"D3M"@,Y]2M.I<4G;1DG+TA>54P*Z_0(/.)<W1BNY:BXOF7^)`
MG)^7<RLT.#6_&RL=CT3J-TPN>Q*JCEZ>J1HYF=J@SL@P5O3T,C;NH8K`K$\0
M42JEA#K<9VA%OG*)"D3D?B[1`A'Y6CI(2ZV_3:Z_V+LK]\]E5+Z^'GJ;ZJOZ
MICA\?N+^ML'F:^R!-_T$GN!JV2OP`'6JGB>VO>+#*_7Y+<8$\$J;-_BZ_*?6
M$3!)ZQPP1:N]FJ!E39]&TT_0"K4L=@3?TV_CX12^5-9B?SV%[T.U\/$4OO;3
MPF^F\)46R>$[%5/U+8>V5[RI^MJ`?`6^$P!CVEZ9!>%4/7F08V;!]32&$U"^
M`MWW-&]]!;IG\%:/&30["'\\X'W]7"[7^^?MVZ'W6CY!R`SK]Y+V^L\/Z%^.
MY@WQS]41_FQ`_=[X"_R9B!*^:SA4'UM^JJHC_@*+&C1_>.+^;P```/__`P!0
M2P,$%``&``@````A``158MM9"@``IC(``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&ULK)O=<N(Z%H7OIVK>@>+^!&P@`5>24P'_8ZBIJ3,SUX0X"=6`
M4T!WNM_^;%G:EJ5E')+IFT[S>6M)7MJ6)2%N__RYVW9^Y(?CIMC?=9VK?K>3
M[]?%TV;_<M?]SU_A'^-NYWA:[9]6VV*?WW5_Y<?NG_?__,?M>W'X=GS-\U.'
M%/;'N^[KZ?3F]7K']6N^6QVOBK=\3U>>B\-N=:*/AY?>\>V0KY[*0KMMS^WW
MKWN[U6;?E0K>X1*-XOEYL\[]8OU]E^]/4N20;U<G:O_Q=?-V9+7=^A*YW>KP
M[?O;'^MB]T82CYOMYO2K%.UV=FLO>=D7A]7CEN[[IS-<K5F[_`#RN\WZ4!R+
MY],5R?5D0_&>)[U)CY3N;Y\V=`?"]LXA?[[K/CC><M#O]NYO2X/^N\G?C[7_
M=XZOQ7MTV#QEFWU.;E,_B1YX+(IO(C1Y$H@*]Z!T6/;`OPZ=I_QY]7U[^G?Q
M'N>;E]<3=?>([DC<F/?TR\^/:W*49*[<D5!:%UMJ`/W;V6U$:I`CJY_EW_?-
MT^GUKCNXOAK=]`<.A7<>\^,IW`C);F?]_7@J=O^308Z2DB*N$J&_#2(M!0>J
MX%`7U)6WE*.FE:VFOZI"Q[ERQR-G="V:W5+R6I6D_.>F7E3C1)6COY^LT:$^
ME1;7[+FH3H?M$?]1M4ZNAN[H9ESV3LMM.N2HK/1":WLR+\HT\U>GU?WMH7CO
MT+-+/7]\6XF1P/&$*B>8K+Q*N7,91ZDF5!Z$S%V77*=D.M)C\N-^=./>]GY0
M:J]5S!1C'#-BQA$BCX6L;X/`!J$-(AO$-DALD-I@;H/,!@L;+&N@1]96_E)2
M_`Y_A8SPEYV9,M"&6W;/.(*+^#8(;!#:(+)!;(/$!JD-YC;(;+"PP;(&##/I
M.?D=9@J9NRY54DO6@9F*4QDCAMHJZ-H,F54AE<-``B`AD`A(#"0!D@*9`\F`
M+(`LZ\0PFP:#WV&VD*'!A0;FRLC1S="T<JJ"VMRN0BJW@01`0B`1D!A(`B0%
M,@>2`5D`6=:)X3;=.KCMCJZJM]W%([$0*OUFGZ:*T*NMZ@%W8B=S%<3%?"`!
MD!!(!"0&D@!)@<R!9$`60)9U8MA+Z0?V.J.K&RK0/)7B%YLH:-HIR5#.ML1;
M:@;$!Q(`"8%$0&(@"9`4R!Q(!F0!9%DGAG<WEG?MAHEHTS!%Y)RR-`R(#R0`
M$@*)@,1`$B!IG1@W*A9-];E0^XV*:/-&)1E,JK?TK"*U1\\9FX.?+X.&-(_4
MS^?`&B&#*HB?SQ!(!"0&D@!))9&M-NR@`<.P0TX-RV?F]+I9?YL6U%Z:]S38
M-*`IH)P8"A'3)4GJ+@'Q)1F2N+9D<F/Z%E1!E25`(B`QD`1(*DF#)6*R__][
M4JJ8IBCD#G3N:%0S`9)'10W=<M+M]AUK(A/H@,HFK<PHTJBELEAKB1D^56;-
M.1,=P,JI5B9DY)<CYLR7/V]EN.6:G'6[]%:MY8GU?,U40;%RU%%HI-+2XWJ@
M"_+=A(@BC5KD8QW%6@FBU$"F66)._`FSY!2:IEU<W=21:&#8,)F8#]5,18F&
MM)FEY(THUYI3!$K+O9&YZ5Q;3W#(E9':^<HBCC(JL_LO;HRRFY2837(F8ZO-
M*<N<:Y+9*6+R7.^4+PV18OEOC9$*#>A551DSZ/?MOI(%/TKL*HI3(6#Y?MDQ
MSM"U;0@YHM7S2$6U-R#64=R`A.5E`R9]NY]2#CA7O]D-8E9=[X:&-Q*UD5])
M8IO#]ENB07WXK9#N`M?..E]I#8;5<Q8@"AEI^4BC%OF8H[1\@BAE5,J;SH@)
M<=V9KR6H4+%&7HF&E%M5@CK]D9V@,HK>:CJJP4,E;_2UG1&!6(I3(]1@XEP/
M1]:;+E01X@FNV@2U1:S3VJ:8M5K;E+"6'.`<!UZ(*>N<:Y/96V(*WM9;?Q5O
MU`V-,ZYZ?LN9O#'V2V3D=X5:W/+%NIU<'^B=IP!1R*B>WY?(QUQ0RR<&,NT1
M$W>TA_>#+UXA.W(!4.^2T8V5NE,5)/JO2B;K73'3,3RP^8@"1"&B"%&,*$&4
M(IHCRA`M$"T-9'HO5@F_PWNYVA"=7-F*VT&.BFHUOXK1Y@,*M!)'A8@B1#&B
M!%&*:(XH0[1`M#20:;Y8C]CF?VESR)$K&[*?[9@RHBM5CPQP)%<%]=K6UP59
M*T`4(HH0Q8@21"FB.:(,T0+1TD"&VV[+&J]]8E&6--^3"M5WBQ#YB`)$(:((
M48PH090BFB/*$"T0+0UD6DGO*B-Q/_!/A%O^*53;/'(!^8@"1"&B"%&,*$&4
M(IHCRA`M$"T-9/I'[ZC/^"?"+?\DJN^VN!72#SQ,DWP5]<&NE([B,2!$%"&*
M$26(4D1S1!FB!:*E0@V;.F)Z:KC\I4ERJ6*9+X1I\J0'S9F*JB%?H0\VNW24
M=EK*4T%&$4;%B!)$*:(YH@S1`M%2H2:G[87:UYS&]9O8`2*GJ6:V8J91:YK+
M@N>WSY0,!;!RJ)4911JU5!9KK3/;9SJ`E5.MS&BN44MEF=92E5E?MB]T`"LO
MM3(A<R02JZ_Z%.2#D5PNUNKS#+%)(+J(#*_-,^PI-4?59WX-@Y/2JNW5Z8)\
M-R&B2"/=")"/=11K)8A21'.-6N0S'<7R"T1+`YE](996G^@+N1(S^D(MSNHN
M#_K6[MS,507I?5OU&)CE-T;!ZEU%#8?ECM/8M;[>"%F%WDWGZXHXJK5%<6.4
MW:)$1?%^@CNVMHU3EFEMTIRC6IN4-4;935JH*&729&"U:,DJYUID9DGS:OF3
M7]^0/3"ED,C:F[3:.E,%11:?[U!?1_&C$"A$A^K$N.4,1M:X%7)`J^.15FZI
M/]917'_"\JK^OKWKFG)`:_USK=Q2?Z:CN/Z%0D.YIW1]8]W^\J/JS200*^)/
M#!5J`5U;'KH2U7>.-&JY-9^C]-9E@"ADI%_<D48M\C%':?D$4<I(R\\U:I'/
M.$K++Q`M&97RIO%-2W9UX.#R+T]=7*XK],'&JXH2,[&VIT_)&YELCTH!:_&W
M./966<BM/#<LE5\$1RS3VJ28M5J;E+"6:E+#V*WNK+5)<Y9I;5)V49,6K*6V
M@J_[UA=K2Y8YUR0C?6CT,Y];>Z)\V4YP*6.N212J/\\:M24+1^FMV@!1R$@_
M<)%&+?(Q1VGY!%'*2,O/-6J1SSA*RR\,)-V7Q[#E^=A=?GC)9_EV>^RLB^_B
MB#4][?>W%9;GOVF?V!/;IC1\6U<>G+'W0'7@E2E=$;M]35<F=*5<+EIJ4[?O
MB8T6+$,GT!_*Q8E=@DZFERM#F[LDU*`S'=!)]@;^,/0>Y-S1%AIZ=)P-&S0=
M>70.JX%?>W3&J(&[KC>5*S>KAAE=$2MF+$/;$YY8Y#==&="5IC*T`T!WWG3%
M=X=>0`L35*,EFY<T7J'U%=735&8Z]J9-73@;>[,F[H\].I6#=?L3CXZF($_'
M'AU00>X[?4^<]L`K=&[#$T<SZ$JOLIA^)?"V>LD7J\/+9G_L;/-G2O%^.3T\
MR-\9R`\G]9W38W&BWP?08$)GQ.GW(#D=?.N+XXG/17'B#Z*"ZA<F]W\#``#_
M_P,`4$L#!!0`!@`(````(0!=9Z[2G`8```4;```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;*R978_:.!2&[U?:_Q#EOD"^&!(!U1#RJ5UIM>KN7F="
M@&@(04FFT_[['L<?B7V`F6GWII1GCE_;KX_MD[#\_*TZ:5^+IBWK\THW)C-=
M*\YYO2O/AY7^SY?PTT+7VBX[[[)3?2Y6^O>BU3^O?_]M^5HWS^VQ*#H-%,[M
M2C]VW<6;3MO\6%19.ZDOQ1G^LJ^;*NO@:W.8MI>FR'9]H^HT-6>S^;3*RK-.
M%;SF/1KU?E_FQ;;.7ZKBW%&1ICAE'8R_/9:7EJM5^7ODJJQY?KE\RNOJ`A)/
MY:GLOO>BNE;E7G(XUTWV=()Y?S/L+.?:_1<D7Y5Y4[?UOIN`W)0.%,_9G;I3
M4%HO=R7,@-BN-<5^I3\:7FHL].EZV1OT;UF\MJ/_:^VQ?HV:<O='>2[`;5@G
ML@)/=?U,0I,=0=!XBEJ'_0K\U6B[8I^]G+J_Z]>X*`_'#I;;@1F1B7F[[]NB
MS<%1D)F8#E'*ZQ,,`/[5JI*D!CB2?5OI)G1<[KKC2K?F$^=A9AD0KCT5;1>6
M1%+7\I>VJZO_:)#!I*B(Q41L(6),%HYCSQ</[Q>!R'XD\,E&XDQLTWE8?&0D
M<R8"GTSD)T8">Z,?"7S^O(C+1.#SYZ=C0#[T0R'_^?!8IG2M^]399EVV7C;U
MJP;[$5:SO61D=QL>4>9)0Y=8I-&M+(+T(2J/1&:E@TN0("VD_M>ULS"7TZ^0
MKCF+V>`80X[P>03)32*[54&@@E`%D0IB%20J2$=@"K8(;V`C_!_>$!GB#9_5
MAH/!+,4JGT?P)EL5!"H(51"I(%9!HH)T!"0C8%,C(RQ(ENLG"\\)T@K.D%%.
M6(N%O.(;&D-.*9$X<SG$%R'"#$0"1$)$(D1B1!)$TC&1/($##GE"YO'!C4-D
M8._!(24,<!:6;,&&!=US280(EQ`)$`D1B1")$4D02<=$<@F&++ET/V-(=&\&
MG\2&$3@YA3V6.Y/M\440;[9%)$`D1"1")$8D020=$VGNL*;2W.G1.B'WX'T;
M2$/9!DIL>FN3D]%'9(M(@$B(2(1(C$B"2#HFTIP?E#G?GRB)EB?*"*TI^HDB
MLD4D0"1$)$(D1B1!)!T3::*D:,;W9K^XW;',GS<U)"Q<+%<,L.!^I+<F$9'G
M3XEIB<O"%V38`::A'*-;&F1#?Z-MHMRN@0CBVR1$)$(D1B1!)*6$CEIR"?;M
MK[M$1&27*!F[),A@`':)!MEF7Y^8,T,Y9@/Q=V&0D.4D0B06K4C5`ZK*79Z(
MOW.-=*PAV44*,,FO*]D#M3A/GSY<=H8A$P[D428H0_)Y%)Q$(@K;=37*5*[G
M@$5!.4#F;YDS)3=#'C!.3M19-'3&;8H'-!JEVG_"Y6G_INLHMT/*`V[U+Z\`
M1'UD!4BXL@(4V5`X"&\M5TDUWV`-X4-$(5.V0Q0W)6#(MGN[G;DB'/(F4,K=
M%HYXU'#.QA@E<E^VZ\KW;LJ;W.I+=I84E[]\8AJT1(5ZB3NR84A)>5L>J\^C
MWDAY*L\>C\G]$["&++\-PU$V0,@#[BYE-/3/!QYCE'`MFLS&S%8Z2WG`K<YD
MRTGQ.K;\C>.$U;IC;RFR1O>1(="=!-OR*%NL4X!1R-$@'V$4<S1H)1BE'/5:
ML@VD.OV`#:R8'=O`T#`"WZ`([J"[-K"&PSX+>,.'?@/;KOD@9VK(`LA*W]O!
MHO\AGU!GB=*9[3IR9^E;G<E&DE)W;"2I:,TY>9NDO;_H(0])ZIE)D;*%E;'Z
MK*$%Q>=M8[8L2MK"5-Z&8DXTM%QE:X5<?KRU+%=9G8A'#=D1XQX3AI0>E9LQ
MY5JW>I3-)S7WV/PW-C,MT:6#DB)I,PLT.'/E&F)10_H'Y($5%M$:4,C1>#,+
M^2%)4<.$-QRT4HZN;&92D8]M&#U5?2`'65T_K.+&8&@8A<_06WN<-1ROHJF6
M*0'7HMO>L&<H_9C,&]N>1HU*WY@/_&[_B=*_8RN%0\IE;O4O)R.I^.^MPI?Z
M`F71U<>?<0%+'QQ@M7E^;.`%>9]80Q;Y`[J;I*SA\)XMX`T'%'(TR$<8Q1P-
M#1.,R+O\8:C4'OINGKY@K8KF4/C%Z=1J>?U"WKM#O;1>"DQ_%-C,/7B:ANDK
M?+OPX$'K"G<]>$[!/'8]>-+`''YT>#2O\`WY,>(:-SUX#8AU-I8'[\(P?[2]
M1S`"_V%C>_!:Z`IW/'AE`GPJ9@P_0ERR0_%GUAS*<ZN=BCV8->N?I1OZ,P;]
MTK&D>JH[^/FASZ\C_-Q40)DVF\`9OZ_KCG\A'8@?L-8_````__\#`%!+`P04
M``8`"````"$`B'2S`+`%``#6%0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6RL6-N.HT80?8^4?T"\KP&#;\CV:FP@62F1HFAW\\S@MHW&T!8PXYF_
M3Q5]H9MF&$^4EYWUH:JZ3IVBN^CUU]?B8KV0JLYIN;&]B6M;I,SH(2]/&_O'
M]^3+TK;J)BT/Z8669&._D=K^NOWUE_6-5D_UF9#&@@AEO;'/37,-':?.SJ1(
MZPF]DA*>'&E5I`W\K$Y.?:U(>FB=BHLS==VY4Z1Y:;,(875/#'H\YAF):/9<
MD+)A02IR21O(OS[GUUI$*[)[PA5I]?1\_9+1X@HA'O-+WKRU06VKR,)OIY)6
MZ>,%>+]Z09J)V.T/(WR19Q6MZ;&90#B')6IR7CDK!R)MUX<<&&#9K8H<-_:#
M%R93UW:VZ[9`/W-RJY7_6_69WGZK\L,?>4F@VJ`3*O!(Z1.:?CL@!,Z.X9VT
M"OQ560=R3)\OS=_T]CO)3^<&Y)X!(R06'MXB4F=040@SF<XP4D8OD`#\:Q4Y
MM@94)'UM_][R0W/>V/Y\,ENXO@?FUB.IFR3'D+:5/=<-+?YA1AX/Q8),>1#X
M.Q!DQ-'GCH%TG$T6GKOR%[#XB!\\;;.&OWQ!;S;Q`G>.28_XS;D?_.5^H^LY
MK%AM[:.T2;?KBMXL:&@H1WU-\?7P0H@EBLY6EC*\IP*4'X,\8)2-#6\B%+B&
MUGG9SI;!VGD!N3-NLS-M/-UB+RQ06PP;]8&X#R0*X``C20OT^Q]H812D)1+:
M":#C.>UQ$!;")>H#<1](%$#C`"W5Y^##6S7\/@@ET`DZ7U$B<'MUWC$;?+>D
M7/,>#6DB>1A(;"")BFA4X*WH4\'E/]EE&`7Z%-I4YCU;SO3,=]QHC)PTD>0,
M)#:01$4T<K"42FY<'S1N.8BU=QQA6QJV_=Y`(@.)#211$2T_J)>:'[[BV$>?
M+#Y&T1/G"*RKR-%O)&DD^$8&$AM(HB(:EX7.9;S6:*RGS!&EU@82&4AL((F*
M:/GA,&)LIQ,\`\9313\]588$2JH&$AE(;"")BFBIKO14Q_-#8ST_CK#CLVU;
M`XD,)#:01$6T_#SH4;66XPFVUGJ&')I!'-F@@=L[EO;<RH<\I-746^J[2L2M
M`CU6;^^).RO1[4D7'B"='YY=P[W2G//L:4<A'[`9X.W#$<L/7G8`PIXH5MQY
M#`+:`MIS"#@**.)0`,:2-DP=.NVXLQ*.B19+)X0'F4)H('$8:F3F[-C3,F?0
M-&@GB*GK&5IQ`W7+&=!JR&IJ4&-6P8*-*PM7IYYX[+FO%DA=2Z>.)]_]U/DY
MJ8K&H`"5?=D"]5YK[3WN\UXZ?&"25D*OF#L&K*CS>:^S$Q$8Z,I&>)\G'H+W
M\^1'ILJ309W$/5GV'C?X0&)IU?%D$-=SOC1XLN=WZ@G+?X(G6O?V'@9U>B[T
M]MKC^(,^'^@IK3J>/#+3<^&N],")"'R?GGC0WJ\G/Y95/1G4Z=DK^QZG->")
M7S.#[<7[5EIU/!G$]5SXQOO)GM^I)Q[8"D_VF=.>RY_8:_FIK])G$,C<L0M<
M0VON^('6TJJK`0_/M`Y6O9<E\;C+?5KC)*#4X(/MF<T-VO;,(-^7I\C>DU#'
M7]T\N+K<*I".L7#LH$1`;7A]=\490<G\OZG'!PU5/0;Y4$79FX%K=#"W@GZ3
M5@,<F97>Y^:APV.Y[3;O+^>]3[/$XP;OM8I6%[B-&:W+=WI];X)0#N(VBKY[
M<4A5NH/&JB"LND_F6(-8^NP*B%U#%*0ZD3VY7&HKH\]XO0,;V'8M87;WM`M"
M^/Z"]Z*/ST+X[AG`YR%\0PS@BQ!F]P%\&<*@/(![;H@#E?D$YL80YRKS"<R*
M(4Z"0T\\>#+D`V-BB).5Z0.W;@_3`7P'MW%#]KLIW-(-V?LA?)X/Q`\@/KN8
MD[6%6[5K>B)_IM4I+VOK0HX@B]ONEA6[EV,_&MY?C[2!^[2VU<YP?TK@&]:=
MP(9_I+01/V!E1][(;O\%``#__P,`4$L#!!0`!@`(````(0"V0AM<!PP``/DY
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*R;6V_C.@['WQ?8[Q#D
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MM-LLR]=]<UA_>8>X_PSB]<;Z;O\0[G?;S:$Y-B^G&W`WT1V5,=]-[B;@Z?'^
M>0L18-I'A_KE8?P4+*MI,)X\WK<)^N^V_G'T_C\ZOC4_\L/V^1_;?0W9AG'"
M$?C2-%_1M'Q&!(TGHK5J1^!?A]%S_;+^]G[Z=_.CJ+>O;R<8[BE$A($MG_]*
MZ^,&,@IN;L(I>MHT[]`!^'>TVV)I0$;6?SZ,0[CQ]OGT]C".9C?3^6T4@/GH
M2WT\J2VZ'(\VWXZG9O<_;=1&U#F)C).X<[*X"1?38#I#)V<:PM7V[O!I[AXN
M;N)P.E^TMS_3<F9:PJ=I>7?V3G-C#Y\]<9ZY$4R4MHOP:1I>&!OTIVT(GU?&
M%D`5M$WQ/^>BF^C!;&LC79_6C_>'YL<()AP,U_%CC=,W6*(36Q4ZSJY./BL3
MJ`_T\H1N'L80.53`$6K[^^-T/KN??(=ZW!B;E;0)J$5B+;#XT&W*0<:!XB#G
MH."@Y*#RP`32TN4&*OU7Y`;=8&YL5"L+7+)"E@AK89ND'&0<*`YR#@H.2@XJ
M#Y!$P*S]%8E`-[!J>$4212SRE;;!=:FK)%9'26?294>03!`E2"Y((4@I2.43
MDB18TGY%DM`-3$98K;H$3.=S6A\K8W0N2YU)ER5!,D&4(+D@A2"E()5/2):@
MRR1+_;N/75;0NDV&#6)E""R577JBF!51TAG99JD@F2!*D%R00I!2D,HG)'88
M4Q*[7FMOYM#@?!JP(4V#)K'>IW&I3`1)!<D$48+D@A2"E()4/B$QPRY*8CX?
M*%K30`W1*J(-5)!4D$P0Y1/2092W_@9XOH-H33NH20@%[Q5D1.=KHHTBR%)G
M%`8+:I0:3U`-SBADBU]F/-VV>VP`$IHZ4>8Z;&G.B7<G$CI,(A*Z5X^GM^WF
MZZH!'^"I)R41W%_O_.B$9D23&!;*K@M1'--^)MHH](UD1HQO-_B9:3;7X4\#
M'KYI`1M9=V_?+0D?Y0Z)OR=.4*4VT-:<1FI0%'5[>^)0?P^,KL%;PU88=PTS
MV]`A95'KGG8=)8M?M3\U=($6/K#7V'5R95`$TZ5+8!1/V>!9J_/U;*Q0V'>^
M0E'0UI>NZ'`NAM0:7%32`4J8<XGYH_GXK*;]L=9*B&1&(S+6'?("]":;&6MC
MY01@UO82AK]%=&!17LC^VP/+Y7K<R!1_A."L1,=Q%1@K?X38@I,X&ULDJ429
M1$JB7*)"HE*BBB":,%0:?L(&)K$1)G[)&P1+1U>F4<P45Q)T5BX-`F722DF4
M2U1(5$I4$433`$-(TN`M"`,9P99L6=/(5Q<HR,'*0ZE$F41*HERB0J)2HHH@
M&C[JCRNJ`,U9S`:YO29!#8Y6#J4291(I@F@_489<T4^C6OQJU8CI#3:QDT!;
M#0@.8S6T0&M?L=YSYW=T#5'V5I<MSRA/KHA?JQG(IYUTJT`CHBYBI@(28S2@
M+HR5-[Z9]1ZW^B)DYPIE6\"*WBT5G\L+U")7Q&JDBQ^K1FRLV0`D@;8:&FOC
MRYT8,MO0:,G%G*5168.+AC;D:LI;@2Y7DZT7.C,-HB/."]X8#8RX]>YF=&8;
M6D6Y8%I'V387C7F(BNKR,6_-6;3H`:2!)RF-%:#^JM,RPUHY_9A)I"R2DC)$
MF7)%U[6J\:=FZP&Z#NM%-SNB*2NJQ%K!XMI9^7/(1*/=P])D9WYF&^IRC:93
MIE24-;BL7+G0.K]+8F&Q'<,@4I=3/CF-T5!=&N]^76H4@\;HTA1-V0-39;OE
M%V<T=<L6V7QP'2$C_',SU*@>;YUJ'<,7`WY?O4ZT(YH8HX%ERKKRQUW?$/8?
M/Q/LA*VL>W_P/\\$5TL#@R\E$NZ9?)IVR/6SI["-E3]-!5+$/1U$%"573%.C
M8?S1TBB"NWJ5Q<_GH;8:*ESCWB]<C5CABE75-+RL<%&!^#'_7.%J'4-6+(U(
MX49\74E";354N<:7GU9YVK6^/CWM6@._COTJHL7`Y11/S&6GW5#*+(/(-J2M
MAK8A8^6==JTO>=H-493(@;WZM-OZ:?=15])3KE17ULH?(;:'),[&[CNI1)E$
M2J)<HD*B4J**(#+@$1=9YQ>NUISJ"XL@\V[VS_@F[:RZ-$B42:0DRB4J)"HE
MJ@BB:4"1).OF@B?I$;9D&='(.]HFQLI#J4291$JB7*)"HE*BBB`:/HHC/_R!
M*M!:RE_X(H/<NIU(E$J42:0(HOV\3F/ARL+'1J/HKI.!B;$"Y`K87R"U?C16
M,<P7K\R9?,J<E2USY=P#HM%P^320=:F3X'%O*QK\:`1*C17KNM-T;8"9LW)=
M]WW1KJ/"\`L&]XEP>@-X(`ALR*:+1G3/G#$YEJ"Z@(;TT8)X--IK)9X0&RM8
M#O!W!<&,'_>5-;AHS\1M7.9BAK]Y&5U^3FV]L,08X0,EZY4<UU6VX6=]->5K
MY)&;GYEI"+H*LQ!&;,E6UK&OJ/QY00L"Q8I?$`-EH+4-64&,*/+.J7CP@S''
M&=0EP.^!"<U8>0+8-G1(623/J?#0G':=:YZ+OK5JO;#Q,\H%^M=U/YHQX9J8
MAICMSJHG2.V+EK\L;'/'3Q_`V)M]5BQT3/O%5+LIMH5]F1C$A95/>8U@8.U:
MDQBKH;$V#3TQ:!LZI"R28XUK("E3/=97Z\/63SO:;M"F"S:#5M8*%P+[*R:N
M#YV-344J42:1DBB7J)"HE*@BB-1`C%KF\GG=FM-98)$[@"<2I1)E$BF)<HD*
MB4J)*H)HS%P-89&@=KSR)VRQE$D6^14Q73`5D3@K5Q/&E\MB)JV41+E$A42E
M1!5!-#^HH:ZH"2VY_+4>'W'ADN"B221*)<HD4A+E$A42E1)5!-&840KY,7N;
MQ/FM#I];L.7/(.\TD$B42I1)I"3*)2HD*B6J"*+AH_KRPQ^(&<W9,J`1//ZQ
M-9U`_&CEH52B3"(E42Y1(5$I4440C9GKNH&8C<+R'HS%&GD!)@ZY+4'N]L8*
ME^5NXXCX,I$Y*YM2)5$N42%1*5%ED.X]S0PJKBNJ00LTL@!H1#+3(1=S3V:T
M57RG1>MMP,X)&3[5A:("`Y>4SK-%N;'R[E_8AN9!VFW`#DBE,[!N*N*&IHB+
MRH'BT<*-I,@H/G_"=.ALBK05*QX6319W5C8:)5$N42%1*5%E4%_Q<%4YD!FI
M'F%LVW4#%M9N=MPQ[958(UAC.J.><C*NB)60U<87CG;G*UJPRE/&"I^R."O^
MK47N^F7S7CCD&HH'O65_)]AIL!KJ!"G2:;\:=@+_HI-/ZX4N]@;A=NI2P;\(
M36Q#/V%RB'JMQ!#9._HU$2V8V%;6EW^D];_3:0^4N;5R9^7"(1>0'*+^3K`?
M_E36UV>=H$/$];>G.ZXX@\%K0'Q#-L@_@SGD12F>L5@K=^#*)%(6N>4KEZBP
MR/DJ"=*YT&\@Z;=,=O7AM4[J]_?C:--\P[>+8,(]WG?8O/H4WRZ?P!/,,78%
M#F5+/._T78'WI>!4T'<EA"MA[Y4(KK0QBOO$<*5]`,&OS);PZV9YEZ<@6C[!
M5QOR"ORL;HF_6.N[`G>!'W'U79G"E59@L_L_A7?+)S@B][2!*_A=0<^5"+(&
M1Z"^*Y`U&`)Y)8WG2]R.Y178:Y>XG<HK:;R`*WTY@)?9GGI'`&[?=_<5#%FO
M/:2R+Y-/\?()?D4IN[3"<>SCD-^^]*ZB:+G2O\-EB8<GS<ND]TH*5_#9L;P[
M/+R%*WWWAP?+2]5[)8UGD,2VQ"9=%^#%NX_U:_W/]>%UNS^.WNL7F#JW[5)_
MT*_NZ3].YN>L7YH3O'('RSJ\P06O6-;P1L`M/MY]:9J3_0.Z.^E>VGS\/P``
M`/__`P!02P,$%``&``@````A`*+Y=?TR`0``0`(``!$`"`%D;V-0<F]P<R]C
M;W)E+GAM;""B!`$HH``!````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`)R1T4K#,!2&[P7?H>2^3=M-D=!FH+(K!X(3AW<Q.=N"31IRHMW>WJSKZD2O
MO`S_GR_?.:EF.],DG^!1M[8F19:3!*QLE;:;FCPOY^D-23`(JT336JC)'I#,
M^.5%)1V3K8='WSKP00,FD62125>3;0B.48IR"T9@%ALVANO6&Q'BT6^H$_)=
M;("6>7Y-#02A1!#T`$S=2"0#4LD1Z3Y\TP.4I-"``1N0%EE!O[L!O,$_+_3)
M6=/HL'=QID'WG*WD,1S;.]1CL>NZK)OT&M&_H*O%PU,_:JKM85<2"#_LIQ$8
M%G&5:PWJ=L]W;[Y)$+<5_9U52O9V3'H0`502WV-'NU/R,KF[7\X)+_-BFN9E
M6DZ79<GR";N:OE;TU!KN\Q%H!H%_$T\`WGO__'/^!0``__\#`%!+`P04``8`
M"````"$`!"H,(?0#``"Y$```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"<6%UOVSH,?1]P_T/@
M]]5IUZV[A>,AS5)LP(IF<-8]"JK-)+JU)4^2@WJ_?O1'$KNC=9N\.1*/>$@=
MD5*"3\]9.MJ"-D+)B7=^-O9&(&.5"+F>>#^6MV\_>B-CN4QXJB1,O!*,]RG\
MYTVPT"H';068$2XAS<3;6)M?^[Z)-Y!Q<X;3$F=62F?<XD^]]M5J)6+XK.(B
M`VG]B_'X@P_/%F0"R=M\OZ#7K'B]M:<NFJBXXF<>EF6.A,-@FN>IB+G%*,,[
M$6MEU,J.YL\QI('?G0R0701QH84MPW'@=W\&4<Q3F.'"X8JG!@+_,!!\`5XE
M;<&%-F&PM==;B*W2(R-^8]HNO-$C-U#1F7A;K@67%FE59LV/^CO-C=7A3Z6?
MS`;`FL!'@V:P_NS:=K_%97AU45O@5]^R6J%A@A-]CDMA4S#WJP77EJ!\U>-<
MLV@8-X1VN\A0&VPN+>:+?97-;@O59;Z/8::D4:E(N(6$W?"4RQA8]%>DK[%G
M"_[_+B*+GBJE&:96[#['#=NO7:6^":3'J@^9J>Q82&1?$?L++[RWT7MB]WK-
MI?A=B[;.<E1D&==E%4PD2&*WJ#[VP-,"V!UP4^@Z?-+TCNLGL/PQQ2UH](Y'
MF;3$D.*G&U1OPC`A>*I-38FTO>/_*<UFA;$JPZ*"VZ2MQ(^-R`VCMVP:_RJ$
M$=71K"*;@88U2'JOVJ)3-J)#7%YM+\D$J6;"UKM/SM=1;52:5#3GN)0M2;NO
M6`TS8$O^/)">:1RKHM+8@I=U.JL#@8.ZP(1](]><9WFJ2@!V@X&NA&4+/`ND
MY?<"$P@Z+=FMD'A>!$_99V[I3$;%HX%?!6:$S;=#>7&KZIQD0<L*<X+JH35#
MJLL%&!"9"^+6&AW)@-A<;FC-N1`=Z;G,"`6ZS+M"=-FY]4BG94AFC1]2$VX=
M-=VH;5W[BD;KR+"FL)%N:`B;)DE5,8Z!1'@O20IL]WLZAQXPX*6%T#FC)=Y"
MZ/)%0]I8Z`(P="Z:<3*8(4CCYSB(,466'P7Y"6*]H4NR^\#2DG%CWI'4W)C+
M$S#O3\!\.`%S=0+FXPF8?TG,4'%T"&<(XCC1;@A]UMP86CF#F+H.D`D8*/7M
MO>L8B*L^==O#[NQC6V\OSZ27+J1E4]V5;@N+5SQ&0JCN<O#V:LC!VPD0>C,I
M9@<W]&;VFM\AC#9I)+4>9%>6ZQLF7F+Y*R"'V_8TMF)+W[C=W98.AKS^[5H:
MW08&&W2=.#*8E[?!O8-::UU([XWXXE7X3<@G\R-?*KQUPN[9VQ\,H@W7D."#
M<#=_&`B^X(M7I]4BLPV7:TAV-G]/5(_TA^:?B/#\\FS\;HSO[\Y8X+?G$Q\J
MX1\```#__P,`4$L!`BT`%``&``@````A`+"Q?7U3`@``ARH``!,`````````
M`````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`
MM54P(_4```!,`@``"P````````````````",!```7W)E;',O+G)E;'-02P$"
M+0`4``8`"````"$`"R&*^[4"``!6*@``&@````````````````"R!P``>&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$``XS<DVT%
M``"?%0``#P````````````````"G"P``>&PO=V]R:V)O;VLN>&UL4$L!`BT`
M%``&``@````A`/W>_X1/!```&P\``!@`````````````````01$``'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````(0"V$!RKB@,``!X-
M```9`````````````````,85``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L!`BT`%``&``@````A`((=Q>YP`P``S`L``!D`````````````````AQD`
M`'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"+0`4``8`"````"$`K->6
MT74"``"$!@``&0`````````````````N'0``>&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+`0(M`!0`!@`(````(0`B6L`W3@,``'H*```9````````````
M`````-H?``!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!`BT`%``&``@`
M```A`-[R9G'.`@``+P@``!D`````````````````7R,``'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"+0`4``8`"````"$`^8M(QK\"```K!P``&0``
M``````````````!D)@``>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+`0(M
M`!0`!@`(````(0#T^^IGJ@,``*H,```9`````````````````%HI``!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L!`BT`%``&``@````A`%O'%G5]`P``
M3@P``!D`````````````````.RT``'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"+0`4``8`"````"$`EG&&*)P#``"&#0``&0````````````````#O
M,```>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+`0(M`!0`!@`(````(0!6
MKZ(;]00``,$6```9`````````````````,(T``!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L!`BT`%``&``@````A`&29N)4.!```/P\``!D`````````
M````````[CD``'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"+0`4``8`
M"````"$`"SK10=H#``";#@``&0`````````````````S/@``>&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;%!+`0(M`!0`!@`(````(0"!*7^#$@4``+X6```9
M`````````````````$1"``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!
M`BT`%``&``@````A``((O^#/`P``Q@T``!D`````````````````C4<``'AL
M+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"+0`4``8`"````"$`7G`4VOD$
M``#(%P``&0````````````````"32P``>&PO=V]R:W-H965T<R]S:&5E=#0W
M+GAM;%!+`0(M`!0`!@`(````(0`&H5&"T00``+<5```9````````````````
M`,-0``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&``@````A
M`#V18=CY`@``E0@``!D`````````````````RU4``'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"+0`4``8`"````"$`9"-U3Y`"``!0!@``&0``````
M``````````#[6```>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+`0(M`!0`
M!@`(````(0#QTZZ<X`(``/T'```9`````````````````,);``!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L!`BT`%``&``@````A`"005L*-!````!$`
M`!D`````````````````V5X``'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"+0`4``8`"````"$`'LTH?]\"``!-"0``&0````````````````"=8P``
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+`0(M`!0`!@`(````(0#[8J5M
ME`8``*<;```3`````````````````+-F``!X;"]T:&5M92]T:&5M93$N>&UL
M4$L!`BT`%``&``@````A`-D-)^&&"P``Y68```T`````````````````>&T`
M`'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`]V1BRA^%``!LM@$`%```
M```````````````I>0``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`
M"````"$`WU>G)XD"``#;!@``&`````````````````!Z_@``>&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A`&J^^^WH!0``G1@``!@`
M````````````````.0$!`'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M
M`!0`!@`(````(0#SQMM&_`(``*@(```9`````````````````%<'`0!X;"]W
M;W)K<VAE971S+W-H965T-S`N>&UL4$L!`BT`%``&``@````A`!L(^KL2`P``
MQ`@``!D`````````````````B@H!`'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"+0`4``8`"````"$`7\3C=2<#```^"0``&0````````````````#3
M#0$`>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+`0(M`!0`!@`(````(0`@
M3`4YF@L```]6```9`````````````````#$1`0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L!`BT`%``&``@````A`+V-]AZ-!```;Q(``!D`````````
M`````````AT!`'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"+0`4``8`
M"````"$`^_B07MH(```W+P``&0````````````````#&(0$`>&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;%!+`0(M`!0`!@`(````(0"E/M=,]0,``%(.```9
M`````````````````-<J`0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L!
M`BT`%``&``@````A`$TD7YTY!```21```!D``````````````````R\!`'AL
M+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"+0`4``8`"````"$`P9A;B,(#
M``"2#```&0````````````````!S,P$`>&PO=V]R:W-H965T<R]S:&5E=#8W
M+GAM;%!+`0(M`!0`!@`(````(0##Y*Q":00``)@1```8````````````````
M`&PW`0!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`
MH@['/#,$```/$```&0`````````````````+/`$`>&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+`0(M`!0`!@`(````(0`%S*A@(0,```,*```9````````
M`````````'5``0!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!`BT`%``&
M``@````A`."'P_L&!P``,AT``!D`````````````````S4,!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`NA@.0ID%```H%0``
M&0`````````````````*2P$`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M`0(M`!0`!@`(````(0"/G6XQJQT``"BF```9`````````````````-I0`0!X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`(2_WYIR
M#@``6DH``!D`````````````````O&X!`'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"+0`4``8`"````"$`>V('I(T&``!?&P``&0``````````````
M``!E?0$`>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````
M(0"C+LAZAP(``&<&```9`````````````````"F$`0!X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`"L%1/']"@``GC<``!D`````
M````````````YX8!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4
M``8`"````"$`%;#&;JH0``#860``&0`````````````````;D@$`>&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(````(0#Z"E_<6Q$``$1E
M```9`````````````````/RB`0!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L!`BT`%``&``@````A`$AS):*7#```0T(``!D`````````````````CK0!
M`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`?3](
M!P($``!A#P``&`````````````````!<P0$`>&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L!`BT`%``&``@````A`!G)`+$6"0``L#```!@`````````````
M````E,4!`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(````
M(0#"VUY,&0<``#<?```8`````````````````.#.`0!X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`,F+EEF(*``"'-```&```````
M```````````OU@$`>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&
M``@````A`+^D5SO`$0``CV(``!@`````````````````Q^`!`'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0"YSF_\``\``&Q0```9
M`````````````````+WR`0!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!
M`BT`%``&``@````A`&?H>(=/`P``Z@H``!D`````````````````]`$"`'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4``8`"````"$`;ELCB;H"
M``"3!P``&0````````````````!Z!0(`>&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+`0(M`!0`!@`(````(0`]FX$II`\``!93```9````````````````
M`&L(`@!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`%``&``@````A
M`-\(>MY,"@``CS0``!D`````````````````1A@"`'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`NQX!#<4%``#$'```&0``````
M``````````#)(@(`>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`
M!@`(````(0`1#=E3C@<``*TM```9`````````````````,4H`@!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L!`BT`%``&``@````A``&TJ7XX`@``(04`
M`!D`````````````````BC`"`'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"+0`4``8`"````"$`PEXF_(P"``!"!@``&0````````````````#Y,@(`
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(M`!0`!@`(````(0`0.P(7
M80(``$\%```9`````````````````+PU`@!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L!`BT`%``&``@````A`*API1@%!0``NA8``!D`````````````
M````5#@"`'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"+0`4``8`"```
M`"$`S.M\:`0,``!7/@``&0````````````````"0/0(`>&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0"B_D207@8``#P:```9````
M`````````````,M)`@!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`BT`
M%``&``@````A`$I;.W#*&0``AX<``!D`````````````````8%`"`'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`!D>YK68.``!+
M2P``&0````````````````!A:@(`>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+`0(M`!0`!@`(````(0#DK<KU^PL``.H\```9`````````````````/YX
M`@!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A`*8R
MJU!L#0``O4(``!D`````````````````,(4"`'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"+0`4``8`"````"$`!%5BVUD*``"F,@``&0``````````
M``````#3D@(`>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(
M````(0!=9Z[2G`8```4;```9`````````````````&.=`@!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`(ATLP"P!0``UA4``!D`
M````````````````-J0"`'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M+0`4``8`"````"$`MD(;7`<,``#Y.0``&0`````````````````=J@(`>&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0"B^77],@$`
M`$`"```1`````````````````%NV`@!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M
M`!0`!@`(````(0`$*@PA]`,``+D0```0`````````````````,2X`@!D;V-0
B<F]P<R]A<'`N>&UL4$L%!@````!1`%$`*18``.Z]`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer's matching contribution percent</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution', window );">Employers matching contribution percentage towards employees contribution</a></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum employer's contribution per employee</a></td>
        <td class="nump">$ 1,500<span></span></td>
        <td class="nump">$ 1,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Aggregate employers contributions to defined contribution plan</a></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employers matching contribution percentage towards employees contribution.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_EmployersMatchingContributionPercentageTowardsEmployeesContribution</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the cost recognized during the period for defined contribution plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanCostRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount the employee may contribute to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Acquisition of Ceregene - Summary of Estimated Fair Value of Net Assets Acquired (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">$ 1,585<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ceregene, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and equivalents</a></td>
        <td class="nump">79<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
        <td class="nump">1,870<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">1,585<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
        <td class="nump">3,556<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
        <td class="num">(748)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(98)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
        <td class="num">(846)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
        <td class="nump">$ 2,710<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of identifiable intangible assets recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues related to Shire Collaboration :</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredUpfrontContractFeeRevenue', window );">Amortization of upfront fee</a></td>
        <td class="nump">$ 2,167<span></span></td>
        <td class="nump">$ 1,986<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
        <td class="nump">14,286<span></span></td>
        <td class="nump">9,026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
        <td class="nump">16,453<span></span></td>
        <td class="nump">11,012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Revenue related to Sigma Collaboration :</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sigma-Aldrich Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Revenue related to Sigma Collaboration :</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="nump">824<span></span></td>
        <td class="nump">1,288<span></span></td>
        <td class="nump">938<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fee and milestone revenues</a></td>
        <td class="nump">1,351<span></span></td>
        <td class="nump">1,000<span></span></td>
        <td class="nump">671<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Total</a></td>
        <td class="nump">$ 2,175<span></span></td>
        <td class="nump">$ 2,288<span></span></td>
        <td class="nump">$ 1,609<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredUpfrontContractFeeRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred upfront contract fee revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DeferredUpfrontContractFeeRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research service revenue under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchServiceRevenueUnderCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Related Parties<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16382449<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.1(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 07<br><br> -Paragraph b<br><br> -Subparagraph 1<br><br> -Article 6<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Data (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table sets forth certain unaudited quarterly
 financial data for the eight quarters ended December&#xA0;31,
 2013.</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,707</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,243</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,402</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,043</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,526</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,885</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,450</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,145</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,144</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,268</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,728</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3,478</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.10</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.07</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Ceregene - Schedule of Supplemental Pro Forma Information (Detail) (Ceregene, Inc. [Member], USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ceregene, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionProFormaInformationLineItems', window );"><strong>Business Acquisition Pro Forma Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (30,997)<span></span></td>
        <td class="num">$ (27,446)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share</a></td>
        <td class="num">$ (0.55)<span></span></td>
        <td class="num">$ (0.52)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionProFormaInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_BusinessAcquisitionProFormaInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ET6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Data - Summary of Quarterly Financial Data (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 6,869<span></span></td>
        <td class="nump">$ 5,707<span></span></td>
        <td class="nump">$ 6,934<span></span></td>
        <td class="nump">$ 4,623<span></span></td>
        <td class="nump">$ 8,931<span></span></td>
        <td class="nump">$ 4,907<span></span></td>
        <td class="nump">$ 4,574<span></span></td>
        <td class="nump">$ 3,243<span></span></td>
        <td class="nump">$ 24,133<span></span></td>
        <td class="nump">$ 21,655<span></span></td>
        <td class="nump">$ 10,319<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expenses</a></td>
        <td class="nump">15,043<span></span></td>
        <td class="nump">11,866<span></span></td>
        <td class="nump">12,402<span></span></td>
        <td class="nump">11,528<span></span></td>
        <td class="nump">12,300<span></span></td>
        <td class="nump">10,709<span></span></td>
        <td class="nump">10,318<span></span></td>
        <td class="nump">10,526<span></span></td>
        <td class="nump">50,839<span></span></td>
        <td class="nump">43,853<span></span></td>
        <td class="nump">46,140<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,144)<span></span></td>
        <td class="num">$ (6,145)<span></span></td>
        <td class="num">$ (5,450)<span></span></td>
        <td class="num">$ (6,885)<span></span></td>
        <td class="num">$ (3,478)<span></span></td>
        <td class="num">$ (5,790)<span></span></td>
        <td class="num">$ (5,728)<span></span></td>
        <td class="num">$ (7,268)<span></span></td>
        <td class="num">$ (26,624)<span></span></td>
        <td class="num">$ (22,264)<span></span></td>
        <td class="num">$ (35,750)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share</a></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.10)<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.07)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.48)<span></span></td>
        <td class="num">$ (0.42)<span></span></td>
        <td class="num">$ (0.71)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SelectedQuarterlyFinancialInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table shows total stock-based compensation expense
 recognized in the consolidated statements of operations (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,769</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,942</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,338</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Estimating Fair Value of Employee Stock Options</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The assumptions used for estimating the fair value of the employee
 stock options are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">1.50-1.88</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.74-1.34</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.93-2.11</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected life of option (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.36-5.38</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.40-5.58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.39-5.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield of stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.87-0.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.83-0.86</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The weighted-average estimated fair value of shares purchased under
 the Company&#x2019;s ESPP during 2013, 2012 and 2011 were $1.47,
 $2.51 and $1.62, respectively, based upon the assumptions in the
 Black-Scholes valuation model. The weighted&#x2013;average
 assumptions used for estimating the fair value of the ESPP purchase
 rights are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.61</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.30</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.61</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected life of option (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield of stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.51-0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.93-1.37</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.58-0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <!-- xbrl,n -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 </p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - CHDI Foundation, Inc. - Additional Information (Detail) (CHDI Foundation, Inc. [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">CHDI Foundation, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FundsDueUnderAgreement', window );">Funds due under agreement</a></td>
        <td class="nump">$ 1.3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">Apr. 30,
				 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementToReceive', window );">Agreement to receive</a></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContractualAgreementTerminationDate', window );">Contractual agreement termination date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aug. 30,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PostAmendmentFundsDueUnderAgreement', window );">Funds due under agreement as per amendment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.1<span></span></td>
        <td class="nump">1.1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.1<span></span></td>
        <td class="nump">$ 1.2<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementToReceive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement to receive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementToReceive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractualAgreementTerminationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual agreement termination date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ContractualAgreementTerminationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FundsDueUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Funds due under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FundsDueUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PostAmendmentFundsDueUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Post amendment funds due under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PostAmendmentFundsDueUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchGrantRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research grant revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchGrantRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to unvested stock options and RSU</a></td>
        <td class="nump">$ 11,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
        <td class="text">2 years 10 months 13 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based employee compensation expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value per share of options granted</a></td>
        <td class="nump">$ 8.29<span></span></td>
        <td class="nump">$ 3.76<span></span></td>
        <td class="nump">$ 3.20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue', window );">Weighted-average estimated fair value of shares purchased under ESPP plan</a></td>
        <td class="nump">$ 1.47<span></span></td>
        <td class="nump">$ 2.51<span></span></td>
        <td class="nump">$ 1.62<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2010 Employee Stock Purchase Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
        <td class="nump">181,000<span></span></td>
        <td class="nump">175,000<span></span></td>
        <td class="nump">153,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice', window );">Stock issued under employee stock purchase plans, average exercise price</a></td>
        <td class="nump">$ 2.75<span></span></td>
        <td class="nump">$ 2.61<span></span></td>
        <td class="nump">$ 3.02<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to unvested stock options and RSU</a></td>
        <td class="nump">$ 5,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
        <td class="text">1 year 11 months 23 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee stock purchase plan rights weighted average estimated fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued under employee stock purchase plans average exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value on date of acquisition (October 1, 2013)</a></td>
        <td class="nump">$ 1,510<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
        <td class="nump">$ 1,570<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Michael J. Fox Foundation for Parkinson's Research - Additional Information (Detail) (Michael J. Fox Foundation for Parkinson's Research [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2007</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2007

</div>
          <div>Additional Funding Agreement Terms [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010

</div>
          <div>Additional Funding Agreement Terms [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>License agreement terms [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,
				 2007<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FundingReceivedFromResearchGrant', window );">Funding received from research grant</a></td>
        <td class="nump">$ 1.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0.4<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FundingReceivedFromResearchGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Funding received from research grant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FundingReceivedFromResearchGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_GrantFundingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchGrantRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research grant revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchGrantRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">$ 81,944<span></span></td>
        <td class="nump">$ 73,129<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
        <td class="nump">7,996<span></span></td>
        <td class="nump">6,770<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsCapitalizedResearch', window );">Capitalized research</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
        <td class="nump">7,927<span></span></td>
        <td class="nump">7,375<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
        <td class="nump">3,563<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump">1,677<span></span></td>
        <td class="nump">937<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
        <td class="nump">103,107<span></span></td>
        <td class="nump">88,216<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(103,107)<span></span></td>
        <td class="num">(88,216)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Net deferred tax liability related to intangible assets</a></td>
        <td class="num">(748)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
        <td class="num">$ (748)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsCapitalizedResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred tax assets capitalized research.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DeferredTaxAssetsCapitalizedResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences net of deferred tax asset attributable to deductible temporary differences and carryforwards after valuation allowances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments - Summary of Future Minimum Payments under Contractual Obligations (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 570<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">668<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">688<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">709<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">730<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="nump">496<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum payments</a></td>
        <td class="nump">$ 3,861<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2007

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>Upfront license fee [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock, valued</a></td>
        <td class="nump">69,492,000<span></span></td>
        <td class="nump">50,219,000<span></span></td>
        <td class="nump">4,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">636,133<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RoyaltyRevenuesExpectedToBeReceived', window );">Royalty revenues expected to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdditionalMilestonePaymentUnderAgreement', window );">Funding available under the amended agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="nump">$ 300,000<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdditionalMilestonePaymentUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional milestone payment under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AdditionalMilestonePaymentUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InitialResearchTermOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduced royalty rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ReducedRoyaltyRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RoyaltyRevenuesExpectedToBeReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty revenues expected to be received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_RoyaltyRevenuesExpectedToBeReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UpfrontLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_UpfrontLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FairValueMeasurementsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 2 &#x2013;FAIR VALUE MEASUREMENT</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company measures certain assets and liabilities at fair value
 on a recurring basis, including cash equivalents,
 available-for-sale securities and contingent consideration
 liability.&#xA0;The fair value is determined based on a three-tier
 hierarchy under the authoritative guidance for fair value
 measurements and disclosures that prioritizes the inputs used in
 measuring fair value as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Level 2: Quoted prices in markets that are not active, or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 When observable market prices for identical securities that are
 traded in less active markets are used, the Company classifies its
 available-for-sale debt instruments as Level 2. When observable
 market prices for identical securities are not available,
 available-for-sale debt instruments are priced using benchmark
 curves, benchmarking of like securities, sector groupings, and
 matrix pricing as well as model processes. These models are
 proprietary valuation models of pricing providers or brokers. These
 valuation models incorporate a number of inputs, including, listed
 in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the Standard Inputs may
 not be applicable.&#xA0;Evaluators may prioritize inputs
 differently on any given day for any security based on market
 conditions, and not all inputs listed are available for use in the
 evaluation process for each security evaluation on any given
 day.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value measurements of cash equivalents, available-for-sale
 securities and contingent consideration liabilities are identified
 at the following levels within the fair value hierarchy (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2013<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Contingent consideration liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2012<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Contingent Consideration Liability</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company initially recorded a liability on the acquisition date
 of the estimated fair value of contingent consideration payments to
 former Ceregene stockholders, as outlined under the terms of the
 merger agreement with Ceregene. These contingent payments are owed
 if the Company grants a third-party license to develop and
 commercialize certain product candidates acquired from Ceregene, or
 if the Company commercializes any of these product candidates
 itself. The fair values of these Level 3 liabilities are estimated
 using a probability-weighted discounted cash flow analysis. Such
 valuations require significant estimates and assumptions including
 but not limited to: determining the timing and estimated costs to
 complete the in-process projects, projecting regulatory approvals,
 estimating future cash flows, and developing appropriate discount
 rates.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Subsequent changes in the fair value of these contingent
 consideration liabilities are recorded to the &#x201C;Change in fair
 value of contingent liability&#x201D; expense line item in the
 Consolidated Statements of Operations under operating expenses.
 From the acquisition date of October&#xA0;1, 2013 through
 December&#xA0;31, 2013, the recognized amount of the liability for
 contingent consideration increased by $0.1 million primarily as the
 result of the passage of time.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="20%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended<br />
 December&#xA0;31,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value on date of acquisition (October 1, 2013)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value at end of period</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FairValueMeasurementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Measurements Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FairValueMeasurementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBUBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="7">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 23, 2013

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 23, 2013

</div>
          <div>Common Stock [Member]

</div>
          <div>Underwriters [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>2013 Stock Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>2010 Employee Stock Purchase Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Stock Option Activity [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Stock Option Activity [Member]

</div>
          <div>2013 Stock Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Restricted Stock Units (RSUs) [Member]

</div>
          <div>Installment</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Restricted Stock Units (RSUs) [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Restricted Stock Units (RSUs) [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,015,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Public offering price of common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.58<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance under public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 69,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">915,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm', window );">Stock option maximum term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SpecifiedStockholderOwnershipPercentage', window );">Specified stockholder ownership percentage</a></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder', window );">Purchase price of common stock percent under stock incentive plans for specified stockholder</a></td>
        <td class="nump">110.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder', window );">Stock option maximum term for specified stockholder</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based vesting rights</a></td>
        <td class="text">The RSUs will vest as follows:  One-third on second anniversary and two-thirds will vest on  the third anniversary of the award date.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Options granted under the 2013 Plan generally vest over four years at a  rate of 25 percent one year from the grant date and one thirty-sixth per month  thereafter and expire ten years after the grant, or earlier upon employment  termination.<span></span></td>
        <td class="text">These awards will vest as follows:  one-third of the award will vest in a series of three successive equal annual  installments.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage', window );">Stock options granted vesting percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm', window );">Stock options expiration term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance under plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,100,000<span></span></td>
        <td class="nump">2,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding', window );">Annual increase in number of shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized under 2004 plan</a></td>
        <td class="nump">4,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockExchangeRatio', window );">Share of common stock subject to a stock option or stock appreciation right</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockSplitRatioOnCommonStock', window );">Fixed ratio shares of common stock</a></td>
        <td class="text">1.33 shares<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanOfferingPeriod', window );">Purchase plan offering period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanPurchasePeriod', window );">Purchase plan purchase period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Shares subject to repurchase rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
        <td class="nump">8,900,000<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values outstanding options</a></td>
        <td class="nump">56,425,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic values exercisable options</a></td>
        <td class="nump">41,073,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and expected to vest, aggregate intrinsic value</a></td>
        <td class="nump">54,900,000<span></span></td>
        <td class="nump">8,500,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">392,500<span></span></td>
        <td class="nump">486,750<span></span></td>
        <td class="nump">550,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.12<span></span></td>
        <td class="nump">$ 5.41<span></span></td>
        <td class="nump">$ 2.55<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment', window );">Share-based compensation arrangement by share-based payment award, number of vesting installment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion', window );">Share-based compensation arrangement by share-based payment award, vesting portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.33<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary', window );">Share-based compensation arrangement by share-based payment award, vesting portion on second anniversary</a></td>
        <td class="nump">0.33<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary', window );">Share-based compensation arrangement by share-based payment award, vesting portion on third anniversary</a></td>
        <td class="nump">0.67<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue', window );">Aggregate value of shares vested in period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockDividendsShares', window );">Shares withheld from issuance in order to pay employee taxes</a></td>
        <td class="nump">167,138<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">8,937<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Total payments for the employees' tax obligations to taxing authorities</a></td>
        <td class="nump">$ 2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,929,590<span></span></td>
        <td class="nump">1,527,763<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockExchangeRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock Exchange Ratio</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CommonStockExchangeRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from issuance public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NetProceedsFromIssuancePublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanOfferingPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase plan offering period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PurchasePlanOfferingPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanPurchasePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase plan purchase period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PurchasePlanPurchasePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than options vest in period intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestInPeriodIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of vesting installment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options expiration term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options maximum term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award vesting percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award vesting portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award vesting portion on second anniversary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnSecondAnniversary</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award vesting portion on third anniversary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPortionOnThirdAnniversary</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SpecifiedStockholderOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Specified stockholder ownership percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_SpecifiedStockholderOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockSplitRatioOnCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Split Ratio On Common Stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_StockSplitRatioOnCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase price of common stock expressed as a percentage of its fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockDividendsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockDividendsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2646-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U
M,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P
M93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V]M/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?4W1O/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI
M>F%T:6]N7V%N9%]3=6UM87)Y7V]F7U-I/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA<FME=&%B;&5?
M4V5C=7)I=&EE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M97)S7U!A<G1N97)S
M:&EP<U]A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M06-Q=6ES:71I;VY?;V9?0V5R96=E;F4\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N=',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO
M;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^06-C;W5N='-?4&%Y86)L95]A;F1?06-C<G5E9%],/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^16UP;&]Y965?
M0F5N969I=%]0;&%N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^475A<G1E<FQY7T9I;F%N8VEA;%]$871A/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO
M;E]A;F1?4W5M;6%R>5]O9E]3:3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT7U1A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA<FME=&%B
M;&5?4V5C=7)I=&EE<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]486)L97,\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-86IO<E]#
M=7-T;VUE<G-?4&%R=&YE<G-H:7!S7V$Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^06-Q=6ES:71I;VY?;V9?0V5R96=E;F5?5&%B
M;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O
M<&5R='E?86YD7T5Q=6EP;65N=%]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]486)L97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?
M17%U:71Y7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DEN8V]M95]487AE<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S$N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R
M=65D7TPQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M475A<G1E<FQY7T9I;F%N8VEA;%]$871A7U1A8FQE/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3=6UM
M87)Y7V]F7U-I,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7U-U;6UA<CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R
M96UE;G1?061D:71I;SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1?4V-H961U;#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A
M<W5R96UE;G1?4V-H961U;#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S@N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y-87)K971A8FQE7U-E8W5R:71I97-?4V-H961U;&4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-87)K971A8FQE
M7U-E8W5R:71I97-?061D:71I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]3=&]C:T(\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A
M<V5D7T-O;7!E;G-A=&EO;E]!9&1I=&D\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#(N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]!<W-U
M;7`\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C
M:T)A<V5D7T-O;7!E;G-A=&EO;E]796EG:'0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#0N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y-86IO<E]#=7-T;VUE<G-?4&%R=&YE<G-H
M:7!S7V$R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M36%J;W)?0W5S=&]M97)S7U!A<G1N97)S:&EP<U]A,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA:F]R7T-U<W1O;65R<U]087)T
M;F5R<VAI<'-?830\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y-86IO<E]#=7-T;VUE<G-?4&%R=&YE<G-H:7!S7V$U/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M97)S
M7U!A<G1N97)S:&EP<U]A-CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T.2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DUA:F]R7T-U<W1O;65R<U]087)T;F5R<VAI<'-?83<\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-86IO<E]#=7-T
M;VUE<G-?4&%R=&YE<G-H:7!S7V$X/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4Q+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M97)S7U!A<G1N97)S:&EP<U]A
M.3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970U,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C<75I
M<VET:6]N7V]F7T-E<F5G96YE7T%D9&ET:3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N7V]F7T-E<F5G96YE7U-U
M;6UA<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970U-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C
M<75I<VET:6]N7V]F7T-E<F5G96YE7U-U;6UA<C$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8W%U:7-I=&EO;E]O9E]#97)E9V5N
M95]3=6UM87(R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#4V+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^06-Q=6ES:71I;VY?;V9?0V5R96=E;F5?4V-H961U/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#4W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP
M;65N=%]3=6UM87)Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#4X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]!9&1I=&EO/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#4Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?061D
M:71I;VYA;%]);F9O<FUA/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#8P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]M;6ET;65N='-?4W5M;6%R>5]O9E]&=71U<F5?/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#8Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S
M7T5Q=6ET>5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#8R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]3=6UM87)Y7V]F/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#8S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD
M97)S7T5Q=6ET>5]3=6UM87)Y7V]F,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?4W5M;6%R>5]O
M9C(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O
M;65?5&%X97-?061D:71I;VYA;%]);F9O<FT\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?4V-H961U;&5?;V9?
M0V]M<&$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M;F-O;65?5&%X97-?4W5M;6%R>5]O9E]!8W1I=FD\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!
M8V-R=65D7TPR/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#8Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^16UP;&]Y965?0F5N969I=%]0;&%N7T%D9&ET:6]N/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#<P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^475A<G1E<FQY7T9I;F%N8VEA
M;%]$871A7U-U;6UA/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#<Q+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W5B<V5Q=65N=%]%=F5N=%]!9&1I=&EO;F%L7TEN/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#<R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X
M.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O
M<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X
M.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X
M.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E
M/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X
M;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI
M<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@
M6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T,#$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5554%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O
M8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#`Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE
M;G0@06YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"U+/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)"3(P,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<R,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=&63QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D
M:6YG(%-Y;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U-'
M34\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)U-!3D=!34\@0DE/4T-)14Y#15,@24Y#/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S`P,#$P,#$R,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%
M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A<V]N960@27-S=65R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F\\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E
M;G0@4F5P;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)UEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#
M871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C8V5L
M97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R
M+#<S-BPX-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@4'5B;&EC($9L;V%T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-#`U+#`R,RPS,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S7S8V8SA?-#8V
M85\Y9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(O5V]R
M:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44]!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U
M:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L
M,3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R,2PV-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#(L-C(W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L.#8X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R
M96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PQ,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!C
M87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW+#(W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#,V-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!S
M96-U<FET:65S+"!N;VXM8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S@L-C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(L-3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S+"!I;BUP<F]C97-S(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PX-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y';V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T,"PX,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,BPU,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N
M="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&-O;7!E;G-A=&EO;B!A;F0@96UP;&]Y964@8F5N
M969I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3DT/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5S8W)O=R!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#<Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@<F5V96YU92P@;F]N+6-U<G)E;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-C<Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1I;F=E
M;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@=&%X(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PQ
M,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RPV,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>3H\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VLL("0P+C`Q('!A<B!V86QU93L@.#`L,#`P+#`P,"!S:&%R97,@875T
M:&]R:7IE9"P@-C(L,C0S+#@Y,B!A;F0@-3,L,#4X+#4R-2!S:&%R97,@:7-S
M=65D(&%N9"!O=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@
M,C`Q,BP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C,L,C`Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,Y+#@T.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,S`R+#$S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R-S4L-3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#<Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T+#@Y-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI
M86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#`L.#,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,BPU,S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
M9#(O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D9!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E
M=',@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E
M;65N="!/9B!&:6YA;F-I86P@4&]S:71I;VX@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#(T,RPX.3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPP-3@L-3(U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L,C0S+#@Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#`U."PU,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S
M7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X
M,3EF9#(O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05I!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!/<&5R871I;VYS("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E
M<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E=F5N=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N(&%G<F5E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$L-C<X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."PQ.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L
M,3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-E87)C:"!G<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPT-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#(P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PQ,S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PV-34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#DW
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Q+#<P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#$T-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`T
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@8V]N=&EN9V5N="!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!O<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0S+#@U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0V+#$T,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BPW,#8I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L
M,3DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,U+#@R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R(&EN8V]M92`H97AP96YS92DL(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(V+#8R-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(R
M+#(V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#,U+#<U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,"XT,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@=7-E9"!I;B!C;VUP=71I;F<@8F%S
M:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-2PY-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,BPW-#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PU,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
M9#(O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2U1!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O
M9B!#;VUP<F5H96YS:79E($QO<W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-T871E;65N="!/9B!);F-O;64@06YD($-O;7!R96AE
M;G-I=F4@26YC;VUE(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#$T-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8L,30U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M-2PT-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@V+#@X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,L-#<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PW.3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#<R."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L,C8X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,C8L-C(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,C(L,C8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,S4L-S4P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('5N<F5A
M;&EZ960@9V%I;B!O;B!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,C8L-C,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C(L,C4P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S4L-S,R*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q
M,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P
M,S@Q.69D,B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T2D1)
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE
M;G1S(&]F(%-T;V-K:&]L9&5R<R<@17%U:71Y("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y4;W1A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM
M;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^061D:71I;VYA;"!086ED+6EN($-A<&ET86P@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@1&5F
M:6-I="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y!8V-U;75L871E9"!/=&AE<B!#;VUP<F5H96YS:79E($EN8V]M92\@*$QO
M<W,I(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"96=I;FYI;F<@0F%L86YC97,@870@1&5C+B`S,2P@,C`Q,#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-2PY,#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0U-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<R
M+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,C$W+#0Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC97,L('-H87)E
M<R!A="!$96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#4L,S<W+#<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M(&EN(&-O;FYE8W1I;VX@=VET:"!U;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R
M:6YG+"!N970@;V8@:7-S=6%N8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P+#(Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,34R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O
M;6UO;B!S=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@=6YD97)W<FET=&5N('!U
M8FQI8R!O9F9E<FEN9RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S+"!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F('-T
M;V-K(&]P=&EO;G,@86YD(&EN(&-O;FYE8W1I;VX@=VET:"!R97-T<FEC=&5D
M('-T;V-K('5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#$Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E
M>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!I;B!C;VYN96-T:6]N('=I
M=&@@<F5S=')I8W1E9"!S=&]C:R!U;FET<RP@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S(T+#0Q-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K('5N9&5R(&5M<&QO>65E('-T;V-K('!U<F-H87-E('!L
M86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5N9&5R(&5M<&QO>65E('-T;V-K
M('!U<F-H87-E('!L86XL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U,BPV-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP.#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP.#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VUP<F5H96YS:79E(&QO<W,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('5N<F5A;&EZ
M960@9V%I;B`H;&]S<RD@;VX@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L-S4P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L-S4P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;7!R96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S4L-S,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E<R!A="!$96,N
M(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PQ
M,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,S(L.#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C4S+#(T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V5S+"!S:&%R
M97,@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4R+#4U-"PW.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!U<&]N(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@86YD(&EN(&-O;FYE
M8W1I;VX@=VET:"!R97-T<FEC=&5D('-T;V-K('5N:71S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Q-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS
M(&%N9"!I;B!C;VYN96-T:6]N('=I=&@@<F5S=')I8W1E9"!S=&]C:R!U;FET
M<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(X
M+#,U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5N9&5R(&5M<&QO
M>65E('-T;V-K('!U<F-H87-E('!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M('5N9&5R(&5M<&QO>65E('-T;V-K('!U<F-H87-E('!L86XL('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-2PS-S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PS,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PS,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP<F5H96YS:79E
M(&QO<W,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T('5N<F5A;&EZ960@9V%I;B`H;&]S<RD@;VX@;6%R:V5T
M86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C(L,C8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C(L,C8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L,C4P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M9&EN9R!"86QA;F-E<R!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-"PX.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,SDL.#0X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<U+#4P.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V5S+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#`U."PU,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@=6YD
M97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9RP@;F5T(&]F(&ES<W5A;F-E(&-O
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PT.3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y
M+#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@:6X@8V]N;F5C=&EO
M;B!W:71H('5N9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<L(&YE="!O9B!I
M<W-U86YC92!C;W-T<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPP,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!I;B!C;VYN
M96-T:6]N('=I=&@@<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#DY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO
M;G,@86YD(&EN(&-O;FYE8W1I;VX@=VET:"!R97-T<FEC=&5D('-T;V-K('5N
M:71S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#@X.2PX,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!E
M;7!L;WEE92!S=&]C:R!P=7)C:&%S92!P;&%N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!U;F1E<B!E;7!L;WEE92!S=&]C:R!P=7)C:&%S92!P;&%N+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L-34Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H
M(&%C<75I<VET:6]N(&]F($-E<F5G96YE+"!);F,N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H(&%C<75I<VET:6]N(&]F
M($-E<F5G96YE+"!);F,N+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY.2PY.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VUP<F5H96YS:79E(&QO<W,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('5N<F5A;&EZ
M960@9V%I;B`H;&]S<RD@;VX@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BPV,C0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BPV
M,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R-BPV,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V5S(&%T($1E
M8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3(Q+#<Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T,C,L,C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S,#(L,3,S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"
M86QA;F-E<RP@<VAA<F5S(&%T($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,BPR-#,L.#DR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V
M-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O
M<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14)&0D<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S
M:"!&;&]W<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(V+#8R-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(R+#(V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#,U+#<U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C
M;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IA=&EO;B!O9B!P<F5M:75M("\@9&ES8V]U;G0@;VX@;6%R:V5T86)L92!S
M96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#$T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M(&]N(&1I<W!O<V%L(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I
M<B!V86QU92!O9B!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;&EA8FEL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYE="!C:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17-C<F]W(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')E8V5I=F%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#`P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,L-#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#4P,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,SDI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R=65D(&-O;7!E;G-A=&EO;B!A;F0@96UP;&]Y964@8F5N969I=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,BPQ.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$L,3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL
M-#@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L,#@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(U+#@Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!U<F-H87-E<R!O9B!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q."PX.30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3$L-#(X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q,BPY
M-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-871U<FET:65S(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L,3(Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#0W,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+#0Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!S86QE<R!O9B!M87)K971A8FQE('-E8W5R:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8W%U:7-T:6]N(&]F($-E<F5G96YE+"!);F,N+"!N970@;V8@8V%S:"!R96-E
M:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R
M8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0S,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,C,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3<V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R
M;W9I9&5D(&)Y("\@*'5S960@:6XI(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V."PQ,3@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,S$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL
M.3DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY&:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!P=6)L:6,@;V9F97)I;F<@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@
M:7-S=6%N8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8Y+#0Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,"PQ-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1A>&5S('!A:60@<F5L871E9"!T;R!N970@<VAA
M<F4@<V5T=&QE;65N="!O9B!E<75I='D@87=A<F1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#`Q-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^."PV,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@
M8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<V+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L.#<V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E("\@
M*&1E8W)E87-E*2!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PT.3,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#DX,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@8F5G:6YN:6YG(&]F('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L-C<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-S8V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L-S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!E;F0@;V8@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PV
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-BPW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F5S(&]F
M(&YO;F-A<V@@:6YV97-T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@<'5R<W5A;G0@=&\@=&AE
M(&%C<75I<VET:6]N(&]F($-E<F5G96YE($EN8RX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R
M,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S
M+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3)P="<^#0H@/&(^3D]412`Q("8C>#(P,3,[
M($]21T%.25I!5$E/3B!!3D0@4U5-34%262!/1B!324=.249)0T%.5`T*($%#
M0T]53E1)3D<@4$],24-)15,\+V(^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y("TM
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0G/@T*(#QB/CQI/E-A;F=A;6\\+VD^/"]B/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%-A;F=A;6\@0FEO4V-I96YC97,L($EN
M8RX@*'1H92!#;VUP86YY(&]R(%-A;F=A;6\I('=A<R!I;F-O<G!O<F%T960-
M"B!I;B!T:&4@4W1A=&4@;V8@1&5L87=A<F4@;VX@2G5N928C>$$P.S(R+"`Q
M.3DU(&%N9"!I<R!F;V-U<V5D(&]N#0H@=&AE(')E<V5A<F-H+"!D979E;&]P
M;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@;F]V96P-"B!T:&5R87!E
M=71I8R!S=')A=&5G:65S(&9O<B!U;FUE="!M961I8V%L(&YE961S+B!386YG
M86UO)B-X,C`Q.3MS#0H@9V5N92!R96=U;&%T:6]N(&%N9"!G96YE(&UO9&EF
M:6-A=&EO;B!T96-H;F]L;V=Y('!L871F;W)M(&ES#0H@96YA8FQE9"!B>2!T
M:&4@96YG:6YE97)I;F<@;V8@82!C;&%S<R!O9B!T<F%N<V-R:7!T:6]N(&9A
M8W1O<G,-"B!K;F]W;B!A<R!Z:6YC(&9I;F=E<B!$3D$M8FEN9&EN9R!P<F]T
M96EN<R`H6D90<RDN(%!O=&5N=&EA;`T*(&%P<&QI8V%T:6]N<R!O9B!386YG
M86UO)B-X,C`Q.3MS('1E8VAN;VQO9WD@:6YC;'5D92!D979E;&]P;65N="!O
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M9&EN9R!:1E`@5&AE<F%P975T:6-S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!386YG86UO(&ES(&-U<G)E;G1L>2!W;W)K:6YG(&]N(&$@
M;G5M8F5R(&]F(&QO;F<M=&5R;2!D979E;&]P;65N=`T*('!R;VIE8W1S('1H
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M,#LS,2P-"B`R,#$S+"!A;&]N9R!W:71H(&5X<&5C=&5D(')E=F5N=65S(&9R
M;VT@8V]L;&%B;W)A=&EO;G,L('-T<F%T96=I8PT*('!A<G1N97)S:&EP<R!A
M;F0@<F5S96%R8V@@9W)A;G1S+"!W:6QL(&)E(&%D97%U871E('1O(&9U;F0@
M:71S#0H@;W!E<F%T:6]N<R!A="!L96%S="!T:')O=6=H(#(P,34N(%-A;F=A
M;6\@=VEL;"!N965D('1O(')A:7-E#0H@<W5B<W1A;G1I86P@861D:71I;VYA
M;"!C87!I=&%L('1O(&9U;F0@<W5B<V5Q=65N="!O<&5R871I;VYS(&%N9`T*
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M)B-X,C`Q.3MS(&)U<VEN97-S(&%N9"!A8FEL:71Y('1O(&1E=F5L;W`@:71S
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M<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4V%N9V%M;R!A
M8W%U:7)E9"!#97)E9V5N92P@26YC+B`H0V5R96=E;F4I(&]N($]C=&]B97(F
M(WA!,#LQ+"`R,#$S+@T*(%5N9&5R('1H92!M97)G97(@86=R965M96YT+"!3
M86YG86UO(&]B=&%I;F5D($-E<F5G96YE)B-X,C`Q.3MS#0H@=&AE<F%P975T
M:6,@<')O9W)A;7,L(&EN8VQU9&EN9R!#15)%+3$Q,"!F;W(@=&AE('1R96%T
M;65N="!O9@T*($%L>FAE:6UE<B8C>#(P,3D[<R!D:7-E87-E("A!1"D@=&AA
M="!I<R!C=7)R96YT;'D@:6X@82!0:&%S92`R#0H@8VQI;FEC86P@=')I86PN
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M86YD(&5X<&%N9"!T:&4@87!P;&EC871I;VX@;V8-"B!386YG86UO)B-X,C`Q
M.3MS(#QI/FEN('9I=F\\+VD^(%I&4"!4:&5R87!E=71I8W,L('!A<G1I8W5L
M87)L>2!T:&]S90T*('1H870@=&%R9V5T('1H92!B<F%I;BX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X
M<'0G/@T*(#QB/CQI/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO:3X\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('!R97!A<F%T:6]N
M(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:`T*
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M;F0@1V5N9&%Q($QI;6ET960L(&%F=&5R(&5L:6UI;F%T:6]N(&]F(&%L;`T*
M(&EN=&5R8V]M<&%N>2!B86QA;F-E<R!A;F0@=')A;G-A8W1I;VYS+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3AP="<^#0H@/&(^/&D^0G5S:6YE<W,@0V]M8FEN871I;VYS/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N
M>2!A8V-O=6YT960@9F]R('1H92!A8W%U:7-I=&EO;B!O9B!#97)E9V5N92!I
M;B!A8V-O<F1A;F-E#0H@=VET:"!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I
M9FEC871I;VX@*$%30RD@5&]P:6,@.#`U+"!"=7-I;F5S<PT*($-O;6)I;F%T
M:6]N<RX@05-#(%1O<&EC(#@P-2!E<W1A8FQI<VAE<R!P<FEN8VEP;&5S(&%N
M9"!R97%U:7)E;65N=',-"B!F;W(@<F5C;V=N:7II;F<@86YD(&UE87-U<FEN
M9R!T:&4@=&]T86P@8V]N<VED97)A=&EO;B!T<F%N<V9E<G)E9`T*('1O(&%N
M9"!T:&4@87-S971S(&%C<75I<F5D+"!L:6%B:6QI=&EE<R!A<W-U;65D(&%N
M9"!A;GD-"B!N;VXM8V]N=')O;&QI;F<@:6YT97)E<W1S(&EN('1H92!A8W%U
M:7)E9"!T87)G970@:6X@82!B=7-I;F5S<PT*(&-O;6)I;F%T:6]N+B!!4T,@
M5&]P:6,@.#`U(&%L<V\@<')O=FED97,@9W5I9&%N8V4@9F]R(')E8V]G;FEZ
M:6YG#0H@86YD(&UE87-U<FEN9R!G;V]D=VEL;"!A8W%U:7)E9"!I;B!A(&)U
M<VEN97-S(&-O;6)I;F%T:6]N.R!R97%U:7)E<PT*('!U<F-H87-E9"!I;BUP
M<F]C97-S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!T;R!B92!C87!I=&%L
M:7IE9"!A=`T*(&9A:7(@=F%L=64@87,@:6YT86YG:6)L92!A<W-E=',@870@
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P
M<'0G/@T*(#QB/CQI/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M871E(&)A;FL-"B!A8V-O=6YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@07,@<&%R="!O9B!T:&4@86-Q=6ES:71I;VX@;V8@0V5R96=E
M;F4L(%-A;F=A;6\@=V%S(')E<75I<F5D('1O('-E=`T*(&%S:61E("0P+C,@
M;6EL;&EO;B!I;B!A;B!E<V-R;W<@86-C;W5N="!U;G1I;"!/8W1O8F5R)B-X
M03`[,2P@,C`Q-"X-"B!4:&4@8V%S:"!H;VQD(&EN(&5S8W)O=R!W87,@<F5C
M;W)D960@87,@<F5S=')I8W1E9"!C87-H+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^
M/&D^36%R:V5T86)L92!396-U<FET:65S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!386YG86UO(&-L87-S:69I97,@:71S(&UA
M<FME=&%B;&4@<V5C=7)I=&EE<R!A<R!A=F%I;&%B;&4M9F]R+7-A;&4-"B!A
M;F0@<F5C;W)D<R!I=',@:6YV97-T;65N=',@870@97-T:6UA=&5D(&9A:7(@
M=F%L=64@8F%S960@;VX@<75O=&5D#0H@;6%R:V5T('!R:6-E<R!O<B!O8G-E
M<G9A8FQE(&UA<FME="!I;G!U=',@;V8@86QM;W-T(&ED96YT:6-A;`T*(&%S
M<V5T<RP@=VET:"!T:&4@=6YR96%L:7IE9"!H;VQD:6YG(&=A:6YS(&%N9"!L
M;W-S97,@:6YC;'5D960@:6X-"B!A8V-U;75L871E9"!O=&AE<B!C;VUP<F5H
M96YS:79E(&EN8V]M92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
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M(&AA<PT*(&)E96X@;&5S<R!T:&%N('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y&86ER(%9A;'5E($UE87-U<F5M96YT
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
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M:6=H(&-R961I="!S=&%N9&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@87)E('-T
M871E9"!A="!C;W-T+"!L97-S(&%C8W5M=6QA=&5D#0H@9&5P<F5C:6%T:6]N
M(&%N9"!A;6]R=&EZ871I;VXN($1E<')E8VEA=&EO;B!I<R!C86QC=6QA=&5D
M('5S:6YG('1H90T*('-T<F%I9VAT+6QI;F4@;65T:&]D(&)A<V5D(&]N('1H
M92!E<W1I;6%T960@=7-E9G5L(&QI=F5S(&]F('1H90T*(')E;&%T960@87-S
M971S("AG96YE<F%L;'D@=&AR964@=&\@9FEV92!Y96%R<RDN($9O<B!L96%S
M96AO;&0-"B!I;7!R;W9E;65N=',L(&%M;W)T:7IA=&EO;B!I<R!C86QC=6QA
M=&5D('5S:6YG('1H92!S=')A:6=H="UL:6YE#0H@;65T:&]D(&)A<V5D(&]N
M('1H92!S:&]R=&5R(&]F('1H92!U<V5F=6P@;&EF92!O<B!T:&4@;&5A<V4@
M=&5R;2X-"B!4:&4@0V]M<&%N>2!R979I97=S(&ET<R!P<F]P97)T>2!A;F0@
M97%U:7!M96YT(&9O<B!I;7!A:7)M96YT#0H@=VAE;F5V97(@979E;G1S(&]R
M(&-H86YG97,@:6X@8VER8W5M<W1A;F-E<R!I;F1I8V%T92!T:&%T('1H90T*
M(&-A<G)Y:6YG(&%M;W5N="!O9B!A;B!A<W-E="!M87D@;F]T(&)E(')E8V]V
M97)A8FQE+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4F5V96YU92!296-O9VYI
M=&EO;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M4F5V96YU97,@9G)O;2!R97-E87)C:"!A8W1I=FET:65S(&UA9&4@=6YD97(@
M<W1R871E9VEC('!A<G1N97)I;F<-"B!A9W)E96UE;G1S(&%N9"!C;VQL86)O
M<F%T:6]N<R!A<F4@<F5C;V=N:7IE9"!A<R!T:&4@<V5R=FEC97,@87)E#0H@
M<')O=FED960@=VAE;B!T:&5R92!I<R!P97)S=6%S:79E(&5V:61E;F-E('1H
M870@86X@87)R86YG96UE;G0-"B!E>&ES=',L(&1E;&EV97)Y(&AA<R!O8V-U
M<G)E9"P@=&AE('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L92P-"B!A
M;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+B!2979E
M;G5E(&=E;F5R871E9"!F<F]M#0H@<F5S96%R8V@@86YD(&QI8V5N<VEN9R!A
M9W)E96UE;G1S('1Y<&EC86QL>2!I;F-L=61E<R!U<&9R;VYT#0H@<VEG;FEN
M9R!O<B!L:6-E;G-E(&9E97,L(&-O<W0@<F5I;6)U<G-E;65N=',L(')E<V5A
M<F-H('-E<G9I8V5S+`T*(&UI;FEM=6T@<W5B;&EC96YS92!F965S+"!M:6QE
M<W1O;F4@<&%Y;65N=',@86YD(')O>6%L=&EE<R!O;B!F=71U<F4-"B!L:6-E
M;G-E928C>#(P,3D[<R!P<F]D=6-T('-A;&5S+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B`\:3Y-=6QT:7!L92!%;&5M96YT($%R<F%N9V5M
M96YT<R!P<FEO<B!T;R!T:&4@861O<'1I;VX@;V8@05-5#0H@3F\N)B-X03`[
M,C`P.2TQ,RP@4F5V96YU92!296-O9VYI=&EO;B8C>#(P,30[375L=&EP;&4@
M1&5L:79E<F%B;&4-"B!2979E;G5E($%R<F%N9V5M96YT<R`H05-5(#(P,#DM
M,3,I/"]I/BX@1F]R(')E=F5N=64@87)R86YG96UE;G1S#0H@96YT97)E9"!I
M;G1O(&)E9F]R92!*86YU87)Y)B-X03`[,2P@,C`Q,2P@=&AA="!I;F-L=61E
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M<FEO<B!T;PT*('1H92!A9&]P=&EO;B!O9B!!4U4@,C`P.2TQ,RP@=&AE($-O
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(#QI/DUU;'1I<&QE($5L96UE;G0@07)R86YG96UE;G1S
M(&%F=&5R('1H92!A9&]P=&EO;B!O9B!!4U4-"B`R,#`Y+3$S+CPO:3X@05-5
M(#(P,#DM,3,@86UE;F1E9"!T:&4@86-C;W5N=&EN9R!S=&%N9&%R9',@9F]R
M#0H@8V5R=&%I;B!M=6QT:7!L92!E;&5M96YT(')E=F5N=64@87)R86YG96UE
M;G1S('1O.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS
M1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L
M969T/G!R;W9I9&4@=7!D871E9"!G=6ED86YC92!O;B!W:&5T:&5R#0H@;75L
M=&EP;&4@96QE;65N=',@97AI<W0L(&AO=R!T:&4@96QE;65N=',@:6X@86X@
M87)R86YG96UE;G0@<VAO=6QD#0H@8F4@<V5P87)A=&5D+"!A;F0@:&]W('1H
M92!A<G)A;F=E;65N="!C;VYS:61E<F%T:6]N('-H;W5L9"!B90T*(&%L;&]C
M871E9"!T;R!T:&4@<V5P87)A=&4@96QE;65N=',[/"]T9#X-"B`\+W1R/@T*
M(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L
M969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F
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M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@-G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D
M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X
M,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/F5L:6UI
M;F%T92!T:&4@=7-E(&]F('1H92!R97-I9'5A;`T*(&UE=&AO9"!A;F0@<F5Q
M=6ER92!A;B!E;G1I='D@=&\@86QL;V-A=&4@87)R86YG96UE;G0@8V]N<VED
M97)A=&EO;@T*('5S:6YG('1H92!R96QA=&EV92!S96QL:6YG('!R:6-E(&UE
M=&AO9"X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!&;W(@<F5V96YU92!A9W)E96UE;G1S('=I=&@@;75L
M=&EP;&4@96QE;65N="!A<G)A;F=E;65N=',L('-U8V@@87,-"B!L:6-E;G-E
M(&%N9"!D979E;&]P;65N="!A9W)E96UE;G1S+"!E;G1E<F5D(&EN=&\@;VX@
M;W(@869T97(-"B!*86YU87)Y)B-X03`[,2P@,C`Q,2P@=&AE($-O;7!A;GD@
M86QL;V-A=&5S(')E=F5N=64@=&\@96%C:`T*(&YO;BUC;VYT:6YG96YT(&5L
M96UE;G0@8F%S960@;VX@=&AE(')E;&%T:79E('-E;&QI;F<@<')I8V4@;V8@
M96%C:`T*(&5L96UE;G0N(%=H96X@87!P;'EI;F<@=&AE(')E;&%T:79E('-E
M;&QI;F<@<')I8V4@;65T:&]D+"!T:&4-"B!#;VUP86YY(&1E=&5R;6EN97,@
M=&AE('-E;&QI;F<@<')I8V4@9F]R(&5A8V@@9&5L:79E<F%B;&4@=7-I;F<-
M"B!64T]%(&]F('-E;&QI;F<@<')I8V4@;W(@5%!%(&]F('-E;&QI;F<@<')I
M8V4N($EF(&YE:71H97(@97AI<W1S#0H@=&AE($-O;7!A;GD@=7-E<R!%4U`@
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M;W)M97)L>2!3:&ER92!!1RP-"B`H4VAI<F4I(&EN($IA;G5A<GD@,C`Q,B!W
M87,@979A;'5A=&5D('5N9&5R('1H97-E(&%M96YD960-"B!A8V-O=6YT:6YG
M('-T86YD87)D<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M=&\@=&AA=`T*(&]B:F5C=&EV97,@=VEL;"!B92!A8VAI979E9"!A;F0@:68@
M=&AE(&%C:&EE=F5M96YT(&ES(&)A<V5D(&]N('1H90T*($-O;7!A;GDF(W@R
M,#$Y.W,@<&5R9F]R;6%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($UI;FEM=6T@86YN=6%L('-U8FQI8V5N<V4@9F5E<R!A<F4@86QS
M;R!R96-O9VYI>F5D(&%S(')E=F5N=64@:6X-"B!T:&4@<&5R:6]D(&EN('=H
M:6-H('-U8V@@9F5E<R!A<F4@9'5E+B!2;WEA;'1Y(')E=F5N=65S(&%R90T*
M(&=E;F5R86QL>2!R96-O9VYI>F5D('=H96X@96%R;F5D(&%N9"!C;VQL96-T
M86)I;&ET>2!O9B!T:&4@<F5L871E9`T*(')O>6%L='D@<&%Y;65N="!I<R!R
M96%S;VYA8FQY(&%S<W5R960N(%1H92!#;VUP86YY(')E8V]G;FEZ97,@8V]S
M=`T*(')E:6UB=7)S96UE;G0@<F5V96YU92!U;F1E<B!C;VQL86)O<F%T:79E
M(&%G<F5E;65N=',@87,@=&AE(')E;&%T960-"B!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@8V]S=',@9F]R('-E<G9I8V5S(&%R92!R96YD97)E9"X@1&5F
M97)R960-"B!R979E;G5E(')E<')E<V5N=',@=&AE('!O<G1I;VX@;V8@<F5S
M96%R8V@@;W(@;&EC96YS92!P87EM96YT<PT*(')E8V5I=F5D('=H:6-H(&AA
M=F4@;F]T(&)E96X@96%R;F5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!386YG86UO)B-X,C`Q.3MS(')E<V5A<F-H(&=R86YT<R!A<F4@
M='EP:6-A;&QY(&UU;'1I+7EE87(@86=R965M96YT<PT*(&%N9"!P<F]V:61E
M(&9O<B!T:&4@<F5I;6)U<G-E;65N="!O9B!Q=6%L:69I960@97AP96YS97,@
M9F]R#0H@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%S(&1E9FEN960@=6YD
M97(@=&AE('1E<FUS(&]F('1H92!G<F%N=`T*(&%G<F5E;65N="X@4F5V96YU
M92!U;F1E<B!G<F%N="!A9W)E96UE;G1S(&ES(')E8V]G;FEZ960@=VAE;B!T
M:&4-"B!R96QA=&5D('%U86QI9FEE9"!R97-E87)C:"!E>'!E;G-E<R!A<F4@
M:6YC=7)R960N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($1U
M<FEN9R`R,#$S+"!R979E;G5E<R!R96QA=&5D('1O(%-H:7)E+"!3:6=M82U!
M;&1R:6-H($-O<G!O<F%T:6]N#0H@*%-I9VUA*2!A;F0@1&]W($%G<F]38VEE
M;F-E<R!,3$,@*$1!4RD@<F5P<F5S96YT960@-C@E+"`Y)2!A;F0@,3(E+`T*
M(')E<W!E8W1I=F5L>2P@;V8@=&]T86P@<F5V96YU97,N($1U<FEN9R`R,#$R
M+"!R979E;G5E<R!R96QA=&5D#0H@4VAI<F4L(%-I9VUA(&%N9"!$05,@<F5P
M<F5S96YT960@-3$E+"`Q,24@86YD(#(R)2!O9B!T;W1A;`T*(')E=F5N=65S
M+"!R97-P96-T:79E;'DN($1U<FEN9R`R,#$Q+"!R979E;G5E<R!R96QA=&5D
M('1O(%-I9VUA+`T*($1!4RP@0V%L:69O<FYI82!);G-T:71U=&4@9F]R(%)E
M9V5N97)A=&EV92!-961I8VEN92`H0TE232D@86YD($-(1$D-"B!&;W5N9&%T
M:6]N+"!);F,N("A#2$1)*2!R97!R97-E;G1E9"`Q-24L(#0S)2P@,3@E(&%N
M9"`Q,24@;V8@=&]T86P-"B!R979E;G5E<RP@<F5S<&5C=&EV96QY+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@
M,7!X.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^
M#0H@/&(^/&D^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&5X<&5N<V5D(&%S(&EN8W5R
M<F5D+B!297-E87)C:`T*(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!C;VYS
M:7-T(&]F(&1I<F5C="!A;F0@<F5S96%R8V@M<F5L871E9`T*(&%L;&]C871E
M9"!O=F5R:&5A9"!C;W-T<R!S=6-H(&%S(&9A8VEL:71I97,@8V]S=',L('-A
M;&%R:65S(&%N9`T*(')E;&%T960@<&5R<V]N;F5L(&-O<W1S+"!A;F0@;6%T
M97)I86P@86YD('-U<'!L>2!C;W-T<RX@26X-"B!A9&1I=&EO;BP@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(&EN8VQU9&4@8V]S=',@<F5L
M871E9`T*('1O(&-L:6YI8V%L('1R:6%L<RP@=F%L:61A=&EO;B!O9B!T:&4@
M0V]M<&%N>28C>#(P,3D[<R!T97-T:6YG#0H@<')O8V5S<V5S(&%N9"!P<F]C
M961U<F5S(&%N9"!A<R!W96QL(&%S(')E;&%T960@;W9E<FAE860@97AP96YS
M97,N#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S(&EN8W5R<F5D
M(&EN(&-O;FYE8W1I;VX@=VET:`T*(&-O;&QA8F]R871O<BUF=6YD960@86-T
M:79I=&EE<R!A<F4@97AP96YS960@87,@:6YC=7)R960N($-O<W1S('1O#0H@
M86-Q=6ER92!T96-H;F]L;V=I97,@=&AA="!A<F4@=71I;&EZ960@:6X@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT#0H@=&AA="!H879E(&YO(&%L=&5R;F%T
M:79E(&9U='5R92!U<V4@87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3AP="<^#0H@/&(^/&D^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>2!M96%S=7)E<R!A;F0@<F5C;V=N:7IE<R!C;VUP96YS871I;VX@97AP
M96YS92!F;W(@86QL#0H@<W1O8VLM8F%S960@<&%Y;65N="!A=V%R9',@;6%D
M92!T;R!386YG86UO(&5M<&QO>65E<R!A;F0@9&ER96-T;W)S+`T*(&EN8VQU
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4;R!E<W1I;6%T92!T:&4@
M=F%L=64@;V8@86X@87=A<F0L('1H92!#;VUP86YY('5S97,@=&AE#0H@0FQA
M8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@5&AI<R!M;V1E;"!R
M97%U:7)E<R!I;G!U=',@<W5C:`T*(&%S(&5X<&5C=&5D(&QI9F4L(&5X<&5C
M=&5D('9O;&%T:6QI='D@86YD(')I<VLM9G)E92!I;G1E<F5S="!R871E+@T*
M(%1H97-E(&EN<'5T<R!A<F4@<W5B:F5C=&EV92!A;F0@9V5N97)A;&QY(')E
M<75I<F4@<VEG;FEF:6-A;G0-"B!A;F%L>7-I<R!A;F0@:G5D9VUE;G0@=&\@
M9&5V96QO<"X@5VAI;&4@97-T:6UA=&5S(&]F(&5X<&5C=&5D(&QI9F4-"B!A
M;F0@=F]L871I;&ET>2!A<F4@9&5R:79E9"!P<FEM87)I;'D@9G)O;2!T:&4@
M0V]M<&%N>28C>#(P,3D[<PT*(&AI<W1O<FEC86P@9&%T82P@=&AE(')I<VLM
M9G)E92!R871E(&ES(&)A<V5D(&]N('1H92!5+E,N(%1R96%S=7)Y#0H@>6EE
M;&0@8W5R=F4@:6X@969F96-T(&%T('1H92!T:6UE(&]F(&=R86YT(&-O;6UE
M;G-U<F%T92!W:71H('1H90T*(&5X<&5C=&5D(&QI9F4@87-S=6UP=&EO;BX@
M1G5R=&AE<BP@=&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\-"B!E<W1I;6%T
M92!F;W)F96ET=7)E<R!A="!T:&4@=&EM92!O9B!G<F%N="!A;F0@<F5V:7-E
M('1H;W-E#0H@97-T:6UA=&5S(&EN('-U8G-E<75E;G0@<&5R:6]D<R!I9B!A
M8W1U86P@9F]R9F5I='5R97,@9&EF9F5R(&9R;VT-"B!T:&]S92!E<W1I;6%T
M97,N(%1H92!#;VUP86YY('5S97,@:&ES=&]R:6-A;"!D871A('1O(&5S=&EM
M871E#0H@<')E+79E<W1I;F<@;W!T:6]N(&9O<F9E:71U<F5S(&%N9"!R96-O
M<F0@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N#0H@97AP96YS92!O;FQY(&9O
M<B!T:&]S92!A=V%R9',@=&AA="!A<F4@97AP96-T960@=&\@=F5S="X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/DEN=&%N9VEB;&4@07-S971S("8C>#(P,3,[
M($EN+5!R;V-E<W,@4F5S96%R8V@@86YD#0H@1&5V96QO<&UE;G0\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M=6QD(&)E(&1E96UE9`T*(&9I;FET92UL:79E9"!A;F0@=V]U;&0@=&AE;B!B
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M=&AE(&9A:7(@=F%L=64@;V8@=&AE($E04B9A;7`[1"!P<F]J96-T<R!B96QO
M=R!T:&5I<@T*(')E<W!E8W1I=F4@8V%R<GEI;F<@86UO=6YT<RX@5&AE($-O
M;7!A;GD@;V)S97)V960@;F\@:6UP86ER;65N=`T*(&EN9&EC871O<G,@;V8@
M=&AE(')E8V]R9&5D($E04B9A;7`[1"!I;B!T:&4@>65A<B!E;F1E9`T*($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D=O
M;V1W:6QL/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
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M#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/CQI/D-O;G1I;F=E;G0@0V]N<VED97)A=&EO;B!,:6%B:6QI='D\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/F5A<FXM;W5T/"]F;VYT/B!P
M87EM96YT<R!W:6QL(&)E8V]M92!P87EA8FQE#0H@:6X@=&AE('!E<FEO9"!T
M:&5Y(&%R92!E87)N960N($EN(&%C8V]R9&%N8V4@=VET:"!!4T,@5&]P:6,@
M.#`U+`T*($)U<VEN97-S($-O;6)I;F%T:6]N<RP@=&AE($-O;7!A;GD@9&5T
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M=&\@97AP96YS92!I;B!T:&4@)B-X,C`Q0SM#:&%N9V5S#0H@:6X@9F%I<B!V
M86QU92!O9B!C;VYT:6YG96YT(&QI86)I;&ET>28C>#(P,40[(&5X<&5N<V4@
M;&EN92!I=&5M(&EN#0H@=&AE($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F
M($]P97)A=&EO;G,@=6YD97(@;W!E<F%T:6YG#0H@97AP96YS97,N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CX\:3Y.970@3&]S<R!097(@4VAA<F4\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M9R!D=7)I;F<@=&AE('!E<FEO9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@0F5C875S92!386YG86UO(&ES(&EN(&$@;F5T(&QO<W,@<&]S
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M(&5N9"!O9B`R,#$S+"`R,#$R(&%N9`T*(#(P,3$@=V5R92`X+#0P-2PX-C0L
M(#DL,3@T+#,T-B!A;F0@."PS-#8L,3DP+"!R97-P96-T:79E;'DN/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CX\:3Y396=M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@;W!E<F%T97,@:6X@
M;VYE('-E9VUE;G0N($UA;F%G96UE;G0@=7-E<R!O;F4-"B!M96%S=7)E;65N
M="!O9B!P<F]F:71A8FEL:71Y(&%N9"!D;V5S(&YO="!S96=R96=A=&4@:71S
M(&)U<VEN97-S#0H@9F]R(&EN=&5R;F%L(')E<&]R=&EN9RX@07,@;V8@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q,BP@86QL#0H@;V8@=&AE($-O
M;7!A;GDF(W@R,#$Y.W,@87-S971S('=E<F4@;6%I;G1A:6YE9"!I;B!T:&4@
M52Y3+B!&;W(@=&AE#0H@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@
M,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@,3`P)2!O9B!R979E;G5E<PT*(&%N9"!O
M<&5R871I;F<@97AP96YS97,@=V5R92!G96YE<F%T960@86YD(&EN8W5R<F5D
M(&EN('1H92!5+E,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E;G0@06-C
M;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@26X@1F5B<G5A<GD@,C`Q,RP@=&AE($9!4T(@
M:7-S=65D($%352!.;RXF(WA!,#LR,#$S+3`R+`T*($-O;7!R96AE;G-I=F4@
M26YC;VUE("A4;W!I8R`R,C`I.B!297!O<G1I;F<@;V8@06UO=6YT<R!296-L
M87-S:69I960-"B!/=70@;V8@06-C=6UU;&%T960@3W1H97(@0V]M<')E:&5N
M<VEV92!);F-O;64N(%1H:7,@;F5W;'D@:7-S=65D#0H@86-C;W5N=&EN9R!S
M=&%N9&%R9"!R97%U:7)E<R!A;B!E;G1I='D@=&\@<')O=FED92!I;F9O<FUA
M=&EO;B!A8F]U=`T*('1H92!A;6]U;G1S(')E8VQA<W-I9FEE9"!O=70@;V8@
M86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV90T*(&EN8V]M92!B>2!C
M;VUP;VYE;G0N(%1H:7,@05-5(&ES(&5F9F5C=&EV92!F;W(@<F5P;W)T:6YG
M('!E<FEO9',-"B!B96=I;FYI;F<@869T97(@1&5C96UB97(F(WA!,#LQ-2P@
M,C`Q,BX@5&AE($-O;7!A;GD@861O<'1E9"!T:&ES#0H@<W1A;F1A<F0@:6X@
M=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,R!A;F0@=&AE(&%D;W!T:6]N(&]F
M('1H:7,-"B!S=&%N9&%R9"!D:60@;F]T(&AA=F4@86X@:6UP86-T(&]N(&ET
M<R!F:6YA;F-I86P@<&]S:71I;VX@;W(-"B!R97-U;'1S(&]F(&]P97)A=&EO
M;G,N/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S
M,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H
M965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY&86ER(%9A;'5E($UE87-U<F5M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1E>'0@0FQO8VL@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!686QU92!-96%S=7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/DY/5$4@,B`F(W@R
M,#$S.T9!25(@5D%,544@345!4U5214U%3E0\+V(^/"]P/@T*(#PA+2T@>&)R
M;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#0E.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@3&5V96P@,3H@56YA9&IU<W1E9"!Q=6]T960@<')I8V5S(&EN(&%C=&EV
M92!M87)K971S('1H870@87)E#0H@86-C97-S:6)L92!A="!T:&4@;65A<W5R
M96UE;G0@9&%T92!F;W(@:61E;G1I8V%L+"!U;G)E<W1R:6-T960-"B!A<W-E
M=',@;W(@;&EA8FEL:71I97,[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-"4[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!,979E;"`R.B!1=6]T960@<')I8V5S
M(&EN(&UA<FME=',@=&AA="!A<F4@;F]T(&%C=&EV92P@;W(@:6YP=71S#0H@
M=VAI8V@@87)E(&]B<V5R=F%B;&4L(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I
M<F5C=&QY+"!F;W(-"B!S=6)S=&%N=&EA;&QY('1H92!F=6QL('1E<FT@;V8@
M=&AE(&%S<V5T(&]R(&QI86)I;&ET>3L\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@
M-G!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`T)3L@34%21TE.+51/4#H@,'!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*($QE=F5L(#,Z(%!R:6-E<R!O<B!V86QU871I
M;VX@=&5C:&YI<75E<R!T:&%T(')E<75I<F4@:6YP=71S('1H870-"B!A<F4@
M8F]T:"!S:6=N:69I8V%N="!T;R!T:&4@9F%I<B!V86QU92!M96%S=7)E;65N
M="!A;F0@=6YO8G-E<G9A8FQE#0H@*&DN92XL('-U<'!O<G1E9"!B>2!L:71T
M;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y*2X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5VAE;B!O8G-E<G9A8FQE(&UA<FME="!P<FEC97,@
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M9R!O9B!L:6ME('-E8W5R:71I97,L('-E8W1O<B!G<F]U<&EN9W,L(&%N9`T*
M(&UA=')I>"!P<FEC:6YG(&%S('=E;&P@87,@;6]D96P@<')O8V5S<V5S+B!4
M:&5S92!M;V1E;',@87)E#0H@<')O<')I971A<GD@=F%L=6%T:6]N(&UO9&5L
M<R!O9B!P<FEC:6YG('!R;W9I9&5R<R!O<B!B<F]K97)S+B!4:&5S90T*('9A
M;'5A=&EO;B!M;V1E;',@:6YC;W)P;W)A=&4@82!N=6UB97(@;V8@:6YP=71S
M+"!I;F-L=61I;F<L(&QI<W1E9`T*(&EN(&%P<')O>&EM871E(&]R9&5R(&]F
M('!R:6]R:71Y.B!B96YC:&UA<FL@>6EE;&1S+"!R97!O<G1E9`T*('1R861E
M<RP@8G)O:V5R+V1E86QE<B!Q=6]T97,L(&ES<W5E<B!S<')E861S+"!T=V\M
M<VED960@;6%R:V5T<RP-"B!B96YC:&UA<FL@<V5C=7)I=&EE<RP@8FED<RP@
M;V9F97)S(&%N9"!R969E<F5N8V4@9&%T82!I;F-L=61I;F<-"B!M87)K970@
M<F5S96%R8V@@<'5B;&EC871I;VYS+B!&;W(@8V5R=&%I;B!S96-U<FET>2!T
M>7!E<RP-"B!A9&1I=&EO;F%L(&EN<'5T<R!M87D@8F4@=7-E9"P@;W(@<V]M
M92!O9B!T:&4@4W1A;F1A<F0@26YP=71S(&UA>0T*(&YO="!B92!A<'!L:6-A
M8FQE+B8C>$$P.T5V86QU871O<G,@;6%Y('!R:6]R:71I>F4@:6YP=71S#0H@
M9&EF9F5R96YT;'D@;VX@86YY(&=I=F5N(&1A>2!F;W(@86YY('-E8W5R:71Y
M(&)A<V5D(&]N(&UA<FME=`T*(&-O;F1I=&EO;G,L(&%N9"!N;W0@86QL(&EN
M<'5T<R!L:7-T960@87)E(&%V86EL86)L92!F;W(@=7-E(&EN('1H90T*(&5V
M86QU871I;VX@<')O8V5S<R!F;W(@96%C:"!S96-U<FET>2!E=F%L=6%T:6]N
M(&]N(&%N>2!G:79E;@T*(&1A>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@5&AE(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&]F(&-A<V@@
M97%U:79A;&5N=',L(&%V86EL86)L92UF;W(M<V%L90T*('-E8W5R:71I97,@
M86YD(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI=&EE<R!A<F4@
M:61E;G1I9FEE9`T*(&%T('1H92!F;VQL;W=I;F<@;&5V96QS('=I=&AI;B!T
M:&4@9F%I<B!V86QU92!H:65R87)C:'D@*&EN#0H@=&AO=7-A;F1S*3H\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R(&)O<F1E<CTS1#`^/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V-24^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F
M(WA!,#LS,2PF(WA!,#LR,#$S/&)R("\^#0H@1F%I<B8C>$$P.U9A;'5E)B-X
M03`[365A<W5R96UE;G1S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"8C
M>$$P.S$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[,SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@07-S971S.CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L.3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV
M+#DS-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(WA!,#LF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(WA!,#LF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S
M96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(Q
M+#(Y,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R
M,2PR.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ,C@L,C(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.3,T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$R,2PR.3`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3&EA8FEL:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI
M='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4W,#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X03`[
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PU-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PU-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(WA!,#LF(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>$$P.R8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3<P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0Q-CX\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P
M.S(P,3(\8G(@+SX-"B!&86ER)B-X03`[5F%L=64F(WA!,#M-96%S=7)E;65N
M=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P
M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[,3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@
M,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^3&5V96PF(WA!,#LS/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!
M<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`U96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K970@
M9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PX,SD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U
M<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3<L-#0Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3<L-#0Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,L
M,C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU-RPT-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M
M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y#;VYT:6YG96YT($-O;G-I
M9&5R871I;VX@3&EA8FEL:71Y/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
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M87EM96YT<R!A<F4@;W=E9`T*(&EF('1H92!#;VUP86YY(&=R86YT<R!A('1H
M:7)D+7!A<G1Y(&QI8V5N<V4@=&\@9&5V96QO<"!A;F0-"B!C;VUM97)C:6%L
M:7IE(&-E<G1A:6X@<')O9'5C="!C86YD:61A=&5S(&%C<75I<F5D(&9R;VT@
M0V5R96=E;F4L(&]R#0H@:68@=&AE($-O;7!A;GD@8V]M;65R8VEA;&EZ97,@
M86YY(&]F('1H97-E('!R;V1U8W0@8V%N9&ED871E<PT*(&ET<V5L9BX@5&AE
M(&9A:7(@=F%L=65S(&]F('1H97-E($QE=F5L(#,@;&EA8FEL:71I97,@87)E
M(&5S=&EM871E9`T*('5S:6YG(&$@<')O8F%B:6QI='DM=V5I9VAT960@9&ES
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M<GD@87!P<F]V86QS+`T*(&5S=&EM871I;F<@9G5T=7)E(&-A<V@@9FQO=W,L
M(&%N9"!D979E;&]P:6YG(&%P<')O<')I871E(&1I<V-O=6YT#0H@<F%T97,N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3
M25I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M3V-T;V)E<B8C>$$P.S$L(#(P,3,@=&AR;W5G:`T*($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3,L('1H92!R96-O9VYI>F5D(&%M;W5N="!O9B!T:&4@;&EA8FEL
M:71Y(&9O<@T*(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!I;F-R96%S960@
M8GD@)#`N,2!M:6QL:6]N('!R:6UA<FEL>2!A<R!T:&4-"B!R97-U;'0@;V8@
M=&AE('!A<W-A9V4@;V8@=&EM92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X\
M(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS
M1#<T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP
M*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY996%R(&5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!
M,#LS,2PF(WA!,#LR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!&86ER('9A;'5E(&]N(&1A=&4@;V8@86-Q=6ES:71I;VX@*$]C=&]B
M97(@,2P@,C`Q,RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PU,3`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-H86YG92!I;B!F86ER('9A
M;'5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9A:7(@=F%L=64@870@
M96YD(&]F('!E<FEO9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3<P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^
M#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C
M.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA<FME
M=&%B;&4@4V5C=7)I=&EE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT<R!$96)T($%N9"!%<75I
M='D@4V5C=7)I=&EE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87)K971A8FQE(%-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T
M)SX-"B`\8CY.3U1%(#,@)B-X,C`Q,SM-05)+151!0DQ%(%-%0U52251)15,\
M+V(^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE('1A8FQE(&)E;&]W('-U;6UA<FEZ97,@=&AE($-O
M;7!A;GDF(W@R,#$Y.W,@8V%S:"!E<75I=F%L96YT<R!A;F0-"B!A=F%I;&%B
M;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`^/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*
M(#QT<CX-"B`\=&0@=VED=&@],T0V-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY!;6]R=&EZ960\8G(@
M+SX-"B!#;W-T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY'<F]S<SQB<B`O/@T*(%5N<F5A;&EZ960\8G(@+SX-"B!'
M86EN<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^1W)O<W,\8G(@+SX-"B!5;G)E86QI>F5D/&)R("\^#0H@*$QO<W-E
M<RD\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/D5S=&EM871E9#QB<B`O/@T*($9A:7(F(WA!,#M686QU93PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y
M("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,SPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<V@@97%U
M:79A;&5N=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-BPY,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.3,T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-BPY,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.3,T/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!!=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@-65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET
M:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,C$L,C<X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3(Q+#(Y,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T
M86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,C@L,C$R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(X+#(R-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B`\8CY$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]B
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!#87-H(&5Q=6EV86QE;G1S.CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`U96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!5+E,N(&=O=F5R;FUE
M;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E8W5R:71I97,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR+#DY-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#5E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($UO;F5Y(&UA<FME="!F=6YD
M<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ-2PX,SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ."PX,S8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+#@S
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@079A:6QA8FQE+69O
M<BUS86QE('-E8W5R:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%4N4RX@9V]V97)N;65N="!S<&]N<V]R960@96YT
M:71Y(&1E8G0@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-30L-#(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-30L-#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B
M;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<S
M+#(V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<S+#(X.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D
M>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S
M(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(&%L;"!O9B!T:&4@0V]M<&%N
M>28C>#(P,3D[<PT*(&EN=F5S=&UE;G1S(&AA9"!M871U<FET>2!D871E<R!W
M:71H:6X@='=O('EE87)S(&%N9"!T:&5R92!W97)E(&YO#0H@;6%T97)I86P@
M=6YR96%L:7IE9"!L;W-S97,@9'5R:6YG(#(P,3,N($%P<')O>&EM871E;'D@
M-S`E(&]F('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@879A:6QA8FQE+69O<BUS
M86QE('-E8W5R:71I97,@;6%T=7)E('=I=&AI;B!T:&4-"B!N97AT('1W96QV
M92!M;VYT:',@;V8@=&AE(&1A=&4@;V8@=&AE(&)A;&%N8V4@<VAE970@9&%T
M92!A;F0-"B!A<'!R;WAI;6%T96QY(#,P)2!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!A=F%I;&%B;&4M9F]R+7-A;&4-"B!S96-U<FET:65S(&AA=F4@;6%T
M=7)I=&EE<R!B971W965N('1W96QV92!A;F0@='=E;G1Y+69O=7(@;6]N=&AS
M#0H@9G)O;2!T:&4@9&%T92!O9B!T:&4@8F%L86YC92!S:&5E="!D871E+B!4
M:&4@0V]M<&%N>2!H860@;F\-"B!M871E<FEA;"!R96%L:7IE9"!L;W-S97,@
M;W(@;W1H97(M=&AA;BUT96UP;W)A<GD@:6UP86ER;65N=',@;V8-"B!A=F%I
M;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!F;W(@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z
M(#%P>#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(`T*(`T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y
M9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!/9B!#;VUP96YS871I;VX@4F5L
M871E9"!#;W-T<R!3:&%R96)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^3D]412`T("8C>#(P,3,[(%-4
M3T-++4)!4T5$($-/35!%3E-!5$E/3CPO8CX\+W`^#0H@/"$M+2!X8G)L+&)O
M9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-H;W=S('1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E#0H@<F5C;V=N:7IE9"!I;B!T:&4@8V]N<V]L:61A=&5D('-T
M871E;65N=',@;V8@;W!E<F%T:6]N<R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.#0E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB
M/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,RPR,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M.#DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#<V.3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@1V5N97)A;"!A;F0@861M:6YI<W1R
M871I=F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DT,CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#0T-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,Q,CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!S
M=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L,30V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,S,X/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,#@Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@07,@;V8@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,RP@=&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M#0H@97AP96YS92!R96QA=&5D('1O('5N=F5S=&5D('-T;V-K(&]P=&EO;G,@
M=&\@8F4@<F5C;V=N:7IE9"!I;@T*(&9U='5R92!P97)I;V1S('=A<R`D,3$N
M,B8C>$$P.VUI;&QI;VXL('=H:6-H(&ES(&5X<&5C=&5D('1O(&)E#0H@97AP
M96YS960@;W9E<B!A('=E:6=H=&5D+6%V97)A9V4@<&5R:6]D(&]F(#(N.#<@
M>65A<G,N($%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=&]T86P@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;PT*('5N=F5S=&5D(%)3
M57,@=&\@8F4@<F5C;V=N:7IE9"!I;B!F=71U<F4@<&5R:6]D<R!W87,@)#4N
M-"!M:6QL:6]N+`T*('=H:6-H(&ES(&5X<&5C=&5D('1O(&)E(&5X<&5N<V5D
M(&]V97(@82!W96EG:'1E9"UA=F5R86=E('!E<FEO9"!O9@T*(#$N.3@@>65A
M<G,N(%1H97)E('=A<R!N;R!C87!I=&%L:7IE9"!S=&]C:RUB87-E9"!E;7!L
M;WEE90T*(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&%S(&]F($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY686QU871I;VX@07-S
M=6UP=&EO;G,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@
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M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!W96EG:'1E9"UA=F5R
M86=E(&5S=&EM871E9"!F86ER('9A;'5E('!E<B!S:&%R92!O9B!O<'1I;VYS
M#0H@9W)A;G1E9"!D=7)I;F<@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2!W87,@)#@N
M,CDL("0S+C<V(&%N9"`D,RXR,"P-"B!R97-P96-T:79E;'DL(&)A<V5D('5P
M;VX@=&AE(&%S<W5M<'1I;VX@:6X@=&AE($)L86-K+5-C:&]L97,-"B!V86QU
M871I;VX@;6]D96PN(%1H92!A<W-U;7!T:6]N<R!U<V5D(&9O<B!E<W1I;6%T
M:6YG('1H92!F86ER('9A;'5E#0H@;V8@=&AE(&5M<&QO>65E('-T;V-K(&]P
M=&EO;G,@87)E(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(^
M/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0V,"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M
M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L
M92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%)I<VLM9G)E92!I;G1E<F5S="!R871E/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G5TA)5$4M
M4U!!0T4Z(&YO=W)A<"<^,2XU,"TQ+C@X/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G5TA)5$4M4U!!0T4Z(&YO=W)A<"<^,"XW
M-"TQ+C,T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G5TA)5$4M4U!!0T4Z(&YO=W)A<"<^,"XY,RTR+C$Q/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N("AI;B!Y96%R
M<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C,V+34N,S@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XT,"TU+C4X/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,SDM-2XT,3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T960@
M9&EV:61E;F0@>6EE;&0@;V8@<W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T960@=F]L871I;&ET
M>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.#@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XX-RTP+C@X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C`N.#,M,"XX-CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!%;7!L;WEE97,@<'5R8VAA<V5D
M(&%P<')O>&EM871E;'D@,3@Q+#`P,"P@,3<U+#`P,"!A;F0@,34S+#`P,`T*
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&AR;W5G:"!T:&4@,C`Q,"!0=7)C
M:&%S92!0;&%N(&%T(&%N(&%V97)A9V4-"B!E>&5R8VES92!P<FEC92!O9B`D
M,BXW-2P@)#(N-C$@86YD("0S+C`R('!E<B!S:&%R92!D=7)I;F<@=&AE#0H@
M9FES8V%L('EE87)S(#(P,3,L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L
M>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE('=E:6=H
M=&5D+6%V97)A9V4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@<VAA<F5S('!U
M<F-H87-E9"!U;F1E<@T*('1H92!#;VUP86YY)B-X,C`Q.3MS($534%`@9'5R
M:6YG(#(P,3,L(#(P,3(@86YD(#(P,3$@=V5R92`D,2XT-RP-"B`D,BXU,2!A
M;F0@)#$N-C(L(')E<W!E8W1I=F5L>2P@8F%S960@=7!O;B!T:&4@87-S=6UP
M=&EO;G,@:6X@=&AE#0H@0FQA8VLM4V-H;VQE<R!V86QU871I;VX@;6]D96PN
M(%1H92!W96EG:'1E9"8C>#(P,3,[879E<F%G90T*(&%S<W5M<'1I;VYS('5S
M960@9F]R(&5S=&EM871I;F<@=&AE(&9A:7(@=F%L=64@;V8@=&AE($534%`@
M<'5R8VAA<V4-"B!R:6=H=',@87)E(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4]
M,T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI
M9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0V,"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%
M;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M
M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)I<VLM9G)E92!I;G1E<F5S="!R
M871E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G5TA)5$4M4U!!0T4Z(&YO=W)A<"<^,"XP-2TP+C8Q/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G5TA)5$4M4U!!0T4Z
M(&YO=W)A<"<^,"XP-2TP+C,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G5TA)5$4M4U!!0T4Z(&YO=W)A<"<^,"XP-2TP+C8Q
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X<&5C=&5D(&QI9F4@;V8@;W!T
M:6]N("AI;B!Y96%R<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XP+C4M,BXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-2TR+C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XU+3(N,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T960@
M9&EV:61E;F0@>6EE;&0@;V8@<W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T960@=F]L871I;&ET
M>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-3$M,"XX-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+CDS+3$N,S<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XU."TP+C@U/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^36%J;W(@0W5S=&]M97)S+"!087)T;F5R<VAI
M<',@86YD(%-T<F%T96=I8R!!;&QI86YC97,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($-O
M;G-O;&ED871I;VX@06YD(%!R97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A
M=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP
M<R!A;F0@4W1R871E9VEC($%L;&EA;F-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^3D]412`U("8C>#(P
M,3,[($U!2D]2($-54U1/34524RP@4$%25$Y%4E-(25!3($%.1"!35%)!5$5'
M24,-"B!!3$Q)04Y#15,\+V(^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y("TM/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`V<'0G/@T*(#QB/D-O;&QA8F]R871I;VX@06=R965M96YT<SPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P="<^#0H@/&(^/&D^0V]L;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!
M9W)E96UE;G0@=VET:"!3:&ER92!);G1E<FYA=&EO;F%L#0H@1VUB2"P@9F]R
M;65R;'D@4VAI<F4@04<L(&EN($AU;6%N(%1H97)A<&5U=&EC<R!A;F0-"B!$
M:6%G;F]S=&EC<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@26X@2F%N=6%R>2`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@82!C;VQL86)O<F%T:6]N(&%N9`T*(&QI8V5N<V4@86=R965M96YT("AT
M:&4@06=R965M96YT*2!W:71H(%-H:7)E('!U<G-U86YT('1O('=H:6-H('1H
M90T*($-O;7!A;GD@86YD(%-H:7)E(&-O;&QA8F]R871E('1O(')E<V5A<F-H
M+"!D979E;&]P(&%N9`T*(&-O;6UE<F-I86QI>F4@:'5M86X@=&AE<F%P975T
M:6-S(&%N9"!D:6%G;F]S=&EC<R!F;W(@;6]N;V=E;FEC#0H@9&ES96%S97,@
M8F%S960@;VX@4V%N9V%M;R8C>#(P,3D[<R!:1E`@=&5C:&YO;&]G>2X@56YD
M97(@=&AE#0H@06=R965M96YT+"!T:&4@0V]M<&%N>2!A;F0@4VAI<F4@;6%Y
M(&1E=F5L;W`@<&]T96YT:6%L(&AU;6%N#0H@=&AE<F%P975T:6,@;W(@9&EA
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M#0H@6D90('1H97)A<&5U=&EC(&9O<B!(=6YT:6YG=&]N)B-X,C`Q.3MS(&1I
M<V5A<V4@*$A$*2P@86X@:6YH97)I=&5D#0H@;F5U<F]D96=E;F5R871I=F4@
M9&ES96%S92!F;W(@=VAI8V@@=&AE<F4@87)E(&-U<G)E;G1L>2!N;PT*('1H
M97)A<&EE<R!A=F%I;&%B;&4@=&\@<VQO=R!T:&4@9&ES96%S92!P<F]G<F5S
M<VEO;BX@4VAI<F4@:&%S('1H90T*(')I9VAT+"!S=6)J96-T('1O(&-E<G1A
M:6X@;&EM:71A=&EO;G,L('1O(&1E<VEG;F%T92!T=V\@861D:71I;VYA;`T*
M(&=E;F4@=&%R9V5T<RX@4'5R<W5A;G0@=&\@=&AE($%G<F5E;65N="P@=&AE
M($-O;7!A;GD@9W)A;G1E9"!3:&ER90T*(&%N(&5X8VQU<VEV92P@=V]R;&0M
M=VED92P@<F]Y86QT>2UB96%R:6YG(&QI8V5N<V4L('=I=&@@=&AE(')I9VAT
M#0H@=&\@9W)A;G0@<W5B;&EC96YS97,L('1O('5S92!386YG86UO)B-X,C`Q
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M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%5N9&5R('1H92!T97)M<R!O9B!T:&4@06=R965M96YT+"!T:&4@
M0V]M<&%N>2!I<R!R97-P;VYS:6)L92!F;W(-"B!A;&P@<F5S96%R8V@@86-T
M:79I=&EE<R!T:')O=6=H('1H92!S=6)M:7-S:6]N(&]F(&%N($EN=F5S=&EG
M871I=F4-"B!.97<@1')U9R!!<'!L:6-A=&EO;B`H24Y$*2!O<B!%=7)O<&5A
M;B!#;&EN:6-A;"!4<FEA;"!!<'!L:6-A=&EO;@T*("A#5$$I+"!W:&EL92!3
M:&ER92!I<R!R97-P;VYS:6)L92!F;W(@8VQI;FEC86P@9&5V96QO<&UE;G0@
M86YD#0H@8V]M;65R8VEA;&EZ871I;VX@;V8@<')O9'5C=',@9V5N97)A=&5D
M(&9R;VT@=&AE(')E<V5A<F-H('!R;V=R86T-"B!F<F]M(&%N9"!A9G1E<B!T
M:&4@86-C97!T86YC92!O9B!A;B!)3D0@;W(@0U1!(&9O<B!T:&4@<')O9'5C
M="X-"B!3:&ER92!R96EM8G5R<V5S(%-A;F=A;6\@9F]R(&ET<R!I;G1E<FYA
M;"!A;F0@97AT97)N86P@<F5S96%R8V@-"B!P<F]G<F%M+7)E;&%T960@8V]S
M=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%5N9&5R('1H
M92!A9W)E96UE;G0L('1H92!#;VUP86YY(')E8V5I=F5D(&%N('5P9G)O;G0@
M;&EC96YS92!F964@;V8-"B`D,3,N,"!M:6QL:6]N+B!);B!A9&1I=&EO;BP@
M=&AE($-O;7!A;GD@=VEL;"!A;'-O(&)E(&5L:6=I8FQE('1O#0H@<F5C96EV
M92`D,S,N-2!M:6QL:6]N(&EN('!A>6UE;G1S('5P;VX@=&AE(&%C:&EE=F5M
M96YT(&]F('-P96-I9FEE9`T*(')E<V5A<F-H+"!R96=U;&%T;W)Y+"!C;&EN
M:6-A;"!D979E;&]P;65N="!M:6QE<W1O;F5S+"!I;F-L=61I;F<-"B!P87EM
M96YT<R!F;W(@96%C:"!G96YE('1A<F=E="!T:')O=6=H('1H92!A8V-E<'1A
M;F-E(&]F(&%N($E.1"!O<@T*($-402!S=6)M:7-S:6]N('1O=&%L:6YG("0X
M+C4@;6EL;&EO;BP@87,@=V5L;"!A<R`D,3@P(&UI;&QI;VX@:6X-"B!P87EM
M96YT<R!U<&]N('1H92!A8VAI979E;65N="!O9B!S<&5C:69I960@8V]M;65R
M8VEA;&EZ871I;VX@86YD#0H@<V%L97,@;6EL97-T;VYE<RX@5&AE('1O=&%L
M(&%M;W5N="!O9B!P;W1E;G1I86P@;6EL97-T;VYE('!A>6UE;G1S#0H@9F]R
M(&5A8V@@;V8@=&AE('-E=F5N(&=E;F4@=&%R9V5T<RP@87-S=6UI;F<@=&AE
M(&%C:&EE=F5M96YT(&]F(&%L;`T*('-P96-I9FEE9"!M:6QE<W1O;F5S(&EN
M('1H92!!9W)E96UE;G0L(&ES("0R,3,N-2!M:6QL:6]N+B!4:&4-"B!#;VUP
M86YY('=I;&P@86QS;R!B92!E;&EG:6)L92!T;R!R96-E:79E(')O>6%L='D@
M<&%Y;65N=',@=&AA="!A<F4-"B!A('1I97)E9"!D;W5B;&4M9&EG:70@<&5R
M8V5N=&%G92!O9B!N970@<V%L97,@;V8@;&EC96YS960@<')O9'5C=`T*('-O
M;&0@8GD@4VAI<F4@;W(@:71S('-U8FQI8V5N<V5E<R!D979E;&]P960@=6YD
M97(@=&AE#0H@8V]L;&%B;W)A=&EO;BP@:68@86YY+B!4;R!D871E+"!N;R!P
M<F]D=6-T<R!H879E(&)E96X@87!P<F]V960@86YD#0H@=&AE<F5F;W)E(&YO
M(')O>6%L='D@9F5E<R!H879E(&)E96X@96%R;F5D('5N9&5R('1H92!!9W)E
M96UE;G0@=VET:`T*(%-H:7)E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M;W)M86YC92P-"B`H:6DI)B-X03`[9F]R('=H:6-H('1H97)E('=A<R!S=6)S
M=&%N=&EV92!U;F-E<G1A:6YT>2!A="!T:&4@9&%T90T*('1H92!A9W)E96UE
M;G0@=V%S(&5N=&5R960@:6YT;R!T:&%T('1H92!E=F5N="!W;W5L9"!B92!A
M8VAI979E9"!A;F0-"B`H:6EI*28C>$$P.W1H870@=V]U;&0@<F5S=6QT(&EN
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M(&%N9`T*(&-O;&QE8W1A8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9"X@
M4F5V96YU92!F;W(@=&AE(&%C:&EE=F5M96YT#0H@;V8@;6EL97-T;VYE<R!T
M:&%T(&%R92!N;W0@<W5B<W1A;G1I=F4@=VEL;"!B92!R96-O9VYI>F5D(&]V
M97(@=&AE#0H@<F5M86EN:6YG('!E<FEO9"!O9B!T:&4@06=R965M96YT+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=&AE($-O;7!A;GD@:&%S
M#0H@9&5F97)R960@<F5V96YU92!O9B`D."XY(&UI;&QI;VX@<F5L871E9"!T
M;R!T:&ES($%G<F5E;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@4F5V96YU97,@<F5C;V=N:7IE9"!U;F1E<B!T:&4@86=R965M96YT
M('=I=&@@4VAI<F4@9F]R('1H92!Y96%R<PT*(&5N9&5D($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,@86YD(#(P,3(L('=E<F4@87,@9F]L;&]W<R`H:6X-"B!T
M:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^665A<B!E;F1E9#QB
M<B`O/@T*($1E8V5M8F5R(#,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2979E;G5E<R!R
M96QA=&5D('1O(%-H:7)E($-O;&QA8F]R871I;VXZ/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@06UO<G1I>F%T:6]N
M(&]F('5P9G)O;G0@9F5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M,38W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#DX-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S
M96%R8V@@<V5R=FEC97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.2PP,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$V+#0U,SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,2PP,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!296QA=&5D(&-O<W1S(&%N9"!E>'!E;G-E<R!I
M;F-U<G)E9"!U;F1E<B!T:&4@4VAI<F4@86=R965M96YT('=E<F4-"B`D,30N
M,B!M:6QL:6]N(&%N9"`D-RXW(&UI;&QI;VX@9'5R:6YG('1H92!T=V5L=F4@
M;6]N=&AS(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q
M,BP@<F5S<&5C=&EV96QY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($EN($IU;'D@,C`P-RP@4V%N9V%M;R!E;G1E<F5D(&EN=&\@82!L
M:6-E;G-E(&%G<F5E;65N="!W:71H(%-I9VUA+@T*(%5N9&5R('1H92!L:6-E
M;G-E(&%G<F5E;65N="P@4V%N9V%M;R!A9W)E960@=&\@<')O=FED92!3:6=M
M82!W:71H#0H@86-C97-S('1O(&ET<R!P<F]P<FEE=&%R>2!:1E`@=&5C:&YO
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M:"!P<F]G<F%M('1O(&1E=F5L;W`@;&%B;W)A=&]R>2!R97-E87)C:"!R96%G
M96YT<PT*('5S:6YG(%-A;F=A;6\F(W@R,#$Y.W,@6D90('1E8VAN;VQO9WD@
M9'5R:6YG('=H:6-H('1I;64@4V%N9V%M;PT*(&%G<F5E9"!T;R!A<W-I<W0@
M4VEG;6$@:6X@8V]N;F5C=&EO;B!W:71H(&ET<R!E9F9O<G1S('1O(&UA<FME
M="!A;F0-"B!S96QL('-E<G9I8V5S(&5M<&QO>6EN9R!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!:1E`@=&5C:&YO;&]G>2!I;B!T:&4-"B!R97-E87)C:"!F:65L
M9"X@4V%N9V%M;R!H87,@=')A;G-F97)R960@=&AE(%I&4"!M86YU9F%C='5R
M:6YG#0H@=&5C:&YO;&]G>2!T;R!3:6=M82X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@26X@3V-T;V)E<B`R,#`Y+"!386YG86UO(&5X<&%N
M9&5D(&ET<R!L:6-E;G-E(&%G<F5E;65N="!W:71H(%-I9VUA+@T*($EN(&%D
M9&ET:6]N('1O('1H92!O<FEG:6YA;"!T97)M<R!O9B!T:&4@;&EC96YS92!A
M9W)E96UE;G0L(%-I9VUA#0H@<F5C96EV960@97AC;'5S:79E(')I9VAT<R!T
M;R!D979E;&]P(&%N9"!D:7-T<FEB=71E(%I&4"UM;V1I9FEE9`T*(&-E;&P@
M;&EN97,@9F]R(&-O;6UE<F-I86P@<')O9'5C=&EO;B!O9B!P<F]T96EN('!H
M87)M86-E=71I8V%L<R!A;F0-"B!C97)T86EN(%I&4"UE;F=I;F5E<F5D('1R
M86YS9V5N:6,@86YI;6%L<R!F;W(@8V]M;65R8VEA;`T*(&%P<&QI8V%T:6]N
M<RX@56YD97(@=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L(%-I9VUA(&UA
M9&4@86X-"B!U<&9R;VYT(&-A<V@@<&%Y;65N="!O9B`D,C`N,"!M:6QL:6]N
M(&-O;G-I<W1I;F<@;V8@82`D-"XY(&UI;&QI;VX-"B!P=7)C:&%S92!O9B`V
M,S8L,3,S('-H87)E<R!O9B!386YG86UO(&-O;6UO;B!S=&]C:RP@=F%L=65D
M(&%T("0T+CD-"B!M:6QL:6]N+"!A;F0@82`D,34N,2!M:6QL:6]N('5P9G)O
M;G0@;&EC96YS92!F964N(%-A;F=A;6\@:7,@86QS;PT*(&5L:6=I8FQE('1O
M(')E8V5I=F4@8V]M;65R8VEA;"!L:6-E;G-E(&9E97,@;V8@)#4N,"!M:6QL
M:6]N(&)A<V5D#0H@=7!O;B!A('!E<F-E;G1A9V4@;V8@;F5T('-A;&5S(&%N
M9"!S=6)L:6-E;G-I;F<@<F5V96YU92!A;F0-"B!T:&5R96%F=&5R(&$@<F5D
M=6-E9"!R;WEA;'1Y(')A=&4@;V8@,3`N-24@;V8@;F5T('-A;&5S(&%N9`T*
M('-U8FQI8V5N<VEN9R!R979E;G5E+B!);B!A9&1I=&EO;BP@=7!O;B!T:&4@
M86-H:65V96UE;G0@;V8@8V5R=&%I;@T*(&-U;75L871I=F4@8V]M;65R8VEA
M;"!M:6QE<W1O;F5S(%-I9VUA('=I;&P@;6%K92!M:6QE<W1O;F4@<&%Y;65N
M=',-"B!T;R!386YG86UO('5P('1O(&%N(&%G9W)E9V%T92!O9B`D,C4N,"!M
M:6QL:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!2979E
M;G5E<R!R96-O9VYI>F5D('5N9&5R('1H92!A9W)E96UE;G0@=VET:"!3:6=M
M82!F;W(@=&AE('EE87)S#0H@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q
M,RP@,C`Q,B!A;F0@,C`Q,2P@=V5R92!A<R!F;VQL;W=S("AI;@T*('1H;W5S
M86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,"4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP
M*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI
M9VX],T1C96YT97(^/&(^665A<B!E;F1E9#QB<B`O/@T*($1E8V5M8F5R(#,Q
M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L
M,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M
M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2979E;G5E(')E;&%T960@=&\@4VEG
M;6$@0V]L;&%B;W)A=&EO;CH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@4F]Y86QT>2!R979E;G5E<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M,C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,S@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QI8V5N
M<V4@9F5E(&%N9"!M:6QE<W1O;F4@<F5V96YU97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#,U,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XV-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$W
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#(X.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#8P.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\
M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].
M5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E;&%T960@8V]S=',@86YD
M(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!3:6=M82!A9W)E96UE;G0@
M=V5R90T*("0P+C(@;6EL;&EO;BP@)#`N,R!M:6QL:6]N(&%N9"`D,"XU(&UI
M;&QI;VX@9'5R:6YG(#(P,3,L(#(P,3(@86YD#0H@,C`Q,2P@<F5S<&5C=&EV
M96QY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^06=R965M96YT('=I=&@@1&]W
M($%G<F]38VEE;F-E<R!I;B!0;&%N=`T*($%G<FEC=6QT=7)E/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!/8W1O8F5R(#(P
M,#4L(%-A;F=A;6\@96YT97)E9"!I;G1O(&%N(&5X8VQU<VEV92!C;VUM97)C
M:6%L#0H@;&EC96YS92!W:71H($1!4RX@56YD97(@=&AI<R!A9W)E96UE;G0L
M(%-A;F=A;6\@:7,@<')O=FED:6YG($1!4PT*('=I=&@@86-C97-S('1O(&ET
M<R!P<F]P<FEE=&%R>2!:1E`@=&5C:&YO;&]G>2!A;F0@=&AE(&5X8VQU<VEV
M90T*(')I9VAT('1O('5S92!T:&4@=&5C:&YO;&]G>2!T;R!M;V1I9GD@=&AE
M(&=E;F]M97,@;W(@86QT97(@=&AE#0H@;G5C;&5I8R!A8VED(&]R('!R;W1E
M:6X@97AP<F5S<VEO;B!O9B!P;&%N="!C96QL<RP@<&QA;G1S+"!O<B!P;&%N
M=`T*(&-E;&P@8W5L='5R97,N(%-A;F=A;6\@:&%S(')E=&%I;F5D(')I9VAT
M<R!T;R!U<V4@<&QA;G1S(&]R#0H@<&QA;G0M9&5R:79E9"!P<F]D=6-T<R!T
M;R!D96QI=F5R(%I&4"!T<F%N<V-R:7!T:6]N(&9A8W1O<G,@*%I&4`T*(%1&
M<RD@;W(@6D90(&YU8VQE87-E<R`H6D9.<RD@:6YT;R!H=6UA;G,@;W(@86YI
M;6%L<R!F;W(@9&EA9VYO<W1I8RP-"B!T:&5R87!E=71I8R!O<B!P<F]P:'EL
M86-T:6,@<'5R<&]S97,N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&%G<F5E;65N
M=`T*('=I=&@@1$%3('!R;W9I9&5D(&9O<B!A;B!I;FET:6%L('1H<F5E+7EE
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M<F]D=6-T<R!A;F0@<&QA;G0M9&5R:79E9`T*(&)I;W!H87)M86-E=71I8V%L
M<RX@5&AE(&5X97)C:7-E(&]F('1H92!O<'1I;VX@=')I9V=E<F5D(&$@;VYE
M+71I;64-"B!C;VUM97)C:6%L(&QI8V5N<V4@9F5E(&]F("0V+C`F(WA!,#MM
M:6QL:6]N+"!P87EM96YT(&]F('1H90T*(')E;6%I;FEN9R`D,BXS(&UI;&QI
M;VX@;V8@=&AE('!R979I;W5S;'D@86=R965D("0T+C`F(WA!,#MM:6QL:6]N
M#0H@:6X@<F5S96%R8V@@;6EL97-T;VYE<RP@9&5V96QO<&UE;G0@86YD(&-O
M;6UE<F-I86QI>F%T:6]N(&UI;&5S=&]N90T*('!A>6UE;G1S(&9O<B!E86-H
M('!R;V1U8W0L(&%N9"!R;WEA;'1I97,@;VX@<V%L97,@;V8@<')O9'5C=',N
M#0H@1G5R=&AE<FUO<F4L($1!4R!H87,@=&AE(')I9VAT('1O('-U8FQI8V5N
M<V4@4V%N9V%M;R8C>#(P,3D[<R!:1E`-"B!T96-H;F]L;V=Y('1O('1H:7)D
M('!A<G1I97,@9F]R('5S92!I;B!P;&%N="!C96QL<RP@<&QA;G1S+"!O<@T*
M('!L86YT(&-E;&P@8W5L='5R97,L(&%N9"!386YG86UO('=I;&P@8F4@96YT
M:71L960@=&\@,C4E(&]F(&%N>0T*(&-A<V@@8V]N<VED97)A=&EO;B!R96-E
M:79E9"!B>2!$05,@=6YD97(@<W5C:"!S=6)L:6-E;G-E<RX@26X-"B!$96-E
M;6)E<B`R,#$P+"!T:&4@0V]M<&%N>2!A;65N9&5D(&ET<R!A9W)E96UE;G0@
M=VET:"!$05,@=&\@97AT96YD#0H@=&AE('!E<FEO9"!O9B!R96%G96YT(&UA
M;G5F86-T=7)I;F<@<V5R=FEC97,@86YD(')E<V5A<F-H('-E<G9I8V5S#0H@
M=&AR;W5G:"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@86=R965M96YT(&%L<V\@<')O=FED
M97,@9F]R(&UI;FEM=6T@<W5B;&EC96YS92!F965S(&5A8V@@>65A<@T*(&1U
M92!T;R!386YG86UO(&5V97)Y($]C=&]B97(L('!R;W9I9&5D('1H92!A9W)E
M96UE;G0@:7,@;F]T#0H@=&5R;6EN871E9"!B>2!$05,N($%N;G5A;"!F965S
M(')A;F=E(&9R;VT@)#(U,"PP,#`@=&\@)#,N,"!M:6QL:6]N#0H@86YD('1O
M=&%L("0R-2XS(&UI;&QI;VX@;W9E<B`Q,2!Y96%R<RX@5&AE($-O;7!A;GD@
M9&]E<R!N;W0@:&%V90T*(&%N>2!P97)F;W)M86YC92!O8FQI9V%T:6]N<R!W
M:71H(')E<W!E8W0@=&\@=&AE('-U8FQI8V5N<VEN9PT*(&%C=&EV:71I97,@
M=&\@8F4@8V]N9'5C=&5D(&)Y($1!4RX@1$%3(&AA<R!T:&4@<FEG:'0@=&\@
M=&5R;6EN871E#0H@=&AE(&%G<F5E;65N="!A="!A;GD@=&EM93L@86-C;W)D
M:6YG;'DL('1H92!#;VUP86YY)B-X,C`Q.3MS(&%C='5A;`T*('-U8FQI8V5N
M<V4@9F5E<R!O=F5R('1H92!T97)M(&]F('1H92!A9W)E96UE;G0@8V]U;&0@
M8F4@;&]W97(@=&AA;@T*("0R-2XS)B-X03`[;6EL;&EO;BX@26X@861D:71I
M;VXL(&5A8V@@<&%R='D@;6%Y('1E<FUI;F%T92!T:&4-"B!A9W)E96UE;G0@
M=7!O;B!A;B!U;F-U<F5D(&UA=&5R:6%L(&)R96%C:"!O9B!T:&4@86=R965M
M96YT(&)Y('1H90T*(&]T:&5R('!A<G1Y+B!);B!T:&4@979E;G0@;V8@86YY
M('1E<FUI;F%T:6]N(&]F('1H92!A9W)E96UE;G0L(&%L;`T*(')I9VAT<R!T
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M=6-T<R!D97)I=F5D(&9R;VT@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!:1E`@
M=&5C:&YO;&]G>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M4F5V96YU97,@=6YD97(@=&AE(&%G<F5E;65N="!W97)E("0S+C`@;6EL;&EO
M;BP@)#0N-R!M:6QL:6]N(&%N9`T*("0T+C4@;6EL;&EO;B!D=7)I;F<@,C`Q
M,RP@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B!296QA=&5D#0H@8V]S
M=',@86YD(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!A9W)E96UE;G0@
M=V5R92`D,"XT(&UI;&QI;VXL#0H@)#`N-B!M:6QL:6]N(&%N9"`D,"XY(&UI
M;&QI;VX@9'5R:6YG(#(P,3,L(#(P,3(@86YD(#(P,3$L#0H@<F5S<&5C=&EV
M96QY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3AP="<^#0H@/&(^1G5N9&EN9R!F<F]M(%)E<V5A<F-H
M($9O=6YD871I;VYS/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B`\8CX\:3Y#86QI9F]R
M;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE("T-"B!(
M258\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN
M($]C=&]B97(@,C`P.2P@0TE232P@82!3=&%T92!O9B!#86QI9F]R;FEA(&5N
M=&ET>2P@9W)A;G1E9"!A#0H@)#$T+C4@;6EL;&EO;B!$:7-E87-E(%1E86T@
M4F5S96%R8V@@07=A<F0@=&\@9&5V96QO<"!A;B!(258O04E$4PT*('1H97)A
M<'D@8F%S960@;VX@=&AE(&%P<&QI8V%T:6]N(&]F(%I&3B!G96YE(&5D:71I
M;F<@=&5C:&YO;&]G>2!I;@T*(&AE;6%T;W!O:65T:6,@<W1E;2!C96QL<R`H
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M96-E:79E9"!F=6YD<R!T;W1A;&EN9R`D-2XR(&UI;&QI;VX-"B!F<F]M('1H
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M86UO)B-X,C`Q.3MS(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT(&5F9F]R
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M(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(&%L;"!R979E;G5E<PT*('5N
M9&5R('1H92!A=V%R9"!H879E(&)E96X@<F5C;V=N:7IE9"!A;F0@86QL(&9U
M;F1S(&AA=F4@8F5E;@T*(')E8V5I=F5D+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0
M.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!2979E;G5E<R!A='1R:6)U=&%B;&4@=&\@<F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT('!E<F9O<FUE9"!U;F1E<@T*('1H92!#25)-(&=R86YT(&%G
M<F5E;65N="!W97)E("0Q+C(@;6EL;&EO;BP@)#$N,B!M:6QL:6]N(&%N9"`D
M,2XW#0H@;6EL;&EO;B!D=7)I;F<@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@<F5S
M<&5C=&EV96QY+B!296QA=&5D(&-O<W1S#0H@9'5R:6YG(#(P,3,L(#(P,3(@
M86YD(#(P,3$@=V5R92`D,2XX(&UI;&QI;VXL("0Q+C(@;6EL;&EO;B!A;F0@
M)#(N,`T*(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*
M(#QB/CQI/D-A;&EF;W)N:6$@26YS=&ET=71E(&9O<B!296=E;F5R871I=F4@
M365D:6-I;F4@+0T*($)E=&$M5&AA;&%S<V5M:6$\+VD^/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($UA>2`R,#$S+"!#25)-(&=R
M86YT960@=&AE($-O;7!A;GD@82`D-BXT(&UI;&QI;VX@4W1R871E9VEC#0H@
M4&%R=&YE<G-H:7`@07=A<F0@=&\@9&5V96QO<"!A('!O=&5N=&EA;&QY(&-U
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M96UE;G0@8F5T=V5E;B!386YG86UO(&%N9`T*($-)4DTL('!A>6UE;G1S(&9R
M;VT@4V%N9V%M;RP@;W(@:71S(&-O;&QA8F]R871O<G,L(&9R;VT@<V%L97,@
M;V8@80T*(&-O;6UE<F-I86P@<')O9'5C="!R97-U;'1I;F<@9G)O;2!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@969F;W)T<PT*('-U<'!O<G1E9"!B>2!T
M:&4@9W)A;G0L(&EN(&%C8V]R9&%N8V4@=VET:"!4:71L92`Q-RP@0V%L:69O
M<FYI80T*($-O9&4@;V8@4F5G=6QA=&EO;G,L(%-E8W1I;VX@,3`P-C`P+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!2979E;G5E(&%T=')I
M8G5T86)L92!T;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<&5R9F]R;65D
M('5N9&5R#0H@=&AE($-)4DT@9W)A;G0@86=R965M96YT(&9O<B!B971A+71H
M86QA<W-E;6EA('=A<R`D,"XQ(&UI;&QI;VX@:6X-"B`R,#$S+B!296QA=&5D
M(&-O<W1S(&1U<FEN9R`R,#$S('=E<F4@)#`N-"!M:6QL:6]N+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,3AP="<^#0H@/&(^/&D^0TA$22!&;W5N9&%T:6]N+"!);F,N/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!!<')I;"`R,#$Q
M+"!386YG86UO(&5N=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!T:&4@
M0TA$22!T;PT*(&1E=F5L;W`@82!N;W9E;"!T:&5R87!E=71I8R!F;W(@2$0@
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M;F<@,C`Q,BP@=&AE#0H@86=R965M96YT('=A<R!A;65N9&5D('1O(&5X=&5N
M9"!T:&4@<')O:F5C="!T:')O=6=H($%U9W5S="`R,#$R(&%N9`T*('1O(&EN
M8W)E87-E('1O=&%L('!O=&5N=&EA;"!F=6YD:6YG(&9R;VT@)#$N,R!M:6QL
M:6]N('1O("0R+C$-"B!M:6QL:6]N+"!P;'5S(')E:6UB=7)S96UE;G0@9F]R
M(&-E<G1A:6X@9&ER96-T(&5X<&5N<V5S(')E;&%T960@=&\-"B!T:&4@<')O
M:F5C="X@5&AE(&%G<F5E;65N="!W:71H($-(1$D@=&5R;6EN871E9"!O;B!!
M=6=U<W0F(WA!,#LS,2P-"B`R,#$R+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!2979E;G5E<R!A='1R:6)U=&%B;&4@=&\@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT('!E<F9O<FUE9"!U;F1E<@T*('1H92!#2$1)(&-O
M;&QA8F]R871I;VX@86=R965M96YT('=E<F4@)#$N,2!M:6QL:6]N(&1U<FEN
M9R`R,#$R(&%N9`T*(#(P,3$N(%)E;&%T960@8V]S=',@9'5R:6YG(#(P,3(@
M86YD(#(P,3$@=V5R92`D,2XQ(&UI;&QI;VX@86YD("0Q+C(-"B!M:6QL:6]N
M+"!R97-P96-T:79E;'DN(%1H97)E('=E<F4@;F\@<W5C:"!R979E;G5E<R!O
M<B!R96QA=&5D(&-O<W1S#0H@:6X@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/CQI/E1H92!*=79E;FEL92!$:6%B971E<R!297-E87)C:"!&;W5N9&%T:6]N
M#0H@26YT97)N871I;VYA;#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@26X@3V-T;V)E<B8C>$$P.S(P,#8L(%-A;F=A;6\@96YT
M97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H('1H90T*($IU=F5N:6QE($1I
M86)E=&5S(%)E<V5A<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"`H2D12
M1BDF(WA!,#MT;PT*('!R;W9I9&4@9FEN86YC:6%L('-U<'!O<G0@9F]R(&]N
M92!O9B!386YG86UO)B-X,C`Q.3MS(%!H87-E(#(@:'5M86X-"B!C;&EN:6-A
M;"!S='5D:65S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('!R;V1U8W0@8V%N
M9&ED871E(%-"+34P.2P@80T*(%I&4"!4:&5R87!E=71I8R!T:&%T('=A<R!I
M;B!D979E;&]P;65N="!F;W(@=&AE('1R96%T;65N="!O9@T*(&1I86)E=&EC
M(&YE=7)O<&%T:'DN($EN($IA;G5A<GD@,C`Q,"P@2D121B!A;F0@4V%N9V%M
M;R!A;65N9&5D('1H90T*(&%G<F5E;65N="!A;F0L('-U8FIE8W0@=&\@:71S
M('1E<FUS(&%N9"!C;VYD:71I;VYS+"!*1%)&(&%G<F5E9"!T;PT*('!R;W9I
M9&4@861D:71I;VYA;"!F=6YD:6YG(&]F('5P('1O("0S+C`@;6EL;&EO;B!F
M;W(@82!0:&%S92`R8@T*('1R:6%L(&EN(&1I86)E=&EC(&YE=7)O<&%T:'DN
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($]C=&]B97(@
M,C`Q,2P@=&AE($-O;7!A;GD@86YN;W5N8V5D('1H870@:70@=V]U;&0@;F]T
M('!U<G-U90T*(&%D9&ET:6]N86P@8VQI;FEC86P@9&5V96QO<&UE;G0@;V8@
M=&AE(%-"+34P.2!P<F]G<F%M+B!);B!-87)C:`T*(#(P,3(L('1H92!#;VUP
M86YY(')E8V5I=F5D(&$@9FEN86P@<&%Y;65N="!O9B`D,"XX(&UI;&QI;VX@
M9F]R('=O<FL-"B!P97)F;W)M960@=6YD97(@=&AE(&%G<F5E;65N="X@5&AE
M($-O;7!A;GD@9&]E<R!N;W0@97AP96-T('1O#0H@<F5C96EV92!A9&1I=&EO
M;F%L(&9U;F1I;F<@=6YD97(@=&AE(&%G<F5E;65N="X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5V96YU97,@871T<FEB=71A8FQE('1O
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W1I=FET:65S#0H@<&5R9F]R
M;65D('5N9&5R('1H92!*1%)&(&%G<F5E;65N=',@=V5R92`D,"XX(&UI;&QI
M;VX@86YD("0P+C4-"B!M:6QL:6]N(&1U<FEN9R`R,#$R(&%N9"`R,#$Q+B!4
M:&5R92!W97)E(&YO('-U8V@@<F5V96YU97,@;W(-"B!R96QA=&5D(&-O<W1S
M(&EN(#(P,3,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,'!T)SX-"B`\8CX\:3Y4:&4@36EC:&%E;"!*+B!&;W@@1F]U
M;F1A=&EO;B!F;W(@4&%R:VEN<V]N)B-X,C`Q.3MS#0H@4F5S96%R8V@\+VD^
M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($IA;G5A
M<GD@,C`P-RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<&%R=&YE<G-H
M:7`@=VET:"!T:&4-"B!-:6-H865L($HN($9O>"!&;W5N9&%T:6]N(&9O<B!0
M87)K:6YS;VXF(W@R,#$Y.W,@4F5S96%R8V@-"B`H34I&1BDF(WA!,#MT;R!P
M<F]V:61E(&9I;F%N8VEA;"!S=7!P;W)T(&]F('1H92!#;VUP86YY)B-X,C`Q
M.3MS#0H@<')O9W)A;2!T;R!D979E;&]P(%I&4"!41G,@=&\@86-T:79A=&4@
M=&AE(&5X<')E<W-I;VX@;V8@9VQI86P@8V5L;`T*(&QI;F4M9&5R:79E9"!N
M975R;W1R;W!H:6,@9F%C=&]R("A'1$Y&*2X@56YD97(@=&AE(&%G<F5E;65N
M="!W:71H#0H@34I&1B!A;F0@<W5B:F5C="!T;R!I=',@=&5R;7,@86YD(&-O
M;F1I=&EO;G,L($U*1D8@<&%I9"!T:&4@0V]M<&%N>0T*("0Q+C`@;6EL;&EO
M;BP@=&AE('1O=&%L(&9U;F1S(&1U92!U;F1E<B!T:&4@86=R965M96YT+B!)
M;B!*=6YE#0H@,C`Q,"P@=&AE($-O;7!A;GD@<F5C96EV960@82!C;VUM:71M
M96YT(&9O<B!A9&1I=&EO;F%L(&9U;F1I;F<@;V8-"B`D,"XY(&UI;&QI;VX@
M9G)O;2!-2D9&('1O('-U<'!O<G0@9G5R=&AE<B!S='5D:65S(&]F(%I&4"!4
M1@T*(&%C=&EV871O<G,@;V8@1T1.1B!A;F0@:6YT96YD960@=&\@<W5B<W1A
M;G1I86QL>2!F=6YD(%-A;F=A;6\-"B!R97-E87)C:"!E9F9O<G1S(')E;&%T
M960@=&\@=&AE(&%G<F5E;65N="X@5&AE($-O;7!A;GD@:&%S(')E8V5I=F5D
M#0H@=&AE(&5N=&ER92`D,2XY(&UI;&QI;VX@:6X@9G5N9&EN9R!A=F%I;&%B
M;&4@=6YD97(@=&AE(&%G<F5E;65N=',-"B!W:71H($U*1D8@86YD(&1O97,@
M;F]T(&5X<&5C="!T;R!R96-E:79E(&%N>2!F=7)T:&5R(&9U;F1I;F<@=6YD
M97(-"B!T:&ES(&%G<F5E;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@4F5V96YU92!A='1R:6)U=&%B;&4@=&\@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT('!E<F9O<FUE9"!U;F1E<@T*('1H92!-2D9&(&%G<F5E
M;65N="!W87,@)#`N-"!M:6QL:6]N(&EN(#(P,3$N(%1H97)E('=E<F4@;F\@
M<W5C:`T*(')E=F5N=65S(&EN(#(P,3,@;W(@,C`Q,BX\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E
M,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N(&]F($-E<F5G
M96YE/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D)U<VEN97-S($-O;6)I;F%T:6]N<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W%U:7-I
M=&EO;B!O9B!#97)E9V5N93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/DY/5$4@-B`F(W@R,#$S.R!!0U%5
M25-)5$E/3B!/1B!#15)%1T5.13PO8CX\+W`^#0H@/"$M+2!X8G)L+&)O9'D@
M+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!!=6=U<W0F(WA!
M,#LR,RP@,C`Q,RP@4V%N9V%M;R!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S
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M8V]M<&%N>2!F;V-U<V5D(&]N('1H92!D979E;&]P;65N=`T*(&]F($%!5B!G
M96YE('1H97)A<&EE<RX@5&AE(&%C<75I<F5D(&%S<V5T<R!I;F-L=61E(&%L
M;"!O9@T*($-E<F5G96YE)B-X,C`Q.3MS('1H97)A<&5U=&EC('!R;V=R86US
M+"!I;F-L=61I;F<@0T5212TQ,3`@9F]R('1H90T*('1R96%T;65N="!O9B!!
M1"!I<R!C=7)R96YT;'D@:6X@82!0:&%S92`R(&-L:6YI8V%L('1R:6%L+B!)
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M871I;VYS(&9O<B!386YG86UO)B-X,C`Q.3MS#0H@/&D^:6X@=FEV;SPO:3X@
M6D90(%1H97)A<&5U=&EC<RP@<&%R=&EC=6QA<FQY('1H;W-E('1H870@=&%R
M9V5T('1H90T*(&)R86EN+B!4:&4@86-Q=6ES:71I;VX@8VQO<V5D(&]N($]C
M=&]B97(F(WA!,#LQ+"`R,#$S("AT:&4@0VQO<VEN9PT*($1A=&4I+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!5;F1E<B!T:&4@365R9V5R
M($%G<F5E;65N="P@=&AE(&%G9W)E9V%T92!C;VYS:61E<F%T:6]N('1R86YS
M9F5R<F5D#0H@;W(@=')A;G-F97)A8FQE(&)Y(%-A;F=A;6\@=&\@9F]R;65R
M($-E<F5G96YE('-T;V-K:&]L9&5R<R!A=`T*(&-L;W-I;F<@8V]N<VES=&5D
M(&]F(#$P,"PP,#`@<VAA<F5S(&]F(%-A;F=A;6\@8V]M;6]N('-T;V-K+"!W
M:71H#0H@86X@87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D,2XR(&UI;&QI
M;VXN($EN(&%D9&ET:6]N+"!386YG86UO(&UA>0T*(&)E(')E<75I<F5D('1O
M(&UA:V4@8V]N=&EN9V5N="!E87)N+6]U="!P87EM96YT<R`H=&AE($5A<FXM
M3W5T#0H@4&%Y;65N=',I('1O('1H92!S=&]C:VAO;&1E<G,@;V8@0V5R96=E
M;F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@
M86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L
M:6=N/3-$;&5F=#Y)9B!T:&4@0V]M<&%N>2!G<F%N=',@82!T:&ER9"UP87)T
M>0T*(&QI8V5N<V4@=&\@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ92!#97)E
M9V5N928C>#(P,3D[<R!#15)%+3$Q,"!F;W(-"B!T:&4@=')E871M96YT(&]F
M("A!1"D@;W(@0T5212TQ,C`@9F]R('1H92!T<F5A=&UE;G0@;V8-"B!087)K
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M;F0\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P
M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@
M=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1T;W`@86QI9VX],T1L969T/DEF('1H92!#;VUP86YY(&-O;6UE<F-I86QI
M>F5S(&%N>0T*($5A<FXM3W5T(%!R;V1U8W0@:71S96QF+"!T:&4@0V]M<&%N
M>2!I<R!R97%U:7)E9"!T;R!P87DL(&9O<B!E86-H#0H@16%R;BU/=70@4')O
M9'5C="P@<F]Y86QT>2UL:6ME(&5A<FYO=70@<&%Y;65N=',@87,@82!P97)C
M96YT86=E(&]F#0H@;F5T('-A;&5S('1H870@<F%N9V4@:6X@=&AE(&QO=R!D
M;W5B;&4@9&EG:71S(&1E<&5N9&EN9R!U<&]N('1H90T*(&%M;W5N="!O9B!N
M970@<V%L97,L('-U8FIE8W0@=&\@8V5R=&%I;B!R961U8W1I;VYS(&)Y('1H
M90T*($-O;7!A;GDN/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@06QS;R!O;B!T:&4@0VQO<VEN9R!$871E
M+"!386YG86UO+"!#97)E9V5N92!A;F0@8V5R=&%I;B!O9@T*($-E<F5G96YE
M)B-X,C`Q.3MS('-T;V-K:&]L9&5R<R!E;G1E<F5D(&EN=&\@86X@:6YD96UN
M:71Y(&5S8W)O=PT*(&%G<F5E;65N="P@<'5R<W5A;G0@=&\@=VAI8V@@)#`N
M,R!M:6QL:6]N(&]F($-E<F5G96YE(')E;6%I;FEN9PT*(&-A<V@@=V%S(&1E
M<&]S:71E9"!I;B!A;B!E<V-R;W<@86-C;W5N="!F;W(@=&AE(&)E;F5F:70@
M;V8@4V%N9V%M;PT*('1O('-A=&ES9GD@:6YD96UN:71Y(&]B;&EG871I;VYS
M(&]F('1H92!S=&]C:VAO;&1E<G,@=6YD97(@=&AE#0H@365R9V5R($%G<F5E
M;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@86-C
M;W)D86YC92!W:71H('1H92!-97)G97(@06=R965M96YT+"!E86-H(&ES<W5E
M9"!A;F0-"B!O=71S=&%N9&EN9R!S:&%R92!O9B!#97)E9V5N92!C87!I=&%L
M('-T;V-K('=A<R!C86YC96QL960@86YD#0H@8V]N=F5R=&5D(&EN=&\@=&AE
M(')I9VAT('1O(')E8V5I=F4@=&AE(&UE<F=E<B!C;VYS:61E<F%T:6]N#0H@
M9&5S8W)I8F5D(&EN('1H92!-97)G97(@06=R965M96YT+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M9@T*($]P97)A=&EO;G,N(%1H92!#;VUP86YY)B-X,C`Q.3MS($-O;G-O;&ED
M871E9"!"86QA;F-E(%-H965T(&%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@
M,C`Q,R!R969L96-T<R!T:&4@86-Q=6ES:71I;VX@;V8@0V5R96=E;F4N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%
M.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T
M)SX-"B`\8CX\:3Y#;VYS:61E<F%T:6]N(%1R86YS9F5R<F5D/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG
M('1A8FQE('-U;6UA<FEZ97,@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F
M('1H90T*(&-O;G-I9&5R871I;VX@=')A;G-F97)R960@8GD@4V%N9V%M;R!T
M;R!T:&4@0V5R96=E;F4@<W1O8VMH;VQD97)S#0H@;VX@=&AE($-L;W-I;F<@
M1&%T92`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X\
M(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS
M1#@V)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO
M='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!386YG86UO('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(P,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]N=&EN9V5N="!E87)N+6]U
M=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PU,3`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L('!U<F-H87-E(&-O;G-I
M9&5R871I;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#<Q,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M.'!T)SX-"B`\8CX\:3Y&86ER(%9A;'5E($5S=&EM871E(&]F($%S<V5T<R!!
M8W%U:7)E9"!A;F0@3&EA8FEL:71I97,-"B!!<W-U;65D/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A
M8FQE('-U;6UA<FEZ97,@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H
M92!N970-"B!A<W-E=',@86-Q=6ER960@87,@;V8@=&AE($-L;W-I;F<@1&%T
M92`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X\(2TM
M($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@V
M)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^
M#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O
M9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#87-H(&%N9"!E<75I=F%L
M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Y/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!!8V-O=6YT<R!R96-E:79A8FQE/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@261E;G1I9FEA8FQE(&EN=&%N9VEB;&4@87-S971S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@W,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1V]O9'=I;&P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L-3@U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!4;W1A;"!A<W-E=',@86-Q=6ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C,L-34V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E
M9"!T87@@;&EA8FEL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-S0X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@06-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#DX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@;&EA
M8FEL:71I97,@87-S=6UE9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@T
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE
M="!A<W-E=',@86-Q=6ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#<Q,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A
M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y);G1A;F=I8FQE($%S<V5T<SPO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26YT86YG:6)L
M92!A<W-E=',@9F]R(&EN+7!R;V-E<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT#0H@*$E04B9A;7`[1"D@8V]N<VES="!O9B!#97)E9V5N928C>#(P,3D[
M<R!T=V\@8VQI;FEC86P@<')O9'5C=`T*(&-A;F1I9&%T97,L($-%4D4M,3$P
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M=6P@;&EF92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&\@
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M(&UA<FME=`T*('!A<G1I8VEP86YT<R!W;W5L9"!U<V4@=&\@=F%L=64@=&AI
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M=&]R:6-A;"!C;&EN:6-A;"!R97-U;'1S(&%N9`T*('1H92!L86-K(&]F(&%P
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M1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*($$@<W5M;6%R>2!O9B!T
M:&5S92!A<W-E=',@86YD(&5S=&EM871E9"!F86ER('9A;'5E<R!A="!T:&4@
M0VQO<VEN9PT*($1A=&4@:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<Y)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/E9A;'5E
M)B-X03`[;V8F(WA!,#M);G1A;F=I8FQE/&)R("\^#0H@07-S971S($%C<75I
M<F5D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#15)%+3$Q
M,"!F;W(@=&AE('1R96%T;65N="!O9B!!;'IH96EM97(F(W@R,#$Y.W,@9&ES
M96%S93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8T,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@0T5212TQ,C`@9F]R('1H92!T<F5A=&UE
M;G0@;V8@4&%R:VEN<V]N)B-X,C`Q.3MS(&1I<V5A<V4\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR,S`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&ED96YT:69I86)L92!I;G1A;F=I8FQE
M(&%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#<P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@25!2)F%M<#M$(&ES(&%N(&EN=&%N
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M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y';V]D=VEL
M;#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
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M('!U<G!O<V5S(&)U="!N;W0@9F]R('1A>"!P=7)P;W-E<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3F]N92!O9B!T:&4@9V]O9'=I;&P@
M:7,@97AP96-T960@=&\@8F4@9&5D=6-T:6)L92!F;W(@:6YC;VUE('1A>`T*
M('!U<G!O<V5S+B!4:&4@0V]M<&%N>2!W:6QL('1E<W0@9V]O9'=I;&P@9F]R
M(&EM<&%I<FUE;G0@;VX@86X-"B!A;FYU86P@8F%S:7,@;W(@<V]O;F5R+"!I
M9B!D965M960@;F5C97-S87)Y+B!!<R!O9@T*($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,L('1H97)E('=E<F4@;F\@8VAA;F=E<R!I;B!T:&4@1V]O9'=I;&P-
M"B!R96-O<F1E9"!F<F]M('1H92!A8W%U:7-I=&EO;B!O9B!#97)E9V5N92X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/CQI/DQI86)I;&ET>2!F;W(@0V]N=&EN9V5N
M="!#;VYS:61E<F%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
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M:7IE('1H92!%87)N+4]U=`T*(%!R;V1U8W1S+"!O<B!A<F4@82!P97)C96YT
M86=E(&]F(&YE="!S86QE<R!I;B!T:&4@8V%S92!386YG86UO#0H@9&5V96QO
M<',@86YD(&-O;6UE<F-I86QI>F5D('1H92!%87)N+4]U="!0<F]D=6-T<R!I
M='-E;&8N(%1H92!T;W1A;`T*(&UA>&EM=6T@<&%Y;65N="!I<R!N;W0@;&EM
M:71E9"P@;W1H97(@=&AA;B!D=64@=&\@<VEZ92!O9B!T:&4-"B!U<&9R;VYT
M(&%N9"!M:6QE<W1O;F4@<&%Y;65N=',@<F5C96EV960@;W(@=&AE(&YE="!S
M86QE<R!O9B!T:&4-"B!P<F]D=6-T<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&QI86)I;&ET>2!F
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M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M(%1H92!F86ER('9A;'5E(&]F('1H92!C;VYT:6YG96YT(&-O;G-I9&5R871I
M;VX@;&EA8FEL:71Y(&%S<V]C:6%T960-"B!W:71H('1H;W-E(&9U='5R92!E
M87)N;W5T('!A>6UE;G1S('=A<R!B87-E9"!U<&]N(')E87-O;F%B;&4-"B!A
M<W-U;7!T:6]N<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D5S8W)O=R!!8V-O
M=6YT($QI86)I;&ET>3PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@3VX@=&AE($-L;W-I;F<@1&%T92P@)#`N,R!M:6QL:6]N(&]F
M($-E<F5G96YE)B-X,C`Q.3MS(')E;6%I;FEN9PT*(&-A<V@L('!A>6%B;&4@
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M97,@:6YC;'5D960@:6X@=&AE($UE<F=E<@T*($%G<F5E;65N="X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#$X<'0G/@T*(#QB/CQI/D%C<75I<VET:6]N+5)E;&%T960@5')A;G-A8W1I
M;VX@0V]S=',\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*(%1H92!#;VUP86YY(')E8V]G;FEZ960@)#`N,2!M:6QL:6]N(&EN(&%C
M<75I<VET:6]N+7)E;&%T960-"B!T<F%N<V%C=&EO;B!E>'!E;G-E<R!I;B!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+@T*(%1H97-E
M(&-O<W1S(&%R92!I;F-L=61E9"!I;B!T:&4@)B-X,C`Q0SM'96YE<F%L(&%N
M9`T*(&%D;6EN:7-T<F%T:79E)B-X,C`Q1#L@97AP96YS92!L:6YE(&ET96T@
M:6X@=&AE($-O;G-O;&ED871E9`T*(%-T871E;65N="!O9B!/<&5R871I;VYS
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3,N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3
M25I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,'!T)SX-"B`\8CX\:3Y2979E;G5E<R!A;F0@3W!E<F%T:6YG($5X<&5N<V5S
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!#97)E
M9V5N92!D:60@;F]T(')E8V]R9"!A;GD@<F5V96YU97,@9F]R('1H92!P97)I
M;V0@9G)O;2!T:&4@0VQO<V4-"B!$871E('1O($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,N(%1H97)E('=E<F4@;F\@;6%T97)I86P@;W!E<F%T:6YG#0H@97AP
M96YS97,@:6YC;'5D960@:6X@4V%N9V%M;R8C>#(P,3D[<R!#;VYS;VQI9&%T
M960@4W1A=&5M96YT(&]F#0H@3W!E<F%T:6]N<RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*
M(#QB/CQI/E!R;V9O<FUA($EN9F]R;6%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M="<^#0H@5&AE(&9O;&QO=VEN9R!U;F%U9&ET960@<W5P<&QE;65N=&%L('!R
M;R!F;W)M82!I;F9O<FUA=&EO;B!P<F5S96YT<PT*('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&9I;F%N8VEA;"!R97-U;'1S(&%S(&EF('1H92!A8W%U:7-I=&EO
M;B!O9@T*($-E<F5G96YE(&AA9"!O8V-U<G)E9"!O;B!*86YU87)Y)B-X03`[
M,2P@,C`Q,BX@5&AI<R!S=7!P;&5M96YT86P-"B!P<F\@9F]R;6$@:6YF;W)M
M871I;VX@:&%S(&)E96X@<')E<&%R960@9F]R(&-O;7!A<F%T:79E('!U<G!O
M<V5S#0H@86YD(&1O97,@;F]T('!U<G!O<G0@=&\@8F4@:6YD:6-A=&EV92!O
M9B!W:&%T('=O=6QD(&AA=F4@;V-C=7)R960-"B!H860@=&AE(&%C<75I<VET
M:6]N(&)E96X@;6%D92!O;B!*86YU87)Y)B-X03`[,2P@,C`Q,BP@;F]R(&%R
M92!T:&5Y#0H@:6YD:6-A=&EV92!O9B!A;GD@9G5T=7)E(')E<W5L=',N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX]
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M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(^#0H@/&(^665A<B8C>$$P.T5N9&5D)B-X03`[1&5C
M96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXH26XF(WA!,#MT
M:&]U<V%N9',F(WA!,#ME>&-E<'0F(WA!,#MP97(F(WA!,#MS:&%R928C>$$P
M.V1A=&$I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E
M9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@
M;&]S<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S`L.3DW/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#(W+#0T-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($)A<VEC(&YE="!L;W-S('!E<B!S:&%R93PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,"XU-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C4R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A
M8FQE/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S
M.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S
M7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(%!L86YT($%N9"!%
M<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#QB/DY/5$4@-R`F(W@R,#$S.R!04D]015)462!!3D0@15%525!-14Y4/"]B
M/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@8V]N<VES="!O9B!T
M:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$
M8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-S<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^
M/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA
M+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@3&%B;W)A=&]R>2!E<75I<&UE;G0\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,#@\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L.34P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!&=7)N:71U<F4@86YD(&9I>'1U<F5S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-38S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0Y.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L,34V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$L,#0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.3(W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"PT.34\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QE<W,@86-C=6UU;&%T960@9&5P
M<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@S+#4R,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0P-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#4T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%
M;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&5X<&5N
M<V4@=V%S("0P+C8@;6EL;&EO;B!F;W(@,C`Q,RP-"B`R,#$R(&%N9"`R,#$Q
M+B!);B`R,#$R+"!T:&4@0V]M<&%N>2!D:7-P;W-E9"!O9B`D,"XU(&UI;&QI
M;VX@:6X-"B!F:7AE9"!A<W-E=',@=VET:"!A<W-O8VEA=&5D(&%C8W5M=6QA
M=&5D(&1E<')E8VEA=&EO;B!O9B`D,"XT#0H@;6EL;&EO;BX@5&AE($-O;7!A
M;GD@<F5C;V=N:7IE9"!A("0P+C$@;6EL;&EO;B!L;W-S(&]N('1H90T*('=R
M:71E+6]F9B!O9B!T:&5S92!A<W-E=',N/"]P/@T*(`T*(`T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q
M,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P
M,S@Q.69D,B]7;W)K<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M
M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UI=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3AP="<^#0H@/&(^3D]412`X("8C>#(P,3,[($-/34U)5$U%3E13
M/"]B/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%-A;F=A;6\@;V-C=7!I97,@;V9F:6-E(&%N9"!L86)O
M<F%T;W)Y('-P86-E('5N9&5R(&]P97)A=&EN9R!L96%S97,-"B!I;B!2:6-H
M;6]N9"P@0V%L:69O<FYI82X@3VX@075G=7-T)B-X03`[,2P@,C`Q,RP@4V%N
M9V%M;R!A;65N9&5D#0H@:71S(&QE87-E(&%G<F5E;65N="!W:&5R96EN('1H
M92!L96%S92!W87,@97AT96YD960@=&AR;W5G:"!!=6=U<W0-"B`R,#$Y+B!2
M96YT(&5X<&5N<V5S('=E<F4@)#`N-R!M:6QL:6]N(&EN(#(P,3,@86YD("0P
M+C8@;6EL;&EO;B!F;W(-"B`R,#$R+"!A;F0@,C`Q,2X@1G5T=7)E(&UI;FEM
M=6T@<&%Y;65N=',@=6YD97(@8V]N=')A8W1U86P-"B!O8FQI9V%T:6]N<R!A
M="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S(&-O;G-I<W0@;V8@=&AE(&9O;&QO
M=VEN9R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$.#0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4)/5%1/
M33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60[(%=)1%1(.B`T,2XU<'0G/@T*(#QB
M/D9I<V-A;"!996%R.CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3W!E<F%T:6YG/&)R
M("\^#0H@3&5A<V4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA
M+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3<P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-C8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$W
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S`Y/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$X/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!4:&5R96%F=&5R/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!4;W1A;"!M:6YI;75M('!A>6UE;G1S/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,RPX-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V
M-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O
M<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^3D]412`Y("8C
M>#(P,3,[(%-43T-+2$],1$524R8C>#(P,3D[($5154E463PO8CX\+W`^#0H@
M/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P="<^#0H@/&(^/&D^4')E9F5R<F5D
M(%-T;V-K/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!4:&4@0V]M<&%N>2!H87,@-2PP,#`L,#`P('!R969E<G)E9"!S:&%R97,@
M875T:&]R:7IE9"P@=VAI8V@@;6%Y(&)E#0H@:7-S=65D(&%T('1H92!";V%R
M9"!O9B!D:7)E8W1O<B8C>#(P,3D[<R!D:7-C<F5T:6]N+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP
M="<^#0H@/&(^/&D^0V]M;6]N(%-T;V-K/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!397!T96UB97(F(WA!,#LR,RP@,C`Q
M,RP@4V%N9V%M;R!C;VUP;&5T960@86X@=6YD97)W<FET=&5N#0H@<'5B;&EC
M(&]F9F5R:6YG(&]F(&ET<R!C;VUM;VX@<W1O8VLL(&EN('=H:6-H('1H92!#
M;VUP86YY('-O;&0@86X-"B!A9V=R96=A=&4@;V8@-RPP,34L,#`P('-H87)E
M<R!O9B!I=',@8V]M;6]N('-T;V-K+"!I;F-L=61I;F<-"B`Y,34L,#`P('-H
M87)E<R!I<W-U960@=&\@=&AE(%5N9&5R=W)I=&5R<R!P=7)S=6%N="!T;R!A
M(#,P+61A>0T*(&]V97)A;&QO=&UE;G0@;W!T:6]N+"!A="!A('!U8FQI8R!O
M9F9E<FEN9R!P<FEC92!O9B`D,3`N-3@@<&5R#0H@<VAA<F4N(%1H92!N970@
M<')O8V5E9',@=&\@4V%N9V%M;R!F<F]M('1H92!S86QE(&]F('-H87)E<R!I
M;B!T:&ES#0H@;V9F97)I;F<L(&%F=&5R(&1E9'5C=&EN9R!U;F1E<G=R:71I
M;F<@9&ES8V]U;G1S(&%N9"!C;VUM:7-S:6]N<PT*(&%N9"!O=&AE<B!E<W1I
M;6%T960@;V9F97)I;F<@97AP96YS97,L('=E<F4@87!P<F]X:6UA=&5L>2`D
M-CDN-0T*(&UI;&QI;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:R!)
M;F-E;G1I=F4@4&QA;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@3VX@07!R:6PF(WA!,#LQ."P@,C`Q,RP@4V%N9V%M;R8C>#(P
M,3D[<R!B;V%R9"!O9B!D:7)E8W1O<G,@861O<'1E9"P-"B!S=6)J96-T('1O
M('-T;V-K:&]L9&5R(&%P<')O=F%L+"!T:&4@0V]M<&%N>28C>#(P,3D[<R`R
M,#$S(%-T;V-K#0H@26YC96YT:79E(%!L86X@*'1H92`R,#$S(%!L86XI(&%S
M('1H92!S=6-C97-S;W(@=&\@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R`R,#`T
M(%-T;V-K($EN8V5N=&EV92!0;&%N("AT:&4@,C`P-"!0;&%N*2X@070@=&AE
M#0H@06YN=6%L($UE971I;F<@;V8@4W1O8VMH;VQD97)S(&AE;&0@;VX@2G5N
M928C>$$P.S$R+"`R,#$S+"!T:&4@,C`Q,PT*(%!L86X@=V%S(&%P<')O=F5D
M(&)Y('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K:&]L9&5R<R!A;F0@8F5C
M86UE#0H@969F96-T:79E+B!);B!C;VYN96-T:6]N('=I=&@@=&AE(&%P<')O
M=F%L(&)Y('-T;V-K:&]L9&5R<R!O9B!T:&4-"B`R,#$S(%!L86XL(&]U='-T
M86YD:6YG(&%W87)D<R!U;F1E<B!T:&4@,C`P-"!0;&%N('=E<F4@=')A;G-F
M97)R960-"B!T;R!T:&4@,C`Q,R!0;&%N+B!4:&4@,C`P-"!0;&%N('=A<R!T
M97)M:6YA=&5D(&%N9"!N;R!F=7)T:&5R#0H@87=A<F1S('=I;&P@8F4@;6%D
M92!P=7)S=6%N="!T;R!T:&4@,C`P-"!0;&%N+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!5;F1E<B!T:&4@,C`Q,R!0;&%N+"!T:&4@;W!T
M:6]N(&5X97)C:7-E('!R:6-E('!E<B!S:&%R92!W:6QL#0H@9V5N97)A;&QY
M(&YO="!B92!L97-S('1H86X@,3`P('!E<F-E;G0@;V8@=&AE(&9A:7(@=F%L
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M<R!G<F%N=&5D('5N9&5R('1H92`R,#$S(%!L86X@9V5N97)A;&QY#0H@=F5S
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M<F%N=&5D('5N9&5R('1H92`R,#`T(%!L86X@=&\@=&AE#0H@0V]M<&%N>28C
M>#(P,3D[<R!N;VXM96UP;&]Y964@9&ER96-T;W)S(&%R92!S=')U8W1U<F5D
M('-O('1H870@=&AE>0T*(&UA>2!B92!E>&5R8VES960@<')I;W(@=&\@=F5S
M=&EN9RP@=VET:"!T:&4@<F5L871E9"!S:&%R97,@<W5B:F5C=`T*('1O(%-A
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M<F5S97)V960@9F]R(&ES<W5A;F-E('5N9&5R('1H92`R,#$S(%!L86XL(&EN
M8VQU9&EN9PT*(#DN-R8C>$$P.VUI;&QI;VX@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!S=6)J96-T('1O(&]U='-T86YD:6YG#0H@87=A<F1S('!R979I;W5S
M;'D@9W)A;G1E9"!U;F1E<B!T:&4@,C`P-"!0;&%N('1H870@=V5R92!T<F%N
M<V9E<G)E9`T*('1O('1H92`R,#$S(%!L86XL(&%N9"!A;B!A9&1I=&EO;F%L
M(#0N-"8C>$$P.VUI;&QI;VX@<VAA<F5S(&]F#0H@8V]M;6]N('-T;V-K+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@;G5M8F5R(&]F
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<F5S97)V960@9F]R(&ES<W5A;F-E
M('5N9&5R#0H@=&AE(#(P,3,@4&QA;B!W:6QL(&)E(')E9'5C960Z("AI*28C
M>$$P.V]N(&$@,2UF;W(M,2!B87-I<R!F;W(@96%C:`T*('-H87)E(&]F(&-O
M;6UO;B!S=&]C:R!S=6)J96-T('1O(&$@<W1O8VL@;W!T:6]N(&]R('-T;V-K
M#0H@87!P<F5C:6%T:6]N(')I9VAT(&=R86YT960@=6YD97(@=&AE('!L86XL
M("AI:2DF(WA!,#MO;B!A(#$M9F]R+3$-"B!B87-I<R!F;W(@96%C:"!S:&%R
M92!O9B!C;VUM;VX@<W1O8VL@:7-S=65D('!U<G-U86YT('1O(&$@9G5L;`T*
M('9A;'5E(&%W87)D(&=R86YT960@=6YD97(@=&AE('!L86X@<')I;W(@=&\@
M=&AE('!L86X@969F96-T:79E#0H@9&%T92P@86YD("AI:6DI)B-X03`[8GD@
M82!F:7AE9"!R871I;R!O9B`Q+C,S('-H87)E<R!O9B!C;VUM;VX-"B!S=&]C
M:R!F;W(@96%C:"!S:&%R92!O9B!C;VUM;VX@<W1O8VL@:7-S=65D('!U<G-U
M86YT('1O(&$-"B!F=6QL+79A;'5E(&%W87)D(&=R86YT960@=6YD97(@=&AE
M('!L86X@;VX@;W(@869T97(@=&AE('!L86X-"B!E9F9E8W1I=F4@9&%T92X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4VAA<F5S('-U8FIE
M8W0@=&\@86YY(&]U='-T86YD:6YG(&]P=&EO;G,@;W(@;W1H97(@87=A<F1S
M('5N9&5R('1H90T*(#(P,3,@4&QA;B!T:&%T(&5X<&ER92!O<B!O=&AE<G=I
M<V4@=&5R;6EN871E('!R:6]R('1O('1H92!I<W-U86YC90T*(&]F('1H92!S
M:&%R97,@<W5B:F5C="!T;R!T:&]S92!O<'1I;VYS(&]R(&%W87)D<R!W:6QL
M(&)E(&%V86EL86)L90T*(&9O<B!S=6)S97%U96YT(&ES<W5A;F-E('5N9&5R
M('1H92`R,#$S(%!L86XN($%N>2!U;G9E<W1E9"!S:&%R97,-"B!I<W-U960@
M=6YD97(@=&AE(#(P,3,@4&QA;B!T:&%T('1H92!#;VUP86YY('-U8G-E<75E
M;G1L>2!P=7)C:&%S97,L#0H@<'5R<W5A;G0@=&\@<F5P=7)C:&%S92!R:6=H
M=',@=6YD97(@=&AE(#(P,3,@4&QA;BP@=VEL;"!B92!A9&1E9`T*(&)A8VL@
M=&\@=&AE(&YU;6)E<B!O9B!S:&%R97,@<F5S97)V960@9F]R(&ES<W5A;F-E
M('5N9&5R('1H92`R,#$S#0H@4&QA;B!O;B!A(#$M9F]R+3$@8F%S:7,@;W(@
M82`Q+C,S+69O<BTQ(&)A<VES("AD97!E;F1I;F<@;VX@=&AE#0H@<F%T:6\@
M870@=VAI8V@@=&AE('-H87)E(')E<V5R=F4@=V%S(&1E8FET960@9F]R('1H
M92!O<FEG:6YA;`T*(&%W87)D*2!A;F0@=VEL;"!A8V-O<F1I;F=L>2!B92!A
M=F%I;&%B;&4@9F]R('-U8G-E<75E;G0@:7-S=6%N8V4@:6X-"B!A8V-O<F1A
M;F-E('=I=&@@=&AE('1E<FUS(&]F('1H92!P;&%N+B!4:&5R92!A<F4@;F\@
M;F5T(&-O=6YT:6YG#0H@<')O=FES:6]N<R!I;B!E9F9E8W0@=6YD97(@=&AE
M(#(P,3,@4&QA;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!X.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X
M03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI/D5M<&QO>65E(%-T;V-K(%!U<F-H
M87-E(%!L86X\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*(%-A;F=A;6\F(W@R,#$Y.W,@,C`Q,"!%;7!L;WEE92!3=&]C:R!0=7)C
M:&%S92!0;&%N("A0=7)C:&%S92!0;&%N*2P-"B!W:&EC:"!S=7!E<G-E9&5S
M('1H92`R,#`P($5M<&QO>65E(%-T;V-K(%!U<F-H87-E(%!L86XL('!R;W9I
M9&5S(&$-"B!T;W1A;"!R97-E<G9E(&]F(#(L,3`P+#`P,"8C>$$P.W-H87)E
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M<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4W1O8VL@3W!T:6]N($%C
M=&EV:71Y/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!!('-U;6UA<GD@;V8@4V%N9V%M;R8C>#(P,3D[<R!S=&]C:R!O<'1I;VX@
M86-T:79I='D@:7,@87,-"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/
M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
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M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H
M,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/DYU;6)E<B!O9CQB<B`O/@T*(%-H87)E<SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT
M960M/&)R("\^#0H@079E<F%G93QB<B`O/@T*($5X97)C:7-E)B-X03`[<&5R
M/&)R("\^#0H@4VAA<F4F(WA!,#M0<FEC93PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960F(WA!,#M!=F5R
M86=E/&)R("\^#0H@4F5M86EN:6YG/&)R("\^#0H@0V]N=')A8W1U86PF(WA!
M,#M497)M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY!9V=R96=A=&4\8G(@+SX-"B!);G1R:6YS:6,\8G(@+SX-"B!6
M86QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/BA);@T*('EE87)S*3PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXH
M26XF(WA!,#MT:&]U<V%N9',I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A
M9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
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M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXT-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($]P=&EO;G,@9W)A;G1E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$L,3$Y+#(P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$N
M-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W!T:6]N<R!E>&5R8VES960\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PW,34L,3(S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-"XW-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/<'1I;VYS(&-A;F-E;&5D/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$X,BPU-3D\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XX+C4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P=&EO;G,@;W5T<W1A
M;F1I;F<@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^."PT,#4L.#8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N,C`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C(V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C4V+#0R-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A="!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX
M+#`T-BPY,S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXQ,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8N,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-30L.#0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/<'1I;VYS(&5X97)C:7-A8FQE(&%T($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.#`P+#DS,3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV+C@T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-2XP-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,2PP-S,\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM
M/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3F5W;'D@
M8W)E871E9"!S:&%R97,@87)E(&ES<W5E9"!U<&]N(&5X97)C:7-E(&]F(&]P
M=&EO;G,N(%1H97)E#0H@=V5R92!N;R!S:&%R97,@<W5B:F5C="!T;R!386YG
M86UO)B-X,C`Q.3MS(')I9VAT(&]F(')E<'5R8VAA<V4@87,@;V8-"B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S+B!4:&4@:6YT<FEN<VEC('9A;'5E(&]F(&]P
M=&EO;G,@97AE<F-I<V5D#0H@=V%S("0X+CD@;6EL;&EO;BP@)#`N-B!M:6QL
M:6]N(&%N9"`D,2XP(&UI;&QI;VX@9'5R:6YG(#(P,3,L(#(P,3(-"B!A;F0@
M,C`Q,2P@<F5S<&5C=&EV96QY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!T:&4@86=G<F5G
M871E(&EN=')I;G-I8R!V86QU97,@;V8@=&AE#0H@;W5T<W1A;F1I;F<@86YD
M(&5X97)C:7-A8FQE(&]P=&EO;G,@=V5R92`D-38N-"8C>$$P.VUI;&QI;VX@
M86YD#0H@)#0Q+C$@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!4:&4@86=G<F5G
M871E(&EN=')I;G-I8R!V86QU92!O9@T*(&]P=&EO;G,@=F5S=&5D(&%N9"!E
M>'!E8W1E9"!T;R!V97-T(&1U<FEN9R`R,#$S+"`R,#$R(&%N9"`R,#$Q('=A
M<PT*("0U-"XY(&UI;&QI;VXL("0X+C4@;6EL;&EO;B!A;F0@)#`N,2!M:6QL
M:6]N+"!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-U;6UA<FEZ97,@:6YF;W)M871I;VX@=VET:"!R97-P96-T
M('1O('-T;V-K#0H@;W!T:6]N<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
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M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N
M=&5R/CQB/D]P=&EO;G,@3W5T<W1A;F1I;F<@86YD#0H@17AE<F-I<V%B;&4\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB
M/D]P=&EO;G,@17AE<F-I<V%B;&4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9#L@
M5TE$5$@Z(#@Q+C`U<'0G/@T*(#QB/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E
M/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B
M*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY.=6UB97(F(WA!,#MO9CQB<B`O/@T*(%-H
M87)E<R!O9CQB<B`O/@T*(&-O;6UO;B8C>$$P.W-T;V-K/&)R("\^#0H@<W5B
M:F5C="8C>$$P.W1O)B-X03`[;W!T:6]N<SPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960F(WA!,#M!=F5R
M86=E/&)R("\^#0H@4F5M86EN:6YG/&)R("\^#0H@0V]N=')A8W1U86PF(WA!
M,#M,:69E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY.=6UB97(F(WA!,#MO9CQB<B`O/@T*(%-H87)E<R8C>$$P.V]F
M/&)R("\^#0H@8V]M;6]N)B-X03`[<W1O8VL\8G(@+SX-"B!S=6)J96-T('1O
M/&)R("\^#0H@;W!T:6]N<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P
M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^5V5I9VAT960F(WA!,#M!=F5R86=E/&)R("\^
M#0H@17AE<F-I<V4@4')I8V4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXH26X-"B!Y96%R<RD\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*("0R+C4U)B-X03`[
M)B-X,C`Q,SLF(WA!,#LD,RXR-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(Q,BPX-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-RXW-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*("0S+C0U)B-X03`[)B-X,C`Q
M,SLF(WA!,#LD,RXT-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L,3(T+#,X,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XT+CDT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,3(T+#,X,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RXT-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M)#,N.#`F(WA!,#LF(W@R,#$S.R8C>$$P.R0U+C(V/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-C8Q+#4V-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XS+C,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*("0U+C,U
M)B-X03`[)B-X,C`Q,SLF(WA!,#LD-2XS-3PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CDP.2PX-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-2XY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XY,#DL.#8V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU+C,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B`D-2XT,28C>$$P.R8C>#(P,3,[)B-X03`[)#4N-#$\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$S-"PU,C0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."XX.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-S`L,#0P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU+C0Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`D-2XT,B8C>$$P.R8C>#(P,3,[)B-X03`[)#4N-C8\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,"PU,#`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XR-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV,"PU,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C4N-#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*("0U+C<P)B-X03`[)B-X,C`Q,SLF(WA!,#LD-2XW
M,#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDT-2PQ,C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXY,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-S8L.3<P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C<P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B`D-2XX-B8C>$$P.R8C>#(P,3,[)B-X03`[)#8N.#(\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX.3DL,#(R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S0Y+#`R,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-BXT-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@)#8N.3(F(WA!,#LF(W@R,#$S.R8C
M>$$P.R0Q,2XY.3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V
M-2PS-#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XT
M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-C<L,S8Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+C8X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B`D,3(N,3(F(WA!,#LF(W@R,#$S.R8C>$$P
M.R0Q-"XV,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#DR
M+#<P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C@S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@W+#`P
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,30N,#4\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#0P-2PX-C0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C(V/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-2PX,#`L.3,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C8N.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O
M9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`F(WA!
M,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#!P="<^#0H@/&(^/&D^4F5S=')I8W1E9"!3=&]C:R!5;FET
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1'5R
M:6YG(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(&ES<W5E9"`S.3(L-3`P
M(&%N9"`T.#8L-S4P#0H@4F5S=')I8W1E9"!3=&]C:R!5;FET<R`H4E-5<RDL
M(')E<W!E8W1I=F5L>2X@5&AE(%)357,@:7-S=65D(&EN#0H@,C`Q,R!A;F0@
M,C`Q,B!H860@82!G<F%N="!D871E(&9A:7(@=F%L=64@;V8@)#$R+C$R(&%N
M9"`D-2XT,2P-"B!R97-P96-T:79E;'DN(%1H97-E(&%W87)D<R!W:6QL('9E
M<W0@87,@9F]L;&]W<SH@;VYE+71H:7)D(&]F('1H90T*(&%W87)D('=I;&P@
M=F5S="!I;B!A('-E<FEE<R!O9B!T:')E92!S=6-C97-S:79E(&5Q=6%L(&%N
M;G5A;`T*(&EN<W1A;&QM96YT<RX@1'5R:6YG(#(P,3$L('1H92!#;VUP86YY
M(&ES<W5E9"`U-3`L,#`P(%)357,@870@80T*(&=R86YT(&1A=&4@9F%I<B!V
M86QU92!O9B`D,BXU-2X@5&AE<V4@87=A<F1S('=I;&P@=F5S="!A<R!F;VQL
M;W=S.@T*(&]N92UT:&ER9"!O9B!T:&4@87=A<F0@=VEL;"!V97-T(&]N('1H
M92!S96-O;F0@86YN:79E<G-A<GD@;V8@=&AE#0H@87=A<F0@9&%T92!A;F0@
M='=O+71H:7)D<R!O9B!T:&4@87=A<F0@=VEL;"!V97-T(&]N('1H92!T:&ER
M9`T*(&%N;FEV97)S87)Y(&]F('1H92!A=V%R9"!D871E+B!4:&4@86=G<F5G
M871E('9A;'5E(&]F('-H87)E<R!V97-T960-"B!D=7)I;F<@,C`Q,RP@,C`Q
M,B!A;F0@,C`Q,2!W87,@)#0N,2!M:6QL:6]N+"`D,"XQ(&UI;&QI;VX@86YD
M("0P+C(-"B!M:6QL:6]N+"!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*($$@<W5M;6%R>2!O9B!386YG86UO)B-X,C`Q
M.3MS(%)352!A8W1I=FET>2!I<R!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%2
M1TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$
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M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYU;6)E
M<B!O9CQB<B`O/@T*(%-H87)E<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L
M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^5V5I9VAT960F(WA!,#M!=F5R86=E/&)R("\^#0H@
M4F5M86EN:6YG/&)R("\^#0H@0V]N=')A8W1U86PF(WA!,#M497)M/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY!9V=R
M96=A=&4F(WA!,#M);G1R:6YS:6,\8G(@+SX-"B!686QU93PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/BA);@T*('EE87)S*3PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXH
M26XF(WA!,#MT:&]U<V%N9',I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A
M9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!24U5S(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`S-BPW
M-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4E-5<R!A=V%R9&5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,SDR+#4P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!24U5S(')E;&5A<V5D/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,T,2PX-#,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)357,@9F]R9F5I=&5D/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(S+#<U,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!24U5S(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#8S+#8U
M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,30L-S<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@4E-5<R!V97-T960@86YD(&5X<&5C=&5D('1O('9E<W0@870@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^.3(U+#@X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,3(L.#8P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%)357,@=&AA="!V97-T960@:6X@,C`Q
M,RP@,C`Q,B!A;F0@,C`Q,2!W97)E(&YE="US:&%R92!S971T;&5D('-U8V@-
M"B!T:&%T('1H92!#;VUP86YY('=I=&AH96QD('-H87)E<R!W:71H('9A;'5E
M(&5Q=6EV86QE;G0@=&\@=&AE#0H@96UP;&]Y965S)B-X,C`Q.3L@;6EN:6UU
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M=VET:&AE;&0@:6X@,C`Q,BX@5&]T86P@<&%Y;65N=',@9F]R('1H90T*(&5M
M<&QO>65E<R8C>#(P,3D[('1A>"!O8FQI9V%T:6]N<R!T;R!T87AI;F<@875T
M:&]R:71I97,@=V5R92`D,BXP#0H@;6EL;&EO;B!A;F0@)#`N,2!M:6QL:6]N
M(&EN(#(P,3,@86YD(#(P,3$L(')E<W!E8W1I=F5L>2P@86YD(&%R90T*(')E
M9FQE8W1E9"!A<R!A(&9I;F%N8VEN9R!A8W1I=FET>2!W:71H:6X@=&AE($-O
M;G-O;&ED871E9`T*(%-T871E;65N=',@;V8@0V%S:"!&;&]W<RXF(WA!,#M4
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M<&5N<V4@=&\@=&AE#0H@0V]M<&%N>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=&AE
M<F4@=V5R92`R+#DR.2PU.3`@<VAA<F5S('=E<F4-"B!R97-E<G9E9"!F;W(@
M9G5T=7)E(&%W87)D<R!U;F1E<B!T:&4@0V]M<&%N>28C>#(P,3D[<R`R,#$S
M(%!L86X@86YD#0H@,2PU,C<L-S8S('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M<F5S97)V960@9F]R(&9U='5R92!I<W-U86YC92!U;F1E<@T*('1H92!0=7)C
M:&%S92!0;&%N+CPO<#X-"B`\(2TM('AB<FPL;B`M+3X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@
M/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S
M.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S
M7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T
M,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)
M;F-O;64@5&%X97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$X<'0G/@T*(#QB/DY/5$4@,3`@)B-X,C`Q,SL@24Y#3TU%
M(%1!6$53/"]B/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(')E8V]R9&5D(&YO(&EN
M8V]M92!T87@@97AP96YS92X@5&AE('!R:6YC:7!A;`T*(&1I9F9E<F5N8V4@
M8F5T=V5E;B!T:&4@<W1A='5T;W)Y('1A>"!R871E(&]F(#,T)2!A;F0@=&AE
M#0H@0V]M<&%N>28C>#(P,3D[<R!E9F9E8W1I=F4@=&%X(')A=&4@:7,@9'5E
M('1O('1H92!#;VUP86YY('!E<FUA;F5N=`T*(&1I9F9E<F5N8V5S(')E;&%T
M960@=&\@<W1O8VL@8V]M<&5N<V%T:6]N(&%N9"!I=',@8VAA;F=E(&EN#0H@
M=F%L=6%T:6]N(&%L;&]W86YC92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@,3)P
M>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M="!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@9&5F97)R
M960@=&%X(&%S<V5T<R!A<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI
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M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\
M(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B`\=3X\8CX\:3Y!<W-E=',Z/"]I/CPO8CX\+W4^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@=&%X(&%S<V5T
M<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W
M87)D<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT('1A>"!C<F5D:70@
M8V%R<GEF;W)W87)D<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<L.3DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S<P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#
M87!I=&%L:7IE9"!R97-E87)C:#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-RPY,C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPS-S4\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E
M9F5R<F5D(%)E=F5N=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS+#4V,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/=&AE<CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C<W/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CDS-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&1E9F5R<F5D('1A>"!A<W-E=#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`S+#$P-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C@X+#(Q-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M5F%L=6%T:6]N(&%L;&]W86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#$P,RPQ,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/BD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@X+#(Q-CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@=&%X(&%S<V5T<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`\8CX\
M:3X\=3Y,:6%B:6QI=&EE<SH\+W4^/"]I/CPO8CX\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&1E9F5R<F5D('1A
M>"!L:6%B:6QI='D@<F5L871E9"!T;R!I;G1A;F=I8FQE(&%S<V5T<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<T.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@9&5F97)R960@
M=&%X(&QI86)I;&ET>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W-#@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@
M16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
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M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%)E86QI>F%T:6]N(&]F(&1E9F5R<F5D('1A>"!A
M<W-E=',@:7,@9&5P96YD96YT('5P;VX@9G5T=7)E#0H@96%R;FEN9W,L(&EF
M(&%N>2P@=&AE('1I;6EN9R!A;F0@86UO=6YT(&]F('=H:6-H(&%R92!U;F-E
M<G1A:6XN#0H@06-C;W)D:6YG;'DL('1H92!N970@9&5F97)R960@=&%X(&%S
M<V5T<R!H879E(&)E96X@9G5L;'D@;V9F<V5T(&)Y#0H@82!V86QU871I;VX@
M86QL;W=A;F-E+B!4:&4@=F%L=6%T:6]N(&%L;&]W86YC92!I;F-R96%S960@
M8GD@)#$T+CD-"B!M:6QL:6]N+"`D-2XT(&UI;&QI;VX@86YD("0Q.2XW(&UI
M;&QI;VX@9F]R('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X@07,@;V8-"B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!386YG86UO(&AA9"!N970@;W!E<F%T
M:6YG(&QO<W,-"B!C87)R>69O<G=A<F1S(&9O<B!F961E<F%L(&%N9"!S=&%T
M92!I;F-O;64@=&%X('!U<G!O<V5S(&]F#0H@87!P<F]X:6UA=&5L>2`D,C`Y
M)B-X03`[;6EL;&EO;B!A;F0@)#$Y.2!M:6QL:6]N+"!R97-P96-T:79E;'DN
M($EF#0H@;F]T('5T:6QI>F5D+"!T:&4@;F5T(&9E9&5R86P@86YD('-T871E
M(&]P97)A=&EN9R!L;W-S#0H@8V%R<GEF;W)W87)D<R!W:6QL(&)E9VEN('1O
M(&5X<&ER92!I;B`R,#$X(&%N9"`R,#$T(')E<W!E8W1I=F5L>2X-"B!4:&4@
M0V]M<&%N>2!A;'-O(&AA<R!F961E<F%L(&%N9"!S=&%T92!R97-E87)C:"!T
M87@@8W)E9&ET#0H@8V%R<GEF;W)W87)D<R!O9B`D-BXR)B-X03`[;6EL;&EO
M;B!A;F0@)#8N-2!M:6QL:6]N+"!R97-P96-T:79E;'DN#0H@5&AE(&9E9&5R
M86P@<F5S96%R8V@@8W)E9&ET<R!W:6QL(&)E9VEN('1O(&5X<&ER92!I;B`R
M,#$X('=H:6QE('1H90T*('-T871E(')E<V5A<F-H(&-R961I=',@:&%V92!N
M;R!E>'!I<F%T:6]N(&1A=&4N(%5T:6QI>F%T:6]N(&]F('1H90T*($-O;7!A
M;GDF(W@R,#$Y.W,@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@
M86YD(')E<V5A<F-H('1A>`T*(&-R961I="!C87)R>69O<G=A<F1S(&UA>2!B
M92!S=6)J96-T('1O('-U8G-T86YT:6%L(&%N;G5A;`T*(&QI;6ET871I;VYS
M(&1U92!T;R!T:&4@;W=N97)S:&EP(&-H86YG92!L:6UI=&%T:6]N<R!P<F]V
M:61E9"!B>2!T:&4-"B!);G1E<FYA;"!2979E;G5E($-O9&4@86YD('-I;6EL
M87(@<W1A=&4@<')O=FES:6]N<RX@5&AE(&%N;G5A;`T*(&QI;6ET871I;VX@
M8V]U;&0@<F5S=6QT(&EN('1H92!E>'!I<F%T:6]N(&]F('1H92!N970@;W!E
M<F%T:6YG(&QO<W,-"B!C87)R>69O<G=A<F1S(&%N9"!R97-E87)C:"!T87@@
M8W)E9&ET(&-A<G)Y9F]R=V%R9',@8F5F;W)E#0H@=71I;&EZ871I;VXN/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(&9I
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M;VT@,C`P-R!A;F0@=&AE<F5A9G1E<B!R96UA:6X@;W!E;B!T;R!E>&%M:6YA
M=&EO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O
M;7!A;GDF(W@R,#$Y.W,@<')A8W1I8V4@:7,@=&\@<F5C;V=N:7IE(&EN=&5R
M97-T(&%N9"]O<@T*('!E;F%L=&EE<R!R96QA=&5D('1O(&EN8V]M92!T87@@
M;6%T=&5R<R!I;B!I;F-O;64@=&%X(&5X<&5N<V4N($%S#0H@;V8@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,RP@=&AE($-O;7!A;GD@:&%D(&YO(&%C8W)U960@
M:6YT97)E<W0-"B!A;F0O;W(@<&5N86QT:65S+B!4:&4@=6YR96-O9VYI>F5D
M('1A>"!B96YE9FET<R!M87D@8VAA;F=E(&1U<FEN9PT*('1H92!N97AT('EE
M87(@9F]R(&ET96US('1H870@87)I<V4@:6X@=&AE(&]R9&EN87)Y(&-O=7)S
M92!O9@T*(&)U<VEN97-S+B!);B!T:&4@979E;G0@=&AA="!A;GD@=6YR96-O
M9VYI>F5D('1A>"!B96YE9FET<R!A<F4-"B!R96-O9VYI>F5D+"!T:&4@969F
M96-T:79E('1A>"!R871E('=I;&P@;F]T(&)E(&%F9F5C=&5D+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X
M.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ
M97,@=&AE(&%C=&EV:71Y(')E;&%T960@=&\@=&AE#0H@0V]M<&%N>28C>#(P
M,3D[<R!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S("AI;B!T:&]U<V%N9',I
M.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A
M;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@5&%B;&4@2&5A
M9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S(E/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$
M8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@
M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)E
M9VEN;FEN9R!B86QA;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M-S,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#<U,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX.38\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($%D9&ET:6]N<R!B87-E9"!O;B!T87@@<&]S:71I;VYS(')E
M;&%T960@=&\@=&AE(&-U<G)E;G0@>65A<CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ-3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3@Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!!9&1I=&EO;G,@9F]R('1A>"!P;W-I=&EO;G,@;V8@<')I;W(@>65A<G,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3,\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C8U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!2961U8W1I;VYS(&9O<B!T87@@<&]S:71I;VYS(&]F('!R:6]R('EE87)S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C(W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5N9&EN9R!B
M86QA;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPQ.#(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,BPW,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPW-3`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V
M-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U;G1S(%!A>6%B;&4@86YD($%C8W)U
M960@3&EA8FEL:71I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@06YD($%C8W)U86QS(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B`\8CY.3U1%(#$Q("8C>#(P,3,[($%#0T]53E13(%!!64%"3$4@04Y$
M($%#0U)5140@3$E!0DE,251)15,\+V(^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y
M("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
M3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@06-C;W5N=',@<&%Y
M86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<R!C;VYS:7-T(&]F('1H92!F
M;VQL;W=I;F<-"B`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I
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M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB
M/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C8V]U;G1S('!A>6%B;&4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPP,C(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L,#0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q
M,'!T)SX-"B!!8V-R=65D(&-L:6YI8V%L('1R:6%L(&5X<&5N<V4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,C<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C$U/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!8V-R=65D('!R;V9E<W-I;VYA
M;"!F965S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3$P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@1&5F97)R960@<F5N=#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R,3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XY-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@3W1H97(\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P@
M86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C0L,S@P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0L,#$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!"
M;V1Y("TM/CPO=&%B;&4^#0H@/"$M+2!X8G)L+&X@+2T^#0H@#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E
M,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5M<&QO>65E($)E;F5F:70@4&QA
M;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VUP96YS871I;VX@06YD(%)E=&ER96UE;G0@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;7!L;WEE92!"96YE9FET(%!L86X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY.3U1%(#$R
M("8C>#(P,3,[($5-4$Q/645%($)%3D5&250@4$Q!3CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!S<&]N<V]R<R!A
M(&1E9FEN960M8V]N=')I8G5T:6]N('-A=FEN9W,@<&QA;B!U;F1E<@T*(%-E
M8W1I;VXF(WA!,#LT,#$H:RD@;V8@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D
M92!C;W9E<FEN9R!A;&P-"B!F=6QL+71I;64@96UP;&]Y965S("A386YG86UO
M(#0P,2AK*2!0;&%N*2X@5&AE(%-A;F=A;6\@-#`Q*&LI(%!L86X-"B!I<R!I
M;G1E;F1E9"!T;R!Q=6%L:69Y('5N9&5R(%-E8W1I;VXF(WA!,#LT,#$@;V8@
M=&AE($EN=&5R;F%L#0H@4F5V96YU92!#;V1E+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P="<^#0H@
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[5&AE($-O;7!A;GD@;6%T8VAE9`T*(&-O;G1R:6)U=&EO;G,@8GD@96UP
M;&]Y965S(&5Q=6%L('1O(#4P)2!O9B!T:&4@9FER<W0@-B4@;V8@96UP;&]Y
M964-"B!C;VYT<FEB=71I;VYS('5P('1O(&$@;&EM:70@;V8@)#$L-3`P(&EN
M(#(P,3,@86YD("0Q+#`P,"!I;B`R,#$R+@T*($UA=&-H:6YG(&9U;F1S(&%R
M92!F=6QL>2!V97-T960@=VAE;B!C;VYT<FEB=71E9"X@0V]N=')I8G5T:6]N
M<R!T;PT*('1H92!386YG86UO(#0P,2AK*2!0;&%N('=E<F4@)#`N,2!M:6QL
M:6]N(&EN(&)O=&@@>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S(&%N9"`R,#$R+B!4:&5R92!W97)E(&YO('-U8V@@8V]N=')I8G5T:6]N
M<PT*(&EN(#(P,3$N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R
M,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S
M+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^475A<G1E<FQY($9I
M;F%N8VEA;"!);F9O<FUA=&EO;B!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U87)T
M97)L>2!&:6YA;F-I86P@1&%T83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/DY/5$4@,3,@)B-X,C`Q,SL@
M455!4E1%4DQ9($9)3D%.0TE!3"!$051!("A53D%51$E4140I/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B
M;&4@<V5T<R!F;W)T:"!C97)T86EN('5N875D:71E9"!Q=6%R=&5R;'D-"B!F
M:6YA;F-I86P@9&%T82!F;W(@=&AE(&5I9VAT('%U87)T97)S(&5N9&5D($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,N#0H@5&AE('5N875D:71E9"!I;F9O<FUA
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M9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS
M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4R)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q
M-"!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@
M86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1,3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^43(\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY1-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^43$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/E$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CY1,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M430\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E=F5N=65S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-C(S/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XV+#DS-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PW,#<\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.#8Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XS+#(T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PU
M-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.3`W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XX+#DS,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@17AP96YS97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L-3(X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
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M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,34L,#0S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3`L-S`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPS,#`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
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M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@U+#0U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V+#$T-3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@X+#$T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W+#(V.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@U+#<R.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#<Y,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@S+#0W.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!L;W-S('!E<B!S:&%R
M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ,SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@P+C$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,3$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH
M,"XQ,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@P+C$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,3$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,"XQ,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y
M85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E
M=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^3D]412`Q-"`F(W@R
M,#$S.R!354)315%514Y4($5614Y4/"]B/CPO<#X-"B`\(2TM('AB<FPL8F]D
M>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]N($IA;G5A<GDF
M(WA!,#LX+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!';&]B
M86P-"B!297-E87)C:"P@1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T
M:6]N($-O;&QA8F]R871I;VX@86YD#0H@3&EC96YS92!!9W)E96UE;G0@*'1H
M92!!9W)E96UE;G0I('=I=&@@0FEO9V5N($ED96,@26YC+B`H0FEO9V5N*2P-
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5;F1E<B!T:&4@06=R
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M86P@=')I86P@9F]R('1H92!F:7)S="!:1E`@=&AE<F%P975T:6,@9&5V96QO
M<&5D#0H@=6YD97(@=&AE($%G<F5E;65N="!F;W(@=&AE('1R96%T;65N="!O
M9B!B971A+71H86QA<W-E;6EA+B!);B!T:&4-"B!30T0@<')O9W)A;2P@8F]T
M:"!P87)T:65S(&%R92!R97-P;VYS:6)L92!F;W(@<F5S96%R8V@@86YD#0H@
M9&5V96QO<&UE;G0@86-T:79I=&EE<R!T:')O=6=H('1H92!S=6)M:7-S:6]N
M(&]F(&%N($E.1"!A<'!L:6-A=&EO;@T*(&9O<B!:1E`@=&AE<F%P975T:6-S
M(&EN=&5N9&5D('1O('1R96%T(%-#1"X@56YD97(@8F]T:"!P<F]G<F%M<RP-
M"B!":6]G96X@:7,@<F5S<&]N<VEB;&4@9F]R('-U8G-E<75E;G0@=V]R;&1W
M:61E(&-L:6YI8V%L#0H@9&5V96QO<&UE;G0L(&UA;G5F86-T=7)I;F<@86YD
M(&-O;6UE<F-I86QI>F%T:6]N(&]F(&QI8V5N<V5D#0H@<')O9'5C=',@9&5V
M96QO<&5D('5N9&5R('1H92!!9W)E96UE;G0N($%T('1H92!E;F0@;V8@<W!E
M8VEF:65D#0H@<F5S96%R8V@@=&5R;7,@9F]R(&5A8V@@<')O9W)A;2!O<B!U
M;F1E<B!C97)T86EN('-P96-I9FEE9`T*(&-I<F-U;7-T86YC97,L($)I;V=E
M;B!R971A:6YS('1H92!R:6=H="!T;R!S=&5P(&EN(&%N9"!T86ME(&]V97(-
M"B!A;GD@<F5M86EN:6YG(&%C=&EV:71I97,@;V8@4V%N9V%M;RX@1G5R=&AE
M<FUO<F4L(%-A;F=A;6\@:&%S(&%N#0H@;W!T:6]N('1O(&-O+7!R;VUO=&4@
M:6X@=&AE(%5N:71E9"!3=&%T97,@86YY)B-X03`[;&EC96YS960@<')O9'5C
M=`T*('1O('1R96%T(&)E=&$M=&AA;&%S<V5M:6$@86YD(%-#1"8C>$$P.V1E
M=F5L;W!E9"!U;F1E<B!T:&4-"B!!9W)E96UE;G0L(&%N9"!":6]G96X@86=R
M965S('1O(&-O;7!E;G-A=&4@4V%N9V%M;R!F;W(@<W5C:`T*(&-O+7!R;VUO
M=&EO;B!A8W1I=FET:65S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B!5;F1E<B!T:&4@06=R965M96YT+"!386YG86UO('=I;&P@<F5C96EV
M92!A;B!U<&9R;VYT(&QI8V5N<V4@9F5E(&]F#0H@)#(P+C`@;6EL;&EO;BX@
M0FEO9V5N('=I;&P@<F5I;6)U<G-E(%-A;F=A;6\@9F]R(&ET<R!C;W-T<R!I
M;F-U<G)E9`T*(&EN(&-O;FYE8W1I;VX@=VET:"!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@86-T:79I=&EE<R!C;VYD=6-T960@8GD-"B!386YG86UO+B!)
M;B!A9&1I=&EO;BP@4V%N9V%M;R!I<R!E;&EG:6)L92!T;R!R96-E:79E(&1E
M=F5L;W!M96YT#0H@;6EL97-T;VYE('!A>6UE;G1S('5P;VX@=&AE(&%C:&EE
M=F5M96YT(&]F('-P96-I9FEE9"!R96=U;&%T;W)Y+`T*(&-L:6YI8V%L(&1E
M=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!M:6QE<W1O;F5S+B!4
M:&4@=&]T86P-"B!A;6]U;G0@;V8@<&]T96YT:6%L(')E9W5L871O<GDL(&-L
M:6YI8V%L(&1E=F5L;W!M96YT+`T*(&-O;6UE<F-I86QI>F%T:6]N(&%N9"!S
M86QE<R!M:6QE<W1O;F4@<&%Y;65N=',L(&%S<W5M:6YG('1H90T*(&%C:&EE
M=F5M96YT(&]F(&%L;"!S<&5C:69I960@;6EL97-T;VYE<R!I;B!T:&4@06=R
M965M96YT+"!I<R`D,CDS+C@-"B!M:6QL:6]N+"!I;F-L=61I;F<@4&AA<V4@
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M9B!A;FYU86P@;F5T('-A;&5S#0H@;V8@<W5C:"!P<F]D=6-T+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M97)T>2!D979E;&]P960@<'5R<W5A;G0@=&\@=&AE($%G<F5E;65N="X\+W`^
M#0H@/"$M+2`O>&)R;"QN<R`M+3X-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C
M8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,3AP="<^#0H@/&(^/&D^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@<')E<&%R871I
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M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0G5S:6YE<W,@0V]M8FEN871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^
M0G5S:6YE<W,@0V]M8FEN871I;VYS/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!A8V-O=6YT960@9F]R('1H
M92!A8W%U:7-I=&EO;B!O9B!#97)E9V5N92!I;B!A8V-O<F1A;F-E#0H@=VET
M:"!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VX@*$%30RD@5&]P
M:6,@.#`U+"!"=7-I;F5S<PT*($-O;6)I;F%T:6]N<RX@05-#(%1O<&EC(#@P
M-2!E<W1A8FQI<VAE<R!P<FEN8VEP;&5S(&%N9"!R97%U:7)E;65N=',-"B!F
M;W(@<F5C;V=N:7II;F<@86YD(&UE87-U<FEN9R!T:&4@=&]T86P@8V]N<VED
M97)A=&EO;B!T<F%N<V9E<G)E9`T*('1O(&%N9"!T:&4@87-S971S(&%C<75I
M<F5D+"!L:6%B:6QI=&EE<R!A<W-U;65D(&%N9"!A;GD-"B!N;VXM8V]N=')O
M;&QI;F<@:6YT97)E<W1S(&EN('1H92!A8W%U:7)E9"!T87)G970@:6X@82!B
M=7-I;F5S<PT*(&-O;6)I;F%T:6]N+B!!4T,@5&]P:6,@.#`U(&%L<V\@<')O
M=FED97,@9W5I9&%N8V4@9F]R(')E8V]G;FEZ:6YG#0H@86YD(&UE87-U<FEN
M9R!G;V]D=VEL;"!A8W%U:7)E9"!I;B!A(&)U<VEN97-S(&-O;6)I;F%T:6]N
M.R!R97%U:7)E<PT*('!U<F-H87-E9"!I;BUP<F]C97-S(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N="!T;R!B92!C87!I=&%L:7IE9"!A=`T*(&9A:7(@=F%L
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M:&4@8G5S:6YE<W,-"B!C;VUB:6YA=&EO;BX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^0V%S:"!A;F0@0V%S
M:"!%<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!<R!P87)T(&]F('1H92!A
M8W%U:7-I=&EO;B!O9B!#97)E9V5N92P@4V%N9V%M;R!W87,@<F5Q=6ER960@
M=&\@<V5T#0H@87-I9&4@)#`N,R!M:6QL:6]N(&EN(&%N(&5S8W)O=R!A8V-O
M=6YT('5N=&EL($]C=&]B97(F(WA!,#LQ+"`R,#$T+@T*(%1H92!C87-H(&AO
M;&0@:6X@97-C<F]W('=A<R!R96-O<F1E9"!A<R!R97-T<FEC=&5D(&-A<V@N
M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!396-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^
M/&D^36%R:V5T86)L92!396-U<FET:65S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!386YG86UO(&-L87-S:69I97,@:71S(&UA
M<FME=&%B;&4@<V5C=7)I=&EE<R!A<R!A=F%I;&%B;&4M9F]R+7-A;&4-"B!A
M;F0@<F5C;W)D<R!I=',@:6YV97-T;65N=',@870@97-T:6UA=&5D(&9A:7(@
M=F%L=64@8F%S960@;VX@<75O=&5D#0H@;6%R:V5T('!R:6-E<R!O<B!O8G-E
M<G9A8FQE(&UA<FME="!I;G!U=',@;V8@86QM;W-T(&ED96YT:6-A;`T*(&%S
M<V5T<RP@=VET:"!T:&4@=6YR96%L:7IE9"!H;VQD:6YG(&=A:6YS(&%N9"!L
M;W-S97,@:6YC;'5D960@:6X-"B!A8V-U;75L871E9"!O=&AE<B!C;VUP<F5H
M96YS:79E(&EN8V]M92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@:6YV97-T;65N=',@87)E('-U8FIE
M8W0@=&\@82!P97)I;V1I8PT*(&EM<&%I<FUE;G0@<F5V:65W+B!4:&4@0V]M
M<&%N>2!R96-O9VYI>F5S(&%N(&EM<&%I<FUE;G0@8VAA<F=E('=H96X-"B!A
M(&1E8VQI;F4@:6X@=&AE(&9A:7(@=F%L=64@;V8@:71S(&EN=F5S=&UE;G1S
M(&)E;&]W('1H92!C;W-T(&)A<VES#0H@:7,@:G5D9V5D('1O(&)E(&]T:&5R
M+71H86XM=&5M<&]R87)Y+B!4:&4@0V]M<&%N>2!C;VYS:61E<G,@=F%R:6]U
M<PT*(&9A8W1O<G,@:6X@9&5T97)M:6YI;F<@=VAE=&AE<B!T;R!R96-O9VYI
M>F4@86X@:6UP86ER;65N="!C:&%R9V4L#0H@:6YC;'5D:6YG('1H92!L96YG
M=&@@;V8@=&EM92!A;F0@97AT96YT('1O('=H:6-H('1H92!F86ER('9A;'5E
M(&AA<PT*(&)E96X@;&5S<R!T:&%N('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
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M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\
M8CX\:3Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&-A<G)Y:6YG(&%M;W5N=',@
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M9RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@
M/&(^/&D^4')O<&5R='D@86YD($5Q=6EP;65N=#PO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4')O<&5R='D@86YD(&5Q=6EP;65N
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M1F]R(&QE87-E:&]L9`T*(&EM<')O=F5M96YT<RP@86UO<G1I>F%T:6]N(&ES
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M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!296-O9VYI
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QB/CQI/E)E=F5N=64@4F5C;V=N:71I;VX\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
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M8V%L;'D@:6YC;'5D97,@=7!F<F]N=`T*('-I9VYI;F<@;W(@;&EC96YS92!F
M965S+"!C;W-T(')E:6UB=7)S96UE;G1S+"!R97-E87)C:"!S97)V:6-E<RP-
M"B!M:6YI;75M('-U8FQI8V5N<V4@9F5E<RP@;6EL97-T;VYE('!A>6UE;G1S
M(&%N9"!R;WEA;'1I97,@;VX@9G5T=7)E#0H@;&EC96YS964F(W@R,#$Y.W,@
M<')O9'5C="!S86QE<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@/&D^375L=&EP;&4@16QE;65N="!!<G)A;F=E;65N=',@<')I;W(@=&\@
M=&AE(&%D;W!T:6]N(&]F($%350T*($YO+B8C>$$P.S(P,#DM,3,L(%)E=F5N
M=64@4F5C;V=N:71I;VXF(W@R,#$T.TUU;'1I<&QE($1E;&EV97)A8FQE#0H@
M4F5V96YU92!!<G)A;F=E;65N=',@*$%352`R,#`Y+3$S*3PO:3XN($9O<B!R
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M;VX@=V%S(&%L;&]C871E9`T*(&%M;VYG('1H92!S97!A<F%T92!U;FET<R!O
M9B!A8V-O=6YT:6YG(&)A<V5D(&]N('1H96ER(&9A:7(@=F%L=65S+`T*(&%N
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M:79E(&)A<VES+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\
M:3Y-=6QT:7!L92!%;&5M96YT($%R<F%N9V5M96YT<R!A9G1E<B!T:&4@861O
M<'1I;VX@;V8@05-5#0H@,C`P.2TQ,RX\+VD^($%352`R,#`Y+3$S(&%M96YD
M960@=&AE(&%C8V]U;G1I;F<@<W1A;F1A<F1S(&9O<@T*(&-E<G1A:6X@;75L
M=&EP;&4@96QE;65N="!R979E;G5E(&%R<F%N9V5M96YT<R!T;SH\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YP<F]V:61E('5P
M9&%T960@9W5I9&%N8V4@;VX@=VAE=&AE<@T*(&UU;'1I<&QE(&5L96UE;G1S
M(&5X:7-T+"!H;W<@=&AE(&5L96UE;G1S(&EN(&%N(&%R<F%N9V5M96YT('-H
M;W5L9`T*(&)E('-E<&%R871E9"P@86YD(&AO=R!T:&4@87)R86YG96UE;G0@
M8V]N<VED97)A=&EO;B!S:&]U;&0@8F4-"B!A;&QO8V%T960@=&\@=&AE('-E
M<&%R871E(&5L96UE;G1S.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@
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M:6-E("A%4U`I+"!I9B!N96ET:&5R(%933T4@;F]R#0H@5%!%(&ES(&%V86EL
M86)L93L@86YD/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YE;&EM:6YA=&4@=&AE('5S92!O
M9B!T:&4@<F5S:61U86P-"B!M971H;V0@86YD(')E<75I<F4@86X@96YT:71Y
M('1O(&%L;&]C871E(&%R<F%N9V5M96YT(&-O;G-I9&5R871I;VX-"B!U<VEN
M9R!T:&4@<F5L871I=F4@<V5L;&EN9R!P<FEC92!M971H;V0N/"]T9#X-"B`\
M+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
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M<F%T:6]N(&%N9"!L:6-E;G-E(&%G<F5E;65N=`T*(&5N=&5R960@:6YT;R!W
M:71H(%-H:7)E($EN=&5R;F%T:6]N86P@1VUB2"P@9F]R;65R;'D@4VAI<F4@
M04<L#0H@*%-H:7)E*2!I;B!*86YU87)Y(#(P,3(@=V%S(&5V86QU871E9"!U
M;F1E<B!T:&5S92!A;65N9&5D#0H@86-C;W5N=&EN9R!S=&%N9&%R9',N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%D9&ET:6]N86QL>2P@
M=&AE($-O;7!A;GD@;6%Y(&)E(&5N=&ET;&5D('1O(')E8V5I=F4@8V5R=&%I
M;@T*(&UI;&5S=&]N92!P87EM96YT<R!W:&EC:"!A<F4@8V]N=&EN9V5N="!U
M<&]N(')E86-H:6YG('-P96-I9FEE9`T*(&]B:F5C=&EV97,N(%1H97-E(&UI
M;&5S=&]N92!P87EM96YT<R!A<F4@<F5C;V=N:7IE9"!A<R!R979E;G5E(&EN
M#0H@9G5L;"!U<&]N(&%C:&EE=F5M96YT(&]F('1H92!M:6QE<W1O;F4@:68@
M=&AE<F4@:7,@<W5B<W1A;G1I=F4-"B!U;F-E<G1A:6YT>2!A="!T:&4@9&%T
M92!T:&4@87)R86YG96UE;G0@:7,@96YT97)E9"!I;G1O('1H870-"B!O8FIE
M8W1I=F5S('=I;&P@8F4@86-H:65V960@86YD(&EF('1H92!A8VAI979E;65N
M="!I<R!B87-E9"!O;B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('!E<F9O<FUA
M;F-E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!-:6YI;75M
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M<FYE9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4V%N9V%M
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M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!$=7)I;F<@,C`Q,RP@<F5V
M96YU97,@<F5L871E9"!T;R!3:&ER92P@4VEG;6$M06QD<FEC:"!#;W)P;W)A
M=&EO;@T*("A3:6=M82D@86YD($1O=R!!9W)O4V-I96YC97,@3$Q#("A$05,I
M(')E<')E<V5N=&5D(#8X)2P@.24@86YD(#$R)2P-"B!R97-P96-T:79E;'DL
M(&]F('1O=&%L(')E=F5N=65S+B!$=7)I;F<@,C`Q,BP@<F5V96YU97,@<F5L
M871E9`T*(%-H:7)E+"!3:6=M82!A;F0@1$%3(')E<')E<V5N=&5D(#4Q)2P@
M,3$E(&%N9"`R,B4@;V8@=&]T86P-"B!R979E;G5E<RP@<F5S<&5C=&EV96QY
M+B!$=7)I;F<@,C`Q,2P@<F5V96YU97,@<F5L871E9"!T;R!3:6=M82P-"B!$
M05,L($-A;&EF;W)N:6$@26YS=&ET=71E(&9O<B!296=E;F5R871I=F4@365D
M:6-I;F4@*$-)4DTI(&%N9"!#2$1)#0H@1F]U;F1A=&EO;BP@26YC+B`H0TA$
M22D@<F5P<F5S96YT960@,34E+"`T,R4L(#$X)2!A;F0@,3$E(&]F('1O=&%L
M#0H@<F5V96YU97,L(')E<W!E8W1I=F5L>2X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI/E)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M
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M;&]P;65N=`T*('1H870@:&%V92!N;R!A;'1E<FYA=&EV92!F=71U<F4@=7-E
M(&%R92!E>'!E;G-E9"!A<R!I;F-U<G)E9"X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RU"87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M<W1R:6-T960@<W1U8VL@=6YI=',@*%)357,I(&%N9`T*(&5M<&QO>65E('-H
M87)E('!U<F-H87-E<R!R96QA=&5D('1O('1H92!%;7!L;WEE92!3:&%R92!0
M=7)C:&%S90T*(%!L86X@*$534%`I+"!B87-E9"!O;B!E<W1I;6%T960@9F%I
M<B!V86QU97,@870@9W)A;G0@9&%T92X@5&AE(&9A:7(-"B!V86QU92!O9B!S
M=&]C:RUB87-E9"!A=V%R9',@:7,@86UO<G1I>F5D(&]V97(@=&AE('9E<W1I
M;F<@<&5R:6]D(&]F#0H@=&AE(&%W87)D('5S:6YG(&$@<W1R86EG:'0M;&EN
M92!M971H;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1O
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M9"!G96YE<F%L;'D@<F5Q=6ER92!S:6=N:69I8V%N=`T*(&%N86QY<VES(&%N
M9"!J=61G;65N="!T;R!D979E;&]P+B!7:&EL92!E<W1I;6%T97,@;V8@97AP
M96-T960@;&EF90T*(&%N9"!V;VQA=&EL:71Y(&%R92!D97)I=F5D('!R:6UA
M<FEL>2!F<F]M('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@:&ES=&]R:6-A;"!D
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M9"!T;R!V97-T+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@07-S971S("T@
M26XM4')O8V5S<R!297-E87)C:"!A;F0@1&5V96QO<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\
M:3Y);G1A;F=I8FQE($%S<V5T<R`F(W@R,#$S.R!);BU0<F]C97-S(%)E<V5A
M<F-H(&%N9`T*($1E=F5L;W!M96YT/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!);G1A;F=I8FQE(&%S<V5T<R!R96QA=&5D('1O
M(&EN+7!R;V-E<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@8V]S=',L
M(&]R($E04B9A;7`[1"P@87)E(&-O;G-I9&5R960@=&\@8F4@:6YD969I;FET
M92UL:79E9"!U;G1I;`T*('1H92!C;VUP;&5T:6]N(&]R(&%B86YD;VYM96YT
M(&]F('1H92!A<W-O8VEA=&5D(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT
M(&5F9F]R=',N($EF(&%N9"!W:&5N(&1E=F5L;W!M96YT(&ES(&-O;7!L971E
M+"!W:&EC:`T*(&=E;F5R86QL>2!O8V-U<G,@:68@86YD('=H96X@<F5G=6QA
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M(&%S<V5T<R!A<F4@8V]N<VED97)E9`T*(&EN9&5F:6YI=&4M;&EV960N($1U
M<FEN9R!T:&ES('!E<FEO9"P@=&AE(&%S<V5T<R!W:6QL(&YO="!B90T*(&%M
M;W)T:7IE9"!B=70@=VEL;"!B92!T97-T960@9F]R(&EM<&%I<FUE;G0@;VX@
M86X@86YN=6%L(&)A<VES(&%N9`T*(&)E='=E96X@86YN=6%L('1E<W1S(&EF
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M86UP.T0@:6X@=&AE('EE87(@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y';V]D=VEL
M;#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1V]O
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M('1H92!R96-O<F1E9"!G;V]D=VEL;"!I;B!T:&4@>65A<B!E;F1E9`T*($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N
M="!#;VYS:61E<F%T:6]N($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D-O;G1I;F=E
M;G0@0V]N<VED97)A=&EO;B!,:6%B:6QI='D\+VD^/"]B/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
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M;G1I;F=E;G0@;&EA8FEL:71Y)B-X,C`Q1#L-"B!E>'!E;G-E(&QI;F4@:71E
M;2!I;B!T:&4@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@3W!E<F%T:6]N
M<PT*('5N9&5R(&]P97)A=&EN9R!E>'!E;G-E<RX\+W`^#0H@/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($QO<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^
M3F5T($QO<W,@4&5R(%-H87)E/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($)E8V%U<V4@
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M8VL@;W!T:6]N(&]U='-T86YD:6YG(&%T('1H92!E;F0@;V8@,C`Q,RP@,C`Q
M,B!A;F0-"B`R,#$Q('=E<F4@."PT,#4L.#8T+"`Y+#$X-"PS-#8@86YD(#@L
M,S0V+#$Y,"P@<F5S<&5C=&EV96QY+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E9VUE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T
M)SX-"B`\8CX\:3Y396=M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@;W!E<F%T97,@:6X@;VYE('-E
M9VUE;G0N($UA;F%G96UE;G0@=7-E<R!O;F4-"B!M96%S=7)E;65N="!O9B!P
M<F]F:71A8FEL:71Y(&%N9"!D;V5S(&YO="!S96=R96=A=&4@:71S(&)U<VEN
M97-S#0H@9F]R(&EN=&5R;F%L(')E<&]R=&EN9RX@07,@;V8@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q,BP@86QL#0H@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@87-S971S('=E<F4@;6%I;G1A:6YE9"!I;B!T:&4@52Y3+B!&
M;W(@=&AE#0H@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@
M,C`Q,B!A;F0@,C`Q,2P@,3`P)2!O9B!R979E;G5E<PT*(&%N9"!O<&5R871I
M;F<@97AP96YS97,@=V5R92!G96YE<F%T960@86YD(&EN8W5R<F5D(&EN('1H
M92!5+E,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B`\8CX\:3Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N
M8V5M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@26X@1F5B<G5A<GD@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%352!.;RXF
M(WA!,#LR,#$S+3`R+`T*($-O;7!R96AE;G-I=F4@26YC;VUE("A4;W!I8R`R
M,C`I.B!297!O<G1I;F<@;V8@06UO=6YT<R!296-L87-S:69I960-"B!/=70@
M;V8@06-C=6UU;&%T960@3W1H97(@0V]M<')E:&5N<VEV92!);F-O;64N(%1H
M:7,@;F5W;'D@:7-S=65D#0H@86-C;W5N=&EN9R!S=&%N9&%R9"!R97%U:7)E
M<R!A;B!E;G1I='D@=&\@<')O=FED92!I;F9O<FUA=&EO;B!A8F]U=`T*('1H
M92!A;6]U;G1S(')E8VQA<W-I9FEE9"!O=70@;V8@86-C=6UU;&%T960@;W1H
M97(@8V]M<')E:&5N<VEV90T*(&EN8V]M92!B>2!C;VUP;VYE;G0N(%1H:7,@
M05-5(&ES(&5F9F5C=&EV92!F;W(@<F5P;W)T:6YG('!E<FEO9',-"B!B96=I
M;FYI;F<@869T97(@1&5C96UB97(F(WA!,#LQ-2P@,C`Q,BX@5&AE($-O;7!A
M;GD@861O<'1E9"!T:&ES#0H@<W1A;F1A<F0@:6X@=&AE(&9I<G-T('%U87)T
M97(@;V8@,C`Q,R!A;F0@=&AE(&%D;W!T:6]N(&]F('1H:7,-"B!S=&%N9&%R
M9"!D:60@;F]T(&AA=F4@86X@:6UP86-T(&]N(&ET<R!F:6YA;F-I86P@<&]S
M:71I;VX@;W(-"B!R97-U;'1S(&]F(&]P97)A=&EO;G,N/"]P/@T*(#PA+2T@
M>&)R;"QN("TM/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T,C,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER
M(%9A;'5E($UE87-U<F5M96YT("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E1E>'0@0FQO8VL@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5M;6%R>2!O9B!&86ER(%9A;'5E($UE87-U<F5M96YT<R!O9B!#
M87-H($5Q=6EV86QE;G1S+"!!=F%I;&%B;&4M9F]R+5-A;&4@4V5C=7)I=&EE
M<R!A;F0@0V]N=&EN9V5N="!#;VYS:61E<F%T:6]N($QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
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M;',@=VET:&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2`H:6X-"B!T:&]U
M<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\
M8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3,\8G(@+SX-"B!&86ER)B-X
M03`[5F%L=64F(WA!,#M-96%S=7)E;65N=',\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&]T
M86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/DQE=F5L)B-X03`[,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P
M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^3&5V96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96PF(WA!,#LS/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O
M9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!<W-E=',Z/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-BPY,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8L.3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>$$P.R8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>$$P.R8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N
M=&ET>2!D96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ,C$L,CDP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3(Q+#(Y,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;#PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$R."PR,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-BPY,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(Q+#(Y,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!,:6%B:6QI=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]N=&EN9V5N="!C;VYS:61E<F%T
M:6]N(&QI86)I;&ET>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3<P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X03`[)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(WA!,#LF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#4W,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T
M86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4W,#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>$$P.R8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X03`[
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PU-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#$V/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X
M03`[,S$L)B-X03`[,C`Q,CQB<B`O/@T*($9A:7(F(WA!,#M686QU928C>$$P
M.TUE87-U<F5M96YT<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96PF(WA!
M,#LQ/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP
M*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY,979E;"8C>$$P.S,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($UO
M;F5Y(&UA<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$U+#@S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET
M>2!D96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW,RPR.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4W+#0T.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!4
M86)L92!";V1Y("TM/CPO=&%B;&4^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!&86ER(%9A;'5E(&]F($-O;G1I;F=E;G0@0V]N<VED97)A=&EO;B!,
M:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/D9R;VT@=&AE(&%C<75I<VET:6]N(&1A=&4@;V8@3V-T;V)E<B8C>$$P.S$L
M(#(P,3,@=&AR;W5G:`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L('1H92!R
M96-O9VYI>F5D(&%M;W5N="!O9B!T:&4@;&EA8FEL:71Y(&9O<@T*(&-O;G1I
M;F=E;G0@8V]N<VED97)A=&EO;B!I;F-R96%S960@8GD@)#`N,2!M:6QL:6]N
M('!R:6UA<FEL>2!A<R!T:&4-"B!R97-U;'0@;V8@=&AE('!A<W-A9V4@;V8@
M=&EM92X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A
M9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S0E/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@96YD
M960\8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9A:7(@=F%L=64@;VX@9&%T
M92!O9B!A8W%U:7-I=&EO;B`H3V-T;V)E<B`Q+"`R,#$S*3PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#4Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@0VAA;F=E(&EN(&9A:7(@=F%L=64\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^
M#0H@1F%I<B!V86QU92!A="!E;F0@;V8@<&5R:6]D/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PU-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^/"]T86)L93X-"B`\(2TM('AB<FPL;B`M+3X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^36%R:V5T86)L92!396-U<FET:65S("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DEN=F5S=&UE;G1S($1E8G0@06YD($5Q=6ET>2!396-U<FET:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-C:&5D=6QE(&]F($EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%1H92!T86)L92!B96QO=R!S=6UM87)I>F5S('1H92!#;VUP86YY
M)B-X,C`Q.3MS(&-A<V@@97%U:79A;&5N=',@86YD#0H@879A:6QA8FQE+69O
M<BUS86QE('-E8W5R:71I97,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-
M05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-C0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^06UO<G1I>F5D/&)R("\^#0H@
M0V]S=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^1W)O<W,\8G(@+SX-"B!5;G)E86QI>F5D/&)R("\^#0H@1V%I;G,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB
M/D=R;W-S/&)R("\^#0H@56YR96%L:7IE9#QB<B`O/@T*("A,;W-S97,I/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY%
M<W1I;6%T960\8G(@+SX-"B!&86ER)B-X03`[5F%L=64\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM
M($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/D1E8V5M8F5R)B-X03`[,S$L(#(P
M,3,\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#87-H(&5Q=6EV86QE
M;G1S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C8L.3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#DS-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.3,T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XV+#DS-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@079A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,Z/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%4N4RX@
M9V]V97)N;65N="!S<&]N<V]R960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(Q+#(W.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R
M,2PR.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&-A
M<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET
M:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(X+#(Q,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R."PR,C0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@/&(^1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO8CX\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@0V%S:"!E<75I=F%L96YT<SH\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M-65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@52Y3+B!G;W9E<FYM96YT('-P
M;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET:65S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPY.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(L.3DW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,34L.#,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3@L.#,V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PX,S8\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%V86EL86)L92UF;W(M<V%L
M92!S96-U<FET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D
M96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T+#0R
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C4T+#0U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O
M<BUS86QE('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,RPR-C(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,RPR
M.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^
M/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%2T@^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L
M;W-U<F4@3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',@4VAA<F5B87-E
M9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX@
M17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A
M8FQE('-H;W=S('1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E#0H@<F5C;V=N:7IE9"!I;B!T:&4@8V]N<V]L:61A=&5D('-T871E;65N
M=',@;V8@;W!E<F%T:6]N<R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@
M34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-B4^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI
M9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#(P-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPX.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L
M-S8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'96YE<F%L(&%N9"!A
M9&UI;FES=')A=&EV93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L.30R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M-#0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S$R
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-BPQ-#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-2PS,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PP.#$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-U
M;7!T:6]N<R!5<V5D(&9O<B!%<W1I;6%T:6YG($9A:7(@5F%L=64@;V8@16UP
M;&]Y964@4W1O8VL@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
M(&%S<W5M<'1I;VYS('5S960@9F]R(&5S=&EM871I;F<@=&AE(&9A:7(@=F%L
M=64@;V8@=&AE(&5M<&QO>65E#0H@<W1O8VL@;W!T:6]N<R!A<F4@87,@9F]L
M;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X
M-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-S`E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@16YD960-"B!$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!2:7-K+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)U=(251%+5-0
M04-%.B!N;W=R87`G/C$N-3`M,2XX.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C`N-S0M
M,2XS-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)U=(251%+5-004-%.B!N;W=R87`G/C`N.3,M,BXQ,3PO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!%>'!E8W1E9"!L:69E(&]F(&]P=&EO;B`H:6X@>65A<G,I
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XS-BTU+C,X/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N-#`M-2XU.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C,Y+34N-#$\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D(&1I
M=FED96YD('EI96QD(&]F('-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D('9O;&%T:6QI='D\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C@X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.#<M,"XX.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XP+C@S+3`N.#8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M079E<F%G92!!
M<W-U;7!T:6]N<R!5<V5D(&9O<B!%<W1I;6%T:6YG($9A:7(@5F%L=64@;V8@
M15-04"!0=7)C:&%S92!2:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
M92!W96EG:'1E9"UA=F5R86=E(&5S=&EM871E9"!F86ER('9A;'5E(&]F('-H
M87)E<R!P=7)C:&%S960@=6YD97(-"B!T:&4@0V]M<&%N>28C>#(P,3D[<R!%
M4U!0(&1U<FEN9R`R,#$S+"`R,#$R(&%N9"`R,#$Q('=E<F4@)#$N-#<L#0H@
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R
M/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2
M:7-K+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G
M/C`N,#4M,"XV,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C`N,#4M,"XS,#PO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%
M.B!N;W=R87`G/C`N,#4M,"XV,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%
M>'!E8W1E9"!L:69E(&]F(&]P=&EO;B`H:6X@>65A<G,I/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XU+3(N,#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XP+C4M,BXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C`N-2TR+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D(&1I=FED96YD('EI96QD(&]F('-T
M;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($5X<&5C=&5D('9O;&%T:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XP+C4Q+3`N.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,"XY,RTQ+C,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C`N-3@M,"XX-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@
M16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\(2TM('AB<FPL;B`M+3X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3AP="<^#0H@/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R
M,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S
M+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-0T%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DUA:F]R($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A
M=&5G:6,@06QL:6%N8V5S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&ER92!!1R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,@4F5C;V=N:7IE
M9"!U;F1E<B!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E=F5N
M=65S(')E8V]G;FEZ960@=6YD97(@=&AE(&%G<F5E;65N="!W:71H(%-H:7)E
M(&9O<B!T:&4@>65A<G,-"B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S
M(&%N9"`R,#$R+"!W97)E(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI
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M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@96YD960\8G(@+SX-"B!$96-E
M;6)E<B`S,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA
M+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5V96YU97,@<F5L871E9"!T;R!3
M:&ER92!#;VQL86)O<F%T:6]N.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($%M;W)T:7IA=&EO;B!O9B!U<&9R;VYT
M(&9E93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$V-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PY.#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H('-E<G9I
M8V5S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,30L,C@V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,#(V/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ-BPT-3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L,#$R
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;6$M06QD
M<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V96YU97,@4F5C;V=N:7IE9"!U;F1E<B!!9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E=F5N=65S(')E8V]G;FEZ
M960@=6YD97(@=&AE(&%G<F5E;65N="!W:71H(%-I9VUA(&9O<B!T:&4@>65A
M<G,-"B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"`R,#$R(&%N9"`R
M,#$Q+"!W97)E(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C
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M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\
M8CY996%R(&5N9&5D/&)R("\^#0H@1&5C96UB97(@,S$L/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(
M96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%)E=F5N=64@<F5L871E9"!T;R!3:6=M82!#;VQL86)O<F%T
M:6]N.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2;WEA
M;'1Y(')E=F5N=65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@R-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&EC96YS92!F964@86YD(&UI
M;&5S=&]N92!R979E;G5E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L,S4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8W
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,3<U/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L,C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M-C`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G
M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y
M9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4Q04%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N
M(&]F($-E<F5G96YE("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)U<VEN97-S($-O;6)I;F%T:6]N
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F($5S=&EM871E9"!&86ER(%9A;'5E(&]F
M($-O;G-I9&5R871I;VX@5')A;G-F97)R960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!E<W1I;6%T
M960@9F%I<B!V86QU92!O9B!T:&4-"B!C;VYS:61E<F%T:6]N('1R86YS9F5R
M<F5D(&)Y(%-A;F=A;6\@=&\@=&AE($-E<F5G96YE('-T;V-K:&]L9&5R<PT*
M(&]N('1H92!#;&]S:6YG($1A=&4@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N
M=&5R(&)O<F1E<CTS1#`^/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0X-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4V%N9V%M;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,2PR,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O
M;G1I;F=E;G0@96%R;BUO=70\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M-3$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A
M;"!P=7)C:&%S92!C;VYS:61E<F%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,BPW,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R
M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F($5S=&EM871E
M9"!&86ER(%9A;'5E(&]F($YE="!!<W-E=',@06-Q=6ER960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H
M92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@;F5T#0H@87-S971S(&%C
M<75I<F5D(&%S(&]F('1H92!#;&]S:6YG($1A=&4@*&EN('1H;W5S86YD<RDZ
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L
M:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X-B4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@0V%S:"!A;F0@97%U:79A;&5N=',\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@06-C;W5N
M=',@<F5C96EV86)L93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C(\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($ED
M96YT:69I86)L92!I;G1A;F=I8FQE(&%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,2PX-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=O
M;V1W:6QL/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4X-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@87-S971S(&%C
M<75I<F5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#4U-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@=&%X(&QI86)I;&ET>3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<T.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8V]U;G1S('!A>6%B;&4@86YD
M(&%C8W)U960@;&EA8FEL:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&QI86)I;&ET:65S(&%S<W5M960\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X-#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@87-S971S(&%C<75I<F5D
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPW,3`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=6UM87)Y(&]F($%S<V5T<RP@17-T:6UA=&5D($9A:7(@5F%L=65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!!('-U;6UA<GD@;V8@=&AE<V4@87-S971S
M(&%N9"!E<W1I;6%T960@9F%I<B!V86QU97,@870@=&AE($-L;W-I;F<-"B!$
M871E(&ES(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-
M05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R
M(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<Y)3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*
M(#QB/E9A;'5E)B-X03`[;V8F(WA!,#M);G1A;F=I8FQE/&)R("\^#0H@07-S
M971S($%C<75I<F5D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#15)%
M+3$Q,"!F;W(@=&AE('1R96%T;65N="!O9B!!;'IH96EM97(F(W@R,#$Y.W,@
M9&ES96%S93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8T,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0T5212TQ,C`@9F]R('1H92!T<F5A
M=&UE;G0@;V8@4&%R:VEN<V]N)B-X,C`Q.3MS(&1I<V5A<V4\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,S`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%1O=&%L(&ED96YT:69I86)L92!I;G1A;F=I8FQE(&%S
M<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#<P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4W5P<&QE;65N=&%L(%!R
M;R!&;W)M82!);F9O<FUA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`^5&AI<R!S=7!P;&5M96YT86P@<')O(&9O<FUA
M(&EN9F]R;6%T:6]N(&AA<R!B965N('!R97!A<F5D(&9O<@T*(&-O;7!A<F%T
M:79E('!U<G!O<V5S(&%N9"!D;V5S(&YO="!P=7)P;W)T('1O(&)E(&EN9&EC
M871I=F4@;V8@=VAA=`T*('=O=6QD(&AA=F4@;V-C=7)R960@:&%D('1H92!A
M8W%U:7-I=&EO;B!B965N(&UA9&4@;VX-"B!*86YU87)Y)B-X03`[,2P@,C`Q
M,BP@;F]R(&%R92!T:&5Y(&EN9&EC871I=F4@;V8@86YY(&9U='5R90T*(')E
M<W5L=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W
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M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@/&(^665A<B8C>$$P.T5N9&5D
M)B-X03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXH
M26XF(WA!,#MT:&]U<V%N9',F(WA!,#ME>&-E<'0F(WA!,#MP97(F(WA!,#MS
M:&%R928C>$$P.V1A=&$I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!.970@;&]S<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S`L
M.3DW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(W+#0T-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($)A<VEC(&YE="!L;W-S('!E<B!S:&%R93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,"XU-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P
M+C4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L
M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP
M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@
M4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!0
M<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN
M9R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<CX\(2TM
M($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<W
M)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R
M)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L
M92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($QA8F]R871O<GD@97%U:7!M96YT/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,L,C`X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#DU,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1G5R;FET=7)E
M(&%N9"!F:7AT=7)E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4V,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT.3D\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QE87-E
M:&]L9"!I;7!R;W9E;65N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#$U-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`T
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#DR-SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C0L-#DU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!,97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A
M;F0@86UO<G1I>F%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPU
M,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#(L.34R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PT,#8\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PU-#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O
M9'D@+2T^/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@
M06YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y
M(&]F($9U='5R92!-:6YI;75M(%!A>6UE;G1S('5N9&5R($-O;G1R86-T=6%L
M($]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=CX-"B`\<#Y&=71U<F4@;6EN:6UU;2!P87EM96YT<R!U;F1E<B!C;VYT
M<F%C='5A;"!O8FQI9V%T:6]N<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P
M,3,@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG("AI;B!T:&]U<V%N9',I.CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A
M8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG
M;CTS1&-E;G1E<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#0E/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60[
M(%=)1%1(.B`T,2XU<'0G/@T*(#QB/D9I<V-A;"!996%R.CPO8CX\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^3W!E<F%T:6YG/&)R("\^#0H@3&5A<V4\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM
M($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$U
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C8X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$V/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C@X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B`R,#$W/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-S`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B`R,#$X/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-S,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4:&5R96%F
M=&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#DV/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!M:6YI;75M
M('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPX-C$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C
M.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970S,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6UM87)Y(&]F(%-T;V-K($]P=&EO;B!!8W1I=FET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!!('-U;6UA<GD@;V8@4V%N9V%M;R8C>#(P,3D[<R!S=&]C:R!O
M<'1I;VX@86-T:79I='D@:7,@87,-"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%2
M1TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$
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M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYU;6)E<B!O9CQB<B`O/@T*(%-H
M87)E<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M5V5I9VAT960M/&)R("\^#0H@079E<F%G93QB<B`O/@T*($5X97)C:7-E)B-X
M03`[<&5R/&)R("\^#0H@4VAA<F4F(WA!,#M0<FEC93PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960F(WA!
M,#M!=F5R86=E/&)R("\^#0H@4F5M86EN:6YG/&)R("\^#0H@0V]N=')A8W1U
M86PF(WA!,#M497)M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP
M*2`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY!9V=R96=A=&4\8G(@+SX-"B!);G1R:6YS:6,\8G(@
M+SX-"B!686QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/BA);@T*('EE87)S
M*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-
M"B`\8CXH26XF(WA!,#MT:&]U<V%N9',I/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R
M)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXT-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($]P=&EO;G,@9W)A;G1E9#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$L,3$Y+#(P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3$N-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W!T:6]N<R!E>&5R
M8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PW,34L
M,3(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"XW-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/<'1I;VYS(&-A;F-E;&5D
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$X,BPU-3D\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX+C4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P=&EO;G,@
M;W5T<W1A;F1I;F<@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^."PT,#4L.#8T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<N,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C(V/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C4V+#0R-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A
M="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XX+#`T-BPY,S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXQ,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,3(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-30L.#0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!/<'1I;VYS(&5X97)C:7-A8FQE(&%T($1E8V5M8F5R
M)B-X03`[,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.#`P
M+#DS,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C@T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-2XP-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,2PP
M-S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!"
M;V1Y("TM/CPO=&%B;&4^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-T
M;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@9F]L;&]W:6YG('1A
M8FQE('-U;6UA<FEZ97,@:6YF;W)M871I;VX@=VET:"!R97-P96-T('1O('-T
M;V-K#0H@;W!T:6]N<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D]P
M=&EO;G,@3W5T<W1A;F1I;F<@86YD#0H@17AE<F-I<V%B;&4\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D]P=&EO;G,@17AE
M<F-I<V%B;&4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9#L@5TE$5$@Z(#@Q+C`U<'0G
M/@T*(#QB/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E/"]B/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY.=6UB97(F(WA!,#MO9CQB<B`O/@T*(%-H87)E<R!O9CQB<B`O/@T*(&-O
M;6UO;B8C>$$P.W-T;V-K/&)R("\^#0H@<W5B:F5C="8C>$$P.W1O)B-X03`[
M;W!T:6]N<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^5V5I9VAT960F(WA!,#M!=F5R86=E/&)R("\^#0H@4F5M86EN:6YG
M/&)R("\^#0H@0V]N=')A8W1U86PF(WA!,#M,:69E/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY.=6UB97(F(WA!,#MO9CQB
M<B`O/@T*(%-H87)E<R8C>$$P.V]F/&)R("\^#0H@8V]M;6]N)B-X03`[<W1O
M8VL\8G(@+SX-"B!S=6)J96-T('1O/&)R("\^#0H@;W!T:6]N<SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960F
M(WA!,#M!=F5R86=E/&)R("\^#0H@17AE<F-I<V4@4')I8V4\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXH26X-"B!Y96%R
M<RD\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D
M("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*("0R+C4U)B-X03`[)B-X,C`Q,SLF(WA!,#LD,RXR-3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q,BPX-#0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXW-SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
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M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M("0S+C0U)B-X03`[)B-X,C`Q,SLF(WA!,#LD,RXT-3PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$L,3(T+#,X,3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XT+CDT/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L,3(T+#,X,3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,RXT-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@)#,N.#`F(WA!,#LF(W@R,#$S.R8C>$$P.R0U
M+C(V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C8Q+#4V-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C,S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
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M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*("0U+C,U)B-X03`[)B-X,C`Q,SLF(WA!,#LD-2XS-3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP.2PX-C8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XY,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,#DL.#8V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XU+C,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`D-2XT,28C>$$P.R8C>#(P,3,[
M)B-X03`[)#4N-#$\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M."XX.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-S`L
M,#0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C0Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`D-2XT,B8C>$$P.R8C>#(P,3,[)B-X
M03`[)#4N-C8\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,"PU
M,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2XR-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,"PU,#`\+W1D
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M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*("0U+C<P)B-X03`[
M)B-X,C`Q,SLF(WA!,#LD-2XW,#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CDT-2PQ,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-BXY,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XV-S8L.3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C<P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`D-2XX-B8C>$$P.R8C>#(P
M,3,[)B-X03`[)#8N.#(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XX.3DL,#(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4N,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S0Y
M+#`R,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXT-3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@)#8N
M.3(F(WA!,#LF(W@R,#$S.R8C>$$P.R0Q,2XY.3PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,V-2PS-#(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-2XT,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR-C<L,S8Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XX+C8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`D,3(N,3(F
M(WA!,#LF(W@R,#$S.R8C>$$P.R0Q-"XV,CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L,#DR+#<P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV+C@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$L,#@W+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,30N,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#0P-2PX-C0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XV+C(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-2PX,#`L.3,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N
M.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA
M+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0
M.B`Q.'!X)SX-"B`F(WA!,#L\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%)E
M<W1R:6-T960@4W1O8VL@56YI="!!8W1I=FET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@02!S=6UM87)Y(&]F(%-A;F=A;6\F(W@R,#$Y.W,@4E-5(&%C=&EV
M:71Y(&ES(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/CPA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-C`E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3G5M8F5R(&]F/&)R("\^#0H@
M4VAA<F5S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY796EG:'1E9"8C>$$P.T%V97)A9V4\8G(@+SX-"B!296UA:6YI;F<\8G(@
M+SX-"B!#;VYT<F%C='5A;"8C>$$P.U1E<FT\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T928C>$$P.TEN
M=')I;G-I8SQB<B`O/@T*(%9A;'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^*$EN#0H@>65A<G,I/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/BA);B8C>$$P.W1H;W5S
M86YD<RD\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)357,@
M;W5T<W1A;F1I;F<@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#,V+#<U,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!24U5S(&%W87)D
M960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.3(L-3`P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%)357,@<F5L96%S960\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,S0Q+#@T,SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@4E-5<R!F;W)F96ET960\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,C,L-S4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%)357,@;W5T<W1A;F1I;F<@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-C,L-C4W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2XT-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"PW
M-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B
M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!24U5S
M('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A="!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,C4L.#@R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XT,SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,BPX-C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N
M9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@#0H@#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V
M-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<R`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M;F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@0V]M
M<&%N>2=S($1E9F5R<F5D(%1A>"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP/E-I9VYI9FEC86YT(&-O;7!O;F5N
M=',@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@9&5F97)R960@=&%X#0H@87-S
M971S(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@
M34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-S,E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX]
M,T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@
M5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#QU/CQB/CQI
M/D%S<V5T<SH\+VD^/"]B/CPO=3X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!T87@@87-S971S.CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-S,L,3(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R961I="!C87)R>69O<G=A
M<F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPY.38\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPW-S`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<&ET86QI>F5D
M(')E<V5A<F-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#DR-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#,W-3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@4F5V
M96YU93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-38S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,2PV-S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.3,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@5&]T86P@9&5F97)R960@=&%X(&%S<V5T/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,#,L,3`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.#@L,C$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!686QU871I;VX@
M86QL;W=A;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3`S+#$P-SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH.#@L,C$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($YE="!D969E<G)E9"!T87@@87-S971S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/CQI/CQU/DQI86)I
M;&ET:65S.CPO=3X\+VD^/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@=&%X(&QI86)I;&ET
M>2!R96QA=&5D('1O(&EN=&%N9VEB;&4@87-S971S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH-S0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L
M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!D969E<G)E9"!T87@@;&EA8FEL
M:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<T.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P
M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H
M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@
M;V8@06-T:79I='D@4F5L871E9"!T;R!#;VUP86YY)W,@56YR96-O9VYI>F5D
M(%1A>"!"96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-U;6UA<FEZ97,@=&AE(&%C=&EV:71Y(')E;&%T960@=&\@
M=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!U;G)E8V]G;FEZ960@=&%X(&)E;F5F
M:71S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/CPA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-S(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP
M+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R
M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!4
M86)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
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M;2!A;&EG;CTS1')I9VAT/C(L-S,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR+#<U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX.38\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%D9&ET:6]N<R!B87-E9"!O
M;B!T87@@<&]S:71I;VYS(')E;&%T960@=&\@=&AE(&-U<G)E;G0@>65A<CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3,\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-3@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!!9&1I=&EO;G,@9F]R('1A>"!P;W-I=&EO
M;G,@;V8@<')I;W(@>65A<G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8U/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!2961U8W1I;VYS(&9O<B!T87@@<&]S:71I
M;VYS(&]F('!R:6]R('EE87)S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,C(W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP
M*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($5N9&EN9R!B86QA;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,RPQ.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPW,S0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,BPW-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\+W1R/@T*(#PO=&%B
M;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T
M-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970S,BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U;G1S
M(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@*%1A8FQE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4&%Y86)L97,@06YD($%C8W)U86QS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@06-C
M;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&QI
M86)I;&ET:65S(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9PT*("AI;B!T:&]U
M<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S8E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE
M860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@06-C;W5N=',@<&%Y86)L93PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS+#`R,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,RPP-#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C8W)U960@8VQI
M;FEC86P@=')I86P@97AP96YS93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C<R-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XV,34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*($%C8W)U960@<')O9F5S<VEO;F%L(&9E97,\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XU,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!$969E<G)E9"!R96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3(Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDT
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!/=&AE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!A8V-O=6YT<R!P87EA8FQE(&%N
M9"!A8V-R=65D(&QI86)I;&ET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS
M.#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PP,3,\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`-
M"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^475A<G1E<FQY
M($9I;F%N8VEA;"!$871A("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I
M86P@26YF;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F
M(%%U87)T97)L>2!&:6YA;F-I86P@1&%T83PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!4:&4@9F]L;&]W:6YG('1A8FQE('-E=',@9F]R=&@@8V5R=&%I;B!U;F%U
M9&ET960@<75A<G1E<FQY#0H@9FEN86YC:6%L(&1A=&$@9F]R('1H92!E:6=H
M="!Q=6%R=&5R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3,N/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W
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M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\
M8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^
M,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CY1,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^43(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/E$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY1-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^43$\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E$R/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1,SPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^430\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
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M9VAT/C0L-C(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#DS-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PW,#<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L.#8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(T,SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PU-S0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C0L.3`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#DS
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AP96YS97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L-3(X/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L,#0S/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
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M/C$P+#,Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L-S`Y/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPS,#`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#0U
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@V+#$T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X+#$T-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@W+#(V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#<R.#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@U+#<Y,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#0W.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($YE="!L;W-S('!E<B!S:&%R93PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,"XQ,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C$P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#`N,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ,SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@P+C$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,3$\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@P+C`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A
M7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U00D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T
M:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@
M)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&EQ=6ED(&EN=F5S=&UE;G1S('!U<F-H87-E9"!W:71H(&]R:6=I
M;F%L(&UA='5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=4:')E92!M;VYT:',@;W(@;&5S<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#`N,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<R!I;7!A:7)M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL(&EM<&%I
M<FUE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@L-#`U+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL,3@T+#,T-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,S0V+#$Y,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(&]P97)A=&EN9R!S96=M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&ER92!!1R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(')E=F5N=65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=M82U!
M;&1R:6-H($-O<G!O<F%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<F5V96YU97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDN,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;W<@06=R
M;U-C:65N8V5S($Q,0R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y097)C96YT86=E(&]F(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;&EF;W)N:6$@
M26YS=&ET=71E(&9O<B!296=E;F5R871I=F4@365D:6-I;F4@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/
M<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!R979E
M;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-(1$D@1F]U;F1A=&EO;BP@26YC+B!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(')E=F5N=65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W)G86YI>F%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<F5V
M96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI=F5S(&]F(')E;&%T
M960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5S=&EM871E9"!U<V5F=6P@;&EV97,@;V8@<F5L871E9"!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-$=#
M23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M
M96YT<R`M(%-U;6UA<GD@;V8@1F%I<B!686QU92!-96%S=7)E;65N=',@;V8@
M0V%S:"!%<75I=F%L96YT<RP@079A:6QA8FQE+69O<BU386QE(%-E8W5R:71I
M97,@86YD($-O;G1I;F=E;G0@0V]N<VED97)A=&EO;B!,:6%B:6QI=&EE<R`H
M1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE
M+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E
M<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(X+#(R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S,L
M,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3
M+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET:65S
M(%M-96UB97)=('P@0V%S:"!E<75I=F%L96YT<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@
M;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M,2PR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T
M('-E8W5R:71I97,@6TUE;6)E<ET@?"!!=F%I;&%B;&4M9F]R+7-A;&4@<V5C
M=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE
M(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT
M<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPT-#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F
M=6YD<R!;365M8F5R72!\($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D
M=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M
M<V%L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&QI86)I
M;&ET>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E
M8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E
M<F%T:6]N(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL
M86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A
M<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DS-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#@S
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5V96P@,2!;365M8F5R72!\(%4N4RX@9V]V97)N;65N="!S<&]N<V]R
M960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\($-A<V@@97%U
M:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L
M92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N
M=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@
M,2!;365M8F5R72!\(%4N4RX@9V]V97)N;65N="!S<&]N<V]R960@96YT:71Y
M(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\($%V86EL86)L92UF;W(M<V%L
M92!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R
M+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV
M86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M=F5L(#$@6TUE;6)E<ET@?"!-;VYE>2!M87)K970@9G5N9',@6TUE;6)E<ET@
M?"!#87-H(&5Q=6EV86QE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B
M;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H
M(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX,SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQE=F5L(#$@6TUE;6)E<ET@?"!#;VYT:6YG96YT(&-O;G-I9&5R871I;VX@
M;&EA8FEL:71Y(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A
M;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C;VYT:6YG96YT(&-O
M;G-I9&5R871I;VX@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`R(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE
M9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R
M+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(Q+#(Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4W+#0T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E<F%T
M:6]N(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5V96P@,B!;365M8F5R72!\(%4N4RX@9V]V
M97)N;65N="!S<&]N<V]R960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M
M8F5R72!\($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V
M86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&-A<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U
M<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C$L,CDP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5V96P@,B!;365M8F5R72!\(%4N4RX@9V]V97)N;65N="!S<&]N<V]R
M960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\($%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I
M;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C
M87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+#0T.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5V96P@,B!;365M8F5R72!\($UO;F5Y(&UA<FME="!F=6YD<R!;365M8F5R
M72!\($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL
M86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A
M<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5V96P@,B!;365M8F5R72!\($-O;G1I;F=E
M;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI='D@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F
M($%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M=F5L(#,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!3
M96-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N=',@
M86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4W,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L
M(#,@6TUE;6)E<ET@?"!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET
M>2!D96)T('-E8W5R:71I97,@6TUE;6)E<ET@?"!#87-H(&5Q=6EV86QE;G1S
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I
M=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A
M=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@6TUE;6)E
M<ET@?"!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E
M8W5R:71I97,@6TUE;6)E<ET@?"!!=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I
M=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E
M8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT<R!A
M;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`S(%M-
M96UB97)=('P@36]N97D@;6%R:V5T(&9U;F1S(%M-96UB97)=('P@0V%S:"!E
M<75I=F%L96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS
M86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L
M96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,979E;"`S(%M-96UB97)=('P@0V]N=&EN9V5N="!C;VYS:61E
M<F%T:6]N(&QI86)I;&ET>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE
M+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]N=&EN
M9V5N="!C;VYS:61E<F%T:6]N(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$L-3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R
M,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S
M+U-H965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5713X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F(&-O;G1I;F=E;G0@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E
M,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970S-RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P155(
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE
M;G0@+2!38VAE9'5L92!O9B!&86ER(%9A;'5E(&]F($-O;G1I;F=E;G0@0V]N
M<VED97)A=&EO;B!,:6%B:6QI='D@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER
M(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;VX@9&%T
M92!O9B!A8W%U:7-I=&EO;B`H3V-T;V)E<B`Q+"`R,#$S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@
M=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&%T(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PU-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I
M<B!686QU92!-96%S=7)E;65N="`M(%-C:&5D=6QE(&]F($9A:7(@5F%L=64@
M;V8@0V]N=&EN9V5N="!#;VYS:61E<F%T:6]N($QI86)I;&ET>2`H4&%R96YT
M:&5T:6-A;"D@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8W%U:7-I=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y/8W0@,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R
M,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S
M+U-H965T,SDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$574D%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/DUA<FME=&%B;&4@4V5C=7)I=&EE<R`M(%-C:&5D=6QE(&]F($EN
M=F5S=&UE;G1S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O
M9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ960@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,C@L,C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`W,RPR-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A
M;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A:7(@
M5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R."PR,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M,RPR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V
M86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DS
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X+#@S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T
M:6UA=&5D($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L.3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@L.#,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2!M87)K970@9G5N9',@6TUE;6)E<ET@
M?"!#87-H(&5Q=6EV86QE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B
M;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@
M0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S
M<R!5;G)E86QI>F5D("A,;W-S97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E
M9"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@
M9&5B="!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M
M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S
M<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"`H3&]S<V5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%<W1I;6%T960@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D
M(&5N=&ET>2!D96)T('-E8W5R:71I97,@6TUE;6)E<ET@?"!!=F%I;&%B;&4M
M9F]R+7-A;&4@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA
M8FQE+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D
M($-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PR-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-"PT,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A:7(@5F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(Q+#(Y,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-30L-#4R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S
M,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S
M.#$Y9F0R+U=O<FMS:&5E=',O4VAE970T,"YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15=/04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^36%R:V5T86)L92!396-U<FET:65S
M("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92!$:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S
M(&UA='5R:71Y('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S(@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%T97)I86P@=6YR96%L:7IE9"!L;W-S97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^079A:6QA8FQE(&9O<B!S86QE('-E8W5R:71I97,@;6%T
M=7)I='D@<&5R8V5N=&%G92!N97AT('1W96QV92!M;VYT:',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4@9F]R
M('-A;&4@<V5C=7)I=&EE<R!M871U<FET>2!P97)C96YT86=E(&EN('1W96QV
M92!A;F0@='=E;G1Y(&9O=7(@;6]N=&AS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5A;&EZ960@;&]S<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R+71H86XM=&5M<&]R
M87)Y(&EM<&%I<FUE;G1S(&]F(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2TE!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX@+2!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T
M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#
M;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@
M0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8L,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@."PP.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#@Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!
M;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#DT,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT-#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0L,S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF
M.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970T,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15=:044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@
M0V]M<&5N<V%T:6]N("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@8V]M<&5N<V%T:6]N(&-O<W0@<F5L871E9"!T;R!U;G9E
M<W1E9"!S=&]C:R!O<'1I;VYS(&%N9"!24U4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E
M('!E<FEO9"!O9B!U;G9E<W1E9"!S=&]C:R!O<'1I;VYS(&%N9"!24U4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R('EE87)S(#$P(&UO;G1H
M<R`Q,R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<&ET86QI>F5D('-T;V-K+6)A<V5D(&5M<&QO>65E
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@97-T:6UA=&5D(&9A:7(@
M=F%L=64@<&5R('-H87)E(&]F(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C<V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D+6%V97)A9V4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@<VAA<F5S('!U
M<F-H87-E9"!U;F1E<B!%4U!0('!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,BXU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,"!%;7!L;WEE92!3
M=&]C:R!0=7)C:&%S92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E
M<B!E;7!L;WEE92!S=&]C:R!P=7)C:&%S92!P;&%N+"!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@:7-S=65D('5N9&5R(&5M<&QO>65E('-T;V-K('!U<F-H87-E
M('!L86YS+"!A=F5R86=E(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(N-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@4W1O8VL@56YI=',@*%)357,I(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O;7!E;G-A=&EO;B!C;W-T(')E
M;&%T960@=&\@=6YV97-T960@<W1O8VL@;W!T:6]N<R!A;F0@4E-5/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"UA=F5R86=E('!E<FEO9"!O9B!U;G9E<W1E9"!S=&]C:R!O<'1I;VYS
M(&%N9"!24U4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q('EE
M87(@,3$@;6]N=&AS(#(S(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S
M,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H
M965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5:5D%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`M($%S<W5M<'1I;VYS(%5S
M960@9F]R($5S=&EM871I;F<@1F%I<B!686QU92!O9B!%;7!L;WEE92!3=&]C
M:R!/<'1I;VYS("A$971A:6PI("A%;7!L;WEE92!3=&]C:R!/<'1I;VX@6TUE
M;6)E<ETI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AP96-T960@9&EV:61E;F0@>6EE;&0@;V8@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XX."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C<T)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N.3,E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!L:69E(&]F(&]P=&EO;B`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`T(&UO;G1H<R`Q,"!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@
M>65A<G,@-"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#0@;6]N=&AS(#(Q(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C@W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N.#,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S
M="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@X)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N
M,S0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BXQ,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N("AI;B!Y96%R<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#0@;6]N
M=&AS(#$W(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-2!Y96%R<R`V(&UO;G1H<R`R.2!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,@
M-"!M;VYT:',@,C@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N.#@E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XX-B4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%251!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@+2!7
M96EG:'1E9"U!=F5R86=E($%S<W5M<'1I;VYS(%5S960@9F]R($5S=&EM871I
M;F<@1F%I<B!686QU92!O9B!%4U!0(%!U<F-H87-E9"!2:6=H=',@*$1E=&%I
M;"D@*#(P,3`@16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B!;365M8F5R
M72D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!E8W1E9"!D:79I9&5N9"!Y:65L9"!O9B!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM
M9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C`U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,#4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N
M("AI;B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU,24\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+CDS)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M-3@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C8Q)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#`N,S`E*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-C$E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!L:69E(&]F(&]P=&EO;B`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`N.#4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2XS-R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C@U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T-#4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$553D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA
M:F]R($-U<W1O;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A=&5G:6,@06QL
M:6%N8V5S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3(\8G(^5&%R9V5T<SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/E1A<F=E=',\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CY0<F]D=6-T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($%R<F%N9V5M
M96YT+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,BPR.#(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#,P-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H:7)E($%'(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@
M0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E(&YU;6)E<B!O9B!G96YE('1A<F=E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!I;FET:6%L(&=E
M;F4@=&%R9V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F(&=E;F4@=&%R9V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&%D9&ET:6]N86P@9V5N92!T
M87)G971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-E87)C:"!P<F]G<F%M('1O(&1E=F5L;W`@;&%B;W)A=&]R>2!R97-E87)C
M:"!R96%G96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5P9G)O;G0@;&EC96YS92!F964\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!A;6]U
M;G0@=&\@8F4@9G5N9&5D(&9O<B!C97)T86EN(%-H:7)E(&UI;&5S=&]N97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0;W1E;G1I86P@86UO=6YT(&5L:6=I8FQE('1O(')E8V5I=F4@9F]R(&-E
M<G1A:6X@4VAI<F4@;6EL97-T;VYE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L(&%M;W5N="!T;R!B
M92!F=6YD960@9F]R(&%C:&EE=F5M96YT(&]F('-P96-I9FEE9"!C;VUM97)C
M:6%L:7IA=&EO;B!A;F0@<V%L97,@;6EL97-T;VYE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.1"!O<B!#5$$@
M<W5B;6ES<VEO;B!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('!R;V1U8W1S(&%P<')O=F5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y
M(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@<F5L
M871E9"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-"PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#<P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3U-!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP
M<R!A;F0@4W1R871E9VEC($%L;&EA;F-E<R`M(%)E=F5N=65S(%)E8V]G;FEZ
M960@=6YD97(@06=R965M96YT("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAI<F4@04<@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY2979E;G5E<R!R96QA=&5D('1O(%-H:7)E($-O;&QA8F]R871I;VX@.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@=7!F<F]N="!F964\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3@V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@<V5R=FEC
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#(X-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,#(V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPT
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,2PP,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=64@<F5L871E9"!T;R!3:6=M82!#
M;VQL86)O<F%T:6]N(#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F]Y86QT>2!R979E;G5E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=M82U!;&1R:6-H($-O<G!O<F%T
M:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4F5V96YU92!R96QA=&5D('1O(%-I9VUA($-O;&QA8F]R
M871I;VX@.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2;WEA;'1Y(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#(X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!F964@86YD(&UI;&5S
M=&]N92!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+#(X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV,#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S7S8V8SA?-#8V85\Y
M9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(O5V]R:W-H
M965T<R]3:&5E=#0W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3E!!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP<R!A;F0@
M4W1R871E9VEC($%L;&EA;F-E<R`M($%G<F5E;65N="!W:71H(%-I9VUA+4%L
M9')I8V@@0V]R<&]R871I;VX@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$
M971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,#D\8G(^
M4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#`W/&)R/E-I9VUA
M+4%L9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`P.3QB<CY3:6=M82U!;&1R
M:6-H($-O<G!O<F%T:6]N(%M-96UB97)=/&)R/E5P9G)O;G0@;&EC96YS92!F
M964@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CY3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N(%M-
M96UB97)=/&)R/DQI8V5N<V4@86=R965M96YT('1E<FUS(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73QB<CY,:6-E
M;G-E(&%G<F5E;65N="!T97)M<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/E-I9VUA+4%L9')I
M8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^3&EC96YS92!A9W)E96UE;G0@
M=&5R;7,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`S,2P@,C`P.3QB<CY3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N
M(%M-96UB97)=/&)R/DQI8V5N<V4@86=R965M96YT('1E<FUS(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A
M8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-E87)C:"!P<F]G<F%M('1O(&1E=F5L;W`@;&%B;W)A=&]R>2!R97-E87)C
M:"!R96%G96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^57!F<F]N="!L:6-E;G-E(&9E93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PQ,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!V86QU960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8Y+#0Y,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PR,3DL,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0=6)L:6,@;V9F97)I;F<L(&-O;6UO;B!S=&]C:R!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-BPQ
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)O>6%L='D@<F5V96YU97,@97AP96-T960@=&\@8F4@<F5C
M96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2961U8V5D(')O>6%L='D@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"XU,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F1I;F<@879A
M:6QA8FQE('5N9&5R('1H92!A;65N9&5D(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL
M86)O<F%T:6]N(&%G<F5E;65N="!R96QA=&5D(&-O<W1S(&%N9"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q
M,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q
M,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE
M970T."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14E304<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^36%J;W(@0W5S=&]M97)S+"!087)T;F5R<VAI<',@86YD(%-T<F%T96=I
M8R!!;&QI86YC97,@+2!!9W)E96UE;G0@=VET:"!$;W<@06=R;U-C:65N8V5S
M(&EN(%!L86YT($%G<FEC=6QT=7)E("T@061D:71I;VYA;"!);F9O<FUA=&EO
M;B`H1&5T86EL*2`H1&]W($%G<F]38VEE;F-E<R!;365M8F5R72P@55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D]C="X@,S$L(#(P,#4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT
M($%R<F%N9V5M96YT+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!P<F]G<F%M('1O(&1E=F5L;W`@;&%B
M;W)A=&]R>2!R97-E87)C:"!R96%G96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]N92UT:6UE(&QI8V5N<V4@9F5E
M(&5A<FYE9"!O;B!E>&5R8VES92!O9B!O<'1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y(')E=F5N
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!E<F-E;G1A9V4@;V8@<F]Y86QT:65S('1O(&)E(')E8V5I=F5D(&9R
M;VT@<W5B;&EC96YS:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;FEM=6T@<W5B;&EC96YS92!A;FYU86P@9F5E<R!S
M<&5C:69I8R!R96-K;VYI;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,3$@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E92!D=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(U+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@871T
M<FEB=71A8FQE('1O(')E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@<F5L871E9"!C;W-T
M<R!A;F0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@86=R965M96YT('1E
M<FUS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E
M;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F]Y86QT>2!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@
M4&5R9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L(&9E97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA
M>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($%R<F%N
M9V5M96YT+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;FYU86P@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T
M-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970T.2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P145704<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^36%J;W(@
M0W5S=&]M97)S+"!087)T;F5R<VAI<',@86YD(%-T<F%T96=I8R!!;&QI86YC
M97,@+2!#86QI9F]R;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE
M9&EC:6YE("T@2$E6("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL
M*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y/8W0N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P
M;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H
M97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F%B;&5S(&9R;VT@<V%L92!A9V%I
M;G-T('1H92!G<F%N="!F=6YD960@=&\@96YT:71Y(&9R;VT@<V%L92!O9B!P
M<F]D=6-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4=V\@
M('1I;65S('1H92!A;6]U;G0@4V%N9V%M;R!R96-E:79E<R!I;B!F=6YD:6YG
M('5N9&5R('1H92!A9W)E96UE;G0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%L:69O<FYI82!);G-T:71U=&4@
M9F]R(%)E9V5N97)A=&EV92!-961I8VEN92!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($%R<F%N9V5M96YT+"!#;VYT<F%C="!T;R!097)F
M;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5N9',@9'5E('5N9&5R
M('1H92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-BXT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q-"XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9W)E96UE;G0@=&\@<F5C96EV93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP96-T960@86UO=6YT('1O(&)E(')E8V5I=F5D(&9O<B!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G<F5E;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^3V-T(#,Q+`T*"0DR,#`Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N
M(&%G<F5E;65N="!R96QA=&5D(&-O<W1S(&%N9"!E>'!E;G-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86QI9F]R;FEA
M($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE(%M-96UB97)=
M('P@3&EC96YS92!A9W)E96UE;G0@=&5R;7,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H
M(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R
M9F]R;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S('5N9&5R
M(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A;&EF;W)N:6$@26YS=&ET=71E(&9O<B!296=E;F5R871I
M=F4@365D:6-I;F4@6TUE;6)E<ET@?"!,:6-E;G-E(&%G<F5E;65N="!T97)M
M<R!;365M8F5R72!\(%1H97)A<&5U=&EC(&9O<B!B971A+71H86QA<W-E;6EA
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE
M;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2979E;G5E<R!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86=R965M
M96YT(')E;&%T960@8V]S=',@86YD(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%2E!!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP<R!A;F0@4W1R
M871E9VEC($%L;&EA;F-E<R`M($-(1$D@1F]U;F1A=&EO;BP@26YC+B`M($%D
M9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*$-(1$D@1F]U;F1A=&EO
M;BP@26YC+B!;365M8F5R72P@55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-(1$D@1F]U;F1A=&EO
M;BP@26YC+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R
M86YG96UE;G0L($-O;G1R86-T('1O(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9U;F1S(&1U92!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9W)E96UE;G0@9&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^07!R(#,P+`T*"0DR
M,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9W)E96UE;G0@=&\@<F5C96EV93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S$@>65A<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W1U86P@86=R965M
M96YT('1E<FUI;F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y!=6<@,S`L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5N9',@9'5E('5N9&5R(&%G
M<F5E;65N="!A<R!P97(@86UE;F1M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86=R965M96YT(')E
M;&%T960@8V]S=',@86YD(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,@=6YD97(@=&AE(&%G<F5E
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V
M,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?
M-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970U,2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14I+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
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M6TUE;6)E<ETL(%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIA;BX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,#8\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DIU=F5N:6QE($1I86)E=&5S(%)E<V5A
M<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S96%R
M8V@@86YD($1E=F5L;W!M96YT($%R<F%N9V5M96YT+"!#;VYT<F%C="!T;R!0
M97)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=R965M96YT(&1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W0@,S$L
M#0H)"3(P,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R86YT(&9U;F1I;F<@86UO=6YT(&UA>&EM=6T@=6YD97(@
M86UE;F1E9"!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E8V5I=F5D(&9O<B!W;W)K('!E<F9O<FUE9"!U;F1E
M<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E=F5N=65S('5N9&5R('1H92!A9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T]!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP
M<R!A;F0@4W1R871E9VEC($%L;&EA;F-E<R`M($UI8VAA96P@2BX@1F]X($9O
M=6YD871I;VX@9F]R(%!A<FMI;G-O;B=S(%)E<V5A<F-H("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H36EC:&%E;"!*+B!&;W@@1F]U;F1A
M=&EO;B!F;W(@4&%R:VEN<V]N)W,@4F5S96%R8V@@6TUE;6)E<ETL(%531"`D
M*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@
M,S$L(#(P,#<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N
M+B`S,2P@,C`P-SQB<CY!9&1I=&EO;F%L($9U;F1I;F<@06=R965M96YT(%1E
M<FUS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3`\8G(^061D:71I;VYA;"!&=6YD:6YG($%G<F5E;65N
M="!497)M<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/DQI8V5N<V4@86=R965M96YT('1E<FUS
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^3&EC96YS92!A9W)E96UE;G0@=&5R;7,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CY,:6-E;G-E(&%G<F5E;65N="!T97)M<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O
M(%!E<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G<F5E;65N
M="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2F%N(#,Q
M+`T*"0DR,#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9U;F1I;F<@<F5C96EV960@9G)O;2!R97-E87)C
M:"!G<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&=6YD<R!D=64@=6YD97(@=&AE(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,@
M=6YD97(@=&AE(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q
M,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q
M,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE
M970U,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14Q&044^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^06-Q=6ES:71I;VX@;V8@0V5R96=E;F4@+2!!9&1I=&EO;F%L($EN9F]R
M;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I
M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>&-E<W,@;V8@8V]N<VED97)A=&EO;B!T<F%N<V9E
M<G)E9"!O=F5R('1H92!F86ER('9A;'5E<R!A<W-I9VYE9"!T;R!A<W-E=',@
M86-Q=6ER960@86YD(&QI86)I;&ET:65S(&%S<W5M960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PU.#4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;"!R96QA
M=&5D('1O(&1E9F5R<F5D('1A>"!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;&EA8FEL:71Y
M(&9O<B!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX@<F5C;V=N:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-S`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#97)E9V5N
M92P@26YC+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY"=7-I;F5S<R!!8W%U:7-I=&EO;B!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@=')A;G-F97)R960L('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!T
M<F%N<V9E<G)E9"P@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@<')I8V4@9&5P;W-I=&5D(&EN(&5S
M8W)O=R!A8V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%<W1I;6%T960@9F%I<B!V86QU97,@;V8@:6XM<')O8V5S<R!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AC97-S(&]F(&-O;G-I9&5R871I;VX@
M=')A;G-F97)R960@;W9E<B!T:&4@9F%I<B!V86QU97,@87-S:6=N960@=&\@
M87-S971S(&%C<75I<F5D(&%N9"!L:6%B:6QI=&EE<R!A<W-U;65D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4X-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG97,@
M:6X@=&AE($=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER('9A;'5E(&QI86)I;&ET>2!F;W(@8V]N=&EN9V5N="!C;VYS
M:61E<F%T:6]N(')E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-Q=6ES:71I;VXM<F5L871E9"!T<F%N<V%C
M=&EO;B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-Q=6ES:71I;VX@<F5L871E9"!O<&5R871I;F<@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C
M.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D
M,B]7;W)K<VAE971S+U-H965T-30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-14%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N(&]F($-E<F5G96YE("T@
M4W5M;6%R>2!O9B!%<W1I;6%T960@1F%I<B!686QU92!O9B!#;VYS:61E<F%T
M:6]N(%1R86YS9F5R<F5D("A$971A:6PI("A#97)E9V5N92P@26YC+B!;365M
M8F5R72P@55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V5R96=E;F4L($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I;VX@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y386YG86UO('-H87)E<R!O9B!C;VUM;VX@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1I;F=E
M;G0@96%R;BUO=70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@<'5R8VAA<V4@8V]N<VED97)A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF
M.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE
M971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$04%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/D%C<75I<VET:6]N(&]F($-E<F5G96YE("T@4W5M;6%R>2!O
M9B!%<W1I;6%T960@1F%I<B!686QU92!O9B!.970@07-S971S($%C<75I<F5D
M("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I;VX@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y';V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#4X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V5R96=E;F4L($EN8RX@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@
M06-Q=6ES:71I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E
M8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M9&5N=&EF:6%B;&4@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PU.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',@86-Q=6ER
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-34V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!T87@@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@W-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!L:6%B:6QI=&EE<R!A<W-U;65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&%S<V5T<R!A8W%U:7)E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A
M7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K
M<VAE971S+U-H965T-38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"34%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D%C<75I<VET:6]N(&]F($-E<F5G96YE("T@4W5M;6%R
M>2!O9B!!<W-E=',L($5S=&EM871E9"!&86ER(%9A;'5E<R`H1&5T86EL*2`H
M0V5R96=E;F4L($EN8RX@6TUE;6)E<ETL(%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"=7-I;F5S
M<R!!8W%U:7-I=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F($EN=&%N9VEB;&4@
M07-S971S($%C<75I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#15)%+3$Q,"!F;W(@=&AE('1R96%T;65N="!O9B!!;'IH
M96EM97(G<R!D:7-E87-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)U<VEN97-S($%C<75I<VET:6]N(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F%L=64@;V8@26YT86YG:6)L92!!<W-E=',@06-Q=6ER960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#15)%+3$R
M,"!F;W(@=&AE('1R96%T;65N="!O9B!087)K:6YS;VXG<R!D:7-E87-E(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D)U<VEN97-S($%C<75I<VET:6]N(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@;V8@
M26YT86YG:6)L92!!<W-E=',@06-Q=6ER960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X
M,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?
M-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970U
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15)+04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
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M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E<F5G
M96YE+"!);F,N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY"=7-I;F5S<R!!8W%U:7-I=&EO;B!0<F\@1F]R
M;6$@26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S`L.3DW*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C<L-#0V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S
M:6,@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S
M,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H
M965T-3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5$3T%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@+2!3=6UM87)Y(&]F(%!R;W!E
M<G1Y(&%N9"!%<75I<&UE;G0@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R
M;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E
M<G1Y(&%N9"!E<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0L.3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+#0Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<R!A8V-U;75L871E9"!D
M97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RPU,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY-3(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q
M=6EP;65N="P@3F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,86)O<F%T;W)Y(&5Q=6EP;65N="!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@
M86YD(&5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPY-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92!A;F0@9FEX='5R97,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E:&]L9"!I;7!R;W9E;65N
M=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,34V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C
M.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D
M,B]7;W)K<VAE971S+U-H965T-3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2D%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@+2!!
M9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R
M96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U-CDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-C`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-#8L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-P
M;W-I=&EO;B!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=R
M:71E+6]F9B!O9B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C
M.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970V,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15A"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M
M;6ET;65N=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A5
M4T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U
M<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296YT(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R,&4S,3,S7S8V8SA?-#8V85\Y
M9CEA7S4R8S$P,S@Q.69D,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(O5V]R:W-H
M965T<R]3:&5E=#8Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3D9!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#;VUM:71M96YT<R`M(%-U;6UA<GD@;V8@1G5T=7)E($UI
M;FEM=6T@4&%Y;65N=',@=6YD97(@0V]N=')A8W1U86P@3V)L:6=A=&EO;G,@
M*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN
M9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1H97)E869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&UI;FEM=6T@<&%Y;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPX-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0E5"2SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M($%D9&ET:6]N86P@
M26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0W/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#(S+"`R,#$S/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(S+"`R,#$S/&)R
M/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CY5;F1E<G=R:71E<G,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CXR,#$S(%-T;V-K($EN8V5N=&EV92!0;&%N(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^,C`Q,"!%;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^4W1O8VL@3W!T:6]N($%C=&EV:71Y(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4W1O
M8VL@3W!T:6]N($%C=&EV:71Y(%M-96UB97)=/&)R/C(P,3,@4W1O8VL@26YC
M96YT:79E(%!L86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY297-T<FEC=&5D(%-T;V-K(%5N
M:71S("A24U5S*2!;365M8F5R73QB<CY);G-T86QL;65N=#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E)E<W1R
M:6-T960@4W1O8VL@56YI=',@*%)357,I(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^4F5S=')I
M8W1E9"!3=&]C:R!5;FET<R`H4E-5<RD@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE
M;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S:&%R
M97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U8FQI8R!O9F9E<FEN9RP@8V]M;6]N
M('-T;V-K('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L,#$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=6)L:6,@;V9F97)I;F<@
M<')I8V4@;V8@8V]M;6]N('-T;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"XU.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E
M9',@9G)O;2!I<W-U86YC92!U;F1E<B!P=6)L:6,@;V9F97)I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDL-3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y386QE(&]F('-T;V-K+"!N=6UB97(@;V8@<VAA<F5S(&ES<W5E9"!I
M;B!T<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDQ-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT(&]F(&9A:7(@=F%L=64@<&5R
M('-H87)E(&]F(&-O;6UO;B!S=&]C:R!O;B!O<'1I;VX@9W)A;G0@9&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!M87AI;75M('1E<FT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M<&5C:69I960@<W1O8VMH;VQD97(@;W=N97)S:&EP('!E<F-E;G1A9V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S92!P<FEC92!O9B!C;VUM;VX@<W1O8VL@<&5R8V5N="!U;F1E
M<B!S=&]C:R!I;F-E;G1I=F4@<&QA;G,@9F]R('-P96-I9FEE9"!S=&]C:VAO
M;&1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VX@;6%X:6UU;2!T97)M(&9O<B!S<&5C
M:69I960@<W1O8VMH;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D('9E<W1I;F<@
M<FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE(%)3
M57,@=VEL;"!V97-T(&%S(&9O;&QO=W,Z("!/;F4M=&AI<F0@;VX@<V5C;VYD
M(&%N;FEV97)S87)Y(&%N9"!T=V\M=&AI<F1S('=I;&P@=F5S="!O;B`@=&AE
M('1H:7)D(&%N;FEV97)S87)Y(&]F('1H92!A=V%R9"!D871E+CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M3W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92`R,#$S(%!L86X@9V5N97)A;&QY
M('9E<W0@;W9E<B!F;W5R('EE87)S(&%T(&$@(')A=&4@;V8@,C4@<&5R8V5N
M="!O;F4@>65A<B!F<F]M('1H92!G<F%N="!D871E(&%N9"!O;F4@=&AI<G1Y
M+7-I>'1H('!E<B!M;VYT:"`@=&AE<F5A9G1E<B!A;F0@97AP:7)E('1E;B!Y
M96%R<R!A9G1E<B!T:&4@9W)A;G0L(&]R(&5A<FQI97(@=7!O;B!E;7!L;WEM
M96YT("!T97)M:6YA=&EO;BX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG5&AE<V4@87=A<F1S('=I;&P@=F5S="!A<R!F
M;VQL;W=S.B`@;VYE+71H:7)D(&]F('1H92!A=V%R9"!W:6QL('9E<W0@:6X@
M82!S97)I97,@;V8@=&AR964@<W5C8V5S<VEV92!E<75A;"!A;FYU86P@(&EN
M<W1A;&QM96YT<RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!V97-T:6YG('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@9W)A;G1E9"!V97-T:6YG('!E
M<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(&5X<&ER871I;VX@=&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC92!U;F1E<B!P;&%N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#$P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06YN=6%L(&EN8W)E87-E(&EN(&YU;6)E<B!O
M9B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<VAA<F5S
M(&%U=&AO<FEZ960@=6YD97(@,C`P-"!P;&%N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@;V8@
M8V]M;6]N('-T;V-K('-U8FIE8W0@=&\@82!S=&]C:R!O<'1I;VX@;W(@<W1O
M8VL@87!P<F5C:6%T:6]N(')I9VAT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I>&5D(')A=&EO('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q
M+C,S('-H87)E<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!P;&%N(&]F9F5R:6YG
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S(@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@<&QA;B!P=7)C:&%S92!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R97,@<W5B:F5C="!T;R!R97!U<F-H87-E(')I9VAT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=65S(&]U='-T
M86YD:6YG(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4V+#0R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&EN=')I;G-I8R!V
M86QU97,@97AE<F-I<V%B;&4@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#$L,#<S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS('9E
M<W1E9"!A;F0@97AP96-T960@=&\@=F5S="P@86=G<F5G871E(&EN=')I;G-I
M8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L.3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O
M8VL@=6YI=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.3(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#@V+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(&1A=&4@
M9F%I<B!V86QU92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S(&ES<W5E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BXQ
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2XT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,BXU-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N
M9V5M96YT(&)Y('-H87)E+6)A<V5D('!A>6UE;G0@87=A<F0L(&YU;6)E<B!O
M9B!V97-T:6YG(&EN<W1A;&QM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!A<G)A;F=E;65N="!B>2!S:&%R92UB87-E9"!P87EM96YT(&%W87)D+"!V
M97-T:6YG('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&%R
M<F%N9V5M96YT(&)Y('-H87)E+6)A<V5D('!A>6UE;G0@87=A<F0L('9E<W1I
M;F<@<&]R=&EO;B!O;B!S96-O;F0@86YN:79E<G-A<GD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S
M960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT(&)Y('-H87)E+6)A<V5D('!A
M>6UE;G0@87=A<F0L('9E<W1I;F<@<&]R=&EO;B!O;B!T:&ER9"!A;FYI=F5R
M<V%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XV-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9V=R96=A=&4@=F%L=64@;V8@<VAA<F5S('9E<W1E9"!I;B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@=VET:&AE;&0@9G)O
M;2!I<W-U86YC92!I;B!O<F1E<B!T;R!P87D@96UP;&]Y964@=&%X97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V-RPQ,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PY,S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L('!A>6UE;G1S(&9O<B!T:&4@96UP;&]Y965S)R!T87@@
M;V)L:6=A=&EO;G,@=&\@=&%X:6YG(&%U=&AO<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<R!R97-E<G9E9"!F;W(@:7-S=6%N8V4@;V8@9G5T=7)E
M(&%W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#DR.2PU.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4R-RPW-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C
M,3`S.#$Y9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S
M,3,S7S8V8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H
M965T-C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$535T%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@4W5M;6%R>2!O9B!3=&]C:R!/
M<'1I;VX@06-T:79I='D@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1&ES8VQO<W5R92!/9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T
M<R!3:&%R96)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T
M86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#$X-"PS-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#,T-BPQ.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@9W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,3DL,C`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-S$U+#$R,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&-A;F-E;&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#(L-34Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@;W5T
M<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@L-#`U+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3@T+#,T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!V
M97-T960@86YD(&5X<&5C=&5D('1O('9E<W0@870@1&5C96UB97(@,S$L(#(P
M,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#0V+#DS,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,3,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.#`P+#DS,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@;W5T<W1A;F1I;F<L(%=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@<&5R
M(%-H87)E(%!R:6-E+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!G<F%N=&5D+"!7
M96EG:'1E9"U!=F5R86=E($5X97)C:7-E('!E<B!3:&%R92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XW-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M97AE<F-I<V5D+"!796EG:'1E9"U!=F5R86=E($5X97)C:7-E('!E<B!3:&%R
M92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!C86YC96QE9"P@5V5I9VAT960M079E<F%G92!%>&5R8VES
M92!P97(@4VAA<F4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@."XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N9&EN9RP@5V5I9VAT960M079E
M<F%G92!%>&5R8VES92!P97(@4VAA<F4@4')I8V4L($5N9&EN9R!"86QA;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXR,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!V97-T960@86YD(&5X<&5C=&5D('1O('9E<W0@870@1&5C96UB
M97(@,S$L(#(P,3,L(%=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4&5R(%-H
M87)E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,3,L
M(%=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@<&5R(%-H87)E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M(&]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT
M<F%C='5A;"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-B!Y96%R<R`S(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<R`U(&UO;G1H<R`Q-B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A="!$
M96-E;6)E<BP@,S$L(#(P,3,L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<V('EE87)S(#$@;6]N=&@@,3,@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@97AE<F-I
M<V%B;&4@870@1&5C96UB97(L(#,Q+"`R,#$S+"!796EG:'1E9"!!=F5R86=E
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S
M=&%N9&EN9RP@06=G<F5G871E($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-BPT,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS('9E<W1E
M9"!A;F0@97AP96-T960@=&\@=F5S="!A="!$96-E;6)E<B`S,2P@,C`Q,RP@
M06=G<F5G871E($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-30L.#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!E>&5R8VES86)L92!A="!$
M96-E;6)E<B`S,2P@,C`Q,RP@06=G<F5G871E($EN=')I;G-I8R!686QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PP-S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V
M-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R+U=O<FMS:&5E=',O4VAE970V-"YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15--0DD^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@+2!3
M=6UM87)Y(&]F(%-T;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<@*$1E=&%I;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!
M=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@
M4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG(&%N
M9"!%>&5R8VES86)L92!.=6UB97(@;V8@4VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!S=6)J96-T('1O(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@L-#`U+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!A;F0@17AE
M<F-I<V%B;&4@5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@3&EF92`H26X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-B!Y96%R<R`S(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I
M<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C
M="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#@P,"PY,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@5V5I9VAT960@079E<F%G
M92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V+C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y286YG92`Q(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L
M86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO=V5R(%)A
M;F=E(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5P<&5R(%)A;F=E(&]F($5X97)C:7-E(%!R:6-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE($YU;6)E<B!O9B!3:&%R
M97,@;V8@8V]M;6]N('-T;V-K('-U8FIE8W0@=&\@;W!T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$R+#@T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S
M=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4@5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@3&EF92`H26X@>65A<G,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<R`Y(&UO;G1H<R`W(&1A>7,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU.2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92`R(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O
M8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO=V5R(%)A;F=E(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P<&5R(%)A;F=E(&]F($5X
M97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE($YU
M;6)E<B!O9B!3:&%R97,@;V8@8V]M;6]N('-T;V-K('-U8FIE8W0@=&\@;W!T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,C0L,S@Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($]U='-T86YD:6YG(&%N9"!%>&5R8VES86)L92!796EG:'1E
M9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E("A);B!Y96%R
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S(#$Q
M(&UO;G1H<R`Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@3G5M8F5R(&]F
M(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$R-"PS.#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@17AE<F-I<V%B;&4@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C0U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG
M92`S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U
M=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES92!0
M<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO=V5R(%)A;F=E(&]F($5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M57!P97(@4F%N9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!A
M;F0@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV-C$L-38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG(&%N9"!%>&5R
M8VES86)L92!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A
M;"!,:69E("A);B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<S('EE87)S(#,@;6]N=&AS(#(Y(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I
M<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C
M="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M.38L,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"XU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@-"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VXL(%-H87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N
M<RP@17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W=E<B!286YG
M92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5<'!E<B!286YG92!O9B!%>&5R8VES92!0<FEC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C,U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($]U='-T86YD:6YG(&%N9"!%>&5R8VES86)L92!.=6UB97(@;V8@4VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!S=6)J96-T('1O(&]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDP.2PX-C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A
M;F1I;F<@86YD($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A9V4@4F5M86EN
M:6YG($-O;G1R86-T=6%L($QI9F4@*$EN('EE87)S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,@,3$@;6]N=&AS(#$@9&%Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VYS($5X97)C:7-A8FQE($YU;6)E<B!O9B!3:&%R97,@;V8@8V]M;6]N
M('-T;V-K('-U8FIE8W0@=&\@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3`Y+#@V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92!796EG
M:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4N,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(#4@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C
M:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]W97(@4F%N9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-2XT,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57!P97(@4F%N9V4@;V8@17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-2XT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4@3G5M
M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$S-"PU,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE(%=E:6=H=&5D
M($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4@*$EN('EE87)S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A<G,@,3`@
M;6]N=&AS(#(Q(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@3G5M8F5R(&]F
M(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S`L,#0P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XT,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@
M-B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H
M;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I
M8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;W=E<B!286YG92!O9B!%>&5R8VES92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C0R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M<'!E<B!286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U+C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG(&%N
M9"!%>&5R8VES86)L92!.=6UB97(@;V8@4VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!S=6)J96-T('1O(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8P+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!A;F0@17AE<F-I
M<V%B;&4@5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@
M3&EF92`H26X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!Y96%R<R`R(&UO;G1H<R`R-R!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A
M8FQE($YU;6)E<B!O9B!3:&%R97,@;V8@8V]M;6]N('-T;V-K('-U8FIE8W0@
M=&\@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-2XT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F%N9V4@-R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL
M(%-H87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@
M17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W=E<B!286YG92!O
M9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5P<&5R(%)A;F=E(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S
M=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY-#4L,3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG
M(&%N9"!%>&5R8VES86)L92!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!,:69E("A);B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<V('EE87)S(#$Q(&UO;G1H<R`U(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV-S8L.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE(%=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y286YG92`X(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T
M:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO
M=V5R(%)A;F=E(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4N.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P<&5R(%)A;F=E(&]F($5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N.#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE($YU;6)E<B!O
M9B!3:&%R97,@;V8@8V]M;6]N('-T;V-K('-U8FIE8W0@=&\@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DY+#`R,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N
M<R!/=71S=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4@5V5I9VAT960@079E<F%G
M92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF92`H26X@>65A<G,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Q(&UO;G1H(#$S
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW-#DL,#(P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A
M8FQE(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXT-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@.2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D('5N
M9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N9V4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W=E<B!286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+CDR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<'!E<B!286YG
M92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,2XY.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!A;F0@17AE<F-I
M<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<W5B:F5C
M="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-C4L,S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG(&%N9"!%>&5R8VES86)L92!7
M96EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E("A)
M;B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE
M87)S(#4@;6]N=&AS(#$@9&%Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE($YU;6)E
M<B!O9B!3:&%R97,@;V8@8V]M;6]N('-T;V-K('-U8FIE8W0@=&\@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8W+#,V,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!%>&5R8VES86)L92!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@N-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A
M;F=E(#$P(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S
M($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES
M92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO=V5R(%)A;F=E(&]F($5X97)C
M:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5<'!E<B!286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"XV,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N
M9&EN9R!A;F0@17AE<F-I<V%B;&4@3G5M8F5R(&]F(%-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@<W5B:F5C="!T;R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#`Y,BPW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<@
M86YD($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O
M;G1R86-T=6%L($QI9F4@*$EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S8@>65A<G,@.2!M;VYT:',@,CD@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N
M<R!%>&5R8VES86)L92!.=6UB97(@;V8@4VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!S=6)J96-T('1O(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,#@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92!796EG:'1E
M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$T+C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X
M,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?
M-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970V
M-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14-3044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VMH;VQD97)S)R!%<75I='D@+2!3=6UM87)Y(&]F(%)E<W1R:6-T960@
M4W1O8VL@56YI="!!8W1I=FET>2`H1&5T86EL*2`H4F5S=')I8W1E9"!3=&]C
M:R!5;FET<R`H4E-5<RD@6TUE;6)E<ETL(%531"`D*3QB<CY);B!4:&]U<V%N
M9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!3=&]C:R!5;FET<R`H4E-5<RD@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4E-5<R!O=71S=&%N9&EN9R!A
M="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PP,S8L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)357,@87=A<F1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SDR+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X-BPW-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y24U5S
M(')E;&5A<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-#$L
M.#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y24U5S(&9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C,L-S4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y24U5S(&]U='-T86YD:6YG(&%T($1E8V5M
M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#`V,RPV-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#`S-BPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y24U5S('9E<W1E9"!A;F0@97AP96-T960@
M=&\@=F5S="!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3(U+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y24U5S(&]U='-T86YD:6YG(&%T
M($1E8V5M8F5R+"`S,2P@,C`Q,RP@5V5I9VAT960M079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@5&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S$@>65A<B`U(&UO;G1H<R`Q-B!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)357,@=F5S=&5D
M(&%N9"!E>'!E8W1E9"!T;R!V97-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S+"!7
M96EG:'1E9"U!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R(#4@;6]N=&AS
M(#4@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y24U5S(&]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R
M,#$S+"!!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$T+#<W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y24U5S('9E<W1E9"!A;F0@
M97AP96-T960@=&\@=F5S="!A="!$96-E;6)E<B`S,2P@,C`Q,RP@06=G<F5G
M871E($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,BPX-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y
M9F0R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V
M8SA?-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T-C8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5564%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN
M8V]M92!487AE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>&5S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O
M;64@=&%X(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&%T=71O<GD@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,T+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU871I;VX@86QL;W=A;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L,3`W+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X+#(Q
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);F-R96%S92!I;B!D969E<G)E9"!T87@@87-S971S('9A;'5A
M=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!T87@@
M87-S971S+"!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!F;W(@
M9F5D97)A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`Y+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@=&%X(&%S<V5T<RP@;F5T(&]P97)A=&EN9R!L
M;W-S(&-A<G)Y9F]R=V%R9',@9F]R('-T871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.3DL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<R!C
M87)R>69O<G=A<F1S+"!E>'!I<F%T:6]N('EE87(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E9&5R86P@<F5S96%R8V@@=&%X
M(&-R961I="!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#DY-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#<W,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T92!R97-E87)C:"!T
M87@@8W)E9&ET(&-A<G)Y9F]R=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487@@8W)E9&ET(&-A<G)Y9F]R=V%R
M9"P@97AP:7)A=&EO;B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG,C`Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T(&%N9"]O<B!P96YA;'1I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YD969I
M;FET92UL:79E9"!A<W-E=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X
M,3EF9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C(P93,Q,S-?
M-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R+U=O<FMS:&5E=',O4VAE970V
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P139%044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M26YC;VUE(%1A>&5S("T@4V-H961U;&4@;V8@0V]M<&%N>2=S($1E9F5R<F5D
M(%1A>"!!<W-E=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D
M('1A>"!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#$L.30T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,RPQ
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!T87@@8W)E9&ET(&-A<G)Y
M9F]R=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.3DV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPW-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<&ET86QI>F5D(')E<V5A<F-H/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#DR
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!2979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8W-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&1E9F5R
M<F5D('1A>"!A<W-E=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`S+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@X+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3`S+#$P-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X."PR,38I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&1E
M9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I
M;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!D969E<G)E9"!T87@@;&EA8FEL:71Y(')E;&%T960@=&\@
M:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@9&5F97)R960@=&%X(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W-#@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?
M-#8V85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T-C@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4R3$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M
M92!487AE<R`M(%-U;6UA<GD@;V8@06-T:79I='D@4F5L871E9"!T;R!#;VUP
M86YY)W,@56YR96-O9VYI>F5D(%1A>"!"96YE9FET<R`H1&5T86EL*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN
M:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BPW,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#@Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYS(&)A<V5D(&]N('1A>"!P
M;W-I=&EO;G,@<F5L871E9"!T;R!T:&4@8W5R<F5N="!Y96%R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N<R!F
M;W(@=&%X('!O<VET:6]N<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9'5C=&EO;G,@9F]R('1A
M>"!P;W-I=&EO;G,@;V8@<')I;W(@>65A<G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,C<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPQ.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L
M-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V
M85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+U-H965T-CDN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4V24%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D%C8V]U;G1S
M(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@+2!3=6UM87)Y(&]F
M($%C8V]U;G1S(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!A>6%B;&5S($%N9"!!8V-R=6%L<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S+#`R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPP-#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8VQI;FEC86P@
M=')I86P@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D('!R;V9E<W-I;VYA;"!F965S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#,X,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP
M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M54I!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%;7!L;WEE92!"96YE9FET
M(%!L86X@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;7!E;G-A=&EO;B!!;F0@4F5T:7)E;65N="!$:7-C;&]S
M=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F:6YE9"!C;VYT<FEB=71I;VX@<&QA;BP@96UP
M;&]Y97(G<R!M871C:&EN9R!C;VYT<FEB=71I;VX@<&5R8V5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65R<R!M
M871C:&EN9R!C;VYT<FEB=71I;VX@<&5R8V5N=&%G92!T;W=A<F1S(&5M<&QO
M>65E<R!C;VYT<FEB=71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9FEN960@8V]N=')I8G5T:6]N('!L86XL(&UA>&EM
M=6T@96UP;&]Y97(G<R!C;VYT<FEB=71I;VX@<&5R(&5M<&QO>65E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G
M9W)E9V%T92!E;7!L;WEE<G,@8V]N=')I8G5T:6]N<R!T;R!D969I;F5D(&-O
M;G1R:6)U=&EO;B!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%5#9!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@+2!3=6UM87)Y(&]F(%%U
M87)T97)L>2!&:6YA;F-I86P@1&%T82`H1&5T86EL*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0X/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T:6]N(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V+#@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-2PW,#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L.3,T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#8R,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PY
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0L.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+#4W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPR-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T+#$S,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$L-C4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PS
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PP-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,2PX-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPT,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,2PU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPS,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PW,#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PU
M,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,"PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,RPX-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-BPQ-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#@L,30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPQ-#4I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#0U,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8L
M.#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,RPT-S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@U+#<Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L-S(X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPR-C@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-BPV,C0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@R,BPR-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@S-2PW-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!P97(@<VAA<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XP-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-#@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P
M+C0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XW,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3$%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U
M96YT($5V96YT("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H
M4W5B<V5Q=65N="!%=F5N="!;365M8F5R72P@55-$("0I/&)R/DEN($UI;&QI
M;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIA;BX@,#@L(#(P,30\8G(^4')O9W)A;3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S
M97%U96YT($5V96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(')E<V5A<F-H('!R
M;V=R86US/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<&9R
M;VYT(&QI8V5N<V4@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y,RXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"971A+71H86QA<W-E;6EA(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEC:VQE(&-E
M;&P@9&ES96%S92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#<N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-C(P93,Q,S-?-C9C.%\T-C9A7SEF.6%?-3)C,3`S.#$Y9F0R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R,&4S,3,S7S8V8SA?-#8V
M85\Y9CEA7S4R8S$P,S@Q.69D,B]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO
M9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB
M;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970T.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#4W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3DN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#8P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970V,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970V-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V-RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#8Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970W,"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-S$N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#<R+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM
M/5].97AT4&%R=%\V,C!E,S$S,U\V-F,X7S0V-F%?.68Y85\U,F,Q,#,X,3EF
&9#(M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZVAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail) (Employee Stock Option [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">0.88%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.50%<span></span></td>
        <td class="nump">0.74%<span></span></td>
        <td class="nump">0.93%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">5 years 4 months 10 days<span></span></td>
        <td class="text">5 years 4 months 24 days<span></span></td>
        <td class="text">5 years 4 months 21 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.87%<span></span></td>
        <td class="nump">0.83%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.88%<span></span></td>
        <td class="nump">1.34%<span></span></td>
        <td class="nump">2.11%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">5 years 4 months 17 days<span></span></td>
        <td class="text">5 years 6 months 29 days<span></span></td>
        <td class="text">5 years 4 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.88%<span></span></td>
        <td class="nump">0.86%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Payments under Contractual Obligations</a></td>
        <td class="text"><div>
 <p>Future minimum payments under contractual obligations at
 December&#xA0;31, 2013 consist of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 41.5pt">
 <b>Fiscal Year:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Operating<br />
 Lease</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">668</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">688</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">730</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">496</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total minimum payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment consist of the following (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,208</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,950</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,156</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,495</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,521</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,952</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,543</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Acquisition of Ceregene - Summary of Assets, Estimated Fair Values (Detail) (Ceregene, Inc. [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Value of Intangible Assets Acquired</a></td>
        <td class="nump">$ 1,870<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">CERE-110 for the treatment of Alzheimer's disease [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Value of Intangible Assets Acquired</a></td>
        <td class="nump">1,640<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">CERE-120 for the treatment of Parkinson's disease [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Value of Intangible Assets Acquired</a></td>
        <td class="nump">$ 230<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of identifiable intangible assets recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EITAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail) (2010 Employee Stock Purchase Plan [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">0.05%<span></span></td>
        <td class="nump">0.05%<span></span></td>
        <td class="nump">0.05%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">6 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">0.51%<span></span></td>
        <td class="nump">0.93%<span></span></td>
        <td class="nump">0.58%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">0.61%<span></span></td>
        <td class="num">(0.30%)<span></span></td>
        <td class="nump">0.61%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">2 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">0.85%<span></span></td>
        <td class="nump">1.37%<span></span></td>
        <td class="nump">0.85%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 A summary of Sangamo&#x2019;s stock option activity is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average<br />
 Exercise&#xA0;per<br />
 Share&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,184,346</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,119,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11.75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,715,123</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.74</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(182,559</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,405,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">56,425</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options vested and expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,046,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">54,849</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,800,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.84</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.05</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">41,073</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Options Outstanding</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes information with respect to stock
 options outstanding at December&#xA0;31, 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="45%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Options Outstanding and
 Exercisable</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Options Exercisable</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 81.05pt">
 <b>Range of Exercise Price</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 Shares of<br />
 common&#xA0;stock<br />
 subject&#xA0;to&#xA0;options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 Shares&#xA0;of<br />
 common&#xA0;stock<br />
 subject to<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Exercise Price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $2.55&#xA0;&#x2013;&#xA0;$3.25</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">212,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.77</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.57</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $3.45&#xA0;&#x2013;&#xA0;$3.45</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,124,381</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,124,381</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $3.80&#xA0;&#x2013;&#xA0;$5.26</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">661,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.33</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.35&#xA0;&#x2013;&#xA0;$5.35</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">909,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">909,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.41&#xA0;&#x2013;&#xA0;$5.41</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,134,524</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">270,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.42&#xA0;&#x2013;&#xA0;$5.66</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.70&#xA0;&#x2013;&#xA0;$5.70</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">945,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">676,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.86&#xA0;&#x2013;&#xA0;$6.82</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">899,022</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">749,020</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $6.92&#xA0;&#x2013;&#xA0;$11.99</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">365,342</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">267,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $12.12&#xA0;&#x2013;&#xA0;$14.62</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,092,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.83</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,087,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14.05</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,405,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,800,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.84</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A summary of Sangamo&#x2019;s RSU activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate&#xA0;Intrinsic<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,036,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs awarded</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs released</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(341,843</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(23,750</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,063,657</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs vested and expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">925,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's Deferred Tax Assets</a></td>
        <td class="text"><div>
 <p>Significant components of the Company&#x2019;s deferred tax
 assets are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <u><b><i>Assets:</i></b></u></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">81,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,129</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capitalized research</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,375</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,677</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">937</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88,216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(103,107</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(88,216</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b><i><u>Liabilities:</u></i></b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax liability related to intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Activity Related to Company's Unrecognized Tax Benefits</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table summarizes the activity related to the
 Company&#x2019;s unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,896</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Additions based on tax positions related to the current year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">589</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Additions for tax positions of prior years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Reductions for tax positions of prior years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(227</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,734</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <b>NOTE 1 &#x2013; ORGANIZATION AND SUMMARY OF SIGNIFICANT
 ACCOUNTING POLICIES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Sangamo</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo BioSciences, Inc. (the Company or Sangamo) was incorporated
 in the State of Delaware on June&#xA0;22, 1995 and is focused on
 the research, development and commercialization of novel
 therapeutic strategies for unmet medical needs. Sangamo&#x2019;s
 gene regulation and gene modification technology platform is
 enabled by the engineering of a class of transcription factors
 known as zinc finger DNA-binding proteins (ZFPs). Potential
 applications of Sangamo&#x2019;s technology include development of
 human therapeutics, plant agriculture and enhancement of
 pharmaceutical protein production. Sangamo will require additional
 financial resources to complete the development and
 commercialization of its products including ZFP Therapeutics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Sangamo is currently working on a number of long-term development
 projects that will involve experimental technology. The projects
 may require several years and substantial expenditures to complete
 and ultimately may be unsuccessful. The Company plans to finance
 operations with available cash resources, collaborations and
 strategic partnerships funds, research grants and from the issuance
 of equity or debt securities. Sangamo believes that its available
 cash, cash equivalents and investments as of December&#xA0;31,
 2013, along with expected revenues from collaborations, strategic
 partnerships and research grants, will be adequate to fund its
 operations at least through 2015. Sangamo will need to raise
 substantial additional capital to fund subsequent operations and
 complete the development and commercialization of its products.
 Additional capital may not be available on terms acceptable to the
 Company, or at all. If adequate funds are not available, or if the
 terms of potential funding sources are unfavorable, the
 Company&#x2019;s business and ability to develop its technology and
 ZFP Therapeutic products would be harmed. Furthermore, any sales of
 additional equity securities may result in dilutions to the
 Company&#x2019;s stockholders, and any debt financing may include
 covenants that restrict the Company&#x2019;s business.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Sangamo acquired Ceregene, Inc. (Ceregene) on October&#xA0;1, 2013.
 Under the merger agreement, Sangamo obtained Ceregene&#x2019;s
 therapeutic programs, including CERE-110 for the treatment of
 Alzheimer&#x2019;s disease (AD) that is currently in a Phase 2
 clinical trial. Sangamo also acquired certain intellectual property
 rights relating to the manufacturing of AAV, and certain toxicology
 data and safety and efficacy data from Ceregene&#x2019;s human
 clinical trials which will enhance and expand the application of
 Sangamo&#x2019;s <i>in vivo</i> ZFP Therapeutics, particularly those
 that target the brain.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. Actual results
 could differ from those estimates. The consolidated financial
 statements include the accounts of Sangamo and its wholly owned
 subsidiaries, Ceregene and Gendaq Limited, after elimination of all
 intercompany balances and transactions.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Business Combinations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company accounted for the acquisition of Ceregene in accordance
 with Accounting Standards Codification (ASC) Topic 805, Business
 Combinations. ASC Topic 805 establishes principles and requirements
 for recognizing and measuring the total consideration transferred
 to and the assets acquired, liabilities assumed and any
 non-controlling interests in the acquired target in a business
 combination. ASC Topic 805 also provides guidance for recognizing
 and measuring goodwill acquired in a business combination; requires
 purchased in-process research and development to be capitalized at
 fair value as intangible assets at the time of acquisition;
 requires acquisition-related expenses and restructuring costs to be
 recognized separately from the business combination; expands the
 definition of what constitutes a business; and requires the
 acquirer to disclose information that users may need to evaluate
 and understand the financial effect of the business
 combination.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo considers all highly liquid investments purchased with
 original maturities of three months or less at the purchase date to
 be cash equivalents. Cash and cash equivalents consist of deposits
 in money market investment accounts, government sponsored entity
 debt securities, US Treasury debt securities and corporate bank
 accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As part of the acquisition of Ceregene, Sangamo was required to set
 aside $0.3 million in an escrow account until October&#xA0;1, 2014.
 The cash hold in escrow was recorded as restricted cash.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Marketable Securities</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at estimated fair value based on quoted
 market prices or observable market inputs of almost identical
 assets, with the unrealized holding gains and losses included in
 accumulated other comprehensive income.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s investments are subject to a periodic
 impairment review. The Company recognizes an impairment charge when
 a decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value. Realized gains and losses on available-for-sale
 securities are included in other (expense)/income, which is
 determined using the specific identification method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The carrying amounts for financial instruments consisting of cash
 and cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value due to their short
 maturities. Marketable securities and contingent consideration
 liabilities are stated at their estimated fair values. The
 counterparties to the agreements relating to the Company&#x2019;s
 investment securities generally can consist of the US Treasury,
 various major corporations, governmental agencies and financial
 institutions with high credit standing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation is calculated using the
 straight-line method based on the estimated useful lives of the
 related assets (generally three to five years). For leasehold
 improvements, amortization is calculated using the straight-line
 method based on the shorter of the useful life or the lease term.
 The Company reviews its property and equipment for impairment
 whenever events or changes in circumstances indicate that the
 carrying amount of an asset may not be recoverable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&#x2019;s product sales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Multiple Element Arrangements prior to the adoption of ASU
 No.&#xA0;2009-13, Revenue Recognition&#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)</i>. For revenue arrangements
 entered into before January&#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Multiple Element Arrangements after the adoption of ASU
 2009-13.</i> ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (VSOE), if available;
 third-party evidence (TPE), if available and VSOE is not available;
 or the best estimate of selling price (ESP), if neither VSOE nor
 TPE is available; and</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire International GmbH, formerly Shire AG,
 (Shire) in January 2012 was evaluated under these amended
 accounting standards.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&#x2019;s performance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Sangamo&#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During 2013, revenues related to Shire, Sigma-Aldrich Corporation
 (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%,
 respectively, of total revenues. During 2012, revenues related
 Shire, Sigma and DAS represented 51%, 11% and 22% of total
 revenues, respectively. During 2011, revenues related to Sigma,
 DAS, California Institute for Regenerative Medicine (CIRM) and CHDI
 Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total
 revenues, respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Research and Development Expenses</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development costs are expensed as incurred. Research
 and development expenses consist of direct and research-related
 allocated overhead costs such as facilities costs, salaries and
 related personnel costs, and material and supply costs. In
 addition, research and development expenses include costs related
 to clinical trials, validation of the Company&#x2019;s testing
 processes and procedures and as well as related overhead expenses.
 Research and development costs incurred in connection with
 collaborator-funded activities are expensed as incurred. Costs to
 acquire technologies that are utilized in research and development
 that have no alternative future use are expensed as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company measures and recognizes compensation expense for all
 stock-based payment awards made to Sangamo employees and directors,
 including employee share options, restricted stuck units (RSUs) and
 employee share purchases related to the Employee Share Purchase
 Plan (ESPP), based on estimated fair values at grant date. The fair
 value of stock-based awards is amortized over the vesting period of
 the award using a straight-line method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 To estimate the value of an award, the Company uses the
 Black-Scholes option pricing model. This model requires inputs such
 as expected life, expected volatility and risk-free interest rate.
 These inputs are subjective and generally require significant
 analysis and judgment to develop. While estimates of expected life
 and volatility are derived primarily from the Company&#x2019;s
 historical data, the risk-free rate is based on the U.S. Treasury
 yield curve in effect at the time of grant commensurate with the
 expected life assumption. Further, the Company is required to
 estimate forfeitures at the time of grant and revise those
 estimates in subsequent periods if actual forfeitures differ from
 those estimates. The Company uses historical data to estimate
 pre-vesting option forfeitures and record stock-based compensation
 expense only for those awards that are expected to vest.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Intangible Assets &#x2013; In-Process Research and
 Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Intangible assets related to in-process research and development
 costs, or IPR&amp;D, are considered to be indefinite-lived until
 the completion or abandonment of the associated research and
 development efforts. If and when development is complete, which
 generally occurs if and when regulatory approval to market a
 product is obtained, the associated assets would be deemed
 finite-lived and would then be amortized based on their respective
 estimated useful lives at that point in time. Prior to completion
 of the research and development efforts, the assets are considered
 indefinite-lived. During this period, the assets will not be
 amortized but will be tested for impairment on an annual basis and
 between annual tests if the Company becomes aware of any events
 occurring or changes in circumstances that would indicate a
 reduction in the fair value of the IPR&amp;D projects below their
 respective carrying amounts. The Company observed no impairment
 indicators of the recorded IPR&amp;D in the year ended
 December&#xA0;31, 2013</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Goodwill</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Goodwill represents the excess of the consideration transferred
 over the estimated fair values of assets acquired and liabilities
 assumed in a business combination and is considered to be
 indefinite-lived. Goodwill is not amortized but is tested for
 impairment on an annual basis and between annual tests if the
 Company becomes aware of any events occurring or changes in
 circumstances that would indicate a reduction in the fair value of
 the goodwill below its carrying amount. The Company observed no
 impairment indicators of the recorded goodwill in the year ended
 December&#xA0;31, 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Contingent Consideration Liability</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Under the merger agreement with Ceregene, the Company may be
 required to make contingent earn-out payments if the Company grants
 a third-party license to develop and commercialize certain product
 candidates acquired from Ceregene, or if the Company commercializes
 any of these product candidates itself. These <font style="WHITE-SPACE: nowrap">earn-out</font> payments will become payable
 in the period they are earned. In accordance with ASC Topic 805,
 Business Combinations, the Company determined the fair value of
 this liability for contingent consideration on the acquisition date
 using a probability-weighted discounted cash flow analysis. Future
 changes to the fair value of the contingent consideration will be
 determined each period and charged to expense in the &#x201C;Changes
 in fair value of contingent liability&#x201D; expense line item in
 the Consolidated Statements of Operations under operating
 expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Income tax expense has been provided using the liability method.
 Deferred tax assets and liabilities are determined based on the
 difference between the financial statement and tax bases of assets
 and liabilities as measured by the enacted tax rates that will be
 in effect when these differences reverse. The Company provides a
 valuation allowance against net deferred tax assets if, based upon
 the available evidence, it is not more likely than not that the
 deferred tax assets will be realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Loss Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are all anti-dilutive. All stock options
 outstanding were excluded from the calculation of diluted net loss
 per share. Stock option outstanding at the end of 2013, 2012 and
 2011 were 8,405,864, 9,184,346 and 8,346,190, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Segments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company operates in one segment. Management uses one
 measurement of profitability and does not segregate its business
 for internal reporting. As of December&#xA0;31, 2013 and 2012, all
 of the Company&#x2019;s assets were maintained in the U.S. For the
 years ended December&#xA0;31, 2013, 2012 and 2011, 100% of revenues
 and operating expenses were generated and incurred in the U.S.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In February 2013, the FASB issued ASU No.&#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income. This newly issued
 accounting standard requires an entity to provide information about
 the amounts reclassified out of accumulated other comprehensive
 income by component. This ASU is effective for reporting periods
 beginning after December&#xA0;15, 2012. The Company adopted this
 standard in the first quarter of 2013 and the adoption of this
 standard did not have an impact on its financial position or
 results of operations.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Accounts payable and accrued liabilities consist of the following
 (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accounts payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,022</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrued clinical trial expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrued professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total accounts payable and accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,380</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities', window );">Investments maturity period</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Material unrealized losses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths', window );">Available for sale securities maturity percentage next twelve months</a></td>
        <td class="nump">70.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo', window );">Available for sale securities maturity percentage in twelve and twenty four months</a></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairments of available-for-sale securities</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized loss accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities maturity percentage in next twelve months and year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesMaturityPercentageInNextTwelveMonthsAndYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities maturity percentage next twelve months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesMaturityPercentageNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments maturity dates available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Ceregene - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Excess of consideration transferred over the fair values assigned to assets acquired and liabilities assumed</a></td>
        <td class="nump">$ 1,585,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Goodwill related to deferred tax liability</a></td>
        <td class="nump">700,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value liability for contingent consideration recognized</a></td>
        <td class="nump">1,570,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ceregene, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock, transferred, shares</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock, transferred, value</a></td>
        <td class="nump">1,200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1', window );">Purchase price deposited in escrow account</a></td>
        <td class="nump">300,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Estimated fair values of in-process research and development</a></td>
        <td class="nump">1,900,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Excess of consideration transferred over the fair values assigned to assets acquired and liabilities assumed</a></td>
        <td class="nump">1,585,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Changes in the Goodwill</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value liability for contingent consideration recognized</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition-related transaction expenses</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Acquisition related operating expenses</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph b<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 740<br><br> -Section 25<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6912350&amp;loc=d3e9979-128506<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 740<br><br> -Section 25<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6912350&amp;loc=d3e9972-128506<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 08, 2014

</div>
          <div>Program</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs</a></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Upfront license fee</a></td>
        <td class="nump">$ 20.0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsPayable', window );">Milestone payments</a></td>
        <td class="nump">293.8<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Beta-thalassemia [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsPayable', window );">Milestone payments</a></td>
        <td class="nump">7.5<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sickle cell disease [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsPayable', window );">Milestone payments</a></td>
        <td class="nump">$ 7.5<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone Payments Payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_MilestonePaymentsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Research Program</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfResearchProgram</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 10,186<span></span></td>
        <td class="nump">$ 21,679<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">82,627<span></span></td>
        <td class="nump">41,868<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
        <td class="nump">338<span></span></td>
        <td class="nump">190<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">3,155<span></span></td>
        <td class="nump">4,129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">457<span></span></td>
        <td class="nump">296<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">320<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">191<span></span></td>
        <td class="nump">203<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">97,274<span></span></td>
        <td class="nump">68,365<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
        <td class="nump">38,663<span></span></td>
        <td class="nump">12,584<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">1,406<span></span></td>
        <td class="nump">1,543<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets, in-process research and development</a></td>
        <td class="nump">1,870<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">1,585<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
        <td class="nump">40<span></span></td>
        <td class="nump">41<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">140,838<span></span></td>
        <td class="nump">82,533<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">4,380<span></span></td>
        <td class="nump">4,013<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump">3,194<span></span></td>
        <td class="nump">2,473<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EscrowLiability', window );">Escrow liability</a></td>
        <td class="nump">275<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">2,282<span></span></td>
        <td class="nump">2,304<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">10,131<span></span></td>
        <td class="nump">8,790<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, non-current</a></td>
        <td class="nump">6,679<span></span></td>
        <td class="nump">8,847<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
        <td class="nump">1,570<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liability</a></td>
        <td class="nump">748<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">19,128<span></span></td>
        <td class="nump">17,637<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 80,000,000 shares authorized, 62,243,892 and 53,058,525 shares issued and outstanding at December 31, 2013 and 2012, respectively</a></td>
        <td class="nump">622<span></span></td>
        <td class="nump">531<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">423,209<span></span></td>
        <td class="nump">339,848<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(302,133)<span></span></td>
        <td class="num">(275,509)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">12<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">121,710<span></span></td>
        <td class="nump">64,896<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 140,838<span></span></td>
        <td class="nump">$ 82,533<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EscrowLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Escrow Liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_EscrowLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedEmployeeBenefitsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Deferred Tax Liability<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph b(2)<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Product</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,282,000<span></span></td>
        <td class="nump">$ 2,304,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateNumberOfGeneTargets', window );">Aggregate number of gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfInitialGeneTargets', window );">Number of initial gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfGeneTargets', window );">Number of gene targets</a></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfAdditionalGeneTargets', window );">Number of additional gene targets</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized', window );">Potential amount to be funded for certain Shire milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">213,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved', window );">Potential amount eligible to receive for certain Shire milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialization and sales milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication', window );">IND or CTA submission amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 14,200,000<span></span></td>
        <td class="nump">$ 7,700,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue to be recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateNumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateNumberOfGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements number of products approved under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InitialResearchTermOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfAdditionalGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfAdditionalGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfInitialGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of initial gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfInitialGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UpfrontLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_UpfrontLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4JDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income/ (Loss) [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2010</a></td>
        <td class="nump">$ 55,907<span></span></td>
        <td class="nump">$ 454<span></span></td>
        <td class="nump">$ 272,954<span></span></td>
        <td class="num">$ (217,495)<span></span></td>
        <td class="num">$ (6)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances, shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,377,739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with underwritten public offering, net of issuance costs</a></td>
        <td class="nump">50,219<span></span></td>
        <td class="nump">67<span></span></td>
        <td class="nump">50,152<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</a></td>
        <td class="nump">1,194<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">1,191<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">324,416<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
        <td class="nump">463<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">461<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">152,640<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">8,081<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,081<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
        <td class="nump">18<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(35,750)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(35,750)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(35,732)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2011</a></td>
        <td class="nump">80,132<span></span></td>
        <td class="nump">526<span></span></td>
        <td class="nump">332,839<span></span></td>
        <td class="num">(253,245)<span></span></td>
        <td class="nump">12<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances, shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,554,795<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</a></td>
        <td class="nump">1,219<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">1,216<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">328,355<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
        <td class="nump">457<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">455<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">175,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">5,338<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,338<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
        <td class="nump">14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(22,264)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(22,264)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(22,250)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2012</a></td>
        <td class="nump">64,896<span></span></td>
        <td class="nump">531<span></span></td>
        <td class="nump">339,848<span></span></td>
        <td class="num">(275,509)<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances, shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53,058,525<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with underwritten public offering, net of issuance costs</a></td>
        <td class="nump">69,492<span></span></td>
        <td class="nump">70<span></span></td>
        <td class="nump">69,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with underwritten public offering, net of issuance costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,015,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units</a></td>
        <td class="nump">6,118<span></span></td>
        <td class="nump">19<span></span></td>
        <td class="nump">6,099<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,889,818<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
        <td class="nump">496<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">495<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,551<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with acquisition of Ceregene, Inc.</a></td>
        <td class="nump">1,200<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,199<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with acquisition of Ceregene, Inc., shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,998<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">6,146<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,146<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
        <td class="num">(14)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(26,624)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(26,624)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(26,638)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2013</a></td>
        <td class="nump">$ 121,710<span></span></td>
        <td class="nump">$ 622<span></span></td>
        <td class="nump">$ 423,209<span></span></td>
        <td class="num">$ (302,133)<span></span></td>
        <td class="nump">$ 12<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances, shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,243,892<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">$ 569,000<span></span></td>
        <td class="nump">$ 660,000<span></span></td>
        <td class="nump">$ 646,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposition of fixed assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Write-off of assets</a></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The decrease in accumulated depreciation, depletion and amortization (relating to property, plant and equipment) as a result of sales or disposals of property, plant and equipment during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisposals</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4GCI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">$ 128,224<span></span></td>
        <td class="nump">$ 73,288<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="nump">1,570<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">121,290<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,449<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Contingent consideration liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="nump">1,570<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">6,934<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Contingent consideration liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">121,290<span></span></td>
        <td class="nump">57,449<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">121,290<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,449<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Contingent consideration liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="nump">1,570<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Contingent consideration liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration liabilities</a></td>
        <td class="nump">$ 1,570<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) (Restricted Stock Units (RSUs) [Member], USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at December 31, 2012</a></td>
        <td class="nump">1,036,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded</a></td>
        <td class="nump">392,500<span></span></td>
        <td class="nump">486,750<span></span></td>
        <td class="nump">550,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">RSUs released</a></td>
        <td class="num">(341,843)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited</a></td>
        <td class="num">(23,750)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at December 31, 2013</a></td>
        <td class="nump">1,063,657<span></span></td>
        <td class="nump">1,036,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">RSUs vested and expected to vest at December 31, 2013</a></td>
        <td class="nump">925,882<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at December, 31, 2013, Weighted-Average Remaining Contractual Term</a></td>
        <td class="text">1 year 5 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">RSUs vested and expected to vest at December 31, 2013, Weighted-Average Remaining Contractual Term</a></td>
        <td class="text">1 year 5 months 5 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue', window );">RSUs outstanding at December 31, 2013, Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 14,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">RSUs vested and expected to vest at December 31, 2013, Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 12,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than option outstanding aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than options released in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. Actual results
 could differ from those estimates. The consolidated financial
 statements include the accounts of Sangamo and its wholly owned
 subsidiaries, Ceregene and Gendaq Limited, after elimination of all
 intercompany balances and transactions.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Business Combinations</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company accounted for the acquisition of Ceregene in accordance
 with Accounting Standards Codification (ASC) Topic 805, Business
 Combinations. ASC Topic 805 establishes principles and requirements
 for recognizing and measuring the total consideration transferred
 to and the assets acquired, liabilities assumed and any
 non-controlling interests in the acquired target in a business
 combination. ASC Topic 805 also provides guidance for recognizing
 and measuring goodwill acquired in a business combination; requires
 purchased in-process research and development to be capitalized at
 fair value as intangible assets at the time of acquisition;
 requires acquisition-related expenses and restructuring costs to be
 recognized separately from the business combination; expands the
 definition of what constitutes a business; and requires the
 acquirer to disclose information that users may need to evaluate
 and understand the financial effect of the business
 combination.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo considers all highly liquid investments purchased with
 original maturities of three months or less at the purchase date to
 be cash equivalents. Cash and cash equivalents consist of deposits
 in money market investment accounts, government sponsored entity
 debt securities, US Treasury debt securities and corporate bank
 accounts.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As part of the acquisition of Ceregene, Sangamo was required to set
 aside $0.3 million in an escrow account until October&#xA0;1, 2014.
 The cash hold in escrow was recorded as restricted cash.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Marketable Securities</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at estimated fair value based on quoted
 market prices or observable market inputs of almost identical
 assets, with the unrealized holding gains and losses included in
 accumulated other comprehensive income.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s investments are subject to a periodic
 impairment review. The Company recognizes an impairment charge when
 a decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value. Realized gains and losses on available-for-sale
 securities are included in other (expense)/income, which is
 determined using the specific identification method.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The carrying amounts for financial instruments consisting of cash
 and cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value due to their short
 maturities. Marketable securities and contingent consideration
 liabilities are stated at their estimated fair values. The
 counterparties to the agreements relating to the Company&#x2019;s
 investment securities generally can consist of the US Treasury,
 various major corporations, governmental agencies and financial
 institutions with high credit standing.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation is calculated using the
 straight-line method based on the estimated useful lives of the
 related assets (generally three to five years). For leasehold
 improvements, amortization is calculated using the straight-line
 method based on the shorter of the useful life or the lease term.
 The Company reviews its property and equipment for impairment
 whenever events or changes in circumstances indicate that the
 carrying amount of an asset may not be recoverable.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&#x2019;s product sales.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements prior to the adoption of ASU
 No.&#xA0;2009-13, Revenue Recognition&#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)</i>. For revenue arrangements
 entered into before January&#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements after the adoption of ASU
 2009-13.</i> ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (VSOE), if available;
 third-party evidence (TPE), if available and VSOE is not available;
 or the best estimate of selling price (ESP), if neither VSOE nor
 TPE is available; and</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire International GmbH, formerly Shire AG,
 (Shire) in January 2012 was evaluated under these amended
 accounting standards.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&#x2019;s performance.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo&#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During 2013, revenues related to Shire, Sigma-Aldrich Corporation
 (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%,
 respectively, of total revenues. During 2012, revenues related
 Shire, Sigma and DAS represented 51%, 11% and 22% of total
 revenues, respectively. During 2011, revenues related to Sigma,
 DAS, California Institute for Regenerative Medicine (CIRM) and CHDI
 Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total
 revenues, respectively.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Research and Development Expenses</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development costs are expensed as incurred. Research
 and development expenses consist of direct and research-related
 allocated overhead costs such as facilities costs, salaries and
 related personnel costs, and material and supply costs. In
 addition, research and development expenses include costs related
 to clinical trials, validation of the Company&#x2019;s testing
 processes and procedures and as well as related overhead expenses.
 Research and development costs incurred in connection with
 collaborator-funded activities are expensed as incurred. Costs to
 acquire technologies that are utilized in research and development
 that have no alternative future use are expensed as incurred.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company measures and recognizes compensation expense for all
 stock-based payment awards made to Sangamo employees and directors,
 including employee share options, restricted stuck units (RSUs) and
 employee share purchases related to the Employee Share Purchase
 Plan (ESPP), based on estimated fair values at grant date. The fair
 value of stock-based awards is amortized over the vesting period of
 the award using a straight-line method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 To estimate the value of an award, the Company uses the
 Black-Scholes option pricing model. This model requires inputs such
 as expected life, expected volatility and risk-free interest rate.
 These inputs are subjective and generally require significant
 analysis and judgment to develop. While estimates of expected life
 and volatility are derived primarily from the Company&#x2019;s
 historical data, the risk-free rate is based on the U.S. Treasury
 yield curve in effect at the time of grant commensurate with the
 expected life assumption. Further, the Company is required to
 estimate forfeitures at the time of grant and revise those
 estimates in subsequent periods if actual forfeitures differ from
 those estimates. The Company uses historical data to estimate
 pre-vesting option forfeitures and record stock-based compensation
 expense only for those awards that are expected to vest.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Intangible Assets - In-Process Research and Development</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Intangible Assets &#x2013; In-Process Research and
 Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Intangible assets related to in-process research and development
 costs, or IPR&amp;D, are considered to be indefinite-lived until
 the completion or abandonment of the associated research and
 development efforts. If and when development is complete, which
 generally occurs if and when regulatory approval to market a
 product is obtained, the associated assets would be deemed
 finite-lived and would then be amortized based on their respective
 estimated useful lives at that point in time. Prior to completion
 of the research and development efforts, the assets are considered
 indefinite-lived. During this period, the assets will not be
 amortized but will be tested for impairment on an annual basis and
 between annual tests if the Company becomes aware of any events
 occurring or changes in circumstances that would indicate a
 reduction in the fair value of the IPR&amp;D projects below their
 respective carrying amounts. The Company observed no impairment
 indicators of the recorded IPR&amp;D in the year ended
 December&#xA0;31, 2013</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Goodwill</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Goodwill represents the excess of the consideration transferred
 over the estimated fair values of assets acquired and liabilities
 assumed in a business combination and is considered to be
 indefinite-lived. Goodwill is not amortized but is tested for
 impairment on an annual basis and between annual tests if the
 Company becomes aware of any events occurring or changes in
 circumstances that would indicate a reduction in the fair value of
 the goodwill below its carrying amount. The Company observed no
 impairment indicators of the recorded goodwill in the year ended
 December&#xA0;31, 2013.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Contingent Consideration Liability</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the merger agreement with Ceregene, the Company may be
 required to make contingent earn-out payments if the Company grants
 a third-party license to develop and commercialize certain product
 candidates acquired from Ceregene, or if the Company commercializes
 any of these product candidates itself. These earn-out payments
 will become payable in the period they are earned. In accordance
 with ASC Topic 805, Business Combinations, the Company determined
 the fair value of this liability for contingent consideration on
 the acquisition date using a probability-weighted discounted cash
 flow analysis. Future changes to the fair value of the contingent
 consideration will be determined each period and charged to expense
 in the &#x201C;Changes in fair value of contingent liability&#x201D;
 expense line item in the Consolidated Statements of Operations
 under operating expenses.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Income tax expense has been provided using the liability method.
 Deferred tax assets and liabilities are determined based on the
 difference between the financial statement and tax bases of assets
 and liabilities as measured by the enacted tax rates that will be
 in effect when these differences reverse. The Company provides a
 valuation allowance against net deferred tax assets if, based upon
 the available evidence, it is not more likely than not that the
 deferred tax assets will be realized.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Loss Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are all anti-dilutive. All stock options
 outstanding were excluded from the calculation of diluted net loss
 per share. Stock option outstanding at the end of 2013, 2012 and
 2011 were 8,405,864, 9,184,346 and 8,346,190, respectively.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Segments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company operates in one segment. Management uses one
 measurement of profitability and does not segregate its business
 for internal reporting. As of December&#xA0;31, 2013 and 2012, all
 of the Company&#x2019;s assets were maintained in the U.S. For the
 years ended December&#xA0;31, 2013, 2012 and 2011, 100% of revenues
 and operating expenses were generated and incurred in the U.S.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RecentlyAccountingPronouncementsPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In February 2013, the FASB issued ASU No.&#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income. This newly issued
 accounting standard requires an entity to provide information about
 the amounts reclassified out of accumulated other comprehensive
 income by component. This ASU is effective for reporting periods
 beginning after December&#xA0;15, 2012. The Company adopted this
 standard in the first quarter of 2013 and the adoption of this
 standard did not have an impact on its financial position or
 results of operations.</p>
 <!-- xbrl,n --></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentConsiderationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent Consideration Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ContingentConsiderationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RecentlyAccountingPronouncementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recently Accounting Pronouncements Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_RecentlyAccountingPronouncementsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2303973<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.15)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 15<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InProcessResearchAndDevelopmentPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196929<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62652-112803<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent liability</a></td>
        <td class="nump">$ 60<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of (increase) decrease in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Schedule of Investments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The table below summarizes the Company&#x2019;s cash equivalents and
 available-for-sale securities (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br />
 Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 (Losses)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,212</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,262</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
        <td class="nump">$ 2,734<span></span></td>
        <td class="nump">$ 2,750<span></span></td>
        <td class="nump">$ 1,896<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
        <td class="nump">294<span></span></td>
        <td class="nump">153<span></span></td>
        <td class="nump">589<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
        <td class="nump">153<span></span></td>
        <td class="nump">58<span></span></td>
        <td class="nump">265<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(227)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
        <td class="nump">$ 3,182<span></span></td>
        <td class="nump">$ 2,734<span></span></td>
        <td class="nump">$ 2,750<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBFBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (26,624)<span></span></td>
        <td class="num">$ (22,264)<span></span></td>
        <td class="num">$ (35,750)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">569<span></span></td>
        <td class="nump">660<span></span></td>
        <td class="nump">646<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium / discount on marketable securities</a></td>
        <td class="nump">912<span></span></td>
        <td class="nump">889<span></span></td>
        <td class="nump">1,576<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">6,146<span></span></td>
        <td class="nump">5,338<span></span></td>
        <td class="nump">8,081<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
        <td class="nump">60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="num">(320)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEscrowLiabilities', window );">Escrow liability</a></td>
        <td class="nump">275<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
        <td class="num">(148)<span></span></td>
        <td class="nump">141<span></span></td>
        <td class="nump">6<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">1,008<span></span></td>
        <td class="num">(3,414)<span></span></td>
        <td class="num">(553)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(160)<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="num">(13)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">269<span></span></td>
        <td class="num">(1,503)<span></span></td>
        <td class="num">(139)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump">721<span></span></td>
        <td class="nump">800<span></span></td>
        <td class="nump">315<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(2,190)<span></span></td>
        <td class="nump">11,134<span></span></td>
        <td class="num">(64)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(19,482)<span></span></td>
        <td class="num">(8,082)<span></span></td>
        <td class="num">(25,895)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
        <td class="num">(118,894)<span></span></td>
        <td class="num">(91,428)<span></span></td>
        <td class="num">(112,974)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
        <td class="nump">51,129<span></span></td>
        <td class="nump">103,470<span></span></td>
        <td class="nump">83,412<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInvestmentProjects', window );">Proceeds from sales of marketable securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,139<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquistion of Ceregene, Inc., net of cash received</a></td>
        <td class="nump">79<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(432)<span></span></td>
        <td class="num">(723)<span></span></td>
        <td class="num">(576)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by / (used in) investing activities</a></td>
        <td class="num">(68,118)<span></span></td>
        <td class="nump">11,319<span></span></td>
        <td class="num">(19,999)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
        <td class="nump">69,492<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,152<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
        <td class="num">(2,015)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(48)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="nump">8,630<span></span></td>
        <td class="nump">1,676<span></span></td>
        <td class="nump">1,772<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">76,107<span></span></td>
        <td class="nump">1,676<span></span></td>
        <td class="nump">51,876<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase / (decrease) in cash and cash equivalents</a></td>
        <td class="num">(11,493)<span></span></td>
        <td class="nump">4,913<span></span></td>
        <td class="nump">5,982<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">21,679<span></span></td>
        <td class="nump">16,766<span></span></td>
        <td class="nump">10,784<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">10,186<span></span></td>
        <td class="nump">21,679<span></span></td>
        <td class="nump">16,766<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued', window );">Fair value of shares of common stock issued pursuant to the acquisition of Ceregene Inc.</a></td>
        <td class="nump">$ 1,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEscrowLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase Decrease In Escrow Liabilities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_IncreaseDecreaseInEscrowLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Common Stock Issued</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfCommonStockIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Issuance Initial Public Offering Net Of Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ProceedsFromIssuanceInitialPublicOfferingNetOfCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of (increase) decrease in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInvestmentProjects">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfInvestmentProjects</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">80,000,000<span></span></td>
        <td class="nump">80,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">62,243,892<span></span></td>
        <td class="nump">53,058,525<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">62,243,892<span></span></td>
        <td class="nump">53,058,525<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 10 &#x2013; INCOME TAXES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company recorded no income tax expense. The principal
 difference between the statutory tax rate of 34% and the
 Company&#x2019;s effective tax rate is due to the Company permanent
 differences related to stock compensation and its change in
 valuation allowance.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Deferred income taxes reflect the net tax effects of temporary
 differences between the carrying amounts of assets and liabilities
 for financial reporting purposes and the amounts used for income
 tax purposes. Significant components of the Company&#x2019;s
 deferred tax assets are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <u><b><i>Assets:</i></b></u></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">81,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,129</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capitalized research</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,375</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,677</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">937</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88,216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(103,107</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(88,216</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b><i><u>Liabilities:</u></i></b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax liability related to intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As part of accounting for the acquisition of Ceregene, the Company
 recorded goodwill and intangible assets. The intangible assets
 acquired are for the use in a particular research and development
 project IPR&amp;D and are considered indefinite-lived assets. They
 will remain indefinite lived until the completion or abandonment of
 the associated research and development efforts. Since the
 intangible assets acquired have no tax basis, a deferred tax
 liability was established due to the difference between the book
 and tax bases for those assets. The indefinite-lived asset is not
 treated as a future source of income and, therefore, no valuation
 allowance is released until the assets are amortized or
 abandoned,</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Realization of deferred tax assets is dependent upon future
 earnings, if any, the timing and amount of which are uncertain.
 Accordingly, the net deferred tax assets have been fully offset by
 a valuation allowance. The valuation allowance increased by $14.9
 million, $5.4 million and $19.7 million for the years ended
 December&#xA0;31, 2013, 2012 and 2011, respectively. As of
 December&#xA0;31, 2013, Sangamo had net operating loss
 carryforwards for federal and state income tax purposes of
 approximately $209&#xA0;million and $199 million, respectively. If
 not utilized, the net federal and state operating loss
 carryforwards will begin to expire in 2018 and 2014 respectively.
 The Company also has federal and state research tax credit
 carryforwards of $6.2&#xA0;million and $6.5 million, respectively.
 The federal research credits will begin to expire in 2018 while the
 state research credits have no expiration date. Utilization of the
 Company&#x2019;s net operating loss carryforwards and research tax
 credit carryforwards may be subject to substantial annual
 limitations due to the ownership change limitations provided by the
 Internal Revenue Code and similar state provisions. The annual
 limitation could result in the expiration of the net operating loss
 carryforwards and research tax credit carryforwards before
 utilization.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company files U.S and state income tax returns with varying
 statutes of limitations. The tax years from 1998 forward remain
 open to examination due to the carryover of net operating losses or
 tax credits. The Company also files a UK income tax return, and the
 tax years from 2007 and thereafter remain open to examination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s practice is to recognize interest and/or
 penalties related to income tax matters in income tax expense. As
 of December&#xA0;31, 2013, the Company had no accrued interest
 and/or penalties. The unrecognized tax benefits may change during
 the next year for items that arise in the ordinary course of
 business. In the event that any unrecognized tax benefits are
 recognized, the effective tax rate will not be affected.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table summarizes the activity related to the
 Company&#x2019;s unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,735</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,896</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Additions based on tax positions related to the current year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">589</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Additions for tax positions of prior years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Reductions for tax positions of prior years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(227</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,734</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 01, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">SGMO<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">SANGAMO BIOSCIENCES INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001001233<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,736,879<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 405,023,312<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 11 &#x2013; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Accounts payable and accrued liabilities consist of the following
 (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accounts payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,022</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrued clinical trial expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrued professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total accounts payable and accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,380</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <!-- xbrl,n -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001193125-14-065170-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-14-065170-xbrl.zip
M4$L#!!0````(`"J(6$1C@8\L4$@!`)$.#@`1`!P`<V=M;RTR,#$S,3(S,2YX
M;6Q55`D``S#!"U,PP0M3=7@+``$$)0X```0Y`0``W%U9<]O(=GY/5?X#HX=4
M4I66>D5WJV;F%M8I5SRV2_;,G9L7%41"$FHH0`%(V[J_/J<!4B)`4`1)`(+C
M!UDB%O9W^BS?Z>W\]+?O#_/)URC+XS3Y^8R<X[-)E$S369S<_7RVS%&83^/X
M;)(OPF06SM,D^OGL*<K/_O;+O_[+3_^&T.3J:N*E21+-Y]'3Y,]I-(^R<!%-
MWB7FB6D$%Z?+ARA9_-?D)LRCV21-)G\Z5^\G])Q,)O>+Q>/EQ<6W;]_.LVRV
M?LWY-'VXF""T_HH_RM9=3B;6.846;ERZ2I?)['(B\`U7@A/$PYD%/Z93%,YN
M;Q&?13<S+C7\KC:><K,H7,`;)S-HZN6$8L(1IHCR+T1>,G%)]?]LWIT^/F7Q
MW?UB\A_3_X2;L4#P!)M<G5^=;V#_]\GG-,GA[H?','F:V//YY,H\E4^NHCS*
MOD:S\]5+O]]D\PF(/<E_/MN0@/GX/,WN+N`KV$6\$N!9>>>EN3I_Y?YYG/QE
M)/Q\O_F@<O\W5MQ-M-87Q=7UK7&><DKD:XTI[WA^=QXWO1EN)1=__O;^\_0^
M>@A1'0$HTUT8/CX_>1OF-\5SJPL71JH($\3(^I%9]/)%18OR:'I^EWZ]@`L-
MM^=W#^GS_7F8W(4/::%,YE9"7VZ$;UP\/49Y8UN**PUO-PV8+:KM6<$6%^7%
MRJUQXZU6>6O\W.;%8]:,T5PQS2#59DQ!Y1?94_,SJXL-K9\NLPP,>]=SJZOF
M05I],/H^O6]^R%QI^*8X^1KEB^9'RFL-#R7+AV;]FRVR"],C%W!'E,73YP?`
M\/8_DR:H]MQRD>U4='T!5\_`1">3PDCGEWFARE?1[:2PF$OSUI_/\OCA<6[T
MNO@LS*99.H_:V6;QQ'T6W<);0%O16C//O^>S(TRWO5>X*&&9+[W\F$1?XH?H
M?3R-DCP*HL@/LP1\\S1-%M'WQ95I793.KS_YDE+*$$+02(S^&V.LKC]_\:[Q
MM5%Z@AF!7S5CF(KO!&O.B3Z;+).X?,7*:US__MD[F\RB:?P0SL'DD#B;Q#.X
M/+MFX'D58]<6=FV'<PNY@6<CSGP+V8()%%A"NCZWF+(IW(SAZ\Y^L7#Q[Z>+
MU[!LH+7OLB@R(<@S@>DPC-8:(Q542L#(N=9TN_T.@,?20Y@SBD`*$D&+&9)<
M!U+;2GC*-:\KVF]>B^"K&%E!J#2PHX9+HU<O#==:46EMM5MKRY:V%R";V!QQ
M[CE($<T1];1'J7)\'[IOH]VR--H>VZUK`B=,"L*W&NY;6F,<8*1\B1&G@8>,
ME)&T'$4]2P5,B;+AK&BX;B5P__MC-%U$,_O!N-$OJ1-=1=,HAM`=I)F)XF#J
M]W8R\Z*OT3Q]-&_H"-X1-M->!/3L%T$W;>8(G!M2NDJ?POGBZ0HN)LLH7[]L
M\S5'2\6BC'W75%F2K?T*:*ZEV5$B"@1EM@_D3DD/S-)W*;@5(1"6.L"*.8YF
MUK-ZBXI;:0%R4^-GL]@0RG#^6SR'``<T^5/X9.3V>S*+LF=].U8NPTB"K)2%
M5D71%EPI#V!FEWZRB!=/P(0?TN3S(IW^]?D^S*+\XW)1I!&06APF",(Q+3KI
M!7I>O'$3];L/P19L95N$<$\B1SK@WYB+D18N0XI)+W"5%U`,"G"M(*A0R2PE
M]4\7[0!TX^X(!!2&-^,+T41N=Y\DF@7<`3_M<.@^)@ER(+(@CS@."1B1Q-.E
M(A/C[@QEY(CA/>XN@-PI]Y;1*3JZ$\$12MH>)9@K89LZV@REAA6Z[=G/9>G#
MVM']FH4'HX80OHFZ#*_/_HN!#(X30:N`#-].35S3=0F\!K!NG9^6-_-X&LS3
M\%#LK,2^'Q\^SAY!"F>_<"PPR)+038/<:',)9Y4Y7OZ>9-$TO4OB?X*+#K\[
M41+=QI!Y']BIAHBW`8;8%C*A'$4<0^P8<1#T6X`<SY;(]Y7RE1T0S\$ONJNT
M5?3<GO9701:.Z#Z=@X;G_O\N01X#XB.:8N$"0\<^!K;!`AO9/G>`5@G&7>SX
MCE9&,2WC@8300$`W`6ZWO8K-#7-#.,Q_YO+7<`[FF]L+-\RR)U#K/\+Y\E#?
M>@I<RR$>MVV%-+8"L$,`;A(4Q)BK`LD"C^-@Q2\!+\%2\0K>5GCZZ5[P0E)H
M"BR*<=:&6A[?V<)T-K(.ZNGN88*[;4.*CH?)"YCP3J[%85A/I#UUJ.!Y.3N8
M!+6%67`_+IB4DND-D,W4I[?^K(/LOC\+EL0%?UN]950HJU><K&"#DNI#H9H>
M=\QHO1G,CI*\&"RW,Z`1=P6O<IY>;EFE`O:W,)M]?#0W;NK*A^7#390=2BFW
M''<[17<L#RB1A"0'>PKQP*?(`7^-F`H\ZF'E:,\JY0(Q6#%N$8UK>MXEZCXH
MRK9H.J8H:_&`DN(WH"BGX&ME%JR@*!SZ'X@L?7..<@K>5AREZ,^"HUC2LD[F
M*"?:R!]1;H:=DMG+>(KYR/\>9=,X#V_FD7T'R=L=Y*GODD46)WD\[5>L#5FH
MI`'3RD:^L,%,2``IF)(^,C3#<>W`YVOO2@WSJUK)FPFH'SL<BDNR@DN"59+#
M3+)[G/V225:026[8I&"4#\LFZUA[9)/%5`T19MQ9""ZU&(Y.[D/9?8^2HD<%
M'3@/V@+:+Y]D!9\$H(Q1Q?1AD;.[D6!Z)#<,*'>8(R62ED^`_$@/@J5P46#Y
M4E!"/.IXU_2:,>A)AH4"Q=V(E'L'@G?>^2[/EX?.A_0.DK8"63:]M]3@[Y%9
M'0/![FN4A7?1*L1%G[)X>FBXWY;7AO)?/T;9];;\MB=Q'5MQ1W@N@CS"3.(&
M$FGN2L.47:&%]F5`G]-'LQ*IE]SA-;&,*TT[5DO;IFG4Y"&:*&`>UF!IVI85
MV,O%?9J9K&=D1DQ,#H-K_/.5YN_$^2G,/F:?%T`I9P65_!1EQ;,#&.$I^$$Y
M\#DFC=AW0:K*P)Y.EP_+N;G+BQXAO8T+78+?YU&A5(F9(<\6\3^+SS]E*:!8
M/'V:AZ!20-$ATAVQ!N!U0>W+X5V7"JD(\GQ;("X#%VE76@@$1J4=8`X9(`@'
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M^A"]3_/\0[3X>`O2&A]J9H%>;UGO(9CZ&'(^*5RU''*FY9`SJ\Y3M!IRWM#_
M#07Y-4UGW^+Y'`+7NP3HWEULALX*^^@6_O<\ODSB^<]G"W`_)]BV&76ZJ"(+
MPC@KV,MO49@OLX+<_CU>W/^>I#=F0X%QY^^21^"S5R"F9`K0"[LW?X)]`,$%
M#ASG:ZD\'3.0VKKSM]=ZN)96RF$^<ET,210D4$#X?8XP9I8B4FF'T9<5$8)L
M='POR#L>?AG"'TC(,WE]K<B^P99:P`<+*#S'*D!NV,CXXCHOUNJ^PEYV@VDD
M-/[#XSQ]BJ*UYQAMO",0VBF7K(G2[`#1[`57ZU7'Z>.L+1>WW;W;/3O>3E-F
MF1K9ZK2VB*JBN(H689Q`=X=9`@XLKZ1KM_$T'J$$F#`S&5((7!T/WH_E5>T=
M;8]3LYX",JQ&`EYM?!N2,DXK-=L1+G8.%O5*(D[H&6V&M,FNL;`&`O#2;<G"
MA?_CQ6C37;/4=Y?.U1J_,]4#1_1#4![PJ8H*QG9E?HTX=J(>'T`*.1Z1%I.[
M`+[J&3\`V1VM<V1F>(++UYSC2_NW'4R\>"C6GR0S%Z!!V(B`V`_K)-LBE5L>
M\K<P^PN"'D3\SR8%&3=Q@8[B1%G5`;17$-0X6Y%%CQ8<!`)+,:NZM*+2YAJ<
MKV$\-["#-/L<;J)?C8:;B:9\2*`.UJYBPD$\4-B,\5M(:>(C10)&?<5L;>MK
M;28A):-6;9"_'9H]XZ'PR_HSLPXIR:/*7%LR6^<BS9-Q`\NK/;411F12-'JH
M+L'O]PUC=N3$C,=04=O1\#J**N)/6?08QL_B&RM0,]Q:&UQI;/D>:_GX:(X\
M@8!E1F*+Q9.W:69FG(>D'^V-@!HC(%2_;@6[0>V1QJ\9/#!*X*K5]$G1_J:(
M-S[]-0OLMLERV=HF!,_#JEZ<3^>I&5D=$)2V78UM+9!9;0:@?`]I[?HH"'PN
M[,#U";6NB_WZ$-:4:L#4T/[^5V@/P9S!#Q%+5BWRB-79Z[&G<@^H<=4?HC?(
M:ENB%H:%UMS0:PCV^!VX<:3C*7@K6]BYMF)HY]ER.8E)&.I[WU['L)]@KH8M
M-B/+>K_R**,'R,"2$N_ECJ_@VD\+QY=E\"9WW-3T*KAREF:L<9,;UU-!M-'>
MG4!&ZTF5F39CN_`TNL\?92-/>^D=OY&G",!*C',GSS8Q-ST[2@\ISW[1K'GX
MK]KZ*D)`'V4@F9>8/UI#,QN4:HN2=K:^9<3OG+9TXB#-?D'!6;N`#Q`V3\,I
MISO=>9S$TW#^)8O#^2J='M_,BEG(3TI>LZ_Q&Q"WM'JU:-2,KHV:P_#RE*L5
MV#8P-CMVY]!BP?C,8JWR63-BL#'C^RYY5QSZ6(SN#TG16S(<5CT;L37,7T/P
MV</@[(+(T>>UA1W"W)#;IS1?V/#AS%SHY&0I^KS!;9B3I8H]O68)TGI3;UM<
M_:PL&VKOK3![;ZG86GK:^P;&+9S][KT59N\MW;%BI>^]MW6L/>Z]%<5)+E;3
M%K^^]][N0]E]CY*B1^LK/P97W9[WWHKBM`'1N(%E[W+0/N<WK\U1G52![7*L
MVQS]>V3X*@Z:HEI7LXNC)CN[&W89#CQO`+][#.:MV5H[N73`W<28N-N`J.GV
M.MINYW>J6.`O+36&OX1DUC4X.\S-7Q)#GG@4SG930>7(S%M!58*T@]K!I-?J
M,!DA.:_-A[2;]QI()EJQEC+IIOMY4_</%\XZZ/Y6!JV*(S,YKV_].B:Z]:P)
M@]D#.<D>^HKQPVD$+S2BMH/[1PGY7?B(EG(:+0$83E5Z'-CIVZLPRL0N>L&H
M-(4V^O(QM)B:-\/<]<.,WCCFUF6RR4->E4D',9>69X8.1;EJ4"OT8@"HO`GJ
M(/1B!?QD36_E(:P=:CXF>M&50-IV/3G)]'N@%P-K!&]"_P/0BP/$U`&]L$9)
M+X:6P78.=O32B')\TI2&S(J:D.5R@"_W8;):-/$A+<04S4XYD,Q$%,Q4$5$L
M>?`@._8L7WD:(^T$&G%.+*2%%$@(3!1Q"/?*Z=32AV!F2='%LI%#9=.W8][@
M9#VZ8K.L;D04;(-T]0>:&=`C&NO9H%\]$BZ^X4S[7`=[79B],-.FC+:9+3YR
M5>QZX1BI'[AUR,+8?@6@%#Z.1;1;%KP^MD?73HH?C0`8W'N<\VHE`+9*(;G6
M1^/O.=\8AD_*(A(JQ3H8P.R26P^%GC>A'S.;'H@[RG'QY\%0;S/F#@_`9GT>
M*TN*`[`M2CE3FAYS`/:IRZ8WUD<?E0,<*Q[A!Y0YED0.UZ:8!G:1\AV!,)&.
MUKYD?L#+P]XED#>%L68=GO^\A;J-4.L'_!:+THH^*M]JXD]>.3_ZRC2G_(*/
MMQM=N&K%0**6.C"U1SEBDH.H`^DBVX<_N8TM['F6)1W(K3`I]@(JCH6R^#Y1
M=RZ+/HYU[]MT:2O3_7&.==^65V_'NA>6;8X'.*?]E(3Z<8YU/U9+VQ[K7ISW
MV-*L.SO6O:?=//\_]-XR>D_ZW_MTO#G<=.3O-^+LJJFO-82\2;^U#X^6*4.A
MZD;T1K+:.@&DW%S2126%8ST2`_477&`D`J:!KG.%')]JLQ_0\BG&KA#!LT=Z
MKGG>#L+0[F6D9-@R12BX!4G5D-ZC#P^_H>X_L"N7C2ZA?[$,D*]L^Z/1Y2NB
M=6K8N2SZJF+3=\XRMBHVQQCL*?A/KV+S<E)3!%J6!\O%,HM^BY/X8?FP,FBS
M9>U=\N5;^H\HS$XWFP/V&[O$]GR`3:2GS;X[BK2++>2Y/G%]S+"P_>NRGE;M
M.,*#48VBM,\ILFHWZV0&FYF@U?U._93V6>\/+LM,G'1T\4DZU,Z2S/8H6=L;
M]1J"/LH8#0#3E#'BE-':_L5698Q:VM3X_`.P3*8L<HR#Z*&0TRF`6YU+0,I"
M3G2K?M>PA9P&P&D6^1-<A]FZD%/K(!&DRVRDL<^<=U<SYL-A]5W?ZA0YM#V>
M@IBC>PF&;]]SADSO!:Z&B%;%RA%2V[?\MA6NAHA>UE:)[Y,J7+6TE"_PWBB\
M770P@-*Y_9MC$&N'T!Z,ZL2*6.M+O0EG^T`.3V.'2.PBQFR*0``*](6X2/H6
M-P<T@U_@91R4M=SP:'1]U$8[B>^WK(U64GZBJF8SBMIHPX0%`B$2[:+VK:&-
MK[9::^D=65NM$%ZQOE;^8+75AHA$TD0BX*)5[_)6Q=7V('Y]65)+LKU=UZ?3
M,FD#=)HID\9(K1;.(672=GC-Y_&!3Q&D&ZLR,^N3_5;O[TT:UK8TF,\M92OD
M*>6:86:-M$<%@KS?9C9T<F#K,CCN#PAMH%5EY"SS.('4"XC839RL:AJL"K(L
MX+<\GA7T)$V>?<#X-(7RTN]5-.4(9,?FF\!=1YIO%@?ZXB/SS36L+HL/#D,B
M(/%`3%BLD42L&CY4;<(A/*6I35B4R!YE;<(A`KPYZ8UA2FKE$=ZD-N$0'L^<
MD$5K6<)@M0D'R@1XZTR@TP*&0W2?+A9O[IH&[;&`X0##O*S@VCLT<\@*AD/X
M'?"\A&/%JEHZ5`G#(535#.)I0G<"/'9^^CZ+QLJ:S-)J=>P,]3.N?FH[#M'E
M9E=(O4)-R]J.&XIQ^J[54[`RPKCC>`%B`;40Q]1'MB7@AT>)*QTNF'!+@KR5
M.;R.H:]:EB<-"K3MV>U:EBT5^PV84#M;-8LYY5$93F,(ZJZTYQ#1QU0$L^C^
MHT([+^TY`#B@2%I261O^V5WDI/=YC>/3L_+8@VI%I>:)BGYV")^"L=4N2%[L
M"89\I#[=]X,6*!TFP3%KF#3=,_\][@*E0U@/+M8#U09S#BE0>A7EBRPV:\O[
M*!DX@`@D2(!68]R!F+JOV#H`;,@\N*B:QYM6;!W&*YCR5$1S_KI;.+IBZ^X'
MB[7'H$GOTVF/:R&W)T"XM+3B+H:XHB'"N+Y&"G0":<MCDMA<B,![%@TICM\X
M5C85B#V4MAU&0U2[E5-=U;8=PL>+QF&4/HO;#I!;TI(3T28*NS>Q[']?53<U
M^TZ1HU86T1)+Y`7$0]S7H/(!<Y#E.-Q7/M>V:[^<#\U5[0RM-Q-1_W6(AQCE
M*=8DJNIBM"/(Q'HJ_G.4?8VG47.G/!]G5\@__Y(NPGF=IGY(%_^(%E?/\]HO
M;RH?JA^1-^`"-N5(Q;3#$/9P`$D0MI!C:?BA;0D&[@32I^5)HT!629$$;4KU
MS4346\7H`?33%,`AHIHTMZ\8_2Z9058$C8O>QU^CK?5A_O?I?&DL?,2C!L9`
M56UHZU!8G9?1/FF4\H"YOY[+:`^P=<N4T:YG]^,IHST,4S7;'71MO?-)9;2;
MSSS8#ODW^S<X5T-ZIZ<_[)%?VU+%Q59)#CR?;=.>7F30^>%\`PP\\D:2O;]F
M>8='T+P9?VZO2&:6Q.)4=,J?=XJ@J^KP0T19L\.R-GW46W7X`?"H8K9^%YX?
MNCK\*02^O:44F::N$?C1EH??.=+EI0_P!?%TE.-X9O$:/F4<;XUNGWB,YH^2
M&)G]");<,X!7-+^>UNPH0#\^3V3V,=7&\_Z/O6OK;1M)UG_E8-[;Z/OE)4`W
M+[,!=C9&)HO%/@4:6TZT(TN!9&>2?W^JFQ1%4C>2(FEZX+PDAA2:7]VKNKKJ
MY-LWC/1[3U=Z\2`DU"X;C@4'"*41N7EA8+/];?9T]Q4DW3>0;!9_/(?!#6`<
MX'_,OLP_K8/4[\H(V_*WKB;(M^?-_/Q`(NF;#'C$D=0.C*>.0+%!BE&JDU1&
M3)C(N4*Q\0V6^7*J'M"5:%7JCX0T]ZNWO!^]&>Z=`(<7L#A.!(V`]98E*1``
M5-H*"$4-)D9)3."C.&M%(3GT4R];'H^<=6-'2TCG[V;+3YO%;)F?:TVOIQ,8
MJ_)<]M++E\5[>[=9_S7EBR-^HKT2>URU-RYA*8VD!G'V*<7/&-SU]G2+0U>X
M]7*#<9I:%R.%!3@5#KRRRC*41LH2@;F*550$^;?TOSF2]N];`GLA1T]K.?HX
M)X>'45WSB$/\\DZ*/-ZX&N$Y0N6C6'QQ=IC*3%\5-EX=UGZAGV!,IM)(.LX3
M9%/&P=AB8*J)+;(1D403ZB(O[]G0E!)#+P!XX6'\5S&U825D"N/W1RCXT&*H
M1.\;,,,#LT%TW\#\!X_]857RY3V9](;QA`\L;QC[OVP&78[WW.N54*3/H2Z3
M1=KS^W2S?MS9HU\A:^VHT)\-%52I'\9H,"6=U-L8">XK3I$%`PWN+(9,G!B.
M:&QB2K5+$GA,OIKR'3%E%;^$Z16-T0="PK?$#[]7B!,]U)1*[)=RO#-<D,N#
MS@<>JO_Z)CN?YM&`@YZ!8_*7=^)&72SXO\2@YTF/>AU/IWPT":'G`8_&'OSZ
M2DP<D%>)P=@1%NQ)2804;R:N-QX-:>)8Z.R]$9.<9?]*3-S0.N6'6QM)N'PS
M<4W8P365;#!VR&#BL+A\)/5FX1JS:$@+)[,@[D![WBS<=%1*C*-2?Q,#)Y@A
MP_D;$89&$,8%?>GE;Z_9Q-69-*2)$[F)JR^_>#-QTU$JX4^W,.9O-JX1.XPR
MF@[&#N-M')."\8O;D]Y,7&,>#6GB3%AX=2/UFXF;K$YY$R<5DR^]@^EUF#A"
MN>1R,';P<-J`C99#EPW^QB;N@$=#FCB>17&L7CI],W'3T2DQDD[]34P<,Y(/
MYG$(]B:.XG"QZ\W&]<:D(5?G8F_C"+_!;T9NNEKE!T!@76V(?[-RI_AAN#$#
MGG#K,%G.&$S?4M7>6#1D&*>S[>#\S<)-5J/"PDK0J#?[UH0;$E-)!N-&N)A.
M"=7\[;2A-Q8-:=_"+#AZ(]2;?9NJ1F4-([S.H3?S=HP92L#/@S&#9J>IE#,]
M=%GT;VS?ZCP:TK[1L/3X+7Z;L$J)L53JHH7K:2V&IYPP](>AC#/>[;Z[H5A$
M7"*<8']Y-+5`/>Z0/]GF$7:),_JS\B?1'!^L@KVT%:-_G'[8PZ`X><!Y;`_1
M1;!!9DK6]$JL#$O>OGFJ*4[RF9.PP`;4P=1+!&44`W.TCK)_CI+`T?JJGM%%
MEU&AFURWZ@Z4!:"<,EI;3WX)ZY$U>_OYA._OYZNGQ<-B5DRHLW?PC$V8A5)>
MDK/=/C^&E5Q'ECM=.YP<J*B%DC_@)R7TB9+,!3(F),5.1@JYF%KD"8<<)AIA
M`?0B/";,EH:ZUW96C4FB%]KNV)[&AS<#':?.2660T""@W,`OTXP+A%W$<60C
M;DU<7'0GN]O<5T`=3I"OWN@TKLRJ7]YI+@>3V9/+HOK\)?DDF?('U06(KX$1
MD`68X6S'11+UN5!E7,(UW[#2)T'WXU=?A9H?&R@[$#D&U_/LF_M!4J^"`6%I
MY]#J?4"9X[P(C]HN,C^Y??KPL'MV`K_SZ>>G#22IL[O=QZ.1]S`L8)HGF"F(
M6T4$$6R"$V3],"J2)D1$,DZT$_GPI1,A04NH`\IN-IFD-%G]-4@M]D-\AY/:
M`YH,1__.\^/&);CV;?MD.#M=S*`;XN'7#'H=E\Q^0*$0PX6]QT;(3CGZ^&P8
MT5*''X$JG:@?:6=)2A(DTI@AKJU&.M)^0!>S$?R4"I,4OI!(_LJ#D6%9<.(J
M5T\LH"$<82_`@2%VQ'I"2JK]I2H0JFZFH]E:GR+=N&)K[`@4@!\-N.T?A@K%
M3M8.SP\>:TH06IH]]C(0M3AQ5-<71/;2$(T^=1K9DU3SJZ6ZY]5<.U(8RK$Q
M57D&0TDQQ[XRKLR)1N)>6$\S0UEG_5A00:Z;0;U>!(J9:Y104Q6"ABO+1B**
MUX0Q^<^/\7_(/;UUX#E4JC#I9@(:358LF*]J2_BZ[/#M;W?(2Q&#']6$TWM%
M7GJT:!<Z]3!VE$UI[.A+R<J`(TE'LJVCN1@R31?#*!.=0HSKB<)\A.&;#`SK
MM"AT+)(T#D5Z\+K,QR*'*^!&@CIJ@,%\@'$$ZB@!1@[\:D%O9">#ZA]*>9?P
M8F!!&$WQR36*/T",-;(\\"/@7T&$U8)*/4189)(1UM@TH`<6\GCS;8.=7%D7
MV_O5%MXGD**^-;?8Q)NUY':FE,%,!W<B5>M63!S+1,<&(^-2@S@G$AFA!!("
M$TT<X;'$GWG><$:P9/+@<LP8M'G5JZ!/LJCGQ="LV"M7.Z!^X;W0V3Z!H41E
MJ$WSK;EV9.D1QRQ-%$>$I]QO2;'(IH2C6-$TDHSJB)E]LL*5XOOD[@7I-0;7
M3JTJ?+TL#,EY6',_.`M;$N\E^5F2ME?AY7QG).2@FKX4#P\(=F'WI.=P]D[+
MY?JOV>KN*ETQ_K(#:71]Y7`QIXF555$L4$0%A%@$J&PY4XCB2-B(.,N4W>_O
M.[.0\A#3*`=BXYQCTM)*K.'RS`98>JBS>:/7-:T<F(G#GM2R49EX!DL/Y8',
M<W6ME`[+QF%/H[.M[M,ZBFX`O`?YY4<2W9.[9$.ZWQV0EL)?_F2T6Y^1B,"=
M*$U0G%CA$_<(F4A)Q)RBRJ:86\?W?>=$-%R0&T"-20"M<;<B5R,"T+S(QRC6
MTR0`@^]V\T6-",#RN$)(UAE_YV!O=Z>Z?B6[*\D8,-'XW01<\?/#@H[4"JC#
M%,C#(,3UE2XG(0R+M43"1"1RJ;04R_W]-E[O9N^="'VD']5G]W!_>20*@T`:
MA?O("4]2H`_RYBG);[,?B\?GQT_SS6-/=*T3+HH(AI@4*0;)`61=%IDT<8C8
MB$E'A74)+C3YEN#_7DNU0V#]2Z/?#;GQ>R+7F_3Y"7S_^^WV^9I$K+EL'LMU
MK</6B-2B%/X@SASDNCHA2-'8@?V,K3"N4'\*UEF8GH7S)$$F;6U]Z$5P:W([
M+6-N;8P2PPCBOJH`3S,HL50)X(`V@A3>F;Y"8SN0>'<D=R/I+DJJ?HFL9"\B
MW0,?K(]S=$K[.TKO\Q1Y+/"O[=QXI%-2.JV3XM%0'Z;,N\KEQ_GW^>IY'ETW
M/H0Q["=,!9?<Z910\%C'3$-0Q9,$<:L5L@D%"XE3GAJLX4-5N'YM:K[H.)@2
MFW];+(%7Z]4\-XX=)QYP3.!'GQA*RM@//]<>B\!'@3GPD0C3[9`4*QQA1BTB
MVAK$HY0CG3KB"R&,2Z:8-+2XD:1$.2P_!6TD]&1$]&P2Z$>#FX>Y3#<'O"\$
MWD&4,&]Y+YWUBS-BW#@11RA243B`9,@2%R&.(;1)HIACMK\_33&N*7490XF=
MNY!FM]?^=K/^LIFUR/H:H<R?>O%T3H994!$"2PXQ'7'^W$AJY'0:8V((<X[M
M(>8L/(&@[)6^;.8AKONTSJ84M!!6%J054C#XA]=5'TCZ;;B&J$,6*6)8REV*
MK.,48E)%D#.I0C%Q#CP(420V187RENR2VL/W.\*@7^>K^:?9YDNKN\[9VU,L
ML[<_X5?RQU[B3B)C+2(6(YX(2'!(PI"+(H-$Y#!V48SCR&16U;>>U+A3>OTC
MX.S]?9B6,%N^)ICL4`B/`JD:DX_KG[/ET\_<N;8`&;)'07!>3`U>PW?'*;:#
M3+#AG'0+&22.0&JY1%$:6Y#=!'1/,(%2*524@"'5EA:RR^O6I0JJK'NKU?-L
MF<Y]NA0BO4_K0MROP`ZZY8\2P/"TQDX.S0XH+2<I!$K287^!.4961Q)1QW5,
M4LPC`C+].?.4?FQJ<>_B#+B1:,!`R-OSOR,-_'#"C`8T$*,%(7J6_I'D?5<_
MR&ZM-Y'WWQ8K7V#\_?F/9>9P]Z3Y_1N\S\/B#FS\G^O58O7E=KY9K%L4J\[3
MH`M#/1G@3ZBQ%NZH/802_O?`B<5LN7/&OM`*5O%J:3^/%>(BIPB-D8Z50IQ2
M@\!6&T13E4@5I\P*6\0-MVP']/R[ED`!]/A%A;4-,ZG7SIV\EEZ_A`>X!HQ]
MFGV90]@4)!DR]$]K-\_#C_MTL][SO]7A2D/HWYXW\_.3K)OK)[AA?$-W`4=K
M;"6Z_+J9K9[2YZPE\M$/JFL+7/DL?A\H&J.IDH6S9N3DNN0+`F",M,K&$%D2
M"\$_CQW2Q'!$8Q-3JEV2$+4_^\9E[A^"&DQ=%5:5`H:FTAP9F)-08F.M$%8<
ML("T(`MI*!*4<I.F&,BDKM'6Z[EH"B>;A?N$*4&:3*P^9%PB#:0T*48Z4:"Y
M-/6:*V*DI-,TECIE6I3.8$5CSEV5U)Q%V1F!=R.\45+S[V\/F[4?#!G\"]BG
M[N^>%4]`]@SF=<'K4CFC0AHM4T#KM%<T<"H)@62`.PN?),)H7AK)0LK\.D!U
M9$BS/R.8W\?/F\)Y9H<)_YK_%3YJD_54*7$">K/3E$:P=]W-DDG"6&UB\T5@
MC8@1FJ<&HT7/8K"+#GF]@-H(W"#J,"+P2I7IG/R'SS[.[Y_OYO>[N!ERA+XQ
MUD.*0\>3"LIL0CC2*J:0WD<4^5T,X(=,BC5SSC!9E(7Q#<&[F.+PY<^ZF[S)
M(*QAL&`"[^?W75VJMS05(XTY-XW.NHYD/`[",*QBA#D#^,0H!#$40PJ\KC+>
MINNH@,\NQ!#G,%:\5'X1X;HR%LGJ.^3L\4C/]9UL#F7AS4[CZ%&1+V)L<5$L
M$3HRRB!#,>0-(/G($4@>L$FD!5FG,MF7Q0EKK,@[`N3AV&OBIS?5M7K=(8H^
M`TD@J^@KD*0*0F86)_[2"FBO`A5VJ<6("<$A!`/KG.R[>20_K[U]QI$G078&
MT#R.O-VL[^;S^VV1VZTW_UEO_@1W^[#>/.:;<#K;7HI97[87##F$3)HAXPA#
M7'"!('6/D`^?B68Z3MV^0E$YH6H'L19DS9:0!8=HI-JZDL4F[U>E2<3MN6XH
MRR)PB95?]X:E+T12HW'7=3`07F#(@/R!3P3Z'"OX5\H3)#1DSAJGX,!4$7P;
M4IV^W@9L[19Q=D,K[]X!RH;_UU7C<[*<($27I5Z-R%*T.N$;H4LW?L]@&R$]
MN4B/'@5C%Y4J7)>,%OE)YAWF3SNU\]6B@GJA:O3AX6&^:5\3:R,9EXI!C:D1
M;F55:@J-H%4%H[:YK:)<I?9C-]LN[NSJ/EXLGY_:]&`R*<(9:];]<KX%^S"H
M5X80+9(461E+Q"'`![+`KXDL%C+E5B4X]:/FP&(`U6HKP;I!.Z(W\>+[XAZB
MX&TF5(.`/Z88G%A!E%+(":$0QU(C+:E"D0`G8IF*19I\9EF7#U,UE:B]=$]-
MN7FG=0@ZMN]7F:[5"!T^C"&<+BY,]4"Q3OL2(53DD0[]%!$$)8(A'0N(DA-+
MB.&QY#K.Z,=N+F]2'HPZ5=:`#OLA]J#'GG_W[N>_M]Z_??@6]@U!C`<^[GO+
MOLHF5+V@B=(1WP"MD<$RA2B/2]\'P1%CD4X52V.>::+ZY1VB0INJD6X.JN:\
M9QM_$+7=N;;^S5"W/9S-K!(8:(1O5&G%XP4\S:MHQT5T5(EHM`L.4A69+;LT
MO(G;/@.N2AS?;;J;3_)I]L-!CO>P\$IWMYG#__3]V\]++UK>$=["HS?9+X#O
MWJZS[1WC*I#03D.*+OVC'?AUER(76X621.M$VY3$#F>W=*FL*D\?4&OG]-G)
M]K@$:*@UOO*.(=2IGLCG+WR%#/P^?WI:!NN]_<_BZ2M\W]N=[$;%P-;T,,AK
MZ-G)X1::7C%7R;E[1CS/_@8'MIE_FRV*+8%^A$7H&+@/4R[:[N88T0NQO.JU
MIULW<%?(6]Y8_3JLCK]1JTUW03L)MDI`;\XW\Z_^:/X[<.!N_3B'R.##`_R/
MB;HN+TF("<6JJ<49(+6[UGGG\:=UOMSBN@LR(ZJ0"1NJC:JZ[49XCCH;+R99
M8#Q%K^/;'NN[:@]>O(JK"%XS_O^SU=WY\9"9(,`ZW$G<8SOR\E5TA\-YZO-[
MHJ\^'7J_:EU*Z\%]*FDT*"K2QH#^1HE!FL<*&1DS12P7(LT3.U+<R^X*[)*/
MM'=WFU"!?)I#XO"TWY37:CW8B(H-MA[)"[[Q'*CC!JYH#04J^EC#[WCVSF&]
MF4"JTI`T%)+7VK+EKO`:2$U8E;JG[!0)XC-8(2X%4H=8:A6-]6I=-3=YK#5%
M<TE\C;EJ*T^^_T'A9MJ>(&@^Q#*B:A`K[]V\`E%,&_7?N7W>W'T%8?#C5R8:
MR7G=K@V-Z02O=O_[_G_/^<56"(F*^R&WD%B\7T6S;XNGV3)8B#_J%N+C/%LC
MNAO7FOWN?.BJ_\(`E=/>B&G\.::NJLG0I!BVQ6Q,ZH73"EHK<;1H*SL9C)^<
M@C1%YT(]&90\GUZ<1%2+Q7W*?B0IV]])_T?FL/W5=&_G/JQ*XPPV"]\J7J;Z
MU+-27QBJ!BI#4>`(G?UTTT_SQV_KS6SS\_WCM]EBXSGB'SK?EF[Z%_,"'M:;
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MTR5UJ$UHF2()B/1%)'Y!!VI`+N'.SEWR8D(^JL/+4U:+FKI5X$"1NG&\`F._
M_3K)C_GF;A&BEOR,QN_]Z+I\H8_`(XYYFD8":>M;9FUBD$VU0)BFV&A!>$K2
M\@%HC]TY36C1A/I3E$)Q)"]O4J#TE@O$T/_E,ZSOX,B]?`;RU(5XBK@91&C"
MZ-HA70M0IT.T71/EAP<@W^-Z%?+T*=*`:E`6I4X'J4>1-'+,64@W?<<<;+`Q
MQC3QS$=`U0\NL\O(OC\+/-AR'0H/$P[,1!@,;JJ%@;,HF@ZS#`/^/I9F&DXS
MA^>5/+45G'JF_FT#[Q,L)?Q[.0\N!OQT-OERLO:?^=M!U;BT"92:&"R7ZSN?
MM!SW'"^A`%1%24)EXEOAF6^*%\@8FB+'M&%66N.LS$[Q#\O2C="<.-K//YWD
M<8[V!QJ$5X.C@S>OL;;$]`\/\?R/)[_+P@>CMYOYX^*YS6BXT80ZV]Y1E>J+
M0"JWDU<0X(W`RB-C_5R2:,DP8MCY^2Y2@L@*AU3H3HO3)"4B:U20Y7L<U3<N
M08G62[!HZTT6\N[NA4U2//U(84)*H$Z\>PG=R3.WC[Z#?EMKI$_`>3]ZQ7[Q
M:P8"R"$,18E1!'$%3#8QCE&4T(0QRA,B5=Z-<B-W,^6NQ7KDGF0YQLNOOE9O
M_H2:?MLYE^-%;](?BQ%!#Z]'MD!6;SA<^7E!F<Q]7&S_W`\0(EUI\-E0QHV?
M4$<$*:\ZJ<\H.#K87#`>@XH@HJF_E^*7>PH=(:.UP8[B")LD&]\:Q*7:<W@:
M2\7:9?%>:%F[LH1T,!*SR\P)FS`;.8<$Z`GB*;ANAUV*F&#"IHET*HZ+P02$
M5LW@(92+QC`ON`9AR-?N76/VQR6!9WIEZDPKC(-+0?<KTH"3$(43%!,_QY=&
M0((DXLCY50I4^TN-24$",5DAN.**/RAX&FN5(L*-\).,*3+"*12GC!++N1-"
M%H.;*9ZL$&0DJ(XH'8X@=&<*50N9&`)W;=A;=]B0GAFC.$5,_3][U_K;N*WL
MOQ]@_P<>]X$M8+EZ/W;/%I!DN0VZB1>QM[U[OP2*S3A"9<M'DG<W]Z^_)"7Y
M;4>6];!DHD6;*"+%^9$S',X,9]!Y1E3P35^6LQB94[NL;EB:I&O+'4"\0$[8
MDYKVC)1$IB9IBF$(C*IKZ&2O]W1<;JF'E"=+,`P+B5W=6,(AG<D59YN0E^J7
MCK21:61/QEMQ#WU]&2Q[6OJC'7C7L]_RFB#SZ#=1U=0CFL9N/HZN*J@X=P-:
M5EVL<^$$BPJO,[(A":QIXD!I(FT4#"O;87F.R\'"GA:>`F<C*;/[EX?6`?:E
MG)J.JNKYX,E\L*I<T'SL!VC/C.R$Z>U^\/&4#^*<CN<HW4<F(C/8.!F-]$6\
MY=7N%MR%4%]3*72@E-/KJ][@5:';$UG&1'H>TOIP8AQ%5AE)Y%C99&6#[:IX
M(N18"K$RE4*7,1^)%)*H%$H]$9G!QE*(_T(%T"[.<0+\PK?=I0#2!"J`+F(^
M$@%4U'S47`#MG8C,8"_5((ZJ08?!+GS;E1(IQ!:U[39*"I4P'[$46L^Y1Z70
M*Q.1&6PLA>3;\@50L?$.""R<LQ#!(ZE"MCJFJ:(?$M.Q*&S=4\@2`%$6)*HF
MIS$;9H0D,1X+BJR=#<FE73'#($H:WOP%44CCDLA^X4RJ[L)9+I>J5U!I`I=M
MO:6%2HRRON5QRSK*VW@P3N!\-+)E:TV+!(<#E#@)[11ID[4>)O4$O/*-U2X-
M*QF';HHB)Z?$*DU0=^XY?ZN!!I?GWD[BDG=1DI)63?[RAB-!OZDODI^Q;(I)
M^E`J5$KD6,\U`42A>0A*14>(^>RLE`15,!E2K.5"L1'B#*9<$_BL!+1(JI7T
M8-4\U4JIT#8\\4JI6`KK\:;GR+RL%J&X?,,L"/T%F;YEUHF]B<3/`%5C!14?
M?U19.5E3TQ&:@JCA^JL2KMNN6XR&K^*(6H\S1!U7-Q%7$3I;QYZRL*EF1@I+
M?']PRK+$IZ>?0!QYV)'R,#[G#>1:G%MQ8_H+!F$RHGSN1J>9QU<"Y-+/GI;$
MC<8!<E4`58(S(2EL<:8K(9T+<\]M#U[2Y"Z>#TDW&9'5=493#(X1)$WA5%$7
M3$E=BD.VDXLP3`M';=!/Z;K919^S>$M46)D1=,UB1%46<.97C+YDF&AFS)[%
M70CZ95OU#F":L@:3C)TYG,X((DY(K^@*HVN*SG0Y059[LLJIUBHJF9-261S2
M6?4B4;7J@90\.]PHN1`5)W'XY".U-7?,,M7Q2HT@+L#989.+8.>17L9UIZ3,
M^_8%F#3WG3C6Y'C3[#(LCRO.*J*$Y*:E,$I7UF155755XR-41%*5E3OEOE/R
M9ES*,C@[U/]00?OTN[4ALZJ(R&)4S=#1[M"U&+3QFT@^&;QD6#U%8KNKZ'YI
MRZRY14CYP?UE`H#80%M75\Z(YR]TW>_<^<EMW?/Q*12M>S7+NB^2;"0119DK
M@FH!4TT"*T3AXJA^K>YT9JK%>,FCN9:R4+U6C"!FB4^V?TXBEI/O[NR:6@Q=
MX44-;722(B+"#4MD#$'N,:PD6&87'5#0(HIX'==CD0^75]BDJ%#A7@JYN#+C
M5A+QO:)]"45<>[Q&)&+I+6QEFMF@(J)P#)UW0]_&<0"#E^FCYYY,G)#</-^^
M/JC+'(>+/AB*(3*B8+*,)IGH."`HW9Z)CL4\#FS$V^S@]]O^?W[=&<EJ@-8L
MQ)%7<$*R%L[".WMZ^B2<.4Z$YT"_^UV_[0/CIC\P;ZP[TQJ`FSLS&OJ^,6Y3
M$%?AN8=SG!P#T1G:X>)T`7$F)5+KMR\P6!_U_G&M1D]*S./-ON?:IU1>/3[<
MKF48HBRR#&JMX!1S/4;GI!XCFYQEF)*I]U`S`OP38@<8#7AC*-OX]AP7^B:2
M5!//?RD;5J7UFSX:01?G=X%C0,:R#O+&X%8C[WHC8L/I.<'(=K]`V^^A)_DM
MBI0H"]@VQ0G1@`^,:7?0PY=Y?HR8<J3X?(MZW1PI'LCN\*)CKC4;=[,80\X<
M)Q\ARG`\(W";H]T8UXZ0(/J&>X/.FM__A*4O8ZSXL2PN\\T+PH:0V!S7]K#_
MAJ[[Y\S[-AM`._!F<$R.S'[9PT>GU#MO?=@'QK4:?BS\5FL][_62<N2XD-GZ
M8CDTKD.B(UI4E0@/!'KORS[1L3:F[?7RE^<ND![M1W*Q]$U0WEXG6^/92C>'
MJ'&]`)TU2&[&-?_LZO"[8YL,AH@>P\V2C?(0<3U5Y@Q1X!G15)#ZI[,]1C5-
MD9$LP=04WN!D0X]$Y,]N^'[L?/UY$KY'E.#?YB`(7USXH76KW_]^<\<,^Y_>
M`78>O@>]_MV0Z>FW-Q^_O`-#9XK.+'?P&[CWIO;L/8A?-_K#8?]VO<7@YG^M
M=X!##UIKGWG$/]_UAQ80P<_V=/[^A^^8H/=@,.R;?S*&/K"ZP.S??K+N!OKP
MIG^'&_U*6I&?YFM]_9MAP/='WVT_>N,7P#"O42/CL0VM_QDR-W==ZV[X#H@_
MY4C>\!F")P]7)<,%Z$E-/1`\>]\"$.(,M6A$:*X9XL1',[X600,CHPCJ8E6R
M$3@S$#X3*1-XKC,F2D.`%*\X8YCW!.*B1K@DY5MGAEJ'S]XBL&?CX)=W.U@=
MGM[7*.37)C":,)W=G8N8W.@;1O^^:]TS9O_C1_W3`'4RPK:A>0!?0WL;6?#H
M^6/H?VBAM8YT)S>8VS@7]_+WN3T>)[]_<\;A\X>6*O[4`K;K3&8?6O@H#OU6
MLGCP>C&0!CX#0S+:/Z`]WEPVH;_^RSCI4V%_6G;R:SC>?.=K_+%'+PR]Z7(<
MTN$F>3V_QD__NCE%?K+D4J\K=5,>[9)"OKNYT%\A?JO%\;:;+))PW0]1PB#`
MS4-`^+VU@S#B(;3\T0/LZMB_P(F8Q+H`0,H`'*./=N$(3A^AOQJ4P+6W1.II
MU-$9V9T1_NB$X/TM7\@OGV#^V@CFBF0JO'$ACM[=MO;M:L:.,I2!)^/==X(`
M\-#V^X-I6E:O=X!-0V^^_I>EJK&A:C$<G*94MCY:/=1@]?ZNJI6DT@)(VP'C
M55KL';4DUV6TI^V/J3;'^%<?!TF19D*;9\543='1U+?G'UK1_\\>;P6T\FU5
MXZ^$5J&MR%JQM)Z]W6Z?R"IEY+CL$.%C>Z/P4.FL?%J+?>M<$VNWSL\G6A3E
M:R-:;`M<P3-]E,MC-II_3Z$VEP#GMK2(U2QB85CI6-]C'6O/!)S*Y85^L&!5
ME.)'\3L+OWSV_VI5>^&(1C!,92O-IAV@OSQYLW"/,$UL$`?7(6YWBD#-J$#*
M;:ZB_?3RL9':@J!2;/9BH[99E:,JR2D26D`2>NPM'EU8UIZ0_8N7N:E2!"F"
MA^3#ILERS289O8J?[AORNG<2>QZ+]-?JQ(NZUT,"L,V^_8K?%G41:R/`CQS]
MJ`%8D+*$Q%F+7?M>=-\(_^41;OIW4?NG1;CP(9B3.(@`?+,#\"/'=?C58*:.
MZZ(.VN#;LS-Z!DY`OCF*/_8(5X,8`^\K]($-OL67,1D[NG`2=X^)Y3NJ`EZ@
M[0>=B/PW!UQ$&P#L4\#62$9]+(F^'WS>2^M>2J6."!+Z4"<'*#R!/M0)U]'4
MA,+A,T2?Q)^:>6`47:0GXUF?41C?UT%M]])IO[)*.CN,LW\QJ\6$4N"+;=&`
MUVZWD2'MCYFH*C`B@?E5S9[,UQB&T)\Z,_3.`B<:>_,O$@QAN#9J.Q@]>RX:
M3,1:6!#&"$R],70[H+_W>?`&AU?\=^&@)8'[<F;S18BG-E@\XBKWSE<\UTL(
MB442O1=L/,6+Q,9=^R_1:@P1+&E70,'B#*.,@X_LV0N8^\[4]AWW!6"@`^"$
M*TPC3!#A"9NAME^7^2L1S;ZWF#R3)C:NK!E@QPI^'Z/V[*#Y\YT1D@IK;0CG
M.:0L&2Y,&\UQ9V-$2%PXF(5GY+VU;F!\'0X#CGJ9>T'(Q,)D?;QV5.3U!3QY
M/H!1.34<9H-[6\D+U`!+5?3*(L!3O"2:1.3@^!S;\<G*@#%%Z+581%_0-.Y(
M.)C4CULG`(D]0&XV1L%`R0*=X/!R].:87.6,!3EVR9(EC5V5D?15.[S6!C\*
M'44F?T$_\6R;<$DPCQC"?6F#B%,7<R^*1UHQ0Q*AM,&4>"UM\^/P>9.S%KC#
MK6G<G!O42[S>-L7&<C?%1",:HFBK@$8[Y1KM)&>(=I(;'')$HYUHM!.=D0N.
M=JJ(S+)CG"HBDT8VY>W^.!K9Y`3_,$\^Q-IKE.,?X`MCF>Q!5?K(\7OK-O._
M_[@96LS@DVXB@M=LSUQ'8AFNHT:&_5.LY?LLV3]5QHBY`<)V%!$!(H@4D`00
M36#X3BR'"@"D61%5268CX#I/:R=#?$4DLHO]4CM9(G4$F4'_J<;Y5P&Y(HO(
ME:Z&7$%#Y(I5NB\;H#@L^7X<IS0#+PYTB=6?V$YJQ_5L`_<\2M-5;L4K4WG]
MN#!1S1N_#R%*%>:JR!4PN05'F]4N*B#)WQB`>9R\<0SL^=SWOA,/C/L".)5K
MLRS;!IPBX1^(]X23!/PSZB!*-HGWW75OV-*OAKT:/,NQ(,D-"4A=`#L$^+^1
MO^?-OU9NL3G)D(EZ^Y'OH._A_\E<XK!A^34O4.SP01_`/C"28"'2^/?Y@-H;
M;I[:^;ZP5A/AO)JE!4Z_^2;R%,=NQWAE(H*U]P&P!I\^'76+X7"!'[F.J&`W
M&`):BH'F.C+?3NL7"V+'&.IBTU^]US&6D+L:J?!^M0I.<YLE3C-"9X(+=NCA
M3U"G&76:4:?9E;AHJ-/LTF:$.LTFU&E&G6;4:9:/2X25T-E-+LPE<BF'U!,!
M$5@*2$DKI*&6NN8XS=B.Q/"=S,;9>IBP\B*1$DN=9-1)=BDKG=)TC5MOK9UD
M$H=]*=*U;$6:@$/4E&LA5U)+F-U-MMYPAD7_DL=QTN95U8XS<T]O%;T;/</Q
MPD5=Z:.1MT`OH@9X(/ILC)[X"SC^Z-B/F$L=&!`#0_Y9K&7#5`U-PW4R!8T1
M=8UG=,%0&%/7.=8P64W5I).R6!=\O3&!"LPCK*)D9A%:Z$"QA(OD<G:"Y5VZ
M9:YHU,=;XC.BZ9M;BEQ`^N8CCI8+],T4_FEJCF_)1PVXU"5RE2Z1R@G.V3E"
MO09'3Q[;^W;IQX[,2699OG:)1K/36G0^M&8=IV,M'8Q<9T;R*X2^0[(LG)$V
MK\*3M<)7?<@LG629*_6@V4BY3EA@[GM/,`C061@QP!.$0>U6O\15[=PHG62^
MZ%M>S1+W7?@$?1\M=K^*Z@?G3C;'%WSIZ_)(U@HN^]!TX=X/G]&YO,R%?KYW
M?+N'W56Q,LZA4Z!8U%!KQ2A\E:[N&J:S;4Z&<XK?)62(OQ2!'^6#MU/Z6++M
M#.[%Y_<6VX):S5F@#M@DIF*Z6:24/4W*.TT1S'?#2']']\V1L(1S(@DV8Q),
M;SIU0A*UL(IUR#_J@&.[1I?O*8Q@L0HC=E6.T2W+9+HR9W0Y1=0L74T;=7`L
M:B#EQKA,&KV^/HAGB!3/5C>+9YO]V]N;X2W:?0=D.E8NI(SULO.B8%_H14+1
MP)Y-[*D'O-%H,7?(E>DG?-<9;^VN_>CY=NCY+P`'#<#H<F]2\GHV`2[$B8U1
M+\X,W#NCYZDW&[>!B5CKR?-GCMT!_1G0%Y-%$*Z6_C*O>?)I&RVKZ!8<SB-,
M^@3VQ(>DR#;XAO.'QUENH[_AQ+EHL9%&RQO=T5=0'_B:<0?<XZ:QO3V([Q2S
M'27)=(X'C`<1W2QF._+R#VC@42=\>WDGN0-Z4>)TG,-XNIAB_2<J`!X!@E>_
M;X_"A>VBMMXCDBQQ27`[/)*T_&`H2H9*XL<B3S87`WMZ*,J)2^]@Y$KJ^!-9
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MD[CYMJU<V?C4O7B7E=!695JN]U3F*L_GDL-'CUSG)`]V/";'_1Q;]S27%SK7
MKWSJOF_/)L1V;;SLW/G4O]G^^&Z!#<+])WT\=D(2&4O>"_1%^.SYI#AF9H?*
M8N9$K:+,G"TPAB-G:KO!AQ8C[?A;>(/E3446&$U2648T9)G1NZK,2)K)F49/
MUGE6?N`?^-9OHD@<8&N^I>*H/W0==O\G[V$0^@Z^O3[`V2,^(P`"\B$]KE98
MT`U9H=<3=(O5&$,614:4V1ZCFEV-X;JZ;J#G>E?62_=5[<L-FS":#H+%=$JJ
M9CXESI>5`POG9KT??%[5>'2"DQ*5-LL#P;%LH2Z(+)E*U>INPS;YT\7[74X_
M>YRTEY?@S8AD-I(;Y,G*FQ%);C*JW-P9F5J4@,'?FTFBT4CT*$7T%B;W<&J3
M6K=;S\V5EWC5Q1#ZTY+AJQQ(?3+QX02GAEP.Y09!X\P"9[2%V5\XHW:^^-2>
MW8^@7@AKG6](2;DNWM[@J(>U3'^7PA.GT1.W2TA:];V*YRAR15/_[Y91`RFU
M`?`681`B['%TS;&@'#Z;L:/*ZUMM5I#;BE3U)<6T+:IZ[\SPZV+?:Y:)GW"<
MC8_@2%NJ&S\)&M^66,I-5\]-%[ZC^9!$P]:/P=X*(M=6Q<R717ZA[%1'=KHH
MYGGR_"?HA'7D'EXX1]G[A>Y*E\Q&-?,%-LJY3U=_U:N_]CI96BN#D&W;<<L+
MJ<C!*B$+;5FJ)G'824!5`D^GZ(1ZU2^AC%$YG-A6E"KS\]1S*ZY56`[=C)NP
M&5_4UOL5!KA^!;ZR"Y-B%J%''E_Y5JSQ4EM5J\E56X>-N."L)=4OH*P;,=]6
MY5*O-N2=]"*7>,'-8$3]J^VX^.\]SQ_8+AS`T<*/LF?D'F"H2G*O9ZDB8_*R
MP8B:;C*ZH>-X0\[2.$OL2:Q2=H#AL502N))Z%+7W"%WO6QQMZ/P?ZNU@-?B1
M'3P#^-^%@Y84R:B`!#CJRDY@9IX\GPEL'`FX1/KD.ATT-/&DT,0,V1&.-,GK
M.?UTJ9^N?9A4&8%L4\\/<<`Z>;(>Z1=$:8`?BU-E+@V+WWTO"+9P^#SS(6JR
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M3+ROT)^1ZG#!W)L%G@_'`/V&LY:.X6.X)JTN7UB=><#@>*[-*P77%FD"3$U&
MB!H#:K(($:]J%U`MA)H#Z!&,HDA1I"A2<T"*BDVD*LR^FWK'[^E=O.Z=^6*L
MVN:;K5">A4Z3@;G"0+4Z+#G$D#QULYVZ(UY;SAB*(\61XE@['.MFP3[W)F6D
M0#TN-XM+5J&K?(_22&FL>NQ-LP24<C>T47-.::0TUH7&NFE25Q8+D-'\P;<U
MK09YEJG1C2)[/<A>-C_77U$M)\E!F;O_N<$E4EL5M":S%(URHA#7'^*Z\'H#
M_5V-BCJA*%(4*8I-0K%NUAF:R@'MQ"K:B1M=RHFJA!3B^D-<%UZG6O=E[]$4
M18HB1;%)*-;?%$Z3.13T'J61TECUV.MM(KBR`(YS3QB2V!;Y1EL3\D"IV0A1
M8T`M%B%F5:G@JX[4&'#91P>*(D61HM@D%.MO#*"I'$[9Q16AS<N-3EAP!CC7
MIV?3T.<+X$>UX&2&#=2J&W;AF^)(<:0X-@_'8S6VUXIH1Z_BI_';T;_D\=CY
MBA_^Y]=%P$QL>_YNZ=[J>?X`*:V#I<XZA-]#P_5&__R&&H/_)`WN%CCI0O^I
M/X>^'3JSR0!.ID0+'J$]#K6YAT\?6M!S'SY9"L_S`L,PG,"QS)\LRZH/@V'W
M09"E!USQFN,%[H%M@<7,B5HE7;7`&(Z<J>T&'UHW=[T6<,8?6L[X04#J@"H(
M#[HDB%U=L1A.Y45&-#29,2359#15U5B#9TU6LQZX!Z[U&[>B].#`-^D;/-L^
M?+0#.#:]Z1S.`O2N-R-/`WT1/GL^+C?_>3:&_B!$Z/3G^.^?7'L66-^A/W("
M^,EW1O#>GDU@?Q$&(3H=H*]%[P5_0[Q9P['^%8UB`N_AU'9FZ,\F`L^W1^'"
M=H?0G_+9T=S"2M%ZNB1)(B,H8H\1>XK)Z!;Z5=19F>UV95DQ.-R>>_A_]MZT
MN7$C21C^WA'Z#XA>3T1W!,`!0!`DQSN.X&EKMP^MI/:\?KYT0"0H80P"-`ZI
M.;_^S<RJ`@J\1%&B"%*8]=HB"=21E9F5=UKO?[FP_ZA_MOHYT$H"C15'U%U<
M%!NR$XS/@Q'Z/^Y=6L8%Z+FC^8N!T[3L1J_=:VL]LU[7++/3U3KUMJG9PY[9
M:PQ;S:;=_(XO_H+TQLEMD7-PC;/[]?KZZ^=_*+F.^F2EE9B/(<1//L^-X`(>
M_D'GHA&X%!E>Q`^\C&%D+Q58U+Z6;./C!37;^ENF9-^YM%`GF"M3UXE3P#52
ML2-W%-X&@'#(:_*-*.X/_-M50/$&D=B'(6+:,^&M,G/FY!US'IQH'"M39^PJ
M2:A<`48ZTU!QIS,_G+M\BK$'DR1A%*LPBA>,_!2Q-7M(B1'UE)!AKPHKBA-`
M;\!@F#(=_4FL+%8^7%Y]BS_B@##*PKNS-!K=P<)B>-EW\$U83`);'HCG"+V5
M"_X<C(!XK'P87%U<?%05MBG<=9P`B\0!)HX7X865XB82Y39R8+MC^*E&L,2?
M811Z0`DG!>!PH'CPXC2,$B1F!1V*M*)[G`)V#PS3"^'["8R"W]-+2AKC;PX,
M%SE(Q9KO!2X<&#"%<>W5$,DP-V%2F$&);4B``.!)FU#I:X%L*9X*?`%O=GT'
M8'0UN@M]^(Z=MS*#H\8]3\.QZR-L`6ST-QSE7ZF':.H%,V!R2IR.[F`4)R;<
M)/SPO8FKYA_O0SA\ST<O+:&V%_^I32(X?0_X%**5$N$!,G*(73$P8D:<WOP;
M!@$&1Z_>N@$P3]^?BU4H,4@NWL0;`1K@(@+'G\<>P^]_IV.Z]!#IQNZ]ZX>S
MFO*O.P\D"`&I&`%46#8-4EPRS`(L'Y8P1JA,G<B#^2=1.)4!FBOQ[9]C&`3@
M!:0%Z_(1.QT&_'SGN&'$Q`S#\6?R<5]'Q`;F,,;<<_VQ`C+*/<)$<2<36"=B
M/3X,&Z#C910`/`*V"N_AN`]><L?/MK`W.*,XG=+YUI1A&L$C41$KO%@`%DD5
MWQ<H!?QFXGH)XT^K5L"8UCU<@O!C2+2<0QE6#R<9P]!X'HS&X%M`3KKW"J./
M/=AG1``F&H2Q\I%J!8Y)2+P`:3QM\3B\/XM<3=`V1^W"5CBKC<8%5B&S7`Y%
M9+IA@"<?1GQ5G*$D=P`0Q)(,V+`$G'.9,RS+I#O<[T4!H8N\R8WCS@C.+?;P
MO3YL_>M$^J)S"SB'I&"\F&S0LT$`[=8'6J^G-S6KW6AK+7U@:;I>MUM&L]7N
MUDTFEN(@&@RM2_+ITQ9=W/`06/SOR-P^L_L2'V&`8?_.9/D7V^O`:IA#<]#1
M>OTZ")-#^*O=M;J:97?;@T;'ZG8LJUQR$,)((2`I$I3B4HM!(R>*YG3-3L,4
M=2PDM(D7.,'(`]KV`KA\TTS[`B;/:'I"+@K.MA>]%2HPF!$;#:C<A:]!^Y.^
M!'F)-$HFO<#744J\TKE!WN\A@YC-HO`'YX&9[*&,4Y?+,O!5#*H!WC[P$-<G
M:\IGJB=`@^>N$;9&P$I8N4M<&_8Q)A6-^$QA8KS<$I)Y&+^%B5:*0<02X67:
MDAO-G(C>YY*6(ZB(RV`(,_[3FIO+"Y!WL2"K?.7YS0M7K3@`A#Y=7%?9M:62
M]`7\/47Q\]]PA,!<9R';(IQ''L(%9PIJ$!PNATMVU+0&V&F2TCOL.KL#L4L9
MP;WDH4V:*5;;\->MN<5JK@HPNH%UT4)>6+O2]<&@U^\/0#OM`5<QX*^6V>MJ
MK0[\"IRFU[-;VW*5C"5L29";:'H]5Q%`462H[,13UC*$%UR_+"AP@D?""9F\
M[^07#6)Q#^101'&45/#A:`RXB%1%R-=AKR/M7"'NT;7?"\<D>-(0'SI7O8\@
M@\^\D=+2&ZHB8`5#R-"J*?!@_AQ2-/`(+P:Y%X5+P/^9GXDE)(@1[<(HN'"A
M%!*7A$>8QD@DC?(8<]C*/$4!?26(09P"PD%A*J37:/]Q[**,/6+2GEKD/2@G
M(N-!7V^`HF@0!AHB?A3Z/LXG)'<2[3)XDMCH1+=N0G!4;G(@C'(@+,+`\>,0
M-A_>P[*!T:0>P7YQPYS#YUN^#</Q@^?[^=2%.>49?\Z4%I0(N;*)SVLP[0@?
MAI]<![YGBC%3%H3N<(-WT\P#X)+*Z""KEZX"!V$`6''KT4W"X5H4D25L0]3,
M5"CI>TVHR%S8%$B`M]XH85L>A0AQ6A*-PDT$(+NZP/;A;5DQ60T(&!W&%:K?
MV`6NFQ'!`PJRB#_$>W$%V2`_RR@IWN:`CTC!\N*1'Y+R!@<WY=B'`X*0'N%=
M,%<"E\G&+@*.B><X:HH6->+IM.[\RN<*#[]DUB#3%G?`>F9>9/J7<.Y!ZEXR
MN))Q;T\2I='J]'K-1E>KUYM=-.I:6KMM#[2&T1\V3&O0&^B]<O%^#AM%`DYI
M.3]?:\QH(2=MM",P!D>&,<([,NDD[BWP(I2<0,CAO":7FYC0YOO.C1!C2#B3
MR,\AB@`JC.Z]$9/=2/4DEC8&NG*)24:D\H/V&Z=.C"8-%W]'7L=42&!?483&
M8YR7U$Z0L4!F&KL^/!W-%6!;2C@"F8PX-DZ)9AH:=>+]0$-"!`\#9YX"FJ.D
M*\1B6#U0$F/P7,MWXA"?F1.SA_%J`FQ<U*/+DNG@!>8(!`'LB6Z@'$3)?(8*
M.(S&[(@`@W0&;],VR$2#HGK$7P8:=UW8%[(S&-R;WJ11S$92\\D$-'$3L!]O
MFD[1B%`<8NK!=9F$<'%STR=GF^'<\>FD4=]/4=<G\9I>=0L2+Q[3&#BL@F%,
M\>/&O/66N!>F/Z*LSREL`T0"9>`3@)1.CB$D,811)NF/N7T#^&7GZAN,\B6L
MY2XV4]?;P*54914E2Q$HV8Q]AG6(1SE-%><'J>>;P@?^F+.#FC*DNYN](>$T
M\FZ7)`>\?.D>@\O"5?['"5(GFN>+9<7-#941!L<I9<J71A=7MKB848+K\T6A
MU3=%9!7HJ3P@Y0$3)6+$>1$I^8W)K=AT1V="GL=N''D2-/8J(S=*'`\UM1&H
M1<`J'%4RG`.9(Y&S2RR7#\+"8+B"Q)VR6RSUQRA=")+E$I<T#JS[`0VK@D_`
M6(61N9$:.5EA])IR#LQD/*;39?`IRH4X*M!K.$(Z1RXQ#;D4N1$PLKD2EB%I
MH8+5$";.9D!JI/L*)(AR9,M@1UQ4+(M6(8LQ@$&N`\?(P;=I637E@A.",-H7
M24')<%^V=4K\&Z3;R,72?QS9.<=2,WX%@Z,$[/Z`LR;.+4R)Y$N)LVTBIT>&
MB3X"$M32F%GC45XF'HS63N`X<`DD\T6OB)@-\37'<8X5F:<B\U#@7R1K$68`
M8[SEMQ-#7Z9YT%;O'&%V2+F/8]5[!=NJ9+X=BVFSE_@2N)`+%.!FX.:284[S
M7'`4,A\B*#O8R)VA%R;SN=24WAV^%&?G*!M^&1$S4RU#00?A&,^X=P`PTSLR
M[NU,$GZDRZR;8VPM9ZHR(@.YNL&8'XQ$GG&FG,)1(8=A_"ICG())KN3-`/;E
M%-^5\*.]/P(/>[88W[@J*H0;R`HQ)KVOGSYU+JY@#!*Z9K'[V-$L'H-R@T@2
M_?,]"-XC(+MXYJ`O*_L\0\[(/S]XX^3NG^\-7?^;?'S%N+^Q>*SQMZ<D!&',
MMGC3_%L6PNB[DT($I:F;YO8#&4]?PN*\7#`%$6U,%)FIW'@QL,L'9:X%I(F9
M/*HJ=^%#\<9%O;L@NZ)%%.XV&.0FY]P@L2(K$&_+CQ?O)O8RTW&S.TKPR.P>
M$+,_&CM4"`^J</I$<5KX@P$1>4(P&KLX]BS<2`LFLI#=1X(W9C*.`\C&K%VD
M99%3%UX"W62.9!*Y'"&E9UA81I"-)7EXT2X.3!OS)>#.0LLAW+W"MYT)>!]^
MO_HZ^*B2:U1$J_U,MZ$7C3744.?2P]<7B\\2B>$8.'40)L51N.WS!EWNF6<7
MY>7"'C#Z@@T;N!Y)HC1@0%<*3$D1%-FP.&-%@A4))C^#N(IV!QY_@I(OE]U!
MI??&*3EV6,B,;$Q<3;'KZ14&8=$X;&1T:=TO4J$<F/-LM-RWM%C0E7.3"CD>
ME@0W66!3N9X;YZ:-)?-U/J!:U+Q1V(R8"`JO;U+`)2\*/YQ<W^&\4W(0<,_F
M$C/=<%H8@L,&X6]AE(X;D!HYW^JDU05])U.HXS4LFAB^I-XSE((1B-,M<41X
M`_G>XO>@9><\DAGKN`):"%`!=LK=3J`P29/F%K=<RO'X"(&LG@K[(2DY(Q@K
MC38JUG3=$6SRS6:@)5>[;,V4K'H2`BY::@@=K^Z08,_Q>V9&!V7VU^G-;RK.
M,W4CT-O9(YU?T1[P@3Y\1/F0(QBUK.,F#:$/,C,L4_>X7L-\\4M:34G4NPZW
MJZ"]LT@@Z.0`B9?8F<]D5A9VX$JFHQ4FRX<[#PF9F4,$":6S$+$`#H^`P(0&
M@DTF-S"5'>"VR@RZ9*(6*$.KF*2^SZ;`">`7(E?.L//AF"F!&:XQ@@N.`B=&
M)ASP+6&('#,$C`7OEYDWO%A`)*2"PAX4<N+=N&(A[';@)CAY<0OA<CF]+]AS
M<T-%21#F,[=>.T&`YI\%(S:=%/E`-QR79/CQ`HXOQ/VS$<8I,A2R>\_%N\(3
M(8=-%KF*ZT3"[+C@),CN;I^;"",^MH@Q7N-%N%YE8HO)UD^N!,G:GVV1L0")
M*]T7KD+N7I&6LLY;RQRDR/1D7PP\'Y")L:;TW<P9GG/0&8Y'%A"$,AJEF"DF
MFT;R7`CZ8OY7EZ)"V7'<.;!J%+EOW`RP)4%`'O]=I)-L=Q2_R0"5^W%(\M#F
M\(1T$MS&*^P'(I:B>*@`N+\`S8E9Y<YL9I!:>W!PQ.2+EN\#!2_Q6"`BK5)V
MS.77)WN#AZ'F:$,(NG2)TBJ8V35?9K:NW/D>D6&37&TE.<4^"P)`M[*:4[AD
M0Z;K5E6NO-NIHW7\<81HV<O#K^A*QA\I7%_IAP]*YS8*KT8>JI.Q\NE33_G0
M[UQ]S&D"!K9;?U.5]M_H%</\F\J.D=M=\0;$`Z+0$[&FFK14<WFIB)#22ME:
M.E>%21L&3&H8;%;3_%LV24ZXS%>8K4.>U%@#'YP.UP^SJ4H/#S^,`L\!B8:'
M/!!*7[K<`XILZ+,[QD!XT(I[YY>?&>!ZO_7/27!'CP'SL)P'HQH\`C\4@6<T
M8!]6'3?3XB`TMMG,%E$-CT8K%(,;>C)WE>S0?1:X`<S[Y<,<AGK#-KJVH5D&
MO&8-6EVM;1AMK3%L-WH]L]5J#SNO'3B[*LKAR]?K@=*0$O'K^,[_?+U4>M^N
M8-;!)>#+1>?R^@O\]=OYQ972^=)7KJXO.]>#7\][*!-^^G3>^=(;7&T(A<`D
MQA\WD:_>Y/F+>]ZLO6*SO8+PGT59QX<)"5X?<=);4E(^\3NXDWMVUV@E,.`Z
MO03EI]]26`I**I$S<]/$&\4\`KCO.;<!R!#P36ECI<^+VE11`RF(VLZRHB>;
M"C(H?L`1,J!^E*$Z2S%8A<7!,3&GJ&GCL;`G\ZE<IO>P&U45USR?G1)5(@SO
M@EM9N:.#2!8.0AGGQT`<>1H&(?!D;X1>40\&QALZTP562C?_;W@!\L/H+@C]
M\!8NAV]"JD!B%5M=,&]D>T$]3BQ[%B:HS\'U1HMELKA8+@7<9(L5H21"`@7^
M3*(WCXG,(K4IY(ZR7D"1EQ]`\P++("%OYXT?@KP/W#DA/7CH4+:>\OOY.5YB
M\)]SN'C^/UKW_Z<*R8PM@*^>![R2IB!FQ0EQ%WQ*H7VEL8B.!:D^X?$Z?&_X
MZ<Z=AK,[T`T<"B[XGY1&81C(H)8MWE$FW@102-I:)BO*0A\Z\6$,.BH)IOCH
M;TSW3^38%#Q6?OK*A]_Z'W'+L"MXTV-21>"FL'_Y]A:/XY`9^J*ZA0B+LEV0
M`&\(PNQ4*?HU,Z8#'L<^]U>)H0#$@#YQ3(&L;.-WCHB(),>_*K+6\'WA@D7;
M:"*"X"DA#8,,B%@>PBQ4@SA7$64N)`HLT&D1>4GZ=3D"DYRN9-$*JO(01OY8
M>P"A715ZG'8#](D'R_F!FJ6-L5V<4;@P$ZISC94M'FV[6U"=./0S"KJ=A<PB
MS#%`Q##+#('P;)$E<,:QCLQ(-U@DL@S9,\$>=0DT.TR*0"2[AO=#046'\1YF
MZ!#'!U(01KMA5`4:2\@M2C$<.??,0EB5D`R!F:5&&7G1*)VBS62T3639JZ2)
M?ENM7:W!*E*AJ-0N!3<S)0[TPY5!E<E=%*:W#(4`A%./B(2GH)Y35@F%FI#Y
M"-?>C]);I<."A5@4/:SW(_*=08HA,O!:SX>3Q-2^ZPB/4WH8E9G>=0>XP`.E
M=#)27%XP\$\^1$'?7+J,'*'U9]A5C(,4G@RV;>("#F(4_4:!\GDXQP@#8AP>
ML(6;!VD15@++S5"6SU(3RE"N1,=9NC8^ZY%_G40;GZ9!C*0/8BUG[\1JLA!R
M,H.4#N&<U3B6F5$`4#QH5(X395%N/QGUFHYV29_X[E)TFQB,)02@,0WML+['
M@O(IH$A88G^JUVL-,11*@YG)E,RABU9'-/I+MM=<KHG<VQ3`'4:@`J_$L<R*
M&DM1@GA:8K[,."]?E#(5K4$DE+\`E20:(VT2N>=/K7QO*EI5'EP$2`P`;.G2
MIN5E/+KM%73"Z(="9J5],M[+C`$LBX\(*I.@ELW49^]61/HMRDTJ2T@1KJ"%
M9?(J"-EB\^6(W!2)N0%_^,DT)`00,MEC")2ASX(9-$__1<ZH`"-$\9O5Q-'&
M\#JE.V,2KW-+IQBX/-08/W`\SP0WW$B(L2]"8>$<(+^`75FV2R6AMB#JLZ"`
M`.3>ZY#,\BH(.3EG(U,EF2DIO9';W+D0Q$)RX7&Q4S(QYZ]PDW%NIBNJ8X*A
ME83]='Q?=JKD2+^\?%4VB:M",.:^S3P^E+@PN3LI&Y%Y\F2K]UW!O25.9ZLE
MR*K7@J_#815H$B;8+F1)K;&J2J3`A:@\TIC05DBGC/0D\[8R=5WNU"FD"#D%
M!Q8+^$7T]WVF9,@S8D9\#H8PGQQ5()IPOA`"++N8"FSE<V%8!L]5[\C#2H8_
MY"@8KNY]S#W<W`^%V:RR[^F&9X8!+H0^H[^`,D.H#(DG`K.W<#[ANYRQ\IP-
MP<<%LT)U-DP3X*XD6:#%'5C<QLH2\@3D8O7D/2VJ.>AHE<&SQF?'_4M2P+RS
MPFG'8O[NZ7<1N2Z[[-AJ%D',GV7;HTC!3-7)D>W&Q8VSG.JB![U&N9<1WIQH
M:A8^FSR+LW`5Y"A#H_"R##+2$UN702+47\E3`(OT1*H"$"(FS`2R`RYSQTMN
MTG@1%$]+N5FQ'Z:L2/24[0=]3(]L002+D\#"ZTQ)@>,%GE,21KW(03'&+6$W
M>K*8BX%<4N2=%C*F,*LA$QZYPBSIHQ1''VBW(8)C*=&(H@Z$-K/,TH'E4!K*
M.*<&,9.(M3M;R"M9R)[`724@&[CL<;I2*;A!<WS$(LJD8'HWNP(<8CS+VD?F
MW&3XS'D"BA'<6,`&*1ZSTD'@,$)<(31GV".(3.@V%,S%Y7+A^V71D85B2!2`
MSQ#/096:?(>2L:N@B0.M1RQEAC.KXEKXAF2'H=@R;0/`V@=Q#&O<Y=RFSF*6
M%K(\[B@\:LS=OAD#@1%`5&YG$G$A$P/V43;JN,S=61F1I\N:E2P_")Y"I@WB
M9HB[Z^'&7&UDSR/KHX,*BN^'#WAQ,KMGF,:8//SQ\3R!M4`QI2#/)7_,EA&=
M3P3RV@#0K<,X[58>9CFBBU$.!A6>`?3O=-U;8$RL3.5OKC,NNGG6A'\V>9#H
MQI!+4<M8O+/^E9?Z_F!3;U%U^=%TYRUJ,N^OBFLQ\EC00J$I0<*;$BP!&9`3
M,!*^L!=13@"+7%%_8&0&D31]%2E_%U$"G,`5H.L%S]4S6]U4QX+'8FX\%F2D
M+POUH]BSN4],*Q;_E;CJ*J;;7?*MGUYGCLM5L2UTYQ=\YCLV['QFUX"#/%?J
M-1];(\9'>L2RVJF9NT2H!A/7?75\V[59B6K8S:U>?>FN&J^_5T-MMTK0A[[<
M['8SQE\NZJ"OSU>?V8#0L%1SWUA0OEVW57W?;8E.L#_,2?5HJZ!8GDYW99&>
MJ:_=;BS<+WU3+,-6K4;]()S^"(!CJ$)5K6Z$[?G*B746JN!XV`Y-A56_K@]%
MBH[CL70\VTMD>DD^%>Z!*Q21.\-`-*MF9FXC'.2G9JV9?3&6RO$^N#Z&,0!O
MNXL5D=>\E?]E<RK0/H&W/AUC,49E79(9.LL_,1M42%TL,O7ITL5ZWQC.=8U5
MB2F@7^D$V/N*I55E46;*110F+CF=+EC,$@[<<WV?^1H'P2W\ATIU$G0.E::Q
M$=TH2-[')`V]J>8M>(H)&LO)&#ET,38TCYY<>C(?D[XB*Z#(S&2)=3P<"Z,(
M8_(5>U0S,IQ%GIM@_LA"N+:HWY>7N:.[DP5EB$IVTO-Y7Y6E2&[)61VQ8S][
ME\>?X=.9#]L+BL[M"78]4=DBJ*YBGCH/&_5&J9^DD>Q0YJULG"0#R`P;D81I
M#-#/(NQ@L?W.51&FJV")22`L+3&#ZB@,J$(H^O>3._B6Y<4N!@/+\/`S"E@"
M1'PF*IAL$T)?=)1C.6G^UMD[:85.3.7XV<(]JL\?N(QJ")_PX-W))(Q85<(I
M-2<009P8(9J=!NO@)'C8RA"DA15Z>5JM?(*U#*24'I'7(:>!<0P@IW3B\-K6
M"-H"9C$2*`TI?QTE(7K5L`*?1,U439N*&L:/TK(4M"RB,T(@,`]#H0K!^*M(
M'0<YDW+.%V@T7B3&L8?=NFXPIQ5@K4VI6#W=0.CC5GPJCD+A\3G7G>6\EL7!
M(P]69G=.-'5&E(OA^"*24$0.XN`N9\=XMCEG=XBS+TZ":)L'\<>U=0D)BWMG
M)9LI_TI8G*G91Q:1,E%^,O4\1GRA1XBC_&3EX1YG>15X_-&NVZI1K[.F9;0"
M<;ZX;JQ(AZV!5!:?0V4O<;"S=U*@-<;_@VS0J!G9`E;$LN<T@0%C?DP=EE;$
M&$MG4J@4@9ML2'ND8$6""*N'N2;0F-BMB"!FH4^\[DP>],NR%S`^"%#`'6?!
MOQ$O$6;HM<;?EH9%]K%BX(4`_74!YE(YW72:\OH^TMZEX#=QH0'J3IT_5Q4\
M.7LG=[I+9ZS9`>`1(-(MW\1/I@2]DO"6IT7V$!B>&MFCLK([7+XTJOB>Q?B>
MEE6Z^)[&X>)[3GGJ*H8%XSD,O8HM*N.Y5+%%^X\M.HH]&_NDKBJ>:G4\U5*I
MH"J<JEIS%0*V@EX6J@R^.F'LZ/]KF=96+Y8H!F;GJ"^SU7HC>VW7][S34X]O
M^R056Z`6BYEMY6`$_NR`-[7>,(X-_Y^_:5W7W]JF[>:>S_D$`SI.*CBM@F(%
MQ;)`\=C$_#<<*&FJ1K-QD,OR&&!S*.VA_+`Q5%MO5Q+'VPY]K.!8P;%,<-Q/
M*.Z/HF<?/R]$->1,:/U>]EC'_:4B??-POT*DKYX'^JKXJ5X,^]6E*I)CN36#
M"+8X>Y?U(CA(.&_K">&\2[T@O$"Y\%DEH4X6=<DR?$M:%%V*T&NLB[>5BB(7
M8]*RULL$C,Y5'I>&D5K+8:)>S&-M\=CA>1B"7MT]UO;L719MNR;6EF+XYJ+@
M<8B0PA9N?I+5^@K2D>]BZ-W(&^-O(H0/L)^7K*;`/CQ7%AJCL@_P7WR:GS<%
M"/(#CXMAG)&+`5L8'E;H<,T&895)Z6\-8$=ABEG(+X4G4@DO!@F,$QQ%'F^C
MS2N;?X"?4/$8QE0%&!^D+5&]=_CQ2_R1'205B6;;EZ(,\Q+16!IOH4P[GL7=
MW,<*7R-1CKI8Y:L8Y2IW0A-8(>*KQZ+/IRANM2HJ&,,9BZ72]99*H[@_$.]B
M'C;*6S^OBOG"/GTW%&:)L9\KH@*Q0#F>5@9F8&\B%)]7<.<'@:6\Q.FPLY?J
M&^<-%;<(^$78YDWO"R'9(X`Q%;L=IQA]ZOC%D.\":L`H-UZX$%S*SD/`1\2"
M<@C!B+>WK!^Z$@:NAM'0J\'"R@8K/]DU/;^9,E8NA8PNELC[R92X/)]="B;G
M`=<_62O&):CDIR\7_UTH/+VBG&[V]-FJ\L`<B"S,E`5F8KUM#$P5A60%G#'.
M>)A&B/O3$%OL(+[=B09:@K]('<C6Q:"?+<9C4P=:JH3I\<AAI'R,#U[-3@K(
MEK$3M@?!4D3E0KEAGLG"3%D+>@KQ+;;KS2*@;^:T.48W5'Q4*E./A'<F!2S!
MQO2%;@^\A3J2X$*4)0XK:K_S`%FI>"(/XR^&KTO]QH+Q<M4Z&H35=5X;IFF6
M)"#UNL""J!0R9WN\&0?O9K?8QHY0E1?]8Z4\\TL8V/Y<7-!JSD6+W(Y5423$
MBU@C67'(-:7#6N?11%3PD=4F_,ELZ.CUP,E^DBJ$G[%&9:P2-4;]2E2-5Y!A
ML.#98I7'0F5&&F)>+.@*&[YE<>L,4;A@E_4FET*AS]X52N-3G4:>1R)M:R5U
M9ML_6ZS+B@5`84W(^'ZFPI)98=2UO!L1E"2<Q>,2)4)9/<;%J'M8*R_QZH</
M]""%WA,HEUC?0K@WXUG4JAH;J63;$86,LSE8V#I>?2,LAZI@.VJZ-6XBN2!X
M_L+-G(_!.BW0'#1Y7IJ6L8YL4HF/2U(<*QE>E&&V37?AQ3(!>CPQBB.YFO4Q
MHR>"$"`'>!KQ`IU3+TE$CA;)(.[9FKY\"_-AK'>>VA%&E!GESJB6+C4584D=
M<JL)=2$5B_`X[PR3"P2;*ADO--`I!V_*@N571LAC5+O,!52\J9NRUH8H;#VF
MMZW2VH1*2?+&-DKEXK+TFI4MBRF7]J(ZV=YF66?ORJ1.#F'#6<WJ+-$S;XQ7
MOJ9BSI.:_FDPR&_GOQ^)VMM6%6Q2")Q(N4IXRHNT89*RX*X0K8)0I\!TYIP<
M^KS'T;7K2,?9>7"B<3&_#('R]\YY_RK3L^;%5M]2CA>N`E0WUM$!*^:3KB'G
M#\(@=R"")^$L!&49U+,X<:=<2?GPVU4O_LCN:>J714J6:$LTFU%*H\.D[R"\
M9^<G9V92)Y_"S>NPYJ9C+QYYL,H`M?/$=7A[("]K5`,:J=2XH_A#7AKY6X!*
M;<Q:YB)/#U.$2"!!'HZ%=]3]+9RYRA?1.IO0#/[;(R,%YT]"9NIZF3$FU\$S
MX1>;$<12VX]&;JLZD^HV%UIQ.'B.68G[,%C!OQ[ITBI22+$]A<B712N'BZK\
M#2N=OG#)JR+[3'140GF;9?HQ52A@8@,7Q6B-K`LZ=KTA"9TI+*S<.?6FQ<T_
MTM-6M#M87GNATK/$I]G\@F[P5LPI9TE$X^=0Z/25IS"*"O!B:RL$&3=YP%X:
M<M8Q(]U<^V,*>W[RA?X`F>+GK$C@7'AXFQ/EI,0()!'M=E62ADG*0:$#H?80
MDOC)X,$1:P$[R7@XX3>#W*)D0<W"#6]3SMOQ\]:R9^_D.Y:0)>],(O?/QH1,
M>(_12?;(69Y!^Y2;\Y@MX:(1>,+2@9TLU70-1N3%Y`G07`?!LUKLL,PE&Z-@
M)C<6JV,8M>;9N]T%+B9ND4JY[LUL':U-ZS!K^IF4L5LB(>HYPDG731SM^L[Q
MG3AVIYY39DGELS/GQY=C$S<"9$89M-EE@C)P8[1/WE*CE`M0]@`&\9TW6R&1
MY$VFX'Z`RXR!"G68Z]P,?,::3=T@S)(<9ALE%[RNA/2";'"5_**@C+):1,DL
M)R#>C.Z878#QI`G9I-VL<]A#&/W)JEB0_L@9LFCZ):^*72^.<D'YZT;>?(R9
M7/$.IFH+*1K\M;$[PVN473J%?9.M,?'PMBE>?D^Z^L[>+5U^3[WZ\+)=OOQR
MQ9HWP<H[7)%DMG`/%BW!JV_"1^]!LI.LO@G1"$\6%S(%T05VC49+Q6C*O<1)
MG1X3%"]9@SC6\O.*E^,P=-W6]7*ITWNY'%92&C86`DTW+Y)`PC\RA06&+[/[
M90VZ-`S[M_[Y4AOX,K/@SBSR?'[=KO.0+DAI=,"X3Q(#<X8+RI;K%YQLU+>W
MO[DO\]F[#4Y1QH46VP%3BSHT!_)N@!SI6(-`:F+F4`6@W_K%AL";VP&C5V]#
M0V"^@K7M@,_>K6X(O**V$!=V`82+NA`J.6NT(97!?.9XQ0L2Y)IZ+L2PA3`E
MC]TJ:'A?881216.>W(V!^1W<6L\`X<6/J5SK3*2R@O&XFM7/*-M4EQ4#[.`T
MS1;!7##<#<=4>>%'Z:2W:9S(P1:H7`:CB`Z%P23O/#F1#54R$,ES8-8,63:<
M^6F<]V/-N)DH>3/V(EQ(ICWG6Q6^(K;4VH(K)<,#V<$!*V`[*6@^C"F6Q2/T
M8DH$[GVA)?V2,F&LT!7D<)KU%\4*C<!8U$7,M3H`"8HN>S,(F4-1:)T*-5DL
MZB.`"'1OE>0J0E3[GQ26B[V0^YX#5R\,M<(D2Q<!M1!F5J@R7U?<MIF3A@G2
MTU-N+AAF*Z`40:)\^)_^Y5!N9!BR>XMJZTV`<@,2,H6,/J%.CZY4.*IHE6*"
MNLFB5E!.%0)[G*1CS\V$Y-4-'[DD.P(,]K!;HW+5U1IHZT59<T'#X0J$0R88
MF2!%R:`$V&/"HQ_H#D.8P'MT5X(V<,?\:?_C!"G>S\QMCM`H^.TS#KW`O>$9
M=1M;GQA2U*^3H"NUAQ0\FYI,+'IX602.`.T-<ABA_:S:5#D8:<%<CS)80?<-
M@A`;=/+^@IYHG8DF..KK1[#.P;.RYS3')(8BHC!AC6G?K%=X=N^N:,!-N.T7
M:JKIN56%0(YJ*AY7D<&O,J4N>=7QPA1RCZATMN*X5PU8CN-[^CV8AP"L@5E.
M!TSQ%:I.:]$YV%AI1,NOO,?N+X*Y?&_N<'\]9@9M'=H,NOEZ_`Q2K@,ZR__4
M@//_D+D_(O:%$_WI!7$8+(JVXKHH\T69\VNL-2L3]T*]V9ED19,NR5U`DP$&
MWO_P^7^&Q0MSPW6YX;9C%\%B,56ZY(84J4$$Q6-)%L):;WV<!+V&9^^HOF46
MA$KW0(+QGZBE4JRI\N'7_I?AQ_4*&P(%]K2M]TIE3R_J:^1AE0,2<J?<1GVM
M&#>Z&+HF,6PT>7E)=L6OO#U9N$$>74`Z$"V7U#PNP["@05DD86`_>R>`CFY/
M^!H!1[O?SD'W-.50OCA8P#';*M<@6$=FA&E;,B%E>\U5]14P1>0BE,_.=?EF
MRN^E8)Z!I'`QT4+DF/!RW4W/5=$8;`KJN&QXX[?&RMN&#IK?-_QR0;UIM1[[
M][%WCQ__^^]IK-TZSNP?4JVE>[>3=W7N>_'(#[%?]K7[(^GZX>C/7V`0Y;_%
MBU>C.W><^N[7R1##L=U/B"\@S\,`6%>U$\=N$G=&?Z6`.>-.C'Z$KY,NACP#
M[P!<N^%Q8MGP2-8)?+AT)_]\[X;^]XM!TS3-NJ9I1MW0M?_5=;WU_>JZ_[UN
M-[[C/@VS;GS7WRO>^)_OO?'WNFY8K7K]>[VGZ[UAR]):`]O6K*[=TUKZP-!Z
M;=.V]&;?[G4[W_'%7Q`D'"*'1*(.'.1TBA<)X]%8@YC`Q\*=XL2;$MU.'"]B
MU7!CT4>^!V?$W!M]9,]((87ZHF^XNNCCW8/%,M>4#VT_O7RH85>5-)]86F1S
M=3Y9JOP=,3\?/9SD?^=\AY[.2V<R-J0(/K0@0NZ_>F;)*Q1MKD30&UP.-,/0
M5YHQE([_GSL71H^*XBFWS^^4T7F0DEUP)VSUZH$+694+*<PU2+%&9SD44CRW
MS)%9+P%N'$/1@?_2Z7^O5U?FV1.>/G/?7'Z.RLR`Z(RZW<0C2<W+;E$N?^Y&
MK_X15!-I-2O"?A*=O5[IAN?/^#327BK-L*PDO[BNNTZ5OL)6*%V,Y$!KC!O$
M]-H5]D'Y2MFX,`N9MN=496(?NO/0[-1;`\UN=2W-Z@P'H$4;+<T:#CM6P^S7
MC7KWM77G34;8@NJ\T@M(361$+C-W#,R9HGSV3JC*;TTW-G1]KZTW&L;3=>?F
MX?I?5%-7MHI5[[Y"UX$O*27*AQ/Z)C=<T$VPF,?WXAK/%F^\`@S^Y:)DYHZU
M!1AT[MW(N5TTZ0QXF8I\W3,W6@6]_(&+R!NYKPS+TD`U7\EJ>%Z*,AP+W_=`
MI(A8'GL^Q+4;3=\:(#NBE]D"@$``C+P@]D8+WS,[Y8L"Z>@YZ0;0[X5K/=\6
M=-@5OJ0-/4/D#U2<A2IP?"P5$>_N$X`M2>$/F:]KG]17]?%9L"1QS50)TP2#
M$5A(0+*AXLZ2,E1V,W!;-5J66K?LK5[?7YG_+=_8T2IFU\PWU[S!KAW\4'<J
MU[S?YT[+8R7X$\]\/3KN8ZB&T5;-@S<9V2_W,8S:@2K#EYH4CW'-Q^\ZVXZA
M9`5%CXZE?##4IM%0#;.^*\5]+!T#L6K-H^LS5_&/MR-^C+""@7^4S*)EJHW&
MSNTWRL<J6K7&H86I$I+=,:[Y5,(L3K4UUXN9$BOL/Y$UOQ7E8%MK:'TW><!_
MO2"[Y\H/+=72&VK+/HQT_B1`[0*>'6609LT\C`QR1)ACU\S#6&=?$48[HD_#
M5BUSS_:R$Q2N3JP#625>56M^"[83+`'.RPNSI'&6Q8Y?OWGA2K=LM5TWRW]/
MOJIP953"U:/"E7$$2',8X<I26U8)V@V?@A[,G604#?6V637HP+H.K/HP039E
M9=5VK74$AH$#8TY-/TQH1/E9M66H>G-G+_8NK'K[/L_L'_IZ0TKAKCE_Q1S"
MP63":JJ>!Z-PZEX[/RZ=Q+UT1V$P\GR/QNPD0Q<;.OI8<3Y-PFA>>'CW),(T
M\-A;LS1RWRMC=T3=82E^=R'!L-%L6L-FQ]:L1J.A68->0^M81D>S;+W>[0S-
M@6%B<1[C_2]ZK6[E\'J!_2TD7:X$NU0!*>[.\V<N6&U&ZH#`3V481A/7H_::
MY\$%%7@6*1<\T4)DJE#ZR0M`UXM#RS2:W[]=];_/W.A[3#E"F^'=[;2L;J/?
MT[IVW]0L8]C4VE:OJ5G];J_1;K0'S:'YO:'KQG?K_2_H%Y50])4A],3S63<Y
M_>MWK)H4W%ZR7H,OE1W;:?2LNM7N:ZU^8PC`[`RT=J?;UZSVT.A:G59_V+4`
M>9OO?\&":I=7WV+658+IJ5EAIG\HRE=LI$NM7;&=+&(Q:K>LIQ5FLU(;S8>0
M/2./`H^SJAOTLOR*:/E`33JP8FWM"4>Y/3"?F+I,*-I)D[LPP@Y!5/=/XFW8
M[!S0J(`'E[BHET]M[O=:AJG;+<UL='O`;P9=K6O8;:W9:@\;3:O9;;]^:C-F
M#PN!F?4Q002A3B<L/YB2FP%P6-N-&J)2&O-B%U3*<88APJ?ZGJJ\YY?->[8:
M3\][;ATN`[B:>B]3'WVVWNJDRKSDSN,9E?;&1#1A&_@J\REJ-3#(K06TLIO]
MJ5FEA,C>]K]_G%RE7VTP-STZ6\;OUT+[9^5?Y_WKWV`L`Q3D%76H29)`P4C(
M%\JJ3/"]Q6(^'VFVJ1V0+V)-$8'EX@)8OCB4$B=)?EAXAE=?SA]*0FFFV:HV
MP\=.H@?(I__D34Z-T;T(SFYXX`G("[+QP@\5XJY'W(U,LO37SYX/:0/LGSWS
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M[,H;^URN9Z-A^S&N9QBU=OOHV%[=;JAUZ\VQ`+)/O+$]FW93K=MO)0BE5;-;
MQ\#V2L/D#!-%@4>YG%6SCT^X,U6];:K-X[/F/%^%;;TY%=90]593U8_OL'=M
M+F7MO8+2J13+S?/.7JD-P;,G?#I!5/"KX%?![UC@=QC=>>MS](^GCN`1=6(X
M+*#>0N.!9]L'CJ><Z?,`5=K"IJ<F<KY><X;GSUC.2[^"8`7!"H+[$CVWK_Q;
M6/)2)<4?Q4J*^+E0%+(E,>T->WEZ3>%G%^,L%O^\B,*9&R5S?"_I!./!7ZDW
MP]*A+U^\<]AN#(:&J6NFWC0T:S!L:=V^W=0:YL!LVF:OW^_IVQ;O)"#;J#`4
M++W6W[8T%6\J_BG.38"&M2P1<$%PQ!Y6<66U6O-RGQ^\`+X)TQB>CS\^7I93
M5-Q\?%'FT\MRKJVS^1B`%H$AE=;<MD)GRUHJT"DH;.>JG,WFTZMR;GCEI;Y?
M-[5]T/J4VQQNJUAK[R7TBR?=3/NNQKBR8"ZMY.:E-*SJ#!ZI1I6U!'DQD._T
MQBMLT]PG9KUL4:@G</[G1:HL^6"?[L9=<S-_<N!2<K`Y0'XO[R29'L"-55=-
M?<\>^Y<BJUWK_ZCM?;=F?S;GE;'IX.@\3*.`6BR0I#GQ?E"[A5='Z&<;$^U#
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M4^:YIQ3#4<6^O`3??5[I%A8"8NXW;**_2:!6W!]8QL55'IQ8^4FOV<K4\WW\
M81)&"OH+51@"'6KT*OQAU)3S@+Y1*=X""\$XP5P9>_$LC$&`#R<X4",;R`M@
MA(GW`WYRXMA-8N7!2^[P[Q!7A5^O$__94!:\SP>K*=?2E/!@>!M@Q1G%P0>-
M;$X_!*TBQ/`/%UY^B+S$U<+)A,>(P';92FH%;#C;)3II1;11,4Z)BN/<+);,
MZ401%L#!$;KS_)$+9XY?=1Z<:,QJY\1?TR1.`/9></LO%YFW.^[<NY%SZUZZ
M4\<+X/L>7!B1,TI2Q[]VHZGY8N%.;;UIU>UA4S,'1DNSFCU#ZU@]6VN:=D.W
MZH-NJ]V%AW7CN_G^EPO[C_IGJR^5#7K]G2^`/JM;=)EAROD89O$F'HQ%*-`9
MP4E&\"D8?_*<&\_W$L^-X;=TZHZ)JE\^BJS5,HRVWM<UJSX<:-:PW]/:IFUI
M5FM@-QIVWZIW[&VCR#9Q@"V9R-K8+<%!K@MA53RL*9U.':SV%!,7<./$FQ(!
M3QPO0JZ=NB(B*W`3&(33OL/A#9_%[SV@'QRX#^\_.6AK4XQ6<8?ZTX.VG@C/
MM3%>6T=JV:VE2"TIWDO<*SL';;4VA$&MBYQJOV[DU,O&5IQ`!YR>$]]E$8^P
MC-T]<^57TIJ'].,>7=N0SF@4IH`-*`>Y@!HH:Y8=,9YK%MQWE[A3[Z<EQ!]B
MGUX`XM6MAW^RV_GDT<=06U77R:?@RZ]A.'X`I>H-8$:C575RV<K&$MW>?-!5
M^+^/KV=.?XDYGV;9.4;>7]](R]=AXOB+>MC)$W9=;>P[*.RT6'[?G;@1:NB)
M\T/QN4UD?O)X\J%I[1P&_O&TV<J6:LC,F9-823;FT2A*`8?\W*9V^AC4/AP"
M57+#L<L-Y9(2)+I%B0&-X:=/OZW=0ZK?]`WPQ4V.3JS<.9>J:93`@'!D[/[U
M_/\O,&D1_DL^_$WM45[$S;C.ASE,,0WMLQ=XTW1Z"<,[/G>:QL,P^CIS(R?Q
M@EO*Y8GWY+EL=%L-NVXTM4ZO;VF69=A:QVRU--OH#PW=,@RS-5SKN<2_V2:4
M*=L%BHRT`27%EC&T3.[.5<(;.'CR&`-724@O69%`3B$*+U<"HO(F/L6;:#W=
MFVCH!RW$D%TF.PEC&UC[ALMVBPHO"YGP!:&5)\/_K/SKO'_]VS\4RZ@U5A1\
M&7KQ"*CF#]>)&)K?9.#96PK?ZCS^5:O?.94_8VOT3:3\G:^`N-S"/I\I(E9^
MZ(U"'C!::[_H]')26J-R\CSQ:!NO?K3/U=9L>\]5&TY=:X-3MX_OU%M'<>HE
M.N/FT9UQ4S^*,*!24W;K^$Z]7MW93SCCZSLW<IT)",Q'=])6NP3^V".SH%4.
MDU+QWVU<*(LVKMWHU"^]2;RNMNR=,];?+$&?BDG\;$/2U(O8KM>9P_-6Y'+J
MT&`Z\\.YZU+W\8LT&MW!$YBT];OCIRS_"&WN+,%H3T;RNCWLF'J]I0V[O:%F
M=>J&UAFVT6;>:=1-N]UI]LW73N]9F60HR1+*`\^PTAR68K4VHR>F9N_*C,-V
MS$SW,(J4#,@1"V#4_CE6!E<7%\HXC=`@3QF%Q7Q"F#IRE9^,FM7$7,.?S%K#
MH!_A*]M4%9AMYHX2[][UYZIRP^:<L>0^YIMFIZEX(M^OZSNC/S5`E="'E=Z+
MDU>FX=CU:X7MYBNM_\QW?O:N,&J*\V$R)`<(I4"ADV$ISXGV*>`"HQ"+C!4'
MZPC&W"D1OS4?Q(K:TR_I@VAN\">L\T%L<%N\U/=O<>K].UZ>KGP\Z3)_$7>&
MH6_T9Z!_!OT*[OALC4>3EK8GI\9;/90CKHK]TCM]X<+8)=ZIL4]*JMR#"SKO
MI1?_J4TBE[+*0*"+$P5D^AT3$@]HG%I4N/_UV_GU0+NZZ/0`9I+BJM?TAJ;7
MN.;[%%5[E1K\MX/1XDL#A%MQ*X#L'T-.RZ`]^(%:'J4,3$BE"DD!HQ"N.4A-
M\<>CXR5ZK:&9M3V[-<I"%M5F7WJSQV\FWY+BQ]Z]-W9!FII[KD\%I&(TWQT?
MO9_@;5?MZ4U>PO>A[R3/2/P\[*UK@-RU[VS^TB!SK5W7C%K],"7:#W&ZK5<X
MW>=4><S:9@:;>V:^F&]GH6U=D5HW>.5>W(56]-4-'2_"=UR>`E-(??GL.E@T
M<?PUN'1':83.(7C@2QA$XB,LS-N7BZZK-P=UNVYJ#;/1T"R]T=:ZP]Y0:_7T
M=M>P=+MCM$OGHI,\3E,&/98[`_+2"(N$207"5,6Y=SP?@:=-PDB+X6L8)4;8
M\J1.0&>$)@`Z:Z(Z)C<LEL^4LS\C5_&R;"9TCB4+23:^>^_ZK*HG<\')*[WS
M8%#`H3DJ<N0E?*O9.(:N[]459C>>[@JK'\X?54U=>>%6O?LR7CAKAUZTV0?A
M$)+RC?`NRQ^@6RW_^%GBQK2GRGWWBJX>BK9[6;"7?].?\,[-E_'"OJXCV;_R
MVL[,<FQ;XEK[Y#:5BW.QT!&I,<MBZ]X-(H=ZKEISM>:C,W`V-M+PYS!PY\K4
MB?YT$V62@A[ZZN2\8YB]K;;KUE:O[L_&=VQ[W?,.5\V^W8X77ER&0-&0D04I
M6R^ZUD-@Q=N`V?&[;C>ST6^UJYIR&]Z[48!:KQ+/PB`.L6@H&@J3N3)V;Q+)
MW/CZ,M,SW0R&::AF^]#1#"^)K2],8B?!C"I,.5U,.<&<P9-*`JZ@6$&Q@N(I
M0?'8+`5;)/'O)K?ZI<_9-\R6:IJ',2>4'SJ',[64'S:'%'=?"3JO8J*HI.*#
MWV=EO$,K*%90K*!X2E`\?E/P9J^X%-.[HVO\%86>0SY7[;':XZ'7?MP*^V:?
M5.^Q:/;R][#;52=3]U[P_`UH9`=W&E<P/G48EX#&=[H$*HM`I8554*R@6$&Q
ML@B\=<]9)6M7<F`%X_+#N`0T_A9D[:.J8U]B":>"XZ&W5,'QA.&XR'F+*[ZC
M;@#_?&_8Z]FK](Q49V#="U7B_HN48:`$[ZH,0SE.LRK#4)5AJ,HPK#CVO99A
M.$;[4%5'H5ISM>93#K8H01V%)YJQEJT\#;55WW.GX6K7S]_UF\A6K4!6U5AX
M:S46&DW5LBI65#:ZJA"E0I078\!'YLTZJ3B3"HH5%"LHGA(4C\V&\(;CQ)IU
MU6RU#B*SE!\X!S1"E!\X!Y1V7PDX1U]@X2V(PB<6`%+!L8)C!<?3@^.NC=K8
M/_3U4H>TEV]<5FR,]G^I$R5NY,^'7N`$(\_QSX-)&$TI77D/S<ZZ/=TP!GVM
M;MDMS>H/NUK+-"S-'#9Z]7J_8[2,YJLW.UOH64?!$U^^7@\4HR[=X/6?E?_[
MUKF\'EQ^^D,9GG_I?.F==SXI_<YU1_GP[4OG6__\>M!GG:'S^(N=>HH]<0/V
M8\W:LO9HO.L8(!)\&25WRLB-$L<+E#1PTK&'W3;_$@@!+T\$3BAC)W'P%6JI
M1M&'XL%8<8,QO+<R@$Y!N-7X,O(YO!S%<#%\+3<NK%*Y<V+XRPV46>3.''0Q
MA-3(#0:)G:FKW"!&*_`0KF35@-A-S@M&?CK&CG&^KSCC?Z=Q0J%X,$@`ZXQC
M)YHK28ASQ.C/P"9Q_IR&7+VV.S=RO:"&^X`QPAGE\P-`X?W49]"$B><"*-2I
M+@@3&&WLC>#1>VHC+CT-H^#SDS0!`E9@/"\<UY2.ST$-6Z3^=;Q!G>+^&+FS
M!)\#4IQ.<6W8,!%&P<=K2ZA6^O9RF7A:9.M\@(;Y]/YQQN$ZJ5535U-74S_K
M^Q,-:_XOG?[W$A'JHA/@*P:W'FJ?+QS$6^'6(S'$__?:P>('V>1KAX8?9).G
MP2(>V:3U%C99T>2I;+*BR;W<V26/J-R<>'+IWKM!>H!(R1T]@99JF_6M7MU?
MV-M^=UB&IH;[W6%#;>K-D]ZAK;;L0P=G[G>'==6T3IL.+;71/&TZM-3VB=-A
M"WBIL=\='EO\V69Q8/!CY@;Q\8@#AJ$VS,.$E+W:%DW5TLW3WJ(!]Z5]VEML
MJ/J)7YB&#K1XXJ>HJW7CQ-F-#M+Y:<NNP%'K^IX+5IZZW>"+FRA^&!^-H/`!
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M@C?Q1@Y,/1J%*;4;O(#Q1IX;[R-M9UBWNGU#:PY,$R`YK&L=NZ]KG99M-HU^
MJPWOOGK:CKDV;:>8M?/U\M?.E_/_U[D^__I%Z7SI*U??/L-`?RA?A\K5^:]?
MSH?GO<Z7:QBFT^M]_?;E^OS+K\K%UT_GO?/!%9$(#;TDZ&&"UX^;R%=O\MRN
M/>_97K%E_,/#/ZX`/YUI2.OTLA6O7OLA4I'X^I2N%UX!F@8C-U:5\V!44SY@
MX@T2&Z;$A)%X\J/RX&`>S"B,9F$$=#"&42@MQE6(+C"GIN_ZS@.FVX2!\C]I
M(-7@-DU5,=KM!LL(PJR;41I3/A$,@V,@Q3G1Z$Y5QEA$-YQ1;3-\&G-LW`CI
MCU,KSA2$\!![%=BMFR;>"*"(Z[H%HJ,4H#28@H(P=3'IQU<"UQW'-;&;'"?;
M/V,BTJT;X!)N4S_/6Z+OIN&82)N^3=S171#ZX>U<F<&#R(=A+_"Z&R`C'RLW
M+&W)#6X]F`]S_G"MCC+R'5!3X$]881"/(F]&XTV<41)&.,"?<&T$F$CU'X`P
MIGK=@DK3_]+1;C!I"8:916'B>D&L?/A_PXOX8TVY@,_`:!P$@C.;^7R--,NJ
M3<J+YQE9!4B'$QCH+@4DDF$*2`$[Q8.XC;Q1ZE."%`+'#>Z`)[KYJS/@PE-G
M1&\!N/EZ\;_C=(0KRV"O/'B^#\#^*_5PL/'8PY]I(WF.&Z!#F$:`E9@9!A@P
M\UU`,03N`GK`6RL1Q$MB,7G,-XQP!.AAWEBVO^5LK7VRR$?)$2@#DT5A;_Y<
M>0BC/PF%`#.4(,6$/MR9'P:W&L@$4QD4>`)1^&\7=YO<.0D#LA?<A_X](.0/
M3&K#YP"T.2)0"EWV'@PQ=>;9P<0P>`2/SX$L8SKS.+V)$X>0CD8$S$1\*!P1
M8B,\"ICB@8SB^G,:\P83#N-TA-E^D]1G\PH>@PA&8[#3EW+Z$)T?O.1.<>X=
MSZ<LNI$3W^7(H;)TN)M0/,T00C""D3(#Z2EPH_C.F\6L'*V:<1KE%H@Q85N;
M1.&491S&<2H6,5$0%`EQP86:BCDRW[B^!Y#B4$>LRQ:+J`G+5=FB<2P0&ETQ
M)9R-RS,AD?")>Z[(VH1!\.9403:%<V?@0."/,-4RXH&+;/U%6*@Y&!`Y9$#@
M]`M04!G"W"!!PDJ1G^.)I+A00@WI2&"?ONO$"6PY"M/;.UQ@8X&\D=WB")'C
MQ90N*N%.3O(`F9E'.,GGPL=@>N(JTH2"S-=R@<=Y`":^=I8G1NS$W%#<>(9D
MQ.JC*4P\PDQ/^@Y6R!)?.=JJB!4`"<<'=#Z?Y&`C+,MR3K-!Z7EOP@=AP\,2
M9X*-TWM([8+OX0AI,''NX4#I_<+T1=Y^D\9PX<3L9'E3:UPQAQ(!0N+_#)X+
MK##GE@]AZH\1(LC2W7%-&:81W@G3,()E(,G&@,<QX_O287)JR:F$\Q/,LT51
M8>SY*3O016`6=Q,G("[?A?X8\%5E6PIX55-^00"8<&A^CQ%N`"$0-1,9PIP)
MW%>)(LDRJR%6,O[OC(CYCI6>"]((""!"*!.?/R)R?@6QH<`GI.3N;P&`C?8-
M](!2!-S<+MW3:C9+>(-YYM(LB^)04D0+8!%3.(G\%NT-+@>:8>A9%GH2N4Z2
M"P,=_S]W+@`C*@)]#+P`]#3E0Z?_D?-+^;[S\)Z[N,,G3#Q3WPM(EH"C=/R<
MOSA^+`%*),U[H%SY/K#%E$D?P#T23)LG73X&C/!9DCA#/4"?($7Q*Q5"6J?S
M.\,U,6`2_O!&1"]G++&;W8'.Q$WF3`2:H&`XFO-\?.3`*^')I*JE#0&=W7G`
M?XE=<G&*C?MCAO^AE/I<L&.`72G994H'K/K>NY>4CB5Q1Z6+`"4YA^78A\2=
MZ2P2!_"%D<P-L.W@%4EC5=&';%=4-@./2-;*2ZM8,8D*JR5DUU`NU<:9`0&1
M?122*0=Y)E[K7`T!F0M.AMT\@-].9E&`88$"O1FR7BZD(8<-'&8(`80E">Y/
M$/=B)GWQ^P!$FNF,,UX\:&<R<3EO!%Q*`R(/4.I8\0:NCZU<=(:7HQ%CJK@L
MN.90(.HPTN-E%8@GXS4"ZM,$N!`7L`#=\M4Q,7"4V5Y@^FQ6DN(D8#&%1<Q-
M:\X5'29/X<T%MP8`#W0I4D]1FO#&GA-Y*"H*XJ2G?P7IU?E+^>1-L68%4/X$
M*T6`+#>%%8B#@Y,@)1=^XOM5;AP?"96#`K4YA[2;U[Q(-E.+$`7@VKOA>XE+
M32U"#^`'BUC`;Q5B\K$GCB,[0+PHX.%HS"5U$HISTQO:(^!THS$"05+?/W2N
M>A^5ZW`&MUI+;ZB*@!431#)H`2Y?]?+G$&%!`O/B.S>6:9!)T42'HIX)+CQR
M1^%MX/T'%X*/3*DN$%T]>%%B;4O">6_,Y5N&1D`D$2%M$N9D1F6&LKM.5?R\
MW!`C:V003#Z"-X,PT-#(&`$1X'R$N+#X6-AILDN3LWJZ<&]R((QR("S"@"Y=
MN%;O/:SD<IMZ!/O%#7/M+]_R;1B.Z8++IB[,*<_X<\;44%T!&1@%`7Q>@VE1
M<<Q5%IQ#5@`25,.$2._]!X&""C$6DD$[?8J01&@`M_!0EA=P93P0N!$9KR1L
M0]3,6*STO49BA#MFZF^<(0%(FZF0)48A0IR61*,PX,`[,;L44"?.U,W5@&`2
M0,QEY+$+7#$C@@?DX(@_"2C?Q.*S07Z645*\S0$?D3K`K-;%NCIT):0Q%@\B
M98@K;BX"SLD5>A0K48,;+]P.+KM,PDEA/PO(]`1>\Z/(:_#S`O/+RR6NKQ:V
M+UZF;V*]/53S$4+TQR#7]TO+?L7]*?@1J]%T!R(S(*GOP0Z*=HJ<++G`$H)X
M[06D1R="Z2-4`)U#F0(ONHM1[_5)-V7D)L9`L=EE0LN-NV0BJ2D9-)>L)[3:
MF'!N#')+S`P4P%BF<O.A?-V9R*!N:IM!E%8P\JC*MROE.B)FMM15@UL=N#$<
MY(+@3Z(V-E-)U,I.3/*^H,XU]VFN&**)G_,/8@+`)G%3B!O*3WJMKDR!E^/;
MR,4#N!A'4?@@-JW@[>NO4TXM47F,CA.U>QR$C\#FQ1L=>7><Z>\N._VRR%:?
M";/(''15;*]2:N)&YP-(03`*RLC3?!,R-DMV2PTN!PU-/)SWLY-A;Q>LEDDF
MRX_ER_;&89X=Y:\T9'XB3I(@/*'H#`PAO($+YYX6D9'K+&5"O>-/X0I5`.<"
M\B40!N*%K3)!+Z'R=4"6[*I'5")1P_&8J9!BPMQ,:>`Z#2!I.DW9[1VB?8/L
MB9%[!_<X5H1#S];4+0G=7J\S6Q7`CT;Z].;?I,N!T,@+UY&YUX-WO8CX7.3>
M>^Y#T>2>224(,/EAX,P@&8*0X1+,@.FAT<(5`J1TR-R\*B^(U0Q,2*>#`Z3B
M@+B66/EW.KYE'`58/4%?`[$CT$"_0_X9S8O+RZ^C>]#=PI1$:^8K(SNBB^93
MD(G0'G[GTF&BJ5EL:N6>5+HBA`$+%PF7R2V@$_)&E`"9Z27A\B2SS2SL&:XM
MNJW<@-UHN(?U)L8<"&I19B+A*&!F4YHV`+&6>71`U(UGY,3A+)O!UW55H12L
M,YJBL,]MX9(!F/AL/@[!@\HCHHQ-Z)+M/T[1GN7Q_3M8I3*KI(B&>]!Z'.9S
M0&-K-,]-!9R""48UY5(0YA)!XFY7\1B9#46N3+><4C]P<?OCWQF5JOQX"+T$
M-L`+*'RRLT4@HN+'N4BF`DX!6\)Q6>X3K">K_$ZHM=2CNHPW"KN^HXC,/L)T
MA#B2JP-PY*`+364YC1M8\2+G%\JB1*?F1AW`+M>[9PZ/[,N9,Z>K@ODMX.LH
MA=,N*,,SH)P?=!7)!#M.A>/&PPCA,$KH,DHR+][GU9<AB79D2R`&(FOK,$!A
M8F3""1$&DV]AHE678BS*E3(;1T1F6%=X0G(C_;*E>A6U$R_+"%I:>6Y`'#F!
M+"CC2)(TB]R0\U:`Q[_#*!-EF>LPEY/17P>CC@1<9"[F<2TT=]2BZJ",0'KT
ML%F`0QZMLE#;!7<*T#90.R/C06F)K;!<5RQW`>'PCE&Y>I4+.,050;:!8\KN
M&"!7P+C_<.-.7_X9G3"./^+"4<9$N2,=_2<:"0&,>>;B'86Z9+B>QNXD]8$X
M[H4.R.P?;%1N<OF0(RC3$<GM#^(711E\K"E#TA9A!KRYF"`3`2Y..9N0-K%N
MV<5%([VO6#;Q`A9.0>*D6/O$5;CMD19!?EJAN.3"$PI4L?`NKSHDY(FY!((6
M2A"H,)Y"08=]0B(PB"7`7I@CP(O@[)!>1O0%E2EVN5>&<8TBUR4Q.6!`E5W8
M_&Y&?E86JN.UE4`L(.FLU+Z;RT(X16YN'"7>O7!HCUUF"UL.,N'VSYR3LVND
M&)\2N;))D%?.1EW(XSY_%LB#9M8Q80WY8C$N!>6U.'5(67'Q=[2_,G\.8$(>
M$`L#N#^`Z\<828?4"*(:UO$.1^1I'3-AE%0Q"L3S?B!91)D<17>ON*A#<JD*
M@=+#V\F)0WQF3@;H",,#Q!$SVJ9[#^!'Q"\9;'V8,"`BE4"4S&>HXOF9+S]6
MTAF\3=N(,:X6A8>(OPQWN\N"?F+4:[SI31K%@C=DDPEHXB902YBF4]23BD-,
M/6":20A<;<:"AKDI-YP[/K-B!;P>.%WX].J"6Y?'2[!@B)(HCKFI`B.P9B#6
M#'SF'91"ILF+$4:9[#$.9\(DU+GZ!J-\"6M2Y*:NMS4,0%I%R1E`K'S&/L,Z
M'@$EWBK,_P'F4?C`'W-VP-@_#VJ2<9K%6*(W`[4"4B.!Q;K*_SA!"MKCHJW)
M4'ET`7<;3OG2Z%[,%L?5,M?GBX+MQRDBJT!/Y0$I;^PQ8L1Y25EA5GS@`AZW
M5^2.)Q;?4Y@$KQ\14X",'`0U8!6.'$V1Z;!+&K8T&*X`U.7<L7KCRJH/(J\T
M#JP;;6H9GT`OM#PRU]R0DQ5&KRGG01;2HW)=7O95X:BH&XZXG`'WD;AV-P%&
MOGQA&9)<+%B-%.Z`TKA`@BA'M@QVQ$7%LIBC5W*M``:YSNA.@&_3LFH@9#%"
MX/!8(`4EP_WD;H7Q9(P>M\C%P"V.[)QCJ1F_@L'1*^?^@+,FSLW'1R;$#)UL
MF]S@PH-5`,'3V.5Z^XJPEDRJXA0L9D-\S7&<8P4*!(SE9_H^_$7^'\(,8(RW
M_';*PM/$5N\<H0BE%("P^KV"\08I-9,)^;392WP)W!,`%.!FX.;>JISFN>E1
M^*$00=G!LE@%OA[JU-#CHI0X1SG(@!%Q9ERF6%IA9<$#(0/-<7%O%JNPFG5S
MC*U),4`2(@.YL@8A4B`%Q1QF#G/6#4/$0`G&*9CD2MX,8/_'SO`C<6R=AVV]
M?Z\,+36>U$/C;T_)6\-4:O&FF3?O\-U)H=F>J9OF]@,93U_"XKQ<,`41C47K
M9&$`>#&PRP=EK@6DB9D\JBIWW#J<?<^\2#+-@UZ6DMYWDW/N,;-]BK?EQXMW
M$WN9^=VS.TKPR.P>$+,_6J]F*3NOPND3Q.DL#R7@?F!A_1[QX(>UZ(9!$G@?
M"=Z8R3@.(!N+P"$M"P:Y\^`ET$WF2":1RQ%2>H9;VK.Q0-,2PZ&E#I@VFLN%
M43LDIT]!$?SP^]77P4<5K_#,QOXSW89>--900YU+#U]?+#Y+)(9CX-2%P/6?
MR<W/HCO@5LUN5I*7"WOX,+BZ8,,&KD>2*`T8T)4"4^+0^;`X8T6"%0DF/XNH
M2U?8XH3L#BJ]-T[)U,R->%*`TVJ*74^O,$AN(V1&]OM%*I3=0_M`RQ>5%@NZ
M<FY2(3O\DN`F"VPJUW/CW+2Q%%*7#Z@6-6\4-B,F@L+KFQ1P*;*3'TZN[W#>
M>98'+7)?RQ(SW7!:F*#%!N%OU91_H<4,U<CY5B>]D%23*]3Q&A9-#%]2[QE*
MP0C$Z98X(KR!?&_Q>TH8$CR2&>NX`BH6DJ*_%-@I#X4%A4F:-+>XY5*.QT<(
M9/54V`])R1G!6&FT4;&FZXY@DV\V`RV+U9:LF9)53T+`14L-H>/5'1+L.7[/
M(@)!F?UU>O.;BO-,L;P!?Z3S*]H#/M"'CR@?<@1#I#*Y24/H@ZG(=,'IF5YS
M]FZE5E,2]2Y//_/G10+A.9+$SGR>.$>.4%<R':TP63(W.#>'"!)*9R%B`1P>
M`8$)#02;3&Y@*CO`;949=,E$+5"&5C%)?9]-@1.X]R(%F$4"9,,Q4P(S7&>Y
M?_=(:VG`MX1>$V8(&`O>+S-O+RXB$E)!80]YQB);"+L=/!'JEB].$J8V15!(
MAHJ2(,QG;KUV@@#-/PM&;#HIBLO><%R2X<<+.+X0]\]&&%/0!MF]YWE"*?-$
MY-ZZ1:[B.I$P.RXX";*[6[@B(SXVQ[!U7H0U\4EHZR=7@F3MS[;(6(#$E>X+
M5R%WKTA+61=!SH*VD>G)OAAX/B`3(SI,LP#]G(/RCJ5L%C)*,5-,-HWDN1#T
M10,0:8_Y<=PY]RYWX&6`+0D"KDPW6\J?1H4F\^.0Y*&A.U<Z"6[C%?8#D=]1
M/%0`W%^`YL2L\@![9I!:>W!PQ!0?+]\'>78M?J!5RHZY_/ID;]`#,MIX\:I+
M5')FY\O,UI4G!+`()G*UE>04^RPQ@:619Q0NV9#INE65*^]VZF@=?QPA6O;R
M@!"ZDO''CP3_?OB@=&ZCK'"(\NE33_G0[UQ]S&D"!K9;?U.5]M_H%</\F\J.
MD=M=\0;$`Z)T&+&FFK14<WFIB)#22ME:.E>%21L&3&H8;%;3_%LV24ZXS%>8
MK4.>U%@#'YP.UP^SJ4H/#S^,`L\!B8:G81!*7[K<`XILZ#/6'<&HB0^]\\O/
M#'"]W_KG)+BCQX!Y6'AV+_Q0!)[1@'U8==Q,BX/0V&8S;R/3XE)F!WV)'11:
M-Y0SQ&#C#83<@[.2,4M:XIPD>Y&S4OG5C/?(B1%`)R/A0V%O:CD9Y7H#>H?N
M7'+SX/Q<,<1H6Q'A1C^HZ.6F/$H>A">H`X,2PB!P??$<Y7\YI$[XO&H(JF/L
M9W0OGKV3'(QK^7JV)^'#9>O+MX`U1XKYU"I9&<:.Y%%:+>@EK"K8&45:8&89
M#VVC3V.J:,+R9I4'%U/7<EZ004LLK_;XD8HCY!F_@3MBCE260)/++F&DH2>1
M4GZS>)/U^-#C:69G68I77N'!$^5(J(9$XK%X7"]8"^XSG@+.11'`#ZZIW;NB
M*SJ:9=:NIB2Q1E=8.$*C4G"*7"ZNM-Q`EGE9TF264B@)P/E&!/29N=AG6=*X
M9Z;?"`D;:W"->;`27E\\$<2=SOQP[O(I&(<(H[@8&2\>8@5UN;^:W3(B)2=.
MTM&?W)_^X?+J6_R1,X6%=T6F5^$N1:H<B.>H=)]RP9^#$2Y\)R`[,AJ2,Z5M
M94`M*H],=$/UD>D/^#/:RT7\A`P<#A2T0;,H0E?RC=\SEI#[R$5``+[$[8;.
MRG#(DLAXUV%NF*<-"1"@@PTWH2[;EYA0V_4=@-'5Z"ZDFB[,GXQF*JJR$HY=
M*M<$8*._\_12GK"#-P;RH#BO2H1AE&K^\3Y$"QSIAH3:7ORG-L'83Y&?K*!?
MCD=94G(J#2REMY!:QRNR"764%ZG*2R_2Q>CX<RP6@0]CSHG(#N:L#NV#GB\'
M!Z`)45XVOUWE):.*#%B!^AI`90J7H)S`NR8Z&^`%I$67$U8'8<#/=TZ.R`6S
MA/*M=E7+`K1AC+GG^F,LCT+922+1=B%IF5$`53\*X#T<5R1)(4'*>Y,*060E
M?8I8X16R_\[R2`[D-Q.75_M:N0+&M.X]"EMA145R*,/JI<).C,8HVL1A<2WR
MZ%*]"*+!%14C"DB\`&FR+//'Z8)W-4';(O1&WDJ6W59@%3++Y5"D8)Z`QQ>Q
M57&&DEVT&;!A"3AG66[%\SSQO<.BL`L5.<\#[8(GV,N2#&H[N8!0VAOT?"FK
M7[IKMJ@=0"(8":YPKN<7EP0:_/^^NA!FQK/7O(#GX[N:3TR!LE[Y=<%+E'G<
M27(#DX6!;""%-888=B^;#ABP"\+O!+",I.6)".P+"@]X<58-C>="%8QU%.K+
M"$R\S6M;AM&<Y<K<LZ)K/'7+8;(PA;-BK1U>'TI=7#,'\4,>@.A.21HO0(0F
MI4?((7'C2C?N0B!@KKN>O5N72T#\!OXU"[V`:E8@Y\E#]R2@G[V3/(=K]`H&
MVFQG+K]I"N&$BV><F0B2.Q:'[87CP@BLY!V9\,[>R;M-D\Q*C5H'KVTB)2>&
M+`2&&7@I%HWCPXV;/*`]D/^4L#H>!:T&GL%LN%CA-5<GE*O',@P0%!3PS0.H
MUV8;L&*1=%I9XH%#"AZOV[DZ]Q._*9!+7GXR2P/UHH+)9REUK,C-64HP!546
M<R?XLC#Y,SM='LU77`%?*-D>A3MH94U%,H65A#O_RBNDE);#B@4NVKO='\18
M^9%LJFB32=FKY7C$VV*A&^Y9S++L2+YDU6[6EH\1A847&?9*<L[V)()="A3K
MQ1*QGKU[G%PW$:OD7=Y`KNN(%:^GQ\GU$6+EEU-6BX<1*&IO"Q2YEB"+0-A`
MD-D<3Z/%LHA*O=R+VBL@]">.C//2DNGZNH],(<B+?2P[GL_>R7(_JR$GQV0X
M4:"%0!B9CWCA'F*.(*320KR9<'U)A4@72[5F_FTA?B#"8]KHF)6O$PRA4%U1
M*J4JE0R0!F7^)N&*C-U,MI&&!O1W_8GP@^.I34(,0&4']Z_?SJ\'VM5%IP?'
M)+5T$*"@(\<7*,(Z]\<S\D(R%TG+9UF5=&Y;@#^95LD]?91QD54SX[7,Y-I;
M:)]96=6M>)12,LAJ#@"\2O!4IL:L2W$6"JE<+F;,]"EA"0&`WO"AM`<7;2+N
MF,I+\0INE.$]038C=')4.7DZU2@+UU\C6*Q=&(?O62'KG\)41&8!XA?5>V!%
MK+CFQD\@UWMZ/_.<`78\Q25(TV<`RU_M_YP-RTIC).XT][7GG21@!7F_"!SV
M:U[0F#D>>85CLD1G!N62<,)S*K2@7#L_2NQ,X8M,G!_9D6"F(_G1LR3*/.@O
MQWYNNJ,[B8DI-(@00X*%X@)1(=5J(9:$&2PHKE:(`4FA0EI6QY+E.<$\-V04
MS>0>;G0J%O<3]F"IJ8##K`LP0$0L+*_SSL4<82,2+FLLLI6MC@6&1+&[4'U=
MU/1SN.&42U-8_X.5I*4Z'HD2N!B$M@PM;R(LM1@5).RF65RQ"#I6,7^'BUM8
M2!JV^Z=+:>`@4.&74K;SJFF$&B7J_I2%4+`)W2=L0G<!%'V5-:$K([ET*0HP
M6.J:EQ,-JM)IPG".\AX%Z8B74#%EZ"BXON9@5.*M*S4HH$%CQDFG4TS,0-L:
M*@)I(HI"*..\)J9(X^IC?7"4-Y=72.&-4K:_O+[L\865*4LK0W?)RK4Q]U]6
MBIT5*K^7:X(\NOIRN`&Z[LA!3YW43X(TIARD8<Q=K^,5T!8`4BAA<<S#8!E7
M60;:BII\[#*#!S._41ZBB*4%,0I0$^"M*1W?YV/QYQ?`3+E[?"U2DP:!"-S1
MN[B3LW<YYM24*VG\PN#<CNT&E!/)HF,HS)098#`<A"V@I5H@A;5L2U7:JM&R
MU+IE$\:T\"_5:.N[!V'LU1WJWI:_GE"F;9(PQ"Q4&$`:L\5CB9ZLPG7*JDBQ
MHAY9O23*:(W"B9>%()+1+W3990,#@=I`#I<DE@N4DB6.A23[>5)I#8LFKFO&
M05C"0HLH0HFY8#?%&HC;"_%HBD&OK/"^)[E\ABP:#CT^U&J%96BNGS_'4AZR
MA'DC+.R0A01Q>2(3+_-@"EI&7J:!M2')PQ/$DDJ"OY<``LQ]S2.Z+Z(P"%/>
M=ZB\>`T:W="]B43@.L\?'W:NNM1?!H"-.;D+51:,NJ:;*C<7Y74)N8S[@:F#
MIJE__(=RF65`8]XOK\,%T!*%'I%]?4V),#I2V<.OE&^P:GCNX0W<!ZS$04L\
M6QE*+U5%EK-O1&"G7%?8N0%F*\3!K,Q\OD;DQ3P=?U-A1A:<@""X(2T?9$R>
MC@`+1C!BG#A=4!2L0CDQQ?QP5K/OU@NHF`A+GEZF+J/!Z*HH'5."-6G4)(%D
M8!!F-B\"R?@OUJ-1W")Y.0,I.WMQ@+$W)NY$$3>\7N&([(O(I7+E0=S7B@B#
MQ>+Z[((5VF217-D_]-52,\G7;GE8;+C('XPOF&$$1NFP2FZ?<L4GG^3E^R;V
MFO5>TVHU-+-9[VM65]>U=K=E:>V.,>SUX(JOM]O;]DW,N->6+&,3UUG3-W&A
M<2)OAWBE7'3^Z'0_#:AY(GQY^6W05SZ==[KGG\ZO7ZQ'XEH6]X+[[:PH[[>R
MN-]"&;M)B+HIDS0_$"&&:8SUTC\^7H9`A)8^OE#SZ0FC:S-`'P/:(H"D'-!M
M<T>;=I[0.:*\F?<"!_#8N\C_E&M:[6\8P%@X_379I3AFADB/];_E[VQXY:6^
M/]C4Q230)"HD"F]SN`O2SDOU-MZZ@7T13P7J_Y=._U.,&0C+>"6\7X(P(#+@
M('QAKT,RXC@K9=8%AO3,[L[5&;PW-YY!YMI^,9"7?\/F/G$,V><`;J8EYKF*
MMW:7;M8=4)3?`;?8?0PN@?_J]0:#X7`-UF)&_:H+KW!O:X8[W?+F_C08P@OY
M\X_?VTN7XHNBS\OU<J^KNFEN]>J*7N[/6>]A]FK9^]WKLSGQHNQ[:*0FN;.8
M4R(L)Z^.XD][8_G\FV;SV##]N5NVC<8Q('RI^3J1`-I2W3AF51HP3?SHL+]A
MZ&\-^\UZZQBPORRXGKG](Q'<?DSX;9C&6\/OMG4,Z%U>YDZV_U=%]$?.8H<1
MEK$B-\Y1">H]+?6H",7<\]6WD5"R4@);F%A>`9:+Y,5M$&0$S@T0/[@!8@7T
MGTHK>YWPZ=A1P>\I\#LM">>:*JNL:J&TRL>RV\W@%X.F5UA9UV*?B)W>=JX=
M[2"66F\=1A<X!M@(4W%U66S)>^K`>\9A"H3T6MQN]QG+>5V<$@0W^0DD1P![
M=*%B;.:+#W)W@1AV*6YCQ\B)8OC%OWA8;(=%Q7ZAH-BO$PI9_IJ'15*0,,P@
M@G%WCK[`^B#T%@NY?8^]1+VIX\?_?*_5EX(SFFW#:#4&0ZUC]VW-JG<&6K<%
MT_0Z>L,>6IWF0!]^-[X;]?>_-!KMI@73YO#9;6M%\%"8*#8=<Z,8F\,E\R]A
MXNXS'F5@][IZJ]O3.K!=S6H,6EK+;G8THVT-^PVC,V@,NMO&H^RSZA:%H[2+
MT2A7UU][__O;UT]`;5=RP*,R^+]OY]=_$!H_.PCE!4/UU@<97D3"%$080.LM
M8TRA')6&\?H-%?`,_Q]K7/`=\.!V)TWNP@B3)$3X=9;FQ\,/>>AS-\10M*Q:
M6!C)1QE3/E=$B?5EB0CML?#S<I_45UB@.TL6(B',NHC>S?IR\PH.&(?+,L(>
M(B])J!'0C$J]PM%,W(C'>5*^KA1^K^8%7>4TP!@[_CI49>U6!#[#VTT0]@AE
MI`R(52/R,E#P>KOX/,<<GK/W32P7FS3/4FQ,Q_L&*W5=&SM8OX8Z$?I^R)J4
MLE!(%5'/6=I>5L_[)T.O-5IR*@*+QPRH>W@X<MUQ+)>TRE("L`F;E'M"86$4
M<2GF4'GDYYBE2L.D&<@IH8/G+L99BJI'+I`LF)K5ZLX2V+.EB]AJE0572XUH
M_;GRD]VN-<ZH=+-?(C)B*1'G`8938-0L5MTJ,SEU`#]\*52WM4!*1;9UL\C5
M8A'&B]'54L?T.+_RLZ(HZOI0?HKMO>*I3$7@*1_P+7H`/W[,&CNF(RR2D/7:
M.UM3>MK4=4M9=2IB8/B9!JXI'9$DUV&U!CZ[KH@$ET48Y0Z+1P%E_T\:N!+H
M3%6*2,>_SGC1-6KL1D#(4PY7KC669V'%#T;.E.JWB#!LRFE>J'7((J)%Z1F8
MH#!.U@`L@Z%:S-5AM9;R$K\92!C9%0M.<":5C<5XB/0*'@]K=BG2(`+@):PD
M%A(\FTVD'%(=/9G)%190DLRO;Q)H,A#B1QZ#[O[`]/A8=/[,4^MPEV=R]2!6
MQT;J<&^@D`%O2W6,I(3I;"1BML4,,9Y(SI>05^O+NMF+G_`TQ$IP?BPN@K>-
M&["D&"J%Q+/M8M9[Y^&.LWX^A!>S"5@%'T!-6'>V;`G9EN;F;V55G2G[EF[0
MG!89;7YE+_R*+ZBLN!&KA+(:M#""5!A(!JBQ%4!9QN(S`8JS(VTR@.:]EFM\
M-QG4"L3%,2C'BK-W5-.,U7*A1A(L68FN\X@+&68CWU;`BW^(&QI1+%LNNU(#
ME\I%)',M]GXDE,.OP%89KXA<=E]38^4?,U;?%`^%SYOUP+MEIT']*B+?@V^I
M.P&K1<D*`')2QQL8.3"O.,%3#E%^OL=&Z/Y\)2@$T]C,P:G+HRAK*5T\U*T[
M`HF#4KGC,$MS1HB*M@\<?\9Y7U9>LT[-6:<H:\8%''Z-,6:WNDP[ZL2LDX0H
MQ$E%,?@`<KW7A)\NKF"!S8GB>?'H#@0G7ZY$2-7RJ5XP%<ET1++/(CDX7M:5
M@2,G(\15MS:OOH\C"?X,F-HI"%6&53/R&XV+5F);=!M@K1^/8RVFM5`5&TKW
MBW%S(W<5KB](O[7FVCD6N9PD4DAW5GZ/;(M@E,[_^&W&:-W)^[3"?6K5K`W+
M7>`B);FQ2*Y_)&E\T_%Q=,N955XB`$1\=_P/Y8/W,8<*-68S-!A',WCI)M'D
M1N@:FT[6*20J([L16>THU+A8(`^_9U2W?,PS.K@/WKH5P3C%-:U9$5?#BBH7
M]F0Y$V5O&36N7D&Q\3-]DPEM,$!^D\!"Y96"N.;P3N&4=(;+,FKU^M*IG?&"
MQ+MLXXPUE]&VV(;4A"K[4A9`64G@<J#Y58%ATTXQW5D2;L5%!%MB:N:BM"O+
MQ8Q-\!M1O/%`=5<%QRR>LB":LRQ1.5Y:$2MH*JUC00+.RGF<O>-L/ZOFNHFE
M`N?&,JT!OUO8O+D5:I7`(:['W)Z1307L,ZLHK9*-)$<>Z8[C/917<OAL/V-6
MD>S&`5SD<%IB1=O<'$)[6L%<$(I$)(5O/XS=F<N//6LK0B2%S#^SYC"JX2L@
M?67LWGBB?B1=I;!/.&U?7#.LPP1MD%63@BG\>>'PUAX=52]:K$&5+#92F0E-
M*F*5X$%E0K.,R/X\>\?2@&/62CH3$U;AQ1,H\XB[5.1ESHGGB3+GY3:WK)0E
MX3^ZLFD[RH?"QX](GZ+9%*ILKJ@E8J))<=-(:K$BD6@0PP@!=0S58';O_+37
MB`XRV9Z]D_"P,%]-&?@>*R"<U\='P3QC*`LW&]!IJY%/OJ#'H9+'N$BFU?$:
MNU(MMI4P7J7GL?SRL9-UU<+6AMZ(<^+D(62-EG([*B]?S_;I.QM>!I5+8\I6
MMM%7KV2SA9&2J]P=UA*CO.47.X#HTRD6?$!#W*KS+8B/O,4'E5QW6#$23&J.
M=V^DSF20XVQY6\SN6^B`*YR&.Z4P-XRGIS`W#Y?"7$W]^HG;65#69FS?(DCI
MM7-HH]N;#W`5JOK'%TBC_2+$7_HF4OY>4%\6N.V^,XH/!`,11Z(MP(#'E2Q\
M.^!VKH(LL`IZ^0,7:!%[95B6!JKY2E;#\]+%`EEP02Q\CT69(]8I)!_B&C23
MMP;(CG#H+P#H'.#C!;$W6OC^=Y0X7Q9(1\])-X!^+USK^1D>AUWASFO=A,@?
MSC-'SL=2$?'3]B.K+;"E?.R\(M$^J>]E"U-L*_4_.\=M-P5,2GA8RIG((D6$
M_;)8Y'-M)45S21DJ>W)75GYTJ]?WE]6VY1L[)B;8M;>7WVK7#GZH.^6X[/>Y
M;?)''N=89>-/W*EU=-S'4`VCK9KZH8LK[)?[&$:MN>=*(L=(BL>XYI=A'^47
M>+(`HJ-C*1\,M6DT5,/<.1'Q8^D8B%5K[KE8Q3'2XC&N^33%CQ$Z1/VC9!8M
M4VTTVJ?#*EJUQJ&%J1*2W3&N^50RW0L&ZU>J[/$2<^Y&MF7$I&/$_F-<\UM1
M#K:UABXW1-X6KJ]5Y^2Y\D/6Q^D@5^Z3`+4+>':409JU?9<,.W[,L6OF8:RS
MKPBC'=&G8:N6><C*N\<I7+U>'9P7F;02KZHU5[:36&1)\J14ES7D9>F:;UZX
MTBU;;=</TV&AO,+5@4J1'Q'FV#7C")#F,,*5I;:LG>V=+R=<G8(>S)UDK`KJ
MFV;5H`/K.K#JPP39E)55V[76$1@&#HPY-?TPH1'E9]66H>K-5RVG^[2"HP?)
M??]"#85'D2N7+L'<89$!/I,K$^5MXWF:,8Q`]3""<$7.^H:B)]0+.R]ZPDM@
MK.?XK#Z4)\+H\<!2>3EY@`6N",;[J55KBZ)NJO*37K/%)U(-?C)J>O;%.*74
MS+QS]]D[J7?W@?K&;SJTSJ;+D=64RDL++@!-JN15L#N3OI3?OP*N=+H_->Q5
MU4O@'1CE)\NH&3FH"^"B4UN[%';HX1:*V]()9>>#AXV+:%B%\V[5&L7SUM>N
M\56/5)S@M=PE5^$9GI2>ZOV'BB/F7;HIU9^O.*N))\%M:^]!E;GZLIFK5N/I
MF:NMP^5P5E/O9>JCS[=ZD;2XS5V'A8+WM7CAG&49FEF3TIO]R<IE!<K>0+!_
MS%PE)V\P&SPZ6\;U-P'\9^5?Y_WKWV`XD.$:*^I37(+82;*A2/]55B7U[BVL
M[M4RP?-UK$D)7TX59Q5,\A=C4:9;>H8+\/E#22C-Q)#V]&CU``G2G[S)"3*]
M%\'<#0\\`85!6E[XH4+?C>B[D6&6_C;:\SEM@/VS9W[%M9Y:UO<QP?[EUUKE
MFV_T+/UDUAJ-I9.C!CGYMS_5:SP\ZIA2+4S#5%O6\:4Q/7/;S5JS^=;VW&BK
MMG5TN][12P,4N^>MGE;<$W`O:QL69QT?BS-4P\3VH&^NU(15VW<S]?+M^6@/
M>T<^EU%DR?E<B86[>JVE/\KY&B(QX)@XGVT;:L,^OAH7S]QVO5;?<WQ&^?;<
M:-NJ<7R5A7:NO-#8\\UV8M)=HU9_7+JCAXZ-Q[7UMMJRCP[QGTWOM?9A8JFK
MHWXE'I=18\EY7(DENT;-,K;@>I9Q=%P/U)RZI3;,-Z??M6JM/:=)E&_/9E-7
M=>OHZL?LS/>L/2OO)R?;6>867,X^0OU55QL'+T)Y`-'N[;'UXSSIW3G<GH78
M-R#9-;>QV37UH^-Y;0NK9!X=*3R;`=3:;\YF9S=MM=T\NJ/>F>OM>ZLG)]>U
M[$=YG%UK'5]W@U:[K>KFF[-?-0Y5_^"`>VY:>-1OA<?9E3?VN5S/1L/V8US/
M,&KM]M&QO;K=4.O6FV,!9)]X8WLV[:9:M]]*$$JK9K>.@>V5ALD9)HH"CW(Y
MJV8?GW!GJGK;5)O'9\UYO@K;>G,JK*'JK28U:3^RC>_:,\C:>V&<$ZR!^K8*
MS%=0K*!80?&(H'@8G7KKT_2/IVS<$17>/RR@WD*=^6?;#8ZG>N7S`%7:.I8G
M*(J^M7+\%1PK.%9P/#HX[J<`[(]B.4;\7*@LV9*8^?J][*NPI;ZB"!?^X>$?
MEVZ<1!Y5\[S"4CW*M\!+6`4>+X-$]LJKK-?>4%JUGU<:%35&3591M1=.9TXP
M%X5QZVT3(]_H(:MEJ\V&?H8%H%;M5OEP>?4M_KBJ."K^((;TL/I*86;ESADK
M#FM'KHRQA.K$\2)$?%;]EMFC6853#+]588"E.;#`[H,3C6/EP?-]W@DCYN5'
MXW\H8>!JR9T7C?/*L/2\]+@7P"IB-_)$^=C(Q7JEHY$;QS"1XOZ5.CXL(X#_
MP.M>$">.[T_=((EK$DB-E9!L-'0T1#)0.+`V&&']CK&BQS;;@D$6-[:TK3"@
MKV-W%`98>3:`O42Q$\T7(4$+02@G#R$;,GYD3'H(WU\:5!IRL3YNMDM>2YF5
MQ(51-M>_57ZRY.JV<JU;4?P62QJ7H/SM^HK&O/HM`6EEW6C`#L7!17L)8HY\
MU+MOH:IK*]^G?'Q;K^K:EF3JHR^:]FHE!9=K7?)*@D7QXL6M'UN\4:("?T^J
M3WGM1M-7!M_!`=D1=W&^E'-1M'X!9K_C9?VR\#EZ<M\`];V0UO.-ER=<&7'%
M?F0-#;:4CYW<A6D,LN)+[ZZJ3[@QGHA4GFT;.!Q?1)&AZG72C+=Z?7]!)MN^
M<:CGGNGNV.]SIQ7!QXP,J(&#M'1L],1M3A4UO75J*OF-%KF^Z\1'2&`?ZI:A
MMJR=HT$_5N1TC.14*N*9A-'$]9)CI!ZS_AQA[V-U*Y69C(XL7N2D`ATK[#\T
M]A^]3+9UF\C=KAW_>,(3#56WZZJ][S+S+P&H@X!G[T5N#H]".R<1J<UF%;KY
MQD.\JLNX_)=QJ:[>39VMW_95W#8;:JMUF"(#QW`1'R8M^0@N8E-MV:]:E.JE
M(GGW&$-'O":Y`X["&8X7K(X8="-7"=Q$HRA#)7:3Q(>GXW1T!Z/0`'*4)O:?
MOW/]L0A*I'[T+%+1_2OUX"\WH,;T+&#2G<[\<.YF/3PI?$^9>H$W3:<`%B=)
MDQ#C_&[@G%B'^TD8L<#(V<SW1@C*,XPA'853%G09PH\1'WA*DSD_W%BEWR)W
MZB7$4&&`D1/?Y2N!X:)P%GD860EOD.*3)G=AY"6>&[/8RR1,'%_>&>T4(20&
M^.%-80!_KAAV4S7J+9JUI;;K35JW'*YK%$,K,1@7?R%XWZ`]7`2'WHLXST1$
M`+,?O$@:@$X1%@VC8*PH13R.W<2-`)8PU,U</J5BK.3(#V/<+O5&56;8S+,&
MP\"&827L^$,Z[Z6=,Y0Q`3@$F)E#`(_%$:T]7X"O=*(Q'<(2R-G4/YDUC)1>
M"%#-(U8YUJX#*GWOT/E$[L1GMRF`QE$F7N`$(YI3Q(GBOKR``RH@TXS#(FJO
M`!%=MC<XAQXBSA"#26M2_!/%&"\2"GL'X[(Y/"83;#4K@G9A4;,T&MW!<<<+
M9X2KA(]S>&2<CIA`0+M(O(@C<"!BV<3!$#4^A"D<S9T#.$&D\(`M6F]<-^`1
MU(AG"`!X(?43@5<<?0A>8V\,1Y[@XN`A)"$G(%DDB-V<8/@ZRQ(23">S7CBB
M6'*!SZ;:-MMJHZUG&.UR%(G=Z!Z@BP@\29,TRJ+&TV#L1NMIB'#PPG<"?DR&
MVC";:M.NBQE@<:P7,2>S55/A^0!.NFPRXJZN<L'Q@T9?!C;>-#]N(E\-BM$O
M>SN$5C%](UL,^X>^&GOW^.5__SV-M5O'F?V#DAON0A]V%0_@%DCF7\+$[7LQ
MLA[8^;7[(^GZ\,PO,(3RW]EK"+HNLD*$.6`?L8M.%&'+=J*L[CQ_YH)QGPZ>
MUU?6N?E7S`N(SX,+-_+"L0A[Y,&.HGTQ=2^&PPD26,6E._GG>S?TOU\,FJ9I
MUC5-,^J&KOVOKNNM[U?7_>]UN_$=3]LPZ\9W_3V<E<?>\N+0,HWF]V]7_>\S
M-_K.#OX]<.$17`I^3$%6WA@>''^OZX;5JM>_=SLMJ]OH][2NW3<URQ@VM;;5
M:VI6O]MKM!OM07-H?F_HNO'=?/^+8=2:#0FHKP>=A6/!T^P#RQR[P3CFS>.?
M#[]E>)U_&2Y!S#(Z#:/9;&K=1@/@I-LMK66;3:W7:.EZI][L-X:#[SCP+W`#
MPP6\@(0+RU[8&$LJ^#JY@`N10#0,HW_=>:.[*Q`2O0E(&T'2NT/XG@??@L@=
MA?#U?]SQM?.CZP;NQ`-PQI>N$X<!R"5S&";V0#[)T'MW*"U`H=>L]W1`',WJ
MF89F-6U;Z[;,@=8>-CM&TQJ:QM!F4$""Y/2X9\Z@;^#.*#RQ_`N\8WA"!$$;
MP!<S<4[<PI'K.USG+5PT18:;2N`G>>*&'X#R@:YP$:#XUM(]VN9>LSV:YM.S
M/1J'2[DXX-16E>WQ&@'ZAKXQ$GNE0$BKN7DIXTQU#H\'Q&?FR1>#^E'LV7SE
M/1]NI\8^::I*!%CP$]!^,3%+N7%\U!AW,_T_P^J[:[MVM;GO;G=EVNNQI#+L
M:E=76^VCZ'!3%KKM@+C.+)ZY@1=4EYE0-Q=T'V641A&:WS"3[-5)_+D.*?,-
M=J5O'+HR\"MMM+'O[HRG'F27<P+RE1280#A!)PQ\30FD1T?WAR>"`Y##VR![
MTRY!4>SCN>XOT7-70BI_Y'QV&&$957(;*6B'UKZ6>E1<XH-I[AQ$O*=4L3>!
M"2<8(_NVTE4J*+YBG/%;A-VI:QL#ELCS+&.A7_HPS[IJ'$-P\$%@@X;7(ZC6
M_[H0V;=Y]@0%C[>6G%/!L8S"QU%!K\@%EH+_5T1+[CL,K1CUUH<7`@PBQ,J%
M-RE.B*&F`Q:Y'7UVDM$=2`^%W]T(_<`O$/0W2R-W<XBDW3)MT^I9FMWJ=C6K
MU6MK+4/7M6%K,+1[]4:[U^VR4#>]UM!S*.Z^K2)XAHX7_8X1^)\\Y\;S*33]
M,\`6%C[^&ERZZ*.!<;I.[,7?@O`&PWKQB,^#60I[!!"-X"V*S7SY.,"&7>_T
M&I:M]3K]EF;I`*&6830U?=@WN^V.W6[9@Z4XP&$43GG(W5^IQU",U:P.)\K7
M41(6XF5X_#16\0[36\SY>"3(6I$"\YQIF`99C+G/(3A'<Q@,A%``T'%,BKVQ
M&[$4#R\81502"&/B"^'^L\C#H$%?A,>?O5N(8Y\Y<>S<LG0)D)AKB\2]%+&X
M113@@AGCT:"_M5%\CXGT"QJ`'+FW;?R?W5J*_Q,BQ.Y!?QMBV=:%OYD;RD*_
MS/<;I:MM0+P0R5Z2&*3_TNE_+Q"6\X?K1(H;\-)U4BW:U4%QV8>7#];:9SC/
M$XCI>>KYDG;]=`5]<4E\FJ'4LR#GQ#)W_L#9LL(9[<?==/C7#X(QU(9Q2"UK
M:^PH"RXPN0[3VO).%J]^V,_U=+QNLNWQ*M8YKW\E8^JS)WP:IS]I5NTD>+F2
M'Y<2J':C4K_TID-@X<V*GI]$7J]GGWC^C,^1W1XK;+"4G+K:X+$/%7LALV]T
MYXY3W_TZ^;_4B4!2]N=#EO_M^.<!:*-3]K:SEVR]H6'5!_VAJ35[W89F6<V>
MUNJT+<UN6G6CT>[VC'KSM;/U-G4U6YFMY[*\_N0.-,\H<4!`20,G'6/I4>4O
M`51X>2+@BH*LDU5KH.Q2\6#,U)+5BL@9ZVJVG.I<^CY*F[7HQ@ZI<\;A\M>J
MJ:NIJZGW9Z$ZWLS`IUBH#*ML>8&'VN<+YP)6N/6(]?/_7C@E\4"(]<@FRYMA
M^H*;/`T6\<@FK;>PR8HF3V63%4WNY<X^ZC#32_?>#5+W]5/6=K1L6JIM'CI7
M;;\[M-7V@<(^7VN'#;6I'Z8T_^N=8<O><[;M@7=85\T#U2Y^/4[3V'<G@(/O
ML'WB=(A5?(W][O"TTE\'K&+LT8@#!A9M/9),[MTKH5OZ87)D7O$46_9A6M*\
MVA8;JG[B%Z:A`RV>^"GJ:MTX<7:C@W1^VK(K<-3ZOGLLG[K=X(N;*'X8'XV@
M\`%4LM;.E5#VV/5WU_TT5.LYC5A+MQ];-:Q3.I\6[&=G];&$^VFJIKWSS5?"
M_334YNZ*0SGWTSXE?E!7K>9+GL]IZ>GB^L4X9M:NY&@N8KUF[*P'E1!/83NG
M1':PG9T-9N7<SHDAVXEMY\20[;2VL[MWX-$+>)N:"KLD`!1S"'X-P_&#Y_N=
M8'P>)$YPBS45.C$&QE^$OC>:OWSB@&$;UM#J=;56`]O\6)V^UM9-71L,&LUV
MMV/U&KWZ:R<.+#8`NR%$@C\\_$,`B4[!$S])(12OT2AN4VZ#6&#>W(ZU'W)_
MC-PX%E4$BN4(DL@)XHD;1=0\+[SGC>"P8]Z4RG7GJ9HT@D-(P1)X(][*U\]3
M6\ZP`5^<3EG/34>Y26,OP,E'X?0&D#(1C0Z].%L(JPE^PUI=CK&TA9>XFN_=
MN^-:OB=X`?OV.=,P2JC^PDV:X)<)Z_#)JBYXTQDLESICTCSP3Y`Z/I8DAT=Q
MWALW><!^@?P'?#M6O$FQ'1,\A2TW8VJ0QQ*6X4N,`,$FB2.>LZ.$D3*BE%88
M(8"W1UXT2J=Q@H7("@T+85O>"%.?'=;QD!>"($A/I`3IR1GKBW<K-GWC^N&#
M@IV?1DX4S:F)(96=8#T[Q7)9VI"+G0V+0.`3AU%V^EC`(L+\E&P.OHYYEE%_
MMJD,QG+JRC)#VIZ;/+$GWG.:OM&/?3B$+"/K0'WQFMU>S^JU+,WJVCW-:C;J
M6JO?T#5]T#&,MM6WK5:?,;Y6S6P_H2?>RT*G>#2?G>A/EZZB*TQ9(UIG9_ER
M%T*_V>T,#%NSS1[`I3W4M7:OT]/LGMF!_S/U?K=1K@LA!XJ20Z6TM\,5X`DP
M#V7D`X?V)MB%%AG+--]$G&V"NJC>.YZ/WVO`6[78H5[$K-$PLA#VMA=@<U76
M"1:3AE=<&WD_B+_2D+6<97.R=KPQLM$\[U'\YF'^([MQ_&D8PQ=CF`28F<^N
M&.`E*FO`C,P+.^:!L(77`K;B1#YYZW@!8_FH_Q.+'OGIF"XF'`*X^#1E'2E8
M5V7@^'!KW@%A8<MAUG2Y)`U@K]>U9BV`'QOSIC?_QAZ\<)\Z/'7;&Q6OA,B]
M]]R'XOV1535"@,D/P_46W;K*`T`%889\S8?[?.7=M80/[/)B(@<<(-W!N)98
M^7<ZOA6W/H.^!K=EH"7N=!9&3C0O+D\("C',!5M*<92),Z)K#58B6D'CJ<-*
MZ3!AZ&Q3*_>DDK2!&$%YH%C!R0UN`9UX<27"'&!KO*/W`Y8H6]SSG8,KH?;#
M/LHXN(<-K:@S(+!24EDRZ1E5BV(]$VC:`*YB#?<$%!)2P^?L^F;P=5W6_'E#
M#TDO2%AS8Q#1>&$JV`82AS0.P0.S6!T8AJ%+MO\XG4R\D<?W[V#&+'L4VS<C
M)7HS(AX$,]PA<T96.#:G8()13;D4A+E$D+C;53Q&9D.1*],MI]0/O%_SQ[\S
M*E7Y\1!Z28W!TUB<+0(1B\MQ+H)EY@C:4\"6<+R-3+/^`ER7C=WEHF\GKW43
M=^?2ISTD8[>;?;MIVEJWWFZ#?&$TM+;5[FKUMM%K-AN6W3`[I4_&+K9.77FC
MA$)>7ZO+8'$U<>'QAD,]T#1NW<!E3:IYQV;4>3C-\D[Q*`2]\3ZK*^JLO62?
MU9;]]&3QUNOFLU9=^1;\*(*65G=\W\VGXA]!>1CS..)?RH(FO;SJ)<@P@1:F
M2>EQX[D%P0Y=!NZ(:@A5/1;*ROWK&\GZ.DP<7YFE$>A.\8(%N?3TO7L-_8JL
MGTQB)UZ]?`?EKJ@>7D0AZ-G)',MU)YU@/(`79JB&[\O-UAZT6KVNI6MV?Z!K
M5JNC:]U.KZ%9AM&R>^V&V>^^NDJXV:HJ0$2F@@P^I36K%I;KBN4R:UQ"BJN3
MD.U'948BR?!(UHI9Y(Z\W"_&_5OT14WIRS^CR\SQ1]QHF1DWT&("FB\R+HV,
M<\RH(;7A+:C1:>Q.4E]!]UJ<*]*B.2]W[WU`13ER?'^.M=%=%W7H"9I%J:'?
MQYHR#"/8#LR`>C0S,$;A/;DA8K6PB77++BX:C<(KEAW?A>C0%M:O;.T35^&U
MUV@1"II\:D5#*3=T,C/U;/4AH3TKMPS"^VCH=-$'*GQ]LH=OP;^7.?7(T<?M
M$44O'?,<,J`J4V=.'LP;5]C,D-]L8WO:EFD464W/B>_@8?P/O@#L%;>T+SYC
MFGJOTS0ZFE5O6YK5MYI:J]NT-;,_,/2N/1ST>OJV?"9C$EO2Z"8R7\]G$#"$
M#_2'!**=6,U:/O&">\@\.)D]'"A4N0,B`CKU/=C!N&"`%P+;F!PE:.H"\<8+
M0)0#5B!,K$1:2.*@S2=WA/*,3R6LYX`0^JAT=Q*2P1OP'$#FYB"K*1DT%W]B
MJXV)%H#;8=L/\@($.*$[S_T]F4$:."02#_"16Z22@+Z,9S!,B)8]-.`F<^*=
M-XED+%:5;U?*=42U->>+/[*EA1&Z%Q)T205_,B<0S?2XFV>]C^8%S[<#1^9$
M6;L'N4@Z?"7LEVJ&!P\.=E7G@1C`H8'+D',,<`,[2]2SSA(>Q4*X\2@*'\2F
M%?A_SU_7$\,2W)2.D]P&7C8"FY?'$=#?P,N]$;)W?'P;EK85<RKR,R%R]?)(
MDKX7C_P0:ZF^/$/K&,-.3Q_6-;,S[&J6U3*UEMUO:/UAKST8#$"<ZK]Z8=.5
M@M.7K]<#Q9;ZD-9_5CJ]__MV?G5^??[UB_)UJ/0&EX-?!U\&&_A95L[V9LF:
M>0BIZFN@=-+;-$YRQ#3KHA&+P'^*(P(.\P#XZ<^U\`&=/G%Z`P3@.<`#>K\B
M44E4=)7>J,IY,*J!B`*RE<_">P1;@"=4A<S=Y&Q"KQ>ZM#JWP!VGPIF&=S!2
MXV<WND57%!(J_SM[\"-S3&<$R_WF3L'S(+OK\H`M6,6]6U,NTBA.'>9ZRV>0
M%Z/*CD8I'`LNA#!-4$8AQV9NKRVL!EWO]\`(X=ZX<X&V;[PP<4=W0>B'MW/R
MA..HDW"42L+8&(0B/YQQ40F&['1^5\BC@EXY9P9LEOEM\]4P:9)[\-CB,,9)
MK*7HLF2CN&GBC5!@NXV<*3#UW$F+6*P9AB[J[J*[$=@]NS1P.7V2-=,H@B_\
M.0M`NZ#+RU30;XW1`_"*Y_@UP`*$`^]4+\"</;00Y;8:V"CO\7+!Z&WU?7>4
M8$Q9)FR2,2%FLC5)O2'WCP8INJ]3#"++(,D\NF+`)/SAC=AI4*EA_"UV)JX0
M8=$WZXS8C^@-Q[9'JZ%ZE\)\"]N/A<>4!YDI=,R9`Q=P$>ZA7">9>#Z%NTT4
M(%3%F<U\[C]EO;\Y.1:FY:R#I"C8SKUW'^9BE?+_AA>(*.*T83EX[WFH(T2D
M<H2Q$*O15R^DZQM0&`()Q3A5XQ7`L'1M@Z</DH</!D(?W\>2Q'9\"\8\YG*1
MC3"L<V[A\RT*+1L#-Z/L"_))%=V?&`,,(Z_T@(*@AXC,O9]<6',I#L#0=16K
MC>5,))=`<^>/*J1+U'1F@/P_2--<\-?^9-1,(8\@]66TE[-S4)"8="G+-%/G
M3U=NIB7<"H`Q<R;ETMD.\.NO*6Z%A[[%'P6]%78K<4(479CW.=[=PVL?HX.7
MU?M^4H'OOSW%5X(6ZJQ95NY+]MU)P;9KZJ:Y_4#&TY>P.._YI,#(;RDB$BZ)
MY,Z+QAKR(,1`X&X878+HPZ\\KCU,@8@P8`=CBE8S6_F*XLRT<$5]Z/0_(JVR
MY\SL*BL\13@<_>F!OA,4AQ][,9H[2$G[K5_$?#1$86AQ_%%="&;VBEH"$`Y&
M<I&]%$:\]1(,_4$_/^\MA^^D,[A2Z)['K0/=@H@/ZEI.=4G!TC)RR9R$NXE3
MN%<X"%'6D$+2Q.66Q4#'N;6'A_20L)"*"(Z%?2R)(4)36H+!S[CL)QM\*YH_
M?9HO4#&:!9#B%_$'M0K7GQ3%OF4R4@GA76=TMV(,58G"N>,G<\WWX`K#>ZMP
M;6&$;9'P8)``9!V,@N/9`Y'HET663M"\9:J-T9SB,C$_G3$9'>DULSQF@ZF/
M$>$"I=7V1CDO*CEU_#A<%;V5212J=-5+LO4&%:0@*BRH@I2<,@TPDI+901#8
MN:PVDU0V)EP73#"RW!&Y4X?"5<EB'-^1087;QGCBS)*U1EP4-ZP)KB2,X3T3
M*I@-$$_FTB+#&Z`$+J9S/EG87BH$3QA@4?0LB6R,8N(([4QH<<^CO9<%9:1!
M(-`X91E)*!`O*L&%$QB!MHHN;0((@7^$4X`*)]X'D?,>\$4</Z7.4)L7%EF,
M]QU3YMA:"K(YV2;A^+P;=IJKUEP2"%_+@9&R4H4PX;C'LJL8PQ+Y7`2A/*/+
M6WU0MZG'ONE<]93K<`:*?4MOD`:'1S0C>,$!L3:W"\+Y).%Z42$R\\ZY=RGD
M^NQ=(3)X;=AU#^W&OC<F[],5>N08_R4N\'7&CRRNK0^R+XS0=7S:T=6="^S5
MX>.LSY>"O4U\BN#>8-)]"C+\*"(#?EXP$?[80A;9%[)M]K@4%-CK7($MK7.W
M"E`NI2Q;!2A7`<I5@/)M%:!<!2A7`<I5@'(5H%P%*%=D?8(!RD\E[*=U,#Y,
M>"]U&6?U-P9<=2(/./.X=^2Z,I\*=64ZK*[,B>J*:*T]>[=<7B>SW57J7YG5
MOW:E_AU6KA?AI^Y"'.\)7OS-/5>=/RV-K\-C?+G5GN[`LB/&<S4^<\]M4(Y?
MG=B,,^>\2@BQ3R\K8<9OYY-''T-M-4N@61P/CRE4ACQMS&CLWASBS>J<E2FI
M5+Q_&U/2@AYV\H1=5QN-/;>D.BV6WW>Y'S=Q?F0%<.<GCR<?FM8SFDV<-%O9
M4@V9.7,2*RDC:#2*,&1)*J!\^AC4/AP"57+#L<L-Y9(2)+H59<]/GWY;ULZ"
MPIN^`;Y0O.!QB965:[)R3;X,PS\&UV3>K("[(VEM9?0UGB_:)%DIFT";12'U
M^L!L<B<:,9](,7'[P_G%)9T;_G__HUR?8TU>]D.8YP_/6';+&68N!&,*BH[5
MI=3LI<1LJK.RD/1VMI"_O3GIK5@27*KRC)DR9^]XG7$,28?O"L[2M;U,LE6S
MD/]L?1C[_I-1:^?YJO+4E"M-Z2!8>YJEO#JC.\QU$V6H%4>94AT25\Y2XRG^
M2VY?Q84C"*=4J#U+[XA8O7!,BZ/"&JQ6^MB-L"T*R_?.*@MAR1:A@>(R,&V6
M3;^B2CM\@[F-<*;\**6#K+%L9`[-Q0VR31<1KWA4TDQ4B]O]BWJLA.NW#W,P
M(*'-!2/^-=2G*2EF@HFYB*^\?0W&Z\&9QA\5)TDB[R;E3NC0QS(&?)+%]5%'
M&QC$(P<03[N1ZTB5)0\CS(MDK3@T&5-S/)4S>)8.*UE$6?CAAB.)]L"[?Q0A
M#90F$CZ<!'O5R%GG^"4./HL\_/H6\##@(+]S(\9:(B_^DR3A$&N6\;I#F%T+
M3&0^<[/^046"RNF3RM`7T$0L2>%E>U:6-!.[T1S6S`294\@XFDCTF801+VN!
MLCHM"_8RP;Q6JAB28$E[JG<6>T#U3L3(B++PY$0-6#AL1DS-HCJBK`@8JV6$
MFZ!R!MZ,\HM9#Z"4912S;1%(."AZV1'`1B)<?%Y\3?12@A>I%\%8<3W6W^`N
M"M/;.R3]&W<>LEX`"E;DIX-@%=)X&2&<1I62!3G\BM7,\@(,G)3.WHD%%I+U
M%W(I61\:D2'$GP)X$R8L]UB847@>58+*KB15`6`D84372W;/B)0@QIHI_]$9
M_4D8-*-2<V.Y],A<,#.XBV[FA$4YLCOC?Z=Q(I:P,L6''RA/RV&[SUCO)$V0
ME>:D(BZPV%W)0Z\76DGYGGLO,CI9R3K8.^O?`+C&"FL4Z%"B,W\N$HBRIBDY
M:C'TF$GY2_#>OVG19^\*Z\7K@G"./T"8EI/3G^Y<'HOE<%-SBQS389$15L5+
M>3&M/'N+"$G4.6'(FN1K.<N38/!A?#`6F>82%OS,Q`;1>0../TPC1,S`=5E/
MJH3*3LQ\EW-(.0^<C&F$%XZ?=[IBRUDAL;#)9"*9A4@Y'F*@G""<O<WQ4&)M
M#,,7\%OP0N!;6*$%,)C7'H-WTX`GH-)WU+>$-D#E`I5QE-[2_H#;C<4!*.%-
MDF6*LO.GI\5.^;FZRK#?88="S`%X%5XD802G"D0RPL(\3[CF'LLP,P^=8;8^
M(Y@'W,US04=HW,@Z5\J!G"B+Q6%(ALNJ@[SQ<+N6M==PN^:&V+EUX7;&AA"]
ME_E^"_O"HP4JM[`^/-F6L*L=`H\=SCJ@CG3%PUS4ARDX-Q\]G.1_YWHG/1TI
M?Q>45PS?75"7GVF6K&(?-\<^;E:^_?_<N3!ZM%*KWLT"^0Q;V,Z);K95`HMB
MF1P4VR#%F@I#CYA:7ATIGAWO6"\!;AR9M;ER+I:*Q6_C;O2..RQU9]9?BFC4
M(R/ORIET6(-NP<E"ZN2R\3QOQ4N)7KS$E-S_G,P&6*:;>S?0^D%&JDAQ;D`9
M#0/9P2!;)R3_#UIV)5N).P&1(&'E9D7]U[RK.G6`I_)3Q881PJ@H_!"9^X7K
MSV-AN!86)FKPSLPUX]HJ@`2%;NYCJH;+C534B52E#N^1P^R=U.4=ABFV;'A%
MZ_U&SV$A`+R,#D,T#G(_"D>6]95I"`6*/HB8V;Z`+>3VO:54Q6"\*B!&>--L
M-&$Q?YJH/IQ5O69V]*PC/2]AQTS`B!7"SH6KR"LHU;*X>WDD[D'C]E91%D18
M8=%)QU[`L=G`S&LHC)-A5A(JKV,E?5<H'L?LCE2:<M$?2[./0\)R]()YDSDK
MC\E**[.>*]2@F-G5';3^X]ZI)B&W.:O*W,5"_>+BS^V1,9*4M'U>C)]7Q(JQ
M]EPSJSTG&6:QA7,>N$I$S<WDS(`\7AG6BN0Z3MVL4-$*$WIQ/X46!CA<D?HE
MG[7<!3D6U;DPDW\68C509`$(0M)B8$GBAY*X[;Y@352^UPQ]T4&TZ+:E6HN(
M'LQ/3[XZ=@#9C@H^,1H(F5X^;)'S4?=DJF$>!.ADI<;2>"_$(:PI4A4/S>LN
M$F#@(MU35^W.H_7*R,,3N<Q!$(1R^QO<I$`Y?MR$=)D5^@6JF^V327_*T!E!
M*56"Z2V5BR@C"Y?<<((0!==>7YI;(E=R(<P?JZ^=ES$5A4J]R<(HJ\HF;U<T
MF;'PI6J]B+;>8V5:"R6^"V5:B7)BJ38Q5GMTUA<U5J@V\XJ:QKRN8U9/<(3.
M2@%7L6OR1CY]WRN6'ZLDQZU8;%X&=L5*<G$N7IYJO+H>L@PI6&I"[';J_/"F
MZ53L7\ADOC?%,J0J=R914WO._&/<3.8@%>!<4R$Z@R8W0.6;RD;(+K-R<//K
M5<$RTBTH3&D2N2S6_>1WX'_R,`5T++G,J<0EH<;*N**S=\6@IJ<NY6RQV&#F
MW756AWY(T1Z9JYCN$\>?PUU2ZC-9=P(2A')EB&0^DN3P)+@W?ZD>,QX.`QD5
M4\8^4F&`FB03?3,_>TDNLP$K#\S32K)2*?/27E]?5Q5J7E<BN6B67JR7K&9)
M-)LJ9ZITI#/?&2W45#[+&G]Q\8Q:X&QNAZ6R_EHC'E-W]DX46I[P5BBBV8MT
M$^<.>5&46<0>$:.(9PL5N4'=3FC=>4S!3825C1G+Y%%!]&[>+0AU$M+DG0@O
M*!9:4"R+N]P\J"Q(+/5FTBZYDD)E81VJ3`ZL,2YQ$*XLKTM\'W#:*'1>DS;)
M-3&4(:1M2KT/Z,"PR:;B!GB$ZP5UWJ"-JIW%7.A9//F<C'H__\K01P2RC.&>
M\;`%)S:<RI_K_RQ6HU`O49`$IGEYY;P.,@R1U5)&Y,P+*6=7TV.[@"%H'T\X
MRR.N?7PIQTY]S6*G!OSH2XOD&6L=>V,2#YG:I_`.JVQ/XLB9X2Y7"$GV.>,A
M-<#I-F`S]8/*U4XT/6*GJCS,[.Q=H4=(AN>KND^M*?J]5/.[)&P0I'3LT.2`
MBD?_+8,:6I"_LJIF:>#`Q910F[W9S!>1VR!?*FP'7KX#$<D;G[U;'WB9F7_R
M@,],XRR:$V1<O'/@9AWQ/C'PZ_\X0>I$\\5;V^3ANO):F=:Q8K5W*/^Y;L"[
MG_&05HH99DPRL]2<L:8XX]!E"A-]'PEA@K<%QA>`+SZ@&9`%`%/E>K%J&`,W
ML;A-6L#4&;N;=J7"K$QOA-?G3!21ILS-AP*FS\#S%PY8VZ*G[_/CU9KV?N/5
MC*?'J^V].OCZJ9M5I-RND7+V8Y%R?X"(DP\^0%DG_[CRLEM@YB\:&'=*H#<S
MI"5@H8CPLJ![D4"DS3&5\NK-ZN!?B.8^G`?YV%E0=OX5>CEG4MO@F4R!U!T@
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M7M"1!$EA>3TK.+A%;()L:XWE!HMRW-P'+R`[8)5$N<XH]8C5:8>F!-;AK$ZG
M//71*]_%2T?0V7_I]#^0:Q*>I+->2S?TC08/M(LI9`X[6Q-KN$^E^TV>R*,6
MJ->VGQU\PR]L<BO_AHU7)ZJC-D5=KBF1=BQ:?5TU=6M7Y?>%LG5?:Z^FVFKO
MN:=):?9:5YMVU>'G*=TW\LBFQ;BFUR;E9R>RJVWKZ/#\^9M^AAGZ6#=MJ76C
M!%V:CL&&F0M)KU2QX-D3[EF6K.!7P:\JE_%HN8S'K)F[20=^Z0MFV*IQH/NT
M_+!IJ/7ZSOU'3APV+55O&95(\A0._7I>P>?/6,Y+M8)@!<%U_&&IDL^RS_D@
M_N.B"_N+FV`)[XLHO/?&[K@[_P;CG`=9CD]GE'CW+/=O9[]S&GCL+2\.+=-H
M?O]VU7^OC-V1-W7\^)_OM?J2;]KN&GVKTVEI;=T>:A:HV%JG:UE:O=YK#9OU
M8=_2A]^-[T;S_2^:T;9:)DR>PW7[316!,>!%^B_<#/K>J!.,^YZ?4J;Q2T+@
M.ZSF.T5BQ3(PS"58--N&T6H,AEK'[MN:5>\,M&X+9NUU](8]M#K-`8.%";#0
M:U8KA\,C^UD(9EB)1C+2=>?+./G@1..O++EX\`,3^6,W/@\N*)7J7SQ9N\,*
MVXO?+R)OY!X(EMU.R^HV^CVM:_=-S3*&3:UM]9J:U>_V&NU&>]`<FM\;NFY\
MK[__Q:HU+8E87Q4^3SR;1Z;^E<H_B'E_C3`0\/D'L`SP\R_#)9`#YIKUKMW4
MNE8;25GO::U!MZ'I1K/;!H#7!T.+@1P0V#",MBF3\AYVO@#:]"9V_TKAM<$]
M'N++Q]DTZL"Q>JV!IO<;;<"T@:6UC):E#?KUIC$8].U^N[MMG$U>1'PK=7-3
M6(Y\89+;[<O7ZX%B6%+>;?UGY>I;]VKP?]]`254&O\._Z2++O73R=8EQ6#]N
M(E^]60H%7[F-5;$^+[BOKRMRT%I9/KS<P0/]D1011"6F?O7#&\JT$RXV5>DO
M%.OO245+')[K[?O.3<CK.+`LY4^\N$J6N*Y\P&FSCQ]988>N%]ZZ`79M'RGG
MP:BF?&#??,0<XUD:Q:G#<OU9V3$Y/Y^_2@661MD*6#D7K(\!?`4'X>Y!58E=
M]\]"??VL%#^FY"U68SE[Q_M3N&GBC>*\),?*I-7_-[Q0$G=T%X1^>$LE/N#]
M.W<:W@(\O2"<.<F=YQ;K`[B)HR5W#M81=*>>0TN`&^I/WZ5`I+-WHJ:O\N&J
MU__X>";@^HH<+XA8WT3CFOPHU;7'\N\0T,K'DD`!%?U)'K`$3E;@$.!_&SG3
M^!\TWA)`^,^LW08\`%`X>R>^I=XFFU[+5^513ZT9%AMA-4'HP&%Y`DWFZMJF
M6XJ3BX"B<0LK(C'QHCA1[E(`8-[Z)*'$9Y%3S1XAW,A128S.*T0N07-UU>?%
M78KMPQ@`EGS/H`[<L3XC+JLK(.V<1MY077+U5K''SM2+8U[F`W8+>(7$X_/R
M&1R@"]O$3.^$E1#`2A^X%UPI;U/%U\G/'\F4HTWQK%C9O>R.4A["R!\_@%2;
M0;RX!56!TT@GL!%6DG*1JK,V,;STT_@L+V24G\NJ4ZDI'58L$QOYP`!8`82J
M^LGXC"6`6$8]EO[(\!<^LQ%%M1#YY4(K'U6`(7+Q0=ZC".4DJF&2N#-6#05K
M_/WIB@99+)]?-,B23C$O:%)3AFF$IS,-L32AH(P[*ED(0X0S49ML%&(CNFF(
MC308@7T+O"P5G\IYY3>*`*/4J"4[[)7\#3!`2N%:!OC9.YFM2.S$P6]CT4B&
M=2[*ML&P9(2U6;+ETTV4@>(8F*<H!XF5MY#,1(TN4:9LXKHLE_XG4Z_I>2$J
MF>%&KC>]@5NS"!NLC<DJC<#U(W+8X72!+0<NJV-"E_$V3)"S<C@T:M:4X5>A
MTY3$>5W?8\4UX>C$YHI-#5?4'Z,R3BS!_@YK?PHNF!&.=(\C\\CX[V)CH67B
MSV:+BQ75>.%2F"3O)R1-LG(*FGII!KK'J5C:\LY45H^*]QS":8L;Q%LIWV2^
M5D&+$MH`;'\RV_5:ZTPJSIJ+%Q?4KLM8!5V8YZ=F7LJ,2RO$LGB-KG6TFW'L
MA?-F*(C;R<@49LO10.H4&(5SA[56ROCD,C-F)5BI3()'TBDS66ECP*5DJ3H@
M%=',2M0A-YNP+DQ\M"<1_XO1.JA6_^95HN@VI[N!PW<%]?,:A8+=(3#='W"8
M,1",RJ$VUVZ`/O%T.<C4O,YM=DO00/`V7)O\J9@J8&$3.W$!X5V=E[B2!%?4
M^B*0I1?(.Z\2P^IHL(YBC%G`<E2I'];"%7SV;HD.I?6/-]Z^\F50RV5,/UZ"
MEA*$@2:!*Y,3D$(Y[)0)#*4JDQ2;\\T<;_QD(.;7:5'X]TB%`DD/62J',$&6
MN&P"LCS@0<IJK0#N)G-IL[**4Q0X5FJ8?R<5$P2#3,%<;UY=I]HO6/VF,S^<
MN^Z5&]W#3E=;'+Z$P3U5\2;C0DP^VD5SZY<P^<--+K,<$V9S&(;195Y;V'@Q
MLT*KVVS5V]VZIO?UH68U=5OKVFWX5[O3;)EF=]@<F&@6?/_+A?F'H7\VZGW)
M,OBJ>R["^YP*"%\[/U;D5[T8=/J&W>JV;4OKM!I=S8)_:]U!:Z!U[.'`:K8M
MO65;KYW<M+*.$K.ZZ$6KR_F7WM?/`^6Z\_\-KE[&XG*(DG)47SD(I8K1(GA!
M]'N$7[P94V&\R02;#X[HZGUP>7M6S,A*R5:!;Y-Q`WA0W?J;4(G/WJWIB0G#
MC:BH4/;BRC+@>)7")ID<EB^BT`^20C&*01@X.\F45&!:H?0PK/')?\4D-51G
MWD;CPKXHNYX?-`&0=?X4U7/I^.E4F!#@3F=AY$3S!;C+IS]RHFA.&AV)IG'6
M@C=>K-?/-7"Y(!=6M:(&GZ(:NS"BB,&HKW!>T1PU-[E&NW+EW;(*F52G%58;
M"-EQ0QGY0@EZL58LDESU8WR=?HSUJK[5&T@N*[3E>CS[:&5=GNP*KG+\GE'R
MJ'2I>R^[^KV6OJH*+"V$ON(T:>$(\`]6;9GN4G9;KJHLFKWVNBDSAWJNA"L]
MK;RL_K(@MRRJ5>AU;.A57MZ'Q>6R>M&L5A?I/Z"AD/GEU9%OUT!L0VU;AT[M
MW>\6FW75,*LLUQ=(5R?N.@(VZR4'QO;GID0VU7;[T'F@K[156VV6H:?M,3/[
MGC/S$H?UO!)NI%=%^4>.9H<1EO$D-T-AT-V^EGH$!+-S^<JW>%5<K4E\/,8;
MP=RY]NYQ(7A3K3>/`LG+>R-D^B;OM7-TZ%Y7&W:]_.C^)BZ^T[H1OF(DR='1
M@Z':S3?"_MOU/6_T5#*O"VZK5ZK'\1)SO@9:O578G;I@P\J9+,=%[,;0_=<K
M1/'L"T"OJX9^F"O@26`Z!'!:+=4T]FPO.RTIZ/?E\+*3)Z$/SZ2ACZ=#,!^>
M1S$K(%$)5>46#"JAJA*J-CF+5X2:EOI"6,66MG/`EM_@<HA;Y93A>8)WTXGU
M8'KEV^G$H'=:J@E.<R/(+0O.I(C,3WF.!@N?R^,T'^L/7Z:[Z]#/[5DWV?MS
M;TX>$[E)<SF1S`L2)V"U`(Y`7GLZ/U^AM3:MG0O6ED1YKQR&QREOG90^6]D"
M*EF+3;/"G9+=-:6_3G;ME'R:MTBEK)?V\C@Q=;-2U@_1;KJPZI>N);*J3IL`
M5R>F`HA4+F$TPFH'F%(D*A@YH[]2+_9$(<">&[FW;N`6BJ*>O<LK>-R&X9A*
MJU'1BT45AI7R6/KZ[!V;!^\HK'\@)L<:3%C`CU5H'*6^$ZTMNG9&U;"HA-3Y
MQ26=$/Y_G_5*BUCS9F_,B[?"E>AAG3[-]^YQTGQUN!M>&PY+!$K/*NQ9!)#/
MVT%/9[[+0!,IS@W,%`:\--G9.P:^.`Y''JET:ZO%N1/8;T(U)+"B":M3L@2C
M'$)WSKV+E5+P-K]Q8@^KI!7N>'@]UR@?G%AQ8\0T+[[#TF!Y59,U951NPO#/
MLW>\;")-P:N/)7=8RZIXDJL`B<53@I"J&V)I0_H:ECA)DQ3.(0[3:$2567@%
M$)B(T"ER)U1M$;9V+]S7N`[AP&;%+GV7@KWS4Y#K9DRQC`>F25")-GXB[EA=
MHNJ#4-JEZ\A%-5=5_\"R,^X,ZX`"8E!9/P:U,RPXQ^JSJXJ'5=SFC`03;RHJ
M=^8E^5CQ7X1(&O`*6S6D]!$2*3SN\Y>#U8XAAF$WB`^L_%<XF>"Q4HDS)S\<
MJ70-8<.*'U@M.SJQF[GRDV'5VF=2_;V?&C4KJZN'>_C):->:<J4]6N<<]AXK
M[J8NRUBJN4[_-FD@;!)+96IGK+*//Z\AIR/"W#1`7NIS3.`I)EG"RX7$,U9'
MQAUG31FI*;Q<PR@K*$,S4PWE']X4'@*P_F3J[7P-"V!HYU`J[N(<!P+R4E*@
M`$3V_"R75_+(\HG1W5#=`.`)[H\9,!CDN`"+E@"C59S_K%BZB<K+85W4Y;GS
M.J]9VM[2`K"VHETSUT#!SJLNJBM7(2;-IF+3/+(Q(`]?\-F%I8KW!8^E-QE.
MC^'!FO*-@)[1\(:B4LO8L[!WW*(,(P3.BN1&9>K,82M86T\42,02OW`]4-%-
M5L^16/[42VAAA=)5X4/@1O&=-Q/EI^3G9KSI!1(GV\HY%K8(8%R>60![&[N\
MUC8<A1-QB-&;6.28WP0KE@'W8^K3%E,_$14Y)8#RVDA;4-DBI%;#Z8;N#W@Y
MS<_H*36U]LCY98J98(51Y5OM:C7#B%S@]T',BBS>.U32BN-IFK`BQ=()\J*L
M\![CD9,HG"K`/%H*!PL78\ZP9K'+B<&!*X/C=(XG!$NLD(PS+)\)SHQW:@Y]
M/G>!$;"].<JW_UW>DBI585M8L*GK3?$KW!830$$A?JU8=?G.M$CXLPCK_S)Y
MA57Q9>4.\\*7L-6_$S1A<[RZ:\'PGT$.+@IXA<K9KJJ+U^'56S==:'+Y.KK4
M0A3SHY3U,*#U,&$/5I2OAYUM&F2+Y[(@B/X3Y(_(DS@_&8O"I8R8?R1TLKR0
MLCN-17%:+\Y*9),4`JB-'"**>9GFFS3V`C>.LTKUR(!$:5M8_/K%.$3U^:]L
MTRN*^M&M@%<GL%.'?G;';Z/J'EV65%*.:BFSHF[I=`K'\A\WYIH>%:TN^*`V
M7&_KC^-MEZQKF_LM66<^O61=XW`EZPXXM555RWODW1>IEF?H5;F\,IQ#Z4KK
ME6'/+UR0;Z<W7F>GQCYIJBH]N.!7I?U2^Y@;Q]\]N>89KJD=G:.FVJSON?9"
MF?;:V'/EH9=B(3ONT%!;^RXC=5KQ$!W>@D7J3T=&VC#F7Q=U'X6Z_P1,HWUU
M$G]N.)W9/G1AO5??LM$X@J(B+['11NLH*@J6]P;/.0$YF0I,`)M:11Y\32;*
MHZ/[PQ/!`<CA;9"]:1]%X:RR$/FEB\VRRD?E;R)*O'Q<XH.Y>XF][2-#*TQX
M`R&?)Q7S7D'Q",-F3PIVIZYM#(+QLXV%?NDS+^JJT3(/(E24'S9H>#V,.>9)
ML'E=B.S;/'N"@L>)94M4<#Q*X>.HH%?D`DM)-\NMH#?U'%[L3GP1A2,WCD7+
MDDXP[N>I'1<@*XWF+]:FV.A9=J_?K6L-P^IJ5M=L:"VST]$LHVT-++O?&_3J
MI6A3C']0P8[S/(N%M61;Z%P<:!Q^A9XO9QBBGP&1SNBQ\A^'Z&!\OI2B4PCB
MU&9\:QLRED9AG&"G]*B8LZ0N)BS!@#<KLFTH">;LW:/)2)M2D<[>K4Y&.I_0
M>A_NW*#P@!>+J;`3/"::P`B8$A8YE"HR&J48L"J]';FW*<`%^S)3_@-P`-S0
MU(G^=!/%.7LGNMKCV.$-9JN(&$YIS1S$#Q13#L`88]]W7'TQ_P@GI4<2G/I&
MS@G*77YWKA=)^00PB!LGE)4QQIRS2>I3KE>L.#S^=!9Z`0MA!V2I*1=D-X0]
MY$`_>R?@_%B>E[J8M92?\]F[I3.N*7V*KX67`#HS:IA>&$&*:877I=VFB<B"
M4!)JS,Y"<J<SQXL87F"6!0_<9XED'!]$,AC_"=^F$Y5#B6]<Y)'PQ@-N(:2,
M)!:Q2S')B`6T;)B2Q0E3$//(BT;I%',71BX/#&:G!=OV1ABBB^@0";.MB!>>
MP)(IN\@50"ZF^/'$/TP!\,,'=KXTCCCAI>;0Q=CU\"9VHWO>?SP#$#L-7%88
MQ?GI\D3'X@KX0BGR^?$\I>4+:\4=M,7-4KR,5C\Y8,'B+WP5M6Q[T&O;AM;6
M=4NS.@U;:_7[MM;7ZZU^K]DP!M:K7T7ZIINHT%-,`H_"X1.7]II9VPV-+@_B
M(#PA@/(LO8""%H!QB!?/WBVS(KYIQGMBNB/&7H3I17*NC<8OM#.6A3DB!HDY
M(G<8`L;FCU-<6@PT.N*EN\2M%CN^$WFNX"KB<@0>%H=!X/KB.9P1>6_DB?2Q
M=#;SY^QGS`;`Z;F[5MW`7L6>``)^.G;Y^O(M(+_V@;6.D*?A9#`W2J/C0CK2
MRF!W9($LR8%?ZKQ#/'T:@WS(/@(8'ES,?<Y%@0Q:8GFUQX]4'"%Q3`058X:8
M$40R@^\[-V&$;$F;I,AL1.P^`7LM/O1H\"0\R[*M85^CNR#TPUO/S?(TW"RQ
M$.??(+S0\R)1SO$I;XR8+4_TQ>SMM:O9@@5NP<^*#+"+=]C722?+8F</L7]G
M$OR+\<!!MVO;_8&NF79]"#RP:6K=0:.C=1OZH&4;@WK?:)9+'"<`(:)?X+$&
M2=XJJXR,#V_H6>3.G#Q?$"0C$!V03U#>'.)#S*D$A)LIY;LS*LDE4F<T<F<D
M0>;5#68@FXR\F4^)5T0*F-(4.+<NZS.)-#)U_G0SN5#0=YQ.9\Q]S*B%DHB8
M.,8$"QAO!B(8$0^7S%<NFF>[T:*(X>"R0(S#U*O.*$E94FOJDSC%$BE9NC[+
MF&.I^-GJF#B#S#PD?H;"GICU[%T16(PYBKEIS0!9D?=,91M0K+P+29Q_"(AW
M8L:I-_:(GZM9%0AZ^E>0=YR_E$^8E(AR.TO?<S%),<@.#DZ"Q"GX:20D2&8,
MYZ"(G"!VF*]^&]ZP':D7V</5'7`C4@)Z4J>X3A2A>(K0Z<[S1RZ<.7[5P1S*
MK^S(!S]@\5Z,YH-_N6C&=,<=X.Z`-)>4JPBKZ`%KP>P_.+YK-YH:+\9KVGK3
MJMO#IF8.C)9F-7N&UK%ZMM8T[89NU0?=5KL+#^O&=^O]+Q>-/XQ6/P?6`3;^
MLI#_G?07N`>0^6/2WG6(7WU-$U0ET+52X@.IPX'8?QB?C?H+'LG+063A"N5)
MF)V\[`OH(4/@K<XYL5A:Y\O?I76]!>^UZUJ[;[0U:]AI:=VZWL>KM6UW]&%K
M..RNO4OQ[VM4CTEP)/`!^P393*$5`]O)5DZE"JBR!;M9F%9,+';*+AJ07[*:
M#23SA"Y5,V'?1DENBT'-$!^G@AL.2D1,ER61B&G`5*U%,/J\D`XM8.H`&R;#
MP?\XH&='\UQ/9&JBB:50(A*A8(#YPI242BYJ@_"KXAF9T2^<:_EHPM5+I%HV
M[?VF6AI/3[5L'2[?L5GE.SXQH"G+KK)795?)$O0?&/^?#3Y`G2O_6*4X/@/T
M9H:T!*P#Y"D^<;FOFW%XN@?_*,U].`_RL;-Z`OE7[@_4Z_+/,YD"8Q2>\H^@
M$CD?]WDR58;DBAKG6#=F)X?P`9(%/]1UM=U^1GAP>;,$/YA-U;*>T0SLS>0+
MH%5A1,6/J%P7<!2%,9)C06*]UM@Y0:34*`P;VSFR\-D(7(6(5:%-Y83>DT.;
MGFC?*1J'+MP`*_YU@C$U6;\(XR1R$R]B!BM>_FE%S-3+68F:_6&O83>T?LOJ
M:-80WNU8`UNSNNV>:39ZS6&]40J/RY>OUP/%,(O13H//%Y^^_C$8*-W!E\'P
M_%JY^-3YLB"4EL'G(J(BXAGZ$Z*851?&H!P-#S+R;E*R8L7./=:C56:^$RCH
MAT0[VA5S5N88;.G&AS\_9G$;*\M+CM!+2M$9Y";`HK,:1MHH[G3FAW,7]O)!
M."CX>!<PZ4?F]ECQ"_H:8G(WD'LT"96_4B#.R9RM<^4J%Y=(?MI\D:];=7"%
MZ>U%_I+/%VA]=$?>'?E88ZP%FL/=_2MEX5H-_6\"0A,OBA/%IL_BR:51TAF^
MY;!BE53GU5`;NLZ+L-9YF5M5S[XRT3/^&==$]<?AH)@SFY4@OF<A3!10EDW$
MO-KRK.2Y2U8CA?+@PG`_Z34C*S`,,P.SOMNZP+"HB6L2YL%H-&00LBB(`@#(
MW45EB+?Q9^W*6A?\+`E\=1['J3MF46,7%"]&GH28?BQZ=-SQ[JPY#3SV%DG(
M\7O@$2-OZOCQ/]^??QDNL>[&8&C6NW93ZUKMH699>D]K#;H-33>:W79[T*P/
MAM;W!O>7&$VC`?-([I(G;VP!,.XM`O*2?+-[#PQH#4W+[K3ZFMGK]C3+'K2U
MCFVWM$&WJ7?U5K_3T<U2!4=Q\)0W!JH0K$=U:5D\81BX2LP67P/>D3GP4ZI7
M&R!7FKH.4HR(A)U%(9"2*(Y?</#`0)%[2^5X,9202TIX'V'<I+BX(H%#O)[X
M-MQ"Y1?;IA`C$<Z)#`5==2P,5@06?JM=U90A*X<.`TG\ZBGET`V=,?&(W6O4
M=P%^S"O]9C%4M`P60Y'PL%HY*DDL:0O.MA7I+5`K7DNI[WZ=]'EQ^FOG!XL?
M!P8I-8DD<]H>Z+<_Z.M6W=3J[697L^IV7^OV[2Y(G1V]W^ZWNW5]O9A)]`1J
M@#?Q1@Z%=$U!CG)YF,7:XU_HWR`W-8AYY=:W7EFU9>W7W5>OW'TGY7IXD<*+
M*]T4V0U:N?Z>Y?HK6<72EUW]7CV!E;]I15?IM'`$F73+)(=_K!5N\R;3KUKE
MZU#/E7"EI^5%ZB]W5%H6U2KT.C;T*B_O^_)(IZ%71[X=O7PM0VU;AZY9NM\M
M-NNJ81Y%Z<ZR(/?:7*EU?:!>G]4^38)<Q@FUO>\JS@<2EI>V:JO-9@EJOAPS
ML^\Y,R]Q6'Z>2,Y[591_$R4+RT(P5;G7)Y`&.8(T5N9A)*75'..-L'NETN-"
M\*9:;QX%DI?W1LCT31ZN<'3H7E<;]J%+EE<7WRG>"!1,<73T8*AV\XVP_W9]
MSQL]P?C>DZK\^\K1O2<%NU,7;*Y#S.,>+YG3=V/H_NO5"'[V!:#754,_S!7P
M)#`=`CBMEFH:5=>S)]#1[XZ?LNH'6,7KX2A*D#\72SX\DX:V[_=1>H+Y\#R*
M60&)2J@JMV!0"5654+7)6;PL4NWH-7NE"V$56]K.`5M^@\LA;I53AN<)WDU'
ME9):NMOIQ*!W6JH)3G,CR"T+SJ2(3"G/@X7/Y7&:CZ4HE>GN.O1S>]9-]O[<
MFY/'?$]DIQ7:22STFB@_SC]7:VU:.S?U+8GR7CD,CU/>.BE]MK(%5+(6FV:%
M.R6[:TI_G>Q:..HT;Y%*62_MY7%BZF:EK.]4?8O]0U\O5T38K;S!BI+ZW<<+
MR'?7%)`?AM'$];!\>'P>L&HJ):P%8[W_Q6B9C49[H7+^RVZ\"-FAXT7H,74_
MYY5#_N4E=]\"UB8,#^4\F*5)?.D"Q+#K$2T!/K&>9]2;0ASCG$UQ'HPB&,[M
MN^R_+P!K+PXMTVA^_W;5EP&^7,ZB9[=;K6Y]H/5Z>E.SVHVVUM('EJ;K=;ME
M-%OM;AW+T9CO?['U',ZO`H8BY`=.A!T*8GB6CG!?]7GZ9GNHFTU=:S<1_^J#
MNM9I]"RMV6J91J/1:0];ZYL-'*1Q#QH)/F%>WP46+\M*DI:Q5,^Z&JIYYP4,
MS<?:75AH#(#KC5E[0S=["4:!G_";!][$0G-8%PLE2+'<`E928:P&_X+QIEB.
M#J/_X=4P[X&AC$7O1)>W3JPI?<^GR5>LT*->.XX_2IG=15Y?]OC"RI2EE<$8
MJ]?&.H:%"1`2-@,:XT*PF4.,%$,,_]'5O]H)LPHQZX[8'3G8W$O46*-2>XHC
M@32,>;>V\0IH"P`I[@_J1133#EUJI;0,-&S/!%<[%=#AW>I8)S9X,&0LG?<A
M9=5RL/T:`%@3X*TI'=_G8_'G%\!,M8[X6L:BO9*;(0+O8+2X$Q@DPYP:2SWA
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ME4`%(4;!FJ`[V>,.F52'S\E&^G_]=GX]T*XN.CV`F62X-FH-73-J+>8V>*ZA
M_F\'HZ07`XA>:UH`D+I5`40`I%W7S!IG)'L`R&FY'46'4L7W)FZNM5,Q6ZIC
M_/'H>$FC5K<U^-?.KL7C2M)MU$#I;M0:;V:[]39LUS+VN]U3%QPRNB<;*AK`
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M_)VOH!?&R0+;WK<`<W!8_!KQWND2'+X%D>OX*P#T*T@$<06A#1#Z@,%S+K<T
MOB$@#5C(R1(\,+@S7QV%>;XL:*IN-=NE/:]OWK=!4-V[BGZHYZHU5VL^.I-;
M_9%R_46-[$UV`JK6_&;7?/Q>KL9&^OX<!BZV4D>;'6M:_NH$OF-JK*VVZX=N
MMO3L---3282M('482)6;?DXP/?JDZD-44*R@6$'QE*!X6LHG57S931[UCZ=2
MV.$$V5<"TINH(U:!^,1!?"2D7LG<Y;ZA*RA64*R@>$I0/'X3\68IO+,I^FY'
M?]!KWMD'?*[:8[7'0Z_]N`T$F[U7WVI7->4VO'>C`(/0E7@6!G&(U6&Q2%4R
M5\;N32)QJ_(SJV<J&(9IJ&;S,!D71P6F4X9090PX$B0$6FWOG.U7F0-.07FH
MH%A!L8+B*4'Q^,T!V[1A6)6IMSE/K_2R]XYQ-(:)[6E/6J!\%G1.&3!O,%#M
M&%`."-*LW&Q/O1&/JG=%B:69"HZ'WE(%QQ.&X[%9L)^;2;E8UK;,(O0AGZOV
M6.WQT&L_-4O`J^2&GM295WNL]G@L>SPV2>J-Q0+L:/XPU7:[N=6K1VH:JHQN
M%62/#;+EIN?C%U1?I\C!:][^SPTN::BM>ON42:J*<JI`?/P@/A9:/T%_UTE%
MG510K*!80?&4H'ALUIFJE`/<Q"VXB??<`*(2"4]<)*Q`7-%Z)7678LY*TJF@
M6)8Y*R@>C]1=WIB-JIA#Y?BO]G@B>SPV$\$;"^!XKH;1L%3+/&EKPDM`Z;0A
M5!D#C@()D50;>TYUK(P!Y58=*BA64*R@>$I0/'YC0%7*X2FW>+.NFO9)%RQX
M!G#>GIQ=A3Z7@!Y;>RYF>()2]8DE?%=PK.!8P?'TX+BIQ[;41)L]BM^N6C67
M=D7W\5P^?K+`3!LW3'R^(#!;?\M\9[$23I3U+:]5N,%\?"2Y<Y5>.)TYP3R_
M^=L_QS"&%]R[<3(E.?O.&2M3)T&A>JZ,G026]>`E=UZ@)`^A,G>=B,GB,%SD
M*@_XKR"$,;`C>N2!Y)YF_>(5GQK$*V,8++BEU=24SFP6A3^H@;H_5YKZW_C:
M8(A5J]LL\[.5NMD*:9C`_9'`8EW_WE6F(!/<Q6+[N!WQ]XWC.\$(!KMSW83]
M`MN"UYW"`NO9`K=='@PA+?#.P54P>.+G&Q=6Y@9B?03)!P#\'-Y/([Y>&&(2
MA=,MUEQ3KO.5T=D5#V/Q*,)("?'DM.3.";3$G<["R(GFB@<#>!'#@'""4-@(
M=OB.%L30P0W&,,-*%(21&!)BS1#:+?QAU);(=#WI_"B2#GXNT$9+DH-6LP'V
M#WTU]N[QR__^>QIKMXXS^\=YCOGG0=^]23K!^#.E9.'>!Z!_)O.K;-_P8\^-
M$L<+KB-G##C=`:`F<=^+1P!?0,1K0+VN'X[^_`5F5/X[GV443MUKY\=%Z'NC
M>?:4,H+CA@^7[N2?[]W0_WXQ:)JF6=<TS:@;NO:_NJZWOE]=][_7[<9W!*1A
MUHWO^GO%&__SO3?^7@?9O56O?^^VK4:];9K:L-_1-:O7[6G==EW7FI;9-?6&
MW6ZV.M_QQ5\0#!P*^^9:0F#G\]P(ONGA'PPDP%A_<,W=R]AJ]N"6&/*\9=H;
M>"M?9.+\4-P?,S>(72`QI&$@8&`2]Q[B?1HC<T-J\#WGQO.1;T[=Y"X<UV"(
MOCMQ(W07XB`.H0N1@7@6J<D!#C9V@6*G7@!/WC@Q_#L4[&SL36`(%^D^8QXP
MV<0+@!<@C<<)4#LY)XF;P#PX`C$]-B&2\^*4P#I=!U$6YIO3@&[@C!*^T(CX
M/O"(!%@K7!\W+MT2B@M+&<%W=VP1`(]\=3$PFWLWBA=X$H<33`E#P(V?.HD'
M>X-+*7P@9N;<`CW%";!M8&DKH.5-5`Z2=!8&,`@N-F-/BHNCPSBJXB6*%P/_
M2X"+1G@:?R(#1T9'7])N.$A73,/WF7',91ZUBGNLINLB]5\E\-5Y'*?NN$\W
MX07PYG#\.\#"O;J#P^_B[A!>@&$,.COSA33PV%M>'%JFT?S^[:K_'O8[@OO,
MC__Y7JLO\0ZC#1RB9]F:/M"!=]2'':TSL+J:H3?J5D_O#KKMUO>VKMO?S?;[
M7VS#:,'L.0R>OKLB=+Z!N#`*;P.$.4"RZP;NQ$-N/(*3`#2^=./43V#<(=R(
M%S!TQ"8@J,<>#AB_*KP:K6[+Z.HV#MW5K'YWJ'7[G:8V&+1:@U9G:/2[.O!:
M\_TO1J->`-5+;+4(O$N@N"!U7Q<`S3;@0&,PU#IVWP:$Z0RT;@OFZG7@IAE:
MG>9`'P(`ZN]_,2VC7@2!6/`S<.#*31*?^%W\+Q#[X'F\B%-@N%PXV1\L&DNP
ML(Q.PV@VFUJWT6AJEFZWM)9M-K5>`ZBD4V_V&\,!P,(`6.CTOQVQX;%-+\D;
M-`:(9/3?\^`B<D'`&XO;:,!N,Y!GOJ(TR,285T4BNVOTK4ZGI;5U>ZA9%O"?
M3M>RM'J]UQHVZ\.^14AD`!89=A%PN^WN&1C72V'4(#D.OH.HUK9VQ[2UFRT"
M$!EZY((<$'OW+KL'O[C)UPF\4=+;JPZWEV;:=KUX?VW82'''%\Z<Z.\Z[(Q`
M+XC<7$_(-812TA!L'#AV:P$KMMK/(R#HHO#KHF9),,/::_R7<1DA8<*EK#7;
MF\&P84\K+U\DFE\C)WAE!KKE+6SB+=QHK+J$\X47]_5UYH+\#^R`4<.G,"[E
MSA@Y-W6[L+<5B]]>&J=S/@1O?P(7PPO17!`EMMU3$1*_@MZ%\/D:]+UXQMG\
MU\G>A8%E*:K3L`96S^YK0\-L:19><IV>;FDM<]#4]4';:+<L)E$:"SO?N(?B
M=G\7NF='J)Y"7@!63R_T0%6\A3N@,PU3T*9?58YLVK#'GJZUVFTTX`S:6LOJ
M-[6VW:\WC0Y0\+#/##B&U5Z`P5,W]IBLV!F-(L"D<]A]Y,:PDY'KW>.U`/RP
MC%S=,!`JK4=DQ$V[6GW+7;J^DP`00P`C"MUWH8\VOV$8E4!KW_;&:Z+F8316
M7GE/W>`6B(/X%>>P+2-(#!0"@(]L@3`+NRGN_TL8A,7+ANL=9;PL#>`<+;.P
MX[7K7]BFFY1;#D#R1[G>+(JWA75O+P(,IC,_G+LN/7.11J,[0(8+WRFK3:X.
MN[?:]M;BP-K]%4'4&?\[Y7X1$(S'8[I7'?\"M.SSH.?,O,3QB4G<+#*)2Y?)
M&Z!$1/?>R&5S7S(%%!^@9905F@VT<%I%<.X;%H^Q55#/D\A#VSSJ(L"=,QFW
M,TJ\^]+JG2"@U\W'3#?;;&Y[ZOWB/M`O997>\3JVVU;;W)I>LQT]HHE?1,C,
MDSF2,CHQT74Y(Z=0"3'#!$G>JILKA9+'=[2@K:*);X41YUL6AO`;$VMR54%R
MZ$8>>N]DJ)?=BM5$Z:5XU>T+!"L`?0V:Q+6(&CC/@@8^472!Y$S/,KHG883!
M`P>RD#7:(#%TNGVMJ3<Z@(^VJ76:G;HV[#4[(!1;S7ZS!_@(7'\1G,_?:!%Z
MH)*A<[<'FX^\FQ29/R)V+R15A!MG7U7EM%LFR$P]2[-;W:YFM7J@<H)8K`U;
M@Z'=JS?:O6YWM=*]U5X6^%44CEQW'),O`\#T=?*;ZX/F\9E'&I7;@FJ"]-PP
M#'/!<KCUGK;R/8@[\2`>SQ^Q]X_`\__Y/@$E>5?7`\#W[X\),T+^Y+KG)RDF
MH80';P!G:)K&(S+,^CTM&-S@I"/'A[NL,YYZ@0>2#T@Z]V76&VV@?G*8%(QN
MF_>QI#^B9'?!PV6Z\V\Q6F&&+'RE[#(LACPT;4-O+NJ66^YIJTO@L_/#FZ;3
M3A"DCB__&`/A"^3:MU'R_,MPURN"0AVVN"">L,\BW(1+!F2<&X`QOH*O`Z3A
M"H:_8CB%B)E`HPA-G70U%ZV>7R=K7A'D.C?*2("H,!2I[Y6`\1@C%S9F[DPJ
M(_$:-EJ&C/9C.NC"5A[;.0LJX-9!4%M0^D->R`S,9;_1K/>_F';[$8ALO<4%
MU7REV5A"P^X\?X0K?)T')QI_G1$;&/QPHY%'`C87>3`7]!P9!>#H:-^6HQ4R
M<K]O#8>]AM;J&'7-Z@S:6F?8:FBZ.=3;K89A#8TAB[EH+7IE7@,6VT"_C$BX
MRLJVC<N!?/$!68H&>6HP`\\B$I=QWW4=E7?#:A>#XIZRK?5J%9J)T/F'O'TZ
M#0.R*I41"F8+R,6NZVN5J94[*6X\,V,SP^H:8O/]<.0PCW"NF#*XHK(:<^,M
M?KMO\6HY9K_5;;;J[6Y=T_LZ0*L)ZE77;L._VIUFRS2[P^;`!&A9!=O$GO:]
ME<C.K![E%]D!8B"P+L8I;[^IQ2B?V'6B$1)H'^0#/R0;9(E5-F"N=;N]$.6T
M<1<+KA]AT4(_<,&B]6L4QO$E-RDR2U@9K7E%BGG2=A;5M5D$ZR%*@K]]EX@K
M0)J)$N\_I;U>Z^]_:2R(>-ML9<%8$89CS(F`AT#H`*'%0QD0HTER:^@>-V\O
MA\@,;*,]'#8UW6C`YGL=8)4#HZ_U0/5LM]I-P^I;+$1&-E5LL8O5^R[:?%]U
MIV;/;'=LD#H'N@529]-J:NU.#RZ*9G]@F\U!MV.;:W=:7/<":;.+P1VOOC<.
MP=3,9F\P,&U@94/<:[_9T-IM<ZAUZZUVO6-WVK!99F)8]LMNM9LUL8W\UU)&
M-(!\U-!!-E@=V"A6OG"T$B%_G6`F(V8EXMU^$;E3+YV6D5$!IVX;13?@H_M@
MVXYOI^'N*E86]Q!Y"U(F"$DC>`KOBAEL<.(!=N'W&!KE1B\`PUD:N8^9W<Q>
MS]`;S;K6K!N`)GV[H[6'@ZYF`!.PNV:CTQWHW#-3,P!VAP&&=!!9'MS^.<@R
MMVPTF]:P";>!U6@T-&L`?+-C&2`?V'J]VQF:`\/L9-QRY7*EG5S"?AW_%9C#
MLJVAUQT,4"W2ZGIW`*NWX7ZK-[I:TT!5J3\<#(T&VT>3FQI6K%C:2B_T0>X)
MN2GP-G*9(;",#`]S5@R[V<IWM6;QTO;6!C)=8J6>^%\N_@?TFWM@F[?N`&1\
M3(H?#^%RW(,=Z3MPY^\QTE<L@\1<AD@#X-%HF]H`)!:XV^&4VWT=I)B!.:C7
M36L`<."!OC6KR:'QW+U*8%LO#@NW):=Z&.@+@.>:ZA1\9F447I[]+0-H2R$?
M!`*]UA3H\IQ=O<2%PFUVW,%Q[4;3):;YVS-OD-WN"+AA+QI_//>*V'I[$BPS
MY/O,\LR)?E=42G@QB%B#;M]L-7N:,02N:77[AM:J@]1L#73`GP9<!I91BAH(
M7[Y>#Q13*K]6_WG8.;]4?N]\^C90/@\Z5]\N!Y\'7ZXW5$/`PC0_;B)?O<EK
MTARP4(*<\,_K"@"W8*4RUE8]2)0)X`C5!,"D?"P*H$1(N%0MYL:)O5A5O&#D
MIQB[M%014GVT2@G..,K\7/AG[NB"E[-R#;6\<`AN)%\5UA-859C!49([N)(T
MF"6"@>[@/VA<F0.?0QJG`@4\-Y<<X\IMZHVIV`$63BGL>BI1!RUXG)$(+\`P
MPP@0V-!_Z`M84S!+X=D4U^(%V1`((FGE#A9IP7R0%?TS]H`AK+"G];?M4>83
MFJ$4XQ_*M\"A`%O8SE]IB/^9H20:8[T)9T3@8TVR.3R`0>')C^"1&+5YA95U
MD"')BN8@K+$V1.*-'%^END0BUA0'8%@)STA(^2IE1W:%E?D/Y?\6`;0(&:IT
MP:"FXMX8LL`0#W?>Z(Z>"&]B-Z)\!E5Q/73T`<X!W27^G+TA/JD(0:QFE-[$
MB0-@='R?E0J9I+ZO(%F(PD0$3!F6\Z=`\I$2/_:C%7Y>]:#T1P^J_@_E@IU0
M&$DE3Q)W=!=X?Z6"L".7XEP%0>-WB)?PS4V8W"FQ=QO`_3H"R"M)R.">T[>,
M[<@VTB`_5QCE@U=S:RH<W6P&^C0K\@+'D@"YP)J"4/2==YC5>_[Q*269]EC-
M[%]862;?B5@F1_@"1<N<7F(,2>2,B3,J/C"(10Z"T$7.J<H5O921#PB,L@S0
M%"N7LWRO4)\/+%03I9Q9QX(N:XO+I@I<6RT\(UDQX9I;;7EV>)$&%P6(;MQ@
M=(>SP@`P_+T+EV?V'3X`I(HE<:395?P[@:7=1F$Z@V?@&U8##=2'R/M!$^"K
ML%40F'VJ&A2.8<LS]-:AP9QJ_<0N^SKF1P"_PIMN@H7%<O3GC\`RQ+"\-%!$
M='(3A7_"GWS`0JT@_B:(`F&$`;E8JDT)4BPVAL,Q^I%$!14V&C,NCW=(7L\-
MYAFS=_BE.O]'#B-E[KG^&,:)7$8S`ID0D+2XOX]=.(N(75,X(0;F1TH\BUP'
M7TP>0BVFFE`<W?`P\_%EP-]X^$*(M9/8M1^YHL@3W%U.OI<<E2+NPE%FZ8WO
M,?\>@`LD\4S2XC,`DY[/7"8@9>DJ@LU,G3F6.6)$`._&6.&*L_$K8/-CD/>5
M\^Q9K*<'^`EO`!QQ6D!+25X:L%,*(S9P+JOD-X^H$$7W"QP'T-LMD&0`&YT3
M8>`WV<HS&8OM&I$Y#-@>&'8R<O&S_;"C)GK(BT+AL+!#):L)Z.;8Q'&7GG$=
M@&<VM_20O%#<@S,O"8.\7GL-$&DM"<F/%BC<)"0O52EC/`R5/L0M)G<Q,1/I
MV4=V&$O%&.65YD+R!X]5\0K3&"://SY#0"5(+5S.6\@*5.1BQTKVO")I[^NG
M3YV+*WAIA*:J6>R^!S+T_7CF(&\CAS]^GB$%\L\/WCBY^^=[0]?_EM651J.$
M&[V'*Q]9$SXF]#U4\;KN+4"251_]#9A,4=,K%HD>B_'MQM^V+OXLWJFO?^6E
MOJ^F?M6IMR@AWMJQ"]O.+8J>5)*X6`%8L(!"AXV$=]A8`C+0)!`B?&%8BY0F
MH$5VE94U2_,/:)NA9R/E[WQQ:-;*'R`#5_Y1-G4M&&^>V>ZI.DT\37/C85*`
MY,N"O?R;)A4D7X;Q)O>OF&]RVQ+7VB>W*19!E\2055)*=\D>?7H=BEAUH1W[
M$C^S.<I!GJO67*WYQ/KZ?@X#=RY,*Y,4]-!7)^<=^P_9:KMN;?7J2_=F.MZ]
M[GF'K]*G*U]5N3IV53`[Z6:-96B/_C+HN1,',DQ#-=OZL5/6\T8XGO:!%:94
MF'+ZO11/JI]Q!<4*BA443PF*QV8IJ#_>CWPWN=4O?3-CPVRIIGD8<T+YH7,X
M4TOY87-(<?>5H'/*[=<KJ;C<=V@%Q0J*%11/"8K';PK>[!67JL+MZ!I_1:'G
MD,]5>ZSV>.BU'[?"OMDGU7LLFGU>>O:TJTZF-IJ51G;T3N,*QJ<.XQ+0^$Z7
M0&41J+2P"HH5%"LH5A:!M^XYJV3M2@ZL8%Q^&)>`QM^"K%V'6W(<IC>^^XI7
M\^Z3EE;"J>!XZ"U5<#QA."YRWN**[ZB2ZC_?&_9Z]BH](]496/="E;C_(F48
M*,&[*L-0CM.LRC!491BJ,@PKCGVO91B.T3Y4U5&HUERM^92#+4I01^&)9JQE
M*T]#;=7;6[U;DKS-M[GK-Y&M6H&LJK'PUFHL-)JJ956LJ&QT52%*A2@OQH"/
MS)MU4G$F%10K*%90/"4H'IL-X0W'B37KJMEJ'41F*3]P#FB$*#]P#BCMOA)P
MCK[`PEL0A4\L`*2"8P7'"HZG!\=-/0NDI@3L4?QVU:I?H_TO_N'A'U*><J^0
MI_RID*?L9<O.`PM>HPW9MOU^O<#CK4$C=X1=K,:*DZ=:8R<UZA`Z^BOU8NKC
M1MU981#>=,X5[<KE;F'8RFQ=&O>,=::.E22$429A-'4CI>=&+CR+7;W"T9]W
MU(T:NY_%2I@F/K7OS9OS8NO2F,]_A@UTHUOXQ1%MYJF#63:B:'$HK2=;`?53
M?6"=!B>%EI*WD4,/P)=>--9F3I1@!\Z1&\!02:B,,7(DG/%^BZ-P"HL8`1BQ
M=9YHYS>+PG$Z@NW#0QX"+69@1-/_)`JGV1*QD=_R$@J#QM3/CFTY=E<,C>\G
ML>M/:@L]YN+\+=[>=*DM7':$,`CK1NG@##<<![0'WJ">FAN':8!_4J>ZB1\^
MP,(<?QY[<4VY2D=W9U+GQSCKD2HW0Q6SL=YU3ARG4]:?O-`U\29-J%6@[TT]
MG"\)_Y'U<L85$A[`;[A8&";'PE$8"]P"",Y\>(?W7=9$ZT#X[[_=$7;7XW_A
M*'`4J8^M$.>LY23L@EHP\I&I/W.:I+"9;.N\HR''!5K*C#7/Q&:5`E@P!O:\
MC)_2@?"1EKJ&>:B>NH^VT+U*;V(X="+[.VQ,'RO+S00SC,R)DHYK4^_"C#OQ
M9KJY>M#[N4<SX40X"4?!12Z4EX_(WNS_K+@_9D33R&.`@MQIWG02N3I:?PBM
MKA+X3]:G\>N,+S/F;"ED7P`*\`'C&HPP1"I?Q3YIC%$2%H)F#57!CF78G#Q,
M;Y&25@;6TD.L`2["!`CK/\BSIXAK@BGG_)OU@%[+C('D(I=Z=M[,E9_TFJ%,
M/=]G?38![2,/[@4GY@")W#CULSEF0+K.+3M,P)9G--@\RC:0=FNO72";UM.[
M0)IZU97PD7=?(:CT#]>)%!>XPIB^RH/>M^Q6N*\`U*H/V(+=>BA=2#E;EEGU
M!\ZC%<YU/^ZD6SU'&=P]\]'8<W;SL?DP-N-"48)@6/'JA_W<^`J[!$=^9-;1
MRJUXG`S;2?"*17X-@K<7CG>C5;_T3J17*%-Q@E1=V4;I:?8/?3WV[O'+__Y[
M?#L-_X&$]#O2D9QJV??BD1_BQVOW1]+UP]&?O\#KRG_3*YU[Q_-Q[&$873F^
M>Y7%JWYV$OQK?N%&*`Z#2G@>?($1KA]<_][]#'1R%W>",8K%UP\AJ:+PZZ4[
M^>=[-_2_7PR:IFG6-4TSZH:N_:^NZZWO5]?][W6[\1V%+L.L&]]![TH#C[TU
M@R6^5\;N"!14/R9QW!O_\[TW_E[7#:M5KW]OM+LML]/M:TV]T=$LRS:U3K-3
MUX:]9L=HZ%:SW^Q]-[[7W_^BU^HZ!\I+[5`"VM6=$[E=5*_1J.<&,2G=G2A"
M80.!WIWGCUPPJV3GP8G&OZ/5*;B]""-\X6L`:PF#<2<(O'LWBIUH_BI@[#1Z
M5MUJ][56OS'4+*,ST-H(5:L]-+I6I]4?=BT`HT5@K',P[F_/$F!SVWO!]'X!
MM^IHGJ'O[D!:`$2_;;>;G<Y0ZW3TMF;95D]KM]N6UFN;]4[=:C7[@]9W?/$7
M)#9.:VNL()EG8<N+<9/1[M6=$VL]"R^XF6^9G7^S85\M6,NGSERY848J;F)/
M0OCRSX+A'P@TT,)4\@"L-/O#*-L8_C>;_='JMHWA?[/9'Y>RV?`OF_WA@:4M
MP@@/GN\#<&!DM-K-Z=[@1EDF/>&?<^8*@-?=<4TY#V#):'!U@I%+0P#D.U<]
MY3J<>2.EI3=4I8N^`K2GP])OO(#90XNG(BSVY%I8903VXJ*M<KVE,@SX$$NV
MU*>X+-#C5'1:#+E1GQNKN75YR5B]R53-X2OM%N`XNA/`)50!EG?+D)(;B-%A
M$ZRQ9,=%170;0S9Z*M:8LK<S9*/O9YTI>UF"*<H3V[%C^6*<P;4S\=SQ5>[N
M^_H0`)^_\V;Y-?LJMYS9ZQEZHUG7FG7#UJR^W=':PT%7,SJ]NMTU&YWN0`?F
M;N(M9PAA8<L-[$,6N$;&5%)1H(%`LILO+0HL;ED"ZU>!K9_"..XY430'+H)C
MQ(,?,X_A(5ED7TH6L)IVNV7U=*W5;NN:U1NTM9;5;VIMNU]O&AVKT1CVF6R)
MD6L<$MNN4MK8!3HKW7&,/J3S.$Z1$9\S7_T%*!G>Z.MD`OPEN/WB)E\G/?)Z
M/A\3O#BT3*/Y_=M57T8(K;X$![MK]*U.IZ6U=1LP`H1LK=.U+*U>[[6&S?JP
M;^E#)!O[_2]VVVJ;,#<'Q@X[D^`R=)&]^)=PV3G1Z.[:^=&#>]5+9*@>]NAM
M.OJ6T+6>O%YILY<N,A)_WAG1)88T$84!_#EB+'Q?`N^@V['K`]BIT>EW-6O8
MZ&OM+DB]K8;>MVW#:IAFOUP"+X.4D@-**4*JM.(N2%I#]R9*D9/GGMUAYZJK
M>$`<<&-WKKXI7\):T5.DZ:9*/NKI+'+O@+<";X2Q2,;[P(0TT]0__D.Y=&?(
M1@$@<-UWR$L<PY<CWXECNL%@E*\I>74!>.D4@R!@TJ^PBFCE\"AI@M@6N`_^
MG"\1I=0<\'$"$@]@M1#%,=!#Y+J"_(.Q%2`B@'""L3],@G)N0&05\AU?8R2M
M$:.`F',F7V%(*QS)*R29BD!P0X+T+`Q@7KY@!"/\QP7F,DIP.RAN1AETF+"&
M8M`-^L$HR,29@$"WPF]G-,@?9-8*D53..)Q1J`K,!L-D8!#Q#UX4)\I?<-`X
M*&R&G/TH'-*N\662<R=+`X"D3[$P=PZL&F#IP7R@`Z#['N`T`=$[0'U!F85<
M+":?/_/6DY079E+>LBB'YJ0?-Y&O!K(9J2C?/9$-R8HZR-P#P`*08^%!R9`"
ML/X-1'1__LF#G\?GP3W<^5,N]K\(#S/:>KW7[8%<9PS@@FKW;*U=K]M:PV[V
M=;MN-3KU)N-AUW>@8"I3LN.@1N:#4B,DVR>O7[["PP31'IA_.'=\>(VK9-?A
M@%'#BUU,^M!H-RQ=LSO#`4AG@[K6-6U#TXU&O]NP^XU!N\ZW^A`J%*X12[2F
M7(%`!G\BR;E`&4S]`&T`:2`/N\OT<'&//[(]"1+G/,P$2(G^>QX,XE$4/DA-
MI\HHO!@`,;/9R$67+?8A[?I+&*#.^36Z`)KG'SJY]LJ_&0KZ_1HAIB7S\R!.
MHG2ZJ$V1P1;EH2E@*JD=Y^Q^*"'@ZM;[7PP4^3+(O0XL&/#36+MUG!FJI<BW
MV"N77OQGKI@9NT+M>]L$/:CYHVT:#2PAN5:'.O\R7*%%U:U^ISG0C)9I:5:W
M;6O=1JNGM5NMMMXU]9[>'@#2Z42J1@V!M\U>%@RC$5P.J>-W!+E>DU&"7NRC
MO63WG3?,9O.'H1MMH]E8VES3:->'5G>("&%J%DC$6K<];&I]H]LUAG6C:?3;
MN#F3ZT:FIK>TS/J^Q<(+V_1]D!D8-++G+UV2#$ACZ`0H59/YXMD;-NK-!I;`
M?)1>EH$"!SOLMYI#S;#:#5`9AJ;6;G0!*,.Z"1J#U6TT;';B!IQX2Z:8)^VQ
MH#,P3>-7M&5>NO=ND#[_S!D(X*-MUNN`_"V[6=\?0$Q!`@46LFICA]@W?@+Y
MX8=A6DV]WM@)#/UZJ]LQ.T`GS7I'L^P&\%'3'&@#2]?;AFW9>GN8<X(G0.$0
ME'%(\`#96&6EFG:[93;M%R`:W&^["5RUWK1!OFL"X^SJQD"SC59?[W0'[4:G
MG6%+R1"E@!GUNFXV?@!8[/9ND.BU&^UFMUO76ITV($9GV`'VT1IJO<&@WNT.
MX&[J=#-(F,]$#''W@K(#"A0(N#Y`$I\"T62&;W^+W4GJ?_(FST$5&ZY*`%#=
ML)8%^RX("@T+E!;;Z.F:9>IPNP[MIM:UNH-.M]-H#VSSNXE[O6C\D0L+6RRX
MN,.=+;59)$$GS^-`Z60(\#W'V%C0BBZ?)W1(\(%/[;IMPB>KU6YM$+ZL98[2
MJ@/6V:`B&7T47`?`49IF1[.[C;K>ZZ$)CR[B.I%033=:K1R>>P?/BM.X>7RZ
MFVVF0Y0>`8JC,/4<J7?#,>P,:H/PUOIL-/L+P-[+[H\4Y^MZ2V_#IW;3V.2T
M6<;YKMFJ]X>6KO6Z%LA:)ORKV[1;6L,R=+NGVUV]WV(2.<-YW38.B_,O-9TX
M]=]#X.[D*CVR\S#9>;0:>SJ/U0`Z-BY4/(B=@8U<R/SC]1G0:X@5=;/=6+;B
M;"56D`AU43]ML8+@\PIBA6"Q1D.OQ(HMCV%G4&=BA5Z)%>N!O?=KS!!BA;ZO
M:^PTQ(K7.P\N5C3V)>8=N5BQ\B!V!C9R(?OSZS.@CN^'(S1JK#Y:;N)X!K":
M<(L!>!JMNKF3#\EL]@8#TQYHW:%5UZQ^LZ&UV^90Z]9;[7K'[K2[G=PF;K8M
M%CKTM.T=!B2MMKV-66M'D`BK>-W4K6>#9#4VTK=Q)TWNP@C+"E`L-OG7OA+>
MH>0'N(?QR;%[$7DC]Q*Q]VN:4+""%]RRY^)_\?C;SKT;.;?NI3MUJ&Z'Y.9!
MU#6?`W/3;/S`^]XREH6%9GO8:30:EE9O6B`L#)L]K3.`CU9'M_5^W[:;70,!
MVL3LA0O[#\/XW'A46'AUZ&QSE^VXJ$_A@QNQO[#"RHN=PRKD_PY:P_>8UOF8
MAW3[<P/>T*@U'Y6F7P8\>SR(;[/9<1^$N=>#6`#/B3(Q@/DJC_J69U`G)E;_
MH_[9;%=,[`7.X95HAPS@]5JK8F('/PAB8J9=,;%GG)G5,NUET7;;,[")B37^
M,#^;CWN#*B;V^#F\$NW83!*SS(J)'?H@B(G9%1-[SIDUZFUC=TFL04RL]8>A
M?S:-BHN]P$&\$O$T.!=[U#+Z]KC8:Q^$N=>#>!M<K-ULMY:3>+<]@S87Q1J?
M*Q[V$L?P2J331AYFU]J5)';P@P`>9ABU_Y^]J^UM&TG2?T7GO5WL`NE,=[/9
M[,Y@`O!UQD`2&X[G<'-?`EFB;<W)HDZ4DGA__54U28ND9(N2*%F::`?8V#)%
MLIZN]ZZNTOJDQ#9?-,:%%'+C11"Y$F/LI,5:68<]"8_(/#%K9<W`#Z?%]KX0
M?*<+\6,H,4M+L;$GQFB^/:E/F?UVUF$_L@/KAL?Y^%MV\L5>?270%Q-OY:Y6
MXD=08UIHO461A2I<L8_,.FFQ[9=A3PZ`RCPQM:N$\M'JL+VO`\>X7ITTV!9+
M)BF7;.,E,$UN+QWPPTY[DRVLPIX$)RL@?6N?0LG77@>.=2[\%$ENL62.#;]O
MO`3<*#"!V;!3(-G",NQ)<GA6(29.&NRUUX'O=!U>U&"F%6.E$V/6B/'WT20V
M7<+[OR5#E+I?0;JPP:SIG9_/+G`G`VR/'<RPH6K6M\ZT5;WN?M]F#6R-Y_0L
M835IB[18%,8TI[8O)*$AI418D0NX"X_@;K/PJ1=Z6GW1N!ML.6?O":N>=]@5
M(%78X=/LMGB'[;'2%MOL;$A3K,072P%67$I>A:M"2$W$YZW3RH#D7#QOS[8]
M_1:5HDQ_,_EL2GO6<4[#_\I=.YH2MP8FX<-XF#S&L;GH<C;IW8,&,$)]^`AQ
MTV',KIS^VXS6-0!;KB8/'RQLNZ645JPI0RTG=`VD/L7?S)\.GY,XZ!D\\5;1
M,LUH:X2'.>RX)\9I7P\#/AJ81S=!YP5*FR.U4SV]"WPL*^MIUPR>M36U^=:S
MRNLX$&+K(/0LK<WAVIWRV8F`.:B`&N-S0-J'V^J9'?R6P+&,]L%^@4>J?_:`
MD-$_;`V$#DX%[0,D[*RI&]GX=920V_]SEC5*3Z\3M]\WH':'EUWLH>YWQX-I
M=[@\*W459XL0?XXG7R%PSIY]%?>2NY&YBWF-X\#6!A%E0E9/\>\8F5<Q!OO0
M=XZ9,,/YMO:@F&=6DO;+21+AD(JP.\&\90HW*;3EH+<%.LIVY'?XS;'5>ON(
MBZ5$`NY%G8`23U@.$2K4Q+,=ETA%A:M\I3RAG[II$%K9#5F7XI5X%4W;LW8\
M:8;_Q<1,^;D9QI]F.$?CXC8+"K9K7_\\BLW"'>WY7J!U2+A-)3:B=H@6-B=*
M1);-(]?B5IBU5BW:+[=+=Q7+7Y.DCV/D,BZMCQG8*:=5!'&QWM;BG/G"\8C4
M((,BB!11'.<!.1Y7FH>^L//9ER6(7B9G.1N5I@A6>OU?3[JC]#:>3.+^-BU^
MU@1BR4%6WY%<ZX@$;N"#1E+`,*'OD(!:7`L,AP,KFQ/'';:<8YJ06`4G&R\1
MQ&:T2S!(;V:3-)NYDG<NODZ*KGPE=MPC3HMGY9CM>YZO!*%VZ!%AVMCXVB)>
M*$"5\]"SS*@X;&13$ZP-B5VIE=)"J;65TMV:EYHK;8")6-C]>Y4*6D[DQJ*V
M5*.YHWZATHY`$LL#!':`P$IH/\?C+MPU'C[FKMB_@8/Q_MV>6;"BV3C<$Y<J
M3N>7O:;"CWRFJ?0\PH4#AI%1ERB;21(&8225LBU?T@6%WR[Y56B+1O9P89!-
MWT6=<#XR<P3W*<=+=%WHZD@)$.'("HEP/9MHR6QB`W14A:XG9#YCRN0#RYRX
M@JI2I_XEPO[,P%5TVI+9-&\>=P0BBFDNFY6Z]&]*:Y5C:G4'5?>K-#3H\^SF
MS[@WO4ZNXG$>L5Y,?)Q'.1QNF_#1U%+?-9<VIR_ZIHLM!F40B"CR;:)<9@%3
M@7%P(V43RB.J011%Q*+RM(?6J6ZIA69YE.L5OMHVHEJ"L^C0R*@0CE@L2VXV
MT!?Q@S`\KU3))G^#XIV/.S/C^4RZ!D=U3[K#X6,'A[QU$L"W<YO,)IU'D."T
MTYUVNIT.JCHSU<_&48)F&&4RBLTEV=!OO*=Y2C:U&@?_X04X9WSZ2-+!]ZF9
M&)W-H>O@Y>`LFP&$>&F,(T+AZGA4/-7\Z>FF9I0X_&$X@$]G8V#=V"1DC"+H
M3.>3E-ZVT/MS<67;''2\]?CG%>S2^FQH9"4'6ZMBA5O+&+0DB_5I:JFIH;B^
M[XYR`0#7\38>@`2`!<K&EF\-OE;263LLIX$,5:`IT5ZDB1``N[8=L*@V98IY
M#-:`?K'SBEPT4&WTTUX?G7TM2ZFFKF$Q70M*-ENXA;`NXBI4$='*`W\GL#51
M6BC"'+!)O@Y\K>VGHMM+ALT#9+W2\%`@VM?JF=%+Z2M+5+/1[45O6<UMNA>1
MJF)SP"['4FEH#JK$^;+@ZW>Z9MY[!]-BF1_13<&+&`Z3;^F[#KH"!%V!?C8`
M.+^\=/5@!%Y&"F#%:78)SJQ-9ST,%G":<?Q_P-W@*HSP'[@:9&(X-,COTN+O
MFT]J$F[^B+,AGWIDMRYDF^3DFW-'TV.BKX!D+1%9;.]E6TS+W_)38L8@QQF[
MI-<)\&#Y[SAF[5,R_2.>SF/][&W`P);VJ[;)7[XDM6"YE*4]B]"`1CA'3Q)/
MXA!6[3J*<R]R0IZMBV5L&&,?>?G$XGY!:-.GQB'G;82S->%8[4$W%P4+/6C+
M:LN#SBAN`\,BD,[O?#Y7K:WC6;IW>V8=2]>W1?5Y#-I`>*7JNHJ'N'%T/,$)
M,+,EF!);`[\V-'M9C__*%%PV,-/,H4CPHX;^]ZM'*#R/4+#E_T$CM;?%++CG
M'!X/ON.@MW-G:D5FO;EZTV?O165"\FL@=4Q3AW8]Z^QISM#.1J@VGC/4]@.#
MP==!/Q[U][("2]H&<1M01J&P79\(ZKI8AL&(96L'C(UK^79U\M:.\2_#L8,(
M/A.T+8*!%O8)>![#7XKZA,B6J&MI.M93Q26>*;RX+6WWY+GDUE!\EE^7>4S-
M,<8]TD6.W0D4;5C5BR=)&.25`ULY-FUQJD+/AOZQK25<2MVQ<.K*$7K+&-53
M,A"N&Y!06XP(].KA7IJ$+G?L*(J4MME3RH:^79C,NT-&/0*+UA#X18O&0AZ:
M/(SEZI`()2VB1(`6S?9\L'9^%+(#L6C[/A;Z#*8-JULE3C-D+K&`E8EP7(>X
MVG%)P"RI(JF8"N<%9A"[-C_*M^I4J%$\Y<\O;F_C^4W:PF-C\>7YM.<5[_D,
M,4\_'P8Q5CYC<L5[E@W>?&U-;X+GES,/32O-"EKGYDVRZ\UYV[3_<9XVY;<B
MO:H-/L`G(U.S]C4>;1,H6Q;-.E0+P?1&D;(GJ1)*N41ISX6@(`@)!-T^J%#P
M#+PP<FP:S/?W:*T,K49(B5/\9#CLWB29_7?O)K%1JGDE+B:QTSRK@5\_#@#P
M2%,Y4[`6B54&\),16NCLJSB'>%ZRL4W`8L``&1&5]DQ-'!A&?09^8D`H]Q1(
MA0"E88<.<0*II0)XE.9P<1&=E[><7J*E9@1[]W%_-@1G)>>7SPG(39S^%G>'
MTWL?9/=B<M<=#?Z=.8U8)GL-0'A#D+"M45$<!'_)02'?I\JBQ/$DQ,3"#XG'
MPI!8OF5+R@*A:%ZN^H_A].?^X.L_[J8_`U'XV[B33A^'\2]G']VK7\\_$>_B
M^OKBX[L.'4]_[D07GZ[)Y_/_"=]UV/R#R/UX_N&/=YWKP0-P_:?X6^<J>>B.
M?N[DM[B^N(3K.5Y_'?[W-3G_%(2?KM]UQ-_/\@?GR*6=R;S<=UYUUBVXL/-M
M,+WO?![</70[MTGV1U/Y!;<`!P6^%,2]&+/R_^@^C'_^VW>7_FRQ-Z9LS?P_
M-W5C\`-\^"V>Q*7]YLX_!R.XS?0^F:5P4?JO=XC&3^--H#&DEHF'*PI2YV^V
M</^I*2+/G[$FU-[%51!>$?_BPP?W\C-\J8=R/$Y!1K"&,1UW>V#'36DE_C[N
M]OO%[]\&_>G]+V<*EJ/3'0[N1K^<(:?'D[,.Z`%8!+P*7Q/?\3\(Z7CQW6#4
M,9S<`2[O=P@I4S$I_](O;N_0OS_=Y*=IOWK-U_RY-\ETFCP\O9+]_%?:^OQ'
M?/1/U26:+&$YM8KCSEXDQ3RWRN@KB*]]X^7OYN^;\WPAAI.[FW_2-_#?OSIL
M/.VDR7#0/UL`&>0"A`$^0)^KRNX%6C?XPQ]8I&J4BOEHTODI?X="Q71`LYBW
MNVFZP*M0.:T+K@M_<5E0E;>+^E'0S']`FMDNI0OM6`B^P((56V;DO*3_6#=R
M&]EIL*AW`$`")O5OOA^&4?2,O$Z3<?DOXPV]@MP'^1!&X&ZQ^*'F@!'XJ.:"
M@0=F//W.-,D=K4I`L.@4M<I8R[[[6M>=WKGEZQJ8MP82M#]YL5Z6E^01XKM'
MD)<L=-F[8/QG(Y\R_W6"I17F:XJ+1E\<)=\FW?$O9]F_V[/7_BEE;[A2/PBM
MVMHQI>T([VN:OY?%.<_Y=6[C[!C:PV`8IU,\C/9J`K[>-Y;QOV6S8^/_[8FF
ME/YH1$MGQ^O<1/K'WQO$GGL`LZXS\BC%Y.$J(<KW/$19L@+KBOFNG[GC>.Z$
MX@G%UE`\-C?_Y;#8'%79S/3#7VZ3T71Y%N]EUL+OK:,O-_0:^1OFV*]B+(\!
MF]>*'@X?&_9&4GWR.-;4N!9HW'XRNQG&>U3SFS_T8*WE"<?7)ND5'EK5!S^9
MK?+R!WD10ZE@;XNRC#V6M>0%'.V7M8BGNERJ-REKR5&+)LE#7OQSV9W@L)C6
M26[>0<MS'2ZTZQ#;$4"X%PKB63(BU+9"/Q`ZTLZ\"!!N6>W4_"Q%.RUCVPNY
M.,;$LMGJ*K8G+++L]3'1"+RL:E-\JE0<4%F6YMK62PJ['>9K)P`*A4<$E1YQ
M)14D8)&*(LNEU.5'7)9UC\VXUBW+*@JR^*D@JUZ0)=7!%60YKU<5M?-'GZIO
ML"I#GHJB#G%93D51NR^*.A4(-2D02BL50L;FGRJ$#O"=CRT-__+VO/N`O8LR
M7QU;O<W&MQ/,D=[&\=[Y;?-DNW0:??6`=J8W3A!K)7=+ZU^](*7HA8[]#;&Q
MVA'6GX@W?-=<<'A4ZS>4'P#K']G>R%]J!_R$XJF.X(>J(V#RC;"M5]'T1P`.
M>U.$JB>+T%RO'-7NY`';A*/"\:^ZRYOO![6_RVL_M0&2:I-=WJ*W9FN[G75*
MF^\$^J$K'8]+8OG8T,M1+M&6)XB@'B"@+2T"_;2YRR08G,I>8)V2G>YW-J5R
M<9*8]D+NTC`B5,@H:\RAG<@GW(X"!RB-F"OG/;5>WNHT_3K.L3-V=UB$B]B4
M[.+VJ6_'CG8RN7!U1+E#7`G+)+30Q/65)D+95N`XG'K.?'["I2Q:"[W\KB6B
MBBORIN(YU:9#S?+^)$?!M[A++R`DGC=;69O.$D9!G,WD^SU+A17\'\7Q,<DR
MMB-BTIE#LI*LUVK'TQB.Q6X\@<>",/`BXE''QLEO(5&*^D0&+!(AU;Y'YSU*
M@46V[,=CON?>P;5W<-%\;'8.8*F?_L?BE-/'>'J/X['-!=>)%[<Q=W%KW%1H
M*U\[FFA.0R*XY1*/>910'4K7\H#!LMD$/&,CRRX#UQH`NP#U8N3V>O%XBA/F
M0`6.Q\-!;\OI>GM$6YR]5[O!^EE<GI7Z43\O='J2C;1HS'\Y2?HS\`C@-I/D
M:][A;'<F(W]<:PY`-LFP39+;X62W=S^`GXY#,>"@A];T0D%Y.SB&$%T-,"!)
MX-(8YQ6]GEO:'%!TOA6E+2&Z@$%+#74WGH/&UUD$B8O`LT58%'3J"$M&#N$A
MP_C-9\05OB0.ES855N@I[3WY0.`C+QL.MU_2FP^,+=W<ZZ:#'@[L'0QGT_64
M0A6^%[JY+ANFJQF#<#B"""0`#]-R0^(I>(SO4EM&PG5"&GT!E@5VM;DCJJ6Q
MFY&VI/=MT1HWS?K`[H3X9;D!P5R;.8Y#/!O;?5*IB)(0CODVB*9K.8$=A4!]
M=1;NLC=NJ9OR[N>2/0/7)KU2'<_WA:\@&C'=$1W;PH$:H.M"ES&(3*1000:>
M]=:1+317;F/6V*=XZG?3>[#ON'Y][_%W,]_F8FQ&/X_NW-X45G;=^OS5J*X0
M0PF1C7!=131%;T8(25Q/"&)9OHH<*PI$)H;.V7NBJ.(5,6Q.4VWN6G>"ZBL%
M(`O`6U9!&[%50XT$'@FA;T6IU^@*>AKUW#8LLYQ#]\H0#!P(VP<VH"&E@$+D
M$C<4'F'4MH1/O=#3ZHND%'Q<B7/^S`SXE6VV7Z"NBL[OHWFI^G7WNQ>/XML!
M"EUO@A.ATJLXG0V1M_`4R"7<>I(]`*Z]3++9ZOL5(%MY"APMB;?VB#!)@L!U
M2!@J%2HW8H%'OQ@W%E5[":DV*%UZXF>_]#>4&G.>1]I+#_34R"@0".+L7U"X
MDWC<'?2+S%*>+`$!,[.,W#2-UYN)NC>M"5035CWRLAEU6PB)/X.[CJ;'(28X
M.K2V+]`.L?5=DX?Q)+X'G"%B@3LE#S'8LHM;^,:!*ELN@)7@/>QJI_,7"*E2
M_"M$#!^2-+T8?>[B;AO8;+"+TT=L#3_%&6'C=5,J^Q(BB3+$JSS1C)HJ`KE#
MEUXG;@^NF,0?NY/_C<T.Y>>X![;J8'TO??9>X[Y#!8)&Y-00**.$2><"J&"0
MCI,47G.'Y"^;AB="B*<#$C&.)P=!.;@^%43QT*$TU$PKD:F$(OW3G)!GC\)F
M/OPA6DA,=`FIEQG(^8M7Z7IRM#/)1XDX1,JT45VPG!7:EKQ\E3KT&;,(#8\3
M8D*Y,)&@W8Q9].\Q<CL?N0_);*?*:Y%YA2.!/7U*E-:@N?U0XXP?A^#`0(>Y
MPK:C/`:U18U[UZ5KE7?D]GJ3&<9=TQABG&F6AT,]`);@(/49,UX16^$6O416
M`T@0N73^I8,$PHC\2O]PD9A:9B$9)559REW(0]0%#"2"2%E-(SQ'P$(&Y;#U
MG&%L>`E97='*>S?/!3P[R>=`/52FSMX+VVF<#7B6OBI$;O_/63HM7)VG_8E+
MB)C.1WYW/)AVA\M3[5<QN`7@_A>3[;-GEW8T=I##;,_?1\MA6563N6LL:LCW
M>K.'F2E3"&*(,GH#<ROX>1CGVYCE4UU+//&R:W:(KB6?CT[:#=$K(I#7`&MC
M:\6ML_=.+0YK3E'-<<7,QI+8%6/][A`C_=^2(>[@E`*]IZ#&G0`GC^[*"N70
M@W=3.%;U?G>$P!*<<=;W=?PP3B;=R>/YP[@[F."*X$WC]'ST-<Y5BONU.QBB
M>W&;3""&>JVHV-9@6W$JND-M%]A1<N(ZKD4BWW&93843.#ZPHUW9&FN)T"IZ
MX)8/1JA'<2KZS0SE'?D::[8VJZ[:6J])Q247OB!2>1X1RH>H`_QH$JDPDKYE
M:]_SLF0KJ^FU1K0LI`MZ<=Q/,?K,]-QO\;!_G7SL3A&NQ\/.FJ`!9=02SD+J
MH"%1C5*NA9=^M/L2F)?G5:>M#5)7!6B%\Y>707X8=&]PY/V!\A(#9:-J`K4.
M3;54+``ZZ0[1D^@_#$:#U-3Y?SWDJ"W;Z1-5$[:"CD;;W]%@U!WU#G[[FVL\
ML>#(>ES7D*1&9N5C]_O@8?;@CD:S[K#\1]Q6+GAKUYFN9;4J#8T.SXS.2I.S
M!IVKM$B1-]N@7GYOJ@-%AS%K59*G1LHJRK.MP3PQ!%XX>C,HB%G.[-#5*>YE
M@2MGK<"D,9'M%D$5$Y*?*GW,T=]S9%1PU'N[SAHL\?J"0$21;Q/E,HL(-]3$
MC91-*(^H5C83$8NRC1)9,U+[@*()^(?(A?:2!$N3"A74^<"%^`]&MU_!B43V
M-/#4>?@0Z;;`,1::U0[?K4'4\U$"9OJRPG^`[R$9F=3>(6+`U1)[OI*21AY-
M%F<>OD<CT"Y9M>JMYC35-UBS8W!8\P8&;)B8G,\!.[0@_!9S:'VW]04J:KG1
M(H40)9//E13"KY,DA1`IR^%DJ8=#3)^(2OID+7+JWNSJ+.DA"@`$OF8;JN*P
MKB:EQ@;#8=+#8&^YX7@-`>".'X9<`MM'`IR%P+&)UAR"?TMIRY6N]ER9UR,N
M;"\THN:9$H1-3FGN2]IQ9\I2M;JRA3>O+6UIT2]N@_@&BTN,*WHYB1\&LX=#
M9&H\UZ>J2FTE'953VR-P[_:PDHL^KN^%H9(6)1;U0B*DE,"QMD<<XZ@$41@Q
M.ZNG*'S<)6^\\F3Q07(GUCPJ5CY5_LS+E\A[=O/T"@\EI+6S"2$8[P<4[%<_
MN6$#'K;F)-0.(\*!5=8!#8@?\M"RN`C!*<M6F;^U68[&MK3NIDU(&94OFEM"
M.]\U9__?WI7VN(TC[;_R8KXKX:5KD`T@^9C-O+F0[LQB/PT4F^G6CBWU2G8?
M\^NW2/EN=UNV19F2"`1!VY9EL9Z'9)&L>LJ&!?]Q,B&!35D?N&!ACXB4%A^8
M;WL]RQ<].22HA_Q!D;DG=K3?[$AF')`)V1(ID"%D9^Z50%-MXKJ/&&$?N_9)
M?=T.!C3HA:%E`Q\L-H0I*D3AT*(VM8/AP`G=?G^56(?Q=G]_WI0Z]`0N9P*T
M:X)3]034L(`Q\"Y.-,$0@PL^L/HX\"U&>F""08]9(0.;$"]$OCM8F<#3E@28
MNC9FIR5!>_ZP[[E#"S/?MEAO2"S?#EVK/Z0$!XR%MNVLU!%P):(22DA0F`!>
M.H12&`0]QRU32^1$@Y#E4$B.X(2*=ON^1URG@F8S!_F^RXA%7?#;F8L\&`SP
MP'*PUT=!./#MP%_-`)IU@HVV'UU,9H\7Z-N^&X;4\@(?%J_!,``">$/P#P8T
M#`<PX@;ARA+TS`YQ]B;IRL,(\GP^+79,Q2P\A%]?A:W"[Y]C7D:%6T$Q$Z]\
MZA!XQ3S?>\7)8,_E:SP*F#@(&-47JX<!K!Y<$EA."&NB7D_$+,N!QBZ4R!"F
MK((]Y++F48B&`'P$!/@C!1Z(PX*GAN%!)![(\Q3AL=]`%6DXO/:#0J_@''_[
M%2!.-K:0<;#_[7PB?A4R#@=;W]!1B"(/^?`*5G#H*-:'Q*/](4-6#UP\</C@
MO]!U/,MF&#D]Y(2H+T6TF!B%+$%[6L515NN'H1H`(8MIP37#4&D@3C:V&(;(
MO\T(]-S.E/@VK6'>90L_"+G&#](#CZ4?9`:@\D"<;.S"#V*?"#-^T,O&5C[M
MTN4HA&PS"FF!QV(4\JD9A4H#<;*QI:C>I_H'(+5G^F`L%V$;S&-[M,S&^8DG
M_"M17<:VHYQ..>2ORR2>[YQ6A+I<T,-BWQ!^AIQM$MTRV(01;5],_I31,L<1
MI^>SV9?+9ZLD!7QM*I_BT_A6UE1,9DU6DA->R#V^>!9^OC4H@E'\:"'+LI;`
M4L8&NS9U-[V9T]IZA,&JC4>NSUCN+^\I3)5V66.5B5RN3WGP13M5W\6P3+'8
M#NTZ5X2P5EF&>FWEP?Q7M43#)7@%[I.CU%9TJ6_IM(%:=9A+ZG_859-+5_V/
M6FVK@1I(.`<7C>>Y%'HHLGR_9NDPS:;17OG;,^SJV:[S"*]<V_/.##AD<"_D
M]I$5P@K58M[`MT+;#2S'0RSP>IX7,G^U5K+0&WM#U??8%A^T5[[\>E5N[&%#
M'6!@>?.((SGB[BXF2S>RHETED9LT>_J0Y+-L+HF_TGW8*]%]AFE]1#VQ0O`<
M]V@W+X!.39G?%ZKD0XOA8&#Y(B.#^4,<@EW[PY"MK,K@%^PJSCF/M,UE$%$F
M*?\B9*>,&N4!%.*4;QBN'[Z2ZO,R-DK=,_W!\]GRB:I)D"V#XT'QI[+H^6N=
ME(L9JH;]]F7)B#-WV\N=\NT)^B>V[_0%'G;0LQ@*`LMW0VQ1VW>QQP+:L[UU
M>..;2O*7RYJC,=8O>;KQW/IX0`;,18Y%`W\`4[Q#A5"IL+X=]@"9WG"`-;%^
MW1M?+]BTW"3O.^*\`P<69:*"BQNX5N"#Z]3'U/&&CH?!F5JG;;BEUD7E]KV*
MH6I]!UDB[.4O+?-B%JG\7S-P^"NWV2FS;'D+BG.,-\XR'^B\IF]S;E&'[93J
MN3MVD:'/&/F,X=-*HH4.\ICG!9;GAT%15PYFP!YTU)#8X6`(%.JOO49W1^EA
MIR'U1X+7:0"\DP5X1O"WFG2P12"\BYF#552-IHO*>.@-(<>D@]72ZMWP_\I:
MS1;8HS<8G]+J#37U!3>^1MDY`@U'9SP\7X&'@4N8#T.?[3*A5#I@5DB=H85L
M.NCUP64%$JWJ]A'B;6\!O=@BI:-<+<TE2]_\T""WLL7)%<(OUD:9UK4+Z9XZ
MX;5T6Y4E[A?.I7U2M]TM#%]Y2ZLOBUU(<&*$M\]:=EM25\'TBUD!.K&/B([U
MTB]F$M'G_<UD?RWJI9]ECM/KI<MQP74K\N4J*ROH(UF<%]$*)`]@$@@]-!A8
M0^"'Q?I.WPI<ZEDPZ@^&#`W#8.C^B<5X88%?LQ%9>%11P>-+OY5HXR&EH7(M
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MQBJ0E,F\(MA2=3^KH25R'P2S6O9!ZFJ3W`?QG`NMSTAU$JNEVNLM^AERZY[/
MSE$V+]<RH1;I4ZQ\/E/?$M'/*'-K69_5U2;I-RZ5^RXTG]77S]@%]AL/M[$*
M)*5$CN/MKU=?Z7RFOB6BGWF[U<V4SF?JVR3ZF8U8*<G[Q=/+7SKBZ>67X>L\
MF<6SI\4K>"W".V?QSYAG_Y>/;OF4_^.7V]GL[M>W;Q\>'M[D?/3F)KU_V_OP
M_[^\ASL+A5]"H7^LO[:\\=NM.[^[6^<MR-?Y+,IDS/M[\5`6/"D2(8*K=U<7
M<NA<Z\N(1;&X]7CCHG=O-V[^[NW"("=9A^AH'5+..D2Y=9:>G%;6H19R2W$'
M^9:0)%3''1VM0\I9AZBTSM:NEE;6`5*P<MQQU%J'Z&@=4LXZI`;K4!U'983+
M68<J&Y6WX@RTL@XM9QVJT#JOQD6I-I:P![^1,7#O'G]DDW'\*W^\F\2C>/:)
M3W_`[<?Q5$CMI,D_?EE'&,Z%EML=6.SI<S3EP6.<__)^D=P69SRX*;[[[NW>
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MM42V0&6%[T>A%?]LP;%,;!:!'/R>3]([R87BG+V;B,H"!\U%]#=P7[-H`H`&
MXVF<Q+G4*KCGW<3TY0H?6B)\_MY0Z9_Z)G8OMG_G$]!E.I]VF2)F+^J,O2C#
MO>KJ,&K)O0L/3]%CUREBAJ=+#4_=Y!X00ZQQ')=V,B:A/&/V+J,V>+^41[I.
MO_+L9YI-AVDF%](+QF^S;2$8MY(1$N7>NK9S8A,7QCV@F^ML,U%/[@6CD6!?
M_CF=\?QC*E1<D_$P3J)D%"<WW_B(Q_?1CPD'O#_RFV@RD`__Y><F9]=$D)S]
M!%R-^.3W8?HXA*O&DK'`FZ]1]E><Y*(0YH)VAL9ZTQACZMJ8=93'O6@2`U>2
M.!)*\_%L/N-`FV_RH*W8F_C$Q_!4R:'-"<-C/7ALF'LL<]O)!L28[VNZ5ZJ`
M#;_/[WD23W@_CG[P&5_-ONO)61:D3J+B_+F;E,`^=NW.4*)W.XXWX>]:U`AE
MOMB<P#;6/6KD-Y[>9-'=;3R*)@6`D@S9TZ_?K[H!EUYI,EJ8Q][("S9I,E4E
M-M6.6)>VI-J)H$F3:2YX)DVFB=!UX*RQE9")1;?+-#W\V\9,]K+KA_3Z-IWG
M43*^!A=EQGD1SOM!EE&)[V7%LVX!:0YQ+Y3OI"473+Y3\]%S;-*,`?H%,!7$
M4)BIX%@"M90Q;4/,I#@V%3F3XMA"-$V*8\,1-"F.[8#1I#BV#UDB]^9M>*TI
MLJNMA\TM!OEN'LQGMVD6_\W'LDSKAL,JEAEY^#1XY-DHSOG73%1T78=\%P5?
MQ6M8L'02<0<174]C%"/^16DDE[Z(,]_'FJYF%",^B&]N9UW$'&/J.TS3Z#W5
M`SOOVJ[%`G+"'*;KXE<MY,-TGG42<^2[OM?-;OY9;6"VQIC;U,>:1N&J[N<R
M*+^+F#./Z"I%HQCSJ_BQFY!CYND:;*_:@[O->$?[.2*LHVNU*U&FJVN@&YFQ
M=B)J9,9:A*F1&3M&2T6YU)/V%#$AH*V5&=.<>WJRS2!E!.%T%.72GB)F(FFM
M()SFW-.3;08I(]UW9-]NME:4CMPSTGU&NJ\M--XKW2=>.90]8L)<1#4]@=%9
M#ZW\O%#D-HAC@UZ:S_(O/[\G=UEZ#PYBE@+HLYCG@\?19#[FXV&63H-I"N_]
M+?M;^+2XYNE+!G_]AX]FF]EH0/WHCL]G\0C:$/)9-+N-)E&>\VD<F5[9P%YI
MNJ$1U&PFCPUSZQ34U)<-1CVQ4Z`;]<3FP*67>J(^YL%&B^\D@N-R".+Z$31:
M?,T%3VM_\A7TM/`+]475*"PV%SJ-7?K7.F2-KKF.X'4@\J)ED)E(B`NI*FK)
M!:.JV&#TC%!7"]$T0ET-1]`(=;4#1B/4U3YD39)@.Q$U28(MPM0D"6J5_J,]
M1<R.1FN3!/7EGDD]TR2I1'N*F.&IM:EG6G+/)#1U(E971^Z9A":3T-06&IO4
M"9,ZT2(>&^9V/$1NF3K!F.]KNE>J@`V_S^]Y$D]X/XY^<+CK<I39C-F"KR91
M<?[<34IH''K7\&P:'4$WV33-@4NO;!H=S(-EKA$"&LOX4^)[J!E!,SV1,__E
MI]SZNE!E.\\B['`J%/(M0NL`CS@.<D45)>30)D#YC<M8BJ]R3H%E20Z+$;@`
MII[-3S9F&BG@_)#%,!$=6GH8/IW,)X*H\7!U\'")A6B)Z4%>IGAZL,T*^/+B
M`7:IS%NX3"D99&KR1MJF3WR[>2EB5[=QQH,;M;VWC',G+U,*&%H"9L;SRX[G
MJ!PCD&I&(!\CDSM_/(#@>$EP#@!87%8/@,59"MC<]1'K))YUGX<4"Y&[GQE<
MO3@3&7*5.<8ZLLZX@1=R`_4A@XM<,X><`*!KB7\'`927*080OQ)E0K&VA1Q-
ME,GST_EUQN<0'A_,4-<YO21S.3XK=FKM;:?6:)<<0LXN-Y78RJ<2>^W-;F6J
M=`A'K;,&]&7*,FG`,$6/`&XMF?(\?MLPI461@EIP#A4[XP[\87;&2^R,.^5V
MQAV+(H6`8<0*P$S@5@V!6ZQ4J`M<I@IS`3D#7+PBTL5&3*QS;5]3J::K^8^<
M_W<.7QK<BV'TV4"[<X%"])A<Y#F'T"LN\Y2@APQZ1Z`7)X`47+T)RO(]9:`L
M#B,(<\#]:@)&51X)7,6COR:\QR>3?@QW/2@R88A4CDB-Z.Q5$DE4!+JNOB)0
M=VBTJG-@W/!78%A)]*N'@2`F`E&)JVO4R8?DGN>SZ=YNT8OR6R$+=A]-X/.*
MU[&7P:,#$AO-P4&$8[E,4R&+;2"*\G4/Z?5M.L^C9'P-0]2,\R(R&I:/XA?O
MN?A."]`1&KZV&+4(T32M9UED4!A\!IZ'&*6DW[%O4VXXSY)X-H<I1>P:/(J_
MVC"6+5`BGH<TG5N.0FGU88N@H>"^MP":CV)-=YM.QA^FL@[HM"7>`+@!/I*2
MY533XCO#*,[^B"9S'CZM_OPGW%,LN)X^BN76SE"WO.A#<C>?Y?(*VB*D;,]N
M,5*D34BY5%/?H0JD<"N00M0729)85XEQ8?5"^6TR21\B\++#IZ4PW'7T&.0Y
MGVUC]2$9\Y\Q>'M\`N[X^$,")KR)?TRXO+8=<Y8ILZ$;))Y#/+%<HK;?K2V?
MTC_Y*?I/FHE?RX6TXX^EQSE[NN*C>1:+BO([X3IIPI\^1=E??":B.EO1<[=H
MLNE[-H$T=7BBAL%-9+#PR;O"X$,>NF%P(QD,:Y6N,/C0RL4PN!$,)@SYQMFL
MB";?KWY+[WF6B*>\NDN3/(4%YD">3F=QSG-QD_5WVTHB4?]&T\VUUT@4W$?Q
M1$1__DRS'(A4&BC#)T5\,DN;ED^KAM]FX6/XW7Y^FV61X7>+^(V1S<3GYMQ?
M$;^*S"J`*$YNN`S\SL$<A:S(QSCZ$4_@2^VE4[>#$PR=JJ93IR,H#)TJH9.>
M!#*8/</,=IU'>.7:'@P!%'N.)U\Z2-,`TG">QPG/\V`$P.7QNCYC`1G/I#;<
MX<3J\H..#.OYN"^L)WR2A)(JYCL/\27A_YPG8_!O@6/7#]#&I^N,1])!__)S
MI7%5+F^QX4S2-..ED4SBR0:-@LG?MQQ^)VLIC=K-FT;`X=H^$9LPMJ>I3[BJ
M)5%,Y*)N;YJ(78Z7Q/J^1C%TOUYT%\^J5IZ^*$3ZUAPI"9&RDA^7A(7`3-AL
M6+[Q603CW7@090EXPZW8EEM@0QG55$JY[*@V&LVG<UFW1RH;B.LR?BON=B]F
MH'3:"I\`KK(??=<FNFZ;KNO);]:-E^_FP7QVFV;QWWPL2REME(T7.7#@^0T>
M>38"!^YK%H_XAH*@="?DZ^N'M#TP.H@XW83Q2]4JY9>$D?D^UM1!5PSC(+ZY
M;46RL`028^H[3-,35M7C*F^%:L("1\(<INLB32V.PW2>M0=(Y+N^U\T.^;GR
M0AX7!=*FVA9T4-TC9666U@#)/.+HNHI7"^15_-@B'#'S=-4:5NWJW&:\33T2
M$=;1Y<<5OV^'V[I1`DE/('4N>J0_PLHQU:G-Q`AO'H,'J0T/(RG8()2,I*"^
MT!A)0<UA,JD%S4*JVU'[C4*JTP'QS4#*B-/I!HD1IVNNK,RE:&(4'%J>`=P9
M!AN-!L/@AC/8J#`8!C>+P497K-6Z'9?BTUZO5&-V-<8K-537E>I;[FO+J5Z+
M^VJHKBW5-_W<EE.]%C_74%TOJNM)9X/A00Q-[GU3(#*Y]SK"8G+O-<;&Y-XW
M`RX9I8T1]K&NF1,*PK1[M^-X'9^M4LJG+B1UBL96WF9L7*@S:8EKA\BX4#K"
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M@G2I^>IC/()?X/7,4G42JIBE,'5MK.D:1\4L%4UB@#R)HP]@X'@VGW%`_YLL
MY"%H*,0,Q_!4ZM0IU4/L"F4F([QU,>$MY,),K11A9Z<3(\9\7;.V%$#\^_R>
M)_&$]^/H!X>[+@'==#_AJTE4K#.4X>RH[LGVME.&D<\8UC3,\Y4)OY\^P/29
M7HUBGHS416PB^W@\YDE<@!'G*2/8_?/[57]EWRF/\GG&WR\^^Q4^>_=V^69Q
M,_']G3OE4O_QV4V*MTM\?^-)_H0'_W/G?N/X'@!;MU]\[_-\*F:O=`U@F:<O
M;+/_^_*V?9ZD4^BI+]QX7XO6]WS^Y7=O-YY];]/OX#;/#"?>+&&VKUEZDT73
MYW87#%Q\6.(VUU%VPV=[X!.W67Q8XC97!8=?N,_RTQ(W$FY*-)F(R_??:^."
M<E8:ST<OW&KQX0NW*3HL_/$_4$L#!!0````(`"J(6$0%05JM31<``!9/`0`5
M`!P`<V=M;RTR,#$S,3(S,5]C86PN>&UL550)``,PP0M3,,$+4W5X"P`!!"4.
M```$.0$``.U=6W,;-[)^WZK]#SS:JE/G5"TE2[:3V!7O%DU),5.6Q16E)'M>
M4M`,2"(>#AA@1A+WUY_&W$G.!3/$"("2%ULD<>FO`32Z&XW&]_]\6GF#!\PX
MH?Z'H]/C5T<#[#O4)?[BP]'=;#B:C2>3HW_^XZ]_^?Z_AL/!S<W@G/H^]CR\
M&?SB8`\S%.#!+7JB/EUM!F/D.:&'`FAM\)GX7^\1QW\?B'_=`7SUR\>;SX.S
MX]/!8!D$Z_<G)X^/C\>,N6F3QPY=G0R&P[2[GV+"W@^^.3X#V@J_W-#0=]\/
MWKZZ?_/=VS>GPS?(_0;^<9PA<N?SX1L7W[MOOGT'?W]7J#5F.*;-!:K?#\Y>
MG;X9OCH;GKVY/?WV_>NW[\_>_5^Q-%UO&%DL@\'_./\+A5^]'4*-UX.;XYOC
M`AO^>S"C/H?2JS7R-X.1YPUN1"T^N,$<LP?L'B>->@E'!L!TGW\X*C#AZ9YY
MQY0M3J";UR=IP:.__F40%W[_Q,E6A<?7:?'3DU^N/L^<)5ZA(?%Y@'QGJZ)H
MK*SJZ;MW[TZB7^/2G+SG42N?J1-Q28+`064)\6F8%AN*KX:G9\/7I\=/W#WZ
MA^CP>T8]?(/G@XB&]\%FC3\<<;):>_@H^6[)\!R^6ZQHQ/G3L[C^W\ZI$ZZP
M#U#="S\@P6;BSRE;150?#42[=S>3C'R._`5:T6AR!<E,/1&%3FK;.3F4RANH
M^>LL@*DF^KB>7Q(?QH8@;THY$5V,/<0YF1/LMB%:LL7G)'^*&&[%^!;-!DL<
M$`=YZ@%-0-"M<$>RD\K*B;H&O$S($H:7V.?D`1]$9F5SR@F?+6&TEM1S069?
M_!["8AKYKF(T[?I0#G&,^/+2HX]\XKN$82?H"&._G8-)/2?<\2@/&;YF"^23
M_T0R#+@S"U<KQ#;`.[+P854YR`]&C@/;9P![_)1ZQ"&8CUPW6GO(ZRI)^^A?
M(5<N$6$_(2_$5QB)SV(@>$9;Z:_Q.(EI]H`\\<7H`1$/W7L8*)S!5S/LA`S(
M!O)]=TPC0%`._N+$%8H18/A,T#WQHD+=V&D"X3V/@\+))]]\SYB$/N:&'BX,
M$0Q+/:LWZC!WZ]Y$GFSK`'H9I%@?R2F\0NPK#L0*S9=F3N'$?\`\B)9V-P;(
M-]\S)H4K7;YYA9AF`76^?A36K-`W0-F(>BC_]N))_-E*TSFLH]YQ*AR]-AWT
MCXOS<+46?_$[^.F2L@L>$-&[ORA(APOHBVYPW,AU7%XI^@/(Z)U'/V/ATL#N
MZ`&$X@++TCJ;3J<A<Y:BN=@IHI)CZHA2*O=^HVP<\@!,$,9ARPA\^'])UD+9
MF@7"7[8@SLCSB'#4J!6)"GK6QXD;_(#]4/SO4#`5_H/=.Q^VX-&"X6C+?A:F
M-!*A<::D-/Q,@B584RLT\EQ&G.68LC5EJD7TLU%G"$?/Z2-\IC,P1\5O$W_J
M"5-U`1A"+X#&#>%M1SKU<7F,/`)T^`1-?)#'01A@$,TW&/3L2,%^`+W<)0[Q
M\:?)3_J8K(!,C3S^=#ZY%$<B$2$3W]'(1SE2]/'JQQ!$//'P.9AU.!"BGF,$
MZD"1Z``S'\5$Z^.D$D+U\?D*A#_"WH^7]"FG&)845/Q*?`Y:6@I('XL/I5$A
M=T?.[R&)3T"NYV/,(L&CD#,MVN\;5>:^3/1ST-6WG#"YZ^66(9_/,6/MCLAZ
MZ5\K5[[@`,P;'/"HZC.R8[_C9^-#W.\^41UMR*Z=]8XW\\3-PC4T%QU(>U-&
M+\6"[&?=R_>I$#TTO\8L.K,3AQ/KR`^;\K_LQVZ`VW?3,T:%0ER^>868QG2U
M(K&#6"&4QE;[09`?G87"6+HB/EF%JRG:1+]&QKXX!F#("4+D7=][9($.</4I
MZ5FU=V_[!%VQ5U>B\5[QY`?.N8-TY(#]UOF`K64?SXZ.7X>!"/L207M](MSJ
MYWE0@O8=,.+`AAP5NO-)T-M8UO6E$&T<G'*+GI3Z?AM;[0=!KD<DX8_\',?J
M,OP<JU0'XY'IHR=TF7*8S(,;[`GE\):FE-SY+',40Y6/H%K-B0K,G7M6JJU&
M83I@16_$.2OH'/`-"[%;B`TI$-I<N*L"JYH,A3Q*3^,2_@M?K,)5+=VZ0D3_
M"A$+,/,V66#F.0I0QN#RG[O!Z]:5RITGO.?X]Q#TKXL'M8JZ5,MJ`A2_T`#S
M6YHQ*0LTY,50/.'6H!YQT[B\*<-<&'VQ75A2N;``?;<V>.\6/P4?/=@RV[#*
M(*I?VC"D7]@Y'!GU?0]+:>QD3K#B62W=FRFP;\7^J6@.M>RS;Q84(MXF_CF^
M#V!RYO%DB5FP%2.+68"(\`8+VR?6.7N;*;U19RM;5<[$GFGLF\6%,/MY,1(J
M,0_&E`<\NB01Q4JEOB7%$_10(@QGDLKIIH:4OADVIIZ'[FD<Y3!B#(!&/_0F
MXMIT:!!XE3.C?;=],^)CR(F/.5"VNB=Q4$%O$T"R+S,@JQSV5CWV#3\]38HC
MR`I'2KV->ZL>38*O<@YTZ+=_(9@=4_4H]&O[T`M1K6B7Z*EON/L'':)L;X,K
MWYTQP%4.>=M.^S?%DJ.$'JW4FAYTPE-K+3;VTS=4F0.-W@:Y:^>&,D7EU#B,
MA-Y5&Y$((7+11MD1IF!G,AR0V/.6GA7VI^5U[;UOMNR?*!6.8Q0S0;(O,R"K
M7!FM>NQ=&]@^AU/M"JMN/@'FY`FQ/@.,+8!0%ONN".6-OQ5]'9JT*.[U9*?;
MWFB1S$44]0\4`&>V>O5$IBG*ML<XZ31*)S5'_#[**17RX0*A]8D8^Q/L!3S]
M)IH-PU>G26JIOR5?_RHCG\<A8U&8:=R]A^ZQ]^&H2PLG&A'>8`>3!T'B%QS(
M02JMH@F#X.A.G$/SP-15TH0C7(613[<J'=%GRCEP^WH.ZF0UL%:M:$&:13),
M$7$G_ABM22`R<Y0CJBBMA?(D'*V<T&(<F0ZZ&J;\5AD=5)8X+IO3V91BZ=*2
M#L0BB9(X`-S)I12,$6,;H#8ZT*[`*%=7"RJZ6B691&H![!;306L:YYF9X5NQ
MA*5TUU;1B2%)+%"_S"L*&T#W%^H[;4@OE&]'_;Z&+[[Y]8([C#Y6B9;2(CJX
M]@.E[B/QJK;#[&<=M$U`OY\3GP3X,Z@3L$+`@E@0H=G&5]^>'"\4,0X-&%HW
MHP<K6*"8![FB6[_PJLOKH+Y9S.F6:H7^HWO5N][O9K++JVG&4C])#+'[RC*?
MU1->5\,4!(T;3$,E'3@B(ZW6K"B6T$QA_10I*:B#WBG#:S`4DY1V]227E]5#
M=<6!/ECJE<375-&!(;_]=HC=T[85/4A%0"=V+Q#S@1!>\+J`$DL<4C5F$A5U
MX)'>?>OVVX)O>,2V24?,21N$/[<<P_MI_Y,2)UQ<XA&M#4%17*7UYXRN]GPN
M:6>TRMTQH`Q(CEZG^.[5JZ/!8Y3V+_H,G]:,4-@--A^.SHX&(0?BZ#IV.9F*
MKFG[R^&^>PEPZZ5C!O;TU4L`V][(RAEP^A(84`;L["4`VU+V<FRO;<.VHU05
M(4KN_+E\LF[&UH"O-:MRR-;-Y1K(-5Z2'/!+FN#U1Z8YYC<O"'.%296#??N"
MP+:V8G(V?/."V%!F]N=(O[4':8DGM(BSS'67;\T6&0L-.&L.8W*X%AD+#7`[
MG35GC#BSR)"0'/?R`]`<L45ZF.S)0<4R+Z*V2!7K@KJL5`[>3B$NH9M)!>SE
M4L\B54V:#[4A<3ETBQ2W>NCE)_PY4(M4,[DQK@H*R2%;M+SEI-E^W%$NRRPR
M,>7`5@9)YI@MDEMRF&6.57+X%LDNR2%O&P&<\Z*+>#,MQ'_[:3Q])"9/OQH=
M(%O(]L#'2_'GQ!^MA/+3_`3AZ<%!M8?UKB28KY#[`NA)'[?9C:&H+:HEN"]Z
M"<83FJF[(C[A09R](WOIKW1DFFKI0`)2*!=)%71OE]%")2SQ=30%_45,2CVG
MJ\MK";U)24F(J`P1VBNGE=K&>5%64E/`2OPPBP_ZQ0/V:'2F7#]#ZNOH01%9
M`)>@<?P`<KDRD&R_G$9J&XCD>O6U4N&VY1TOF^M6QI@T0JT1H59&F50*U9U#
MH#K)8.4QGQ3P1@7%RD,_*>C/IGU;>6!8L[MO+YQ4O%MY_"^)LF0^59R-#LW&
MN[L;9Z[42OO*RLB=,I@UZM-AH3I:G!95#B,=;HP2,AINK=?5^-.XK;V94<(Z
M\:X'\L2K'I^H%T6*(N(+*J_]0EYB1F"[6YS#1W\QQ3"IW89!ZJT[K:)!8K)N
M:</;,\-*:=@2<G_3S$(Y&V5:WGZ?S*_TUFMT8HN@M4N//O*)[Q*&G4!+`IT5
M94'R[L/U7*1*%QF[A)X\97A%PE6%I&FN9W;ZBC^.=[[/-!FQM("5!&*&XW,<
M_U^E0;1I0D\R!)`.#HG8#7][.!HJ,+,+<[T"FU15+:<9N<!'XG&UK6LZA2=8
MRP\UY"KKN?J_/6%@_>Q%?5>@DJIJ#"81);0?P5]]Y;1E(V;@W(F4D8:V6\\,
M-&E05_+\0W.>AU9-*#F;+>EQ*S!KGU;I:F:,01P;+_5:H>20R+=H!@>2&R'I
M$DG<8*DJ7)O/H&-C9N#>OAQR25GF"4Q>V6PSZ%*-:7)_"(I@1WX`%=']N+GC
M0L0GL3L26%LT8!"^^&&G`_"5-6`0/OFYVJ*!/]USE2D]DJ>8LG=W;]'3SR18
M+F-O":SW_-FFXL-.%8`Z-Z<3^RT=.:#*`UF)^8KC\,7(7(M_<1OP2C5A!,:R
MZ[^RX$KK&H&J,O>"++3J!I1HF]"\@['+Q0'.A/,0=AC86X&!R)N&]QYQKN>@
M5\`*B6>->"ZM3/OLTHRF1$%[=$8/PZ6A\57#TEA/-YK8#?`)>R#;KE`@%L&F
M>2')-V`&OOSU2/CM-^Q4ZLE25;4D"VJS:S7M25K./SJX&W?.@*35*RNO6O7$
MH%+]VLH;J#TQJ-3`LO+"2WL+,HL\Z;2?6WFCMQN3#C<O*F[-&1ZJ=""WFM4F
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MPR4B+$J4=P7#`I^3Y\83)*6_QOZI8K;K!T0\(1``CS`I"C>[?+=!%Q;SQ2CP
M%HS/S%EB-Q2F6_9KL\WQ`B!H3?Z6XRD[_\CQY"YNKN4Z7;H6+_?68NP7$@X0
M7OG^LV1M)4%9U9W]P"CG^=51X;`HYGE,O<B5V=P4M?R\*(5+IA>0M0V;\BYC
MQ82L#WG4H0?5$;_EAI5=B%;Z[INXH'2!6^G$5\NA>N%0X<^7-5%-V40-4[VB
MD(^](X/R;]/45X81:P5'1QS64S0CN;`I82E<\("L(JNRH!VF%G74R'5<WC0H
M/T<K#[NC!]!=%U@6V6PZG8;,68KF;D0+&H%=H=\H&X<\H"O,.*C<@0__+\DZ
M?E$"5'*\(,[(\X@(CS)MS;:D/LWY=(,="C8["-H[Z)YEN:ST9$;R@4XGX/5W
MD?>**=%64Z_,W1IVL\@.BSJY%(ZL,FHD*^EY;]V)TJ[5LW&WE!(NIIDA9Y@]
M0/M)V]'4*L^95L;5]HUH3BR;N#K%HJM6Z*O+:Z&>;I`7;.JGR$XAS6F9RH5#
MIE%*+&`K#8Y&X!W6G)5V1>."V\I;N#._K0S\:85X3^H?%N!C@0Z336@1V#\C
MBQ4:>2XCSG),V3J=]%9K:5L(S^DC?*8SAV#QV\2/(T(7@#CT`FC<;JQCL/>!
M:I^@B0^V0A`&PC=P@Q=1SF619?D*N\0A/OXT^<ERJ)_.)Y<T]-V(G(GOV`WG
MQQ`D#O'P.0'U(1`2*-Z0BA`#S.*@,N39#?8*Y`O"WH^7]"G'!Q,5*GXE/@>#
M-\N.;A;.*)P\?E7H>C[&+%I8-M"8G<DF+@3L;I^<Y>=EMPSY/-8"V]FO%=9,
M&A-9(*OBI$Z\R47#(`G>+S-J.K=E3C+'4D:WR\A8T83A&.-4IFFL'1<WY+`+
MTB&Z*E>=[4YE#UKUT"[3H3FVN".KK33BNG+P0#%D2PKA0W:`+SB(`Q:S>V-F
M")/<LSIQ83#(G$21@UNDPL0N/EPLG.;P95U^N!XZ,D3X=H:1I!LHA&4]`^]*
M.K6>C_$CN7')/&;Z6;A9U?4+X6GQA^U(XN=C;@T-MG,Y=?W>HJ?"CU^H[VR_
M$-TCDQM)L)W'H)+!]DV>22`4>[.=<\T9;_OJS7;.5:?:5MV+EOSPE+J/Q/,J
M(&8_FV:X*%)L&PQ$I>K@2[$936=]I09IY8&C?0.PM4E;>>3Y/#S/1:^561!Z
MUD[ZFIW-:KJ5N0$L'0T)T[0B_\`?9S@*"FA?P[!WV=JFEX,MX[5,&@F3KP[4
M.\=C!NR[R#6&5)<3G-T8G(7KM1?%MR!ORNBE.(`VXAPZ30Q43+>6\;GL1RT7
M'O-;,3(IP=IFJE?6O*;,XN741+>+*A`W5#(*1[5KI+:*UMU"!LQ.%LW:0;32
MJ&S+!'6KW,*[<F6BUK"0)9$DF<37$<VE+$]K$8I`T2OBDU6X2E.-)J'B<9AY
MB+SK>X\L(J*T7.3/$JM\%OE2>"G)YY5W%F1K:WF27(ZV<>VI5<M&#,8ITI,_
MX']CQ*IVY`X-F8V7ADP-WJPAH_'>0J]J!KC0DMF('ZD:O&D[!J.]78)%A^8!
M9H>A+;2C535KN?$4M;2VDMW*`ZG^^5-</U9J]\_"HH)0M?*,YSF85-AIK3SB
M>18>Y=J7E=[G_GE4W.$..YO2EJE#/'B$&8_CZ@VS4/<)S#-)YKE.DOR:&O/X
MR=')K\.`!\@7[TL926N>=#PJ=.>30#]OX\<\;M&3<1E5"I3E1Q8BYPWR-[QP
MEIV<X&G0T_<RR99JX;NEE*9+R?"/T9H$<<JN]`)DV34XJ7HZ;)X]PNI."BH*
M&T%W]<E`:5$C:,ZW8V#C&#&V@?7_B)@K/0`U+9B!4&01EP83%3:";OAC#)])
ML,73BA7>M153D.[DP]]*U>:['[&/YR3@Y0_JU.26[:4K(W@FX@MBFCV//HK[
M\;(L**FI&5%SF'Y%87/H3L,:Q7W9+!*T]CIA^W:T6GSUF_3V(VDMMA@KO7$'
M\*))J%OI>FOF1PO%U4J_VF$SXO#-STI'6WNFE238LNF9N$-D:*S$6AFE76<G
MU8+>"S:R*!:Z,^@RQ>[`@%G]+&@(KN^@4U6\LV:P3[CHU,H"AQ,G8))C\):F
M3BZ1A3T-M88JZ1Z@,YZX^1FN`BR)-[OTQ.TVTE4?`M2F!1W6R3Y]Z2-J>T^F
M2>*KJF\`NE9#U6U4JAY8B?DQAI+B7:!;1I"7IN,O<;W6%=?$1T'/E-$YYCP2
MC)=88NK75=)IB]^(;$RQ654+H;J\UHVR@UC:B5,N7156VM8=>=&\*JVTK`^?
M&;7KW$I;^T">U,@,*ZUHM<*C3F$X+%)%A]*:/M^2J,_B9H9A)]W_"A$+,/,V
ME\0'6P\$UCD*4*9(E_^L,<0AO.?X]Q#FTL6#*1="OM``\UN:<6@6@"D5/QI:
M>"M5)&ND'G%3K]J482YN/XJ/U_.2R@73QW=K7U>]!<(_@I;S]8^+//W"'`Z4
MOB*;(S-PS&0IOHT3NQA#=^%5./'"\KVX^Y:_M)8$0FV]SHM9@(A(O"KBM6*'
MCM$CTQ="TT:R\,KTO'C&D'BGQ%%#X10B#=8T<,`.!&+:N!3>DGG`(\:@B>@'
MHQ=-"Z)-XW=)X@NC62U'KVE<KKPO;32OVU!M&L<+UY*-YG$]G:9Q=3_L6Y0U
MFL'2))O&Z^P,S6CVUE%I&D=EW$=&,[LC`-/&80HZ:FR?1_ZW*:BH#`<D-@/3
MXU^C!V+?5U5P"EE+KVGS9,<#)V-]?7\BNKX'4P<^_#]02P,$%`````@`*HA8
M1%,7_RX.-```N>`#`!4`'`!S9VUO+3(P,3,Q,C,Q7V1E9BYX;6Q55`D``S#!
M"U,PP0M3=7@+``$$)0X```0Y`0``[7U;<^.VEN[[5,U_\.FI.C6G:MP7=V?O
MG=3.3,FW;NURMSR6G.PY+RF:A"2D*5(!2-O*KY\%DA))D0!!"B1`B2^)6\1E
MK0^W=</"W__K=>6>/2-"L>_]_.;#V_=OSI!G^P[V%C^_>9R>CZ97X_&;__K/
M?_V7O_^?\_.SAX>S:]_SD.NBS=D_;>0B8@7H;&:]^IZ_VIQ=HSGV<`"-G=UA
M[_N31=%_G+'_.F?PTS\O'^[.+MY^.#M;!L'ZIW?O7EY>WA+B;%M\:_NK=V?G
MY]O>?HGI^NGL+V\O@+3,EP<_])R?SGYX__3I;S]\^G#^R7+^`O^Q[7/+F<_/
M/SGHR?GTUQ_A[[]E:ET19$6T.4#T3V<7[S]\.G]_<7[Q:?;AKS]]_.&GBQ__
M?[:TO]X0O%@&9_]N_S\H_/Z'<ZCQ\>SA[</;#`K_]VSJ>Q1*K]:6MSD;N>[9
M`ZM%SQX01>09.6^31MT$D3/`W*,_O\F`\/I$W+<^6;R#;CZ^VQ9\\Z__<A87
M_NF5XER%EX_;XA_>_?/KW=1>HI5UCCT:6)Z=J\@:*ZOZX<<??WP7?<V6!CJ<
M8%<\2]8/[^*/<6F*?Z)1GW>^'6$JP<X9MP3[U_FVV#G[Z?S#Q?G'#V]?J?/F
M/UF'?R>^BQ[0_"RB^*=@LT8_OZ%XM7;1F^2W)4%S^&VQ\J-Q^G`1U_^W:]\.
M5\@#8)P;+\#!9NS-?;**J'YSQMI]?!COR*>6M[!6?C05@V1:OV.%W@G;>7<H
ME0]0\[=I`!.3]3&9WV(/1A);[KU/HP5UY5J4XCE&3AVB)5OLDOQ[BZ!:P-=H
M-EBB`-N6JYZA,>R**]20[*2R<J(FP"]A.P]!2^11_(P.(I/;G'+"ITL8K:7O
M.K##W_P1PF(:>8YB;NKUH9S%*XLN;UW_A8X]!Q-D!PW9*+9S,*G7F-JN3T."
M)F1A>?C/:`\#=*;A:F61#6"'%QZL*MOR@I%MPV$;@$!P[[O8QHB.'"=:>Y;;
M="=MHW^%J-Q:F/QBN2'ZBBSV;S80=$=;Z==XG-@T>[9<]L/HV<*N]>0BH'`*
M/TV1'1(@&\CWG"L_8@C*P5\4.TR*`A[NL/6$W:A0,SA-(+SE<5`X^>2;;YDG
M)KTYH8LR0P3#(H9ZHX[G9MV;B$E>!M`+D&)Y)*7PJT6^HX"MT'1IIA2.O6=$
M@VAI-P-`OOF6>5*XTN6;5\C3-/#M[Y=,]V7R!@@;40_EO]Z\LC]K23J'==0Z
MGPI'KTX'[?-%:;A:L[_H(WRZ]<D-#3#KW5MD=H<;Z,O?H+B125Q>*?<'D-$Z
M1K\B9@!!SN@9-L4%DJ5U>G]_'Q)[R9J+32@J$5-'E-)][W>?7(4T`!6$4#@R
M`@_^O\1K)FQ-`V9<6V![Y+J8F774;HD*>M:'Q`-Z1E[(_F_[H"K\B9Q'#X[@
MT8*@Z,CN!)1*(C3.E"T-O^)@"=K4RAJY#L'V\LHG:Y^HWJ([H\X01*_]%_BW
M/P5UE'T;>_<N4U47P$/H!M"X(=@VI%,?RE>6BX$.#UMC#_;C(`P0;,T/".3L
M2,!^!KG<P3;VT)?Q+_I`5D"F1HR_7(]OF0,E(F3LV1IQE"-%'U;_"&&+QRZZ
M!K4.!6RKI\@"<2!+=("(9\5$ZT-2":'Z</X*F[^%W'_<^J\IQ;"DH.)W[%&0
MTK8,Z8/X4!H5HCNR_PAQ[`&9S*\0B38>A<C4:+]MKG;FRT0^!UD]9X1)32\S
M8GETC@BIYR)KI7^MJ'Q#`:@W**!1U0[A*';<&0YQOT6B&NJ033MKG=^=)6X:
MKJ&YR"'MWA/_EBW(=M:]?)\*N8?FUXA$/COFG%A'=M@M_F4?FS%<OYN6>52X
MB<LWKY"G*W^UPK&!6"$KE:VVPT'J.@N9LO05>W@5KNZM3?0U4O:9&X!8=A!:
M[N3)Q0OK`%.?DIY56_?R'G3%5EV)QEOE)W4XIP;2D0WZ6V,'6\T^.N>.3L*`
M!8FQ"+\V.<SUTPV7('T'!-MP($>%'CT<M#:6HKX4<AL'I\RL5Z6VW\I6V^$@
ME2.28$EZC6)Q&3['(M7!_,CTT1)W.^$PF0</R&7"X<S?4O+HD9VA&*I<@F@U
MQRIX;MRS4FDU"M,!+7K#_*P@<\`O)$1.)C8D0VAUX:8"K&HR%&*T]<8E^#-;
MK,)5+=VZ0H[^.[1(@(B[V05F7EN!M0.X_',S]IIUI?+D"9\H^B,$^>OF6:V@
M+M6RF@#%;WZ`Z,S?@;0+-*394#QFUO!=[&SC\NX)HDSIB_7"DLJ9!>@YPN"]
M&7H-+ETX,NM`91#5QS8,VQ_Z.1P[ZML>EM+8R91@Q;-:NC=3V)ZQ\U/1'*K9
M9]L09"+>QMXU>@I@<J;Q9(E:D(N1122P,+,&,]TGECE;FRFM4==76%7.Q)9I
M;!OB3)C]/!L)E:@'5SX-:'1)(HJ5VMJ6%$_00XDP'"25TTT-*6T#=N6[KO7D
MQU$.(T*`T>A#:UM<G0X-8E[ES*C?;=M`7(84>X@"9:LG'`<5M#8!)/LR@V65
MPUZKQ[;9WWJ3X@BRC$NIM7&OU:-)[*N<`PWZ;7\3W+FI6MSTA7WH95'MUB[1
M4]OL%AT=K&QK@RO?G3&,JQSRNIVVKXHEKH06M51!#SK94ZLM5O;3-JLR#HW6
M!KEIYX:"HG)J'$9"ZZ(-2X00F6BC[`CWH&<2%.#8\K;U%;8GY37MO6U8BAZE
MC#M&,0B2?9G!LLJ54:O'UJ6!O!].M2F,WWS"F$5L6=XXJ92V29I8#J4?(I8M
MUWUSEC2<96!7"WO!.P>OWB5EWK$*+=(#7<4+_MQ!<RMT@WK4%:MW0ZN_LK#7
MF-2X=IN41CV<K]#J"9&:9.:JMDCC$IH@=OB$SG?(U*.TK(&$7F>7=^X.*,O1
M#(L,>0Z+@8]_94T=FNTK[O1=OM>V*)%,X64@3?D4&+H(3!(\Z>J>FW%*%T'U
M\F)%!`%)<$[EZ'!9WC^?E.X%T0J>6_0I6L8A/5]8UOH=.XG?(3>@VU^BL_G\
M_8<DT=^_)3__!K)QN`HCGP>/K*_)1A=W[EI/R/WY3?WZ[W1PMXONN;>P,_:N
MK#4.+%?,D;".'BY^#Q/7Z,SGD!=-M*?]/`P/*+YB@J:(/&,;W2."?2>Y0L\*
M1+Y_+A`M=ZL#2V8"3/*U"&=!L9PF:O=7TS<$V\K,>N73S:VA@X-XTV-4^1XS
MI">R72GMY65[2?5O%UKHAJ&.Q_S.IY1#;[Z,#BIY!P4C:#M9XRT#?B<(=I=K
M%/]_]$2C:S@<UA0T;!(>+)+<<ED<^1>0(+"W^`PSB_$R\3*1,`1V6F]Q#?_T
M%C%S%5M$:]WIP.X!L2`@Y-Q8Q`.*J'!3YQ3607=T<.;O!Y627"RGA=JM1+NW
MV='1*^;M,^(Z6KD`01^-X<]*TM."6NF-3')5M,:%]-"Y[V/CTEHHJ(W>,:4A
M<K+[6+S4,K>R^=-#MKYQW.5RU&USK;%PAT:\"EHSCO-OZ"7ZU(C1M+)Q?*5!
MBED-K`F3G)8,XCA2&YLOT&)UTWCC+J@&C/+;,HWKADMSKZYI7*E8F**&=ORF
M!LP1R7-N$7O;7V+7K^NB2&K/B;^JTM.W/?LB(\J93^#P9X_??/C;^_=OSM;`
M)2@6FY_?7+PY"RG0YZ]C,U,?^*LP+Z:\_MA_7GF*UH[)B_?]9[*&-3SE^X.Q
M?*LSM&1!:L]<D2Z8'TX,TSW#70K$7TX,"*'%.X7EKYI@*094E$$C92[)<LW9
MH';\OM>UMQ:",MIC][<+`QB.(GB$/!9L1UG&]BTV6W[>OT\XBN,T?F+Q=<CY
M^4U`(N];\J/O!>@UN(F3OOW\AJ)%G&O-R.4O"TC1-)0.LKDGIR1W12-NRMQ%
MWYF3T]A2AC\>)\,%\U'*\:?CY%BHOJ;<FRNC*1CO:O;-E<P.'WR!'2H%0)<,
MULGXBPSE*03FVC`.GP-Y.VO*L[FV#`7#SF'Z@[FV#3FFVP\A2['JNU2G0K%-
MT=`D!I8&@`LQR3F92Y6:<O6NKLZF(0JW^*QKIY2T\@1K+6]'\78.^^4W^9=5
M2L-JFK51ST_#I3S[CNI7*V#FQ4V\*K_@Q=+=W&'X[*19A<IIK]V*&NJ7#LZ]
MQ"*`EU-43S2J9R.6!SLZ%S#]#DBQ'ZP%^L`-1Q54T<-#R)YF65LDV'RS5D@0
MP%1:5,GX)R]%T>2EJ#M7,`&X976@]]GWG1?LNK!WC=EUG05F-VQ9ZJWQ:FUA
M4K+0:E75R5-*AB!XEE-8!]U?K5>6IEX8\)@OHX7*.)F^F,I<&2UQTR'K>C*?
MK*,SRUM,8]LK-X::6U[)_M!(3"C(M-E=Y,`6]7%5%OIX:&LZ9A@WM=`C1?/0
MO<-S7H"G3$TMD=<L,9K@^$R_:Z-.'`R>*:$G<GV=F)5VKTCN2QS">R?R]96L
MWO01!B8UL_R;.>&Y;(E65=$2L15OU)^1OR#6>LDNRPI1YI?O-?6:[B>56]4S
M218O-X6DFZ,7BSC%=T[B(YC'M_)^E*RAZ1(36*U\83]?0$V?Y2_^"F@05M!Z
M#R([CV5NGA3*-Z>>(OOMPG]^%TD49!,3G_QCG^[DY]\>IWL$9CYH#=@0*<'Y
MF#_I(\J\R`V%DC3#Y&`1]@AC0=J`N(EES^2(DC8PJI3%3(Y"40Q(+07+Y&"5
MEG`1&VU-CF5I"1`Y&Z;)82XM`[-O"#4YY*4E*%K04TR.FVD)18%557L(3:5_
M7)'),B=.IQ8S[>*R#OX%>ER"Q\5)X5&NAB50?#0\Z+]@_BW,],)-*6T,54<&
ME9B+L_SL>;'Z$`Q7Q5'>>Z@]7DF&H[H&\YV^M&=WZT-8WP',B@U^*?/FJ4"'
M,\^/K$CY-D_3.9SO^I%<?;AK>0`>O`BK/MRLK/3R,#:S1F;]L;<U[T7R#/DY
M:9&/@GZ)HMZ]R(/8;7(OLOO(UM*'1'?R<>G7."XW-5O2T;.%728LPTXVA9_R
MSSWZD5`=;0$`O8/B8RW[>KB.U*S1LY,[]E(\.*XI?GDMB64S@-,<X.(,N575
MM`1VYN>2.+EK:5DUH;WB:;H11/K*U=2![6Z^7FYV?W[!0"`<SIL[](Q$WEC)
MREKY&GOK,*`1,1^$,T=4PQ0.+FIS<&$8!Q]K<_#1!`ZRAUMQJ@L#=>JU<1)<
M:@I12OW*,^A*L*^5%-1/[Q5(G`N0#?_D!_G4J'AD_&B:41D155Y0K*BDY\+!
M[SYAV(+DGCS07GB6G;]<9&L;RIEP7Y.O?]3<:5I?7WT/;;Y:Y#L*;D//$8O^
MG,):PAKM)7)"%TWF.X7J=E_Q+?A7]T,=:[5A*I?"_-;2]75P]SC][#\CXK%C
M9[H&O<TGB+UAA<B:8`H+`]:+I%;=J"F]]KQZ>F'6VE53FNR)P:\C/(S(E"9A
MQVZD,I2B4J:?FQSTV2H"%T4$S'7:MH+`QR("NIR9<ALE7ZG,LBJC^NA?]U([
MH2J&^[+5R6NMN0"@<INUR0&7AS%<[7#0'R8IMZ)K*L/YT!MI?4S_U)=:[5V`
MT9>=H+:VG46CF3JA/9BV;5AX&GX?XO`:,5[+E:@]G(V?-+F)A2,7%"%O/#C"
MZW7*8!1$*9A\`4@9_U46>.V7?>2S]=6UII6J4A7F">W';#=P2$LMYE].4()'
MF<Y6]S*"&8%G@HR)9A"8CM/NZV1>==[WGH%[B\"W)0I8<*,N;F(QDJV!=$FD
MW*1K0$\X(7?5CE8^"=C;.E<^Y:78DZVM)-"-W]EGXE.:/@;$7@&BF8>5QEX6
MY#PG*EONEDMV5;85)H4-#T&C_0H:'4*4CB%$:0B$Z6L@3/'HYS)24G0(;AF"
M6X;@EF,*;NG`@VF`.46?_]+<JZ7M^R]U^6Z-\=CU8^:W[)@R+]G/*3LJ!T^5
MX9X::0-8'Z+_&J.AU,#6ARC!CI`2&^GT!Q-VL,#*=6#M7F`S/7['[@$5>/RD
MG9UF>'",\OA%+TP6LD>6_WKSROY$6IQ-;M0X<LJS76XIXYCSY2KK,%OLGFZ-
M'ZSDY/*,Z8>_)O/D,4LX(.(TTTS"J#1.J>Y%R]-7478HE@EWY*Q@.=`@SA65
MC)[0HB-75X^[@;W6F;[UF8R`T$_"KV$0!T+3N[C.47"AZ7[I`Z*(A4C!5+]F
M05)^E%9<9HW(U-1KME:SB\F9N%7VU;5]H*4SI=R"H'10CMC:T,&@R,I(^LT1
MLA?1*L_&O((@W,*UJTFRKAQU3/?E&HK4X9M_ZT?BE.N#+:DVYY)2L';S4`.;
M0`O'N\1*,?M=^"H]7<%SZXKT<_:@1$6$5[Y,?[7M*VN-@]A(.UJQS+:M:MW%
MWHQ%[IL?V>B`4#;2=.8#W=GOC)]O?O`_*-CG-,K_'/W$RO$>:.^8B*/".6TI
MKC0)EHC,EI:7O`+3->25]&A%GVVV0FVYK*22(.Y<P_=)1G'V3M@#7BP#^BMB
M_P/0GD$,6*`;&N`5$_EW-QO*XK</;E/+(]1`W_Y[C_NO36>+Z*11:";:*]03
M.O79KY+7`J/)^@A[,7V8/E99K@1U]-JL*A_GHKS7N>3L5(>VWZN'E:O<'`H:
M[A4>R5'Y&0H&=.S%4LS>;AY]O(;MG'="Z*+"2*2YJR7573Q':C=MI:L!L]I=
MZ7H\GIU$8TI#Y%R'A#VP%BV+B'K*E<?XCX0W:TW-H^QIYX^>@PB_OZT`^8J(
MC>$W.)1+Y=$#6]1KE2ZU=-1ZC[/1@M%OQY4R7VM!QPP[M]ST*5-K<D]#]W/<
MZ[%EQH!5F^?+3ZTL7Z46`^VIGAI8WQ4I*CE_9'XOT#[@9J"27RG:T[7P;QDH
MT]+*`P<.AO:(@P7:P5ZC;5E_R,'1@<YQG/3!ZZT1Z2;./>W.=&V0=FZ9TGZW
M0Q_430T&?;C`K!8R)58)_7>?M<!VN'NQ#]>%V[19[L6AB;Q5=:\0&Q-5!,MJ
M%>_@C_`)9(QD(L"VE$FAEYM+6U%/@ZWU&LT1(=RQ_A4'R['GX&?LA)9;&':8
M"FR\V26[DF;XSN>V>]4>_Q"/J'P41*Z\GI1)KW@5KL19AW)EM%`)B[F2REP9
M+7YX-H\%LS_]KHTZ<4Q`IL00`7`T$0"[TR=S1+'09W8$7[.]%H[#!Q!85/NX
MI?O5AN93-5=/=;B:(;+BQ6&VV.'1S,9??!>:89F$NYZ/>SWW'M$'3+_?$H3&
M+&,/"-Q=X5G:;Z_0+*B!QQ$OQ1><A=$EE=6.B)=LU(L6-W='.EE6&:^&4KL'
M4LZ7;B!V9CCLI=`K:"XY@TU6<=#/4+4EJT33R24)RBN3?7"S57&45^*UN[/,
M"!K(3&KML]8,1%K?)(?(C"$RPW@_J[P]9'!BMZB,GK#;ND7;T^EYMCNU2/7!
M`RZK'G-#<O-.K+J^:U,<LGMN>5G_[/3^?NOB=V+_O@[W;)>7J@='HFF.Q.$:
M]^"4'9RR@U-V<,H.3EGMLW%PR@Y.6=UH=NF4-?\FJ`'V["[N@>H*E1X\9H/'
M[#3]0Z77;$_=:59T(P[NK<&]U4]S]N#>&MQ;@WNKOZB:YM[2\3;8[SZY"FG@
MKQ"A]Q8)//C_$J_IR'.F++$[6F![Y+K8\FSALV$'9O@:+18$+:"[M(L'](R\
M$&5R"WS%+FP(O@>2:+#TG:3`R%YB^&L'0C;-EXIFE60P.X"0&Q<O,)SZ,Q^*
M(OQ<FL],:?NZ.9[YERC-C*"8W;W&S>)UXHUL&ZT#MMHF\]%Z[>(X542K(/![
M58O.MY!M\Y,Y>T%B9I$%"O8M4-7EE5!TY;O0H4_B31]ZB[;\!Q0]<QKEX&!/
M7<;O69226*^!%FCVX'BS6>N[SND6K7OB.Z$-%*S7Q'].<A/LBE5ST[QI'4;0
M*Y8@!9$U'%V;"B=O:5$=-&^#29+%>!7"/[A/.'`**YE38[9'L%TC?LN&286P
M_D53I:*&$JJVLRW=UBHV#'$%I31)4M):_PG^DF24E-:347V=Q`#M9LK^6A3&
M/<C7/VKNC'K/,:,J7?D>:`IV,//O$6%JP:U/HOQKE8_"*FE:"R;^QG)!S8OW
M9!YW^4)ZPTT.@%HNWN3@#M1DBEYB`NNH-`:HI("2/A_7<P*\)5+3+2I5T(J%
M]-Z.%,E-^?Q"TKN;=@^'G*]1.>=FW$R4<.+5/:C23&?Y5;5C]H,FLR'7<:/R
MK"IWW1R^CQZQ[T8U_!+F@UYXS]N`1:01:'?`ZP:%@X:YCKE6T>`HTGWPJ;6"
M2Y79HP]NL5:`*9%D^W!%J]UCYW#_A?X@O/YAF'KUZJ8P'=`K]1EJ?Q&DAS!*
M.^=2C<AD]:\%<)5YI5($3T>.YUD34RQ.1WRO\HVEF)R8$%_35YWBI$FH;Q!F
MK,HVG9U'Y5:^NF8ZXR.RDF5"TU-J;V/5XI*/1XN*W2.%8L<?/L!Q(&SWO$3]
MV@(#^E<Y@I*5=."9G/\50[]?ZJC=MH/3]F"G+6?=;"E)GEM*9E.T`9:?FF7K
MJ'XC>L8S(NL63M#DZ&='`RY$IU67UT@]'3W1:&:(B4Z+#:Y]@6O?<G<;:#)W
MZ3<45$!<56L(4CC2((4I7JRLD>L0;"^O?+).=C4!#<(*Q^7!/U7_O=&FP,;,
MBF>Z=E/=$+Q@ZHQKR;I7$'Y.T1\D+;;TP]U3+L_N]B`)C;X?@2L5?#;0P/H1
MF\+GFV_EZD.<B:36(.6=,#ALI`&;!<M5'Z)`F@PGWY*@/=9C\!UT>IM[NRFS
MEPHX4G.+-[YW+>]\[\D]^^H+B])UC_^VZ!&Y033?1E3J`-D1P6BBPI2THAJ*
MS.1.:"-G>XX7TR3R2@UN&8/<,O%S,:+4RTK:[ADJ!CJKM&/"QK)BC:AH6\W>
ME%,NTOQ$<>`=BUPLS?\A4VUP973ARFC)K=#EF+%\J6-*0^1<AP1["X`+^TZ4
M_@F4J9?H$S=5KEQE@_B*DE<U9&NOKA&W9Y7V72ZIB<L.KK!C]`YI<XW)Y4M6
M*4?FYXD2L4/['!J<;*8N7*WW^4QVM71]G\]D]TM+:U1.(NJ#'Z=CB`K"<!^<
M0*TL*2F%M0^NHW;0*3$U:O<J:;MX*.WA.,6`D(,N-QD=&Z+0<,<_R:DQ\6PZ
M,)'RMFB_4GI4[NQC14>1*EWW,9-^10=<^R_P;W]J8\2^C3WVMDT`/V$[=`-H
MO,4X`<\++9?M>,FQ,//%L0&B\D,\0(_B`?8F'=\T6UY0"0TPCZ[+[U\F7X;(
M!Q,B'T[M\NKP/+A@-25-3L,G-YE@NR-A"MHZGF,;5/7OOK<S;Y2ML`:M**%^
MXJ$9R$.II']C$:_<"\XKJH0.X`F:#:P%D[LB?1XCFC5SL`C2'3H`0AF%]1O1
M$FLQ/&K>'87:LI@/<65#7-D05W9L<64G@HJN7;,OR1#Z&'<WQ`MU^N)!G]X8
M5_IH>F_>)VCV;+K)21*;/9MN=(K#IH%W'&N>?O>5Y.XQ1-P=?^"B$3OE$+IH
MZM8WA"YV!PS7#'K*`8S\5`PF2PPMS(X&QNF3C5@4.]!/-E2QB9?H9$,9MV[P
M4PQ4Y'J'CSP:D3\;&D=MFIQN<(A0'"(4S40G8^>K&V5XM)`H#=K\>#1!FU>6
MBX%;#UMCCP8X"`,$C#^@!8)JL%T_HZ_(P3;L[%_&ORB(V53CO1G9-ML`Z#<_
M0/3.MSS&W"WV@"40OF*1GLT$&+L[M+#<&P]8VTSFV6VCPHFMM`LE\36[$^&:
MDY`G7T!MGYEWP00=IZ74Q,U*3TY^J&?M-K1$SUIK'`"A?R;2T&3^Z,6O7MT3
M'_9/IJS>O-INZ,2*ZFCEPV]_1NOO<I.4V4P(_/4[L@-1\&T+/1U_C#2'YNU=
M/@`I9),_8TU@4ZSLQ"FCO$DS2NC_#*=?<!MZ#NQH<>=EY)64TA)KF^ZR;%_-
M[[3">`J9FD?'D:;X#P.SV=W#">Y%-O/8&)I<J:0S/T:P-`RUJHX.;),]5XAF
MODPOJ-06WSE$0`X1D$<1ZZ?V<:SHO!>\(U=:;HCAZR!WW@S:L]8H#+`-S5^B
MP`J6EFM1BE;8XJM`,M7TQLJTH<_G;*HRDI9VZZ%<0(P!6!D1]2(YM5I4K;.H
M[4D])J$C"N[5`(X9DZ?:P5-#.TO]7+4-5GUP"99*]#N>I0XEDX(V>QML:,"Z
M&4(-S5RBK7CMR\R#)QM>6.8).<7(PN:&[Y.-/=QSW)UL7&&U(?9D8PO+;2\G
M&SW8.%[L*(,,5<2+Z8JD,R3\1ZW11+L8;@BJFC+A'2N<K5ACCB]B[<OU^!:6
MI1/Q/?;L(2IMB$KK-"IMZ>#<!!0$GW&*GFS$U'97#"TW)[#`#&9$\.:03#4U
MV1MAK.AU\B"U,)\BI^31Q1&IBL&AP0@`<AA(\B#+5.M91$!!Z=$?)3'$`YQ8
M3A\#7,@&*%%M^0!YXH%V5]_@O#%SEK5S`9=SR`X.G'TK_(GY;L2.K!-SS4CI
M(R?LL)&0VD_69]/827%BSIPJWY8FGXTA1E^]G@GCK;W_"&&^8!==8U#%`I9+
M(QZ"K(0-,,3;-6SB@RWXQ&S!Q2"E)$EF?$ZMHMDJ-#+5;$$)U36G-=_"W*RA
MP4I9;J4DOHV00S/!3+_ZY'NRER-'PF!9KX7!=CG8+@?;Y6"[-,5VV?!8TJX"
M#I9-,^=@MX:\$S-HUI5\3];B65>L.UEK:)6E1I/Y<[#4],%2\Q7;2PNY_[CU
M7U-Q`5"%BM^Q1WUO)TT,1II.C#2*,-H-UO:HD4_M(U>WMZ:GA*EL!O'<#LH+
M&Q/6&1)['4%B+_.28,GOSGQ;8^TV>F;>&M(Z]<3HIQV3(:W38`H=3*%';0JM
M?V!JMX(..4X&8_)@3!Z,R4W#A<6Z[,F:C\5I<`83L0DF8IT)&"0M9$<>_ZDD
M2<40"CHDJ5"-JJ8D%=W[:T;V'R&F4>,P)Q")LDX:XVNY#"D<*I1FJ(S^A`U!
M:$FIKJ?#1M$:-YJ2X9?1Q;>#\DH;0CF[>S&9)[@ZB=X/RYW"(D\^U^!,JC5#
M.+^!OX)-%*.%@*PQI2%R)H3]GVV/WT)VX$[FTZ4%W^.O\D`T:=P07*ILV,(J
M.GFX\E=/R5TT.*8H=E!\W2B:@'-$V(PL&Q8X[+;C4L&RBA[,02@`02D^TE-.
M[K#UA-WB0R^'M&0(QU,$0I\5('<#TJ&_\%CJJ,S>1+>WSV"P[GP:/46[+28/
MQB&=J$D:D\@RXE0[A4(ZQN@:Q4MF9KUN)PM&]+/O.R_8==F:\0(0Y3"LFA%`
M%>P^<8:C>7LZN+^A(/F_7*.U#WLH"*9/(:&1B)T^)+[-4I;9:3]P>&_:F@[.
M*X91ZZAL.X_?)(?U09!%T36*_U]!,:>2.?[:L1>%=])Z[NFTEEX/9XG@`5IG
MYE]R?DS)9O09EJ3UI?1V=7'3U_[XM>23(Q7*5-8X(8&+=CN.G%M1)=-&/!'"
M=0/*Z!?E[CW9U7[$3KRZX*E2<OO@V&N*C1(EL0_NO;H`-99'^^#>JPM&I?C4
M!R=>7:93N5Q_=(YZ[@[0-OO@C6PZV#Q%1[N?L;,SH,(,ICT383>"@IP?0/L3
M"=W,BH-,A=J?;VO@2ZZG6E?I)SVYLU?J`YZ&JY5%-I/Y#0WPBLD]MQ8FOUAN
M&(7"EDN,@X^XCSY5C@6]=',L/25N+.+Y89`\S51F:&_<EB%C<,R^0)XIO583
MAO/8.W]G_[U:@[WZ,'NU-IM3YY;;P6X[V&T'VZ0(H`/EL6.T3-83<+2;*0==
MM"U=]!L*8COEUF8S**%]5$('U4VPLZ5FM;$#.SJ>8VMGGM].>V:#2^WY\"U<
MP8]1$7GMYM".^H[7E469KXM)%\^6RYQ^'6!7TFGO<0SAX/62C3ES":D+-'E=
M'PFFV0_)W2\0].H9,5JDH>\HE[M'O_F>';/>`<B5)/0=X]3#W,6&D.VM[\AE
M?ND`N6QO?4<.U(0.$&.]G)JAU^0P]L$(/1BA!R/T8(0^S+"H5)T\)KMTMZKC
MB9BQU8C5VBW>0V"NQJFPM?L=8\1NM]K^B<3_MFF5.N;(8>5*_8E$%A^FQP^A
MQ4?ASHV'N^C4I8,+=W#A#B[<?AG+=1HR!7U///0E])R8WQGR9@19`3-7P/;C
M_KE$L'T3V*_892\Q??4;:HF'%^ASD^E]EUR\`1N2;>E80[?L4$)W++'P_HW$
MRTW\S)1KP9KG[VIU6C",PY2Z;]9*?/[4;>5D.-64%7%P.0PNA\'E,+@<!B.P
M?/*C!F=]%K_:QXOV=2>WV70+BQ$)E"165T-A(G?X--`*^N"W4P^-K+*AW3?7
M3XM<OV&HM3_U-!=^BM,T7*]C^<-R[XE_RQ+C#_GQ!YME.2W;&<+NXF%O0>\1
MB9++75H4V_(LB9MI*\]#R?3FV6`;-=$AW64Z=NWJALPINB7P&PI`=?97B&7=
MD9],G/I&V'E-4-(&JT5/K1:'[&.B^]7\_>0(K1>'@MA@XS)9IVH1C@K9P'Q=
MJNGY>R11#;O\KW%H;Y03=1?44/91AVXPLNUP%489:Z_1FB`;1^,!?[LH`MMS
M1BN?!/A/*QFZB.Q[U_*"'.WEXH6RYK6\.;'MO514X972XCD+88L(F'+*7O5[
M97]1(=&""CKHOV-&HJ7O.N/5FOC/<2)E(0.B&CHXX,[<XL/6>YS(U#2*H\^$
MKTY45#**#YZN6J.B4?SP[RX*JQC%`YOQ0IN43,VCXTA[C`*?1JG8A(KJ>KV*
M-7;NK&`J->#:=6`YQ;\]"(SP%G+#%^2/AO(@AJIE<83J_V'05<D4^B,1VN)<
MG9[5ATMMBF='_C:'P9?4:D@!N<=D]A5-_0;CUG@5J:HF&_H.9%NHX9IORFLJ
M$DHM[ZR4T4^SWLAQ<$Q6P=7?/8%7_FJ%HT`<:BI=.S/H;<@V@*_0YRI<)9EH
MZ2-T0UC26F+906BYDR<7+R+2J2[:IX%O?V?+%Q$:)Q460-NQ!??%(DZ%C2E?
M1H<N&87X3.81CD)UN*1@S^BMK:WS?.6P7GPO:OCFU5["+$4/;):5NLQY9;5@
MEQ(CM.$6RVFQ\J_6KK]!J)K>LI*Z_!+!)LIA[MEHZQ8$]2'D^F&$593,5I#1
MH^?^D$-O0638=17"YFU/YG-$L+<HF[IR%;78]$!086&P(N-]MHA.&L4FQGPA
M/?;1)(=&M'CB!U1'8;`$Z>[/]%PNF$:%E93,V_N0P'Y)$<-H.]OB5_[*)JN@
MM')J=G]+4;-76L\KZI%]X]X"Z5@X'TL*]HQ>31;Y+"'9%_8N-]DO@OVJ1@-Z
M^*,!P7:0K/A'$.?IP_11>"J+ZVCQFUA1(#BCINS%Z+&709[G.ZG3A%[?T#8F
M"3D@S[&''JW8*D&8$!KI<Y>;M$RBX\4*B93SZ-#VM:!313./Y.@_O\",WITK
MO'?7E';16XP>\&+)S;ZOLH=>(;1]]@@VQC!:(9-@B<@,U,))9#VCGZ&)@(Z]
M4M&B\^Z/&=M?$9L_R!D](V(M4/3Q&@[:718CS>!7TZ=$KFV/';9,M\R,/9`$
M/(KM,F3UT=&K^5WPT*F:F'=:HZ8:D[T5OU)[KZ3RVF:/O42P*]S:L1,H(FL2
M!C2P/(=C#&NA%Y.X!UT-D6?DW/HD]OQLK7TM8L'OTPQD$CF3'2V6ZY;$TK?6
MC;9=Y*F:CZ=]/I)C]N85$1M3IMGE3UFAGM1.A[W:A?/LH)T`./,#YL(4"$Z=
M=JUW3>XH7>/D?5!$5DJ78WD/1G#]U7IE7OBV6,XV;QJ_<#9,U\C&<YQ8$;]$
MKOZ68>#UVL=])2-Q=+*9\/OK(WKL<(XRZ<"^@)@I>^:SGS)GSVBQ(&@!BGDG
MZ#:GIU<RQ<YG1K"-)O-,/`(<4'91$NN@0[T[8R5]A2UKJ7ZC;$R$7NQ2DSJC
MT5JHU6F*K9O!+0M9+WBQE#9M$I\3;XILWX.=T<//B%"+;%IDO:PWL]"8+3'I
M#(Q"9T:>]%QO9!J#Z3E243NM=*5F_I3LOI,7#X9EB=<5&Z!D52UC&X`\PT#,
MQG0*@BGXY?50SR)0\3-VD.?0V/;%);RDJ#::XY"&ZS"-I8HI^H9>HD]"+JHK
M:^,KEJ6%L2O%<FK69Q0NMW9Q$`4!3[R,#%6Z*$7EE5`T>_%G2S^DH+&Q;3Q`
M*&Y][+$%#SLZVZ;X&<'J5%=";W0%X87@`#8F/EDEI73,MD>/[/)`SZS72^2A
M.68N7INP6T?,`AZZ["AE\;53%`3Q%5/Z*PZ64!X^),X2P8/1:OO0@=*>ISOO
M),A,^&GX]#OHO#/_`:T3361"KIC#P'4M0<B6NO:UW@4OO4Z2N_[<B@2D_9*X
MQ-4__IV0+#XEMQ]VS'W4]3J@7!J`DGCWW`6^'HY9N:2]R^97ZUQ*A]'<1_?X
M_`KON^Q8^V3NA6-^N/9N.,N.[734=+TK*9>'I'YL=W94R\#1OSZEMAW5C!N1
M<Z3!C6I%@=2YK!/YPWQ`I>2<JYMQ_DA!$1@_$H0^GCA"=?:I!+)/YN4\4A<8
M6IX3Z6#@CSAI4CO85UVM[$,RF99FI:1YL0]Y9]I!2'R57'M>FLYQJ7.5O0_)
MREI:5[4N./8A85E+.+48F-*'=&@MK$VE08XIAKKL<GHPE'7?IOCH,IWT:XXU
M#Y]*D3;7M&@2TC5">'?0?C#72MWB\=.DU;(;UBF,)Z=%J(!Q=YD_Q?%4=`WE
M894IA">EEJB^U9+">'+ZRZ&7Z01&E@^GHN2T=BLVA?)4-)M.+JFGL)Z4LL//
MHID"<EK:C3`X,`7EI!0141;`'207IZ)`5*8B3"$Y-65`811A"N*I:`+=7F)/
M\3T5-:&#R[PIJ">I-#0QYDMDKDA1/17M0?]-Y0SH@YXAV6KMQ((IQJ>B=)B7
MP"\S"*>EZ!RJ39=E9DJQ/"G]Z&#S[?:>>!J-?5+*E"+\2N^?IY">BC+6]B7V
M%-%3T<PT)FE-P3XY-:WTQG:*QZEI6(KOL:9`GHI2U5&JSA38'BM.!^3I**SA
M_$W_]"Y=CT4<1?!4/.B10J7KH)6[FU>9&21W`;CDFK#VFU=R5_$.Y+/)S3L3
MWG+</4>96<TC.X"3.=B8\^)D&94YS[F*Q!</;`.X828%?MJ+0ADE*3>B5F]!
M"*_H.%-$8;]^2*KZ38NHZ_<;'.,5_6:*J.MW4MGMI(5>I^@9";*\%,HH[!F_
M5O6[*Z&NUUDEM[,6>)U!D:K1S991V/.+7]7OKH2)CU;M!\U$Z00RNRV3=T`P
MVKH?HS#OF*T#7K(ZL%-SDN`U9D248JV%GGJ&6)&+!ED##^MI0*QF3YJ>ARQW
M43?D).-"363-/5=3KDJ]YQ<Z(JGW\[9@Y6ESZJ:=]1\W_P61A*D5%J;Q;JO+
MWF.X-0<6%UT7<`IZ/QID,[J[!F1+>N_]F57D:>^`>$#L>(;/5[X7$,L.0LME
MMV$NNCB^#J"N]W/^<;WN>D?>[]+TY$1JM,_J&*0#]3233-E"FWU[2JHBC/EZ
MBDD8B]P%O878B!R!C?UT2K3@G<-XWR#<WWQ1+>"2,6GV-TM4&[ADC<S]S1/5
M`C)95U)_4T2U`4S&M]??G%`M`)-Q3O4WJU,;N&3=A?W-U=0",CD'?7^S-+6`
M3-:AWM^D2FT<V"5+25=&I)K):549S^LDK#U4&3^Y++:M#%*K/H'^9K0R'NN"
MM:^_6:^,QUKD3>AOIJS68#?`F-_CS%N]60UE7LO^YN@R?C74#A:IF^3+J`#L
MDEL-^7#Q;AUUI4^V[7G6\F5TN!,KKH*44BVN8V((:>T71FI&B\JWK_>EZ*HK
MH9GCDYN@HQA#K),<<USP*F[DWOIDCG#`DO5O<W74\,BW0\%Q(;R?"J5C>/>Z
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M3^J-O;E/5O'C31HL=]=HC@B),B./*$6!T/;&*:S#XJB`;DWIE/:)H9,U8@^H
M>HL[G](KBY`-S`BV,BC0R;+*VY)LR;1D.,=1JEC8#>Z`&O=PMO/-&<$[_'$%
M_\9!CE"6%QNVW*4LRQ6M*/%.571ZN]>I:.@.;\^(L6.'<GRXN:[_$J<MEQNO
MDIHZ.+J9SQ$+*4V/H@<`^8&]_F%C%\<4!K<(3E++90,0`B&;7&$.QRI:5C)K
MDRZVLZATH:1O5O\/%"J;JPU:44)]1D3@N0KYY5134!916EY&;<],-O:HN.=M
M&1VK:.PE4B)R8<*SIT=`^,/L4;AHK0MCC^7J*L&3?RQ6SW_INCKPY[_H$<^-
M>P1R-7NM`TX/`!@1IF'9-@D1+V#RD!9U(%`\3BXW^V>.(&Q?NKH9O.V3=A6]
MMSWV1BL_]'A)OVHWHT^!%NLR6158<N?1?B^RX,2N/-QVMI?B^7.$?N4&<.P.
M19-=N5)\*15&37:ZUD)#2MDPV?]9B]OZF[S)/LG#!EK&_F-R9J.VN-\S*)CL
M&97?S^6%<I,=D(<->94)S&1/G_Q('V8^,]GS)H]!$V.,R2ZO6O/^(#55>QJ9
MRNA<H;5(?-;SE%7MP;>228#KJM^BW="8<&RY8'7UK/?C>;_,1$]#IIF_V_(V
MM+#5ZWK>+TOE-JW$-H?$`W*M*.!@2S5G?])%.VQ]3-*G]]:&[22P*2:;X1VV
MGD`?9#MEAJGJPKH8N5FM77^#4`(H"VP0N/N[I^^_0XO`:>-N;K$'"QA;[K45
M6#MHRS]K>[`R?*+HCQ!YP<TS"QLY/&Z"8RV_1($U6UKL]5&TPA;_Q;GR@CHL
MI7?89B:A*Y\&/$MOKH@2K\)7[(*<XGLH">39+L$RJ+AEE5"R3<JTE2[OB;\@
M5NGE15Y131EK(AI@S[I&S\CUUU$\5!HNM8U\G/GWB+!)#JI"%$=&+S<5^7C4
MM-TS5!C=PO`?-6VKN?&+[>\NND*N"UL<N]S`WV=X1;7<[\SOP@6U9_^.)J^X
M`;0+O;/E90V@6IC<J:RH"32+]RI>:4,H%U]"YI;O-?79B$@=RJ72HW$O=%C%
MZ:)?1Z]V)BL]2'>&/(YT;+);HEU`N`>Y=C<%_P)YQ2&>NXQ5>OP<H2>^#CAB
MK<-DOWR3*9#7+DWVL]<>0[X.J]W!+I\40R`@BE:R.9DNE+.J2'Q(@+DPP1(O
M?(I0+&Y73`)S9!JY1P$5,-N;Y_FJY'D!MTW?".O*LOO-#Q"=^3O;<N3VCJ]*
MDH7EX3\CBRXL5.J[V(D]39YS3V!I>T'TS\F\I'+&C>`Y4[SP\!S;EA<D?@+L
M+>ZA/1M#WT#X)2ACW[NU:)O#]_8'4_B_M3");KM^!3$:&-GCR[CQDJ4W.J:,
M07D<)01*_KQ&3P',EZ\6^0YZ'9"99*)'=DAP$I%PA4@`6\Z,6-$-\<BM:?"H
MM,6?6:.8$A@[G[>7K1/?;B2K%ZY:F[?E'<B&66-RY;NN]>2S$*9GE!$V#5XL
M-4C.8MVM5?.*'6"(K"T2;%AB`($IN;2H'B_6.@0%!&;M:$%0HG/D::OP5,G6
MU_M*Q0-[0S-$4Q^H1?0+LMQ@>07K-2O+1#,GG?H<4_0A32K*P8M!>%H(_'"Y
M`HJ\@(N5-7(=@NWEE4_6?AS_*/(%BBIHF0O;S:32%U@LJ)5>H2<M7TBKPBO:
M_O)&#^DMIP^Z;^T=-).T)[>0^V"P/(!9\0ZBW8S)=T)P]XV<46-OM1ZSXT$.
MD(..7NVN"7E3;^DVG46B?%\T-8"8+X-?AA0&G((LOGJ"KZQ3@S4&.6K-4LSN
MB0^S+MBP`%QF#F!&@+7AFED=FLU"&V;&"@>F&^_$5)J%:/&I2%;68'"E"38+
MY]VE"8.A%=%H%IHR-S,,!KHA^6:-P7TL8@'QD7?[WJ<!00&.?17;>SX&#T+Q
M"DKFMD=/J35KANQYC25<!']_QWIF+SO#/_X74$L#!!0````(`"J(6$3S;M5?
M")(``+-7"``5`!P`<V=M;RTR,#$S,3(S,5]L86(N>&UL550)``,PP0M3,,$+
M4W5X"P`!!"4.```$.0$``.V]>W/DN+$G^O]&['?`G;VQMB.DF2K6>^XYNZ%6
MM\;:[6EI);6]YTYL.*@JE$1/%5DF6>HN?_J+!Q_@.TF"`$J^$>=XU!*9R$SF
M[X=7(O%O__W[?H?>L!\XGOOO/XQ_'/V`L+OV-H[[\N\_?'V\O'J\OKW]X;__
MM__\G_[M_[J\1`\/Z*/GNGBWPR?TO]=XAWT[Q.C)_NZYWOZ$/MO/>!>@SX[[
M^[,=X`M$_W>#/!?][P\/GY'UXQBAUS`\_/S33]^^??O1]S>QM!_7WOXG='D9
MM_07KM//:/ZC1=02_O+@'=W-SV@V>IXN9]/QY=3>S,G_K->7]F:[O9QN\/-F
MNEB1GY?"6]<^MD,B$&V(PC\C:S2>7HZL2VOZ-%[\/)G];*W^7_%I[W#RG9?7
M$/UQ_2?R\&AV2=Z8H(<?'WX4//!?T:/G!N3I_<%V3^AJMT,/]*T`/>``^V]X
M\V,D=!=Y!!%_N\&__R`XX?NSO_O1\U]^(LU,?HH?_.$__R?$'_[Y>^!D7O@V
MB1\?__2_?_W\N'[%>_O2<8/0=M>9%ZFPLE?'J]7J)_97_G3@_!PP*9^]-?,2
M0$%4^03]UV7\V"7]U>78NIR,?_P>;'[X;[3!?_.]'7[`6\1T^#D\'?"__Q`X
M^\,._Q#][M7'VW(M=K[_$WW_)Q>_D&^YH2VL:`OC.6WAOT2_9J'X`Z)/?GVX
MK31HE9'%7_I)F9)/7FCO.FDJO!FINZ/_H,C+*(R_A]C=X$VL,I51\W59$RPP
MF%`JUEMG!.YHB'A^J0N8K*T=/#.!Q^#RQ;8//U'D_(1W81#_AF'I<C2.8N*_
M1+_^V]5Z3;`=$NZY]W;.VL'!U7,0^O8ZC%MC-O[[#X`7?DKTIZ]D+/!QX!W]
M-6[E$OZ-6FKQM]TS?6F_(Z]00L7NY=?''Y"S^?<?G,W?)H2#EI/)WU;6<K58
M_FW\M_$/_RV5A6)AZ+=8W/_Y-ZZ'7--"PK3X\_#V6=WLN_*S\6?[ZUA/\F.#
M@=$3/ZT]PHR'\#+S&;>^MP?%4MR^!_;)3_K0$WSQ0AQ\]FPWN'(W-XY+.@6B
MY@->8^?-?M[AX,/I,^&0W2>B?GBZVU[3M[!_L/WP]$24O/KN!/61(*<)]0B5
MHC<TYF?68I'!=(!8\XBUCX@"*-$`"2J@#V08195`7`MTMT6B'H@J0C!#5-'+
M!^J]R1@DXQLOZYN+)N<H)A.I6"RA'WF?0"=AW=LGJBNQ@/S&/Y)1F&,_.SLG
M)*QZ??1][#;T_R`)&N@&H!8P_B<S:Y5GDT@Z8Y)(/A(:0%$+>CE"M@NLC`L.
MD0MLX@([<L$N;6`8TX4ANU+3Y]1T-NRGMG9V@&H*;('N,H:#>M%4`OOH!.N=
M%QQ]_$2F8A^(-K_WB)LR:8816XF*T$Y^,1Z-6I)<VAKZC;:'6(.:!T9#NL<J
M=8]=[A[3\5\#CK9<4.57,WCA+GS%?E%I<!Q5O:\5^Q5*03NUZ<):UJ"=28<&
MM0YLRS"?H9D),@NJ#?%:#\XZQQ@`QU93"OVSAY9#Q<EB,:M`E4D3@BY6E8[]
M#<(-?#1KRL`U72CX@D,8+DI?T8".,CV@T;1<%,:9J3A$Y)D!E=XF9@'C)^),
MP$Q=Z)4AI](9[?`3O.P]AHJQ%6&"_N9O46]U39YTUO;NR7?LW:?O!^P&./>1
M&A^7C(6-MS[NB:UL6[:E+K!@&8^FX]ET_+=)%"ULO+6.Q*&0RD.8"_QQ$$"4
MP5VN:6/1M%@<8O)0)%`MU.6:9S5_.1V0AR*+PAWD$$U=)=7IT_ZP\TX8?\`N
MWCIA\[ITW4MJN\L:3>!SE5D.1+%`%$O4WF7*,C,+)F]/PX]G#M%%%AS;_1PU
MH;DO!<1FKC=M\I-&D-W[WA8'-.W+WMU@P.9/W4OJ05:A"7B.LQHMLB`3!2(J
MT0B0R3`S`[*#:.86:U^V!(1B":;JW*()4\?]<4=SQ3[B`QG\.XS%R,\[3'^@
MJZA[SP^=?[+?$_4/V`]/]^3KA>1OG_YQ=`[[6O3)$:\6IU)T!H?Z=+%*$!VW
MC,2F4=(VW^$06D=Q\XBUS_Z>:""7`,IR($WRX)3G?00!W>-,_+@1_<@V0(66
M-5.(5.3ER$;>!S@#6GJT=_AN.S`Y-35B+D4U:`Z%V7R\&G<G*JH$S5)31U@M
M1BRZO&GEO2G2U1FQ$Q"`/3@*XG7-3,5VM.@I#Q^_DNF@\X9O73(UQ)^](/B"
MP[OMD_V].01!4O1P#40U\"S:LB9%,N';N9DF$&\#T4;8JCOA$-*.=JJ0[HP"
M%WC,&>N,,QS6AB',T";@*Z`/]J*AV/X5[Y^QWSU:HO?-PC-7"IIP-)E.IJV0
M_!N7KR_]:@#["^"MMO\G]$<:W7^J]8-!:,Z&>$L<"Z[4@N#-Q@GY8LO1I<=5
MKUY\C.F`X0G[^Z`>O:!W52(7HA"TRR&CSS@#)!&+(KDH$8R89-V(E6ZW)<%N
M90AM$\(9=(+=)F=S/&GN5V>'@]!S\;U]HLU]=3?83QHOW>.$OJM\VQRH&##Z
M%HNI-8JVT-/HV\>B:;82B[XC%8[L6+KJ#?4AC,Y332(:1;(1$YY"4,=6^Q"&
M,ZZ)"<9^LYT=RQ_BGYCTFLC>LZ/7Z>?6MPO?$L+IEGP;Q^D=!]S;SN;6O;8/
M3F@W=SC9I[7T]1D5X)F0R>PZA1R51,:@*)*ENS/O;EB^^SX029>.B];5AJGO
MK4L#K;Q_+GK"((P`Q\AE[^C'2[NQH35;SIM08\Q8N*^=>1#=1R""V*D939`Q
M;Y5[]"#K[\<@I!U@\.15J/CX:ON8U4&Z%K*)'O`_CD[@A/@1^V_.&M]CW_$V
M#WCMO;A,RE_LW3&??*JL6:7X'M86\!G;U31>[$HU0D\>JF&,5"\D*H82S5"D
M&N*Z(4$YQ+33Q34&^9S1U6/HK7^_Y*X4D^[T<I0:<&=I3L&7T<Z45"MW[;!<
M_G17X,F[MH/7>]][<\BLZ</I*['PUKT[T!IS=)%C'3IO["194U6H(9K2Q8B2
M](<N>:^LZ;*4!1,]V$Z=N'-'_DB50;$VM(`-U8<29:(12E727\]*MW^MO']#
MCY[.B?SK$O_NJ&/);^G/:^K<(W4H&<-YB4/M1(>?C2%)R;BN)$:9'TW.$NG+
MB\^RYU+*?L!OV#UB@8"3%91?<?A*J9D]<+5^=<A/FURP2A.K?&&UO\[`TR\$
M2D2O:-$U;E4<KD5B,Z.N='62-YT\%#>N>$56M;?&9^"MAK5<U2YC='WOA23J
MZ8DJ>T\/)"*\<UX<NM[+R1O3;>"MYZ,U]D.;,/7CJ^/C=`=`2U*[;&Y*EX4E
M?0/=Y/LI^HBL2Z&?4'+`%>6?$1T7E&\#F[$L7HZUB`:A5(^SH>B>'I3$U:H\
M.!AM]W1C.7\3VGXFC'UD.W24N&U.3&S'TMNBX(#7SM;AZQ%[[*_)NW'&,SUM
M$-BT6.=Y\WLE_<D@^O*OIIOQG[P/\4/_E#[HS@D_(Z[/:@[%UVBTF!0&X'9*
M4W[$0+Y`4VE.Q)[35/P0!Z2?**$Z-T*/\R1Q/*'V#\FC_SRW<7D?!P+9_3T-
MR\LY3`9GEWP(LPC[SKU:4[?2FR[NME>'P\Y9#\^'U:V>+<57FM0&?85!OBSN
MIS?&V(E^=#AFIQJ>:\<@R>4#]1CHSD6I?O0LCJ#A.7<GDMS.^IG;+Q\1Z4RN
MGZY0<'S>.^R\?]3GG']/TDBN\KN8^H\CM^_Y<J2Y(G?;7["+GVS_!8?Y`JS-
MSVOC^Q)EH,FJX^F\,$AWF3A*K"]$(`JY1%W,VM>X'"5R<93"J$`42=3)87T-
MM"!?3S\!U2"L2!U5/I$$^B@Q^2-IJ?S3B`^HA[70.K38V]B:+V<QD./C+/0Z
M.^6P[:S\.*L\%:`%EIT-L(K>UPB[DA@7<)8W4BZP&K9,"D]I@UC;5>/1;#6>
MC_,X2W?Y=*&MHQTYR&G>`^AGBU7U3?1CL&X)O=1H+4EX.R8<;U@*X8=\"F%Y
MQ=N6+ZM,E`-I!!QH34?6,AY)QG)Y@B_Z4,SPU5(U=D"[K?1RH:`B%5=G*=EN
M`9S)'X/[K#LR`[S^\<5[^VF#'0Y*\D,>B^17?[NB!P,I)=SL[)?<1R[^70&B
M"HU"\QG'JVE<M#)^'='WU0*CG_H63/VA8[PR,&@8EUNHI0\12C?=;3_BYY!>
MO4,7P.Y]O'>.^RK2:GQ/9<_1I`R8/!?3^&"96!+M;HNH4!1+19%83?V%5&NM
M@K7>%AVX(/03VL0FT_5^V_\=A^Q4-*'&H^]HOY0*&KR9K@/D/CFS*]<]\O*Q
M#WC'K_FN+Z]0][SR&5>-,L!Q/O''?#Z-YEY,'"L(3(;YO/8.&?%KJYT@S;JQ
M8!VKZAP)9(?-=!9)D&:AE?M^^J9G`#RE$[4F^[5TMT%0W*?(_5%EQ\E:!-]"
M,TZ.7;/W-%W(VEYG\:[52LV5=5J9$,CT3*EE^F*SZ31>]B'EL=KVA-9R.AN)
M,:O_N%IW,S@//SY^>GH<1/<W[#][@VD_MM*OH/>,6VF<%X'8XUR93$`V7)N1
M>48Y'%O>%K$8Y]`XZ`T8L)ZDBPE"A[+FKQO3L=1=;5&P5WM4@WJ;_+.ZHKPM
M[<W'TUE9M!O2!_6QBG'Y=2;T#>#TBJ"JQ(`A#']C.SXKYY#>>EW[X<J>5XZ)
M$B7@8_+5-(,+*HL74!%N@-<)C;[&"?LO[+P_+>;Q9N]8=0!VMTE<7O!RZ_F7
M].R1*2MJ30%9Q%*5K[3@*?;KC>?3BP@>$Z=&JWYTFRBH[&V`;ZO$&DPE\.#%
MFL<]4E+@DDCF=WZDLE$B'%'IFI`X@.GB8G>-<<K0UBY<,]AKX1VSD/B+[P7!
M`Z;'+_&&%OK`E>MAK608@<H2Q:`!NIHO%Q!LLB90W`;BC9@&T;Y^8$!-;-Q5
MVJ@?J37A#,-KE:OD[$#5-_O5]:.&?[$=-Q#N";AU;]TW')7H*=U>D"-9^:Z6
M%+6A^R>K^6*\B/:_$E#3\XNY(1]Z8:`^)JVC%]I\YH(\QR7_EVB@>KM,@]O`
M7)BVCECS2+S?X]9%@@8Z]N$TN([19[ES]&W>2:6B=)M/GGO5,BZE^D$(MU:P
ML7Q;IS4T^&<S:S7I1+>L0M_YL:T\IW4A6U8O\CRY5I[C&-7^2H3XM%Y!+J1D
M#\R;K_;5%C_3TB[GCWQ`^R?S>QT(';?O=!H=/'"?0P*3_G2ZQR3$"$V_X%OW
M"_X>/GW#NS?\J^>&K\&5N_D/;/M/W[QVL=12MCD]3SO%H6=:1JO1$C36WT?-
MHT/2/NUN7*(!"ID*:,]T8$O%)Z(%^;5G3!<TI/<`O5#</$K;I_T.U0!Q%1#7
M@=U83+4@O_:,ZHN&]*#5.?ZBT*,Q1WYTR=^WQ"-1*!K(W]VH#4#A'3Z/<A;/
MZ],W``OR3&;KO+)@A%B+^;PK0Q?IV6!&[N>ACBQ<I&##6;>?ESHR;3&.SH);
MJPBG$Y^6.E[K+A7Y>D%6Z=K;M)I>T[$75:$+-*UG,1J/<\B/)(JXUWRIEDQ;
ML_@M2\0PXVHM8(B6;C;5^<FL7>$G0@D?2,N_M]YJ3-\T8@<X40=\+?EL`5I^
M^XU*1DRT;OA),II?%;5^Q9OCCE4%;%@\U+_96XA2V!9OUCU:@/?-]C=/I)6K
M[TYEND7F&95@$AL&7[TSFL17&]'7$7T?_48EZ$)'9RLLL!7*$%`6+IE8+QBK
M(ZH_V($3W&VOUNSXKN.^W'L[9WWB_]O4HP!?5H@#F$;0/)K1*"ZEQ^2R$J")
M9,2%QO_1W[<,8+N5VD[ZEGNB=KP`H1-:[6)6Q%P+%TE9C_J`0_OIU=[1]/Z]
M8Y?.B&H>5+V"5*H%^&J)^6@65=6D<I`@:-@Y3^5RCP1SQNK-J5^<D6"3%=MT
M&0)M4K*44HN59(VDVGXMO><Q<%Q,]R?Y5:,$5^Q''^./WMYV\BB#OZ>RSVQ2
M!GRL:;)818B)1")!)HJ%HM^X6%W=I%1SK2IS+V#V*NLSH9&:Z2Y!KC(%>-73
MLJJG-8.LQ21G.5O,:Z"E<](FP[)*%!DPD6L(M2:\=)O<58TGBPU<>VP@2X9U
MY*?`V;"[73WWD^V[WC&\MT]5E9(ZRU(^*NVH*'0ORIJM%E&%I=(03!M#F=90
MU!R*VE,\N%7BE6K*T>J5AC&R$M?P\]NI%S"1=4F$Z1M`]R2'=(S=QW^&C`;H
MR3TZT6>CE<TGHGUX>O)M-Z"WA/,_MQ@M@*3I'4U`5`0?P$[N8:N`?A#RM3#>
M&.*M(:$Y]HRF(W4JG,/7F],&+I-Z?((/HO+`6C=B>D*C870#]JLAK$`K_T?Z
M1L.SN)S=&!Y,=4+T<D"-9N!=Q55<(;\4^K2%!/KQO#XI/S\V!O"R/)''N;;[
M+?H%=0.,F[QE"'H_D9_"TZU+`@(38KD-@B/>W/GTOW3/.+X^A]4SC_X*CY@N
MPO6BO8/&\&ISHV4-"_"64=(TXM+1G8_BUH4KI[@"T3/&,,30WHNF!_L]\1>[
M0.""CPVVV"==Y04*F&##J*0'PAHHIJN[#:&>S^07MR'>MY@SI*_HI8E$#^@`
MUYHLZT;_OU&!B$DT9\6QFY$URXX-1FK$:"$4&Y"7=8TA>+KWO1O/W]MT`<%Q
M7X)[[,?7D#AK^&>O%Z,7=[6Z@?>8+*NN(R9M(-8(BENAIPG22WJ<M3$(E>>.
M)"EEC5P<\G/G!V(UZU$-`RLHSAL`W.RYH?86XI9OW2W]3UU'V$F$`3L)=?I!
M+P%9+!>KFOV#%*1"(\-WHVUV#J1Y`4)52KW0>J=`FBNJ!Q?=7*%K#P%"`G5;
M!XT.5<A>3W2NT3T0^.MFLA;3#5IP8KR<D"EJ:\IB;1C)5AVL;TU5`UHO@Z4Z
MN*`U156[P"!VRH"\)3.E3C1LHB3JV)25WU**&=.D,M7`N>K3N/!%JV#6GK`_
MH#<*!\,>CX?#CJWIV[MRCQ@Z=:J+?.#,J=*;AH`\B!7]@L-;=^WM,2UZ!(^:
MBO?U`KM<*6@03Y>SFME$($0P$8^X?%9-S1@H2["?@?A+M,9A&#SK8[8!F#6^
MT0G):V__[+AVE/"4ICD]I1LW37D"(!$:@`G1"QJ;$VN5'SX+XG/I@$(#0^4'
M-%U2-)@/A#N,#D3K5SO`:"U*-@&S;8*Z#+9@KQF.W-(=R"MW$V]!]@^>QA;,
MQ'V3VE!(S%:S22=:J$HGH-7G8B7T=NNJO=B4//!&+XO1=8&AMM#B<QKRH+WW
MHOP).K-9"WXZ$\*%<E%'/@:YW1RZ+LLLO_*).2]LOAI<O](?;]VK/3VU?;>M
M>.6S8S\[.V)XNS&:_-:UT[QTD\`W!,UGL_HNH/S,B*@<XMK1BJ1</YI#5OEF
MHJ/NY%.3O@#O/K@;'1=MZ=UPK,O@=)FX,C-61;NX,;,Z%LW!#/5EK??T=D&#
M\6MS]S3,QS.[ZTJ4[1WFJ20CNY1$/?"BUFJ4SRP$=0^?!V4FB13?S2/YDX1G
M2\L=`X+9?Y,2:V(QJPA;V5_Y>.V]N/2*@/.@W`(O=*//K),-H<+TXE+H[F3#
MRWH)KT0C</+_O+`7*7)<*MF@#4B)EA<.3)%1TC69AI(P-B(W$Q:S#<BL<I(A
M8'Q(B/%V0]C#V3ITTL^O&H[/:EZYFYA(Z(6G07#<DU^R1^#!TK<AO2#OJ3WX
M,L[9M&Y9--4"B6J@Z%[OY(PU70P55$&1+M%SQFRLJ'2JL/UB<V_940N&,8TD
M0#:PD@S7GSN#7=O!*_D#70"-+HM7$+HEC9XILQ4M`5=%6$WSY\9ELAQ5C/U1
M4,V8,9,N=_-Y(_4,O7$(UWOF'.FO&LU#46'%%SE[6CSZ/GF!/TFD8&(=>5,)
M.58U?:X466$/&+G6)%]62RI1<O7BYP4%WP%=RG!]-$%E!:`#NH8427DWG-D`
M]<&8L^[CO!/^%/\01="]?6J7/#2@#N?-J-6&M<@2J<M+E$6MF;_%1!*IJOJN
MXC/X'M,,X1ZX"#9BM==KG^9Y[=*6WAD+-Q/&P'3<\!'/G9<_8I[P]&1_%_[X
MA7QK;KX"M#2J<*:LW&07.%%Z-1IR82!6$Q$],P^DFKX'3I;[-1@E)YX+B>=,
MS5X9G!F&XE_0!SMW^KUU0Q)MCJ*5!+&U,R55P01P%MID9@W(GX)&Y[]`T-6]
M;$T@XSXGD11M+1F4?*,^^IA__A(G/:9B\E'V7CJ/$EX;JI_(?Y-S[Q*$WRB(
M:+&U,^T2A-^`Y]76HBZ-LF^7(/QNR*'SD\KL@LY>7J4Y!L(R!>T4J-CW0G@E
MJ!V*\/)?XMP)[PM6L<I`6SE3@B.J@[-ZQM-\T0>9Q$8T.?\\J;;NG,<U)-YI
MBI2`OZ$H*W:Y(5057#T'H6^O6_!.^HI>$DGT`)=IGBUKMG0"]%LLT)P,ZFXV
M6EUMU(C90B`V`##K&4/0](@/MD_&H[M3R@_"%3;!I^@2'\H,'N&*('T,'A-]
M&M&+V!Z:@],R1K5U(U(-Q`&`J`.*E>`]/U-#>-889E#ER\(9C/AR*N_`SA"Y
M+T9=3247C`T<U/<;&,):`;^ROD6O%+V@N?_G6D!/%$W'JQIF"!"79@R^NUA7
MW>\;!LU<Q#5U]8(KI-1WOK9WSM;S7<>^=8/0"8\AOO'\!W:NC'+:&_X5;YPU
MT2-[<7STU;K)4%WIN:V"T&J_D\5L'-UPFS:!G+@-=LS6%UI!^ZB9']76>A[6
M_G'._J0-6D@2B:V@N!GT&V](1]7G89UA53ICV\D92NH_=R6!I`AT)Y_JZ/*O
M[8,3$F7)L(-=HGFW_>H>?.\-;^Y].HJCJQ.?OJ]WQPW>W!`'7>T]\KM_,F;Y
M<(J>.=WYY*>_XW4H7EB>Z\>&:$GA(&,`]<&7T<PG":DD2O"+;VG)HE@/E"J"
M8DT0506)NJ`/I_C!$[U'+]*'3/Z)1IH6-W3[EG%4LR-4#8H&Q*0XFAK*ZWIH
MC!VGHO\1CE1=A=>V[Y_(/)3E%%1&'^1=I50#4`A^%F4YB<DC.MK(?A`DHZL0
MQ;+17P:K^$C"Q?$VG]S:7$;YMD\SAQ?7]`?A!.,%PN2WWA9Q[08T_#&T_5"M
MZ;,&TY_QB^/2J[X&=@"@`Y!MNE5KNEYV;T%56;Z&.LD<!KYG077KKGUL!_@C
MYO]M%045(K3S<;E>X""=QQ7*JFF9MX#B)E#<AIZ]Y<&\D&P<.[&A/Z$_;B))
M?Z*U$-?G@^/Z@&^&<XT_#4(U6W-K*L`%>U<_CK,*P8M0Q;<0U@"8B3:@_I9\
MR[/]:]YR`W%9'K(`0)8X2=)"L]C.KW9X])WPQ/'_9^?E=7?Z[)`_$RYXPT&X
M+QXRZRI%_6)S6Q6A*XRKR7BYC)>;,Q&(XF;B3I0WA'A+*&U*];KSL*X8&^>*
MIJ7G8?W!6"HRU$ED!,DE*AOTS0E?D><[9")D[]">:Z#I?'!/6A`6GSMY5=?X
M0B#;TBVU^F<5CQ\*"H"3KQ8KJQ2?@::]'WE6I6,!#+1*Y5B@,KSR?7^Y$W2A
MXF;G?:.G.,F/'*=DAD]&)S>$I]PU_7D=.F^,JM(BH0WYFKW%*L9:'UVA@]G9
M;#058$F;1%&;*&F4C>Z39E':;J;*KN8,4:4>XS?DB#=];A*![*X<-_*AD_C0
M3MK^63<ER,!6GCUZNU[.I"*J@'SKKFO24PH/*9\2Y#4`#NNLR6*6C/@C&1=T
M@>S'83O1Z@%]/T/&HB'4#JUY(/ULL5I^%#6CZ2H\I(/E4JNE@?'.Q7\^NAM^
MXN,)NT\^MMF0^VY[M?OG*W;VV">$0!?YZ@';7I`.4+?6$AYC=*DX`3XB#:&H
M)=8[D[90TAC-BDB:0U%[&AEB8*^,C?5*,^$,[!I.2I\>/EV.QR.6<1:^8A0F
M+O$$E_PAH(.81J<HXZW.U)'AMFX.'HC_OI%V3X(&][;_N^,&[**#MA0(E*6?
M!6&*MHGK61T1LN:RJ$]:-(X+A_!-#1WJ]TU;1AS"00(I6A6DF#1C-BFVXY,:
M7FSA9CG4^+IQ;CS2/N.1^ME:Q:/*B:U<#V#HC<:K\2+FK3]_O$6I*#Y74,Q$
M,HSA1$,D"<9HG\3),,RJ_$H&D$`]<E*,USA"RYKNS@Z"N^TCO3SZH[>WG3S(
M:AY4N>Y::+W%Z?)X)97*H'TKDX)^XW)T+8OV,\A*#?(@!BE;QJP,I\S"9+GQ
M<KHP;T?T\Z*K5E]\S%:"'_@)8)903N^WB$ZYEE)5*P'*N[LVVD%WI<?S13)X
M%^4C.VX@.4*]9L<[V'TK42.JN\CA'#`N.B!I`$4M1.=;V%4\-6?(A^Y.AW."
MU2T*]'6\7?">=L>M'3D@2;6@(U.(!WJ@:;8B/W"&><!OV#UBA&W?):&T.?IT
M&XY.]7BJ/Z(?EV[47?HXKI8?'/>TG]M[+CXA^YOMTS-DH4<B$-%*1F3R3/ZQ
MI@GGR#N&R$;!`:^=K;.F*34'+Z!53!$]1.30%VGJ;GF`FT%F[9Q:QUKF<%,[
MF^I(R#2J@9+*8/1!2W:M*4&E37TYTDG%W?;>]S;'-2&Q`S]!]]7=8#]YK/GK
M=1>MEYXZZPU=L1J-%A.K=,3DTOL\6-M"R"*7M<[.,T7M(SM2`!VI!NG#6BE(
MD>/*.(L5+>2.2QM'O'6V(AH[+E8`,0W2A[5SG2+G,7+\4AU0AO!C;UJJX--^
M7M:RQI+J_X:O?)]\8Z80_-+X-A)4KLK`U0(7!;+FXP(]O!%*2*6;=8?\4#Y@
M*/_5_KOGH^MC$'I[HL@%W0`)7?+3JW/@\Z_'D%;S>B$CW:O=SK$)0/6><FD?
MZIF%H9;.U(/F_=[A"?OT6([GTI0Z[*ZK*[[7O:$4K95J0-<>Y_,D+345Q@^9
MB>)T(5&.?5;>/G;$L\D^=0AK#+\LHNJ=8AB"X$GCK628@;+.R<V3T6@Z!N#.
MJ+SOP?Q0BL^.?C``M<!<[M;NU(SL-H/;VI?T8+?'\&TRL:PB6`T;M$HS-(]&
M0U`&'G`V.D+2BMU^[[ELP_/3]_4K'=<^T.EL^:)"Q;/JU]3*%8$NY2[G\T6\
M1D8E1?O4L2S$A*E>[9)@TEB'24T+41+LXJ>G7FV?77.VY@8&S,#@^,RJT-$]
ME^A7WH&MVY'Y*?\W77[":X>OYOG.RVOI@IRBA:AZM`DK2S5NT]6!1@K5'SHN
M/*>XF\PT#AZ^S:>3$O1H/FC<RQJKE34J.\+2,,KW?47#-4?]O>W?^8\AW7YG
MA</NL<\8J?GC5;ZI!QE5ZD"C:[P0IWQ)=!&QM#PJ%\RK(M("&HC)U@X@*4:+
MD&)=RP4Z$*O?JBI`:@!54Y16P*S6/9J!QQ0)KH[AJ^?77.Y2]X8>H.75@-/W
M8EX","X.I?*T@ZJ7@25@"KB%=JV%&D!5%8$58"IUBQ$@N@V"(QQ`T=,ZP<-5
M`%=:6,S+1G$1<+@L0T#3P;!JP#B5EFD#2S;2:H$BN,((D-P=PR"TW8WCOD"_
MIOB*3K@(>H"7RM*R"B68$00:`IRN)E:CQZNW41N$2N*P%D=YSV@&4VT%^?QC
M>D#3JDKV;+Z<E0!EN/+O;;#1WI(2//S?HQ]'XW1&\_^@Y>AB-&+_7QR:7:"Y
M=6%-)Q?+E<7VN6:3B]%L>3&S9MENB?U1P!BR0UJ8F<WKT61\@6@HL8?(#]8%
M(F\>,*W]@W>E%XAIP&-UA?&R+Z`)=_0D0)R']H!#Q\_EIS1O6X,EJ$4K5"UH
M=[":CT<)D!/A;,\Z%6_8AO4@/K`*/K`[^D`A)MN&>0ZNK1RI"\D^?B5J$@:\
M==?>'G_!X=WVR?Y>$QY5;RA&:H4:T(YI,A%6X5-AB$NCM\33=&LB4!\.95AH
M%2TDP3=0;EKC+062C)K#C5+)%@U0RK-#G2?TL`&QT@UY@OF#$_Q^CWWZ"_L%
MCRL_:,TK2OF@6@_PJOMDFFQJ"](0%8=2>6BLBQ`DF<CO4TOM\;9D&,P.(VH&
M4'/T91'4X`])&2M1BEE(?@J<#>;M?7;L9V?GA*>:RC"P-]5GLT#4@E8DF4U'
MH[CB9R(8922C1+2NNE8#6#PVP>*F7!CY9ELYL]<9LW<@LQ6EOK2!K9`(`_;9
MD.Q2?X-/FS<-89=.=]F,1]9B,IXUL(NJ6WS:TDLOD^OI1?O%18/9G>>7"EHU
MC59JKB]JZRI-XWZV#!%$-2FJ!Z#9Q]2.[S-MPV>+\U&*)B8!12)TS8![&,*F
MO4^T"<T#]=)PR0W.BV9*ZS*IY*.]2XXT/V%_[[@,4Q_M,!^_X-=T=)8-.D'I
M<SF:)`6X4ZE"R:(PE8LV1+#R\@J231WG34U+5`ER$16LJ6^4:JX%_[):.T<@
M,C,](\11>KK%HTN<>[#]\/3%WF/QIO8"JY<\JK1[++8/[EE&5C+@3*4@*@;]
M1@5IVXCJ:9/5UB9U'6AU8&4[T0H/=$=#@-<_OGAO/VVPPX%`?LC'/_G5WZZ/
MOD^@>.,$:WOW']CV/[F;DJZU]E$%\5_7/G1WDK00'^;GDA`7A:@L1(1IZ$2D
MV65UL6MH'$`"C.*@T0LZ>H6/>(N)2IO,]FY:HN.O3OAZZVZ<-V=#^C26*_6!
M7F5Y;Y_8\<H/IR>BX=VV5$QU!S-TJPK[JH%-`2<E3.;1\>18$LIF:`B5=JA.
M*%6*YRLBIA:*]4(?3HAJ1C>-RR7J[$Q-<CKC).8JK[VK5/71BF`N=O<JOI%.
MQN2[W$_V]W@=K[I44.TK&KBJ3`_P6'0^&>>()DHQ(?*0(%`O,_0VT<J8&!+;
M=CK7:]M$7QD**_VA$T(/=`F9_-<)HW%1PT<M/J\!/`4EP*G#B_$\AYP'MBO`
MA*%(FE[8]#,NBYDJ:U1#I3+*RG!2[@"](*G;Q<@_I040K9;^9U:\AR'`8(`M
MC!6WP,4O]&0N+/@[&#*%6J(^["NW,\H,-B#$H9U`YF%]`=^6(:=5<6\*]7>V
M*L_[IF$`Q/L%ZPU`!+WCNPTHA.?UX2)5`ER@DX11!31284:@HZ-MI0"Y8-=A
MU%BG"2W%H*L!3,XA.C%#)C=708##V@O/*A[6@):L!M`EI_EB-<M!A<Z[F23-
MEY]),,SJ8)AJE)2'61E$2APA)6<D+S^XM@].:._HT=(''&!BU&O9-C[H/=59
M(Q"EH'==C1;CZ9BGC616;FPF&*U3R?2D+!.M.'%$OK457!`@03**16O('9%O
M,=\$+/F6VE)%V@`RR14!.\:$/C7XQ?>"IN7MW,,:^U2N`72(MEC-\PMS`HZ8
M*#W9E1+,2G,LT:9`B29UI]D(J^M.!2\8`8TON&EVEGE4)RQ(^]#H62YG-9W+
ME_+@T0")MB8Q0-#3T$4X:#TO6!=6M6B('6`*%AIJ9=2^HAD;;2\NL*S%LA8C
MVLM?2+.RN!W*(?.S:9BIJV'1Z`TC,'1W8`=JW)?/I)N[IM>?;CV?WHX*'G_5
M2-")L&JUP$.:Q3B_ABX`+I&/:`,HTX(A\)/D`BONQ+S$9%HP@E^66V>R-F0V
M!W4M4!O\9CAN/WI['(3.NG^4))+,Q'&L'C"8IZ.)E5_X!^(9Q4T9#^Q./JGJ
M;B^0VX!Z1'Y`6TP/96H]5M<#'AV9(.-HPQF!E0NGEYX2;23$6%:<F=R0T1'<
MVRW'JXX$P=KC%Q#3%HWGB>[^Z4D60:CIX(0LW'3DBZ+#S2"-\+7R@IB*A[4"
MGFH`[MOFD\K=2P)G*LH4G+8VBZ&PT@1]6!+#J1XIB<E&X(#\$"5BBJ"MV-_L
M*D4G<NI5@_8`*^+.:DC1'^/\X@SQZ]D15.$+AL,;/@!.M@99K[CFCFB<)/>V
M_PW[SYX^#XR9"^)766':#7[#.^_`3]BW<(4VVH*AOY;/`!X=)ATCV_!-KN&Z
MH7]_>=K3-UHH"][V'R]&D^JTCGP\HX3D$O2S(2X#`OVP.]U)'X/Y"-P/H)M\
M1Z!WOJ383_Q.3&9PIQY"3U9)!UZISC9IZUM3QH3Q[SY]I\=!<:XL^0?LXJT3
M!NEY4O&!:R\`;TO*:$KSZ+*O_N!%B,F\@7J2WT>JY,ZF$\Z)M<D<1L\\134R
M9[2JU+<177GKWR^?F6/6@C33AFVR`-HTMI/R!8Q@-7K]"==[M_.^V6X:ODV!
M6/*F3LXIJ@,-\^EH54,AB5R4"#:$"7I:S("=6F</8UW[DY#2ONBTA8':2*L:
M?[4<5.$;S90"KT;QI+T.Q5.G\@RSV;0L"63PTA,M4A.[6E65K6M4Z8GR(*N`
MBDGE)K+J_.)YFV_.;D<&"[=N2+Z-\[S#'-FM/G"='.V8JE$.3.2S\:(>;BAN
MA8WDTW:B[EM[5SV`/ZS2+.+TQ@`?[]A5[J&'G-0?1F49MX-",[R;7'L6R(__
M)"NH$GDF,T'\)S`"IJ.R\S)P1DC^?";4T,E!C"(2/PB$<"X]>PN8]&*'C'>E
M[LA\/1`[V2T%+,7[!N/R8CK`EW3MK51J!"VZ/5^.%M/<!LJ1"Z5WWC"I:(MQ
M7)E`T_Z()#NSS!0)1;%41,0.>V<":(]#DJV,9*[VGA\Z_^13;&^;?%KR1;5O
M7C1"L+!#4>\93:,(QZ4+B$0CY_G([CHA'X<N(C[@M??BTB.[U7T-X%VUHX-F
MA<"KTZ-E>DB0BD6B7$0%LW5[E(K6UN5+MIHC[^7%9ZMJ".\/.^]$U."$&K41
M1/T]<XWX!W0@36CN\N$QG>O>@9XT"*J?HJ_SJQVN7QWW)?-W?L]BN\"!"-0/
M:H"6T/(LB]7(:D)ZW!R*V\L]PULTB@!D>\@2/50`_$5"$W\(T#YV4O:Q:B=I
MIH86&`+P!=3Q!I'(K_9W9W_<7[GNT=Z)?PR(PI$]F(S%CFW)I(U@_:320EMP
MASI=3)K()6H6\78S#P246F+VP8BW;13-#.6S)KK91TX3:"?/-O'?=&_)24(<
M@'K:?@P]%'3P\=KAMT;APPY':0WB5*\R!`&O*J619GW`Z<V+53+?2*6B1"Q;
M;A0%ZV(!R29;!9-I+JO=8*@Z],*#-8M/H)NT(-`)UCLO./KX;BNF#CWPA5PZ
MW^')1<_BK15-Q4_Z"56)VEZ:0H-[-$_V%I/VZ(TSF<2_J$FVD!#E!SYG[ZK1
M7F5%G;.LG+.\.F==<&]=MG*7,M:0`K`,G_3_#$8S3>9^G*KKU&5)-9%KRE6%
M3M`GXZ3,7RNRR=^,I>^B<AT.$W*/BTG99\$?];#I1"`U?I6S@1EM#9+!T"<W
M=,+3K;OU_#W/-BP?8L#?4[Z-"5`*&)*SL35:1!N9D50VY.=RD2!XZ#%!]6:F
M;&O'!EC;L*<IVV2KO\EJ-CE;P#3=YX1Z:_AK<6-5^'6D]]AWO,T-^5T^`;+^
M6447XU8J`+]!-JDE$X=6=(4L%X:8-/4WX\HQS.IBV-`H`059?#=NO1]4HX%>
MS@O#0OJD%B0DS4/#9;Q*DF1RX<*N4C8"!=V,*L5`O5'J$5`(K/+XSWI`7?1S
MW%7?CU[^G.+(SS0.#Y%EGO\C?M1W*WI_@ZRV!JF,^-)@RL=[T79UT?Y$Q-9\
M%O9GQ;%-VVP1`7DJIZ_KB^/6REL@Y57&K!@2^5!-S),TR_]V]>)[P=K!1+/@
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M",8Z7)5Y1`NNMEN\#ITW?.NNO3U^LK\_V"&F)Y#<M;/C.857850&F%8S/!)%
M3IF'JV)`@F25^.RO+K2_F"4)-$FCB`MBY_^I*)1M&%W1\[:\%'/2=OX=35!7
M[+>DY"CW`3W[[VN^=T$BAC*4(<FS6F@E2O]_Q/Z;L\;EU0-IO:\U^^ENFYYY
MY,O8+$=(N,FW]CS04*VII)]A3`!GQX^7\;`B/OX3:5)=2#35AF;_I?K$FR<\
M]4^\8%KGB2(3'%RX<3L0:I'&YX<R14D1YE4YM=+;L%C.4-Z`'^E\:?"SX^+;
M$.^KZJG);N7L:"]1'7P5ZVHQ'X;N?J.Z(*:,KKF71I=:U2Z-6$Y4XD+TJ=?=
MI^=%A`4TRR?`[,<SEOB^>.X;#D+"TJQF/JO7F:\N_<4+_P.'>2MO/#_Z%7UN
MW`<)\I0PC3:E609>!YW-6P\B$R41UQ+QJJV%BO7DP1`154M(@FB+!'71V&#>
MU?--&"W_%3LOKZ3E2_N-3!A?,%VBINZCA:[B;\#&H\@[\&H`=-'^X?&K\90K
MG4=:,[+<S_JN"#N5Q%]BM^,]O=KN'8\RU6AJU.<]T'B3D=!!W7*V4LKHHM#H
M;:8ZHKJC2/EW1N]2OY65%C[/+".LJ<.%VJG_@HP/)2(EY`_ZZ%K[`1H7I2E8
M=4_JX,ZT>?"8:#$>Y5F-P4!/QI(LBQCVR6<=H9Q9]T355Q)KO`"4SA0F0)25
MPB_G$>W`X"B%PR/SO"Z0B$I``VNZ7"U+H<*%F828SN99W<S3@I6RP*M$3,$C
M4M)T,TW$U$*9Y8'.+X-XFGG%9YF?@M#9TU''C>WX]*:?TIKAO66J3O[MJS`T
M?=R:CN<\33@)4#YB.\2<3@O4(9^UBKY%S:)XBH_CAM&6M(S>:-.*\XN5>JJ,
MJ;*]'V\5Q<VBJ%V4-(QHR^RF-!UES95ZJWQ9J"QFZ"(1RV8,DL#;D#G$AI:+
M?+R_UU:%62HA)=G34CZ"3*[U@YKRKD2%)X]-(F*]`_&IFBCK)583X_;1&5H[
M8S%;CC.DZS=4&::P"7G#R39^MD*H'M)5YJQQUEFU=:NILZ*&DXE*D'E2'^\J
M<Y@E-;IT4Z\,?LJS;^]/,?SA9UYVYAK3"S9VMZ0W_/X_\2D77=7/*3H.7=HX
M_&AQLO[+"P=%<A`3A(@D]4>D^QMDM35(Q;'IVF"*ST]7VZXLVKW]WG/9R(BM
M809WQS`(;7=#@%K]L>I>4HN#&DW@98*F5A843&@TW>!BD2!7&T1DV6I5V'H!
M-%8A?`#1F<-2DY.4`>OH^P37#_A`BS:[+RRANZQH4NWC:L%4J@.<BO,PXN)0
M(H\?==!00TF:>59'\Q0BIC;L<EBI=H@JE-PX.^Q?D]GVB^=7#[6R3RG%1*9I
M>*S,9ADH,"DH%J,+`-UML5K9HB[:2\,G&^1%HU7%]OWQ>>>L;W:>G3_G4OZ,
MTK@6&FXQUIYDHIK+0$R(KICN:H?5P@YU\5P2,MEHSINK*I8?\(M#2["ZX1=[
M7U89K/0QI1&=;1L>#)/LC#@5@Z@<77'=PQJKG37JHKL\B+(!7F*WJAC_B[<[
MNJ'M\RZC>JB>?TYIE.<:A\_[K&R8)W)X?ZYM4-[''JNE/>HBO2*4LJ%>9KJJ
M6/\KWNW^I^M]<Q^Q'7@NWMP&P;&0^]+\O-+8KU`"'C.C[/B%RD-,((HE(BY2
M%QID6&CE++S\'6JA.GPTA%\6)W5.T9(Y]H^C<Z![F_7Y8KFG5&:)99N&1L]R
M&5]EFPC0G0_6PQ`&`R+<\VU66`*#;%*6!%8>0YG4KQ+C=85[>&JXP"WWD.)@
M3UL&GVZ=)$?;V/O:KTKK888%-D-E=!=#)A_<.7/UQ39-[B?]BAM^]/:V4W5_
M:/FSRB,]IP#X%NZ)-<L$?"('_<8E:0W\/E99K:U2BX.*\"K"H<P)^E!!1UDV
M,3&N<%9?L:?N%>48*=<#7J5NNLQ`)18G5.;36OE&EHT,.-'BI[?=8I]N8AU\
M>AK0V]+S9G1GF*<G.W3(75K"5"V6ZH.R"*D:+VE!5D#L_?81'[S`"3\ZP?.1
M?&MV65YTE=Z3=^][!^R3OG%-#`CJZR%TE*82C]U4A(;Q=!1?!,<;0E%+*--4
M<GGEDX?BUI#0G+8*`PJ<$V$\/ES`P+WA+1*'."["W''V>EW%:,H0W@\<&?#W
M\*R<1&^FP&?'?G9VA(9R`5#ZB/($[&S[T&KJ\]%J.8JRJ7GH)"(4YT3WT7^L
M3/^&/.4^1EB"$;LZ(]3D#I>'?)H'7&*J'*Q]/^!U&->&>_(^T)J:V'G#O!A'
M@(D%K[3D-7[#.X\MJ91^B@YBE&.VO8[0D)I-IU9\-"UJ!=FL&5I?X!DC/VH)
M;3V?_(.WQ0O!IZVI/A<QM#_&&7_P9N@PX@.KZ,O]P>L51?Y@!?_3UG10RM`^
ML7K&B#Z&ZDX4*8MU]*Z.V49R@.TJ"'`8$*UB]G7H'2(VO=![<^<2`XX^G?N1
M![YXKA__DUX5$#S9SSO<5)9_@(84SE'D:P]=OIK/XQM'TT.JB&O!B$30`\6*
MH#L7):JPIT1EV+4C`6+J&'!O@&;7\MKBQ_V>Y@5X6^$H<.Q./C\D?[JV@U=$
MUPS>[!W]W06Z>K.='6W[DI#9Y2/Y-7JDBO'/03F-'E$B6M+51O)CX-#"W6P^
M*1BI<T(U'/[%N=9`WU@K87XX)3_^V2%?E7#ZZ3-E]*OO3E6%,^#+.HBM5B-X
M39K5J$!6'TXBJ!+AB$E'OU'YNJE'GO%6UO@+P=YJ2Y6#'12[I0!N]I164'YT
M@O7.HW02-.Q&U[ZB`X`E>D!7\4;+T;(`.T&>]IUK:49:G8U4CK&:4"Q%5I5K
MM.+IUCT<PX`!?%R;RE3WA@XT%=4`WSBSF,P+8.+BHBYKK#GE29:1//T)8))R
M[%2'72ET*OQ@"G*LULBQS$".U3*HEK-Q/7(L`Y'3Q4@!.?4FZ42.U0XYEH'(
MF;1&SL0,Y$Q:UO)<3AJ0,S$0.5V,%)!3;Y).Y$S:(6=B"G+J%U78*LI7UWL.
ML/]&%U.8"=F[Y<"KN#*;TH%5B?J#$Q%7*ZL`\N;E6[Y:*RK#F2%_7:1!*[FZ
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M?\3\ORU"2W[;FEE#ND'@8V2S53&!39Q\4,U*UC>"_`)'?DDDT2^^%#36$,4J
MFL-4>KW/[Z!_)0]B>IPGO>/!-&(;#/%-A#C,]SDG(@TJS"N[OV?8MLZ`*&L-
M`)^]F\V+FSX=B#&H8<;A[K3A-PE_<C=#4*$\_TX3__)+;>P089==@,P-&-`W
MCZ'MAV9[9Y;S#NEE-W;(%LMMX>SK'^_6H?>,?32^0)1V_G2._0:(X&3T$\V?
M1\XJ'*;[%[OX/,F3_?W:QQLGO+9]_[3U?'I5QJ?O!X?O<?P'>:AT!:2]%.4K
M<ZU5A"[7K.96LD;'&TD/)(7V=[1F[:"UT!#"24OH1)Y4?)AM:%^,15\D!]9(
M,XBW@\2&4-H2HDWI6,`;V!_\;N7R4+C(QX*^Q;W.5)`N\W5SI"0FPQ_+[XB,
M_J*><6BSP$@AH;*T1C&+8+11?MUB%W7'L;H?M=QYV$5E2_"P1JB)L2K`)[%'
MRZ3/<9T0?Z9'3&])7+LO#AF;\+-6'TZ_VG_W_.N='01U)Y-:2%`Y08.K!2]K
M-(]7OYEPQ*2C5'Q\NO+#";$6$&M"[T&E@=Q@I6ZXK'+#,]0-RB8`[8,],ZQO
MZ4O#\)QJ2(N?U^]JM91B!J[+5`.G>2RF(Q"VQ8BFS>C>W!K0'0",7[3SAP%`
MKT,!$.R5CI4SICVRZ\22P@_$L'AL_0N]N:!T4-3TCO)Q<(-"T+G4=#R>1'5C
M(I%"%1`B-)UUOU"QJH?/4JT<BU:F]5^HE<E\FHG5,>J6:JD%_9[Z!NM`$*;#
M>(B#I/%#0*8,7^F%ZE<O/L95-:<JGM3!!44UH#.XR6JQF*0,$-`Y7'29O!W+
MT@#[O@:-4X.(),1$H426)H3W-<JJ_4I:P5R-F`R$*SR@921_],D(Y.CC*W=S
MXWRG/P7UA]JJ7U`Y/J_4`EQVWK*2SC"2Q2H1Q=)TGV>38Z"5-9!6_-E"#%0V
MA&X,O\QHN=XI.O#S"QF5?_:"X,[]Z`2L5"OIG^ZV?`A?\6WKWU&(HEI%H'$V
ML^(K5Z@X1.71`V*"1'2WC29R>K`DSTP&I[_Z=*KJ;;=L&[K2+E40`D6@B*)F
M=^@%$BU3=K>-:QO?D\\2)O?(-'[AVI>U0*M.(VCP36;320G&6$$W`JZD(#B3
MCA+Q<N&VXE:[^(56GX8!3I[Q+%'F"P[1CAI/$T%8\-H[EBL3.X!V<+C.?/6H
MA(1S.3P;G:<%I]BE&[&D![[:[!V77709DLDH+2KJ5J8P-[VE$IGUJD"C<C&-
M:UI%`MGH,2L213(U=7L2#;5$0RG([(Q(K4B#!60&8@#/&(BMVGD9[%US<-:V
MJLW$@J)-\\Q-OMT-X#-B(M<J=%M@4??TSO,VWYQ=Y;>._ZP25U&;8/X>+Z,T
M[OA-3;CHHG=4IWV-@X#?YR26Q:!7;`=;[-.2)-X;]E'XBH7#(P&=G#DO]+[8
MT(LF:CQMF+Y`<;03BIN0OQ_WY==#]?8-T>W9&\`[8ZOILRJ#?PXG&82+IND$
M,>&8W";K[?Y`PJ5N8@EY50/XZ_2!AM`J[5,CJ:Q3S>^^HU2R7N*09C-#C6!F
M1`U.K9VJD00)UC*4-7K)+`0&L#HX+008@<:\5N!KGZWI"H#)P)Q2.`/YP+B>
M#1ZZ,%26>D<G-E.:H*M/#5\[][`&S&4U`,;6=#2*$_`2?*6"V+JJ7A3UL"J#
M&,,ZL_+8*@-*B0-T@J)5G8:&ES2`I-_9?&MDY<%B5B4#B68*)0@"6H.`3B5-
MZG[@Y0,`3I&2(<82SJ*$M-)[M:N>4IT95E0!RJO69!$=G&(RT#9*)N3WQ2G.
M!^MIQC@U(\Z)U'$!N`Q32A/`*&#U)X%5@R))`*LP?B!,_FI_=_;'/<\V(Z[9
MX$UM-F=+"?JQ7*<>,*J69`1E5>,<[7D3<:8A;T1;7NB`+JCD"!0U$6>01B[0
MF4DZH!NLKI%@$.U`<%]#28V^U#$H)V,9;X\?"3LP/1HNT*IZ6N$PO$(%<,WP
MY2SJM[D@E$C2?F&6#,NL#I:I&G8WA)HXWJYSA0$H^4Q;(KUIS=GJNC?TH454
M`QQ7H_&L`C&Q.*WGI&696`X=@(F:\%,6A#48*OC%(!S5GFBN?T<_EMI5GQVO
M1N-&-&D]ERS/S"9$&7#<&!20`%1IKJ3+M7JROZ=%ND$CN?(WE&.J5`WP4N/$
MLC*(HJ6;Q'+S1@SK^IMH=351+99J@["(I&J_&(*CIEWTVE?T(JGU+O%JL9C5
M0DG[SK@T*W-HPEJ/&T'"K@$Z`USYDK2"@\^.BV])CY>?[50_IWH1LTP):&F#
M^70VC?8DQ(A`OU%)B(E2?$%+?VO&ZJVI7UOL;U(!LHTF*5DGK(-)LAI8:;UL
MI#[1"K4-_N?/:$0H4P!<"'`T&B_*T,FDZ`-F!R-*0#F@$6`\=K"D!(O5EJB&
M808#91!,#98+O_+S>N7/:(-?NZ-JL_%R6D#?H&?PFK'7Q8+\J%;+*<+^9HBX
MH]6J<;49:E%7<C*PVEJM4SM8<G3EXSJF=-V2?B?6;#$O!+XQ2<Y2K#-S&@=(
M8JZU7A,^,DEMM^[5>DVWK0->&:UD7-GJ5;6X:=0'7**$3#T2#&7S,]&MBV+!
M*)6LJT"$?*M9>8C$0K_60H48`X=I#F\P[QB#/?_(ZI=B$BYAJN,77+.BWT:(
M;CQ6:@:.T<G<JD<F;0+%;0@(1:05HU`JR1?3Z`P>M]=@O#:&=B-RZSUF!H8_
M8GZ.^@&_8;?R/K7F][0B-:<,-""78V&YHPC.6"J*Q&H;@4JTE@U%$\/\:L/T
M0:\B(NO15N83,P#V:7_8>2>,'_".T6Y:>0#\P6M$:(5=M5[@8@:3Y;(&@7$#
M*&H!"4V8@D9)3K"B82P;#I!9%UV'X!DHK+)9[(AG[.*MH[?N8)<8KT=O@P]E
MK7_F6PV(R=^J`0E^3<,J:9-.P(5RRQI-5NG*:0D"F>#!<5>WG"K7U!JR46-J
MX[JK7'MY'1UN6ESUYJ1S)18*0G%Q%N02,[K[NP,K4N2^7-L')[1WS1EN4`%:
MN_HJK<`7OB1U3$NQEXA'D7P3$N*&<($5%S-=IR>.O<3XN%15MD+5SV9U]DT1
M7M_5UWK1$`B'K]B/%][N[1.=M-,J=7QPUF4`#Y>H%^10-<%3SDGM!)NUEZY.
M1RWR`H_12-C``?\P7K(RR]B'R!6LYF/DBEV]*S020EN\-#!$*_^:01GW/C[8
MSB9>A8BVD8G6W)BZ.P$Z"M-*%!`-P46^K?&\AB.BIM+%N+C6*V6)B$`&N&&@
MSUJY?.^P-?/8$U$V!1\F>,P#^N\BZ`>)>D(`^],,+GC`9$3CK$G87-O!ZXWG
M)T.>JW7HO+4;.8"$:>4"B(;0:)];JUD-%Z1-(=H6(HT),X>T.7.H0+YS&!4(
MCE@3N68!OTW\UP,?[#T]P-_@;?4EGI^^KW='6E:AH9!T:S%*P=Y.-_"`=SE>
MQ3"/6ZB\$#=II;8JEXJ)P(#.*"],>X$<]_+@>ZP(=G)S)>WV-_@-[SSM=YUT
MQ4`6]AW\JA?PN]);>^ON:("]JP7:-0I!0W@T'D_R>-Y5P%GO%0WRS;:R9E]R
MN^UF8]5C%!"VY<!L\I6D_3G2G]N[^%;;)^SO[[:U%<L:WE"_*U>G#O04V6AI
M+<;QAAP3F#(_">\]NWI.4P$RF1:.10N3^Z>I2'9IH,;Z8C*MM*+1.K>.=.4O
MOKVGEU)$'3@B#7L^Q<@I_<QD]/M"6M(RGV\!16&#KM%A>OKK>SYTBA6[<C<?
MTW$33VFO["<@[RKMKP$*P<^6+Y.SMRB2FV*0+JP)HJ.S&+KZ:]EFYT?:T;#D
MD@Q5+@NNL+.NT-N-MXCF;#<.=:$>D.;38Z^/OE]]+4OU\TK!6*$$N&S[<IP`
ML)CX'0G3A3@9MEE&)GDWA%H6-75NT(.4-Z(/A6SP$3^'!,7T2M#P](C71Y\M
MA36FFH`%*,425"MP5:_Y*ME02F0C*IQU;5P\2N4;D&HRB`NLG`LNN`_L#CY0
M!]&V,9[%;"L_:@8QS5EG2OYJ^[_CD%),05UW<XW]T';<)]]F)7K98*5-V:>!
MFM-#$%)M@!<)7,Z*=,*.AT2,DFI3`BSZ0*01BE2*QYR&U:PRP,V,L@1WI@T:
MPDJ#@+:"P^1_!DGK=(F&O]HA5>3TT0Z)+F^VLZ-*WG@^O;\\U;)\D:6U%/7K
M>6U5!%>*FLU&R1I?RBG[J!6TH<T@.VX';3T?!:0E%"1-*5_Y&]87!7Z-6T&L
M&92TP_;\:4L-W##X&N&P_LB/W=+8.+#+?30N#79%O[!<V,EWW8=K!#4_OGAO
M/SFL83Y8XS_GAVG\MZ*&C^M7O#GNJ@K5`EY0,%1JU@*Z1#8934O`&$O3-E.2
M;&`!74`#AT88//PHF(!.T3O->2)-U5Y`4'A0R]0B;AU^<UQ:O3*6@:@0S9<,
M]++':F>/^N%W/IC*!\X9V_5'_S7IVUX\W_DG&V@V9(DTOJ@-'67:@*-K/EJ5
MHR4K57MRB%2#"[V,&5<)0&.S&ER5GI$RO_P?QS?L.CO\T2%6D&%AO&UUXQW=
M#6N1K<V[[$=[5PJH'H)4SS([:0F=3$RGJU5TO]W3*T9_C]I"FZBQ-.=@FS2'
M'+$]Q?-,!=Y@/!2W@^*&TCW?M"F4:4L3.:ERBS6$6Y1,27L11C(K[>YB'4.,
MSS1!_M7;;6[W!]][PWPV73>VJ'M#X:"B1@WP%&YB10ORB3`D2M,\BI!EH96U
MT(%:J&HD`0A!<0C1Y!8]*'JQ=Y_<T`E/=%QSM[VF9TZQ?[#]\%1[W1?D3:6H
M:E0'OG4\&\?H(D(1E\I'ZW=;)`K6?`68;*.M<J.]%D:KPQXX<+,8A'E,"Q8;
MRRIH*I/0X4#_?&Q%\]W!RQ=XH;VK!4E'[>=LSD"EFU)WH*&.@`EU`00=&G*Q
MRI[4$]-M%]!GD_FT$-O:4ZCZ&F3E#-):<J<FC"HB7ON"OZB+NWD,O?7O=*Q'
M/AM/60!\MM+7-&&B3!=PE>/%8ED$"$T#$F5&F4+:.X7^II;W%"S-,!`D_P'A
M2HMU`*LN2JM05NDK$R'7H@>J?=T@"+:NN)94EP5`T:@^3)KUO&.[O?IP^_GV
MZ?;3([KZ\A$]/MU=_\\_WWW^^.GA\0_HT__Z>OOT'R;C$MH+-GI-,T[KC[:4
M/*@'>^T.?$RF5IS`):)LT$,L+3JX+L8(7=J:OV[@)*CF\$J%^69$/[Q?RK^@
M%0UMV7>U6"XJ46%27]/'/M:[7!<A8LKTJ2+DZK%B4H]Q8SO^7^S=$:<IW<U?
MM.PE/=@IT02\"C6S2L9N5"!B$H73$]HAU-=,2^AO/)?6MZ)X(C\&SH85O/)<
M`SN@FMBL`%B5G_2`;,VJ",9E"FC5@H8=U)HWE,*K4@TH=R_GBTF,K34OIAE+
M8Q4XM&^A2C+1$DU,BJ:P,BJ&[*$V!V$62O5^T8BC:R^HK'";>40]4EB[X-/K
MB\DT"PWVNE8<M#>`!?[7`PDV-B[CAFRQUN/W98%2$MRIL1JC.:B_#2W_E/J8
M#EK>_36=3,>9L`[T7FK6QXP,JY.@9DO->V>'@]!S<7RGV3"0?</^LS><:>.H
M7A1[$]EAZ#O/1WX4-O2,K`!9`9@28`>ZKV;[U?Z[Y].\A^!N6U4?H/JD"O1M
MA5P`5`D^9(IG7$PPRWX):,Y/;>D,?:==AC#?RIOO;>NK9N@^'-,RJ$5<MO&?
MH7BMS=&#OV\69ENEKEG+Y6S>&K5:\_:&<4%;Y!J0Q=<ZP%NB5W-&7UJVHK(4
M1.VC2E%9;!\Z<%O-IK,8@,#")<-O@/4V:,ZO#0R=/;MW-5UWU0N8ZHC*8J/"
M>E-@4+\17/>&9E"TW$V=K^:+&FSHK70HR[Y\T:*@%OLZL5*S9=SD#%.0\X58
MWAH\PDN:\9-J`KX<>A[?E5$.H52B.2CJ:&4UD"Z0Z[F7-7;J1%4Q))N`E?./
M*=BJK8A=\X)F3+4K`KV<U>-)9[5K2=:9646O.>*:8*.Y5/6O]G=G?]S7[A%G
MGU$*#*%A\#G3<5S%)GI=\[YO=R,LJ!'JHKTD6+(!GK=52O6,7YWUJXUW_^/&
M^YZ>7+_Q_'N")\<-/#<YV%Y=.*.U#-4U,]HJ"`REU=):S'FUC*@%]#\0:4,L
MCD%+,2;-_"$MH*&X3L:@'A@7/2!4?[@1/2`4B-!8'F-0;U@9;_R8=T<^($#^
M4%(7HRL5)"4Q.KE5$HM%N[GW]HD5"HBN@2[_^!7/JF>E<D7`E3\79!X4TT^\
MFQW+BB]'5TTS,DP::S"IB3!DV&5E[3I$LC0"OAXU`K!KS-<RM';<YJ%UYAF5
M0VNQ87`%N-5L$@>^:\+0NK,1%M0(94/KLF#)#*T+MDKJE)C8Q^-SE%%WY;I'
M>W>#<?!XP&MGZZP?\/IWSW7<EWM6I;F<>EI+4=^1M541&%#SR6IJQ3T<#Z@@
M:039K!6:T16@(&J'7AW$&XH*7RL?9P_JB@Q!I(T@W@JBS:"X'90TA.XK:X`/
MWF\.Z@ZK3V1H[':[\H+0(7?RJY:NF@P;3GQU[H;,">J/3%0\K++S+M4`W`%.
M9O%B,943W?2"F"3='7I_PZS4L#TW;-MHF+).OC;,,KU]M2-TX.,+#J_MX/7>
M]]Z<#=Y\.'T-Z-W)-XYKNVMZ0\LZ=-[J<F%:"%"(([A6X"V_:3Q")K(1%8YB
MZ>C#"5'Y]):EI`64-J$GIV8@%\QC%ZRI"PZQ"YY/:)N8;M>:K@J3[4-;Q&E+
M]YF-W89#[!T$&8GEUB5'YJ-11TQK/Q(_L%=89WM3@FBM9^6[1WPW:&L_6U^A
M*B]PWZ-[+A.@'](E6H&S0*VX5GHME),63.V>^[J@NGO^"?WQ2+W@N']"3N(&
MH[OJFC`'X+G*E6;CN%M772?(2%RW[I2F<17UUO@VM:N6Y17AXA;SNVI`Q'>#
MMJE=]=V!E43IWE67"=`/Z1*MX.>?)I"N.FG!U*ZZKPNR7774-R,O,=OHKKDF
MK`'XK7*=V;CMUC77"3(2QRT[H<EH%5^7UAK/IG;-LKS"NN:[$D2;V#4#(KX;
MM$WHFF_=M;?'G[V@IO<5GE$+S+1A<"GK^62>8HZ_CZ@`;3#J:(,5V[`;3'E`
M]]Y1^7F3\@H170SP'%AS-DK),2%B"?[7&&^"&Z+0;1`<;:+L/=L8OMMNL4^(
MH&QG'O:BZDP2D%;0I+O19&E%V2,T1`Z18$2_''(BT>C`9",O$JXX7V0`@Q-2
MB@4C*AG%HA&7C6+A&K)"!C#::OC*1W>#_?RWUI8!T@JU2=('W&URJ(480887
M=S1].XS^<;7^Q]$)'`K?Z#?1FKV]N_-Y.8E;EXPU&,JOQ7JDK!8`O4!JO_=<
M5G6=ZH]+4]X4M:R<W)28!<2--;%FDY@=><OHCIU,"%'\;T&YY'>)>O3IJ$Q*
MJB'*J!@5WF6WP%$M^2T*B.NIF&<-]/WX??F^@?,-_`!\BY56*GECSO*V*'BU
M?5X+:,W=QJZD8?T(F40?CC[EW)`6UPM?,9E.IA^)7ON'??R"74RG`Z7C"#6=
MBU+>3GLG=1]8RPS6<Y.%03Z0__3]0#,OJ^8TE<^KG-E6*0&?9%GSA*?2A=%H
MNAL)TS3CE6(;7Q\B6/:1PXWZ(^9B_G2!7*RU=D1CR&7FE[7ND#,@/-)$R;OM
MU6;C\$NM?R%D]V3[+[A0RAGP@O+A5YTVP(YC/)J-)M-HU,3D4=ZW$XF(T7_(
M9:J>2LJS;RS81T80J41$1:)(IHY1A#P;+=`WU->+0\"6=KZ-?I'*`$#<FX#V
M]O$Q&JU&RV4>XP8`N[,I.3@;@N'.YEC57T8[7"$@'12:MRXA`'#/7/*T+J`6
M58'R^62\'%EYO#I<G`FX[6M9#KZ1.%-@W-<ZJ_F[:4=U-:@*X*YPAY8I:Z12
MLB'\B%_8Z?VJ&57E\RJGK%5*@,L[S1>K/&32!(!8FJ8YJQ3C<HA)I^5!C7'*
M)JU-09>9M-;Z0VJ_&%>>N?>]%]_>US%:_E%=/6).#^C:YG0^FLTRW2%!0%)E
M*!*FIR?L9=%8@T6P+K"763DT)W>V'+@P_9U?!7(*/5^9%Z1`^(YTI<X>1]?"
MW&#\R?;=\IW#JD=50[A"#^C(:+Q:+:/*3G=T&$1$B;=R(<RD*1[.2K%I'-M$
M1:'X4B8B#'%I&E`LQ2XKLNNRXELAST7X._;73H!YITU#1QNV&R"58+O.-SJ&
MM,E`(5K<KAK*%I]3.(0M-`Z^BF^^C$ZXIP/66(:>`6L_4Q@HAC6@*;6PGP'"
MO>[I*!O7&*1JE%V)`W%T76Z[$;!M2.2O?EXGC-N>#5LD:?E%.&O/NY=C72Z]
M/H:&UN3ZQF"KQ8CV5/F[["YN3<)\V9,Z\-$^=WN:W$%VE\\I&"Z%'MQ5=+2'
M=1;T+9YZ&G48GFM&1U&?G5YENU8`?,8V`>3-,3SZ."IX%M<?_5AYU2[T;1U`
MJ5<)&FR319P[F(*'2T9<-(HKXB6%<S\.=6TO&%,231<&9?O(4)V5=#N&;2GZ
M`%XR&)'UEY2U%&(>/MM>]35?%D9_S3#5>\/9@)Y@(T427],SP&C-M6<=/&0P
M8FG)I3?\']CV&\>8<$'F(5?0#IP<.IJ/.Z"7U2I[PXBU932&N_HDQO'R#'!<
M$MX=L)SWE-EX)@$E!\^)("/Q'&L'GJ&-%HN.>"9-G0>>._DDQO/B//"<#^]N
M>,YXRF@\/Y%6Y730@B03$9VJ!QY6CKMVT:RML\!T1Z_$H)Z?!:B+,=X)U3E?
MF0WK;YX<4,=RC(1TI!QX=<>:C3H"^IMW'G#NXI$8S+/S`',NLKM!6?23P4!^
M>L4^MK=AY7T6[>68!^14.?#`TIK,.@`Y;<AH&'?T!X-QO8F&@;D8W1W`G/.6
MG(3`I&DO"*YMWS]M/?^;[6^"3]\/#M]UH_Q1FNT%?5=YRB!0,?"5@[/Q.,XA
M3%!(RV2AM2B<[ME'TM&)B%>=5#B(U7GNH59GA*-4.ALXZ$@[',1RJ^E[7^0_
MN+X<Q)8H3I,2VWA.#N'X+[;K_)-)OG(WC\?]WO9/=]M'Y\6E=VW9;GBU7GM'
MEVK%;IUW</#9<?%MB/>E!_!Z2E1.3KW4A8;P;+Z:KB+*$AI$I$44-4DS_X5&
M4=HJBIM%O]&&$6MYF.2J:C93Z*:Q\6YJX#^%OK(*OK(%7WG]?:6&,*6P4$JC
M_3^`/G)]JKK=NX>TLR#5IS;73H\7"VM10J@T^H,T^@,A^NTT^@]1DZJ'A(K<
MTI]`6:-GPYT=7%3D37DN,I<RGTKO0._I<RVK6(+*M+H:46H3ZW]/#QI&Y'2W
M3<JR/9+?8#9W;TK1ER);Y6J7#(7!R?'+^+*<#'HR[3(LB2U30*4E'M/&]9\5
M4.ZZ`O%<Y'QGYWWG=?*=LA4WF4C,K,))^S1G1U`?G6"]\X*CCRD=U[(P_AY^
M(&;\/D1\=U'C7&BO@VU@F(]F4WD,F2K*1RB-PQ*B+F+ZGB.E#OU9^DZ7SY9I
M>U"*-%+N^G&U\#<MG'H5!,4J8V5/J&2]M%GPY9W+:7PFC96#Y6]K8H>.Z@O5
M;.U*]94AL1@<&9#D;-0<OPV'5XH/ZHGFED<O5JOIM!C4F@^9]+-&B/$U?]VL
M6*\[/%)NN;;(O_;V!Q^_8C=PWG!Z\O,+#N^V3_;W>^P[WH;\WJ<[_!\Q_V_3
MND!_P:J1U4M;\,#*FBY$)&8:%0\_(WJ+#1GGDI81;QK%;:.X<?TK`FK]QC"?
M]1C=V=9;9D`:@@H4T=^Q)E'*5Y?HMW/^B3=_]G8;,G[]Q79<:L^=^X@)A?,;
M"GTG('_Z>*1W&'$#8W-;AF#OY@R@G[XV@)/%%]-E(RFERJ!(&T35X61UYZ)4
M(Q2IA+A.,7VEA&8662GU,J>P5_(@II<,'U.GOE!GTCGVF^WLZ'[!Y=;S+P-[
MAU&0J#&(Y]ZP_^R=@>_&R>UN>;?]D78#?Z+>V]O^[SBD[FOPFN[^018=0GH-
M*5])6U_R1-#RA/<'S[?]T^W^8#L^72&A^N.`7T#/E[%CX!#<4-BDIM4%M03I
MJGN*_BJ#8;=:93H&VC)*FD9IVX@WCH364;YYH8?0V`$H=EXZ3;T,2<N78>(\
M)VF;W3/6FO:5$I@\#!;X2M('T4%/]_:)*A1<N9NK]=H_VKNF[?*Z-Q322(T:
MX&O5%^-H:SL6QK9<8G':IZ:R3+0R)MIP$U7A$Q"$(N::_*()1PSB#WAGAWCS
MY)$QQU^=\/65CU9N//^1WL?X@4QO-W1X0\8V9=ETO<6I16`G'<%%.B:K>0)/
MWLE$3:$GCRTJ":TATAQB[2'6(!);E`O?%7>-BU^H+@T`5N"A*3N.97\GV"8]
MSP;YD9-"CU[[Q^\!)1UQ&.[8MASMJ3&_<=5F1PTT([\7;'*TT-W;.CGCR6.W
MBQ+5CF3Z@NF@@4U;KN-[1_U"B?A.(C1P`T0O\!'B99QGD?`!X8%("DH;B%=I
MKI/+AWW9U=C;4X!\1S#8\VMI\[?V7K!K>]FMG^S^7^H('Z\QF4V7.D(UVML$
M?!G"P<XT`M6_)NLYC=-YV+LZ<5RF$#AN9[-)-8!3R8/-LGO`MK_=#*_W1-=7
M=GR<X-*XA;Y6H5L+S$IW&8'(>Y^6-`Y/]SN:C>1NZ/W=AWUUSD0+`3JQ6:D5
M>+EG-J[I86/QB,EG4^6D!6-P*LD'1;`>8NOI_!G7V:T-K8UA70O9>L]IP2W=
M`&"IAFR5[=XC<WP<$E6I5A_(.&?KB$F&3;G1G<6IQ'1''<'K0?-1O.3%6V(P
MYBOCV<90W)J8D:P_VUB)@_AM+_O#SCMA'#N"T9Y6O/>$0P;]?=PHY:SL/2:A
MX8;V"[[;/G@G>T>'"$_>!_P0351NB/&/QV=^`169O^<"HJ,0U2=C6VL(OG)V
M/AE%5WNG;;!K]^)6Z`+0,TXF?OPNAT!H2O%IV(%=,<ZY@EZLF+B"#&,^8!0W
MA&A+2&Q*P\G7@=UA]8D,;:=<.[-"<KBUFUNU#&_(9_QB[_'5=Z=R/4!\1.4P
M1&@7W',NXSNBZ-N(OHY^HP)TC12ZVF!!;5#6\9<$2J8SSUNJ,YH_>GO;J=S6
MRCZD(:)YR]!X&$^6\T),<Q&:H[J#'?FXKK%#=61G@Z8LM@5[Y0P_R8CWBHS<
M-G3T=G-T-[3"WU=W@_VK%Q_CDL4@\&O*AYC-.D%K95CSQ6(:#2J)5&3'8M&6
MRD6;(T9'*AG9L6C5@TC9QHX38Q.QB,EEA3R99)2(UC%,E&TPHX&;JL^)[``=
MZ"_B)O4-!>$(30=_0&=)HI"0R'/L'1]FGM(5M4_DU^&I_&LVO*.>/.H5@MX`
M/QHM)@ES1"*C^=<)B:O)7*QJTI!IY%BKD4UL(=-21A5\WL1SQ_A$D29VVC1I
MG9!F^(K1BV]'/03/.L&L*>%AOGR^.:YUL@D,K`*5`#RI9:!-9&'?QYO'T%O_
MSE):@JMC^.KY-#N^:MA8_Y+*@7BM)M"S=*O9-"JPG\A#3"#/`0M0*E+3.%V>
MF5;6S(`;:-<:J&P`#PK&S("^V3&:4$63YZ*[D^N/T)<_JQ9#106@<\'%8K1(
MH,,2!B,Y>L_2][?)$FTRX6K[VIC*8:+"=CD#5=];8[P)Z,KG;1`<;:+YK>O0
MSNV>+83>;0DD'?>%)U&1,71IH><N8I0/9]OK")T]K<;+^2P:X4:M\'V$N!T4
M-81X2RAN*LE'I*TI'O@.[8ZQB>YH&"(/[1,KXQ,V"CYP%WBQ"VA2IK??>RX*
M:"^89&HZL>_65<Y1,UCN3ACI^+FCF_5T_D5=J4[T"[%A2F6?U?2>TD%!@S+0
MSG2Y6DUK@<W`RZ*7R=4U7I!I;@EF$RSFP*IW1`$,U.SH`N(IW;A[M'=$JS_C
MW>;)^]4.:<[HJ3E?&BY`$Q+KM0*/;\>C4DA2Z12.5#Y==XI;T'Y.>2`7,)A&
M,AQ3DZA;!W456`&.,P.UZ1%G\K>_XW5E#470JUJ16M0''*`36MRC&J.I9!2+
M-@6;/8TNZ3SILN^YP+,Z>NN!6>$UJ5/V)&G)\__J^;_?8W_K^7N\`>Q4MY.@
M:Z(.4P\Z`5O.5I-5;HZ>9KEY/OI&VJ#[F[P1W7O9`_H@2T1IXB/Q`6T#)8V8
ML,4]H!^$+2Q0"&B?<[=#?&&ZW<*'FL8.E"E_Q?OGRIMFL\^H'0VD#<.W:!;S
M!&WT=?0;%Z`K0:RS$5;&"!.RP\J")=<GYVS5%-/E!Z>:"NDTOJ<V]NN5@8;2
M<CE/IZJ5YP7UU]:1:J\EVGL1&6RW,%@AI&"QFH,9P%=&0>_#Z8FT79=9#WC3
M!/BEZH"Y7-R7J0;@AQ.BDO6FZ$NVNAF&%TU&:P=B,7)!4,QYS"@PMCBBVT:$
M"?#L?M+4FBTL"$[-.GT[E!\RR,U"UDB40H_9MO67:;@]>(&]:]V'IB\:@E&N
M#711<[J863!D<KGF8;&#O0R!_%4GKB>U=;[CC0%WDL`C%`H^P4%&0>X7WPM:
MPXV_9`+4F";@C??E#-(!,IF&0:R]G<4.#J=CTDH3M0,L$X\@<*6N,0I8G_.7
MQT,_=?JB"0#[G+FT'C*ZFBQ6D.48*A@QR:8-+;N9#%F1:;!9._@*,0L"8-9?
M1H'P"VZ]%DI?,0%X1`]@_$U'R_D8`#DBT3"DM;6QMD]SAS+/"^V=$O/F=>95
M?#WMG"%`#,06L5.,X@EV+>RI\V)1_G43^".G$WAW83Y>`KB$2S=Y@:B/_>>V
M.%01OB`\EOG)*&QV1J59>&R_3#F=+R`#:7,AV,UD!C[APO0SPF$W!)J,/=)R
M?7TEP)M&H"]1!UR9:SJ%+!;QW3V]%9HD&PW?U#0C90<:NC`P9GUF%!J_!GA[
MW'UVMKAM)`AOFH#&5!WPL&P*2O+A@A&5;!@6.YK,"P,'H;-G-^P<N7T[YXTG
MN\<W[QB\8U(,6A`.<_Z2E>/>U!CY[5_LW1%7W4G778Z&?/?62D(SG1=TFI1D
MO8MPM*O@R(#*6QLZ%:^,DA2YI!5#*71)8SK\P'ZQA@D557GRG5E#S);OYF(Y
MQ!?=*T%;CT_!\]N*2\.A^FGE)%:I"K@$X2(M$Q<)0P?R2EH:X<#DJ3Z)(\FP
M<<8P5FLU*7O!Y>G@$TG&68U?31\I-"(JA7Z]-Z0#//D9!/#<TSH!GE4%&BKS
MT7@Y*P/X(?F7;H#W,:P$X.F_3`!X'^-*`)[[:D8`O!Q1I0`O\8:.)83_=;1]
M\@EWIQO'M=VU8^]N77HLC^$P305M."_45HK"I866JH'GW*OX*$/2`$I:0$(3
MF2QIS2>+AO2%)=47JA8C.H:_N##1Q:G&(;UIZPSXLBFX;KV?-%\N@7#6OXLV
M@.65X/UHA[:Q^*S=1&OA)1UH?"`?I>X08/IWA9A*&@4'SW02[3RS5[6>V.NF
MO`517E6T%X)"#.BL?5(F@TSD)^?EM;SJ0?DSJB=^>06@B7*KU3BZA(Y_7DQ%
M*)[;]=)=P!43H:EZ0W]#!(PM:XU0,E^K"OIDEE9JJSR\W3AON`%NPB-:T):V
M#YVESR:K\4Q$VY:(T`&VKJH+8*,BM&.MJQT"UF:&8*T8\%FHY4R5B#3R89J0
MECZB!VE)^]`K-*WI?#K/((V(T(*TCJJ+2",B]".MHQT"TJ:F(*T0\#FD94W5
M-N^IK;$E/J%Z[M-J<#,9+;.C-+W5M;H:(,Z`#$C3*PF0PBQHD-[BB^,VC<N$
M1[3T%FG[X++_B]72$GL+EXC0T5MT55V`%Q6AO;?H:H>`LI4AO44QX+.]1<Y4
M>4B[:P3:G5Z<W;7[QJOYR(JSW/@G]O2`K)O>`L3N#$!8-R,$?(T-P5<AS+/P
MNAL(78_X#;L-^!*?T8(P00$HCXZL:79!+Z`R=,"LL_("TI@,[5CK;(D`MX4A
M<"N)^RS@\L9*A)SSO0EPR1-ZX!8W#_W*TZ4UGV3`YGS7`K5NBHM`<[[KAUDW
M*P20S4T!63[2<Q#+&"H/8$^-/=J3WO[LJ26-CB>K^30S,0OU]&4=%1<`]F1`
M/];1"G'0.#($8850SR+L::`N[(D\TC0K$Y_1@[)4`2B3DO\N,AM3(96A!6E=
ME1>Q1F7H1UM72P2\34R!6S'N<X#+&2L1<M^\)L`E3^B!6]P\<":^F!$C,UC[
MYFE!6B>]19A]\_2#K),1`L(L4Q"6#_,<OC)VRD$77I/8WIVNUFOOZ(;T%(WO
MN>3'-;MA)JBOX=1)A')\MM,//"R:C9/M@J@%E#:!LFTH*^U4C?8AO3`VS`L-
MG#&D*ZS4%=6.T,<RW>">TE`'UTGBJ<UQC3</WLG>A:<'.\Q7ZZAZ2CW;Y%4`
M'^H>+6;3F%"8$.1S*<@G8E2/#GK:,1;MB*0@*D8+X/O98E5]$XTXKH*#`-52
MH[4DLO""*O>V'YYJ"U^5/*@RK:70.C0YQ!I;22?(:\<P(9I+6/6TQVIGC[*D
ME\I@RN2^E-NN._J??-L-[#7M/((/)_$O=>=;X`(TH:5>*_`AD_EH488B43J]
M\"H7DSK/T0SC@S+DZ3]PTSJ,J_`(\)2D,2,9I^T^?3]@-\!Y<)4]H7ZL*#8/
M#)'9<CD>Q<-$^C["D0#E(\3.VH\%[6,!6L:%G2VP8@L2[VL<"Y:%N3`.+!BI
MIQ>,BU`DUQ=?TRDD]@\4^5_L?7U-5/C[2OM`H%)0^I^.IJL8'4G1CD0V$H4C
M*EW["',(^QFVVIFJKA-L&<79/K"-M_2`-,#$&Z]7[N8C?L,[#W(!<L-+2N%8
MIPDX!JUI,@SE\ECM/$&B]N(D$@VU,H;:K0Q5ASI(6&:AUN@@@_#E^W1WA_.!
MRS1\\NZQ3TLPW'C^7?A*XJ'Q*F0YLO6CM9W"X'F5-9DT@%IH&<5-HR</18TC
MTCKBS1MQZ[)Z]]53A=#R1>J_,/7?-O&?,=<W2\4C@'\Z?)PSHZG/#1?T21%]
M'B3UN>6-=Q-KOAC+XRC]=P$J]YTT@C+F4D&92)3$3Y^U7TS80WE*K0W+##)D
MGP=!I0K#9PSSE3R&XH,`S0L8JKTG?1!EQ*J(1$!*HJG<YS&'IZ*5V%8!&;^C
MG5<B1:"]\FHZ:EI*B22:!/\N1A9AO4D%FH?-7!`V8T[TB7%8JJ^1`GC3%%RU
MRF*FM82;UC0BN;K+K4BVN19L6E.Y.X0K&'NZJQ'5Z<;S/KM\_NA-4Q#(U8%&
MXVJYF`,1R`4;B+\.%M>/8>LV](W`7S98P?@3'&4._F[=>]];XZ#=>EOZEG;<
M):J`AUO+^;0!<[<NBH2:A+=NEN;N*MS:CH_>^#5>WA8Y[N6!"T7^V0P^"S';
M#,&L[R1EA_&&?B&3R?"!UKLX5IPI*'E.?:9840E@&"W'LWE\JC<.D1<JAD0,
MDZ,\;:RG*5GL,S$HDJ,EAZRG.5%GREX,T-'=8!_9<7[((`:]8?_9&]*D<9E-
MX2NNMTM1LEPUZH64N0H'2"6>1^R_.6L<R?]*G73M[8CBGL]X($D2JOM&<"&Z
M*`NL88N"+^-ICM`"WDA,:5'(K<5VTN#31'@#.2)+AU$C,2$BU@S*M)/F$VJD
MRX&<895%A<[4W(Y0+U!1.W_)XJG0=]9DU'EM!W0\1O]#KU@EP\]J5JI]10,'
MU>D#/=D[7DRM=`@52414%IMZL!]2J<K919Z)8YTF-A*'/#NMG)UK:AZ=-[$?
M<*V=JH@#@CV1)AJ]HVG1HDZOX"J\MGW_Y+@O[);FZOET*REJ%S7:J`:=^B_F
MTR48C0&Z"E'<#+_C6]NZQV#.*(.LYJ6-+I&=6^IH[2Z]('X,O?7O7UTG#!X>
MOS;MNM6\HP6@)8K`5[WGBP(<F3S$!*('](B^ZM]EDV1I'FNBI7\D(H,_F;+)
MUAR7Y8"K\I`>>(6VX^+-)]MW"=:#JS49U1[9H=B/>.NLG>J#-XTO*@5:DS90
MOI]-9TD>+)>)8J%(D(HBL;K0)M5<!CG1N$VU<>KP!0W,+,A`CC$!:0T]6.G#
M&A'5DLDGXTD5BG1W5+WM*L`E"BU#^J6Z,*O#BO:>B*TNW1!KV-)W]:9R_CFE
MJ,@U#N59\I]D3L471ZD,OH&D;:.XCRU6<4]/<])%1?AD0[[,9,W1+M0@<0J5
M0IJ?UQ/]626@D3.9SR8E*!"KS3A#%>/P0GL'A$,/X^;4N"?:EB%@*(^N"E"4
M&*X1'`]X[;V0:9+CN?658.'OJ0=+M3+PDQNS518T@DS]54V'L=>JL-<`5#6'
M90FZ&MRB$64-/8Z.#@9.N>-Q%AIZAU+M]+:&UQO8Y[73.^WBXHP'$P9^=5V;
M]IXL:*QBDWM,`^;:%G`A1)T=RP4&5*;I84HV;<R/AJ2AAQY?'1_GLEA^5IT;
M)^=K96PLM4$U:NOKZ)38J@7%41GCTCS=BH=4(CC3,I3+YZ-97`LQ+I"M(X]5
M@A&6:(0_H!$0?/;X%F5VZ.U:2^,^`]&BN7+2OS)R`WH(ANZ</7D?Z$@:.V]X
M4YJG`WA->1I8LT[@_*'Y<AY77\V%":L$NHYZK&>:B\I%JTXWE6UL&4$%*)9+
M:SM\8/-#)EI'9IAL@TM)H.KKZDL1@^,S31,#NDI'#_]H[_#=EFW,?SG2;1#R
MCU>;A,MM$!SQYM85RD97,'\K$0I'!VWT@O97X]4D@B:5CNZV498&;X#]FS6!
M>!OT3)S0BIX!QF!^L!(_>%L44/D7R.6.H+_@CG"X(QP7A?6.4-6W=XEXL>=O
M[4Y=L`XBPHF2V(,ON*FF;--;BL%;HPIT]K<8CZP4KT%R0",6B8A,[;-WF;9F
MEH_%N;SSLK<A<WF5,`1$:!YY37[2`K;U*]X<*2M$%W0%]_;)?M[A*W=#?N,3
M5OCLV,_.SJ&;2T_T+TT;.KU$JH1I#SVA<3VQEG&?&[5&^]FX/10UR%*THR:1
MT"9BC1JP3:3,5;Q;/N[WMG^B'7'!4W:YI[2R@00(9:BBK[,U\\B;[>RH4C>>
M3UGO$:^//E/U<T.EUW8R]#!%LV+@`LFC>(<X0PUQ`ZSL(1N@IFT84*%U.%=8
M&5=X@BLNMYY_&;1TA0;TPP._`NY`CYJ*;T9%/>*&OV\8KIE2X`V;>0=,LQ8,
MAG-[#[2%<K4'3$)Q)KS;(CAUHE[T?C@&A$N"X&K]CZ,3.-&-:L*_8"`&BM&"
M99ANT-6B49+]*$(Z;@.)C=!+'H1_FX+L`?Q1`'BI/R[0,]@AZH'>#@GE>&_A
M6M-A#Y[4MQ!E*/S;SDR7,VO>F0+,F;H/Y)C\E#VM/'=#*\^Q@\CT]]>D.6>#
MH_4[MM"\Q;ZO9S],!D*Z4H)!<_5K;T\+5;)/<NT%(1VVT/V`#W9`$\I/N=KI
MP=6.J46>CC8.V(-Y*<3>>Q(X+1<+5>JBA9@4&@@&\&)9,K@1FT"T#3YOH2H@
MI@.*M!4O'R`\F.B;["5&CQ<$,IZD:ANXPFGJ9^(\2[?N+DN\6E,47SV7:J"5
M<C)6_2WULOE'S#O4)_O[51!@8H[;8_.FG30MC-I*17!ZP'0T+7)BW!0AK.^(
M-\9V;<S>K1G.0849(`6)[9[^$)2YR@Q:ZH2/<F)I[UB]U/!I?]AY)QQO/9=S
MF\A^T=&G?Q*:Q+[C;1COP=:&9+:EA58D&@#MX6?S)-=#()U8D:1&9^6@*COV
M2O5!7*%HT&7(@I0N_Q8XJ]R_E\\%_UZ(#O8Z.5@]W0V`^7(RE/T]]5+EC>,Z
M(?Y,,UMOW9!$E4.WWCG)TUD\8?VK@!ZV3N?ZQ,YGQ[7;K:/):D<+14I2'GRZ
M>&J5T"-7`C$M4*I&,CR+%"'_9D4*,HMV@C9&C=AT.+:0=,.:NRA=R3-D*"<9
MI.6\)O-;:.:T8WCT\:_$GOUQ_T`/ONRBV6]`KS\\L%59]^4S)JS==I[81[8>
M[NJN,#BA95PVG.,-HZAEQ)N.U]("?L]IW#KBS1LXIU3EOCPKY;R7N.T8U:OG
MUWH>B4?OGG?."\.@*6S5'WX5#-7S6^AEI7O?(QJ&;#$M)!-H6LB6W=T#FV<V
MO*Z%6^IU`J^PC*<E6<.Q;+9P'K+5IT2\*5,[B?8S_,?R+B*C;:C1ZD$.B^9R
M'`/<IA>J_^M(ACG8WYW(F,AVUXZ]NW7IY<EVDN0`'S"TD:4%Q"T4!._@C,8E
M`X*D(92TA(2F#.S\AW)-OK,O\\Q'.[3-@'H'-)3COJT[]9)`NFQSNR'<Y&P=
M.@'*3(<RJ^#D;\<]72-O10]R6M%"'%)4!R]I+I<E^U3"RF2J0W%%)+=S%2EB
M(.&H=RDTGXF>OLSYU0QVD@K3<MZ2]U5T,UK9U:%"1D`\K7SR[K%/F9E.J\)7
M$K^P.4KO!C3Q6#^MP>/\T;0D_>BAZI)>08%DOD^+B40Z\`44IH4ITR&ECBQL
M;SV(]_M6./(B]628>G(+\J0.:I.#URI6D_"U=!,:/V'.@CKX,[9WX>NU[>,[
M_\4F?-UENM9!I";2:JLG_/Z`Z:R,IJ)R#+Q!Q%NDMVJ1/PMM&CFH&M15V:*,
MPHB4+]767B:J@U.Z0J:*13HY5R]O5.S9"ZF1'T[%S,EOMK^!C8/ZRM?"*#V5
M!I^HFBV617JI3O41<ZX_G,KSLJD2I@R"5+JQ,`:JRNC)NO'YE'D0[$;U;"4)
MJ.74)>-+F<AC9;>X,;6OUJ'SYH2GED,B.:T8Q&DM50>7=)FL2N9WE<Q6<7\@
M1V&LB8'#*?4^S:]1E7HN<9G)S-41FFWXJ\N',)'%>*6^JV/XZOET.,VN=&<F
MW1W8%14D<`A!?_J._;43X'N?WOY.F;O/$*UGHP9Q7#]+P(7L%I,V@[FHXF:J
M%6)J12CFBK&M;S;4BW5#3#G$M#-[E*?0Z>"AWT6)UX\57F<E#-JZW11NE4,8
M;:A6PN=^7\S;<T@IH>%WP<"M-_(FJY**#<.RL.GC4<7>SP]115\&Z.X8!J'M
M;ASWY7TR:)\!JZ0O9223IE8$4B??`,$F,6&CMN`#',NR+=1JILN@\.SFU)+]
M5L=19S%[AL.I%?_`O&P*OXCKD,E11&K"/8G/5_($Y4N:ML-7,VDJ"K>M,_'(
M:E$S(TDR`WRJ8[8J25BKWKY(3^<R6,9*\;HQB5I(T,MH'M/A;49P?\7.RVN(
M-Y=7;]BW7W#&8U^IWVFZ1Y3F1H\>9?/</CW>WZ?.?Z"R##E6,Q@%-)&ES$]I
M(HN*'<!@Q-FR$8.XLIWFX!RNY:IAY3!+C]FAW'GSX8`>9138DO&R'4^DE\F<
MUPVP;6BNPQ?2PFSXA:K\"_9>?/OPZJSMW4=O;SN5]W]5/J^2;ZJ4`"^X3)--
M!RX*B;+0;UR:+NQ+L8[!&&R5,EPVA5L&8K6.T(B6!WSP?,J#_)+[W%7W]9^U
MX5WU**I7")Q,M%S,LHA*Y"(N,OZ/`9VK=,,MP7"]_5Z;`"W!&L`G>G"W8[=H
MUA[_:[KOKI4,I3ALH1AX*+=8Q2?B(_&-AV>UWXPWF!\LB7Y0A^0.(9]%=%MW
M:D%VZ8)J5824/ZP2JZ4:0(-Q.5V,(U!6[#=H0EY_JX1BRSR!9-U@E3(<U098
M!C#57C`'&4)N<55J,?N?O^"`=>.L7."XU7?OV(1V%';3&YPR-4JNM0$<-*@_
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MYZR^DZ0NBFN-!+5Y^0U$%8\3T@354:([2I3G^Y=J.[:S^E:\+,'CUR`;\2'Z
MB-=X_TR\/1E?($K7%^W\.W1?J=O+8L>J6Y?SFQTTV4PK]6ZQ$](BXWP*)'OT
MV$&#<YA=M#<+?,;6FDI;'(%0.ZO]S54E#T8K*'*9?,4_A,L@M1EDDC+T]Y@F
M_+V-!9WES*4[(4B9V73\3.^+<W\A(L)`&^'FFG\7;)NU"0SMZ43:0@^,:KF>
M0_'LX$M!0WZ'J'!74DLB8,O91U:%PPF"8SGA]G;6&_:?O3-TUSB=4;#I]GOM
MC\K)4DUG5/)YWG-/%)_5B(YJL#]^)",VFJ!<MH!GGG[OL"]K-!I<'7$V43RO
MR'=V*+8%Q8>!V!.TMCX6LN#?=Y\H]WORS&3FQ0WUXI9Z\2T^2^"W[4W?6W<!
M9C0=_0DL$MY7A_/%<^GV']Y\.=)%3^58S+?_+CJ,G%'P"P=4+S0EBB*NZ2!,
MSQ->/KF:UIGZ?(PI>)-@0,\]AK8?GI_O9E#?6>^SXZM@5C4=6]F'>U\=E[`Y
ME.NW'S`]1D5^+]P"^83]O?0\K$%T?!<=8`?#6U0\G:KM),6=]L*$*;$G<^<H
ML^B]39N&_JB-._(7PI9\H8Q%]8=XG]U+#_Y3TP5U#1>SD^J"![RC]^=6;<^K
M;OW=I,P53(-QQW@T68XG"Y4I<@'R(U7)<U$Z_WM)B.OY%93VR[&J^I(DS/X6
MZ>0UCM?WEZY62<?#9Z>5?Q[#>Z^_L$DAO5/Z^X$=H'WRZ*],R`]OJ]O[Z?G:
M&0X<4R]&X\5*;;<8+272^P5Q9`F]1I#^^OVGD@_Y%95VJ]P.=MUF;`F]5I/^
M^E\CT7S(+YG.<6O!\J^>A=ZQGU+0Z7>(C?,<$@C3]]*M05.T>O?#@(+)0,)9
M+>:+D3D#`'%-SV5VO/>>O]^',Z;/%Y>_!]PE-JRS[_?QNG?S_SI]>64'HZ\7
M+__HY]E_`]?<C0`;5-=WW]<#'0%<"!R/%K/IW)PAP+=X\]2.]NS\9,]N+>S9
MD9Y@_]['!H-\:&.&#"UVR?\5QA*#?.P^*PF&;YX;_97TCU+:A-,9C%WB[1/=
M6P\5>KRO,4>YD5#FF4RMB:5^/)%NL[_KS0,9WT;Y$$`X3/3>MP1D?!]^_TBR
MD)\<#&(P2;KR)-[?:>];3_F*>M::SWE6F=+)Z23A_I5XP/#1>7,VV-T\D&"3
MG2\*;O<<,IJAQD`36I?SZ5(6&0O7$8DW%R6SKE@_1!4\LZ3C0?S.2#9QSR9V
MS\G!NPTC6WKT\BRS@MMB74JF;ZMOI(TZGYLM>VYC&9U"U986'Z9!U60YB!7@
M6RDG"Y$EGV$D^=R!(ZE:6HN0Z_=SEA5WSI8-/*.JGW\D0\X3MOW@3]IY<5`@
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MEEX2&M#B.?!7LQGP`B#R;OCB6J&[+4KUXH\'*-7LS"A/LJOY/G3JGFC_V4ZD
MH:.[(4XDIDW1@0@\2Z:#`UL*!0*_T5ERHRI&/&L>[`K)U41>V?N4_=X+Y?7R
MJG`1*Q&"_3?BL*WGLY*[-F&>B.?.GN*4$)L$.I.=8II533C`(S4_K+J5LTD/
MK30!>G[=&ELS,?=3*DD)^IQ)2J<<?PY%^D/[<Z`\3#E.Y8-;UZ5G&!QW[=,J
M/32GDA\[%M(M[=JNT>Q$RT;BZY]&6?\U3.+]AZAKO_'\FV-X]/%MU+T/&)W5
M;9YIGU!I$#3%>6HMYM*.&Q;`FAF^;9F"R2CN7,X!#.+PH?J06#UZ'2'B"J)8
MP_/M5"0Y/5U,#BHF%B1RHRAE`:WE7G6E'"N[PZG_4F9T/]&=\/2H@;W;T3\/
M$KHES9Q=)U.T`5K/TII.%Q/Y_<H;5XB=0(LT.K=^I*]/I7<=D4)(T.@<NXJ^
M?BUL-3;&ZF5)K%[4!^OY=BC5K"FO#ZGXA&=U/N$N3I3#_MH)[.==KKR<]/,)
MS0V>P_F$1BN`JPF3U6@VD7,^X2[)M$UTRI^7/;OC"7+=G#L9FSOH'2`L>"XZ
M'*[U^EG]'N,7SL:1)?KG#.J'JN-&*4<^8%_NK'9VBR8-<P5@93OGL+-;I3PX
M&W8B[U:$LC[D;*_MD^+8:1L"U,YR0X!4RO9N[;<X<T[+%4N*_H+O?:>P.:"Z
M]?/DOSJ3H,.7D363MO59QHJ%^G.QEHBI>69Y,`-^@Y8CR$+=N,2OI+.(OE&E
MA\^0:R'D,1`#-W[B,U_(`!:Q4[#"`=;D/)<^H.:!>6-L2:K9`&+NZLJ4[V"]
M9)!O`^'TLILT.Q9K/<.%@K;<,]`*0JNO?\;#<!S$I=:>O-#>U=;Y5-KT^0W`
M:^V!LL1R.I)VI52.PW$@U(-D*NJM"FFL^QE)WV;7N--R/`EOZTE,U('_`8;1
MS5]+;PY)HNW!\=D[TN]C*&_A;#)'2M6'IFG-9K.)M&3$%):Q*F=U2X$$1TKO
M+Q)'GMLM`!*<*1Q*JHBL\\OMJ&6S_FD=U5X_QY'QC>=OL4-S&H.*>^2';.F,
MQKTEZD/'6>/96%H]])BV!'7TW3INC&\SVV]KFIF[.^\!:PTL98Y/JQQ_CDSV
M"WDP3,SXQ?<"Z35]:EHZ(R8K41]\D'DVDCX`X^H(LW6FT7G.SONZ-K-B^D*%
MG3>-U6!2)HU5N?W\:2RW,LO^^)%TQTE!-B6!W*S%V=)?HVG@>O^3F?3\J@(U
M%G9(V!.(*BS4AGP/W"GWNS!>37(&XDL?:5[^GHYMT9;ZCB]]TOP!OOPB+(*^
M.RH&\\IP-`W[PD8LC/YJ?W?VQ_U0JZ*B^'-;$A5T!]\:N5K,I5T''R-TS_4X
MQ\70SBZ4W-M$>ISK,FAG-Q;60#/!=+;KGR6D)6WQ,^]KTUCZQO,?#WCM;!V\
M85_VS]YN4SA0H*K5,^;T"I.@9U!'UF*U')+J6:&#(-:0WZ>%7IF.Y]L+2''Z
M@)T#*\.1:(@X=7(=S[O?D.+X^NZD+&!?*UUW;AU-`^\.T?_4?;-S7/\1BELI
MR4^K;N^,UG0JC0`?8UV,I*_>"$J]C]PS.5YN.E[M"6XSX7BU=H=E3U<+[C'Y
M(/60#"AS3:K^$YUY!S+H,>IB.^?98;0[[;L<6X-V%.=^C+J?8Z<53`<^1BW)
M28^A[8?FNFG6PDW6V8\U.CBH)*W1JZ]#?(:=XW#G[\N=?^:=H8;S]]#6S[/C
ME'#VVUHL:.[><-VICO/WJOM9:=^AJO=M<=S^`GWBCO]@[P:KSJN^CY;FXJJ>
MNY6+/^`7QW4;O'R&'9KJ(@=M/O`Y%CFHMJ_JA*]5!R7%FIQ1D8,.YH'O_5YF
MCCP]P_K'YZ[=8TV1`YT3"8._3?7BW+](.8,>+".SG$'7[WR.LQI:49B8YV[B
MB^N?//HKH:)#LC"L9`^INSYG-//I;"203J8C2_[2(E<:$:U1K#9Z\MBO,]5N
M6FTDF+]ZI.9;9:C_C7N:,!`]0<L]'7KLUQ?(KMKNTD[\.EE(YEB^WQ=_1YV`
MT`\:T0D`]#G_3J#92'!-%FLQ5MD)B+,!M9V`DF4R-=]K"NP(SJX<NDYZ4M`[
M`,/@??8.@R8'@)M_5]S?;J=RM5Q*3].%4OVYIQD,\BUZT?C[YNKA]II;?<GW
MR<0:=J9[*O6N6%O&YM[2DK^/#>7R=[O'K?#3]1S!5V_>WK^?<O1RB$QMW_$N
M]W5;FZVZIKU$!<]H%UB>U>`JZY.9)7=SN'.?\_ZJXVOZG-!-A7_Q(OKR.5#F
M9K3DV#FK3NJ>(/G5COK8NRUY>^^Y+!>;C(76N'`ON8(&SZ$3:;0"G&<X&<WD
M=`JQ2GSH2B_5YEI%)[XCO<Z,W>7ZF;%U]"(M&%552&K-'<?K$Y`?HI/AK*X4
MVMBA_HG!H%"7PJVP+Z>W%$FCCH7CZJ_R*Y-T5N)L"I5TM1":WC%>C:>RRI8<
M8A8],!;-D\$A(H_*NA#G4L=$R3>1M,0&Z]G*ZIQ4U^H8KL\[@^_"^T%8I!_=
M#>T:V>\<E_[*>2/OD%:"]U0=I6]7T+]82J\OK[<?I;,E,AN*]"03)*F0*$H_
MFYZOH#JTUMUT82UGLOJT-ZY%#&FBQKGT4CW])ZG_B;1`J1KGU*/T]&')X>RH
MOFY)7)T?[U=25W]"+W>\&4SM^8-Q723Z[#B:ZPT=1UF3Q5@Z/W,5SHV<.SA.
M-C%S%<Z1E3LXSTJ<=PF,NLN2J+O(A]WY<G>6S.01M_!M3&+M._<1$Y]NKER7
M3,7\P/9/`X9F66MGRNTEID"+A8Y'TYFT-:8<\.@*<\`40W:JV7GV`KU=/$S/
M@.Y<Q!5#@F;GVU_T=O-`?4AY*)][SU)#N+([FZH/:U;_\_3J^,JZGT)C9]O[
MY"V!0G8V'5G2KN`H06Q(]7H/?4\_!P_7]3"]WDO/T\_)`W8\A3`^_WZGBFCE
M=SNE7]7(`QQ!E4GL?YZ(?E?NYI[$XA=[CS]Z-%.K:\9[EZ9,.FS107]P'OZL
MS?IZ4$^9_'^I/BR7E6J$J$KH-Z[4_S&TKL70_F5D^>D?1R<\13ZJ<X@Q)Q-Z
M(+35>8.N[C\O6DMNL.>'(:INY)-R#DVN$F=!A5TL`Y]3G<Y:7,#<0))QEGFB
M:=U-HPH.E0U(GX-_DTS:/H[$;%J4]3Q/_NU#)7*8N?.7/4O.OO'\+7;"HZ^7
MM=NJ<4Z\W=(V<+'(R;3%@@"0N05=WSUW#_E=,NR]IB65=_\ZY-V14Z32=Y>/
M>Y8$7GL'MA+N;J'!.=$VW"SP`1]K.9'.V%S-=T_6`WV-#$]'28/_*C3=GCFD
M,G3++VH..7/]K]S-;7S6@"[@!/?>SEGG]QG[2-).EK7J06$V64V;2(^WP]95
MDY;8"FN`>%LF<98\IZ1IRY=%IYC'+*"P;V:(9O^9@W3VV^#J&+YZOO-/O/E*
M#QJQ+\:M8)I_.&7(ZH'RW]5W)V@55?U:TLX4O=2'=]A6TWX.UP.EBB"F270*
M+^(9SBQD<)4=&"&F$/J-JF34;HXZY_+-G'9>T4M*4A#:3%K]/\&9D5K1D@[;
MU/U:.@]2JU(?6J+'6LDDM7+L&KA#K<ZWA6P>48V+$N<>*YQ[T=Z[9\"-34"7
MQ(VUG]*<:D0=;1$NA8@FMW73V79%\A2II+VBD1H[P;DMTTQMB")S]&9E\;*<
M>`&J8>G.K,)W!GZPS&J>Z.`.:Z)Z:R6I):+F:DH*/_;9CY0_.RZ^#?%^@!6`
MNL;.=;R<6``=UHVGD\&'S%0IQ+1Z#\/F;BX>?.3<X.2S'#T7P#_8`#K[4<^?
M-;UOV(\,VSNU-3V':O)L&31K![@Z\"A3['D('F6:Q3]3W=X#F?;P-J-4T2G>
MUK2AZ,!X'HX.2S[+V9,BOZGF;EL<1ZN(])K6SY4JJTT"XW@Z;TJ8[\N:7$E:
M1+)DD>`=,*BDCU`YVX_\1[@U^A+YPI'!\?GO>!W2RO=>M5?/DG:;&6,P!F[X
MK.^&C(6B^QK(N*3U<R?CHDG05;_I;-ITXZ$\,A:O*WE_9-SS(V3(6/24S6Y^
M^?_)&<8@@Y-SQ6<^^RVXHEW`"U$L%9L>/;0[UXVY[B:#DR@7D_&P>W0EC-_J
MHBKK'>S7*?J.X/X#Z/_/SA:C/]ZZZ(1M/_B3]BY$_^<8?+.O9Z2<_?S@Z^&@
M>@4[W^2YS@1R=H`3O";6T&LQ3+-WMH+=Q]N,IT6GO-\5[`H\#S9$+_LLVD@Q
M$-B\+B8SSZFF'[%Q^&@CPQF9P8;FFZT[F\,NF_[$QTL?[!T];AY<\-)TPRQ1
M<)L>0]L/A[-J1JWZ@%\<UX4:II1GRB!2((>"]9+*I#H^OGKYE5W6FG-^R0/J
MRY$*K0._^<I:S59Q!5'R.KKZ!?W&)0R3@E/&+CVU'PO:OPRK?5,ES:XF6.`/
MH*A,94F@"Z4E\V;*09>S_GV'K_%N]Y%TT*1WK\%9Q:/*$5>N![#PJ36=CV;Q
M72%,$J*B4"1+%PYEV#368E,#.F489@F&K:EA&X!A:C!;#Y\4O35ND(3CE[U]
MM=N0$?;KM><?/)_AIP[-=2^HQW2--D!27UKSU20&-A%W&<E#ZU2@ZE+:TLP:
M)V:AV"Q!H%Z$R[+1*GXZJ(V*P`[`F`#Y)K_(`7[)'91WWUSRR5Z=0\,5D,!7
ME9,!3"]HI?/I>#:U(EXHNQT5>;%LC5<R#F'R.&NR(!HELC7?HCB$V5:[+ZV/
M3MHA-R66%D[3LJ9&D,VJ(EWO[""XVS(UZZJ$5#ZO<HVM2@GX`>QE7*(R%H68
M+)I.PU?@M9;;D&(?@Q:WRFNV2MD*55/`95:J:AVA%2^\M#Q=7?=<6E0,@IG2
M=W3@IDP1<$&6V<K*8R>JLY\*-`,^O<T4+Q$`&:<<175A6(JD2I]H1=,OV'OQ
M[<.KL[9W$"05GM>!HKP2X$V$Z6J11Y`HRPSP]+*.`0=HDW+,5`5;*5Y*W:`5
M*Y^;CG$7']2!CL\MS_9:\]FB,"@SX+QS/WNL=O8HQT(AF$I!\%G_D=Y8E;OM
MM1V\WNR\;\'5<\"RM9J^7-DK.A!1H@=X0+](;D-)8HE,5:@\Q`02?HU$ZL9)
M7RMSB/%:6*D</37!6(JC*M]H1M2-X]KNVK%W]U[@T(4^.+*J7]6#L$I]P(=&
MT@5\$6F)7!0+-@EQ<JPN(J^UU1H0V!B\%4BL]YEF1-ZZ:V]/KV"C$S4?OV(W
M<-YP]%LP.$%2].`4HAH\_W-66)$@D.7"6/7N3"/Q'PS"KW1OE'2B[5V@`<QM
MXKX"UV!?:H:XL"$0\$49.+!KWM4#YVJ%P+,E:[DJ`;$H.%YF-`BXDNPNPE44
M_`>8X1K@VAS#%2!M\)M6:#[1XUQ-GYX_I`-LK&5P="T6X\*:"I.@&SOMS<@O
MI52;H1P)F9`I#?G47#VQ3>#VT7ES-MC=!#S_N_(#E3RJ-,Z+[8/W;";SN``C
MV^U,Q$2GK72%?$^+TGJ'`?KFA*^O>+=!-!*1$P1'>O8`.2[R?)HT$7KH8)\0
MWA]VW@EC%-K?-9](J`F]+%(JO*0-+YGNJ>[;9A]4C95,Z]!)PG2^M`2D9`=8
M&D\;]3.H[+B1UF-&_<RI.&<T#(MYH;T;T)8YM>6)-B+F>)&A+:X,.:4,50KV
M`C\5[3>#G1IGCF9,%_O.E6;CY;R2M0R8%DJQS\K;%V/D9[-`4C_3,W!ZEU?I
MBQ?BCTZPWGG!T<=/^'OX@;3_._CK5KVO%5(52H''FV-K48TP*ARETLD4C,A'
MK`%C,"?#`240K!X9Z4-@0P#7`[+.3]KP>4OF,WCS\>B3\0Z_?C4J6;`F.O-=
MFMIY*^A]U?B$*`4-3[J\+\YPN6S$A<<7+<>E103Y&M$IW7R&SMMXYINOTD=F
MP@1,+EZSW4HZ749VVA+;"<$^?L$NOJ"[(#\:<6J_;>P7H`UVLG'0_A2M5+"'
M[DD(OMH!OWFU2U#52#,%]M4J@E$P'5E0$HA;B_+_X_9X92$#64&2=^HY@M\'
MDJR1\5\>8M<<B'SC6:$9-F".:'"Y<8SQ!7]C?^I$$.G+IO!!HA%X@W^Y`(\!
MB'#^=Q.QWLWRUMT_0_LWWPE#[!*4/^^<-7EMBZDZ%\C%;+\U64E?>T$X;(VB
M-^P_>\K=-F9^N\^;GZUPS(/&80T;2WT%_(.9+NLYXXBMO&A;EQ"ID&0*Y96K
M![X#;#0>0?FOJORB@6PHP2D-HYX#^1'')1')7_FOHUKFK)YM"7L2S4+?68?Q
MX6Q"ITX]01I!$O58`C-&S4<QCS[20HY)$<=-IT@L%60,>91I![Z?93Y?@KE#
MJ,2:%F$M[1>[>V/%O>'B%YM`K#MY]'?*5"QTC>NL-0/@==$.QW>EWPR"]U_L
MW1%W7P(MOJX?R@6=P)O)R\6\$<!,NKGKG_V,E[O\:2"^*\,=@.IRUYJ&Y<H5
MEPYQ5"W+$)17*@B-^MERUKS<R2%?M]II'@7(\4S?I4Y3&:`1)%`ZJ'>S:=S0
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M8V=6-););XRGPMBCX`%Y0XO'P\X)'VCO>^?R*3#[=25O5CVO95A0H0STWA3+
MFEISL=-G\A`3B.Y<%"T)L+]IZ,VE6#?69QV@%Y9B(H/YC?.==*[L]H@XG2HW
MJ=';>S;@+-LWUKE%2\]W?`[P/XZTBO$;I!!JU>,J^\$*'<"%V4:+>*";2$),
ME`FU46489W4R3EGGV!!RF3ZRSAT&X*5^M%CZK#ZDM!IG3<:SI*1V(9+TCAQ[
M6U6!#Q,&CG7A50.,S@/(05#16$:XZG%]V&A;6->:+9+2VKE`,J!PL`S;2D%B
M3+G@AH"K@8H!98)S"C6>DZ]\7B->6A\#7\W&JTK`Z#_U+L6\4LR8A)/Z$^VU
M/C``*;5E!,L>U8>/-K7X)J/%>%(UU-):6;"O314#+0/*#-8$5@TD-)<<S"E#
MVJN[V*?B:8V8B%0`'[*;C:85L*"B]-[I(\&T<G0TF*8+(;E@JP.)Z`M#</+1
MV]M.90)-Y?-ZL<*5``]`TC/,Y2'%Q9F#EP[FU2&FQCR-F,D&7@-J!(_HP<U^
M;_NGNVU\?4-PX_E_?776KX_.B^MLG;7MAM>OY#/A6_>KZ^.U1W[]3[QYLK]_
MP"[>.F%P&SQ@._!<TE&>B)C`(1UF\_QFZ':5XGA@8^!U;M/U.Z82K?V>*(6(
M5HBIA02]$%<,W;I(5`T1W5"L'+H-4*H>BO4S8@YGDNLMT?7>-MV@?L`[>C"1
MUA6FB66V>_I#4.UNO7RFB!"RO*CB*^K@UT2#AN71XG,*^:O0.'AEW8I+**5$
MH'TEM)\U5BMK5*&R,HQ$%)4;+B6YY.D5^_8!'T-G39#Y`8=V^&K3RZ3QWK%+
M-\3`KZE.-0'H!$U8F"Y&DQG/.!&DHBWI9I^)W$M!\+#[9Y69)]*-'>>-I6.*
MG%Q->X7#&&SU_KI*LE):`#1)3H'ZJGN_&>#UCR_>VT\;[/`ND_R0[RG)K_[V
MY-NTVOSC:?_LY3]K\>\*>L9"H]!AX'@55_Z-7D?\?;50Z*>^!5-_Z+BN#`P:
MP.46RNGKOGE/K]XQL-W-TZOCAQCS?*U;HJE+QO,LE[FFSVOQNO*^#ZX;-#%^
M.EU,HZ,61#J*Q:-8?G1Z(&F!'1_0U1L.9?[8)/,;.LBA?,!8@Z*IO<EJ>LCV
ML$Y[RI9.TS+3)`W<;3_B+?;][/&UVH7PQM=4SD,;=`&OQ2SBTG9LF?ANBV*9
MF9.@FI?'I5IK)=9Z%=9>H*O=CJV;!T8LG$/C-3/#A;A,RB#@:WQ>GGS%ZKZ^
MY"G577I1!6#<S$>C^81WW*(,35US3S/&:LVH[V)[VF*ULD5)WUF-AJ2+K#!:
M1T]8L4!<0<-53ROL]RI4`-<SF\X7,0):["CT-@ET%YT,V\0+Z9[Y]6TZ[Z.3
M85+N4KH:JU3UQPVH$;OA.@<8!/B/>.UC.\#!`PZ.NY#X^898?$^^L<]+/I!G
MDPVG=M^ZG6C]5-)*7V@@+R:C>0/OH*1AE+2,:-.(M1U7;*&O),WKJ@RKWG6,
MUQ[PYKCF^_-T:3DDKC@D._9D,']@CCIAV]>Z+RP38P`N:>]U@XCGUEU[>TPU
MQ*Y-E,?!E;NY=<G0"`?AU7KM'RLK2O>1J)]F(&J"N\G%PFIB%]X>IX^X142:
M1'&;*&I4SPQ?E9?8C"%Z$3FQZ;:[^8DPQR%NQ$#V:`,4`&F`'6L65Y00W?71
M]\FLO^\PI:UP(QBDC<;@(FF3T0I`)N5#E:AU!8.5_L0RF/,XQVPVT<#DF=75
M\]S<>,5/\]S"5XS6D>?HZ,5,^NF"/1@3M?X2QI.2E)E3.]&F$E+/X?]D/(:,
M;?3.G`8A(QF.RU'1&<Z:.N&K,^V<SZRI1/E''(8[3+=`@K\ZX2MYGOSAZAB^
M>KY#1W@R@K*Q#5-IJ$EQ.*QFC2LYE7PD*(&H%HBK@00]SH"8I+J2[\9ZH;U#
M!_O$7<-HBHR)XEJ1P1\8:WG/.^?%YKQ%1TW<=W:][XRD+RA2._,8Z!/)V?T]
M$#_0TD-K[`;X!I=6WBT^I'SO-Z\!-&-G/AO-5]'>+Y>!=EP(VF+5M6Y[6C$6
MK8B$(")%Q\9O/TNLBN^A;]NW"@;IKF^IQ<-@L"X/H^I9[8ALE0`P'HT6J]&T
M$IB!;F1VLJ8*H'IS-*285H58`S(V&M!3C6`YV1MQYO_:.[JA?^*3@^@?^7E!
M].N_44=GOI3P!P4C\+0U<+;\;!P/F]&CVB#NJ"P/V!\?M09H\7O3:,Q9I&5B
M^OB+]X9]EU+\XX&,R#T?;S[1_8.#[Y#1Z$?\'#[B]9$/-VOK0'82I7*:V4$_
M>#W2U2J!!4K;04E#2&@)T:90VI;F2I.#.R:&X(_H)?5,D'B&YI.')[2A3@E@
M3E$V&^P!C\RDKZN+=7`"O1:&#?>N=COO&TW2^G"*$Y#)#/0J"'!84Y$)_+I"
M[$-U`I=I&4TBO">242(:?3BE^>AT08F)UUK':1#[K2K[GUO:KPK-;0-;1'`K
M#YJ!VKQZ<36)JST==X`CI4&,5A37ZP:^#742'YXIB^:24$[KQ_"&3`&U1'?P
MZ]6B14EZ5]HF=@-=PJ4GIL.`73+)W67'*IB%;Q@$ZG$.<*H.O/\5.R^O(=Y$
M-PQ].=(QP]V67>=V=PR#T&;9XQ_LP%E?N9N/SNX85N;@=12F$/O=-`0?*!O'
MJS9Q.\EM7[PE>J*.7Z\H-(98:RS[+FI/#Q$H\`TO\\2O)3D&.+H]<7\XACR7
MG_J!'@+><-GL>M6=%P3H0'S'KC/120S]L"+20P]7FT82@7`QR^/Q^>]X'3YY
M#SB^R>W.OZ;LM]O57<HJ3[XA5-)*:7`9U,ER"6.7('.I$8HT0$\>2G5`=SX2
MM3"/<X9SHDA#0>2<T$-^ZAR?JJ5U!UDZYJ#\T][M''21LSZ3MLB_R;_(#S39
MD?SC_P-02P,$%`````@`*HA81&(-Y5`\3@``/6P&`!4`'`!S9VUO+3(P,3,Q
M,C,Q7W!R92YX;6Q55`D``S#!"U,PP0M3=7@+``$$)0X```0Y`0``[7U;<^0V
MEN;[1,Q_T'HB-F8CMERN*O=,V]$]$ZE;63TJI487>WI?'!0)9:*+2:9!4E+6
MKU^`=V8"($""!(G$BZV20."<#[=SQU_^\VWCG[P`%,$P^.MW'[[_X;L3$+BA
M!X/57[][O'^WN#^[NOKN/__CG__I+__KW;N3N[N3\S`(@.^#W<G_N,`'R(G!
MR8/S%@;A9G=RBT`$@MB)<7<GUS#X^N1$X/^>D/]Z)_A7_W-Z=WWR\?L/)R?K
M.-[^_/[]Z^OK]PAY19_?N^'F_<F[=\5XOV:4_7SR;]]_Q,35_G(7)H'W\\F?
M?GCZ\<]_^O'#NQ\=[]_P?USWG>,]/[_[T0-/WH___A/^^<^UK\X0R&CS,-D_
MGWS\X<./[W[X^.[CCP\?_OWG3W_Z^>-/_Z_>.MSN$%RMXY-_=?\/;OS#G][A
M+SZ=W'U_]WT-A_]]<A\&$6Z]V3K![F3A^R=WY*OHY`ZC@5Z`]WW>J9\C<H)1
M#Z*_?E<#X>T)^=^':/4>#_/I?='PNW_^IY.L\<]O$6Q\\/JI:/[A_?]\N;YW
MUV#CO(-!%#N!V_B0=$;[],-//_WT/OUKUCJ"/T=I+]>AFZ(D0.`)LP7YU[NB
MV3ORJW<?/K[[].'[M\C[[C_(@']!H0_NP/-)2L//\6X+_OI=!#=;'WR7_VZ-
MP#/^W6H3ILA_^)A]_R_GH9MLR$(+O(L@AO'N*G@.T2:E^KL3TN_CW55)?N0$
M*V<3IHLKSI?J>]+H/;>?]WVIO,-?_GZ/=P,@8RR?+V&`YP8Z_FT803+$F>]$
M$7R&P),A6K#',<F_=1"0`EZBVW@-8N@ZOGJ&KO!)MP$=R<X_5D[4$O.+R%F"
MP!H$$7P!O<AD=J><\/LUGJUUZ'OXS+[X(\&;:1%XBKF1&T,YBV=.M+[TP]?H
M*O`@`F[<D8W#?GJ3>@XCUP^C!($E6CD!_):>81B=^V2S<=`.8P=7`=Y5KA/$
M"]?%UV>,+_G;T(<N!-'"\]*]Y_A=3](AQE>(RJ4#T:^.GX`OP"'_)A,1E;11
M_YK-$UEF+XY/?K%X<:#O//D`4WB/?W4/W`1ALC'Y@7<6I@SA=OBG"'I$,L(\
M7$/G"?IIHVYP3H'P@>=!X>(3[WY@GH@\YB4^J$T1GA8^U#MU/'<;?HJ8-&4`
MO0`IED<J"K\XZ"N(R0ZMMF9%X57P`J(XW=K=`!#O?F">%.YT\>X5\G0?A^[7
M4Z+-$GD#"QOI"/3?7KR1'Z4DG7X##<ZGPMF3&6!XOJ(HV6S)3]$C_M-EB"ZB
M&)+1@U7M=+C`8X4[D'6RS-HKY;X'&8-C]!L@)@W@+5[PH;@"HK3>W][>)LA=
MD^XRHXA*Q-01I?3<^T>(SI(HQBH(BO"5$0?X_VNX)<+6?4P,9BOH+GP?$D.-
MVB-1P<CZD+@#+R!(R/_=$*L*WX#W&.`K>+%"(+VR1P&EE0B-*Z6@X3<8K[$V
MM7$6OH>@NSX+T39$JH_HT:B;"*+GX2O^=WB/U5'RMZO@UB>JZ@KSD/@Q[GPB
MV':D4Q_*9XX/,1T!=*X"?!['20SPT7P'L)R="M@O6"[WH`L#\,O5K_I`5D"F
M1HQ_.;^Z)"Z1E)"KP-6(HQ@I^K#Z6X*/>.B#<ZS6@9@<]1%PL#A0)SH&*'`R
MHO4AJ810?3A_P8>_`_R_789O%<5X2^$/O\(@PE):P9`^B/O2J!#=A?M'`C,/
MR/+Y#*#TX%&(C$3_0W-5FB]S^1S+Z@TC3&5Z>4!.$#T#A.1<9(.,KQ65&Q!C
M]0;$4?KIB'`<#CP:#MFXAT1UU"&[#C8XOZ4E[C[9XNY2A[1_B\)+LB&'V??B
M8RKD'G>_!2CUV1'GQ#:UPQ;XT_[8C6'Y80;F4>$A+MZ]0I[.PLT&9@9BA:RT
M]CH,!Y7K+"'*TA<8P$VRN75VZ5]399^X`9#CQHGC+Y]\N')ZF/J4C*S:NM?T
MH"NVZ@IT/B@_E<.Y,I`N7*R_=7:P28XQ.G?1,HE)V!>)VAN2P\8XXW")I>\8
M01=?R&FCQP#&@\TE;RR%W&;!*0_.FU+;;VNOPW!0R1%Y^&-T#C)Q&?\Y$ZEZ
M\R,RQD#<E<)AO@[N@$^$PX>PH.0Q0*6A&']RBD6K9ZB"Y\XC*Y56TS`=K$7O
MB)\5RQSX-R@!7BTVI$9H>^.N`JQJ,A1B5'CC<OR)+5;AKA;N72%'_YTX*`;(
MWY6!F>=.[)0`T__<C;UN0ZF\>9*G"/R18/GKXD6MH"[4LYH`Q9LP!M%#6()4
M!AI&]5`\8M8(?>@5<7GU4/U:$&[U<6T#!AXW>.\!O,6G/KXR9:":$-6F34/Q
MBWE.1TG]T--"C9VL"%:\JH5'FPK;#^3^5+2&),<<&H):Q-M5<`Z>8KPXJWBR
M7"UHQ,@"%#N06(.)[I/)G(.ME,&HFRNL*E?BP#0.#7$MS/ZY'@F5JP=G811'
M:9)$&BM5V)84+]"^1$P<))7+30TI0P-V%OJ^\Q1F40X+A#"CZ1\&.^)D!IP0
M\RI7AORP0P-QFD0P`!&F;/,$LZ""P1:`X%C38%GEM$N-.#3[A3<IBR"KN90&
MFW>I$:?$OLHUT&'<X0_!TDTUX*'/'4,OBVJ/=H&1AF;WT-%!V@XVN>+#389Q
ME5,N.^CPJECN2AA02^6,H),]M=IBZSA#LRKBT!ALDKL./E%05"Z-?B0,+MJ0
M0@BIB3:MCG"+]4P$8IA9W@I?X7!27M?1AX;ET*-4<\<H!D%PK&FPK')G2(TX
MN#30],.I-H6QN\\9V]8\)->8CP:'N#$(/!++F_V6#-:W:E$Z+!X8$]$8RR=%
MG4+4A#,?*JW<%`'W^U7X\MX#\#U!F/R00OWNAP]YW:9_P;_Z?8&']LCPE[ZS
M*KKSG2?@__6[P[^_'YR>LP21K/Q+?)PX_M^!@RX"[QS/#X4T9E,Y*@\7(?G-
M[\6T+"C3LGB*TL"^/:+$OQL>QX*,#)U;@&#H7>+?110@V6W'II/,HAB55<OQ
M:,R082](>KOQZ'O`W7+(2O\\/#79JC\#)/85WQ4>>/LOL*.016\W&GU8J\]+
M,*06^V;4)8M8WD>C49X=>W=@&R+B<B?7%W7#<)N/1>TE]`$Z(WE:(6*O@F:K
ML6B[39Y\Z%[ZH;-_DM/;C$77'5A!<E$$\8VSH>UH:K.QJ/LU]+&FY*!LTM@+
M;[_=6/3]!GS_OX+P-;@'3A0&P+N*H@0@)IVL]L/3FWNA[W>;I]"GT-?\>TE/
M70A=H"9M#G*+CO"/#0GTL*AGWN+]-BV$],Y=0[\47I]1N)&1:`HJ0LJ=<Q(B
M#Z"T(.V''W[X[@0SD$7\7F>\,@E,J</*1P32EN1+&"),P5^_^_C=21)AYL)M
M%H@W+WCVI.X*GX\6'X[$5>'TR>+$E9XKI'ZT2+7H0Q56?[)84>ZE"I]_L_BP
MI;0*IG^W,'$4P0JG/UN<^":O"JJ?+%0"$GZ)%Q8S+5ZM%H,*+BN6<Q37&DY6
M/&<:;6HH6>%<U&98`\W*Z0RK6PVCH>7SO[S?=_`-Y_83?/>CLQ'JV8F>4BR2
MZ-W*<;:9)0KX<53\9M\DE?_Z=Y%8B/Q*V3-:=>FANYFM/X=WP`7PA9!X`V(Q
MEJB?:.*!(+J74]P^,;R/-/&1;)(T?X+U],=U&$48[>7S@_/&9DRJ%RV<EEG#
MMP[TKH(S9PMC9]_PV]9:"^5YZ0<ZH?6:#3KH8GCC&8WTT=FR-1MMM%,I!.I^
M6QU44U(PVA_FH/+4I2<=')/G8$@JX]ZK,/&9@]`.4YNFYC)X%/M6"U>U`F*U
M9VRRS'<Z+YPO='&02_K<*=AOIH/6HN9.&1+=J.M"I9O[B4X>\B+O_..5T7@"
M=-^$@2M#>JV]DD"WBP@K<Z^LPY':1`=JG\/0>X4^2UPJ_ZR#-F+<?H8!C,$U
M%C?Q#L'Z_0H2S2<K0_KF^@G1]UMXD.Y&#Z]8I0917"E"_(W';J^#^O9C3O>I
M5AL_K7&]GXG43C;]LRGRTB)D"G^NF3?^!IB(S>.0#''TIR#GTUX(XP//^V(J
M'+1>_BT?Z>`C-;!P30+U%IHIY"\12D,=]-XBL'6@ES_]QB>9WE8/U8S$]QO`
M)I[SB0X>JBJQ?;1JV5[T<$H*'P'OPD$!)B2J64RQ@@%=R)HS@0]U\,/SG[3<
M;$*?ZN%)4-J;B'PG+=&)R'`C>BGY=F3BDFRQC9:NR8]F!>B(`],FU)0(?3(K
M)$<<(?XU6>%C5@R..#[RQI,*,[/B<<0QHV'1(>KF!:"G</YH-!22"A"S(FID
M[ZHZ$EWB9L+8\>>`!,.840=$4+0W-1Q2&B^NJ<748$AIE#B&<%-#(:4QX@=:
MF1K\*`T3P_XS7N#CQ/&1MM)4R)F5LB2-',T26H%C5J*2_.G$PJ5+8M+TY259
M;UP=*I[WJ,+-3"-(']PXL1Z5[<A,RT@?V#H%]56`FBF_JUB']'BO"CDS97I%
M)U\=J"Z"O=E7!#>`LP+.3%&_#W"\UA5N9JH`BG8F(U*J0J^+&C"K[2JAC`OE
M=9E:LJ<S=-QD*U,+^,BA10\G-K5H3[>5Q`I:-[5@3S>4^">2F>X,F8"60RL&
M360PT[S3%2=Q4:-"T*P*->)A._MR?3.MR=2"4-WP8:;UFEH0JAM,(O&'II:&
MZKBP9#/C32T7U0T^KD+8J4"4C`PQO5(BMRF^:Q!#%U.I-S\6T[)$*=E>>J?<
M`I06QV&$C8I\J3GC-ZOMLTCB-5X7WZHI9'-R\,4D.$A+J0E3G[>>!.7L`NY"
MGQ@=PSXC,5WHE##=.J4`O,,#R70CE3+0BC/0=,N5,L#H)>T&MV1IDK$RT5N'
M!"7N%J\]01V=K<F/5\%B0\S_Y.5ROB?]`^/*&6MT)54M:@]R8WI6"&34[+'&
M;:I#(BBTX^*J.W4BZ"X"[QSZ2<R4R]J^TE*O`P1X:GWB9?(V,$A+99/'T?,@
M1P8G;5_IJ7A!]GMY`+0(9JS6.BB_`7%E)V#0VVRCA4I\S&[38R!89:3PUPB[
MO99<\X*4G`AF3OQ!NTE0V[*:V>VU4M^ZJFDM->67`RR0D9CE<_`"_##-_..O
M;_XW>KA(G9676'K\3!X\8*%^V$XCM2U$ZJ6M9=L=---!ZV\`KM98?%B\X+VT
M`C?)Y@F@Y7,J8=0D?C$1I6-G.M6CEGN_Z=S8G]9>6M`L\C(EX.'<.J8^OM,'
MI?KMUL_7.OVH!PE\.'*BZ:Y6&92:,G\_EZI1ZZ=5MS;=?RJ!5=>[W]07>(3U
MI[VT19[P;WJ^N116K>8BT_/.I=`:S1#<*Y-]%F*L%.X48T^_)/;I7[`LC;4,
M^&9:VDUWTO*0X5A.3'?#2L`2]?6QSB`BBQ6ZIRD":Y^,EG=U>%]8CP:W_BP%
MNL<``<<GT1B_A'Y:T\R!`:%R&525=A8(XLM]=8[_&:RRAXI;)FFPX33'1&5<
MI,FD![R)AT<)]3*1,`P9CH64?C-O7@6(#;=%3;_?%8#/O8>,EPA2(THSC#U@
M1OAK>@"R+?'@"R`&(<;A*_[]A)[AXW/$_48/%_](HJS:PD/(("]=:$].!-+]
MB>%/5_0=P&LN@C&X!^@%NB`[O^Z`&ZZ"M!=>I?/!A]4<2LY=!8?M-%$[<R$^
M._0(56&`5])YN,%W+"NTC=K6JAZRJD<]4RS;>OCW6-2)P#G(_M\6"=2_XRGA
M854Q^2<CN(<CH[$6%5(P'V@B24!=J?W]HUX%?>]HCA9OD'4N\K_1R@46\,$5
M_K&5]*JA9K-(AU<W1+[5RM4#J4C41G[6:!H/G3!IG>C#+,+T:CM5,"%9XE7]
M_LNSV-Q,=\!:`GN;BGX_.>Z*JE)9SF."W#46FLAK(9UXY?0V.<YOP&OZITZ,
M5A]/CJ\BO*BI`7=ADM'3A#A.U?;N&_3P\ZGQQMQ0'1AE]S4UKCMNS;UOI\:5
MBHW)ZTBG79YK56&D[Q8:7;_2Y]/W60ACTV(<-KW4N3!.+-.`Z47-Q1>2N`_%
M]+KEZDR2(SMPNSR[,H^8QT%FA!6$8.@;+,.`*.8:-_3E%B'38B.E@WX<5R$$
M9MY";..E<`&\+I%!VTPQC1T4&X$/KW9-A]@=T^`1TPY[A>O,XK;L!=>!H<OT
M0M_]%Q=+23<]55C!.FN'SDQ9K/^BXUCY3$\N5K#N>"X,\XLZ]UU[3>NYZ5G(
M"I8;`S!#<X[%`!L^(-3T?&4QG%6H_:;G,G?53W__V#/C.%/!+@+/"'PH`5_]
MTHWG!H](K%-S137#B8[&#M0(GZ(B0K>H%0#]8!&J[\42EA%PT92$1%Y0O_3#
MU^@*'RT(X/VD.XF%"!R!"WW0\",\A(326Q2^0,SOZ>XQ(H_8EG48%FX,7S*7
M#C\&<I"AM"3^;$(4PV_INE@^GX.G^!Q&Z<..MPAL8+)A`=#ZG0YN1BMD0L5D
MK-&UI`GAM4PR,_'_R-G_XOCIL1^?.0CM,+F\+"^Q;XWD2E/X*YTVNAXAQ1ZC
M"UT\DBOG!I^]^,>KX`5$Z<$:>/GS`_5#EIQ.?A@EJ"TQJ7>W.K`X!_A^=V%Z
M4."??9`>,H%7/Z49_`I]JJ7B>Q5H@=?>\AG?I/CNC'?$#IC*GVGY,P97@A]K
MJO_>V#SXY,]?4L9R!,`;C9VZ(/3I9'@B3QQ?!5AZQ1NHH@_+2#+<L3N9!I][
M#_`*L[;_W32X*0SO=R`--:N]<2K,&*<+)2]Q4$9L/!%]2*OP9].8@U)#R*VL
M[0]$B'8P$?Z(Q5/D\7AQAH5[G`8"6$/:.M`KCH"\^%]1M2-[@%F8>:'.IL'W
M'3[#$73QJ9`*62&B*,/"?`MUIBFQGZ;X4X1'!J\2'4R;OY:3JT-'$^*W4@PZ
MSB>M@VGSUVT^>1U-B%_QLTBB@VGSUVT^IV;!'+J0"D,.S>T#2W3KH#C_1RV0
M(/]-^1#B$F4NDZL`0Y5L]JU[J;&(V/[*7"KJR[ECCJQC+K'PEMI$<^7A(7QP
MWGZ#\7J=Y5[@6UXJY:YS=SIY?PC3R<1DY>9DD`4"G!73C)BOXDAU,0D>OSCH
M*XB)P%YETX@R1_UV$EPUK$U8%&^S5DETH.3LPMV[`'@1J2--=CL^*+!$C0%T
M_-ODR8?N\AEK$WB'9*LFC.@O77;I1LO\4.ALG'BL:6G]3C<WF7'S%^#CL^V+
M$Y--L&O?2.(=3(._3((DRQ__[1_`96K'0I]J*\HDG"@^G3N)YN$7KPYT^(G.
MV(TAHP/J$2!BOAC3LP_&0EL@?L'T;(6QH&[/!C$SH6$L?$4=GMTR('[*\`[`
M*G7+6,3'#!<R/0E#52Q&^0K06-85TY,]Y-V+]?W1U873K;#`G$ZH;KB*.[!-
MKZ"D>EWRPTVZU5DR?SW*A21U*\9TS"B*.?J[%6PZ9EPE0D@J<,W,C5,-+2\"
MK,*RRU,ZQX?E06Q@!:"9Q3JZAX:4TE$GUT2%JYG&M'ZX]G>N5OC*6-#F=$,I
M0KC=T51!:::Q3`V0,C%T%:)=5*7IOYC</3Z+MOE;/._=BC(8L--EX91PPII>
MGF$H1&ENWU[E'(X'2ZE0HFXU((YPSTN$^70K^GM\F,H$5_>K`#S;BU[2IW5D
M;S>K`6T8AZ/I3S>KP5[&ZM+O,>=C050FPZ%?_=CI'ZHB$6S=L*.LRH]F>O<5
M8<@5#4H,/YGIB%>$(=>.4F%HYETOBZ%<%90*O2ZWM7DGH6!MG`JVS@46YU3C
M7B5XC0*,GXZB`*,P>/VBR2I4AW8(C5EOK^)TB59.D$<]8U3ND\W&0;OE\SU<
M!?`9NL0>D;G'2:GCT(<NN2C**KY7P7.(-IES1T4^T9GC0]QC`!T2@`?C)`:7
M(;H#*Q"D8M,+^`(\3$,`J&]^=^M#2294<X,6UMOLBO@%KM;^[AKB/WN5+9).
MNW0O:JA?>_`2S[*73B6^TCCP,IIJJ=R%]S7&((O-O(/15XP4^86S`JS2>MQ/
M]/"0D%@S?/C%NQMG`SBOE5.;*IG_\_!UL4)AA'<WAB>Z]CD+@-E62VVO,/1>
MH>_CL^L*3V*P@B2"A\1#76VV#D2\REXBG^KDJ2*#DY#.:*R#[B_.&]PD&^K*
MH;?10B4,VJELM-%2BR`A0R^?2W/!/5BE5D4&Q>SV2LZ'3F+"]7X1\?HITK-'
M?5P]4,KJ]>U-QPJKDTMR'#!!7D'[;4WF7#Z7R1&E^-V6NJFF;TTYPW1/W&,$
MGA/_&CZS*O.)?*F#HSN28\01*JJ_:Z..>Q;76VBA$&SS=X.PU`-`EA+4E,.:
MK^WNTR_\O9(SK9E7<V`YH!U<;9]HR1?/KJ_/(%PA9[O&IZ?/19G=?CI9^K74
MO]-=U22/!EB\.LA;IC:!^ML:V<7.XEKY.$K6X/T:(KS:V2I$LX&:,>%JXRQ\
M#R_D]5F(MF&FX7%HX'Z@M49"?15S3FYV^^[41\#]?A6^O$_E%+3+B,__L4]W
M_NO?'^_W"*S]06LN*4>S;KX9+WS"F_IPBT(AOPS`[V(1,S7(9`A\6V]Z4Z-&
M%(,I)?J;&C<R$*9\`ZVI3PX/!*:8K=/4>D`#@[IO;#6UUL]`,`Z@\9A:#6B@
M&>!8C$U]Z5B1$;>A"U36,F/?(!P`-H[J6L!H=:9V&.D::X'@1XL@$T$EA^J8
MSVOJ,8DH=?KTP_U(GL(]<+\<W#:%B?(HD&C:8^M8[/GE32]TUX9&,Y;"],Q?
M:2=;>?;L^1I,+\/7`RB^@\3T?.CNP+%CXWJ]>6\T9O)QO-WRG(\"2U9L;K\T
MYNE#UAH#0""J.R&[U1R9$2!M#N*&2LY&;SQ)4T]2PZ4#49H7\P4XY-^I]E)J
M)=2_9@DE]0R;%P?Z1$7!QQBI(E+582&>-GZA9I(/JR%^("L#6;)7X<&('V"W
MUQ']4`<\:@#.#0]K_4S7B^*UM<1E@-Y6359'2SUQ3I*'V)<ZL"W7Z^FN_/$7
MB`G$M^ON&KP`7LB,X,=:^:KV85N8+?<3K3Q<!=LDCE)`/W!7/^^+J7#P49J#
MCQ/CX),T!Y^FP$']@C[<KMQX4+D^]+QJ7(0]/>"A.&<6I:%^>L^P)+K"LM\W
M=I2EQ(<Z^*D):^(B4\M'>K*N_A$B@FR4O5J41R[5*P=R%I?HUQ/EC'L&B'^O
MA;LP`+NL=N8E5N[Y0B*CL98H97<-O(2452Q%[\M]%>D@4&$_<EFJCZER2<L$
MD_]>!W>/]Y_#%X`"<BC?;XD?D#PJD!JC$(SPML"[15#_ZM253B.*G/Y0MZA(
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M.*M[;""\>]U:LWG?9"RP)0_:H_'JZESCC6=HNCB`I9^AF;ET=IO.ZQK$)#M+
MIR*8OD,;I<KIN1,3+;[Z19FOV*;/"79BU3(]:IGH'(\7/J1G]]+>JZ]V;V7Z
MTY/#Q[2>8?T8Q?`;*;`6L=:LZ-=*LLO8@WU&810]!OCJ]<F0GQT8X-7G)IO$
M)\]1%P\XTMZS4-GSN%R2LH&#,,GMV&9JSBM3LTYU46L;IO.9T9S]O$]M]MN:
M6Z(\L!B7F,`'^G.(;,[3!#-J;*[0%'.%*"(+DQ%*4YO?9/.;;'Z3V?E-XC*"
M3<JAZM4VM%]S:+^947'#A_:;F1)A0_MG$(=^M%DE-A]B[,!T4<.HZ=FOG9%4
M:K0UW9\Z$LI\HW$W7^I/&<@!6)$N#869;QGIEZH2QHX_?]C4Y0C85`O9'`%C
MQ4F;(S"T)WHR.0(M=]A=[09C&J/E^K#^VMX\UEY9S9]9O`IN\#I]>`7^"\#Z
M7+PF]8O_#AST\!K*L2G9]^B<[M/2E[N#_HP*7.HS*[4%7<!&(HHB-KJTN>C0
MBXX96,9K@![63O``-N31#+1K/A4)HAHC;+,=8[)4]3Z'@+3.:\=TE5X*0.6Z
MI9D*O"),1:X9TVM>#08E7S8QO=Z$;!ROI$!NNE]-%CYE]_AXCC<]6NE]'+I?
M#YYRIO_VXHW\"+3HIW[:.?#H3T\7E#$44[&/=<B;U420_)&*ICN07N/$R1&E
M5#_5GM)NTPEZ=JH#AXO-U@]W`&\]]`)=P'A@/)M'2%XL)8E*JX`<@5D26,K4
M@?%X#QC5H^A`ZG/ZJ)J/[\Z%MX$!))-&GEC+5S$WO$GL6SVQM_B0`N635]?Y
M#'"#AME?3(@#;APJ_QL=7-SANX848<)+Y)R480JWA#"1M27RI=[81S6[7RQ.
M4N58.N4N-?<3W2^@=#Y,#^T9Z()LJ!R",I;I!AJ!NZCI&N0>_*8O3*%[K_$,
MNL@58[K!2AHU0;'/=.O4H+>YP*X^NEB)@6%6?JV9'T=`M\U,)Y+@U4%>2\)G
MLXVUN\S=[G+F;&&<&:2SPGZ#VE\.1YLL<C=A:F7&A)(5'SV08,/ZWPD_-V'\
M=Q#O<WH9HOQ7I!VK&,O(1!B%<]53]E'I,EBFIWPO&^(@]&A%GUPZ7/L/K:62
M^)-&Q[<)UAPP1K>^$]S!U3J.?@/D?QBT%RP?K\!%%,,-.6U+CQ$M&J5WGSKF
M@M!WXVQX%VNCB4X:N6;/O4::[)PQ@BXQ=I`E\(A/N.CN_K'-PLGY1J]MDW&5
MUBKOGNZJ-KGHD8EA0O;,OOUK0:>-9A;);6XD!1W/"H_\`OJ,&\;159#)!GMG
M9/I'$MO%.G=U43%)I)F[I=*,`D_H+!UD*"V8D3/U*HH2X)TGI.1D-L$I[1'S
MOF9NT8Z]*9%8:H,_8E4?L<<K!(PW@%R(?X>O%ZJ\TK-'G:8DJCV@X1`:9+.8
M;G8?TC'76Y@P'7R:)%Z'\M@6(_VFHMIYZWJDZ2_<*1?/&][:YKEZ1"Z)`<!L
M;N@C2NP<`$L5:M>87AQ-4Z!,.95VIPUC+#4]*F1F$\;P(I@>5Z%QEKIXR8P/
MUQAD.D8W9)F>G#30-'6UZ)B>S*06;B4F)]/K"PX`>7^_I.F5]88T@^]%E/*<
M>>-5VYM40!@^##;9??>(_X0EP7P)XH.X]FA18Q47PKR.@*Q\4A@KA;Q6=15X
M\`5ZB>,?+!J\D,AJ(26N*-VP_>5#CVI#VR80VE:M;/$`ED9[/8\`O,%-LN'7
MT6^TT4(E#-JI;+31$NQ!]C/G%*C^KHTZ?N!)K84-,S$FS*2\A6M7-4GG((+,
M.;ESL%APAT]7U8$4PN-J0_.IG:LG&:X>`-JP0F@''-"8U?AKB&_Y]`W+L=?C
MWLBS1_0.1E\O$0!7I$0X5EO&PI,Z[JS0-#0HCZU`<,.^6C_3&ILRCBY7-P&T
MPVAZ#(8-"-((_H&&T3!/U07\HT""_=+-GL)HNM.X#8VFDF^\<W;(L)/:%K2Q
M4'V`'/SVMN%5-KQ*N^MIW,`#<5./C0C1/C%T'=W&@'2>F(',>39,1/M681D(
M30\G$;7:,%,@FO[(\0)!IA2AL!<A(QJP<'][6T3;>%FHC99X!>ME9R?VM/O7
MK6?=",^Z+4EAHQ1LE(*-4K!1"C9*0?MJM%$*-DI!-YIC1BE8)_-Q.9EMU0G%
M52?,S+JQL0@V%L'&(DRPG(BYSM:1XSJ,/;!LX(#^*9B/T\T&#DQL8FS@@`T<
M,'Q&S`D<T.,)_^+\(T1G212'&TSLK8/B`/]_#;?D,>Q[\J836$%WX?O0"5P0
M*7C5A5&C=K%:(;#"PU5#W($7$"2@5C#J"_3Q,18&6&V(UZ&7-UC@I8=_*D&H
M%ZI5T:V2&KP]"+GPX0IB(>HAQ$T!?*%6Y%7:OVZ.'\)34)6L4LSN7N?3XG49
M+%P7;&.RVY;/B^W6AUD-KT%!8(^J%IV;A"CSRV?R>-R#@U8@WK=+M[=70M%9
MZ.,!0Y1=&7BT],*H6XWQ\9<_94<E4:Z#`6@.\.7HDM[+P:,"K5L4>HF+*=AN
M4?B2%V`JF[5ST[UK':Z1,U*Y#B`LA<2[EM`/:E,M)5%R*2+?C&<)0H<ST])8
MR9JZ(F<$.36R)S")/(KW/V^IM'RAA*IBM57'6LN!P?]`*4V"E`PV?HZ_(!F4
MUGI>M]GF$9+E2MG?B]QH*/'OI_-&>4MH9<M'$^*C4JC.PB"E[B&\!8B(_Y<A
M2@OO'K[C+,:M7-=:,`EWCH^5P>SL97'7;*0WV*P'U&+19KT'4/.FR1HB?!I0
M(P`I#92,^;A]1IBW7#JZ!%1%[+"13M,+3SIJEBP4/J&-]]+*7E95T=/FFBR!
M^F"F64_LWJ,'U_0_I<Q?ANINXW*%\C5QXR,.AH"4)YB;'K0P**`,),WT)@Z*
M)$./-MT1.`BF;183TWUY@X!*$:Q-S]@=]GKO[W(Q/BIU8OA73LSQRL-;Y!GN
M5=,?`IS:%`C[0"N5VBI]PA.CS'%8H6_U0Q'T64;D"D>K%LK@R'*;5GA:Y;#C
MJ=`:`E%A;*:RJ-Z!4E^Y=#/\$25B#`&JFFTQ9@K!+&(\\],UJ@2R/3E`2Y!/
M-I,1WQ%[T,S\@"2&J[*X*G/+2@',)0!T!`4_TH%G+JZV3/U^*QOF8L-<CB',
MA;'_"TKR%X+S79$>Y'3!CW8>R'>B9SY3LBZQY)%+K^2*@P=QN^WM-5+?5HGO
MH)D-AN($0SE^>1'D:S>Z`6U'5=M7-JS+T+"N>[C:.`O?0]!=GX5HFY]J'!JX
M']APKUGIJ.K#O8QU&G0&BK_!CM2H;^/D)FD<90MFUB7>#<E6<<Q\CS==QB\/
M2`%KC?FQF2T8==!HS0^_9&/&MISV"Z4,8\>?-BJ"VI^0@[9+9.0+0$_AU)=.
M!Y`.[+"FASIV64AL6U2_@,89;#OK0)T;J-:!.DR1G$("(4\3,G3?`0OIE#V7
ML79Y\:/V.A#"WYI?A,,@7[#F(@]*O<`E$82FB/O^!^\+13XV+W&!5PB/AS7I
M6:VL;]KZII7[IK-W;GGO]2CI>V:H3-!CKQT3,I<M>UU%WVK.V(9F7A7.S!(&
M2+8&M3R<R&?6GSN&/W<@W^J8<T8>:[B*H@1XYPF"P0K#!4,OK2T:W8#7]$_,
M]U7$/IX07VEEU(YL[7T[B:(K2L>F2YS\MC8>8%8FE^'=W,;&!U@W]R2=LX>:
M@2(C8%V0M/@/6DS"5*?OV,4D3'4$#Q2Y(28BVN(\2N$]T"S,=T</<A`(V0Y,
M=V(/@RS%\FT+]G2IF2'LK+/!AR/FN!L;AZC09LR6MZ(C#^SNCJ>0L]/T*BPV
MD&AVH"HR3AS1>YH3FX5K&\XE%LYU'K[B?X?W+@3D;U<!>5HWQK^";N+'N/,!
M`[N"('%\<K_F`LQ#R`_FXK6W`5PS"N#:6W1L'Q2]H1(:\#HZIU<-R?]B0]6F
M$*IV;"57]EZ)I]+9;*.%2ABT4]EHHV0WY5W>)T]^OL#**^%^"USX#-T[X'X-
M@]+T2-MA'7I10OTR``]P`RJ]\L)!`3W<A]54"1V8)Y<((RLBMJ46+PBBNA&1
M9'N4Z&`0:!3*=Z(EJ*QZVYZZ1JN_:Z..NX?J+6R0K7KN;)"M#;*U0;;S#;(]
MLC)0<PRVM4&"<S#D'0A*#9SJ<LI1(-$4RNI8[&D^QE<^;T&CJ:V:7[>\:R@M
MP^)UI`Y%&T*KVUUK0VBG&N)A0V@'`)5I>K.!M(I?@.D2,7N\$9T=3+'VD<LN
M88E<5[,-F>T`:1=?C`VI[0!TX:BV`;/=KBI.F;<.4;''>U=UCCT^JNQ0&RL[
MX8!"&RL[1)1F93JV\:Y3BCK^:&?!1AU/)NKXS/$A!BN`SE40Q3!.8H!QNP,K
M@#_#)+Z`+\"#+D;PEZM?%00=JW&Y+ER7W!G131B#Z#IT`L+<)0PP2UBOR;1T
MLI#P!KP&*\>_"#!KN^5S_:9IB;!0.H22`+%2]#AGE`!L-E`[9NW5<L[`52LU
M@=_"BY,=JRS=AY;P;V<+8TSHMUQD7SX_!MG;V+<HW(*TM//%F^LG7F9[6FQ"
M_+MOZ?X[W>5M=DN$?_H'<&->]/@`(YD?Y,^@N4CUQB`E9/'7#(1DB=$N+!KE
M7;I10O]G?'G&ETG@X1,M&YQ&'J65EF#QZI0EYVKSI.6&0(E\>6P!_*P@9'S;
M!:FC*_,DY%GBT4.8X4>-.6[[1@>V^?G$1;/99D*!?S;4U8:ZVE#7682ZMKR+
MF]Z=G*>PJ>UL$.L(%6,?<'_.%B0Q=''WIP#KXVO'=Z((;*##5B=$/M-IA!E"
M,VZ8P46D,-,CC`94U^I8[\DPIJ,J(>!7WB]I"X'IQ7>H@F^)E]"I9\-?]W>B
M#7^UX:]'@#\[RH!F*;(AKUU"WB@&=1OMV@'(3K976T&VSY(]WRO`:2-=Q2.*
M6^VJ-MJU4X%8FIG%QK..&4=HPUX'B",T-#ISV!`AM;8O&W\XI:@Y8]6U@4-K
MA[!4VDA&&\DXP4C&7\ZO+O%)[J7D7`6NC5:TT8JC1BNN/=A8@)R@1$;3HXVD
M*XZ\Q/$;DC%>P80(UAH2^4Q-65H\5]%Y`MK?MF>T//:(.6:\610O,$`>`4D<
M9)'/)A3=<DSQ7`<6!OV12S9&Y[@*S=D8F*E&:[`D)-.#,FS$P41MM6Q[.$L8
ML5YOE2Y$Z_!6%#E@_=D2GBX!7=-ZN3MYN06T.>OH'M,[:SW@RH().CBZ9U&6
MR#IECV8RK.MI$-?3WQ)\6$`?G$/,54QJFF4PUW5=S'4F7V"IPSJFCLPQ=1@^
MG9=HSX2C3;I:N19OR1Z44"VYK-GNKFX=69<)W66"0A<`+ZJ%._\6HJ_Y>0T\
M`>^)7`\3<D!81XIUI%A'BG6DF"3Q=W&D=+R9C]3T8MTLTS6Z,#T#UKO2(SF3
MKUU8]TL7V[:DV&U=,P.88#OX8JP)UII@IS09U@0[B`GV"W37#O#_=AF^54(P
M1@Y_^!4&41B4,K*UOHYB?56$43E9A7PC7BQ3[-O9VI1SINI/4C6N3U9P.O<;
M6U;6EI4=8'^(G\YL)X)T'Q.R]QZ3W=H6=)V)-5\[)K:@J_5Q6!^']7'0?1SR
M,H-U;UCWAJU;>83X6_?2T)E0?$.#=2@I+ZEJG4;6:30<F/P2=8)&5YMD,FP)
M0#,+*UI7Y]%,ABT!./-9."J'\\+](X%1>O'A\P"@]`V1R3B+3Y,(3T84U:A,
M?\17"->$VOZ=#N,DC2JVPX#5>B*4D_3;Y7..JI=;N?#NBO">RO\LP9E0;Q/A
M_`+_%._24&.`R;J*H@1X2T3^3TZCFX2(-,OG^S4^`O._B@/1I?.)X-+F[.%^
MHI.'LW#SE)=!P+="!#V099RG"S`[[JG3@N^68EY:6%8QPG00BK%0F=V@%2?7
MT'F"_N%;J7UZF@C'48LCF_O)1'BX!U@@<V+@[[`V$*X"4AJY=KY&11$%O."N
MPR@BN15%,W&N^PRBIIYF+K_PJY`>--(Q1^>Y'/G@O!4+'H+H<QAZK]#WR;['
M(E^P@GCG+S!4<?DGQG1T[T\']Q<1UA)>S\$VQ/<`%D:?$BPH$ZD\RHM[8*D\
MK\)=NRT^,'COVIL.SENF4>NL%(-CA0B&>,&X"#@1.`?9_ULH9GPTG>",JR!-
M9HCD8E&JK_2&,U"$I^BTOIS%@A8$N]%I%Q#6^:HR08?'?O68HYDNKQ95LFX)
M$<#3=">KB++2`EDGI<]TQVM77)4H7*:[7V7![2Q3F>Y^E06R57PPO4JB+&"5
M3&MZ+)HL,CVT/-/]S%T7&4LY,=V#K.:N;3'=]:I(/HOP$06BH)CGP_1'#16L
MQUY&R4K#,UMGX1FBZ4'/HJ8"T[6^KL:3-N7YV()DE*)G@ROND\W&0;OE\T44
MPPU1S"X=B'YU_"3-$*&KPS;X8H[!%PPW%56FH(IF%PX*PB3.WTVG>;,Z]S61
M.3`Y:(#EKY+J8N(\VL`(#6$"\W=_6\=67\?6\;@4K&/+0`>,4<:BGE*==<!T
M7J4?^GICPMCQYX&>-01-S)1A#4'6$#28(>@&Q)E'L/`S6`O0'"U`UF["N<8J
M=\Z5A_<>?(9.Z0@OECWQ_52><_RW9(-_F381U[/[#C1WO,Z<B$2S$)'^Q?%)
M2-`(V%$&G3V."2*W9=:REE8]!IJLH0W!M/Z'/)L=ZT=R%L0!:9@[RO1`I)LP
M<#/61P"YE82Y8US%<HUQ(-1'FSMRM=^,@%Q]M+DCA]6$$1`CHTP$*>ME,239
MS'J`K`?(>H"F8%M7JE;:K)P!\6:JG]:#-!SJ#;'>IOX,DOICE#=X2(MGOZR@
M^3@[=6#<;B/IEF/T4X9^`%;$QV/Q[V$)[):?9">@@QFF6_Y2$^H'>^"T&F_Z
MY3'-!V`;OC*Q``P;OF+#5Y2$KV0GW6$02V1#5FS(B@U9L<[!8W+<<,9>!N"7
M)/"R.7L`P0,"3DPBP/$1ZG];`[@!")^YI)P%GS[YC@;BX16/N:N-7CY2UH$-
MP;YTK.9+&,`87)-G@/;KM9SNLA>[?0>?6^R36::'B7%847?C;/AWJ&POUNUH
MW8Z3T1.LVW$N9A-U#IE9N1VL`:4K@AWN[SJ@TI?C$>/)DQ8:MTL'8=CTT`+U
ML(K*YZ:'#U@+JF[TI([@(WKZS-JDU=JD2V#OD^W63\L?._XM"B_)*V;V,3-K
MFJ;34JP04ID!!JOH%J"TDONI$T%7G"5^-T/5#J,L;Y:IO5,7(])-,[E(?SZ1
M-145!-Z`^"K`1QD@14S%%Q/C>VO.5V3.GX;5Q!KBK"&N"UI]+H,6"%D'EZGZ
M]X!0ML@5INK=76_\X]:W^Z#6;0V/J25.VW@NC_UX%XL>_;I\*RA+\$K?P"E#
MOFA_U*%2+UPWV23IZT;G`./APA0-_+,/TE46>(M-B&+XS<EG,R7[UG>"N$$[
M78A5UKV6-S:+T:G2,:N5ENB#!-^.,;'I!-XE?",_15RB.1_HH/^:V-+7H>]=
M;;8H?,D>W>(RP/M"!P?,E7NZ>\!C<PP[(E].BJ//B*V%MWPT*3Y8)AZ)#R?%
M#[N2!?>32?%`5CS7E"ORI1+C"'.@QP@\)_XU?"9G9Q:FS;#D=.]';UP7&V.A
M>*Z6SW4*LQ*G=%V3$EJNIMI)Y,]1(>CR6\3T=/!NJ*F3RKLEE<\IWU/QNFRF
M%!J:)"YQ_S8>R-U7B$RWI'?$B:>.F6H#[@D95P,TVLK;1]"D1ZVVR6^F2RJR
MDJS0O5"7$(TUH`^*H":S^72,OPO/@QEIFN.H),7+>X>[$M28?ML&T:$2B]#-
MX%[H4RT5+?$%3+S12Q+"O`V+^#]N07C^-Y,R(+4$U;1_-REN,K@=7]I$67TX
M25F0)\>(;;JCU3QXT(FLHZ/5/WC`J;X03558>H'<<O.,9PG4(Q&>A9L-3-.(
MHLD(@G6:`J]\;,^%(*KE"?"O5+D^E/AF[M*DA(NW+0BB@VH@M!8Z]THGC,N(
MFGU6Q[OWM.^2,E;F,B$6M"\P@)MDD[_Y&#WB81!!D\"6./[RR8>K+#S)[J2A
MN%QNTP<D@U5JKHNH$W.>L%R$HE]/F+,S[F,ODIU,F,^KX!*^@+\#![%4CPX=
M39O?,$%J^"T[FC2_#WA4-1-<ZVG:'+^&:O@M^IDPMP]K@(#S'#/CY^3[F:4,
MU?5X-]V\,!:@]5UGNN5A1$QK9[?IIH;Q4*U)`*9')8T(:B5&]GK?PH)*O=O[
M!2I93"N-M=O+%%U"OO085N[CT/U*`FSPI!-S;;R;C!5R\>H@KR5+HME&A^2=
MEM=9/J<X<D/4*0W5I.OCO1`&:;<7;^X:SSFX(W-&LW\RVVI!KB*&F]-SV$Z+
MT[_<,LMG3!$QO.;5%E/_T%D8Q5&:@OR$#Q2O.$-:3'L].]62_;;9^N$.@/9Y
MH[74E:\7[ZZB*'$"%Q29XHL->0&'13KO$R6[]@;$MRAT`?"B2WRUE4,E3SYT
ME\_XDL&7$VT+BWVH)5S!=P)218^7U%9OHI-&?C)1LY&>T(]<SD@W3[KZHD42
MK[$(\:VZ[0_"/K@?J<E_2A"^-R)`,"I6&]X?,-PGJJVU<FK*GX6HV6NM8X[S
M0_[60?&.NQXI#773^X`<?%6YJ5_M=%?_"V?W2W2@AS]\K4(WSO?/8P#CZ.[^
MD7O'\;_1DJ^7!J&DU-PDA`K\C_0D(#<%*1)90Y[!E%07>G,2BZ(O1%:JQ*<%
M0D2T386ETUW5)A>@,J5!*&FQ;_]:T&FCF45R^I]?\8HN3^D/+(!4#C%;C.[@
M:LT,CE4YPJP0RF7G`!^,2;I#EO$:H`>L;"Y3@T?T&7<11U<!]:(>?7B3L?T-
MD/4#O,4+0,X*I'\\QQ=M^9*89O#;Z5,B)0['#MFF!3-7`98$@@BZ-&3UT3&K
M]7W=4GM#0<>SPJ,0ORJ;K*`J..2(LT1P+-R&T;H5D;5,XBAV`H]A6AI@E"EQ
MCW4U@%Z`=QFBS-]3V,X&Q((]YC20R>5,<K4XOD])VQML&&VGR%,['T_[?.37
M[,4;0"Z,B&;7O&6Y>M(P`\[J%&ZR`TH!,'W'G"LXC3JTWCU94KJ%*"N("=!&
MZ7:DCS`)KK\X;\3W/A3+]>ZGQB^^&^ZWP(7/,+<B_I*ZXP>&@37J',^5FL0Q
MRF'"'F^.Z)'+.7W6BJ03$5/V0TA^5;M[%JL52FL^C8)N=WIF)5.4'B@$W<S]
M7T0YX`O*/93$1AA0[\G82M_!D;56?U!V)D(O=I5)G=#HK-3J-(>]3X-;DGI]
MX,52VO64^%P&]\`-`WPR!O`%H,A!NP%9IXTV+30>UA"-!L;!8).\Z9G>R"I.
M,O"$8F`&&4K-^J&<OLO7`$_+&FY;#D#!3[7,;8SE&0)B/4Z4$TS!;J^'>A+5
M"E^@!P(O"UED$TYIJHWF+*3A/*DBDS**;L!K^B<N%^T?:^,KDZ6YL2N'[=3L
MSS3X;.O#.`TM7@8U&8JZ*7GME5#T\!H^K,,DPAH;.<9C`++>KP*RX?&)3HXI
M]E-G,I\KH3>M8?"*($G$8)-%::5CM3T&J'QO_L%Y.P4!>(;$Q>NB-+7B#D2)
M3ZY2$JUZ#^(X>SPT^@W&:]P>_R%WEI"'Z!DK5>T8.E#:\W0WG02U!7^?//T#
MZ[P/X1W8YIK($IT1AX'O\^K*J>M?9UH/->.C4<QT$`'(],*G[!25.K:4=(P2
MF$]=DI^F#XR:G`YZM=W>D8FFKTI:ND"C:MV1[5*Z6E96?)(28JJ-^].18<5-
M4RIA^=',\@WLC()R&=%DRVJU_-EX6,02%^HKB0:JZ6>1\@#[1E7-II1W1%73
M!P"S>8L66-J%V05+C@FN`/:C!;8#L#('<('T)XMTER6L(/+:_,>+U<6G-\ML
M\W-V32\>-@RJHE;Z7F7$7@!Z"H\37WYU!-/+B*G%5*:R@^FUQ`8Z#:2RFTTO
M+380Q@-&M)E>F&R`\T1I9'6_<F;'B;]HO$F%K9EFM"FM[>ZQHM4LF6D:G](L
M2>0ZE-/RP:J<DE=UEUYI92RJ*;#ZZ<A34%9;J>;`S&+84SJ=*#'S%?Q6W1WI
M<MA/=ZRFP.K%(YQ"[/H(U418Y7GHO<`ITU!-@]681]P/O(HKU918)5IP9["+
M5%=@6JU9])CA1MA7@%H%5Q!07E';$LZ/5C'M`.=^5=X*3JMDBE]G"M,'J@FP
M&N8(\H14Y9MJ;JSZ.=[<<*J'5!-BE=$1'(@"9;:J&;%:Z7A;I$>)F&K"K/XZ
MPH1)5U^NYL<JL].;'X$*SM4$6@5Z+#L=K6QF-0]6[Q[+=5,4`*HRF*R2/B[V
MU*)$U718)7_LZ3BLBE3-AM7XAYZ-7B\&5!-EU7_)!(&#TD,5EE9S%\=2<3&7
M:A*LLCZN"YE3Z[Z:E"-5R'L4R3LX=YIEMJKZ`D<JABJ"MN4EO@IF0P6:ME*`
MC;(]E.(^XY4GF,JCY??)9H.%W1R';%<NW!A+!?%.Q]OE]K7HX5T!5(P&''"2
M%5_%_(Z$G4Q`X,&F=)R9H[5G>"W\MVF^R?`8<D>?^3[>X^T.D#L+:PYG89">
M4XGCDTC@$3:X,"5S7,M8\G\&D(C^@SVUR1EICH@U/2^?41@I?X:0,](<$;/O
MKBCB9M"[^7`<BY;$.+]_G#M>&F09T=$ML@.-KG/5]I#.V-RQI+./`\F)72B9
MXVIFA';5V)_$ZU\"])B)_J"7G?#P9F*KX?CN2=0<SW1IEL<V"2@D<)+[A.F5
M824G#+$OU!(Q2YPIAA(=2,N2,4NLN6&TH\`L0<'D7K^J>='*C<DT'\IW9-B;
M'^HM&[U*Q6XS_&,'Q=/V<T]O*J@FX%Z596<0;C#`-'0X6[I5FOTI0SE(]4'O
MZ'`>PD?4K3"MG0C51N=^U6NS2^`BL%,QF$6F5RU;.S_J(EIZ%;6U$S&T&Z17
M75PKS(ZC`YM>%G>"TR-I=C.]0NX$9TC:8&=Z"=W9WD(->;I+;5TK)FCRPO4J
MR6MG;>A(:-/+]0XT-6.'R)A>S'=ZTZ32ZVUZ#>#IS5ZG?`73ZP)/[YH2*=W7
MI:[P+-X#G-YT](@E[%6U^+C%/#7''*?28@=[@^0&FG(:<:,<OTTE[I!*3`I;
MI-Q]^)CSEI:ZN".+]()<KD5B?X-4>AMU(U_"%]`R<*V)PG'#!+6-6S51-^X-
M#-KXK351-^ZR==CE`*/>@Q<0M(Q;;Z-P9/C6-F[90MVH#ZW</@S`ZP-NTC:[
M]38*1WX-V\8M6V@)KVMYY3V+A:E>%7G$-QFJW3JD2$ITNFM86S*VZD^_[X?B
M#3OH=`)!.S-2KZ(B%/#9;Z29(7;(1;-&CSK$F"--)\&A(Q\UD3J7'WD&5+F4
MAI%(FOVJO=XOKS;DPJT&FS]NX2M`.5,;R-(=!AUR]A@6=?@.-]T8<')&-P;9
MFCZN`5G*Z+._LPYY&B3Y>GSJ9K_F'[?;L4_D_2$-LY@.K)>-5WI14VW*4?3:
M=J=$3PVPF*8?[#Q-8)ZX$GPY5>;.U7`VCL$F:/Q2L[.;FS9K2EGS>]],WBO[
MTV)*-1*;GL0Y'J9UDW^WI$V+Z@&J=:=@MP1,"^HAJ#4/;Z]D2@LJU;W9*P'2
M8LIP5O?*9K2H,D)+>B4A6E3I822F)PV.)U11MK^A:7[#.OJ&,TCLN\9,3_6;
MZ3P=&,Q[9?W9>1IJGGC.O%XI?W;*6N/#-7@)34\3G/DNI`4KF)XR.--=*!U?
M-E[RX.2R."CO".I\%*YZ!)$=A=ILHR-^8?[Y)FIP:'F$DLHF_YLIQJ&+5$/I
M$W(NWK^2W(#.&8QM#W=+OX>@G9SIQ#ZI>#<]+\4#O*$>,^M`@5D(-ZN%C0[O
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M1M&9@]`.XTI69X2IQ.L.NH),B?0T<8[O\0HF._(:4^/W9[O9W21XQS^<X7_#
MN$$H/E\`/O76HBRW]*+$X=\RZ.7>H+RIZ]_?).:.7*K9!>/[X:L3N*P0<9$O
M=7!T\?P,2#9(=:#?89#O@!L&+O1A1F%\"?!MYOAD`A),R*[1F,&QBIZ5K-I\
MB&(543<*%IX@2DGZ.VY$6ZL=>M$QGR5^U57=DI7"^T()_C51@14_PFZGF@):
M&@>]C=J1B70>1/R1BS9ZUHT'GK%Z'@,?;UD/:PU8"(08A^RTXB;\B'VK!$_V
MQ=Z^@X6_U8'_8X#PR;@*2!(D7@JG(,"0$N=:OC9N`9:O8XBE[8``#!#1\5P7
M)8"5I="G1QT('%Z(I[O]6Y.3,RC\^31XVR?M;$WTTZM@L0F3@'542W>C-8*)
MJXW556G!L\?T(A8"5W=I3SJ\T4R-R6H5(0XQ*>]:4VN("F&B5,(WM7*H%))"
MVI^IU4"ED)*_[TRM]]EO@8D8`DTMZCD4<GM6*5/#`<3O37&=RE2O>[^EUF:_
M-=6]+;["^MF-374WB^/7Q8)IJI]7:J_VLJJ86MR2:Q+E2W$LBXRQ22RM6'&6
MH_EY);(F.]XU.GYBG_;`B2HSBH2J.,$N.K@HM51H2T=N\1KM-=+IC+TCA>,/
MJAFP6@WC"#]SMC!V?'+/,!SWXM]-PK']&6%E0-27G36>!-TW@%E]C]9T*C2W
M50[D?3()'MA*9/^8G8EP2`(OA9E)&T^"[@F&%PW':?&[W`70"`$-O$+^I\>(
MDIQZ"3AZ#S4)S&8?P%2CZQHZ3]"'1)]K9Z+>>#IT?PY#[Q7Z?J:/-MR@4BSQ
M^CFVL"0U'-3`;:&<UE)KA1:J/,\U:38D$E/M(#WPX3K^I,(3YI2WVVTA]7W*
M(L3ZT=QQH1X>IC\'(:+G=/3AF>MF5P:>N%>JP^J;1;$.40@E+#JF^MI5KKK^
M*IBI+OF^*)>&SFY^^#F)&OWOCLQ:8ZKO71E.N9VWGX]]^B*:8&PM2Z+KY4R?
MQ67)46\9ZT?4:F%J$*X2Y/I&ULKL//W^SN))JN+]J;R8Z4-8^#\9\1HZO*#S
MMUBQP*13SVH]6\HUO4#!H.8<N(A4XR,:6.(3I?82GR*W9,]FA=](-%(8I844
M)!F5ZWI"F.`-0R'\+$'DR.V+BFSGD\=%R5J1ZWI&$AOSR#B.TK%JT)+>D*:F
M!8T!*W,_FV[:5`.JY(5J?E55-;".7]Q4CUJR<%V2>!;=.CL2THLUUSSNNZ:<
MU?25]L9:(C4%Z,I/;U88IT0/.B2D0_I2PQX%?E'^6-]/@#NIJ>HV*XQXUAR/
M,]P2NH[_@*#C<RJ6\)IKPI'0<XO"9Q!%Z>%R"026/N\CO1'-09P[[[@LL-OK
MH#Y?F%%QB#A^6Z0,[PN=5ZD`)PUK,6,;FV[Y%(2I_80Q78V07T_<X\QT!4$2
M+LZI:6I5`34'%4^:,CW2H3=R'$F[7_S"]%TZ%YNM'^X`R'5&4BMY,C6`]\)-
M[D`,45KV6=B-(].#)B$1!B1LAA3V?DH(F60&2.C,7:G1LP5&@6\GQ%6^U-`7
M)\:;.7\[H/@[0"Y7-N[:X83X_^*\P4VR600!/J'J?XPPL<4^Y-:,4]"Q$A6S
M`#[B(.^LP$.851[)*8CJK6BJJ(IN==Y#'<ZK/=FG\[8Q73WI"*VZU6JZ6C/,
MVI4Z\DQ7A8:!>%]6&$]-TB.P_G?B($RFO[N$@1.XT/'/G=@IS?OT/^N07B\<
M1%Y((BN]")"&+I[W<^@G,5.J:_M*ASQS`^+,(77-KB/0;*.#RC+#)#=%L2@]
M;*>#VCS^FT5D^6<=M-T#/WU]Z'`OU13"%LU+K@^MCPQUX;;Y>E`QE:9+8;VA
MHNQ1TP6KWICMG;ZF2TF]\6J]=\?,EM,C(]TG3Q'X(\$#7."C*59@T&,8`DY!
M[#RL'=^)(K"!#O5E"4Y#/;G_;I;*%C&#D!M-E!A,OD`?1'$8@/R-NL+V3(.*
MV58))=G+N<OG(@_R%H4KY&QHA+":ZA&7,AK(/L;7K1]NTZ?^JI<`BX=('T*\
M[\DBOPQ1ZA")3G?I.X#LUR;4]#TS5`C=W#?UU/2M9,W>0_>K#\Z`[^,CCL0)
MLL\95E,M8G3S%+YFO)?4VGP"M'.?#**WG0#5;2$KS.83H)WVMA6WZ11HYI^S
MK-83H9Q[&K+;ZY25E=Z*>P_BJKA83'W'9I#[M_17,(1JTZ,XA@&3*3N87IBB
M3?HH$6)J!,9;LP00HFN-QMNL1-<.6Z\UWDS5(FK6%P]=M#/]<N0)M#QT2K'$
MV(<(9!%2).85>-H5QSS>S'_FH45E:]F8QR+8MZJ'')P.!4R3`C%NPAA$#V'I
ME$G?=TJO_B5:.0'\EM=^"Z+0AUX1ZW);HV3Y3/FX%@(3>/=P%<!GZ#I!G,=J
MPV!UB_MS(1X;$W[JA^Y7C4F:-7+:GM9@?Z`E1F+L.6*$8(Q-AM:*LJUKIN$A
M'WV&QE/SCO.<*GYASRMY^HGO/BIS]@NJ=ME_VTX9P8^U\)5$6.B,HK-P\X07
M6181F]+%XH7]@0[ZSYR(:"/D?Q=_)/#%\5/E7VA:Q+Y5XC@D>A&>]TQ#BJ`'
MLD<5^73*?*D#^_WX%C'4V[[2P<FE`Q&IO@^^`(<<J>2$E=G@XM_KX(Y32%.,
M/8D.M#X#(L8-L[D>VF]1Z.+SE&Y:X1[%8M_JX.J+@[Z"F%@][H&;H#21E<L*
MYP,M12=0N`4HWI&TAABC2JZ'&J9M*TSX<R5WRQT@>4/^KB9>("Q_)H&;28H"
MEXQL%],),<K#=[F+2^1+C9'W><Y,NSP@_IV>6/T5@?4.;$,D*R"+?:N%*^J+
M`LMMKJ;ANP33#5\`V>K\(ZY+3_.Q%HCJ1Z:[<B51XVA?IKMVY9`2U/-,=_;*
M@<83PTPO8B.'E(0":'KTDQQPXI*RZ6%.<K@)R'[=WN,Q%S`!\=_TAWGD(.LD
MN_9[L\<T"`7-,[U>\C$.-!E[H_'/P`HA)^4CZ/8DK&F0M1M_^ST0:QI.K<X:
MTQ^.E;P[Q:Q9%6C'K`QT,T-7V`VM$$PCW(.F8];".#J&DS&<`L*#4;P!PM_J
M,,B6H[?$CQRVT[F/F%27VT=\PHXM3$H4F33*6DMP4TEA_L)G4"_@FU/M+8,[
M8H1#^&#$#6Y"\E)*]L_4=IY2+QQGH&X@K>$6?.I3<A^#\"D"Z(50?15LD[3$
M'%XA/DR7GS!B*H>RYYZ2<V_([6.ZGTD.6*7[;#S'U#3NGZO@!41Q_N,Y>")F
M[LJS0@S>\:[RKQ`G%4"Q`X,'Y'ADM::+NK><IRK<J.0EY^2`_K;G:(4[T!-.
M-=!<M:*A=CB]3[[)KI&F/6:H&3@VN7<H)/7)R8L7!_ID],L0W3MUKW3;1A/Y
M4O-Y,]YY.KLS06C>CVU[5SMS^5SWS^7/UZ<%'BH/7E'60*OT($SR4YWDEAW0
MLU,MSVKTG+J>0#!ZU7D^J%D9C2+S?3&VYXD48/JD`GNJY"XG=PV\Q-\CF%!*
MKLW]F:L5W8@6?DI6FBI*#_I(^3U-H[2$#(UZ:-&+^B%;Y!F6XFV0^YADT";(
M7>,6A'9B6,F.V"A*-NF)(&;$'7+$*2*8\I%%'46#@28YB%EWI::3PW0;ZY`3
MI6:KF)XC,/X,]#KNQ\L^F(;(>1;Z^)@.29S:"Z@=*Q,Q=LN01[]U9'J8716=
M%@E:3=\Z3P^EZ#22D606UK'IH1+@Z-,YSTB(&D!X#<6[&V?#*Q9.;6HW.W>S
MCYI$O<UOZ<4*@;P(97/&6EZ7$/U>KVZ5)PS=AYA:$/T"'#]>G^$CL#YSDII4
MAR[5O**QA@BCS7D[H]%`T<L=JXVS\#T$W?59B+9A%ES/>[^#]X&6M5!LN.NV
M]SL.&VJEE_N"1+.1WE=1V7=",Q--^,0QO3KI8!+6_MHQ'4CI6ZQZ5J!YF)IN
M$>@!%/\&,+UR`/OVH)M'NL@;IAL$Z3=:4S.DW2&FGU[MN-!6WY@ESJ>A&E/*
MO4S$5"9(&5V&$_QX*N5-6U1A[B<Z=YD(+RW%A:R!2G@7ZK--%?0MW#\2&&6U
M05!X29[+K;V:*[HI17LQ:G=JL=!0$(].=[5_B5MF)+K2RS/>7C`&U_`%')1Z
M2*G%Q\@BNL724,53;>;$`5$UCFX;7EKMYQMFPL,G$7R&A.P&$XW<I]35"#QI
MLYZ*4>9TTW7;@Z9K*]U15+1.3;=%=`=8V;%INM6BJ\PK+#L=V]M(S'I]$U%$
MF?2UR(7MWTVJCKBX<BW5A<ZM*CQS0N4CK:8JN5GUZ:M'LF4[;U03M^<1;THL
MBFQ@K*9XDZI@II(BD@5<E!$DU;IJKX3Q-Z-<'UI>>N+CWLK6U.[+3K/6]#7Q
M`;$;<QKWXW%LSYIRF\28F"]8Q=TDFSLR_WX1F4]>@]ZF=4V#U35P(B";_-.G
M[UEO=D7P'MN9D*9QK$,?<QUE%0M(VXG<VQE!+3M_KY&>0#Y1$!G;5_A[G5N4
M/AO-(`9A'.P^8T"C[QJ>S6ZC9*@U<]\P<="-098M^!A`?*>0U+6%&\,73'WG
M?-H^HTP1J?2WT2*)UW@+?0/>(U[RJ)9BF;Y[<+J[>`/(A1&XQ?R".Y*NTA<\
M!0-/$L]:=JK2Q2;0\<1O!@7(F>Z.5("B@OULND^R/\K2]\NQ93V7+TY,1(V@
MT--:=([]A=8'G&4J;W(^T5LIKW4VJ,^76#6B96OITQSFO\&J,_\\7T&8-EJU
M;4EQ3JXW+9PGFXV#=LOGVS`/![L,T6]KZ*[OX2J`S]!U@OAL3:2$J^"1%!7/
M(Y\P2Z<@`,_X]KN*[H`3X<WRY.]P-Q$4P6CP<6=TR'5>?J;+Q+(X#K^8CZVX
M>_Y:473K[,C:P\L1_P8EH+XJ)R+G=265?D!U[4U+3$9&8U00Z?AM:0*\+[1&
M8;1STBB<W'7*CTUP[`B4QJ"I89:T%IE2!'Q)P;)#ES/:UOV@.[:]?0N"*"LI
ML8S7`&&A)48@AME#8(58,Y$[NFY(PP3?E73*1'H(]Z#E+NXZ&XQ3K6MWFJ,Y
M9&>Y$579&<)CV_K_G3@(D^WORK]1LS@T;`,N9<*;7;87'1M><`XZ,#B-S=QQ
M)NL;6A0BNWUIN.@3PH]G$U<2)W].Y*1TF;YFOL4[`GAL._X^>8K`'PG^\>(%
MZ'ZN:)^8EGW,;*[';\$"4HSX:6R\MAEH&K>9'&O>17]Y3X@E)>;Q/_X_4$L#
M!!0````(`"J(6$1NCXJ@Y1@``.H?`0`1`!P`<V=M;RTR,#$S,3(S,2YX<V15
M5`D``S#!"U,PP0M3=7@+``$$)0X```0Y`0``[5W=<]LVMG_?F?T?</UPMSL3
M69&=I$TFZ8YCQZT[=N1K*6WO?>E`)"1A0P$J0-I6__I[`'Z!(@F1E&136;XD
M,H%S<#Y^Q,<Y`/C^7X\+#]T3(2EG'XX&QR^/$&$.=RF;?3CZ,NJ=C<ZOKH[^
M]>/?__;^OWH]='>'+CACQ//("OWN$(\([!,TQH^<\<4*C9PY6>`7:((E<1%G
MZ/>/=]?HY'B`T-SWE^_Z_8>'AV,AW)C)L<,7?=3KQ0W\&HKR#KTY/@%IC)([
M'C#W'7K]<O+JA]>O!KU7V'T#_SA.#[O3:>^52R;NJ^_?PN\?#*IS0;`/#)$+
M<KY#)R\'KWHO3WHGK\:#[]^=OGYW\O;_S-I\N1)T-O?1=\X_H?++USV@.$5W
MQW?'AN+_C4:<2:B]6&*V0F>>A^X4E41W1!)Q3]SCB*G4]D!@9"8_'!DF>#@]
MYF+6AR8&_=]OKD.['?W];RBL^^YQ(CR:H5!/8IK3/F72Q\PA!HE'V5<+A2I6
M;C$;R9%$8@W>OGW;UZ5&[4#V9A@OD_I3+">Z=E305Z;JO1ST3@=9*G^U)+*0
M3)<4T\G9@B<T$K,97G`-%E5[<)*IR\`SP:)8=]<7?=5,'RKUH!81U#%)-]/E
M:%0=UT_(3#._[H>%1FT'<.N+5;:Z),[QC-_WH\)B$SB!$/`REI%&I8KV)$?K
M$EI,!@7%K9%'9UY,HDJ*:2B[)](OI@K+2ISK+T4QE2I1-`.#QL=B1OS/>$'D
M$CMD,RJ@6UH0YE]RL;@@4QQX(.*?`?;HE!+W"&'?%W02^"13(6!IE1\5E_>8
M,>[KWD/_K9XLEY1->?0G/%"OR#O!/3(&J"#UX\O=5:&`?M1%]E6E_@5W`B4B
M9NXGYE-_=05LQ4(W=H2H^^'(6B,1(!;!)5/*J!9U\'*`>B@F-W\"*Q3R0@:S
M]_UU#NO,`^C+A^Q'_=O!GA-XFO`:_HZ(HQHVPJ6`KI'Y#2A3R<KIHJ>Q)[9W
MT`@DU2`:3B\I@YZ68N^62RW&N8>EC+"D7'4'!']4)+![[A3<E3!":CQBDGM4
MC5TN^H@]U>.CT9P07W9N:^ZV6PP]IS\G/@6[U/:AIM[@R%?5'8F^RXCSS\ZQ
M&QQ[!?/3!2EV6U1F=\YKFW.2`HGX%`V7:H(+9-W[MLDM0T"P4%-B0>:$27I/
M;(XJK6UWW9OJKLLP1]=<=B[<Y,+1''JB.?=<6(1]^C.`B<(9<^OYM1X+N[._
MK^[LD<^=KU&S_T!APYV[-[C[',OYI<<?Y!5SJ2".7^S2?#6[VWZH\8X":Z1Y
M=\XJ<M9G[A,YYLED)+7>4,PPHW]I15(#PQ_PNMT:2AHSF93X@DK'XS(0!&J/
MZ(S!O,;!S#]S]'J4LMDM\',HM$T>_8\>O%L&-%HDE!V(;]7B)^$*?YCRZ=70
M*%@LL%CI'B1M$:5-HKC-#I_U\'F)J?@5>P&Y(5A9?\W%]7!5F9D5#X.7ZWA0
M?)%FC`S.G:OKN?I*!WJBGQ=DXL/[>X/%5^+CB4?"L7A$G$"`R$1"X3D1/J9L
M++`*,Y])29I#8V^-VZ$T6(=2VB9*F^N05`])J45AU@'319@K:J7NB*<F#^=<
M^E)/,#^J],(M7FFJ>H#9M@T[+D[6<:$GICW-"YG-=="H!XUS[GEXPM5B_)Z<
M"0$L=$'3?J,./[O+3_-=P;^Y0.>!]&&)(^0+=(N%S^#7G"YE..WP5=9L1AV5
M.J(J%M1U%37Q\#&0E!$)?EQ,H%3)U10*%5G94?!J'05G#HP]8>A0KW2((#/"
M2.?G>GZ^%7P)(_;JUE-+`>:J$7VYS8M?BZ'=YZ_7?1[S#C,M,>/.Y76[^L6"
M^ELM&#:PL+OUS;I;#6Z=+^OYTHS+A9-Q5;>I6ZMSLWOX^\)96A<^W'(9J$*Z
M8_S8?"EG86!WZ`_K#@UYJ7U)W=2JKB.CZ)>$M8]:S\(8"4]$0-QKBB?4TRO;
MICYNRMON_ER@+VX&1>WH`3EJ"1E-=="H.1M3V1L=SM4IG5M8+`OBTS!N]A&F
MMU/:?-!NS-P*CI-<U._38NGQ%2$HXHG45+!#0CTD_$\`BUHBO%529FPIJN?W
MBJSL7LX%Y!*N*&&++K"/.T?7G,$%$TG^#.#GI_OZT;9R:KL[\W&TA!'2G#HW
MMCM?&#]H9=XP$<X.PEQD;XO\(?HN_M5M\-I3*G&L9GK5`%>3I1TFN=!?<5H1
M?1=RZ_S?DOQB#;SL600[OG)AQL)<8P>OYTDZUD#1;EJR@R47O"Q+0'9XV7\F
ML@8VZG.UXR`7XFR4E>Q`LM?T9`U\U&)HAT8N6%J2JNR<_P0YRQH0:,#6#H1<
MV+0X?]GA8"^)S%J#0P5&5E^?YJ*@!L_.P?O.;M;P=5V>=K?GPJ)%F<[._WM(
M>=9:76YD8_=R+EIJIC\[[SYM'K2&X[=KP8Z)7/"R:DZTP\M>4V(UX%&+H1T-
MN1AE67JL\[[]WH8TA&/D`E3B(<P$#*?6#,29ZVJ),YZ,[GO8!V<[*'*!Q6WR
M&]#!)"*8UTN@[RZ(CVEWKGT3H`IS$HGS"TO#LYEJ$G>//3V@W(.EU?L+YA_!
MHVQ,FFN703V58Z-N=++=Z/K7D=@&D>P0SH4[BW,O4F>0$RR758I/I!KBOT")
M`CW0H*=4,*/NZBU)M4`9-;*C:O<:-'X-*G6;U0GMD,I%3DO2>5V'MP=/JWO0
MW,`C1N^B<B767F)5!0G-&-N1D@NDEB(E;GVM\]&W5&SH.U8=GIX:3P77`^V]
M%3O2<I':/2$M>Q-1A[R*R$L3\NG,(,6$L7E@'4S5":WX>)6+[A9O$<C"PV#?
M>7H+3U>:G50GM'NZVL'S;G*RK:-UG%SOFC`W310__?2H?I)UES=A87=^Y=/E
MMJ*HJ0X)6R&ATDM?A]3N^5PTU^+Y[LW?A[^E#!9+]4M^@:)++CY)GRK3LIDQ
MZ8O/EF@FP[!^151LT8`=.[G8KPT[J11(B8$`/R@59&U*F9RDT1Q1)$Z'M*V0
M]AM15XD3]^P>)N@S4A47H]O;VT`X<\4NO(R\&NYVUYP=A;E@LP6%L4R]2*BZ
ML`3A4")=?#5[A\JJ4]Q_<Y'L$S1W":ID1+Q',-DB6''VNP.>=GSE(L'--CQV
MP^?3PN>.W!,6J/\=/F/T+^)^82X19S-!=$AC2R1M9&\'U8YVT?90+`=*!4&!
MD@0EHG0(VU,'%1OX-^K/1W2VP&>>*Z@S/^=BR47UV?R3M6O'9"[JW+BC2Y#W
M`!(B+6(ODA$90G9]XG,B]H(_P-]\Y%"BRJY8N/UW!EX*/%^=>MPW=AM*8$=Q
M+J*](Q2#L,B4%E&FS_?[R!"X0_03(_I<?5B%"T;Q%8-9NQ]^>^5.'S,(C[S<
M$)<ZE)&?KW[=!Z!W((`5SZ\+(O#-\)Q*BA)1]7+'%!;%T@(!"-SA^:GQ_//%
MU:7Z'IG6](HY>\%LM4;LN"S(%S3$)4B#4G%>J#W&QQWPGAAXOP2PCJ`>N:!X
M0GRUKI$$"V=NXL0G(CP@AKU]P'(G(MA!F\MS-`5M+"N*A46QM`:444;>#M)/
M#.D;6&Y@XOURR1]3G\#@#(1?*9.<)0C;!YJW;=T.Y-W<#:SH0C'1+\<`W$<3
MO&IJD`C[#P/@'8ZWQ+%Q+'8XC0_%5L)@#4H[?JK>*MPY>R_.3K8Z1ZD&XF;W
M=Z6;J,8",SDE0L3?!-P+9SM8<AF6<K`8>Z$3`?+;Q8P]8H84':3V!JG/Q`^O
MBM&D.\%2GJ4=1+DTRE8@@M91V#R*V^_@LQ/XA%;->SR7]6W*Q@Z37&*D$DS"
MUEX4PJ5+T&X'C&37Z"A8+L/O'V/O5G#UC6-<=ZY2G9L=)I6O&LGN3#4;59=2
M(-UL-Z]I`);X2@_SOI#D[2\J7,='?09V2%2]="33<91=3-*!H#$(*BUDJA-:
MG?XF%QTO=7JWC-G*T\:M+I4<O+&^W:^YZ+)YJTSGS-TY,SUT&Z@$Y@V(M0@6
M\16!>D^+.M\CL.,'V!M./#K3^N:F@SOA:0=%+GJ;!85Y#E<WC**64=QTM#/&
M:!P9K7?PJ;.]-/LIYLJ;UBN0V4%0O&%]_>*AKHO8N8_3ZR+2'>)GCD_O"P[*
MUJ2V>[QXFWG>X^:=$L:V<10WT_E^I[Z7P\"7/DRS*)LU\W^&@QT#Q9N\*V-`
M(J.I#@?;X^".2%]0QR>NKO0%I&S0%]BXV/%0?!NQ%0]I8Q$T5'-=YU`7%,F=
M<A5WZ&^L;W=T+AZ8N8&N&^9WY\TT-*<.S6"VDA<D3,Q`<1A@M?BV"K7=T]9/
MK:W%\:(V_B%1W(JJ%F<$.N?7=WX2MX_ZP^CJ^#&/W?F%B>2$`9#$G\VR0:(Q
M3SM0<H&^=:`8>8&X=X^:1CXWL&,VK_$3"]`AJ'+&8/,]DP8,-E?.)Q%VW8`5
M6]_GXHF5+[=<PUW5*S$[H%4"6GP@.'I#U<;[2K./RG1V6.3"D86?^NNF(]NZ
M.7\QJ;HZ-'G!BXO7?=Z,B1T`N=!CZ36GF7Z@_#+4#A#5EJ#9S_Q5BS-6H;&[
M.Q]D7/M*8/>JPV/USP1+<D>FZ%$_\:'2AR-)H7<D1]$S+!Q%G[C]X>'A^.'T
MF(M9?_#V[=N^KM5?AGD[&!/[,=N808[Z<2(\37_R\N5IB)@U^T52Q1SF@DQ!
MK-F"]TY>#DX')Z>#/X#B^''AQ55\ZJM6SE,^2#&2+Q#VO*-^>S7/NK&"XD!0
MH/A%PN9`]/;PA'@558:Z!2I?*PX'HNWZ:UY!:2`I4-K\ZF61[N_[>+FDT)_I
MO^$OQGA8.WP`JG/A(X871"ZQ8Q.<,A5Q=4!/"4OW!;[FCF9D(5%_]6*ZGGK4
M&YST3@?'C]*-1*PC06KI>A+$='4E,%F]UG^Y?N6V8P+5Z.M*S4VQG&CJ0/84
M,F5?.;_W<@#REC:KFS0I9Q@O-6&?>+Y,>/527O6M[_JBK[CT6;`@@CK5C+!.
MI2SQ5IE_\&8;$3CK-12#L\_-)"FT[_:.44_J^D6SE<0YGO'[OEZ5BE5E<8KH
MXC^V$R00@C!'<SRI)8E)F/S52]G4E\4EM+9!8AKU8RM#D$=G7KOUA$C_VJI]
MJN_JK"V!01;]WDH*Z2^%8C:H(T-"I'_U4G*S?1)N]]0"?#B*0C#GT,&KBVC'
M`A9DF4L6U1#ZA[56.`50@M!W"\Y@LB]65SY9J/GQ$<(3J;>6?#B:8D\/\;HB
M#/V4NV--&@YO?EPTP9X:[#X<.8+`@N((,>KI6^$_'/D@!9@"EA[ZM#88XB?!
M@V7<.H562]1,EB8WU`/?@)C1%IBB.W!"G2N3[,T`+IGL2O\9B#O#OG$T*KHG
M)[HE1SU+]+PA_IR[484S9T[AEVN:9A?<MK::&XAHM;M'W#37])-'9Q1:'W.H
M2N@]V8T!"]A^ZY8<\X\DO<QI-V9<Y_F?9<,A@QZ=+/6B8C@]6RX]ZAB1H]T:
MU]+885D=IKX3(H;3GP@C8RQF2?XW:Z_":J:FE/ED1D1#17>B431V78"X&14R
MSTV977C2;$S;I;S%?6F^,"-Y9+EG-#=C`?8NB;K`(<KW%DXXK-7V]ZKL<)81
M?[_G<OT#1,!`ZN0V]E27\!,&>$"O$"P"K>D5R]W<'YID1PP/88965=5K^&N7
MIK/S.XC)?:FJ-]A7OU:W1#@JQC<C5^PS>?3'#\2[)S><^7-U5\7_$BS&#[R2
M]>JR#`W(@H6RBJ)XQGZHAE+K*C6T39Y-B^SQ$=`\G@,@I20+BF^(&K<-14O*
M(PTX4TJX?`%=3Y$.H5C[5B'Z5KUQV+/D8SB?L&`\\*,EK*EE8Q8',7LK4*_@
M<.TUU%&B2[MA[)2F/=3.6C9K$RX*9-??'ZVM<43UQ-JZ_KOY2G49P43;NUCO
MZI</YM[V^J1MZ@BRGX(T.F)H[F<ZFWNK:PK%;CJX9U2O3QPJ'^=&]/I@5(J"
MI^G/XR/N5\S)>S=?UBKW@7A#1GX.F`M='\P?QH2-88:FC0V+9N^O.:$+(BZH
M)%@6@+<9?;M-\`"%*T.+Y.ZMZE:HRJ)5AIB[-',995[/LAJM4H,K%O'MV_%"
M-EK:GG/IJVERE$0PA]V:=(>P+BY6:;/2>U5OAW.LK/3,O::.\DZJ1QP2@]F$
M&SC@P>52\/OB#Q`4V&,+CJV*NZG3V=%GR3X].G,,4^P[Q3VC>%D54Y.E.E?P
M7-&X35_;S'=7%0G:U7L5RJR_P;X:PZKVHP<NVJQDCB"CI!\_?TY,)D?_TT@J
M$0L:WM*Z%B&N5'NKN/%.E<N=N#K'2^J'<:_X]DY#NVK5#R"8F%,$?ISK_OX<
M"[&"=<T#%FYRW^K(5VD>Z&5Y\A7>8GO48K,[.^W0(E^64\'U.ZI;OR0DRED5
MJ&VI>Q##\@5W`GV-$,R7H'/R5\8B_BP2T52[4O46!3FBKV7(Z/L3UUY^IEQ>
MI4V#S=IG/\JT6"]ODPJ9CR7&'X131X#"3\*M??HN?PNBH>WVK#(QYM$<UYPL
M[<,P0@7'G3F\+KH[H1/-(PV4C[GN2F/=I5DK;YOMN&T7@M]EK_Q).H(_)!-!
M4]'UDD-(1*E5J;I.X6RA-H1&NR!41MK5D<3H<G/F7L`PXO'EVIJG$?4!3$:2
M%_.&8'5X2*_?TK-$19/IZB1MFTY?$C7S]V)W92=,TW#"!(ZF89,J2VBJW8#8
M!,!,/7I.W<E%IB>/'QQ"C.8RT%?A)*^<X(O8#S\)G'E1-U<]A,Y*:2'!/:4Q
MF+(*!]#E:#=$;@J[4T.OHL)#0&A>[AO\J&[S"QT$-5T8/`H<69?P(!8WQK4:
M1<G;XN(6+5X,`=?3L/FB5N9:$S'SYP7R18?P@H'40B6%+DCX_Q7+SD(I64/8
MYMJ'H38(:\PZB%@,IT7]R*:*F;C?L^^Z-+:QQ1EM%9Z4Y=N7,JK6)]Y:_5VN
MK&I^.BP7<FA(WZ:01/7O3>6TKT_:+L6SYY7BZW\R"I95.8#9772)\2B8>%%:
M,-DY/8(E-)U2!^;F7SF#<3+<Q)+1O#YQNSJVS\2_%=PAQ)5JZ7$E9:`L?*LU
M&DZG1"3WCVJ-*]8_A*'J,V<.EO.A>A']Z`]CLUKT)+E99BC":R_5ABZA8]N9
MW%SR#:@DY:ILDSEA]%0-'L24.\ZYIP>"BD_";*C7JI2\_4Q/^X_RQ!)&<S.[
M&D656JE-/+I"OS43>%&@2JY&J_08@H'I@D2[5F!L45NG,QU+:8T#&'^'2]V?
ML9DZ.F+&)F5I9+,Z28OBF4,QPXS^%>]!2B_LIC.FY@E@Y>A:0S574!L]:'$P
M8EM&+0I;-%)E/<"Q#9-6AD+2S!OT3'R%/;4BS&1P8.*53#FST[,&M-LE\':*
MAULN?1U!5,\VAI0KU3Z`'O"6^_"'BH5HAZWB5=28ASLG,BIOJEH-T4_DSH*%
M0C1KR*X78%&A)K(R,\]H1'T(ZXY8,2,A^QL77^'553MD+/M8ZQ(>B#'T!\74
ME@S?_%S9%TFF@7=-IVH36/BER8)M1LW(6S0$FEM28D#GP@RV2NT*)YB2)K]M
MZJQ7:I<Z=VK+]">U12@7U<L7M2EJIZ6[U,?,BN0V2]HG-@]$B=A&2>O$_EQT
M#C!7TCJQAV52#ULL]$AMG2T6.U/4/L'I8XG8:4'KA!Z7V7K<8DN/YS`/*A';
M+&J?X`^\1.RTH%5"$[5H]%;&(EMP!C^=<*==^2F7VI09M5NP/^^.N(%#W&@Q
M=I<]W5)4V**U]IT*$W@%1R;7"PYA%9'9,9<_@U%<?!!IDN0X#!'WU(G/C$0?
M>2TZYEF@=@W:0[%)]*DY==<`K.^R5PYD+6"O>0#AH;@#";TGXXW=9E#/U+A*
M[;UIO4,GZY,6'V%EZ*HO2D%?%$)5"#44JGH?5VF5*`YVIO<TKR5-Y="?$S&>
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M3!VW"7?G$U=OG/Z9>^YNYL8U&OM&X)@D\`5ULMO1H[UH.0/,=V;MYFVW*!#?
M6/MH9$BW_.W"I`5,OR5;<1'*LCM#Q1S-U[GVC7IM--*0C8C#&:P*&87UGX3U
MQ.[M5MC(-VC*\9R*?5LRWT:;#$D%.9OE$MMKS]N4UQY1YZM'SHGGE=T07%JC
M76K,%OC,<V&(G)]SL8QR?@7*6.NU2J6"(7WXP`#U<[HL'@ZK4K1IK$N/].F4
M;>E-9C*^O.P11*;1;,A4?DM&&9L\\P5H6N;1TJ.^OLAVR(PYW[K*I=6J;?]]
MDE7->`X67Q(@<6"NJKX1XEN^(5*I=IO>U/$#'\]Y(#%SU>CD$Q*=5&7JW8*!
M2L$NKV8=JC:IJU^O!P$51/[>Q:+"5@D?7E":'B(T9<^7'42\.2=W@5M*JSRC
M<][WPR_TPL__!U!+`0(>`Q0````(`"J(6$1C@8\L4$@!`)$.#@`1`!@`````
M``$```"D@0````!S9VUO+3(P,3,Q,C,Q+GAM;%54!0`#,,$+4W5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`"J(6$0%05JM31<``!9/`0`5`!@```````$`
M``"D@9M(`0!S9VUO+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``S#!"U-U>`L``00E
M#@``!#D!``!02P$"'@,4````"``JB%A$4Q?_+@XT``"YX`,`%0`8```````!
M````I($W8`$`<V=M;RTR,#$S,3(S,5]D968N>&UL550%``,PP0M3=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`*HA81/-NU5\(D@``LU<(`!4`&```````
M`0```*2!E)0!`'-G;6\M,C`Q,S$R,S%?;&%B+GAM;%54!0`#,,$+4W5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`"J(6$1B#>50/$X``#UL!@`5`!@`````
M``$```"D@>LF`@!S9VUO+3(P,3,Q,C,Q7W!R92YX;6Q55`4``S#!"U-U>`L`
M`00E#@``!#D!``!02P$"'@,4````"``JB%A$;H^*H.48``#J'P$`$0`8````
M```!````I(%V=0(`<V=M;RTR,#$S,3(S,2YX<V155`4``S#!"U-U>`L``00E
>#@``!#D!``!02P4&``````8`!@`:`@``IHX"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreements', window );">Collaboration agreements</a></td>
        <td class="nump">$ 21,678<span></span></td>
        <td class="nump">$ 18,186<span></span></td>
        <td class="nump">$ 6,110<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump">2,455<span></span></td>
        <td class="nump">3,469<span></span></td>
        <td class="nump">4,209<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">24,133<span></span></td>
        <td class="nump">21,655<span></span></td>
        <td class="nump">10,319<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">36,979<span></span></td>
        <td class="nump">31,709<span></span></td>
        <td class="nump">32,098<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">13,800<span></span></td>
        <td class="nump">12,144<span></span></td>
        <td class="nump">14,042<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent liability</a></td>
        <td class="nump">60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">50,839<span></span></td>
        <td class="nump">43,853<span></span></td>
        <td class="nump">46,140<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(26,706)<span></span></td>
        <td class="num">(22,198)<span></span></td>
        <td class="num">(35,821)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
        <td class="nump">82<span></span></td>
        <td class="num">(66)<span></span></td>
        <td class="nump">71<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (26,624)<span></span></td>
        <td class="num">$ (22,264)<span></span></td>
        <td class="num">$ (35,750)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num">$ (0.48)<span></span></td>
        <td class="num">$ (0.42)<span></span></td>
        <td class="num">$ (0.71)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share</a></td>
        <td class="nump">55,974<span></span></td>
        <td class="nump">52,741<span></span></td>
        <td class="nump">50,512<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of (increase) decrease in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>NOTE 5 &#x2013; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC
 ALLIANCES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Collaboration Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Collaboration and License Agreement with Shire International
 GmbH, formerly Shire AG, in Human Therapeutics and
 Diagnostics</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In January 2012, the Company entered into a collaboration and
 license agreement (the Agreement) with Shire pursuant to which the
 Company and Shire collaborate to research, develop and
 commercialize human therapeutics and diagnostics for monogenic
 diseases based on Sangamo&#x2019;s ZFP technology. Under the
 Agreement, the Company and Shire may develop potential human
 therapeutic or diagnostic products for seven gene targets. The
 initial four gene targets selected were blood clotting Factors VII,
 VIII, IX and X, and products developed for such initial gene
 targets will be used for treating or diagnosing hemophilia. In June
 2012, Shire selected a fifth gene target for the development of a
 ZFP therapeutic for Huntington&#x2019;s disease (HD), an inherited
 neurodegenerative disease for which there are currently no
 therapies available to slow the disease progression. Shire has the
 right, subject to certain limitations, to designate two additional
 gene targets. Pursuant to the Agreement, the Company granted Shire
 an exclusive, world-wide, royalty-bearing license, with the right
 to grant sublicenses, to use Sangamo&#x2019;s ZFP technology for the
 purpose of developing and commercializing human therapeutic and
 diagnostic products for the gene targets. The initial research term
 of the Agreement is six years and is subject to extensions upon
 mutual agreement and under other specified circumstances.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Under the terms of the Agreement, the Company is responsible for
 all research activities through the submission of an Investigative
 New Drug Application (IND) or European Clinical Trial Application
 (CTA), while Shire is responsible for clinical development and
 commercialization of products generated from the research program
 from and after the acceptance of an IND or CTA for the product.
 Shire reimburses Sangamo for its internal and external research
 program-related costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Under the agreement, the Company received an upfront license fee of
 $13.0 million. In addition, the Company will also be eligible to
 receive $33.5 million in payments upon the achievement of specified
 research, regulatory, clinical development milestones, including
 payments for each gene target through the acceptance of an IND or
 CTA submission totaling $8.5 million, as well as $180 million in
 payments upon the achievement of specified commercialization and
 sales milestones. The total amount of potential milestone payments
 for each of the seven gene targets, assuming the achievement of all
 specified milestones in the Agreement, is $213.5 million. The
 Company will also be eligible to receive royalty payments that are
 a tiered double-digit percentage of net sales of licensed product
 sold by Shire or its sublicensees developed under the
 collaboration, if any. To date, no products have been approved and
 therefore no royalty fees have been earned under the Agreement with
 Shire.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 All contingent payments under the Agreement, when earned, will be
 non-refundable and non-creditable. The Company has evaluated the
 contingent payments under the Agreement with Shire based on the
 authoritative guidance for research and development milestones and
 determined that certain of these payments meet the definition of a
 milestone and that all such milestones are evaluated to determine
 if they are considered substantive milestones. Milestones are
 considered substantive if they are related to events (i)&#xA0;that
 can be achieved based in whole or in part on either the
 Company&#x2019;s performance or on the occurrence of a specific
 outcome resulting from the Company&#x2019;s performance,
 (ii)&#xA0;for which there was substantive uncertainty at the date
 the agreement was entered into that the event would be achieved and
 (iii)&#xA0;that would result in additional payments being due to
 the Company. Accordingly, revenue for the achievement of milestones
 that are determined to be substantive will be recognized in its
 entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Revenue for the achievement
 of milestones that are not substantive will be recognized over the
 remaining period of the Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has identified the deliverables within the arrangement
 as a license to the technology and on-going research services
 activities. The Company has concluded that the license is not a
 separate unit of accounting as it does not have stand-alone value
 to Shire apart from the research services to be performed pursuant
 to the Agreement. As a result, the Company will recognize revenue
 from the upfront payment on a straight-line basis over a six-year
 initial research term during which the Company will perform
 research services. As of December&#xA0;31, 2013, the Company has
 deferred revenue of $8.9 million related to this Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues recognized under the agreement with Shire for the years
 ended December&#xA0;31, 2013 and 2012, were as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year ended<br />
 December 31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues related to Shire Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Amortization of upfront fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Related costs and expenses incurred under the Shire agreement were
 $14.2 million and $7.7 million during the twelve months ended
 December&#xA0;31, 2013 and 2012, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <b><i>Agreement with Sigma-Aldrich Corporation in Laboratory
 Research Reagents, Transgenic Animal and Commercial Protein
 Production Cell-line Engineering</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July 2007, Sangamo entered into a license agreement with Sigma.
 Under the license agreement, Sangamo agreed to provide Sigma with
 access to its proprietary ZFP technology and the exclusive right to
 use the technology to develop and commercialize research reagent
 products and services in the research field, excluding certain
 agricultural research uses that Sangamo previously licensed to DAS.
 Under the agreement, Sangamo and Sigma agreed to conduct a
 three-year research program to develop laboratory research reagents
 using Sangamo&#x2019;s ZFP technology during which time Sangamo
 agreed to assist Sigma in connection with its efforts to market and
 sell services employing the Company&#x2019;s ZFP technology in the
 research field. Sangamo has transferred the ZFP manufacturing
 technology to Sigma.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In October 2009, Sangamo expanded its license agreement with Sigma.
 In addition to the original terms of the license agreement, Sigma
 received exclusive rights to develop and distribute ZFP-modified
 cell lines for commercial production of protein pharmaceuticals and
 certain ZFP-engineered transgenic animals for commercial
 applications. Under the terms of the agreement, Sigma made an
 upfront cash payment of $20.0 million consisting of a $4.9 million
 purchase of 636,133 shares of Sangamo common stock, valued at $4.9
 million, and a $15.1 million upfront license fee. Sangamo is also
 eligible to receive commercial license fees of $5.0 million based
 upon a percentage of net sales and sublicensing revenue and
 thereafter a reduced royalty rate of 10.5% of net sales and
 sublicensing revenue. In addition, upon the achievement of certain
 cumulative commercial milestones Sigma will make milestone payments
 to Sangamo up to an aggregate of $25.0 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues recognized under the agreement with Sigma for the years
 ended December&#xA0;31, 2013, 2012 and 2011, were as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended<br />
 December 31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenue related to Sigma Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Royalty revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 License fee and milestone revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">671</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Related costs and expenses incurred under the Sigma agreement were
 $0.2 million, $0.3 million and $0.5 million during 2013, 2012 and
 2011, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Agreement with Dow AgroSciences in Plant
 Agriculture</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2005, Sangamo entered into an exclusive commercial
 license with DAS. Under this agreement, Sangamo is providing DAS
 with access to its proprietary ZFP technology and the exclusive
 right to use the technology to modify the genomes or alter the
 nucleic acid or protein expression of plant cells, plants, or plant
 cell cultures. Sangamo has retained rights to use plants or
 plant-derived products to deliver ZFP transcription factors (ZFP
 TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic,
 therapeutic or prophylactic purposes. The Company&#x2019;s agreement
 with DAS provided for an initial three-year research term. In June
 2008, DAS exercised its option under the agreement to obtain a
 commercial license to sell products incorporating or derived from
 plant cells generated using the Company&#x2019;s ZFP technology,
 including agricultural crops, industrial products and plant-derived
 biopharmaceuticals. The exercise of the option triggered a one-time
 commercial license fee of $6.0&#xA0;million, payment of the
 remaining $2.3 million of the previously agreed $4.0&#xA0;million
 in research milestones, development and commercialization milestone
 payments for each product, and royalties on sales of products.
 Furthermore, DAS has the right to sublicense Sangamo&#x2019;s ZFP
 technology to third parties for use in plant cells, plants, or
 plant cell cultures, and Sangamo will be entitled to 25% of any
 cash consideration received by DAS under such sublicenses. In
 December 2010, the Company amended its agreement with DAS to extend
 the period of reagent manufacturing services and research services
 through December&#xA0;31, 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The agreement also provides for minimum sublicense fees each year
 due to Sangamo every October, provided the agreement is not
 terminated by DAS. Annual fees range from $250,000 to $3.0 million
 and total $25.3 million over 11 years. The Company does not have
 any performance obligations with respect to the sublicensing
 activities to be conducted by DAS. DAS has the right to terminate
 the agreement at any time; accordingly, the Company&#x2019;s actual
 sublicense fees over the term of the agreement could be lower than
 $25.3&#xA0;million. In addition, each party may terminate the
 agreement upon an uncured material breach of the agreement by the
 other party. In the event of any termination of the agreement, all
 rights to use the Company&#x2019;s ZFP technology will revert to
 Sangamo, and DAS will no longer be permitted to practice
 Sangamo&#x2019;s ZFP technology or to develop or, except in limited
 circumstances, commercialize any products derived from the
 Company&#x2019;s ZFP technology.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues under the agreement were $3.0 million, $4.7 million and
 $4.5 million during 2013, 2012 and 2011, respectively. Related
 costs and expenses incurred under the agreement were $0.4 million,
 $0.6 million and $0.9 million during 2013, 2012 and 2011,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Funding from Research Foundations</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>California Institute for Regenerative Medicine -
 HIV</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2009, CIRM, a State of California entity, granted a
 $14.5 million Disease Team Research Award to develop an HIV/AIDS
 therapy based on the application of ZFN gene editing technology in
 hematopoietic stem cells (HSCs). The four year grant supports an
 innovative research project conducted by a multidisciplinary team
 of investigators, including investigators from the University of
 Southern California, City of Hope National Medical Center and
 Sangamo BioSciences. Sangamo received funds totaling $5.2 million
 from the total amount awarded based on expenses incurred for
 research and development efforts by Sangamo as prescribed in the
 agreement, and subject to its terms and conditions. The award is
 intended to substantially fund Sangamo&#x2019;s research and
 development efforts related to the agreement. The State of
 California has the right to receive, subject to the terms and
 conditions of the agreement between Sangamo and CIRM, payments from
 Sangamo resulting from sales of a commercial product resulting from
 research and development efforts supported by the grant, not to
 exceed two times the amount Sangamo receives in funding under the
 agreement with CIRM. As of December&#xA0;31, 2013, all revenues
 under the award have been recognized and all funds have been
 received.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Revenues attributable to research and development performed under
 the CIRM grant agreement were $1.2 million, $1.2 million and $1.7
 million during 2013, 2012 and 2011, respectively. Related costs
 during 2013, 2012 and 2011 were $1.8 million, $1.2 million and $2.0
 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>California Institute for Regenerative Medicine -
 Beta-Thalassemia</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2013, CIRM granted the Company a $6.4 million Strategic
 Partnership Award to develop a potentially curative ZFP Therapeutic
 for beta-thalassemia based on the application of its ZFN gene
 editing technology in HSCs. The four year grant provides matching
 funds for preclinical work that will support an IND application and
 a Phase 1 clinical trial in transfusion-dependent beta-thalassemia
 patients. The State of California has the right to receive, subject
 to the terms and conditions of the agreement between Sangamo and
 CIRM, payments from Sangamo, or its collaborators, from sales of a
 commercial product resulting from research and development efforts
 supported by the grant, in accordance with Title 17, California
 Code of Regulations, Section 100600.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenue attributable to research and development performed under
 the CIRM grant agreement for beta-thalassemia was $0.1 million in
 2013. Related costs during 2013 were $0.4 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>CHDI Foundation, Inc.</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In April 2011, Sangamo entered into an agreement with the CHDI to
 develop a novel therapeutic for HD based on Sangamo&#x2019;s
 proprietary ZFP technology. The ZFP therapeutic approach targets
 the gene that causes HD, an inherited neurodegenerative disease for
 which there are currently no therapies available to slow the
 disease progression. Under the agreement with CHDI, and subject to
 its terms and conditions, CHDI paid the Company $1.3 million, the
 total funds due under the agreement, over a period of one year
 which is intended to substantially fund the Company&#x2019;s
 research efforts related to the agreement. During 2012, the
 agreement was amended to extend the project through August 2012 and
 to increase total potential funding from $1.3 million to $2.1
 million, plus reimbursement for certain direct expenses related to
 the project. The agreement with CHDI terminated on August&#xA0;31,
 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues attributable to research and development performed under
 the CHDI collaboration agreement were $1.1 million during 2012 and
 2011. Related costs during 2012 and 2011 were $1.1 million and $1.2
 million, respectively. There were no such revenues or related costs
 in 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>The Juvenile Diabetes Research Foundation
 International</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October&#xA0;2006, Sangamo entered into an agreement with the
 Juvenile Diabetes Research Foundation International (JDRF)&#xA0;to
 provide financial support for one of Sangamo&#x2019;s Phase 2 human
 clinical studies of the Company&#x2019;s product candidate SB-509, a
 ZFP Therapeutic that was in development for the treatment of
 diabetic neuropathy. In January 2010, JDRF and Sangamo amended the
 agreement and, subject to its terms and conditions, JDRF agreed to
 provide additional funding of up to $3.0 million for a Phase 2b
 trial in diabetic neuropathy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In October 2011, the Company announced that it would not pursue
 additional clinical development of the SB-509 program. In March
 2012, the Company received a final payment of $0.8 million for work
 performed under the agreement. The Company does not expect to
 receive additional funding under the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues attributable to research and development activities
 performed under the JDRF agreements were $0.8 million and $0.5
 million during 2012 and 2011. There were no such revenues or
 related costs in 2013.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>The Michael J. Fox Foundation for Parkinson&#x2019;s
 Research</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In January 2007, the Company entered into a partnership with the
 Michael J. Fox Foundation for Parkinson&#x2019;s Research
 (MJFF)&#xA0;to provide financial support of the Company&#x2019;s
 program to develop ZFP TFs to activate the expression of glial cell
 line-derived neurotrophic factor (GDNF). Under the agreement with
 MJFF and subject to its terms and conditions, MJFF paid the Company
 $1.0 million, the total funds due under the agreement. In June
 2010, the Company received a commitment for additional funding of
 $0.9 million from MJFF to support further studies of ZFP TF
 activators of GDNF and intended to substantially fund Sangamo
 research efforts related to the agreement. The Company has received
 the entire $1.9 million in funding available under the agreements
 with MJFF and does not expect to receive any further funding under
 this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenue attributable to research and development performed under
 the MJFF agreement was $0.4 million in 2011. There were no such
 revenues in 2013 or 2012.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 4 &#x2013; STOCK-BASED COMPENSATION</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table shows total stock-based compensation expense
 recognized in the consolidated statements of operations (in
 thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,892</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,769</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,942</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,338</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As of December&#xA0;31, 2013, total stock-based compensation
 expense related to unvested stock options to be recognized in
 future periods was $11.2&#xA0;million, which is expected to be
 expensed over a weighted-average period of 2.87 years. As of
 December&#xA0;31, 2013, total compensation expense related to
 unvested RSUs to be recognized in future periods was $5.4 million,
 which is expected to be expensed over a weighted-average period of
 1.98 years. There was no capitalized stock-based employee
 compensation expense as of December&#xA0;31, 2013.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Valuation Assumptions</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The employee stock-based compensation expense was determined using
 the Black-Scholes option valuation model. Option valuation models
 require the input of subjective assumptions and these assumptions
 can vary over time.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company primarily bases its determination of expected
 volatility through its assessment of the historical volatility of
 its common stock. The Company relied on its historical exercise and
 post-vested termination activity for estimating its expected term
 for use in determining the fair value of these options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The weighted-average estimated fair value per share of options
 granted during 2013, 2012 and 2011 was $8.29, $3.76 and $3.20,
 respectively, based upon the assumption in the Black-Scholes
 valuation model. The assumptions used for estimating the fair value
 of the employee stock options are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">1.50-1.88</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.74-1.34</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.93-2.11</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected life of option (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.36-5.38</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.40-5.58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.39-5.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected dividend yield of stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.87-0.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.83-0.86</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Employees purchased approximately 181,000, 175,000 and 153,000
 shares of common stock through the 2010 Purchase Plan at an average
 exercise price of $2.75, $2.61 and $3.02 per share during the
 fiscal years 2013, 2012 and 2011, respectively.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The weighted-average estimated fair value of shares purchased under
 the Company&#x2019;s ESPP during 2013, 2012 and 2011 were $1.47,
 $2.51 and $1.62, respectively, based upon the assumptions in the
 Black-Scholes valuation model. The weighted&#x2013;average
 assumptions used for estimating the fair value of the ESPP purchase
 rights are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.61</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.30</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">0.05-0.61</font></td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected life of option (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.5-2.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected dividend yield of stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.51-0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.93-1.37</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.58-0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value measurements of cash equivalents, available-for-sale
 securities and contingent consideration liabilities are identified
 at the following levels within the fair value hierarchy (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2013<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Contingent consideration liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2012<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value of Contingent Consideration Liability</a></td>
        <td class="text"><div>From the acquisition date of October&#xA0;1, 2013 through
 December&#xA0;31, 2013, the recognized amount of the liability for
 contingent consideration increased by $0.1 million primarily as the
 result of the passage of time.
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="20%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended<br />
 December&#xA0;31,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Fair value on date of acquisition (October 1, 2013)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Change in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Fair value at end of period</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <!-- xbrl,n --></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=SL7498348-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 12 &#x2013; EMPLOYEE BENEFIT PLAN</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company sponsors a defined-contribution savings plan under
 Section&#xA0;401(k) of the Internal Revenue Code covering all
 full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan
 is intended to qualify under Section&#xA0;401 of the Internal
 Revenue Code.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The Company matched
 contributions by employees equal to 50% of the first 6% of employee
 contributions up to a limit of $1,500 in 2013 and $1,000 in 2012.
 Matching funds are fully vested when contributed. Contributions to
 the Sangamo 401(k) Plan were $0.1 million in both years ended
 December&#xA0;31, 2013 and 2012. There were no such contributions
 in 2011.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 8 &#x2013; COMMITMENTS</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo occupies office and laboratory space under operating leases
 in Richmond, California. On August&#xA0;1, 2013, Sangamo amended
 its lease agreement wherein the lease was extended through August
 2019. Rent expenses were $0.7 million in 2013 and $0.6 million for
 2012, and 2011. Future minimum payments under contractual
 obligations at December&#xA0;31, 2013 consist of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 41.5pt">
 <b>Fiscal Year:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Operating<br />
 Lease</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">570</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">668</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">688</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">730</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">496</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total minimum payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RentalExpenses', window );">Rent expenses</a></td>
        <td class="nump">$ 0.7<span></span></td>
        <td class="nump">$ 0.6<span></span></td>
        <td class="nump">$ 0.6<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RentalExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_RentalExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Ceregene<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Ceregene</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 6 &#x2013; ACQUISITION OF CEREGENE</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On August&#xA0;23, 2013, Sangamo and its wholly-owned subsidiary CG
 Acquisition Sub, Inc., a Delaware corporation, entered into an
 Agreement and Plan of Merger (the Merger Agreement) with Ceregene,
 and a stockholders&#x2019; representative. Pursuant to the Merger
 Agreement, the Company acquired all outstanding shares of Ceregene,
 a privately held biotechnology company focused on the development
 of AAV gene therapies. The acquired assets include all of
 Ceregene&#x2019;s therapeutic programs, including CERE-110 for the
 treatment of AD is currently in a Phase 2 clinical trial. In
 addition to the clinical assets acquired, the Company acquired
 certain intellectual property rights relating to the manufacturing
 of AAV, and certain toxicology data and safety and efficacy data
 from Ceregene&#x2019;s human clinical trials, which will be used in
 the preparation and filing of IND applications for Sangamo&#x2019;s
 <i>in vivo</i> ZFP Therapeutics, particularly those that target the
 brain. The acquisition closed on October&#xA0;1, 2013 (the Closing
 Date).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Under the Merger Agreement, the aggregate consideration transferred
 or transferable by Sangamo to former Ceregene stockholders at
 closing consisted of 100,000 shares of Sangamo common stock, with
 an approximate fair value of $1.2 million. In addition, Sangamo may
 be required to make contingent earn-out payments (the Earn-Out
 Payments) to the stockholders of Ceregene as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">If the Company grants a third-party
 license to develop and commercialize Ceregene&#x2019;s CERE-110 for
 the treatment of (AD) or CERE-120 for the treatment of
 Parkinson&#x2019;s diseases or HD (the Earn-Out Products), the
 Company is required to pay a double digit percentage of any upfront
 and milestone payments the Company receives for such license,
 subject to certain reductions based on expenses incurred by the
 Company in the development of the Earn-Out Products; and</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">If the Company commercializes any
 Earn-Out Product itself, the Company is required to pay, for each
 Earn-Out Product, royalty-like earnout payments as a percentage of
 net sales that range in the low double digits depending upon the
 amount of net sales, subject to certain reductions by the
 Company.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Also on the Closing Date, Sangamo, Ceregene and certain of
 Ceregene&#x2019;s stockholders entered into an indemnity escrow
 agreement, pursuant to which $0.3 million of Ceregene remaining
 cash was deposited in an escrow account for the benefit of Sangamo
 to satisfy indemnity obligations of the stockholders under the
 Merger Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In accordance with the Merger Agreement, each issued and
 outstanding share of Ceregene capital stock was cancelled and
 converted into the right to receive the merger consideration
 described in the Merger Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Ceregene acquisition was accounted for as a business
 combination in accordance with the guidance ASC Topic 805. The
 operating results of Ceregene after the Closing Date have been
 included in the Company&#x2019;s Consolidated Statements of
 Operations. The Company&#x2019;s Consolidated Balance Sheet as of
 December&#xA0;31, 2013 reflects the acquisition of Ceregene.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Consideration Transferred</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the estimated fair value of the
 consideration transferred by Sangamo to the Ceregene stockholders
 on the Closing Date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Sangamo shares of common stock</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Contingent earn-out</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total purchase consideration</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value Estimate of Assets Acquired and Liabilities
 Assumed</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the estimated fair value of the net
 assets acquired as of the Closing Date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash and equivalents</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">79</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounts receivable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Identifiable intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,585</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounts payable and accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total liabilities assumed</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(846</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net assets acquired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Intangible Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Intangible assets for in-process research and development
 (IPR&amp;D) consist of Ceregene&#x2019;s two clinical product
 candidates, CERE-110 for the treatment of AD and CERE-120 for the
 treatment of Parkinson&#x2019;s disease. The Company determined that
 the combined Closing Date estimated fair values of CERE-110 and
 CERE-120 was $1.9 million. The Company used an income approach,
 which is a measurement of the present value of the net economic
 benefit or cost expected to be derived from an asset or liability,
 to measure the fair value of these two product candidates. Under
 the income approach, an intangible asset&#x2019;s fair value is
 equal to the present value of the incremental after-tax cash flows
 (excess earnings) attributable solely to the intangible asset over
 its remaining useful life.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 To calculate the fair value of CERE-110 and CERE-120 under the
 income approach, the Company used probability-weighted cash flows
 discounted at a rate considered appropriate given the inherent
 risks associated with this type of asset. The Company estimated a
 present value discount rate based on the estimated weighted-average
 cost of capital for companies with profiles substantially similar
 to that of Ceregene. This estimates the rate that market
 participants would use to value this asset. Cash flows were
 generally assumed to extend either through or beyond the patent
 life of the asset, depending on the circumstances particular to the
 asset. In addition, the Company compensated for additional risks,
 including the phase of development, historical clinical results and
 the lack of approved gene therapy products, by
 probability-adjusting the Company&#x2019;s estimation of the
 expected future cash flows for these product candidates. The
 Company believes that the level and timing of cash flows
 appropriately reflect market participant assumptions. The projected
 cash flows from this project were based on key assumptions such as
 estimates of revenues and operating profits related to the project
 considering its stage of development; the time and resources needed
 to complete the development and approval of the related product
 candidate; the life of the potential commercialized product and
 associated risks, including the inherent difficulties and
 uncertainties in developing a drug compound such as obtaining
 marketing approval from the FDA and other regulatory agencies.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 A summary of these assets and estimated fair values at the Closing
 Date is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>Value&#xA0;of&#xA0;Intangible<br />
 Assets Acquired</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 CERE-110 for the treatment of Alzheimer&#x2019;s disease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 CERE-120 for the treatment of Parkinson&#x2019;s disease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total identifiable intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 IPR&amp;D is an intangible asset classified as an indefinite-lived
 until the completion or abandonment of the associated research and
 development effort, and will be amortized over an estimated useful
 life to be determined at the date the project is completed.
 IPR&amp;D is not amortized during this period, but rather tested
 for impairment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Goodwill</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The excess of the consideration transferred over the fair values
 assigned to the assets acquired and liabilities assumed was $1.6
 million, which represents the goodwill amount resulting from the
 acquisition. Goodwill represents benefits that Sangamo believes
 will result from combining its operations with the operations of
 Ceregene and any intangible assets that do not qualify for separate
 recognition, as well as any future, yet unidentified products.
 Goodwill recorded includes $0.7 million related to a deferred tax
 liability. The deferred tax liability is due to the Company&#x2019;s
 recognition of the acquired IPR&amp;D assets for financial
 statement purposes but not for tax purposes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 None of the goodwill is expected to be deductible for income tax
 purposes. The Company will test goodwill for impairment on an
 annual basis or sooner, if deemed necessary. As of
 December&#xA0;31, 2013, there were no changes in the Goodwill
 recorded from the acquisition of Ceregene.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Liability for Contingent Consideration</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In addition to the transfer of Sangamo common stock, the Company
 may be required to make contingent Earn-Out Payments if the Company
 grants a third-party license to develop and commercialize the
 Earn-Out Products or if the Company commercializes any Earn-Out
 Product itself. These payments are a percentage of any upfront or
 milestone payments received in the case Sangamo grants a
 third-party license to develop and commercialize the Earn-Out
 Products, or are a percentage of net sales in the case Sangamo
 develops and commercialized the Earn-Out Products itself. The total
 maximum payment is not limited, other than due to size of the
 upfront and milestone payments received or the net sales of the
 products.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of the liability for the contingent consideration
 recognized on the Close Date was $1.5 million. The Company
 determined the fair value of the liability for the contingent
 consideration based on a probability-weighted discounted cash flow
 analysis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of the contingent consideration liability associated
 with those future earnout payments was based upon reasonable
 assumptions.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Escrow Account Liability</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On the Closing Date, $0.3 million of Ceregene&#x2019;s remaining
 cash, payable to the Ceregene stockholders, was placed in an escrow
 account to be held until October&#xA0;1, 2014, to secure the
 indemnification rights of Sangamo and other indemnities with
 respect to certain matters, including breaches of general
 representations and warranties included in the Merger
 Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Acquisition-Related Transaction Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company recognized $0.1 million in acquisition-related
 transaction expenses in the year ended December&#xA0;31, 2013.
 These costs are included in the &#x201C;General and
 administrative&#x201D; expense line item in the Consolidated
 Statement of Operations for the year ended December&#xA0;31,
 2013.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Revenues and Operating Expenses</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Ceregene did not record any revenues for the period from the Close
 Date to December&#xA0;31, 2013. There were no material operating
 expenses included in Sangamo&#x2019;s Consolidated Statement of
 Operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Proforma Information</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following unaudited supplemental pro forma information presents
 the Company&#x2019;s financial results as if the acquisition of
 Ceregene had occurred on January&#xA0;1, 2012. This supplemental
 pro forma information has been prepared for comparative purposes
 and does not purport to be indicative of what would have occurred
 had the acquisition been made on January&#xA0;1, 2012, nor are they
 indicative of any future results.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(In&#xA0;thousands&#xA0;except&#xA0;per&#xA0;share&#xA0;data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(30,997</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(27,446</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.52</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6996-128479<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7000-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 7 &#x2013; PROPERTY AND EQUIPMENT</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment consist of the following (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,208</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,950</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,156</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,927</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,495</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,521</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,952</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,543</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Depreciation and amortization expense was $0.6 million for 2013,
 2012 and 2011. In 2012, the Company disposed of $0.5 million in
 fixed assets with associated accumulated depreciation of $0.4
 million. The Company recognized a $0.1 million loss on the
 write-off of these assets.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>NOTE 9 &#x2013; STOCKHOLDERS&#x2019; EQUITY</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Preferred Stock</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company has 5,000,000 preferred shares authorized, which may be
 issued at the Board of director&#x2019;s discretion.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Common Stock</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On September&#xA0;23, 2013, Sangamo completed an underwritten
 public offering of its common stock, in which the Company sold an
 aggregate of 7,015,000 shares of its common stock, including
 915,000 shares issued to the Underwriters pursuant to a 30-day
 overallotment option, at a public offering price of $10.58 per
 share. The net proceeds to Sangamo from the sale of shares in this
 offering, after deducting underwriting discounts and commissions
 and other estimated offering expenses, were approximately $69.5
 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock Incentive Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On April&#xA0;18, 2013, Sangamo&#x2019;s board of directors adopted,
 subject to stockholder approval, the Company&#x2019;s 2013 Stock
 Incentive Plan (the 2013 Plan) as the successor to the
 Company&#x2019;s 2004 Stock Incentive Plan (the 2004 Plan). At the
 Annual Meeting of Stockholders held on June&#xA0;12, 2013, the 2013
 Plan was approved by the Company&#x2019;s stockholders and became
 effective. In connection with the approval by stockholders of the
 2013 Plan, outstanding awards under the 2004 Plan were transferred
 to the 2013 Plan. The 2004 Plan was terminated and no further
 awards will be made pursuant to the 2004 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Under the 2013 Plan, the option exercise price per share will
 generally not be less than 100 percent of the fair value per share
 of common stock on the option grant date, and the option term will
 not exceed ten years. If the person to whom the option is granted
 is a 10 percent stockholder, and the option granted qualifies as an
 Incentive Stock Option Grant, then the exercise price per share
 will not be less than 110 percent of the fair value per share of
 common stock on the option grant date, and the option term will not
 exceed five years. Options granted under the 2013 Plan generally
 vest over four years at a rate of 25 percent one year from the
 grant date and one thirty-sixth per month thereafter and expire ten
 years after the grant, or earlier upon employment termination.
 Certain options previously granted under the 2004 Plan to the
 Company&#x2019;s non-employee directors are structured so that they
 may be exercised prior to vesting, with the related shares subject
 to Sangamo&#x2019;s right to repurchase any shares that have not
 vested pursuant to the vesting schedule in effect for such award at
 the exercise price paid if the option holder&#x2019;s board service
 terminates. Approximately 14.1&#xA0;million shares were initially
 reserved for issuance under the 2013 Plan, including
 9.7&#xA0;million shares of common stock subject to outstanding
 awards previously granted under the 2004 Plan that were transferred
 to the 2013 Plan, and an additional 4.4&#xA0;million shares of
 common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The number of shares of common stock reserved for issuance under
 the 2013 Plan will be reduced: (i)&#xA0;on a 1-for-1 basis for each
 share of common stock subject to a stock option or stock
 appreciation right granted under the plan, (ii)&#xA0;on a 1-for-1
 basis for each share of common stock issued pursuant to a full
 value award granted under the plan prior to the plan effective
 date, and (iii)&#xA0;by a fixed ratio of 1.33 shares of common
 stock for each share of common stock issued pursuant to a
 full-value award granted under the plan on or after the plan
 effective date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Shares subject to any outstanding options or other awards under the
 2013 Plan that expire or otherwise terminate prior to the issuance
 of the shares subject to those options or awards will be available
 for subsequent issuance under the 2013 Plan. Any unvested shares
 issued under the 2013 Plan that the Company subsequently purchases,
 pursuant to repurchase rights under the 2013 Plan, will be added
 back to the number of shares reserved for issuance under the 2013
 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the
 ratio at which the share reserve was debited for the original
 award) and will accordingly be available for subsequent issuance in
 accordance with the terms of the plan. There are no net counting
 provisions in effect under the 2013 Plan.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Employee Stock Purchase Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sangamo&#x2019;s 2010 Employee Stock Purchase Plan (Purchase Plan),
 which supersedes the 2000 Employee Stock Purchase Plan, provides a
 total reserve of 2,100,000&#xA0;shares of common stock for issuance
 under the Purchase Plan. Eligible employees may purchase common
 stock at 85&#xA0;percent of the lesser of the fair market value of
 Sangamo&#x2019;s common stock on the first day of the applicable
 two-year offering period or the last day of the applicable
 six-month purchase period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock Option Activity</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 A summary of Sangamo&#x2019;s stock option activity is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average<br />
 Exercise&#xA0;per<br />
 Share&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,184,346</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,119,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11.75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,715,123</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.74</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(182,559</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,405,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">56,425</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options vested and expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,046,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">54,849</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,800,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.84</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.05</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">41,073</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Newly created shares are issued upon exercise of options. There
 were no shares subject to Sangamo&#x2019;s right of repurchase as of
 December&#xA0;31, 2013. The intrinsic value of options exercised
 was $8.9 million, $0.6 million and $1.0 million during 2013, 2012
 and 2011, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At December&#xA0;31, 2013, the aggregate intrinsic values of the
 outstanding and exercisable options were $56.4&#xA0;million and
 $41.1 million, respectively. The aggregate intrinsic value of
 options vested and expected to vest during 2013, 2012 and 2011 was
 $54.9 million, $8.5 million and $0.1 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes information with respect to stock
 options outstanding at December&#xA0;31, 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="45%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Options Outstanding and
 Exercisable</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Options Exercisable</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 81.05pt">
 <b>Range of Exercise Price</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 Shares of<br />
 common&#xA0;stock<br />
 subject&#xA0;to&#xA0;options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 Shares&#xA0;of<br />
 common&#xA0;stock<br />
 subject to<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Exercise Price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $2.55&#xA0;&#x2013;&#xA0;$3.25</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">212,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.77</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.57</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $3.45&#xA0;&#x2013;&#xA0;$3.45</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,124,381</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,124,381</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $3.80&#xA0;&#x2013;&#xA0;$5.26</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">661,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.33</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.35&#xA0;&#x2013;&#xA0;$5.35</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">909,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">909,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.41&#xA0;&#x2013;&#xA0;$5.41</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,134,524</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">270,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.42&#xA0;&#x2013;&#xA0;$5.66</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">60,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.70&#xA0;&#x2013;&#xA0;$5.70</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">945,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">676,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $5.86&#xA0;&#x2013;&#xA0;$6.82</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">899,022</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">749,020</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.45</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $6.92&#xA0;&#x2013;&#xA0;$11.99</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">365,342</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">267,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 $12.12&#xA0;&#x2013;&#xA0;$14.62</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,092,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.83</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,087,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14.05</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,405,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,800,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.84</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Restricted Stock Units</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 During 2013 and 2012, the Company issued 392,500 and 486,750
 Restricted Stock Units (RSUs), respectively. The RSUs issued in
 2013 and 2012 had a grant date fair value of $12.12 and $5.41,
 respectively. These awards will vest as follows: one-third of the
 award will vest in a series of three successive equal annual
 installments. During 2011, the Company issued 550,000 RSUs at a
 grant date fair value of $2.55. These awards will vest as follows:
 one-third of the award will vest on the second anniversary of the
 award date and two-thirds of the award will vest on the third
 anniversary of the award date. The aggregate value of shares vested
 during 2013, 2012 and 2011 was $4.1 million, $0.1 million and $0.2
 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A summary of Sangamo&#x2019;s RSU activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Term</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate&#xA0;Intrinsic<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(In
 years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(In&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,036,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs awarded</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs released</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(341,843</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(23,750</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,063,657</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 RSUs vested and expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">925,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 RSUs that vested in 2013, 2012 and 2011 were net-share settled such
 that the Company withheld shares with value equivalent to the
 employees&#x2019; minimum statutory obligation for the applicable
 income and other employment taxes, and remitted the cash to the
 appropriate taxing authorities. The total shares withheld were
 approximately 167,138 and 8,937 for 2013 and 2011, respectively,
 and were based on the value of the RSUs on their respective vesting
 dates as determined by the Company&#x2019;s closing stock price.
 There were no such shares withheld in 2012. Total payments for the
 employees&#x2019; tax obligations to taxing authorities were $2.0
 million and $0.1 million in 2013 and 2011, respectively, and are
 reflected as a financing activity within the Consolidated
 Statements of Cash Flows.&#xA0;These net-share settlements had the
 effect of share repurchases by the Company as they reduced and
 retired the number of shares that would have otherwise been issued
 as a result of the vesting and did not represent an expense to the
 Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013, there were 2,929,590 shares were
 reserved for future awards under the Company&#x2019;s 2013 Plan and
 1,527,763 shares of common stock reserved for future issuance under
 the Purchase Plan.</p>
 <!-- xbrl,n -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 </p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESMBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Outstanding (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">8,405,864<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">6 years 3 months 4 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">5,800,931<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 6.84<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 2.55<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 3.25<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">212,844<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">7 years 9 months 7 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">59,647<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 2.57<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 3.45<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 3.45<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">1,124,381<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">4 years 11 months 9 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">1,124,381<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 3.45<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 3.80<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 5.26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">661,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">3 years 3 months 29 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">596,146<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 4.54<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 4 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 5.35<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 5.35<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">909,866<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">5 years 11 months 1 day<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">909,866<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 5.35<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 5 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 5.41<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 5.41<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">1,134,524<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">8 years 10 months 21 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">270,040<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 5.41<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 6 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 5.42<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 5.66<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">60,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">5 years 2 months 27 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">60,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 5.46<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 7 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 5.70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 5.70<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">945,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">6 years 11 months 5 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">676,970<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 5.70<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 8 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 5.86<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 6.82<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">899,022<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">5 years 1 month 13 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">749,020<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 6.45<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 9 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 6.92<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 11.99<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">365,342<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">5 years 5 months 1 day<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">267,361<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 8.68<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 10 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
        <td class="nump">$ 12.12<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
        <td class="nump">$ 14.62<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">2,092,700<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
        <td class="text">6 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options</a></td>
        <td class="nump">1,087,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump">$ 14.05<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxExpense', window );">Income tax expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
        <td class="nump">34.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="nump">103,107,000<span></span></td>
        <td class="nump">88,216,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in deferred tax assets valuation allowance</a></td>
        <td class="nump">14,900,000<span></span></td>
        <td class="nump">5,400,000<span></span></td>
        <td class="nump">19,700,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets, net operating loss carryforwards for federal</a></td>
        <td class="nump">209,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, net operating loss carryforwards for state</a></td>
        <td class="nump">199,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal research tax credit carryforwards</a></td>
        <td class="nump">7,996,000<span></span></td>
        <td class="nump">6,770,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal', window );">State research tax credit carryforwards</a></td>
        <td class="nump">6,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FederalResearchTaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration year</a></td>
        <td class="text">2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and/or penalties</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Indefinite-lived assets [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred tax assets tax credit carry forwards research state and local.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DeferredTaxAssetsTaxCreditCarryForwardsResearchStateAndLocal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FederalResearchTaxCreditCarryforwardExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal research tax credit carryforward expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FederalResearchTaxCreditCarryforwardExpirationYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_IncomeTaxesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax Expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_IncomeTaxExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OperatingLossCarryforwardsExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_OperatingLossCarryforwardsExpirationYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the change in the period in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2012</a></td>
        <td class="nump">9,184,346<span></span></td>
        <td class="nump">8,346,190<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
        <td class="nump">1,119,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
        <td class="num">(1,715,123)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled</a></td>
        <td class="num">(182,559)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2013</a></td>
        <td class="nump">8,405,864<span></span></td>
        <td class="nump">9,184,346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at December 31, 2013</a></td>
        <td class="nump">8,046,932<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at December 31, 2013</a></td>
        <td class="nump">5,800,931<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise per Share Price, Beginning Balance</a></td>
        <td class="nump">$ 6.21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted-Average Exercise per Share Price</a></td>
        <td class="nump">$ 11.75<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted-Average Exercise per Share Price</a></td>
        <td class="nump">$ 4.74<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled, Weighted-Average Exercise per Share Price</a></td>
        <td class="nump">$ 8.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise per Share Price, Ending Balance</a></td>
        <td class="nump">$ 7.20<span></span></td>
        <td class="nump">$ 6.21<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at December 31, 2013, Weighted-Average Exercise Per Share Price</a></td>
        <td class="nump">$ 7.10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at December 31, 2013, Weighted-Average Exercise per Share Price</a></td>
        <td class="nump">$ 6.84<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">6 years 3 months 4 days<span></span></td>
        <td class="text">6 years 5 months 16 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at December, 31, 2013, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">6 years 1 month 13 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at December, 31, 2013, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">5 years 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 56,425<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at December 31, 2013, Aggregate Intrinsic Value</a></td>
        <td class="nump">54,849<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at December 31, 2013, Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 41,073<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMPBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment', window );">Liquid investments purchased with original maturities</a></td>
        <td class="text">Three months or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RestrictedCashAndCashEquivalent', window );">Restricted cash and cash equivalent</a></td>
        <td class="nump">$ 0.3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible assets impairment</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
        <td class="nump">8,405,864<span></span></td>
        <td class="nump">9,184,346<span></span></td>
        <td class="nump">8,346,190<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="nump">68.00%<span></span></td>
        <td class="nump">51.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sigma-Aldrich Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="nump">9.00%<span></span></td>
        <td class="nump">11.00%<span></span></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Dow AgroSciences LLC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="nump">12.00%<span></span></td>
        <td class="nump">22.00%<span></span></td>
        <td class="nump">43.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California Institute for Regenerative Medicine [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">CHDI Foundation, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Equivalent Maturity Period Highly Liquid Investment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RestrictedCashAndCashEquivalent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Cash And Cash Equivalent</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_RestrictedCashAndCashEquivalent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NumberOfOperatingSegments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Juvenile Diabetes Research Foundation International - Additional Information (Detail) (Juvenile Diabetes Research Foundation International [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2006</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Juvenile Diabetes Research Foundation International [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,
				 2006<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmountMaximumUnderAmendedAgreement', window );">Grant funding amount maximum under amended agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsReceivedForWorkPerformedUnderAgreement', window );">Received for work performed under agreement</a></td>
        <td class="nump">0.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.8<span></span></td>
        <td class="nump">$ 0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmountMaximumUnderAmendedAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount maximum under amended agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_GrantFundingAmountMaximumUnderAmendedAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsReceivedForWorkPerformedUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds received for work performed under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ProceedsReceivedForWorkPerformedUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchGrantRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research grant revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchGrantRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 14 &#x2013; SUBSEQUENT EVENT</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On January&#xA0;8, 2014, the Company entered into a Global
 Research, Development and Commercialization Collaboration and
 License Agreement (the Agreement) with Biogen Idec Inc. (Biogen),
 pursuant to which Sangamo and Biogen will collaborate to discover,
 develop, seek regulatory approval for and commercialize
 therapeutics based on Sangamo&#x2019;s ZFP technology for
 hemoglobinopathies, including beta-thalassemia and sickle cell
 disease (SCD).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the Agreement, Sangamo and Biogen will jointly conduct two
 research programs: the beta-thalassemia program and the SCD
 program. In the beta-thalassemia program, Sangamo is responsible
 for all discovery, research and development activities through the
 first human clinical trial for the first ZFP therapeutic developed
 under the Agreement for the treatment of beta-thalassemia. In the
 SCD program, both parties are responsible for research and
 development activities through the submission of an IND application
 for ZFP therapeutics intended to treat SCD. Under both programs,
 Biogen is responsible for subsequent worldwide clinical
 development, manufacturing and commercialization of licensed
 products developed under the Agreement. At the end of specified
 research terms for each program or under certain specified
 circumstances, Biogen retains the right to step in and take over
 any remaining activities of Sangamo. Furthermore, Sangamo has an
 option to co-promote in the United States any&#xA0;licensed product
 to treat beta-thalassemia and SCD&#xA0;developed under the
 Agreement, and Biogen agrees to compensate Sangamo for such
 co-promotion activities.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the Agreement, Sangamo will receive an upfront license fee of
 $20.0 million. Biogen will reimburse Sangamo for its costs incurred
 in connection with research and development activities conducted by
 Sangamo. In addition, Sangamo is eligible to receive development
 milestone payments upon the achievement of specified regulatory,
 clinical development and commercialization milestones. The total
 amount of potential regulatory, clinical development,
 commercialization and sales milestone payments, assuming the
 achievement of all specified milestones in the Agreement, is $293.8
 million, including Phase 1 milestone payments of $7.5 million for
 each of the beta-thalassemia and SCD programs. In addition, Biogen
 agrees to pay Sangamo incremental royalties for each licensed
 product that are tiered double-digit percentage of annual net sales
 of such product.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Subject to the terms of the Agreement, Sangamo grants Biogen an
 exclusive, royalty-bearing license, with the right to grant
 sublicenses, to use certain ZFP and other technology controlled by
 Sangamo for the purpose of researching, developing, manufacturing
 and commercializing licensed products developed under the
 Agreement. Sangamo also grants Biogen a non-exclusive, worldwide,
 royalty free, fully paid license, with the right to grant
 sublicenses, of Sangamo&#x2019;s interest in certain other
 intellectual property developed pursuant to the Agreement.</p>
 <!-- /xbrl,ns -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues recognized under the agreement with Shire for the years
 ended December&#xA0;31, 2013 and 2012, were as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year ended<br />
 December 31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues related to Shire Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Amortization of upfront fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sigma-Aldrich Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenues recognized under the agreement with Sigma for the years
 ended December&#xA0;31, 2013, 2012 and 2011, were as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended<br />
 December 31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenue related to Sigma Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Royalty revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 License fee and milestone revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">671</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 605<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25502053&amp;loc=SL9156464-115641<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 605<br><br> -Section 55<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=9156477&amp;loc=SL9156489-173031<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - HIV - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 31, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PotentialRoyaltyPaymentsToEntity', window );">Receivables from sale against the grant funded to entity from sale of product</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Two  times the amount Sangamo receives in funding under the agreement<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California Institute for Regenerative Medicine [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
        <td class="nump">$ 6.4<span></span></td>
        <td class="nump">$ 14.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementToReceive', window );">Agreement to receive</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment', window );">Expected amount to be received for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,
				 2009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.8<span></span></td>
        <td class="nump">1.2<span></span></td>
        <td class="nump">2.0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California Institute for Regenerative Medicine [Member] | License agreement terms [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.2<span></span></td>
        <td class="nump">1.2<span></span></td>
        <td class="nump">1.7<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California Institute for Regenerative Medicine [Member] | License agreement terms [Member] | Therapeutic for beta-thalassemia [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration agreement related costs and expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementToReceive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement to receive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementToReceive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected amount to be received for research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_GrantFundingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PotentialRoyaltyPaymentsToEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential Royalty Payments To Entity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PotentialRoyaltyPaymentsToEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchGrantRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research grant revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchGrantRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 6,146<span></span></td>
        <td class="nump">$ 5,338<span></span></td>
        <td class="nump">$ 8,081<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">3,204<span></span></td>
        <td class="nump">2,892<span></span></td>
        <td class="nump">3,769<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 2,942<span></span></td>
        <td class="nump">$ 2,446<span></span></td>
        <td class="nump">$ 4,312<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,144)<span></span></td>
        <td class="num">$ (6,145)<span></span></td>
        <td class="num">$ (5,450)<span></span></td>
        <td class="num">$ (6,885)<span></span></td>
        <td class="num">$ (3,478)<span></span></td>
        <td class="num">$ (5,790)<span></span></td>
        <td class="num">$ (5,728)<span></span></td>
        <td class="num">$ (7,268)<span></span></td>
        <td class="num">$ (26,624)<span></span></td>
        <td class="num">$ (22,264)<span></span></td>
        <td class="num">$ (35,750)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14)<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="nump">18<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (26,638)<span></span></td>
        <td class="num">$ (22,250)<span></span></td>
        <td class="num">$ (35,732)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Marketable Securities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 3 &#x2013;MARKETABLE SECURITIES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The table below summarizes the Company&#x2019;s cash equivalents and
 available-for-sale securities (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br />
 Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 (Losses)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,290</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,212</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">128,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,262</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013, all of the Company&#x2019;s
 investments had maturity dates within two years and there were no
 material unrealized losses during 2013. Approximately 70% of the
 Company&#x2019;s available-for-sale securities mature within the
 next twelve months of the date of the balance sheet date and
 approximately 30% of the Company&#x2019;s available-for-sale
 securities have maturities between twelve and twenty-four months
 from the date of the balance sheet date. The Company had no
 material realized losses or other-than-temporary impairments of
 available-for-sale securities for the years ended December&#xA0;31,
 2013, 2012 and 2011.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for  investments in certain debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Debt Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Equity Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
        <td class="nump">$ 4,927<span></span></td>
        <td class="nump">$ 4,495<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
        <td class="num">(3,521)<span></span></td>
        <td class="num">(2,952)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, Net</a></td>
        <td class="nump">1,406<span></span></td>
        <td class="nump">1,543<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
        <td class="nump">3,208<span></span></td>
        <td class="nump">2,950<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and fixtures [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
        <td class="nump">563<span></span></td>
        <td class="nump">499<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
        <td class="nump">$ 1,156<span></span></td>
        <td class="nump">$ 1,046<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">$ 3,022<span></span></td>
        <td class="nump">$ 3,046<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AccruedClinicalTrialExpense', window );">Accrued clinical trial expense</a></td>
        <td class="nump">727<span></span></td>
        <td class="nump">615<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
        <td class="nump">510<span></span></td>
        <td class="nump">238<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
        <td class="nump">121<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
        <td class="nump">$ 4,380<span></span></td>
        <td class="nump">$ 4,013<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AccruedClinicalTrialExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued clinical trial expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AccruedClinicalTrialExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of liabilities incurred and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndOtherAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Ceregene (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Estimated Fair Value of Consideration Transferred</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the estimated fair value of the
 consideration transferred by Sangamo to the Ceregene stockholders
 on the Closing Date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Sangamo shares of common stock</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Contingent earn-out</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total purchase consideration</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Value of Net Assets Acquired</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the estimated fair value of the net
 assets acquired as of the Closing Date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash and equivalents</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">79</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounts receivable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Identifiable intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,585</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(748</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounts payable and accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total liabilities assumed</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(846</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net assets acquired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Summary of Assets, Estimated Fair Values</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A summary of these assets and estimated fair values at the Closing
 Date is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>Value&#xA0;of&#xA0;Intangible<br />
 Assets Acquired</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 CERE-110 for the treatment of Alzheimer&#x2019;s disease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 CERE-120 for the treatment of Parkinson&#x2019;s disease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total identifiable intangible assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Supplemental Pro Forma Information</a></td>
        <td class="text"><div>
 <p>This supplemental pro forma information has been prepared for
 comparative purposes and does not purport to be indicative of what
 would have occurred had the acquisition been made on
 January&#xA0;1, 2012, nor are they indicative of any future
 results.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(In&#xA0;thousands&#xA0;except&#xA0;per&#xA0;share&#xA0;data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(30,997</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(27,446</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.52</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlock</Role>
      <ShortName>Fair Value Measurement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</Role>
      <ShortName>Marketable Securities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Acquisition of Ceregene</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</Role>
      <ShortName>Acquisition of Ceregene</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock</Role>
      <ShortName>Commitments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Quarterly Financial Data</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFairValueMeasurementsDisclosureTextBlockTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Acquisition of Ceregene (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables</Role>
      <ShortName>Acquisition of Ceregene (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Quarterly Financial Data (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableforSaleSecuritiesAndContingentConsiderationLiabilities</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation</Role>
      <ShortName>Fair Value Measurement - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiability</Role>
      <ShortName>Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureFairValueMeasurementScheduleOfFairValueOfContingentConsiderationLiabilityParenthetical</Role>
      <ShortName>Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Parenthetical) (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Marketable Securities - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfInvestments</Role>
      <ShortName>Marketable Securities - Schedule of Investments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformation</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptions</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRights</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgroSciencesInPlantAgricultureAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - HIV - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCaliforniaInstituteForRegenerativeMedicineHIVAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - HIV - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Major Customers, Partnerships and Strategic Alliances - CHDI Foundation, Inc. - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesCHDIFoundationIncAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - CHDI Foundation, Inc. - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Juvenile Diabetes Research Foundation International - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesJuvenileDiabetesResearchFoundationInternationalAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Juvenile Diabetes Research Foundation International - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Michael J. Fox Foundation for Parkinson's Research - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesMichaelJFoxFoundationForParkinsonsResearchAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Michael J. Fox Foundation for Parkinson's Research - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Acquisition of Ceregene - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformation</Role>
      <ShortName>Acquisition of Ceregene - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Acquisition of Ceregene - Summary of Estimated Fair Value of Consideration Transferred (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfConsiderationTransferred</Role>
      <ShortName>Acquisition of Ceregene - Summary of Estimated Fair Value of Consideration Transferred (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Acquisition of Ceregene - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfEstimatedFairValueOfNetAssetsAcquired</Role>
      <ShortName>Acquisition of Ceregene - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Acquisition of Ceregene - Summary of Assets, Estimated Fair Values (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneSummaryOfAssetsEstimatedFairValues</Role>
      <ShortName>Acquisition of Ceregene - Summary of Assets, Estimated Fair Values (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Acquisition of Ceregene - Schedule of Supplemental Pro Forma Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAcquisitionOfCeregeneScheduleOfSupplementalProFormaInformation</Role>
      <ShortName>Acquisition of Ceregene - Schedule of Supplemental Pro Forma Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipment</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Commitments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation</Role>
      <ShortName>Commitments - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Commitments - Summary of Future Minimum Payments under Contractual Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureCommitmentsSummaryOfFutureMinimumPaymentsUnderContractualObligations</Role>
      <ShortName>Commitments - Summary of Future Minimum Payments under Contractual Obligations (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstanding</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Outstanding (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity</Role>
      <ShortName>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>168 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanysDeferredTaxAssets</Role>
      <ShortName>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>169 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanysUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>170 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>171 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>172 - Disclosure - Quarterly Financial Data - Summary of Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyFinancialData</Role>
      <ShortName>Quarterly Financial Data - Summary of Quarterly Financial Data (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>173 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_BusinessCombinationContingentConsiderationLiability had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueCurrent had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_DeferredTaxAssetsValuationAllowance had a mix of decimals attribute values: -6 -3.</Log>
    <Log type="Info">Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RoyaltyRevenue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '143 - Disclosure - Stock-Based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '146 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '148 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '149 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '154 - Disclosure - Acquisition of Ceregene - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '160 - Disclosure - Property and Equipment - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '163 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '167 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>sgmo-20131231.xml</File>
    <File>sgmo-20131231.xsd</File>
    <File>sgmo-20131231_cal.xml</File>
    <File>sgmo-20131231_def.xml</File>
    <File>sgmo-20131231_lab.xml</File>
    <File>sgmo-20131231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Fair Value of Contingent Consideration Liability (Parenthetical) (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Acquisition date</a></td>
        <td class="text">Oct.
				01,
				 2013<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the business acquisition agreement was executed, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Data<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>NOTE 13 &#x2013; QUARTERLY FINANCIAL DATA (UNAUDITED)</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table sets forth certain unaudited quarterly
 financial data for the eight quarters ended December&#xA0;31, 2013.
 The unaudited information set forth below has been prepared on the
 same basis as the audited information and includes all adjustments
 necessary to present fairly the information set forth herein. The
 operating results for any quarter are not indicative of results for
 any future period. All data is in thousands except per common share
 data.</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Q4</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,707</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,243</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,402</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,043</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,526</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,885</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,450</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,145</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,144</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,268</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,728</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3,478</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.10</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.13</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.07</td>
 <td valign="bottom" nowrap="nowrap">)</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
